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Note: In general, it is STRONGLY recommended that health professionals NOT rely on printed copies of 
the Epi Manual. Anyone considering updating a “paper copy” of the Epi Manual may want to consider 
printing out the entire manual as most chapters during this review have grammar, statistical or new 
terminology corrections, revised review dates as well as the edits listed below. All fact sheets were 
reviewed and almost all have edits. Included in detail here are edits of a more substantial nature. 
 
General Contact Information 
 
The following contact information maps were replaced with new versions in this section: 
 
Public Health Epidemiologists 
Disease Prevention Specialists  
Child care Consultants  
Community Health Consultants  
State Veterinarians 
 
 
 
Reportable Disease Information 
 
 
Cyclospora 
Edits to “Responsibilities” for investigation 
 
E. coli 
Many edits to classification of the various types of E. coli throughout the chapter. 
E. coli Fact sheet was replaced 
 
Hepatitis B - Maternal 
All materials updated and replaced, primarily for the IDPH contact information. 
 
Legionella 
Laboratory information section replaced with updated information on legionella testing. 
 
Meningitis 
The Entire chapter has undergone grammar and other small edits. The 
most substantive changes are in Child Care Contacts 
 
Polio 
Edits made to the following sections and HP Fact Sheet: 
Epidemiology 
Protection of Contacts of a Case 
Polio Vaccine and Travel 
 
Plague 
The Epidemiology section replaced with updated information. 
 
Q Fever 
Edits to “Responsibilities” for investigation 
 
Rubella 
Added comments to “Protection of Contacts” in this chapter. 
 
Salmonella 
The entire chapter has undergone edits to grammar and IDSS instructions 
 
Shigella 
The entire chapter has undergone edits to grammar and IDSS instructions. Child care investigations 
has important changes. In addition, edits to investigation of food handlers, fact sheet etc. 
 
Syphilis 
Laboratory information section replaced with updated information on syphilis testing. 
 
Tetanus 
Edits to Epidemiology section 
 
Tuberculosis 
New Tuberculosis Patient info sheet 
 
Typhoid Fever 
New language added to section on food handlers, and restrictions with diagnosis. 
Epidemiology information updated 
Fact sheet updated also 
 
Viral Hemorrhagic Fever 
Edits to Reservoirs, incubation period, and epidemiology 
 
Law Changes 
New Iowa Code 139A 
New Iowa Code 141A 
New IAC 641.1 
Added HIPAA statement back in 
 
Glossary - food handler definition added. 
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Iowa Department of Public Health 
Mission & Vision Statements 
 
Mission: 
Promoting and protecting the health of Iowans 
 
Vision: 
Healthy Iowans living in healthy communities 
 
One of the goals of public health professionals at the local and state level, in 
cooperation with private health professionals across the State of Iowa, is to prevent 
epidemics and the spread of disease.  Strategies used to achieve this goal include 
monitoring for infectious diseases, detecting and investigating these diseases and 
providing disease prevention and control services.  Members of this local, state and 
private medical “team” are in critical positions to deter potential public health threats 
due to communicable diseases.  An effective surveillance system and prompt evaluation 
and response by the “team” are essential to the control of disease. 
 
The purpose of this manual is: 
 
1.  To be a reference for all health care providers at the time of a suspected case, a 
particular disease or condition, or at the time of an outbreak of a communicable disease 
to institute public health prevention and control measures. 
 
2.  To assure more rapid and appropriate responses to situations that present danger to 
high-risk populations or the population at large. 
 
3.  To standardize the reporting and investigation of communicable diseases throughout 
the state. 
 
4.  To clarify the roles of the public and local providers and to optimize the surveillance 
of a population when a communicable disease(s) occur. 
 
The book Control of Communicable Diseases Manual, Heymann, D., MD, Editor; 
Nineteenth Edition, 2008, (an official report of the American Public Health Association*) 
may also be consulted about disease investigation or follow-up.  
 
If there are questions for which this manual or the Control of Communicable Diseases 
Manual does not provide answers, please contact the Iowa Department of Public Health, 
Center for Acute Disease Epidemiology (CADE) anytime at (800) 362-2736 or (515) 242-
5935. 
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Introduction 
 
 
 
Purpose of Guide to Surveillance, Investigation, and Reporting:  Infectious diseases are 
a continuing threat to all people, regardless of age, gender, lifestyle, ethnic background, or 
socioeconomic status. They cause illness, suffering and even death, and place an enormous 
financial burden on society. Although modern advances have controlled some infectious 
diseases, new ones are constantly emerging. State public health officials rely on local public 
health agencies, healthcare providers, laboratories and other public health personnel to report 
the occurrence of notifiable diseases. Without such data, trends cannot be accurately 
monitored, unusual occurrences of diseases (such as outbreaks) might not be detected or 
appropriately responded to, and the effectiveness of control and prevention activities cannot be 
evaluated.  
 
The Iowa Department of Public Health (IDPH), Center for Acute Disease Epidemiology (CADE) is 
placing increased emphasis on strengthening infectious disease surveillance and response. This 
reference manual is part of the IDPH focus on providing more training and technical assistance 
to local public health agencies and healthcare facilities. The purpose of this manual is to guide 
local public health agencies and healthcare providers through specific surveillance and reporting 
responsibilities for the diseases reportable to the IDPH.  For more specific information on 
surveillance and reporting of reportable diseases, contact CADE (800) 362-2736.  
 
The manual is arranged alphabetically by reportable disease, with each disease in its own 
chapter. While this manual is targeted to local public health agency personnel and infection 
preventionists, other healthcare professionals can also use the information to facilitate their 
understanding of communicable diseases. The private provider and laboratory responsibility in 
reporting and surveillance is a vital and collaborative piece in acquiring timely and accurate 
information for assuring healthy Iowa communities. 
 
The terms “local public health agency” and “local health department” are used interchangeably. 
 
“You” and “your” refers to the people/audience for whom this manual is intended, namely, 
personnel of local public health agencies and local health departments and infection 
preventionists from health care facilities. 
 
All information in this manual must be considered in light of newer information available after 
publication. The three-ring binder format of this manual allows for addition of new and updated 
material as they become available. The web based version of the manual will have the most 
current information. 
 
Organization 
The Iowa Department of Public Health is a division of state government. The Division of Acute 
Disease Prevention and Emergency Response, and the Division of Environmental Health and 
Bureau of Health Statistics are located within IDPH, and are housed at the Lucas State Office 
Building in Des Moines, Iowa. 
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The Iowa Reportable Disease Surveillance System 
A.  What is surveillance?  Disease surveillance is the regular collection, monitoring and analysis 
of data relevant for control and prevention of diseases. The data is used to define baseline 
levels of disease. By knowing the baseline, one may then identify unusual occurrences of 
disease.  
 
The purposes of infectious disease surveillance are to interrupt transmission of disease to 
susceptible persons and to reduce morbidity and mortality through: 
 Timely reporting,  
 Identification and investigation of individual cases and outbreaks, and 
 Interpretation of investigative data and dissemination of findings
 
Surveillance is often categorized into two types: “active surveillance” and “passive surveillance.” 
Active Surveillance:  An active surveillance system is one in which public health officials 
regularly solicit disease reports.  This is often accomplished by regularly (daily, weekly, bi-
weekly) telephoning selected individuals and asking if specific diseases have been identified.  
The reports are generally solicited from health care providers, infection preventionists, 
laboratories, schools, minor emergency clinics, etc.  This type of system has been shown to 
double the number of reports of some diseases. 
 
In the case of active surveillance, the organization receiving information takes direct action in 
collecting this information. This may occur through direct review of medical records, laboratory 
records, or screening of high-risk populations.  
 
Passive Surveillance:  A passive surveillance system, such as Iowa has, is one in which reporting 
is left to individuals (i.e. physicians, nurse practitioners, physician assistants, infection 
preventionists, laboratories, etc.).  Passive surveillance is the most common type of surveillance 
used in state and local health departments.  The two major limitations of this type of system 
have been under reporting and delayed reporting. 
 
Traditional reporting of diseases by healthcare providers and laboratories is considered passive 
surveillance. This means that the organization receiving the information waits for initial data on 
a case to be submitted. This usually leads to collection of additional information and the 
implementation of follow-up activities. An example of this would be when a local public health 
agency receives a report of invasive Neisseria meningitidis infection from a healthcare provider 
or facility and then initiates patient interview and contact tracing with recommendations on 
post-exposure prophylaxis. 
 
A sub-category of passive surveillance is “enhanced passive surveillance.” In this situation, the 
organization receiving data works closely with healthcare providers and laboratories that are 
most likely to report a particular disease or group of diseases and sets up systems to increase 
timeliness and completeness of reporting.  
 
Guide to Using the Specific Disease Format: The format chosen for describing the specific 
diseases is designed to make the information easy to read and to orient the reader with 
terminology specific for communicable disease investigation.  The following information defines 
the headings used and provides helpful hints in interpreting the information included in the 
specific disease sections. 
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Synonyms:  Some disease names have changed over time, and some health professionals or 
laypersons may describe the disease by other terms. 
 
Agent:  The specific pathogen that produces the disease.  Whether the agent is bacteria, virus, 
fungus, parasite, or other organism, it is important to refer to it appropriately when conversing 
with health professionals or the public.  If the agent is an insect (e.g., lice) producing an 
infestation, the appropriate terminology for the problem is infestation, not disease or infection. 
 
Reservoir:  The normal habitats where the infectious agent can live, multiply, and reproduce.  
These habitats can include man, animals, or the environment. 
 
Mode of Transmission: The direct (person-to-person or animal-to-person) or indirect 
(through vehicles such as food or water, vectors, etc.) transfer of an infectious agent from a 
reservoir to a susceptible host.  The reservoir and mode of transmission are integrally related 
and the specific information about them should direct the types of questions asked during the 
case investigation.  Let's take the example of two enteric diseases, salmonellosis and shigellosis.  
The reservoir for Salmonella includes domestic and wild animals and man.  The mode of 
transmission is most often by ingestion of contaminated food, but also may be by the fecal-oral 
route resulting from contact with infected animals or persons.  Having this information, the case 
investigation to determine the source must include a complete food history and investigation of 
possible ways persons and animals could transmit the organism via their feces.  For Shigella the 
only reservoir is man and the mode of transmission is the fecal-oral route.  In this instance, the 
case investigation to determine the source centers only on the possible ways that a person(s) 
can transmit the organism via their feces.  No history about animals is necessary. 
 
Incubation Period: The interval between exposure to an agent that results in infection and 
the appearance of the first symptom of illness.  There will be a range (shortest - longest) and 
an average incubation period for each disease. 
 
When investigating the occurrence of a specific disease, the shortest and longest incubation 
periods should compose the time frame in question.  For example, the incubation period for 
hepatitis A is 15-50 days, average 28-30.  When interviewing the case, you should ask, "In the 
15-50 days (2-6 weeks) before you became ill . . ." or preferably use specific dates.  For 
example, if the person with hepatitis A had onset of symptoms on February 14, ask about 
specific exposures from January 1-30. 
 
Period of Communicability: The time during which a person or animal with an infectious 
disease is a potential source of infection.  Period of communicability is important when 
assessing the risk that the case under investigation may have transmitted his/her disease to 
others.  For example, when investigating a case of hepatitis A, request the names of "contacts" 
in the 2 weeks prior to and 1 week after the onset of illness (the period of communicability for 
hepatitis A). 
 
Clinical Illness: The symptoms commonly associated with a particular disease.  If specific 
laboratory testing is not completed, a good clinical history of signs (objective physical findings) 
and symptoms (experienced by the patient) are necessary to determine the likelihood of 
diseases for which follow-up would be indicated. 
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Diagnosis:  The use of scientific and skillful methods to establish the cause and nature of a 
person's disease.  Cases may be grouped as follows: 
 Confirmed:  A person who has a laboratory-confirmed infection with a particular agent.  
The person may have clinical symptoms or the infection may be sub clinical 
(asymptomatic).  Sub clinical disease can only be diagnosed by laboratory testing. 
 
 Probable:  A person with clinical symptoms of a disease (but no laboratory confirmation) 
who is a contact to a laboratory-confirmed case or is associated with a documented 
outbreak.  The case is then epidemiologically linked. 
 
 Suspect:  (frank, apparent) A person with a clinical syndrome suggesting a particular 
disease.  Epidemiologically, this refers to a case which is not (yet) either laboratory 
confirmed or epidemiologically linked. 
Prevention:  Slowing or stopping the occurrence of disease.  This may include direct 
intervention by the public health or educating the cases and contacts about the disease, how it 
is transmitted and how to prevent transmission.   
 
Glossary: A glossary of other pertinent terms can be found at the end of this manual.  
 
Investigation of Communicable Diseases:  Not every disease reported requires a detailed 
follow-up.  Diseases are to be reported by health care providers, laboratories, infection 
preventionists, school nurses, local health department personnel, and can be reported by 
private citizens. 
 
Confirmation: The first step taken before any action is initiated is to confirm the diagnosis (if 
at all possible). If the disease is being reported by a physician or infection preventionists, 
confirmation in most instances is obtained by requesting information on specific laboratory tests 
to confirm the diagnosis. 
 
When a disease that requires public health follow-up is reported by a private citizen, 
confirmation requires contact with the appropriate physician, laboratory, or both, and 
requesting specific test results used to make the diagnosis.  If the diagnosis is a clinical 
diagnosis without laboratory confirmation, it is sometimes necessary to request a clinical history 
in order to determine if the illness is consistent with the diagnosis.  If the symptoms are not 
consistent with the diagnosis, contact the Center for Acute Disease Epidemiology (CADE) at 
(800) 362-2736 for recommendations. 
 
Case Investigation:  Case investigation involves determining possible sources of the person's 
infection, assessing the likelihood that the individual will transmit the infection to others, and 
providing education regarding prevention of further spread to the ill person and their contacts.  
This may lead to investigation of the possible source and/or other cases.   
 
Critical factors in any case investigation include: 
  
 Timely response to the initial disease report.  Investigation of diseases requiring 
follow-up should be initiated within 24 hours. 
 
 Collection of appropriate data needed to make an accurate assessment.  Prior 
to interviewing, review material related to the specific disease.  Critical information to 
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consider when collecting data is the reservoir(s), incubation period, mode of 
transmission, period of communicability and appropriate control measures necessary for 
the disease. 
 
 Follow-up of leads regarding a possible source of infection. 
 
Example:  An adult with shigellosis reports his child had fever and diarrhea a few days earlier 
and the child attends a child care center.  An appropriate response would be to visit the child 
care center to evaluate if other children in the center are, or have been, ill with fever and 
diarrhea. 
 
Intervening appropriately to interrupt transmission and prevent disease. 
Example:  A patient with salmonellosis reports that she had eaten at a local food 
establishment with a large group and several members of the group had become ill with fever 
and diarrhea.  While you are taking food histories on all ill persons, an environmental health 
specialist/sanitarian should be consulted to visit the food establishment to conduct an 
inspection, gather necessary information, and collect food samples if warranted. 
 
Accurate documentation of information obtained. 
Complete information regarding any case investigation should be recorded in a neat, organized 
manner and filed.  Case investigations should either be filed in a communicable disease file (for 
example: Hepatitis A Cases - 1985), in a patient file (by patient name) or entered into the Iowa 
Disease Surveillance System (IDSS), Iowa’s secure web-based disease reporting system.  If the 
patient file is used, a log of all case investigations performed in the county should be kept.  The 
record should not only include information given to you about the case but also any 
recommendations, instructions and education that was provided to the case.  Recording should 
be done as information is obtained or service given.  Do not rely on your memory. 
 
Legal Basis:  Reporting of communicable diseases is required under Iowa Code Chapter 139A. 
These laws are implemented by regulation under Iowa Administrative Code Chapter 641.1 The 
purpose of these regulations is “to list those diseases declared dangerous by the Iowa 
Department of Public Health, and to establish reporting, isolation, and quarantine requirements. 
This is intended for use by local public health agencies, hospitals, healthcare providers, 
laboratories, educational and recreational program health officials, food industry officials, and 
the public.”  
 
Infectious diseases designated as a threat to the public health must be reported directly to the 
local public health agency and the Iowa Department of Public Health. The only exceptions to 
this are sexually transmitted diseases, tuberculosis, and HIV/AIDS, which are reported directly 
to the IDPH. Local public health agencies or their designees are authorized to accept, 
investigate and submit reportable disease case information to IDPH, Center for Acute Disease 
Epidemiology (CADE).  
 
Reporting of Tuberculosis: Healthcare providers, laboratories, or local public health agencies 
who have knowledge of a case of confirmed tuberculosis (TB) or clinically suspected 
tuberculosis case shall notify the Tuberculosis Program within 24 hours. Upon receipt of such 
notice, the TB Program shall notify the local public health agency within 24 hours. This notice 
shall include the case name, date of birth, age, sex, case address, and provider name and 
provider phone number. For more information, local public health agencies should contact the 
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TB Program directly at (515) 281-7504. 
 
Reporting of HIV/AIDS: HIV and AIDS (as determined by a laboratory test diagnostic of HIV 
infection or AIDS) are reportable directly to the IDPH, HIV/AIDS Surveillance Program.  
Perinatal exposures to HIV (i.e., births to HIV-infected women) are also reportable, as are 
deaths of persons with HIV/AIDS. Reporting is to be done by healthcare providers, laboratories, 
and other officials using the HIV/AIDS Case Report Form developed and approved by the IDPH. 
Because information beyond what can be captured in the Iowa Disease Surveillance System is 
needed for HIV/AIDS reports, reporting through IDSS will prompt the HIV/AIDS Surveillance 
Office to send the initial reporter the case report form to complete reporting. Local public health 
agencies should contact the HIV/AIDS Surveillance Program directly at (515) 242-5141 to 
obtain a case report form or if there are any questions regarding reporting of HIV/AIDS. 
 
Reporting of STDs:  Cases of certain sexually transmitted diseases (STD), as determined by a 
clinical diagnosis and/or from laboratory evidence of an infection, are reportable directly to the 
IDPH, STD Prevention Program. Specifically, Syphilis, Gonorrhea, and Chlamydia are reportable.  
Reporting is accomplished by clinicians, laboratories and other officials designated by the IDPH 
using a form or format approved by the IDPH or by reporting through the Iowa Disease 
Surveillance System.  When using IDSS to report STDs, providers should indicate any treatment 
provided in the NOTES tab because the follow-up form is closed from view due the partner 
services information located within it. Local public health agencies, clinicians and laboratories 
can contact the STD Prevention Program directly at (515) 281-3031. 
 
Reportable sexually transmitted diseases include chlamydial infection, syphilis, and gonorrhea.  
Minors may give consent for STD prevention, tests, and treatment without parental consent or 
notification. Case investigation will be conducted by trained disease prevention specialists at the 
state or local level. 
 
Reporting and Case Investigation; State versus Local Role:  CADE collaborates with 
local public health agencies and health care facilities in the investigation of cases of 
communicable disease and the implementation of appropriate control and prevention measures. 
The guidelines in this manual, as well as other referenced material, form the basis for local 
public health agency communicable disease reporting, investigation and control measures.   
 
When clusters or outbreaks of illness, potential bioterrorist agents, emerging infections or other 
serious threats to public health are identified, IDPH will provide technical assistance to local 
public health agencies. IDPH assistance may range from serving in a medical consulting 
capacity to direct management of the investigation, implementation of control and prevention 
measures, and initiating follow-up activities. In special situations, IDPH may request technical 
assistance from the Centers for Disease Control and Prevention (CDC). (Note: Requests for 
CDC technical assistance must be made by the IDPH.) 
 
When an institution such as a healthcare facility or a school is the site of possible transmission, 
the infection preventionist of the healthcare facility or the school nurse is typically actively 
involved in the investigation and the application of control and prevention measures. Ideally 
decisions about control measures are made collectively by the IDPH, the local public health 
agency, and the infection preventionist (or equivalent) in the affected institution. However, 
IDPH and the local board of health working together have ultimate authority. 
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Timeliness of Reporting: Cases of diseases reportable to IDPH are reported to CADE. Certain 
diseases should be immediately reported by phone to the IDPH when a suspect or 
confirmed case is identified. Diseases that require immediate reporting should always be 
prioritized above other case investigations. In addition, any disease where a cluster exists or 
where there is a suspected cluster or outbreak of disease should be reported immediately and 
prioritized accordingly. Post investigation, the local public health agency can follow up with the 
official case report form(s).  All diseases that are not categorized as “immediate” should be 
reported as outlined in IAC 641.1 and investigated within a week and a completed case report 
form with appropriate laboratory test confirmation (if applicable for the disease) should be 
submitted preferably through the IDSS. 
 
Note: Local public health agencies (LPHA) are responsible for residents of their county.  
Reports of illness received for residents of other cities/towns outside of the county should be 
forwarded to CADE or the appropriate LPHA.  
 
The importance of timely reporting cannot be overemphasized.  For example, if a local health 
authority holds reports of salmonella and only submits them once a month, a potential outbreak 
occurring across city/town limits may go unnoticed and uncontrolled. 
 
The Center for Acute Disease Epidemiology (CADE) has an epidemiologist available during 
normal business hours (515) 242-5935 or (800) 362-2736 to answer questions about case 
investigation and control measures.  Surveillance information is available during normal 
business hours at (515) 281-6493 for questions about reporting requirements.  For disease 
reporting please call the Disease Reporting Hotline at (800) 362-2736.  A medical epidemiologist 
is also available during non-work hours and weekends for emergency situations e.g., if you 
receive several complaints and are concerned about a potential foodborne illness outbreak.  All 
calls are returned promptly.  
  
Examples of top priorities include: 
 Clusters of illness 
 Diseases that require prompt administration of countermeasures to prevent further 
spread and/or to reduce morbidity and mortality (e.g., rabies, hepatitis A, or 
meningococcal invasive disease) 
 Diseases with high mortality rates (e.g., eastern equine encephalitis) 
 Suspect bioterrorist agents (e.g., anthrax or smallpox) 
 Diseases that are unusual in the infected individual’s demographic group or within a 
geographic region  
 Disease with a high potential for spread to others (e.g., measles) 
 
Note: To help local public health agencies distinguish those diseases that pose a more serious 
public health threat, certain chapters have been flagged. These disease chapters have a box 
with the notation “Report Immediately” at the top of the first page. If you are unsure about 
which investigations to do first, or need technical assistance, contact the epidemiologist on-call 
 at (800) 362-2736. 
 
Confidentiality 
Confidentiality is a legal requirement. The information that public health officials collect is often 
personal. Success and cooperation lies in protecting an individual’s right to privacy. It is 
important to realize that confidentiality concerns extend beyond the investigator. Clerical staff, 
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administrative staff, interns and local public health agency members who may be aware of 
personal information on a case should all be familiar with and mindful of the basic tenets of 
maintaining confidentiality. Only individuals who have a “need to know” should have access to 
sensitive records. During and after an investigation, only those individuals directly involved in 
interviewing a case or contacts and/or those directly involved in follow-up activities to control 
the spread of the disease, fall into the category of “need to know.” This category would 
normally not include general administrators, town officials, elected officials and others involved 
in town government who are not directly providing disease control services. Individuals 
assisting in general education to the public also have no need to know personally identifying 
information about a case.  
 
If you are unsure about whether it is appropriate to release information, do not release it!  
Check with a supervisor, the municipal attorney or legal advisor, or contact the Center for Acute 
Disease Epidemiology at (515) 242-5935 or (800) 362-2736 for advice.  Make sure information 
is released only to people who are authorized to receive it. Do not be pressured into a hasty 
decision. Do not confirm an individual case unless you are certain it is appropriate to release 
that information. If you are unsure about who is requesting information, obtain confirmation of 
the requestor’s identity before releasing information i.e., a signed consent form with 
documented identification such as a driver’s license; for guardians, documentation of 
guardianship. Inappropriate release of data could pose a liability threat to your agency and/or 
municipality and possibly endanger affected individuals. 
 
It is important to realize that information may be shared between local public health officials, 
healthcare providers, and with IDPH during the course of a public health investigations and 
control activities. However, even in these instances “need to know” applies. Information on 
individual cases may be obtained from IDPH Center for Acute Disease Epidemiology (CADE) 
only by the responsible representative of a local public health authority involved in an 
investigation of the case, the person who is the case, the health care provider involved, or the 
individual’s guardian or designee (with written informed consent). 
 
The IDPH strongly encourages local public health agencies to acquire a secure fax machine for 
the use of individuals involved in communicable disease reporting, investigation and control. 
This machine should be located in a secured area where disease control staff work and should 
not be accessible to the general public. Communicable disease control personnel's use of a fax 
machine shared by many personnel in town government presents a heightened risk for breach 
of confidentiality. 
 
Remember the type of information released cannot personally identify a case. What facts could 
be released can change with each situation. For example, demographic information such as 
age, race, sex, or zip code could or could not be used depending how large the outbreak is, and 
whether it can be traced back to an individual case.  The rule remains that if released 
information can identify or be traced back to an individual case, the information should not be 
released.  
 
Local and state public health authorities have investigated cases of infectious disease and 
collected sensitive information for more than 100 years. These efforts would not be as 
successful if all personnel did not uphold the public’s trust by maintaining strict confidentiality. 
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Reporting by Clinicians:  Throughout the country, reporting of diseases by clinicians is 
variable. Clinicians are more likely to report disease with high mortality or diseases spotlighted 
in local and national media.  Some strategies to increase reporting by clinicians include: 
 Education on the importance of reporting. 
 Appropriate mechanisms for reporting.  
 Identification of professional or support staff who work with clinicians and who are able 
to take on the responsibility for reporting of clinician-diagnosed reportable disease.  
 Prioritization of reportable diseases that pose a more serious risk to public health.  
 
Note:  Local public health agencies (LPHA) having difficulty obtaining information from 
clinicians should contact the Center for Acute Disease Epidemiology at (515) 242-5935 for 
assistance. Also, sample letters outlining the roles and responsibilities of the local public health 
agency for use with healthcare providers and patients are available in disease specific chapters. 
 
An important strategy to improve reporting by healthcare providers is to develop better working 
relationships with those in your jurisdiction through education, provision of reports on public 
health activities and disease data, and by asking for their participation in timely public health 
initiatives. This includes such things pandemic influenza planning, or a bioterrorism response 
and/or surveillance planning for emerging infections. 
 
Healthcare providers do not always inform patients that a disease is reportable to local or state 
health departments. This may lead to distress in a patient when they are contacted for a case 
investigation. Healthcare provider education on this issue is a good strategy for LPHAs.  The 
LPHA should ask when the test results and diagnoses were communicated to a patient.  It is 
usually best to begin an investigation by contacting the reporting clinician. 
 
Laboratory Reporting:  Laboratory results are often reported directly to the IDPH from 
laboratories. This has led to more timely disease reporting. IDPH sends these laboratory results 
to LPHAs for follow-up using the Iowa Disease Surveillance System (IDSS). Some laboratories 
batch their test results and submit them periodically, potentially leading to long delays in receipt 
and identification or confirmation of cases. IDPH is working to eliminate this situation through 
laboratory education and the implementation of electronic laboratory data transmission via 
IDSS. The University of Iowa State Hygienic Laboratory (SHL) reports directly into IDSS. As 
 
Important Points Regarding Confidentiality 
 Everyone with access to case information is required to maintain confidentiality. 
 Confidential information can be released only to those who “need to know.” 
 Be certain of the identity of the person to whom you release confidential information. 
Insist on confirmation of identity e.g. copy of driver’s license, if unsure. 
 Maintain confidentiality during reporting. If reporting by fax, be certain that the receiving 
number is a confidential fax e.g., (515) 281-5698 is the number of the Center for Acute 
Disease Epidemiology, Surveillance Program confidential fax. When receiving information 
by fax to your office, confidentiality also must be maintained. 
 Personally identifying information from case report forms and other forms cannot be 
released without the individual’s signed consent, except to those directly involved in case 
investigation, control and prevention who have a “need to know.”   
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time progresses IDPH will reach out to additional laboratories to initiate secure electronic data 
submission. 
 
Current laboratory systems often are not equipped to collect much of the information needed, 
nor are they linked directly to clinical/patient information systems. As hospital and laboratory 
databases become more integrated, better demographic information will become available. 
IDPH currently attempts to gather additional information when patient information is too limited 
to allow local public health agency follow-up. 
 
Sentinel Surveillance and Reporting of Selected Diseases:  In addition to passive, 
enhanced passive and active surveillance, IDPH has several “sentinel” surveillance projects. The 
primary purpose of sentinel surveillance is the initial and/or representative detection of disease, 
whether it is emergent or recurrent. This requires that the organization receiving data work 
closely with a select number of sites, e.g., healthcare providers, laboratories, or school nurses, 
to supplement standard reporting. Sentinel surveillance reporting is particularly useful in 
providing warning of the arrival of a disease. For diseases that are high in volume and not 
individually reportable, such as influenza, it can also provide estimates about the burden of 
disease among the general population. Sentinel surveillance and reporting may also be helpful 
when monitoring a disease that is newly introduced to a population, such as West Nile virus, or 
when providing information about a disease disproportionately affecting specific populations, 
such as varicella surveillance in schools. 
 
Limitations of Data; Under-Reporting and Incomplete Data:  Because most surveillance 
systems are based on a passive disease reporting, under-reporting is inevitable. It is estimated 
that, depending on the disease, only 5% to 80% of cases that actually occur will be reported. 
For example, foodborne illness is often underreported because individuals with disease do not 
consult a healthcare provider, or a diagnosis of “gastrointestinal illness” is made and treated 
without any diagnostic tests that might identify the particular pathogen. Even with incomplete 
information, it is often possible to detect key trends and/or sources of infection. For diseases 
that occur less frequently, the need for completeness becomes more important. Each individual 
case must be treated as a “key” event. 
 
Lack of Representativeness of Reported Cases:  Health conditions are not reported 
randomly. For example, illnesses in a healthcare facility are reported more frequently than those 
diagnosed by outpatient care providers. A provider is more likely to report a case of hepatitis A 
if the patient is ill than if the patient has few or no symptoms. A case of meningitis is more 
likely to be reported than a case of chickenpox. Reporting bias can distort interpretation of 
disease data.   
 
Changing/Evolving Case Definitions:  Different practitioners frequently use different case 
definitions for health problems. The more complex the disease syndrome, the greater the 
difficulty in reaching consensus on a case definition.  With newly emerging diseases and as 
understanding progresses, case definitions are frequently adjusted to allow greater accuracy of 
diagnosis. Also, as new diagnostic tests are developed, case definitions sometimes change to 
incorporate these tests. Case definitions establish uniform criteria for disease reporting and are 
not definitive for diagnosis. The case definitions used by IDPH for disease reporting are put 
forth by the Council of State and Territorial Epidemiologist (CSTE) and are used nationwide for 
accurate comparison of disease burden across states. The case definitions can be found at: 
www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
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Bioterrorism:  Bioterrorism is the intentional use of disease agents to create fear, disrupt 
society or cause injuries and/or death. The use of biologic agents by terrorists may involve acts 
that are announced or otherwise immediately recognized. Alternatively, and considered to be 
more likely, would be the silent introduction of a biologic agent into the population that could 
take days to weeks before illness becomes apparent. 
 
Because some diseases caused by bioterrorism may initially resemble common infectious 
diseases, the detection of a bioterrorist event may be difficult.  Local health departments 
should immediately notify the epidemiologist on-call for Center for Acute Disease 
Epidemiology at (800) 362-2730 if any of the following are noticed: 
 
 A cluster of illness that is unexplained after preliminary investigation 
 One or more cases of disease in a community in which the disease does not normally 
occur 
 Illness in an unusual geographic distribution e.g., patients all residing in one area 
possibly downwind of a point-location or in an unusual population or e.g., serious 
pneumonia among young adults. 
 
Local communities must lead the response to a bioterrorist event, or to any infectious disease 
emergency. Planning, exercising plans, and communication are important and will be most 
effective if a strong partnership among public health, first responders e.g., fire departments, 
emergency management, law enforcement, local health care providers and hospitals have been 
developed in advance. 
 
Conclusion:  The best surveillance lies in collecting accurate and timely data, and in carefully 
and correctly interpreting the data. The interpretation should focus on elements that might lead 
to control and prevention of the condition. Investigators can use surveillance as a basis for 
appropriate public health actions. The results of such actions can be assessed for effectiveness.  
This manual is designed to give an overview of local public health agency responsibility for 
surveillance, reporting, control, and prevention of the diseases reportable to the Center of Acute 
Disease Epidemiology. As experience has proved, case investigation can vary greatly from 
setting to setting, and it is impossible to address all the questions and situations that may arise. 
The Center for Acute Disease Epidemiology is available at (515) 242-5935 to offer guidance and 
assistance as needed.   
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139A.1  TITLE. 
         This chapter shall be known as the "Communicable and Infectious Disease 
Reporting and Control Act".   
 
139A.2  DEFINITIONS. 
For purposes of this chapter, unless the context otherwise requires: 
1.  "Area quarantine" means prohibiting ingress and egress to and from a building or 
buildings, structure or structures, or other definable physical location, or portion thereof, 
to prevent or contain the spread of a suspected or confirmed quarantinable disease or to 
prevent or contain exposure to a suspected or known chemical, biological, radioactive, 
or other hazardous or toxic agent. 
2.  "Business" means and includes every trade, occupation, or profession. 
3.  "Care provider" means an individual who is trained and authorized by federal or state 
law to provide health care services or services of any kind in the course of the 
individual's official duties, for compensation or in a voluntary capacity, who is a health 
care provider, emergency medical care provider as defined in section 147A.1, fire 
fighter, or peace officer.  "Care provider" also means an individual who renders 
emergency care or assistance in an  emergency or due to an accident as described in 
section 613.17. 
4.  "Communicable disease" means any disease spread from person to person or animal 
to person. 
5.  "Contagious or infectious disease" means hepatitis in any form, meningococcal 
disease, tuberculosis, and any other disease, with the exception of AIDS or HIV infection 
as defined in section 141A.1, determined to be life-threatening to a person exposed to 
the disease as established by rules adopted by the department, based upon a 
determination by the state epidemiologist and in accordance with guidelines of the 
centers for disease control and prevention of the United States department of health 
and human services. 
6.  "Department" means the Iowa department of public health. 
7.  "Designated officer" means a person who is designated by a department, agency, 
division, or service organization to act as an infection control liaison officer. 
8.  "Exposure" means the risk of contracting disease as determined by the centers for 
disease control and prevention of the United States department of health and human 
services and adopted by rule of the department. 
9.  "Exposure-prone procedure" means a procedure performed by a health care provider 
which presents a recognized risk of percutaneous injury to the health care provider and 
if such an injury occurs, the health care provider's blood is likely to contact a patient's 
body cavity, subcutaneous tissues, or mucous membranes, or an exposure-prone 
procedure as defined by the centers for disease control and prevention of the United 
States department of health and human services. 
10.  "HBV" means hepatitis B virus. 
11.  "Health care facility" means a health care facility as defined in section 135C.1, an 
ambulatory surgical center, or a clinic. 
12.  "Health care provider" means a person licensed to practice medicine and surgery, 
osteopathic medicine and surgery, chiropractic, podiatry, nursing, dentistry, optometry, 
or as a physician assistant, dental hygienist, or acupuncturist. 
13.  "HIV" means HIV as defined in section 141A.1. 
14.  "Hospital" means hospital as defined in section 135B.1. 
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15.  "Isolation" means the separation of persons or animals presumably or actually 
infected with a communicable disease or who are disease carriers for the usual period of 
communicability of that disease in such places, marked by placards if necessary, and 
under such conditions as will prevent the direct or indirect conveyance of the infectious 
agent or contagion to susceptible persons. 
16.  "Local board" means the local board of health. 
17.  "Local department" means the local health department. 
18.  "Placard" means a warning sign to be erected and displayed on the periphery of a 
quarantine area, forbidding entry to or exit from the area. 
19.  "Public health disaster" means public health disaster as defined in section 135.140. 
20.  "Quarantinable disease" means any communicable disease designated by rule 
adopted by the department as requiring quarantine or isolation to prevent its spread. 
21.  "Quarantine" means the limitation of freedom of movement of persons or animals 
that have been exposed to a quarantinable disease within specified limits marked by 
placards for a period of time equal to the longest usual incubation period of the disease 
in such manner as to prevent the spread of a quarantinable disease which affects 
people. 
22.  "Reportable disease" means any disease designated by rule adopted by the 
department requiring its occurrence to be reported to an appropriate authority. 
23.  "Sexually transmitted disease or infection" means a disease or infection as identified 
by rules adopted by the department, based upon a determination by the state 
epidemiologist and in accordance with guidelines of the centers for disease control and 
prevention of the United States department of health and human services. 
24.  "Terminal cleaning" means cleaning procedures defined in the isolation guidelines 
issued by the centers for disease control and prevention of the United States 
department of health and human services.   
 
139A.3  REPORTS TO DEPARTMENT -- IMMUNITY -- CONFIDENTIALITY -- 
INVESTIGATIONS. 
1.  The health care provider or public, private, or hospital clinical laboratory attending a 
person infected with a reportable disease shall immediately report the case to the 
department. However, when a case occurs within the jurisdiction of a local health 
department, the report shall be made to the local department and to the department.  A 
health care provider or public, private, or hospital clinical laboratory who files such a 
report which identifies a person infected with a reportable disease shall assist in the 
investigation by the department, a local board, or a local department.  The department 
shall publish and distribute instructions concerning the method of reporting.  Reports 
shall be made in accordance with rules adopted by the department and shall require 
inclusion of all the following information: 
         a.  The patient's name. 
         b.  The patient's address. 
         c.  The patient's date of birth. 
         d.  The sex of the patient. 
         e.  The race and ethnicity of the patient. 
         f.  The patient's marital status. 
         g.  The patient's telephone number. 
         h.  The name and address of the laboratory. 
         i.  The date the test was found to be positive and the collection date. 
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         j.  The name of the health care provider who performed the test. 
         k.  If the patient is female, whether the patient is pregnant. 
2. a.  Any person who, acting reasonably and in good faith, files a report, releases 
information, or otherwise cooperates with an investigation under this chapter is immune 
from any liability, civil or criminal, which might otherwise be incurred or imposed for 
such action. 
b.  A report or other information provided to or maintained by the department, a local 
board, or a local department, which identifies a person infected with or exposed to a 
reportable or other disease or health condition, is confidential and shall not be accessible 
to the public. 
c.  Notwithstanding paragraph "b", information contained in the report may be reported 
in public health records in a manner which prevents the identification of any person or 
business named in the report.  If information contained in the report concerns a 
business, information disclosing the identity of the business may be released to the 
public when the state epidemiologist or the director of public health determines such a 
release of information necessary for the protection of the health of the public. 
3.  A health care provider or public, private, or hospital clinical laboratory shall provide 
the department, local board, or local department with all information reasonably 
necessary to conduct an investigation pursuant to this chapter upon request of the 
department, local board, or local department.  The department may also subpoena 
records, reports, and any other evidence necessary to conduct an investigation pursuant 
to this chapter from other persons, facilities, and entities pursuant to rules adopted by 
the department. 
         
139A.3A  INVESTIGATION AND CONTROL. 
When the department receives a report under this chapter or acts on other reliable 
information that a person is infected with a disease, illness, or health condition that may 
be a potential cause of a public health disaster, the department shall identify all 
individuals reasonably believed to have been exposed to the disease, illness, or health 
condition and shall investigate all such cases for sources of infection and ensure that 
such cases are subject to proper control measures.  Any hospital, health care provider, 
or other person may provide information, interviews, reports, statements, memoranda, 
records, or other data related to the condition and treatment of any individual, if not 
otherwise prohibited by the federal Health Insurance Portability and Accountability Act of 
1996, Pub. L. No. 104-191, to the department to be used for the limited purpose of 
determining whether a public health disaster exists.   
         
139A.4  TYPE AND LENGTH OF ISOLATION OR QUARANTINE. 
1.  The type and length of isolation or quarantine imposed for a specific communicable 
disease shall be in accordance with rules adopted by the department. 
2.  The department and the local boards may impose and enforce isolation and 
quarantine restrictions. 
3.  The department shall adopt rules governing terminal cleaning. 
4.  The department and local boards may impose and enforce area quarantine 
restrictions according to rules adopted by the department. Area quarantine shall be 
imposed by the least restrictive means necessary to prevent or contain the spread of the 
suspected or confirmed quarantinable disease or suspected or known hazardous or toxic 
agent.   
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139A.5  ISOLATION OR QUARANTINE SIGNS ERECTED. 
When isolation or a quarantine is established, appropriate placards prescribed by the 
department shall be erected to mark the boundaries of the place of isolation or 
quarantine.   
 
139A.6  COMMUNICABLE DISEASES. 
         If a person, whether or not a resident, is infected with a communicable disease 
dangerous to the public health, the local board shall issue orders in regard to the care of 
the person as necessary to protect the public health.  The orders shall be executed by 
the designated officer as the local board directs or provides by rules. 
 
139A.7  DISEASED PERSONS MOVING -- RECORD FORWARDED. 
If a person known to be suffering from a communicable disease dangerous to the public 
health moves from the jurisdiction of a local board into the jurisdiction of another local 
board, the local board from whose jurisdiction the person moves shall notify the local 
board into whose jurisdiction the person is moving.   
 
139A.8  IMMUNIZATION OF CHILDREN. 
1.  A parent or legal guardian shall assure that the person's minor children residing in 
the state are adequately immunized against diphtheria, pertussis, tetanus, poliomyelitis, 
rubeola, rubella, and varicella, according to recommendations provided by the 
department subject to the provisions of subsections 3 and 4. 
2. a.  A person shall not be enrolled in any licensed child care center or elementary or 
secondary school in Iowa without evidence of adequate immunizations against 
diphtheria, pertussis, tetanus, poliomyelitis, rubeola, rubella, and varicella. 
b.  Evidence of adequate immunization against Haemophilus influenza B and invasive 
pneumococcal disease shall be required prior to enrollment in any licensed child care 
center. 
c.  Evidence of hepatitis type B immunization shall be required of a child born on or after 
July 1, 1994, prior to enrollment in school in kindergarten or in a grade. 
d.  Immunizations shall be provided according to recommendations provided by the 
department subject to the provisions of subsections 3 and 4. 
3.  Subject to the provision of subsection 4, the state board of health may modify or 
delete any of the immunizations in subsection 2. 
4. a.  Immunization is not required for a person's enrollment in any elementary or 
secondary school or licensed child care center if either of the following applies: 
  (1)  The applicant, or if the applicant is a minor, the applicant's parent or legal 
guardian, submits to the admitting official a statement signed by a physician, advanced 
registered nurse practitioner, or physician assistant who is licensed by the board of 
medicine, board of nursing, or board of physician assistants that the immunizations 
required would be injurious to the health and well-being of the applicant or any member 
of the applicant's family. 
  (2)  The applicant, or if the applicant is a minor, the applicant's parent or legal 
guardian, submits an affidavit signed by the applicant, or if the applicant is a minor, the 
applicant's parent or legal guardian, stating that the immunization conflicts with the 
tenets and practices of a recognized religious denomination of which the applicant is an 
adherent or member. 
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  b.  The exemptions under this subsection do not apply in times of emergency or 
epidemic as determined by the state board of health and as declared by the director of 
public health. 
5.  A person may be provisionally enrolled in an elementary or secondary school or 
licensed child care center if the person has begun the required immunizations and if the 
person continues to receive the necessary immunizations as rapidly as is medically 
feasible.  The department shall adopt rules relating to the provisional admission of 
persons to an elementary or secondary school or licensed child care center. 
6.  The local board shall furnish the department, within sixty days after the first official 
day of school, evidence that each person enrolled in any elementary or secondary school 
has been immunized as required in this section subject to subsection 4.  The department 
shall adopt rules pursuant to chapter 17A relating to the reporting of evidence of 
immunization. 
7.  Local boards shall provide the required immunizations to children in areas where no 
local provision of these services exists. 
8.  The department, in consultation with the director of the department of education, 
shall adopt rules for the implementation of this section and shall provide those rules to 
local school boards and local boards. 
 
139A.8A  VACCINE SHORTAGE -- DEPARTMENT ORDER -- IMMUNITY. 
1.  In the event of a shortage of a vaccine, or in the event a vaccine shortage is 
imminent, the department may issue an order controlling, restricting, or otherwise 
regulating the distribution and administration of the vaccine.  The order may designate 
groups of persons which shall receive priority in administration of the vaccine and may 
prohibit vaccination of persons who are not included in a priority designation.  The order 
shall include an effective date, which may be amended or rescinded only through a 
written order of the department.  The order shall be applicable to health care providers, 
hospitals, clinics, pharmacies, health care facilities, local boards of health, public health 
agencies, and other persons or entities that distribute or administer vaccines. 
2.  A health care provider, hospital, clinic, pharmacy, health care facility, local board of 
health, public health agency, or other person or entity that distributes or administers 
vaccines shall not be civilly liable in any action based on a failure or refusal to distribute 
or administer a vaccine to any person if the failure or refusal to distribute or administer 
the vaccine was consistent with a department order issued pursuant to this section. 
3.  The department shall adopt rules to administer this section. 
 
139A.9  FORCIBLE REMOVAL -- ISOLATION -- QUARANTINE. 
The forcible removal and isolation or quarantine of any infected person shall be 
accomplished according to the rules and regulations of the local board or the rules of 
the state board of health.   
  
139A.10  FEES FOR REMOVING. 
The officers designated shall receive reasonable compensation for their services as 
determined by the local board.  The amount determined shall be certified and paid in 
the same manner as other expenses incurred under this chapter.   
  
Revision date 2008                                                        Iowa Code Chapter 139A                                                                                   7 
139A.11  SERVICES AND SUPPLIES -- ISOLATION -- QUARANTINE. 
If the person under isolation or quarantine or the person liable for the support of the 
person, in the opinion of the local board, is financially unable to secure proper care, 
provisions, or medical attendance, the local board shall furnish supplies and services 
during the period of isolation or quarantine and may delegate the duty, by rules, to one 
of its designated officers. 
 
139A.12  COUNTY LIABILITY FOR CARE, PROVISIONS, AND MEDICAL 
ATTENDANCE. 
The local board shall provide proper care, provisions, and medical attendance for any 
person removed and isolated or quarantined in a separate house or hospital for 
detention and treatment, and the care, provisions, and medical attendance shall be paid 
for by the county in which the infected person has a legal settlement, if the patient or 
legal guardian is unable to pay. 
  
139A.13  RIGHTS OF ISOLATED OR QUARANTINED PERSONS. 
Any person removed and isolated or quarantined in a separate house or hospital may, at 
the person's own expense, employ the health care provider of the person's choice, and 
may provide such supplies and commodities as the person may require.   
 
139A.13A  EMPLOYMENT PROTECTION. 
1.  An employer shall not discharge an employee, or take or fail to take action regarding 
an employee's promotion or proposed promotion, or take action to reduce an 
employee's wages or benefits for actual time worked, due to the compliance of an 
employee with a quarantine or isolation order or voluntary confinement request issued 
by the department, a local board, or the centers for disease control and prevention of 
the United States department of health and human services. 
2.  An employee whose employer violates this section may petition the court for 
imposition of a cease and desist order against the person's employer and for 
reinstatement to the person's previous position of employment.  This section does not 
create a private cause of action for relief of money damages.   
 
139A.14  SERVICES OR SUPPLIES -- AUTHORIZATION. 
All services or supplies furnished to persons under this chapter must be authorized by 
the local board or an officer of the local board, and a written order designating the 
person employed to furnish such services or supplies, issued before the services or 
supplies are furnished, shall be attached to the bill when presented for audit and 
payment.   
 
139A.15  FILING OF BILLS. 
All bills incurred under this chapter in establishing, maintaining, and terminating isolation 
and quarantine, in providing a necessary house or hospital for isolation or quarantine, 
and in making terminal cleanings, shall be filed with the local board.  The local board at 
its next regular meeting or special meeting called for this purpose shall examine and 
audit the bills and, if found correct, approve and certify the bills to the county board of 
supervisors for payment.   
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139A.16  ALLOWING CLAIMS. 
All bills for supplies furnished and services rendered for persons removed and isolated or 
quarantined in a separate house or hospital, or for persons financially unable to provide 
their own sustenance and care during isolation or quarantine, shall be allowed and paid 
for only on a basis of the local market price for such provisions, services, and supplies in 
the locality furnished.  A bill for the terminal cleaning of premises or effects shall not be 
allowed, unless the infected person or those liable for the person's support are 
financially unable to pay.   
  
139A.17  APPROVAL AND PAYMENT OF CLAIMS. 
 The board of supervisors is not bound by the action of the local board in approving the 
bills, but shall pay the bills for a reasonable amount and within a reasonable time.   
  
139A.18  REIMBURSEMENT FROM COUNTY. 
If any person receives services or supplies under this chapter who does not have a legal 
settlement in the county in which the bills were incurred and paid, the amount paid shall 
be certified to the board of supervisors of the county in which the person claims 
settlement or owns property, and the board of supervisors of that county shall 
reimburse the county from which the claim is certified, in the full amount originally paid.   
 
139A.19  CARE PROVIDER NOTIFICATION. 
1. a.  Notwithstanding any provision of this chapter to the contrary, if a care provider 
sustains an exposure from an individual while rendering health care services or other 
services, the individual to whom the care provider was exposed is deemed to consent to 
a test to determine if the individual has a contagious or infectious disease and is 
deemed to consent to notification of the care provider of the results of the test, upon 
submission of an exposure report by the care provider to the hospital or other person 
specified in this section to whom the individual is delivered by the care provider.  The 
exposure report form may be incorporated into the Iowa prehospital care report, the 
Iowa prehospital advanced care report, or a similar report used by an ambulance, 
rescue, or first response service or law enforcement agency. 
b.  The hospital or other person specified in this section to whom the individual is 
delivered shall conduct the test.  If the individual is delivered by the care provider to an 
institution administered by the Iowa department of corrections, the test shall be 
conducted by the staff physician of the institution.  If the individual is delivered by the 
care provider to a jail, the test shall be conducted by the attending physician of the jail 
or the county medical examiner.  The sample and test results shall only be identified by 
a number and shall not otherwise identify the individual tested. 
c.  A hospital, institutions administered by the department of corrections, and jails shall 
have written policies and procedures for notification of a care provider under this 
section.  The policies and procedures shall include designation of a representative of the 
care provider to whom notification shall be provided and who shall, in turn, notify the 
care provider.  The identity of the designated representative of the care provider shall 
not be revealed to the individual tested.  The designated representative shall inform the 
hospital, institution administered by the department of corrections, or jail of those 
parties who received the notification, and following receipt of this information and upon 
request of the individual tested, the hospital, institution administered by the department 
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of corrections, or jail shall inform the individual of the parties to whom notification was 
provided. 
d.  Notwithstanding any other provision of law to the contrary, a care provider may 
transmit cautions regarding contagious or infectious disease information in the course of 
the care provider's duties over the police radio broadcasting system under chapter 693 
or any other radio-based communications system if the information transmitted does not 
personally identify an individual. 
2.  If the individual tested is diagnosed or confirmed as having a contagious or infectious 
disease, the hospital or other person conducting the test shall notify the care provider or 
the designated representative of the care provider who shall then notify the care 
provider. 
3.  The notification to the care provider shall advise the care provider of possible 
exposure to a particular contagious or infectious disease and recommend that the care 
provider seek medical attention.  The notification shall be provided as soon as is 
reasonably possible following determination that the individual has a contagious or 
infectious disease.  The notification shall not include 
      the name of the individual tested for the contagious or infectious 
      disease unless the individual consents.  If the care provider who 
      sustained an exposure determines the identity of the individual 
      diagnosed or confirmed as having a contagious or infectious disease, 
      the identity of the individual shall be confidential information and 
      shall not be disclosed by the care provider to any other person 
      unless a specific written release is obtained from the individual 
      diagnosed with or confirmed as having a contagious or infectious 
      disease. 
4.  This section does not require or permit, unless otherwise provided, a hospital, health 
care provider, or other person to administer a test for the express purpose of 
determining the presence of a contagious or infectious disease, except that testing may 
be performed if the individual consents and if the requirements of this section are 
satisfied. 
5.  This section does not preclude a hospital or a health care provider from providing 
notification to a care provider under circumstances in which the hospital's or health care 
provider's policy provides for notification of the hospital's or health care provider's own 
employees of exposure to a contagious or infectious disease that is not life-threatening if 
the notice does not reveal a patient's name, unless the patient consents. 
6.  A hospital, health care provider, or other person participating in good faith in 
complying with provisions authorized or required under this section is immune from any 
liability, civil or criminal, which might otherwise be incurred or imposed. 
7.  A hospital's or health care provider's duty of notification under this section is not 
continuing but is limited to a diagnosis of a contagious or infectious disease made in the 
course of admission, care, and treatment following the rendering of health care services 
or other services to which notification under this section applies. 
8.  A hospital, health care provider, or other person who is authorized to perform a test 
under this section who performs the test in compliance with this section or who fails to 
perform the test authorized under this section, is immune from any liability, civil or 
criminal, which might otherwise be incurred or imposed. 
9.  A hospital, health care provider, or other person who is authorized to perform a test 
under this section has no duty to perform the test authorized. 
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10.  The department shall adopt rules pursuant to chapter 17A to administer this 
section.  The department may determine by rule the contagious or infectious diseases 
for which testing is reasonable and appropriate and which may be administered under 
this section. 
11.  The employer of a care provider who sustained an exposure under this section shall 
pay the costs of testing for the individual who is the source of the exposure and of the 
testing of the care provider, if the exposure was sustained during the course of 
employment.  However, the department shall pay the costs of testing for the individual 
who is the source of the significant exposure and of the testing of the care provider who 
renders direct aid without compensation.   
  
139A.20  EXPOSING TO COMMUNICABLE DISEASE. 
A person who knowingly exposes another to a communicable disease or who knowingly 
subjects another to a child or other legally incapacitated person who has contracted a 
communicable disease, with the intent that another person contract the communicable 
disease, shall be liable for all resulting damages and shall be punished as provided in 
this chapter. 
 
139A.21  REPORTABLE POISONINGS AND ILLNESSES -- EMERGENCY 
INFORMATION SYSTEM. 
1.  If the results of an examination by a public, private, or hospital clinical laboratory of 
a specimen from a person in Iowa yield evidence of or are reactive for a reportable 
poisoning or a reportable illness from a toxic agent, including methemoglobinemia, the 
results shall be reported to the department on forms prescribed by the department.  If 
the laboratory is located in Iowa, the person in charge of the laboratory shall report the 
results.  If the laboratory is not in Iowa, the health care provider submitting the 
specimen shall report the results. 
2.  The health care provider attending a person infected with a reportable poisoning or a 
reportable illness from a toxic agent, including methemoglobinemia, shall immediately 
report the case to the department.  The department shall publish and distribute 
instructions concerning the method of reporting.  Reports shall be made in accordance 
with rules adopted by the department. 
3.  A person in charge of a poison control information center shall report to the 
department cases of reportable poisoning, received. 
4.  The department shall adopt rules designating reportable poisonings, including 
methemoglobinemia, and illnesses which must be reported under this section. 
5.  The department shall establish and maintain a central registry to collect and store 
data reported pursuant to this section. 
6.  The department shall timely provide copies of all reports of pesticide poisonings or 
illnesses received pursuant to this section to the secretary of agriculture who shall timely 
forward these reports and any reports of pesticide poisonings or illnesses received 
pursuant to section 206.14 to the registrant of a pesticide which is the subject of any 
reports. 
7.  The department shall adopt rules specifying the requirements for the operation of an 
emergency information system operated by a registrant pursuant to section 206.12, 
subsection 3, paragraph "c", which shall not exceed requirements adopted by a poison 
control center as defined in section 206.2.  The rules shall specify the qualifications of 
individuals staffing an emergency information system and shall specify the maximum 
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amount of time that a registrant may take to provide the information to a poison control 
center or an attending physician treating a patient exposed to the registrant's product.   
  
139A.22  PREVENTION OF TRANSMISSION OF HIV OR HBV TO PATIENTS. 
1.  A hospital shall adopt procedures requiring the establishment of protocols applicable 
on a case-by-case basis to a health care provider determined to be infected with HIV or 
HBV who ordinarily performs exposure-prone procedures as determined by an expert 
review panel, within the hospital setting.  The protocols established shall be in 
accordance with the recommendations issued by the centers for disease control and 
prevention of the United States department of health and human services.  The expert 
review panel may be an established committee of the hospital.  The procedures may 
provide for referral of the health care provider to the expert review panel established by 
the department pursuant to subsection 3 for establishment of the protocols.  The 
procedures shall require reporting noncompliance with the protocols by a health care 
provider to the licensing board with jurisdiction over the relevant health care providers. 
2.  A health care facility shall adopt procedures in accordance with recommendations 
issued by the centers for disease control and prevention of the United States 
department of health and human services, applicable to a health care provider 
determined to be infected with HIV or HBV who ordinarily performs or assists with 
exposure-prone procedures within the health care facility.  The procedures shall require 
referral of the health care provider to the expert review panel established by the 
department pursuant to subsection 3. 
3.  The department shall establish an expert review panel to determine on a case-by-
case basis under what circumstances, if any, a health care provider determined to be 
infected with HIV or HBV practicing outside the hospital setting or referred to the panel 
by a hospital or health care facility may perform exposure-prone procedures.  If a health 
care provider determined to be infected with HIV or HBV does not comply with the 
determination of the expert review panel, the panel shall report the noncompliance to 
the licensing board with jurisdiction over the health care provider.  A determination of 
an expert review panel pursuant to this section is a final agency action appealable 
pursuant to section 17A.19. 
4.  The health care provider determined to be infected with HIV or HBV, who works in a 
hospital setting, may elect either the expert review panel established by the hospital or 
the expert review panel established by the department for the purpose of making a 
determination of the circumstances under which the health care provider may perform 
exposure-prone procedures. 
5.  A health care provider determined to be infected with HIV or HBV shall not perform 
an exposure-prone procedure except as approved by the expert review panel 
established by the department pursuant to subsection 3, or in compliance with the 
protocol established by the hospital pursuant to subsection 1 or the procedures 
established by the health care facility pursuant to subsection 2. 
6.  The board of medicine, the board of physician assistants, the board of podiatry, the 
board of nursing, the dental board, and the board of optometry shall require that 
licensees comply with the recommendations issued by the centers for disease control 
and prevention of the United States department of health and human services for 
preventing transmission of human immunodeficiency virus and hepatitis B virus to 
patients during exposure-prone invasive procedures, with the recommendations of the 
expert review panel established pursuant to subsection 3, with hospital protocols 
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established pursuant to subsection 1, and with health care facility procedures 
established pursuant to subsection 2, as applicable. 
7.  Information relating to the HIV status of a health care provider is confidential and 
subject to the provisions of section 141A.9.  A person who intentionally or recklessly 
makes an unauthorized disclosure of such information is subject to a civil penalty of one 
thousand dollars.  The attorney general or the attorney general's designee may maintain 
a civil action to enforce this section.  Proceedings maintained under this section shall 
provide for the anonymity of the health care provider and all documentation shall be 
maintained in a confidential manner.  Information relating to the HBV status of a health 
care provider is confidential and shall not be accessible to the public.  Information 
regulated by this section, however, may be disclosed to members of the expert review 
panel established by the department or a panel established by hospital protocol under 
this section.  The information may also be disclosed to the appropriate licensing board 
by filing a report as required by this section.  The licensing board shall consider the 
report a complaint subject to the confidentiality provisions of section 272C.6.  A licensee, 
upon the filing of a formal charge or notice of hearing by the licensing board based on 
such a complaint, may seek a protective order from the board. 
8.  The expert review panel established by the department and individual members of 
the panel shall be immune from any liability, civil or criminal, for reasonable actions 
taken in the good faith performance of functions authorized or required by this section.  
A hospital, an expert review panel established by the hospital, and individual members 
of the panel shall be immune from any liability, civil or criminal, for reasonable actions 
taken in the good faith performance of functions authorized or required by this 
section.Complaints, investigations, reports, deliberations, and findings of the hospital 
and its panel with respect to a named health care provider suspected, alleged, or found 
to be in violation of the protocol required by this section constitute peer review records 
under section 147.135, and are subject to the specific confidentiality requirements and 
limitations of that section.   
 
139A.23  CONTINGENT REPEAL. 
If the provisions of Pub. L. No. 102-141 relating to requirements for prevention of 
transmission of HIV or HBV to patients in the performance of exposure-prone 
procedures are repealed, section 139A.22 is repealed.   
 
139A.24  BLOOD DONATION OR SALE -- PENALTY. 
A person suffering from a communicable disease dangerous to the public health who 
knowingly gives false information regarding the person's infected state on a blood 
plasma sale application to blood plasma-taking personnel commits a serious 
misdemeanor.   
 
139A.25  PENALTIES. 
1.  Unless otherwise provided in this chapter, a person who knowingly violates any 
provision of this chapter, or of the rules of the department or a local board, or any 
lawful order, written or oral, of the department or board, or of their officers or 
authorized agents, is guilty of a simple misdemeanor. 
2.  Notwithstanding subsection 1, an individual who repeatedly fails to file any 
mandatory report specified in this chapter is subject to a report being made to the 
licensing board governing the professional activities of the individual.  The department 
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shall notify the individual each time that the department determines that the individual 
has failed to file a required report.  The department shall inform the individual in the 
notification that the individual may provide information to the department to explain or 
dispute the failure to report. 
3.  Notwithstanding subsection 1, a public, private, or hospital clinical laboratory that 
repeatedly fails to file a mandatory report specified in this chapter is subject to a civil 
penalty of not more than one thousand dollars per occurrence.  The department shall 
not impose the penalty under this subsection without prior written notice and 
opportunity for hearing.   
 
139A.26  MENINGOCOCCAL DISEASE VACCINATION INFORMATION FOR 
POSTSECONDARY STUDENTS. 
1.  Each institution of higher education that has an on-campus residence hall or 
dormitory shall provide vaccination information on meningococcal disease to each 
student enrolled in the institution. The vaccination information shall be contained on 
student health forms provided to each student by the institution, which forms shall 
include space for the student to indicate whether or not the student has received the 
vaccination against meningococcal disease.  The vaccination information about 
meningococcal disease shall include any recommendations issued by the national 
centers for disease control and prevention regarding the disease.  Vaccination 
information obtained under this section that is in the possession of an institution of 
higher education pursuant to this section shall not be considered a public record.  Data 
obtained under this section shall be submitted annually to the department in a manner 
prescribed by the department and such that no individual person can be identified. 
2.  This section shall not be construed to require any institution of higher education to 
provide the vaccination against meningococcal disease to students. 
3.  This section shall not apply if the national centers for disease control and prevention 
no longer recommend the meningococcal disease vaccine. 
4.  This section does not create a private right of action. 
5.  The department shall adopt rules for administration of this section.  The department 
shall review the requirements of this section at least every five years, and shall submit 
its recommendations for modification to, or continuation of, this section based upon new 
information about the disease or vaccination against the disease in a report that shall be 
submitted to the general assembly no later than January 15, 2010, with subsequent 
reports developed and submitted by January 15 at least every fifth year thereafter.   
  
139A.27 THROUGH 139A.29  Reserved. 
         
139A.30  CONFIDENTIAL REPORTS. 
Reports to the department which include the identity of persons infected with a sexually 
transmitted disease or infection, and all such related information, records, and reports 
concerning the person, shall be confidential and shall not be accessible to the public. 
However, such reports, information, and records shall be confidential only to the extent 
necessary to prevent identification of persons named in such reports, information, and 
records; the other parts of such reports, information, and records shall be public 
records.  The preceding sentence shall prevail over any inconsistent provision of this 
subchapter.   
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139A.31  REPORT TO DEPARTMENT. 
Immediately after the first examination or treatment of any person infected with any 
sexually transmitted disease or infection, the health care provider who performed the 
examination or treatment shall transmit to the department a report stating the name of 
the infected person, the address of the infected person, the infected person's date of 
birth, the sex of the infected person, the race and ethnicity of the infected person, the 
infected person's marital status, the infected person's telephone number, if the infected 
person is female, whether the infected person is pregnant, the name and address of the 
laboratory that performed the test, the date the test was found to be positive and the 
collection date, and the name of the health care provider who performed the test.  
However, when a case occurs within the jurisdiction of a local health department, the 
report shall be made directly to the local health department which shall immediately 
forward the information to the department.  Reports shall be made in accordance with 
rules adopted by the department.  Reports shall be confidential.  Any person filing a 
report of a sexually transmitted disease or infection who is acting reasonably and in 
good faith is immune from any liability, civil or criminal, which might otherwise be 
incurred or imposed as a result of such report.   
 
139A.32  EXAMINATION RESULTS FROM LABORATORY -- REPORT. 
A person in charge of a public, private, or hospital clinical laboratory shall report to the 
department, on forms prescribed by the department, results obtained in the examination 
of all specimens which yield evidence of or are reactive for those diseases defined as 
sexually transmitted diseases or infections, and listed in the Iowa administrative code.  
The report shall state the name of the infected person from whom the specimen was 
obtained, the address of the infected person, the infected person's date of birth, the sex 
of the infected person, the race and ethnicity of the infected person, the infected 
person's marital status, the infected person's telephone number, if the infected person is 
female, whether the infected person is pregnant, the name and address of the 
laboratory that performed the test, the laboratory results, the test employed, the date 
the test was found to be positive and the collection date, the name of the health care 
provider who performed the test, and the name and address of the person submitting 
the specimen.   
 
139A.33  DETERMINATION OF SOURCE. 
The local board or the department shall use every available means to determine the 
source and spread of any infectious case of sexually transmitted disease or infection 
which is reported.   
 
139A.34  EXAMINATION OF PERSONS SUSPECTED. 
The local board shall cause an examination to be made of every person reasonably 
suspected, on the basis of epidemiological investigation, of having any sexually 
transmitted disease or infection in the infectious stages to ascertain if such person is 
infected and, if infected, to cause such person to be treated.  A person who is under the 
care and treatment of a health care provider for the suspected condition shall not be 
subjected to such examination.  If a person suspected of having a sexually transmitted 
disease or infection refuses to submit to an examination voluntarily, application may be 
made by the local board to the district court for an order compelling the person to 
submit to examination and, if infected, to treatment.  The person shall be treated until 
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certified as no longer infectious to the local board or to the department.  If treatment is 
ordered by the district court, the attending health care provider shall certify that the 
person is no longer infectious.   
 
139A.35  MINORS. 
A minor shall have the legal capacity to act and give consent to provision of medical 
care or services to the minor for the prevention, diagnosis, or treatment of a sexually 
transmitted disease or infection by a hospital, clinic, or health care provider.  Such 
medical care or services shall be provided by or under the supervision of a physician 
licensed to practice medicine and surgery or osteopathic medicine and surgery, a 
physician assistant, or an advanced registered nurse practitioner.  Consent shall not be 
subject to later disaffirmance by reason of such minority.  The consent of another 
person, including but not limited to the consent of a spouse, parent, custodian, or 
guardian, shall not be necessary.   
 
139A.36  CERTIFICATE NOT TO BE ISSUED. 
A certificate of freedom from sexually transmitted disease or infection shall not be issued 
to any person by any official health agency.   
 
139A.37  PREGNANT WOMEN. 
The department shall adopt rules which incorporate the prenatal guidelines established 
by the centers for disease control and prevention of the United States department of 
health and human services as the state guidelines for prenatal testing and care relative 
to infectious disease.   
 
139A.38  MEDICAL TREATMENT OF NEWLY BORN. 
A physician attending the birth of a child shall cause to be instilled into the eyes of the 
newly born infant a prophylactic solution approved by the department.  This section 
shall not be construed to require treatment of the infant's eyes with a prophylactic 
solution if the infant's parent or legal guardian states that such treatment conflicts with 
the tenets and practices of a recognized religious denomination of which the parent or 
legal guardian is an adherent or member.   
  
139A.39  RELIGIOUS EXCEPTIONS. 
A provision of this chapter shall not be construed to require or compel any person to 
take or follow a course of medical treatment prescribed by law or a health care provider 
if the person is an adherent or member of a church or religious denomination and in 
accordance with the tenets or principles of the person's church or religious denomination 
the person opposes the specific course of medical treatment.  However, such person 
while in an infectious stage of disease shall be subject to isolation and such other 
measures appropriate for the prevention of the spread of the disease to other persons.   
 
139A.40  FILING FALSE REPORTS.  
A person who knowingly makes a false statement in any of the reports required by this 
subchapter concerning persons infected with any sexually transmitted disease or 
infection, or who discloses the identity of such person, except as authorized by this 
subchapter, shall be punished as provided in section 139A.25.   
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139A.41  CHLAMYDIA AND GONORRHEA TREATMENT. 
Notwithstanding any other provision of law to the contrary, a physician, physician 
assistant, or advanced registered nurse practitioner who diagnoses a sexually 
transmitted chlamydia or gonorrhea infection in an individual patient may prescribe, 
dispense, furnish, or otherwise provide prescription oral antibiotic drugs to that patient's 
sexual partner or partners without examination of that patient's partner or partners.  If 
the infected individual patient is unwilling or unable to deliver such prescription drugs to 
a sexual partner or partners, a physician, physician assistant, or advanced registered 
nurse practitioner may dispense, furnish, or otherwise provide the prescription drugs to 
the department or local disease prevention investigation staff for delivery to the partner 
or partners.   
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141A.1  DEFINITIONS. 
As used in this chapter, unless the context otherwise requires: 
1. "AIDS" means acquired immune deficiency syndrome as defined by the centers for
disease control and prevention of the United States department of health and human 
services. 
2. "AIDS-related conditions" means any condition resulting from the human
immunodeficiency virus infection that meets the definition of AIDS as established by the 
centers for disease control and prevention of the United States department of health 
and human services. 
3. "Blinded epidemiological studies" means studies in which specimens which were
collected for other purposes are selected according to established criteria, are 
permanently stripped of personal identifiers, and are then tested. 
4. "Blood bank" means a facility for the collection, processing, or storage of human
blood or blood derivatives, including blood plasma, or from which or by means of which 
human blood or blood derivatives are distributed or otherwise made available. 
5. "Care provider" means an individual who is trained and authorized by federal or state
law to provide health care services or services of any kind in the course of the 
individual's official duties, for compensation or in a voluntary capacity, who is a health 
care provider, emergency medical care provider as defined in section 147A.1, fire 
fighter, or peace officer.  "Care provider" also means an individual who renders 
emergency care or assistance in an emergency or due to an accident as described in 
section 613.17. 
6. "Department" means the Iowa department of public health.
7. "Good faith" means objectively reasonable and not in violation of clearly established
statutory rights or other rights of a person which a reasonable person would know or 
should have known. 
8. "Health care provider" means a person licensed to practice medicine and surgery,
osteopathic medicine and surgery, chiropractic, podiatry, nursing, dentistry, or 
optometry, or as a physician assistant, dental hygienist, or acupuncturist. 
9. "Health facility" means a hospital, health care facility, clinic, blood bank, blood
center, sperm bank, laboratory organ transplant center and procurement agency, or 
other health care institution. 
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10.  "HIV" means the human immunodeficiency virus identified as the causative agent of 
AIDS. 
11.  "HIV-related condition" means any condition resulting from the human 
immunodeficiency virus infection. 
12.  "HIV-related test" means a diagnostic test conducted by a laboratory approved 
pursuant to the federal Clinical Laboratory Improvement Amendments for determining 
the presence of HIV or antibodies to HIV. 
13.  "Infectious bodily fluids" means bodily fluids capable of transmitting HIV infection 
as determined by the centers for disease control and prevention of the United States 
department of health and human services and adopted by rule of the department. 
14.  "Legal guardian" means a person appointed by a court pursuant to chapter 633 or 
an attorney in fact as defined in section 144B.1.  In the case of a minor, "legal guardian" 
also means a parent or other person responsible for the care of the minor. 
15.  "Nonblinded epidemiological studies" means studies in which specimens are 
collected for the express purpose of testing for the HIV infection and persons included in 
the nonblinded study are selected according to established criteria. 
16.  "Release of test results" means a written authorization for disclosure of HIV-related 
test results which is signed and dated, and which specifies to whom disclosure is 
authorized and the time period during which the release is to be effective. 
17.  "Sample" means a human specimen obtained for the purpose of conducting an HIV-
related test. 
18.  "Significant exposure" means the risk of contracting HIV infection by means of 
exposure to a person's infectious bodily fluids in a manner capable of transmitting HIV 
infection as determined by the centers for disease control and prevention of the United 
States department of health and human services and adopted by rule of the 
department.   
 
141A.2  LEAD AGENCY. 
1.  The department is designated as the lead agency in the coordination and 
implementation of the Iowa comprehensive HIV plan. 
2.  The department shall adopt rules pursuant to chapter 17A to implement and enforce 
this chapter.  The rules may include procedures for taking appropriate action with regard 
to health facilities or health care providers which violate this chapter or the rules 
adopted pursuant to this chapter. 
3.  The department shall adopt rules pursuant to chapter 17A which require that if a 
health care provider attending a person prior to the person's death determines that the 
person suffered from or was suspected of suffering from a contagious or infectious 
disease, the health care provider shall place with the remains written notification of the 
condition for the information of any person handling the body of the deceased person 
subsequent to the person's death.  For purposes of this subsection, "contagious or 
infectious disease" means hepatitis in any form, meningococcal disease, tuberculosis, 
and any other disease including AIDS or HIV infection, determined to be life-threatening 
to a person exposed to the disease as established by rules adopted by the department 
based upon a determination by the state epidemiologist and in accordance with 
guidelines of the centers for disease control and prevention of the United States 
department of health and human services. 
4.  The department shall provide consultation services to all care providers, including 
paramedics, ambulance personnel, physicians, nurses, hospital personnel, first 
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responders, peace officers, and  fire fighters, who provide care services to a person, and 
to all persons who attend dead bodies regarding standard precautions to prevent the 
transmission of contagious and infectious diseases. 
5.  The department shall coordinate efforts with local health officers to investigate 
sources of HIV infection and use every appropriate means to prevent the spread of the 
infection. 
6.  The department, with the approval of the state board of health, may conduct 
epidemiological blinded and nonblinded studies to determine the incidence and 
prevalence of HIV infection.  Initiation of any new epidemiological studies shall be 
contingent upon the receipt of funding sufficient to cover all the costs associated with 
the studies.  The informed consent, reporting, and counseling requirements of this 
chapter shall not apply to blinded studies.   
 
141A.3  DUTIES OF THE DEPARTMENT. 
1.  All federal and state moneys appropriated to the department for HIV-related 
activities shall be utilized and distributed in a manner consistent with the guidelines 
established by the United States department of health and human services. 
2.  The department shall do all of the following: 
a.  Provide consultation services to agencies and organizations regarding appropriate 
policies for testing, education, confidentiality, and infection control. 
b.  Provide health information to the public regarding HIV infection, including 
information about how the infection is transmitted and how transmittal can be 
prevented.  The department shall prepare and distribute information regarding HIV 
infection and prevention. 
c.  Provide consultation services concerning HIV infection in the workplace. 
d.  Implement HIV education risk-reduction programs for specific populations at high 
risk for infection. 
e.  Provide an informational brochure for patients who provide samples for purposes of 
performing an HIV test which, at a minimum, shall include a summary of the patient's 
rights and responsibilities under the law. 
f.  In cooperation with the department of education, recommend evidence-based, 
medically accurate HIV prevention curricula for use at the discretion of secondary and 
middle schools.   
 
141A.4  TESTING AND EDUCATION. 
1.  HIV testing and education shall be offered to persons who are at risk for HIV 
infection including all of the following: 
a.  All persons testing positive for a sexually transmitted disease. 
b.  All persons having a history of injecting drug abuse. 
c.  Male and female sex workers and those who trade sex for drugs, money, or favors. 
d.  Sexual partners of HIV-infected persons. 
e.  Persons whose sexual partners are identified in paragraphs "a" through "d". 
2. a.  All pregnant women shall be tested for HIV infection as part of the routine panel 
of prenatal tests. 
b.  A pregnant woman shall be notified that HIV screening is recommended for all 
prenatal patients and that the pregnant woman will receive an HIV test as part of the 
routine panel of prenatal tests unless the pregnant woman objects to the test. 
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c.  If a pregnant woman objects to and declines the test, the decision shall be 
documented in the pregnant woman's medical record. 
d.  Information about HIV prevention, risk reduction, and treatment opportunities to 
reduce the possible transmission of HIV to a fetus shall be made available to all 
pregnant women.   
 
141A.5  PARTNER NOTIFICATION PROGRAM -- HIV. 
1.  The department shall maintain a partner notification program for persons known to 
have tested positive for HIV infection. 
2.  In administering the program, the department shall provide for the following: 
a.  A person who tests positive for HIV infection shall receive post-test counseling, 
during which time the person shall be encouraged to refer for counseling and HIV 
testing any person with whom the person has had sexual relations or has shared drug 
injecting equipment. 
b.  The physician or other health care provider attending the person may provide to the 
department any relevant information provided by the person regarding any person with 
whom the tested person has had sexual relations or has shared drug injecting 
equipment. 
c. (1)  Devise a procedure, as a part of the partner notification program, to provide for 
the notification of an identifiable third party who is a sexual partner of or who shares 
drug injecting equipment with a person who has tested positive for HIV, by the 
department or a physician, when all of the following situations exist: 
(a)  A physician for the infected person is of the good faith opinion that the nature of 
the continuing contact poses an imminent danger of HIV infection transmission to the 
third party. 
(b)  When the physician believes in good faith that the infected person, despite strong 
encouragement, has not and will not warn the third party and will not participate in the 
voluntary partner notification program. 
(2)  Notwithstanding subsection 3, the department or a physician may reveal the identity 
of a person who has tested positive for HIV infection pursuant to this subsection only to 
the extent necessary to protect a third party from the direct threat of transmission.  This 
subsection shall not be interpreted to create a duty to warn third parties of the danger 
of exposure to HIV through contact with a person who tests positive for HIV infection. 
(3)  The department shall adopt rules pursuant to chapter 17A to implement this 
paragraph "c".  The rules shall provide a detailed procedure by which the department or 
a physician may directly notify an endangered third party. 
3.  In making contact the department shall not disclose the identity of the person who 
provided the names of the persons to be contacted and shall protect the confidentiality 
of persons contacted. 
4.  The department may delegate its partner notification duties under this section to 
local health authorities unless the local authority refuses or neglects to conduct the 
partner notification program in a manner deemed to be effective by the department. 
5.  In addition to the provisions for partner notification provided under this section and 
notwithstanding any provision to the contrary, a county medical examiner or deputy 
medical examiner performing official duties pursuant to sections 331.801 through 
331.805 or the state medical examiner or deputy medical examiner performing official 
duties pursuant to chapter 691, who determines through an investigation that a 
deceased person was infected with HIV, may notify directly, or request that the 
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department notify, the immediate family of the deceased or any person known to have 
had a significant exposure from the deceased of the finding.   
 
141A.6  HIV-RELATED CONDITIONS -- CONSENT, TESTING, AND REPORTING 
-- PENALTY. 
1.  Prior to undergoing an HIV-related test, information shall be available to the subject 
of the test concerning testing and any means of obtaining additional information 
regarding HIV infection and risk reduction.  If an individual signs a general consent form 
for the performance of medical tests or procedures, the signing of an additional consent 
form for the specific purpose of consenting to an HIV-related test is not required during 
the time in which the general consent form is in effect.  If an individual has not signed a 
general consent form for the performance of medical tests and procedures or the 
consent form is no longer in effect, a health care provider shall obtain oral or written 
consent prior to performing an HIV-related test.  If an individual is unable to provide 
consent, the individual's legal guardian may provide consent.  If the individual's legal 
guardian cannot be located or is unavailable, a health care provider may authorize the 
test when the test results are necessary for diagnostic purposes to provide appropriate 
urgent medical care. 
2.  Within seven days of the receipt of a test result indicating HIV infection which has 
been confirmed as positive according to prevailing medical technology or immediately 
after the initial examination or treatment of an individual infected with HIV, the 
physician or other health care provider at whose request the test was performed or who 
performed the initial examination or treatment shall make a report to the department on 
a form provided by the department. 
3.  Within seven days of diagnosing a person as having AIDS or an AIDS-related 
condition, the diagnosing physician shall make a report to the department on a form 
provided by the department. 
4.  Within seven days of the death of a person with HIV infection, the attending 
physician shall make a report to the department on a form provided by the department. 
5.  Within seven days of the receipt of a test result indicating HIV infection which has 
been confirmed as positive according to prevailing medical technology, the director of a 
blood bank shall make a report to the department on a form provided by the 
department. 
6.  Within seven days of the receipt of a test result that is indicative of HIV, the director 
of a clinical laboratory shall make a report to the department on a form provided by the 
department. 
7.  The forms provided by the department shall require inclusion of all of the following 
information: 
         a.  The name of the patient. 
         b.  The address of the patient. 
         c.  The patient's date of birth. 
         d.  The gender of the patient. 
         e.  The race and ethnicity of the patient. 
         f.  The patient's marital status. 
         g.  The patient's telephone number. 
         h.  If an HIV-related test was performed, the name and address of the laboratory 
or blood bank. 
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         i.  If an HIV-related test was performed, the date the test was found to be 
positive and the collection date. 
         j.  If an HIV-related test was performed, the name of the physician or health care 
provider who performed the test. 
         k.  If the patient is female, whether the patient is pregnant. 
8.  An individual who repeatedly fails to file the report required under this section is 
subject to a report being made to the licensing board governing the professional 
activities of the individual.  The department shall notify the individual each time the 
department determines that the individual has failed to file a required report. The 
department shall inform the individual in the notification that the individual may provide 
information to the department to explain or dispute the failure to report. 
9.  A public, private, or hospital clinical laboratory that repeatedly fails to make the 
report required under this section is subject to a civil penalty of not more than one 
thousand dollars per occurrence.  The department shall not impose the penalty under 
this subsection without prior written notice and opportunity for hearing. 
 
141A.7  TEST RESULTS -- COUNSELING -- APPLICATION FOR SERVICES. 
1.  At any time that the subject of an HIV-related test is informed of confirmed positive 
test results, counseling concerning the emotional and physical health effects shall be 
initiated. Particular attention shall be given to explaining the need for the precautions 
necessary to avoid transmitting the virus.  The subject shall be given information 
concerning additional counseling.  If the legal guardian of the subject of the test 
provides consent to the test pursuant to section 141A.6, the provisions of this 
subsection shall apply to the legal guardian. 
2.  Notwithstanding subsection 1, the provisions of this section do not apply to any of 
the following: 
a.  The performance by a health care provider or health facility of an HIV-related test 
when the health care provider or health facility procures, processes, distributes, or uses 
a human body part donated for a purpose specified under the revised uniform 
anatomical gift Act as provided in chapter 142C, or semen provided prior to July 1, 
1988, for the purpose of artificial insemination, or donations of blood, and such test is 
necessary to ensure medical acceptability of such gift or semen for the purposes 
intended. 
b.  A person engaged in the business of insurance who is subject to section 505.16. 
c.  The performance by a health care provider or health facility of an HIV-related test 
when the subject of the test is deceased and a documented significant exposure has 
occurred. 
d.  The performance by a health care provider or health facility of an HIV-related test 
when the subject of the test is unable to provide consent and the health care provider or 
health care facility provides consent for the patient pursuant to section 141A.6. 
3.  A person may apply for voluntary treatment, contraceptive services, or screening or 
treatment for HIV infection and other sexually transmitted diseases directly to a licensed 
physician and surgeon, an osteopathic physician and surgeon, or a family planning clinic.  
Notwithstanding any other provision of law, however, a minor shall be informed prior to 
testing that, upon confirmation according to prevailing medical technology of a positive 
HIV-related test result, the minor's legal guardian is required to be informed by the 
testing facility.  Testing facilities where minors are tested shall have available a program 
to assist minors and legal guardians with the notification process which emphasizes the 
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need for family support and assists in making available the resources necessary to 
accomplish that goal.  However, a testing facility which is precluded by federal statute, 
regulation, or centers for disease control and prevention guidelines from informing the 
legal guardian is exempt from the notification requirement.  The minor shall give written 
consent to these procedures and to receive the services, screening, or treatment.  Such 
consent is not subject to later disaffirmance by reason of minority.   
 
141A.8  CARE PROVIDER NOTIFICATION. 
1. a.  Notwithstanding any provision of this chapter to the contrary, if a care provider 
sustains a significant exposure from an individual, the individual to whom the care 
provider was exposed is deemed to consent to a test to determine the presence of HIV 
infection in that individual and is deemed to consent to notification of the care provider 
of the HIV test results of the individual, upon submission of a significant exposure report 
by the care provider as provided by rule. 
b.  The hospital or clinic in which the exposure occurred or any other person specified in 
this section to whom the individual is delivered shall conduct the test.  If the individual is 
delivered by the care provider to an institution administered by the Iowa department of 
corrections, the test shall be conducted by the staff physician of the institution.  If the 
individual is delivered by the care provider to a jail, the test shall be conducted by the 
attending physician of the jail or the county medical examiner.  The sample and test 
results shall only be identified by a number. 
c.  A hospital, institutions administered by the department of corrections, and jails shall 
have written policies and procedures for notification of a care provider under this 
section.  The policies and procedures shall include designation of a representative of the 
care provider to whom notification shall be provided and who shall, in turn, notify the 
care provider.  The identity of the designated representative of the care provider shall 
not be revealed to the individual tested.  The designated representative shall inform the 
hospital, institution administered by the department of corrections, or jail of those 
parties who received the notification, and following receipt of this information and upon 
request of the individual tested, the hospital, institution administered by the department 
of corrections, or jail shall inform the individual of the parties to whom notification was 
provided. 
2. a.  If the test results are positive, the hospital or other person performing the test 
shall notify the subject of the test and ensure the performance of counseling and 
reporting requirements of this chapter in the same manner as for an individual from 
whom actual consent was obtained.  The report to the department required pursuant to 
section 141A.6 shall include the name of the individual tested. 
b.  If the HIV test results of the subject of the test are positive, the hospital or other 
person performing the test shall notify the care provider or the designated 
representative of the care provider who shall then notify the care provider who 
sustained the exposure. 
c.  The notification shall be provided as soon as is reasonably possible following 
determination that the HIV test results of the subject of the test are positive.  The 
notification shall not include the name of the individual tested for HIV infection unless 
the individual provides a specific written release.  If the care provider who sustained the 
significant exposure determines the identity of the individual tested, the identity of the 
individual shall be confidential information and shall not be disclosed by the care 
Iowa Department of Public Health 2008                                             Chapter 141A Acquired Immune Deficiency Syndrome (AIDS) 8 
provider to any other person unless a specific written release is obtained from the 
individual tested. 
3.  This section does not preclude a hospital or health care provider from providing 
notification to a care provider under circumstances in which the hospital's or health care 
provider's policy provides for notification of the hospital's or health care provider's own 
employees of exposure to HIV infection if the notice does not reveal a patient's name, 
unless the patient consents. 
4.  A hospital, health care provider, or other person participating in good faith in making 
a report under the notification provisions of this section, under procedures similar to this 
section for notification of its own employees upon filing of a significant exposure report, 
or in failing to make a report under this section, is immune from any liability, civil or 
criminal, which might otherwise be incurred or imposed. 
5.  A hospital's or health care provider's duty to notify under this section is not 
continuing but is limited to the diagnosis of HIV infection made in the course of 
admission, care, and treatment following the rendering of health care services or other 
services to the individual with the infection to which notification under this section 
applies. 
6.  Notwithstanding subsection 5, if, following discharge from or completion of care or 
treatment by a hospital, an individual for whom a significant exposure report was 
submitted but which report did not result in notification, wishes to provide information 
regarding the individual's HIV infection status to the care provider who submitted the 
report, the hospital shall provide a procedure for notifying the care provider. 
7.  A hospital, health care provider, or other person who is authorized to perform an HIV 
test under this section, who performs the HIV test in compliance with this section or 
who fails to perform an HIV test authorized under this section, is immune from any 
liability, civil or criminal, which might otherwise be incurred or imposed. 
8.  A hospital, health care provider, or other person who is authorized to perform a test 
under this section has no duty to perform the HIV test authorized. 
9.  The employer of a care provider who sustained a significant exposure under this 
section shall pay the costs of HIV testing for the individual who is the source of the 
significant exposure and of the testing and counseling of the care provider, if the 
significant exposure was sustained during the course of employment.  However, the 
department shall assist an individual who is the source of the significant exposure in 
finding resources to pay for the cost of the HIV test, and shall assist a care provider who 
renders direct aid without compensation in finding resources to pay for the cost of the 
testing and counseling.   
 
141A.9  CONFIDENTIALITY OF INFORMATION. 
1.  Any information, including reports and records, obtained, submitted, and maintained 
pursuant to this chapter is strictly confidential medical information.  The information 
shall not be released, shared with an agency or institution, or made public upon 
subpoena, search warrant, discovery proceedings, or by any other means except as 
provided in this chapter.  A person shall not be compelled to disclose the identity of any 
person upon whom an HIV-related test is performed, or the results of the test in a 
manner which permits identification of the subject of the test, except to persons entitled 
to that information under this chapter. 
2.  HIV-related test results shall be made available for release to the following 
individuals or under the following circumstances: 
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a.  To the subject of the test or the subject's legal guardian subject to the provisions of 
section 141A.7, subsection 3, when applicable. 
b.  To any person who secures a written release of test results executed by the subject 
of the test or the subject's legal guardian. 
c.  To an authorized agent or employee of a health facility or health care provider, if the 
health facility or health care provider ordered or participated in the testing or is 
otherwise authorized to obtain the test results, the agent or employee provides patient 
care or handles or processes samples, and the agent or employee has a medical need to 
know such information. 
d.  To a health care provider providing care to the subject of the test when knowledge 
of the test results is necessary to provide care or treatment. 
e.  To the department in accordance with reporting requirements for an HIV-related 
condition. 
f.  To a health facility or health care provider which procures, processes, distributes, or 
uses a human body part from a deceased person with respect to medical information 
regarding that person, or semen provided prior to July 1, 1988, for the purpose of 
artificial insemination. 
g.  To a person allowed access to an HIV-related test result by a court order which is 
issued in compliance with the following provisions: 
(1)  A court has found that the person seeking the test results has demonstrated a 
compelling need for the test results which need cannot be accommodated by other 
means.  In assessing compelling need, the court shall weigh the need for disclosure 
against the privacy interest of the test subject and the public interest which may be 
disserved by disclosure due to its deterrent effect on future testing or due to its effect in 
leading to discrimination. 
(2)  Pleadings pertaining to disclosure of test results shall substitute a pseudonym for 
the true name of the subject of the test. The disclosure to the parties of the subject's 
true name shall be communicated confidentially in documents not filed with the court. 
(3)  Before granting an order, the court shall provide the person whose test results are 
in question with notice and a reasonable opportunity to participate in the proceedings if 
the person is not already a party. 
(4)  Court proceedings as to disclosure of test results shall be conducted in camera 
unless the subject of the test agrees to a hearing in open court or unless the court 
determines that a public hearing is necessary to the public interest and the proper 
administration of justice. 
(5)  Upon the issuance of an order to disclose test results, the court shall impose 
appropriate safeguards against unauthorized disclosure, which shall specify the persons 
who may gain access to the information, the purposes for which the information shall be 
used, and appropriate prohibitions on future disclosure. 
h.  To an employer, if the test is authorized to be required under any other provision of 
law. 
i.  Pursuant to section 915.43, to a convicted or alleged sexual assault offender; the 
physician or other health care provider who orders the test of a convicted or alleged 
offender; the victim; the parent, guardian, or custodian of the victim if the victim is a 
minor; the physician of the victim if requested by the victim; the victim counselor or 
person requested by the victim to provide counseling regarding the HIV-related test and 
results; the victim's spouse; persons with whom the victim has engaged in vaginal, anal, 
or oral intercourse subsequent to the sexual assault; members of the victim's family 
Iowa Department of Public Health 2008                                             Chapter 141A Acquired Immune Deficiency Syndrome (AIDS) 10 
within the third degree of consanguinity; and the county attorney who may use the 
results as evidence in the prosecution of sexual assault under chapter 915, subchapter 
IV, or prosecution of the offense of criminal transmission of HIV under chapter 709C.  
For the purposes of this paragraph, "victim" means victim as defined in section 915.40. 
j.  To employees of state correctional institutions subject to the jurisdiction of the 
department of corrections, employees of secure facilities for juveniles subject to the 
department of human services, and employees of city and county jails, if the employees 
have direct supervision over inmates of those facilities or institutions in the exercise of 
the duties prescribed pursuant to section 80.9B. 
3.  Release may be made of medical or epidemiological information for statistical 
purposes in a manner such that no individual person can be identified. 
4.  Release may be made of medical or epidemiological information to the extent 
necessary to enforce the provisions of this chapter and related rules concerning the 
treatment, control, and investigation of HIV infection by public health officials. 
5.  Release may be made of medical or epidemiological information to medical personnel 
to the extent necessary to protect the health or life of the named party. 
6.  Release may be made of test results concerning a patient pursuant to procedures 
established under section 141A.5, subsection 2, paragraph "c". 
7.  Medical information secured pursuant to subsection 1 may be shared between 
employees of the department who shall use the information collected only for the 
purposes of carrying out their official duties in preventing the spread of the disease or 
the spread of other reportable diseases as defined in section 139A.2.   
 
141A.10  IMMUNITIES. 
1.  A person making a report in good faith pursuant to this chapter is immune from any 
liability, civil or criminal, which might otherwise be incurred or imposed as a result of the 
report. 
2.  A health care provider attending a person who tests positive for the HIV infection has 
no duty to disclose to or to warn third parties of the dangers of exposure to HIV 
infection through contact with that person and is immune from any liability, civil or 
criminal, for failure to disclose to or warn third parties of the condition of that person.   
 
141A.11  REMEDIES. 
1.  A person aggrieved by a violation of this chapter shall have a right of civil action for 
damages in district court. 
2.  A care provider who intentionally or recklessly makes an unauthorized disclosure 
under this chapter is subject to a civil penalty of one thousand dollars. 
3.  A person who violates a confidentiality requirement of section 141A.5 is guilty of an 
aggravated misdemeanor. 
4.  A civil action under this chapter is barred unless the action is commenced within two 
years after the cause of action accrues. 
5.  The attorney general may maintain a civil action to enforce this chapter. 
6.  This chapter does not limit the rights of the subject of an HIV-related test to recover 
damages or other relief under any other applicable law. 
7.  This chapter shall not be construed to impose civil liability or criminal sanctions for 
disclosure of HIV-related test results in accordance with any reporting requirement for a 
diagnosed case of AIDS or a related condition by the department or the centers for 
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disease control and prevention of the United States department of health and human 
services.   
IAC 10/7/09 Public Health[641] Ch 1, p.1
CHAPTER 1
REPORTABLE DISEASES, POISONINGS AND CONDITIONS, AND
QUARANTINE AND ISOLATION
641—1.1(139A) Definitions. For the purpose of these rules, the following definitions shall apply:
“Acute or chronic respiratory conditions due to fumes, vapors or dusts” means acute chemical
bronchitis; any acute, subacute, or chronic respiratory condition due to inhalation of a chemical fume or
vapor; or pneumoconioses not specifically listed elsewhere in these rules. (ICD-10 codes J63.0 to J64,
J66, and J68.0 to J68.9) “Acute or chronic respiratory conditions due to fumes, vapors or dusts” excludes
those respiratory conditions related to tobacco smoke exposure.
“Agriculturally related injury” means any nonhousehold injury to a farmer, farm worker, farm
family member, or other individual, which occurred on a farm, or in the course of handling, producing,
processing, transporting or warehousing farm commodities.
“AIDS” means AIDS as defined in Iowa Code section 141A.1.
“Area quarantine”means prohibiting ingress to and egress from a building or buildings, structure or
structures, or other definable physical location, or portion thereof, to prevent or contain the spread of a
suspected or confirmed quarantinable disease or to prevent or contain exposure to a suspected or known
chemical, biological, radioactive, or other hazardous or toxic agent.
“Business” means and includes every trade, occupation, or profession.
“Care provider” means an individual who is trained and authorized by federal or state law to
provide health care services or services of any kind in the course of the individual’s official duties,
for compensation or in a voluntary capacity, who is a health care provider, emergency medical care
provider as defined in Iowa Code section 147A.1, firefighter, or peace officer. “Care provider” also
means an individual who renders emergency care or assistance in an emergency or due to an accident
as described in Iowa Code section 613.17.
“Case” means an individual who has confirmatory evidence of disease.
“Clinical laboratory”means any laboratory performing analyses on specimens taken from the body
of a person in order to assess that person’s health status.
“Communicable disease” means any disease spread from person to person or animal to person.
“Congenital or inherited disorder” means congenital or inherited disorder as defined in Iowa Code
section 136A.2.
“Contagious or infectious disease” means hepatitis in any form, meningococcal disease,
tuberculosis, and any other disease, with the exception of AIDS or HIV infection as defined in Iowa
Code section 141A.1, determined to be life-threatening to a person exposed to the disease based upon
a determination by the state public health medical director and epidemiologist and in accordance with
guidelines of the Centers for Disease Control and Prevention of the United States Department of Health
and Human Services.
“Department” means the Iowa department of public health.
“Designated officer”means a person who is designated by a department, agency, division, or service
organization to act as an infection control liaison officer.
“Director” means the director of the Iowa department of public health.
“Exposure” means the risk of contracting disease.
“Fetal death”means an unintended death occurring after a gestation period of 20 completed weeks,
or an unintended death of a fetus with a weight of 350 or more grams. “Fetal death” is synonymous with
stillbirth.
“HBV” means hepatitis B virus.
“Health care facility” means a health care facility as defined in Iowa Code section 135C.1, an
ambulatory surgical center, or a clinic.
“Health care provider” means a person licensed to practice medicine and surgery, osteopathic
medicine and surgery, osteopathy, chiropractic, podiatry, nursing, dentistry, optometry, or licensed as a
physician assistant, dental hygienist, or acupuncturist.
“HIV” means HIV as defined in Iowa Code section 141A.1.
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“Hospital” means hospital as defined in Iowa Code section 135B.1.
“Hypersensitivity pneumonitis” means a disease in which the air sacs (alveoli) of the lungs become
inflamed when certain dusts are inhaled to which the person is sensitized or allergic. “Hypersensitivity
pneumonitis” includes but is not limited to farmer’s lung, silo filler’s disease, and toxic organic dust
syndrome.
“IDSS”means the Iowa disease surveillance system, a secureWeb-based statewide disease reporting
and surveillance system.
“Infectious disease” means a disease caused by the entrance into the body of organisms, including
but not limited to bacteria, protozoans, fungi, prions, or viruses which grow and multiply.
“Infectious tuberculosis” means pulmonary or laryngeal tuberculosis as evidenced by:
1. Isolation of M. tuberculosis complex (positive culture) from a clinical specimen or positive
nucleic acid amplification test, or
2. Both radiographic evidence of tuberculosis, such as an abnormal chest X-ray, and clinical
evidence, such as a positive skin test or whole blood assay test for tuberculosis infection, coughing,
sputum production, fever, or other symptoms compatible with infectious tuberculosis that lead a
physician to diagnose infectious tuberculosis according to currently acceptable standards of medical
practice and to initiate treatment for tuberculosis.
“Injury” means physical damage or harm to the body as the result of an act or event.
“Investigation”means an inquiry conducted to determine the specific source, mode of transmission,
and cause of a disease or suspected disease occurrence and to determine the specific incidence,
prevalence, and extent of the disease in the affected population. “Investigation” may also include the
application of scientific methods and analysis to institute appropriate control measures.
“Isolation” means the separation of persons or animals presumably or actually infected with a
communicable disease, or that are disease carriers, for the usual period of communicability of that
disease. Isolation shall be in such places, marked by placards if necessary, and under such conditions to
prevent the direct or indirect conveyance of the infectious agent or contagion to susceptible persons.
“Local board” means the local board of health.
“Local department” means the local health department.
“Noncommunicable respiratory illnesses” means an illness indicating prolonged exposure or
overexposure to asbestos, silica, silicates, aluminum, graphite, bauxite, beryllium, cotton dust or other
textile material, or coal dust. “Noncommunicable respiratory illnesses” includes, but is not limited to
asbestosis, coal worker’s pneumoconiosis, and silicosis.
“Occupationally related asthma, bronchitis or respiratory hypersensitivity reaction” means any
extrinsic asthma or acute chemical pneumonitis due to exposure to toxic agents in the workplace.
(ICD-10 codes J67.0 to J67.9)
“Pesticide” means (1) any substance or mixture of substances intended for preventing, destroying,
repelling, or mitigating directly or indirectly any insects, rodents, nematodes, fungi, weeds, and
other forms of plant or animal life or viruses, except viruses on or in living persons, which the Iowa
secretary of agriculture shall declare to be a pest; and (2) any substances intended for use as a plant
growth regulator, defoliant, or desiccant. Pesticides include active and inert ingredients of herbicides,
insecticides, rodenticides, repellants, fumigants, fungicides, wood treatment products, and disinfectants
as well as adjuvants that are added to a pesticide formulation to improve or change properties such as
deposition, persistence, or mixing ability.
“Pesticide poisoning” means any acute or subacute systemic, ophthalmologic, or dermatologic
illness or injury resulting from or suspected of resulting from inhalation or ingestion of, dermal exposure
to, or ocular contact with a pesticide. Laboratory confirmation is not required.
“Placard” means a warning sign to be erected and displayed on the periphery of a quarantine area,
forbidding entry to or exit from the area.
“Poison control or poison information center” means any organization or program which has as
one of its primary objectives the provision of toxicologic and pharmacologic information and referral
services to the public and to health care providers (other than pharmacists) in response to inquiries about
actual or potential poisonings.
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“Public health disaster” means an incident as defined in Iowa Code section 135.140.
“Quarantinable disease” means any communicable disease which presents a risk of serious harm
to public health and which may require isolation or quarantine to prevent its spread. “Quarantinable
disease” includes but is not limited to cholera; diphtheria; infectious tuberculosis; plague; smallpox;
yellow fever; viral hemorrhagic fevers, including Lassa, Marburg, Ebola, Crimean-Congo, South
American, and others not yet isolated or named; novel influenza; and severe acute respiratory syndrome
(SARS).
“Quarantine” means the limitation of freedom of movement of persons or animals that have been
exposed to a quarantinable disease within specified limits marked by placards for a period of time
equal to the longest usual incubation period of the disease in such manner as to prevent the spread of a
quarantinable disease which affects people.
“Reportable cancers”means those cancers included in the National Cancer Institute’s Surveillance,
Epidemiology and End Results (SEER) Program.
“Reportable disease” means any disease designated by this chapter.
“Severe skin disorder”means those dermatoses, burns, and other severe skin disorders which result
in death or which require hospitalization or other multiple courses of medical therapy.
“Sexually transmitted disease or infection”means a disease or infection as identified by this chapter
that is transmitted through sexual practices. “Sexually transmitted disease or infection” includes, but
is not limited to, acquired immunodeficiency syndrome (AIDS), chlamydia, gonorrhea, hepatitis B and
hepatitis C, human immunodeficiency virus (HIV), human papillomavirus, and syphilis.
“Suspected case” means an individual that presents with clinical signs or symptoms indicative of a
reportable or quarantinable disease.
“Toxic agent” means any noxious substance in solid, liquid or gaseous form capable of producing
illness in humans including, but not limited to, pesticides, heavy metals, organic and inorganic dusts
and organic solvents. Airborne toxic agents may be in the form of dusts, fumes, vapors, mists, gases or
smoke.
“Toxic hepatitis” means any acute or subacute necrosis of the liver or other unspecified chemical
hepatitis caused by exposure to nonmedicinal toxic agents other than ethyl alcohol including, but
not limited to, carbon tetrachloride, chloroform, tetrachloroethane, trichloroethylene, phosphorus,
trinitrotoluene (TNT), chloronapthalenes, methylenedianilines, ethylene dibromide, and organic
solvents. (ICD-10 codes K71.0 to K71.9)
[ARC 8231B, IAB 10/7/09, effective 11/11/09]
641—1.2(139A) Purpose and authority.
1.2(1) Purpose. The purpose of this chapter is to establish rules that identify diseases, poisonings
and conditions, and incidents that are to be reported to the department in accordance with Iowa Code
chapters 135, 136A, 139A, 141A, and 144. These rules also establish the information to be reported,
how and when to report, and who is to report. This chapter provides for disease investigation and disease
control through preventive measures including but not limited to quarantine and isolation.
1.2(2) Authority. The director is the principal officer of the state to administer disease, poisoning
and condition, and incident reporting and control. The State Health Registry of Iowa, administered by
the Department of Epidemiology of the College of Public Health at the University of Iowa, is a public
health authority for purposes of collecting cancer data in accordance with this chapter.
[ARC 8231B, IAB 10/7/09, effective 11/11/09]
REPORTABLE COMMUNICABLE AND INFECTIOUS DISEASES
641—1.3(139A,141A) Reportable communicable and infectious diseases. Reportable communicable
and infectious diseases are those listed in Appendix A. The director may also designate any disease,
poisoning or condition or syndrome temporarily reportable for the purpose of a special investigation.
[ARC 8231B, IAB 10/7/09, effective 11/11/09]
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641—1.4(135,139A) Reporting of reportable communicable and infectious diseases. Each case of a
reportable disease is required to be reported to the Iowa Department of Public Health, Lucas State Office
Building, 321 E. 12th Street, Des Moines, Iowa 50319-0075, in a manner specified by this chapter.
1.4(1) Who is required to report communicable and infectious diseases.
a. Health care providers, hospitals, clinical laboratories, and other health care facilities are
required to report cases of reportable communicable and infectious diseases.
b. School nurses are required to report suspected cases of reportable diseases occurring among the
children supervised.
c. School officials, through the principal or superintendent as appropriate, are required to report
when there is no school nurse.
d. Laboratories are required to report cases of reportable diseases and results obtained in the
examination of all specimens which yield evidence of or are reactive for sexually transmitted diseases.
e. Poison control and poison information centers are required to report inquiries about cases of
reportable diseases received by them.
f. Medical examiners are required to report their investigatory findings of any death which was
caused by or otherwise involved a reportable disease.
g. Occupational nurses are required to report cases of reportable diseases.
h. Hospitals, health care providers and clinical laboratories outside the state of Iowa shall
immediately report any confirmed or suspect case of a reportable disease, poisoning or condition in an
Iowa resident.
1.4(2) What to report. Each report shall contain all of the following information:
a. The patient’s name.
b. The patient’s address.
c. The patient’s date of birth.
d. The sex of the patient.
e. The race and ethnicity of the patient.
f. The patient’s marital status.
g. The patient’s telephone number.
h. The name and address of the laboratory.
i. The date the test was found to be positive and the collection date.
j. The name and address of the health care provider who performed the test
k. If the patient is female, whether the patient is pregnant.
l. The name of the reportable disease.
1.4(3) How to report.
a. Immediate reporting by telephone of diseases identified in Appendix A as immediately
reportable. A health care provider and a public, private, or hospital clinical laboratory shall immediately
report any confirmed or suspected case of a disease identified in Appendix A as immediately reportable
to the department’s disease notification hotline at 1-800-362-2736. The report shall include all
information required by 1.4(2) and the following:
(1) The stage of the disease process.
(2) Clinical status.
(3) Any treatment provided for the disease.
(4) All household and other known contacts.
(5) Whether household and other known contacts have been examined and the results of such
examinations.
b. Other diseases that carry serious consequences or spread rapidly. A health care facility, health
care provider and a public, private, or hospital clinical laboratory shall immediately report any confirmed
or suspected case of a common source epidemic or disease outbreak of unusual numbers by telephone
to the department’s 24/7 disease reporting telephone hotline at 1-800-362-2736.
c. Reporting of other reportable diseases. Cases of other reportable communicable or infectious
diseases not included in 1.4(3)“a” shall be reported to the department in accordance with Appendix A by
mail, telephone, facsimile, or other secure electronic means. The preferred method is secure Web-based
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reporting when available. If the department determines that reporting by mail hinders the application of
organized control measures to protect the public health, the department may require that the reportable
disease be reported by telephone, facsimile or secure Web-based reporting.
1.4(4) Contagious or infectious disease notification at time of death. The purpose of this subrule is
to establish contagious or infectious disease notification requirements for the information of any person
handling a dead body.
a. A health care provider attending a person prior to the person’s death shall, at the time of death,
place with the body a written notice which specifies or signifies either “known contagious or infectious
disease” or “suspected contagious or infectious disease.”
b. The health care facility in which the health care provider is working shall be responsible for
establishing written procedures and implementing the specific internal practices necessary to satisfy this
notification requirement.
[ARC 8231B, IAB 10/7/09, effective 11/11/09]
REPORTABLE POISONINGS AND CONDITIONS—NONCOMMUNICABLE
641—1.5(139A,135) Reportable poisonings and conditions. Reportable poisonings and conditions are
those listed in Appendix B. The director may also designate any disease, poisoning or condition or
syndrome temporarily reportable for the purpose of a special investigation.
[ARC 8231B, IAB 10/7/09, effective 11/11/09]
641—1.6(135,139A) Reporting poisonings and conditions.
1.6(1) Who is required to report.
a. Health care providers, hospitals, and clinical laboratories and other health care facilities are
required to report cases of reportable poisonings and conditions. Health care providers are exempted
from reporting blood lead testing if the laboratory performing the analysis provides the report containing
the required information to the department.
b. School nurses are required to report suspected cases of a reportable poisoning or condition
occurring among the children supervised.
c. School officials, through the principal or superintendent as appropriate, are required to report
when there is no school nurse.
d. Poison control and poison information centers are required to report inquiries about cases of a
reportable poisoning or condition received by them.
e. Medical examiners are required to report their investigatory findings of any death which was
caused by or otherwise involved a reportable poisoning or condition.
f. Occupational nurses are required to report cases of reportable poisonings and conditions.
g. Hospitals, health care providers and clinical laboratories outside the state of Iowa shall
immediately report any confirmed or suspected case of a reportable poisoning or condition in an Iowa
resident.
1.6(2) What to report. Each report shall contain all of the following information:
a. The patient’s name.
b. The patient’s address.
c. The patient’s date of birth.
d. The sex of the patient.
e. The race and ethnicity of the patient.
f. The patient’s marital status.
g. The patien’s telephone number.
h. The name and address of the laboratory.
i. The collection date.
j. The analytical result.
k. In the case of blood lead testing, whether the sample is a capillary or venous blood sample.
l. For conditions not identified by a laboratory analysis, the date that the condition was diagnosed.
m. The name and address of the health care provider who performed the test.
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n. If the patient is female, whether the patient is pregnant.
o. In the case of occupational conditions, the name of the patient’s employer.
1.6(3) How to report.
a. Blood lead testing. All analytical results greater than or equal to 20 micrograms per deciliter
(µg/dL) in a child under the age of six years or a pregnant woman shall be reported to the department
immediately by telephone at 1-800-972-2026. All other analytical results shall be reported to the
department at least weekly in an electronic format specified by the department.
b. Each instance of carbon monoxide poisoning shall be reported to the department immediately
by telephone at 1-800-972-2026.
c. Reportable poisonings and conditions other than blood lead testing and carbon monoxide
poisoning shall be reported to the department in accordance with Appendix B.
d. Occupational nurses shall submit cases of occupationally related reportable poisonings or
conditions on report forms provided by the department.
[ARC 8231B, IAB 10/7/09, effective 11/11/09]
INVESTIGATION
641—1.7(135,139A) Investigation of reportable diseases. A health care provider and a public, private,
or hospital clinical laboratory shall assist in a disease investigation conducted by the department, a local
board, or a local department.
1.7(1) A health care provider and a clinical laboratory shall provide the department, local board, or
local department with all information necessary to conduct the investigation, including but not limited
to medical records; exposure histories; medical histories; contact information; and test results necessary
to the investigation, including positive, pending, and negative test results.
1.7(2) Issuance of investigatory subpoenas.
a. The department may upon the written request of a local board of health, the state public health
medical director and epidemiologist or designee, or the state public health veterinarian or designee,
subpoena records, reports, or any other evidence necessary to conduct a disease investigation. The
subpoena shall be signed by the division director of the division of acute disease prevention and
emergency response or the division director’s designee following review and approval of the written
request for subpoena.
b. A written request for a subpoena shall contain the following:
(1) The name and address of the person, facility, or entity to which the subpoena will be directed;
(2) A specific description of the records, reports, or other evidence requested; and
(3) An explanation of why the documents sought to be subpoenaed are necessary for the department
to conduct the disease investigation.
c. Each subpoena shall contain:
(1) The name and address of the person, facility, or entity to which the subpoena is directed;
(2) A description of the records, reports, or other evidence requested;
(3) The date, time, and location for production, inspection, or copying;
(4) The time within which a motion to quash or modify the subpoena must be filed;
(5) The signature, address, and telephone number of the division director;
(6) The date of issuance; and
(7) A return of service.
d. Process to challenge a subpoena.
(1) Any person who is aggrieved or adversely affected by compliance with the subpoena and who
desires to challenge the subpoena must, within five days after service of the subpoena, or before the time
specified for compliance if such time is less than five days, file with the department a motion to quash
or modify the subpoena. The motion shall describe the reasons why the subpoena should be quashed or
modified, and may be accompanied by legal briefs or factual affidavits.
(2) Upon receipt of a timely motion to quash or modify a subpoena, the department may request
an administrative law judge to issue a decision. Oral argument may be scheduled at the discretion of the
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administrative law judge. The administrative law judge may quash or modify the subpoena, deny the
motion, or issue an appropriate protective order.
(3) A person aggrieved by a ruling of an administrative law judge who desires to challenge that
ruling must appeal the ruling to the department by serving on the department director, either in person or
by certified mail, a notice of appeal within ten days after the service of the decision of the administrative
law judge. The department director’s decision is final for purposes of judicial review.
e. Subpoenas issued under this subrule and requests, motions, and pleadings related to the issuance
of subpoenas are confidential pursuant to Iowa Code sections 139A.3 and 22.7.
[ARC 8231B, IAB 10/7/09, effective 11/11/09]
ISOLATION AND QUARANTINE
641—1.8(139A) Isolation and quarantine. Isolation and quarantine should be consistent with
guidelines provided by the Centers for Disease Control and Prevention’s 2007 Guideline for Isolation
Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings, June 2007;
http://www.cdc.gov/ncidod/dhqp/pdf/guidelines/Isolation2007.pdf.
[ARC 8231B, IAB 10/7/09, effective 11/11/09]
641—1.9(135,139A) Quarantine and isolation.
1.9(1) Examination, testing, and treatment of quarantinable diseases.
a. A health care provider who attends an individual with a suspected or active quarantinable
disease shall make all reasonable efforts in accordance with guidance from a local health department
or the department to examine or cause all household and other known contacts of the individual to be
examined by a physician. The physician shall promptly report to the department the results of such
examination. If the individual refuses or is unable to undergo examination, the health care provider shall
promptly report such information to the department.
b. When required by the department, all contacts not examined by a physician, including all adult
and minor contacts, shall submit to a diagnostic test or tests. If any suspicious abnormality is found, steps
satisfactory to the department shall be taken to refer the individual promptly to a physician or appropriate
medical facility for further evaluation and, if necessary, treatment. The referring health care provider or
facility shall notify the receiving health care provider or facility of the suspicious abnormality. When
requested by the department, a physician shall report the results of the examination of a contact to the
case or suspected case or incident.
c. Upon order of the department or local board of health, an individual with a suspected or active
quarantinable disease shall not attend the workplace or school and shall not be present at other public
places until the individual receives the approval of the department or a local board of health to engage in
such activity. Upon order of the department or local board of health, employers, schools and other public
places shall exclude an individual with a suspected or active quarantinable disease. An individual may
also be excluded from other premises or facilities if the department or a local board of health determines
the premises or facilities cannot be maintained in a manner adequate to protect others against the spread
of the disease.
d. Aperson diagnosedwith or clinically suspected of having infectious tuberculosis shall complete
voluntary treatment until, in the opinion of the attending physician or the state public health medical
director and epidemiologist, the person’s tuberculosis is cured or such person is no longer a threat to
public health. If such person refuses to complete the course of voluntary treatment, the department or
local board of health may issue an order compelling mandatory treatment. Such order shall include the
identity of the person subject to the mandatory treatment order, a description of the treatment ordered,
the medical basis upon which the treatment is ordered, and a description of the potential medical and
legal consequences of violating such order. A person who violates a mandatory treatment order may
be subject to the penalties provided in Iowa Code section 135.38 or 137.21 and may be placed under
mandatory quarantine or isolation in accordance with the provisions of this chapter.
e. A person diagnosed with extrapulmonary tuberculosis or clinically suspected of having
infectious tuberculosis who fails to comply with a physician’s recommendation for diagnostic testing
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may be ordered to undergo diagnostic testing by the department or local board of health. Such order
shall include the identity of the person subject to mandatory diagnostic testing, a description of the
diagnostic testing ordered, the medical basis upon which the diagnostic testing is ordered, and a
description of the potential medical and legal consequences of violating such order. A person who
violates a mandatory diagnostic testing order may be subject to the penalties provided in Iowa Code
section 135.38 or 137.21 and may be placed under mandatory quarantine or isolation in accordance
with the provisions of this chapter.
1.9(2) General provisions.
a. Voluntary confinement. Prior to instituting mandatory isolation or quarantine pursuant to this
rule, the department or a local board of health may request that an individual or group of individuals
voluntarily confine themselves to a private home or other facility.
b. Quarantine and isolation. The department and local boards of health are authorized to impose
and enforce quarantine and isolation restrictions. Quarantine and isolation shall rarely be imposed by
the department or by local boards of health. If a quarantinable disease occurs in Iowa, individuals with a
suspected or active quarantinable disease and contacts to the case may be quarantined or isolated as the
particular situation requires. Any quarantine or isolation imposed by the department or a local board of
health shall be established and enforced in accordance with this rule.
1.9(3) Conditions and principles. The department and local boards of health shall adhere to all of the
following conditions and principles when isolating or quarantining individuals or a group of individuals:
a. The isolation or quarantine shall be by the least restrictive means necessary to prevent the
spread of a communicable or possibly communicable disease to others and may include, but not be
limited to, confinement to private homes, other private premises, or public premises.
b. Isolated individuals shall be confined separately from quarantined individuals.
c. The health status of isolated or quarantined individuals shall be monitored regularly to
determine if the individuals require further or continued isolation or quarantine.
d. If a quarantined individual subsequently becomes infected or is reasonably believed to have
become infected with a communicable or possibly communicable disease, the individual shall be
promptly removed to isolation.
e. Isolated or quarantined individuals shall be immediately released when the department or local
board of health determines that the individuals pose no substantial risk of transmitting a communicable
or possibly communicable disease.
f. The needs of isolated or quarantined individuals shall be addressed in a systematic and
competent fashion including, but not limited to, providing adequate food; clothing; shelter; means of
communicating with those in and outside of isolation or quarantine; medication; and competent medical
care.
g. The premises used for isolation or quarantine shall be maintained in a safe and hygienic manner
and shall be designed to minimize the likelihood of further transmission of infection or other harm to
isolated or quarantined individuals.
h. To the extent possible, cultural and religious beliefs shall be considered in addressing the needs
of individuals in isolation or quarantine premises and in establishing and maintaining the premises.
1.9(4) Isolation and quarantine premises.
a. Sites of isolation or quarantine shall be prominently placarded with isolation or quarantine signs
prescribed and furnished by the department and posted on all sides of the building wherever access is
possible.
b. An individual subject to isolation or quarantine shall obey the rules and orders of the department
or the local board of health and shall not go beyond the isolation or quarantine premises.
c. The department or a local board of health may authorize physicians, health care workers, or
others access to individuals in isolation or quarantine as necessary to meet the needs of isolated or
quarantined individuals.
d. No individual, other than an individual authorized by the department or a local board of
health, shall enter isolation or quarantine premises. If the department has requested the assistance of
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law enforcement in enforcing the isolation or quarantine, the department shall provide law enforcement
personnel with a list of individuals authorized to enter the isolation or quarantine premises.
e. Any individual entering an isolation or quarantine premises with or without authorization of
the department or a local board of health may be isolated or quarantined pursuant to this rule.
1.9(5) Isolation and quarantine by local boards of health.
a. A local board of health may:
(1) Isolate individuals who are presumably or actually infected with a quarantinable disease;
(2) Quarantine individuals who have been exposed to a quarantinable disease;
(3) Establish and maintain places of isolation and quarantine; and
(4) Adopt emergency rules and issue orders as necessary to establish, maintain, and enforce
isolation or quarantine.
b. Isolation and quarantine undertaken by a local board of health shall be accomplished according
to the rules and regulations of the local board of health so long as such rules are not inconsistent with
this chapter.
1.9(6) Isolation and quarantine by the Iowa department of public health.
a. Authority.
(1) The department, through the director, the department’s medical director, or the director’s or
medical director’s designee, may:
1. Isolate individuals or groups of individuals who are presumably or actually infected with a
quarantinable disease; and
2. Quarantine individuals or groups of individuals who have been exposed to a quarantinable
disease, including individuals who are unable or unwilling to undergo examination, testing, vaccination,
or treatment, pursuant to Iowa Code section 135.144(9).
(2) The department may:
1. Establish and maintain places of isolation and quarantine; and
2. Adopt emergency rules and issue orders as necessary to establish, maintain, and enforce isolation
or quarantine.
(3) Isolation and quarantine undertaken by the department, including isolation and quarantine
undertaken by the department in the event of a public health disaster, shall be established pursuant to
paragraph 1.9(6)“b” or “c.”
b. Temporary isolation and quarantine without notice. The department may temporarily isolate or
quarantine an individual or groups of individuals through an oral order, without notice, only if delay in
imposing the isolation or quarantine would significantly jeopardize the department’s ability to prevent or
limit the transmission of a communicable or possibly communicable disease to others. If the department
imposes temporary isolation or quarantine of an individual or groups of individuals through an oral order,
the department shall issue a written order as soon as is reasonably possible and in all cases within 24
hours of issuance of the oral order if continued isolation or quarantine is necessary to prevent or limit
the transmission of a communicable or possibly communicable disease.
c. Written order. The department may isolate or quarantine an individual or groups of individuals
through a written order issued pursuant to this rule.
(1) The written order shall include all of the following:
1. The identity of the individual, individuals, or groups of individuals subject to isolation or
quarantine.
2. The premises subject to isolation or quarantine.
3. The date and time at which isolation or quarantine commences.
4. The suspected communicable disease.
5. A description of the less restrictive alternatives that were attempted and were unsuccessful, or
the less restrictive alternatives that were considered and rejected, and the reasons such alternatives were
rejected.
6. A statement of compliance with the conditions and principles for isolation and quarantine
specified in subrule 1.9(3).
7. The legal authority under which the order is requested.
Ch 1, p.10 Public Health[641] IAC 10/7/09
8. The medical basis upon which isolation or quarantine is justified.
9. A statement advising the individual, individuals, or groups of individuals of the right to appeal
the written order pursuant to subrule 1.9(7) and the rights of individuals and groups of individuals subject
to quarantine and isolation as listed in subrule 1.9(8).
10. A copy of this chapter and the relevant definitions.
(2) A copy of the written order shall be provided to the individual to be isolated or quarantined
within 24 hours of issuance of the order in accordance with any applicable process authorized by the Iowa
Rules of Civil Procedure. If the order applies to a group or groups of individuals and it is impractical to
provide individual copies, the order may be posted in a conspicuous place in the isolation or quarantine
premises.
1.9(7) Appeal from order imposing isolation or quarantine.
a. Contested case. The subject of a department order imposing isolation or quarantine may appeal
a written order and has the right to a contested case hearing regarding such appeal. The subject of a
department order imposing isolation or quarantine may appeal the order by submitting a written appeal
within ten days of receipt of the written order. The appeal shall be addressed to the Department of Public
Health, Division of Epidemiology, Emergency Medical Services, and Disaster Operations, Lucas State
Office Building, Des Moines, Iowa 50319-0075. Unless stayed by order of the director or a district
court, the written order for quarantine or isolation shall remain in force and effect until the appeal is
finally determined and disposed of upon its merits.
b. Presiding officer. The presiding officer in a contested case shall be the director or the director’s
designee. The director or the director’s designee may be assisted by an administrative law judge in
conducting the contested case hearing. The decision of the director or the director’s designee shall be
the department’s final decision and is subject to judicial review in accordance with the provisions of Iowa
Code chapter 17A.
c. Proceeding. The contested case hearing shall be conducted in accordance with the provisions
contained at 641—Chapter 173. The hearing shall be held as soon as is practicable, and in no case
later than ten days from the date of receipt of the appeal. The hearing may be held by telephonic or
other electronic means if necessary to prevent additional exposure to the communicable or possibly
communicable disease. In extraordinary circumstances and for good cause shown, the department may
apply to continue the hearing date for up to ten additional days on a petition filed pursuant to this rule.
The presiding officer may use discretion in granting a continuance giving due regard to the rights of the
affected individuals, the protection of the public’s health, and the availability of necessary witnesses and
evidence.
d. Judicial review. The aggrieved party to the final decision of the department may petition for
judicial review of that action pursuant to Iowa Code chapter 17A. Petitions for judicial review shall be
filed within 30 days after the decision becomes final.
e. Immediate judicial review of department order. The department acknowledges that in certain
circumstances the subject or subjects of a department order may desire immediate judicial review of a
department order in lieu of proceeding with the contested case process. The department recognizes that
the procedural step of pursuing exhaustion of administrative remedies may be inadequate for purposes
of Iowa Code section 17A.19, and the department may consent to immediate jurisdiction of the district
court when requested by the subject or subjects of a department order and justice so requires. Unless
stayed by order of the director or a district court, the written order for quarantine or isolation shall remain
in force and effect until the judicial review is finally determined and disposed of upon its merits.
1.9(8) Rights of individuals and groups of individuals subject to isolation or quarantine. Any
individual or group of individuals subject to isolation or quarantine shall have the following rights:
a. The right to be represented by legal counsel.
b. The right to be provided with prior notice of the date, time, and location of any hearing.
c. The right to participate in any hearing. The hearing may be held by telephonic or other
electronic means if necessary to prevent additional exposure to the communicable or possibly
communicable disease.
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d. The right to respond and present evidence and argument on the individual’s own behalf in any
hearing.
e. The right to cross-examine witnesses who testify against the individual.
f. The right to view and copy all records in the possession of the department which relate to the
subject of the written order.
1.9(9) Consolidation of claims. In any proceeding brought pursuant to this rule, to promote the fair
and efficient operation of justice and having given due regard to the rights of the affected individuals, the
protection of the public’s health, and the availability of necessary witnesses and evidence, the department
or a court may order the consolidation of individual claims into group claims, if all of the following
conditions exist:
a. The number of individuals involved or to be affected is so large that individual participation is
impractical.
b. There are questions of law or fact common to the individual claims or rights to be determined.
c. The group claims or rights to be determined are typical of the affected individuals’ claims or
rights.
d. The entire group will be adequately represented in the consolidation.
1.9(10) Implementation and enforcement of isolation and quarantine.
a. Jurisdictional issues. The department has primary jurisdiction to isolate or quarantine
individuals or groups of individuals if the communicable disease outbreak has affected more than one
county or has multicounty, statewide, or interstate public health implications. When imposing isolation
or quarantine, the department shall coordinate with the local health department as appropriate. If
isolation or quarantine is imposed by the department, a local board of health or local health department
may not alter, amend, modify, or rescind the isolation or quarantine order.
b. Assistance of local boards of health and local health departments. If isolation or quarantine is
imposed by the department, the local boards of health and the local health departments in the affected
areas shall assist in the implementation of the isolation or quarantine order.
c. Assistance of law enforcement. Pursuant to Iowa Code section 135.35, all peace officers of
the state shall enforce and execute a lawful department order for isolation or quarantine within their
respective jurisdictions. The department shall take all reasonable measures to minimize the risk of
exposure to peace officers and others assisting with enforcement of an isolation or quarantine order.
d. Penalty. Pursuant to Iowa Code section 135.38, any individual who knowingly violates a
lawful department order for isolation or quarantine, whether written or oral, shall be guilty of a simple
misdemeanor. The court-ordered sentence may include a fine of up to $500 and imprisonment not to
exceed 30 days.
e. Enforcement action. The department may file a civil action in Polk County district court or in
the district court for the county in which the individual resides or is located to enforce a department
order for isolation or quarantine. Such action shall be filed in accordance with the Iowa Rules of Civil
Procedure.
[ARC 8231B, IAB 10/7/09, effective 11/11/09]
641—1.10 and 1.11  Reserved.
641—1.12(135,137,139A) Quarantine and isolation—model rule for local boards.
1.12(1) Applicability. The provisions of rule 641—1.12(135,137,139A) are applicable in
jurisdictions in which a local board has adopted this rule by reference in accordance with Iowa Code
section 137.6. This rule shall not be construed to require a local board to adopt this model rule.
1.12(2) Definitions.
“Board” means [insert the name of the city, county, or district board of health].
“Department” means the Iowa department of public health.
“Isolation” means the separation of persons or animals presumably or actually infected with a
communicable disease, or that are disease carriers, for the usual period of communicability of that
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disease. Isolation shall be in such places, marked by placards if necessary, and under such conditions to
prevent the direct or indirect conveyance of the infectious agent or contagion to susceptible individuals.
“Quarantinable disease” means any communicable disease which presents a risk of serious harm
to public health and which may require isolation or quarantine to prevent its spread. “Quarantinable
disease” includes but is not limited to cholera; diphtheria; infectious tuberculosis; plague; smallpox;
yellow fever; viral hemorrhagic fevers, including Lassa, Marburg, Ebola, Crimean-Congo, South
American, and others not yet isolated or named; novel influenza; and severe acute respiratory syndrome
(SARS).
“Quarantine” means the limitation of freedom of movement of persons or animals that have been
exposed to a communicable disease, within specified limits marked by placards, for a period of time
equal to the longest usual incubation period of the disease. The limitation of movement shall be in such
manner as to prevent the spread of a communicable disease.
1.12(3) General provisions.
a. Voluntary confinement. Prior to instituting mandatory isolation or quarantine pursuant to this
rule, the board may request that an individual or group of individuals voluntarily confine themselves to
a private home or other facility.
b. Quarantine and isolation. The board is authorized to impose and enforce quarantine and
isolation restrictions. Quarantine and isolation shall rarely be imposed by the board. If a quarantinable
disease occurs in Iowa, individuals with a suspected or active quarantinable disease and contacts to the
case may be quarantined or isolated as the particular situation requires. Any quarantine or isolation
imposed by the board shall be established and enforced in accordance with this rule.
c. The local board of health shall notify, consult and work cooperatively with the Iowa department
of agriculture and land stewardship and the state veterinarian office on issues relating to isolation and
quarantine of animals.
1.12(4) Conditions and principles. The board shall adhere to all of the following conditions and
principles when isolating or quarantining individuals or a group of individuals:
a. The isolation or quarantine shall be by the least restrictivemeans necessary to prevent the spread
of a communicable or possibly communicable disease to others and may include, but is not limited to,
confinement to private homes, other private premises, or public premises.
b. Isolated individuals shall be confined separately from quarantined individuals.
c. The health status of isolated or quarantined individuals shall be monitored regularly to
determine if the individuals require further or continued isolation or quarantine.
d. If a quarantined individual subsequently becomes infected or is reasonably believed to have
become infected with a communicable or possibly communicable disease, the individual shall be
promptly removed to isolation.
e. Isolated or quarantined individuals shall be immediately released when the board determines
that the individuals pose no substantial risk of transmitting a communicable or possibly communicable
disease.
f. The needs of isolated or quarantined individuals shall be addressed in a systematic and
competent fashion including, but not limited to, providing adequate food; clothing; shelter; means of
communicating with those in and outside of isolation or quarantine; medication; and competent medical
care.
g. The premises used for isolation or quarantine shall be maintained in a safe and hygienic manner
and shall be designed to minimize the likelihood of further transmission of infection or other harm to
isolated or quarantined individuals.
h. To the extent possible, cultural and religious beliefs shall be considered in addressing the needs
of individuals in isolation and quarantine premises and in establishing and maintaining the premises.
1.12(5) Isolation and quarantine premises.
a. Sites of isolation or quarantine shall be prominently placarded with isolation or quarantine signs
prescribed and furnished by the department and posted on all sides of the building wherever access is
possible.
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b. An individual subject to isolation or quarantine shall obey the rules and orders of the board and
shall not go beyond the isolation or quarantine premises.
c. The department or the board may authorize physicians, health care workers, or others access
to individuals in isolation or quarantine as necessary to meet the needs of isolated or quarantined
individuals.
d. No individual, other than an individual authorized by the department or the board, shall enter
an isolation or quarantine premises. If the department has requested the assistance of law enforcement
in enforcing the isolation or quarantine, the department shall provide law enforcement personnel with a
list of individuals authorized to enter the isolation or quarantine premises.
e. Any individual entering an isolation or quarantine premises with or without authorization of
the department or the board may be isolated or quarantined pursuant to this rule.
1.12(6) Isolation and quarantine.
a. Authority. The board may:
(1) Isolate individuals who are presumably or actually infected with a quarantinable disease;
(2) Quarantine individuals who have been exposed to a quarantinable disease;
(3) Establish and maintain places of isolation and quarantine; and
(4) Adopt emergency rules and issue orders as necessary to establish, maintain, and enforce
isolation or quarantine.
b. Isolation and quarantine undertaken by the board shall be accomplished in accordance with this
rule.
c. Temporary isolation and quarantine without notice. The board may temporarily isolate or
quarantine an individual or groups of individuals through an oral order, without notice, only if delay
in imposing the isolation or quarantine would significantly jeopardize the board’s ability to prevent or
limit the transmission of a communicable or possibly communicable disease to others. If the board
imposes temporary isolation or quarantine of an individual or groups of individuals through an oral
order, the board shall issue a written order as soon as is reasonably possible and in all cases within 24
hours of issuance of the oral order if continued isolation or quarantine is necessary to prevent or limit
the transmission of a communicable or possibly communicable disease.
d. Written order. The board may isolate or quarantine an individual or groups of individuals
through a written order issued pursuant to this rule.
(1) The written order shall include all of the following:
1. The identity of the individual, individuals, or groups of individuals subject to isolation or
quarantine.
2. The premises subject to isolation or quarantine.
3. The date and time at which isolation or quarantine commences.
4. The suspected communicable disease.
5. A description of the less restrictive alternatives that were attempted and were unsuccessful, or
the less restrictive alternatives that were considered and rejected, and the reasons such alternatives were
rejected.
6. A statement of compliance with the conditions and principles for isolation and quarantine
specified in subrule 1.12(4).
7. The legal authority under which the order is imposed.
8. The medical basis upon which isolation or quarantine is justified.
9. A statement advising the individual, individuals, or groups of individuals of the right to appeal
the written order pursuant to subrule 1.12(7) and the rights of individuals and groups of individuals
subject to quarantine and isolation as listed in subrule 1.12(8).
10. A copy of this rule and the relevant definitions.
(2) A copy of the written order shall be provided to the individual to be isolated or quarantined
within 24 hours of issuance of the order in accordance with any applicable process authorized by the Iowa
Rules of Civil Procedure. If the order applies to a group or groups of individuals and it is impractical to
provide individual copies, the order may be posted in a conspicuous place in the isolation or quarantine
premises.
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1.12(7) Appeal from order imposing isolation or quarantine.
a. Appeal. The subject of a board order imposing isolation or quarantine may appeal a written
order by submitting a written appeal within ten days of receipt of the written order. The appeal shall be
addressed to [insert name of board and board address]. Unless stayed by order of the board or a district
court, the written order for quarantine or isolation shall remain in force and effect until the appeal is
finally determined and disposed of upon its merits.
b. Proceeding. The appeal proceeding shall be conducted in accordance with this rule [or insert
specific board rule governing appeal proceedings]. The proceeding shall be held as soon as is practicable,
and in no case later than ten days from the date of receipt of the appeal. The hearing may be held by
telephonic or other electronic means if necessary to prevent additional exposure to the communicable or
possibly communicable disease. In extraordinary circumstances and for good cause shown, the board
may continue the proceeding date for up to ten days, giving due regard to the rights of the affected
individuals, the protection of the public’s health, and the availability of necessarywitnesses and evidence.
At the appeal proceeding, the subject of the appeal shall have the right to introduce evidence on all issues
relevant to the order. The board, by majority vote, may modify, withdraw, or order compliance with the
order under appeal.
c. Judicial review. The aggrieved party to the final decision of the board may petition for judicial
review of that action by filing an action in the appropriate district court. Petitions for judicial review
shall be filed within 30 days after the decision becomes final.
d. Immediate judicial review of board order. The board acknowledges that in certain
circumstances the subject or subjects of a board order may desire immediate judicial review of a board
order in lieu of proceeding with the board’s appeal process. The board may consent to immediate
jurisdiction of the district court when requested by the subject or subjects of a board order and justice
so requires. Unless stayed by order of the board or a district court, the written order for quarantine or
isolation shall remain in force and effect until the judicial review is finally determined and disposed of
upon its merits.
1.12(8) Rights of individuals and groups of individuals subject to isolation or quarantine. Any
individual or group of individuals subject to isolation or quarantine shall have the following rights:
a. The right to be represented by legal counsel.
b. The right to be provided with prior notice of the date, time, and location of any hearing.
c. The right to participate in any hearing. The hearing may be held by telephonic or other
electronic means if necessary to prevent additional exposure to the communicable or possibly
communicable disease.
d. The right to respond and present evidence and argument on the individual’s own behalf in any
hearing.
e. The right to cross-examine witnesses who testify against the individual.
f. The right to view and copy all records in the possession of the board which relate to the subject
of the written order.
1.12(9) Consolidation of claims. In any proceeding brought pursuant to this rule, to promote the fair
and efficient operation of justice and having given due regard to the rights of the affected individuals,
the protection of the public’s health, and the availability of necessary witnesses and evidence, the board
or a court may order the consolidation of individual claims into group claims, if all of the following
conditions exist:
a. The number of individuals involved or to be affected is large enough that consolidation would
be the best use of resources.
b. There are questions of law or fact common to the individual claims or rights to be determined.
c. The group claims or rights to be determined are typical of the affected individuals’ claims or
rights.
d. The entire group will be adequately represented in the consolidation.
1.12(10) Implementation and enforcement of isolation and quarantine.
a. Jurisdictional issues. The department has primary jurisdiction to isolate or quarantine
individuals or groups of individuals if the communicable disease outbreak has affected more than one
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county or has multicounty, statewide, or interstate public health implications. If isolation or quarantine
is imposed by the department, the board may not alter, amend, modify, or rescind the isolation or
quarantine order.
b. Assistance of local boards of health and local health departments. If isolation or quarantine is
imposed by the department, the local boards of health and the local health departments in the affected
areas shall assist in the implementation of the isolation or quarantine order.
c. Penalty. Pursuant to Iowa Code sections 137.21 and 139A.25(1), any individual who violates
a lawful board order for isolation or quarantine, whether written or oral, shall be guilty of a simple
misdemeanor. The court-ordered sentence may include a fine of up to $500 and imprisonment not to
exceed 30 days.
d. Enforcement action. The board, through the office of the county attorney, may file a civil action
in the appropriate district court to enforce a board order for isolation or quarantine. Such action shall be
filed in accordance with the Iowa Rules of Civil Procedure.
[ARC 8231B, IAB 10/7/09, effective 11/11/09]
641—1.13(135,139A) Area quarantine.
1.13(1) General provisions. The department and local boards of health are authorized to impose
and enforce area quarantine in accordance with this rule. Area quarantine shall rarely be imposed by the
department or by local boards of health.
1.13(2) Conditions and principles. The department and local boards of health shall adhere to all of
the following conditions and principles when imposing and enforcing area quarantine:
a. Area quarantine shall be imposed by the least restrictive means necessary to prevent or contain
the spread of a suspected or confirmed quarantinable disease or suspected or known hazardous or toxic
agent.
b. Area quarantine shall be immediately terminated when the department or a local board of health
determines that no substantial risk of exposure to a quarantinable disease or hazardous or toxic agent
continues to exist.
c. The geographic boundaries of an area quarantine shall be established by risk assessment
procedures including medical and scientific analysis of the quarantinable disease or hazardous or
toxic agent, the location of the affected area, the risk of spread or contamination, and other relevant
information.
1.13(3) Area quarantine sites.
a. Sites of area quarantine shall be prominently identified to restrict ingress to and egress from
the area, to the extent practicable. The department or a local board of health may placard or otherwise
identify the site, or may request the assistance of law enforcement in identifying the site.
b. No individual, other than an individual authorized by the department or a local board of health,
shall enter a building, structure, or other physical location subject to area quarantine. The department
or a local board of health may authorize public health officials, environmental specialists, health care
providers, or others access to an area quarantine site as necessary to conduct public health investigations,
to decontaminate the site, or for other public health purposes. Notwithstanding any provision in this
chapter to the contrary, law enforcement, fire service, and emergencymedical service providersmay enter
an area quarantine site to provide emergency response services or to conduct emergency law enforcement
investigations or other emergency activities without authorization by the department or a local board
of health. If the department has requested the assistance of law enforcement in enforcing the area
quarantine, the department shall provide law enforcement personnel with a list of individuals authorized
to enter the area quarantine site.
c. An individual authorized to enter an area quarantine site may be required to wear personal
protective equipment as appropriate.
d. No individual, other than an individual authorized by the department or a local board of health,
shall remove any item or object from a building, structure, or other physical location subject to area
quarantine.
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e. An individual entering an area quarantine site without authorization of the department or a local
board of health may be isolated or quarantined pursuant to rule 641—1.9(135,139A) and may be found
guilty of a simple misdemeanor.
1.13(4) Area quarantine by local boards of health or the department of public health.
a. Authority.
(1) The department, through the director, the department’s medical director, or the director or
medical director’s designee, may impose area quarantine through oral or written order. Prior to imposing
area quarantine, the department shall attempt to notify the local board or boards of health in the affected
geographic area. If attempts to notify the local boards of health are initially unsuccessful, the department
shall continue to make regular notification attempts until successful.
(2) A local board of health may impose area quarantine through oral or written order. Prior to
imposing area quarantine, a local board of health shall attempt to notify the department by contacting the
director, medical director, or department duty officer by telephone. If attempts to notify the department
are initially unsuccessful, the local board of health shall continue to make regular notification attempts
until successful.
b. Temporary area quarantine without notice. The department or a local board of health may
temporarily impose area quarantine through an oral order, without notice, only if delay in imposing
area quarantine would significantly jeopardize the department’s or local board’s ability to prevent or
contain the spread of a suspected or confirmed quarantinable disease or to prevent or contain exposure
to a suspected or known hazardous or toxic agent. If the department or local board imposes temporary
area quarantine through an oral order, a written order shall be issued as soon as is reasonably possible
and in all cases within 24 hours of issuance of the oral order if continued area quarantine is necessary.
c. Written order. The department or local board may impose area quarantine through a written
order issued pursuant to this rule.
(1) The written order shall include all of the following:
1. The building or buildings, structure or structures, or other definable physical location, or portion
thereof, subject to area quarantine.
2. The date and time at which area quarantine commences and the date and time at which the area
quarantine shall be terminated, if known.
3. The suspected or confirmed quarantinable disease or the chemical, biological, radioactive, or
other hazardous or toxic agent.
4. A statement of compliance with the conditions and principles for area quarantine specified in
subrule 1.13(2).
5. The legal authority under which the order is imposed.
6. The medical or scientific basis upon which area quarantine is justified.
7. A statement advising the owner or owners of the building or buildings, structure or structures,
or other definable physical location subject to area quarantine of the right to appeal the written order
pursuant to subrule 1.13(5) and the rights of owners of sites subject to area quarantine pursuant to subrule
1.13(6).
8. A copy of 641—Chapter 1 and the relevant provisions of this rule.
(2) A copy of the written order shall be provided to the owner or owners of the building or buildings,
structure or structures, or other definable physical location subject to area quarantine within 24 hours of
issuance of the order in accordance with any applicable process authorized by the Iowa Rules of Civil
Procedure; or, if the order applies to a group of owners and it is impractical to provide individual notice
to each owner, the written order shall be posted in a conspicuous place at the site of area quarantine.
1.13(5) Appeal from order imposing area quarantine.
a. Contested case. The subject of a department order imposing area quarantine may appeal a
written order and has the right to a contested case hearing regarding such appeal. The subject of a
department order imposing area quarantine may appeal the order by submitting a written appeal within
10 days of receipt or other notice of the written order. The appeal shall be addressed to the Local Board
of Health or to the Department of Public Health, Division of Acute Disease Prevention and Emergency
Response, Lucas State Office Building, Des Moines, Iowa 50319-0075. Unless stayed by order of the
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director or a district court, the written order for area quarantine shall remain in force and effect until the
appeal is finally determined and disposed of upon its merits.
b. Presiding officer. The presiding officer in a contested case shall be the director or the director’s
designee. The director or the director’s designee may be assisted by an administrative law judge in
conducting the contested case hearing. The decision of the director or the director’s designee shall be
the agency’s final decision and is subject to judicial review in accordance with the provisions of Iowa
Code chapter 17A.
c. Proceeding. The contested case hearing shall be conducted in accordance with the provisions
contained at 641—Chapter 173. The hearing shall be held as soon as is practicable, and in no case
later than 10 days from the date of receipt of the appeal. In extraordinary circumstances and for good
cause shown, the department may apply to continue the hearing date on a petition filed pursuant to this
paragraph for up to 10 days, which continuance the presiding officer may grant in the presiding officer’s
discretion giving due regard to the rights of the affected individuals, the protection of the public’s health,
and the availability of necessary witnesses and evidence.
d. Judicial review. The aggrieved party to the final decision of the department may petition for
judicial review of that action pursuant to Iowa Code chapter 17A. Petitions for judicial review shall be
filed within 30 days after the decision becomes final.
e. Immediate judicial review of department order. The department or local board acknowledges
that in certain circumstances the subject or subjects of a department order may desire immediate judicial
review of a department order in lieu of proceeding with the contested case process. The department
recognizes that the procedural step of pursuing exhaustion of administrative remedies may be inadequate
for purposes of Iowa Code section 17A.19, and the department may consent to immediate jurisdiction of
the district court when requested by the subject or subjects of a department order and justice so requires.
Unless stayed by order of the director or a district court, the written order for area quarantine shall remain
in force and effect until the judicial review is finally determined and disposed of upon its merits.
1.13(6) Rights of owners of sites subject to area quarantine. An owner of a building, structure, or
other physical location subject to area quarantine shall have the following rights:
a. The right to be represented by legal counsel.
b. The right to be provided with prior notice of the date, time, and location of any hearing.
c. The right to participate in any hearing.
d. The right to respond and present evidence and argument on the owner’s own behalf in any
hearing.
e. The right to cross-examine witnesses who testify against the owner or individual.
f. The right to view and copy all records in the possession of the department which relate to the
subject of the written order.
1.13(7) Consolidation of claims. In any proceeding brought pursuant to this rule, to promote the fair
and efficient operation of justice and having given due regard to the rights of the affected individuals, the
protection of the public’s health, and the availability of necessary witnesses and evidence, the department
or a court may order the consolidation of individual claims into group claims, if all of the following
conditions exist:
a. The number of individuals involved or who may be affected is so large that individual
participation is impractical.
b. There are questions of law or fact common to the individual claims or rights to be determined.
c. The group claims or rights to be determined are typical of the affected individuals’ claims or
rights.
d. The entire group will be adequately represented in the consolidation.
1.13(8) Implementation and enforcement of area quarantine.
a. Jurisdictional issues. The department has primary jurisdiction to impose area quarantine if the
quarantinable disease or hazardous or toxic agent has affected more than one county and implicates
multicounty or statewide public health concerns. If area quarantine is imposed by the department, a local
board of health or local health department may not alter, amend, modify, or rescind the area quarantine
order.
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b. Assistance of local boards of health and local health departments. If area quarantine is imposed
by the department, the local boards of health and the local health departments in the affected areas shall
assist in the implementation of the area quarantine.
c. Assistance of law enforcement. Pursuant to Iowa Code section 135.35, all peace officers of the
state shall enforce and execute a lawful department order for area quarantine within their respective
jurisdictions. The department shall take all reasonable measures to minimize the risk of individual
exposure of peace officers and others assisting with enforcement of an area quarantine order.
d. Emergency response, investigation, and decontamination—authority of other
agencies. Emergency response, investigation, and decontamination activities in and around an area
quarantine site shall be conducted by law enforcement, fire service, emergency medical service
providers, or other appropriate federal, state, or local officials in accordance with federal and state law
and accepted procedures and protocols for emergency response, investigation, and decontamination.
This rule shall not be construed to limit the authority of law enforcement, fire service, emergency
medical service providers, or other federal, state, or local officials to conduct emergency response,
investigation, or decontamination activities to the extent authorized by federal and state law and
accepted procedures and protocols.
e. Penalty. Pursuant to Iowa Code section 135.38, any individual who knowingly violates a lawful
department order for area quarantine, whether written or oral, shall be guilty of a simple misdemeanor.
The court-ordered sentence may include a fine of up to $500 and imprisonment not to exceed 30 days.
f. Enforcement action. To enforce a department order for quarantine, the department may file
a civil action in Polk County District Court or in the district court for the county in which the area
quarantine will be enforced. Such action shall be filed in accordance with the Iowa Rules of Civil
Procedure.
[ARC 8231B, IAB 10/7/09, effective 11/11/09]
SPECIFIC NONCOMMUNICABLE CONDITIONS
641—1.14(139A) Cancer. Each occurrence of a reportable cancer that is diagnosed or treated in an Iowa
resident or occurs in a nonresident who is diagnosed or treated in an Iowa facility shall be reported to
the State Health Registry of Iowa, administered by the Department of Epidemiology of the College of
Public Health at the University of Iowa, by mail, telephone or electronic means.
1.14(1) Who is required to report. Occurrences of reportable cancers shall be reported by registrars
employed by the State Health Registry of Iowa, registrars employed by health care facilities, and health
care providers involved in the diagnosis, care, or treatment of individuals with a reportable cancer.
1.14(2) What to report. The content of the reports shall include, but not be limited to, follow-up
data and demographic, diagnostic, treatment, and other medical information. Tissue samples may also
be submitted under the authority of this rule.
1.14(3) How to report. For these particular diseases, physicians and other health practitioners should
not send a report to the department.
a. The department has delegated to the State Health Registry of Iowa the responsibility for
collecting these data through review of records from hospitals, radiation treatment centers, outpatient
surgical facilities, oncology clinics, pathology laboratories, and physician offices.
b. Prior to collecting the data from an office or facility, the State Health Registry of Iowa shall
work with the office or facility to develop a process for abstracting records which is agreeable to the
office or facility.
c. Where applicable, reportable cancers shall be reported on forms developed and distributed by
the State Health Registry of Iowa.
d. Data will be supplemented with information obtained from records from hospitals, radiation
treatment centers, outpatient surgical centers, oncology clinics, pathology laboratories, and physician
offices through an abstracting process developed by the State Health Registry of Iowa.
[ARC 8231B, IAB 10/7/09, effective 11/11/09]
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641—1.15(144) Congenital and inherited disorders. Each occurrence of a congenital and inherited
disorder that is diagnosed or treated in an Iowa resident or occurs in a nonresident who is diagnosed
or treated in an Iowa facility is a reportable condition, and records of these congenital and inherited
disorders shall be abstracted and maintained in a central registry. Congenital and inherited disorder
surveillance shall be performed in order to determine the occurrence and trends of congenital and
inherited disorders, to conduct thorough and complete epidemiological surveys, to assist in the planning
for and provision of services to children with congenital and inherited disorders and their families, and
to identify environmental and genetic risk factors for congenital and inherited disorders.
1.15(1) Who is required to report. Occurrences of reportable congenital and inherited disorders
shall be reported by registrars employed by the Iowa Registry for Congenital and Inherited Disorders,
registrars employed by health care facilities, and health care providers involved in the diagnosis, care,
or treatment of individuals with reportable congenital and inherited disorders.
1.15(2) What to report. The content of the reports shall include, but not be limited to, follow-up
data and demographic, diagnostic, treatment, and other medical information. Tissue samples may also
be submitted under the authority of this rule.
1.15(3) How to report.
a. The department has delegated to the Iowa Registry for Congenital and Inherited Disorders the
responsibility for collecting these data through review of records from hospitals, radiation treatment
centers, outpatient surgical facilities, oncology clinics, pathology laboratories, and physician offices.
b. Prior to collecting the data from an office or facility, the Iowa Registry for Congenital and
Inherited Disorders shall work with the office or facility to develop a process for abstracting records.
1.15(4) Fetal death (stillbirth). Each occurrence of a fetal death that occurs in an Iowa resident or
occurs in a nonresident who is identified in an Iowa facility is a reportable condition.
a. Providers shall complete the fetal death certificate supplied by the department.
b. Fetal death certificates are to be filed with the department’s bureau of vital records within seven
days.
[ARC 8231B, IAB 10/7/09, effective 11/11/09]
641—1.16(139A) Agriculturally related injury.
1.16(1) Who is required to report.
a. Health care providers are required to report all cases of agriculturally related injury attended
by them.
b. Clinics, hospitals and other health care facilities are required to report all cases of agriculturally
related injury treated at their facility.
c. Health care providers who reside and health care facilities that are located outside the state of
Iowa shall report all cases of agriculturally related injury of an Iowa resident that are attended or treated
by them.
d. Medical examiners are required to report their investigatory findings of any death occurring
within the state of Iowa which was caused by or otherwise involved a reportable agriculturally related
injury.
1.16(2) What to report. Each report shall contain all of the following information:
a. The patient’s name.
b. The patient’s address.
c. The patient’s date of birth.
d. The sex of the patient.
e. The race and ethnicity of the patient.
f. The patient’s marital status.
g. The patient’s telephone number.
h. If the patient is female, whether the patient is pregnant.
i. In the case of occupational conditions, the name of the patient’s employer.
j. The date that the injury occurred.
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k. The name and address of the health care provider who diagnosed and treated the injury, and the
name of the reporting site, clinic, or hospital.
l. Injury diagnosis and description, including diagnostic and external cause of injury codes
utilizing the international classification of diseases (ICD) coding system.
m. Severity of injury.
1.16(3) How to report.
a. All data shall be reported to the department at least quarterly using formats approved by the
department. Reports, using the Iowa Agricultural Injury Report Form found at www.idph.state.ia.us,
may be submitted by facsimile to (515)281-4529, or by mail to the Iowa Department of Public Health,
Bureau of Lead Poisoning Prevention, Occupational Safety and Health Surveillance Program, Lucas
State Office Building, 321 E. 12th Street, Des Moines, Iowa 50319-0075. Information may also be
reported by telephone to 1-800-972-2026 during normal office hours.
b. Trauma centers may report using the Iowa Trauma Patient Registry COLLECTOR software
by indicating “Yes” for farm and agriculturally related injury. For more information about using the
Iowa Trauma Patient Registry for reporting, contact the Iowa Department of Public Health Bureau of
Emergency Medical Services at 1-800-728-3367.
[ARC 8231B, IAB 10/7/09, effective 11/11/09]
CONFIDENTIALITY
641—1.17(139A,22) Confidentiality.
1.17(1) A report or other information provided to or maintained by the department, a local board, or
a local department which identifies a person infected with or exposed to a reportable or other disease or
health condition is confidential and shall not be accessible to the public.
1.17(2) The identity of a business named in a report or investigation is confidential and shall not
be accessible to the public. If information contained in a report or other information provided to or
maintained by the department, a local board, or a local department concerns a business, information
disclosing the identity of the business may be released to the public when the state public health medical
director and epidemiologist or the director determines such a release of information necessary for the
protection of the public.
1.17(3) Reportable disease records and information, with the exception of AIDS and HIV records,
which identify a person or a business named in a report, may be disclosed under the following limited
circumstances:
a. By and between department employees and agents who have a need for the record in the
performance of their duties.
b. By and between department employees and agents and local boards of health and local health
departments as necessary to conduct an investigation.
c. By and between department employees and agents and health care providers, laboratories, and
hospitals as necessary to conduct an investigation.
d. By and between department employees and agents and employees and agents of federal, state,
and local agencies as necessary to conduct an investigation.
e. Reportable disease information may be included in a quarantine or isolation order or placard as
necessary to prevent the spread of a quarantinable disease.
f. Pursuant to rule 641—175.9(17A,22) or 641—175.10(17A,22).
[ARC 8231B, IAB 10/7/09, effective 11/11/09]
These rules are intended to implement Iowa Code chapters 135, 136A, 139A, 141A and 144.
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APPENDIX A
Iowa Department of Public Health
Table of Reportable Communicable and Infectious Diseases
Report cases of the diseases listed in the following table to the department within the time frame specified
in the When to Report column and by the reporting method in the How to Report column.
To report diseases immediately, use the 24/7 disease reporting telephone hotline: 1-800-362-2736.
IMMEDIATELY report diseases, syndromes, poisonings and conditions of any kind suspected or
caused by a biological, chemical, or radiological agent or toxin when there is reasonable suspicion
that the disease, syndrome, poisoning or condition may be the result of a deliberate act such as
terrorism.
IMMEDIATELY report to the department outbreaks of any kind, diseases that occur in unusual
numbers or circumstances, unusual syndromes, or uncommon diseases. Outbreaks may be
infectious, environmental or occupational in origin and include food-borne outbreaks or illness
secondary to chemical exposure (e.g., pesticides, anhydrous ammonia).
Report diseases by:
Entering into the Iowa Disease Surveillance System (IDSS): For IDSS-related questions, call the Center
for Acute Disease Epidemiology (CADE) at 1-800-362-2736.
Fax: (515)281-5698
Mail:
Iowa Department of Public Health
Center for Acute Disease Epidemiology
Lucas State Office Building
321 E. 12th Street
Des Moines, Iowa 50319
Isolates shall be sent to:
University Hygienic Laboratory
102 Oakdale Campus, H101 OH
Iowa City, Iowa 52242
For specimen submission questions, call (319)335-4500 or go to http://www.uhl.uiowa.edu/.
Diseases When to Report How to Report
Acquired immune deficiency syndrome (AIDS)
and AIDS-defining conditions
7 days Report by mail
● Health care providers: use the Pediatric
or Adult Confidential Case Report Form
● Laboratories: send copy of lab report or
the Iowa Confidential Report of Sexually
Transmitted Disease & HIV Infection.
Mark envelope “Attention 03”
For HIV/AIDS-related questions, call
(515)242-5141
Anthrax 1 day Phone, IDSS, or fax
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Diseases When to Report How to Report
Arboviral disease (includes West Nile Disease,
St. Louis, LaCrosse, WEE, EEE, VEE
encephalitis)
3 days Phone, IDSS, fax or mail
Botulism Immediately 24/7 disease reporting telephone hotline:
800-362-2736
Brucellosis (Burcella) 3 days Phone, IDSS, fax or mail
Campylobacteriosis (Campylobacter) 3 days Phone, IDSS, fax or mail
Chlamydia 3 days Use the Iowa Confidential Report of Sexually
Transmitted Disease and HIV Infection
Cholera Immediately 24/7 disease reporting telephone hotline:
800-362-2736
Cryptosporidiosis 3 days Phone, IDSS, fax or mail
Cyclospora 3 days Phone, IDSS, fax or mail
Diphtheria Immediately 24/7 disease reporting telephone hotline:
800-362-2736
Enterococcus invasive disease 3 days Laboratories send isolate to the UHL
Escherichia coli shiga toxin-producing and
related diseases (includes HUS and TTP)
3 days Phone, IDSS, fax or mail
Laboratories send isolate to the UHL
Giardiasis (Giardia) 3 days Phone, IDSS, fax or mail
Gonorrhea 3 days Use the Iowa Confidential Report of Sexually
Transmitted Disease and HIV Infection
Group A Streptococcus invasive disease 3 days Send isolate to the UHL
Haemophilus influenza type B invasive disease Immediately 24/7 disease reporting telephone hotline:
800-362-2736
Laboratories send isolate to the UHL
Hansen’s disease (leprosy) 3 days Phone, IDSS, fax or mail
Hantavirus syndromes 3 days Phone, IDSS, fax or mail
Hepatitis A 1 day Phone, IDSS or fax
Hepatitis B, C, D, E 3 days Phone, IDSS, fax or mail
Human immunodeficiency virus (HIV) cases
Death of a person with HIV
Perinatally exposed newborn and child
(newborn and child who was born to an
HIV-infected mother)
7 days Report by mail
● Health care providers: use the Pediatric
or Adult Confidential Case Report Form
● Laboratories: send copy of lab report or
the Iowa Confidential Report of Sexually
Transmitted Disease & HIV Infection.
Mark envelope “Attention 03”
For HIV/AIDS-related questions, call
(515)242-5141
Legionellosis (Legionella) 3 days Phone, IDSS, fax or mail
Listeria monocytogenes invasive disease 1 day Phone, IDSS, or fax
Laboratories send isolate to the UHL
Lyme disease 3 days Phone, IDSS, fax or mail
Malaria 3 days Phone, IDSS, fax or mail
Measles (rubeola) Immediately 24/7 disease reporting telephone hotline:
800-362-2736
Meningococcal invasive disease Immediately 24/7 disease reporting telephone hotline:
800-362-2736
Laboratories send isolate to the UHL
Mumps 3 days Phone, IDSS, fax or mail
Pertussis 3 days Phone, IDSS, fax or mail
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Diseases When to Report How to Report
Plague Immediately 24/7 disease reporting telephone hotline:
800-362-2736
Poliomyelitis Immediately 24/7 disease reporting telephone hotline:
800-362-2736
Psittacosis 3 days Phone, IDSS, fax or mail
Rabies, animal 3 days Phone, IDSS, fax or mail
Rabies, human Immediately 24/7 disease reporting telephone hotline:
800-362-2736
Rocky Mountain spotted fever 3 days Phone, IDSS, fax or mail
Rubella (including congenital) 1 day Phone, IDSS, fax or mail
Salmonellosis (Salmonella) 3 days Phone, IDSS, fax or mail
Laboratories send isolate to the UHL
Severe acute respiratory syndrome (SARS) Immediately 24/7 disease reporting telephone hotline:
800-362-2736
Shigellosis (Shigella) 3 days Phone, IDSS, fax or mail
Laboratories send isolate to the UHL
Smallpox Immediately 24/7 disease reporting telephone hotline:
800-362-2736
Staphylococcus aureus invasive disease:
Methicillin-resistant invasive disease (number
of S. aureus isolates should be reported to the
department quarterly)
_________________________
Vancomycin-resistant S. aureus
3 days
___________
Immediately
Laboratories send isolate to the UHL
Mail the number of staphylococcus isolated
quarterly to UHL
_____________________________
24/7 disease reporting telephone hotline:
800-362-2736
Streptococcus pneumoniae invasive disease 3 days Laboratories send isolate to the UHL
Syphilis 3 days Use the Iowa Confidential Report of Sexually
Transmitted Disease and HIV Infection
Tetanus 3 days Phone, IDSS, fax or mail
Toxic Shock Syndrome 3 days Phone, IDSS, fax or mail
Trichinosis 3 days Phone, IDSS, fax or mail
Tuberculosis 3 days Phone, IDSS, fax or mail
Typhoid fever 1 day Phone, IDSS or fax
Yellow fever Immediately 24/7 disease reporting telephone hotline:
800-362-2736
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APPENDIX B
Iowa Department of Public Health
Table of Reportable Poisonings and Conditions
Report cases of the poisonings and conditions listed in the following table to the department within the
time frame specified in the When to Report column and by the reporting method in the How to Report
column.
To report diseases immediately, use the 24/7 disease reporting telephone hotline: 1-800-362-2736.
IMMEDIATELY report diseases, syndromes, poisonings and conditions of any kind suspected or
caused by a biological, chemical, or radiological agent or toxin when there is reasonable suspicion
that the disease, syndrome, poisoning or condition may be the result of a deliberate act such as
terrorism.
IMMEDIATELY report to the department outbreaks of any kind, diseases that occur in unusual
numbers or circumstances, unusual syndromes, or uncommon diseases. Outbreaks may be
infectious, environmental or occupational in origin and include food-borne outbreaks or illness
secondary to chemical exposure (e.g., pesticides, anhydrous ammonia).
Mailing address:
Bureau of Lead Poisoning Prevention Division of Environmental Health
Iowa Department of Public Health
321 East 12th Street
Des Moines Iowa 50319-0075
Telephone: 1-800-972-2026
Fax: (515)281-4529
Poisoning or Condition Cases to Report When to Report How to Report
Arsenic poisoning Blood arsenic values equal to or
greater than 70 µg/L
Urine arsenic values equal to or
greater than 100 µg/L of urinary
creatinine
Weekly Format specified by department.
Web-based reporting if available.
Alternatives include by mail,
telephone, and facsimile.
All analytical results greater than
or equal to 20 micrograms per
deciliter (µg/dL) in a child under
the age of 6 years or a pregnant
woman
Daily By telephone: 800-972-2026Blood lead testing
All other analytical values for all
blood lead analyses
Weekly Electronic format specified by
the department
Cadmium poisoning Blood cadmium values equal to
or greater than 5 µg/L
Urine cadmium values equal to
or greater than 3 µg/g
Weekly Format specified by department.
Web-based reporting if available.
Alternatives include by mail,
telephone, and facsimile.
Carbon monoxide (CO)
poisoning
Blood carbon monoxide level
equal to or greater than
10% carboxyhemoglobin or its
equivalent with a breath analyzer
test, or a clinical diagnosis of
CO poisoning regardless of any
test results
Daily By telephone: 800-972-2026
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Poisoning or Condition Cases to Report When to Report How to Report
Hypersensitivity
pneumonitis
All cases Weekly Format specified by department.
Web-based reporting if available.
Alternatives include by mail,
telephone, and facsimile.
Mercury poisoning Blood mercury values equal to
or greater than 2.8 µg/dL
Urine mercury values equal to or
greater than 20 µg/L
Weekly Format specified by department.
Web-based reporting if available.
Alternatives include by mail,
telephone, and facsimile.
Methemoglobinemia Blood analyses showing greater
than 5% of total hemoglobin
present as methemoglobin
Weekly Format specified by department.
Web-based reporting if available.
Alternatives include by mail,
telephone, and facsimile.
Noncommunicable
respiratory illness
All cases Weekly Format specified by department.
Web-based reporting if available.
Alternatives include by mail,
telephone, and facsimile.
Occupationally related
asthma, bronchitis or
respiratory hypersensitivity
reaction
All cases Weekly Format specified by department.
Web-based reporting if available.
Alternatives include by mail,
telephone, and facsimile.
Pesticide poisoning
(including pesticide-related
contact dermatitis)
All cases Weekly Format specified by department.
Web-based reporting if available.
Alternatives include by mail,
telephone, and facsimile.
Severe skin disorder All cases Weekly Format specified by department.
Web-based reporting if available.
Alternatives include by mail,
telephone, and facsimile.
Toxic hepatitis All cases Weekly Format specified by department.
Web-based reporting if available.
Alternatives include by mail,
telephone, and facsimile
[Filed November 20, 1970; amended August 31, 1971]
[Filed emergency 8/15/77—published 9/7/77, effective 8/15/77]
[Filed 11/10/77, Notice 10/5/77—published 11/30/77, effective 1/4/78]
[Filed 4/3/81, Notice 2/18/81—published 4/29/81, effective 6/5/81]
[Filed 2/12/82, Notice 10/28/81—published 3/3/82, effective 4/7/82]
[Filed 11/18/83, Notice 8/31/83—published 12/7/83, effective 1/13/84]
[Filed 8/14/85, Notice 4/24/85—published 9/11/85, effective 10/16/85]
[Filed emergency 7/10/87—published 7/29/87, effective 7/10/87]
[Filed 11/17/88, Notice 6/1/88—published 12/14/88, effective 1/18/89]
[Filed 5/10/89, Notice 4/5/89—published 5/31/89, effective 7/5/89]
[Filed 11/9/89, Notice 10/4/89—published 11/29/89, effective 1/3/90]
[Filed 9/24/90, Notice 8/8/90—published 10/17/90, effective 11/21/90]
[Filed 7/17/92, Notice 4/1/92—published 8/5/92, effective 9/9/92]
[Filed 11/6/92, Notice 9/16/92—published 11/25/92, effective 1/1/93]
[Filed 7/16/93, Notice 4/28/93—published 8/4/93, effective 9/8/93]
[Filed emergency 1/11/96 after Notice 11/8/95—published 1/31/96, effective 1/12/96]
[Filed 3/15/96, Notice 1/31/96—published 4/10/96, effective 5/15/96]
[Filed 7/10/98, Notice 5/6/98—published 7/29/98, effective 9/2/98]
[Filed 11/10/98, Notice 9/23/98—published 12/2/98, effective 1/6/99]
[Filed 5/10/01, Notice 4/4/01—published 5/30/01, effective 7/4/01]
[Filed emergency 9/14/01—published 10/3/01, effective 9/14/01]
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[Filed 11/19/01, Notice 10/3/01—published 12/12/01, effective 1/16/02]◊
[Filed 1/16/04, Notice 12/10/03—published 2/4/04, effective 3/10/04]
[Filed 1/13/05, Notice 11/24/04—published 2/2/05, effective 3/9/05]
[Filed 5/12/05, Notice 3/30/05—published 6/8/05, effective 7/13/05]
[Filed 1/10/07, Notice 11/22/06—published 1/31/07, effective 3/7/07]
[Filed 11/14/07, Notice 10/10/07—published 12/5/07, effective 1/9/08]
[Filed ARC 8231B (Notice ARC 7966B, IAB 7/15/09), IAB 10/7/09, effective 11/11/09]
IAC 12/11/13 Public Health[641] Ch 11, p.1
CHAPTER 11
HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION AND
ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS)
641—11.1(139A,141A) Definitions. For the purpose of rules 641—11.1(139A,141A) to
641—11.34(915), the following definitions shall apply:
“AIDS”means acquired immune deficiency syndrome as defined by the Centers for Disease Control
and Prevention of the U.S. Department of Health and Human Services.
“AIDS-related condition”means any condition resulting fromHIV infection thatmeets the definition
of AIDS as established by the Centers for Disease Control and Prevention of the U.S. Department of
Health and Human Services.
“Blood bank” means a facility for the collection, processing, or storage of human blood or blood
derivatives, or from which or by means of which human blood or blood derivatives are distributed or
otherwise made available.
“CDC”means the Centers for Disease Control and Prevention of the U.S. Department of Health and
Human Services.
“CLIA” means Clinical Laboratory Improvement Amendments as administered by the Centers for
Medicare and Medicaid Services of the U.S. Department of Health and Human Services.
“Clinical laboratory”means a facility for themicrobiological, serological, chemical, hematological,
radiobioassay, cytological, immunohematological, pathological or other examination of materials
derived from the human body for the purpose of providing information for the diagnosis, prevention, or
treatment of any disease or assessment of a medical condition.
“Confirmed positive test” means a reactive result or detectable quantity on any HIV-related test,
including an antibody test, an antigen test, a culture, a nucleic acid amplification test, or other test or
combination of tests, that is considered to be confirmatory according to prevailing medical technology
and algorithms or guidance from CDC. When the confirmed positive test involves more than one test,
all test results should be included in any reports to the department.
“Department” means the Iowa department of public health.
“Director of a plasma center, blood bank, clinical laboratory, or public health laboratory” means
the person responsible for direction and operation of the facility, the medical director, or the person
designated by the director or medical director to ensure compliance with applicable regulations and
requirements.
“Emergency medical services personnel” means “emergency medical care provider” as defined in
641—131.1(147A).
“Health care facility” means a health care facility as defined in Iowa Code section 135C.1, an
ambulatory surgical center, or a clinic.
“Health care provider” means a person licensed to practice medicine and surgery, osteopathic
medicine and surgery, chiropractic, podiatry, nursing, dentistry, or optometry, or licensed as a physician
assistant, dental hygienist, or acupuncturist.
“Health facility”means a hospital, health care facility, clinic, blood bank, blood center, sperm bank,
laboratory organ transplant center and procurement agency, or other health care institution.
“HIV” means the human immunodeficiency virus identified as the causative agent of AIDS.
“HIV infection” means having acquired the human immunodeficiency virus.
“HIV-related test” means a diagnostic test conducted by a laboratory approved pursuant to CLIA
for determining the presence of HIV or antibodies to HIV.
“Laboratory” means a clinical or public health laboratory, a plasma center, or a blood bank inside
or outside the boundaries of Iowa.
“Physician” means a person currently licensed pursuant to Iowa Code chapter 148.
“Plasma center” means a facility that conducts plasmapheresis.
“Plasmapheresis” means the removal of blood from a human being to obtain plasma with the
subsequent reinfusion of the remaining formed elements into the donor, but excludes such a procedure
performed for the purpose of improving the health of the donor.
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“Public health laboratory” means a laboratory operated by an agency of city, county or state
government for the purpose of supporting disease control activities.
“Sexually transmitted disease or infection” means “sexually transmitted disease or infection” as
defined in 641—1.1(139A).
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.2(141A) HIV testing—obtaining consent—voluntary HIV-related tests for adults who are
not pregnant.
11.2(1) Prior to conducting a voluntary HIV-related test on an adult, the health care provider
requesting the test shall provide information to the subject of the test concerning HIV testing and where
to obtain additional information regarding HIV infection and risk reduction.
11.2(2) All adults who are able must give consent for an HIV test, but a separate written consent
solely for the purpose of HIV testing shall not be required. If an adult signs a general consent form for
the performance of medical tests or procedures, the signing of an additional consent form for the purpose
of consenting to an HIV-related test is not required during the time in which the general consent form
is in effect. If an adult has not signed a general consent form for the performance of medical tests and
procedures, or if the consent form is no longer in effect, a health care provider shall obtain oral or written
consent prior to performing the HIV-related test.
11.2(3) If an adult is unable to give consent, the adult’s legal guardian may provide oral or written
consent. If the adult’s legal guardian cannot be located or is unavailable, a health care provider may
authorize the HIV-related test when the test results are necessary for diagnostic purposes to provide
appropriate urgent medical care.
11.2(4) Once an adult has been informed of a confirmed positive HIV-related test, no HIV-specific
consent for medical procedures and tests shall be required for subsequent medical procedures and tests
involved in the care or treatment of the adult with HIV infection.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.3(139A,141A) HIV testing—obtaining consent—voluntary HIV-related tests for minors
who are not pregnant.
11.3(1) A minor shall have the legal capacity to act and give consent to the provision of medical
care or services for the prevention, diagnosis, or treatment of HIV by a hospital, clinic, or health care
provider. Consent shall not be subject to later disaffirmance by reason of such minority. The consent of
another person, including but not limited to the consent of a spouse, parent, custodian, or guardian, shall
not be necessary.
11.3(2) Prior to conducting a voluntary HIV-related test on a minor, the health care provider
requesting the test shall provide information to the subject of the test concerning HIV testing and where
to obtain additional information regarding HIV infection and risk reduction.
11.3(3) A minor shall be informed prior to testing that, upon confirmation according to prevailing
medical technology of a positive HIV-related test result, the minor’s legal guardian is required to be
informed by the health facility conducting the test. Health facilities where minors are tested shall have
available a program to notify the legal guardian of a newly diagnosed minor. The notification process
shall emphasize the need for family support and shall assist in making available the resources necessary
to accomplish that goal. However, a health facility which is precluded by federal statute, regulation, or
CDC guidelines from informing the legal guardian is exempt from the notification requirement.
11.3(4) Prior to the test, a minor shall give written consent for performance of the HIV-related test
and to the notification of the legal guardian should the test be confirmed as positive.
11.3(5) If a minor is unable to provide consent for an HIV-related test, the minor’s legal guardian
may provide oral or written consent for the minor. If the minor’s legal guardian cannot be located or is
unavailable, a health care provider may authorize the HIV-related test when the test results are necessary
for diagnostic purposes to provide appropriate urgent medical care.
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11.3(6) Once a minor has been informed of a confirmed positive HIV-related test and the legal
guardian has been notified, no HIV-specific consent for medical procedures and tests shall be required for
subsequent medical procedures and tests involved in the care or treatment of a minor with HIV infection.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.4(141A) HIV testing—obtaining consent—voluntary HIV-related tests for pregnant
women.
11.4(1) All pregnant women, includingminors, shall be tested for HIV infection as part of the routine
panel of prenatal tests. The health care provider requesting the test shall notify a pregnant woman that
HIV screening is recommended for all prenatal patients and that the pregnant woman will receive an
HIV test as part of the routine panel of prenatal tests unless the pregnant woman objects to the test. No
written or oral consent shall be required.
11.4(2) The testing shall occur as early as possible during each pregnancy.
11.4(3) The health care provider requesting the test shall make information about HIV prevention,
risk reduction, and treatment opportunities to reduce the possible transmission of HIV to a fetus available
to all pregnant women.
11.4(4) A pregnant woman who is a minor shall be informed prior to testing that, upon confirmation
according to prevailing medical technology of a positive HIV-related test result, the minor’s legal
guardian is required to be informed by the health facility conducting the test. Health facilities where
minors are tested shall have available a program to notify the legal guardian of a newly diagnosed
minor. The notification process shall emphasize the need for family support and shall assist in making
available the resources necessary to accomplish that goal. However, a health facility which is precluded
by federal statute, regulation, or CDC guidelines from informing the legal guardian is exempt from the
notification requirement.
11.4(5) If a pregnant woman objects to and declines the test, the decision shall be documented in the
pregnant woman’s medical record by the health care provider. A health care provider shall encourage
women who decline the test early in prenatal care to be tested at a subsequent visit.
11.4(6) Once a pregnant woman has been informed of a confirmed positive HIV-related test and, if
the pregnant woman is a minor, the legal guardian has been notified, no HIV-specific consent for medical
procedures and tests shall be required for subsequent medical procedures and tests involved in the care
or treatment of a pregnant woman with HIV infection.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.5(141A) HIV test results—post-test counseling.
11.5(1) At any time that the subject of an HIV-related test is informed of a confirmed positive
test result, the health care provider who requested the test or other designated personnel shall initiate
counseling concerning the emotional and physical health effects of HIV infection. Particular attention
shall be given to explaining the need for the precautions necessary to avoid transmitting the virus. The
subject of the test shall be given information concerning where to obtain additional counseling. If a
legal guardian of the subject of the test provided consent to the test, the counseling shall be given to
the legal guardian.
11.5(2) Post-test counseling requirements do not apply to any of the following:
a. The performance of an HIV-related test by a health care provider or health facility when the
health care provider or health facility procures, processes, distributes, or uses a human body part donated
for a purpose specified under the revised uniform anatomical gift Act as provided in Iowa Code chapter
142C, or semen provided prior to July 1, 1988, for the purpose of artificial insemination, or donations of
blood, and such test is necessary to ensure medical acceptability of such gift or semen for the purposes
intended.
b. A person engaged in the business of insurance who is subject to Iowa Code section 505.15.
c. The performance of an HIV-related test by a health care provider or health facility when the
subject of the test is deceased and a documented significant exposure has occurred.
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d. The performance of an HIV-related test by a health care provider or health facility when the
subject of the test is unable to provide consent and the health care provider or health facility provided
consent for the subject of the test.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.6(141A) Reporting of diagnoses and HIV-related tests, events, and conditions to the
department.
11.6(1) The following constitute reportable events related to HIV infection:
a. A test result indicating HIV infection, including:
(1) Confirmed positive results on any HIV-related test or combination of tests, including antibody
tests, antigen tests, cultures, and nucleic acid amplification tests.
(2) A positive result or report of a detectable quantity on any other HIV detection (non-antibody)
tests, and results of all viral loads, including nondetectable levels.
b. AIDS and AIDS-related conditions, including all levels of CD4+ T-lymphocyte counts.
c. Birth of an infant to an HIV-infected mother (perinatal exposure) or any (positive, negative,
or undetectable) non-antibody detection test (antigen test, viral culture, viral load, or qualitative nucleic
acid amplification test) on an infant 18 months of age or younger.
d. Death resulting from an AIDS-related condition, or death of a person with HIV infection.
11.6(2) Within seven days of the receipt of a person’s confirmed positive test result indicating HIV
infection, the director of a plasma center, blood bank, clinical laboratory or public health laboratory that
performed the test or that requested the confirmatory test shall make a report to the department on a form
provided by the department.
11.6(3) Within seven days of the receipt of a test result indicating HIV infection, which has been
confirmed as positive according to prevailing medical technology, or immediately after the initial
examination or treatment of a person infected with HIV, the physician or other health care provider at
whose request the test was performed or who performed the initial examination or treatment shall make
a report to the department on a form provided by the department.
11.6(4) Within seven days of diagnosing a person as having AIDS or an AIDS-related condition, the
diagnosing physician shall make a report to the department on a form provided by the department.
11.6(5) Within seven days of the death of a person with HIV infection, the attending physician shall
make a report to the department on a form provided by the department.
11.6(6) Within seven days of the birth of an infant to an HIV-infected mother or a receipt of a
laboratory result (positive, negative, or undetectable) of a non-antibody detection test (antigen test, viral
culture, viral load, or qualitative nucleic acid amplification test) on an infant 18months of age or younger,
the attending physician shall make a report to the department on a form provided by the department.
11.6(7) The report shall include:
a. The person’s name, address, date of birth, gender, race and ethnicity, marital status, and
telephone number.
b. The name, address and telephone number of the plasma center, blood bank, clinical laboratory
or public health laboratory that performed or requested the test, if a test was performed.
c. The address of the physician or other health care provider who requested the test.
d. If the person is female, whether the person is pregnant.
11.6(8) All persons who experience a reportable event while receiving services in the state,
regardless of state of residence, shall be reported.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.7(141A) Penalties.
11.7(1) A director of a plasma center, blood bank, clinical laboratory or public health laboratory
or a physician or other health care provider who repeatedly fails to file the report required pursuant to
these rules is subject to a report being made to the licensing board governing the professional activities
of the individual. The department shall notify the individual each time the department determines that
the individual has failed to file a required report. The department shall inform the individual in the
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notification that the individual may provide information to the department to explain or dispute the failure
to report.
11.7(2) A public, private, or hospital clinical laboratory that repeatedly fails to make the report
required under these rules is subject to a civil penalty of not more than $1,000 per occurrence. The
department shall not impose the penalty without prior written notice and opportunity for hearing.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.8(141A) Immunity. An individual who makes a report in good faith pursuant to these rules is
immune from any liability, civil or criminal, which might otherwise be incurred or imposed as a result
of the report.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
Rules 641—11.1(139A,141A) to 641—11.8(141A) are intended to implement Iowa Code sections
139A.35, 141A.4, 141A.6, 141A.7 and 141A.10.
641—11.9 and 11.10 Reserved.
TRAINING PROGRAMS
641—11.11(135) Purpose. The purpose of this rule is to describe the required content of AIDS training
programs and to identify the groups of personnel involved.
11.11(1) Nonemergency personnel. Within six months of their initial employment, all supervisory
and patient care personnel of any agency listed below shall complete a minimum of two hours of training
concerning AIDS-related conditions and the prevention of HIV infection:
a. A licensed hospice,
b. A homemaker-home health aide provider agency which receives state homemaker-home health
aide funds, or
c. An agencywhich provides respite care services and receives state funds for respite care services.
11.11(2) Content. Training programs must address the following topics:
a. HIV disease processes,
b. Signs and symptoms,
c. Transmission,
d. High-risk activities,
e. Prevention recommendations, and
f. Standard precautions as defined by the CDC and the Occupational Safety and Health
Administration of the U.S. Department of Labor.
11.11(3) Emergency and law enforcement personnel. All emergency medical services personnel,
firefighters, and law enforcement personnel shall complete a minimum of two hours of training
concerning AIDS-related conditions and the prevention of HIV infection.
11.11(4) Content. Training programs must address the following topics:
a. HIV disease processes,
b. Signs and symptoms,
c. Transmission,
d. High-risk activities,
e. Prevention recommendations, and
f. Standard precautions as defined by the CDC and the Occupational Safety and Health
Administration of the U.S. Department of Labor.
This rule is intended to implement Iowa Code section 135.11.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.12 to 11.14 Reserved.
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PARTNER NOTIFICATION SERVICES AND DIRECT NOTIFICATION OF AN IDENTIFIABLE THIRD PARTY
641—11.15(139A,141A) Purpose. The purpose of rules 641—11.15(139A,141A) to 641—11.18(141A)
is to establish a voluntary partner notification program, including a procedure to allow a physician or the
department to notify an identifiable third party of an HIV-infected person directly that the party has been
exposed to HIV when the HIV-infected person will not participate in the voluntary partner notification
program.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.16(139A,141A) Definitions. For the purpose of rules 641—11.15(139A,141A) to
641—11.18(141A), the following definitions shall apply:
“Identifiable third party” means a sexual partner of or a person who shares drug injecting equipment
with a person who has been diagnosed with HIV infection.
“Partner notification” means services provided to a person who has tested positive for a sexually
transmitted disease or infection or to the person’s sexual or needle-sharing partners or social contacts.
These services include, but are not limited to, counseling about the nature of the disease, modes
of transmission, and risk reduction techniques; treatment or linkage to medical care and treatment;
assessment for and referral to social or medical services; elicitation of exposed partners’ names and
contact information; testing for other diseases or conditions; and provision of or referral to other
prevention services.
“Significant exposure” means “significant exposure” as defined in 641—11.22(139A).
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.17(139A,141A) Partner notification services by the department.
11.17(1) The department shall maintain a partner notification program for persons known to have
tested positive for sexually transmitted diseases or infections. In administering the program, the
department shall provide for the following:
a. A physician or other health care provider shall encourage a person who tests positive for a
sexually transmitted disease or infection to refer for counseling and testing any party with whom the
newly diagnosed person has had sexual relations or has shared drug injecting equipment.
b. The physician or other health care provider attending the personwho tests positive for a sexually
transmitted disease or infection may provide to the department any relevant information provided by the
tested person regarding any party with whom the tested person has had sexual relations or has shared
drug injecting equipment.
11.17(2) When making contact with partners of a person with a sexually transmitted disease or
infection, the department shall not disclose the identity of the person who provided the names of the
partners and shall protect the confidentiality of the partners who are contacted.
11.17(3) The department may delegate its partner notification duties under subrule 11.17(1) for
persons who have tested positive for HIV infection to a local health authority unless the authority
refuses or neglects to conduct the partner notification program in a manner deemed to be effective by
the department.
11.17(4) The department may delegate its partner notification duties under subrule 11.17(1) for
persons who have tested positive for sexually transmitted diseases other than HIV infection to a local
health authority or a physician or other health care provider unless the authority or physician or other
health care provider refuses or neglects to conduct the partner notification program in a manner deemed
to be effective by the department.
11.17(5) In addition to the provisions for partner notification provided under these rules and
notwithstanding any provision to the contrary, a county medical examiner or deputy medical examiner
performing official duties pursuant to Iowa Code sections 331.801 through 331.805 or the state medical
examiner or deputy medical examiner performing official duties pursuant to Iowa Code chapter 691
who determines through an investigation that a deceased person was infected with HIV may notify
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directly, or request that the department notify, the immediate family of the deceased or any person
known to have had a significant exposure from the deceased of the finding.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.18(141A) Direct notification of an identifiable third party by a physician or the
department.
11.18(1) Direct notification shall be used when an HIV-infected person is having continuing contact
with a sexual or needle-sharing partner who is unaware of the person’s infection and when both of the
following situations exist:
a. A physician for the HIV-infected person is of the good-faith opinion that the nature of the
continuing contact through sexual intercourse or the sharing of drug injecting equipment poses an
imminent danger of HIV transmission to the third party.
b. When the physician believes in good faith that the HIV-infected person, despite strong
encouragement, has not and will not warn the third party and will not participate in the voluntary partner
notification program.
11.18(2) The department or a physician may reveal the identity of an HIV-infected person pursuant
to this rule only to the extent necessary to protect a third party from the direct threat of transmission.
Notification of a person pursuant to this rule shall be made confidentially. Nothing in this rule shall be
interpreted to create a duty to warn third parties of the danger of exposure to HIV through contact with
an HIV-infected person.
11.18(3) When the physician is of the good-faith opinion and belief that third-party notification
should be performed, notification of a person pursuant to this rule shall be made:
a. Directly by the physician in accordance with subrules 11.18(4), 11.18(5) and 11.18(7), or
b. By the department at the request of the physician in accordance with subrules 11.18(6) and
11.18(7).
11.18(4) Notification by the physician. Prior to notification of a third party by an HIV-infected
person’s physician, the physician shall make reasonable efforts to inform, in writing, the HIV-infected
person. The written information shall state that, due to the nature of the person’s continuing contact
through sexual intercourse or the sharing of drug injecting equipment with the third party and the
physician’s belief that the HIV-infected person, despite strong encouragement, has not and will not warn
the third party and will not participate in the voluntary partner notification program, the physician is
forced to take action to provide notification to the third party. The physician, when reasonably possible,
shall provide the following information to the HIV-infected person:
a. The nature of the disclosure and the reason for the disclosure.
b. The anticipated date of disclosure.
c. The name of the party or parties to whom disclosure is to be made.
NOTE: Reasonable efforts to inform, in writing, the HIV-infected person shall be deemed satisfied when
the physician delivers the written notice in person or directs a written notice to the HIV-infected person’s
last-known address by restricted certified mail, return receipt requested, at least five days prior to the
anticipated date of disclosure to the third party.
11.18(5) When performed by the HIV-infected person’s physician, notification of the third party and
any disclosure concerning the purpose of that notification shall be made in person. However, initial
contact with the third party may be made by telephone, mail, or other electronic means to arrange the
meeting with the physician at the earliest opportunity to discuss an important health matter. The nature
of the health matter to be discussed shall not be revealed in the telephone call, letter, or other electronic
message.
11.18(6) Notification by the department.
a. The physician attending the HIV-infected person shall provide by telephone to the department
any relevant information provided by the HIV-infected person regarding any party with whom the
HIV-infected person has had sexual relations or has shared drug injecting equipment. The information
may include the third party’s name, address, telephone number, and any other locating information
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known to the physician. The department shall use the information in accordance with procedures
established for the voluntary partner notification program.
b. Notification of the third party and any disclosure concerning the purpose of that notification
shall be made in person. However, initial contact with the third party may be made by telephone, mail,
or other electronic means to arrange the meeting with the department representative. The nature of the
matter to be discussed shall not be revealed in the telephone call, letter, or other electronic message.
11.18(7) Confidentiality. The HIV-infected person’s physician and the department shall protect
the confidentiality of the third party and the HIV-infected person. The identity of the HIV-infected
person shall remain confidential unless it is necessary to reveal it to the third party so that the third
party may avoid exposure to HIV. If the identity of the HIV-infected person is revealed, the third party
shall be presented with a statement in writing at the time of disclosure which includes the following
or substantially similar language: “Confidential information revealing the identity of a person infected
with HIV has been disclosed to you. The confidentiality of this information is protected by state law.
State law prohibits you from making any further disclosure of the information without the specific
written consent of the person to whom it pertains. Any breach of the required confidential treatment
of this information subjects you to legal action and civil liability for monetary damages. A general
authorization for the release of medical or other information is not sufficient for this purpose.”
11.18(8) Immunity. A health care provider attending an HIV-infected person has no duty to disclose
to or to warn third parties of the dangers of exposure to HIV through contact with the HIV-infected
person and is immune from any liability, civil or criminal, for failure to disclose to or warn third parties
of the condition of the HIV-infected person.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
Rules 641—11.15(139A,141A) to 641—11.18(141A) are intended to implement Iowa Code sections
139A.33 and 141A.5.
641—11.19 and 11.20 Reserved.
CARE PROVIDERS EXPOSED TO CONTAGIOUS OR INFECTIOUS DISEASES
641—11.21(139A) Purpose. The purpose of these rules is to implement Iowa Code section 139A.19,
relating to care providers who are exposed to contagious or infectious diseases.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.22(139A) Definitions. For the purpose of rules 641—11.21(139A) to 641—11.26(139A), the
following definitions shall apply:
“AIDS” means acquired immune deficiency syndrome as defined by CDC.
“Blood-borne viral hepatitis” means hepatitis B or hepatitis C.
“Care provider” means an individual who is trained and authorized by federal or state law to
provide health care services or services of any kind in the course of the individual’s official duties,
for compensation or in a voluntary capacity, who is a health care provider, emergency medical care
provider as defined in Iowa Code section 147A.1, firefighter, or peace officer. “Care provider” also
means an individual who renders emergency care or assistance in an emergency or due to an accident
as described in Iowa Code section 613.17.
“CDC”means the Centers for Disease Control and Prevention of the U.S. Department of Health and
Human Services.
“Certification of a significant exposure report” means the determination by an authorized infection
preventionist, occupational health professional, or other personnel trained in infection control or
infectious disease medicine and designated by a facility to review significant exposure reports that the
incident described by the exposed care provider meets the definition of a significant exposure as defined
in this rule.
“Contagious or infectious disease”means blood-borne viral hepatitis, meningococcal disease, AIDS
or HIV, tuberculosis, and any other disease determined to be life-threatening to a person exposed to the
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disease as established by the department based upon a determination by the state epidemiologist and in
accordance with guidelines from CDC.
“Department of corrections” means the Iowa department of corrections.
“Designated representative” means a person who is designated by a department, agency, division,
or service organization to act on behalf of the exposed care provider as a liaison with the facility that
received the source patient when the exposure occurred in the field or during patient transport.
“Exposure” means a specific eye, mouth, other mucous membrane, nonintact skin, or parenteral
contact with blood or other potentially infectious bodily fluids.
“HBV” means hepatitis B virus.
“Health care facility” means a health care facility as defined in Iowa Code section 135C.1, an
ambulatory surgical center, or a clinic.
“Health care provider” means a person licensed to practice medicine and surgery, osteopathic
medicine and surgery, chiropractic, podiatry, nursing, dentistry, optometry, or as a physician assistant,
dental hygienist, or acupuncturist.
“HIV” means the human immunodeficiency virus identified as the causative agent of AIDS.
“Home health services” means health care services provided by a care provider in a patient’s home
or other residence.
“Infectious bodily fluids” means bodily fluids capable of transmitting HIV as listed in “Guidelines
for Prevention of Transmission of Human Immunodeficiency Virus and Hepatitis B Virus to Health-Care
and Public-Safety Workers,” found in Morbidity and Mortality Weekly Report, dated June 23, 1989,
Volume 38, Number S-6, published by the U.S. Department of Health andHuman Services, Public Health
Service, Centers for Disease Control, Atlanta, Georgia 30333, or subsequent CDC statements on this
topic. To prevent HIV and blood-borne viral hepatitis disease transmission, this reference indicates that
standard precautions should be followed for exposure to the following infectious bodily fluids: blood,
amniotic fluid, pericardial fluid, peritoneal fluid, pleural fluid, synovial fluid, cerebrospinal fluid, semen,
vaginal secretions, and saliva contaminated with blood. HIV and blood-borne viral hepatitis disease
transmission has not occurred from feces, nasal secretions, sputum, sweat, tears, urine, vomitus, and
saliva when it is not contaminated with blood.
“Respite care services” means health care services provided by a care provider in a patient’s home
or other residence on a short-term, temporary basis as relief to those who are caring for family members.
“Significant exposure” means a situation in which there is a risk of contracting disease through
exposure to a patient’s infectious bodily fluids in a manner capable of transmitting an infectious agent
as determined by CDC. Exposure includes contact with blood or other infectious bodily fluids to which
standard precautions apply through percutaneous inoculation or contact with an open wound, nonintact
skin, or mucous membranes during the performance of normal job duties. Significant exposures include:
1. Transmission of blood, bloody fluids, or other infectious bodily fluids of the source patient onto
a mucous membrane (mouth, nose, or eyes) of the care provider.
2. Transmission of blood, bloody fluids, or other infectious bodily fluids of the source patient onto
an open wound or lesion with significant breakdown in the skin barrier, including a needle puncture with
a needle contaminated with blood, bloody fluids, or other infectious bodily fluids.
“Significant exposure report” means the Report of Exposure to HIV or Other Infectious Disease
form provided by the department. This is the only form authorized to be used to document a significant
exposure to infectious bodily fluids such that the source patient is deemed to consent to a test to determine
if the patient has a contagious or infectious disease, and is deemed to consent to notification of the care
provider of the results of the test, pursuant to Iowa Code section 139A.19.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.23(139A,141A) Exposures in non-clinical settings.
11.23(1) If a care provider sustains a significant exposure from a patient while rendering health care
or other services, other than home-health or respite care services, outside of a health care facility or
hospital, the care provider shall file a significant exposure report as soon as reasonably possible following
the exposure. When the exposure occurred outside a clinical setting, a care provider who has sustained
Ch 11, p.10 Public Health[641] IAC 12/11/13
a significant exposure should file this report with the infection control, occupational health, or other
designated office of the facility to which the patient was transported.
11.23(2) The source patient to whom the care provider was exposed is deemed to consent to a test
to determine if the patient has a contagious or infectious disease and is deemed to consent to notification
of the care provider or the designated representative of the results of the test, upon submission of
a significant exposure report and certification of the significant exposure by an authorized infection
preventionist, occupational health professional, or other professional trained in infectious disease
control. No further consent from the source patient is required. However, the source patient shall be
notified that an exposure has occurred and shall be told which specific tests are being performed to
determine the presence of contagious or infectious diseases. If the source patient is a minor, the minor
shall be informed prior to an HIV-related test that, upon positive confirmation of an HIV-related test
result, the minor’s legal guardian shall be informed of the positive result, pursuant to Iowa Code section
141A.7(3).
11.23(3) Hospitals, clinics, or other health care facilities, institutions administered by the
department of corrections, and jails shall have written policies and procedures for reviewing and
certifying significant exposure report forms, testing a source patient, and notifying a care provider
who sustained a significant exposure while rendering health care services or other services to the
source patient when the source patient is delivered to the facility and the exposure occurred prior to the
delivery. The policies and procedures shall include the possibility for the care provider to designate a
representative to whom notification shall be provided and who shall, in turn, notify the care provider.
The identity of the designated representative of the care provider shall not be revealed to the source
patient. The designated representative shall inform the hospital, clinic, or other health care facility,
institution administered by the department of corrections, or jail of those parties who received the
notification and, following receipt of this information and upon request of the source patient, the
hospital, clinic, or other health care facility, institution administered by the department of corrections,
or jail shall inform the source patient of the parties to whom notification was provided.
11.23(4) The hospital, clinic, or other health care facility to whom the source patient is delivered
shall conduct the test. If the source patient is delivered to an institution administered by the department
of corrections, the test shall be conducted by the staff physician of the institution. If the source patient is
delivered to a jail, the test shall be conducted by the attending physician of the jail or the county medical
examiner. If the source patient was deemed to consent upon certification of a significant exposure report,
the sample and test results shall only be identified by a number.
11.23(5) If a test result is positive, the hospital, clinic, or other health care facility, or other person
performing the test shall notify the source patient and make any required reports to the department
pursuant to Iowa Code sections 139A.3 and 141A.6. The report to the department shall include the
name of the source patient.
11.23(6) If a source patient is diagnosed or confirmed as having a contagious or infectious disease,
the hospital, clinic, or other health care facility, or other person performing the test shall notify the care
provider or the designated representative of the care provider who shall then notify the care provider. If
the source patient is a minor and is diagnosed with HIV infection, the hospital, clinic, or other health
facility, or other person performing the test shall notify the legal guardian of the minor.
11.23(7) The notification shall advise the care provider of possible exposure to a particular
contagious or infectious disease and recommend that the provider seek medical attention. The
notification shall be provided as soon as reasonably possible following determination that the source
patient has a contagious or infectious disease. The notification shall not include the name of the
source patient unless the patient consents. If the care provider who sustained a significant exposure
determines the identity of a source patient who has been diagnosed or confirmed as having a contagious
or infectious disease, the identity of the source patient shall be confidential information and shall not
be disclosed by the care provider to any other person unless a specific written release is obtained from
the source patient.
11.23(8) This rule does not preclude a hospital, clinic, other health care facility, or a health care
provider from providing notification to a care provider under circumstances in which the hospital’s,
IAC 12/11/13 Public Health[641] Ch 11, p.11
clinic’s, other health care facility’s, or health care provider’s policy provides for notification of the
hospital’s, clinic’s, other health care facility’s, or health care provider’s own employees of exposure
to a contagious or infectious disease that is not life-threatening if the notice does not reveal a source
patient’s name, unless the patient consents.
11.23(9) The infection control, occupational health, or other designated office of the facility shall
maintain a record of all significant exposure reports it receives and shall retain each report for a period
of five years.
11.23(10) The report form “Report of Exposure to HIV or Other Infectious Disease” is a confidential
record pursuant to Iowa Code section 141A.9.
11.23(11) The employer of a care provider who sustained a significant exposure shall pay the cost
of testing for the source patient and for the testing of the care provider, if the significant exposure was
sustained during the course of employment. However, the department shall assist a source patient and
an exposed care provider in finding resources to pay for the costs of the testing when a care provider was
exposed while rendering direct aid without compensation.
11.23(12) A hospital’s, clinic’s, other health care facility’s, or health care provider’s duty to notify
under these rules is not continuing. It is limited to the diagnosis of a contagious or infectious disease
made in the course of admission, care, and treatment following the rendering of health care services or
other services to a patient who was the source of the significant exposure.
11.23(13) Notwithstanding subrule 11.23(12), the hospital, clinic, or other health care facility may
notify the exposed care provider if, following discharge from or completion of care or treatment by the
hospital, clinic, or other health care facility, the patient who was the source of the significant exposure,
and for whom a significant exposure report was submitted that did not result in notification of the exposed
care provider, wishes to provide information regarding the source patient’s contagious or infectious
disease status to the exposed care provider.
11.23(14) Notwithstanding any other provision of law to the contrary, a care provider may transmit
cautions regarding contagious or infectious disease information, with the exception of AIDS or HIV
pursuant to Iowa Code section 80.9B, in the course of the care provider’s duties over the police radio
broadcasting system under Iowa Code chapter 693 or any other radio-based communications system if
the information transmitted does not personally identify an individual.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.24(139A,141A) Exposures in clinical settings.
11.24(1) If a care provider sustains a significant exposure from a patient while rendering health
care services or other services within a hospital, clinic, or other health care facility, or while delivering
home-health or respite care services, the care provider shall file a report as soon as reasonably possible
following the exposure. A care provider who has sustained a significant exposure should file the report
with the infection control, occupational health, or other office designated by the facility in which the
exposure occurred, or by the facility which has oversight for the delivery of home-health or respite care
services.
a. If a general consent form was signed and in effect at the time of the significant exposure and
the source patient is an adult, a significant exposure report form shall not be required to document the
significant exposure. The health care facility or hospital may use an employee incident report or other
similar form for this purpose. The source patient to whom the care provider was exposed is deemed
to consent to a test to determine if the patient has a contagious or infectious disease and is deemed to
consent to notification of the care provider or the designated representative of the results of the test, upon
submission and review of an employee incident report and certification of the significant exposure by
an authorized infection preventionist, occupational health professional, or other professional trained in
infectious disease control. No further consent from the source patient is required. However, a source
patient shall be notified that an exposure has occurred and shall be told which specific tests are being
performed. Prior to conducting an HIV-related test, the health care facility or hospital shall provide
information to the source patient concerning testing and a means of obtaining additional information
regarding HIV infection and risk reduction pursuant to Iowa Code section 141A.6.
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b. If no consent form was signed or in effect at the time of the exposure, or if the source patient
is a minor, the source patient is deemed to consent to a test to determine if the patient has a contagious
or infectious disease and is deemed to consent to notification of the care provider or the designated
representative of the results of the test upon submission of a significant exposure report form and
certification of the significant exposure by an authorized infection preventionist, occupational health
professional, or other professional trained in infectious disease control. Source patients shall be notified
that an exposure has occurred and shall be told which specific tests are being performed to determine
the presence of contagious or infectious diseases. If the source patient is a minor, the minor shall be
informed prior to an HIV-related test that, upon positive confirmation of an HIV-related test result,
the minor’s legal guardian shall be informed of the positive result, pursuant to Iowa Code section
141A.7(3).
11.24(2) Hospitals, clinics, or other health care facilities, institutions administered by the department
of corrections, and jails shall havewritten policies and procedures for reviewing and certifying significant
exposure report forms or other employee incident report forms, testing a source patient, and notifying a
care provider who sustained a significant exposure while rendering health care services or other services
to a patient during the admission, care, or treatment of the patient at the facility, or while delivering
home-health or respite care services.
11.24(3) The hospital, clinic, or other health care facility where exposure occurred or which has
oversight for the delivery of home-health or respite care services shall conduct the test. If a general
consent form was signed and in effect and the source patient is an adult, the sample and test results shall
be identified by name. If the source patient was deemed to consent to a test and to notification of the
care provider upon certification of a significant exposure report pursuant to subrule 11.24(1) because no
general consent was signed and in effect at the time of the exposure or because the source patient is a
minor, the sample and test results shall be identified only by a number.
11.24(4) If a test result is positive, the hospital, clinic, or other health care facility or other person
performing the test shall notify the source patient and make any required reports to the department
pursuant to Iowa Code sections 139A.3 and 141A.6. The reports to the department shall include the
name of the source patient.
11.24(5) If a source patient is diagnosed or confirmed as having a contagious or infectious disease,
the hospital, clinic, or other health care facility or other person performing the test shall notify the care
provider or the designated representative of the care provider who shall then notify the care provider. If
the source patient is a minor and is diagnosed with HIV infection, the hospital, clinic, or other health
care facility or other person performing the test shall notify the legal guardian of the minor.
11.24(6) The notification shall advise the care provider of possible exposure to a particular
contagious or infectious disease and recommend that the provider seek medical attention. The
notification shall be provided as soon as reasonably possible following determination that the source
patient has a contagious or infectious disease.
11.24(7) This rule does not preclude a hospital, clinic, other health care facility, or a health care
provider from providing notification to a care provider under circumstances in which the hospital’s,
clinic’s, other health care facility’s, or health care provider’s policy provides for notification of the
hospital’s, clinic’s, other health care facility’s, or health care provider’s own employees of exposure
to a contagious or infectious disease that is not life-threatening if the notice does not reveal a source
patient’s name, unless the patient consents.
11.24(8) The infection control, occupational health, or other designated office of the facility shall
maintain a record of all significant exposure reports it receives and shall retain each report for a period
of five years.
11.24(9) The report form “Report of Exposure to HIV or Other Infectious Disease” is a confidential
record pursuant to Iowa Code section 141A.9.
11.24(10) The employer of a care provider who sustained a significant exposure shall pay the cost
of testing for the source patient and for the testing of the care provider, if the significant exposure was
sustained during the course of employment.
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11.24(11) A hospital’s, clinic’s, other health care facility’s, or health care provider’s duty to notify
under these rules is not continuing. It is limited to the diagnosis of a contagious or infectious disease
made in the course of admission, care, and treatment following the rendering of health care services or
other services to the patient who was the source of the significant exposure.
11.24(12) Notwithstanding subrule 11.24(11), the hospital, clinic, or other health care facility may
notify the exposed care provider if, following discharge from or completion of care or treatment by the
hospital, clinic, or other health care facility, the patient who was the source of the significant exposure,
and for whom a significant exposure report was submitted that did not result in notification of the exposed
care provider, wishes to provide information regarding the source patient’s contagious or infectious
disease status to the exposed care provider.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.25(139A) Immunity. Hospitals, clinics, health care providers, or other persons participating in
good faith in complying with provisions authorized or required under these rules are immune from any
liability, civil or criminal, which may otherwise be incurred or imposed.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.26(139A) Duty to test. A hospital, clinic, other health care facility, health care provider,
or other person who is authorized to perform a test under these rules has no duty to perform the test
authorized.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
Rules 641—11.21(139A) to 641—11.26(139A) are intended to implement Iowa Code section
139A.19.
641—11.27 to 11.29 Reserved.
HIV-RELATED TEST FOR CONVICTED OR ALLEGED SEXUAL-ASSAULT OFFENDERS AND VICTIMS
641—11.30(915) Purpose. The purpose of these rules is to describe procedures to follow for testing of
a convicted or alleged offender for HIV pursuant to Iowa Code chapter 915, and to establish procedures
to follow for providing counseling, health care, and support services to the victim.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.31(915) Definitions. For the purpose of rules 641—11.30(915) to 641—11.34(915), the
following definitions shall apply:
“AIDS”means acquired immune deficiency syndrome as defined by the Centers for Disease Control
and Prevention of the U.S. Department of Health and Human Services.
“Alleged offender” means a person who has been charged with the commission of a sexual assault
or a juvenile who has been charged in juvenile court with being a delinquent as a result of actions that
would constitute a sexual assault.
“Authorized representative” means an individual who is authorized by the victim to request an
HIV-related test of a convicted or alleged offender and who is any of the following:
1. The parent, guardian, or custodian of the victim if the victim is a minor.
2. The physician of the victim.
3. The victim counselor or person requested by the victim who is authorized to provide the
counseling regarding the HIV-related test and results.
4. The victim’s spouse.
5. The victim’s legal counsel.
“Convicted offender” means a person convicted of a sexual assault or a juvenile who has been
adjudicated delinquent for an act of sexual assault.
“Department” means the Iowa department of public health.
“Department of corrections” means the Iowa department of corrections.
“Division” means the crime victim assistance division of the office of the attorney general.
“HIV” means the human immunodeficiency virus identified as the causative agent of AIDS.
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“HIV-related test” means a diagnostic test conducted by a laboratory approved pursuant to CLIA
for determining the presence of HIV or antibodies to HIV.
“Petitioner”means a personwho is the victim of a sexual assault which resulted in alleged significant
exposure, or the parent, guardian, or custodian of a victim if the victim is a minor, for whom the county
attorney files a petition with the district court to require the convicted offender to undergo an HIV-related
test.
“Sexual assault” means sexual abuse as defined in Iowa Code section 709.1, or any other sexual
offense by which a victim has allegedly had sufficient contact with a convicted or an alleged offender to
be deemed a significant exposure.
“Significant exposure”means contact of the victim’s ruptured or broken skin or mucous membranes
with the blood or bodily fluids, other than tears, saliva, or perspiration, of the convicted or alleged
offender. “Significant exposure” is presumed to have occurred when there is a showing that there was
penetration of the convicted or alleged offender’s penis into the victim’s vagina or anus, contact between
the mouth and genitalia, or contact between the genitalia of the convicted or alleged offender and the
genitalia or anus of the victim.
“Victim” means a petitioner or a person who is the victim of a sexual assault which resulted in
significant exposure, or the parent, guardian, or custodian of such a victim if the victim is a minor, for
whom the victim or the peace officer files an application for a search warrant to require the alleged
offender to undergo an HIV-related test. “Victim” includes an alleged victim.
“Victim counselor”means a person who is engaged by a crime victim center as defined in Iowa Code
section 915.20A, who is certified as a counselor by the crime victim center, and who has completed at
least 20 hours of training provided by the Iowa coalition against sexual assault or a similar agency.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.32(915) HIV-related test—convicted or alleged sexual assault offender.
11.32(1) Unless a petitioner chooses to be represented by private counsel, the county attorney shall
represent the victim’s interest in all proceedings under Iowa Code chapter 915.
11.32(2) If a person is convicted of sexual assault or adjudicated delinquent for an act of sexual
assault, the county attorney, if requested by the petitioner, shall petition the court for an order requiring
the convicted offender to submit to an HIV-related test, provided that all of the following conditions are
met:
a. The sexual assault for which the offender was convicted or adjudicated delinquent included
sufficient contact between the victim and the convicted offender to be deemed a significant exposure
pursuant to 641—11.31(915).
b. The authorized representative of the petitioner, the county attorney, or the court sought to obtain
written informed consent to the testing from the convicted offender.
c. Written informed consent was not provided by the convicted offender.
11.32(3) If a person is an alleged offender, the county attorney, if requested by the victim, shall make
application to the court for the issuance of a search warrant, in accordance with Iowa Code chapter 808,
for the purpose of requiring the alleged offender to submit to an HIV-related test, if all of the following
conditions are met:
a. The application states that the victim believes that the sexual assault for which the alleged
offender is charged included sufficient contact between the victim and the alleged offender to be deemed
a significant exposure pursuant to 641—11.31(915) and states the factual basis for the belief that a
significant exposure exists.
b. The authorized representative of the victim, the county attorney, or the court sought to obtain
written informed consent to the testing from the alleged offender.
c. Written informed consent was not provided by the alleged offender.
11.32(4) Upon receipt of the petition or application, the court shall:
a. Prior to the scheduling of a hearing, refer the victim for counseling by a victim counselor or
a person requested by the victim who is authorized to provide the counseling regarding the nature,
IAC 12/11/13 Public Health[641] Ch 11, p.15
reliability and significance of the HIV-related test and of any test results of the convicted or alleged
offender.
b. Schedule a hearing to be held as soon as is practicable.
c. Cause written notice to be served on the convicted or alleged offender who is the subject of
the proceeding, in accordance with the Iowa Rules of Civil Procedure relating to the service of original
notice, or if the convicted or alleged offender is represented by legal counsel, provide written notice to
the convicted or alleged offender and the convicted or alleged offender’s legal counsel.
d. Provide for the appointment of legal counsel for a convicted or alleged offender if the convicted
or alleged offender desires but is financially unable to employ counsel.
e. Furnish legal counsel with copies of the petition or application, written informed consent, if
obtained, and copies of all other documents related to the petition or application, including, but not
limited to, the charges and orders.
11.32(5) A hearing under this rule shall be conducted in an informal manner consistent with orderly
procedure and in accordance with the Iowa Rules of Evidence.
a. The hearing shall be limited in scope to the review of questions of fact only as to the issue of
whether the sexual assault for which the offender was convicted or adjudicated delinquent or for which
the alleged offender was charged provided sufficient contact between the victim and the convicted or
alleged offender to be deemed a significant exposure, and to questions of law.
b. In determining whether the contact should be deemed a significant exposure for a convicted
offender, the court shall base the determination on the testimony presented during the proceedings on
the sexual assault charge, the minutes of the testimony or other evidence included in the court record, or
if a plea of guilty was entered, based upon the complaint or upon testimony provided during the hearing.
In determining whether the contact should be deemed a significant exposure for an alleged offender, the
court shall base the determination on the application and the factual basis provided in the application for
the belief of the applicant that a significant exposure exists.
c. The victim may testify at the hearing, but shall not be compelled to testify. The court shall
not consider the refusal of a victim to testify at the hearing as material to the court’s decision regarding
issuance of an order or search warrant requiring testing.
d. The hearing shall be in camera unless the convicted or alleged offender and the petitioner or
victim agree to a hearing in open court and the court approves. The report of the hearing proceedings
shall be sealed and no report of the proceeding shall be released to the public, except with the permission
of all parties and the approval of the court.
e. Stenographic notes or electronic or mechanical recording shall be taken of all court hearings
unless waived by the parties.
11.32(6) Following the hearing, the court shall require a convicted or alleged offender to undergo
an HIV-related test only if the petitioner or victim proves all of the following by a preponderance of
evidence.
a. The sexual assault constituted a significant exposure.
b. An authorized representative of the petitioner or victim, the county attorney, or the court sought
to obtain written informed consent from the convicted or alleged offender.
c. Written informed consent was not provided by the convicted or alleged offender.
11.32(7) A convicted or alleged offender who is required to undergo an HIV-related test may appeal
to the court for review of questions of law only, but may appeal questions of fact if the findings of fact
are clearly erroneous.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.33(915) Medical examination costs. The cost of a medical examination for the purpose of
gathering evidence and the cost of treatment for the purpose of preventing venereal disease shall be paid
from the victim compensation fund as established in Iowa Code chapter 915. Information is available
from the department of justice, crime victim assistance program, telephone (515)281-5044.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
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641—11.34(915) Testing, reporting, and counseling—penalties.
11.34(1) The physician or other practitioner who orders the testing for HIV of a convicted or alleged
offender under Iowa Code chapter 915 shall disclose the results of the test to the convicted or alleged
offender and to the victim counselor or a person requested by the victim who is authorized to provide
the counseling regarding the HIV-related test and results, who shall disclose the results to the petitioner.
11.34(2) Prior to ordering an HIV-related test on a convicted or alleged offender, the physician or
practitioner shall provide information to the subject of the test concerning testing and where to obtain
additional information on HIV transmission and risk reduction, pursuant to Iowa Code section 141A.6.
The department may be contacted for brochures that may assist in meeting the requirements of Iowa
Code section 141A.6.
11.34(3) At any time that the subject of an HIV-related test is informed of confirmed positive test
results, the physician or other practitioner who ordered the test shall initiate counseling concerning the
emotional and physical health effects of HIV infection, as required under Iowa Code section 141A.7,
and shall make any required reports to the department pursuant to Iowa Code section 141A.6.
a. The physician or other practitioner shall encourage an HIV-infected person to participate in the
voluntary partner notification program pursuant to rule 641—11.17(139A,141A).
b. The physician or other practitioner may provide to the department any relevant information
provided by the HIV-infected person regarding any party with whom the HIV-infected person has had
sexual relations or has shared drug injecting equipment.
11.34(4) Subsequent testing arising out of the same incident of exposure shall be conducted
in accordance with the procedural and confidentiality requirements of 641—11.30(915) to
641—11.34(915).
11.34(5) Results of a test performed under 641—11.30(915) to 641—11.34(915), except as provided
in subrule 11.34(6), shall be disclosed only to the physician or other practitioner who ordered the test of
the convicted or alleged offender; the convicted or alleged offender; the victim, the victim counselor or
person requested by the victim who is authorized to provide the counseling regarding the HIV-related
test and results; the physician of the victim if requested by the victim; the parent, guardian, or custodian
of the victim, if the victim is a minor; and the county attorney who filed the petition for the HIV-related
testing under 641—11.30(915) to 641—11.34(915), who may use the results to file charges of criminal
transmission of HIV. Results of a test performed under these rules shall not be disclosed to any other
person without the written informed consent of the convicted or alleged offender. A person to whom
the results of a test have been disclosed under 641—11.30(915) to 641—11.34(915) is subject to the
confidentiality provision of IowaCode section 141A.9, and shall not disclose the results to another person
except as authorized by Iowa Code section 141A.9.
11.34(6) If HIV-related testing is ordered under 641—11.30(915) to 641—11.34(915), the court shall
also order periodic testing of the convicted offender during the period of incarceration, probation, or
parole or of the alleged offender during a period of six months following the initial test if the physician or
other practitioner who ordered the initial test of the convicted or alleged offender certifies that, based upon
prevailing scientific opinion regarding the maximum period during which the results of an HIV-related
test may be negative for a person after being HIV-infected, additional testing is necessary to determine
whether the convicted or alleged offender was HIV-infected at the time the sexual assault or alleged
sexual assault was perpetrated. The results of the subsequent periodic tests conducted pursuant to subrule
11.34(6) shall be released only to the physician or other practitioner who ordered the test of the convicted
or alleged offender; the convicted or alleged offender; the victim counselor or person requested by the
victim to provide the counseling regarding the HIV-related test and results, who shall disclose the results
to the petitioner; the physician of the victim if requested by the victim; and the county attorney, who may
use the results as evidence in the prosecution of the sexual assault or in the prosecution of the offense of
criminal transmission of HIV.
11.34(7) The court shall not consider the disclosure of an alleged offender’s serologic status to an
alleged victim, prior to conviction, as a basis for a reduced plea or reduced sentence.
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11.34(8) The fact that HIV-related tests were performed under 641—11.30(915) to 641—11.34(915)
and the results of the tests shall not be included in the convicted offender’s medical or criminal record
unless otherwise included in department of corrections records.
11.34(9) The fact that HIV-related tests were performed under 641—11.30(915) to 641—11.34(915)
and the results of the tests shall not be used as a basis for further prosecution of a convicted offender
in relation to the incident which is the subject of the testing, to enhance punishments, or to influence
sentencing.
11.34(10) If the serologic status of a convicted offender, which is conveyed to the victim, is based
upon an HIV-related test other than a test which is authorized as a result of the procedures established
in 641—11.30(915) to 641—11.34(915), legal protections which attach to such testing shall be the same
as those which attach to an initial test under 641—11.30(915) to 641—11.34(915), and the rights to a
predisclosure hearing and to appeal provided under Iowa Code chapter 915 shall apply.
11.34(11) HIV-related testing required under 641—11.30(915) to 641—11.34(915) shall be
conducted by the state hygienic laboratory.
11.34(12) Notwithstanding the provision of these rules requiring initial testing, if a petition is filed
with the court under Iowa Code section 915.42 requesting an order for testing and the order is granted,
and if a test has previously been performed on the convicted offender while under the control of the
department of corrections, the test results shall be provided in lieu of the performance of an initial test
of the convicted offender, in accordance with 641—11.30(915) to 641—11.34(915).
11.34(13) Test results shall not be disclosed to a convicted offender who elects against disclosure.
11.34(14) In addition to the counseling received by a victim, referral to appropriate health care and
support services shall be provided.
11.34(15) In addition to persons to whom disclosure of the results of a convicted or alleged
offender’s HIV-related test results is authorized under these rules, the victim may also disclose the
results to the victim’s spouse, persons with whom the victim has engaged in vaginal, anal, or oral
intercourse subsequent to the sexual assault, or members of the victim’s family within the third degree
of consanguinity.
11.34(16) A person to whom disclosure of a convicted offender’s HIV-related test results is
authorized under these rules shall not disclose the results to any other person for whom disclosure is
not authorized under these rules. A person who intentionally or recklessly makes an unauthorized
disclosure in violation of this subrule is subject to a civil penalty of $1,000. The attorney general or the
attorney general’s designee may maintain a civil action to enforce these rules. Proceedings maintained
under this subrule shall provide for the anonymity of the tested subject, and all documentation shall be
maintained in a confidential manner.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
Rules 641—11.30(915) to 641—11.34(915) are intended to implement Iowa Code sections 915.40
to 915.43.
641—11.35 to 11.39 Reserved.
AIDS DRUG ASSISTANCE PROGRAM (ADAP)
641—11.40(141A) Definitions. For purposes of rules 641—11.40(141A) to 641—11.49(141A), the
following definitions shall apply:
“ADAP advisory committee” means the committee appointed by the bureau of HIV, STD, and
hepatitis to provide advice and technical assistance to the department regarding ADAP.
“ADAP formulary” means the list of drugs approved for use in ADAP by the bureau upon
recommendation of the ADAP advisory committee.
“AIDS”means acquired immune deficiency syndrome as defined by the Centers for Disease Control
and Prevention of the U.S. Department of Health and Human Services.
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“AIDS drug assistance program” or “ADAP” means the Iowa AIDS drug assistance program
administered by the bureau of HIV, STD, and hepatitis within the department and includes two
components, the medication assistance program and the health insurance assistance program.
“Bureau” means the bureau of HIV, STD, and hepatitis within the department.
“Deductible” means an amount of money that an insured person must pay out of pocket before any
benefits from the health insurance policy can be used.
“Department” means the Iowa department of public health.
“Director” means the director of the Iowa department of public health.
“Health insurance assistance program” means a component of ADAP that purchases health
insurance and pays insurance premiums, copayments for medications, and deductibles for eligible
enrollees in ADAP.
“HIV” means the human immunodeficiency virus identified as the causative agent of AIDS.
“Household” means a group of individuals residing together who are related by birth, marriage, or
adoption; or an individual who does not reside with any other individual to whom the individual is related
by birth, marriage, or adoption.
“Medication assistance program” means a component of ADAP that provides medications directly
to eligible enrollees in ADAP.
“Modified adjusted gross income” or “MAGI” means the calculation of income based upon
applicable Internal Revenue Code and regulations of the Centers for Medicare and Medicaid Services
of the U.S. Department of Health and Human Services.
“Payer of last resort” means a requirement to coordinate services and seek payment from all other
sources before Ryan White funds are used.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.41(141A) Purpose. The AIDS drug assistance program is a state-administered program that
provides certain HIV/AIDS medications to eligible low-income individuals diagnosed with HIV if
adequate funding is available for administration of the program. There are two components to the Iowa
AIDS drug assistance program: the medication assistance program and the health insurance assistance
program. The AIDS drug assistance program is authorized under Part B of Title XXVI of the Public
Health Service (PHS) Act, as amended by the Ryan White HIV/AIDS Treatment Extension Act of 2009
(Public Law 111-87). This legislation requires that the Ryan White program, including the AIDS drug
assistance program, be the payer of last resort for HIV-related services. ADAP is not an entitlement
program and does not create a right to assistance. In the event that funding is exhausted or terminated or
there are changes in state or federal guidelines, programs, or regulations that impact funding available
to ADAP, the department reserves the right to close enrollment, cease to provide medication assistance
or health insurance assistance, or alter eligibility criteria until such time that funding is again sufficient.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.42(141A) Ensuring payer of last resort. To ensure that ADAP is the payer of last resort, the
Iowa Medicaid enterprise shall grant the department access to client information for persons enrolled in
Medicaid.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.43(141A) Eligibility requirements.
11.43(1) An applicant is eligible to participate in the ADAP medication assistance program if the
applicant:
a. Applies for enrollment in ADAP on a form provided by the department;
b. Has no health insurance to cover the cost of the drugs that are or may become available from
ADAP;
c. Is currently being prescribed a drug on the ADAP formulary;
d. Has an annual MAGI that is less than or equal to 200 percent of the poverty level as determined
by the most recent federal poverty guidelines published annually by the U.S. Department of Health and
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Human Services for the size of the household (this income shall be determined after a $500 work-related
allowance is deducted from the monthly salary of an employed person with HIV/AIDS);
e. Has a medical diagnosis of HIV infection or AIDS or is an unborn infant or an infant under 18
months of age who has an HIV-infected mother; and
f. Is a resident of Iowa.
11.43(2) An applicant is eligible to participate in the ADAP health insurance assistance program if
the applicant:
a. Applies for enrollment in ADAP on a form provided by the department;
b. Has creditable health insurance coverage;
c. Is currently being prescribed a drug on the ADAP formulary;
d. Has an annual MAGI that is less than or equal to 400 percent of the poverty level as determined
by the most recent federal poverty guidelines published annually by the U.S. Department of Health and
Human Services for the size of the household;
e. Has a medical diagnosis of HIV infection or AIDS or is an unborn infant or an infant under 18
months of age who has an HIV-infected mother; and
f. Is a resident of Iowa.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.44(141A) Enrollment process.
11.44(1) The department shall review each completed application and shall determine enrollment
based upon applicant eligibility, the date on which the application was completed, and the availability of
funds. When the department determines that an applicant is eligible for enrollment, the applicant may be
enrolled for six months commencing with the date of the determination or may be enrolled for a shorter
time period at the discretion of the department.
11.44(2) An applicant shall provide the department with all requested information and shall execute
any consent forms or releases of information necessary for the department to verify eligibility.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.45(141A) Discontinuation of services.
11.45(1) The department shall review eligibility semiannually after enrollment unless one of the
following events occurs within the six-month period to end eligibility:
a. The enrolled individual dies;
b. The enrolled individual is determined eligible and enrolled to fully receive medical services
through a third-party payer and is able to fully pay the insurance deductibles and copayments;
c. The enrolled individual’s annual MAGI increases to an amount above the respective ADAP
component’s income guidelines;
d. The enrolled individual establishes residency outside the state of Iowa;
e. The enrolled individual does not request drugs over a 90-day period; or
f. The enrolled individual is placed in an institution such as a nursing home, state prison, or jail
for more than 30 days.
11.45(2) An applicant must submit renewal documentation on a semiannual basis, accompanied by
all information requested by the department.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.46(141A) Distribution requirements.
11.46(1) Enrolled individuals shall be eligible to receive financial assistance only for drugs that:
a. Have received Food and Drug Administration approval to treat HIV or prevent the deterioration
of health due to HIV, coinfections, or opportunistic infections; and
b. Are on the ADAP formulary.
11.46(2) The primary care provider shall write each drug prescription for an applicant or enrolled
individual.
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11.46(3) The enrolled individual must obtain the approved drug from the department’s contracted
pharmacy unless an exception to this requirement is granted by the department.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.47(141A) ADAP waiting list.
11.47(1) If an applicant is eligible for ADAP and sufficient funds are available to provide services
to the applicant, the department shall enroll the applicant. If the applicant is eligible for ADAP and
sufficient funds are not available to provide services to the applicant, the department shall place the
applicant’s name on the ADAP waiting list in the order provided for in this rule.
11.47(2) The department shall place names on the waiting list in chronological order based upon the
date of receipt of a completed application by the department.
11.47(3) To verify that applicants on the waiting list continue tomeet ADAP eligibility requirements,
the department shall require applicants on the waiting list to submit reapplication forms semiannually.
11.47(4) The department shall remove applicants from the waiting list in the chronological order in
which their completed applicationswere approved, provided all updateswere received by the department.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.48(141A) Appeals. The department shall cause an applicant to be notified of the department’s
decision to approve or deny an application or to place an applicant on the ADAPwaiting list. In the event
an applicant is dissatisfied with the department’s decision, the applicant may submit a formal appeal in
writing to the ADAP advisory committee. Such request shall be delivered in person or shall be mailed
by certified mail, return receipt requested, to ADAP Advisory Committee, Iowa Department of Public
Health, Lucas State Office Building, 321 E. 12th Street, Des Moines, Iowa 50319. Upon receipt of
such an appeal, the ADAP advisory committee shall review the case and issue a written determination
within 15 days of receipt of the request. The decision shall refer to the applicant by initials or other
nonidentifying means. The ADAP advisory committee’s decision shall be final and binding. This appeal
process does not constitute a contested case proceeding as defined in Iowa Code chapter 17A.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
641—11.49(141A) Confidentiality. The ADAP application and all information received or maintained
by the department in connection with ADAP shall be considered confidential information in accordance
with Iowa Code section 141A.9.
[ARC 1215C, IAB 12/11/13, effective 1/15/14]
Rules 641—11.40(141A) to 641—11.49(141A) are intended to implement Iowa Code section
141A.3.
[Filed emergency 9/18/87—published 10/7/87, effective 9/18/87]
[Filed 9/26/88, Notice 8/10/88—published 10/19/88, effective 11/23/88]
[Filed emergency 1/11/89—published 2/8/89, effective 1/11/89]
[Filed 11/9/89, Notice 10/4/89—published 11/29/89, effective 1/3/90]
[Filed emergency 1/10/90—published 2/7/90, effective 1/10/90]
[Filed emergency 9/28/90—published 10/17/90, effective 10/1/90]
[Filed emergency 11/9/90—published 11/28/90, effective 11/9/90]
[Filed 3/15/91, Notice 11/28/90—published 4/3/91, effective 5/8/91]
[Filed emergency 5/10/91—published 5/29/91, effective 6/1/91]
[Filed emergency 3/11/92—published 4/1/92, effective 4/1/92]
[Filed 3/13/92, Notice 2/5/92—published 4/1/92, effective 5/6/92]
[Filed 11/15/93, Notice 8/4/93—published 12/8/93, effective 1/12/94]
[Filed 11/15/93, Notice 9/1/93—published 12/8/93, effective 1/12/94]
[Filed 7/14/94, Notice 6/8/94—published 8/3/94, effective 9/7/94]
[Filed 7/11/97, Notice 6/4/97—published 7/30/97, effective 9/3/97]
[Filed 9/18/98, Notice 7/15/98—published 10/7/98, effective 11/11/98]
[Filed 9/10/04, Notice 8/4/04—published 9/29/04, effective 11/3/04]
[Filed emergency 1/9/08—published 1/30/08, effective 1/9/08]
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[Filed 3/13/08, Notice 1/30/08—published 4/9/08, effective 5/14/08]
[Filed ARC 0755C (Notice ARC 0650C, IAB 3/20/13), IAB 5/29/13, effective 7/3/13]
[Filed ARC 1215C (Notice ARC 1044C, IAB 10/2/13), IAB 12/11/13, effective 1/15/14]
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The Iowa Department of Public Health (IDPH), in conjunction with the Attorney General's Office, has 
completed a comprehensive review of its programs and has determined that neither the agency as a 
whole, nor any of its programs, are covered entities under HIPAA. However, both the EPSDT 
Program and Enhanced Services for Maternal Health Program are actually a part of the Medicaid 
Program of the Iowa Department of Human Services and, as such these programs, will be business 
associates of the Iowa Department of Human Services and, therefore, subject to many HIPAA 
provisions. Because IDPH is not a covered entity, many agencies and facilities in Iowa that are 
covered entities have questioned whether they can continue to disclose the protected health 
information of their patients or clients to the IDPH as they have in the past. The short answer is 
YES, such disclosures may continue to occur under HIPAA. 
 
First, HIPAA recognizes that if there is a statute or administrative rule that requires a specific 
disclosure of protected health information, a covered entity must obey that law. (Section 164.512). 
Therefore, if there is another federal or state statute or administrative rule which requires a covered 
entity to disclose protected health information to the IDPH, the covered entity should follow that 
requirement. Many disclosures of PHI to IDPH are required by state laws, including Iowa Code 
chapters 135, 136A, 136B, 136C, 139A, 141A, 144, 147A, and 272C and the administrative rules 
that implement these chapters. These disclosures are legally required and must continue to be made 
as mandated by state law. 
 
Second, HIPAA allows a covered entity to disclose protected health information to public health 
authorities for public health activities. (Section 164.512). HIPAA defines a public health authority as 
"an agency or authority of the United States, a State, a territory, a political subdivision of a State or 
territory, or an Indian tribe, or a person or entity acting under a grant of authority from or contract 
with such public agency, including the employees or agents of such public agency or its contractors 
or persons or entities to whom it has granted authority, that is responsible for public health matters 
as part of its official mandate." (Section 164.501). The IDPH has such a mandate and, therefore, is 
a public health authority under HIPAA. 
 
The IDPH, in conjunction with the Iowa Attorney General's Office, has reviewed its programs and 
determined that protected health information being received by the Department from covered 
entities in Iowa is disclosed for public health activities. The disclosure of such information to IDPH 
is, therefore, unaffected by HIPAA and should continue in accordance with past practices. Because 
IDPH is a public health authority that is authorized to receive PHI under this provision, covered 
entities are not required to enter into a business associate agreement with IDPH in order for the 
exchange of protected health information to take place. 
 
Third, in some instances, the IDPH is a health oversight agency as defined by HIPAA. Under HIPAA, 
a "health oversight agency" is "an agency or authority of the United States, a state, a territory, a 
political subdivision of a State or territory, or an Indian tribe, or a person or entity acting under a 
grant of authority from or contract with such public agency, including the employees or agents of 
such public agency or its contractors or persons or entities to whom it has granted authority, that is 
authorized by law to oversee the health care system (whether public or private) or government 
programs in which health information is necessary to determine eligibility or compliance, or to 
enforce civil rights laws for which health information is relevant." 
 
HIPAA permits a covered entity to disclose protected health information to a health oversight agency 
for oversight activities authorized by law, including audits; civil, administrative, or criminal 
investigations; inspections; licensure or disciplinary actions; civil, administrative, or criminal 
proceedings or actions; or other activities necessary for appropriate oversight of: 
 
1. The health care system (e.g. State insurance commissions, state health professional 
licensure agencies, Offices of Inspectors General of federal agencies, the Department of 
Justice, state Medicaid fraud control units, Defense Criminal Investigative Services, the 
Pension and Welfare Benefit Administration, the HHS Office for Civil Rights, the FDA, 
data analysis to detect health care fraud);  
 
2. Government benefit programs for which health information is relevant to beneficiary 
eligibility (e.g. SSA and Dept. of Education); 
 
3. Entities subject to government regulatory programs for which health information is 
necessary for determining compliance with program standards (e.g. Occupational Health 
and Safety Administration and the EPA; the FDS's oversight of food, drugs, biologics, 
devices, and other products pursuant to the Food, Drug, and Cosmetic Act and the 
Public Health Service Act); or  
 
4. Entities subject to civil rights laws for which health information is necessary for 
determining compliance (the U.S. Department of Justice's civil rights enforcement 
activities, enforcement of the Civil Rights of Institutionalized Persons Act, the Americans 
with Disabilities Act, the EEOC's civil rights enforcement activities under titles I and V of 
the ADA). (Section 164.512(d)).  
 
"Overseeing the health care system," encompasses activities such as oversight of health care plans, 
oversight of health benefit plans; oversight of health care providers; oversight of health care and 
health care delivery; oversight activities that involve resolution of consumer complaints; oversight of 
pharmaceutical, medical products and devices, and dietary supplements; and a health oversight 
agency's analysis of trends in health care costs, quality, health care delivery, access to care, and 
health insurance coverage for health oversight purposes. 
 
Health oversight agencies may provide more than one type of health oversight. Such entities are 
considered health oversight agencies under the rule for any and all of the health oversight functions 
that they perform. The disclosure of protected health information to IDPH for these purposes is 
unaffected by HIPAA and should continue in accordance with past practices. 
 
Finally, local public health departments and local contractors which are covered entities may release 
protected health information to IDPH under the above-cited legal authority applicable to all covered 
entities. For example, certain statutes and rules require local public health departments and local 
contractors to disclose protected health information to IDPH. Further, as a health oversight agency a 
local health department is permitted, and in most cases required, to disclose protected health 
information to IDPH. Disclosures of PHI by local public health departments and local contractors to 
IDPH do not require business associate agreements and are not prohibited or otherwise affected by 
HIPAA. 
 
Please call Janet Hoffman, Assistant Attorney General, (515) 281-8330 should you have additional 
questions regarding these issues. 
 
    
 
 
Effective Dates    From: ____________ Through: _______________ 
 
Due To Communicable Disease (___________________) 
 
No one shall enter or leave these premises without authorization by the Iowa 
Department of Public Health or the ____________________County Board of Health.  
Any individual entering a quarantine premises with or without authorization of the 
health department or County Board of Health may be isolated or quarantined. 
Pursuant to Iowa Code section 135.38, any individual who knowingly violates a 
lawful department order for isolation or quarantine, whether written or oral, shall be 
guilty of a simple misdemeanor.  The court ordered sentence may include a fine up 
to $500 and imprisonment not to exceed 30 days.  No person other than an 
authorized employee of the Iowa Department of Public Health or county health 
department shall alter, destroy, or remove this notice.  Address inquiries to the Iowa 
Department of Public Health at 1-800-362-2736. 
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Facts about Quarantine and Isolation 
  
 
Quarantine and isolation are public health measures used to prevent or control the spread of communicable 
diseases which present a risk of serious harm to the public.  The Iowa Department of Public Health 
(Department) and county boards of health (local boards) have the authority to impose quarantine and 
isolation in very limited circumstances to prevent the spread of certain diseases.  Quarantine and isolation 
are used to protect the public by preventing exposure to infected persons or persons who may be infected.   
 
Here are some facts about quarantine and isolation you should know: 
 
The Department and local boards will impose quarantine or isolation only in the event of an outbreak of a 
"quarantinable disease," which means a serious and unusual or novel disease such as cholera, diphtheria, 
measles, infectious tuberculosis, plague, SARS, smallpox, certain viral hemorrhagic fevers, and other 
diseases spread person to person which present a risk of serious harm to the public's health.   
 
 
Quarantine means confining a person who has been exposed to a quarantinable disease to see if they 
become ill and infectious to others.  Quarantine is imposed for a period of time equal to the longest 
incubation period of the disease, which could range from a couple of days to two weeks, depending on the 
disease. 
 
 
Isolation means confining a person who is actually infected with a quarantinable disease for the period of 
time that they are infectious to others, which could range from a couple of days to weeks, depending on the 
disease. 
 
 
Prior to imposing quarantine or isolation, the Department and local boards will request that an individual 
voluntarily confine him or herself to their private home.  Only if a person refuses to voluntarily confine 
themselves will the Department or local boards consider mandatory quarantine or isolation. 
 
 
The Department and local boards are required by law to impose mandatory quarantine or isolation by the 
least restrictive means necessary to prevent the spread of the disease.  Typically this means the exposed or 
infected person will be quarantined or isolated in their home. 
 
 
Only if a person refuses to comply with voluntary home confinement and refuses to comply with quarantine 
or isolation in their own home will the Department or a local board consider imposing quarantine or isolation 
to a facility.  If a person is quarantined or isolated in a facility the Department or the local board will ensure 
that the person is confined to a safe and hygienic facility and that they have access to adequate food, 
medical care, and a means of communication with those outside the facility.   
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DEAF RELAY (Hearing or Speech Impaired) 711 or 1-800-735-2942 
 
BEFORE THE IOWA DEPARTMENT OF PUBLIC HEALTH 
________________________________________________________________ 
 
DIRECTED TO:   ) [insert case #] 
) 
[insert full name and   ) 
address of subject of order] ) FACILITY ISOLATION ORDER 
 
The Iowa Department of Public Health (Department) has determined that you 
have recently developed some symptoms of [insert name of quarantinable disease 
(qd)]. [insert qd] is a disease which is spread from person to person and is associated 
with [insert symptoms of qd -- fever, cough, respiratory illness, etc.].  [insert qd] 
presents a risk of serious harm to public health and if it spreads in the community severe 
public health consequences may result.   
 
The Department has determined that it is necessary to confine your movement to 
a specific facility to prevent further spread of this disease.  The Department has 
determined that isolation in your home and other less restrictive alternatives are not 
acceptable because [insert the reason home isolation is not acceptable (e.g. the person 
violated a previously issued home isolation order, the person does not have an 
appropriate home setting conducive to home isolation, etc.)] The Department is 
therefore ordering you to comply with the following provisions during the entire period 
of isolation: 
 
1.     Terms of confinement.     You are ordered to remain at the isolation facility, 
_____________________[insert name and address of facility], from ___________ to 
____________[insert dates of isolation]. 
 
2.     Requirements during confinement.  During the period of isolation: 
 
a. You must not leave the isolation facility at any time unless you 
have received prior written authorization from the Department to 
do so. 
 
b. You must not come into contact with anyone except the following 
persons: 
 
(i) other persons who are also under similar isolation order at 
the isolation facility; 
(ii)  authorized healthcare providers and other staff at the 
isolation facility; 
(iii)  authorized Department staff or other persons acting on 
behalf of the Department; and 
(iv)  such other persons as authorized by the Department. 
 
c. Your daily needs, including food, shelter, and medical care, will be 
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provided for you during the period of isolation at the isolation 
facility.  You should bring clothing, toiletries, and other personal 
items with you to the isolation facility.  You will have limited 
access to a telephone at the isolation facility.  You may bring your 
cell phone with you should you desire to have greater access to a 
means of communication.      
 
d. You should inform your employer that you are under isolation 
order and are not authorized to physically come to the work place.  
You should be aware that Iowa law prohibits an employer from 
firing, demoting, or otherwise discriminating against an employee 
due to the compliance of an employee with an isolation order 
issued by the Department.  (Iowa Code section 139A.13A). 
 
3.     Information about [qd].  You should review the information contained at 
Attachment A for information about [qd].  You should refer to information provided at 
the isolation facility to address specific concerns and questions you have about [qd].  In 
order to find out more information about [qd] and its symptoms and spread, you may also 
access the Department=s web-page at www.idph.state.ia.us.  If you do not have access to 
the internet from the isolation facility, you may contact the Department at 1-800-362-
2736. 
 
4.     Legal authority.    This order is issued pursuant to the legal authority 
contained at Iowa Code chapter 139A, [include Iowa Code chapter 135 if a public health 
disaster exists], and 641 Iowa Administrative Code chapter 1, a copy of which is labeled 
Attachment B and is attached to this order for your review.  The Department shall comply 
with the principles for quarantine and isolation contained in subrule 1.9(3) of this 
attachment when issuing and implementing this order.   
 
5.     Ensuring compliance.   In order to ensure that you strictly comply with this 
Isolation Order the Department or persons authorized by the Department may regularly 
inspect the isolation facility.   
 
6.     Violations of order.     If you fail to comply with this Isolation Order you 
may be ordered to be isolated in a more restrictive facility.  In addition, failure to comply 
with this order is a simple misdemeanor for which you may be arrested, fined, and 
imprisoned. 
 
7.     Your rights -- appeal rights.    While under isolation you have the rights as 
described in subrule 1.9(8) of Attachment B.  In addition, you have the right to appeal 
this order pursuant to subrule 1.9(7) of Attachment B.    
 
 
 
_____________________________   ________ 
DIRECTOR or MEDICAL DIRECTOR   DATE 
Iowa Department of Public Health Revised 11/07   Facility Isolation Order Template                                   2 
IOWA DEPARTMENT OF PUBLIC HEALTH 
Lucas State Office Building 
Des Moines, IA 50319 
 
Attachments to this Order: 
Attachment A -- Facts About [qd] 
Attachment B B 641 Iowa Administrative Code chapter 1 
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BEFORE THE IOWA DEPARTMENT OF PUBLIC HEALTH 
________________________________________________________________ 
 
DIRECTED TO:   ) [insert case #] 
) 
[insert full name and   ) 
address of subject of order] )FACILITY QUARANTINE 
ORDER 
________________________________________________________________ 
 
The Iowa Department of Public Health (Department) has determined that you have had 
contact with [insert name of quarantinable disease (qd)]. [insert qd] is a disease which is 
spread from person to person and is associated with [insert symptoms of qd -- fever, cough, 
respiratory illness, etc.].  [insert qd] presents a risk of serious harm to public health and if it 
spreads in the community severe public health consequences may result.   
 
The Department has determined that it is necessary to quarantine your movement to a 
specific facility to prevent further spread of this disease.  The Department has determined that 
quarantine in your home and other less restrictive alternatives are not acceptable because [insert 
the reason home quarantine is not acceptable (e.g. the person violated a previously issued 
home quarantine order, the person does not have an appropriate home setting conducive to 
home quarantine, etc.)] The Department is therefore ordering you to comply with the following 
provisions during the entire period of quarantine: 
 
1.     Terms of confinement.     You are ordered to remain at the quarantine facility, 
_____________________ [insert name and address of facility], from ___________ to 
____________ [insert dates of quarantine]. 
 
2.     Requirements during confinement.  During the period of quarantine: 
 
a. You must not leave the quarantine facility at any time unless you have 
received prior written authorization from the Department to do so. 
 
b. You must not come into contact with anyone except the following 
persons: 
 
(i) other persons who are also under similar quarantine order at the 
quarantine facility; 
(ii)  authorized healthcare providers and other staff at the quarantine 
facility; 
(iii)  authorized Department staff or other persons acting on behalf of 
the Department; and 
(iv)  such other persons as are authorized by the Department. 
 
c. Your daily needs, including food, shelter, and medical care, will be 
provided for you during the period of quarantine at the quarantine 
facility.  You should bring clothing, toiletries, and other personal items 
with you to the quarantine facility.  You will have limited access to a 
telephone at the quarantine facility.  You may bring your cell phone with 
you should you desire to have greater access to a means of 
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communication.      
 
d. You should inform your employer that you are under quarantine order 
and are not authorized to physically come to the work place, although 
you may work from the facility via electronic or other means if 
appropriate.  You should be aware that Iowa law prohibits an employer 
from firing, demoting, or otherwise discriminating against an employee 
due to the compliance of an employee with a quarantine order issued by 
the Department. (Iowa Code section 139A.13A). 
 
3.     Information about [qd].  You should review the information contained at 
Attachment A for information about [qd].  You should refer to information provided at the 
quarantine facility to address specific concerns and questions you have about [qd]. In order to 
find out more information about [qd] and its symptoms and spread, you may also access the 
Department=s web-page at www.idph.state.ia.us.  If you do not have access to the internet from 
the quarantine facility, you may contact the Department at 1-800-362-2736.  
 
4.     Legal authority.    This order is issued pursuant to the legal authority contained at 
Iowa Code chapter 139A, [include Iowa Code chapter 135 if a public health disaster exists], and 
641 Iowa Administrative Code chapter 1, a copy of which is labeled Attachment B and is 
attached to this order for your review.  The Department shall comply with the principles for 
quarantine contained in subrule 1.9(3) of this attachment when issuing and implementing this 
order.   
 
5.     Ensuring compliance.   In order to ensure that you strictly comply with this 
Quarantine Order the Department or persons authorized by the Department may regularly inspect 
the quarantine facility.   
 
6.     Violations of order.     If you fail to comply with this Quarantine Order you may be 
ordered to be quarantined in a more restrictive facility.  In addition, failure to comply with this 
order is a simple misdemeanor for which you may be arrested, fined, and imprisoned. 
 
7.     Your rights -- appeal rights.    While under quarantine you have the rights as 
described in subrule 1.9(8) of Attachment B.  In addition, you have the right to appeal this order 
pursuant to subrule 1.9(7) of Attachment B.    
 
 
_____________________________   ________ 
DIRECTOR or MEDICAL DIRECTOR   DATE 
IOWA DEPARTMENT OF PUBLIC HEALTH 
Lucas State Office Building 
Des Moines, IA 50319 
Attachments to this Order: 
Attachment A -- Facts About [qd] 
Attachment B B 641 Iowa Administrative Code chapter 1 
 
Iowa Department of Public Health Revised 11/07       Facility Quarantine Order Template                           2 
BEFORE THE IOWA DEPARTMENT OF PUBLIC HEALTH 
 
DIRECTED TO: ) [insert case #] 
) 
[insert full name and  ) 
address of subject of order] ) HOME ISOLATION ORDER 
 
The Iowa Department of Public Health (Department) has determined that you have 
recently developed some symptoms of [insert name of quarantinable disease (qd)]. [insert qd] 
is a disease which is spread from person to person and is associated with [insert symptoms of qd -
- fever, cough, respiratory illness, etc.].  [insert qd] presents a risk of serious harm to public 
health and if it spreads in the community severe public health consequences may result.   
 
The Department has determined that home isolation of persons who are known or suspected to 
have [insert qd] is necessary to prevent further spread of this disease.  The Department has 
determined that isolation in private homes is the least restrictive means necessary to prevent the 
spread of [insert qd]. The Department is therefore ordering you to remain in your home and to 
comply with the following provisions during the entire period of isolation: 
 
1.     Terms of confinement.     You are ordered to remain in your home at 
_____________________[insert address] from ___________ to ____________[insert dates of 
isolation]. 
 
2.     Requirements during confinement.  During the period of isolation: 
 
a. You must not leave your home at any time unless you have received 
prior written authorization from the Department to do so. 
 
b. You must remain reachable by telephone at all times and answer and 
respond fully and truthfully to telephone calls from Department staff and other 
persons acting on behalf of the Department. 
 
c. You must not come into contact with anyone except the following 
persons: 
 
(i) family members and other persons who reside in your home who 
are also under Home Isolation Order or Home Quarantine Order; 
(ii)  authorized healthcare providers; 
(iii)  authorized Department staff or other persons acting on behalf of 
the Department; and 
(iv)  such other persons as are authorized by the Department. 
d.         You should arrange by telephone for relatives, neighbors, or friends to 
assist with any needs you may have during the period of confinement.  These 
persons should not have direct contact with you.   If you need assistance in 
providing for your daily needs, you should call [insert telephone number]. 
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 e. You must follow the directions contained in the attachment to this order 
labeled Attachment A to monitor your health status on a daily basis.  
 
f. You will have access to medical care during the period of confinement.  
If the symptoms you are experiencing become more severe, or if you develop 
any additional symptoms of [qd] detailed in Attachment A, including [insert 
main symptoms here], you should immediately call a public health official at 
[insert telephone number].  If emergency medical treatment is required for 
conditions other than those listed in this paragraph (e.g. chest pain or severe 
accidental injury at home), you should call 911 for an ambulance.  When 
seeking such assistance, you must inform the operator of the 911 line and the 
ambulance that you are under Home Isolation Order. 
g. If other persons also reside in your home you must maintain good 
personal hygiene at all times, including complying with the directions 
contained in Attachment A, to prevent disease transmission.  If any member of 
your household develops any symptoms of [qd] detailed in Attachment A, 
such person should immediately call a public health official at  [insert 
telephone number].  
 
h. You should inform your employer that you are under home isolation and 
are not authorized to physically come to the work place.  You should be aware 
that Iowa law prohibits an employer from firing, demoting, or otherwise 
discriminating against an employee due to the compliance of an employee 
with an isolation order issued by the Department.  (Iowa Code section 
139A.13A). 
 
3.     Information about [qd].  You should review the information contained at 
Attachment A for information about [qd].  In order to find out more information about [qd] and 
its symptoms and spread, you may access the Departments web-page at www.idph.state.ia.us.  If 
you do not have access to the internet from your home, you may contact the Department at 
800.362.2736 for more information about this disease. 
4.     Legal authority.    This order is issued pursuant to the legal authority contained at 
Iowa Code chapter 139A, [include Iowa Code chapter 135 if a public health disaster exists], and 
641 Iowa Administrative Code chapter 1, a copy of which is labeled Attachment B and is 
attached to this order for your review.  The Department shall comply with the principles for 
isolation and quarantine contained in subrule 1.9(3) of this attachment when issuing and 
implementing this order.   
5.     Ensuring compliance.   In order to ensure that you strictly comply with this Home 
Isolation Order the Department or persons authorized by the Department may contact you by 
telephone on a regular basis and may carry out spot checks of your residence.   
6.     Violations of order.     If you fail to comply with this Home Isolation Order you 
may be ordered to be isolated in a hospital or other facility as determined by the Department.  In 
addition, failure to comply with this order is a simple misdemeanor for which you may be 
arrested, fined, and imprisoned. 
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7.     Your rights – appeal rights.    While under isolation you have the rights as 
described in subrule 1.9(8) of Attachment B.  In addition, you have the right to appeal this order 
pursuant to subrule 1.9(7) of Attachment B.    
 
 
 
_____________________________   ________ 
DIRECTOR or MEDICAL DIRECTOR   DATE 
IOWA DEPARTMENT OF PUBLIC HEALTH 
Lucas State Office Building 
Des Moines, IA 50319 
 
 
Attachments to this Order: 
 
Attachment A -- Facts About [insert disease name] 
Attachment B -- 641 Iowa Administrative Code chapter 1 
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BEFORE THE IOWA DEPARTMENT OF PUBLIC HEALTH 
 
DIRECTED TO:   ) [insert case #] 
) 
[insert full name and   ) 
address of subject of order] ) HOME QUARANTINE ORDER 
________________________________________________________________ 
 
The Iowa Department of Public Health (Department) has determined that you have had 
contact with [insert name of quarantinable disease (qd)]. [insert qd] is a disease which is 
spread from person to person and is associated with [insert symptoms of (e.g. fever, cough, 
respiratory illness, etc.)]. [Insert qd] presents a risk of serious harm to public health and if it 
spreads in the community severe public health consequences may result.   
 
The Department has determined that home quarantine of persons who have been exposed 
to [insert qd] is necessary to prevent further spread of this disease.  The Department has 
determined that quarantine in private homes is the least restrictive means necessary to prevent the 
spread of [insert qd]. The Department is therefore ordering you to remain in your home and to 
comply with the following provisions during the entire period of quarantine: 
 
1.     Terms of confinement.     You are ordered to remain in your home at 
_____________________[insert address] from ___________ to ____________[insert dates of 
quarantine]. 
 
2.     Requirements during confinement.  During the period of quarantine: 
 
a. You must not leave your home at any time unless you have received 
prior written authorization from the Department to do so. 
 
b. You must remain reachable by telephone at all times and answer and 
respond fully and truthfully to telephone calls from Department staff and 
other persons acting on behalf of the Department. 
 
c. You must not come into contact with anyone except the following 
persons: 
 
(i) family members and other persons who reside in your home; 
(ii)  authorized healthcare providers; 
(iii)  authorized Department staff or other persons acting on behalf of 
the Department; and 
(iv)  such other persons as are authorized by the Department. 
 
d. If family members or other persons who reside in your home have not 
been issued a Home Quarantine Order, they may leave your home to 
carry on their daily routines and to assist you with any needs you may 
have during the period of confinement.  If you live alone, or if every 
member of your household is under Home Quarantine Order, you should 
arrange by telephone for relatives, neighbors, or friends to assist with any 
needs you may have during the period of confinement.  These persons 
should not have direct contact with you.   If you need assistance in 
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providing for your daily needs, you should call [insert telephone 
number] 
 
e. You must follow the directions contained in the attachment to this order 
labeled Attachment A to monitor your health status on a daily basis.  
 
f. If you develop any symptoms of [qd] detailed in Attachment A, 
including [insert main symptoms here], you should immediately call a 
public health official at [insert telephone number].  If emergency 
medical treatment is required for conditions other than those listed in this 
paragraph (e.g. chest pain or severe accidental injury at home), you 
should call 911 for an ambulance.  When seeking such assistance, you 
must inform the operator of the 911 line and the ambulance that you are 
under Home Quarantine Order. 
 
g. If other persons also reside in your home you must maintain good 
personal hygiene at all times, including complying with the directions 
contained in Attachment A, to prevent disease transmission.  If any 
member of your household develops any symptoms of [qd] detailed in 
Attachment A, such person should immediately call a public health 
official at  [insert telephone number].  
 
h. You should inform your employer that you are under home quarantine 
and are not authorized to physically come to the work place, although 
you may work from home via electronic or other means if appropriate.  
You should be aware that Iowa law prohibits an employer from firing, 
demoting, or otherwise discriminating against an employee due to the 
employee’s compliance with a quarantine order issued by the 
Department. (Iowa Code section 139A.13A). 
 
3.     Information about [qd].  You should review the information contained at 
Attachment A for information about [qd]. In order to find out more information about [qd] and 
its symptoms and spread, you may access the Department=s web-page at www.idph.state.ia.us.  If 
you do not have access to the internet from your home, you may contact the Department at 1-800-
362-2736. 
 
4.     Legal authority.    This order is issued pursuant to the legal authority contained at 
Iowa Code chapter 139A, [include Iowa Code chapter 135 if a public health disaster exists], and 
641 Iowa Administrative Code chapter 1, a copy of which is labeled Attachment B and is 
attached to this order for your review.  The Department shall comply with the principles for 
quarantine contained in subrule 1.9(3) of this attachment when issuing and implementing this 
order.   
 
5.     Ensuring compliance.   In order to ensure that you strictly comply with this Home 
Quarantine Order the Department or persons authorized by the Department may contact you by 
telephone on a regular basis and may carry out spot checks of your residence.   
 
6.     Violations of order.     If you fail to comply with this Home Quarantine Order you 
may be ordered to be quarantined in a hospital or other facility as determined by the Department.  
In addition, failure to comply with this order is a simple misdemeanor for which you may be 
arrested, fined, and imprisoned. 
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7.     Your rights -- appeal rights.    While under quarantine you have the rights as 
described in subrule 1.9(8) of Attachment B.  In addition, you have the right to appeal this order 
pursuant to subrule 1.9(7) of Attachment B.    
 
 
 
_____________________________   ________ 
DIRECTOR or MEDICAL DIRECTOR   DATE 
IOWA DEPARTMENT OF PUBLIC HEALTH 
Lucas State Office Building 
Des Moines, IA 50319 
 
 
Attachments to this Order: 
 
Attachment A -- Facts About [qd] 
Attachment B -- 641 Iowa Administrative Code chapter 1  
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Iowa Department of Public Health 
Lucas State Office Building 
321 E. 12th Street  
Des Moines, IA 50319-0075 
Main Number:  515-281-7689 
 
Center for Acute Disease 
Epidemiology (CADE) 
Lucas State Office Building 
321 E. 12th Street  
Des Moines, IA 50319-0075 
 
Main Number: 
515-242-5935 
Fax: 
515-281-5698 
The center works to protect and preserve the health and safety of Iowans from infectious diseases 
through disease surveillance; investigation of acute outbreaks; institution of interventions to prevent 
ongoing spread of disease, education and consultation to county, local, and private health agencies on 
infectious diseases; immunization and vaccine guidelines; treatment after animal bites; and vaccines for 
international travel. 
 
The center also provides consultation to county and local health agencies on diseases requiring public 
health intervention, collaborates with Centers for Disease Control and Prevention by weekly reporting of 
nationally reportable diseases, and offers health education opportunities through lectures and 
organizational seminars. 
   
Disease Reporting Number 
(24/7) 
 800-362-2736 
   
Iowa State Patrol   515-323-4360 
   
Bureau of Immunization and 
TB 
Lucas State Office Building 
321 E. 12th Street  
Des Moines, IA 50319-0075 
Main Number:  
515-281-5424 
 
The Bureau of Immunization and Tuberculosis works to protect the health of Iowans from vaccine 
preventable diseases and tuberculosis with the goal of reducing and ultimately eliminating the incidence 
of these diseases.  The Bureau conducts surveillance and prevention activities in conjunction with public 
and private healthcare providers.  Surveillance activities include disease monitoring and reporting, 
laboratory testing, disease investigation and rapid institution of disease control measures including 
isolation and quarantine.  Bureau prevention and treatment activities include targeted disease testing, 
vaccination programs, dispensing medications, healthcare provider consultation and education.  
   
Immunization   800-831-6293 
Refugee Health  515-281-7504 
Tuberculosis  515-281-7504 
 
Bureau of HIV, STD and 
Hepatitis 
Lucas State Office Building 
321 E. 12th Street  
Des Moines, IA 50319-0075 
Main Number 
515-281-6801 
Prevention and care services target Chlamydia, syphilis, gonorrhea, HIV/AIDS, and hepatitis B and C. 
Staff from the Sexually Transmitted Disease, HIV/AIDS, and Adult Viral Hepatitis Prevention Programs 
partner with local public health departments, private health care agencies, regional disease prevention 
specialists, and community-based organizations to interrupt the disease transmission process and 
provide access to testing, treatment, immunizations, and prevention programs. 
   
STD  515-281-3031 
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HIV/AIDS  515-242-5141 
Hepatitis B – Perinatal  515-281-7228 
Hepatitis B – Other  515-242-5935 
Hepatitis C  515-281-5027 
 
Bureau of Environmental 
Health Services 
Lucas State Office Building 
321 E. 12th Street  
Des Moines, IA 50319-0075 
Main Number: 
515-281-7726 
 
The Bureau of Environmental Health Services is actively engaged in work related to hazardous spills, 
evaluation of waste sites, healthy homes, emergency preparedness, Grade A milk inspection, swimming 
pool and spa safety, water fluoridation, food safety, Grants-to-Counties, healthy homes and several 
other areas of environmental health practice.  Bureau staff also acts as a resource for new county 
environmental health professionals, and are available to local board of health members to provide 
education about the everyday impact of environmental health practice. 
   
Bureau of Lead Poisoning 
Prevention  
Lucas State Office Building 
321 E. 12th Street  
Des Moines, IA 50319-0075 
Main Number: 
800-972-2026 
The Bureau of Lead Poisoning Prevention oversees programs related to occupational health and safety, 
work-related fatal injuries, pesticide poisoning surveillance, and the prevention of lead poisoning.  The 
occupational health and safety surveillance program tracks standard occupational health.  The work-
related fatal injuries program investigates work-related fatal injuries and disseminates information about 
how to prevent work-related fatalities.  The pesticide poisoning surveillance program collects information 
on all exposures of Iowans to pesticides.  The lead poisoning prevention activities include the collection 
of the results of all blood lead testing done on Iowans of all ages.  The Bureau implements the 
requirement that all Iowa children be tested for lead poisoning, works with local childhood lead 
poisoning prevention programs to follow up on cases of childhood lead poisoning, and follows up on 
cases of adult lead poisoning.  Finally, the Bureau implements programs that require those who conduct 
renovation, lead abatement, and lead inspections to be certified and requires the owners and occupants 
of housing and child-occupied facilities be notified when paint is disturbed in these buildings.   
   
Bureau of Radiological 
Health 
Lucas State Office Building 
321 E. 12th Street  
Des Moines, IA 50319-0075 
Main Number: 
515-281-3478 
The Bureau of Radiological Health programs protect Iowans from unnecessary exposure to radiation. 
Each year, Iowans are exposed to an average of 300 millirem of naturally occurring radiation and 60 
millirem of manmade radiation. The Bureau functions under legislative mandates per Iowa Code, 
Chapters 136B, C and D. 
 
   
Bureau of Family Health Lucas State Office Building 
321 E. 12th Street  
Des Moines, IA 50319-0075 
Main Number: 
800-383-3826 or 515-281-
3826 
 The Bureau of Family Health guides the development of preventive health services for Iowa families in 
partnership with families, communities, health care providers and public health providers.  Programs 
promote development of local systems of health care to assure that all women have access to 
reproductive health services and all Iowa children receive regular, preventive health care.  Programs 
support family centered, community based and culturally sensitive health services for all Iowa families.   
The toll free Healthy Families line (800-369-2229), a 24-hour information and referral service, promotes 
access to community-based health resources. 
   
Child Care Resources and 
Referral Services 
 www.iowaccrr.org to 
locate the phone number 
for local/regional CCRR 
personnel 
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Other Important Phone Numbers 
 
University of Iowa State 
Hygienic Laboratory 
102 Oakdale Campus 
Iowa City, IA 52242-5002 
 
 
Main Number: 
319-335-4500 
As a state agency under the Iowa Board of Regents, within the Health Sciences Center of The 
University of Iowa, the State Hygienic Laboratory (SHL) provides multidisciplinary analytical and 
diagnostic scientific services, leadership and education to support environmental quality and public 
health. The Laboratory provides services for assessment, surveillance, research and development, and 
technology transfer in support of public policy and its development on a state, national and 
international level. 
 
The Laboratory's Statement of Mission is derived from, and consistent with, its responsibilities as 
specified in the Code of Iowa under Chapter 263.7-8. (Rules implementing this statute and governing 
the operation of the Laboratory are found in the Iowa Administrative Code, Sections 720-5.1 through 
720-5.3.) The Mission of the SHL has been affirmed by the Iowa Supreme Court. 
   
Iowa Department of 
Agriculture and Land 
Stewardship 
Wallace State Office Building                                                  
502 E. 9th St. 
Des Moines, Iowa 50319 
 
 
Main Number:
515-281-5321 
Iowa Department of Agriculture and Land Stewardship (IDALS) works to build a department of 
agriculture that can respond quickly and efficiently to changing global conditions in agriculture. The 
department wants to increase Iowa’s agricultural market share -- both domestic and foreign, and assist 
in the removal of unnecessary barriers to agricultural trade. They work to develop and encourage 
agricultural education and new avenues for Iowa producers to market their products, increasing the 
independent farmer’s impact on the market.  IDALS adds value in Iowa to agriculture by developing 
new products and creating links for Iowa farmers with consumer-ready markets.  The fight to preserve 
Iowa’s precious soil, and improve water quality to ensure opportunities for future generations of 
Iowans and protect consumers and producers by assuring the quality of Iowa agricultural products and 
animal health.  
   
Iowa Department of Natural 
Resources (DNR) 
Wallace State Office Building                                                  
502 E. 9th St. 
Des Moines, Iowa 50319 
 
 
Main Number:
515-281-5918 
The Iowa Department of Natural Resources is the government agency that leads Iowans in caring for 
their natural resources. It is responsible for maintaining state parks and forests, protecting the 
environment, and managing energy, fish, wildlife, and land and water resources in Iowa.  
 
   
Iowa State University – 
Entomology Department 
 
Entomology Department  
Rm 442, Science II Building  
Iowa State University 
Ames, Iowa 50011-3222 
 
Main Number(s): 
515-294-4387 
 
Entomologists at Iowa State university have engaged in teaching, research, and extension for more 
than a century. Professor Herbert Osborn taught the nation's first entomology course in 1880, 
beginning a tradition of excellence in basic and applied entomology. The Department of Entomology 
faculty work to provide education, develop innovative research programs and supply a creative, highly 
visible problem-solving extension program.  
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Iowa State University 
Veterinary Diagnostic 
Laboratory 
Iowa State University 
College of Veterinary Medicine 
1600 South 16th St. 
Ames, IA 50011 
Main Number:  
515-294-1950 
After Hours: 
515-290-1969 
Fax: 
515-294-3564 
The Iowa State University Veterinary Diagnostic Laboratory (VDL) is accredited as a full service 
laboratory by the American Association of Veterinary Laboratory Diagnosticians (AAVLD). 
   
Iowa Department of 
Inspections and Appeals 
Lucas State Office Building                                                                  
321 E. 12th St.                                                                                                   
Des Moines, Iowa 50319-0075    
 
Main Number:
515-281-7102
The Department of Inspections and Appeals (DIA) is a multifaceted regulatory agency charged with 
protecting the health, safety and well being of Iowans. The agency is responsible for inspecting, 
licensing and/or certifying health care providers and suppliers, restaurants and grocery stores, social 
and charitable gambling operations, hotels and motels, and barber and beauty shops.  In addition, DIA 
staff investigates alleged fraud in the State's public assistance programs and conducts contested case 
hearings to settle disputes between Iowans and various state government agencies. 
 
The Department was created in 1986 to coordinate and conduct various audits, appeals, hearings, 
inspections, and investigations related to the operations of the executive branch of state government. 
DIA is organized into four major divisions, each with its own specific duties and responsibilities. 
Overseeing the daily operation of the agency is the Administration Division, which includes the 
Director's Office and staff. The Director's Office sets policy for the Department and is responsible for 
coordinating DIA's various programs and functions. 
 
Iowa Statewide Poison 
Control Center 
St. Luke's Regional Medical 
Center 
401 Douglas St, Suite 402 
Sioux City, IA 51101 
 
Main Number(s): 
800-222-1222 
(712) 277-2222 
The Iowa Statewide Poison Control Center (ISPCC) was formed in 2000 by combining the poison 
control resources and expertise of Iowa Health System and University of Iowa Hospitals and Clinics. 
The IHS and the UIHC each have a 25-year history of providing poison control services throughout the 
state.  
 
The jointly sponsored statewide poison control center provides all of Iowa’s 2.9 million citizens 24-hour 
toll-free telephone access to emergency poison information and treatment. 
 
Specially trained nurses staff the ISPCC’s hotline 24 hours a day and are backed-up by a physician 
toxicologist. These poison specialists answer questions about household products, drug overdoses, 
chemicals at work or in the environment, plant and mushroom ingestions, medication errors, bites and 
stings, or any other toxicology-related subject.  
   
Clearinghouse 
 
Website: 
 Main Number: 
319-398-5133 
 
healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295 
Materials on reportable diseases are free of charge and may be obtained by contacting the 
clearinghouse.  These materials are provided to local public health agencies and relevant partners.  
Among the materials available is disease reporting forms, disease brochures, and disease posters. The 
recommended way of ordering is by using the clearinghouse website.  
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Iowa Department of Public Health — Bureau of HIV, STD, and Hepatitis
          Region 1          Region 2       Region 2A Polk Co.                 Region 3   Region 3A Black Hawk Co.
Jodie Liebe (708) LaShaina Woods (706) *Kari Lebeda Townsend (749) Gina Mallett (704) *Carla Bergmeier (703)
Siouxland District Health Dept Iowa Dept of Public Health *Beth Dooley (732) Black Hawk County Health Dept *Brenda Hostetler (715)
1014 Nebraska St Lucas State Office Building *Jaimie Schwab (735) 1407 Independence Ave 5th Fl *Ange Miller (751)
Sioux City  IA 51105 321 E 12th 5th Fl *Kate Gilmore (738) Waterloo  IA 50703 *Claudia Robinson (754)
Office 712-234-3926 Des Moines  IA  50319 *Jean Phillips (740) Office 319-292-2235 Black Hawk County Health Dept
Mobile 515-783-4076 Office 515-281-6087 Polk County Health Dept Mobile 515-783-4086 1407 Independence Ave 5th Fl
Fax 712-234-3920 Mobile 515-783-4077 1907 Carpenter Fax 319-291-2529 Waterloo  IA 50703
jodie.liebe@idph.iowa.gov Fax 515-281-0466 Des Moines  IA  50314 gina.mallett@idph.iowa.gov Phone 319-292-2413
lashaina.woods@idph.iowa.gov Phone 515-286-3798 Fax 319-291-2529
Fax 515-286-2033
          Region 4    Region 4A Linn Co.
Shannon Wood (746) *Barbara Chadwick (761)
Johnson County Public Health *Carissa Griffin (724)
855 S Dubuque St *Sherri Schuchmann (729)
Iowa City  IA 52240 *Heather Meador (747)
Office 319-358-1834 Linn County Public Health
Mobile 515-783-4079 501 13th St NW
Fax 319-356-6039 Cedar Rapids  IA 52405
shannon.wood@idph.iowa.gov Phone 319-892-6000
Fax 319-892-6098
        Region 5    Region 5A Scott Co.          Region 6
Mary Costello (710) *Roma Taylor (719) Linda McQuinn (702)
Scott County Health Dept *Stuart Scott (707) Council Bluffs City Health
600 W 4th St 4th Fl *Lashon Moore (736) 209 Pearl St
Davenport  IA 52801 *Jane Morehouse (739) Council Bluffs  IA  51503
Office 563-326-8216 Scott County Health Dept Office 712-328-3194
Mobile 515-783-4078 600 W 4th St 4th Fl Mobile 515-783-4081
Fax - 563-326-8774 Davenport  IA 52801 Fax 712-328-4917
mary.costello@idph.iowa.gov Phone 563-326-8618 linda.mcquinn@idph.iowa.gov
Fax 563-326-8774
Disease Prevention Specialist Regions
*County Employee 
REVISED OCT. 2013
Lyon 
Montgomery 
Audubon 
Buena  
Vista 
Clay 
Dickinson 
Sioux 
Plymouth 
Woodbury 
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Pottawattamie 
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Fremont Page 
Shelby 
Crawford Carroll 
Cass 
Ida Sac 
Cherokee 
O'Brien 
Osceola 
Taylor Ringgold Decatur Wayne Appanoose Davis Van Buren 
Lee 
Des 
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Henry Jefferson Wapello Monroe Lucas Clarke Union Adams 
Adair Madison Warren Marion Mahaska Keokuk Washington 
Louisa 
Guthrie 
Greene 
Calhoun 
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Palo Alto 
Emmet Kossuth 
Webster 
Boone 
Dallas Polk 
Story 
Hamilton 
Wright 
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Gordo 
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Hardin 
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Jasper Poweshiek Iowa Johnson 
Muscatine 
Scott 
Clinton 
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Dubuque 
Clayton 
Allamakee 
Winneshiek Howard Mitchell 
Floyd Chickasaw 
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Buchanan Delaware 
Jones 
Cedar 
Linn Benton Tama 
Grundy 
Black Hawk 
Bremer Butler 
Dr. Greg Schmitt 
Le Mars IA 51031 
515-669-5633 cell 
712-541-6033 fax 
Dr. Wayne Rychnovsky 
Corning, IA 50841 
515-971-7391 cell 
Dr. R.E. Welander 
Mt. Pleasant, IA 52641 
515-669-5929 cell 
319-385-7000 fax 
Dr. Gary E. Eiben 
Colesburg, IA 52035 
515-669-6095 cell 
563-856-3009 fax 
Dr. Tim Smith 
Nevada, IA 50201 
515-669-6231 cell 
515-382-4270 fax 
Humboldt 
March 2013 
STATE VETERINARIAN DISTRICTS 
Dr. David Schmitt, State Veterinarian 
515-281-8601  *  515-669-3527 cell 
Assistant State Veterinarian 
515-281-0866 – office March 2013 
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Erin Barkema, RCHC 
 
Cell: (515) 829-0515 
 
Erin.Barkema@idph.iowa.gov 
Diane K. Anderson, RCHC   
 
Cell: (515) 745-2163 
Diane.K.Anderson@idph.iowa.gov 
 
 
 
Diane.K.Anderson@idp
h.iowa.gov 
 
Heather Bombei, RCHC   
 
Cell: (515) 745-4877 
Heather.Bombei@idph.iowa.gov 
 
Berdette Ogden, RCHC  
Office: (641) 634-2132 
Cell: (515) 745-2373 
Fax: (641) 634-2097 
Berdette.Ogden@idph.iowa.gov 
VACANT, RCHC  
 
Cell:  
 
Email: 
Gerd Clabaugh, Division Director 
Gerd.Clabaugh@idph.iowa.gov 
Office: (515) 281-7996 
 
 
Diane M. Anderson, PP2  
Office: (515) 242-6522 
Fax: (515) 242-6384 
 
Diane.M.Anderson@idph.iowa.gov  
 
Dawn Mouw, RCHC  
 
Cell: (515) 745-2368 
Dawn.Mouw@idph.iowa.gov 
 
RCHC = Regional Community Health Consultant  
 
PP2 = Program Planner 2 
    
 
Bureau of Local Public Health Services 
Iowa Department of Public Health – Division of Health Promotion and Chronic Disease Prevention 
 Healthy Child Care Iowa Map 
December 2012 
 CCNC 
Number CCNC Name Child Health Agency CCNC Phone CCNC E-Mail Address 
1 Kate Phillips Black Hawk County Health Department  
(319) 292-2229 Office 
(319) 29-1734 Cell Kphillips@co.black-hawk.ia.us 
2 New Opportunities, Inc New Opportunities, Inc (712) 792-9266  
 3 Washington County Public Health Washington County Public Health (319) 653-7758 
 4 Cyndi Mason Lee County Health Department (319) 372-5225 cmason@leecountyhd.org  
5 Darla Butikofer Visiting Nurse Association of Dubuque (563) 245-1145 darla.butikofer@finleyhospital.org  
6 Deb Baldwin Mid-Sioux Opportunity, Inc (712) 786-3487 dbaldwin@midsioux.org  
7 Deb Gimer 
MATURA (BV), New Opportunities, Inc (Sac), NICAO (Koss, Winn) & Webster County Health 
Department (Greene, Emmet, Cal, PA, Poc) (712) 297-8323 dgimer@calhouncountyiowa.com  
8 Deidre Buttz Marion County Public Health (641) 342-3724 DButtz@grm.net 
9 Johnson County Public Health Johnson County Public Health (319) 356-6042 
 10 Family, Inc Family, Inc  (712) 256-9566 
 11 Emily Schroder Family, Inc  (712) 256-9566 emily@familyia.org  
12 Heidi Hotvedt Visiting Nurse Services of Iowa (563) 652-4048 heidi.hotvedt@jcrhc.org  
13 Jane Matzen Lee County Health Department (641) 682-3449 jmatzen@ahfa.org 
14 Jean Randolph Hawkeye Area Community Action Program (319) 739-0029 jrandolph@hacap.org  
15 Julie Kixmiller Crawford County Home Health (712) 243-8006 kixmiljk@ihs.org  
16 Julie Thomas Taylor County Public Health (712) 523-3405 jthomasmch@frontier.com  
17 Chris Lee New Opportunities, Inc (712) 792-9266 Ext. 208 CLee@newopp.org 
18 Kelly Bailey Warren County Health Services (641) 342-3724 bkelly@iowatelecom.net  
19 Kim Gonzales, Cynthia Klein Dubuque Visiting Nurse Association (563) 556-6200 
Kim.Gonzales@FinleyHospital.org; 
cynthia.klein@finleyhospital.org  
21 Lori Hoch Crawford County Home Health (712) 263-3303 lorihochrn@yahoo.com  
22 Lee County Health Department Lee County Health Department (319) 372-5225 
 23 Jessica Redden Scott County Health Department (563) 326-8618  Jessica.Redden@scottcountyiowa.com 
24 Mid-Iowa Community Action Mid-Iowa Community Action (800) 890-8230   
25 Mid-Sioux Opportunity, Inc Mid-Sioux Opportunity, Inc (800) 859-2025   
26 Nancy Granaman Lee County Health Department (319) 750-5258 bngranaman@gmail.com 
27 North Iowa Community Action North Iowa Community Action (641) 423-5044 
 28 Nicole Olhausen Siouxland Community Health Center (712) 252-2477  nolhausen@slandchc.com  
29 Patti Scieszinski Marion County Public Health (641) 774-4312 pski@lucasco.org  
30 Sandy Hill Trinity Muscatine Public Health (563) 263-0122 Sandra.Hill@trinitymuscatine.org. 
31 Marion County Public Health Marion County Public Health (641) 828-2238 rcecil@marionph.org 
32 Shannon Knudson Mid-Iowa Community Action (515) 298-4896 shannon.knudsen@micaonline.org  
33 Sharon Campbell MATURA (641) 782-8431 scampbell@maturaaction.org  
34 Shelly Jensen Warren County Health Services (515) 961-1074 shellyj@co.warren.ia.us  
35 Jennifer Matters Mid-Iowa Community Action (641) 328-9133 jennifer.matters@micaonline.org 
36 Tricia Nichols Webster County Health Department (515) 573-4107 tnichols@webstercountyia.org  
37 Trish Dillard MATURA (712) 240-0281 tdillard@maturaact.org  
38 Jeanette Luthringer Visiting Nurse Services of Iowa                                                (515) 558-9604 jeannettel@vnsia.org  
  Heather Jenks Visiting Nurse Services of Iowa                                                (515) 557-9013 heatherj@vnsdm.org  
  Kara Wall Visiting Nurse Services of Iowa                                                (515) 557-9025 karaw@vnsia.org  
  Amy Karaidos Visiting Nurse Services of Iowa                                                (515) 558-9947 amyk@vnsdsm.org 
  Kristin Sjulin Visiting Nurse Services of Iowa                                                (515) 558-9960 Kristins@vnsdsm.org  
  Joanna Cox Visiting Nurse Services of Iowa                                                (515) 558-9968 joannac@vnsia.org  
39 Wendy Taylor 
North Iowa Community Action Organization (Butler, Cerro Gordo, Franklin, Hancock & Worth) &                                                                               
Black Hawk County Health Department  (Bremer, Grundy) (641) 423-5044 wtaylor@nicao-online.org  
40 Marsha Platt Black Hawk County Health Department  
(319)415-8912 Cell 
(319) 292-2409 Office mplatt@co.black-hawk.ia.us 
41 Terri Sinclair Marion County Public Health (641) 437-4332 tsinclair@appanoosecounty.net  
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Iowa Department of Public Health 
Environmental and Occupational Surveillance 
Reportable Poisonings, Injuries, Diseases, Conditions, and Exposures 
 
IDPH Environmental Health (EH) hotline (Mon-Fri 8 am-4:30 pm): 800-972-2026   
IDPH 24/7 Disease reporting hotline: 800-362-2736  
IDPH Environmental Health Fax:  515-281-4529 
IDPH EH Division Web Page: www.idph.state.ia.us/eh/default.asp   
IDPH Bureau of Emergency Medical Services (EMS) Web Page:  www.idph.state.ia.us/ems/data.asp  
 
OUTBREAK REPORTING - CALL THE 24/7 DISEASE REPORTING HOTLINE: 800-362-2736 
IMMEDIATELY report to the department outbreaks of any kind, diseases (including those not specifically noted) that occur in unusual numbers or circumstances, 
unusual syndromes, or uncommon diseases. Outbreaks may be infectious, environmental or occupational in origin and include food-borne outbreaks or illness 
secondary to chemical exposure (e.g., pesticides, carbon monoxide, anhydrous ammonia).  
 
BIOTERRORISM REPORTING - CALL THE 24/7 DISEASE REPORTING HOTLINE: 800-362-2736 
IMMEDIATELY report diseases, syndromes, poisonings and conditions of any kind suspected or caused by a biological, chemical, or radiological agent or toxin 
when there is reasonable suspicion that the disease, syndrome, poisoning or condition may be the result of a deliberate act such as terrorism (but are not limited 
to) anthrax, mustard gas, sarin gas, ricin, tularemia and small pox.  
 
ELEVATED BLOOD LEAD TEST RESULTS GREATER THAN OR EQUAL TO 20 UG/DL- CALL THE EH HOTLINE:  800-972-2026 
IMMEDIATELY during regular business hours (Mon-Fri 8am to 4:30 pm) report all blood lead test results greater than or equal to 20 ug/dL to the 
Environmental Health hotline and fax a hard copy of the result to the EH fax.  
 
ROUTINE REPORTING  
Reports not meeting the conditions given for immediate reporting shall report as directed below, using electronic or web-based reporting if available, or another 
IDPH approved reporting format. Iowa trauma nurse coordinators and data registrars in the trauma hospitals of Iowa can continue to use the Trauma Registry 
software for reporting agricultural related injuries and traumatic brain and spinal cord injuries or EMS approved hard copy report forms.  Refer to the IDPH EH Web 
page for more details, approved formats, forms, and specific disease/poisoning/injury/condition reporting information.  
 
WHO IS REQUIRED TO REPORT 
Mandatory Reporting is required of health care providers, clinics, hospitals, clinical laboratories, and other health care facilities; school nurses or school officials; 
poison control and information centers; medical examiners; occupational nurses.  Hospitals, health care providers, and clinical laboratories outside the state of 
Iowa for confirmed or suspect cases in an Iowa resident. Complete information can be found in the Iowa Administrative Code [641] Chapter 1, which is linked at 
the IDPH EH Division Web page. 
 
For more information, please refer to the IDPH EH Division Web page at www.idph.state.ia.us/eh/default.asp or call the Environmental 
Health hotline during regular business hours. 

      
IOWA DISEASE REPORTING CARD                   FAX VERSION 
Disease reporting is required by Iowa Administrative Code [641]-1 (139A) 
Fax report to (515) 281-5698 or call (800) 362-2736 
DISEASE AND LABORATORY INFORMATION 
DISEASE/EVENT:       Laboratory: 
 
      
Diagnosis date: 
 
     /     /      Lab city/state/zip: 
 
      
Onset date:      /     /      Collection date: 
 
     /     /      
Outcome: 
Survived this illness    Died from this illness 
Died unrelated to this illness   Unknown Specimen source:       
Provider name:  Lab test:  
Provider title: ARNP     DO     MD     NP     PA Result date:      /     /      
Facility name:       Result: 
Positive/detected   
Negative/undetected   
Undetermined   
Equivocal   
Address:             
Other:  
 
Phone : (     )        -      City/State/Zip:       
Clinical sx: 
Abdominal pain 
Anorexia 
Bull’s eye rash 
Cough 
Diarrhea 
Fever     
Gland swelling 
Jaundice 
Rash 
Sore throat 
Stiff neck    
Vomiting 
Other:   
                                    Specimen sent to UHL  
PATIENT INFORMATION 
Name (last, first, middle):       
Address:       
City:       County:       Zip:       
Long-term care     
resident: Yes     No     Unk Facility name:       
DOB:       /       /       Age:       Years   Months Gender: M  F  Unk 
Pregnant? Yes  No  Unk Due Date:      /     /      
Race: 
White 
Black or African American 
American Indian or Alaska Native 
Hawaiian or Pacific Islander 
Asian 
Unknown       Other 
 Marital 
status: 
Single   
Married   
Widowed   
Unknown  
Divorced   
Ethnicity: Hispanic or Latino   Not Hispanic or Latino   Unknown 
If minor, Parent name(s):       
Phone: Home (       )              -      Work (       )              -      Other (       )              -      
OCCUPATION INFORMATION 
Job title: 
 
      Facility name: 
 
      
Worked after 
symptom onset: 
 
Yes     No     Unknown Address: 
 
      
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
Yes     No     Unknown 
Yes     No     Unknown 
Yes     No     Unknown 
Yes     No     Unknown 
Zip code: 
 
      
City/State/County: 
 
      
Work in a health care setting: 
Direct patient care duties in lab 
or health care setting: 
Health care worker type: 
Yes     No     Unknown 
                          
Yes     No     Unknown 
      
Phone:  (     )           -              Type: 
 
 
 
HOSPITALIZATION INFORMATION 
Was the case 
hospitalized? 
 
 Yes    No    Unknown Hospital: 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /        Still hospitalized 
 
Days hospitalized: 
 
    
REPORTER INFORMATION 
Reporter name:  Reporter facility name:  
Reporter phone:  Date reported to IDPH:  
Comments: 
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GENERAL INFECTION CONTROL MEASURES 
              
Implementation and adherence to infection control practices are the keys to preventing the 
transmission of infectious diseases, including respiratory diseases spread by droplet or airborne 
routes. Recommended infection control practices include:  
1. Hand hygiene; 
2. Standard Precautions/Transmission-Based Precautions (Contact, Droplet, Airborne) 
3. Respiratory hygiene  
Hand hygiene is the single most effective means of preventing the spread of all infections 
among hospital patients and personnel. When followed properly, each of these practices 
decreases the risk of spreading common respiratory pathogens 
 
Hand Hygiene  
Proper hand hygiene is the most effective way to prevent the spread of infection. Detailed hand 
hygiene information is available on the CDC website at www.cdc.gov/handhygiene. To properly 
wash and clean hands, the following procedure should be followed:  
 Wash hands when they are visibly dirty or soiled with blood or other body fluids. Wash 
hands with either a non-antimicrobial soap or an antimicrobial soap and water. When 
washing hands with soap and water, wet hands first with water, apply to hands the 
amount of product recommended by the manufacturer, and rub hands together 
vigorously for at least 15 seconds, covering all surfaces of the hands and fingers. Rinse 
hands with water and dry thoroughly with a disposable towel or air dryer. Use a dry 
paper towel, if available to turn off the faucet.  
 If hands are not visibly soiled, an alcohol-based hand rub or gel may be used in place of 
soap and water in most circumstances. When using an alcohol-based hand rub or gel, 
apply product to the palm of one hand and rub hands together, covering all surfaces of 
hands and fingers, until the hands are dry.  
 Avoid wearing artificial fingernails when caring for patients at high risk for infection, and 
keep natural nail tips less than 1/4-inch long.  
 Wear gloves when contact with blood or other potentially infectious materials, mucous 
membranes, and non-intact skin could occur.  
 Remove gloves after caring for a patient. Always perform hand hygiene after removing 
gloves. Do not wear the same pair of gloves for the care of more than one patient, and 
do not wash gloves between uses with different patients.  
 Change gloves during patient care if moving from a contaminated body site to a clean 
body site.  
Standard Precautions  
The Standard Precautions/Transmission-Based Precautions system is designed to prevent the 
transmission of infectious agents. It requires the use of work practice controls and protective 
apparel for all contact with blood and body substances, but uses Airborne Infection Isolation, 
Droplet, and Contact Precautions for patients with diseases known to be transmitted in whole or 
in part by those routes. Standard Precautions include consistent and prudent preventive 
measures to be used at all times regardless of a patient’s known infection status, and include:  
Iowa Department of Public Health 
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Hand hygiene. Practice hand hygiene after touching blood, body fluids, secretions, 
excretions, or contaminated items, whether or not gloves are worn. Wash hands 
immediately after gloves are removed, between patient contacts, and when otherwise 
indicated to avoid transfer of microorganisms to other patients or environments.  
 
Gloves. Wear gloves (clean, nonsterile gloves are adequate) when touching blood, body 
fluids, secretions, excretions, or contaminated items. Put on clean gloves just before 
touching mucous membranes and non-intact skin. Change gloves between tasks and 
procedures. Practice hand hygiene whenever gloves are removed.  
 
Mask, eye protection/face shield. Wear a mask and adequate eye protection 
(eyeglasses are not acceptable), or a face shield to protect mucous membranes of the 
eyes, nose, and mouth during procedures and patient care activities that are likely to 
generate splashes or sprays of blood, body fluids, secretions, or excretions.  
 
Gown. Wear a gown (a clean, nonsterile gown is adequate) to protect skin and to 
prevent soiling of clothing during procedures and patient care activities that are likely to 
generate splashes or sprays of blood, body fluids, secretions or excretions. Carefully, 
remove a soiled gown as promptly as possible, to avoid contamination of personal 
clothing, and wash hands.  
 
Patient care equipment. Handle used patient care equipment soiled with blood, body 
fluids, secretions, or excretions in a manner that prevents skin and mucous membrane 
exposures, contamination of clothing, and transfer of microorganisms to one’s self, other 
patients and the environment. Ensure that reusable equipment is not used for the care 
of another patient until it has been cleaned and sanitized appropriately. Ensure that 
single-use items are discarded properly.  
 
Contact Precautions  
In addition to Standard Precautions, Contact Precautions should be used for the care of patients 
known or suspected to have illnesses that could be spread by usual contact with an infected 
person, or by the contaminated environmental surfaces or patient care items in the room.  
Example of diseases/organisms requiring Contact Precautions include:  
 Severe Acute Respiratory Syndrome (SARS): See “SARS Infection Control” section  
 Parainfluenza virus  
 Respiratory syncytial virus  
 Varicella (chickenpox): Also requires Airborne Infection Isolation  
 Herpes Zoster (disseminated or in the immunocompromised host): Also requires 
Airborne Infection Isolation  
 
Gown. Wear a gown when entering the room. Remove the gown before leaving the 
patient’s environment. After gown removal, ensure that clothing does not contact potentially 
contaminated environmental surfaces. Wash hands.  
 
Patient transport. Limit the movement of the patient from the room to essential purposes 
only. During transport, ensure that all precautions are maintained.  
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Patient care equipment. When possible, dedicate the use of noncritical patient care 
equipment to a single patient (or cohort of patients infected or colonized with the pathogen 
requiring precautions) to avoid sharing between patients. If use of common equipment or 
items is unavoidable, then adequately clean and disinfect them before use for another 
patient.  
 
Patient placement (private room). Place the patient in a private room. If a private room 
is not available, place the patient in a room with other patients with the same illness 
(cohorting).  
 
Contact Precautions include:  
Gloves, gown and hand hygiene. Wear gloves when entering the room. During the 
course of providing care for a patient, change gloves after having contact with infective 
material. Wear gown to protect clothing if contact with body fluids is anticipated. 
Remove gloves and gown before leaving the patient’s room and practice hand hygiene 
immediately with an antimicrobial agent or a waterless antiseptic agent. After glove 
removal and hand hygiene, ensure that hands do not touch potentially contaminated 
surfaces or items in the patient’s room.  
 
Droplet Precautions  
In addition to Standard Precautions, use Droplet Precautions for a patient known or suspected 
to be infected with microorganisms transmitted by droplets (large-particle, wet droplets [larger 
than 5µm in size]) that can be generated by the patient during coughing, sneezing, talking, or 
the performance of procedures.  
Examples of diseases/organisms requiring Droplet Precautions include:  
 Invasive Hemophilus influenzae disease: meningitis, pneumonia (in infants and small 
children), epiglottitis  
 Invasive Neisseria meningitidis disease: meningitis, pneumonia, and bacteremia  
 Mycoplasma pneumonia  
 Group A streptococcal pneumonia, pharnygitis, or scarlet fever in infants and young 
children  
 Influenza  
 Adenovirus: Also requires Contact Precautions  
 Parvovirus B19  
 Rubella  
 
Droplet Precautions include:  
Patient placement. Place the patient in a private room. When a private room is not 
available, place the patient in a room with a patient(s) who has active infection with the 
same microorganism but with no other infection (cohorting). When a private room is not 
available and cohorting is not achievable, maintain spatial separation of at least three feet 
between the infected patient and other patients and visitors. Special air handling and 
ventilation are not necessary, and the door may remain open.  
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Mask. In addition to standard precautions, wear a mask or respirator when working within 
three feet of the patient. (Hospitals may want to implement the wearing of a mask to enter 
the room.)  
 
Patient transport. Limit the movement and transport of the patient from the room to 
essential purposes only. If transport or movement is necessary, minimize patient dispersal 
of droplets by masking the patient, if possible.  
 
Airborne Infection Isolation  
In addition to Standard Precautions, Airborne Infection Isolation measures are designed to 
reduce the risk of transmission of infectious agents that may be suspended in the air in either 
small particle aerosols or dust particles. Patients requiring Airborne Infection Isolation must be 
given a private room with special air handling and ventilation (negative pressure). Respiratory 
protection for healthcare workers is necessary when entering the patient’s room.  
Examples of diseases/organisms requiring Airborne Infection Isolation include:  
 SARS: See “SARS Infection Control” section  
 Tuberculosis (pulmonary or laryngeal, suspected or confirmed)  
 Varicella: Also requires Contact Precautions  
 Herpes Zoster (shingles) in an immunocompromised patient: Also requires Contact 
Precautions  
 Measles (rubeola)  
 
Airborne Infection Isolation includes:  
Patient placement. Airborne Infection Isolation requires a negative pressure room in 
addition to a private room. Keep the room door closed and the patient in the room. 
When a private room is not available, place the patient in a room with a patient who has 
active infection with the same microorganism, but with no other infection (cohorting).  
 
Respiratory protection. Respiratory protection must be worn when entering the room 
of a patient in Airborne Infection Isolation. A NIOSH-certified, fit-tested disposable N-95 
respirator mask is recommended for all persons entering the room, including visitors. 
The use of higher-level respirators may be considered for certain procedures. If a 
particulate respirator with filter efficiency of 95% or greater is not available, a surgical 
mask should be worn. The mask should fit tightly around the nose and mouth to protect 
against large droplet transmission.  
 
Respiratory Hygiene/Cough Etiquette  
“Respiratory hygiene” is a term that has been adopted by the Centers for Disease Control and 
Prevention (CDC) and the Iowa Department of Public Health (IDPH) to describe measures that 
can be taken to decrease the risk of spreading respiratory pathogens. A universal “respiratory 
hygiene/cough etiquette” strategy for a healthcare facility should include the following:  
 Place signs at the entrances of all outpatient facilities requesting that patients and 
visitors inform healthcare personnel of respiratory symptoms upon registration.  
 Provide masks (e.g., surgical) for all patients presenting with respiratory symptoms 
(especially cough) and provide instructions on the proper use and disposal of masks.  
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 If a patient cannot wear a mask, provide tissues and instructions on when to use them 
(i.e., when coughing, sneezing or controlling nasal secretions), how and where to 
dispose of them, and the importance of hand hygiene after handling this material 
(cough etiquette).  
 Provide hand hygiene materials in waiting room areas and encourage patients with 
respiratory symptoms to wash their hands.  
 If possible, designate an area in waiting rooms where patients with respiratory 
symptoms can be segregated (ideally by more than three feet) from other patients 
without respiratory symptoms.  
 Place patients with respiratory symptoms in a private room or cubicle as soon as 
possible for further evaluation.  
 Healthcare workers evaluating patients with respiratory symptoms should wear a 
surgical or procedure mask.  
 Consider the installation of Plexiglas barriers at the point of triage or registration to 
protect healthcare workers.  
 If a physical barrier is not possible, instruct registration and triage staff to remain at 
least three feet from unmasked patients. Staff should consider wearing a surgical mask 
during registration and triage.  
 Continue to use Droplet Precautions to manage patients with respiratory symptoms until 
it is determined that the cause of symptoms is not an infectious agent that requires 
precautions beyond Standard Precautions. 
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Minimal Recommendations for Use of Surgical or Procedure 
Masks and Respirators Around Patients with Cough Illness 
 
Influenza, pertussis and other diseases are transmitted via droplets produced by coughing. The following 
infection prevention guidelines are recommended when caring for anyone presenting with a cough illness. 
Clinicians or infection preventionists may recommend additional infection prevention measures if 
indicated by a specific patient or situation in the community.  
 
Standard Precautions and Droplet Precautions should be used when caring for all patients 
with a cough illness. 
 
Masks 
A mask should fit snugly around the nose and mouth to prevent gaps, forcing air flow through the mask. 
 
Standard Precautions 
For complete guidelines visit: www.cdc.gov/hicpac/2007IP/2007isolationPrecautions.html. 
 
Droplet Precautions  
Health care providers should wear surgical or procedure masks when giving direct care to patients with a 
cough illness. 
 
Specimen collection:  
Use standard and droplet precautions for most specimen collection. 
 
Aerosol-generating procedures (e.g. intubation, bronchoscopy, open-system respiratory suctions, 
resuscitation, autopsy, etc.) 
 Particulate respirator (e.g. EU FFP2, USNIOSH-certified N-95) 
 Eye protection 
 A clean non-sterile, long sleeved gown 
 Gloves (some of these procedures require sterile gloves) 
 
Transport within healthcare facilities (for transport of patients with cough illness).  
 Patient should wear a surgical or procedure mask when outside the patient’s room.  
 Encourage performance of hand hygiene frequently and follow respiratory hygiene and cough 
etiquette practices.  
 
Transport between patient residence and healthcare facilities (for transport of patients with 
cough illness) 
 Patient should wear a surgical or procedure mask when outside the patient’s room. 
 Transporters should wear a surgical or procedure mask whenever the patient is not masked. 
 
Clinics, medical offices or other ambulatory care settings  
 Patients with a cough illness in outpatient settings should be asked to wear a surgical or 
procedure mask until being examined in the exam room and again upon leaving the exam room.  
 Staff who have close contact, including examining or providing direct patient care, should wear a 
surgical or procedure mask and put the mask on before entering the room.  
 Staff should perform hand hygiene, and then put on mask followed by gloves. When patient care 
is complete, first remove gloves, then remove the mask, and lastly perform hand hygiene.  
 
For additional information on Standard Precautions and Droplet Precautions, respiratory hygiene and 
cough etiquette go to www.cdc.gov/hicpac/2007IP/2007isolationPrecautions.html. 
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Recommended Initial Followup Timelines for Infectious Diseases 
 
Reportable 
disease 
Clinical Diagnosis Laboratory Criteria Investigation  
Begins 
Botulism, 
foodborne 
Clinical symptoms include diplopia, 
blurred vision, and bulbar weakness.  
Symmetric paralysis that progresses 
rapidly & that can be linked to a 
potential food source in the previous 
48 hours. 
Detection of botulinum toxin in serum, 
stool, or patients food or isolation of 
Clostridium botulinum from stool 
Immediate 
Botulism, Infant Characterized by constipation, poor 
feeding and “failure to thrive” that 
may be followed by progressive 
weakness, impaired respiration and 
death 
Detection of botulinum toxin in stool or 
serum or isolation of Clostridium 
botulinum from stool 
Immediate 
Brucellosis 
 
 
Clinical symptoms include fever, 
night sweats, undue fatigue, 
anorexia, weight loss, headache and 
arthralgia 
Isolation of Brucella species from  clinical 
specimen, or 4-fold or greater rise in 
Brucella  titer > 2 weeks apart or 
demonstration by immunofluorescence of 
Brucella sp. in clinical specimen 
24 hours 
Diphtheria Insidious onset, membranous 
pharyngitis with fever, enlarged 
anterior cervical lymph nodes, and 
edema of the surrounding soft tissue 
– “Bull Neck” 
Isolation of C. diphtheriae from a clinical 
specimen, or Histopathologic diagnosis of 
diphtheria. 
Immediate strict 
isolation 
Encephalitis, 
arboviral 
 
Clinical symptoms include febrile 
illness of variable severity associated 
with neurologic symptoms ranging 
from headache to aseptic meningitis 
or encephalitis. 
4-fold or greater change in serum 
antibody titer, or isolation of virus form 
tissue, blood, CSF or other body fluid or 
specific IgM. 
72 hours 
Escherichia coli 
O157:H7 
 
Clinical symptoms include diarrhea, 
often bloody and abdominal cramps, 
may be complicated by HUS or TTP, 
asymptomatic infection may also 
occur 
Isolation of E. coli O157:H7 from a 
specimen or isolation of Shiga toxin-
producing E. coli O157:NM from a clinical 
specimen 
24 hours 
Haemophilus 
Influenzae type B 
Invasive disease caused by H. 
influenzae may produce any of 
several clinical syndromes, including 
meningitis, bacteremia, epiglottitis, 
or pneumonia. 
Isolation of H. influenzae from a normally 
sterile site (e.g., blood or cerebrospinal 
fluid (CSF) or, less commonly, joint, 
pleural, or pericardial fluid) 
48 hours 
Hansen’s Disease 
 
 
Characterized by the involvement of 
primarily of skin as well as 
peripheral nerves and the mucosa of 
the upper airway. 
Demonstration of AFB in skin or dermal 
nerve, obtained from full-thickness skin 
biopsy of a lepromatous lesion  
5 days 
Hantavirus 
syndromes 
 
Characterized by bilateral interstitial 
pulmonary infiltrates and respiratory 
compromise usually requiring 
supplemental oxygen and clinically 
resembling ARDS. 
Detection of hantavirus-specific IgM or 
rising titers of hantavirus-specific IgG, or 
detection of hantavirus-specific ribonucleic 
acid sequence by PCR in clinical 
specimens 
5 days 
Hepatitis A 
 
 
Clinical symptoms include discrete 
onset of symptoms and Jaundice 
Hepatitis A IgM antibody Immediate 
Hepatitis B 
 
 
Clinical symptoms include discrete 
onset of symptoms and Jaundice 
Hepatitis B core IgM antibody positive, or 
HBsAg positive 
72 hours 
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Legionellosis 
 
 
Characterized by fever, myalgia, 
cough, pneumonia  
Isolation of legionella from clinical 
specimen, 4-fold rise in titer against L. 
pneumophila serogroup 1, detection of L. 
pneumophila serogroup 1 in respiratory 
secretions, lung tissue, or pleural fluid by 
direct fluorescent antibody testing or , 
demonstration of L. pneumophila 
serogroup 1 antigens in urine by 
radioimmunoassay or enzyme-linked 
immunosorbent assay. 
72 hours 
Listeria 
monocytogenes 
invasive disease 
Clinical symptoms include those of 
meningitis or bacteremia.  Infection 
during pregnancy may result in fetal 
loss through miscarriage or stillbirth 
or neonatal meningitis or 
bacteremia. 
Isolation of L. monocytogenes for a 
normally sterile site.  Isolation of L. 
monocytogenes from placental or fetal 
tissue 
48 hours 
Lyme Disease 
 
 
The best clinical marker for Lyme 
disease is the initial skin lesion-
erythema migrans, late 
manifestations effect the 
musculoskeletal system, nervous 
system or cardiovascular system 
Isolation of Borrelia burgdorferi from a 
clinical specimen, IgM antibodies to 
Borrelia burgdorferi in serum or CSF. 
5 days 
Malaria 
 
 
Clinical symptoms include fever, 
headache along with various other 
symptoms including back pain, 
chills, sweats, nausea, vomiting, 
diarrhea and cough. 
Demonstration of malaria parasites in 
blood films. 
5 days 
Measles An illness characterized by all of the 
following:  a generalized 
maculopapular rash lasting > 3 
days; a temperature > 101ºF 
(38.3ºC); cough, coryza, or 
conjunctivitis 
Positive serologic test for measles 
immunoglobulin M (IgM) antibody, or 
significant rise in measles antibody level 
by any standard serologic assay, or 
isolation of measles virus from a clinical 
specimen. 
Immediate 
Meningococcal 
invasive disease 
Manifests most commonly as 
meningitis and/or meningococcemia. 
Isolation of Neisseria meningitidis from 
normally sterile site. 
Immediate 
Mumps An illness with acute onset of 
unilateral or bilateral tender, self-
limited swelling of the parotid or 
other salivary gland, lasting >2 
days, and without other apparent 
cause. 
Isolation of mumps virus from clinical 
specimen, or significant rise between 
acute and convalescent-phase titers in 
serum mumps immunoglobulin G (IgG) 
antibody level by any standard serologic 
assay, or positive serologic test for 
mumps immunoglobulin M (IgM) 
antibody. 
48 hours 
Pertussis A cough illness lasting at least 2 
weeks with one of the following:  
paroxysms of coughing, inspiratory 
“whoop,” or post-tussive vomiting, 
and without other apparent cause. 
Isolation of B. pertussis from a clinical 
specimen, or positive polymerase chain 
(PCR) reaction assay for B. pertussis. 
48 hours 
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Polio Acute onset of a flaccid paralysis of 
one or more limbs with decreased or 
absent tendon reflexes in the 
affected limbs, without other 
apparent cause, and without 
sensory or cognitive loss. 
Poliovirus isolation is highest from stool 
specimens, intermediate from pharyngeal 
swabs, and very low from blood or spinal 
fluid.  To increase the probability of 
poliovirus isolation, at least two stool 
specimens should be obtained 24 hours 
apart from patients with suspected 
poliomyelitis as early in the course of 
disease as possible (ideally within 15 days 
after onset). 
48 hours 
Psittacosis  
 
 
Characterized by fever, chills, 
headache, photophobia, cough and 
myalgia 
Isolation of Chlamydia psittaci from 
respiratory secretions, or 4-fold or greater 
rise in antibody titer against C. psittaci,  
or presence of IgM antibody against  
C. psittaci 
24 hours 
Rocky Mountain 
Spotted Fever 
 
Characterized by acute onset of 
myalgia, headache, and petechial 
rash. 
4-fold rise in titer to Rickettsia rickettsii, 
Positive PCR to Rickettsia rickettsii, 
demonstration of positive 
immunofluorescence of skin lesion or 
organ tissue, or isolation of R. rickettsii 
from clinical specimen. 
5 days 
Rubella An illness that has all of the 
following characteristics:  acute 
onset of generalized maculopapular 
rash; temperature >99ºF (37.2ºC), 
if measured; arthralgia/arthritis, 
lymphadenopathy, or conjunctivitis 
Isolation of rubella virus, or significant rise 
between acute and convalescent-phase 
titers in serum rubella immunoglobulin G 
(IgG) antibody level by any standard 
serologic assay, or positive serologic test 
for rubella immunoglobulin M (IgM) 
antibody. 
24 hours 
Salmonellosis 
 
 
Common symptoms include 
diarrhea, abdominal pain, nausea 
and sometimes vomiting, 
asymptomatic infections may occur. 
Isolation of Salmonnella from clinical 
specimen. 
24 hours 
Shigellosis 
 
 
Characterized by diarrhea, fever, 
nausea, cramps and tenesmus, 
asymptomatic infections may occur. 
Isolation of Shigella from a clinical 
specimen. 
24 hours 
Tetanus Acute onset of hypertonia and/or 
painful muscular contractions 
(usually of the muscles of the jaw 
and neck) and generalized muscle 
spasms without other apparent 
medical cause. 
There are no laboratory findings 
characteristic of tetanus.  The diagnosis is 
entirely clinical. 
48 hours 
Toxic Shock 
Syndrome 
 
Fever > 102, diffuse macular 
erythroderma rash, BP < 90, and 
multisystem involvement. 
May be negative or positive culture for 
Staphylococcus aureus or group A 
Streptococcus from a normally sterile site. 
5 days 
Trichinosis 
 
 
Characterized by fever, myalgia, and 
periorbital edema 
Demonstration of Trichinella larvae in 
tissue obtained by muscle biopsy, or 
positive serologic test for Trichinella  
5 days 
Tuberculosis 
 
 
Positive TB skin test, prolonged 
cough, night sweats, and weight 
loss. 
Isolation of M. tuberculosis from a clinical 
specimen.  
48 hours 
 
        
 
Iowa Department of Public Health Table of Reportable Communicable and Infectious Diseases 
 
To report diseases immediately, use the 24/7 disease reporting telephone hotline: 1-800-362-2736 
 
OUTBREAK REPORTING 
IMMEDIATELY report to the department outbreaks of any kind, diseases that occur in unusual numbers or circumstances, unusual syndromes, or uncommon diseases. 
Outbreaks may be infectious, environmental or occupational in origin and include food-borne outbreaks or illness secondary to chemical exposure (e.g., pesticides, anhydrous ammonia). 
 
BIOTERRORISM REPORTING  
IMMEDIATELY report diseases, syndromes, poisonings and conditions of any kind suspected or caused by a biological, chemical, or radiological agent or toxin when there 
is reasonable suspicion that the disease, syndrome, poisoning or condition may be the result of a deliberate act such as terrorism.  Examples of these include (but are not      
limited to) anthrax, mustard gas, sarin gas, ricin, tularemia and small pox. 
 
Report cases of the diseases listed in the following table to the department within the time frame specified in the When to Report column and by the reporting method in the 
How to Report column. 
 
 
Disease 
When to 
Report 
How to Report  
Acquired immune deficiency syndrome (AIDS) and  
AIDS-defining conditions 
7 days Report by mail 
 Health care providers: Use the Pediatric or Adult Confidential Case Report form 
 Laboratories: Send copy of lab report or the Iowa Confidential Report of Sexually Transmitted  
    Disease & HIV Infection  
 Mark envelope “Attention 03” 
 
Anthrax 1 day Phone, IDSS, or fax  
Arboviral disease (includes West Nile Disease,  St. Louis,  LaCrosse, 
WEE, EEE, VEE encephalitis) 
3 days Phone, IDSS, fax or mail  
Botulism Immediately 24/7 disease reporting telephone hotline: 800-362-2736  
Brucellosis (Brucella) 3 days  Phone, IDSS, fax or mail  
Campylobacteriosis (Campylobacter) 3 days Phone, IDSS, fax or mail  
Chlamydia  3 days  Report by mail 
 Health care providers: Use the Iowa Confidential Report of Sexually Transmitted Disease and  
     HIV Infection  
 Laboratories: Use the Laboratory Report of Tests Processed for STD 
 Mark envelope “Attention 00” 
 
Cholera Immediately 24/7 disease reporting telephone hotline: 800-362-2736  
Cryptosporidiosis 3 days Phone, IDSS, fax or mail  
Cyclospora 3 days Phone, IDSS, fax or mail  
Diphtheria Immediately 24/7 disease reporting telephone hotline: 800-362-2736  
Enterococcus invasive disease 3 days Laboratories: Send isolate to the University Hygienic Laboratory  
Escherichia coli shiga toxin-producing and related diseases (includes 
HUS and TTP) 
3 days Phone, IDSS, fax or mail 
Laboratories: Send isolate to the University Hygienic Laboratory 
 
Giardiasis (Giardia) 3 days Phone, IDSS, fax or mail  
Gonorrhea 3 days Report by mail 
 Health care providers: Use the Iowa Confidential Report of Sexually Transmitted Disease and  
     HIV Infection  
 Laboratories: Use the Laboratory Report of Tests Processed for STD 
 Mark envelope “Attention 00” 
 
Group A Streptococcus invasive disease 3 days Send isolate to the University Hygienic Laboratory  
Haemophilus influenzae type B invasive disease Immediately 24/7 disease reporting telephone hotline: 800-362-2736 
Laboratories: Send isolate to the University Hygienic Laboratory 
 
Hansen’s disease (leprosy) 3 days Phone, IDSS, fax or mail  
Hantavirus syndromes 3 days Phone, IDSS, fax or mail  
Hepatitis A 1 day Phone, IDSS or fax  
Hepatitis B, C, D, E 3 days Phone, IDSS, fax or mail  
Human immunodeficiency virus (HIV) cases 
Death of a person with HIV 
Perinatally exposed newborn and child (newborn and child who was 
born to an HIV-infected mother) 
7 days Report by mail 
 Health care providers: Use the Pediatric or Adult Confidential Case Report Form 
 Laboratories: Send copy of lab report or the Iowa Confidential Report of Sexually 
     Transmitted Disease & HIV Infection 
 Mark envelope “Attention 03” 
 
Legionellosis (Legionellae) 3 days Phone, IDSS, fax or mail  
Listeria monocytogenes invasive disease 1 day Phone, IDSS, or fax –  
Laboratories: Send isolate to the University Hygienic Laboratory 
 
Lyme disease 3 days Phone, IDSS, fax or mail  
Malaria 3 days Phone, IDSS, fax or mail  
Measles (rubeola) Immediately 24/7 disease reporting telephone hotline: 800-362-2736  
Meningococcal invasive disease Immediately 24/7 disease reporting telephone hotline: 800-362-2736   
Laboratories: Send isolate to the University Hygienic Laboratory 
 
Mumps 3 days Phone, IDSS, fax or mail  
Pertussis 3 days Phone, IDSS, fax or mail  
Plague Immediately 24/7 disease reporting telephone hotline: 800-362-2736  
Poliomyelitis Immediately 24/7 disease reporting telephone hotline: 800-362-2736  
Psittacosis 3 days Phone, IDSS, fax or mail  
Rabies, animal 3 days Phone, IDSS, fax or mail  
        
Rabies, human Immediately 24/7 disease reporting telephone hotline: 800-362-2736  
Rocky Mountain spotted fever 3 days Phone, IDSS, fax or mail  
Rubella (including congenital) 1 day Phone, IDSS, fax or mail  
Salmonellosis (Salmonella) 3 days Phone, IDSS, fax or mail 
Laboratories: Send isolate to the University Hygienic Laboratory 
 
Severe acute respiratory syndrome (SARS) Immediately 24/7 disease reporting telephone hotline: 800-362-2736  
Shigellosis (Shigella) 3 days Phone, IDSS, fax or mail  
Laboratories: Send isolate to the University Hygienic Laboratory 
 
Smallpox Immediately 24/7 disease reporting telephone hotline: 800-362-2736  
Staphylococcus aureus:  
 
     Invasive disease  
 
     Methicillin-resistant, invasive disease  
      
     
      Vancomycin-resistant S. aureus  
 
 
Quarterly 
 
3 days 
 
Immediately 
 
24 hours 
 
 
 
Laboratories: Mail the number of isolates to University Hygienic Laboratory 
 
Laboratories: Send isolates to University Hygienic Laboratory 
 
24/7 disease reporting telephone hotline: 800-362-2736 
 
Laboratories: Send isolates to University Hygienic Laboratory 
 
 
Streptococcus pneumoniae invasive disease 3 days Laboratories: Send isolate to the University Hygienic Laboratory  
 Syphilis 3 days Report by mail 
 Health care providers: Use the Iowa Confidential Report of Sexually Transmitted Disease and  
     HIV Infection  
 Laboratories: Use the Laboratory Report of Tests Processed for STD 
 Mark envelope “Attention 00” 
 
 Tetanus 3 days   Phone, IDSS, fax or mail  
  Toxic Shock Syndrome 3 days   Phone, IDSS, fax or mail  
Trichinosis 3 days Phone, IDSS, fax or mail  
Tuberculosis 
 
      Pulmonary and laryngeal (infectious) 
 
      Extra-pulmonary 
 
 
Immediately 
 
3 days 
 
 
24/7 disease reporting telephone hotline: 800-362-2736 
 
Phone, IDSS, fax or mail 
 
Typhoid fever 1 day Phone, IDSS or fax  
Viral hemorrhagic fever (VHF) (e.g., Lassa, Marburg, Ebola, Crimean-
Congo, South American) 
Immediately 24/7 disease reporting telephone hotline: 800-362-2736  
Yellow Fever Immediately 24/7 disease reporting telephone hotline: 800-362-2736  
 
 
Reporting of the above diseases is required by Iowa Administrative Code [641] Chapter 1 
 
Iowa Department of Public Health/Center for Acute Disease Epidemiology 
Lucas State Office Building, 321 E. 12th Street Des Moines, Iowa 50319-0075 Phone- 800-362-2736 Secure fax- 515-281-5698 
 
Iowa Disease Surveillance System (IDSS) related questions, call the Center for Acute Disease Epidemiology (CADE) at 1-800-362-2736 
STD questions- call 515 281-3031….HIV/AIDS questions- call 515-242-5141 
Immunization questions- call 515-281-4938……TB questions- call 515 281-7504 
Specimen submission questions –call the University Hygienic Laboratory 319-335-4500 or go to http://www.uhl.uiowa.edu/ 
 
Reporting forms may be obtained from the Clearing house at: http://www.drugfreeinfo.org/state/cart.php 
 
Visit our web site at http://www.idph.state.ia.us 
 
 
       
                                                                                                                                                  
 
 
 
 
 
Revised Dec 2009 
POISONING OR 
CONDITION 
CASES TO REPORT 
WHEN TO 
REPORT 
HOW TO REPORT 
Agricultural related 
injury 
A non-household injury to a farmer, farm worker, farm family member, or other individual, 
which occurred on a farm, or in the course of handling, producing, processing, 
transporting or warehousing farm commodities 
Quarterly 
(recommend  
weekly) 
Routine reporting 
See EH Div Web page 
Trauma Registry Users, see 
EMS Web page. 
Arsenic poisoning 
Blood arsenic values equal to or greater than 70 μg/L 
Urine arsenic values equal to or greater than 100 μg/L of urinary creatinine Weekly 
Routine reporting 
See EH Div Web page 
Blood lead testing 
All analytical results greater than or equal to 20 micrograms per deciliter (μg/dL) in a child 
under the age of 6 years or a pregnant woman Daily Phone: 800-972-2026 
All other analytical values for all blood lead analyses 
 
Weekly Electronic format specified by the department 
Cadmium poisoning 
Blood cadmium values equal to or greater than 5 μg/L 
Urine cadmium values equal to or greater than 3 μg/g Weekly 
Routine reporting 
See EH Div Web page 
Carbon monoxide 
(CO) poisoning 
Blood carbon monoxide level equal to or greater than 10% carboxyhemoglobin or its 
equivalent with a breath analyzer test, or a clinical diagnosis of CO poisoning regardless 
of any test result 
Daily 
Phone: 800-972-2026 See 
EH Div Web page 
Or: 
Iowa Statewide Poison 
Control Center 
800-222-1222 for 24 hour 
consultation followed by fax 
to IDPH EH. 
Hypersensitivity 
pneumonitis 
A disease in which the air sacs (alveoli) of the lungs become inflamed when certain dusts 
are inhaled to which the person is sensitized or allergic. Includes but is not limited to 
farmer’s lung, silo filler’s disease, and toxic organic dust syndrome. 
Weekly Routine reporting See EH Div Web page 
Mercury poisoning 
Blood mercury values equal to or greater than 2.8 μg/dL 
Urine mercury values equal to or greater than 20 μg/L Weekly 
Routine reporting 
See EH Div Web page 
Methemoglobinemia Blood analyses showing greater than 5% of total hemoglobin present as methemoglobin 
Weekly 
(recommend 
immediate) 
Routine reporting 
See EH Div Web page 
Microcystin (Blue-
green algal) 
poisoning* 
Gastrointestinal symptoms, respiratory symptoms, dermal symptoms or elevated serum 
GGT (gamma glutamyl transpeptidase) and a history of exposure within the past seven 
days to water testing positive for microcystin 
Daily from 
May 1 to 
Oct. 31 
Phone: 800-972-2026  
Non- 
communicable 
respiratory illness 
An illness indicating prolonged exposure or overexposure to asbestos, silica, silicates, 
aluminum, graphite, bauxite, beryllium, cotton dust or other textile material, or coal dust. 
Includes, but is not limited to asbestosis, coal worker’s pneumoconiosis, and silicosis. 
Weekly Routine reporting See EH Div Web page 
POISONING OR 
CONDITION 
CASES TO REPORT 
WHEN TO 
REPORT 
HOW TO REPORT 
Occupationally 
related 
asthma, bronchitis 
or respiratory 
hypersensitivity 
reaction 
Any extrinsic asthma or acute chemical pneumonitis due to exposure to toxic agents in the 
workplace. (ICD-10 codes J67.0 to J67.9) All cases of occupationally induced or 
exacerbated asthma. 
Weekly Routine reporting See EH Div Web page 
Pesticide poisoning 
Any acute or subacute systemic, ophthalmologic, or dermatologic illness or injury resulting 
from or suspected of resulting from inhalation or ingestion of, dermal exposure to, or 
ocular contact with a pesticide. Laboratory confirmation is not required. 
Weekly 
Iowa Poison Control Center 
800-222-1222 for 24 hour 
consultation. 
See EH Div Web page 
Severe skin disorder 
Dermatoses, burns, and other severe skin disorders which result in death or which require 
hospitalization or other multiple courses of medical therapy. Weekly 
Routine reporting 
See EH Div Web page 
Traumatic Spinal 
Cord Injury (TSCI) 
An acute, traumatic lesion of the neural elements in the spinal canal, resulting in any 
degree of sensory deficit, motor deficit, or bladder/bowel dysfunction. The deficit can be 
temporary, permanent, or result in death. The lesion can occur at any level of the spinal 
cord and may be complete or incomplete. Spinal cord injuries include: cauda equina, conus 
medullaris injuries, central cord syndrome, anterior cord syndrome, posterior cord 
syndrome, Brown-Sequard syndrome, mixed syndrome, and cord compression. Patients 
presenting neurological symptoms upon admission which resolve before hospital discharge 
should also be reported. 
Quarterly See Bureau of EMS Web page 
Toxic hepatitis 
Any acute or subacute necrosis of the liver or other unspecified chemical hepatitis caused 
by exposure to nonmedicinal toxic agents other than ethyl alcohol including, but not limited 
to, carbon tetrachloride, chloroform, tetrachloroethane, trichloroethylene, phosphorus, 
trinitrotoluene (TNT), chloronapthalenes, methylenedianilines, ethylene dibromide, and 
organicsolvents. (ICD-10 codes K71.0 to K71.9) 
Weekly Routine reporting See EH Div Web page 
Traumatic Brain 
Injury 
(TBI) 
Clinically evident brain damage resulting from trauma or anoxia which temporarily or 
permanently impairs a person's physical or cognitive functions". The injury may be a 
penetrating or closed head injury resulting in death, or temporary or permanent 
impairment. Persons with brain injuries may display loss of consciousness, post-traumatic 
amnesia, a skull fracture, or damage to brain tissue as evidenced by neurological findings 
that can be reasonably attributed to a traumatic brain injury. 
Quarterly See Bureau of EMS Web page 
*The Director of IDPH has temporarily designated suspected or confirmed cases of exposure to microcystin as a reportable disease.  
 
Reporting of the above diseases is required by Iowa Administrative Code [641] Chapter 1.Chart Revised April 2010.  
Visit our web site at http://www.idph.state.ia.us 
Iowa Department of Public Health, Lucas State Office Building, 321 E. 12th Street Des Moines, Iowa 50319-0075 

Guide to Surveillance, Investigation and Reporting 
ANTHRAX  
 
Potential Bioterrorism Agent: Category A 
 
Also known as Woolsorter Disease 
 
Responsibilities: 
Hospital: Report immediately by phone if bioterrorism suspected, otherwise within 1 day 
Lab: Report by phone immediately if bioterrorism suspected, otherwise within 1 day.  Send 
isolates to the State Hygienic Laboratory (SHL) for confirmation 
Physician: Report immediately by phone if bioterrorism suspected, otherwise within 1 day 
Local Public Health Agency (LPHA): Follow-up required.  Iowa Department of Public 
Health will lead the follow-up investigation.  
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Anthrax is a disease caused by the bacterium Bacillus anthracis. It is primarily a disease of wild and 
domestic animals.  
 
B. Clinical Description 
Anthrax is an acute bacterial disease, which usually involves the skin, but may involve the upper 
throat, lower respiratory tract, chest cavity or intestinal tract. Toxins produced by the bacteria cause 
the tissue and organ damage associated with anthrax.  
 
In anthrax affecting the skin (cutaneous anthrax), itching of an exposed skin surface occurs first. 
Itching is followed by a small red lesion that progresses to a blister and, ultimately, a scabbed black 
ulcer (eschar) with significant surrounding edema. Roughly 5% - 20% of people with untreated 
cutaneous anthrax die, although prompt treatment with effective antibiotics can substantially reduce 
the risk of death.  
 
Initial symptoms of anthrax of the lower respiratory tract (inhalation anthrax) are usually mild, 
resembling an upper respiratory infection. Severe symptoms follow within 3 - 5 days, and include 
respiratory distress, fever and shock, with death following shortly. X-rays typically show a widened 
mediastinum. Hemorrhagic mediastinitis and/or meningitis are frequent severe complications. Case-
fatality estimates for inhalational anthrax are based on incomplete information, but the rate appears 
to be extremely high. The case-fatality rate is estimated to be approximately 75%, even with all 
possible supportive care, including appropriate antibiotics. 
 
Intestinal anthrax is rare and tends to occur in foodborne outbreaks. Fever, vomiting of blood, severe 
diarrhea, blood infection and death typically follow abdominal pain. Even with treatment, the case-
fatality rate for intestinal anthrax can approach 50%.  
 
A form of anthrax affecting the upper throat (oropharyngeal anthrax) has also been described. 
 
   Report Immediately  
          by phone 
If bioterrorism suspected 
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C. Reservoirs 
Wild and domestic hoofed herbivores (plant-eating animals), including livestock, are the main 
reservoir for anthrax.. The anthrax bacteria are shed in terminal hemorrhages or blood at death. 
These spores are very resistant to disinfection and adverse environmental conditions, so they are 
capable of surviving in soil for decades. Skins and hides of infected animals may harbor the spores 
for years. Worldwide spread of anthrax occurs primarily through dissemination of contaminated skins 
and hides.  
 
D. Modes of Transmission 
Cutaneous infection occurs through: 1) contact with contaminated skins, wool or hides, or products 
made from these; 2) contact with tissues of animals that are clinically ill or dead from anthrax; 3) 
contact with soil contaminated with spores or contaminated bonemeal used in gardening; or, 4) 
rarely, bites by insects that have bitten infected animals or humans.  
 
Inhalation anthrax may occur in environments where animal hides and wool are processed. It may 
also occur due to accidental or intentional aerosolization of spores, as may occur with a laboratory 
accident or bioterrorism event.  
 
Intestinal and oropharyngeal anthrax occurs through ingestion of undercooked contaminated meat.  
 
E. Incubation Period 
The incubation period for anthrax is usually 1- 7 days, and most cases occur within 2 days of 
exposure. However, incubation periods of up to 60 days have been reported. 
 
F. Period of Communicability or Infectious Period 
Person-to-person transmission has not been documented with inhalation or intestinal anthrax. 
Person-to-person transmission with cutaneous anthrax rarely occurs. Products and soil contaminated 
with spores may remain infectious for decades. 
 
G. Epidemiology 
Anthrax is primarily a disease of wild and domestic herbivorous (plant-eating) animals. Unaffected 
herds of livestock may be exposed through feed containing contaminated bonemeal. Anthrax is an 
infrequent cause of disease in the United States and a sporadic cause of disease in most 
industrialized countries. Anthrax in animals is common in Central and South America, southern and 
Eastern Europe, Africa and Asia. Persons at greatest risk of contracting anthrax are those whose 
occupations may expose them to contaminated meat, hides or wool. Veterinarians and others who 
handle and treat infected animals are also at risk. In Iowa, anthrax in animals is reported on rare 
occasions. 
 
H. Bioterrorism Potential 
Category A Bacillus anthracis is considered a potential bioterrorism agent. If acquired and properly 
disseminated, Bacillus anthracis could cause serious public health harm and would challenge public 
health in terms of ability to limit the numbers of casualties.  
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To identify potential sources of transmission in the United States (e.g., imported wool, livestock, 
or soil), and to stop transmission from such sources. 
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• To identify sources of transmission and geographical areas of risk outside the United States and 
to stop transmission from such sources. 
• To identify human and animal cases as early as possible to prevent transmission to other persons 
or animals, either through direct contact (unlikely) or through spores that form in carcasses of 
dead animals. 
• To identify cases and clusters of human illness that may be associated with a bioterrorist event. 
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and healthcare provider 
immediately report any suspicion of anthrax called to your attention by a healthcare provider or any 
positive laboratory result pertaining to anthrax. (A case with widened mediastinum and/or 
hemorrhagic mediastinitis with or without presumptive or confirmatory laboratory results is a suspect 
case.)  
 
The reporting number for IDPH Center for Acute Disease Epidemiology (CADE) is (800) 362-2736, if  
calling after business hours, call the Iowa State Patrol Office at (515) 323-4360 and they will page a 
member of the on-call CADE staff. 
 
Laboratory Testing Services Available  
The University of Iowa State Hygienic Laboratory (SHL) provides services for testing clinical 
specimens for B. anthracis and for confirmation of isolates from sentinel laboratories. Sentinel 
laboratories can send specimens (blood, tissue biopsies, discharge fluid, vesicle fluid, etc.) to SHL.  
Isolates submitted from other laboratories will be confirmed and/or identified. Additionally, SHL 
requests that all laboratories submit all isolates cultured for further identification to aid in the public 
health surveillance necessary for this illness as rapidly as possible.  SHL needs to be contacted before 
samples are submitted. For more information on submitting samples, contact SHL at (319) 335-4500, 
or visit: www.shl.uiowa.edu/  
 
C.  Local Public Health Agency Follow-up Responsibilities 
 
Case Investigation 
a. The most important thing a LPHA can do upon learning of a suspect or confirmed case 
of anthrax, or potential exposure to anthrax, if bioterrorism is suspected, is to 
immediately call IDPH any time at (800) 362-2736. 
 
b. Case investigation of anthrax in Iowa residents will be directed by IDPH. If a bioterrorism event is 
suspected, IDPH and other response authorities will work closely with LPHAs and provide 
instructions/information on how to proceed. 
 
c. Following immediate notification of IDPH, the LPHA may be asked to assist in investigating cases 
that live within their communities, including gathering the following:  
1) The case’s name, age, address, phone number, status (hospitalized, at home, deceased), 
and parent/guardian information, if applicable. 
2) The name and phone number of the hospital where the case is or was hospitalized. 
3) The name and phone number of the case’s attending physician. 
4) The name and phone number of the infection prevention staff at the hospital. 
5) If the patient was seen by a healthcare provider before hospitalization, or seen at more than 
one hospital, be sure to document these names and phone numbers as well.   
 
d. Institution of disease control measures is an integral part of case investigation. It is the LPHA 
responsibility to understand, and, if necessary, institute the control guidelines listed below in 
Section 3), Controlling Further Spread.    
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3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements  
Minimum Period of Isolation of Patient 
Until lesions are healed or free of anthrax bacilli.  
 
Minimum Period of Quarantine of Contacts 
No restrictions. 
 
B. Protection of Contacts of a Case  
There is no immunization or prophylaxis for contacts of cases. Anthrax is essentially non-contagious. 
 
Standard Precautions are recommended for use for healthcare providers when caring for a patient with 
anthrax . This includes use of gloves and gowns if soiling of clothing is possible and when in contact with 
any open wound.  
 
In the event of death, it should be assumed that all body fluids of the deceased person have very high 
concentrations of B. anthracis. Gloves and gowns should be worn when placing the body in a body bag. 
Contaminated dressings and bedclothes of cases should be burned or steam sterilized to destroy spores. 
The patient room may require fumigation, depending on the perceived level of contamination.  
Consultation with CADE is recommended in this type of situation. 
 
C. Managing Special Situations 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
 
Even a single case of human anthrax, especially of the inhalation variety, would be so unusual in the 
United States that it would warrant immediate reporting to public health and law enforcement 
authorities for consideration of deliberate use.  
 
Note: For a potential bioterrorism event, IDPH and other response authorities will work closely with 
local agencies and provide instructions/information on how to proceed.  
 
If the threat of exposure to aerosolized anthrax is credible or confirmed, persons at risk should begin 
post-exposure with both an appropriate antibiotic and vaccine.  
 
D.  Preventive Measures 
Environmental Measures 
Implicated food items must be removed from the environment. A decision about testing implicated 
food items can be made in consultation with the Department of Inspection and Appeals (DIA) and 
CADE. Coordination for pickup and testing of food samples can be done through the DIA. If a 
commercial product is suspected, DIA will also coordinate follow-up with relevant outside agencies.  
 
Personal Preventive Measures/Education 
To avoid cases of anthrax, IDPH recommends the following: 
• Individuals at significant on-going risk of acquiring anthrax (e.g., laboratory workers) should be 
vaccinated. 
• Employees who work with hides of potentially infected animals should be educated about anthrax 
and how to minimize exposures and possibly receive vaccine.  
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4) ADDITIONAL INFORMATION 
 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for anthrax 
can be found at:      www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
 
 
References 
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FACT SHEET                  Anthrax 
 
What is anthrax? 
Anthrax is a serious disease caused by Bacillus anthracis, a bacterium that forms spores. A bacterium is a 
very small organism made up of one cell. A spore is a cell that is dormant (asleep), but may come to life 
with the right conditions.  There are three main types of anthrax: skin (cutaneous), respiratory 
(inhalation), and digestive (gastrointestinal). 
 
How do people get anthrax? 
Anthrax is not known to spread from one person to another.  Anthrax can be spread naturally by 
exposure to contaminated soil or animals or intentionally when used as a weapon. 
• Anthrax from animals. Humans can become infected with anthrax by handling products from 
infected animals or by breathing in anthrax spores from infected animal products (like wool, for 
example). People also can become infected with gastrointestinal anthrax by eating undercooked 
meat from infected animals. 
• Anthrax as a weapon. Anthrax was used as a weapon in the United States in 2001.  It was 
deliberately spread through the postal system by sending letters with powder containing anthrax. 
This caused 22 cases of anthrax infection. 
 
What are the symptoms? 
The symptoms (warning signs) of anthrax are different depending on the type of the disease: 
• Skin: The first symptom is a small sore that develops into a blister. The blister then develops 
into a skin ulcer with a black area in the center. This is typically not painful in the beginning 
stages.  
• Digestive: Symptoms  include nausea, loss of appetite, bloody diarrhea, and fever, followed by 
bad stomach pain.  
• Lungs: The first symptoms of inhalation anthrax are like cold or flu symptoms and can include a 
sore throat, mild fever and muscle aches. Later symptoms include cough, chest discomfort, 
shortness of breath, tiredness and muscle aches. (Caution: Do not assume that just because a 
person has cold or flu symptoms that they have inhalation anthrax.)  
 
How soon do infected people get sick? 
Symptoms usually appear within 7 days of exposure to the bacterium for all three types of anthrax.  
 
How is anthrax treated? 
Antibiotics are used to treat all three types of anthrax. Early identification and treatment are important. 
 
What is the prevention after exposure?  
Treatment is different for a person who is exposed to anthrax, but is not yet sick. Healthcare providers 
will use antibiotics (such as ciprofloxacin, doxycycline, or penicillin).  The anthrax vaccine may be given 
along with these antibiotics to prevent anthrax infection. 
 
Can anthrax be prevented? 
There is a vaccine to prevent anthrax, but it is not yet available for the general public. Anyone who may 
be exposed to anthrax, including certain members of the U.S. armed forces, laboratory workers, and 
workers who may enter or re-enter contaminated areas, may get the vaccine. Also, in the event of an 
attack using anthrax as a weapon, people exposed may get the vaccine. 
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Anthrax                          Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Long-term care     
resident:  Yes      No      Unknown        Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Facility name:       
Parent/Guardian 
name: 
 
      
Facility phone: (     )-     -        Type:        
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis 
date: 
 
     /     /      Onset date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome: 
 Survived this illness     Died from this illness 
 Died unrelated to this illness    Unknown 
Date of death      /     /       First name: 
 
      
Event exception 
 Case could not be found 
 Case could not be interviewed 
 Case refused interview 
 Other – see notes  
Title:  ARNP  DO 
 MD 
 NP  PA 
Outbreak related:  Yes      No      Unknown  
Outbreak name:       Facility name:       
Exposure setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location acquired:  In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive    Negative   
 
Organism: 
 
      Type (e.g. serogroup): 
 
        Other                 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive    Negative   
 
Organism: 
 
      Type (e.g. serogroup): 
 
        Other                 
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Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive    Negative   
 
Organism: 
 
      Type (e.g. serogroup): 
 
        Other                 
 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or healthcare settings: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or healthcare settings: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
Anthrax type: 
 Cutaneous 
 Gastrointestinal 
 Pulmonary 
Symptoms: 
 Abdominal pain 
 Black eschar 
(necrotic area) 
 
 Chest pain 
 Chills 
 Cough 
                                                 
 Diarrhea  
 Edema 
 Erythema 
 
 Fever 
 Itching 
 Malaise 
 
 Muscle pain 
 Nausea 
 Swollen lymph nodes 
 
 Shortness of breath 
 Vomiting 
 Other       
Pre-existing wound 7 
days prior to onset?  Yes    No    Unk 
Wound 
location: 
 Head 
 Trunk 
 Upper extremity 
 Lower extremity 
Chest x-ray done?  Yes    No    Unk 
Widened 
mediastynum:   Yes    No    Unk 
Date:      /     /      Results:  
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
 
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
 
 OTHER LABORATORY FINDINGS 
 
Biopsy performed? 
 Yes    No    Unknown 
 
Date :      /     /      
 
Site: 
 
Result: 
 
 
TREATMENT 
 
Antibiotics prescribed?   Yes    No    Unknown 
  
Antibiotic:       
  
Antibiotic:       
 
 
Antibiotic:       
Date 
started: 
 
     /     /      
Date 
started: 
 
     /     /      
Date 
started: 
 
     /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
 
O 
 RISK FACTORS/TRAVEL 
 
Vaccinated for anthrax?  Yes    No    Unknown 
  
Date vaccinated: 
 
     /     /      
  
Date vaccinated: 
 
     /     /      
  
Date vaccinated: 
 
     /     /      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
 
Number of vaccinations:       
THER LABORATORY FINDINGS 
In the 7 days prior to the onset of the symptoms has the case: 
Traveled within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
 
Mail handled or 
opened?  Yes    No    Unk Mail suspicious:  Yes    No    Unk Setting:  Home      School      Work 
 
From date: 
 
     /     /      
 
To date: 
 
     /     /      
  
Worked in broadcast 
or print media?  Yes    No    Unk From date:      /     /      To date:      /     /      
Animal hide, hair, or 
bone contact?  Yes    No    Unk Animal:  
 Cattle 
 Deer 
 Goats 
 Horses 
 Pigs 
 Sheep 
Contact 
type: 
 Bone      
 Hair 
 Hide 
 Other 
 
From date: 
 
     /     /      
 
To date: 
 
     /     /      
  
 
Ground meat consumed?  Yes    No    Unknown Meat other than ground meat consumed?  Yes    No    Unknown 
Meat fully cooked:  Yes    No    Unknown Meat fully cooked:  Yes    No    Unknown 
Source/type:       Source/type:       
Brand name:       Brand name:       
 
From date consumed:      /     /      
 
From date consumed:      /     /      
To date consumed:      /     /      To date consumed:      /     /      
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
 Average incubation period for 
anthrax is 1-7 days with a 
range of 60 days. 
Person to person transmission of 
anthrax is rare.  
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Worked with another 
case?  Yes    No    Unknown From date:      /     /      To date:      /     /      
Lived with another case?  Yes    No    Unknown From date:      /     /      To date:      /     /      
 
Number of people living in case’s household:       Others with the same exposures?      Yes    No    Unknown 
Close contacts with the same exposures 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
 
 
NOTES:       
 
 
 
 
 
 
 
CONTACTS 
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BOTULISM  
         
Potential Bioterrorism Agent: Category A 
  
Also known as: Clostridium botulinum , C. botulinum, intestinal botulism, infant 
botulism  
 
Responsibilities: 
Hospital: Report immediately by phone 
Lab: Report immediately by phone 
Physician: Report immediately by phone 
Local Public Health Agency (LPHA): Report immediately by phone; begin Active 
Surveillance for additional cases and interview case or family members for possible 
source. 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A.   Agent  
Botulism is caused by exposure to a neurotoxin produced by Clostridium botulinum. C. botulinum is 
an anaerobic, spore-forming bacterium. The toxin is produced as the bacteria multiply. The bacteria 
multiply under anaerobic conditions and in an acidic environment (generally pH>4). There are 7 
types of botulinum toxin (A-G), but human botulism is caused only by types A, B, E, and F. 
 
Clinical Description 
General information: C. botulinum toxin is one of the most potent lethal substances known. In 
humans, botulism manifests itself in one of 4 clinical forms: foodborne botulism, wound botulism, 
infant (intestinal) botulism and, rarely, adult infectious (intestinal) botulism. The site of toxin 
production is different in each form, but flaccid paralysis is common to all. 
 
Foodborne botulism is a severe poisoning caused by the ingestion of pre-formed C. botulinum 
toxin. 
Symptoms: The clinical syndrome is dominated by neurologic signs and symptoms, including blurred 
or double vision, dysphagia, dry mouth, and peripheral muscle weakness. Symmetric descending 
flaccid paralysis is classic diagnostic for botulism. Paralysis begins with the cranial nerves, then 
affects the upper extremities, respiratory muscles, and finally the lower extremities. 
 
Complications: Patients usually require ventilatory support, which is commonly for 2 - 8 weeks. 
Clinical manifestations are similar regardless of toxin type, but type A has been associated with a 
higher case-fatality rate than Type B or Type E. In general, the case-fatality rate for foodborne 
botulism is 5% - 10%. Recovery may take months. 
 
Wound botulism usually presents with the same clinical picture as foodborne botulism. In wound 
botulism, the organism multiplies and produces its toxin in the wound. The toxin is absorbed into the 
bloodstream. 
 
Infant (intestinal) botulism has a distinctly different clinical presentation than wound and 
foodborne botulism. In infant botulism, the C. botulinum spores are ingested, and the toxin is formed 
Report Immediately 
by phone 
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in the intestines in the absence of mature gastrointestinal flora. This disease is usually confined 
exclusively to infants less than one year of age.  
 
Symptoms: The earliest clinical sign of infant botulism is constipation, followed by poor feeding, 
decreased sucking, lethargy, listlessness, ptosis (drooping eyelids), difficulty swallowing, a weak cry, 
and lack of muscle tone--giving rise to the term “floppy baby syndrome.” 
 
Complications: Respiratory failure may occur in some cases. Infant botulism presents with a wide 
range of severity, from mild illness to sudden death. Some studies suggest that infant botulism may 
be responsible for up to 5% of cases of sudden infant death syndrome (SIDS). Among hospitalized 
cases in the United States, the case-fatality rate is less than 1%. 
 
Adult infectious (intestinal) botulism occurs as a result of toxin production in the intestines in a 
manner similar to infant botulism. Most people with adult infectious botulism are found to have 
suffered from a disruption of their natural intestinal flora due to abdominal surgery, antibiotic 
treatment, or gastrointestinal tract abnormalities. 
 
B.   Reservoirs 
C. botulinum spores are ubiquitous in soils worldwide. The spores can survive indefinitely in soil 
under almost any environmental condition. Spores are also found in marine sediment. 
 
C. Modes of Transmission 
Foodborne botulism usually results from ingesting toxin in food that has been inadequately 
processed or prepared before being eaten. The most frequent source is home-canned foods, but 
outbreaks have also been attributed to potatoes baked in foil, minced garlic in oil, and sautéed onions 
held under a layer of butter. Tomato products, once considered low-risk foods because of their low 
ph, can no longer be dismissed as a potential vehicle. Boiling for ten minutes destroys the toxin. 
 
Wound botulism occurs when wounds are contaminated with dirt or gravel containing botulism 
spores. Wound botulism has also been reported among chronic drug abusers. 
 
Infant (intestinal) botulism, which is the most common form of botulism in the United States, 
results from ingestion of bacterial spores, which germinate and produce toxin in the intestines. 
Botulism can result ingestion of food, soil or dust contaminated with botulinum spores. Honey often 
contains C. botulinum spores. Some cases of infant botulism have occurred in children living in areas 
of construction and earth disruption. 
 
Adult infectious (intestinal) botulism occurs in a manner similar to infant botulism.  
 
Inhalational botulism can result from inhalation of aerosolized botulism neurotoxin 
 
Iatrogenic botulism can result from accidental injection of botulism neurotoxin into the systemic 
circulation instead of the intended therapeutic location.  
 
D. Incubation Period 
The incubation period is variable. 
Foodborne botulism: neurologic symptoms appear within 12 - 36 hours (range: 6 hours to 8 days) 
after eating contaminated food. 
 
Wound botulism: Median incubation period 7 days, with a range of 4 - 14 days. In general, the 
shorter the incubation period, the more severe the disease. 
 
Infant botulism: Incubation period is unknown since the date of spore ingestion is usually not known. 
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Inhalation botulism: Ranges from 12-80 hours after exposure. 
 
E. Period of Communicability or Infectious Period 
Person-to-person transmission has not been documented. 
 
F. Epidemiology 
      Botulism occurs worldwide, as sporadic cases and as family and general outbreaks. In the United  
      States an average of 110 cases of botulism are reported each year. Of these, approximately 25% 
      are foodborne, 72% are infant botulism, and the rest are wound botulism.  
A total of 112 laboratory-confirmed cases of botulism were reported to CDC in 2010. Foodborne 
botulism accounted for 9 (8%), infant botulism for 85 (76%), wound botulism for 17 (15%), and 
botulism of unknown or other etiology for 1 (<1%) cases. Since 1994, the use of black tar heroin by 
injection drug users has led to a dramatic increase in the number of cases of wound botulism.   
 
G. Bioterrorism Potential 
Category A: C. botulinum toxins are considered a potential bioterrorism agent. If acquired and 
properly disseminated, botulinum toxin could cause a serious public health challenge in terms of 
ability to limit the numbers of casualties and control other repercussions from such an attack.  
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A.  Purpose of Surveillance and Reporting 
• To assist in the diagnosis and treatment of potential cases.  
• To identify sources of public health concern (e.g., a commercially-distributed food product) and 
stop transmission from the source. 
• To properly classify reported cases as foodborne, infant or wound botulism. 
• To identify cases and clusters of human illness that may be associated with a bioterrorist event. 
 
B.  Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must immediately report any suspected or confirmed case. The reporting number for IDPH Center for 
Acute Disease Epidemiology (CADE) is (800) 362-2736. If you call after business hours, you may call 
the Iowa State Patrol Office at (515) 323-4360. They will page a member of the on-call CADE staff. 
 
Laboratory Testing Services Available 
After communicating with IDPH, contact the University of Iowa State Hygienic Laboratory 
bacteriology department at (319) 335-4500 for further instructions. 
 
C. Local public health agency (LPHA) and Follow-Up Responsibilities 
 
Case Investigation 
a. LPHA should immediately call IDPH Disease Reporting Hotline (800) 362-2738 upon learning of 
a suspected case of botulism. 
 
b. Case investigation of botulism in Iowa residents will be directed by IDPH Center for Acute 
Disease Epidemiology (CADE) in collaboration with local and federal agencies.  
 
c. Following notification of IDPH, the LPHA may be asked to assist in investigating any case(s) of 
botulism. The investigation form is available from the Iowa Disease Surveillance System (IDSS).  
Use the following guidelines in the investigation: 
 
d. Determine type of botulism: Foodborne botulism is a true medical and public health emergency, 
and should be investigated as such. Infant and wound botulism do not require the same 
investigative urgency, so it is essential to determine which illness is occurring.  
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1) Foodborne botulism  
The source of exposure and names of all potentially exposed persons must be identified.  
The case must be interviewed concerning possible food sources. In most cases, information 
will need to be obtained from family members or other close contacts, since the case’s 
condition will most likely not permit interviewing. Use of IDPH Enteric Disease Investigation 
Report will facilitate recording information pertinent to foodborne transmission. Please 
contact IDPH Center for Acute Disease Epidemiology for assistance in determining possible 
food sources. Use the following guidelines to investigate. 
a) Identify all home-canned foods eaten during the week prior to symptoms. The most 
suspect foods are those eaten less than two days before onset, low in acid, and not 
eaten by persons who stay well. Keep in mind that some cases may experience less 
severe symptoms later than the identified case. 
b) Identify all commercially canned foods eaten during the week prior to the onset of 
illness. For each implicated food, determine and record the brand, manufacturer, 
package size, lot number, and place and date of purchase. 
c) Identify all sausage and other preserved meats eaten during the week prior to onset of 
illness. Meat or potato products not adequately refrigerated should also be suspected. 
d) Identify all smoked or otherwise preserved fish eaten during the week before onset of 
symptoms.  
e) Identify other potentially exposed persons. All persons who have eaten implicated foods 
must be reached as soon as possible and advised to seek healthcare immediately. 
Depending on the time of ingestion, other exposed persons might be candidates for 
purging. At the very least they should be under close medical supervision. 
1. Obtain the name, address, and telephone number of every person who may have 
eaten the suspected food item. 
2. Obtain the name, address, and telephone number of every person who may have 
the suspect home-processed food in his or her possession.  
f) Remove implicated food items from the environment for testing. The University of Iowa 
State Hygienic Laboratory will coordinate testing of food samples. 
 
2) Wound botulism: Investigate to determine the cause and do possible traceback. 
 
3) Infant botulism: Ask caretakers about honey consumption; otherwise, extensive 
epidemiological follow-up is not usually required. Prevention education should be provided.   
 
4) Adult infectious botulism: As with infant botulism, extensive epidemiological follow-up is 
not usually required. Prevention education should be provided.  
 
e. Botulism Testing: In all cases of suspected botulism, the Center for Acute Disease 
Epidemiology and the case’s healthcare provider determine the appropriateness of botulism 
testing, based on available clinical and epidemiological data.  Arrangements are then made to 
submit appropriate specimens.  
 
Botulism Antitoxin: Antitoxin therapy is only administered to adult patients with foodborne or wound 
botulism. Antitoxin is a horse serum product, and may cause serum sickness in approximately 20% of 
treated persons. Antitoxin is not indicated in cases of infant botulism. The healthcare provider, in 
consultation with the Center for Acute Disease Epidemiology must determine the need for antitoxin therapy. 
CDC must release and approve its use. If needed, antitoxin will immediately be flown to the nearest airport. 
LPHAs should be prepared to assist with logistic arrangements. The decision to administer antitoxin must be 
made immediately. The longer the wait, the less effective it will be. Testing for the presence of toxin or 
bacteria in clinical specimens can take many days. The decision to administer antitoxin cannot wait for 
testing results to confirm the infection.  Tests to rule out myasthenia gravis, stroke and Guillain-Barre 
syndrome should be completed before antitoxin is released by the Centers for Disease Control and 
Prevention (CDC). 
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3) CONTROLLING FURTHER SPREAD 
 
A.   Isolation and Quarantine Requirements  
Minimum Period of Isolation of Patient 
No restrictions.  
 
Minimum Period of Quarantine of Contacts 
No restrictions.  
 
B.  Protection of Contacts of a Case 
None.  
 
C.  Managing Special Situations 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
Any case of botulism is considered an outbreak and must be investigated to determine the source of 
infection and mode of transmission.  
 
D.  Preventive Measures 
Personal Preventive Measures/Education 
To avoid future exposure, recommend that individuals: 
• Learn about the proper time, pressure and temperature required destroying spores if they are 
interested in home canning and other preservation techniques. More information can be obtained 
from the Iowa Department of Inspections and Appeals, Food and Consumer Safety Division; US 
Food and Drug Administration, Center for Food Safety and Applied Nutrition; or Iowa State 
University Extension’s web site http://www.extension.iastate.edu/answerline/  
• Do Not open bulging containers, or eat, or even “taste-test” foods with “off” odors. 
• Do Not feed unpasteurized sugar products, such as honey, to children less than one year old. 
  
4)  ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Botulism 
can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
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What is botulism? 
Botulism is a rare but serious muscle-paralyzing illness caused by a nerve toxin (botulinum toxin) 
produced by the bacterium Clostridium botulinum. There are three forms of the disease–foodborne, 
infant, and wound botulism.  
 
Who is at risk? 
Foodborne botulism can affect anyone who eats food containing the toxin. Infant botulism almost 
exclusively affects children under 1 year of age, but can rarely affect adults. Wound botulism, 
although rare, can affect anyone. 
 
How do you get botulism? 
Foodborne botulism is acquired by eating foods in which toxin has formed, usually after inadequate 
heating during canning or cooking at the time they are eaten. Other less common sources of spread 
have been reported, including mixing minced garlic with oil, improperly handled baked potatoes 
wrapped in aluminum foil, and home-canning or fermenting fish. 
 
Infant botulism occurs when a baby ingests botulinum spores that then grow in the intestine and 
produce toxin. Possible sources of spores include foods (especially honey), and dust. 
 
Wound botulism is often acquired from dirt in wounds, but can also be due to injection drug use. 
 
Can botulism be spread from person-to-person? 
There have been no reports of person-to-person spread of botulism. Identifying botulism in food is 
considered a public health emergency because the contaminated food may still be available to 
infect others besides the person with the disease. 
 
What are the symptoms of botulism? 
Symptoms are caused by the toxin, and may include double vision, blurred vision, drooping eyelids, 
slurred speech, difficulty swallowing, dry mouth, and muscle weakness. These symptoms may 
progress to include paralysis, respiratory failure and death. 
 
Foodborne botulism: symptoms usually appear 12 - 36 hours after eating contaminated food, but 
they can occur as early as 6 hours or as late as 10 days after the food is eaten. 
 
Wound botulism: symptoms usually appear within 7 days after the bacteria get into the wound, but 
symptoms can occurred within 4 - 14 days. 
 
Infant botulism: The incubation period is unknown since the date when the baby ingested the 
spores is usually uncertain. 
 
How is botulism diagnosed? 
Foodborne is diagnosed by finding botulinum toxin in blood, stool, stomach contents or food, or by 
growing Clostridium botulinum from stomach contents or stool. 
 
Infant is diagnosed by finding the organisms and/or toxin in patient’s stool. 
 
Wound is diagnosed by finding toxin in the patient’s blood or by growing the organisms from wound 
tissue.  
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How is botulism treated? 
Good supportive care in a hospital is the best treatment for all forms of botulism. Specific 
treatment includes giving botulinum antitoxin. In foodborne botulism, other treatment may be 
needed, including the removing foods still in the gut by inducing vomiting or using enemas. In 
wound botulism, the wound is treated, usually with surgery, to remove the source of the 
bacteria. 
 
How can botulism be prevented? 
People who do home canning or other food preservation should learn and use proper canning 
techniques. People who eat home-canned foods should boil them for at least 10 minutes before 
eating, to destroy the toxin. Because it can contain spores of Clostridium botulinum, and has been a 
source of infection for infants, honey should not be fed to children less than 12 months old. Honey 
is safe for persons 1 year of age and older. Wound botulism can be prevented by promptly seeking 
medical care for infected wounds. 
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FACT SHEET        BOTULISM  
For Health Professionals 
 
What is botulism? 
Botulism is a rare but serious paralytic illness caused by a potent neurotoxin produced by an anaerobic, 
spore-forming bacterium (Clostridium botulinum). There are three forms of botulism – foodborne, infant, 
and wound botulism.  
 
Who is at risk? 
Foodborne botulism can affect anyone who eats food that contains the botulinum toxin. Infant botulism 
almost exclusively affects children under 1 year of age. Intestinal botulism may rarely affect adults. 
Wound botulism, although rare, can affect anyone. 
 
How is botulism spread? 
Foodborne botulism is acquired by ingestion of foods in which toxin has been formed, predominantly 
after inadequate heating during canning or subsequent inadequate cooking (of the canned foods). Other 
less common sources of infection have been reported, including minced garlic in oil, improperly handled 
baked potatoes wrapped in aluminum foil, and home-canned or fermented fish.  
 
Infant botulism is acquired by ingestion of botulinum spores which grow in the intestine and produce 
toxin. Possible sources of spores include foods (especially honey), and dust.  
 
Wound botulism is often acquired from contamination of wounds or from improperly treated compound 
fractures. Injection drug users are at increased risk for wound botulism. Wound botulism from the use of 
black-tar heroin has increased, especially in California.  
 
What are the symptoms of botulism? 
Symptoms are due to the paralyzing effect of the toxin on the cranial nerves, and may include double 
vision, blurred vision, drooping eyelids, slurred speech, difficulty swallowing, dry mouth, and muscle 
weakness, with progression to paralysis, respiratory failure, and death. Incubation periods for each form 
of botulism are: 
 
Foodborne: Symptoms usually appear within 12 - 36 hours after eating contaminated food, ranging 6 
hours to 10 days. 
 
Wound: Symptoms usually appear within 7 days after introduction of the bacteria, ranging 4 - 14 days. 
 
Infant: Incubation period is unknown since it is usually not known when the spores were ingested.  
 
Can botulism be spread? 
There have been no reports of person-to-person spread. Botulism is considered a public health 
emergency, and the source, particularly if it is foodborne, must be identified. 
 
How is botulism diagnosed? 
Physicians may consider a diagnosis of botulism if the patient's history and physical examination suggest 
the disease, but these clues are often not enough to allow a diagnosis. Physicians may confirm diagnosis 
by: 
 
Foodborne: Diagnosed by presence of botulinum toxin in serum, stool, gastric aspirate or incriminated 
food; or by culture of Clostridium botulinum from gastric aspirate or stool in a clinical case. 
 
Infant: Diagnosed by presence of Clostridium botulinum organisms and/or toxin in patient’s feces or in 
autopsy specimens. 
 
Wound: Diagnosed by presence of toxin in serum or by culture of Clostridium botulinum from the wound.  
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How is botulism treated? 
Specific treatment includes intravenous administration of tri-valent (ABE) botulinum antitoxin, available 
through the Centers for Disease Control and Prevention (CDC). The Iowa Department of Public Health is 
available 24 hours a day at (800) 362-2736 to facilitate shipment of the antitoxin.  Antitoxin is not used in 
infants because of the hazard of sensitization and anaphylaxis. Serum should be collected to identify the 
specific toxin before antitoxin is administered, but antitoxin should not be withheld pending test results. 
Immediate access to an intensive care unit is critical so that respiratory failure, the usual cause of death, 
can be anticipated and managed promptly. The decision to administer antitoxin to asymptomatic persons 
should be weighed carefully, balancing the potential protection when antitoxin is administered within 1 - 
2 days after eating the implicated food against the risk of adverse reaction and sensitization to the horse 
serum from which the antitoxin is derived. In foodborne botulism, other treatment may be warranted, 
including the removal of contaminated foods still in the gut by induction of vomiting or use of enemas. In 
wound botulism, the wound should be thoroughly cleansed and debrided, usually surgically.  Tests to rule 
out myasthenia gravis, stroke, and Guillain-Barre syndrome should be completed before antitoxin is 
released by CDC.   
  
How can botulism be prevented? 
People who do home canning and use other food-preservation techniques should follow strict hygienic 
practices and observe proper canning techniques. Those eating home-canned foods should boil them for 
at least 10 minutes before eating to destroy the toxin. Because it can contain spores of Clostridium 
botulinum, honey should not be fed to children less than 12 months old.  Wound botulism can be 
prevented by promptly seeking medical care for infected wounds, and not using injectable street drugs.  
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CONFIDENTIAL                      Iowa Department of Public Health 
Botulism                                 Agency:   
           
Investigator:                                                          Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -      
  
Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:        
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Disease 
type Foodborne  Wound  Infant  Adult intestinal toxemia  
Diagnosis 
date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome: 
 Survived this illness     Died from this illness 
 Died unrelated to this illness    Unknown 
Date of death      /     /      First name: 
 
      
Event exception 
 Case could not be found 
 Case could not be interviewed 
 Case refused interview 
 Other – see notes 
 
   
Outbreak 
related:  Yes      No      Unknown Provider title: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
       
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive    Negative   
 
Organism: 
 
      Toxin Type: 
 A 
 B    Other                 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive    Negative   
 
Organism: 
 
      Toxin Type: 
 A 
 B 
 E 
 F   Other                 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
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Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive    Negative   
 
Organism: 
 
      Toxin Type: 
 A 
 B 
 E 
 F   Other                 
 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
Symptoms: 
 Abdominal cramps                                          
 Blurred vision                                                  
 Constipation                                                  
 Diarrhea 
 Diplopia (double vision)                                                 
 Dizziness  
Dry Mouth                                                          
 Erythema
 Fever                                  
 Slurred Speech 
Vomiting
 
Preexisting wound 14 prior to onset?       Yes    No    Unk  
  
Wound location: 
 Head 
 Trunk 
 Upper extremity   
 Lower extremity 
Wound type: 
 Abrasion                     
 Avulsion    
 Burn                           
 Compound fracture  
 
 Crush  
 Frostbite 
 Linear laceration  
 Puncture 
 Stellate laceration 
Wound depth: 
 1 cm or less     >1 cm 
Signs of infection:     
 Yes    No    Unk 
Contaminated:  
 Yes    No    Unknown  
Devitalized, ischemic, or denervated tissue:   
 Yes    No    Unknown     Date wound occurred:      /     /      
Setting: 
 Automobile 
 Farm/yard 
 Petting Zoo 
 Work      
 Other      _________ 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
 Home 
 
 
Other wound details:       
 
 
Botox injections 14 days prior to symptoms?  Yes    No    Unknown 
(If Yes, complete the following section. If No, skip to the next section.) 
Injection date:      /     /      
 
Facility name:       
 
Provider name:       
Address:       City:       State:       Zip:       
County:       Phone: 
 
(     )-     -         Type:       
 
Tensilon test performed:   Yes    No    Unk  Date:      /     /      Results: 
 Positive      
 Equivocal 
 Negative     
 Unknown 
EMG test performed:   Yes    No    Unk Date:      /     /      
Compatible with Botulism diagnosis?  
 Yes    No    Unk  
 
OTHER LAB FINDINGS 
 
Food, medication or environmental samples tested?  Yes    No    Unknown              
(If Yes, complete the following section. If No, then skip to the next section.) 
Tested for preformed 
toxin:  Yes    No    Unk Laboratory:       Toxin type: 
 A           
 F 
 B           
 G 
 E 
Describe samples:   List positive samples:  
 
  
   
Tested for C. botulinum 
or other serotype:  Yes    No    Unk Laboratory:        
Describe samples:   List positive samples:  
   
   
 
TREATMENT 
 
For the illness, were any of the following treatments required: 
Tracheotomy:  Yes    No    Unk Ventilator:  Yes    No    Unk Duration in days:       
 
Antitoxins prescribed?  Yes    No    Unk             Therapeutic medications prescribed?  Yes    No    Unk 
Date started:        List medications:       
Dose:       Unit:       
 
 
# days:       
# times 
each day:       
  
Route:       
  
 
INFECTION TIMELINE 
 
    ______________________________________Onset________________________________________ 
 
 
 
RISK FACTORS/TRAVEL 
 
 
 
 
 
In the 36 hours prior to onset of symptoms did the case consume: 
Home canned 
foods:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Fish:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Meat other than 
fish:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  There are no documented 
cases of person to person 
transmission.  
The incubation period for botulism 
12-80 hours, depending on the 
type. The shorter the incubation 
period, the more severe the 
disease and higher case fatality 
rate.  
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List all source/types:       List all brand names:       
Potato or potato 
products:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Describe 
preparation:  
Other root 
vegetable:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
 
In the 14 days prior to symptoms did the case Inject street drugs or steroids?   Yes    No    Unknown 
 
Contacts with the same exposures   Yes    No    Unknown 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case:                      List symptoms Symptom  onset date 
Same foods 
consumed? 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
      
     /     /       Yes 
 No 
 
 Yes 
 No 
      
      
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case:                      List symptoms Symptom  onset date 
Same foods 
consumed? 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
      
     /     /       Yes 
 No 
 
 Yes 
 No 
      
      
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case:                      List symptoms Symptom  onset date 
Same foods 
consumed? 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
      
     /     /       Yes 
 No 
 
 Yes 
 No 
      
      
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case:                      List symptoms Symptom  onset date 
Same foods 
consumed? 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
      
     /     /       Yes 
 No 
 
 Yes 
 No 
      
      
If this contact is a case create a new event and/or case for this contact. 
NOTES:       
 
 
 
CONTACTS 
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Infant Botulism                    Agency:   
           
Investigator:                                                          Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Asian 
 Unknown 
 White   State:       County:       
Phone: (     )-     -        Type:              Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care 
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis 
date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider title: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive    Negative   
 
Organism: 
 
      Toxin Type: 
 A 
 B    Other                 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive    Negative   
 
Organism: 
 
      Toxin Type: 
 A 
 B 
 E 
 F   Other                 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive    Negative   
 
Organism: 
 
      Toxin Type: 
 A 
 B 
 E 
 F   Other                 
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Child Care   
 
Is the case attending a child care facility?  Yes      No      Unknown 
(If yes, complete the following sections for each known occupation. If No, skip to the next section.) 
Date attend  from: 
 
     /     /      Facility name: 
 
      
Date attended to: 
 
     /     /      Address: 
 
      
 
 
Zip code:       
  City: 
 
      
 
 
Phone: 
 
(     )-     -        Type: 
 
Date attend  from: 
 
     /     /      Facility name: 
 
      
Date attended to: 
 
     /     /      Address: 
 
      
 
 
Zip code: 
 
      
  City: 
 
      
 
State: 
 
      
 
County: 
 
      
 
 
Phone: 
 
(     )-     -        Type: 
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
OTHER DEMOGRAPHIC INFORMATION 
 
Father’s age 
in years: 
 
      Education: 
 Grade school 
 Middle school 
 High school 
 Vocational/trade school 
 Associate’s degree 
 Bachelor’s degree or higher 
Occupation: 
 
 Student – child care/preschool                                     
 Student-elementary thru high school                            
 Student-post high school, college, etc                          
 Child (0-18 yrs) not attending school/day care             
 Child care provider/worker,  
other work with children    
 Teacher/staff – preschool                                             
 Teacher/staff – elementary/high school                       
 
 Teacher/staff – post high school, college, etc  
 Healthcare worker/staff                                                
 Resident – long term care facility                                 
 Worker- farming                                                           
 Worker – manufacturing/industrial     
 Worker – Sales/retail 
 Worker –  transportation 
 Worker - business 
 Worker – food service  
Worker – non manufacturing/service 
Worker - other  
Retired 
 Works at home/stay at home parent 
 Unemployed 
 Other adult 
 Unknown, adult (19 yrs or older) 
Mother’s age 
in years: 
 
      Education: 
 Grade school 
 Middle school 
 High school 
 Vocational/trade school 
 Associate’s degree 
 Bachelor’s degree or higher 
Occupation: 
 
 Student – child care/preschool                                     
 Student-elementary thru high school                            
 Student-post high school, college, etc                          
 Child (0-18 yrs) not attending school/day care             
 Child care provider/worker,  
other work with children    
 Teacher/staff – preschool                                             
 Teacher/staff – elementary/high school                       
 
 Teacher/staff – post high school, college, etc  
 Healthcare worker/staff                                                
 Resident – long term care facility                                 
 Worker- farming                                                           
 Worker – manufacturing/industrial     
 Worker – Sales/retail 
 Worker –  transportation 
 Worker - business 
 Worker – food service  
Worker – non manufacturing/service 
Worker - other  
Retired 
 Works at home/stay at home parent 
 Unemployed 
 Other adult 
 Unknown, adult (19 yrs or older) 
Number of pregnancies: 
 
      Number of live births: 
 
      
 
For this birth:  
Delivery type:  C-section      Vaginal Complications:  Yes    No    Unknown 
Describe complications:       
Premature?  Yes    No    Unknown 
Gestational age in 
weeks: 
 
      Birth 
weight/units: 
 
      
Unit: 
 Pounds/ounces 
 Kilograms  
 Grams 
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CLINICAL INFO & DIAGNOSIS 
 
Interviewee:  Father  Mother  Both   Other _________________ 
For the period from birth to the onset of symptoms: 
Fever (>101°F)  Yes    No    Unknown 
Onset 
Date:        /     /      
Describe 
frequency:  
Highest known 
fever:       °C or °F Date of highest fever:       /     /       
Cold  Yes    No    Unknown 
Onset 
Date:        /     /      
Describe 
frequency:  
Constipation  Yes    No    Unknown 
Onset 
Date:        /     /      
Describe 
frequency:  
Diarrhea  Yes    No    Unknown 
Onset 
Date:        /     /      
Describe 
frequency:  
Frequency of bowel 
movements: 
 2 or more per day 
 1 per day 
 Every other day 
 2-3 times per week 
 1 per week 
 Less than 1 per week 
 
For the period after the onset of symptoms: 
Constipation: Onset Date:        /     /      
 
First Symptom: 
 
 Altered cry                
 Cold                          
 Constipation              
 Diarrhea                    
 Fever 
 General weakness 
 Poor feeding 
 Poor head control Poor eating: Onset Date:        /     /      
 
Altered cry: Onset Date:        /     /      
 
Second Symptom: 
 
 Altered cry                
 Cold                          
 Constipation              
 Diarrhea                    
 Fever 
 General weakness 
 Poor feeding 
 Poor head control Poor head control: Onset Date:        /     /      
 
General weakness: Onset Date:        /     /      
 Bowel movement 
frequency: 
 
 2 or more per day 
 1 per day 
 
 2-3 times per week 
 1 per week 
      Every other day  Less than 1 per week 
 
Health care provider visited?  Yes    No    Unknown               Spinal tap performed?  Yes    No    Unknown 
    Dates visited:      /     /     ,      /     /      
 Date:       /     /      
  Facility name:       
 Normal:   Yes    No    Unk 
Address line 1:       
 Spinal fluid protein:       in (unit of measure)  mg/dL   g/L  µmol/L 
 
Address line 2:       
 Spinal fluid glucose:       in (unit of measure)  mg/dL  µmol/L 
Zip code:       
 
WBC count:        in (unit of measure)  cells / mm3   cells/mL 
      State:       
 
City: 
 
  
Phone : (     )-     -      
 
County: 
 
  
 
Last name:       
 
   Type: 
 
  
First name:       
    
Provider title:  ARNP    DO 
    
      
 
 
OTHER LAB FINDINGS 
 
Food, medication or environmental samples tested?  Yes    No    Unknown              
(If Yes, complete the following section. If No, then skip to the next section.) 
Tested for preformed 
toxin:  Yes    No    Unk Laboratory:       Toxin type: 
 A           
 B           
 E 
 F  
 G  
Describe samples:        List positive samples:       
 
  
   
 
Tested for C. botulinum 
or other serotype:  Yes    No    Unk Laboratory:        
Describe samples:        List positive samples:       
   
   
Center for Acute Disease Epidemiology             Fax: 515-281-5698             Do not complete shaded fields               Infant Botulism   Rev. Mar-15         3                             
CONFIDENTIAL PATIENT NAME: ______________________________                          Iowa Department of Public Health 
EXPOSURE PERIOD COMMUNICABLE PERIOD 
   
 
TREATMENT 
 
For the illness, were any of the following treatments required: 
Oxygen:  Yes    No    Unk Ventilator:  Yes    No    Unk Duration in days:       
Tracheotomy:  Yes    No    Unk Intubation:  Yes    No    Unk Duration in days:       
  Feeding tube:  Yes    No    Unk Duration in days:       
      
 
Botulism immune globulin (BIG) prescribed?  Yes    No    Unk Therapeutic medications prescribed?  Yes    No    Unk 
Date 
started:        List medications:       
Dose:       Unit:       
 
 
Number 
of days:       
Number of 
times each day:       
  
Route:       
  
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Primary feeding method:  Breastfed exclusively    Formula fed exclusively 
 Predominantly breastfed 
 Predominantly formula fed 
 Both equally 
Pacifier use:  Yes    No    Unk Frequency:  Often      Sometimes      Rarely 
 Pacifier dipped in substance:  Yes    No    Unk Substance:  Honey      Syrup 
Environmental change or 
disruption prior to onset:  Yes    No    Unk  
Gardening work near 
infant prior to onset:  Yes    No    Unk 
Describe environmental 
change/disruption:        Describe work:       
   
   
Infant away from home more 
than 1 week prior to onset:  Yes    No    Unk 
Describe circumstances:       
 
 
Dietary Information – in the time period from birth to onset of symptoms: 
 
Infant formula:  Yes    No    Unknown 
Frequency: 
 Once/few times 
 Many times 
 Daily/most days 
Formula 
brand: 
 Enfamil 
 Good start 
 Similac 
 Store brand 
 Other       
Ready to eat formula:  Yes    No    Unk 
 
Cow’s milk:  Yes    No    Unknown 
Frequency:  Once/few times  Many times  Daily/most days Source/type:       Brand name:       
  
Cow’s milk products (cheese, whip cream, etc.):  Yes    No    Unknown 
Frequency:  Once/few times  Many times  Daily/most days Source/type:       Brand name:       
       
Fruit juice:  Yes    No    Unknown 
Frequency:  Once/few times  Many times  Daily/most days Source/type:       Brand name:       
       
Cereal:  Yes    No    Unknown 
Frequency:  Once/few times  Many times  Daily/most days Source/type:       Brand name:       
       
Bread:  Yes    No    Unknown 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation period for 
infant botulism is 
unknown. 
There are no documented 
cases of person to person 
transmission.  
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Frequency:  Once/few times  Many times  Daily/most days Source/type:       Brand name:       
       
Syrup:  Yes    No    Unknown  
Frequency:  Once/few times  Many times  Daily/most days Source/type:       Brand name:       
       
Honey:  Yes    No    Unknown 
Frequency:  Once/few times  Many times  Daily/most days Source/type:       Brand name:       
       
Sugar:  Yes    No    Unknown 
Frequency:  Once/few times  Many times  Daily/most days Source/type:       Brand name:       
       
Tea:  Yes    No    Unknown 
Frequency:  Once/few times  Many times  Daily/most days Source/type:       Brand name:       
       
Cooked fruits:  Yes    No    Unknown 
Frequency:  Once/few times  Many times  Daily/most days Source/type:       Brand name:       
       
Raw fruits:  Yes    No    Unknown 
Frequency:  Once/few times  Many times  Daily/most days Source/type:       Brand name:       
       
Cooked vegetables:  Yes    No    Unknown 
Frequency:  Once/few times  Many times  Daily/most days Source/type:       Brand name:       
       
Raw vegetables:  Yes    No    Unknown 
Frequency:  Once/few times  Many times  Daily/most days Source/type:       Brand name:       
       
Home canned food:  Yes    No    Unknown 
Frequency:  Once/few times  Many times  Daily/most days Source/type:       Brand name:       
       
Baby food:  Yes    No    Unknown 
Frequency:  Once/few times  Many times  Daily/most days Source/type:       Brand name:       
 
 
NOTES:       
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Guide to Surveillance, Investigation, and Reporting 
BRUCELLOSIS 
 
Potential Bioterrorism Agent: Category B  
 
Also known as:  Undulant Fever, Malta Fever, Mediterranean Fever    
 
Responsibilities: 
Hospital: Report immediately by phone if bioterrorism suspected, otherwise within 3 days 
Lab: Report immediately by phone if bioterrorism suspected, otherwise within 3 days 
Physician: Report immediately by phone if bioterrorism suspected, otherwise within 3 days 
Local Public Health Agency (LPHA): Follow-up required.  Iowa Department of Public 
Health will lead the follow-up investigation.  
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Brucellosis is caused by Brucella bacteria. The species of Brucella which infect humans are B. abortus, 
B. melitensis, B. suis, and rarely, B. canis.  
 
B. Clinical Description 
Symptoms: May be non-specific, including sustained or irregular fever of variable duration, headache, 
weakness, sweats, chills, arthralgias, malaise, weight loss, depression and generalized aching. 
 
Onset: May be acute or insidious. Localized infections of organs (including the liver and spleen) and 
chronic localized infections can occur. The disease may last for days, months, or occasionally longer if 
inadequately treated. Relapse is not uncommon.  
 
Complications: Most commonly include osteomyelitis, splenic abscess, genitourinary tract infection, 
pulmonary disease, and endocarditis. The case-fatality rate of untreated brucellosis is 2% or less with 
death often resulting from endocarditis caused by Brucella melitensis.  
 
C. Reservoirs 
Common reservoirs: Cattle (B. abortus), swine (B. suis), goats (B. melitensis) and sheep. 
 
Less common reservoirs: Bison, elk, coyotes, caribou, and some species of deer may also harbor 
Brucella species. B. canis is an occasional problem in laboratory dog colonies and kennels; a small 
percentage of pet dogs and a higher proportion of stray dogs have B. canis antibody titers. 
 
D. Modes of Transmission 
Spread through direct contact (of mucosal surfaces and non-intact skin) with secretions of living or 
dead infected animals, including their tissues, blood, urine, vaginal discharges, aborted fetuses, and 
especially placentas. It may also be spread through ingestion of raw milk and dairy products (e.g., 
unpasteurized cheese) from infected animals. 
 
Report Immediately 
by phone 
If bioterrorism suspected 
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Airborne transmission may occur through inhalation of contaminated aerosols (e.g., in laboratory 
settings).   
 
 
Transmission from strain 19 Brucella animal vaccine or Rev-1 animal vaccine may occur in veterinary 
practices and associated personnel and farmers.  
 
Person-to-person spread is extremely rare, although it has been reported to occur through bone-
marrow transplantation. 
 
E. Incubation period 
The incubation period for brucellosis is highly variable, ranging from 5 - 60 days; illness most 
commonly occurs about 1-2 months after exposure. 
 
F. Period of Communicability or Infectious Period 
Person-to-person transmission of brucellosis is extremely rare.   
 
G. Epidemiology 
• Humans are accidental hosts, although there is worldwide distribution of brucellosis. 
• Commonly seen in farmers, ranchers, veterinarians, and other people who work directly with 
animals. It may also be found in laboratory and slaughterhouse employees, or meat inspectors. 
• Sporadic cases and outbreaks, especially among overseas travelers may occur among consumers 
of raw (unpasteurized) milk and milk products, especially soft cheeses. Less than 10% of 
reported cases occur in children under 19 years old. Fewer than 120 cases per year are reported 
in the United States; incidence worldwide may be largely unrecognized and under reported.  
 
H. Bioterrorism Potential 
Category B: Brucella species are considered potential bioterrorism agent. If acquired and properly 
disseminated, Brucella could cause a serious public health challenge in ability to limit the numbers of 
casualties and control other repercussions from such an attack.  
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To identify the source of infection and prevent further transmission from this source (e.g., an 
infected animal, a contaminated unpasteurized dairy product, etc.).  
• To identify cases and clusters of human illness that may be associated with a bioterrorist event. 
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report. The preferred reporting method is through the Iowa Disease Surveillance System, unless 
Bioterrorism is involved. The reporting phone number for IDPH Center for Acute Disease 
Epidemiology (CADE) is (800) 362-2736; fax number (515) 281-5698, mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
Des Moines, IA 50319-0075 
 
Note: Due to the infrequent occurrence and potential severity of brucellosis, IDPH requests that 
information about any suspect or known case be reported within 24 hours, however any suspected 
exposure to Brucella that may be bioterrorist in nature should be immediately reported to the 
Iowa Dept. of Public Health Reviewed 12/13  Brucellosis 2 
Guide to Surveillance, Investigation, and Reporting 
local public health agency where diagnosed. If this is not possible, call IDPH Center for Acute Disease 
Epidemiology at (800) 362-2736.  
 
C.  Local Public Health Agency (LPHA) Follow-up Responsibilities 
1. Case Investigation 
a) The most important thing a LPHA can do if it learns of a suspect or confirmed case of brucellosis, 
or any suspected exposure to Brucella that may be due to a bioterrorist event, is to call IDPH 
immediately, any time of the day or night. The 24-hour number for the Center of Acute Disease 
Epidemiology is (800) 362-2736. 
b) Case investigation of brucellosis in Iowa residents will be directed by CADE. If a bioterrorist event 
is suspected, IDPH and other response authorities will work closely with LPHA(s) and provide 
instructions/information on how to proceed. 
c) Following immediate notification to IDPH, the LPHA(s) may be asked to assist in investigating 
cases that live within their community.  They may be asked to:  
1) Confirm diagnosis. 
2) Inform CADE of the presence of the disease and request assistance if needed. 
3) Work with CADE staff on completion of CDC Brucellosis Case Surveillance form.  
4) Confirm that the laboratory where the culture was identified exercised the proper 
precautions when working with the bacteria. Infectious aerosols can occur when 
manipulation of the isolate is done outside of a biosafety hood. Laboratory workers exposed 
to these aerosols should take preventive antibiotics. 
5) Ask questions regarding exposure to the Brucella vaccine to determine other potential 
sources of exposure. 
 
If it is suspected that the case became infected through milk (or other food), CADE will work with 
the Department of Inspections and Appeals (DIA) to address food safety concerns. 
 
d) Institution of disease control measures is an integral part of case investigation.  The LPHA will 
work with CADE to institute the control guidelines listed below in Section 4), Controlling Further 
Spread.  CADE staff will also be available to assist in development of any risk communications or 
other needs of its local partners regarding the investigation. 
 
3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements 
Isolation: Standard Precautions. 
Quarantine: None. 
 
B.  Protection of Contacts of a Case 
• Follow Standard and Contact Precautions if the case has draining lesions followed by disinfection 
of purulent discharges. 
• Licensed Brucella vaccines are currently available only for livestock.  
 
C.  Managing Special Situations 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
If more than one case of brucellosis is reported or suspected, or an outbreak is suspected, 
investigate to determine the source of infection and mode of transmission. A common vehicle, such 
as unpasteurized milk products or infected animals, should be sought and applicable preventive or 
control measures should be instituted (e.g., removing an implicated food item from the 
environment). Consult with an epidemiologist at CADE at (800) 362-2736 as soon as possible. The 
center can help determine a course of action to prevent further cases and can perform surveillance 
for cases that may cross county lines and be difficult to identify. 
Iowa Dept. of Public Health Reviewed 12/13  Brucellosis 3 
Guide to Surveillance, Investigation, and Reporting 
  
Exposure of a Laboratory Worker  
Laboratory workers exposed to Brucella (e.g., failure to use the protection of a laminar air 
flow/biosafety hood), should receive prophylaxis consisting of: 
• Doxycycline 100 mg bid plus rifampin 600-900 mg once daily for 21 days; for conjunctiva  
inoculations, prophylaxis should be maintained for 4 - 6 weeks. Consult with an 
epidemiologist at CADE at (800) 362-2736.  
 
     Inadvertent inoculation with Brucella animal vaccine 
Veterinarian and others in veterinary practices, farmers and others exposed to Brucella animal 
vaccine should receive prophylaxis consisting of: 
• Doxycycline 100 mg bid for 21 days; for conjunctiva inoculations, prophylaxis should be 
maintained for 4 - 6 weeks. 
• Consult with an epidemiologist at CADE at (800) 362-2736.  
 
D. Preventive Measures 
• Pasteurize milk and dairy products. 
 
Environmental Measures 
Implicated food items must be removed from the environment. A decision about removing these can 
be made in consultation with the Department of Inspections and Appeals and CADE officials. 
 
Preventive Measures/Education 
To prevent future exposures, advise the following: 
• Do not consume raw (unpasteurized) milk or milk products (including imported cheeses, etc.). 
• Workers at occupational risk (farmers, slaughterhouse workers, meat processors or butchers) 
should know symptoms of the disease, how it is spread, and the risks of handling infected animal 
carcasses and products. They should know the proper way to reduce exposure, such as 
ventilating slaughterhouses and handling carcasses carefully. For more information refer to the 
USDA, Animal and Plant Health Inspection Service (APHIS) web site,  www.aphis.usda.gov/  
• Hunters should use barrier protection (gloves or clothing) when dressing wild pigs and burying 
the remains. 
• Wear gloves and protect skin from secretions or excretions when handling and disposing of 
placenta, discharges, and fetus from an aborted animal.  Disinfect contaminated areas. 
 
Local officials and farmers should search for infection among livestock and eliminate infected animals. 
In areas of high prevalence, immunization of livestock may be appropriate. Ultimate control of human 
brucellosis relies on eliminating the disease in domestic animal populations. 
 
4) ADDITIONAL INFORMATION 
 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for brucellosis 
can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
 
Contact the Iowa Department of Agriculture and Land Stewardship (IDALS), (515) 281-8601  (after                               
hours 515-242-0247) with questions about the disease in animals. For information about the risk to  
humans, contact CADE at (800) 362-2736. If after hours, instructions will be given to  reach on-call 
staff. 
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Additional Resources 
USDA web site providing information regarding brucellosis in animals: 
www.aphis.usda.gov/animal_health/animal_diseases/brucellosis/  
FDA web site providing the latest food recalls: 
www.fda.gov/opacom/7alerts.html   
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What is brucellosis? 
Brucellosis is a disease that affects a wide range of animals.  Cattle, sheep, goats, dogs, pigs, 
horses and humans are susceptible to the bacteria.  There are six species of Brucella, each 
infecting a different animal.  All are capable of causing disease in humans.  The Brucella bacteria 
are found in high numbers in animal secretions, the reproductive organ tissue of animals, and in 
aborted fetuses of a diseased female animal. 
 
How is the Brucella organism spread? 
Human infection can result from direct contact of the organism to mucous membranes such as 
eyes and lips and openings in the skin (cuts, sores or breaks in the intact surface of the skin); 
drinking unpasteurized milk from an infected animal; or by breathing in the bacteria if it is 
released in the air by accident or on purpose. Person-to-person transmission is rare.   
 
What are the clinical signs of infection? 
Most animals are ill with reproductive problems including abortions and uterine or testicular 
infections.  Humans at high risk for exposure to animal infection with Brucella include: farmers, 
packing plant workers, veterinarians, and animal care professionals.  Signs of infection with the 
bacteria include: recurrent fever, muscle aches, weight loss, and headaches.  The disease is 
often called undulant fever in humans.  A detailed history of exposure to possibly infected 
animals is the key to diagnosing this disease.   
 
How can brucellosis be diagnosed? 
Laboratory testing to screen for the bacteria is performed on all milk and dairy products 
commercially produced in the United States.  Tests are also routinely performed on animal blood 
after slaughter. Positive laboratory results need to be reported to the state veterinarian. 
 
Can Brucella infections be treated? 
Yes, these infections can be treated with antibiotics, if the disease is identified early in its course. 
 
How can Brucella infection be prevented? 
Stopping the disease in domestic animals is the best defense against infection.  Due to national 
efforts to eliminate brucellosis from animal herds, any animals that test positive are removed 
from the food chain to break the cycle of infection. Bulk tank milk is tested to identify and 
eliminate infected herds.  All dairy cows are vaccinated against brucellosis at approximately 2 
months of age.  Humans, especially pregnant women, should not consume raw milk or eat 
cheese made from unpasteurized milk.  
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Information for Health Professionals 
 
What is brucellosis? 
Brucellosis is a systemic bacterial infectious disease caused by the bacterium Brucella abortus,B. 
melitensis, B. suis, and B. canis.  Although brucellosis infection has a low mortality rate, it can be 
an incapacitating and disabling disease in its natural form. 
 
How is the disease transmitted? 
Cattle, swine, goats and sheep are the primary reservoirs.  Brucellosis is transmitted by contact 
with tissues, blood, urine, vaginal discharges, aborted fetuses and placentas; and by ingestion of 
raw milk and unpasteurized dairy products from infected animals.  Airborne infection of humans 
occurs in laboratories and meat packing plants.  Person-to-person transmission is rare.  The 
incubation period is usually 5 - 60 days.   
 
What are the symptoms of brucellosis? 
Brucellosis may present as a non-specific febrile illness with fever, headache, myalgia, arthralgia, 
back pain, sweats, chills, and generalized weakness and malaise as common complaints.  Cough 
and pleuritic chest pain may occur in up to 20% of cases.  Gastrointestinal symptoms occur in up 
to 70% of adult cases. Hepatomegaly and splenomegaly can occur in up to 60% of cases.  
Osteoarticular complications, including sacroiliities, are seen in 20% - 60% of cases.  
Genitourinary involvement and skin rashes are reported with lesser frequency.  The case-fatality 
rate of untreated brucellosis is < 2% and usually results from endocarditis. Rarely, patients may 
exhibit a draining fistula from an infection that occurred several years earlier. 
 
How is the diagnosis made? 
Chest x-ray may be normal, or it may show lung abscesses, bronchopneumonia, enlarged hilar 
lymph nodes, and pleural effusions. Vertebral involvement may be demonstrated by plan 
radiographs, CT scan or MRI.  Bone scans are 90% sensitive for detecting sacroiliitis.  Peripheral 
joint effusions usually show mononuclear cell predominance.  Culture of joint effusions or CSF 
has sensitivity of 50%.  Cultures of blood and bone marrow during the acute febrile phase are up 
to 70% - 90% positive respectively.  Brucella antibodies can be demonstrated by serum 
agglutination and ELISA tests. 
 
What is the treatment for brucellosis? 
Doxycycline 200 mg/day orally plus rifampin 600-900 mg/day for a minimum of 6 weeks.  
Ofloxacin 400 mg/day and rifampin 600 mg/day orally is also an effective combination.  
Combination therapy with rifampin, tetracycline, and an aminoglycoside is indicated for infections 
with complications such as meningoencephalitis or endocarditis. 
 
What are the isolation precautions for brucellosis? 
Healthcare workers should use standard precautions when caring for persons with brucellosis.   
 
Is there prophylactic treatment after exposure? 
Although efficacy has not been demonstrated in clinical trials, it is recommended that people 
inadvertently inoculated with Strain 19 or Rev-1 animal vaccines be given doxycycline 100mg 
twice daily, combined with rifampin 600-900mg once daily for 21 days; for conjunctiva 
inoculations, prophylaxis should be maintained for 4 - 6 weeks.  Prophylaxis for exposure to RB51 
vaccine strain would exclude rifampin because the organism was developed in rifampin media 
and is resistant in vitro. 
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Veterinary                                                                                                                       
 
What is brucellosis? 
Brucellosis is a disease that affects a wide range of animals.  Cattle, sheep, goats, dogs, pigs, horses and 
humans are susceptible to the bacteria.  There are six species of Brucella, each infecting a different 
animal.   
 
How is the Brucella organism spread? 
The bacteria are found in high numbers in reproductive tissue, infected calves, placentas, blood or 
amniotic fluid of infected females.  The organism can be spread by direct contact to non-intact skin, 
ingestion through milk, or inhalation of this material.  The bacteria then localize in the reticuloendothelial 
system and in the chorioendothelial layer of the placenta in cattle.   
 
What are the clinical signs of infection? 
The disease manifests in a variety of ways, depending on the sex and species of animals and the species 
of Brucella.  Brucella abortus produces abortion and metritis in cows and an epididymo-orchitis in bulls.  
Brucella ovis in sheep primarily affects the male reproductive tract.  Horses infected with Brucella suis 
present with a chronic suppurative reaction in the neck called fistulous withers.  Brucella in dogs and pigs 
localize to the vertebra and produce an osteomyelitis and/or diskospondylitis.  
  
How is brucellosis diagnosed? 
Worldwide, serology screening tests are performed on milk using agglutination techniques like the milk-
ring assay.  Tests on blood, including immunofluorescence and ELISA, can be used as well as culture of 
infected placental or fetal tissues.  Positive laboratory results should be reported to the state veterinarian. 
 
Can Brucella infections be treated or prevented? 
As part of national efforts to eliminate brucellosis from herds, positive animals are removed from the food 
chain to break the cycle of infection. Bulk tank milk is screened with the milk-ring test to identify and 
eliminate reactor herds. All dairy cows are inoculated with a live attenuated vaccine, RB51, at 
approximately 2 months of age. 
 
What are the risks to veterinarians, farmers, and animal health professionals? 
Infection with Brucella abortus in humans produces a condition called undulant fever.  Symptoms include 
a high fever, headache, and weakness and can be treated with tetracycline antibiotics. Women affected 
by Brucella while pregnant can abort and men can present with epididymitis.  Direct contact with aborted 
fetuses, affected calves, and reproductive tissue, as well as accidental inoculation with the vaccine, can 
result in infection.        
  
Is there prophylactic treatment after exposure? 
While efficacy has not been demonstrated in clinical trials, it is recommended that people inadvertently 
inoculated with Strain 19 or Rev-1 animal vaccines be given doxycycline 100mg twice daily, combined 
with rifampin 600-900mg once daily for 21 days; for conjunctiva inoculations, prophylaxis should be 
maintained for 4 - 6 weeks.  Prophylaxis for exposure to RB51 vaccine strain would exclude rifampin 
because the organism was developed in rifampin media and is resistant in vitro.  Any suspected 
accidental or purposeful exposure to animals or humans should be reported immediately to the local 
public health agency and the Iowa Department of Public Health at (800) 362-2736. 
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Brucellosis                         Agency:   
           
Investigator:                                                       Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -      
  
Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:        
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis 
date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome: 
 Survived this illness     Died from this illness 
 Died unrelated to this illness    Unknown 
Date of death      /     /       First name: 
 
      
Event exception 
 Case could not be found 
 Case could not be interviewed 
 Case refused interview 
 Other – see notes  
 
Provider title:  ARNP  DO 
 MD 
 NP  PA 
Outbreak 
related:  Yes      No      Unknown  
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
      Type         
 
biovar           Other                 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
      Type         
 
biovar           Other                 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
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Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
      Type         
 
biovar           Other                 
 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’ 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
Episode Type: 
 First attack 
 Recurrence
 Chronic     
 Episode Severity:  
 Mild 
 Moderate 
 Severe        
Symptoms: 
 Anorexia   
 Chills 
 Headache 
 Muscle Pain   
 Muscle Weakness   
 Weight Loss    
Date Returned to Normal Activities: 
 
     /     /      
 
 
 
 
TREATMENT 
 
Antibiotics prescribed?   Yes    No    Unknown 
  
Antibiotic: 
 
      
  
Antibiotic: 
 
      
 
 
Antibiotic: 
 
      
 
Date started: 
 
     /     /      
 
Date 
started: 
 
     /     /      
 
Date started: 
 
     /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
 
Unit: 
 
 mg      ml     
IU 
 
Unit: 
 
 mg      ml     
IU 
 
Unit: 
 
 mg      ml     
IU 
 
Number 
of days:       
Number 
of times 
a day:       
 
Number 
of days:       
Number 
of times 
a day:       
 
Number 
of days:       
Number 
of times a 
day:       
 
Route: 
 
      
 
Route: 
 
      
 
Route: 
 
      
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
RISK FACTORS/TRAVEL  
 
In the 60 days before the onset of symptoms did the case:  
Travel within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Travel within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Travel outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
Give birth:  Yes    No    Unknown    
Have animal contact:  Yes    No    Unknown    
Animal type:  Deer       Dogs 
 Elks       
 Goats   
 Horses       
 Pigs    
 Rabbits       
 Rats    
 Sheep       
 Other        
Were any of these 
animals birthing:  Yes    No    Unknown 
   
Exposed to potential 
Infection sources:  Yes    No    Unknown 
Check all 
possible 
sources: 
 Aborted animal fetuses or placentas 
 Laboratory       
 Livestock Handling 
 Livestock Vaccine 
 Packing Plant     
 Unpasteurized dairy product  
 
 
Others with the same exposures?      Yes    No    Unknown 
 
Others with the same exposures 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
CONTACTS 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start 
and end of communicable 
period.  
  The incubation period for 
brucellosis is usually 5-60 days 
and occasionally several 
months.  
 
There is no evidence of person 
to person transmission of 
brucellosis.  
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Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
 
 
NOTES:  
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Guide to Surveillance, Investigation, and Reporting 
CAMPYLOBACTERIOSIS 
 
Also known as: Campylobacter enteritis, Vibrionic enteritis  
 
Responsibilities: 
Hospital: Report by IDSS, facsimile, mail or phone  
Lab: Report by IDSS, facsimile, mail or phone 
Physician: Report by IDSS, facsimile, mail or phone  
Local Public Health Agency (LPHA): No follow-up required, except in outbreak 
situations 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Bacteria of the genus Campylobacter are responsible for campylobacteriosis. Campylobacter jejuni (C. 
jejuni) a species of Campylobacter is responsible for about 99% of campylobacteriosis in humans, with 
the remainder of cases caused by other species. 
 
B. Clinical Description 
Symptoms: of campylobacteriosis are diarrhea (sometimes bloody), abdominal pain, malaise, fever, 
nausea, and sometimes vomiting. Infection can cause a spectrum of disease ranging from mild, 
uncomplicated gastroenteritis to severe disease similar to acute appendicitis. Asymptomatic infections 
also occur. The illness is usually over within a week but may be prolonged in some individuals and can 
sometimes relapse. 
 
Long-term complications: include reactive arthritis and Guillain-Barré syndrome, a rare disease that 
affects the nerves of the body beginning several weeks after the diarrheal illness. This complication 
results in paralysis that lasts several weeks and usually requires intensive care. It is estimated that 
approximately 1 in every 1000 reported campylobacteriosis cases leads to Guillain-Barré syndrome and as 
many as 40% of Guillain-Barré syndrome cases in this country are triggered by campylobacteriosis. 
 
Campylobacteriosis can cause life-threatening sepsis in persons with compromised immune systems.  
 
C. Reservoirs 
Campylobacter bacteria are present in animals, most frequently cattle and poultry, although swine, 
sheep, and even pets such as birds, kittens and puppies may be sources of human infection. A large 
percentage of raw poultry is contaminated with C. jejuni. 
 
D. Modes of Transmission 
Campylobacter is transmitted via food. The most common mode of transmission is ingestion of food or 
water that has been contaminated with animal or human feces. This includes raw and undercooked 
poultry or pork, inadequately treated drinking water, and raw milk and raw milk products. However, any 
food contaminated with the bacteria can be a source of infection. In addition, farm animals and pets, 
such as puppies with diarrhea, can be sources of infection. Person-to-person spread can also occasionally 
occur, especially among household contacts, pre-school children in child care, the elderly and 
developmentally disabled persons living in residential facilities. Transmission can also occur through 
certain types of sexual contact (e.g., oral-anal contact). A low dose of organisms is all that is needed to 
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cause infection, but the infectious dose may be lower for certain susceptible groups such as children, the 
elderly and the immunocompromised. 
 
E. Incubation Period 
The incubation period can vary from 1 - 10 days but is usually about 2 - 5 days; incubation period may 
vary based on number of bacteria ingested. 
 
F. Period of Communicability or Infectious Period 
The disease is communicable for as long as the infected person excretes Campylobacter bacteria in their 
stool. This can occur from days to several weeks. People who are not given antibiotics have been known 
to shed these bacteria for as long as 7 weeks.  
 
G. Epidemiology 
Campylobacter is the most common bacterial cause of diarrheal illness in the United States. It is 
estimated that 1.3 million cases occur annually with almost all cases occurring as isolated, sporadic 
events. Although common source outbreaks due to this organism have occurred, larger outbreaks due to 
Campylobacter are not usually associated with undercooked, pork, poultry and cattle but are typically 
related to consuming unpasteurized milk, cheese or contaminated water. Outbreaks due to 
Campylobacter are uncommon. Children and young adults have the highest incidence of infection. 
Campylobacter doesn’t commonly cause death, however there are an estimated 76 persons with 
Campylobacter infections that die each year. 
 
H. Bioterrorism Potential 
None. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION  
 
A.  Purpose of Surveillance and Reporting 
• To identify transmission sources of major public health concern (e.g., a restaurant or commercially 
distributed food product) and to stop transmission from such sources. 
• To identify whether the case may be a source of infection for other persons (e.g., a diapered child, 
child care attendee or food handler) and, if so, to prevent further transmission. 
 
B.  Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider must 
report. The preferred reporting method is through the Iowa Disease Surveillance System (IDSS). The 
reporting phone number for IDPH Center for Acute Disease Epidemiology (CADE) is (800) 362-2736; fax 
number (515) 281-5698, mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
      Des Moines, IA 50319-0075 
 
Postage-paid disease reporting forms are available free of charge from the IDPH clearinghouse.   
Call (319) 398-5133 or visit the website: 
healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295 to request a supply. 
 
Laboratory Testing Services Available   
The University of Iowa State Hygienic Laboratory (SHL) will test stool specimens for the presence of 
Campylobacter and will confirm and speciate isolates sent from clinical specimens at other laboratories. 
Additionally, SHL requests that all laboratories submit all organisms isolated during an outbreak for 
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possible strain typing to aid in the public health surveillance necessary for this illness. Call the SHL (319) 
335-4500 for more information, or visit: www.shl.uiowa.edu/   
 
The SHL will test implicated food items from a cluster or outbreak.  Specimens are submitted through 
local public health departments. 
 
C.  Local Public Health Agency (LPHA) Follow-Up Responsibilities 
Case Investigation 
a. Individual cases: no routine follow-up required 
b. Multiple cases/possible outbreak: 
If the number of reported cases of campylobacteriosis in a city/town is higher than usual, or if an 
outbreak is suspected, an investigation is warranted to determine the source of infection and mode of 
transmission. A common vehicle, such as water or food, should be sought and applicable preventive 
or control measures should be instituted (e.g., removing an implicated food item from the 
environment). Consult with an epidemiologist at IDPH or contact your regional epidemiologist if an 
outbreak is suspected. CADE can help determine a course of action to prevent further cases and can 
perform surveillance for cases that may cross several county lines and therefore be difficult to identify 
at a local level. 
c. If a food or water source is suspect, follow-up may include involvement of a representative of the 
Iowa Department of Inspections and Appeals, Food and Consumer Safety Bureau who is involved in 
enforcement of the Iowa Food Code. 
d. Institution of disease control measures is an integral part of case investigation. It is the LPHA 
responsibility to understand, and, if necessary, institute the control guidelines listed below in Section 
3), Controlling Further Spread. 
 
3) CONTROLLING FURTHER SPREAD 
 
A.  Isolation and Quarantine Requirements 
Food handlers, those caring for patients or individuals in hospital, custodial intuitions and child cares with 
Campylobacter are to be excluded from work until diarrhea ceases and education on proper handwashing 
is given. 
 
Minimum Period of Isolation of Patient 
After diarrhea has resolved, food handlers may return to work.  
 
Minimum Period of Quarantine of Contacts 
Contacts of a case with diarrhea who are food handlers shall be considered cases and handled in the 
same fashion. No restrictions otherwise. 
 
Note: A food handler is any person directly preparing or handling food. This can include a parent or child-
care provider. 
 
B. Protection of Contacts of a Case 
None. 
 
C.  Managing Special Situations 
Child Care  
Since campylobacteriosis may be transmitted person-to-person through fecal-oral transmission, it is 
important to carefully follow up on outbreaks of campylobacteriosis in a child care. General 
recommendations include:  
• Children with Campylobacter infection who have diarrhea should be excluded until their diarrhea is 
gone. 
 
Iowa Dept. of Public Health Reviewed 12/13                                                      Campylobacter 3  
Guide to Surveillance, Investigation, and Reporting 
• Children with Campylobacter infection who have no diarrhea and are not otherwise ill may be 
excluded or remain in the program if special attention is given to proper handwashing. 
 
Minimum Period of Quarantine of Contacts 
Contacts of a case with diarrhea who are food handlers shall be considered cases and handled in the same 
fashion. No restrictions otherwise. 
 
Note: A food handler is any person directly preparing or handling food. This can include a parent or child-
care provider. 
 
D.  Preventive Measures  
Environmental Measures 
Implicated food items must be removed from use. A decision about testing food items implicated in an 
outbreak can be made in consultation with the Department of Inspections and Appeals, Food and 
Consumer Safety Division and CADE. 
 
Personal Preventive Measures/Education 
To avoid exposures, recommend that people: 
• Always wash their hands thoroughly with soap and water before eating or preparing food, after 
using the toilet, after changing diapers, and after touching their pets or other animals. 
• After changing diapers, wash the child’s hands as well as their own. 
• In a child care, dispose of feces in a sanitary manner. 
• When caring for someone with diarrhea, scrub their hands with plenty of soap and water after 
helping the person use the toilet, or changing diapers, soiled clothing or soiled sheets. 
• Keep food that will be eaten raw, such as vegetables, from becoming contaminated by animal-
derived food products. 
• Avoid letting infants or young children come into contact with pets that are sick with diarrhea, 
especially puppies and kittens. 
• Make sure to cook all food products from animals thoroughly, especially poultry products, and 
avoid consuming raw eggs or cracked eggs, unpasteurized milk, or other unpasteurized dairy 
products. 
• Avoid sexual practices that may permit fecal-oral transmission. Latex barrier protection should be 
emphasized as a way to prevent the spread of campylobacteriosis to case’s sexual partners as 
well as being a way to prevent the exposure to and transmission of other pathogens. 
 
4) ADDITIONAL INFORMATION 
 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for 
Campylobacteriosis can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria in 
this chapter. (CSTE case definitions are used by the state health department and the CDC to maintain 
uniform standards for national reporting.)  
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What is Campylobacteriosis? 
Campylobacteriosis is a diarrheal illness caused by infection with a bacterium called Campylobacter. People who 
become ill with campylobacteriosis typically get diarrhea, cramping, abdominal pain, and fever. The illness 
usually occurs in the summer months. 
 
Who can be infected? 
Anyone may become infected, however campylobacteriosis is most common in infants and young adults. 
 
How are the bacteria spread? 
Improper handling of raw poultry, eating raw or undercooked poultry, and drinking unpasteurized milk are all 
means of becoming infected. In addition, eating or drinking food or water that is contaminated by the feces 
(stool) of infected people or animals, without washing hands afterwards, can spread the bacteria.   
 
What are the symptoms of Campylobacter infection? 
The major symptom is diarrhea, which may be either mild or severe.  Stomach cramps, fever, nausea, vomiting 
and generally "not feeling well" can also occur.  Severe cases can mimic appendicitis. 
 
How soon after infection do symptoms appear? 
The symptoms usually start 2 - 5 days after infection, with a range from 1 - 10 days.  Many persons who are 
infected may have no symptoms. 
 
Are there long-term consequences of Campylobacter infection? 
Most people recover completely within 2 - 5 days, although sometimes recovery can take up to 10 days.  
Relapses can occur. Rarely, some long-term consequence can occur.  Some people may have arthritis 
following campylobacteriosis, others may develop a rare disease called Guillain-Barré syndrome. This 
syndrome may lead to paralysis that lasts several weeks and usually requires intensive care.  
 
Where is Campylobacter found? 
Many animals, such as cats, cows, dogs, and birds (especially chickens), carry the bacteria in their intestines.  
Infected animals may contaminate meat products, water supplies, milk, and other food items. 
 
How long can a person spread Campylobacter? 
People can spread the bacteria to others for a few days to several weeks after they are infected. 
 
Should infected persons be excluded from school or work? 
Since the bacteria are passed in the feces, people with diarrhea (especially children in child care or people who 
handle food) should not go to school or work.  After diarrhea ends, persons may return to normal activities but 
they should carefully wash their hands after using the toilet and before preparing or eating food.   
 
What is the treatment for Campylobacter infection? 
Most people get well without treatment.  Persons with diarrhea should drink plenty of liquids.  Antibiotics such 
as erythromycin or a fluoroquinolone can be used, and can shorten the duration of symptoms if they are 
given early in the illness.  
 
How can the spread of Campylobacter infection be stopped? 
1. Always refrigerate poultry and meat products.  Never leave raw poultry or meat at room temperature. 
2. Always cook poultry completely.  Never eat raw poultry. 
3. Avoid consuming unpasteurized milk. 
4. Carefully wash hands before and after preparing food. 
5. Make sure children wash their hands carefully, especially after using the toilet, having diapers 
changed or handling pets. 
6. Always wash hands with soap and warm water after using the toilet or changing diapers. 
7. Always wash food preparation surfaces and utensils between cutting up raw meat or poultry and 
handling other foods 
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Campylobacter                       Agency: 
     
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak related:  Yes      No      Unknown Provider title:  ARNP    DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure setting:       Address line 1:       
Epi-linked:  Yes   No  Unk To whom: ______________  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
Laboratory: 
 
      Accession #: 
 
      
Collection 
date: 
 
     /     /      
 
Date received: 
 
     /     /      
Specimen 
source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Campylobacter  Serotype:    
 
Laboratory: 
 
      Accession #: 
 
      
Collection 
date: 
 
     /     /      
 
Date received: 
 
     /     /      
Specimen 
source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Campylobacter  Serotype:    
 
Laboratory: 
 
      Accession #: 
 
      
Collection 
date: 
 
     /     /      
 
Date received: 
 
     /     /      
Specimen 
source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Campylobacter  Serotype:    
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OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ’occupation’ 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /       
       Isolated at entry: 
 
 Yes    No    Unk 
Isolation type 
(entry): 
 
      
Days 
hospitalized:        Currently isolated: 
 
 Yes    No    Unk 
Current isolation 
type: 
 
      
 
CLINICAL INFO & DIAGNOSIS 
 
Guillain- 
Barré         
Diagnosis  Yes    No    Unk Onset Date      /     /      
Reactive 
Arthritis 
Diagnosis  Yes    No    Unk Onset Date      /     /      
 
S
ym
pt
om
s 
Diarrhea 
Nausea 
Vomiting 
Headache 
Muscle weakness 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
      Days/Hours 
      Days/Hours 
      Days/Hours 
      Days/Hours 
      Days/Hours 
Visible bloody 
diarrhea  
Fever 
 
Abdominal cramps 
Chills 
 
 Yes    No    Unk 
 Yes    No    Unk 
Highest known fever: 
 Yes    No    Unk 
 Yes    No    Unk 
 
      Days/Hours 
      Days/Hours 
       °F    °C 
      Days/Hours 
      Days/Hours 
First symptom:       
Most severe 
symptom:       
Date returned to normal 
activities:      /     /      
 
OTHER LAB FINDINGS 
 
Clinical specimen from case 
 
Was PFGE performed:  Yes    No    Unk 
IA-XbaI 
Pattern       
IA-BlnI 
 Pattern       
CDC-XbaI 
Pattern       
CDC-BInI 
Pattern       
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
Environmental specimen testing 
Food, Medication, or 
environmental samples tested?  Yes    No    Unk 
Describe 
samples: (indicate which test positive)       
For what were the samples 
tested? 
 Campylobacter  E. coli or EHEC             Salmonella   
 Shigella               Other testing (specify): 
         Positive?  Yes    No    Unk 
PFGE 
performed?  Yes    No    Unk 
IA-XbaI 
Pattern       
IA-BlnI 
 Pattern       
CDC-XbaI 
Pattern       
CDC-BInI 
Pattern       
 
TREATMENT 
 
Antibiotics prescribed?   Yes    No    Unknown 
 
  
Antibiotic:       
  
Antibiotic:       
 
 
Antibiotic:       
Date 
started:      /     /      
Date 
started:      /     /      
Date 
started:      /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Risk Factors/Travel Information – In the 10 days prior to onset of symptoms did the case: 
Tr
av
el
 
Travel within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       Departure date:      /     /      Return date:      /     /      
Travel within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Travel outside U.S.?   
 Yes    No    Unk Country:       Departure date:      /     /      Return date:      /     /      
 
Visit restaurants?  Yes    No    Unknown 
If Yes, complete the table below:   County and address are missing from this table 
Establishment name Address/Zip Date visited Foods consumed Others ill? 
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
 
Attend Group Gatherings (e.g. weddings, parties)?  Yes    No    Unknown 
If Yes, complete the following table: 
Location name Address/Zip Date visited Foods consumed Others ill? 
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
 
Where did the case purchase groceries in the 2 weeks before the onset of symptoms: 
Store name Address City/State/Zip County Date purchased 
                        
 
     /     /      
                        
 
     /     /      
                        
 
     /     /      
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation period for 
Campylobacter  is 1 to 
10 days. 
Campylobacter is communicable as 
long as a person excretes bacteria in 
their stool, this can be days to weeks.  
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Dietary Information – In the 10 days prior to onset of symptoms did the case consume the following: 
Meat and poultry 
Any of these meat 
products?  Poultry      Ground beef      Meat other than ground meat (salami, jerky, wild game) 
Was the meat fully cooked?  Yes    No    Unknown 
List all source/types:       
List all brand names:       
From dates consumed:      /     /     ,      /     /      To dates consumed:      /     /     ,      /     /      
 
Other poultry products 
Raw/partially 
cooked eggs or in 
foods (e.g. cookie 
dough): 
 Yes    No    Unk 
From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
 
Unpasteurized products 
Unpasteurized 
milk:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Unpasteurized 
juice:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Other 
unpasteurized 
products 
(e.g. cheese): 
 Yes    No    Unk 
From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
 
Animal Exposures – In the 10 days prior to the onset of symptoms did the case: 
Check all that apply 
Visit or live on a farm: 
Exposed to manure: 
Have farm animal contact: 
 Yes    No    Unknown 
 Yes    No    Unknown 
 Yes    No    Unknown 
 
 
Animals:       
   
Have other animal  
contact in home: 
 
 Yes    No    Unknown Animal:       Animal sick:  Yes    No    Unk 
Visit a petting zoo: 
 
 Yes    No    Unknown Touched animals: 
 
 Yes    No    Unk Animal:       
Zoo name:       Address/Zip/County:       
 
Water Exposures – In the 10 days prior to the onset of symptoms did the case: 
 
Drinking water supply 
Home:  Bottled 
 Commercial Delivery 
 Municipal 
 Rural water 
 Well 
 
School:  Bottled 
 Commercial Delivery 
 Municipal 
 Rural water 
 Well 
 
Work:  Bottled 
 Commercial Delivery 
 Municipal 
 Rural water 
 Well 
 
Child care:  Bottled 
 Commercial Delivery 
 Municipal 
 Rural water 
 Well 
 
 
Other Exposures – In the 10 days prior to the onset of symptoms did the case: 
Wear diapers  Yes    No    Unk Have contact with diapers:  Yes    No    Unk 
    
Have contact with 
immunocompromised person:  Yes    No    Unk Setting: 
 Home 
 Work      Other _______________________________________ 
     
Have sex with someone with 
similar symptoms:  Yes    No    Unk 
Sexual 
preference: 
 Hetero 
 Homo 
 Bisexual 
 Unknown 
 
 
Number of people living in case’s household:          
 
Are there close contacts of the case with same symptoms:   Yes    No    Unknown 
 
Close contacts of the case with the same symptoms 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
CONTACTS 
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Relationship to case                      List symptoms Symptom  onset date 
Same 
exposures 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
      
 
     /     /      
 Restaurant    
 Gatherings   
 Food 
 Animal 
 Water 
 
 Yes 
 No 
      
      
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
Same 
exposures 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
      
 
     /     /      
 Restaurant    
 Gatherings   
 Food 
 Animal 
 Water 
 
 Yes 
 No 
      
      
If this contact is a case create a new event and/or case for this contact. 
 
NOTES:       
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CHLAMYDIA  
 
Also known as: Chlamydia trachomatis, “Silent” STD.   
 
Responsibilities: 
Hospital: Report cases by mail, phone or in IDSS 
Infection Preventionist:  Report cases by mail, phone or in IDSS 
Lab: Report positive lab results by mail, phone or in IDSS 
Physician: Report cases by mail or phone 
Cases may be reported to your Local Public Health Agency (LPHA) or to Iowa 
Department of Public Health 
 
Iowa Department of Public Health 
Sexually Transmitted Disease Reporting Hotline: (515) 281-3031 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Chlamydia is a common sexually transmitted disease caused by a bacterium called Chlamydia 
trachomatis. Chlamydia are obligate intracellular bacteria sensitive to broad-spectrum antimicrobials. 
  
B. Clinical Description 
Symptoms:  Chlamydia is known as a “silent” disease because more than half of persons diagnosed 
have no symptoms.   
 
• Men with signs or symptoms may have a discharge from the penis or a burning sensation 
when urinating. Men might also have burning and itching around the opening of the penis. 
Pain or swelling of the testicles is uncommon.  Most men have no symptoms.  
 
• Women often have no symptoms, but if symptoms exist they may include an abnormal 
vaginal discharge or a burning sensation on urinating. When infection spreads to the fallopian 
tubes, some women still have no signs or symptoms; others have lower abdominal pain, low 
back pain, nausea, fever, pain during intercourse, or bleeding between menstrual periods.  
 
• Men or women who have receptive anal intercourse may acquire chlamydia in the rectum, 
which can cause rectal pain, discharge, or bleeding.  Chlamydia can also be found in the 
throats of men and women having oral sex with an infected partner. 
 
Onset: If symptoms are present, they usually appear within 1 - 3 weeks after exposure. 
 
Complications:  If untreated, chlamydia can progress to serious reproductive and other health 
problems, with both short-term and long-term consequences.  
 
• In women, untreated infection can spread into the uterus or fallopian tubes and cause pelvic 
inflammatory disease (PID). PID can cause permanent damage to the fallopian tubes, uterus, 
and surrounding tissues, leading to chronic pelvic pain, pain during intercourse, infertility, 
and potentially fatal ectopic pregnancy. Women infected with chlamydia are at increased risk 
for HIV infection if exposed to HIV while infected with chlamydia. 
 
• To help prevent the serious consequences of chlamydia, an annual screening test for 
chlamydia is recommended for all sexually active women age 25 years and younger. An 
annual screening test is also recommended for women over 26 years of age with a new sex 
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partner, multiple sex partners, if signs and symptoms are present or with sex partner(s) who 
are known to have had chlamydia, urethritis, or another STI. 
 
• Complications among men are rare. Infection sometimes spreads to the epididymis (the tube 
that carries sperm from the testis), causing pain, fever and, rarely, sterility. 
 
• Rarely, genital chlamydia can cause a severe arthritis (Reiter’s syndrome) that may be 
accompanied by skin lesions and inflammation of the eye and urethra. 
 
C. Reservoirs 
• Common reservoirs: Humans are the only known reservoir. 
 
D. Modes of Transmission 
Person-to-person:  Chlamydia is spread through contact between the penis, vagina, mouth, 
and anus. Ejaculation does not have to occur for chlamydia to be transmitted or acquired. 
Chlamydia can be spread from mother to baby during birth.  An infected infant usually has 
signs and symptoms of conjunctivitis or pneumonia. 
Any sexually active person can be infected with chlamydia. The greater the number of sex 
partners, the greater the risk of infection. Because the cervixes of teenage girls and young 
women are not fully matured, they are at particularly high risk of infection if sexually active. 
Since chlamydia can be transmitted by oral or anal sex, men who have sex with men are also 
at risk for chlamydia. In rare cases, women who have sex with women have contracted 
chlamydia from a female partner through oral sexual contact or the sharing of sex toys.  
 
E. Incubation period 
The incubation period is highly variable and poorly defined.  A range of 7 - 21 days has been 
documented, but 7 - 14 days is more common. 
 
F. Period of Communicability or Infectious Period 
A person can spread the disease from the time he/she is infected with chlamydia, until properly 
treated. Re-infection is common if partners are not adequately treated in a timely manner. 
 
G. Epidemiology 
Chlamydia is one of the most frequently reported sexually transmitted infections in the United States. 
In 2011, 1,412,791 chlamydial infections were reported to CDC from 50 states and the District of 
Columbia Under-reporting is substantial, because most people with chlamydia are not aware of the 
infection and do not seek testing. Testing is not often done if patients are treated for symptoms. An 
estimated 3 million Americans are infected with chlamydia each year. Women are frequently re-
infected if their sex partners are not treated. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To interrupt disease transmission, the Iowa Department of Public Health provides partner 
services for persons at highest risk for re-infection and complications resulting from 
infection. This group includes those patients aged 18 and younger, pregnant women, those 
patients diagnosed in an E.R., those patients co-infected with another STD, those patients 
who are re-infected, and those patients for which a provider specifically requests partner 
services.  
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B. Laboratory and Healthcare Provider Reporting Requirements: 
Iowa Administrative Code 641-1.3(139) stipulates that both the laboratory and healthcare providers 
must report. Laboratory personnel should forward results of tests directly to the Iowa Department of 
Public Health or local health department.  Providers with IDSS access may report in IDSS. 
 
Healthcare Providers must complete an “Iowa Confidential Report of STD & HIV Infection” morbidity 
card within 3days of a positive Chlamydia trachomatis infection.  For each reported case, the provider 
should provide a home address, phone number, gender, race, test performed including the specimen 
source, treatment information, and any known partner information including treatment of partners.  
 
Reporting forms and confidentially coded postage-paid envelopes are available free of charge from 
the clearinghouse at healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295   
Please send reports to the address below. 
 
 Iowa Department of Public Health 
STD Program 
 Bureau of HIV, STD, and Hepatitis (00) 
321 East 12th Street 
 Des Moines, IA  50319-0075 
 
C.  Local Public Health Agency Follow-up Responsibilities 
Case Investigation:   
Risk reduction counseling and partner notification/referral services will be provided by Disease 
Prevention Specialists employed by the Iowa Department of Public Health, or by Black Hawk or Polk 
County health departments.  Chlamydia partner follow-up is not offered in Scott or Linn counties.   
 
3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements 
None. 
 
B. Protection of Contacts of a Case 
The Iowa Department of Public Health may initiate voluntary partner services with persons who have 
been diagnosed with Chlamydia Trachomatis infection.  Healthcare providers can facilitate this 
process by describing the program to the patient and encouraging the patient to meet with the 
department’s Disease Prevention Specialist assigned to his or her region. 
 
Patients who may receive partner services for Chlamydia infection include:  
• Those aged 18 and under 
• Those seen in an E.R. 
• Those who are pregnant 
• Those who are re-infected 
• Those who are not treated 
• Those who are co-infected with another STD  
• Those who do not fit any other category, but in which the health care provider specifically 
requests partner services 
 
Patients’ names and times of exposure are not used in the notification of partners.  Referral for 
testing and treatment are offered to all partners.  Appropriate referrals for other services are 
provided.  
 
Physicians may assist the Disease Prevention Specialist with collecting partner information.  In such 
cases, the healthcare provider should collect the following information:  partner name, address, home 
phone number, age and/or date of birth, race, sex, partner marital status, height, size/build, general 
description of the partner, and dates of first and last exposure.  Any other information that may help 
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in locating and counseling the partner may also be included, such as medical conditions, place of 
employment, cell phone numbers, or other unusual circumstances/situations.  Providers should report 
any partner treatment. 
 
Patients who fall outside of the above criteria for assisted partner services should be encouraged to 
inform their partners of the need for testing and treatment.  The targeted partners include all sexual 
partners within 60 days of date of onset of symptoms or within 60 days of the date of positive test – 
whichever is greater.  If there have been no sexual partners within 60 days, the most recent partner 
should be informed.   
 
Partner-delivered therapy/ Expedited Partner Therapy:  When a patient has partners who may not be 
willing or who may be unable to submit to testing, partner-delivered therapy is an option.  A 
physician, physician assistant, or advanced registered nurse practitioner who diagnoses a sexually 
transmitted chlamydial or gonococcal infection may prescribe, dispense, furnish, or otherwise provide 
prescription oral antibiotic drugs to that patient's sexual partner or partners without examination of 
the partner(s) (see Iowa Code 139A.41). If the infected individual patient is unwilling or unable to 
deliver such prescription drugs to a sexual partner or partners, a physician, physician assistant, or 
advanced registered nurse practitioner may dispense, furnish, or otherwise provide the prescription 
drugs to the department or local disease prevention investigation staff for delivery to the partner or 
partners.  Medications or prescriptions should be provided for all partners who have been sexually 
exposed to the patient within the two months prior to diagnosis or within the two months prior to the 
onset of symptoms, whichever is greater.  However, expedited partner therapy should not be used if 
the partner is a pregnant woman or if the patient is a man who has sex with other men (MSM).  
Further information on expedited partner therapy can be found at 
www.idph.state.ia.us/adper/std_control.asp. 
 
C.  Managing Special Situations 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
Report unusual cases to the Iowa Department of Public Health at 515-281-3031. 
  
D. Preventive Measures 
Preventive Measures/Education 
Risk reduction counseling/education and testing should be offered to all persons with risk for 
Chlamydia trachomatis infection and transmission. 
The surest way to avoid transmission of sexually transmitted diseases is to abstain from 
sexual contact, or to be in a long-term mutually monogamous relationship with a partner 
who has been tested and is known to be uninfected.  
Latex condoms, when used consistently and correctly, can reduce the risk of chlamydia 
transmission. 
Chlamydia screening is recommended annually for all sexually active women 25 years of age 
and younger. All pregnant women should have a screening test for chlamydia. Women older 
than 25 years whose sexual practices put them at risk for chlamydial infection should be 
tested at least once a year. It has been shown that screening and treatment of chlamydial 
infection of the cervix reduces the likelihood of PID. 
The Center’s for Disease Control and Prevention’s 2010 STD Treatment Guidelines recommend 
specific STD prevention services that should be provided for all sexually active men who have sex 
with men (MSM).  The first recommendation for this population is that STD screening be performed 
at least annually.   
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Any genital symptoms such as discharge or burning during urination or unusual sore or rash 
should be a signal to stop having sex and to consult a healthcare provider immediately. If a 
person has been treated for chlamydia (or any other STD), he/she should notify all recent 
sex partners to see a healthcare provider and be treated. This will reduce the risk that the 
sex partners will develop serious complications from chlamydia, and will also reduce the 
person’s risk of becoming re-infected. The person and all of his or her sex partners must 
avoid sex until treatment is completed.  
An infected patient treated for chlamydia should be tested for other sexually transmitted diseases. 
 
See www.hivtest.org/STDTesting.aspx for a current list of sites that can provide STD testing. 
 
4) ADDITIONAL INFORMATION 
Treatment information 
Chlamydia can be treated and cured with antibiotics. A single dose of azithromycin, or 7 days of 
doxycycline (twice daily), are the most common treatments.  Refer to the current “CDC Guidelines for 
Treatment of Sexually Transmitted Diseases” for appropriate treatment.  HIV-positive persons with 
chlamydia should receive the same treatment as those who are HIV negative.  
All sex partners within 60 days of onset of symptoms or within 60 days of a positive test 
(whichever is greater) should be evaluated, tested, and treated if necessary. When there has 
been no sexual partner in the last 60 days, the most recent partner should be evaluated, 
tested, and treated if necessary.  The CDC recommends presumptive treatment at the time 
of exam for all exposed partners to a known infected patient.  Persons with chlamydia should 
abstain from sexual intercourse until they and their sex partners have completed treatment 
to avoid re-infection. 
Women whose sex partners have not been appropriately treated are at high risk for re-
infection. Multiple infections increase a woman’s risk of serious reproductive health 
complications, including infertility. Women, especially adolescents, should consider retesting 
for chlamydia three to four months after treatment is completed. This is especially true if 
they are uncertain whether sex partners received treatment. 
 
Laboratory criteria for diagnosis 
 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Chlamydia 
can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
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Additional Resources 
CDC Website with most current guidelines for prevention, surveillance, and treatment:  
www.cdc.gov/nchstp/dstd/chlamydiaInfo.htm 
STD Program web site, Iowa Department of Public Health. 
www.idph.state.ia.us/HivStdHep/STD.aspx?prog=Std&pg=StdHome  
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What is chlamydia? 
Chlamydia is a common sexually transmitted disease (STD) caused by the bacterium Chlamydia 
trachomatis. 
 
How common is chlamydia? 
An estimated 3 million Americans are infected with chlamydia each year. Women are frequently re-
infected if their sex partners are not treated. 
 
How do people get chlamydia? 
Chlamydia can be transmitted during vaginal, anal, or oral sex, or passed from an infected mother to her 
baby during vaginal childbirth. 
 
Any sexually active person can be infected with chlamydia. The greater the number of sex partners, the 
greater the risk of infection.  
 
What are the symptoms of chlamydia? 
Chlamydia is known as a “silent” disease, because more than 50% of infected persons do not have 
symptoms. If symptoms do occur, they usually appear within 1 - 3 weeks after exposure. 
 
Women with symptoms might have an abnormal vaginal discharge, or a burning sensation when 
urinating (peeing). As the infection progresses, some women may still have no signs or symptoms; others 
have lower abdominal pain, low back pain, nausea, fever, and pain during intercourse, or bleeding 
between menstrual periods.  
 
Men with symptoms may include a discharge from the penis or a mild burning sensation when urinating, 
burning and itching around the opening of the penis, and occasionally, pain and swelling in the testicles. 
 
Men or women who have anal intercourse may acquire chlamydial infection in the rectum, which can 
cause rectal pain, discharge, or bleeding.  
 
Chlamydia can be found in the throats of men and women having oral sex with an infected partner. 
 
What complications can result from untreated chlamydia? 
Untreated infections can progress to serious reproductive and other health problems with both short-term 
and long-term results.  
 
In women, untreated infection can spread into the uterus or fallopian tubes and cause pelvic 
inflammatory disease (PID). PID can cause permanent damage to the fallopian tubes, uterus, and 
surrounding tissues. The damage can lead to chronic pelvic pain, chronic pain during intercourse 
infertility, and potentially fatal ectopic (outside the uterus) pregnancy. Women infected with chlamydia 
are at increased risk for HIV infection if exposed. 
 
Complications among men are rare. Infection sometimes spreads to the epididymis (the tube that carries 
sperm from the testis), causing pain, fever, and, sometimes, sterility. 
 
How does chlamydia affect a pregnant woman and her baby? 
There is some evidence that untreated infections can lead to premature delivery. Babies who are born to 
infected mothers can get chlamydia infections in their eyes and respiratory tracts. Chlamydia is a leading 
cause of early infant pneumonia and conjunctivitis (eye infection) in newborns. 
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How is chlamydia diagnosed? 
There are laboratory tests to diagnose chlamydia.  A discussion about risk factors will help your medical 
provider decide whether you should be tested. 
 
What is the treatment for chlamydia? 
Chlamydia can be treated and cured with antibiotics.  All sex partners should be evaluated, tested, and 
treated if necessary. Persons with chlamydia should abstain from sexual intercourse until they and their 
sex partners have completed treatment, to avoid re-infection. 
 
How can chlamydia be prevented? 
The best way to avoid transmission of sexually transmitted diseases is to abstain from sexual contact, or 
to be in a long-term mutually monogamous relationship with a partner who has been tested and is known 
to be uninfected, and is faithful.  
 
Latex male condoms, when used consistently and correctly, can reduce the risk of transmission of 
chlamydia. 
 
Chlamydia screening is recommended annually for all sexually active women 25 years of age and 
younger. All pregnant women should have a screening test for chlamydia. Women older than 25 years 
whose sexual practices put them at risk for chlamydia should be tested at least once a year.  
 
Any genital symptoms such as discharge, burning during urination, or unusual sore or rash should be a 
signal to stop having sex and consult a healthcare provider immediately. A person treated for chlamydia 
(or any other STD) should notify all recent sex partners so they can seek treatment. This will reduce the 
risk of sex partners developing serious complications from chlamydia, and reduce the person’s risk of 
becoming re-infected. The person and all of his/her sex partners must avoid sex until they have 
completed treatment.  
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Guide to Disease Surveillance, Investigation and Reporting 
CHOLERA 
 
Potential Bioterrorism Agent: Category B 
 
Also known as: Vibrio cholera, Asiatic cholera and epidemic cholera 
 
Responsibilities: 
Hospital: Report immediately by phone 
Lab: Report immediately by phone 
Physician: Report immediately by phone 
Local Public Health Agency (LPHA): Report immediately by phone; begin active 
surveillance for additional cases. Iowa Department of Public Health will lead the follow-
up investigation.  
 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A.   Agent 
Cholera is an acute watery diarrheal disease caused by enterotoxins produced by Vibrio cholerae bacteria. 
Two serogroups, O1 and O139, cause extensive epidemics and worldwide pandemics of disease. Non-
toxigenic or non-O1, non-O139 V. cholerae infections can cause sporadic illness but do not cause 
epidemics. 
 
Note: This chapter only pertains to Vibrio cholerae. Other species of Vibrio (e.g., V. parahaemolyticus, V. 
vulnificus) are not reportable except in outbreak situations. 
 
B.   Clinical Description 
Symptoms: (Mild illness) Infection by O1 or O139 serogroups of V. cholerae usually results in 
asymptomatic or mild diarrhea. 
 
Symptoms:  (Severe illness) In approximately 1 out of 20 people infected, disease is more severe 
characterized by profuse watery stools, nausea, some vomiting and muscle cramps. 
 
Complications: Dehydration may develop rapidly and lead to shock and sometimes death within hours. 
The case-fatality rate in severe untreated cases may exceed 50%; with proper treatment, the rate is less 
than 1%.  
 
C. Reservoirs 
Humans are the primary reservoir although environmental reservoirs exist in brackish or estuarine aquatic 
environments. 
 
D. Modes of Transmission 
V. cholerae is usually transmitted via the ingestion of food or water contaminated (directly or indirectly) 
by feces or vomitus of infected persons (e.g., via sewage) or by ingestion of raw or undercooked seafood 
harvested from polluted waters. Large epidemics often related to fecal contamination of water supplies or 
Report Immediately 
by phone 
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street vendor foods have been recognized. The disease can spread rapidly in areas with inadequate 
treatment of sewage and drinking water. 
 
E. Incubation Period 
The incubation period ranges from a few hours to 5 days; more commonly within 2 - 3 days.   
 
F. Period of Communicability or Infectious Period 
The disease is not likely to spread directly from one person to another as long as standard infection 
prevention practices are followed; therefore, casual contact with an infected person is not a risk for 
becoming ill. However, cholera presumably has the potential to be transmitted person to person as long 
as stools test positive for the bacterium, most likely until a few days after recovery from symptoms. 
Shedding of bacteria may occasionally persist for several months. Antibiotics effective against the 
infecting strains shorten the period of communicability.  
 
G. Epidemiology 
Since the early 19th century, pandemic cholera has appeared off and on in most parts of the world. 
Cholera is a major cause of epidemic diarrhea throughout the developing world. There has been an 
ongoing global pandemic in Asia, Africa and Latin America for the last four decades. In 2009, 45 countries 
reported 221,226 cholera cases and 4,946 cholera deaths (case-fatality rate 2.24%) to the World Health 
Organization (WHO).  Poor areas continue to report the vast majority of cases; 99% of cases were 
reported from Africa, continuing a trend.  
In the United States, most cases occur among travelers returning from areas experiencing epidemic 
cholera. Sporadic cases have also occurred among persons ingesting inadequately cooked shellfish 
harvested from coastal waters along the Texas and Louisiana borders. Currently, most cholera outbreaks 
have been linked to the El Tor biotype. Studies show that some protection against biotypes (strains) 
within a serogroup is conferred from previous infection. No protection, however, results from infection 
with O1 serogroup against O139 serogroup and vice versa.   
 
H. Bioterrorism Potential 
Category B Agent:  Vibrio cholerae O1 and O139 are identified as a Category B bioterrorism agent, 
seen particularly as a water safety threat by the CDC. If acquired and properly disseminated, Vibrio 
cholerae O1 and O139 could cause a serious public health challenge because the bacteria are moderately 
easy to disseminate, result in moderate morbidity rates and low mortality rates, and require specific 
enhancements of CDC's diagnostic capacity and enhanced disease surveillance.   
  
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A.  Purpose of Surveillance and Reporting 
• To identify sources of major public health concern (e.g., contaminated water or a contaminated lot of 
shellfish) and to stop transmission from such a source. 
• To identify human cases of epidemic strains of V. cholerae to prevent transmission from such 
individuals. 
• To identify cases and clusters of human illness that may be associated with a bioterrorist event. 
 
B.  Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
immediately report any suspected or confirmed case. The reporting number for IDPH Center for Acute 
Disease Epidemiology (CADE) is (800) 362-2736.  After business hours please call the Iowa State Patrol 
Office at (515) 323-4360 and they will page a member of the on-call CADE staff. 
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Report any suspicion of cholera called to your attention. This could take the form of a healthcare provider 
or laboratory inquiring about cholera testing.  Note: Due to the rarity and potential severity of cholera, 
IDPH requests information about any suspect or known case of cholera, or any suspected exposure that 
may be bioterrorism in nature, is immediately reported to IDPH by the Disease Reporting Hotline (800) 
362-2736. 
 
Laboratory Testing Services Available   
The University of Iowa State Hygienic Laboratory (SHL) will test stool specimens for the presence of 
Vibrio cholerae. It will further identify isolates of V. cholerae as serogroup O1. All V. cholerae non-O1 are 
sent to CDC for serogroup 139 testing. SHL will also confirm and/or further identify isolates of other 
Vibrio species obtained from stool specimens or other sources. 
 
Additionally, SHL requests that all laboratories submit all isolates of V. cholerae, V. vulnificus and 
V.parahaemolyticus cultured for further testing to aid in the public health surveillance necessary for this 
illness.  Blood specimens requiring serologic testing for evidence of recent infection are sent to the 
Centers for Disease Control and Prevention (CDC).  Contact SHL for submitting blood samples to CDC. For 
more information about submitting specimens, contact SHL at (319) 335-4500. 
 
SHL can test implicated food items from a cluster or outbreak.  Food is submitted through the local public 
health department. 
    
C.  Local Public Health Agency Follow-Up Responsibilities 
 
1. Case Investigation 
a. Case investigation of cholera in Iowa residents will be directed by IDPH Center for Acute Disease 
Epidemiology (CADE) (due to the rare occurrence of cholera, the primarily imported nature of the 
disease, and its potential severity). If a bioterrorism event is suspected, IDPH and other response 
authorities will work closely with LPHA(s) and provide instructions/information on how to proceed. 
 
b. Following notification to IDPH, the LPHA may be asked to assist in completing a Surveillance Report 
form by interviewing the case and others who may be able to provide pertinent information. The 
Iowa Disease Surveillance System (IDSS) is the preferred method of recording investigation 
information. Much of the information required on the form can be obtained from the healthcare 
provider or the medical record. 
 
c. If several attempts have been made to obtain case information, but have been unsuccessful (the 
case or healthcare provider does not return calls or respond to a letter, or the case refuses to 
divulge information or is too ill to be interviewed), please contact IDPH/CADE staff for assistance. 
Please notify IDPH/CADE at (800) 362-2736 regarding progress on the case and use IDSS for case 
information data entry. 
 
3) CONTROLLING FURTHER SPREAD 
 
A.  Isolation and Quarantine Requirements 
Food handlers with cholera must be excluded from work. 
 
Minimum Period of Isolation of Patient 
After diarrhea has resolved, food handling facility employees may only return to work after producing one 
negative stool specimen. If the case is treated with an antimicrobial, the stool specimen shall not be 
submitted until at least 48 hours after cessation of therapy. In outbreak circumstances, a second 
consecutive negative stool specimen will be required prior to returning to work.  
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Minimum Period of Quarantine of Contacts 
Contacts with diarrhea, who are food handling facility employees, shall be considered the same as a case 
and handled in the same fashion. No restrictions otherwise. 
 
B.  Protection of Contacts of a Case 
Persons who shared food or water with a case during their infectious period should be observed for 5 
days from last exposure for signs of illness. Preventive antibiotic therapy is usually not recommended for 
household contacts in the United States since secondary spread is rare. Immunization of contacts is not 
indicated. 
 
C. Managing Special Situations 
Locally Acquired Case 
A locally acquired case of cholera is an unusual occurrence as most cases occur among travelers 
returning from areas experiencing epidemic cholera. If it is determined during the course of an 
investigation that a case or suspect case does not have a recent travel history to an endemic country, 
contact IDPH/CADE at (800) 362-2736 as soon as possible for assistance in instituting an investigation to 
determine source of infection and mode of transmission.  
 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
If an outbreak is suspected, or if multiple cases are reported among people who have not traveled out of 
the United States, investigate to determine the source of infection and mode of transmission. A 
contaminated vehicle (such as water or food) should be sought and applicable preventive or control 
measures should be instituted. Since person-to-person transmission is theoretically possible, special 
emphasis should be placed on personal cleanliness and sanitary disposal of feces. Consult with 
IDPH/CADE at (800) 362-2736. CADE can help determine a course of action to prevent further cases and 
can perform surveillance for other cases that may cross several town lines and therefore be difficult to 
identify at a local level. If a bioterrorist event is suspected, IDPH and other response authorities will work 
closely with LPHA(s) and provide instructions/information on how to proceed.  
 
D.  Preventive Measures 
Environmental Measures 
Implicated food items from Iowa or elsewhere in the United States must be removed from the 
environment. A decision about testing implicated food items can be made in consultation with the 
Department of Inspections and Appeals, Food and Consumer Safety Division (DIA). If a commercial 
product is suspected, DIA will coordinate follow-up with relevant outside agencies. 
 
Note: The role of the DIA is to provide policy and technical assistance with the environmental 
investigation such as interpreting the Iowa Food Code, conducting a Hazard Analysis Critical Control Point 
(HACCP) risk assessment, initiating enforcement actions and collecting food samples.  
 
Personal Preventive Measures/Education 
To avoid exposure, recommend that individuals: 
• Not eat raw or undercooked fish or shellfish. Despite good sanitation, even shellfish harvested from 
coastal United States waters have periodically been contaminated with V. cholerae. 
• Always wash their hands thoroughly with soap and water before eating or preparing food, after using 
the toilet and after changing diapers. 
• After changing diapers, wash the child’s hands and their own. 
• In a child care, dispose of feces in a sanitary manner. 
• When caring for someone with diarrhea, scrub their hands with plenty of soap and water after 
cleaning the bathroom, helping the person use the toilet, or changing diapers, soiled clothes, or 
soiled sheets. 
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International Travel 
Travelers going to cholera endemic areas should pay attention to what they eat and drink. Avoiding risky 
foods may help protect against other illnesses, including traveler’s diarrhea, typhoid fever, dysentery, and 
hepatitis A.  
 
Travelers should:  
• “Boil it, cook it, peel it, or forget it.”  
• Drink only bottled or boiled water, keeping in mind that bottled carbonated water is safer than un-
carbonated water.  
• Ask for drinks without ice unless the ice is made from bottled or boiled water. 
• Avoid popsicles and flavored ices that may have been made with contaminated water. 
• Eat foods that have been thoroughly cooked and that are still hot and steaming.  
• Avoid raw vegetables and fruits that cannot be peeled. Vegetables like lettuce are easily 
contaminated and are very hard to wash well.  
• Peel their own raw fruits or vegetables and do not eat the peelings.  
• Avoid foods and beverages from street vendors. 
• Avoid undercooked or raw fish or shellfish, including ceviche.  
• Not bring any perishable food back to the United States. 
 
For more information regarding international travel and the cholera vaccines, contact the CDC’s Traveler’s 
Health Office at (800) 232-4636 (general number) or through the Internet at www.cdc.gov/travel   
 
At the present time, the manufacture and sale of cholera vaccine in the United States has been 
discontinued. It is not recommended for travelers because of the brief and incomplete immunity if offers. 
No cholera vaccination requirements exist for entry or exit in any country.  
 
Two vaccines available in other countries may be more effective but neither is available in the U.S. 
(Dukoral®, Biotec AB and Shanchol®).  
 
4) ADDITIONAL INFORMATION 
 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Cholera can 
be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria in 
this chapter. (CSTE case definitions are used by the state health department and the CDC to maintain 
uniform standards for national reporting.)  
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What is cholera? 
Cholera is an acute diarrhea disease caused by toxins produced by Vibrio cholerae bacteria.  
 
Who is at risk? 
Any person who ingests food or water contaminated by the bacteria is at risk of becoming ill. Those traveling 
to areas where cholera is more common and those with weakened immune systems are at an increased risk 
of becoming ill.  
 
How is cholera spread? 
V. cholerae is usually transmitted through the ingestion of food or water contaminated (directly or indirectly) 
by stool or vomit of infected persons (e.g., via sewage) or by ingestion of raw or undercooked seafood 
harvested from polluted waters.  
 
What are the symptoms of cholera? 
Most individuals infected with cholera develop mild illness involving only diarrhea. Less common are infected 
individuals that develop more severe illnesses characterized by profuse watery stools, nausea, some vomiting 
and leg cramps. These symptoms may become more severe because of rapid loss of body fluids and 
dehydration.  Shock can occur in the most severe cases. Without rehydration therapy, death may occur 
within hours if severe illness is untreated. With proper treatment, the risk of fatal illness is significantly 
reduced. 
 
How is cholera diagnosed? 
Often the diagnosis is made by either isolation of the bacteria in the stool or laboratory testing for evidence 
of infection through a blood test. 
 
How is cholera treated? 
When diarrhea is present, aggressive fluid replacement is an important part of treatment. In addition, a 
physician may prescribe certain antibiotics.  
  
How can cholera be prevented? 
Although the risk of cholera infection is low in the United States, travelers to coastal regions and those 
traveling to areas where cholera is typically found are at an increased risk of becoming ill. 
General Tips: 
• Do not eat raw or undercooked fish or shellfish, including ceviche. 
• Always wash hands thoroughly with soap and water before eating or preparing food, after using the 
toilet, and after changing diapers. 
• After changing diapers, wash the child’s hands and your own. 
• In a child care, dispose of feces in a sanitary manner. 
When traveling: 
• “Boil it, cook it, peel it, or forget it.”  
• Drink only bottled or boiled water, keeping in mind that bottled carbonated water is safer than 
uncarbonated water.  
• Ask for drinks without ice unless the ice is made from bottled or boiled water. 
• Avoid popsicles and flavored ices that may have been made with contaminated water. 
• Eat foods that have been thoroughly cooked and that are still hot and steaming.  
• Avoid raw vegetables and fruits that cannot be peeled. Vegetables like lettuce are easily 
contaminated and are very hard to wash well.  
• Peel your own raw fruits or vegetables and do not eat the peelings.  
• Avoid foods and beverages from street vendors. 
• Do not bring any perishable food back to the United States. 
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Cholera                          Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis 
date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider title: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
      Type (e.g. serogroup): 
 
        Other                 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
      Type (e.g. serogroup): 
 
        Other                 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
      Type (e.g. serogroup): 
 
        Other                 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
 
CLINICAL INFO & DIAGNOSIS 
 
Symptoms               Abdominal cramps  
 Diarrhea 
 Headache 
 Muscle pain 
 Nausea 
 Shock 
 Visible bloody diarrhea 
 Vomiting 
 Watery diarrhea   
                      
In the 30 days prior to onset, were any of the following treatments received:  
Antibiotics?   Yes    No    Unknown If Yes, complete the following table: 
  
Antibiotic:       
  
Antibiotic:       
 
 
Antibiotic:       
Date 
started:      /     /      
Date 
started: 
 
     /     /      
Date 
started: 
 
     /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 
 mg      ml     IU 
 
Unit: 
 
 mg      ml     IU 
 
Unit: 
 
 mg      ml     IU 
# of days:       
# of times 
a day:       # of days:       
# of times 
a day:       # of days:       
# of times 
a day:       
Route:       Route:       Route:       
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
 The incubation period for 
Cholera is a few hours to 5 
days; average is 2-3 days.  
Cholera is communicable 
several days after symptoms 
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TREATMENT 
 
Antibiotics prescribed?   Yes    No    Unknown 
  
Antibiotic:       
  
Antibiotic:       
 
 
Antibiotic:       
Date 
started:      /     /      
Date 
started: 
 
     /     /      
Date 
started: 
 
     /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 
 mg      ml     IU 
 
Unit: 
 
 mg      ml     IU 
 
Unit: 
 
 mg      ml     IU 
# of days:       
# of times 
a day:       # of days:       
# of times 
a day:       # of days:       
# of times 
a day:       
Route:       Route:       Route:       
 
 RISK FACTORS/TRAVEL 
 
Vaccinated for cholera?  Yes    No    Unknown 
  
Date vaccinated: 
 
     /     /      
  
Date vaccinated: 
 
     /     /      
  
Date vaccinated: 
 
     /     /      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
 
Number of vaccinations:       
THERLABORATORY FINDING 
In the 7 days prior to the onset of the symptoms has the case: 
Traveled outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
O
th
er
 E
xp
os
ur
es
 Raw/partially cooked seafood consumed?  Yes    No    Unk Source/ type:       
Brand 
name:       
 
From date consumed: 
 
     /     /      
 
To date consumed: 
 
     /     /      
Street vendor food 
consumed?  Yes    No    Unk 
 
Vendor name: 
 
 
 
Address: 
 
      
 
Zip: 
 
      
 
City: 
 
      
 
State: 
 
      
 
County: 
 
      
 
Phone: 
 
      
 
Type: 
 
      
 
Worked with a Case:       Yes    No    Unk From date:  
 
     /     /      
 
  To date: 
 
     /     /      
Lived with another Case:       Yes    No    Unk From date:  
 
     /     /      
 
  To date: 
 
     /     /      
 
 
Went Swimming?  Yes    No    Unk 
 
Water type: 
 Location 
type: 
 
 
Facility name: 
 
      
From date 
swam:      /     /      
To date 
swam:      /     /      
 
Address: 
 
      
 
Zip: 
 
      
 
City: 
 
      
 
State: 
 
      
 
County: 
 
      
 
Phone: 
 
      
 
Type: 
 
      
 
 
Number of people living in case’s household:          Close contacts with the case and/or same exposures?      Yes    No    Unknown 
 
Close contacts of case or close contacts with same exposures 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
Chemotherapy:  Yes    No    Unk Type: 
 Immuno- 
suppressant: 
 
 Yes    No    Unk Type: 
 
Radiation therapy:  Yes    No    Unk Type: 
 
Antacid: 
 
 Yes    No    Unk Type: 
 
Systemic steroid:  Yes    No    Unk Type: 
 Ulcer 
medication: 
 
 Yes    No    Unk Type: 
 
CONTACTS 
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 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
 
NOTES:       
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CRYPTOSPORIDIOSIS  
 
Potential Bioterrorism Agent: Category B 
 
Responsibilities: 
Hospital: Report by IDSS, facsimile, mail or phone  
Laboratory: Report by IDSS, facsimile, mail or phone  
Physician: Report by facsimile, mail or phone  
Local Public Health Agency (LPHA):  Follow-up Required   
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax:  (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Cryptosporidiosis refers to disease caused by Cryptosporidium, a coccidian protozoan. Many species 
of Cryptosporidium exist that infect humans and a wide range of animals.  Cryptosporidium 
parvum and Cryptosporidium hominis, are the most prevalent species causing disease in 
humans, infections by C. felis, C. meleagridis, C. canis, and C. muris have also been 
reported. Cryptosporidium was not recognized as a cause of human illness until 1976.    
 
B. Clinical Description 
Symptoms: The most common symptom of cryptosporidiosis is profuse and watery diarrhea, which 
may be preceded by anorexia and vomiting in children.  The diarrhea is associated with cramping 
abdominal pain.  Other signs and symptoms include weight loss, stomach cramps, nausea, vomiting, 
and low-grade fever. Some people with cryptosporidiosis will have no symptoms at all. While the 
small intestine is the site most commonly affected, Cryptosporidium infections could possibly affect 
other areas of the digestive or respiratory tract. Asymptomatic infections are common and often 
serve as a source of infection for others.   
Complications:  Symptoms often wax and wane, but improve in fewer than 30 days in most 
immunocompetent people (average is 10 days). Immunodeficiency, especially in HIV infection, is 
associated with an inability to clear the parasite, and the disease may have a prolonged and 
fulminant clinical course, leading to death. 
 
Treatment: FDA licensed nitazoxanide (Alinia®) for the treatment of diarrhea caused by 
Cryptosporidium in immunocompetent individuals >1 years of age.   
 
C. Reservoirs 
Common reservoirs:   The reservoirs for the Cryptosporidium species that infect humans are humans, 
cattle, and other domesticated animals, including pets. 
 
D. Modes of Transmission:  
Spread:  Transmission is fecal-oral, which includes person-to-person, animal-to-person, waterborne 
and foodborne.  
 
Survivability: The oocyst of the parasite can survive in feces for a prolonged length of time and is 
resistant to chlorination.   
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Person-to-person: Many persons are infected by hand-to-mouth transfer of oocysts from the feces of 
an infected person, especially in institutions and child care centers.  Transmission can also occur 
person-to-person through sexual contact, particularly oral-anal contact. Infected animals and people 
excrete large numbers of oocysts in stool and, although the infectious dose is not certain, it is 
probably very low. 
 
Waterborne/Foodborne: Oocysts are relatively hardy and can survive in the environment for weeks or 
months. They are resistant to concentrations of chlorine and other disinfectants commonly used for 
drinking water or swimming pool treatment. Large outbreaks traced to contaminated drinking water 
have been reported, including an outbreak in Milwaukee that reportedly affected 400,000 people. 
Localized outbreaks may occur from fecally contaminated water, such as streams/lakes and 
swimming pools open to contamination by human and animal feces. Outbreaks have resulted from 
eating food contaminated by animal feces (e.g., unpasteurized apple cider). An infected food worker 
could be a source of foodborne transmission. There have also been outbreaks associated with 
“recreational water”, meaning water used for swimming such as municipal swimming pools, lakes, 
etc. 
 
Zoonotic: Transmission can occur through contact with feces from infected animals (a risk for 
livestock handlers, dairy farmers and veterinarians). People are not infected through contact 
with blood.  
 
E. Incubation period 
The incubation period is not precisely known; 1 - 12 days is the likely range, with an average of 
about 7 days. 
 
F. Period of Communicability or Infectious Period 
The disease is communicable for as long as the infected person excretes Cryptosporidium oocysts. 
Excretion generally begins at the onset of symptoms. Oocysts continue to be excreted in the stool for 
several weeks after symptoms subside, and they may remain infective outside the body for 2 - 6 
months in a moist environment. 
 
G. Epidemiology 
Cryptosporidiosis has a worldwide distribution. Cases occur year-round with a peak during summer 
and early fall. Prior to 2006, approximately 70 cases were reported each year in Iowa. In recent 
years the number of cases reported in Iowa has dramatically increased with 397 cases in 2010, 364 
cases reported in 2011 and 328 cases in 2012.  In developed countries, the prevalence of infection 
ranges from < 1% to 4.5% of individuals surveyed by stool examination.  The prevalence is 
significantly higher in developing regions of the world. Cryptosporidiosis is among the most common 
causes of persistent diarrhea in patients with AIDS in the United States. Children under two years of 
age, animal handlers, travelers to endemic areas, men who have sex with men, and close contacts of 
infected individuals are most likely to be infected. Outbreaks have been reported in child care centers 
and have been associated with public drinking water; swimming in contaminated pools, lakes and 
ponds; and drinking unpasteurized cider made from apples contaminated with cattle manure. It is 
estimated that 50% of dairy calves shed oocysts and that the parasite is present on >90% of dairy 
farms. 
 
H. Bioterrorism Potential 
Category B Agent: Cryptosporidium parvum is identified as a Category B bioterrorism agent, seen 
particularly as a water safety threat by the CDC. If acquired and properly disseminated, 
Cryptosporidium parvum could cause a serious public health challenge because the protozoans are 
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moderately easy to disseminate, result in moderate morbidity rates and low mortality rates, and 
require specific enhancements of CDC's diagnostic capacity and enhanced disease surveillance.   
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To identify whether the case may be a source of infection for other persons (e.g., a diapered 
child, child care attendee, or food handler) and, if so, prevent further transmission. 
• To identify transmission sources of public health concern (e.g., a contaminated public water 
supply) and stop transmission from the source. 
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report. The preferred method of reporting is by utilizing the Iowa Disease Surveillance 
System (IDSS).  However, if IDSS is not available to your facility the reporting number for IDPH 
Center for Acute Disease Epidemiology (CADE) is (800) 362-2736; fax number (515), 281-5698, 
mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
Des Moines, IA 50319-0075 
 
Postage-paid disease reporting forms are available free of charge from the IDPH clearinghouse.   
Call (319) 398-5133 or visit the website: 
healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295 to request a 
supply. 
 
Laboratory Testing Services Available   
The University of Iowa State Hygienic Laboratory (SHL) tests stool specimens for Cryptosporidium.  
Submit specimens in SHL’s ova and parasite kit.  Specimen collection kits are available from SHL.  
Contact SHL at (319) 335-4500 or visit the web site www.shl.uiowa.edu/kitsquotesforms/  for further 
instructions. 
    
C.  Local Public Health Agency Follow-up Responsibilities 
Case Investigation  
a. It is the LPHA’s responsibility to complete a Cryptosporidiosis case investigation in the Iowa 
Disease Surveillance System (IDSS) by interviewing the case and others who may be able to 
provide pertinent information.  Much of this information can be obtained from the case’s health 
care provider or the medical record.  
b. Use the following guidelines in completing the investigation:  
1. Record the demographic information, event information, laboratory findings, date of 
symptom onset, symptoms, treatment, and other clinical information.  
2. When asking about exposure history (food, travel, activities, etc.), use the incubation-
period for cryptosporidiosis (1-12 days).  
3. Ask about travel history and group gatherings to help identify where the case became 
infected.  
4. If possible, record any restaurants at which the case ate, including food items(s) and date 
consumed.  
5. Ask about water exposures. If exposure is thought to be related to a swimming pool, 
wading pool, spray/splash pad, or spa exposure, the responsible environmental health 
agency should be notified (refer to the Pool Inspection Contractor Contact List) so that an 
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exposure risk assessment can be conducted and action can be taken to prevent further 
exposure at that site.   
6. Ask about water supply because cryptosporidiosis may be acquired through water 
consumption.  
7. Household/close contact, pet or other animal contact, child care, and food handler 
questions are designed to examine the case’s risk of having acquired the illness from, or 
potential for transmitting it to, these contacts. Determine whether the case attends or 
works at a child care and/or is a food handler or has recently shown calves at a county fair.  
8. Ask if the patient knows others who have similar illness about the same time.  
9. If several attempts have been made to obtain case information, but have been 
unsuccessful (e.g., the case or health care provider does not return calls or respond to a 
letter, or the case refuses to divulge information or is too ill to be interviewed), please 
enter as much information as has been gathered. Please enter into the Notes section the 
reason why any information could not be obtained. In IDSS, select the appropriate reason 
under the Event tab in the Event Exception field. 
 
c. Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report. The preferred reporting method is through the Iowa Disease Surveillance System. 
The reporting phone number for IDPH Center for Acute Disease Epidemiology (CADE) is (800) 
362-2736; fax number (515) 281-5698, mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
Des Moines, IA 50319-0075 
 
3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements 
In health care settings Standard Precautions should be used. Use Contact Precautions for diapered or 
incontinent persons for the duration of illness or to control institutional outbreaks.   
 
B.  Managing Special Situations 
Child Care  
Since cryptosporidiosis may be transmitted person-to-person through fecal-oral transmission, it is 
important to follow up on outbreaks of cryptosporidiosis in a child care setting.  General 
recommendations include: 
 
• Children with Cryptosporidium who have diarrhea should be excluded until their diarrhea is 
resolved. Children are not required to provide two negative stools to return to child care.   
 
• Children with Cryptosporidium who have no diarrhea and are not otherwise ill may remain in the 
program if special precautions are taken. (Proper hand-washing practices, separation of diapering 
and food preparation areas, excluding if symptoms should occur.) 
 
Schools 
Since cryptosporidiosis may be transmitted person-to-person through fecal-oral transmission, it is 
important to follow up on suspected outbreaks of cryptosporidiosis in a school setting carefully.  
General recommendations include:  
 
• Students or staff with Cryptosporidium who have diarrhea should be excluded until the diarrhea 
is resolved.  
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• Students or staff with Cryptosporidium who do not handle food, have mild or no diarrhea and are 
not otherwise sick may remain in school if special precautions are taken. (Proper hand-washing 
practices, separation of diapering and food preparation area, excluding if symptoms should 
occur.) 
Food Handler 
Note: A food handler is any person directly preparing or handling food, including a patient care or 
child care provider. See glossary for a more complete definition. 
Since Cryptosporidium can be transmitted person-to-person through fecal-oral contact, it is important 
to carefully follow up on outbreaks of Cryptosporidium in any setting.  General recommendations 
include:  
• Food handlers with Cryptosporidium infection who have diarrhea should be excluded until 24 
hours after last bout of diarrhea, or until stools are formed.   
• Food handlers must practice frequent and thorough handwashing, using warm, running 
water, soap with friction for at least 15 seconds, and thoroughly drying hands with paper 
towels or a blow dryer. 
 
Swimming Pools 
In recent years, outbreaks from community swimming pools have become more frequent, especially 
in the summer months. The increased availability of shallow water for infants and toddlers (diaper-
age children) may be a major reason for these outbreaks. Normal chlorination (1-8 ppm) will not 
destroy Cryptosporidium oocysts. All cases should be counseled not to swim for 2 weeks after 
resolution of diarrhea. This is due to the low infectious dose and hardy nature of Cryptosporidium 
oocysts, which are resistant to chlorine.   
 
Signs should be posted prominently at all swimming venues directing that anyone who has a 
diarrheal illness should not use a public pool. Careful attention should be given to children in diapers 
so that “fecal accidents” do not contaminate a swimming or wading pool. Diaper-age children should 
always wear swim diapers to help prevent swimming pool water contamination by gross fecal 
material. Children in diapers should not have contact with public swimming or wading pool water if 
they have a diarrheal illness.   Caregivers should not change diapers on the deck of a swimming pool; 
most newer facilities have diaper changing areas within the bathhouse. Dirty diapers should be 
disposed of in a sanitary fashion (never rinsed in pool water). Caregivers should thoroughly wash 
their hands and those of the child after changing a diaper. 
 
Swimming pool inspections in most counties are done by a city, county or regional environmental 
health agency. If a sporadic case or an outbreak of Cryptosporidium occurs and is thought to be 
related to a swimming pool, wading pool, spray/splash pad, or spa exposure, the responsible 
environmental health agency should be notified (refer to the Pool Inspection Contractor Contact List) 
so that an exposure risk assessment can be conducted and action can be taken to prevent further 
exposure at that site. Include the number of suspect and confirmed cases linked to the implicated 
site and the date potential exposure began (12 days before symptom onset of earliest case) when 
notifying the environmental health agency.  
 
If public health and environmental health officials recommend superchlorination (refer to the CDC 
Fecal Accident Response Recommendations) of a pool, the superchlorination should be done to 
minimize the time the pool facility is closed. Closing a facility to superchlorinate may move users to 
other facilities nearby. Public health and environmental health officials should consider a 
recommendation that nearby swimming facilities also superchlorinate as a precaution against further 
transmission of Cryptosporidium. 
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Community Residential Programs 
Actions taken in response to an outbreak of cryptosporidiosis in community residential programs will 
depend on the type of program and the level of functioning of the residents.  
 
In long-term care facilities, residents with cryptosporidiosis should be placed on standard precautions 
until symptoms subside. Contact Precautions should be used for diapered or incontinent persons for 
the duration of illness or to control institutional outbreaks. Staff members with Cryptosporidium 
infection should not work until diarrhea is gone. 
 
In residential facilities for the developmentally disabled, staff and clients with cryptosporidiosis must 
refrain from handling or preparing food for other residents until diarrhea has subsided.  Staff 
members with cryptosporidiosis who are not food handlers should not work until diarrhea is gone.  
 
C.   Reported Incidence Is Higher than Usual/ Community Outbreak Suspected 
If the number of reported cases of cryptosporidiosis in your city or county is higher than usual, or if 
you suspect an outbreak, investigate to determine the source of infection and mode of transmission. 
A common vehicle (such as water, food, or association with a child care center) should be sought and 
applicable preventive or control measures should be instituted. Control of person-to-person 
transmission requires special emphasis on personal hygiene and sanitary disposal of feces. Consult 
with the CADE ((800) 362-2736) for assistance with investigation and control.   
  
D. Preventive Measures 
Personal Preventive Measures/Education 
All cases regardless of whether or not they received treatment should be counseled not to swim for 2 
weeks after resolution of diarrhea. This is due to the low infectious dose and hardy nature of 
Cryptosporidium oocysts, which are resistant to chlorine.  Children in diapers should not have contact 
with public swimming or wading pool water if they have a diarrheal illness.    
 
To avoid exposure, recommend that individuals: 
• Always wash hands thoroughly with soap and water before handling food or eating, after using 
the toilet or changing diapers, and after contact with animals, especially cattle. 
• Wash the child’s hands and their own after changing diapers. 
• Avoid drinking raw milk, other unpasteurized dairy products, or unpasteurized juices.  
• Wash all raw fruits and vegetables before serving.  
• Dispose of feces in a sanitary manner, especially in child care centers or other institutional 
settings. 
• Avoid drinking water from streams or lakes. Avoid drinking unboiled water while traveling in 
developing countries or whenever water quality is unknown. (Bringing water to a full, rolling boil 
is sufficient to kill Cryptosporidium, or use filters capable of removing particles 0.1-1.0 
micrometers in diameter.) 
• Adhere to local advisories to boil water. 
• Avoid swallowing water when swimming.  Lakes, streams, other surface waters and swimming 
pools may be contaminated with Cryptosporidium.  Chlorination does not effectively eliminate the 
parasite. 
 
It is unlikely that Cryptosporidium could cause illness in regulated, public drinking water, but 
immunocompromised individuals may want to consider the following recommendations: 
• Boil tap water before drinking or making ice cubes. 
• Consider the use of a home water filtering system with a very fine filter (absolute pore size of 1 
micron or smaller). Such filters include reverse-osmosis filters; filters labeled “absolute” 1 micron; 
and those labeled as meeting National Sanitation Foundation (NSF) standard #53 for cyst 
removal.  
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• Avoid fecal contact. 
• Avoid sexual practices that may involve direct contact with feces. Latex barrier protection should 
be used to prevent the spread of Cryptosporidium and exposure to and transmission of other 
pathogens to case’s sexual partners. 
 
 
4) ADDITIONAL INFORMATION 
 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for 
Cryptosporidiosis can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
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What is cryptosporidiosis? 
Cryptosporidium is a parasite that causes diarrhea in both animals and humans.  People can become ill 
with cryptosporidiosis (often called “crypto”) by coming into contact with persons or animals shedding the 
parasite or by drinking contaminated water. Cases occur year round with a peak during summer or early 
fall.  
 
Who gets cryptosporidiosis? 
Anyone can get cryptosporidiosis. Children under 2 years of age, animal handlers, travelers, men who 
have sex with men, and close contacts of infected persons are more likely to be infected. 
 
How is cryptosporidiosis spread? 
Cryptosporidium is found in the feces (stool) of an infected person or animal. It is spread by putting 
something in the mouth that has been contaminated with the stool from an infected person or animal. It 
can also be spread by swallowing contaminated food or water. 
 
What are the symptoms of cryptosporidiosis? 
The major symptom of cryptosporidiosis is frequent and watery diarrhea accompanied by cramping belly 
pain. Other symptoms may include headache, nausea, vomiting, and low-grade fever. Some people have 
no symptoms. Symptoms may briefly improve and then get worse again, but people who are healthy 
usually get well in 14-30 days. Persons whose immune systems do not work properly may become 
seriously ill. 
 
How soon do symptoms appear? 
Symptoms appear between 1 - 12 days after infection with the parasite. 
 
What is the treatment for cryptosporidiosis? 
People who are healthy often improve without taking any medications.  They should drink plenty of fluids 
to prevent dehydration due to diarrhea. Consult with a health care provider before taking anti-diarrheal 
medication.  A medication called nitazoxanide (Alinia®) may be used to treat some people with 
cryptosporidiosis.   
 
What can be done to prevent the spread of cryptosporidiosis? 
• Always wash hands thoroughly with soap and water before handling food or eating, after using 
the toilet or changing diapers, and after contact with animals, especially cattle. 
• Wash both the child’s hands and their own after changing diapers. 
• Avoid drinking raw milk, other unpasteurized dairy products, or unpasteurized juices.  
• Wash all raw fruits and vegetables before serving.  
• Dispose of feces in a sanitary manner, especially in child care centers or other institutional 
settings. 
• Avoid drinking water from streams or lakes. Avoid drinking unboiled water while traveling in 
developing countries or whenever water quality is unknown. (Bringing water to a full, rolling boil 
is sufficient to kill Cryptosporidium, or use filters capable of removing particles 0.1-1.0 
micrometers in diameter.) 
• Adhere to local advisories to boil water. 
• Avoid swallowing recreational water.  Lakes, streams, other surface waters and swimming pools 
may be contaminated with Cryptosporidium.  Cryptosporidium  is resistant to chlorine and can 
survive for days in chlorine-treated water. Persons should stop using swimming pools or other 
aquatic facilities while ill and for at least 2 weeks after diarrhea resolves.  People can pass the 
parasite in stool and contaminate water for weeks after symptoms have stopped.  
• Crypto is resistant to bleach.  Instead, use 3% hydrogen peroxide to clean.      
• Ill individuals should remain out of child care, schools, and work until diarrhea is resolved.   
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For Healthcare Providers                            (Commonly referred to as “Crypto”)            
 
What is Cryptosporidiosis?   
Cryptosporidiosis is a parasitic infection caused by the protozoan Cryptosporidium. Cryptosporidium 
parvum and Cryptosporidium hominis, are the most prevalent species causing disease in humans.  Once 
an animal or person is infected, the parasite lives in the intestine and passes in the stool. The infectious 
oocyst of the parasite is protected by an outer shell that allows it to survive outside the body for long 
periods of time and makes it very resistant to chlorine-based disinfectants.    
 
What is the clinical description of Cryptosporidiosis? 
The most common symptom of cryptosporidiosis is profuse and watery diarrhea.  Other signs and 
symptoms include weight loss, stomach cramps, nausea, vomiting, and low-grade fever.  Although 
infection is usually limited to the gastrointestinal tract, Cryptosporidium infections could possibly affect 
other areas of the digestive or the respiratory tract. Asymptomatic infections are common and often 
serve as a source of infection for others.  Symptoms often wax and wane, but remit in fewer than 30 
days. In most immunocompetent people (including children), the illness is self-limited, lasting 1 to 20 
days (average 10 days).  Immunodeficiency, especially in HIV infection, is associated with an inability to 
clear the parasite, and the disease may have a prolonged and fulminant clinical course, leading to death. 
 
How is Cryptosporidium  transmitted? 
In order for infection to occur, the susceptible host must ingest water or other materials contaminated 
with the Cryptosporidium oocysts, referred to as fecal-oral transmission.  Important routes of 
transmission include person-to-person, animal-to-person, foodborne, and waterborne (drinking and 
recreational).   
 
Who is most at risk for Cryptosporidiosis?   
Anyone can get cryptosporidiosis.  People who are most likely to become infected with Cryptosporidium 
include:  Child care workers and diaper-aged children who attend child care centers; Parents of infected 
children; International travelers; Swimmers who swallow water while swimming in swimming pools, lakes, 
rivers, ponds, and streams; and backpackers, hikers, and campers who drink unfiltered, untreated water.  
 
How long is Cryptosporidiosis communicable? 
The disease is communicable for as long as the infected person excretes Cryptosporidium oocysts. 
Excretion generally begins at the onset of symptoms. Oocysts continue to be excreted in the stool for 
several weeks after symptoms subside, and they may remain infective outside the body for 2 - 6 months 
in a moist environment. 
 
What laboratory tests are used to diagnose Cryptosporidium? 
Diagnosis is generally made by the microscopic identification of oocysts in fecal smears (Ova and Parasite 
Exam).  Organisms can also be identified in intestinal biopsy tissue.  For microscopic examination, there 
are three techniques available: wet mounts, stained smears (e.g., modified acid fast stain), and 
immunofluorescent staining. In addition, new and more sensitive enzyme immunoassay (EIA) tests have 
recently become available.  EIA kit sensitivities and specificities reportedly range from 93 to 100 percent 
when used in a clinical setting.  Since the infectious oocysts are excreted from the body intermittently, at 
least two stool samples should be examined before the test can be considered negative and 
Cryptosporidium is ruled out as the diagnosis. 
The State Hygienic Laboratory uses the routine Ova and Parasite (O & P) microscopic exam and a special 
acid fast stain for Cryptosporidium if requested.   
 
Is there a treatment for diarrhea caused by Cryptosporidium? 
Yes, FDA licensed Nitazoxanide (Alinia®, Romark Laboratories, Tampa, FL, USA) for persons with healthy 
immune systems > 1 year of age.   
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What about patients with compromised immune systems? 
Nitazoxanide has been approved for treatment of diarrhea caused by Cryptosporidium in people with 
healthy immune systems.  It is currently not approved to treat immunodeficient persons.   
 
What is the dosage used for Nitazoxanide? 
 
Immunocompetent Persons 
Adult dosage 500 mg BID x 3 days 
Pediatric dosage 
1-3 years; 100 mg BID x 3 days 
4-11 years; 200 mg BID x 3 days 
 
Nitazoxanide oral suspension (100 mg/5 ml; patients >1 year of age) and Nitazoxanide tablets (500 mg; 
patients >12 years of age) are indicated for the treatment of diarrhea caused by Cryptosporidium.   
 
What is the efficacy of Nitazoxanide? 
Clinical cure (resolution of diarrhea) occurs in 72-88 percent of patients. Parasitologic cure (no 
Cryptosporidium detected in the stool) occurs in 60-75 percent. It may take up to 5 days for diarrhea to 
resolve in approximately 80 percent of patients.   
 
What should I tell my patients with cryptosporidiosis? 
• All infected persons, including those who have completed treatment, should not swim for two 
weeks after resolution of symptoms.  Cryptosporidium oocysts are chlorine-resistant.  It is critical 
that this recommendation is followed to prevent the spread of cryptosporidiosis through public 
swimming pools and other aquatic venues.   
• Wash hands with soap and water after using the toilet, changing diapers, and before eating or 
preparing food.   
• Avoid fecal exposure during sexual activity. 
 
Is my patient required to have two negative stools before returning to school, child 
care, or work settings? 
IDPH does not require persons with confirmed cryptosporidiosis to provide two negative stools to return 
to school, child care, or work settings. Persons with cryptosporidiosis should stay home until diarrhea and 
vomiting resolve.     
 
For more information: 
• CDC: www.cdc.gov/parasites/crypto/index.html  
• CDC: www.cdc.gov/parasites/crypto/health_professionals/tx.html  
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Purpose:  Information for school settings when Crypto is present in their facility. 
 
What is Crypto?   
Crypto, or Cryptosporidiosis, is an illness that is caused by a parasite.  It affects both animals and 
humans.  People can get Crypto by coming in contact with other people or animals that have the 
parasite, swimming or playing in water with the parasite in it, or by drinking contaminated water. 
 
Who can get Crypto?   
Anyone.  Employees who work with children in diapers are at increased risk for getting Crypto. 
 
How is Crypto spread?   
Crypto is found in the feces (stool) of an infected person or animal.  It is spread: 
• By putting something in your mouth or accidentally swallowing something that has come in 
contact with the stool of a person or animal infected with Crypto.  This could be items such as 
toys, hands, eating utensils, etc.  Items can be contaminated by a person who has not properly 
washed their hands after a diaper change or toileting. 
• By accidentally swallowing Crypto picked up from surfaces (such as toys, bathroom fixtures, 
changing tables, diaper pails) contaminated with stool from an infected person.  
• By swallowing recreational water contaminated with Crypto. Recreational water is water in 
swimming or wading pools, hot tubs, lakes, rivers, ponds, or streams that can be contaminated 
with sewage or feces from humans or animals. Note: Crypto is chlorine resistant and can live for 
days in pools. 
• By eating uncooked food contaminated with Crypto. Thoroughly wash with uncontaminated 
water all vegetables and fruits you plan to eat or serve raw. 
 
What are the symptoms of crypto?   
The most common symptom of crypto is frequent and watery diarrhea.  Other symptoms may include 
headache, nausea, vomiting and low-grade fever.  Symptoms may briefly improve and then get worse 
again, but people who are healthy usually get well in 14-30 days.  However, some people may not show 
symptoms of illness, but can still spread the disease to others. 
 
How can schools prevent the spread of crypto? 
• Frequent hand washing by both staff and students.  Wash hands with hot, soapy water before 
handling foods and eating, and after using the toilet, diapering young children, and handling 
animals 
• Exclude students and staff with diarrhea from school 
• Disinfect surfaces and toys that may be contaminated with Crypto* 
• Educate parents and staff about the illness and outbreak 
• Employees and students with diarrhea should not prepare food for anyone 
• Suspend the use of child wading pools, water tables, and other water based activities.  
• If the school has a pool, contact your local environmental public health agency for more 
information on how to prevent the spread of Crypto through water exposure. 
• Infected persons should not swim or be involved in any water activities – swimming, wading, etc. 
while ill and for at least 2 weeks after diarrhea resolves.   
• Separate diapering and food-handling areas and staff responsibilities 
• Use disposable gloves with every diaper change 
• Use disposable paper to cover diaper-changing area; change the paper with every diaper change 
• Separate diaper-changing areas from children’s play areas 
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*Disinfection of surfaces and objects 
Disinfect bathrooms and food preparation surfaces daily. Use a 3% hydrogen peroxide solution, or if 
available, 6% concentration of hydrogen peroxide, and let it sit on the surface for 20 minutes**.  No 
disinfectant is guaranteed to be completely effective; however the 3% hydrogen peroxide is usually 
effective.  Toys and tabletops also should be cleaned and disinfected with the 3% hydrogen peroxide 
solution for 20 minutes at least twice daily.  Cloth toys may be washed and heat-dried in the clothes 
dryer for 30 minutes. 
 
** This solution is for schools that have staff or children with Crypto- usually two or more cases.  This is 
not for general disinfection in schools without illness. 
 
Should hydrogen peroxide be used in addition to bleach? 
If there is a confirmed case of crypto in the school, instead of a bleach solution, use a 3% (99% kill rate) 
or, if available, 6% (99.9% kill rate) concentration of hydrogen peroxide for cleaning.  If for some reason 
schools are using both bleach and hydrogen peroxide, the surface to which the hydrogen peroxide was 
applied should be wiped and be completely dry before using bleach. Bleach, not hydrogen peroxide, 
should be used for general disinfection in schools without Crypto illness.      
 
When is it safe for schools to switch back to normal non-hydrogen peroxide 
cleaning? 
It is likely safe to switch back to normal routine cleaners and disinfectants one incubation period (12 
days) after resolution of diarrhea and vomiting in child care cases.  However, if there is a community-
wide outbreak of Crypto, it might be reasonable to continue to use hydrogen peroxide longer than the 12 
days.  
 
Where do we find 6% hydrogen peroxide? 
Any janitorial or cleaning supply warehouse that supplies hospitals will usually carry 6% hydrogen 
peroxide.  The 6% concentration may also be labeled “20 volume.” A 3% hydrogen peroxide solution 
may be referred to as a “10 volume” solution. 
 
Are students and/or staff required to have two negative stools before returning to 
school? 
IDPH does not require students or staff confirmed with Crypto to provide two negative stools before 
returning to school.  Both students and staff should remain out of schools until diarrhea and vomiting has 
stopped.   
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Purpose:  Information for child care settings when Crypto is present in their facility. 
 
What is Crypto?   
Crypto, or Cryptosporidiosis, is an illness that is caused by a parasite.  It affects both animals and 
humans.  People can get Crypto by coming in contact with other people or animals that have the 
parasite, swimming or playing in water with the parasite in it, or by drinking contaminated water. 
 
Who can get Crypto?   
Anyone.  Child care workers and diaper-aged children who attend child care centers are at increased risk 
for getting Crypto. 
 
How is Crypto spread?   
Crypto is found in the feces (stool) of an infected person or animal.  It is spread: 
• By putting something in your mouth or accidentally swallowing something that has come in 
contact with the stool of a person or animal infected with Crypto.  This could be items such as 
toys, hands, eating utensils, etc.  Items can be contaminated by a person who has not properly 
washed their hands after a diaper change or toileting. 
• By accidentally swallowing Crypto picked up from surfaces (such as toys, bathroom fixtures, 
changing tables, diaper pails) contaminated with stool from an infected person.  
• By swallowing recreational water contaminated with Crypto. Recreational water is water in 
swimming or wading pools, hot tubs, lakes, rivers, ponds, or streams that can be contaminated 
with sewage or feces from humans or animals. Note: Crypto is chlorine resistant and can live for 
days in pools. 
• By eating uncooked food contaminated with Crypto. Thoroughly wash with uncontaminated 
water all vegetables and fruits you plan to eat or serve raw. 
 
What are the symptoms of Crypto?   
The most common symptom of Crypto is frequent and watery diarrhea.  Other symptoms may include 
headache, nausea, vomiting and low-grade fever.  Symptoms may briefly improve and then get worse 
again, but people who are healthy usually get well in 14-30 days.  However, some people may not show 
symptoms of illness, but can still spread the disease to others. 
 
How can child care facilities prevent the spread of Crypto? 
• Frequent hand washing by both staff and children.  Wash hands with hot, soapy water before 
handling foods and eating, and after using the toilet, diapering young children, and handling 
animals 
• Separate diapering and food-handling areas and staff responsibilities 
• Disinfect diapering areas and toys* 
• Use disposable gloves with every diaper change and change the paper with every diaper change 
• Use disposable paper to cover diaper-changing areas 
• Separate diaper-changing areas from children’s play areas 
• Educate parents and staff about the illness and outbreak 
• Employees with diarrhea should not prepare food for anyone 
• Suspend the use of child wading pools, water tables, and other water-based activities 
• Children may come back to child care once they do not have diarrhea 
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*Disinfection of diaper changing areas and toys 
The Centers for Disease Control and Prevention (CDC) recommends the following procedure for child care 
centers with staff or children who have Crypto: 
To reduce the level of Crypto, clean and disinfect tabletops and highchairs after each use by a child.  Use 
a 3% hydrogen peroxide solution or if available, a 6% concentration of hydrogen peroxide, and let it sit 
on the surface for 20 minutes**.  No disinfectant is guaranteed to be completely effective; however the 
3% hydrogen peroxide is usually effective.  Toys should also be cleaned and disinfected with the 3% 
hydrogen peroxide solution for 20 minutes at least twice daily.  Cloth toys may be washed and heat-dried 
in the clothes dryer for 30 minutes. 
 
**This solution is for child care centers that have staff or children with Crypto.  This is not for general 
disinfection in child care centers without illness. 
 
Should hydrogen peroxide be used in addition to bleach? 
If there is a confirmed case of Crypto in the child care center, instead of a bleach solution, use a 3% 
(99% kill rate) or, if available, 6% (99.9% kill rate) concentration of hydrogen peroxide for cleaning.  If 
for some reason, child care centers are using both bleach and hydrogen peroxide, the surface to which 
the hydrogen peroxide was applied should be wiped and be completely dry before using bleach. A proper 
bleach solution, not hydrogen peroxide, should be used for general disinfection in child care centers 
without Crypto illness.      
 
When is it safe for child care centers to switch back to normal non-hydrogen 
peroxide cleaning? 
It is likely safe to switch back to normal routine cleaners and disinfectants one incubation period (12 
days) after resolution of diarrhea and vomiting in child care cases.  However, if there is a community-
wide outbreak of Crypto, it might be reasonable to continue to use hydrogen peroxide longer than the 12 
days.  
 
Where do we find 6% hydrogen peroxide? 
Any janitorial or cleaning supply warehouse that supplies hospitals will usually carry 6% hydrogen 
peroxide.  The 6% concentration may also be labeled “20 volume.” A 3% hydrogen peroxide solution 
may be referred to as a “10 volume” solution. 
 
 
Is it safe to use child wading pools, water tables, and other water-based activities 
when there is a case of Crypto? 
Child care centers should immediately suspend the use of child wading pools, water tables, and other 
water-based activities upon learning of a confirmed case of Crypto. All children with diarrhea should be 
excluded from water-based activities and should remain out of water-based activities for an additional 
two weeks after diarrhea stops regardless of whether or not they have been treated. In any situation, 
portable wading pools are strongly discouraged.  The American Academy of Pediatrics and the American 
Public Health Association state, “small portable wading pools do not permit adequate control of sanitation 
and safety, and they promote the transmission of infectious diseases”.      
 
Are children and/or staff required to have two negative stools before returning to 
child care centers? 
IDPH does not require children or staff confirmed with Crypto to provide two negative stools before 
returning to child care settings.  Both children and staff should remain out of child care settings until 
diarrhea and vomiting has stopped.   
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Cryptosporidiosis         Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Long-term care     
resident:  Yes      No      Unknown        Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Facility name:       
Parent/Guardian 
name: 
 
      
Facility phone: (     )-     -        Type:        
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis 
date: 
 
     /     /      Onset date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome: 
 Survived this illness     Died from this illness 
 Died unrelated to this illness    Unknown 
Date of death      /     /       First name: 
 
      
Event exception 
 Case could not be found 
 Case could not be interviewed 
 Case refused interview 
 Other – see notes  
Title:  ARNP    DO 
 MD 
 NP  PA 
Outbreak related:  Yes      No      Unknown  
Outbreak name:       Facility name:       
Exposure setting:       Address line 1:       
Epi-linked:  Yes  No  Unk  To whom______________  
Address line 2: 
 
      
Location acquired:  In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
Laboratory: 
 
      Accession #: 
 
      
Collection 
date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive    Negative   
 
Organism: 
 
Cryptosporidium Type (e.g. serotype): 
 parvum 
 hominis   
 
Laboratory: 
 
      Accession #: 
 
      
Collection 
date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive    Negative   
 
Organism: 
 
Cryptosporidium Type (e.g. serotype): 
 parvum 
 hominis   
 
Laboratory: 
 
      Accession #: 
 
      
Collection 
date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final       /     /      Result:  Positive    Negative   
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Result date: 
 
Organism: 
 
Cryptosporidium Type (e.g. serotype): 
 parvum 
 hominis   
 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’ 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Ext: Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties: 
Health care worker type: 
 Yes      No      Unknown 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Ext: Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties: 
Health care worker type: 
 Yes      No      Unknown 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /       
       Isolated at entry: 
 
 Yes    No    Unk 
Isolation type 
(entry): 
 
      
Days 
hospitalized:        Currently isolated: 
 
 Yes    No    Unk 
Current isolation 
type: 
 
      
 
CLINICAL INFO & DIAGNOSIS 
 
Is case immunosuppressed?    Yes    No     Unk 
Symptoms: 
 Diarrhea Onset date:      /     /      Duration:       hours/days 
 Fever Onset date:      /     /      Duration:       hours/days 
 Vomiting Onset date:      /     /      Duration:       hours/days 
 Abdominal cramps Onset date:      /     /      Duration:       hours/days 
 Other       Onset date:      /     /      Duration:       hours/days 
 Unexplained Weight loss Weight lost:       lbs/Kg   
 
TREATMENT 
 
Medications prescribed?   Yes    No    Unknown 
  
Medication:       
  
Medication:       
 
 
Medication:       
Date started:      /     /      
Date 
started:      /     /      Date started:      /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 
 mg      ml     IU 
 
Unit: 
 
 mg      ml     IU 
 
Unit: 
 
 mg      ml     IU 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
# of times a 
day:       Route:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Risk Factors/Travel Information – In the 12 days prior to onset of symptoms did the case: 
Traveled within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
Visit restaurants?  Yes    No    Unk If Yes, complete the table below:    
Establishment name Address/Zip Date visited Foods consumed Others ill? 
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
 
Attended Group Gatherings (e.g. weddings)?  Yes    No    Unk If Yes, complete the following table: 
Type of gathering Address/Zip Date visited Foods consumed Foods prepared Others ill? 
            
 
     /     /      
             Yes    
 No    Unk             
            
 
     /     /      
             Yes    
 No    Unk             
            
 
     /     /      
             Yes    
 No    Unk             
 
Dietary Information – In the 12 days prior to onset of symptoms did the case consume the following: 
Unpastuerized milk:  Yes    No    Unk 
From dates 
consumed: 
     /     /      To dates 
consumed: 
     /     /      
     /     /           /     /      
List all source/types:       List all brand names:       
Other unpastuerized 
milk products:  Yes    No    Unk 
From dates 
consumed: 
     /     /      To dates 
consumed: 
     /     /      
     /     /           /     /      
List all source/types:       List all brand names:       
Other unpastuerized 
products (i.e. juice):  Yes    No    Unk 
From dates 
consumed: 
     /     /      To dates 
consumed: 
     /     /      
     /     /           /     /      
List all source/types:       List all brand names:       
 
Animal Exposures – In the 12 days prior to the onset of symptoms did the case have the following exposures: 
Visit or live on a farm:  Yes    No    Unk Contact with manure: Contact with which animals on farm: 
 Yes            No  Unk 
 Cows  Sheep/goats  Pigs 
Visit any animal exhibits 
(petting zoo, county fair):  Yes    No    Unk Type of animals at exhibit:  Cows          Sheep/goats  Pigs 
Exhibit name:       Address/Zip/County:       
 
Water Exposures – In the 12 days prior to the onset of symptoms did the case: 
Go swimming or have contact with recreational types of water?  Yes    No    Unk If Yes, complete the table below: 
Type Location Type Date visited Facility name/ Street address & Zip 
 Hot tub/spa 
 Kiddie pool 
 River/stream 
 Lake 
 
 Pond  
 Water park 
 Swimming pool 
 Water fountain/ splash pad 
 Other_________________ 
 Hotel/motel 
 Indoor private 
 Indoor public   
 Outdoor private 
 Outdoor public 
     /     /      
 
 
 
 
 
 
 Hot tub/spa 
 Kiddie pool 
 River/stream 
 Lake 
 
 Pond  
 Water park 
 Swimming pool 
 Water fountain/ splash pad 
 Other_________________ 
 Hotel/motel 
 Indoor private 
 Indoor public   
 Outdoor private 
 Outdoor public 
     /     /      
 
 
 
 
 
 
 Hot tub/spa 
 Kiddie pool 
 Pond  
 Water park 
 Hotel/motel 
 Indoor private 
     /     /      
  
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation period for 
cryptosporidiosis is 1-
12 days. 
Cryptosporidiosis is 
communicable for several weeks 
after symptoms resolve.  
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 River/stream 
 Lake 
 
 Swimming pool 
 Water fountain/ splash pad 
 Other_________________ 
 Indoor public   
 Outdoor private 
 Outdoor public 
 
 
  
 
Drinking water supply 
Home:  Bottled 
 Commercial Delivery 
 Municipal 
 Rural water 
 Well 
 
School:  Bottled 
 Commercial Delivery 
 Municipal 
 Rural water 
 Well 
 
Work:  Bottled 
 Commercial Delivery 
 Municipal 
 Rural water 
 Well 
 
Child care:  Bottled 
 Commercial Delivery 
 Municipal 
 Rural water 
 Well 
 
 
Did patient use a water filter at home?  Yes       No       Unk  What type:      ______________ 
 
Other Exposures – In the 12 days prior to the onset of symptoms 
Wear diapers  Yes    No    Unk Have contact with diapers:  Yes    No    Unk 
    
Have contact with 
immunocompromised person:  Yes    No    Unk Setting: 
 Home 
 Work      Other 
     
Have sex with someone with 
similar symptoms:  Yes    No    Unk 
Sexual 
preference: 
 Hetero 
 Homo 
 Bisexual 
 Unknown 
 
Other risk factors 
Do you have a child in child care?  Yes    No    Unk List child care names:       
 
 
       
 
 
       
 
 
Number of people living in case’s household:          
 
Are there close contacts of the case with same symptoms:   Yes    No    Unknown 
 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case:                      List symptoms Symptom  onset date 
Same 
exposures 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
      
     /     /       Restaurant    
 Gatherings   
 Food 
 Animal 
 Water 
 Yes 
 No 
      
      
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case:                      List symptoms Symptom  onset date 
Same 
exposures 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
      
     /     /       Restaurant    
 Gatherings   
 Food 
 Animal 
 Water 
 Yes 
 No 
      
      
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case:                      List symptoms Symptom  onset date 
Same 
exposures 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
      
     /     /       Restaurant    
 Gatherings   
 Food 
 Animal 
 Water 
 Yes 
 No 
      
      
If this contact is a case create a new event and/or case for this contact. 
 
 
CONTACTS 
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 CYCLOSPORA  
  
Also known as:  Cyanobacterium-like, coccidia-like, and Cyclospora-like bodies (CLBs) 
Cyclospora infection = cyclosporiasis 
 
Responsibilities: 
Hospital: Report by IDSS, facsimile, mail or phone 
Lab: Report by IDSS, facsimile, mail or phone 
Physician: Report by facsimile, mail or phone 
Local Public Health Agency (LPHA):  Follow-up required.  Iowa Department of Public 
Health will lead the follow-up investigation. 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A.   Agent 
This disease is caused by Cyclospora cayetanensis, a single cell microscopic protozoan parasite. 
Humans with cyclosporiasis shed the parasite in a non-infectious form that takes from several days to 
a couple of weeks to mature into its infectious form. The time required for maturation to the 
infectious form depends on factors such as temperature and moisture. 
 
B.   Clinical Description 
This parasite infects the small intestine (bowel) and typically causes watery diarrhea, which can be 
severe. Other symptoms can include nausea, vomiting, abdominal cramping, gas and bloating, 
fatigue and loss of appetite, anorexia, weight loss, abdominal pain, myalgias, and low-grade fever. 
Occasionally, infected individuals may not have any symptoms. Untreated, symptoms may last from 
several days to several weeks (longer in immunocompromised individuals), and weight loss can be 
significant (exceeding 20 pounds in some cases).   
 
C.  Reservoirs 
Humans are the only known reservoir for Cyclospora cayetanensis, however animal reservoirs have 
been suspected.  Cyclospora has been found on a variety of fruits and vegetables including lettuce 
and raspberries. 
 
D.  Modes of Transmission 
Current knowledge of human cyclosporiasis suggests that it is not likely to be transmitted directly 
from person-to-person. After being shed in human stool, the parasite must undergo developmental 
changes (taking days to weeks) before becoming infectious. Humans become infected by consuming 
food or water that has been contaminated with human feces containing Cyclospora.   
 
E.   Incubation Period 
The incubation period is about 1 - 2 weeks, with an average of 1 week. 
 
F.   Period of Communicability or Infectious Period 
People may shed Cyclospora parasites for days to over one month (while actively ill). It is not known 
how long the parasite may be shed after symptoms have stopped. 
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G. Epidemiology 
Cyclosporiasis was first recognized in 1979. The parasite appears to be widely distributed throughout 
the world with a predominant number of cases occurring during the warmer months. Cyclospora may 
be transmitted by ingestion of water or food contaminated with oocysts. Outbreaks linked to 
contaminated water and fresh produce have been reported in recent years.  The largest documented 
outbreaks of cyclosporiasis in the United States occurred during the summers of 1996 and 1997; a 
majority of those cases had consumed imported raspberries.  
To date, the fresh produce items that have been implicated in U.S. outbreaks include fresh imported 
raspberries, basil, snow peas, and mesclun lettuce. Persons of all ages are at risk for infection. 
Persons living or traveling in developing countries may be at increased risk. 
H. Bioterrorism Potential 
 None.  
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To identify transmission sources of public health concern (e.g., contaminated food or water) and 
to stop transmission from such sources. 
• To provide education about how to reduce the risk of infection.   
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report. The preferred method of reporting is by utilizing the Iowa Disease Surveillance System 
(IDSS).  However, if IDSS is not available to your facility the reporting number for IDPH Center for 
Acute Disease Epidemiology (CADE) is (800) 362-2736; fax number (515) 281-5698, mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th Street 
Des Moines, IA 50319-0075 
 
Postage-paid disease reporting forms are available free of charge from the IDPH clearinghouse.   
Call (319) 398-5133 or visit the website 
healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295 to request a supply. 
 
Laboratory Testing Services Available 
The University of Iowa State Hygienic Laboratory (SHL) provides ova and parasite testing of stool 
specimens for Cyclospora.  Submit specimens in 10% formalin.  Specimen collection kits are available 
from the SHL.  Contact the SHL at (319) 335-4500 for further instructions. 
 
C. Local Public Health Agency Follow-Up Responsibilities 
Case Investigation 
a. Individual cases: IDPH will conduct followup.  
 
b. Multiple cases/possible outbreak 
If the number of reported cases of cyclosporiasis in a city/town is higher than usual, or if an  
outbreak is suspected, an investigation is warranted to determine the source of infection and 
mode of transmission. A common vehicle, such as water or food, should be sought and applicable 
preventive or control measures should be instituted (e.g., removing an implicated food item from 
the environment). Consult with an epidemiologist at IDPH or contact your regional epidemiologist 
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if an outbreak is suspected. CADE can help determine a course of action to prevent further cases 
and can perform surveillance for cases that may cross several town lines and therefore be 
difficult to identify at a local level. 
 
c. If a food or water source is suspect follow-up may include involvement of a representative of the 
Iowa Department of Inspections and Appeals, Food and Consumer Safety Bureau who are 
involved in enforcement of the Iowa Food Code. 
 
d. Institution of disease control measures is an integral part of case investigation. It is the LPHA 
responsibility to understand, and, if necessary, institute the control guidelines listed below in 
Section 3), Controlling Further Spread.    
 
3) CONTROLLING FURTHER SPREAD 
 
A.  Isolation and Quarantine Requirements    
Cyclosporiasis (Cyclospora infection) is not identified as a quarantinable disease under Iowa 
Administrative Code. The following guidelines are recommended. 
 
Minimum Period of Isolation of Patient 
Food handlers with confirmed Cyclospora infection should be excluded from work. After diarrhea has 
resolved, food handlers may only return to work after instruction on proper handwashing technique.  
 
Minimum Period of Isolation of Contacts 
Contacts with diarrhea who are food handlers shall be considered the same as a case and handled in 
the same fashion. No restrictions otherwise. 
 
Note: A food handler is any person directly handling or preparing food.  
 
B. Protection of Contacts of a Case 
None. 
 
Preventive Measures 
Personal Preventive Measures/Education 
To avoid infection with Cyclospora, recommend that individuals: 
• Avoid drinking un-boiled or untreated water when hiking, traveling in developing countries or 
wherever the water quality is unknown. Bringing water to a full, rolling boil is sufficient to kill 
Cyclospora.  
• Thoroughly wash all fresh fruits and vegetables prior to consumption, but this may not eliminate 
the risk entirely. 
 
4) ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for 
Cyclospora can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
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FACT SHEET CYCLOSPORA 
Information for Health Professionals 
 
What is Cyclospora? 
Cyclospora cayetanensis (Cyclospora) is a unicellular parasite formerly known as cyanobacterium-like, coccidia-
like, and Cyclospora-like bodies (CLBs).  Cases have been reported more frequency since the mid-1980s, in part 
because of the availability of better techniques for detection of the parasite in stool samples. 
 
How is Cyclospora transmitted? 
Cyclospora is transmitted by a person ingesting water or food that is contaminated with infected stool.  Outbreaks 
linked to contaminated water, and outbreaks linked to various types of fresh produce, have been reported in 
recent years. It is unknown whether animals can be infected or serve as sources of humans infection.   
 
Cyclospora is not infectious at the time it is excreted in the stool of an infected person.  In fact, the parasite does 
not become infectious until days to weeks after it is excreted (the time depends on factors such as temperature 
and humidity).  Indirect transmission occurs when the stool from an infected person contaminates something in 
the “environment” (e.g., water) to which someone else is exposed after the parasite has had time to become 
infectious. 
 
Who gets Cyclospora? 
Persons of all ages are at risk for infection.  Although persons living or traveling in developing countries may be at 
increased risk. Infections occur worldwide, including North America.  The risk may vary by season; some evidence 
suggests that infection is most common in spring and summer. 
 
What are the symptoms of Cyclospora? 
Cyclospora infects the small intestine and typically causes illness characterized by watery diarrhea, with 
sometimes explosive stools. Other symptoms can include loss of appetite, substantial loss of weight, bloating, 
increased flatus, stomach cramps, nausea, vomiting, muscle aches, low-grade fever, and fatigue. Some persons 
notice flu-like symptoms before they notice gastrointestinal symptoms.  Some infected persons are asymptomatic. 
 
How soon do symptoms appear? 
The incubation period is usually about 1 week.  If the illness is not treated the person may have a remitting-
relapsing course of variable duration, with a range of 9 - 43 days.  Persons with weakened immune systems may 
experience symptoms for a longer period of time if infected. 
 
How can cyclospora infection be treated?  
Cyclospora infection can be treated with 7-10 day course of oral trimethoprim-sulfamethoxazole (for adults 
160mg trimethoprim plus 800mg sulfamethoxazole twice daily; for children, 5mg/kg trimethoprim plus 25mg/kg 
sulfamethoxazole twice daily.   
 
How is the infection identified? 
Identification of this parasite in a stool requires special kinds of laboratory techniques that are not routinely used.  
Currently, the most practical diagnostic method consists of the identification of oocysts in stool specimens by 
light microscopy.  Other methods are also available or under investigation. Therefore requests should specify 
that you are looking for Cyclospora.  More than one stool sample may need to be checked to find the organism.   
 
Can infection with Cyclospora occur more than once? 
Yes.  Persons who have previously been infected with Cyclospora can become infected again. 
 
How can infection with Cyclospora be prevented? 
Avoiding water or food that may be contaminated with stool may help prevent infection.  Infected persons should 
wash their hands often to prevent the spread of infection.  Thoroughly wash fruits and vegetables before eating. 
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What is Cyclospora? 
Cyclospora is a parasite that is too small to be seen with the naked eye.  Its full name is Cyclospora 
cayetanensis. Cases of Cyclospora infection (cyclosporiasis) have been reported with increased frequency 
since the mid-1980s. In the last several years, outbreaks of cyclosporiasis have been reported in the 
United States and Canada. 
 
How is Cyclospora spread? 
Cyclospora is spread by swallowing water or food that was contaminated with infected stool. For 
example, outbreaks of cyclosporiasis have been linked to various types of fresh produce. We do not know 
how common the various ways of spread are.  It is unknown if animals can be infected and spread infection 
to humans.   
 
Cyclospora is not infectious at the time it is passed in bowel movements.  The parasite does not become 
infectious until days to weeks after it is excreted.  Because of this, direct person-to-person transmission is 
unlikely.  However, so-called indirect transmission might occur.  For example, Cyclospora might be spread if 
stool from an infected person contaminates something in the “environment” (for example, water) to which 
someone else is exposed after the parasite has had time to become infectious. 
 
Who gets Cyclospora? 
Persons of all ages are at risk for infection.  However people living in or traveling to developing countries 
may be at increased risk, infections also occur in the United States and Canada.  The risk may vary with the 
season.  Evidence suggests that infection is most common in spring and summer. 
 
What are the symptoms of Cyclospora? 
Cyclospora infects the small intestine (bowel). It typically causes watery diarrhea with frequent possibly 
explosive stools.  Other symptoms can include loss of appetite, weight loss, bloating, increased gas, 
stomach cramps, nausea, vomiting, tiredness, muscle aches, and low-grade fever.  Some persons infected 
with Cyclospora do not develop any symptoms. 
 
How soon do symptoms appear? 
The time between being infected and becoming sick is usually about 1 week. 
 
How long will symptoms last? 
If left untreated the illness usually lasts for a few days to a month or longer and symptoms may come back 
one or more times.  Persons with weakened immune systems may experience symptoms for a longer period 
of time if infected with Cyclospora. 
 
What should you do if you think you may be infected? 
If you think you may be infected with Cyclospora, you should see your healthcare provider.  Stool 
specimens will need to be tested to identify the parasite.  More than one stool sample may need to be 
checked to find the parasite.  
 
Can infection with Cyclospora occur more than once? 
Yes.  Persons who have been infected with Cyclospora once can become infected again. 
 
How can infection be prevented? 
Avoiding water or food that may be contaminated with stool may help prevent Cyclospora infection.  An 
infected person should wash their hands often to prevent the spread of infection and thoroughly wash fruits 
and vegetables before eating. 
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DIPHTHERIA 
 
 
Responsibilities: 
Hospital: Report immediately by phone 
Lab: Report immediately by phone 
Physician: Report immediately by phone 
Local Public Health Agency (LPHA): Follow-up required.  Iowa Department of Public 
Health will lead the follow-up investigation.  
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Diphtheria is caused by toxin-producing Corynebacterium diphtheriae, a gram-positive, irregularly-
staining bacterium. Not all Corynebacterium diphtheriae produce toxin. The four strains or biotypes of 
C. diphtheriae in order of their likelihood to produce toxin are gravis, mitis, intermedius, and belfanti. 
 
B. Clinical Description 
Symptoms:  Diphtheria has two forms—respiratory and cutaneous.  This chapter deals mainly with 
respiratory diphtheria.  Respiratory (nasal, pharyngeal, tonsillar, and laryngeal) diphtheria is typically 
caused by toxin-producing (toxigenic) strains of C. diphtheriae. In the respiratory form of the disease 
a membrane, usually visible on the throat or tonsils, is formed.  Respiratory diphtheria begins 2 - 5 
days after infection. Initial symptoms include a sore throat and low-grade fever. Swelling of the neck 
(“bull-neck”) can develop from inflammation, and is a sign of severe disease. Persons can die from 
asphyxiation if the membrane obstructs breathing. Remote effects of the diphtheria toxin can cause 
complications including myocarditis (inflammation of the heart muscle) and nerve paralysis. The 
respiratory form of diphtheria usually lasts several days, but complications can persist for months. 
 
Membranous pharyngitis from nontoxigenic C. diphtheriae is also reportable, although disease is 
usually mild and does not cause systemic complications. The isolation of C. diphtheriae from the 
throat does not necessarily indicate a pathogenic role. Although the frequency with which this occurs 
is unknown, a small percentage of the population may carry nontoxigenic or toxigenic strains of C. 
diphtheriae without disease symptoms. Rarely, other Corynebacterium species (C. ulcerans or 
pseudotuberculosis) may produce diphtheria toxin and lead to classic respiratory diphtheria. Note: 
Other pathogens can cause a membrane of the throat and tonsils, including Streptococcus species, 
Epstein-Barr virus and cytomegalovirus, Candida, and anaerobic organisms (Vincent’s angina). 
 
Onset:  The onset is indistinguishable from the common cold, usually characterized by a 
mucopurulent nasal discharge (containing both mucus and pus), which may become blood-tinged.  A 
white to grayish membrane usually forms on the nasal septum and throat in respiratory disease.   
 
Complications:  The severity of the disease and complications are generally related to the extent of 
local disease.   When absorbed, the toxin affects organs and tissues distant from the site of invasion.  
The most frequent complications of diphtheria are myocarditis and neuritis.   
 
Myocarditis may present as abnormal cardiac rhythms, and can occur early in the course of the illness 
or weeks later, and lead to heart failure.  If myocarditis occurs early, it is often fatal.   
Neuritis most often affects motor nerves and usually resolves completely.  Paralysis of the soft palate 
is most frequently seen during the third week of illness.  Eye muscles, limbs, and diaphragm paralysis 
Report Immediately 
by phone 
Iowa Dept. of Public Health Reviewed 12/13  Diphtheria 1 
Guide to Surveillance, Investigation, and Reporting 
can occur after the first week.  Secondary pneumonia and respiratory failure may result from 
diaphragmatic paralysis.   
 
Other complications include otitis media, and respiratory insufficiency due to airway obstruction, 
especially in infants.   
 
The overall case-fatality rate for respiratory diphtheria is 5% - 10%, with higher death rates (up to 
20%) in persons <5 and >40 years of age.  The case-fatality rate for diphtheria has changed very 
little during the last 50 years, and is higher for those who have never received vaccine than for those 
who have been fully immunized. 
 
C. Reservoirs 
Humans are the only known reservoir of C. diphtheria, which is present in discharges from the nose, 
throat, and eye and skin lesions for 2 - 6 weeks after infection.   
 
D. Modes of Transmission 
Diphtheria is transmitted person-to-person by droplet or direct contact with an infected person’s 
nasopharyngeal secretions. Contact with articles soiled with discharges from cutaneous lesions can be 
a source, but this has rarely been documented. Raw milk contaminated with Corynebacterium 
diphtheriae has served as a vehicle for transmission. 
 
E. Incubation period 
The incubation period is usually 2 - 5 days but may occasionally be longer. 
 
F. Period of Communicability or Infectious Period 
The infectious period is variable, typically lasting 2 weeks or less.  Antibiotic treatment promptly 
terminates shedding, usually in less than 4 days; but chronic carriage may occur, even after 
antimicrobial therapy. Patients are considered infectious until two successive pairs of nose and throat 
cultures obtained not <24 hours after completion of antimicrobial therapy and > 24 hours apart are 
negative. (See Section 3) B. 2. d [page 5] for more details.) Asymptomatic carriers are important in 
sustaining transmission.  If cultures remain positive, contact IDPH, CADE at (800) 362-2736 for 
further guidance. 
 
G. Epidemiology 
Infection can occur in immunized, partially immunized and unimmunized persons, but it is usually less 
severe in those who are partially or fully immunized. Diphtheria is endemic in many parts of the 
world, including countries of the Caribbean and Latin America. The incidence of respiratory diphtheria 
is greatest in the fall and winter. During the last few years, large epidemics of respiratory diphtheria, 
primarily in adolescents and adults, have occurred in the former Soviet Union, Algeria, and Ecuador. 
In the states of the former Soviet Union (including Russia, the Ukraine and Central Asian Republics), 
more than 150,000 cases and 5,000 deaths from diphtheria occurred between 1990 and 1997. In 
recent epidemics in the former Soviet Union, the case fatality rate has ranged from 3% to 23%.  
 
While most cases of diphtheria reported recently in the United States were imported, enhanced 
surveillance in a previously endemic Northern Plains Indian community has revealed ongoing 
circulation of a toxigenic strain of C. diphtheriae first identified in that region in the 1970s. The last 
reported case in Iowa occurred in 1967.  It is estimated that more than 40% of US adults lack 
protective levels of circulating antitoxin. 
 
H. Bioterrorism Potential 
None. 
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2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To identify and evaluate contacts and provide necessary antimicrobial prophylaxis to prevent further 
spread of the disease 
• To alert public health authorities to the presence of cases of C. diphtheriae and the potential for 
increased cases development in the area, particularly given the large number of susceptible adults. 
• To assure early and appropriate treatment with diphtheria antitoxin and antibiotics. 
• To obtain necessary laboratory specimens before antibiotic or antitoxin treatment. 
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3 stipulates that the laboratory and the healthcare provider must 
report any suspected or confirmed cases of diphtheria immediately by phone. The reporting number 
for IDPH Center for Acute Disease Epidemiology (CADE) is (800) 362-2736, if calling after business 
hours, call the Iowa State Patrol Office at (515) 323-4360. They will page a member of the on-call 
CADE staff. 
 
Laboratory Testing Services Available 
After communicating with IDPH, contact the University of Iowa State Hygienic Laboratory (SHL) 
bacteriology department at (319) 335-4500 for further instructions. 
 
C.  Local Public Health Agency Follow-up Responsibilities 
Case Investigation 
Diphtheria follow-up and case investigation is undertaken by the Local Public Health Agency (LPHA), 
and will be coordinated, if necessary, with the IDPH Bureau of Immunization and Center for Acute 
Disease Epidemiology (CADE).    
 
A healthcare provider and a public, private, or hospital clinical laboratory will assist in a disease 
investigation conducted by the department, or local health department.  A healthcare provider and a 
public, private, or hospital clinical laboratory will provide the department or local health department 
with all information necessary to conduct the investigation, including but not limited to medical 
records, exposure histories, medical histories, contact information, and positive, pending, and 
negative test results necessary to the investigation.    
 
Initial Questions to Ask Healthcare Providers and Patients 
To assess the likelihood that a suspect case is a true case prior to laboratory testing, LPHA or other 
public health staff should ask about: 1) symptoms, 2) diphtheria immunization history, 3) recent 
travel history (where and dates), 4) recent out-of-town visitors (from where and dates), and 5) 
recent contact with anyone with similar symptoms. 
 
3) CONTROLLING FURTHER SPREAD 
A. Isolation and Quarantine Requirements 
 
Minimum Period of Isolation of Patient 
Maintain Droplet Precautions for respiratory diphtheria in healthcare facility or home until two 
successive pairs of nose and throat cultures obtained not <24 hours after completion of antimicrobial 
therapy and > 24 hours apart are negative. If cultures remain positive contact IDPH, CADE at (800) 
362-2736 for further guidance. If there was no antimicrobial therapy, the two sequential pairs of 
cultures should be taken after symptoms resolve, and > 2 weeks after onset.  If cultures remain 
positive, contact IDPH, CADE at (800) 362-2736 for further guidance. 
 
If an avirulent (nontoxigenic) strain is documented, isolation is not necessary.  
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Minimum Period of Quarantine of Contacts 
Contacts whose occupations involve handling food or working with unimmunized children must be 
excluded from work until two successive pairs of nose and throat cultures, obtained not <24 hours 
after completion of antimicrobial therapy and > 24 hours apart, are negative. If cultures remain 
positive, contact IDPH, CADE at (800) 362-2736 for further guidance. These requirements may be 
extended to other contacts who work in high-risk settings, as determined by IDPH. 
 
B.  Protection of Contacts of a Case 
Close contacts are defined as those who sleep in the same house or who share food, drink, or 
eating/drinking utensils with the case, or otherwise share saliva with case such as child care contacts, 
and healthcare workers in contact with the case’s oral or respiratory secretions. Those contacts that 
were in brief contact with the case, but do not meet the definition of a close contact, are not 
considered significant contacts.   
 
Below, management of cases and contacts is divided into four categories: 1) cases, 2) cases and 
symptomatic close contacts, 3) asymptomatic close contacts, and 4) nonsignificant contacts. It is 
important to follow the sequence of actions, as administration of antibiotics, diphtheria antitoxin 
(DAT), and diphtheria toxoids will interfere with interpretation of diagnostic testing. Attachment C (at 
the end of this chapter) presents these recommendations in diagram form. 
 
1. Case(s)  
Place cases of respiratory diphtheria in Droplet Precautions until two cultures from both the nose 
and the throat are negative for toxigenic C. diphtheriae. Material for these cultures should be 
obtained not <24 hours after completion of antimicrobial therapy and > 24 hours apart. If 
cultures remain positive, contact IDPH, CADE at (800) 362-2736 for further guidance.  If there 
was no antimicrobial therapy, the cultures should be taken after symptoms resolve, > 2 weeks 
after their onset, and > 24 hours apart. Continue as described in Section 2 immediately below. 
 
2. Cases and Symptomatic Close Contacts 
a. Do not delay treatment to collect specimens. 
b. Collect cultures as described in Attachment A (located at the end of this chapter). If 
antibiotics have been started, it is useful to collect specimens for PCR and serology, which 
are described in Attachment B (at the end of this chapter). If possible, serology specimens 
should be collected before administration of diphtheria antitoxin (DAT) or diphtheria toxoid.   
c. Treat with appropriate antibiotic, and evaluate cases and symptomatic close contacts for 
initiation of therapy with DAT. DAT can be obtained from CDC through an Investigational 
New Drug (IND) protocol. Healthcare providers treating a case of suspected diphtheria can 
contact IDPH, CADE at (800) 362-2736 for assistance in obtaining DAT.  Serology specimens 
should be collected before administration of DAT. 
d. If cases or symptomatic close contacts are culture-positive, they will need two repeat pairs of 
nose and throat cultures obtained not <24 hours after completion of antimicrobial therapy 
and > 24 hours apart. If cultures remain positive, contact IDPH, CADE at (800) 362-2736 for 
further guidance. If a case or symptomatic close contact has not received antibiotics, two 
successive pairs of nose and throat cultures taken after symptoms resolve, > 2 weeks after 
the onset of symptoms, and > 24 hours apart are needed. If cultures remain positive, 
contact IDPH, CADE at (800) 362-2736 for further guidance. 
e. Cases and symptomatic close contacts that are not up to date should be immunized with a 
diphtheria toxoid-containing preparation appropriate for age during convalescence. (Refer to 
Section 3) D for recommendations on completing the schedule).  Remember, serum should 
be collected before vaccinating.   
f. Close contacts should be monitored for symptoms daily for at least 7 days after the last 
exposure. Active surveillance for suspect cases in affected settings should take place for at 
least two incubation periods (10 days). 
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3. Asymptomatic Close Contacts 
a. Where diphtheria is confirmed or highly suspected in the case, asymptomatic close contacts 
should be excluded from work if work involves food or unimmunized children. 
b. Where diphtheria is confirmed or highly suspected in the case, all asymptomatic close 
contacts should have cultures collected as described in Attachment A (at the end of this 
chapter). 
c. Assess and monitor for signs and symptoms of diphtheria for at least 7 days. 
d. Assess diphtheria toxoid vaccination status and vaccinate as outlined below: 
• If < 3 doses or unknown administer a dose of diphtheria toxoid (DTaP, DT, or Td as 
appropriate) and complete primary series according to schedule. 
• If > 3 doses and last dose were >5 years ago, administer a booster dose of diphtheria 
toxoid. 
• If > 3 doses and last dose was < 5 years ago, children needing their fourth primary dose 
or booster dose should be vaccinated; otherwise vaccination is not required. 
 
All close contacts (regardless of culture result or immunization status) should begin antibiotic 
prophylaxis with oral erythromycin (40-50 mg/kg/day for 7 days, maximum 2 g/day, for children; 
and 1/g/day for adults.  A single IM dose of benzathine penicillin G (600,000 U for persons < 6 
years of age and 1,200,000 U for persons > 6 years of age) is an alternative. (The lower dose of 
penicillin is for patients weighing less than 30 kg.) 
 
e. All asymptomatic close contacts who were initially culture-positive will need two repeat pairs 
of nose and throat cultures taken not < 24 hours after antibiotics have been discontinued 
and > 24 hours apart. If an asymptomatic contact has not received antibiotics, two 
successive pairs of nose and throat cultures taken > 24 hours apart are needed. If any of the 
repeat cultures is positive, an additional 10-day course of oral erythromycin should be given 
and the cultures repeated as described above. 
f. Close contacts should be monitored for symptoms daily for at least 7 days after their last 
exposure. Active surveillance for suspect cases in affected settings should be conducted for 
at least two incubation periods (10 days). 
 
4. Non-Significant Contacts 
Contacts who do not sleep in the same house as the case; do not share food, drink, or 
eating/drinking utensils with the case; and are not healthcare workers in contact with the case’s 
oral or respiratory secretions should be immunized with the appropriate diphtheria toxoid-
containing preparation as described in Section 3) D above. They do not need to be cultured or 
placed on antibiotic prophylaxis. 
 
C.  Managing Special Situations 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
Immunize the largest possible proportion of the population group involved, emphasizing protection of 
infants and preschool children.  In an epidemic involving adults, immunize groups that are most 
affected and at highest risk.  Repeat immunization procedures one month later to provide a second 
dose.   
  
D. Preventive Measures 
Vaccination, including routine childhood vaccination and Td boosters beginning at age 11−12 years 
and continuing every 10 years thereafter, is the best preventive measure against diphtheria. Tetanus 
toxoid-containing formulations should always be used. The Advisory Committee on Immunization 
Practices (ACIP) recommends that all children receive a routine series of five doses of tetanus and 
diphtheria vaccine at ages 2, 4, 6, 15−18 months, and 4−6 years. Booster doses of diphtheria and 
tetanus toxoids should be administered beginning at age 11−12 years (provided at least 5 years have 
passed since the last dose) and every 10 years thereafter. DTaP should be used in persons < 7 years 
of age, whereas Td is the preferred preparation for persons > 7 years of age.  
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The Td schedule for those beginning immunization at ≥ 7 years of age consists of 3 doses. The 
second dose is usually given 1−2 months after the 1st dose and the 3rd dose 6 months after the 2nd 
dose. 
 
Due to the presence of diphtheria worldwide, it is important for all international travelers to be up to 
date with DTaP/DT/Td vaccination. Good personal hygiene (which consists of proper handwashing, 
disposal of used tissues, not sharing eating utensils) and avoiding sick people is important in 
prevention.   
 
4) ADDITIONAL INFORMATION 
 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Diphtheria 
can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
 
 
Note on Cutaneous diphtheria  
Cutaneous diphtheria, caused by either toxigenic or nontoxigenic strains, is usually mild, typically 
consisting of nondistinctive sore or shallow ulcers, and only rarely involving toxic complications (1-
2% of infections with toxigenic strains). Cutaneous diphtheria was removed from the nationally 
reportable disease list in 1980, but it remains reportable in Iowa.   
 
Place the cutaneous case in contact precautions until two cultures of skin lesions are negative. 
Material for all these cultures should be taken not <24 hours after cessation of antimicrobial therapy 
and > 24 hours apart. If cultures remain positive, contact IDPH, CADE at (800) 362-2736 for further 
guidance. If there was no antimicrobial therapy, the cultures should be taken after symptoms 
resolve, > 2 weeks after their onset, and > 24 hours apart.  
 
Work restrictions are the same as for respiratory diphtheria. 
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Additional Resources 
Manual for the Surveillance of VPDs", Chapter 1: Diphtheria.  Available at the following website:  
www.cdc.gov/vaccines/pubs/surv-manual/default.htm  
 
ATTACHMENTS: 
Attachment A:  Collection of Specimens for Isolation of C. diphtheriae (1 page) 
 
Attachment B:  Overview of Requirements for Laboratory Testing for Diphtheria (1 page) 
 
Attachment C:  Algorithm for Diagnosis, Treatment, and Follow-Up of Suspect Diphtheria Cases and 
Infected Contacts 
 (1 page)  
 
Attachment D:  Important Telephone Contacts for Diphtheria Control (1 page) 
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COLLECTION OF SPECIMENS FOR ISOLATION OF C. diphtheriae 
Clinical specimens for culture should be obtained as soon as possible when diphtheria of any 
type is suspected, even if treatment with antibiotics has already begun.  Unless the index of 
suspicion is low, specimens should be collected from the nose and throat of all close contacts of 
suspected cases. (Culture of C. diphtheriae from close contacts may confirm the diagnosis of 
the case, even if the patient’s culture is negative.)  Use a dry, sterile swab. 
 
Throat swabs 
 
1. Pharynx should be clearly visible and well illuminated. 
 
2. Depress tongue with an applicator and, Using a dry, sterile swab, swab the throat 
without touching the tongue or inside of the cheek. 
 
3. Rub vigorously over any membrane, white spots, or inflamed areas; slight pressure 
with a rotating movement must be applied to the swab. 
 
4. If membrane is present, lift the edge and swab beneath it to reach the organisms 
deeper in the throat.  A portion of the membrane may also be submitted for testing. 
 
Nasopharyngeal specimens 
 
1. Insert the swab into the nose through one nostril beyond the anterior nares. 
 
2. Gently introduce the swab along the floor of the nasal cavity, under the middle 
turbinate, until the pharyngeal wall is reached.  Force must not be used to overcome 
any obstruction. 
 
Skin diphtheria and other lesions 
 
1. Lesions should be cleansed with sterile normal saline and crusted material removed. 
 
2. Press the swab firmly into the lesion. 
 
 
• Place swabs in a transport system.  If transport time is anticipated to be < 
24 hours, Amies or Modified Stuart’s medium is recommended.  If 
transport time is to be > 24 hours, silica gel is recommended.  Send 
specimen overnight, with the attached submission form, to the State 
Hygienic Laboratory (SHL).   
• Call the SHL Bacteriology Reference Laboratory at (319) 335-4500 to 
notify them that specimens for diphtheria culture are on the way, since 
isolation of C. diphtheriae requires special tellurite media.  
• If C. diphtheriae is isolated, regardless of association with disease, SHL 
staff will arrange for shipment of isolates to the Diphtheria Laboratory, 
National Center for Infectious Diseases, CDC, as directed by CDC. 
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Attachment B 
 
 
A. Overview of Requirements for Laboratory Testing for Diphtheria 
Test 
name 
Specimens to 
take 
Timing for 
specimen 
collection 
Transport 
requirements 
Collection & 
notification 
requirements 
Notes 
 
Culture • Swabs of 
nose, throat, 
and 
membrane 
(or other 
infected body 
site) of case 
• Swabs of 
nose and 
throat of 
close 
contacts 
As soon as 
possible, when 
diphtheria is 
suspected 
< 24 hours: Amies or 
modified Stuart’s 
medium 
 
>24 hours: silica gel 
sachets 
Physicians or labs call 
UHL Bacteriology Lab  
(319) 335-4500 and 
IDPH Disease Reporting 
Hotline  (800) 362-2736  
regarding suspect case. 
IDPH may call CDC 
diphtheria lab at (404) 
639-1730 or  
(404) 639-4057  
Available at SHL and elsewhere.  
Alert lab that diphtheria is 
suspected to ensure that tellurite 
medium is used.  After isolation, 
biotype (strain) and toxigenicity 
can be determined. 
PCR Swabs (as 
above), or pieces 
of membrane or 
biopsy tissue of 
case 
As soon as 
possible, when 
diphtheria is 
suspected 
Silica gel sachet, or a 
sterile dry container 
at 40 C 
Contact as above Available only at CDC. Alert lab 
that diphtheria is suspected so 
that specific PCR assay is used. 
Can detect non-viable organisms 
and toxin gene. Provides 
supportive evidence for, but not 
confirmation of, diagnosis. 
Toxigenicit
y testing 
(Elek test) 
Isolate from 
culture of case 
(above) 
After C. 
diphtheriae has 
been isolated 
Transport medium 
such as Amies 
medium or silica gel 
sachets 
Contact as above Available at SHL, CDC, and 
elsewhere. 
Serology 
(antibodies 
to 
diphtheria 
toxin) 
Serum of case If possible 
before 
administration of 
antitoxin or 
vaccine, collect 
first of paired 
sera,  taken 2-3 
weeks apart 
Frozen (-20 0 C)  Available only at CDC.  If acute 
antibody levels are low, diphtheria 
can’t be ruled out; if acute levels 
are high, diphtheria is unlikely to 
be cause of illness. 
 
Adapted from Manual for the Surveillance of Vaccine-Preventable Diseases, CDC, September 1999, Chapter 19, Table 3. 
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Attachment C 
Algorithm for Diagnosis, Treatment 
and Follow-up  
Suspected Diphtheria Cases and Infected Contacts 
 
 
 
  Suspected or Proven Diphtheria 
 Institute strict isolation 1 
 Notify lab and obtain nasal & pharyngeal cultures for C. diptheriae 2 
 Obtain serum for antibodies to diphtheria toxin 3  
 Consider treatment with diphtheria antitoxin  
 Begin antimicrobial therapy 4 
 Provide active immunization with tetanus diphtheria (Td) toxoid                                                             
during convalescence 5 
 Take two repeat pairs of nasal and pharyngeal cultures (> 24 hours apart) 
at > 2 weeks after completion of antibiotic therapy. If antibiotics are not 
taken, cultures should be done after symptoms resolve and > 2 weeks after 
the onset. 6 
Notify Health Dept. 
Identify 
Close Contacts 7 
None Stop 
Assess and monitor 
for signs/symptoms 
of diphtheria for at 
least 7 days 
Obtain cultures 
for C. diphtheria 2 
Administer 
antimicrobial 
prophylaxis 8 
 
Assess diphtheria toxoid 
vaccination status 
Positive Negative < 3 doses 
or unknown 
> 3 doses, 
last dose 
> 5 years 
ago 
> 3 doses, 
last dose 
< 5 years 
ago 
Stop 
– Place in isolation  
– Identify close contacts and proceed with preventative measures 
        described for close contact of a case 9 
– Take two repeat pairs of nasal and pharyngeal cultures (> 24 hours 
        apart) at > 2 weeks after completion of antibiotic therapy 6 
Administer immediate 
dose of Td toxoid and 
complete primary 
series according to 
schedule 10 
Administer 
immediate 
booster 
dose  
of 
diphtheria 
toxoid 
Children in need of 
their 4th primary dose 
or booster dose should 
be vaccinated; 10 
otherwise vaccination 
not required 
1 Maintain isolation until elimination of the organism is demonstrated by negative cultures of two samples obtained at least 24 hours apart and taken > 2 weeks after completion of 
antimicrobial therapy.  If antibiotic therapy is not taken, cultures should be done after symptoms resolve and it is > 2 weeks since their onset. 
2 Both nasal and pharyngeal swabs should be obtained for culture. 
3 If equine diphtheria antitoxin is needed, contact your State Health Department. Before administration, patients should be tested for sensitivity to horse serum and, if necessary, desensitized. The recommended dosage and 
route of administration depend on the extent and duration of disease. Detailed recommendations  
can be obtained from the package insert and other publications. 
4 Antimicrobial therapy is not a substitute for antitoxin treatment. Antimicrobials: 1) Intramuscular procaine penicillin G (25,000 - 50,000 units/kg/day for children and 1.2 million units/day for adults, in two divided doses), 
or 2) aqueous crystalline penicillin G intramuscularly (100,000 to 150,000 units/kg/day, in four divided doses), or 3) parenteral erythromycin (40-50 mg/kg/day, maximum 2 g/day) have been recommended until the patient 
can swallow comfortably, at which point oral erythromycin in four divided doses or oral penicillin V (125-250 mg four times per day) may be substituted for a recommended total treatment period of 14 days. 
5 Vaccination with Td toxoid is required because clinical diphtheria does not necessarily confer immunity. 
6 Persons who continue to harbor the organism after treatment with either penicillin or erythromycin should receive an additional 10-day course of oral erythromycin and should submit samples for follow-up cultures. 
7 Close contacts include household members and other persons with a history of direct contact with a case-patient (e.g. caretakers, relatives, or friends who regularly visit the home) as well as medical staff exposed to oral or 
respiratory secretions of a case-patient. 
8 A single dose of intramuscular benzathine penicillin G (600,000 units for persons < 6 years of age and 1.2 million units for persons > 6 years of age) or a  
7- to10-day course of oral erythromycin (40 mg/[kg/d] for children and 1g/d for adults) has been recommended. 
9 Preventive measures may be extended to close contacts of carriers but should be considered a lower priority than control measure for contacts of each case. 
10 Refer to published recommendations for the schedule for routine administration of DTaP. 
 
Adapted from: Farizo KM, Strebel PM, Chen RT, et al. Fatal respiratory disease due to Corynebacterium diphtheriae: Case report and review of guidelines for management, investigation, and control. Clin Infect Dis 1993: 
16:59-68. As reproduced in : Centers for Disease Control and Prevention. Manual for the Surveillance of Vaccine-Preventable Diseases 1996; 2-9. 
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Diphtheria Control 
Important Telephone Contacts 
 
State Hygienic Laboratory:     (319) 335-4500 
102 Oakdale Campus 
Iowa City, Iowa 52242-5002  
 
 
Center for Acute Disease Epidemiology   (800) 362-2736 
(Epidemiologist-on-call: 24 hours/7 days a week 
  
Disease Reporting Hotline      (800) 362-2736 
  
        
  
The information below is for reference only, contact IDPH to 
access CDC. 
 
Centers for Disease Control and Prevention:  
Child Vaccine-Preventable Disease Branch 
Epidemiology and Surveillance Division 
National Immunization Program  
 
Dr. Tanja Popovic        (404) 639-1730 
Building 5; Room 346 (Diphtheria Laboratory)  (404) 639-4057 (lab) 
 
CDC 
1600 Clifton Road, Mailstop C02 
Atlanta, GA 30333 
 
Diphtheria duty officer       (404) 639-8255 
(Officer available: Monday through Friday, 8:00 am to 4:30 pm) 
 
Diphtheria duty officer       (404) 639-2889 
(Officer available: nights, weekends, holidays) 
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FACT SHEET DIPHTHERIA 
Information for Health Professionals  (Cutaneous)        
 
What is cutaneous (skin) diphtheria? 
The bacterium Corynebacterium diphtheriae causes cutaneous diphtheria.   
 
Who gets cutaneous diphtheria? 
This form of diphtheria is more common in temperate climates.  In the United States, cutaneous 
diphtheria most often infects unvaccinated and indigent people, and is secondary to skin trauma 
or infections.    
 
How is cutaneous diphtheria spread? 
Diphtheria spreads person-to-person by indirect or direct contact with infected skin lesions. 
Transmission in crowded and unsanitary living conditions has also been documented.   
 
What are the symptoms? 
Cutaneous diphtheria is characterized by a non-healing, gray ulcer with a demarcated membrane 
on the skin. Because cutaneous diphtheria is often indistinguishable from other skin diseases, 
prompt laboratory confirmation of diagnosis is essential.  
 
How long can an infected person spread the bacteria? 
The infectious period usually lasts less than 2 weeks without treatment.  If persons are treated 
with antibiotics, communicability lasts fewer than 4 days, but chronic carriage can occur for up to 
6 months in rare instances.  The infection is no longer communicable when two cultures of the 
skin lesions taken 24 hours apart, not less than 24 hours after completing antimicrobial therapy 
are negative. 
 
Can a patient get diphtheria again?  
Yes.  Ensure that the patient’s diphtheria vaccinations are current per established guidelines.  
 
Do the patient’s close contacts need diphtheria prophylaxis?   
If laboratory results show that the infectious strain of diphtheria produces toxin, administer 
prophylactic treatment to the patient’s close contacts, and monitor their health status.  If the strain 
does not produce toxin, close contact follow-up is unnecessary.   
 
Who is a close contact needing prophylactic treatment? 
All who share living space, food, drink, eating utensils, and/or saliva (kissing), with the patient, 
including child care contacts need prophylactic treatment.  Healthcare workers with patient contact 
are at risk. Those not meeting these criteria do not need prophylactic treatment. 
 
What management is appropriate for household contacts? 
All close contacts should have cultures taken from the nose and throat, and should be kept under 
surveillance for 7 days. A single dose of benzathine penicillin G (IM)(600,000 units for persons 
less than 6 years of age and 1.2 million units for persons 6 years of age or older), or a 7-10 day 
course of erythromycin (PO) (40mg/kg/d for children and 1g/d for adults), is recommended. 
 
What isolation procedures are appropriate in the healthcare setting? 
Contact Precautions are appropriate for cutaneous diphtheria.  In other words, cover the infected 
skin.  
 
Is there a vaccine to prevent cutaneous diphtheria?  
Yes, see the respiratory diphtheria fact sheet for more detailed information. 
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FACT SHEET                                                                           DIPHTHERIA  
Information for Health Professionals               (Respiratory) 
 
What is diphtheria? 
Diphtheria is an acute, toxin-mediated disease caused by Corynebacterium diphtheriae, which usually 
presents in two forms: respiratory and cutaneous.    
 
Who gets respiratory diphtheria? 
Diphtheria is a rare disease in the United States, primarily because children are usually 
vaccinated, and because of the apparently low circulation of toxigenic strains of Corynebacterium 
diphtheriae.  Most cases occur among unvaccinated or inadequately-vaccinated persons.  The 
age distribution of recent cases and results of serosurveys indicate that many adults in the United 
States are not protected against diphtheria.   
 
How is respiratory diphtheria spread? 
Diphtheria is transmitted person-to-person by droplet or direct contact with nasopharyngeal secretions 
of an infected person.  Contact with articles soiled with discharges from cutaneous lesions of infected 
people can be a source, but this has rarely been documented.  Raw milk has served as a vehicle for 
transmission. 
 
What are the symptoms of respiratory diphtheria? 
Initial symptoms of illness include a sore throat and low-grade fever; Persons may die from 
asphyxiation when the membrane obstructs breathing. Swelling of the neck (“bull neck”) from 
inflammation can develop and is a sign of severe disease. Remote effects of the diphtheria toxin 
may cause other complications, including myocarditis (inflammation of the heart), and nerve 
paralysis. The respiratory form of diphtheria usually lasts several days; complications can persist 
for months. 
 
How soon do the symptoms appear? 
Respiratory diphtheria begins 2 - 5 days after infection. 
 
How long can an infected person spread the virus? 
The infectious period typically lasts 2 - 4 weeks after infection. If patients are treated with 
antibiotics, communicability usually lasts less than 4 days, but chronic carriage may occur, even 
after antimicrobial therapy. Patients are considered infectious until 2 successive pairs of nose and 
throat cultures (and cultures of skin lesions in cutaneous diphtheria), obtained not <24 hours 
after completion of antimicrobial therapy and taken at least 24 hours apart, are negative. 
Asymptomatic carriers are important in sustaining transmission.  If cultures remain positive, 
contact IDPH, CADE at (800) 362-2736 for further guidance. 
  
How are susceptible staff members impacted after significant exposure to diphtheria? 
If the exposure was significant, the exposed susceptible staff member should not provide direct 
patient care.  The person may be reassigned to work with others that are immune, or be relieved 
from duty until antimicrobial therapy is completed and 2 nasopharyngeal cultures, obtained at least 
24 hours apart taken not <24 hours after completion of antimicrobial therapy, are negative.  If 
cultures remain positive, contact IDPH, CADE at (800) 362-2736 for further guidance. 
 
What are the criteria for significant exposure to diphtheria? 
Close contacts are defined as those who sleep in the same house, share food, drink, or 
eating/drinking utensils with the case, child care contacts, and healthcare workers in contact with the 
case’s oral or respiratory secretions. Persons who had brief contact with the case, but do not meet 
the definition of a close contact, are not considered significant contacts.   
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What are diphtheria isolation guidelines? 
Maintain isolation until two successive pairs of nose and throat cultures (and cultures of skin 
lesions in cutaneous diphtheria), obtained not <24 hours after completion of antimicrobial 
therapy and > 24 hours apart, are negative. If cultures remain positive, contact IDPH, CADE at 
(800) 362-2736 for further guidance. 
If there was no antimicrobial therapy, these two sequential pairs of cultures should be taken after 
symptoms resolve, and > 2 weeks after their onset. If cultures remain positive, contact IDPH, CADE 
at (800)362-2736. If an avirulent (nontoxigenic) strain is documented, isolation is not necessary.  
 
Can a person get diphtheria again? 
Lifelong immunity is usually, but not always, acquired after disease or inapparent infection.   
 
What is the treatment for diphtheria?   
After collection of specimens, cases and symptomatic close contacts should begin antibiotic 
treatment as follows: 
• if diphtheria is strongly suspected on the basis of clinical findings, antitoxin should be given 
immediately after bacteriologic specimens are taken, without waiting for results.  Diphtheria 
antitoxin is available from CDC.  Contact the Iowa Department of Public Health, Center for 
Acute Disease Epidemiology (CADE) at (800) 362-2736for assistance. 
• erythromycin parenterally (40 to 50 mg/kg/day, maximum 2 g/day) until patient can swallow 
comfortably, at which point either oral erythromycin in 4 divided doses or oral penicillin V, 
125−250 mg 4 times a day, may be substituted, for a total treatment period of 14 days; or 
• aqueous crystalline penicillin G intramuscularly (100,000 to 150, 000 U/kg/day, in four 
divided doses) for 14 days; or  
• aqueous procaine penicillin intramuscularly (25,000 to 50,000 U/kg/day, maximum 1.2 million 
U, in two divided doses for children and 1.2 million U for adults) for 14 days.   
 
Is there a vaccine to prevent diphtheria? 
Yes, there is a vaccine to protect against diphtheria.   
 
Vaccination, including routine childhood vaccination and Td boosters beginning at age 11−12 
years and continuing every 10 years thereafter, is the best preventive measure against 
diphtheria. Tetanus toxoid-containing formulations should always be used. The Advisory 
Committee on Immunization Practices (ACIP) recommends that all children receive a routine 
series of five doses of tetanus-and diphtheria-containing vaccine at ages 2, 4, 6, 15−18 months, 
and 4−6 years. Booster doses of diphtheria and tetanus toxoids should then be administered 
beginning at age 11−12 years (provided at least 5 years have passed since the last dose) and 
every 10 years thereafter. One of these booster doses should be Tdap (tetanus, diphtheria, and 
acellular pertussis) vaccine.  DTaP and DT should be used in persons < 7 years of age, whereas 
Td is the preferred preparation for persons > 7 years of age.  
 
The Td catch-up schedule for those starting immunization at ≥ 7 years of age consists of 3 doses. 
The second dose is usually given 1−2 months after the 1st dose, and the 3rd dose 6 months after 
the 2nd dose. 
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FACT SHEET         DIPHTHERIA 
 (Cutaneous - skin)   
 
What is cutaneous (skin) diphtheria? 
Cutaneous diphtheria is a skin disease caused by the same bacterium that causes respiratory 
diphtheria.   
 
Who gets skin diphtheria? 
Skin diphtheria is more common in warm climates.  In the United States, skin diphtheria most 
often infects unvaccinated and homeless people.    
 
How is skin diphtheria spread? 
Skin diphtheria spreads by contact with infected skin, and in crowded, dirty homes.   
 
What are the symptoms? 
The sign of skin diphtheria is a non-healing, gray bump on the skin; but sometimes people can’t 
tell the difference between it and other skin diseases. 
 
Can others get this disease?  
Yes: The disease can spread for up to 2 weeks without medicine.  With medicine, the disease 
stops spreading in 4 days. To be sure that others won’t get sick, the skin infection must pass two 
lab tests after someone has finished proper medication.  
 
How can I prevent others from getting sick? 
Cover the infected area with a bandage. Wash hands with soap and water after touching the 
infected area.  
 
Can I get skin diphtheria again?  
Yes: unless you get vaccinated for diphtheria after infection.  
 
If I’m sick with skin diphtheria, does my family need medicine also?   
Yes. All those who live in the same home and/or share food, drink, eating utensils, or saliva (e.g. 
kissing) need medicine to prevent illness, even if they received the vaccine.  
 
What is the best way to prevent skin diphtheria? 
Vaccination!  Most Americans are vaccinated for diphtheria in childhood.  However, adults need 
to receive “booster” shots once every ten years. Ask your doctor whether your diphtheria vaccine 
is current. 
 
 
 
 
Iowa Dept. of Public Health Reviewed 12/13  Diphtheria Cutaneous Fact Sheet 1 
FACT SHEET                                          DIPHTHERIA  
 (Respiratory) 
 
What is diphtheria? 
Diphtheria is an acute disease with two main forms: respiratory and skin. 
 
Who gets respiratory diphtheria?  
Diphtheria is a rare disease in the United States, primarily because children are usually well 
vaccinated.  Most cases occur among unvaccinated or inadequately vaccinated persons.   
 
How is respiratory diphtheria spread? 
Diphtheria is transmitted person-to-person by direct or indirect contact with the nose secretions of 
an infected person.  Contact with clothing soiled with discharges from skin sores can cause illness, 
but this happens rarely.  Some people have become ill after drinking raw milk. 
 
What are the symptoms of respiratory diphtheria? 
Initial symptoms of illness include a sore throat and low fever; persons may die because they 
can’t breathe when the membrane obstructs the throat.  Swelling of the neck (“bull neck”) from 
inflammation can develop and is a sign of severe disease. Other possible symptoms include 
inflammation of the heart muscle and nerve paralysis. The respiratory form of diphtheria usually 
lasts several days; complications can persist for months. 
 
How soon do the symptoms appear? 
Respiratory diphtheria begins 2 - 5 days after infection.  
 
How long can an infected person spread the virus? 
A person is typically infectious 2 weeks or less. Persons who are treated with antibiotics are 
usually contagious for less than 4 days, but may carry the disease even after being treated. 
Persons are considered infectious until two nose and throat cultures (and cultures of skin lesions 
if present) are taken  
 
What are the criteria for significant exposure to diphtheria? 
Close contacts are defined as those who sleep in the same house or who share food, drink, or 
eating/drinking utensils with the case, child care contacts, as well as healthcare workers in 
contact with the case’s oral or respiratory secretions. Those contacts that were in brief contact 
with the case, but do not meet the definition of a close contact are not considered significant 
contacts.   
 
Can a person get diphtheria again? 
Lifelong immunity is usually, but not always, acquired after disease.   
 
What is the treatment for diphtheria?   
After collection of specimens, cases and symptomatic close contacts should begin antibiotic 
treatment as follows: 
 
Is there a vaccine to prevent diphtheria? 
Yes, there is a vaccine to protect against diphtheria.  Vaccination, including routine childhood 
vaccination and Td boosters beginning at age 11 − 12 years and continuing every 10 years 
thereafter, is the best preventive measure against diphtheria. 
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List all Contacts 
Name Address/phone 
number 
(if different than case) 
 
7 day 
surveillance 
Completion date 
PEP 
given 
     Y/N 
Date 
Diphtheria 
vaccine 
given 
Date 
specimens 
obtained 
Nose and 
throat 
swab 
results 
Exclude 
from work 
if food 
preparer or 
work with 
children 
until known 
culture 
negative 
Date 
Returned to 
work 
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CONFIDENTIAL                                   Iowa Department of Public Health 
Diphtheria                      Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -      
  
Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
EVENT  
Disease Type 
 
Diagnosis 
date: 
Cutaneous 
Respiratory 
 
     /     /      
Onset 
date: 
 
 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome: 
 Survived this illness     Died from this illness
 Died unrelated to this illness 
Date of Death       /     /      
 Unknown First name: 
 
      
Event exception 
 Case could not be found 
 Case could not be interviewed 
 Case refused interview 
 Other – see notes  
Provider title:  ARNP  DO 
 MD 
 NP  PA 
Outbreak 
related:  Yes      No      Unknown  
Outbreak 
name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
LABORATORY FINDINGS 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
       
 
  Other                 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
       
 
  Other                 
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Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
       
 
  Other                 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’ 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting:          
Health care worker type: 
 Yes      No      Unknown 
 
Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting:          
Health care worker type: 
 Yes      No      Unknown 
 
Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
Symptoms (check all that apply): 
 Bloody nasal discharge 
 Draining ears 
 Fever 
 Pharyngeal membrane 
 Skin ulcers 
 Sore throat 
 Stridor 
 Swollen lymph nodes 
 
Antibiotics prescribed?   Yes    No    Unknown 
  
Antibiotic:       
  
Antibiotic:       
 
 
Antibiotic:       
Date 
started:      /     /      
Date 
started: 
 
     /     /      
Date 
started: 
 
     /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 
 mg      ml     IU 
 
Unit: 
 
 mg      ml     IU 
 
Unit: 
 
 mg      ml     IU 
# of days:       
# of times 
a day:       # of days:       
# of times 
a day:       # of days:       
# of times 
a day:       
Route:       Route:       Route:       
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
 
 
Antitoxins prescribed?  Yes    No    Unk        Therapeutic medications prescribed?  Yes    No    Unk 
 Date 
started:      /     /      
 
List Medications: 
 
Dose: 
 
      
 
 
Unit: 
 
 mg      ml     IU 
 
# of days:       
# of times 
a day:        
Route:        
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Vaccinated for diphtheria  Yes    No 
  
Date vaccinated: 
 
     /     /      
  
Date vaccinated: 
 
     /     /      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
 
Number of vaccinations:       
 
In the 7 days prior to the onset of symptoms did the case: 
Traveled within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
THER LABORATORY  
Worked with a Case:       Yes    No    Unk From date:  
 
     /     /      
 
  To date: 
 
     /     /      
Lived with another Case:       Yes    No    Unk From date:  
 
     /     /      
 
  To date: 
 
     /     /      
Close contact with someone with 
similar symptoms: Yes   No     Unk Treated for nasopharyngeal symptoms: Yes   No     Unk 
 
CONTACTS 
Number of people living in case’s household:       
Close contacts with similar symptoms 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sexual contact 
 Family member (non-household)  
 
           /     /      
 
 Yes 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  
Average incubation period for 
diphtheria is 2-5 days; 
occasionally longer. 
Diphtheria is communicable for ~2 
weeks or less. The rare chronic 
carrier may shed organisms for 6 
months or more.   
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 Sibling 
 Roommate 
 Parent/ guardian 
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
       
 No 
       
If this contact is a case create a new event and/or case for this contact. 
 
Notes: __________________________________________________________________________________ 
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  ENCEPHALITIS (ARBOVIRAL) 
 
Potential Bioterrorism Agent: Category B 
 
Includes: St. Louis Encephalitis (SLE), Eastern Equine Encephalitis (EEE), Western 
Equine Encephalitis (WEE), LaCrosse Encephalitis (LAC), and West Nile Virus (WNV). 
 
Responsibilities: 
Hospital: Report by IDSS, facsimile, mail, or phone 
Hospital Infection Preventionist: Follow-up required  
Lab: Report by IDSS, facsimile, mail, or phone 
Physician: Report by facsimile, mail, or phone 
Local Public Health Agency (LPHA): Follow-up Required  
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY   
 
A. Etiologic Agent  
There are hundreds of viruses worldwide that are spread through insects or other arthropods. More 
than 30 of these arboviruses have been identified as human pathogens in the Western Hemisphere. 
In Iowa, four mosquito-borne arboviruses that cause encephalitis in humans have been identified: 
LaCrosse encephalitis (LAC), St. Louis encephalitis (SLE), Western Equine encephalitis (WEE), and 
West Nile virus (WNV).  
 
B. Clinical Description   
Encephalitis is an inflammation of the brain. Arboviral infection may result in an acute febrile illness 
of variable severity and rate of progression associated with neurologic symptoms ranging from 
headache to aseptic meningitis (inflammation of the linings of the brain and spinal cord) to 
encephalitis. Many arboviral infections are asymptomatic. Arboviral encephalitis cannot be 
distinguished clinically from many other causes of encephalitis. Manifestations can include headache, 
confusion, lethargy, nausea, altered consciousness, vomiting, fever, cranial nerve palsies, paresis 
(muscular weakness) or paralysis, sensory deficits, altered reflexes, tremors, convulsions, abnormal 
movements, coma of varying degree, and, in some cases, death. Case-fatality rates range from less 
than 1% - 60%. 
 
LAC encephalitis initially presents as a nonspecific summertime illness with fever, headache, nausea, 
vomiting and lethargy. Severe disease occurs most commonly in children under the age of 16 and is 
characterized by seizures, coma, paralysis, and a variety of neurological sequelae after recovery. 
Death from LAC encephalitis occurs in less than 1% of clinical cases. In many clinical settings, 
pediatric cases presenting with central nervous system (CNS) involvement are routinely screened for 
herpes or enteroviral etiologies. Since there is no specific treatment for LAC encephalitis, physicians 
often do not request the tests required to specifically identify LAC virus, and the cases are reported 
as aseptic meningitis or viral encephalitis of unknown etiology.  
Less than 1% of SLE viral infections are clinically apparent and the vast majority of infections remain 
undiagnosed. Illness ranges in severity from a simple febrile headache to meningoencephalitis, with 
an overall case-fatality ratio of 5% - 15 %. The disease is generally milder in children than in adults, 
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but in those children who do have disease, there is a high rate of encephalitis. The elderly are at 
highest risk for severe disease and death.  
WNV can infect a wide range of vertebrates; in humans it usually produces either asymptomatic 
infection or mild febrile disease, but can cause severe and fatal infection in a small percentage of 
patients. With WNV infections, mild infections are common and include fever, headache, and body 
aches, often with a skin rash and swollen lymph glands. More severe infections are often associated 
with high fever, neck stiffness, stupor, disorientation, coma, tremors, occasional convulsions, 
paralysis, and rarely, death. Case-fatality rates for WNV range from 3% - 15% of cases with clinical 
encephalitis. For more information on WNV see the WNV section in this manual. 
 
Most arboviral infections are asymptomatic. Clinical disease ranges from mild febrile illness to severe 
encephalitis. For the purposes of surveillance and reporting, based on their clinical presentation, 
arboviral disease cases are often categorized into two primary groups: neuroinvasive disease and 
non-neuroinvasive disease. 
Neuroinvasive disease 
Many arboviruses cause neuroinvasive disease such as aseptic meningitis, encephalitis, or acute 
flaccid paralysis (AFP). These illnesses are usually characterized by the acute onset of fever with stiff 
neck, altered mental status, seizures, limb weakness, cerebrospinal fluid (CSF) pleocytosis, or 
abnormal neuroimaging. AFP may result from anterior ("polio") myelitis, peripheral neuritis, or post-
infectious peripheral demyelinating neuropathy (i.e., Guillain-Barré syndrome). Less common 
neurological manifestations, such as cranial nerve palsies, also occur. 
 
Non-neuroinvasive disease 
Most arboviruses are capable of causing an acute systemic febrile illness (e.g., West Nile fever) that 
may include headache, myalgias, arthralgias, rash, or gastrointestinal symptoms. Rarely, myocarditis, 
pancreatitis, hepatitis, or ocular manifestations such as chorioretinitis and iridocyclitis can occur.  
 
  
C. Reservoirs 
LAC virus is a zoonotic pathogen cycled between the daytime-biting treehole mosquito, Aedes 
triseriatus, and vertebrate amplifier hosts (chipmunks, tree squirrels) in deciduous forest habitats. 
The virus is maintained over the winter by transovarial transmission in mosquito eggs. If the female 
mosquito is infected, she may lay eggs that carry the virus, and the adults coming from those eggs 
may be able to transmit the virus to chipmunks and humans.  
During the summer season, SLE virus is maintained in a mosquito-bird-mosquito cycle, with periodic 
amplification by peridomestic birds and Culex mosquitoes. In Florida, the principal vector is Cx. 
nigripalpus, in the Midwest, Cx. pipiens and Cx. p. quinquefasciatus and in the western United States, 
Cx. tarsalis and members of the Cx. pipiens complex.  
Birds carry WNV.  The virus usually stays in birds and the mosquitoes that feed on them. Rarely, 
other kinds of mosquitoes that also bite people and horses pick up the viruses. Humans and horses 
are generally considered dead-end hosts.  WNV is transmitted principally by Culex species 
mosquitoes, but also can be transmitted by Aedes, Anopheles, and other species. 
 
D.  Modes of Transmission 
The bite of an infected mosquito transmits the four types of arboviral encephalitis found in Iowa.  
WNV can also be transmitted by blood transfusion.  See the WNV chapter for further information. 
 
E.  Incubation period 
Incubation period for LaCrosse (LAC), Eastern Equine Encephalitis (EEE), Saint Louis Encephalitis 
(SLE) and West Nile Encephalitis (WNV) is 5 - 15 days.   
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F. Period of Communicability or Infectious Period  
The arboviral encephalitides are not communicable from person-to-person.  
 
G. Epidemiology  
LaCrosse (LAC) encephalitis was discovered in La Crosse, Wisconsin in 1963. Since then, the virus 
has been identified in several Midwestern and Mid-Atlantic states. During an average year, 80-100 
cases of LAC encephalitis are reported in the U.S. to the Centers for Disease Control and Prevention 
(CDC).   
  
Western equine encephalitis (WEE) was first isolated in the United States in 1930. In 1941, a U.S. 
WEE epidemic involved 300,000 horses and 3,340 humans. Since then, occasional smaller epidemics 
have occurred.  
 
St. Louis encephalitis (SLE) is the leading cause of epidemic flaviviral encephalitis in the U.S. SLE is 
the most common mosquito-transmitted human pathogen in the U.S. While periodic SLE epidemics 
have occurred only in the midwest and southeast, SLE virus is distributed throughout the lower 48 
states. Since 1964, case numbers have fluctuated widely and there have been more than 4,000 
confirmed cases of SLE with an average of 100 cases per year (range 2 - 1,967). 
WNV was first isolated in the West Nile Province of Uganda in 1937. The first recorded epidemics 
occurred in Israel during 1951-1954 and in 1957. Epidemics have been reported in Europe in the 
Rhone delta of France in 1962 and in Romania in 1996. The largest recorded epidemic occurred in 
South Africa in 1974. 
An outbreak of arboviral encephalitis in New York City and neighboring counties in New York state in 
late August and September 1999 was confirmed as caused by West Nile virus based on the 
identification of virus in human, avian, and mosquito samples.  By the end of October 1999, WNV had 
been confirmed in multiple native species of birds from New York City and areas within a 200-mile 
radius. WNV has also been found to cause encephalitis in horses.  By 2006, WNV had spread to 48 
states in the United States.  The first human case of WNV occurred in Iowa in 2002: a total of 37 
human cases were reported in 2006.  There were 31 cases of WNV reported in Iowa in 2012. 
 
Over the last 10 years Iowa has averaged 2 cases of arboviral encephalitis other than West Nile per 
year. 
 
H. Bioterrorism Potential 
Category B Agent.  Eastern Equine encephalitis (EEE) virus, is recognized as a category B 
bioterrorism agent by the CDC because it is moderately easy to disseminate, results in moderate 
morbidity rates and relatively high mortality rates; and requires specific enhancements of CDC's 
diagnostic capacity and enhanced disease surveillance. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting   
• To identify cases of WNV infection to understand the epidemiology of this emerging disease in 
our area. 
• To identify locally acquired cases of LaCrosse infection in humans to better understand the local 
epidemiology of LaCrosse virus. 
• To help target mosquito control measures. 
• To identify cases of other arboviral infections (e.g., California encephalitis, St. Louis encephalitis) 
in Iowa residents or visitors to determine whether they are imported or locally acquired. 
• To provide residents of Iowa and travelers to the state with appropriate preventive health 
information. 
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B. Laboratory and Healthcare Provider Reporting Requirements   
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider must 
report. The preferred method of reporting is by utilizing the Iowa Disease Surveillance System (IDSS).  
However, if IDSS is not available, the reporting number for IDPH Center for Acute Disease Epidemiology 
(CADE) is (800) 362-2736; fax number (515), 281-5698, mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
Des Moines, IA 50319-0075 
 
Postage-paid disease reporting forms are available free of charge from the clearinghouse.   
Call (319) 398-5133 or visit: 
healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295 to request a supply. 
 
If the patient is hospitalized at the time of diagnosis, the hospital’s Infection Preventionist (IP) may 
need to assist with the investigation. 
 
 
 
Laboratory Testing Available 
 
Arboviral Infections (WEE, EEE, SLE, WNV) The University of Iowa State Hygienic Laboratory (SHL) 
performs antibody detection for arboviral infections (SLE, WEE, EEE) using immunofluorescent assay 
(IFA) methods and will be performed on specimens submitted for the arboviral panel and are negative for 
WNV IgM. Single acute sera are tested for the presence of IgM antibodies to arboviruses and, if found, 
usually indicates recent infection. IgG testing is not routinely performed unless indicated by case. 
Confirmatory testing, if indicated, is performed at CDC. Accurate information about date of specimen 
collection, date of onset of symptoms, travel history, vaccination and disease history are helpful for test 
result interpretation. For information on specimen submission and testing, contact SHL at (319) 335-
4500. Additional information, test request forms, and sample collection instructions can be found at the 
SHL web site at: www.shl.uiowa.edu/  
 
West Nile Virus 
The University of Iowa State Hygienic Laboratory (SHL) performs antibody detection for West Nile virus 
using enzyme immunoassay (EIA) methods.  This method will be performed on all specimens submitted 
for WNV testing. Single acute sera and cerebrospinal fluid (CSF) are tested for the presence of IgM 
antibodies. WNV antibodies develop soon after onset and peak around 8 day, therefore, sera and CSF 
collected 5-10 days post onset are ideal specimens for testing. The presence of IgM antibody usually 
indicates recent infection by this virus; however, it has been shown that IgM antibodies to WNV may 
persist for many months after onset. IgG testing is not routinely done. Confirmatory testing, if indicated, 
is performed at CDC. Accurate information about date of specimen collection, date of onset of symptoms, 
travel history, vaccination and disease history are helpful for test result interpretation. For information on 
specimen submission and testing contact SHL at (319) 335-4500. Additional information and test request 
forms and sample collection instructions can be found at the SHL web site at: www.shl.uiowa.edu/  
 
C. Local Public Health Agency Responsibilities 
1. Reporting Requirements 
IDPH stipulates that local public health agencies (LPHA) must report the occurrence of any case of 
arboviral encephalitis.  
 
2. Case Investigation 
LPHAs may initiate the follow-up on reported cases of arboviral encephalitis.  Due to the significant 
morbidity and mortality associated with symptomatic illness individuals are likely to be hospitalized at 
the time of diagnoses. The LPHA should work with the infection preventionist (IP) at the hospital to 
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complete the Iowa Disease Surveillance System (IDSS) investigation concerning WNV. 
Epidemiologists with IDPH/CADE are available 24 hours a day to provide assistance and consultation 
regarding case investigation. Please contact IDPH/CADE at (800) 362-2736 with any questions. 
 
a. Case investigation of arboviral encephalitis in Iowa residents will be directed by the LPHA.  
1) The LPHA may be asked to assist in completing an IDSS arbovial encephalitis case followup  
by interviewing the case and others who may be able to provide pertinent information. Most 
of the information required can be obtained from the patient, healthcare provider, or the 
medical record.  
 
b. It is preferred to use IDSS to report cases and submit followup information. If IDSS is 
unavailable, print and complete the IDSS form and fax or mail (in an envelope marked 
“Confidential”) to IDPH Center for Acute Disease Epidemiology. The confidential fax number is 
(515) 281-5698. The mailing address is:  
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th Street 
Des Moines, IA 50319-0075 
 
c. Institution of disease control measures is an integral part of case investigation. It is the LPHA 
responsibility to understand, and if necessary, institute the control guidelines listed below in 
Controlling Further Spread.    
 
3) CONTROLLING FURTHER SPREAD  
 
A. Isolation and Quarantine Requirements  
For most cases of encephalitis there are no isolation and quarantine requirements. However, for 
encephalitis caused by an organism that is otherwise reportable, please refer to the chapter of that 
specific organism or disease for the appropriate isolation and quarantine requirements. 
 
B. Protection of Contacts of a Case 
In most cases of encephalitis, there are no recommendations for protection of contacts of a case. 
There is no approved vaccine available, and transmission from person-to-person and animal-to-
person (except from ratites, ostriches and emus) does not occur.  
 
 C. Managing Special Situations   
 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
If an outbreak is suspected, contact the Center for Acute Disease Epidemiology (CADE) at (800) 362-
2736. The situation may warrant an investigation of clustered cases or implementation of effective 
prevention and control measures (e.g., spraying for mosquitoes). CADE can help determine a course 
of action to prevent further cases and can perform surveillance for cases across town lines and 
therefore be difficult to identify at a local level. 
 
D.  Preventive Measures  
Surveillance  
In Iowa, CADE, SHL, Iowa State University, and the Iowa Department of Agriculture and Land 
Stewardship conduct environmental surveillance of mosquitoes, sentinel chickens, through dead bird 
collection and testing and the reporting of WNV and EEE positives in domestic and wildlife species in 
several sites throughout the state. Results of these surveillance efforts are used to detect presence of 
the virus to help target prevention and control messages throughout the state. 
 
 
 Iowa Dept. of Public Health   Reviewed 12/13  Encephalitis (arboviral) 5 
 
CADE in cooperation with other state agencies may provide guidance in the use of pesticides for the 
control of mosquitoes. Decisions about the need for mosquito pesticide spraying are normally made 
by local cities and towns based on mosquito habitat and density, surveillance for LAC, SLE, and WNV 
in mosquitoes, numbers of cases in birds and other animals, and numbers of cases in humans. 
 
Environmental Measures 
Make sure there are good screens on windows and doors to keep mosquitoes out. Get rid of 
mosquito breeding sites by emptying standing water from flowerpots, buckets, barrels and children’s 
wading pools when not in use. Change the water in pet dishes and replace the water in birdbaths 
every 3-4 days. Drill holes in tire swings so water drains out. 
 
Personal Preventive Measures/Education 
People, are encouraged to protect themselves from mosquito bites. When outdoors, use insect 
repellents such as those containing DEET (N, N-diethyl-meta-toluamide) and follow the directions on 
the package. DEET is the most effective insect repellent available. The more DEET a repellent 
contains the longer it will be effective. DEET concentrations higher than 50% do not increase the 
length of protection. Repellants containing picaridin and oil of leman eucalyptus have also been found 
to be effective. Use repellents at the lowest effective concentration. Wash treated skin with soap and 
water after returning indoors. Wear long-sleeved shirts, long pants, and socks when possible. Spray 
clothing with products containing DEET or permethrin, as mosquitoes may bite through thin clothing. 
Permethrin should only be used on clothing; do not apply it directly to skin. Wash treated clothing 
before wearing it again. Many mosquitoes are most active at dusk and dawn; consider staying 
indoors during these hours. Persons should also use gloves when handling horses and birds that are 
sick with or have died from arboviral infection. Persons in the environment of ratites (emus, 
ostriches, rheas) infected with EEE should take strict precautions when handling sick or dead animals 
or their secretions/excretions. 
4) ADDITIONAL INFORMATION 
 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for arboviral 
encephalitis can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
 
Comment 
 
Because closely related arboviruses exhibit serologic cross-reactivity, positive results of serologic tests 
using antigens from a single arbovirus can be misleading. In some circumstances (e.g., in areas 
where two or more closely related arboviruses occur, or in imported arboviral disease cases), it may 
be epidemiologically important to attempt to pinpoint the infecting virus by conducting cross-
neutralization tests using an appropriate battery of closely related viruses. This is essential, for 
example, in determining that antibodies detected against St. Louis encephalitis virus are not the 
result of an infection with West Nile (or dengue) virus, or vice versa, in areas where both of these 
viruses occur. Because dengue fever and West Nile fever can be clinically indistinguishable, the 
importance of a recent travel history and appropriate serologic testing cannot be overemphasized. In 
some persons, West Nile virus-specific serum IgM antibody can wane slowly and be detectable for 
more than one year following infection. Therefore, in areas where West Nile virus has circulated in 
the recent past, the co-existence of West Nile virus-specific IgM antibody and illness in a given case 
may be coincidental and unrelated. In those areas, the testing of serially collected serum specimens 
assumes added importance.  
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The seasonality of arboviral transmission is variable and depends on the geographic location of 
exposure, the specific cycles of viral transmission, and local climatic conditions. Reporting should be 
etiology-specific (see below; the six diseases printed in bold are nationally reportable to CDC):  
• St. Louis encephalitis virus disease  
• West Nile virus disease  
• Powassan virus disease  
• Eastern equine encephalitis virus disease  
• Western equine encephalitis virus disease  
• California serogroup virus disease (includes infections with the following viruses: California 
encephalitis, Jamestown Canyon, Keystone, La Crosse, snowshoe hare, and trivittatus)  
Note: Due to the continued risk of unintentional or intentional introduction of exotic arboviruses into 
the United States (e.g., Venezuelan equine encephalitis virus), or the reemergence of indigenous 
epidemic arboviruses (e.g., St. Louis encephalitis and western equine encephalitis viruses), physicians 
and local public health officials should maintain a high index of clinical suspicion for cases of potential 
exotic or unusual arboviral etiology, and consider early consultation with arboviral disease experts at 
state health departments and CDC.  
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Additional Resources 
Additional information regarding EEE, pesticide use, occupational exposures and other topics may be 
obtained using the following websites: 
Centers for Disease Control and Prevention www.cdc.gov/EasternEquineEncephalitis/index.html  
Centers for Disease Control and Prevention www.cdc.gov/ncidod/dvbid/westnile/index.htm  
Centers for Disease Control and Prevention www.cdc.gov/lac/  
Centers for Disease Control and Prevention www.cdc.gov/sle/  
Centers for Disease Control and Prevention www.cdc.gov/ncidod/dvbid/arbor/weefact.htm  
Environmental Protection Agency www.epa.gov/pesticides/factsheets/chemicals/deet.htm  
U.S. Department of Labor/OSHA www.osha.gov/dts/shib/WestNileVirus_8-29-03.pdf  
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FACT SHEET                                    ARBOVIRUSES 
  (LaCrosse, St. Louis, and Eastern Equine Encephalitis) 
 
What are arboviruses? 
Arboviruses are those viruses transmitted by mosquitoes. “Arbo” is a shortened form of “arthropod-
borne” meaning transmitted by arthropods, which are insects. There are four arboviruses in Iowa: 
LaCrosse encephalitis, St. Louis encephalitis, western equine encephalitis, and West Nile virus.  West Nile 
virus is addressed in a separate fact sheet. 
 
What are the symptoms of an infection with arboviruses? 
Arboviruses infect the brain and may cause it to swell. However, most infected people will not develop 
any symptoms. A few will develop fever, headache, stiff neck, and lethargy or sleepiness. 
 
How is the disease diagnosed? 
Two blood tests, spaced 2 - 4 weeks apart are required to confirm the diagnosis. However, your doctor 
may diagnose these diseases based on symptoms. 
 
How soon do symptoms appear? 
Symptoms usually occur between 5 − 15 days after being bitten by an infected mosquito. 
 
What are the complications of arboviral infections? 
Severe infections may result in mental confusion, nervous movements, coma, and occasionally 
convulsions. Approximately 1% of ill patients will experience permanent brain damage or die. 
 
How are these viruses spread? 
Mosquitoes pick up the virus from feeding on infected birds and small wild animals. Then these 
mosquitoes bite humans and transfer the virus to them. Western equine virus can also infect horses.  
Infected humans and horses do not directly pass the virus to other humans and horses. 
 
Who gets arboviral infections? 
Anyone can get them, depending on exposure to mosquitoes. 
 
How long is a person infectious? 
Arboviruses are not spread person to person.  
 
What is the treatment for this illness? 
There is no specific treatment. General treatment is given to reduce pain and control swelling of the 
brain. After having an infection, usually you cannot get it again. 
 
Do infected people need to be excluded from school, work, or child care? 
No. 
 
What can be done to help prevent the spread of these viruses? 
Protect yourself from mosquitoes by properly screening windows in homes and use of repellents 
containing DEET (N, N-diethyl-m-toluamide) when outside. The use of large amounts of DEET on small 
children may cause them to become ill and have seizures. Read and follow directions on all repellents. 
Since mosquitoes reproduce in water, drain water from containers around homes that collect rain such as 
tires, ponds and trash receptacles.  Reducing stagnant standing water is the most effective way of 
controlling mosquito numbers. In serious situations communities may spray chemicals to kill mosquitoes 
or their larvae.  There is no vaccine for protection against arboviral diseases. 
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What is Western Equine Encephalitis? 
Western Equine Encephalitis (WEE) is a mosquito-borne viral disease. WEE is a member of the family 
Togaviridae, genus Alphavirus. WEE occurs in the western parts of the United States, including Iowa and 
Canada. The word Equine means “horse”. 
  
How is WEE transmitted? 
WEE virus is transmitted to humans by the bite of an infected mosquito. Mosquitoes acquire the virus 
from infected birds and can spread this to people and horses.  
 
What are the signs and symptoms of WEE? 
Most infections do not have any symptoms or may present as mild, nonspecific illness. For those that 
develop illness, there is usually a sudden onset of symptoms with fever, headache, nausea, vomiting, loss 
of appetite and extreme tiredness. This can also be followed by confusion, weakness and signs and 
symptoms of encephalitis. Symptoms can range from mild flu-like illness to severe encephalitis, coma and 
death. Serious illness is most common in young children.  WEE causes “sleeping sickness” in horses 
especially in young horses. 
 
How soon after infection do symptoms occur? 
Symptoms usually occur between 5 − 15 days after being bitten by an infected mosquito. 
  
How can WEE be prevented? 
Avoiding the bite of mosquitoes is the best way to prevent infection with WEE, West Nile virus and other 
illnesses carried by mosquitoes. Remove standing water from your property. Emptying unused buckets, 
covering stored tires, and replacing the water in birdbaths weekly are all effective ways to reduce 
mosquito-breeding pools. Wear lightweight long sleeved shirts and long pants when outdoors to reduce 
the amount of exposed skin. Use insect repellents containing DEET (N, N-diethyl-meta-toluamide) 
according to the directions on exposed skin and clothing. A vaccine is available for horses but not 
humans. 
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CONFIDENTIAL                                                                                           Iowa Department of Public Health 
Eastern Equine Encephalitis (EEE)                        
 
Investigator:  
       Agency:                                                Phone number:                                          
FOR STATE USE ONLY 
Status:    Confirmed       Probable 
 Suspect          
 Not a case 
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Married         
 Parent with partner     
 Separated     Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Long-term care     
resident:  Yes      No      Unknown        Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Facility name:       
Parent/Guardian 
name: 
 
      
Facility phone: (     )-     -        Type:        
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Onset 
date: 
 
     /     /      
Diagnosis 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider type: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
Specimen 
source: 
 
      
 
Test type: 
 Serology (ELISA) 
 PCR      Other            
 
Accession #: 
 
      
 
Result date: 
 
     /     /      Result type:  Preliminary      Final 
 
Collection date: 
 
     /     /      Test type: 
 Acute 
 Convalescent 
 IgM 
 IgG Result: 
 Negative 
 Positive 
 Equivocal 
 Indeterminate 
 
Date received: 
 
     /     /      Organism: Eastern Equine virus Type:  
 
 
Laboratory: 
 
      
Specimen 
source: 
 
      
 
Test type: 
 Serology (ELISA) 
 PCR      Other            
 
Accession #: 
 
      
 
Result date: 
 
     /     /      Result type:  Preliminary      Final 
 
Collection date: 
 
     /     /      Test type: 
 Acute 
 Convalescent 
 IgM 
 IgG Result: 
 Negative 
 Positive 
 Equivocal 
 Indeterminate 
 
Date received: 
 
     /     /      Organism: Eastern Equine virus Type:  
 
 
Laboratory: 
 
      
Specimen 
source: 
 
      
 
Test type: 
 Serology (ELISA) 
 PCR      Other            
 
Accession #: 
 
      
 
Result date: 
 
     /     /      Result type:  Preliminary      Final 
 
Collection date: 
 
     /     /      Test type: 
 Acute 
 Convalescent 
 IgM 
 IgG Result: 
 Negative 
 Positive 
 Equivocal 
 Indeterminate 
 
Date received: 
 
     /     /      Organism: Eastern Equine virus Type:  
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OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’ 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties: 
Health care worker type: 
 Yes      No      Unknown 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties: 
Health care worker type: 
 Yes      No      Unknown 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
Physician 
diagnosis: 
 Encephalitis 
 Meningitis 
 Meningoencephalitis 
 Fever 
 Asymptomatic 
 Hepatitis/jaundice 
 Multi-system organ failure 
 Other            
 Dengue hemorrhagic 
fever/ Dengue shock  
Clinical 
classification: 
 Neuroinvasive  
 Non-neuroinvasive 
  
 
 
Symptoms:  Acute flaccid paralysis 
 Altered mental state 
 Anorexia 
 Coma 
 Confusion 
 Cranial nerve palsies 
 Diarrhea 
 Double vision 
 Eye pain 
 Fatigue 
 Fever 
 Gait/balance difficulty 
 Headache 
 Joint pain 
 Muscle pain 
 Nausea 
 Photophobia 
 Rash 
 Stiff neck 
 Swollen lymph nodes 
 Tremors 
 Vertigo 
 Vomiting 
 Other symptoms:                           
 
Pre-existing Conditions 
Before your West Nile virus (WNV) infection, did a health care provider ever tell he/she had any of the following medical conditions? 
 Diabetes 
 High blood pressure (hypertension) 
 Heart attack (myocardial infarction) 
 Angina or coronary artery disease 
 Congestive heart failure 
 Stroke 
 Chronic obstructive pulmonary disease (COPD) 
 Chronic liver disease 
 Kidney disease or failure 
 Bone marrow transplant 
 Alcoholism 
 Case had none of the conditions listed 
 
Before WNV infection, did the case ever 
have a solid organ transplant? 
 
 Yes    No    Unk 
 
If yes, what organ was transplanted:       
  If yes, what year was the transplant:       
Before WNV infection, has the case ever 
had cancer?  Yes    No    Unk If yes, what cancer type(s):       
  If yes, what year were you diagnosed:       
Center for Acute Disease Epidemiology                  Fax: 515-281-5698                   Do not complete shaded fields         EEE              Revised Feb 11   2 
CONFIDENTIAL PATIENT NAME: ______________________________                           Iowa Department of Public Health 
EXPOSURE PERIOD COMMUNICABLE PERIOD 
  If yes, are you currently being treated for cancer:  Yes      No      Unk 
Before WNV infection, did the case have 
any medical condition that limited 
his/her ability to fight infection?  Yes    No    Unk If yes, what condition:       
At the time WNV infection was diagnosed, was the case taking any of the following types of prescription medications or treatments? 
 Chemotherapy      
 Other treatments for cancer  
 Hemodialysis 
 Other treatments for kidney disease 
 Oral or injected steroids      
 Inhaled steroids         
 Insulin or other medications to treat diabetes 
 Medications to treat high blood pressure  
 Medications to treat coronary artery disease   
 Medications to treat congestive heart failure  
 Medications that suppress the immune system 
 Case was not on any medication/treatments listed 
    
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Ever vaccinated for Yellow Fever or Japanese encephalitis (JE)?   Yes    No    Unknown 
If yes, list MOST RECENT vaccination information ONLY: 
 Disease:  Yellow fever  JE 
 Disease:  Yellow fever  JE 
 
 
Date vaccinated: 
 
     /     /      
 
Date vaccinated: 
 
     /     /      
 
  
Lot #: 
 
      
  
Lot #: 
 
      
 
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
 
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
 
 
Number of vaccinations:       
 
Risk Factors/Travel Information  
In the 15 days prior to onset of symptoms did the case:  
Traveled within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
Exposed to mosquitoes:  Yes    No    Unk    
Use a mosquito repellent:  Yes    No    Unk If yes, how often?  Sometimes    Never 
  If yes, 
what type? 
 Picaridin 
 DEET 
If the patient is female, was she:  
 Always   
 Most of the time 
  Oil of lemon eucalyptus 
 Other            
Pregnant? 
Breastfeeding? 
 Yes    No    Unk 
 Yes    No    Unk 
   
 
In the 30 days prior to onset of symptoms did the case: 
Donate blood, blood products, 
organs or tissues?  Yes    No    Unk Date donated:      /     /        
Receive blood or blood products?  Yes    No    Unk Date received:      /     /        
Receive organs or tissue?  Yes    No    Unk Date received:      /     /        
 
Case acquired infection: 
 
 Naturally 
 Transplantation  
 
 Transfusion  
 Trans-placental  
 
 Breastfeeding  
 Occupationally 
 Unknown   
 
NOTES:       
 
 
 
 
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
 The incubation period for 
EEE is 3 to 14 days.  
No direct person to 
person transmission.  
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Lacrosse Encephalitis          
     Investigator:      
  
Agency:                                                       Phone number:                                          
FOR STATE USE ONLY 
Status:    Confirmed       Probable 
 Suspect          
 Not a case 
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Married         
 Parent with partner     
 Separated     Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Long-term care     
resident:  Yes      No      Unknown        Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Facility name:       
Parent/Guardian 
name: 
 
      
Facility phone: (     )-     -        Type:        
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Onset 
date: 
 
     /     /      
Diagnosis 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider type: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
Specimen 
source: 
 
      
 
Test type: 
 Serology (ELISA) 
 PCR      Other            
 
Accession #: 
 
      
 
Result date: 
 
     /     /      Result type:  Preliminary      Final 
 
Collection date: 
 
     /     /      Test type: 
 Acute 
 Convalescent 
 IgM 
 IgG Result: 
 Negative 
 Positive 
 Equivocal 
 Indeterminate 
 
Date received: 
 
     /     /      Organism: Lacrosse virus Type:  
 
 
Laboratory: 
 
      
Specimen 
source: 
 
      
 
Test type: 
 Serology (ELISA) 
 PCR      Other            
 
Accession #: 
 
      
 
Result date: 
 
     /     /      Result type:  Preliminary      Final 
 
Collection date: 
 
     /     /      Test type: 
 Acute 
 Convalescent 
 IgM 
 IgG Result: 
 Negative 
 Positive 
 Equivocal 
 Indeterminate 
 
Date received: 
 
     /     /      Organism: Lacrosse virus Type:  
 
 
Laboratory: 
 
      
Specimen 
source: 
 
      
 
Test type: 
 Serology (ELISA) 
 PCR      Other            
 
Accession #: 
 
      
 
Result date: 
 
     /     /      Result type:  Preliminary      Final 
 
Collection date: 
 
     /     /      Test type: 
 Acute 
 Convalescent 
 IgM 
 IgG Result: 
 Negative 
 Positive 
 Equivocal 
 Indeterminate 
 
Date received: 
 
     /     /      Organism: Lacrosse virus Type:  
 
  
 
Center for Acute Disease Epidemiology      Fax: 515-281-5698         Do not complete shaded fields       Lacrosse Encephalitis               Revised Feb-11 1 
CONFIDENTIAL PATIENT NAME: ______________________________                           Iowa Department of Public Health 
 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’ 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties: 
Health care worker type: 
 Yes      No      Unknown 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties: 
Health care worker type: 
 Yes      No      Unknown 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
Physician 
diagnosis: 
 Encephalitis 
 Meningitis 
 Meningoencephalitis 
 Fever 
 Asymptomatic 
 Hepatitis/jaundice 
 Multi-system organ failure 
 Other            
 Dengue hemorrhagic 
fever/ Dengue shock  
Clinical 
classification: 
 Neuroinvasive  
 Non-neuroinvasive 
  
 
 
Symptoms:  Acute flaccid paralysis 
 Altered mental state 
 Anorexia 
 Coma 
 Confusion 
 Cranial nerve palsies 
 Diarrhea 
 Double vision 
 Eye pain 
 Fatigue 
 Fever 
 Gait/balance difficulty 
 Headache 
 Joint pain 
 Muscle pain 
 Nausea 
 Photophobia 
 Rash 
 Stiff neck 
 Swollen lymph nodes 
 Tremors 
 Vertigo 
 Vomiting 
 Other symptoms:                           
 
Pre-existing Conditions 
Before your West Nile virus (WNV) infection, did a health care provider ever tell he/she had any of the following medical conditions? 
 Diabetes 
 High blood pressure (hypertension) 
 Heart attack (myocardial infarction) 
 Angina or coronary artery disease 
 Congestive heart failure 
 Stroke 
 Chronic obstructive pulmonary disease (COPD) 
 Chronic liver disease 
 Kidney disease or failure 
 Bone marrow transplant 
 Alcoholism 
 Case had none of the conditions listed 
 
Before WNV infection, did the case ever 
have a solid organ transplant? 
 
 Yes    No    Unk 
 
If yes, what organ was transplanted:       
  If yes, what year was the transplant:       
Before WNV infection, has the case ever 
had cancer?  Yes    No    Unk If yes, what cancer type(s):       
  If yes, what year were you diagnosed:       
Center for Acute Disease Epidemiology         Fax: 515-281-5698                   Do not complete shaded fields   Lacrosse Encephalitis Revised Feb 11 2 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
  If yes, are you currently being treated for cancer:  Yes      No      Unk 
Before WNV infection, did the case have 
any medical condition that limited 
his/her ability to fight infection?  Yes    No    Unk If yes, what condition:       
At the time WNV infection was diagnosed, was the case taking any of the following types of prescription medications or treatments? 
 Chemotherapy      
 Other treatments for cancer  
 Hemodialysis 
 Other treatments for kidney disease 
 Oral or injected steroids      
 Inhaled steroids         
 Insulin or other medications to treat diabetes 
 Medications to treat high blood pressure  
 Medications to treat coronary artery disease   
 Medications to treat congestive heart failure  
 Medications that suppress the immune system 
 Case was not on any medication/treatments listed 
    
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Ever vaccinated for Yellow Fever or Japanese encephalitis (JE)?   Yes    No    Unknown 
If yes, list MOST RECENT vaccination information ONLY: 
 Disease:  Yellow fever  JE 
 Disease:  Yellow fever  JE 
 
 
Date vaccinated: 
 
     /     /      
 
Date vaccinated: 
 
     /     /      
 
  
Lot #: 
 
      
  
Lot #: 
 
      
 
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
 
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
 
 
Number of vaccinations:       
 
Risk Factors/Travel Information  
In the 15 days prior to onset of symptoms did the case:  
Traveled within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
Exposed to mosquitoes:  Yes    No    Unk    
Use a mosquito repellent:  Yes    No    Unk If yes, how often?  Sometimes    Never 
  If yes, 
what type? 
 Picaridin 
 DEET 
If the patient is female, was she:  
 Always   
 Most of the time 
  Oil of lemon eucalyptus 
 Other            
Pregnant? 
Breastfeeding? 
 Yes    No    Unk 
 Yes    No    Unk 
   
 
In the 30 days prior to onset of symptoms did the case: 
Donate blood, blood products, 
organs or tissues?  Yes    No    Unk Date donated:      /     /        
Receive blood or blood products?  Yes    No    Unk Date received:      /     /        
Receive organs or tissue?  Yes    No    Unk Date received:      /     /        
 
Case acquired infection: 
 
 Naturally 
 Transplantation  
 
 Transfusion  
 Trans-placental  
 
 Breastfeeding  
 Occupationally 
 Unknown   
 
NOTES:       
 
 
 
 
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
 The incubation period for 
Lacrosse encephalitis is 
5 - 15 days.  
No direct person to 
person transmission.  
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St. Louis Encephalitis (SLE)                    
 
Investigator:  
       Agency:                                                Phone number:                                          
FOR STATE USE ONLY 
Status:    Confirmed       Probable 
 Suspect          
 Not a case 
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Married         
 Parent with partner     
 Separated     Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Long-term care     
resident:  Yes      No      Unknown        Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Facility name:       
Parent/Guardian 
name: 
 
      
Facility phone: (     )-     -        Type:        
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Onset 
date: 
 
     /     /      
Diagnosis 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider type: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
Laboratory: 
 
      
Specimen 
source: 
 
      
 
Test type: 
 Serology (ELISA) 
 PCR      Other            
 
Accession #: 
 
      
 
Result date: 
 
     /     /      Result type:  Preliminary      Final 
 
Collection date: 
 
     /     /      Test type: 
 Acute 
 Convalescent 
 IgM 
 IgG Result: 
 Negative 
 Positive 
 Equivocal 
 Indeterminate 
 
Date received: 
 
     /     /      Organism: St. Louis virus Type:  
 
 
Laboratory: 
 
      
Specimen 
source: 
 
      
 
Test type: 
 Serology (ELISA) 
 PCR      Other            
 
Accession #: 
 
      
 
Result date: 
 
     /     /      Result type:  Preliminary      Final 
 
Collection date: 
 
     /     /      Test type: 
 Acute 
 Convalescent 
 IgM 
 IgG Result: 
 Negative 
 Positive 
 Equivocal 
 Indeterminate 
 
Date received: 
 
     /     /      Organism: St. Louis virus Type:  
 
 
Laboratory: 
 
      
Specimen 
source: 
 
      
 
Test type: 
 Serology (ELISA) 
 PCR      Other            
 
Accession #: 
 
      
 
Result date: 
 
     /     /      Result type:  Preliminary      Final 
 
Collection date: 
 
     /     /      Test type: 
 Acute 
 Convalescent 
 IgM 
 IgG Result: 
 Negative 
 Positive 
 Equivocal 
 Indeterminate 
 
Date received: 
 
     /     /      Organism: St. Louis virus Type:  
  
 
Center for Acute Disease Epidemiology                Fax: 515-281-5698                   Do not complete shaded fields          SLE                   Revised Feb-11 1 
CONFIDENTIAL PATIENT NAME: ______________________________                           Iowa Department of Public Health 
 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’ 
ccupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties: 
Health care worker type: 
 Yes      No      Unknown 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties: 
Health care worker type: 
 Yes      No      Unknown 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
Physician 
diagnosis: 
 Encephalitis 
 Meningitis 
 Meningoencephalitis 
 Fever 
 Asymptomatic 
 Hepatitis/jaundice 
 Multi-system organ failure 
 Other            
 Dengue hemorrhagic 
fever/ Dengue shock  
Clinical 
classification: 
 Neuroinvasive  
 Non-neuroinvasive 
  
 
 
Symptoms:  Acute flaccid paralysis 
 Altered mental state 
 Anorexia 
 Coma 
 Confusion 
 Cranial nerve palsies 
 Diarrhea 
 Double vision 
 Eye pain 
 Fatigue 
 Fever 
 Gait/balance difficulty 
 Headache 
 Joint pain 
 Muscle pain 
 Nausea 
 Photophobia 
 Rash 
 Stiff neck 
 Swollen lymph nodes 
 Tremors 
 Vertigo 
 Vomiting 
 Other symptoms:                           
 
Pre-existing Conditions 
Before your West Nile virus (WNV) infection, did a health care provider ever tell he/she had any of the following medical conditions? 
 Diabetes 
 High blood pressure (hypertension) 
 Heart attack (myocardial infarction) 
 Angina or coronary artery disease 
 Congestive heart failure 
 Stroke 
 Chronic obstructive pulmonary disease (COPD) 
 Chronic liver disease 
 Kidney disease or failure 
 Bone marrow transplant 
 Alcoholism 
 Case had none of the conditions listed 
 
Before WNV infection, did the case ever 
have a solid organ transplant? 
 
 Yes    No    Unk 
 
If yes, what organ was transplanted:       
  If yes, what year was the transplant:       
Before WNV infection, has the case ever 
had cancer?  Yes    No    Unk If yes, what cancer type(s):       
  If yes, what year were you diagnosed:       
Center for Acute Disease Epidemiology                  Fax: 515-281-5698                   Do not complete shaded fields          SLE               Revised Feb-11   2 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
  If yes, are you currently being treated for cancer:  Yes      No      Unk 
Before WNV infection, did the case have 
any medical condition that limited 
his/her ability to fight infection?  Yes    No    Unk If yes, what condition:       
At the time WNV infection was diagnosed, was the case taking any of the following types of prescription medications or treatments? 
 Chemotherapy      
 Other treatments for cancer  
 Hemodialysis 
 Other treatments for kidney disease 
 Oral or injected steroids      
 Inhaled steroids         
 Insulin or other medications to treat diabetes 
 Medications to treat high blood pressure  
 Medications to treat coronary artery disease   
 Medications to treat congestive heart failure  
 Medications that suppress the immune system 
 Case was not on any medication/treatments listed 
    
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Ever vaccinated for Yellow Fever or Japanese encephalitis (JE)?   Yes    No    Unknown 
If yes, list MOST RECENT vaccination information ONLY: 
 Disease:  Yellow fever  JE 
 Disease:  Yellow fever  JE 
 
 
Date vaccinated: 
 
     /     /      
 
Date vaccinated: 
 
     /     /      
 
  
Lot #: 
 
      
  
Lot #: 
 
      
 
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
 
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
 
 
Number of vaccinations:       
 
Risk Factors/Travel Information  
In the 15 days prior to onset of symptoms did the case:  
Traveled within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
Exposed to mosquitoes:  Yes    No    Unk    
Use a mosquito repellent:  Yes    No    Unk If yes, how often?  Sometimes    Never 
  If yes, 
what type? 
 Picaridin 
 DEET 
If the patient is female, was she:  
 Always   
 Most of the time 
  Oil of lemon eucalyptus 
 Other            
Pregnant? 
Breastfeeding? 
 Yes    No    Unk 
 Yes    No    Unk 
   
 
In the 30 days prior to onset of symptoms did the case: 
Donate blood, blood products, 
organs or tissues?  Yes    No    Unk Date donated:      /     /        
Receive blood or blood products?  Yes    No    Unk Date received:      /     /        
Receive organs or tissue?  Yes    No    Unk Date received:      /     /        
 
Case acquired infection: 
 
 Naturally 
 Transplantation  
 
 Transfusion  
 Trans-placental  
 
 Breastfeeding  
 Occupationally 
 Unknown   
 
NOTES:       
 
 
 
 
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
 The incubation period for 
SLE is 5 - 15 days.  
No direct person to 
person transmission.  
Center for Acute Disease Epidemiology                  Fax: 515-281-5698                   Do not complete shaded fields          SLE               Revised Feb-11   3 
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Venezuelan Equine Encephalitis (VEE)                
 
Investigator:  
       Agency:                                                Phone number:                                          
FOR STATE USE ONLY 
Status:    Confirmed       Probable 
 Suspect          
 Not a case 
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Married         
 Parent with partner     
 Separated     Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Long-term care     
resident:  Yes      No      Unknown        Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Facility name:       
Parent/Guardian 
name: 
 
      
Facility phone: (     )-     -        Type:        
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Onset 
date: 
 
     /     /      
Diagnosis 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider type: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
Specimen 
source: 
 
      
 
Test type: 
 Serology (ELISA) 
 PCR      Other            
 
Accession #: 
 
      
 
Result date: 
 
     /     /      Result type:  Preliminary      Final 
 
Collection date: 
 
     /     /      Test type: 
 Acute 
 Convalescent 
 IgM 
 IgG Result: 
 Negative 
 Positive 
 Equivocal 
 Indeterminate 
 
Date received: 
 
     /     /      Organism: Venezuelan Equine virus Type:  
 
 
Laboratory: 
 
      
Specimen 
source: 
 
      
 
Test type: 
 Serology (ELISA) 
 PCR      Other            
 
Accession #: 
 
      
 
Result date: 
 
     /     /      Result type:  Preliminary      Final 
 
Collection date: 
 
     /     /      Test type: 
 Acute 
 Convalescent 
 IgM 
 IgG Result: 
 Negative 
 Positive 
 Equivocal 
 Indeterminate 
 
Date received: 
 
     /     /      Organism: Venezuelan Equine virus Type:  
 
 
Laboratory: 
 
      
Specimen 
source: 
 
      
 
Test type: 
 Serology (ELISA) 
 PCR      Other            
 
Accession #: 
 
      
 
Result date: 
 
     /     /      Result type:  Preliminary      Final 
 
Collection date: 
 
     /     /      Test type: 
 Acute 
 Convalescent 
 IgM 
 IgG Result: 
 Negative 
 Positive 
 Equivocal 
 Indeterminate 
 
Date received: 
 
     /     /      Organism: Venezuelan Equine virus Type:  
  
 
Center for Acute Disease Epidemiology                  Fax: 515-281-5698                   Do not complete shaded fields                     VEE    Revised Feb–11 1 
CONFIDENTIAL PATIENT NAME: ______________________________                           Iowa Department of Public Health 
 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties: 
Health care worker type: 
 Yes      No      Unknown 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties: 
Health care worker type: 
 Yes      No      Unknown 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
Physician 
diagnosis: 
 Encephalitis 
 Meningitis 
 Meningoencephalitis 
 Fever 
 Asymptomatic 
 Hepatitis/jaundice 
 Multi-system organ failure 
 Other            
 Dengue hemorrhagic 
fever/ Dengue shock  
Clinical 
classification: 
 Neuroinvasive  
 Non-neuroinvasive 
  
 
 
Symptoms:  Acute flaccid paralysis 
 Altered mental state 
 Anorexia 
 Coma 
 Confusion 
 Cranial nerve palsies 
 Diarrhea 
 Double vision 
 Eye pain 
 Fatigue 
 Fever 
 Gait/balance difficulty 
 Headache 
 Joint pain 
 Muscle pain 
 Nausea 
 Photophobia 
 Rash 
 Stiff neck 
 Swollen lymph nodes 
 Tremors 
 Vertigo 
 Vomiting 
 Other symptoms:                           
 
Pre-existing Conditions 
Before your West Nile virus (WNV) infection, did a health care provider ever tell he/she had any of the following medical conditions? 
 Diabetes 
 High blood pressure (hypertension) 
 Heart attack (myocardial infarction) 
 Angina or coronary artery disease 
 Congestive heart failure 
 Stroke 
 Chronic obstructive pulmonary disease (COPD) 
 Chronic liver disease 
 Kidney disease or failure 
 Bone marrow transplant 
 Alcoholism 
 Case had none of the conditions listed 
 
Before WNV infection, did the case ever 
have a solid organ transplant? 
 
 Yes    No    Unk 
 
If yes, what organ was transplanted:       
  If yes, what year was the transplant:       
Before WNV infection, has the case ever 
had cancer?  Yes    No    Unk If yes, what cancer type(s):       
  If yes, what year were you diagnosed:       
Deleted: Is the case employed, enrolled in 
school, or attending a child care facility?  
Yes      No      Unknown¶
(If yes, complete the following sections for each 
known occupation)¶
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
  If yes, are you currently being treated for cancer:  Yes      No      Unk 
Before WNV infection, did the case have 
any medical condition that limited 
his/her ability to fight infection?  Yes    No    Unk If yes, what condition:       
At the time WNV infection was diagnosed, was the case taking any of the following types of prescription medications or treatments? 
 Chemotherapy      
 Other treatments for cancer  
 Hemodialysis 
 Other treatments for kidney disease 
 Oral or injected steroids      
 Inhaled steroids         
 Insulin or other medications to treat diabetes 
 Medications to treat high blood pressure  
 Medications to treat coronary artery disease   
 Medications to treat congestive heart failure  
 Medications that suppress the immune system 
 Case was not on any medication/treatments listed 
    
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
z 
RISK FACTORS/TRAVEL 
 
Ever vaccinated for Yellow Fever or Japanese encephalitis (JE)?   Yes    No    Unknown 
If yes, list MOST RECENT vaccination information ONLY: 
 Disease:  Yellow fever  JE 
 Disease:  Yellow fever  JE 
 
 
Date vaccinated: 
 
     /     /      
 
Date vaccinated: 
 
     /     /      
 
  
Lot #: 
 
      
  
Lot #: 
 
      
 
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
 
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
 
 
Number of vaccinations:       
 
Risk Factors/Travel Information  
In the 15 days prior to onset of symptoms did the case:  
Traveled within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
Exposed to mosquitoes:  Yes    No    Unk    
Use a mosquito repellent:  Yes    No    Unk If yes, how often?  Sometimes    Never 
  If yes, 
what type? 
 Picaridin 
 DEET 
If the patient is female, was she:  
 Always   
 Most of the time 
  Oil of lemon eucalyptus 
 Other            
Pregnant? 
Breastfeeding? 
 Yes    No    Unk 
 Yes    No    Unk 
   
 
In the 30 days prior to onset of symptoms did the case: 
Donate blood, blood products, 
organs or tissues?  Yes    No    Unk Date donated:      /     /        
Receive blood or blood products?  Yes    No    Unk Date received:      /     /        
Receive organs or tissue?  Yes    No    Unk Date received:      /     /        
 
Case acquired infection: 
 
 Naturally 
 Transplantation  
 
 Transfusion  
 Trans-placental  
 
 Breastfeeding  
 Occupationally 
 Unknown   
 
NOTES:       
 
 
 
 
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
 The incubation period for 
VEE is 5 - 15 days.  
No direct person to 
person transmission.  
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Western Equine Encephalitis (WEE)                
 
Investigator:  
       Agency:                                                Phone number:                                          
FOR STATE USE ONLY 
Status:    Confirmed       Probable 
 Suspect          
 Not a case 
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Married         
 Parent with partner     
 Separated     Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Long-term care     
resident:  Yes      No      Unknown        Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Facility name:       
Parent/Guardian 
name: 
 
      
Facility phone: (     )-     -        Type:        
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Onset 
date: 
 
     /     /      
Diagnosis 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider type: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
Specimen 
source: 
 
      
 
Test type: 
 Serology (ELISA) 
 PCR      Other            
 
Accession #: 
 
      
 
Result date: 
 
     /     /      Result type:  Preliminary      Final 
 
Collection date: 
 
     /     /      Test type: 
 Acute 
 Convalescent 
 IgM 
 IgG Result: 
 Negative 
 Positive 
 Equivocal 
 Indeterminate 
 
Date received: 
 
     /     /      Organism: Western Equine virus Type:  
 
 
Laboratory: 
 
      
Specimen 
source: 
 
      
 
Test type: 
 Serology (ELISA) 
 PCR      Other            
 
Accession #: 
 
      
 
Result date: 
 
     /     /      Result type:  Preliminary      Final 
 
Collection date: 
 
     /     /      Test type: 
 Acute 
 Convalescent 
 IgM 
 IgG Result: 
 Negative 
 Positive 
 Equivocal 
 Indeterminate 
 
Date received: 
 
     /     /      Organism: Western Equine virus Type:  
 
Laboratory: 
 
      
Specimen 
source: 
 
      
 
Test type: 
 Serology (ELISA) 
 PCR      Other            
 
Accession #: 
 
      
 
Result date: 
 
     /     /      Result type:  Preliminary      Final 
 
Collection date: 
 
     /     /      Test type: 
 Acute 
 Convalescent 
 IgM 
 IgG Result: 
 Negative 
 Positive 
 Equivocal 
 Indeterminate 
 
Date received: 
 
     /     /      Organism: Western Equine virus Type:  
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OCCUPATIONS 
 
Interpret  ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties: 
Health care worker type: 
 Yes      No      Unknown 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties: 
Health care worker type: 
 Yes      No      Unknown 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
Physician 
diagnosis: 
 Encephalitis 
 Meningitis 
 Meningoencephalitis 
 Fever 
 Asymptomatic 
 Hepatitis/jaundice 
 Multi-system organ failure 
 Other            
 Dengue hemorrhagic 
fever/ Dengue shock  
Clinical 
classification: 
 Neuroinvasive  
 Non-neuroinvasive 
  
 
 
Symptoms:  Acute flaccid paralysis 
 Altered mental state 
 Anorexia 
 Coma 
 Confusion 
 Cranial nerve palsies 
 Diarrhea 
 Double vision 
 Eye pain 
 Fatigue 
 Fever 
 Gait/balance difficulty 
 Headache 
 Joint pain 
 Muscle pain 
 Nausea 
 Photophobia 
 Rash 
 Stiff neck 
 Swollen lymph nodes 
 Tremors 
 Vertigo 
 Vomiting 
 Other symptoms:                           
 
Pre-existing Conditions 
Before your West Nile virus (WNV) infection, did a health care provider ever tell he/she had any of the following medical conditions? 
 Diabetes 
 High blood pressure (hypertension) 
 Heart attack (myocardial infarction) 
 Angina or coronary artery disease 
 Congestive heart failure 
 Stroke 
 Chronic obstructive pulmonary disease (COPD) 
 Chronic liver disease 
 Kidney disease or failure 
 Bone marrow transplant 
 Alcoholism 
 Case had none of the conditions listed 
 
Before WNV infection, did the case ever 
have a solid organ transplant? 
 
 Yes    No    Unk 
 
If yes, what organ was transplanted:       
  If yes, what year was the transplant:       
Before WNV infection, has the case ever 
had cancer?  Yes    No    Unk If yes, what cancer type(s):       
  If yes, what year were you diagnosed:       
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  If yes, are you currently being treated for cancer:  Yes      No      Unk 
Before WNV infection, did the case have 
any medical condition that limited 
his/her ability to fight infection?  Yes    No    Unk If yes, what condition:       
At the time WNV infection was diagnosed, was the case taking any of the following types of prescription medications or treatments? 
 Chemotherapy      
 Other treatments for cancer  
 Hemodialysis 
 Other treatments for kidney disease 
 Oral or injected steroids      
 Inhaled steroids         
 Insulin or other medications to treat diabetes 
 Medications to treat high blood pressure  
 Medications to treat coronary artery disease   
 Medications to treat congestive heart failure  
 Medications that suppress the immune system 
 Case was not on any medication/treatments listed 
    
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Ever vaccinated for Yellow Fever or Japanese encephalitis (JE)?   Yes    No    Unknown 
If yes, list MOST RECENT vaccination information ONLY: 
 Disease:  Yellow fever  JE 
 Disease:  Yellow fever  JE 
 
 
Date vaccinated: 
 
     /     /      
 
Date vaccinated: 
 
     /     /      
 
  
Lot #: 
 
      
  
Lot #: 
 
      
 
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
 
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
 
 
Number of vaccinations:       
 
Risk Factors/Travel Information  
In the 15 days prior to onset of symptoms did the case:  
Traveled within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
Exposed to mosquitoes:  Yes    No    Unk    
Use a mosquito repellent:  Yes    No    Unk If yes, how often?  Sometimes    Never 
  If yes, 
what type? 
 Picaridin 
 DEET 
If the patient is female, was she:  
 Always   
 Most of the time 
  Oil of lemon eucalyptus 
 Other            
Pregnant? 
Breastfeeding? 
 Yes    No    Unk 
 Yes    No    Unk 
   
 
In the 30 days prior to onset of symptoms did the case: 
Donate blood, blood products, 
organs or tissues?  Yes    No    Unk Date donated:      /     /        
Receive blood or blood products?  Yes    No    Unk Date received:      /     /        
Receive organs or tissue?  Yes    No    Unk Date received:      /     /        
 
Case acquired infection: 
 
 Naturally 
 Transplantation  
 
 Transfusion  
 Trans-placental  
 
 Breastfeeding  
 Occupationally 
 Unknown   
 
 
NOTES:       
 
 
 
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
 The incubation period for 
WEE is 5 - 15 days.  
No direct person to 
person transmission.  
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E. coli -Pathogenic 
 
Potential Bioterrorism Agent: Category B 
 
Responsibilities: 
Hospital: Report by IDSS, facsimile, mail or phone 
Lab: Report by IDSS, facsimile, mail or phone, send isolate to SHL - (319) 335-4500 
Physician: Report by facsimile, mail or phone  
Local Public Health Agency (LPHA): Follow-up required 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY  
 
Six major categories of Escherichia coli strains cause diarrhea: 
1) Enterohemorrhagic 
2) Enterotoxigenic 
3) Enteroinvasive 
4) Enteropathogenic 
5) Enteroaggregative 
6) Diffuse-adherence 
 
A. Agent 
Escherichia coli includes over a hundred different serotypes belonging to the group of gram-negative bacteria.  Most 
serotypes are harmless and live in the intestines of healthy humans and animals.   
• Enterohemorrhagic (EHEC) E. coli include O157:H7, O26, O111, O103, O45, and O121. EHEC produce potent 
cytotoxins called Shiga toxin 1 and 2.  
• Enterotoxigenic (ETEC) category includes E. coli O6,08,O15, O020, O25, O27, O49, O63, O78, O128ac, O148, 
O153, O159, 167, and O169. This category of E. coli is a major cause of travelers’ diarrhea in people from 
industrialized countries who visit developing countries.  
• Enteroinvasive (EIEC) category includes O28ac, O29, O112, O124, O0136, O143, O144, O152, O164, and 
O167. The inflammatory disease of the gut mucosa and submucosa caused by EIEC strains of E. coli closely 
resembles that produced by Shigella.  
• Enteropathogenic (EPEC) category includes O55:NM, O55:H6, O55:H7, O86:NM, O86:H34, O111:NM, 
O111:H2, O111:H12, O111:H21, O114:NM, O127:H6, O127:H9, O127:H21, O128:H2, O128:H7, O128:H12, 
O142:H6, and O157:H45. Diarrheal disease in this category almost always occurs in children aged less than 
one year. 
• Enteroaggregative (EAEC) category includes O3:H2 and O44:H18. This category of diarrhea-producing E. coli 
is increasingly recognized as a cause of both acute and persistent diarrhea among children and adults. 
However, there is some debate about whether all strains of EAEC cause diarrhea. 
• Diffuse-adherence (DAEC) category. DAEC is the least well-defined category of diarrhea-causing E. coli. Little 
is known at present about the reservoir, modes of transmission, host risk factors, or period of 
communicability of DAEC.  
 
All pathogenic E. coli should be approached by public health in a similar manner.  
 
B. Clinical Description 
Infection with pathogenic E. coli may present with a wide spectrum of clinical manifestations. An individual may be 
asymptomatic, have mild non-bloody diarrhea, or have grossly bloody diarrhea. Most diagnosed cases develop bloody 
diarrhea 6 to 48 hours after the onset of non-bloody diarrhea. Abdominal cramps, nausea and vomiting may also be 
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present. Fever is usually absent. In severe cases, the patient may progress to develop other clinical syndromes such 
as hemolytic uremic syndrome (HUS) or thrombotic thrombocytopenic purpura (TTP).  Hemolytic uremic syndrome 
(HUS) is characterized by the acute onset of microangiopathic hemolytic anemia, renal injury, and low platelet count. 
Thrombotic thrombocytopenic purpura (TTP) is characterized by anemia and low platelet counts but can include 
central nervous system (CNS) involvement and fever. 
 
C. Reservoirs 
• EHEC: Cattle appear to be a reservoir of significant public health importance; however, other animals, such as 
deer, are also known to carry EHEC. In addition, humans serve as a reservoir. 
• ETEC: Humans; although also occurs in animals people are the reservoir for strains causing diarrhea in 
humans. 
• EIEC and EPEC: humans 
 
D. Modes of Transmission 
• EHEC and ETEC transmission occurs fecal-orally via contaminated food, drinking water or recreational water.  
Transmission may also occur directly from person-to-person; and can include certain types of sexual contact. 
The infectious dose for E. coli O157:H7 is very low (about 100 organisms). E. coli O157:H7 has been 
associated with the consumption of undercooked contaminated ground beef, unpasteurized apple juice and 
cider, unpasteurized milk and other dairy products, raw fruits and vegetables, and salami. 
• EIEC: Scant available evidence suggests that it is transmitted by contaminated food. 
• EPEC transmission has occurred through contaminated infant formula and weaning foods. In infant nurseries, 
transmission by fomites and contaminated hands can occur. Outbreaks due to contaminated rice and water 
have been reported. 
 
E. Incubation Period 
• EHEC: The incubation ranges from 2 - 10 days with a median of 3 - 4 days. 
• ETEC: The incubation ranges from 10 to 72 hours. 
• EIEC: The incubation period of 10 to 18 hours have been observed 
• EPEC: Incubations periods as short as 9 to 12 hours have been observed in adults studies 
 
F. Period of Communicability or Infectious Period 
• EHEC:  One week or less in adults but up to 3 weeks in about one-third of infected children. Prolonged 
carriage is uncommon. 
• ETEC and EPEC: for duration of excretion of the pathogen, which may be prolonged. 
• EIEC: for the duration of the pathogen excretion. 
  
G. Epidemiology 
• EHEC was first identified in 1982 in an outbreak in the United States. Since then, infections have been 
recognized as an important cause of bloody diarrhea in North America, Europe, Japan, Australia and southern 
South America. As with other enteric illnesses, the young and old are usually more severely ill when infected. 
Infection in young children may lead to complications such as HUS in about 5 to 10% of cases. Sporadic 
cases of E. coli O157:H7 infections occur throughout the year with a peak in the incidence of disease during 
the summer months. Outbreaks in the United States have been associated with undercooked ground beef, 
unpasteurized milk and apple cider, and other food products. Most cases are due to inadequately cooked 
ground beef.   
• ETEC: This category of E. coli is a major cause of travelers’ diarrhea in people from industrialized countries 
who visit developing countries. ETEC is also a major cause of dehydrating diarrhea in infants and children in 
developing countries, especially among children less than 2 years of age. It has been estimated that globally 
ETEC causes as many as 380,000 deaths annually in children under five. 
• EIEC infections are endemic in developing countries and cause about 1%-5% of diarrheal episodes among 
people visiting treatment centers. Rarely, infection and outbreaks of EIEC diarrhea have been reported in 
industrialized countries. 
• EPEC: The oldest recognized category of diarrhea-producing E. coli, implicated in outbreaks in the 1940’s and 
1950’s. Diarrheal disease in this category is virtually confined to children aged less than one year. It is rarely 
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seen in North America and Europe but remains a major agent of infant diarrhea in many developing area, 
including South America sub-Saharan Africa, and Asia. 
• EAEC: This category of diarrhea-producing E. coli is increasingly recognized as a cause of both acute and 
persistent diarrhea among children and adults. EAEC associated with infant diarrhea have been reported from 
Latin America, Asia, and sub-Saharan Africa and may be responsible for a proportion of diarrheal disease in 
developed countries. EAEC associated diarrhea has also been associated with HIV-infected adults and 
international travelers to developing countries. 
•  
H.  Bioterrorism Potential 
Category B Agent: E. coli has been identified as a potential category B bioterrorism agent as a food safety threat. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION  
 
A. Purpose of Surveillance and Reporting 
• To identify whether the case may be a source of infection for other persons (e.g., a diapered child, child care 
attendee or food handler) and if so, to prevent further transmission. 
• To identify sources of public health concern (e.g., a contaminated food source or recreational water) and to stop 
transmission from such a source. 
 
B.  Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider must report. 
The preferred method of reporting is by utilizing the Iowa Disease Surveillance System (IDSS).  However, if IDSS 
is not available, the reporting number for IDPH Center for Acute Disease Epidemiology (CADE) is (800) 362-2736; 
fax number (515), 281-5698, mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
Des Moines, IA 50319-0075 
 
Postage-paid disease reporting forms are available free of charge from the IDPH clearinghouse.   
Call (319) 398-5133 or visit the website 
healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295 to request a supply. 
 
Laboratory Testing Services Available 
The University of Iowa State Hygienic Laboratory (SHL) tests stool specimens for the presence of pathogenic E. coli 
and will confirm and serotype isolates obtained from clinical specimens at other laboratories. Additionally, all 
laboratories in Iowa are required to submit pathogenic E.coli isolates for typing to aid in the public health surveillance 
necessary to prevent transmission of this disease. For more information on submitting specimens call SHL at (319) 
335-4500 or visit www.shl.uiowa.edu/. 
 
SHL will test implicated food items from a cluster or outbreak of disease.  Food is submitted through local public 
health departments. 
 
C.  Local Public Health Agency (LPHA) Reporting and Follow-Up Responsibilities 
Case Investigation 
All cases of E. coli causing illness require public health follow-up, excluding urinary tract infections caused by normal 
bowel flora E. coli. 
 
a. It is the LPHA responsibility to complete an E. coli Pathogenic disease investigation by interviewing the case and 
others who may be able to provide pertinent information. 
 
b. Use the following guidelines to assist you in completing the investigation: 
1) Record the demographic information, date of symptom onset, symptoms, and medical information. 
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2) When asking about exposure history (food, travel, activities, etc.), use the incubation range for E. coli of (10 
hrs −10 days). Specifically, focus on the period beginning a minimum of 10 hours prior to the case’s onset 
date back to no more than 10 days before onset. If the person ate ground meat, ask how well the meat was 
cooked. 
3) If possible, record any restaurants at which the case ate, including food item(s) and date consumed. If it is 
suspected that the case became infected through food, refer to the Iowa’s Foodborne Illness Outbreak 
Investigation Manual. 
4) Ask questions about water supply because pathogenic E. coli  may be acquired through water consumption.   
5) Household/close contact, pet or other animal contact, child care, and food handler questions are designed to 
examine the case’s risk of having acquired the illness from, or potential for transmitting it to, these contacts. 
Determine whether the case attends or works at a child care facility and/or is a food handler. 
6) If  several attempts have been made to obtain case information, but have been unsuccessful (e.g., the case 
or healthcare provider does not return calls or respond to a letter, or the case refuses to divulge information 
or is too ill to be interviewed), enter into IDSS as much information as has been gathered. Please explain in 
the notes section in IDSS the reason why the investigation could not be completed. If using IDSS, select the 
appropriate reason under the Event tab in the Event Exception field. 
 
After completing the interview enter the information into IDSS.  If IDSS is not available, fax [(515), 281-5698] 
the investigation form or mail to: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
Des Moines, IA 50319-0075 
 
c. Institution of disease control measures is an integral part of case investigation. It is the LPHA responsibility to 
understand, and, if necessary, institute the control guidelines listed below in 4) Controlling Further Spread.   
 
4) CONTROLLING FURTHER SPREAD  
 
A.  Isolation and Quarantine Requirements  
In the healthcare setting patients should be placed in contact isolation for the duration of the diarrhea. 
 
In homes, persons with diarrhea should not cook food for others and must use good handwashing technique after 
using the toilet. 
 
 Cases must be instructed on proper handwashing, especially after-toilet use. 
 
B.  Managing Special Situations 
 
Foodhandlers 
Contacts with diarrhea who are food handlers shall be considered a case and handled in the same fashion.  
 
 Food handlers with pathogenic E. coli must be excluded from work. A food handler is any person directly preparing 
or handling food. This can include a patient-care or child-care provider.  
 
No foodservice worker, healthcare or child care provider should be at work while experiencing active diarrhea. 
 
After diarrhea has resolved, food-handling employees may only return to food handling after producing two 
consecutive negative stool tests taken at least 24 hours apart. If a case has been treated with an antimicrobial, the 
stool specimens shall not be submitted until at least 48 hours after cessation of therapy. Food handling employees 
may be reassigned to tasks where they do not handle food once they have had no diarrhea for 24 hours while awaiting 
the two negative stool tests.   
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Households: 
 Enteric diseases spread easily through households because both close, personal contact and foodborne modes of 
transmission can be involved. The case interview should provide valuable information about the household that can give 
clues to the most likely source of the illness. This will also help identify possible vehicles for transmission to other 
family/household members. 
 
 Person-to-person transmission of enteric disease among household members (or household-like contacts) occurs very 
readily. The potential for transmission is greater if any of the following risk factors are present in the household: 
•  Diapered children, especially toddlers. 
•  Crowded, unsanitary conditions. 
•  Lack of adequate handwashing facilities. 
•  A fecally incontinent adult who is cared for by other household members. 
•  Any activity in which contact with feces is likely. 
•  Situations where enteric diseases can be sexually transmitted (e.g. homosexual males) 
 
The steps in assessment of the household are: 
 
1. Try to determine whether the source of the illness was in the household (either via person-to-
person transmission or a common source, such as food). 
  2. Teach about foodborne and person-to-person transmission patterns, which can occur within the 
household.  Provide fact sheets. 
3. If other household members are ill, determine if they are at high risk for transmission outside the 
household (child care, food establishment, patient care). (See guidelines for specific high-risk 
setting.) 
4. Make recommendations for exclusion from work and/or cohorting/exclusion from child care if 
indicated. (See guidelines for specific high-risk setting.) 
  5. Report case(s) to CADE; IDSS is the preferred method for this. 
  6. If household contacts are in high-risk settings, and are having symptoms, they should be 
excluded from the high-risk situation and a stool test done. If the household contacts are in high 
risk settings, but have no symptoms, instruct them on good hygiene, and warn if symptoms 
develop they should exclude themselves immediately from the high risk situation and have a 
stool test done. 
 
Child Care 
The role that child care centers play in the transmission of enteric diseases has been well documented. Because young 
children lack hygiene skills, are not always fecally continent (in diapers), and are highly mobile, they serve as very 
efficient "spreaders" of enteric organisms. Child care employees may also contribute to the spread of enteric diseases if 
they care for other children or prepare food without properly washing their hands after changing diapers. However, food 
and water are rarely vehicles for transmission in child care centers. Enteric diseases are commonly spread from person to 
person as a result of the combination of poor hygiene and highly infectious enteric pathogens. Since E. coli may be 
transmitted person-to-person through fecal-oral transmission, it is important to follow up on cases of pathogenic E. 
coli in a child care setting carefully. General recommendations include: 
 
• Children with pathogenic E. coli should be excluded until two consecutive negative stool tests taken more 
than 24 hours apart are obtained. If a case has been treated with an antimicrobial, the stool specimens shall 
not be submitted until at least 48 hours after cessation of therapy.  
• Staff with diarrhea due to pathogenic E.coli should not return to food handling work or direct child or care 
until they have had 2 consecutive negative stool cultures taken 24 hours or more apart but not sooner than 
48 hours following the discontinuation of antibiotics.   
• Staff of child care programs are considered food handlers. No one should be at work with active diarrhea. 
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School  
Since E. coli may be transmitted person-to-person through fecal-oral transmission, it is important to follow up on 
cases of pathogenic E. coli in a school setting carefully. General recommendations include: 
• Students or staff with E. coli infection who have diarrhea should be excluded until their diarrhea is gone. 
• Students or staff with E. coli who do not have diarrhea or vomiting and do not handle food may remain in 
school if proper hygienic practices are maintained. 
• Students or staff who handle food and have E. coli infection (symptomatic or not) should not prepare food 
until their diarrhea is gone and they have had two negative stool tests (submitted at least 48 hours after 
completion of antibiotic therapy, if antibiotics are given).  
 
      Patient Care Settings 
 Reports of enteric disease in patient-care settings should be followed up as soon as possible, since outbreaks among the 
ill and elderly may cause significant morbidity and mortality. When a case of shiga-toxin producing E. coli occurs in a 
patient-care setting, the local public health agency (LPHA) may be called upon to assess the potential for transmission 
and to recommend interventions to prevent further transmission to patients/residents or other staff members. 
  
 A.   Assessment of Potential for Transmission by a Health-care Worker (HCW) 
   
1. Obtain and review a description of the HCW duties. 
2. Determine the presence of acute diarrhea. 
   
 B.  Prevention of Transmission 
   
1. If the HCW does have contact with the patient, the patient’s environment or food and has diarrhea, 
exclude from work until diarrhea is resolved and two successive stool cultures collected at least 24 hours 
apart and at least 48 hours after discontinuation of antibiotics are negative. Once they have had no 
diarrhea for 24 hours they can be assigned to duties not involving contact with patient, patient 
environment or food while awaiting negative stool testing.  
2. If the person with a shiga-toxin producing E. coli disease is a patient or resident in a hospital, nursing 
home or other residential care facility, Contact Precautions should be followed until the patient is free of 
diarrhea. Standard Precautions should be used at all times.  
  
 C. Contact Precautions 
   
1. Gowns and gloves should be worn when handling the patient's feces or fecally soiled items such as 
the patient's bed linens, towels, washcloths and clothing. In addition, wear gowns when entering the 
room if it is anticipated that clothing will have substantial contact with environmental surfaces, items 
in the environment, or if the patient is incontinent. 
2. If rinsing is necessary, fecally soiled clothing and linens should be rinsed only in a commode or 
hopper sink designed for this purpose. Never rinse in a handwashing sink! 
3. The patient's soiled clothing and linens should be bagged in bags that do not leak through for 
transport to the laundry. 
4. If at all possible, use disposable diapers for incontinent patients. 
5. Articles used to care for the patient should be used only for that patient until diarrhea is resolved.  
This would include blood pressure cuff, stethoscope, thermometer, etc. 
6. As always, hands should be washed thoroughly after caring for each patient. Patient hands should also 
be washed. 
 
Community Residential Programs 
Actions taken in response to a case of pathogenic E. coli in a community residential program will depend on the type 
of program and the level of functioning of the residents.  
 
In long-term care facilities, residents with pathogenic E. coli should be placed on Contact Precautions until their 
symptoms subside. 
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Staff members who give direct patient care that includes oral contact (e.g., feed patients, give mouth or denture 
care, or give medications) are considered food handlers and are subject to food handler restrictions, meaning they 
should not return to those duties until they have 2 consecutive negative stool cultures taken 24 hours or more apart but 
not sooner than 48 hours following the discontinuation of antibiotics. Once they have had no diarrhea for 24 hours they 
can be assigned to duties other than patient care or food handling. In addition, staff members with E. coli infection who 
are not food handlers should not work until their diarrhea is gone.   
 
In residential facilities for the developmentally disabled, staff and clients with E. coli should refrain from handling or 
preparing food for other residents until their diarrhea has subsided and 2 consecutive negative stool cultures taken 24 
hours or more apart but not sooner than 48 hours following the discontinuation of antibiotics are reported as negative. In 
addition, staff members with E. coli infection who are not food handlers should not work until their diarrhea is gone. 
 
Household Contacts Employed In High Risk Occupations 
 Household contacts should be questioned about their employment in high-risk occupations such as food  
 handling, direct patient care, or child care establishments. All household contacts should be educated about the 
symptoms of the disease and about hygienic methods to avoid further transmission. Proper hand hygiene should be 
stressed. If they have symptoms, a stool test should be done. 
  
Household contacts that are symptomatic and employed as food handlers, child care workers, or persons responsible 
for direct patient care should be excluded from their duties until their diarrhea ceases. Household contacts with 
pathogenic E. coli should not return to food handling or direct child or patient care until they have had 2 consecutive 
negative stool cultures taken 24 hours or more apart but not sooner than 48 hours following the discontinuation of 
antibiotics. Once they have had no diarrhea for 24 hours they can be assigned to duties other than patient care or 
food handling. They should all be educated on good hygiene, not to work if they become ill, and if diarrhea develops they 
should be tested and the guidelines above followed regarding returning to work. 
 
No one should be at work with active diarrhea. 
 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
Consult with the epidemiologist on-call at CADE, (800) 362-2736. CADE can help determine a course of action to 
prevent further cases and can perform surveillance for cases that may cross several county lines and therefore may 
be difficult to identify at a local level. 
 
If the number of reported cases in any city or county is higher than usual, or if an outbreak is suspected, investigate 
clustered cases in an area or institution to determine the source of infection and mode of transmission. A common 
vehicle (such as water, food or association with a child care center) should be sought and applicable preventive or 
control measures should be instituted. Control of person-to-person transmission requires special emphasis on 
personal cleanliness and sanitary disposal of feces.  
 
Note: Refer to Iowa’s Foodborne Illness Outbreak Investigation Manual for comprehensive information on 
investigating foodborne illness complaints and outbreak.  
 
D.  Preventive Measures 
 
Environmental Measures 
Implicated food items must be removed from the environment. A decision about testing implicated food items can be 
made in consultation with the CADE. CADE can help coordinate pickup and testing of food samples. If a commercial 
product is suspected, CADE will coordinate follow-up with relevant outside agencies. If waterborne spread is 
suspected, contact the county environmental health office and IDPH Division of Environmental Health at (515) 281-
7726. 
 
• Environment, such as countertops and bathrooms should be cleaned with an EPA approved disinfectant. 
• Follow recommended procedures for fecal coliform testing of recreational water supplies (e.g., pools, lakes).  
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The general practice of the SHL is to only test food samples implicated in suspected outbreaks, not single cases. The 
LPHA may suggest that the holders of food implicated in single case incidents locate a private laboratory, which will 
test food or store the food in their refrigerator for a period of time in case additional reports are received. Note: Refer 
to the Iowa’s Foodborne Illness Outbreak Investigation Manual for comprehensive information in investigating 
foodborne illness complaints and outbreak. 
 
Preventive Measures/Education 
To avoid exposure, advise individuals: 
• To always wash their hands thoroughly with soap and water before eating or preparing food, after using the toilet 
and after changing diapers. (After changing diapers, wash the child’s hands also.) 
• In all settings, especially child care, dispose of feces in a sanitary manner. 
• When caring for someone with diarrhea, the care giver should wash their hands with plenty of soap and water 
after helping the person use the toilet, changing diapers, cleaning the bathroom, soiled clothes or soiled sheets. 
The patient’s hands should be washed also. 
• Avoid sexual practices that may permit fecal-oral transmission. Latex barrier protection should be emphasized as 
a way to prevent the spread of E. coli  to a case’s sexual partners as well as being a way to prevent the exposure 
to and transmission of other pathogens. 
• If diagnosed with pathogenic E. coli , seek medical attention if symptoms compatible with hemolytic uremic 
syndrome (HUS) occur. (See chapter on HUS.) 
• Keep food that will be eaten raw, such as fruits and vegetables, from becoming contaminated by animal-derived 
food products. (Wash thoroughly, especially those that will not be cooked.) 
• If served an undercooked hamburger or other ground beef product in a restaurant, send it back for further 
cooking. 
• Cook all ground meats thoroughly. 
• Drink only pasteurized milk, juice, or cider. 
 
4) ADDITIONAL INFORMATION 
 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for pathogenic E. coli can be 
found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria in this chapter. 
(CSTE case definitions are used by the state health department and the CDC to maintain uniform standards for 
national reporting.)  
 
REFERENCES  
American Academy of Pediatrics. 2006 Red Book: Report of the Committee on Infectious Diseases, 27th Edition. 
Illinois, Academy of Pediatrics, 2003. 
CDC. Case Definitions for Infectious Conditions Under Public Health Surveillance, 2005: 
www.cdc.gov/osels/ph_surveillance/nndss/casedef/case_definitions.htm  
CDC Website. Escherichia coli O157:H7. www.cdc.gov/ecoli/index.html  
Heymann, D.L., ed. Control of Communicable Diseases Manual, 19th Edition. Washington, DC, American Public Health 
Association, 2008. 
Iowa Administrative Code (641) Chapter 1   Notification & Surveillance of Reportable Communicable & Infectious 
Diseases, Poisonings & Conditions. 
 
Resources 
 Centers for Disease Control and Prevention: www.cdc.gov/ 
 Iowa Department of Public Health: www.idph.state.ia.us/ 
  Center for Acute Disease Epidemiology 
  Bureau Of Environmental Health 
Iowa Department of Inspections and Appeals, Food Inspections: www.state.ia.us/government/dia/index.html 
 Iowa Department of Natural Resources: www.iowadnr.com/ 
 University of Iowa State Hygienic Laboratory: www.shl.uiowa.edu/   
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What is pathogenic E. coli ? 
Pathogenic E. coli are a type of bacteria that can cause bloody diarrhea.  It is usually seen in the summer.  The term 
“O157:H7” means a certain type of E. coli.  Most types of E. coli are harmless and live in the gut but some E. coli including 
O157:H7 can cause you to be sick. 
 
How is E. coli spread? 
E. coli  is spread by a person eating or drinking food or water that contains stool of infected people or animals.  Raw milk, 
unpasteurized cider or other juices, or poorly cooked meat, especially ground beef, or can also contain the bacteria.   
 
Who gets pathogenic E. coli ? 
Anyone can be infected. 
 
What are the symptoms of pathogenic E. coli ? 
The major symptom is diarrhea, which can look like bloody water.  Stomach cramps and chills may occur.  There is usually 
no fever.  Rarely, the infection can cause the kidneys to stop working, especially in young children. 
 
How soon do symptoms appear? 
Symptoms usually start in 3 - 4 days after exposure but can be anywhere from 10 hours - 10 days. 
   
What Should You Do If You Think You May Be Infected?  
Contact your doctor.  Do not go to work or school and do not prepare food when diarrhea is present. 
 
Can infection with E. coli occur more than once? 
Yes 
  
How is infection with E. coli prevented? 
• Do not fix food for others while having diarrhea. 
• Always wash hands thoroughly with soap and water before eating and before and after fixing any food, especially raw 
meat.  
• Wash hands after using the toilet and after changing diapers. (Wash the diapered child’s hands also.) 
• When caring for someone with diarrhea, wash your hands with plenty of soap and water after cleaning the bathroom, 
helping the person use the toilet, or changing diapers, soiled clothes or soiled sheets.  Be sure to wash their hands 
also. 
• Always refrigerate meat.  Never leave raw meat at room temperature. 
• Keep food that will be eaten raw, such as fruits and vegetables, from being in contact with food products from 
animals. (Wash thoroughly, especially those that will not be cooked.) 
• Never eat raw meat.  If you are served an undercooked hamburger or other ground beef product in a restaurant, 
send it back for further cooking. 
• Cook all ground beef and hamburger thoroughly – to a temperature of 155 degrees F for at least 15 - 16 seconds or 
until juices run clear and no pink is visible. 
• Always wash hands, cutting boards and utensils between fixing raw meat or poultry and other items such as fruits 
and vegetables. 
• Drink only pasteurized milk, juice, or cider. 
• Avoid sexual practices that may permit fecal-oral transmission. Latex barrier protection (condoms) should be used to 
prevent the spread of pathogenic E. coli to sexual partners as well as other pathogens. 
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E. Coli O157:H7 and other Shiga-Toxin 
producing strains                   Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome: 
 Survived this illness     Died from this illness 
 Died unrelated to this illness   Unknown 
Date of Death      /     /      First name: 
 
      
Event exception 
 Case could not be found 
 Case could not be interviewed 
 Case refused interview 
 Other – see notes 
Provider title:  ARNP    DO 
 MD 
 NP  PA 
Outbreak related:  Yes      No      Unknown  
Outbreak name:       Facility name:       
Exposure setting:       Address line 1:       
Epi-linked:  Yes   No  Unk To whom: ______________  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
Laboratory: 
 
      Accession #: 
 
      
Collection 
date: 
 
     /     /      
 
Date received: 
 
     /     /      
Specimen 
source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
E. coli  Serotype:    
 
Laboratory: 
 
      Accession #: 
 
      
Collection 
date: 
 
     /     /      
 
Date received: 
 
     /     /      
Specimen 
source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
E. coli  Serotype:    
 
  
Center for Acute Disease Epidemiology      Fax: 515-281-5698           E. coli O157:H7 and other shiga-toxin producing strains     Revised June-11      1   
CONFIDENTIAL                            PATIENT NAME __________________________                                 Iowa Department of Public Health 
 
Laboratory: 
 
      Accession #: 
 
      
Collection 
date: 
 
     /     /      
 
Date received: 
 
     /     /      
Specimen 
source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
E. coli   Serotype:    
 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’ 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
 
Hospital: 
 
      Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /       
       Isolated at entry: 
 
 Yes    No    Unk 
Isolation type 
(entry): 
 
      
Days 
hospitalized:        Currently isolated: 
 
 Yes    No    Unk 
Current isolation 
type: 
 
      
 
CLINICAL INFO & DIAGNOSIS 
 
HUS 
Diagnosis  Yes    No    Unk Onset Date      /     /      
TTP 
Diagnosis  Yes    No    Unk Onset Date      /     /      
 
If HUS or TTP diagnosis create  new HUS event for this case 
 
S
ym
pt
om
s 
Diarrhea 
Nausea 
Vomiting 
Headache 
Muscle weakness 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
      Days/Hours 
      Days/Hours 
      Days/Hours 
      Days/Hours 
      Days/Hours 
Visible bloody 
diarrhea  
Fever 
 
Abdominal cramps 
Chills 
 
 Yes    No    Unk 
 Yes    No    Unk 
Highest known fever: 
 Yes    No    Unk 
 Yes    No    Unk 
 
      Days/Hours 
      Days/Hours 
       °F    °C 
      Days/Hours 
      Days/Hours 
First symptom:       
Most severe 
symptom:       
Date returned to normal 
activities:      /     /      
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
 
OTHER LAB FINDINGS 
 
Clinical specimen from case 
 
Was PFGE performed:  Yes    No    Unk 
IA-XbaI 
Pattern       
IA-BlnI 
 Pattern       
CDC-XbaI 
Pattern       
CDC-BInI 
Pattern       
 
Environmental specimen testing 
Food, Medication, or 
environmental samples tested?  Yes    No    Unk 
Describe 
samples: (circle positives)       
For what were the samples 
tested? 
 E. coli or EHEC  Salmonella   
 Shigella              Other testing (specify): 
Laboratory:       Positive?  Yes    No    Unk 
PFGE 
performed?  Yes    No    Unk 
IA-XbaI 
Pattern       
IA-BlnI 
 Pattern       
CDC-XbaI 
Pattern       
CDC-BInI 
Pattern       
 
TREATMENT 
 
Antibiotics prescribed?   Yes    No    Unknown 
 
  
Antibiotic:       
  
Antibiotic:       
 
 
Antibiotic:       
Date 
started:      /     /      
Date 
started:      /     /      
Date 
started:      /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Risk Factors/Travel Information – In the 10 days prior to onset of symptoms did the case: 
Tr
av
el
 
Travel within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       Departure date:      /     /      Return date:      /     /      
Travel within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Travel outside U.S.?   
 Yes    No    Unk Country:       Departure date:      /     /      Return date:      /     /      
 
Visit restaurants?  Yes    No    Unknown 
If Yes, complete the table below:   County and address are missing from this table 
Establishment name Address/Zip Date visited Foods consumed Others ill? 
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
 
Attend Group Gatherings (e.g. weddings, parties)?  Yes    No    Unknown 
If Yes, complete the following table: 
Location name Address/Zip Date visited Foods consumed Others ill? 
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation period for 
E. coli O157:H7 is 2 to 
10 days. 
E. coli O157:H7 is communicable 
while a person has diarrhea and in 
adults for 1 week after. Children may 
shed bacteria for 3 weeks after 
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Where did the case purchase groceries in the 2 weeks before the onset of symptoms: 
Store name Address City/State/Zip County Date purchased 
                        
 
     /     /      
                        
 
     /     /      
                        
 
     /     /      
 
Dietary Information – In the 10 days prior to onset of symptoms did the case consume the following: 
Meat and poultry 
Any of these meat 
products?  Poultry      Ground beef    Pork     Meat other than ground meat (salami, jerky, wild game) 
Where was grilling done? 
 At own  home    Another person’s home    Picnic    Vendor stand  
 Other; Please list:_______________________________________________________________________________ 
From dates consumed:      /     /     ,      /     /                    To dates consumed:            /     /     ,      /     /      
 
 Was the meat fully cooked?  Yes    No    Unknown          
List all source/types:       
List all brand names:       
From dates consumed:      /     /     ,      /     /      To dates consumed:      /     /     ,      /     /      
 
Other meat and poultry products 
Deli/lunch meat  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Raw/partially 
cooked eggs or in 
foods (e.g. cookie 
dough): 
 Yes    No    Unk 
From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
 
Unpasteurized products 
Unpasteurized 
milk:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Unpasteurized 
juice:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Other 
unpasteurized 
products: 
 Yes    No    Unk 
From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
 
Other products 
Health supplements:  Yes    No    Unk From date consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Infant formula:  Yes    No    Unk From date consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Baby food:  Yes    No    Unk From date consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
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Fruits and vegetables 
Raw fruits:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Raw vegetables:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
 
Other 
Leftover foods consumed: 
 Yes    No    Unk 
Reheated: 
 Yes    No    Unk 
 
From date consumed:      /     /      
 
To date consumed:      /     /      
Describe leftovers consumed: 
 
 
Animal Exposures – In the 10 days prior to the onset of symptoms did the case: 
Check all that apply 
Visit or live on a farm: 
Exposed to manure: 
Have farm animal contact: 
 Yes    No    Unknown 
 Yes    No    Unknown 
 Yes    No    Unknown 
 
 
Animals:       
 
Have reptile contact: 
Reptile lived with case: 
 
 Yes    No    Unknown 
 Yes    No    Unknown 
 
 Iguana    Lizard    Turtle    Snake    Other _____________________ 
Have other animal  
contact in home: 
 
 Yes    No    Unknown Animal:       Animal sick:  Yes    No    Unk 
Visit a petting zoo: 
 
 Yes    No    Unknown Touched animals: 
 
 Yes    No    Unk Animal:       
Zoo name:       Address/Zip/County:       
 
Water Exposures – In the 10 days prior to the onset of symptoms did the case 
Go swimming?  Yes    No    Unknown 
If Yes, complete the table below: 
Water Type Location Type Dates visited Facility name /  Street address & Zip 
 Hot tub/spa 
 Kiddie pool 
 River/stream 
 Lake 
 
 Pond  
 Water park 
 Swimming pool 
 Water fountain/ splash pad 
 Other_________________ 
 Hotel/motel 
 Indoor private 
 Indoor public   
 Outdoor private 
 Outdoor public 
From 
     /     /      
To 
     /     /      
 
 
 
 
Drinking water supply 
Home:  Bottled 
 Commercial Delivery 
 Municipal 
 Rural water 
 Well 
 
School:  Bottled 
 Commercial Delivery 
 Municipal 
 Rural water 
 Well 
 
Work:  Bottled 
 Commercial Delivery 
 Municipal 
 Rural water 
 Well 
 
Child care:  Bottled 
 Commercial Delivery 
 Municipal 
 Rural water 
 Well 
 
 
Other Exposures – In the 10 days prior to the onset of symptoms did the case: 
Wear diapers  Yes    No    Unk Have contact with diapers:  Yes    No    Unk 
    
Have contact with 
immunocompromised person:  Yes    No    Unk Setting: 
 Home 
 Work      Other _______________________________________ 
     
Have sex with someone with 
similar symptoms:  Yes    No    Unk 
Sexual 
preference: 
 Hetero 
 Homo 
 Bisexual 
 Unknown 
 
 
Number of people living in case’s household:          
 
Are there close contacts of the case with same symptoms:   Yes    No    Unknown 
 
Close contacts of the case with the same symptoms 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
Same 
exposures 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
      
 
     /     /      
 Restaurant    
 Gatherings   
 Food 
 Animal 
 Water 
 
 Yes 
 No 
      
      
If this contact is a case create a new event and/or case for this contact. 
CONTACTS 
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Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
Same 
exposures 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
      
 
     /     /      
 Restaurant    
 Gatherings   
 Food 
 Animal 
 Water 
 
 Yes 
 No 
      
      
If this contact is a case create a new event and/or case for this contact. 
 
 
NOTES:       
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GIARDIASIS 
 
Responsibilities: 
Hospital: Report by IDSS, facsimile, mail or phone  
Lab: Report by IDSS, facsimile, mail or phone 
Physicians: Report by facsimile, mail or phone 
Local Public Health Agency (LPHA): Only clusters of cases warrant specific follow-up 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Giardia lamblia is a protozoan parasite that has two forms: cyst (inactive form) and trophozoite 
(active form). Infected persons can shed both trophozoites and cysts in stool 
 
B. Clinical Description 
Symptoms: of giardiasis are variable, and usually asymptomatic, but can include soft, non-bloody, 
foul-smelling diarrhea. Abdominal cramps and a “bloated” feeling with excess gas often accompany 
the diarrhea. The diarrhea can be chronic or intermittent and it can be accompanied by fatigue and 
steatorrhea (fatty stools). Appetite loss combined with malabsorption can lead to significant weight 
loss, failure to thrive and anemia.  
 
Onset: is usually abrupt.  Diarrhea may occur after meals, is non-bloody and is mucous-like 25% of 
the time.  
 
Complications: are not common.  However diarrhea may last 2 - 6 weeks. 
 
C. Reservoirs 
Common reservoirs: Humans and some animals (dogs, cats, rodents, cattle, deer, elk, beaver, and 
muskrats) are reservoirs, although the public health importance of most nonhuman reservoirs is 
debated. Overall, humans are the most important source of other human infections. Wildlife such as 
deer, elk, and beaver may be important in contaminating surface water supplies; domestic animals 
(e.g., dogs) may be a source for some human exposures. The most common source in Iowa is young 
children, especially those in child care. 
 
D. Modes of Transmission 
Spread: Giardia is principally spread person-to-person. Persons become infected by fecal-oral transfer 
of cysts from the feces of an infected individual, especially in institutions and child care centers. 
Transmission can also occur person-to-person through certain types of sexual contact (e.g., oral-anal 
contact.  Giardiasis has developed with ingestion with as few as 10 cysts.  
 
Environmental: Localized outbreaks may occur from fecally contaminated water, such as stream and 
lake waters and swimming pools that are contaminated by human and animal feces. Eating food 
contaminated by an infected food handler can be a source, but this has been rarely documented. 
Diapered children using “kiddie” pools filled with tap water without added chlorine or bleach is a 
high-risk source of transmission. 
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E. Incubation period 
The incubation period can vary from 3 - 25 days (or longer); the median is 7−10 days. 
 
F. Period of Communicability or Infectious Period 
The disease is communicable for as long as the infected person excretes the organism, which may be 
many months. The asymptomatic carrier rate is high. 
 
G. Epidemiology 
Giardiasis has a worldwide distribution. Children are infected more frequently than adults. Prevalence 
is higher in areas of poor sanitation and in institutions with children who are not toilet trained, 
especially child care centers. It infects nearly 2% of adults and 6% to 8% of children in developed 
countries worldwide. Nearly 33% of people in developing countries have had giardiasis. In the United 
States, Giardia infection is the most common intestinal parasitic disease affecting humans. Surveys 
conducted in the United States have demonstrated prevalence rates of Giardia in stool specimens 
that range from 1% to 30%, depending on location and age. Cases occur more commonly in the 
summer and fall months. 
  
H. Bioterrorism Potential 
None. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A.  Purpose of Surveillance and Reporting 
• To assess the magnitude of the disease in different areas and among different risk groups. 
• To identify outbreaks as soon as possible. 
• To design implement effective control or prevention methods. 
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report. The preferred method of reporting is by utilizing the Iowa Disease Surveillance 
System (IDSS).  However, if IDSS is not available, the reporting number for IDPH Center for 
Acute Disease Epidemiology (CADE) is (800) 362-2736; fax number (515) 281-5698, mailing 
address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
Des Moines, IA 50319-0075 
 
Postage-paid disease reporting forms are available free of charge from the IDPH clearinghouse.   
Call (319) 398-5133 or visit the website 
healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295 to request a supply. 
 
 Laboratory Testing Services Available 
 The University of Iowa State Hygienic Laboratory (SHL) provides testing services for ova and 
 parasites including Giardia from stool specimens.  For additional information, contact the SHL at 
 (319) 335-4500 or visit www.shl.uiowa.edu/. 
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C.  Local Public Health Agency Follow-up Responsibilities 
Case Investigation 
a. Case investigation of giardiasis in Iowa residents may be necessary in certain settings where 
outbreaks are likely to occur (child cares, nursing homes, etc). Follow-up of individual cases is 
usually not warranted. 
b. Following IDPH notification of an outbreak or cluster of cases, LPHA(s) may be asked to assist in 
an official investigation. An investigation can be completed by interviewing the case and others 
who may be able to provide pertinent information. Most of the information required can be 
obtained from the healthcare provider or the medical record. Use the following guidelines to 
assist in completing the investigation: 
1) Record “giardiasis” as the disease being reported. 
2) Record the case’s demographic information. 
3) Record the date of symptom onset, symptoms, date of diagnosis, and hospitalization 
information (if applicable).  
4) When asking about exposure history (food, travel, activities, etc.), use the incubation period 
range for giardiasis (3−25 days). Specifically, focus on the period beginning a minimum of 3 
days prior to the case’s onset date back to no more than 25 days before onset. 
5) Ask questions about travel history, contact with children, and outdoor activities to help 
identify where the case became infected. 
6) Ask questions about water supply because giardiasis may be acquired through water 
consumption.   
7) Household/close contact, pet or other animal contact, child care, and food handler questions 
are designed to examine the case’s risk of having acquired the illness from, or potential for 
transmitting it to, these contacts. Determine whether the case attends or works at a child 
care facility and/or is a food handler. 
c. Discuss the findings with IDPH or mail (in an envelope marked “Confidential”) to IDPH, Center 
for Acute Disease Epidemiology.  The mailing address is:  
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th Street 
Des Moines, IA 50319-0075 
 
3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements 
Food handlers with giardiasis must be excluded from work until diarrhea has ceased. 
 
B.  Protection of Contacts of a Case 
 None. 
 
C.  Managing Special Situations 
Child care  
Since giardiasis may be transmitted person-to-person through fecal-oral transmission, it is important 
to carefully follow up on cases of giardiasis in child care settings. 
 
• Children with giardiasis who have diarrhea should be excluded until their diarrhea is gone. 
 
• Children with giardiasis who have no diarrhea and are otherwise not ill may be excluded or can 
remain in the program if special precautions are taken. 
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• Since most staff in child-care programs are considered food handlers, those with Giardia in their 
stools who are symptomatic should not be at work until diarrhea has ceased.  When returning to 
work good hand hygiene should be practiced at all times.  
 
• All child care staff and children should practice good hand hygiene at all times. 
 
School  
Since giardiasis may be transmitted person-to-person through fecal-oral transmission, it is important 
to carefully follow up on cases of giardiasis in a school setting. General recommendations include:  
 
• Students or staff with giardiasis who have diarrhea should be excluded until their diarrhea is 
gone. 
 
• Students or staff with giardiasis, who do not handle food, have no diarrhea and are not 
otherwise sick, may remain in school if special precautions are taken. Students and staff 
must practice frequent and thorough handwashing using warm running water, soap, with 
friction for at least 15 seconds, and thoroughly drying their hands with paper towels or a 
blow dryer.  If symptoms of giardiasis occur the person should be excluded. 
 
Food Handler 
Note: A food handler is any person directly preparing or handling food. This can include a patient 
care or child-care provider. See glossary for a more complete definition. 
 
Since Giardia may be transmitted via food, it is important to follow up on outbreaks of Giardia in any 
setting carefully.  General recommendations include:  
• Food handlers with Giardia infection who have diarrhea should be excluded until their 
diarrhea is gone, (until 24 hours after last bout of diarrhea or until formed stools are 
occurring).  
• Food handlers must practice frequent and thorough handwashing using warm running water 
and soap, with friction for at least 15 seconds, and thoroughly dry their hands with paper 
towels or a blow dryer. 
 
Community Residential Programs  
Actions taken in response to a case of giardiasis in a community residential program will depend on 
the type of program and the level of functioning of the residents. In long-term care facilities, 
residents with giardiasis should be placed on standard (including enteric) precautions until their 
symptoms subside. Staff members who give direct patient care (e.g., feed patients, give mouth or 
denture care or give medications) are considered food handlers and are subject to food handler 
restrictions. In residential facilities for the developmentally disabled, staff and clients with giardiasis 
must refrain from handling or preparing food for other residents until their diarrhea has subsided. 
 
Reported Incidence Is Higher than Usual or an Outbreak is Suspected 
If the number of reported cases of giardiasis in your city or county is higher than usual, or if an 
outbreak is suspected, investigate to determine the source of infection and mode of transmission. A 
common vehicle (such as water, food or association with a child care center) should be sought and 
applicable preventive or control measures should be instituted (e.g., removing an implicated food 
item from the environment). Control of person-to-person transmission requires special emphasis on 
personal cleanliness and sanitary disposal of feces. Consult with CADE at (800)-362-2736. CADE can 
help to determine a course of action to prevent further cases and can perform surveillance for cases 
in an outbreak that may cross several county lines and therefore be difficult to identify at a local 
level. 
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D. Preventive Measures 
Environmental Measures 
To avoid exposure, recommend that individuals: 
• Always wash their hands thoroughly with soap, water, and friction for at least 15 seconds 
before eating or preparing food, after using the toilet and after changing diapers. 
• In child cares, dispose of feces in a sanitary manner. 
• When caring for someone with diarrhea, scrub hands with plenty of soap and water after 
cleaning the bathroom, helping the person use the toilet, or changing diapers, soiled clothes, 
or soiled sheets. 
• When hiking or camping, be aware of the risks of drinking water from streams or lakes. 
Bringing water to a full, rolling boil is sufficient to kill Giardia. Several filters are also available 
that remove Giardia cysts. Additionally, some chemical water treatments are effective against 
Giardia.  
• Avoid sexual practices that may involve direct contact with feces. Latex barrier protection 
should be emphasized as a way to prevent the spread of Giardia to case’s sexual partners as 
well as being a way to prevent the exposure to and transmission of other pathogens. 
 
International Travel 
Travelers to developing countries should: 
• “Boil it, cook it, peel it, or forget it."   
• Drink only bottled or boiled water, keeping in mind that bottled carbonated water is safer 
than uncarbonated water.  
• Ask for drinks without ice unless the ice is made from bottled or boiled water. Avoid popsicles 
and flavored ices that may have been made with contaminated water.  
• Eat foods that have been thoroughly cooked and are still hot and steaming.  
• Avoid raw vegetables and fruits that cannot be peeled. Vegetables like lettuce are easily 
contaminated and are very hard to wash well.  
• Peel their own raw fruits or vegetables and do not eat the peelings.  
• Avoid foods and beverages from street vendors.  
 
Note: For more information regarding international travel, contact the CDC’s Traveler’s Health Office 
at (877) 394-8747 or visit: www.cdc.gov/travel. 
 
4) ADDITIONAL INFORMATION 
 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Giardiasis 
can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
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FACT SHEET GIARDIA Infection; Giardiasis 
 
What is giardiasis (also called Giardia  infection)? 
Giardiasis is a gut infection caused by a germ called Giardia lamblia.  It is a common cause of diarrhea in 
the US.  Over three hundred cases of giardiasis are reported each year in Iowa.   
 
What are the symptoms of giardiasis? 
People with Giardia infection may experience mild or severe diarrhea, stomach cramps, bloating and 
fatigue.  Diarrhea may last several weeks or months and might cause weight loss.  Fever is rare.  
However, some people infected with Giardia do not become ill.  Many young children have no symptoms.  
(Children in child care centers are often infected, but do not need treatment unless they get diarrhea).  
 
How soon do symptoms appear? 
Diarrhea usually begins 7 - 10 days, but it can range from 3 - 25 days after infection with Giardia. 
 
How is Giardia infection spread? 
Giardia germs are passed in the feces of an infected person or animal and may contaminate water or 
food.  The disease can spread from person to person in child care centers or other settings where people 
sometimes don't wash their hands well enough.  People who go camping or hunting can get giardiasis by 
drinking untreated water. 
 
Who gets Giardia infection? 
Anyone can become infected with Giardia, but children are infected more often than adults.  It occurs 
frequently in hospitals, prisons, or child cares.  Persons who travel overseas or who drink untreated water 
also have a higher risk of giardiasis. 
 
For how long is a person infectious? 
An infected person can spread Giardia for a few weeks to months.  Treatment may shorten this length of 
time. 
 
What is the treatment for this illness? 
Antibiotics are often prescribed by doctors to treat Giardia infection.  However, some persons may 
recover on their own without treatment. Not everyone infected with Giardia needs to be treated. 
 
Do infected people need to be excluded from school, work, or child care? 
Since Giardia germs are found in the feces (stool), people with diarrhea should not go to school or work.  
However, they may return when the diarrhea stops. Everyone should wash his or her hands each time 
after using the toilet.   
 
What can be done to help prevent the spread of Giardia? 
1. Carefully wash hands thoroughly after using the toilet or handling dirty diapers. 
2. Properly dispose of sewage so water sources will not be infected. 
3. Do not drink water that has not been properly treated.  When camping, treat your drinking water by 
boiling or by using "purification tablets" before drinking. 
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GONORRHEA 
 
Also known as:  Gonorrhea, Gonococcal Infection (GC), Neisseria gonorrhoeae (NG), 
Clap, Drip, Dose 
 
Responsibilities: 
Hospital: Report cases by IDSS, fax, phone, or mail 
Lab: Report positive lab results by IDSS, fax, phone, or mail 
Physician: Report cases by fax, phone, or mail 
Local Public Health Agency (LPHA): Follow-up conducted by Iowa Department of 
Public Health or by Black Hawk, Linn, Polk or Scott County Health Departments 
 
Iowa Department of Public Health 
Sexually Transmitted Disease Reporting Hotline: (515) 281-3031 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Gonorrhea is a common sexually transmitted disease (STD) caused by Neisseria gonorrhoeae, a 
bacterium that can grow and multiply easily in the warm, moist environment of the reproductive 
tract, including the cervix, uterus, and fallopian tubes in women, and in the urethra in women and 
men. The bacterium can also grow in the oropharynx, anorectum, and eyes. 
  
B. Clinical Description 
Symptoms: Men may have some signs or symptoms that appear 2 – 5 days after infection, but the 
symptoms can take as long as 30 days to appear. There may also be no signs or symptoms as this 
infection is often asymptomatic.  Signs and symptoms may include a burning sensation when 
urinating, or a white, yellow, or green discharge from the penis, but these are often mild. Sometimes 
men with gonorrhea have painful or swollen testicles. 
 
In women, symptoms are often mild.  Many who are infected have no symptoms. Even when a 
woman has symptoms, they can be non-specific and mistaken for a bladder or vaginal infection. 
Initial signs and symptoms in women can include a painful or burning sensation when urinating, 
increased vaginal discharge, or vaginal bleeding between periods or during or after intercourse. 
Women with mild or no symptoms are still at risk of developing serious complications.  
 
Symptoms of rectal infection in both men and women may include discharge, anal itching, soreness, 
bleeding, or sometimes painful bowel movements. Rectal infection can sometimes have no 
symptoms. Infections in the throat may cause a sore throat, but usually there are no symptoms.  
 
Onset:  If symptoms are present, a range of 0 - 30 days, with 2 - 7 days being the most common. 
Often there are no symptoms; 10% - 15% of men and about 80% of women have no symptoms.  
People with no symptoms are at increased risk for developing complications, because they receive no 
treatment.  Asymptomatic individuals may spread the infection unknowingly. 
 
Complications:  Untreated gonorrhea can cause serious and permanent health problems in both 
women and men.  
 
• In men, gonorrhea can cause epididymitis, a painful condition of the testicles that can lead to 
infertility if untreated. Without prompt treatment, gonorrhea can also affect the prostate, and 
lead to scarring inside the urethra, making urination difficult.  
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• In women, gonorrhea is a common cause of pelvic inflammatory disease (PID). About one 
million women in the United States develop PID each year. Women with PID do not 
necessarily have symptoms. When symptoms are present, they can be very severe and can 
include abdominal pain and fever. PID can lead to internal abscesses (pus-filled “pockets” 
that are hard to cure) and long lasting, chronic pelvic pain. PID can cause infertility, or 
damage the fallopian tubes enough to increase the risk of ectopic pregnancy. Ectopic 
pregnancy is a life-threatening condition in which a fertilized egg grows outside the uterus, 
usually in a fallopian tube. 
• If a pregnant woman has gonorrhea, she may give the infection to her baby as the baby 
passes through the birth canal during delivery. This can cause blindness, joint infection, or a 
life-threatening blood infection in the baby. Treatment of gonorrhea as soon as it is detected 
in pregnant women will reduce the risk of these complications. Pregnant women should 
consult a healthcare provider for appropriate examination, testing, and treatment, if 
necessary.  
• Gonorrhea can spread to the blood or joints. This condition, called Disseminated Gonococcal 
Infection, can be life threatening. People with gonorrhea can more easily contract HIV, the 
virus that causes AIDS. HIV-infected people with gonorrhea are more likely to transmit HIV 
to someone else. 
 
C. Reservoirs 
Common reservoirs:  Humans 
 
D. Modes of Transmission 
Person-to-person:  Gonorrhea is spread through contact between the penis, vagina, mouth, and 
anus. Ejaculation does not have to occur for gonorrhea to be transmitted or acquired. Gonorrhea can 
also be spread from mother to baby during birth. 
 
Gonorrhea can spread to other unlikely parts of the body. For example, a person can get an eye 
infection after touching infected genitals and then the eyes. People who have had gonorrhea and 
received treatment may get infected again if they have sexual contact with a person infected with 
gonorrhea. 
 
Any sexually active person can be infected with gonorrhea. The greater the number of sex partners, 
the greater the risk of infection. Because the cervixes of teenage girls and young women are not fully 
matured, they are at particularly high risk for infection if sexually active. Since gonorrhea can be 
transmitted by oral or anal sex, men who have sex with men are also at risk for gonorrheal infection.  
 
E. Incubation period 
The average incubation period is 2 - 5 days, but may range from 0 - 30 days. Men who are infected 
may have no symptoms, and may not believe that they are infected. Most women who are infected 
have no symptoms. Most women who develop local symptoms do so within 10 days of infection. 
 
F. Period of Communicability or Infectious Period 
A person who is infected with gonorrhea can spread disease from the time he or she is infected until 
properly treated. Reinfection is common if partners are not adequately treated in a timely manner. 
 
G. Epidemiology 
Gonorrhea is the second most commonly reported notifiable disease in the United States. It is 
estimated that approximately 800,000 people in the United States are infected with gonorrhea each 
year. Only about ½ of these infections are reported to CDC. In 2011, 321,849 cases of gonorrhea 
were reported in the U.S. to CDC. In 2011, the rate of reported gonorrhea infections was 104.2 per 
100,000 persons.   In Iowa, there were 1,966 cases reported in 2011 (Rate: 65 per 100,000). Rates 
are highest among persons 15 to 29 years of age.  People in this age range account for 81% of 
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diagnoses.  In addition, rates among African Americans remain markedly higher than among other 
racial and ethnic groups.    
H. Bioterrorism Potential 
None. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To monitor trends in gonorrhea diagnoses and prevalence so that prevention and treatment 
funds may be targeted efficiently, and prevention programs may be evaluated. 
• To monitor perinatal exposures to gonorrhea and morbidity in infants born with gonorrhea. 
• To monitor trends in antimicrobial resistant gonorrhea to ensure appropriate treatment has been 
provided to the infected individual. 
• To interrupt disease transmission chains by providing risk reduction counseling and partner 
notification and referral services to persons recently diagnosed with gonorrhea. 
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139A) stipulates that the laboratory and healthcare provider must 
report. The Sexually Transmitted Disease reporting number for IDPH is (515) 281-3031. 
 
Healthcare providers must complete an “Iowa Confidential Report of Sexually Transmitted Disease” 
morbidity form within 3 days of a positive N. gonorrhoeae diagnosis.  Healthcare providers should 
provide the name, date of birth, sex, pregnancy status (for women), race/ethnicity, home address, 
phone number, and treatment information for each reported case.  In addition, Iowa Code 139A 
allows for reporting of partner names, addresses, and treatment information for health department 
follow up. 
 
Morbidity forms and postage-paid envelopes are available for order from the clearinghouse at 
http://healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=303     
They are also available by phoning the STD Program. 
 
Fax completed forms to the STD Program at: (515) 281-0466 
 
Alternatively, they may be mailed to the address below: 
 
Iowa Department of Public Health 
Bureau of HIV, STD, and Hepatitis (00) 
321 East 12th Street, 5th Floor 
Des Moines, IA 50319-0075 
 
C.  Local Public Health Agency Follow-up Responsibilities 
Case Investigation: 
Risk reduction counseling and partner notification/referral services will be provided by Disease 
Prevention Specialists employed by the Iowa Department of Public Health, or by Black Hawk, Linn, 
Polk or Scott County Health Departments. 
 
3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements 
None. 
 
B.  Protection of Contacts of a Case 
The Iowa Department of Public Health may initiate a voluntary partner notification/referral service 
with persons who have been diagnosed with N. gonorrhoeae infection.  Healthcare providers can 
Iowa Dept. of Public Health Revised 12/13   Gonorrhea 3 
Guide to Surveillance, Investigation, and Reporting 
facilitate this process by describing the program to the patient and encouraging the patient to meet 
with the Department’s Disease Prevention Specialist assigned to his or her region. 
 
Patient’s names and times of exposure are not used when notifying partners.  Referral for testing and 
treatment are offered to all partners.  Appropriate referrals for other services are provided. 
 
Physicians may assist the Disease Prevention Specialist with collecting partner information for 
notification.  In such cases, the healthcare provider should collect the following information:  Partner 
name, address, home phone number, age and/or date of birth, race, sex, partner’s marital status, 
height, size/build, general physical description, dates of first and last exposure, and any other 
information that may help in locating and counseling the partner, such as medical conditions, place of 
employment, cell phone number, or other unusual circumstances/situations.  Providers should also 
report any partner treatment. 
 
Patient-delivered partner therapy/ Expedited Partner Therapy:  When a patient has partners who may 
not be willing or who may be unable to submit to testing, patient-delivered partner therapy is an 
option.  A physician, physician assistant, or advanced registered nurse practitioner who diagnoses a 
sexually transmitted chlamydial or gonococcal infection may prescribe, dispense, furnish, or otherwise 
provide prescription oral antibiotic drugs to that patient's sexual partner or partners without 
examination of the partner(s) (see Iowa Code 139A.41). If the infected individual patient is unwilling 
or unable to deliver such prescription drugs to a sexual partner or partners, a physician, physician 
assistant, or advanced registered nurse practitioner may dispense, furnish, or otherwise provide the 
prescription drugs to the department or local disease prevention investigation staff for delivery to the 
partner or partners.  Medications or prescriptions should be provided for all partners who have been 
sexually exposed to the patient within the two months prior to diagnosis or within the two months 
prior to the onset of symptoms, whichever is greater.  However, expedited partner therapy should 
not be used if the partner is a pregnant woman or if the patient is a man who has sex with other 
men (MSM).  Further information on expedited partner therapy can be found at: 
www.idph.state.ia.us/IDPHChannelsService/file.ashx?file=CDA25C68-F6DA-4471-8C1C-
016C2CA44C81   
 
C.  Managing Special Situations 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
Report unusual cases to the Iowa Department of Public Health at (515) 281-3031, including     
antimicrobial resistant cases. 
 
D. Preventive Measures 
Preventive Measures/Education 
Risk reduction counseling/education and testing should be offered to all persons with risk factors for 
N. gonorrhoeae infections and transmission. 
 
The surest way to avoid transmission of sexually transmitted diseases is to abstain from sexual 
contact, or to be in a long-term mutually monogamous relationship with a partner who has been 
tested and is known to be uninfected. 
 
Latex male condoms for vaginal, oral or anal sex, when used consistently and correctly, can reduce 
the risk of transmission of N. gonorrhoeae. 
 
N. gonorrhoeae screening is recommended for all sexually active women 25 years of age and 
younger.  All pregnant women should have a screening test for N. gonorrhoeae.  Women older than 
25 years whose sexual practices put them at risk for N. gonorrhoeae infection should be tested at 
least once a year.   It has been shown that screening and treatment of women with N. gonorrhoeae 
infection of the cervix reduces the likelihood of PID. 
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The Centers for Disease Control and Prevention’s 2010 STD Treatment Guidelines provide specific 
recommendations for STD prevention services that should be available to all sexually active men who 
have sex with men (MSM).  The first recommendation for this population is that STD screening be 
performed at least annually.   
 
Any genital symptoms such as discharge or burning during urination or unusual sore or rash should 
be a sign to stop having sex and consult a healthcare provider immediately.  In cases of rectal or anal 
infection, symptoms may include anal or rectal itching, discharge and pain during defecation.  
Symptoms for N. gonorrhoeae of the mouth or throat include soreness and redness.  If N. 
gonorrhoeae infects the eye, men and women might experience conjunctivitis (redness, itching and 
discharge from the eye).  If a person has been treated for N. gonorrhoeae (or any other STD), he or 
she should notify all recent sex partners so they can see a healthcare provider and be treated.  This 
will reduce the risk that the sex partners will develop serious complications from N. gonorrhoeae and 
the person’s risk of becoming re-infected.  The person and all sex partners must avoid sex until they 
have completed treatment for N. gonorrhoeae. 
 
An infected patient should be tested for other sexually transmitted diseases. 
 
See www.hivtest.org/STDTesting.aspx for a current list of sites that can provide STD testing. 
 
4) ADDITIONAL INFORMATION 
      
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for 
Gonorrhea can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
 
     Treatment Information 
N. gonorrhoeae can be treated and cured with antibiotics.  For uncomplicated gonococcal infections 
of the cervix, urethra, and rectum: 250 mg ceftriaxone, delivered in a single dose by intramuscular 
injection plus 1 gram of azithromycin, given orally in a single dose. Pregnant women should be 
treated with the same regimen. HIV-positive persons with N. gonorrhoeae should also receive the 
same treatment as those who are HIV-negative. Refer to the 2010 CDC Sexually Transmitted 
Diseases Treatment Guidelines for complete treatment guidelines.   
 
Treatment failure has occurred among individuals with gonococcal infections who were treated with 
oral cephalosporins. Although antimicrobial resistant strains of N. gonorrhoeae are most common in 
Asian countries, treatment failures with oral cephalosporins have been documented in North America.  
Decreasing susceptibility to cephalosporins has been observed throughout the United States, 
occurring more frequently on the West Coast. People diagnosed with N. gonorrhoeae should tell their 
healthcare provider if they or their sex partners have recently traveled to areas in which resistance 
appears to be developing more rapidly (e.g., Southeast Asia), to ensure proper treatment.   
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Additional Resources 
 CDC Website with most current guidelines for prevention, surveillance, and treatment: 
 www.cdc.gov/std/Gonorrhea/default.htm  
 
 STD Program web site, Iowa Department of Public Health. 
  www.idph.state.ia.us/HivStdHep/STD.aspx?prog=Std&pg=StdHome 
 
 American Sexual Health Association. 
 www.ashasexualhealth.org/std-sti/gonorrhea.html  
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What is gonorrhea? 
Gonorrhea is a sexually transmitted disease (STD) caused by a bacterium that can grow and multiply 
easily in the warm, moist areas of the reproductive tract, including the cervix (opening to the womb), 
uterus (womb), and fallopian tubes (egg canals) in women, and in the urethra (urine canal) in women 
and men. The germ can also grow in the mouth, throat, eyes, and anus (butt). 
 
How do people get gonorrhea? 
Gonorrhea is spread through contact between the penis, vagina, mouth, and anus. A man does not have 
to ejaculate to give gonorrhea to a sexual partner. Gonorrhea can also be transmitted to a baby during 
birth if the mother is infected. 
 
Gonorrhea infection can spread to other parts of the body. For example, a person can get an eye 
infection after touching infected genitals (private areas) and then the eyes. People who have been 
treated for gonorrhea may get it again if they have sexual contact with another person or untreated 
partner who has gonorrhea. 
 
Who is at risk for gonorrhea?  
Any sexually active person can be infected with gonorrhea. In the United States, the highest reported 
rates of infection are among sexually active teenagers, young adults, and African Americans.  
 
What are the signs and symptoms of gonorrhea? 
Some men have signs or symptoms that appear 2 - 5 days after infection, but the symptoms can take as 
long as 30 days to appear or may not appear at all. Signs and symptoms include a burning sensation 
when urinating (peeing), or a white, yellow, or green discharge from the penis. Sometimes men with 
gonorrhea get painful or swollen testicles. 
 
In women, the signs and symptoms of gonorrhea are often mild, and many women who are infected 
have no symptoms. Even when a woman has signs, they can be so mild they may be mistaken for a 
bladder or vaginal infection. The first signs and symptoms for women include a painful or burning 
sensation when urinating (peeing), increased vaginal discharge, or vaginal bleeding between menstrual 
periods. Women with mild or no symptoms are still at risk of developing serious complications.  
 
Symptoms of rectal infection in both men and women may include discharge, anal itching, soreness, 
bleeding, or sometimes painful bowel movements. Rectal infection may also cause no symptoms.  
Infections in the throat may cause a sore throat or hoarseness, but usually causes no symptoms.  
 
What are the complications of gonorrhea? 
Untreated gonorrhea can cause serious and permanent health problems in both women and men. 
 
In women, gonorrhea is a common cause of pelvic inflammatory disease (PID). About 1 million women in 
the United States develop PID each year. Women with PID do not necessarily have symptoms right away. 
When symptoms are present, they can be very severe and can include abdominal pain and fever. PID can 
lead to internal abscesses (pus-filled “pockets” that are hard to cure) and long lasting, chronic pelvic 
(lower belly) pain. PID can cause infertility, or damage the fallopian tubes enough to increase the risk of 
ectopic pregnancy. Ectopic pregnancy is a life-threatening condition in which a fetus grows outside the 
uterus, usually in a fallopian tube. 
 
In men, gonorrhea can cause epididymitis, a painful condition of the testicles that can lead to infertility if 
left untreated. Without prompt treatment, gonorrhea can also affect the prostate, and lead to scarring 
inside the urethra, making urination difficult.  
 
Gonorrhea can spread to the blood or joints. This condition can be life threatening. People with 
gonorrhea can more easily contract HIV, the virus that causes AIDS. HIV-infected people with gonorrhea 
are more likely to transmit HIV to someone else. 
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How does gonorrhea affect a pregnant woman and her baby? 
If a pregnant woman has gonorrhea, she may give the infection to her baby as the baby passes through 
the birth canal during delivery. This can cause blindness, joint infection, or a life-threatening blood 
infection in the baby. Treatment of gonorrhea as soon as it is detected in pregnant women will reduce 
the risk of these complications. Pregnant women should consult a healthcare provider for appropriate 
prenatal care, testing, and treatment, if necessary.  
 
How is gonorrhea diagnosed? 
Several laboratory tests are available to diagnose gonorrhea. Your doctor will choose the one appropriate 
for you. 
 
What is the treatment for gonorrhea? 
Several antibiotics can successfully cure gonorrhea in adolescents and adults, but drug-resistant strains of 
gonorrhea are increasing in many areas of the world, including the United States, and successful 
treatment of gonorrhea is becoming more difficult. Because many people with gonorrhea also have 
chlamydia, another sexually transmitted disease (STD), antibiotics for both infections are usually given 
together. Persons with gonorrhea should be tested for other STDs.  
 
It is important to take all of the medication prescribed to cure gonorrhea, even if the signs or symptoms 
stop before all the medication is gone. Although medication will stop the infection, it will not repair any 
permanent damage done by the disease. People who have had gonorrhea and have been treated can get 
the disease again. If you continue to have symptoms even after you are treated, you should return to 
your doctor to be re-tested. 
 
How can gonorrhea be prevented?  
The surest way to avoid spreading sexually transmitted diseases is to abstain from sexual intercourse, or 
to be in a long-term mutually faithful relationship with a partner who has been tested and you know is 
uninfected. 
Latex condoms, when used consistently and correctly, can reduce the risk of getting gonorrhea.  
Any genital symptoms such as discharge or burning during urination or unusual sore or rash should be a 
signal to stop having sex and see a doctor immediately. If a person has been treated for gonorrhea (or 
any other STD), he/she should notify all recent sex partners so they can see a healthcare provider and be 
treated. This will reduce the risk of sex partners developing serious complications, and the person’s risk 
of becoming re-infected. The person and all sex partners must avoid sex until they have completed 
treatment. 
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Haemophilus influenzae type b 
(Invasive) 
 
Also known as:  Hib disease, H. flu, spinal meningitis, Haemophilus 
 
Responsibilities: 
Hospital: Report immediately by phone, follow up required 
Infection Preventionist:  Report immediately by phone, follow up required 
Lab Report /Isolate submission requirements: Isolates from invasive sites, should be 
submitted to State Hygienic Laboratory (SHL), for serotyping.  
Lab: Report positive isolates immediately by phone 
Physician: Report immediately by phone 
Local Public Health Agency (LPHA): Report immediately by phone, follow up 
required 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY   
 
A. Agent 
Haemophilus influenzae disease is caused by small gram-negative coccobacilli that may be either 
encapsulated (types a−f) or unencapsulated (nontypeable). Type b (Hib) is the only kind for which 
there is a vaccine and for which control measures are considered necessary. It is the only type that is 
reportable. 
 
B. Clinical Description 
Symptoms:  Invasive disease may produce various clinical syndromes, including meningitis, 
bacteremia or sepsis, epiglottitis, pneumonia, septic arthritis, osteomyelitis, pericarditis, empyema, 
and abscesses. In contrast, mucosal infections such as bronchitis, sinusitis, and otitis, which can be 
caused by Hib, are considered noninvasive disease 
 
Onset:  Onset will depend on the site of infection.  With meningitis sudden onset of high fever, 
vomiting, lethargy, and meningeal irritation consisting of bulging fontanelle in infants or stiff neck in 
older children can occur. 
 
C. Reservoir 
Humans are the only known host. 
 
D. Modes of Transmission 
Haemophilus influenzae type b is transmitted person-to-person by droplet or direct contact with 
nasopharyngeal secretions of an infected person. The most common portal of entry is the 
nasopharynx. Newborns can become infected by inhaling amniotic fluid or genital tract secretions 
containing the organism. 
 
Report Immediately  
by phone 
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E. Incubation Period 
The incubation period is unknown but probably short, 2 − 4 days. 
 
F. Period of Communicability or Infectious Period 
• If not on antibiotic therapyas long as organisms are present in the upper respiratory tract, 
which may be for a prolonged period even without symptoms. 
• If on antibiotic therapynoncommunicable within 24−48 hours after starting effective 
antibiotic therapy.  
 
The contagious potential of invasive Hib disease is considered to be limited. However, certain 
circumstances, particularly close contact with a case (e.g., in a household, child care center, or 
institutional setting), can lead to outbreaks of Hib or direct secondary transmission of the disease. 
Asymptomatic carriage is known to occur. 
 
G. Epidemiology 
Hib occurs worldwide. Invasive Hib is most prevalent among children 2 months to 3 years old and is 
unusual in healthy individuals over the age of 5 years (though can occur in adults with chronic 
conditions such as chronic obstructive pulmonary disease). In the United States, peak incidence is in 
children 6 − 12 months of age. Secondary cases may occur in households, child care centers, and 
other institutional settings.   
 
Before the widespread use of Hib conjugate vaccines, Haemophilus influenzae type b (Hib) was a 
leading cause of bacterial meningitis in the United States among children less than 5 years old and a 
major cause of other life-threatening invasive bacterial diseases in this age group. Meningitis 
occurred in approximately two-thirds of children with invasive Hib disease, resulting in hearing 
impairment or severe permanent neurologic sequelae (mental retardation, seizure disorder, cognitive 
and developmental delays,) and paralysis in 15−30% of survivors. Approximately 5% of all cases 
were fatal. Invasive Hib disease now occurs in unvaccinated or under vaccinated children and adults. 
Type f is the most common other serotype causing invasive infections in the U.S.  Iowa had 
approximately 64 cases of Hib per year prior to the vaccine.  In the last 10 years Iowa has averaged 
0.7 cases per year in persons less than 5 years of age. 
 
Invasive disease has been more frequent in boys, African Americans, Alaskan Eskimos, Apache and 
Navajo Indians, child-care center attendees, children living in overcrowded conditions, and children 
who were not breastfed. Unimmunized children, particularly those younger than 4 years old, in 
prolonged close contact (such as in a household setting) with a child with invasive Hib disease, are at 
increased risk for invasive Hib disease. Other factors predisposing to invasive disease include sickle 
cell disease, asplenia, HIV infection, certain immunodeficiency syndromes, and malignant neoplasms. 
 
H. Bioterrorism Potential 
None. 
 
2)  DISEASE REPORTING AND CASE INVESTIGATION 
A. Purpose of Surveillance and Reporting   
• To ensure that all cases of invasive Haemophilus influenza are typed and to identify all cases of 
Hib. 
• To identify household and child care contacts of Hib cases that need antimicrobial prophylaxis 
and/or immunization and to prevent further spread of the disease for Hib cases. 
• To distinguish between failure to vaccinate and vaccine failure. 
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B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
immediately report any suspected or confirmed case. The reporting number for IDPH Center for 
Acute Disease Epidemiology (CADE) is (800) 362-2736, if calling after business hours, call the Iowa 
State Patrol Office at (515) 323-4360 and they will page a member of the on-call CADE staff. 
Note: Due to the potential severity and spread of invasive Haemophilus influenzae, IDPH requests 
that information about any case be immediately reported to the local public health agency where 
diagnosed. If this is not possible, call IDPH Center for Acute Disease Epidemiology (CADE) at (800) 
362-2736.  
 
What to Report to the Iowa Department of Public Health (IDPH) 
• A case clinically compatible with invasive Hib (e.g., with meningitis, bacteremia, epiglotittis, or 
pneumonia), as diagnosed by a healthcare professional, or 
• Isolation (culture) of Hib from a normally sterile body site (blood, cerebrospinal fluid (CSF), or 
less commonly joint, pleural, or pericardial fluid), or  
• Detection of Hib antigen in CSF.  
 
Laboratory Testing Services Available   
Confirmation and serotyping of Haemophilus influenzae isolates are available at the University of 
Iowa State Hygienic Laboratory (SHL). All strains of Haemophilus influenzae isolated from normally 
sterile sites must be serotyped in order to identify the strain and to differentiate between serotype B 
and other serotypes, for which no control measures are necessary. Subcultures should be sent with a 
requisition form to SHL.  Call (319) 335-4500 for shipping directions. 
 
Note: Positive antigen results from urine and/or serum samples are not reliable for diagnosis of Hib 
disease and should not be used as a substitute for culture results, but can help in determining 
immediate control measures while awaiting laboratory results. 
 
C. Local Public Health Agency Follow-Up Responsibilities 
If a case of Hib is identified, IDPH Center for Acute Disease Epidemiology (CADE) will become 
involved in the investigation and disease control recommendations, in collaboration with the local 
public health agencies. The infection preventionist and the local public health agency should fax the 
lab report and/or other information to the CADE. The confidential fax number is (515) 281-5698.   
 
2.   Case Investigation 
a. Ensure that typing of the Haemophilus influenzae isolate has been or is being done, preferably at 
the SHL.  
b. The local public health agency in conjunction the hospital infection preventionist will collect 
pertinent information (demographic, clinical, exposure setting, transmission setting, detailed 
immunization history, and other pertinent history on the case) and record in the Iowa Disease 
Surveillance System (IDSS). To assess and prepare for the possibility of a type b case, it is 
important to pay special attention to the case’s Hib vaccination history, whether the case had 
contact with another case of invasive Hib, whether a child care setting is involved, and the ages 
and Hib vaccination histories of children exposed to the case in the household and child care 
center. 
c. If type b is identified, notify CADE (800) 362-2736.After completing the investigation and 
gathering the information to complete the investigation form, enter information into IDSS, or FAX 
the report form with supporting laboratory documentation to (515) 281-5698  
d. If type b is not identified, no additional control measures are necessary and a case investigation 
form does not need to be completed. 
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3) CONTROLLING FURTHER SPREAD  
Control measures are for Haemophilus influenzae type b (Hib) only. There are no control measures 
for other types. 
 
A. Isolation and Quarantine Requirements  
Current recommendations are as follows: 
Period of Isolation of Patient 
Isolate the case until 24 hours after initiating appropriate antimicrobial treatment to eliminate 
carriage. Cefotaxime and ceftriaxone or chloramphenicol is recommended for treatment concurrently 
or singly until antibiotic sensitivities are known.  Rifampin should be given to eliminate nasal carriage 
of the organism.   
 
Protection of Contacts 
Prophylaxis is indicated to protect children less than 12 months old or a child of 1-3 years who is 
inadequately immunized.  If this circumstance is found, everyone around them, including household 
contacts of any age, should receive prophylaxis.  
 
When 2 or more cases of invasive disease have occurred within 60 days and unimmunized or 
incompletely immunized children attend the child-care facility, administration of rifampin to all 
attendees and supervisory personnel is indicated. For a single case of Hib disease in a child who 
attends childcare, the decision to offer chemoprophylaxis to the childcare contacts should be made 
based on a case by case basis.  
 
B. Protection of Contacts of a Case    
1. Isolate the case until 24 hours after initiating appropriate antimicrobial treatment. Currently, 
only the treatment drugs cefotaxime and ceftriaxone are known to eradicate Hib from the 
nasopharynx.  Patient’s who are younger than 2 years of age or have susceptible household 
contacts, treated with ampicillin or chloramphenicol, must also receive rifampin prophylaxis to 
eliminate nasal carriage. Also, note that Hib disease does not necessarily confer immunity to 
subsequent disease.  Immunize as follows: 
• Children with invasive Hib disease at less than 24 months oldimmunize according 
to the age-appropriate schedule for unvaccinated children and as if they had received no 
prior doses. Begin 1 month after onset of disease or as soon as possible thereafter. For 
additional information, please refer to the table in Section 4) B. 3.  
• Children with invasive Hib disease at older than 24 months oldno immunization is 
necessary, regardless of previous immunization status, because the disease probably induced 
a protective immune response and second episodes at this age are rare.  
 
2. Antimicrobial prophylaxis for close contacts. Although several antibiotics are useful for 
treatment of invasive Hib disease and elimination of carriage in the case, rifampin is the 
appropriate drug to use for antibiotic prophylaxis of contacts. Several studies have shown that 
rifampin eradicated Hib carriage in greater than or equal to 95% of contacts of primary Hib 
cases, including children in child cares.   
 
Prophylaxis is needed when contacts include children less than 12 months old who have not 
received a primary vaccine series, or a child of 1-3 years who is inadequately immunized, or a 
household with an immunocompromised child regardless of that child’s Hib immunization status.  
 
If the criteria in the above paragraph are met, prophylaxis should be initiated as soon as 
possible. Most secondary cases in households occur in the first week after hospitalization of the 
index case. Prophylaxis of household contacts that begins more than or equal to 1 week after 
hospitalization of the case may still be of benefit, although initiation of prophylaxis beyond 4 
weeks after that date is probably of limited utility. It is important for all children and employees 
having at least four hours of contact with the ill child in the week before onset or hospitalization 
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to take rifampin, unless immunization criteria are met.  Prophylaxis is not recommended for 
pregnant women who are contacts because the effect of rifampin on the fetus has not been 
established.  
Rifampin Prophylaxis against Hib 
Age Group Dosage/Schedule 
Infants < 1 month of age 10 mg/kg PO QD x 4 days 
Children 20 mg/kg PO QD x 4 days 
(maximum: 600 mg/dose) 
Adults 600 mg PO QD x 4 days  
The risk of secondary disease in children attending child-care centers appears to be lower than 
that observed for age-susceptible household contacts, and secondary disease in child-care 
contacts is rare when all contacts are older than 2 years. Also, the efficacy of rifampin in 
preventing disease in child care groups is not established. Nevertheless, rifampin prophylaxis is 
recommended in certain situations, as indicated in the table below. 
 
Indications and Guidelines for Rifampin Chemoprophylaxis for Contacts of  
Index Cases of Invasive Haemophilus influenzae Type b (Hib) Disease 
 
 
Chemoprophylaxis recommended 
• In certain index cases: 
- Index case, if treated with regimens other than cefotaxime or ceftriaxone. 
Chemoprophylaxis (rifampin) usually is provided just before discharge. 
• In certain household situations: 
-     All household contacts (except pregnant women),1 irrespective of age, in households 
where at least 1 contact is < 48 months of age and is unimmunized or incompletely 
immunized1 
-     All household contacts (except pregnant women),1 irrespective of age, in households 
where a child is < 12 months of age, even if the primary series has been given 
-     All household contacts (except pregnant women),1 irrespective of age, in households with 
an immunocompromised child, irrespective of the child’s Hib immunization status 
• In certain child care situations: 
-     Nursery and child care centers contacts where > 2 cases occurred within 60 days, with  
> 1 unimmunized or incompletely immunized child < 48 months of age2,3 For a single 
case of Hib disease in a child who attends childcare, the decision to offer 
chemoprophylaxis to the childcare contacts should be made based on a case by case 
basis. 
 
Chemoprophylaxis not recommended 
• In certain individuals: 
-     Pregnant women 
• In certain household situations: 
-     Occupants of households with no children < 48 months of age other than the index 
patient 
-     Occupants of households when all household contacts < 48 months of age have 
completed their Hib immunization series4 
• In certain child care situations: 
-     Nursery and child care contacts of 1 index case, when all children < 48 months of age 
have completed their Hib immunization series4 
- Nursery and child care center contacts where > 2 cases occurred within 60 days, when all 
children < 48 months of age have completed their Hib immunization series4 
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1 Defined as persons residing with the index patient or nonresidents who spent > 4 hours with the 
index case for > 5 of the 7 days preceding the day of hospital admission of the index case. 
2 Only children who are age-appropriately immunized and on rifampin should be permitted to enter 
the child care group during the time prophylaxis is given. Children enrolling in the child care center or 
other setting during the time prophylaxis is given should also receive rifampin, as should supervisory 
personnel.   
3 When a single case has occurred, the advisability of rifampin prophylaxis in exposed child care 
groups with unimmunized or incompletely immunized children is controversial, but many experts 
recommend no prophylaxis. 
4 Complete immunization is defined as having had > 1 dose of conjugate vaccine at > 15 months of 
age; 2 doses between 12 and 14 months of age; or a 2- or 3-dose primary series (number of doses 
required depends on vaccine type and age at initiation) when < 12 months with a booster dose at > 
12 months of age.  Note that all infants (< 12 months of age) are by definition incompletely 
immunized. 
 
3. Ensure appropriate immunization of contacts. The number of doses required is determined 
by the current age of the child and the number, timing, and type of Hib vaccine doses previously 
received. Unvaccinated and incompletely vaccinated children less than 5 years old should be 
scheduled for completion of the recommended age-specific immunization schedule (see definition 
of “complete immunization” in Footnote 4 of the table above). Infants should be placed on an 
accelerated schedule using minimum intervals between doses. Unvaccinated high-risk individuals 
older than 5 years should receive one dose.   
 
The accelerated schedule for situations in which an incompletely vaccinated child has been 
exposed follows: 
 
Accelerated schedule for Hib vaccination—to be used for unvaccinated and incompletely 
vaccinated children (including all infants) after exposure to invasive Hib disease. 
Type of Hib 
vaccine 
Minimum 
age for 
first dose 
Minimum interval 
from dose 1 to 2 
Minimum interval 
from dose 2 to 3 
Minimum interval 
from dose 3 to 4 
HbOC 
(HIB-
TITER®) 
6 weeks 1 month 1 month 
 
This booster at > 12 
mo. of age and > 2 
mo. after previous 
dose PRP-T 
(ActHIB®, 
OmniHIB®) 
6 weeks 1 month 1 month 
PRP-OMP 
(PedVax-
HIB®) 
6 weeks 1 month This booster at > 12 
mo. of age and > 2 
mo. after previous 
dose 
Not required 
 
4. Conduct surveillance.  Careful observation of exposed contacts, especially children younger 
than 4 years, is essential. Those in whom a febrile illness develops should receive prompt medical 
attention, regardless of Hib vaccination status.  
 
D. Preventive Measures  
Routine childhood vaccination is the best preventive measure against Hib disease. Good personal 
hygiene (which consists of proper handwashing, disposal of used tissues, not sharing eating utensils, 
etc.) is also important.   
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Guide to Surveillance, Investigation, and Reporting 
Please consult the chapter on Haemophilus influenzae in the Red Book of the American Academy of 
Pediatrics for a full discussion of vaccines, immunization schedules, and special circumstances.  For 
example, children, including those older than 5 years, with underlying conditions predisposing them 
to Hib disease may need additional doses.   
 
4) ADDITIONAL INFORMATION 
 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for 
Haemophilus influenza type b can be found at:  
www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
 
 
Comment  
Positive antigen test results from urine or serum samples are unreliable for diagnosis of H. influenzae 
disease, but may help determine need for control measures while waiting for definitive laboratory 
results. 
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Resources 
 
www.cdc.gov/vaccines/vpd-vac/hib/default.htm 
State Hygienic Laboratory www.shl.uiowa.edu/  
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FACT SHEET            Haemophilus Influenzae Type b 
                      (Hib, H. flu, haemophilus b) 
 
What is Haemophilus influenzae type b disease? 
Haemophilus influenzae type b (Hib) causes a serious bacterial infection in young children, most 
commonly meningitis (infection of the coverings of the spinal cord and brain).  Some persons who 
recover from Hib meningitis may have long-lasting brain and nerve problems.  Hib can also cause blood 
infections, pneumonia, arthritis, and infections in other parts of the body.  In some instances, Hib disease 
may cause death. 
 
Who gets Hib disease? 
Hib disease is most common in children between 3 months and 3 years of age. 
 
How is Hib disease spread? 
It is spread through the air after an infected person coughs or sneezes, especially if he/she does not 
cover their mouth or nose. 
 
What are the symptoms of Hib disease? 
Hib disease usually causes fever, nausea and vomiting.  Persons with Hib disease may become irritable or 
sluggish.  The bacteria can infect different parts of the body, so other symptoms may occur. 
 
How long is an infected person able to spread Hib disease? 
An infected person can spread Hib disease for as long as the bacteria are present in the nose and throat, 
even after he appears to be well or after 1 to 2 days of treatment with effective antibiotic therapy.   
 
Can a person get Hib disease again? 
Yes, one infection does not protect from getting Hib disease again. 
 
What is the treatment for Hib disease? 
Antibiotics are used to treat serious infections.   
 
Should people who have been around a person infected with Hib disease be treated? 
Some household members, child care playmates, and children under 4 years of age who have been 
around an infected person may need to take an antibiotic like Rifampin to prevent illness in themselves or 
those around them.  Persons who have had casual contact in a regular classroom, office, or factory 
setting usually do not need treatment. 
 
How can the spread of Hib disease be stopped? 
There are several vaccines for Hib disease currently available.  The vaccine should be given to young 
children beginning at 2 months old.  This is especially important for those children attending child care.  
For more information about the Hib vaccine, contact your local health department. 
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Note: This is a sample letter to be adapted on local or state health department letterhead and to be 
used when case is reported within 14 days after case's last day in a child care. 
 
PARENT AND EMPLOYEE ADVISORY LETTER 
Haemophilus influenzae invasive disease in a Child care Center 
 
Dear Parents of (name of child): 
 
Your child has been in contact with a child who has had disease caused by a bacteria called Haemophilus 
influenzae (commonly called "H. flu" or Hib).  Despite its name, the bacteria has nothing to do with flu 
virus and does not cause "the flu".  Hib can cause pneumonia, joint, blood, and skin infections, and 
meningitis in children under four years old. 
 
Because your child was in contact with the child with H. flu disease for more than four hours 
in the week before the child's illness, the Iowa Department of Public Health and the 
______________________ Health Department recommend that your child take an 
antibiotic called rifampin to reduce his/her risk of developing a serious H. flu infection.  Your 
child may need rifampin whether or not his/her vaccination is complete.  Please contact your child's 
pediatrician or family doctor to obtain this medication as soon as possible.  Persons who are known to be 
allergic to rifampin, and women who are pregnant or who might be pregnant shouldn't take rifampin.  
Persons wearing soft contact lenses should remove the lenses for the four-day treatment period as 
rifampin may discolor them.  Rifampin will turn the urine a reddish-orange color and may decrease the 
effectiveness of birth control pills. 
 
Watch for the following signs of infection in your child:  high fever, irritability, breathing 
difficulty, or other unusual behavior accompanied by fever.  If your child develops any of 
these symptoms in the next few weeks, you should contact his/her doctor, explain the 
symptoms and tell the doctor that your child was in contact with a child who had a serious H. 
flu infection. 
 
Please feel free to contact the ________________ Health Department at (telephone number) or the Iowa 
Department of Public Health, Center for Acute Disease Epidemiology, (800) 362-2736, if you have 
questions regarding this subject. 
 
There is now a vaccine to prevent H. flu disease, including meningitis.  It is recommended that all 
children receive a series of a Hib conjugate vaccine beginning at two months of age.  If your child is two 
months of age or older, and has not received this vaccine consult your physician or your local health 
department to obtain this vaccine, commonly referred to as Hib vaccine. 
 
For child care employee exposure, rifampin is recommended to eliminate the H. flu organism 
from the employee's nose and throat to prevent children under four years in the center from 
having further exposure to H. flu. 
 
Sincerely,      
________________________________________ _______________________________  
                          (Name)                (Local Health Department) 
 
Note for your doctor:  The recommended dose of rifampin for H. flu prophylaxis is 20 mg/kg once daily 
for four days (maximum dose 600 mg/day); for infants less than 1 month old, 10 mg/kg once daily for 4 
days. 
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Letter  
Note: Sample letter to be adapted on local or state health department letterhead and 
to be used when case is reported more than 14 days after case's last day in a 
child care 
 
 PARENT INFORMATION LETTER 
 Haemophilus influenzae invasive disease in a child care center 
 
Dear Parents Of (name of child): 
 
Your child has been in contact with a child who has had a serious disease caused by a bacteria 
called Haemophilus influenzae (commonly called "H. flu" or Hib).  If your child is at least 15 
months old and up to date on his or her immunizations, they are probably fully protected against 
H. flu infection.  The bacteria has nothing to do with flu virus and does not cause "the flu", 
despite its name.  H. flu can cause pneumonia, blood, joint and skin infections, and meningitis in 
children less than four years of age.  There is a small risk that children spending several hours 
with the child with H. flu disease in the days prior to illness might develop a serious H. flu 
infection.  An antibiotic called rifampin can reduce this risk if given soon after exposure.  Since 
your child's exposure occurred more than 14 days ago, we are not currently recommending 
rifampin.  Please contact your child's doctor to discuss this exposure. 
 
Watch for the following signs of infection in your child:  high fever, irritability, 
breathing difficulty, or other unusual behavior accompanied by fever.  If your child 
develops any of these symptoms in the next few weeks, you should contact his or her 
doctor immediately and tell the doctor that your child was in contact with a child who 
had a serious H. flu infection. 
 
Please feel free to contact the __________________ Health Department at (telephone number) 
or the Iowa Department of Public Health, Center for Acute Disease Epidemiology, (800) 362-2736 
if you have questions regarding this subject. 
 
A vaccine is available for children two months of age and older to prevent H. flu disease, 
including meningitis.  It is recommended for all children to receive a series of an approved Hib 
conjugate vaccine beginning at two months of age.  If your child is two months of age or older, 
consult your physician, or your Local health department to obtain Hib vaccine.   
 
Sincerely, 
 
 
 
__________________________________ __________________________________ 
                   (Name)           (Local Health Department) 
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FACT SHEET    Haemophilus influenzae type b 
FOR CHILD CARE ADMINISTRATORS 
 
• Haemophilus influenzae type b (Hib) is an important cause of serious disease in young children.  
Commonly called H. flu, this bacteria has nothing to do with flu virus and does not cause "the 
flu."  
 
• Approximately 23 cases of invasive Hib disease were reported in 2003. 
 
• Nearly all cases of Hib disease occur in children under 4 years old and most cases occur in 
children between 2 months to 3 years. For children who develop meningitis, 2-5% will die and 
most of the survivors will have permanent neurologic problems such as hearing loss or deafness, 
learning disabilities and mental retardation. 
 
• There have been numerous clusters of cases reported in child cares of all types (babysitters, 
mother's day out, home child cares and centers). 
 
• Symptoms of the disease vary with the type of illness the child develops, but high fever, 
irritability, lethargy or other unusual behavior are consistent with Hib disease. 
 
• The bacteria are spread from person-to-person by contact with the organisms found in nose and 
throat secretions through coughing, sneezing, etc.  The reasons that some children become ill 
and others do not is not clearly understood. 
 
• An antibiotic, rifampin, eliminates the Hib bacteria from the nose and throat of persons carrying 
it, thus reducing the risk of exposed young children developing a serious Hib infection.  It is 
important for all children and employees having at least four hours of contact with the ill child in 
the week before onset or hospitalization to take rifampin, unless immunization criteria are met.  
Call the Iowa Department of Public Health, Center for Acute Disease Epidemiology, (800) 362-
2736 for follow-up assistance.  This prevents disease in those already exposed.    
 
• Persons who are known to be allergic to rifampin and women who are pregnant or who might be 
pregnant should not take rifampin.  Persons wearing soft contact lenses should remove the 
lenses for the four day treatment period as rifampin may discolor them.  Rifampin will turn the 
urine a reddish-orange color and may decrease the effectiveness of birth control pills. 
 
• There are now several vaccines to prevent Hib disease. All children should receive the full Hib 
series. The approved conjugate vaccines are recommended for all children beginning at 2 months 
old. 
 
• For further information, contact your local health department or the Iowa Department of Public 
Health, Center for Acute Disease Epidemiology (800) 362-2736. 
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CONFIDENTIAL                                                            Iowa Department of Public Health 
Haemophilus influenzae B (HIB) 
         Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome: 
 Survived this illness     Died from this illness 
 Died unrelated to this illness    
 Date of Death      /     /        
  Unknown First name: 
 
      
Event exception 
 Case could not be found 
 Case could not be interviewed 
 Case refused interview 
 Other – see notes 
Provider title:  ARNP  DO 
 MD 
 NP  PA 
Outbreak 
related:  Yes      No      Unknown  
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes   No  Unk To whom: ______________  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
Specimen 
source: 
 
      Result: 
 Positive 
 Negative    No growth 
 
Date received: 
 
     /     /      Test type: 
 Gram stain 
 PCR 
 Latex 
aggulination 
 Culture 
 Immuno- 
histochemistry Serogroup: 
 A 
 B 
 C 
 W-135      
 Y 
Result type:  Preliminary      Final Collection date: 
 
     /     /       
 
Accession #: 
 
      
 
Result date: 
 
     /     /      
 
Organism: 
 
Neisseria meningitidis 
 
 
Laboratory: 
 
      
Specimen 
source: 
 
      Result: 
 Positive 
 Negative    No growth 
 
Date received: 
 
     /     /      Test type: 
 Gram stain 
 PCR 
 Latex 
aggulination 
 Culture 
 Immuno- 
histochemistry Serogroup: 
 A 
 B 
 C 
 W-135      
 Y 
Result type:  Preliminary      Final Collection date: 
 
     /     /       
 
Accession #: 
 
      
 
Result date: 
 
     /     /      
 
Organism: 
 
Neisseria meningitidis 
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Laboratory: 
 
      
Specimen 
source: 
 
      Result: 
 Positive 
 Negative    No growth 
 
Date received: 
 
     /     /      Test type: 
 Gram stain 
 PCR 
 Latex 
aggulination 
 Gram stain 
 Culture 
 Immuno- 
histochemistry Serogroup: 
 A 
 B 
 C 
 W-135      
 Y 
Result type:  Preliminary      Final Collection date: 
 
     /     /       
 
Accession #: 
 
      
 
Result date: 
 
     /     /      
 
Organism: 
 
Neisseria meningitidis 
 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /       
       Isolated at entry: 
 
 Yes    No    Unk 
Isolation type 
(entry): 
 
      
Days 
hospitalized:        Currently isolated: 
 
 Yes    No    Unk 
Current isolation 
type: 
 
      
 
CLINICAL INFO & DIAGNOSIS 
Purpura fulminans present:  Yes    No    Unk   
Infection type:  Primary bacteremia             Meningitis  Pericarditis  Epiglottitis 
 
 Peritonitis  Pneumonia  Arthritis  Septecemia  Other       
Other infection type (specify):       
Spinal tap performed 
  Yes    No    
Unk 
 Date      /     /      
 
Normal    Yes    No    
                  Unk 
 
Spinal Fluid Results 
 
Protien      _          __unit  Glucose     _          __unit White Blood Count      _          __unit  
 
Center for Acute Disease Epidemiology         Do not complete shaded fields                  Fax: 515-281-5698                  HIB   Revised Mar-15           2  
CONFIDENTIAL PATIENT NAME: ______________________________                           Iowa Department of Public Health 
EXPOSURE PERIOD COMMUNICABLE PERIOD 
 
TREATMENT 
 
Antibiotics prescribed?   Yes    No    Unknown 
  
Antibiotic:       
  
Antibiotic:       
 
 
Antibiotic:       
Date 
started:      /     /      
Date 
started:      /     /      
Date 
started:      /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Vaccinated for Haemophilus influenzae type B:   Yes    No    Unknown 
 Date 
vaccinated: 
 
     /     /      
 
Date vaccinated: 
 
     /     /      
 
Date vaccinated: 
 
     /     /      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
 
Number of vaccinations:       
 
 
Number of people living in case’s household:         Number of people living in case’s home age 3 or less _:          
 
Close contacts of the case:   Yes    No    Unknown 
 
Close contacts of the case 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
PROPHYLAXIS 
Vaccinated for HIB:  Yes    No    Unknown Antibiotics prescribed:  Yes    No    Unknown 
Date vaccinated:      /     /      
 
Antibiotic:       
 
Lot #: 
 
      Date started:      /     /      
 
Vaccine type: 
 
      
 
Dose: 
 
      
 
Manufacturer: 
 
      Unit:  mg      ml     IU 
  # of times a day:       Route:       
 
 
 
 
 
 
 
 
 
 
 
 
 
CONTACTS 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation period for 
HIB is 2-4 days. 
HIB may spread person to 
person until 24-48 hours after the 
start of effective antibiotics.  
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Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
PROPHYLAXIS 
Vaccinated for HIB:  Yes    No    Unknown Antibiotics prescribed:  Yes    No    Unknown 
Date vaccinated:      /     /      
 
Antibiotic:       
 
Lot #: 
 
      Date started:      /     /      
 
Vaccine type: 
 
      
 
Dose: 
 
      
 
Manufacturer: 
 
      Unit:  mg      ml     IU 
  # of times a day:       Route:       
 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
PROPHYLAXIS 
Vaccinated for HIB:  Yes    No    Unknown Antibiotics prescribed:  Yes    No    Unknown 
Date vaccinated:      /     /      
 
Antibiotic:       
 
Lot #: 
 
      Date started:      /     /      
 
Vaccine type: 
 
      
 
Dose: 
 
      
 
Manufacturer: 
 
      Unit:  mg      ml     IU 
  # of times a day:       Route:       
 
 
 
NOTES:       
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Hansen’s Disease (Leprosy)          
 Agency:  
 
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -      
  
Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome: 
 Survived this illness     Died from this illness 
 Died unrelated to this illness    Unknown 
Date of death      /     /      First name: 
 
      
Event exception 
 Case could not be found 
 Case could not be interviewed 
 Case refused interview 
 Other – see notes 
Provider title:  ARNP   
 DO 
 MD 
 NP  PA 
Outbreak 
related:  Yes      No      Unknown  
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
See Other Lab Findings 
 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting:          
Health care worker type: 
 Yes      No      Unknown 
 
Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting:          
Health care worker type: 
 Yes      No      Unknown 
 
Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
Hypopigmented skin lesion: 
Anesthetic skin lesions: 
Red papules or nodules: 
 Yes    No    Unknown 
 Yes    No    Unknown 
 Yes    No    Unknown 
Papules bilateral: 
Thickening of skin at papules or nodules: 
Hypopigmented macules with ill-defined borders: 
 Yes    No    Unknown 
 Yes    No    Unknown 
 Yes    No    Unknown 
 
OTHER LAB FINDINGS 
 
Biopsy performed: 
  Yes    No    Unknown 
Date of biopsy: 
     /     /      Biopsy site:       Result:          
Acid fast test performed: 
 Yes    No    Unknown 
 
 
 
TREATMENT 
 
Antibiotics prescribed?   Yes    No    Unknown 
  
Antibiotic:       
  
Antibiotic:       
 
 
Antibiotic:       
Date 
started:      /     /      
Date 
started: 
 
     /     /      
Date 
started: 
 
     /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 
 mg      ml     IU 
 
Unit: 
 
 mg      ml     IU 
 
Unit: 
 
 mg      ml     IU 
# of days:       
# of times 
a day:       # of days:       
# of times 
a day:       # of days:       
# of times 
a day:       
Route:       Route:       Route:       
 
INFECTION TIMELINE 
 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
 
 
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The average incubation 
period for Hansen’s disease 
is 4 years with a range of 9 
months to 20 years. 
Hansen’s disease is communicable 
while case is symptomatic and has 
not been treated. However 
transmission is not well understood 
and takes long term close contact. 
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RISK FACTORS/TRAVEL 
 
In the 20 years prior to the onset of symptoms: 
Has the case lived outside the U.S.:  Yes    No    Unknown  
Country:          From date:       /     /      To date:       /     /      
 
Country:          
 
From date:       /     /      
 
To date:       /     /      
 
Country:          
 
From date:       /     /      
 
To date:       /     /      
Has the case had armadillo contact? 
 Yes    No    Unknown    
 
From date:       /     /      
 
To date:       /     /      
 
CONTACTS 
 
Number of people living in case’s household:       
List all close contacts 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
 
 
NOTES:       
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Guide to Surveillance, Investigation, and Reporting 
HANSEN’S DISEASE 
 
Also known as:  Leprosy 
  
Responsibilities: 
Hospital: Report by IDSS, facsimile, mail or phone 
Lab: Report by IDSS, facsimile, mail or phone.  Send isolates to the State Hygienic Laboratory 
(SHL) for testing  
Physician: Report by facsimile, mail or phone 
Local Public Health Agency (LPHA):  Report by facsimile, mail or phone. Follow Up 
Required 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800)-362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Hansen’s disease (also called leprosy) is a chronic infectious disease caused by the bacterium 
Mycobacterium leprae. Even though the medical community is moving away from using diseases 
named after people, this is one that will retain the moniker “Hansen’s” disease because of the stigma 
of the name leprosy. 
  
B. Clinical Description 
A chronic bacterial disease characterized primarily by the involvement of skin, which can also involve 
peripheral nerves, testicles, and the mucosa of the upper airway. Clinical forms of Hansen’s disease 
represent a spectrum reflecting the degree of cellular immune response to Mycobacterium leprae. 
The following characteristics are typical of the major forms of the disease. 
 
• Tuberculoid:  One or a few well-demarcated, hypopigmented, and anesthetic skin lesions, 
frequently with active, spreading edges and a clearing center; peripheral nerve swelling or 
thickening also may occur. 
• Lepromatous:  A number of erythematous papules and nodules or an infiltration of the face, 
hands, and feet with lesions in a bilateral and symmetrical distribution that progress to thickening 
of the skin. 
• Borderline (dimorphous): Skin lesions characteristic of both the tuberculoid and lepromatous 
forms. 
• Indeterminate:  Early lesions, usually hypopigmented macules, without developed tuberculoid or 
lepromatous features.   
 
Its main targets are the skin and nerves, though other organs can be involved.  If not treated, the 
nerves are damaged and patients may be unable to feel, which can result in injuries or burns. Such 
wounds may result in ulcers. The patient may suffer muscle weakness and paralysis. Serious 
disabilities and deformities may occur.  Prompt and appropriate treatment prevents most of these 
complications. 
 
C. Reservoirs 
Humans are the only reservoir of proven significance for leprosy. There have been reports suggesting 
that leprosy in armadillos may be naturally transmitted to humans. 
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D. Modes of Transmission 
Although the mode of transmission of Hansen's disease remains uncertain, most investigators think 
that M. leprae is usually spread from person to person in respiratory droplets after prolonged close 
contact.  Most humans probably are not susceptible. 
 
E. Incubation period 
The incubation period probably ranges from 9 months to 20 years. 
 
F. Period of Communicability or Infectious Period 
Evidence suggests that infectiousness is lost in most instances within a day of beginning treatment 
with multidrug therapy. 
 
G. Epidemiology 
While worldwide prevalence of leprosy decreased to less than 1 million registered cases in 1998, 
incidence has changed little since 1985. The majority of cases occur in developing countries, with 
92% in just 16 countries, led by India and Brazil. In the United States, cases usually occur in 
immigrants or refugees. Although leprosy affects people of all ages and gender, cases in children 
under 3 years of age are rare. 
  
H. Bioterrorism Potential 
None. 
  
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To identify source of infection and possible modes of acquisition.  
• To connect infected individual with available free treatment from CDC. 
• To ensure that close contacts, primarily family, are examined for possible disease and treatment 
is initiated. 
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report. The preferred method of reporting is by utilizing the Iowa Disease Surveillance System 
(IDSS).  However, if IDSS is not available, the reporting number for IDPH Center for Acute Disease 
Epidemiology (CADE) is (800) 362-2736; fax number (515), 281-5698, mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
Des Moines, IA 50319-0075 
 
Postage-paid disease reporting forms are available free of charge from the IDPH clearinghouse.   
Call (319) 398-5133 or visit the website 
healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295 to request a supply. 
 
Laboratory Testing Services Available 
The University of Iowa State Hygienic Laboratory (SHL) performs acid-fast bacillus smear testing, 
which will detect M. leprae. Although it is not possible to grow M. leprae in culture, further testing of 
specimens may be coordinated between SHL and the CDC. For more information, call the SHL 
Mycobacteriology department at (319) 335-4500, or visit: www.shl.uiowa.edu/  
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C.  Local Public Health Agency Follow-up Responsibilities 
Follow up is required.  Make sure household and close contacts are assessed for disease.  Periodic 
examination of household and other close contacts is recommended at 12-month intervals for at least 
5 years after last contact with an infectious case. 
 
3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements 
Minimum Period of Isolation of Patient 
No restrictions, but should be under medical care.  
 
Minimum Period of Quarantine of Contacts 
No restrictions.  
 
B. Protection of Contacts of a Case 
Handwashing is recommended for all contacts of lepromatous cases, and appropriate disposal of 
nasal discharges of the case should be considered during the infectious period. 
  
D. Preventive Measures 
Detection and treatment of cases is needed to prevent further spread. Antibiotics for treatment can 
be provided through the National Hansen’s Disease Program, www.hrsa.gov/hansensdisease/  
 
Preventive Measures/Education 
• Education of the case should stress the availability and efficacy of therapy. 
• Education on the importance of following the medication regime exactly.  
• Education of the case’s household contact(s) should include modes of transmission, preventive 
therapy (if appropriate), and referral to a healthcare provider for follow-up. 
• It is important to convey to the case and contacts the low communicability of this disease and 
the availability of effective treatment and prevention regimens. 
 
4) ADDITIONAL INFORMATION 
 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Hansen’s 
Disease can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
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Heymann, D.L., ed. Control of Communicable Diseases Manual, 19th Edition. Washington, DC, 
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FACT SHEET Hansen’s disease 
 (Leprosy) 
 
What is Hansen’s disease? 
Hansen’s disease (commonly referred to as Leprosy) is a chronic disease due to an infection with a 
bacterium similar to the bacterium that causes tuberculosis.  The main targets are the skin and nerves, 
though other organs can be involved.  If not treated, the nerves are attacked and patients may be unable 
to feel pain when they get injured or burn themselves. The resulting wound may lead to ulcers. In 
addition, muscle weakness and paralysis may occur. Serious disabilities such as deformities may occur.  
However, prompt and appropriate treatment prevents most of these complications. 
 
What are the symptoms of Hansen’s disease? 
Hansen's disease is associated with skin lesions (located identically on both sides of the body), spots on 
the skin that are light colored, bumps, and thickened skin. The nose is often affected, causing congestion 
and nosebleeds. 
 
How soon do symptoms appear? 
Symptoms of Hansen’s disease usually will not start to appear until several years after contact with a 
person with this disease.   
 
How is Hansen’s disease spread? 
Although the exact method of spread is not clear, it appears that this disease is spread by tiny droplets 
from the nose. However, not all people are susceptible, or prone, to getting this disease.  In fact, only 
5% of the population is thought to be susceptible.  In addition, it appears that living in the same 
household with a person with this disease for a long period of time is necessary for spread of this 
disease; casual contact with someone over brief periods of time does not put people at risk.    
 
How long is a person infectious? 
Once a person has been on medication for 3 days, he or she can no longer spread the disease to others 
and can return to usual activities.  
 
What is the treatment for this illness? 
There are effective antibiotics that can be used to treat this disease, but these antibiotics must be taken 
over a long period of time (at least two years). 
 
Do infected people need to be excluded from school, work, or child care? 
People with Hansen’s disease, including healthcare providers, can return to their usual activities 
(including work and school) after being on medications for 3 days.  After this time, they are no longer 
considered to be able to spread this to others.  
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Hantavirus Pulmonary Syndrome 
 
Also known as: Hantavirus Disease, HPS, Sin Nombre Virus  
 
Responsibilities: 
Hospital: Report by IDSS, facsimile, mail or phone 
Lab: Report by IDSS, facsimile, mail or phone 
Physician: Report by facsimile, mail or phone 
Local public health agency (LPHA): Follow-up required 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
The genus Hantavirus, family Bunyaviridae, comprises at least 14 viruses, including those that cause 
hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS). 
Hantaviruses are primarily rodent-borne. 
 
Hantavirus pulmonary syndrome (HPS) occurs in the U.S. with most of the cases being associated 
with Sin Nombre virus (SNV).  Other agents include Black Creek Canal virus and Bayou virus.   
 
HFRS is caused by puumala virus in Europe. Seoul virus, which is widely distributed, also causes 
HFRS of variable severity as does Hantaan virus, which is found principally in Asia.  Renal failure and 
hemorrhagic manifestations, common in HFRS, have been mild or absent in most recognized cases of 
HPS. 
 
B. Clinical Description 
Symptoms: during the 3 to 5 day prodrome are non-specific flu-like symptoms, including fever, 
fatigue, and muscle aches, especially in the large muscle groups. Gastrointestinal manifestations or 
dizziness may also occur. 
 
Onset:  As the disease progresses, symptoms can include cough and shortness of breath as the lungs 
fill with fluid. Once the cardiopulmonary phase begins, the disease progresses rapidly, necessitating 
hospitalization and often assisted ventilation within 24 hours. 
 
Complications: of HPS include an acute febrile illness that progresses rapidly to severe respiratory 
failure (acute respiratory distress syndrome or ARDS) and shock.  The mortality rate is still not well 
known but appears to be approximately 40%. For survivors, recovery from the acute illness is rapid 
with apparent restoration of normal lung function.   
 
C. Reservoirs 
Common reservoirs: The main reservoir for Sin Nombre virus is the deer mouse, Peromyscus 
maniculatus, native to most of the United States. 
 
Less Common reservoirs:  Black Creek Canal virus is associated with the cotton rat, Sigmodon 
hispidus, is found in the southeastern U.S. The rice rat, Oryzomys palustris, found in the southern 
U.S., is a reservoir for Bayou virus.  
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D. Modes of Transmission 
Infected rodents shed live virus in their saliva, feces and urine. 
Airborne: Humans are infected when they inhale dust that contains dried contaminated rodent urine 
or feces. Transmission may also occur when dried materials contaminated by rodent feces or urine 
are disturbed and are directly introduced into broken skin or the eyes, nose or mouth. 
 
Person-to-person: There is no evidence of person-to-person transmission of HPS in the United States. 
 
E. Incubation period 
The incubation period is weakly defined, but is thought to be approximately 2 weeks, with a range of 
a few days to 6 weeks. 
 
F. Period of Communicability or Infectious Period 
Person to person spread of hantaviruses appears to be rare, but further study is needed. 
 
G. Epidemiology 
HPS was first recognized in 1993 following an outbreak in the southwestern United States. As of 
November, 2013, 585 cases have been identified in the U.S. About 75% of patients with HPS have 
been residents of rural areas. Most cases have occurred in spring or summer, although cases have 
occurred throughout the year. Cases of HPS have also been reported in Canada and in several 
countries in South America. Anyone whose occupational activities (biologists, pest-control workers, 
etc.) or recreational activities (hikers, campers, etc.) put them in frequent contact with rodents or 
their droppings are potentially at risk. Disturbing, cleaning or inhabiting closed, actively rodent-
infested structures is an important risk factor. 
  
H. Bioterrorism Potential 
Category C agent.  Third-highest priority agents include emerging pathogens that could be 
engineered for mass dissemination in the future because of availability, ease of production and 
dissemination and potential for high morbidity and mortality and major health impact.  
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To assess the magnitude of the disease in different areas and among different risk groups. 
• To identify outbreaks as soon as possible. 
• To identify rodent sources of infection. 
• To monitor the emergence of HPS in new areas and new risk groups. 
• To design more effective control or prevention methods. 
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report. The preferred method of reporting is by utilizing the Iowa Disease Surveillance System 
(IDSS).  However, if IDSS is not available, the reporting number for IDPH Center for Acute Disease 
Epidemiology (CADE) is (800) 362-2736; fax number (515) 281-5698, mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
Des Moines, IA 50319-0075 
 
Postage-paid disease reporting forms are available free of charge from the clearinghouse.   
Call (319) 398-5133 or visit the website 
healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295 to request a supply. 
 
 
Iowa Dept. of Public Health Reviewed 12/13  Hantavirus Fact Sheet 2 
Laboratory Testing Services Available 
The University of Iowa State Hygienic Laboratory (SHL) tests for hantavirus. For more information on 
submitting specimens contact SHL at (319) 335-4500, or visit: www.shl.uiowa.edu/  
 
C.  Local Public Health Agency (LPHA) Follow-up Responsibilities 
Case Investigation 
a. Case investigation of hantavirus disease in Iowa residents will be directed by the IDPH Center 
for Acute Disease Epidemiology (CADE).  
 
b. Following notification of IDPH, the LPHA(s) may be asked to assist in completing an official 
IDPH investigation.  Access the Iowa Disease Surveillance System (IDSS) to conduct the 
investigation.  Interview the case and/or others who may be able to provide information to 
complete the investigation form and then enter into IDSS. Most of the information required can 
be obtained from the healthcare provider or the medical record. Use the following guidelines to 
assist in completing the form: 
1) Record “Hantavirus Disease” (or “Hantavirus Pulmonary Syndrome”) as the disease being 
reported. 
2) Record the case’s demographic information. 
3) Record the date of symptom onset, symptoms, date of diagnosis, hospitalization information 
(if applicable), and outcome of disease (e.g., recovered, died). 
4) Exposure history: Use the approximate incubation period range for hantavirus (1-6 weeks). 
Specifically, focus on the period beginning about 1 week prior to the case’s onset date back 
to approximately 6 weeks before onset for the following exposures: 
a) Travel history: Determine the date(s) and geographic area(s) visited by the case.  
b) Rodent contact: Ask the case about potential direct or indirect occupational or 
recreational exposure to rodents and/or rodent droppings. Document in the “Notes” 
section. 
5) Complete the import status section to indicate where hantavirus was acquired. If unsure, 
check “Unknown.” Include any additional comments regarding the case. 
6) If several attempts have been made to obtain case information, but have been unsuccessful 
(e.g., the case or healthcare provider does not return your calls or respond to a letter, or 
the case refuses to divulge information or is too ill to be interviewed), please enter as much 
information as can be gathered. If the information cannot be obtained, please explain the 
reason in the “Notes” section in IDSS. If using IDSS, select the appropriate reason under 
the Event tab in the Event Exception field. 
 
c. If IDSS is not being used, after completing the form, attach lab report(s) if available and mail 
(in an envelope marked “confidential”) to IDPH Center for Acute Disease Epidemiology.  The 
mailing address is:  
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th Street 
Des Moines, IA 50319-0075 
 
d. Institution of disease-control measures is an integral part of case investigation. It is the LPHA’s 
responsibility to understand, and, if necessary, institute the control guidelines below. 
 
3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements 
None. 
 
B.  Protection of Contacts of a Case 
 None. 
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C.  Managing Special Situations 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
If any cases of Hantavirus infection are reported in your county or if an outbreak is suspected, 
investigate to determine the source of infection and mode of transmission. Consult with an 
epidemiologist at CADE at (800) 362-2736. CADE can help determine a course of action to prevent 
further cases and perform surveillance for cases that may cross several county lines and therefore be 
difficult to identify at a local level.  
 
D. Preventive Measures 
Environmental Measures 
The best way to prevent HPS is to eliminate or minimize human contact with rodents. 
• Clear brush, grass, and garbage from around building foundations to eliminate a source of 
nesting materials. Keep tight-fitting lids on all garbage. 
• Use metal flashing around the base of wooden, earthen or adobe dwellings to provide a 
strong metal barrier. 
• Seal all entry holes one-fourth inch wide or wider with lath screen or lath metal, cement, wire 
screening or other patching materials, inside and out. 
• Elevate hay, woodpiles and garbage cans to eliminate possible nesting sites. 
• Use an EPA-approved rodenticide with bait under plywood or plastic shelter along 
baseboards, or trap and properly dispose of rodents. Live trapping of rodents is not 
recommended. 
• Clean all food-preparation areas. Store all food (both human and pet) in rodent-proof 
containers. 
• Do not leave open bowls of pet food outside. Discard any uneaten pet food properly at the 
end of the day. 
 
Preventive Measures/Education 
People involved in cleaning rodent-contaminated areas should keep the following in mind: 
• Clean droppings using a wet method, rather than a dry method such as sweeping or 
vacuuming. Spray disinfectant, such as dilute bleach, prior to cleaning and use a wet mop or 
towels moistened with disinfectant to clean.  This prevents dust from being produced. 
• Work in well-ventilated areas.  If possible before cleaning areas that have been closed for 
prolonged periods, open windows and allow to air out for 24 hours before initiating cleaning. 
• In areas of heavy infestation gloves, dust-mist masks, long-sleeved clothing, and protective 
eyewear may help prevent exposure. 
 
4) ADDITIONAL INFORMATION 
 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for 
Hantavirus can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
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FACT SHEET  HANTAVIRUS PULMONARY SYNDROME  
What is Hantavirus Pulmonary Syndrome (HPS)? 
It is a respiratory disease caused by a member of the hantavirus famly called Sin Nombre virus.  This virus 
is carried in wild rodents such as deer mice (Peromyscus maniculatus).  Mice do not appear ill while carrying 
it.  
How does a person get HPS? 
People become infected after breathing in airborne particles of urine, droppings or saliva from infected 
rodents.  Most cases in the U.S. have been associated with occupying rodent-infested vacant cabins or 
other dwellings, cleaning barns or other outbuildings, disturbing rodent-infested areas while hiking or 
camping, planting or harvesting fields, and living in or visiting areas where there has been an increase in 
rodents.  Handling infected rodents, their nests or droppings, and then touching the nose, mouth, or eyes 
may spread the virus.  There is no evidence of person-to-person spread.  
Who can be affected by HPS? 
Anyone can get HPS.   
Can animals transfer HPS? 
Cats and dogs are not known to spread the hantavirus from rodents to people.  Predators such as snakes, 
hawks, owls and coyotes help control rodents and do not spread the disease. 
What are the symptoms of HPS infection? 
The first symptoms, appearing a few days to six weeks (usually 2 weeks) after contact with the virus, are 
flu-like and may include fever, muscle and body aches, chills, cough, headaches, nausea, vomiting, and 
diarrhea, or feeling tired.  The lungs then begin filling with fluid, making breathing difficult.  If you have 
been exposed to rodents and experience these symptoms, notify your healthcare provider immediately. 
How should I get rid of dead rodents, droppings or nests? 
Removing the rodents from your home will decrease your risk for HPS.  Follow these standard rodent-
removal and clean-up guidelines: 
• Set spring traps that will kill mice. 
• Wear rubber gloves.  Spray the nest and/or dead rodent with a household disinfectant solution of 3 
tablespoons of bleach in 1 gallon of water until thoroughly soaked. Other disinfectants can also be 
used as directed. Let the area soak thoroughly for 10-15 minutes. 
• Remove the nest and/or rodent using a long-handled shovel or rubber gloves. 
• Double-bag the rodent and/or nest securely with plastic bags and dispose of them in the trash. 
People in rural areas may bury the waste 2-3 feet deep. 
• While still wearing gloves, wipe up the area with paper towels or rags. Double-bag all paper towels, 
rags, and gloves used in the cleanup.  Dispose of them in a tightly covered trash container. 
• Clean gloves before taking them off with disinfectant or soap and water. 
• Wash your hands with soap and water after completing the cleanup. 
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How should I clean my home after rodents are removed? 
Floors, countertops, cabinets and other surfaces should be cleaned. Use a solution of bleach or other 
household disinfectant. A solution of 1½ cups of household bleach in 1 gallon of water (or a 1:10 solution) 
can be used in place of a commercial disinfectant. Avoid spilling the mixture on clothing or other items 
that might be damaged by bleach. Wear rubber, latex, vinyl, or nitrile gloves when preparing and using 
chlorine solutions. They should be prepared fresh daily. Do not sweep floors with a broom, or vacuum, 
until the area has been disinfected.  Rugs can be steam cleaned.  Hard floors should be sprayed with a 
disinfectant solution. 
How can I prevent rodents from entering my home? 
• Seal, cover or screen all holes in walls or floors larger than one-quarter inch. 
• Keep food (including pet food) and water covered and stored in rodent-proof metal or thick or thick 
plastic containers with tight-fitting lids. Clean up spilled food. Keep dishes clean. 
• Store garbage in rodent-proof metal or thick containers with tight-fitting lids. Keep containers at 
least 12 inches off the ground. 
• Place three inches of gravel under the base of mobile homes to discourage rodent burrowing. 
• Place wood piles 100 feet or more away from the house and elevate wood at least one foot off the 
ground. 
• Remove any food sources near buildings that might attract rodents. 
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CONFIDENTIAL                             Iowa Department of Public Health 
Hantavirus                              Agency:   
           
Investigator:                                                          Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider title: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive    Negative   
 
Organism: 
 
           
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive    Negative   
 
Organism: 
 
           
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive    Negative   
 
Organism: 
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OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
Fever:  Yes    No    Unk Onset of fever date:       /     /      Highest known fever:      °F/C 
Other 
Symptoms:   Fever     Hypotension      Muscle Pain      Respiratory distress      Shock   
Chest X-ray 
done:   Yes    No    Unk 
Date of chest 
X-ray:      /     /      X-ray result:           
Unexplained Bilateral Infiltrates on X-ray:   
X-ray suggestive of RDS:  
Respiratory compromise requiring 
oxygen: 
 Yes    No    Unk 
 Yes    No    Unk 
 
 Yes    No    Unk 
Oxygen saturation less than 90% at any time:  
Tissue specimens available for testing: 
 Yes    No    Unk 
 Yes    No    Unk 
Other explanations for acute illness:        
 
 
 
OTHER LAB FINDINGS 
 
Thrombocytopenia:  Yes    No    Unk Elevated hematocrit:  Yes    No    Unk Hypoalbuminaemia:  Yes    No    Unk 
 
Center for Acute Disease Epidemiology                                              Fax: 515-281-5698                                         Hantavirus   Revised Mar-15              2 
CONFIDENTIAL PATIENT NAME: ______________________________                         Iowa Department of Public Health 
EXPOSURE PERIOD COMMUNICABLE PERIOD 
 
TREATMENT 
 
For the illness, were any of the following treatments required?  
Intubation:  Yes   No   Unk Duration:       
 Hours 
 Days 
Respiratory 
assistance:  Yes    No    Unk Duration:       
 Hours 
 Days 
Oxygen:  Yes   No   Unk    Ventilator:  Yes    No    Unk Duration:       
 Hours 
 Days 
4 
INFECTION TIMELINE 
 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
In the 6 weeks prior to illness was the case: 
Exposed to rodents/rodent droppings:  Yes    No    Unknown 
 
Exposure date:       /     /      Rodent Type           
State within US:       City within US:        
 
 
 
 
 
NOTES:       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  Person to person spread appears 
to be rare. More study is needed 
The incubation period for 
hantavirus is approximately 2 
weeks, with a range of a few 
days to 6 weeks. 
Deleted: The incubation period for hantavirus 
is a few days to 6 weeks. 
Deleted: Person to person spread was 
documented in one outbreak. Hantavirus is 
communicable while an infected person is 
symptomatic.
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Guide to Surveillance, Investigation, and Reporting  
Hemolytic Uremic Syndrome (HUS)  
and Thrombotic Thrombocytopenic Purpura 
(TTP) 
      
Responsibilities: 
Hospital: Report by IDSS, facsimile, mail or phone,  
Lab: Report by IDSS, facsimile, mail or phone, send isolate to SHL - (319) 335-4500 
Physician: Report by facsimile, mail or phone 
Local Public Health Agency (LPHA): Report by IDSS, facsimile, mail or phone. 
Follow-up required 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Hemolytic uremic syndrome (HUS) is a syndrome of anemia, renal failure and low platelet count, for 
which there are several causes. Among children, the most common cause of HUS is infection with a 
Shiga toxin-producing organism, most commonly Escherichia coli O157:H7 or some other strain of 
enterohemorrhagic E. coli (EHEC). Shigella dysenteriae also produces Shiga toxin and HUS can also 
occur after infection with this organism.  
 
Thrombotic thrombocytopenic purpura (TTP) is a disorder characterized by lesions in various organs 
that contain platelet clots, low platelet counts, and hemolytic anemia [due to breakdown of red blood 
cells (RBC)].  Tissue hypoxia resulting from these clots may cause organ damage, most frequently 
affecting the nervous system or kidney. 
 
B.  Clinical Description 
HUS is an acute illness involving the renal system and blood clotting mechanisms. For HUS caused by 
infection with a Shiga toxin-producing organism, the syndrome will usually manifest itself within 
weeks after the onset of a diarrheal illness, which often includes bloody diarrhea. Worldwide 
approximately 2−7% of cases of enterohemorrhagic E. coli (EHEC), such as E. coli O157:H7, develop 
HUS.  
 
Thrombotic thrombocytopenic purpura (TTP) is another potential consequence of infection with a 
Shiga toxin-producing organism. TTP symptoms include hemolytic anemia and signs of intravascular 
hemolysis, low platelet count, diffuse and nonfocal neurologic findings, decreased renal function, and 
fever.   
 
HUS is most commonly seen in children, whereas TTP is more commonly seen in adults. 
 
Both syndromes can be fatal. Most cases of HUS, but few cases of TTP, follow an acute 
gastrointestinal illness (usually diarrhea). Only HUS or TTP that follows an acute diarrheal illness 
should be reported.  
 
C.  Reservoirs 
While cattle appear to be the most significant reservoir for E. coli O157:H7 and other EHEC strains, 
other animals, such as deer, are also known to carry these bacteria. In contrast, humans are the only 
known reservoir for Shigella dysenteriae. 
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D. Modes of Transmission 
See the chapters on E. coli -pathogenic and Shigella for modes of transmission for each organism.  
 
E. Incubation Period 
Onset of HUS or TTP usually occurs within 3 weeks of the onset of diarrhea. Diarrhea may have 
resolved and the case may appear to be improving when the onset of HUS or TTP occurs. (For the 
incubation periods of the specific bacteria, refer to the chapters on E. coli -pathogenic and Shigella.)  
 
F. Period of Communicability or Infectious Period 
People with HUS or TTP rarely are infectious due to shedding E. coli or Shigella in their stool. (Refer 
to the chapters on each of these organisms for information on their infectious periods.)  These 
illnesses usually do not appear until after the shedding period is over.  Thus, at this time, stool 
specimens are negative. 
 
G. Epidemiology 
HUS is seen worldwide and may occur in 2% - 7% of E. coli EHEC infections of children under 10 
years of age. A bacterial pathogen is often not laboratory confirmed in cases of HUS, and therefore, 
the proportion of cases of HUS due to specific bacterial infections is difficult to ascertain. Cases of 
HUS have been attributed to several non-O157:H7 E. coli serotypes (e.g., other EHEC strains). 
Treatment with TMP-SMX, fluoroquinolones and other antibiotics may increase the risk of HUS and 
other complications. 
 
     Post diarrheal TTP is seen less frequently than HUS. 
 
H. Bioterrorism Potential 
None.  
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A.  Purpose of Surveillance and Reporting 
• HUS has been clearly demonstrated to be an important sequela of infection with E. coli EHEC 
strains. Because HUS cases generally come to medical attention, surveillance for HUS can serve 
as a marker for E. coli EHEC activity in the community and may lead to the identification of 
outbreaks at the state or local level. HUS is also an important event for assessing morbidity 
caused by E. coli EHEC strains. 
• TTP may also occur after infection caused by E. coli EHEC, therefore risk factors for the disease 
must be assessed as in HUS. 
• To identify whether the case may be a source of infection for other persons (e.g., a diapered 
child, child care attendee or food handler) and, if so, to prevent further transmission. 
• To identify transmission sources of public health concern (e.g., a restaurant or a commercially 
contaminated food product) and to stop transmission from such sources. 
 
B.  Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
report any case of HUS or TTP related to E. coli O157:H7 or enterohemorrhagic E. coli (non-O157). 
The reporting number for IDPH Center for Acute Disease Epidemiology (CADE) is (800) 362-2736.  
After completing the investigation and gathering the information to complete the investigation form, 
enter information into IDSS, or FAX the report form with supporting laboratory documentation to  
(515) 281-5698 or mail (in an envelope marked “Confidential”) to the IDPH/CADE, mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
Des Moines, IA 50319-0075 
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Laboratory Testing Services Available 
After communicating with IDPH, contact the University of Iowa State Hygienic Laboratory (SHL) 
bacteriology for further instructions at (319) 335-4500. 
 
C. Local Public Health Agency Reporting and Follow-Up Responsibilities 
 
1. Case Investigation 
a. It is the LPHA responsibility to complete a HUS Disease Case nvestigation form by interviewing 
the case and others who may be able to provide pertinent information. The Iowa Disease 
Surveillance System (IDSS) is the preferred method of recording case information.  
 
b. Use the following guidelines to assist you in completing the investigation: 
1) Accurately record the demographic information, date of symptom onset, symptoms, and 
medical information. 
2) When asking about exposure history (food, travel, activities, etc.), use the incubation period 
of 21 days.  
3) If possible, record any restaurants at which the case ate, including food item(s) and date 
consumed.  If it is suspected that the case became infected through undercooked food, 
especially ground meats, refer to the Iowa Foodborne Illness Outbreak Investigation 
Manual. 
4) Ask questions about unpasteurized juices and the water supply.  
5) Ask what grocery stores they have bought food at. 
6) Household/close contact, pet or other animal contact, child care, and food handler questions 
are designed to examine the case’s risk of having acquired the illness from, or potential for 
transmitting it to, these contacts. Determine whether the case attends or works at a child 
care facility or is a food handler. 
7) If several attempts have been made to obtain case information, but have been unsuccessful 
(e.g., the case or healthcare provider does not return calls or respond to a letter, or the 
case refuses to divulge information or is too ill to be interviewed), complete the case report 
with as much information as possible. Note on the form the reason why it could not be filled 
out completely, or if using IDSS, select the appropriate reason under the Event tab in the 
Event Exception field. 
 
c. After completing the case investigation form, enter the data into IDSS, FAX or mail to CADE. 
Reports may be faxed to CADE’s secured fax at 515 281-5698. The mailing address is:  
 
Iowa Department of Public Health 
Center for Acute Disease and Epidemiology  
321 East 12th Street 
Des Moines, Iowa 50319 
  
d. Institution of disease control measures is an integral part of case investigation. It is the LPHA 
responsibility to understand, and, if necessary, institute the control guidelines listed below in 
Section 3), Controlling Further Spread.   
 
3) CONTROLLING FURTHER SPREAD 
HUS and TTP are not spread person to person.  If shigella or E. coli EHEC strains are determined to 
be the cause of the illness see chapters specifically dealing with those diseases.   
 
Note: Because the onset of symptoms of HUS or TTP usually occur within 3 weeks after diarrheal 
illness, stool cultures taken at the time of HUS or TTP frequently fail to identify a causative agent. 
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A.  Isolation and Quarantine Requirements  
Standard Precautions while hospitalized.   
 
B. Protection of Contacts of a Case 
Persons caring for the case should practice good hygiene with attention to good handwashing 
practices. 
 
C.  Managing Special Situations 
      See chapters on specific enteric disease. 
 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
If the number of reported cases in your city/town is higher than usual, or if an outbreak is suspected, 
an investigation is indicated and consideration should be given to early consultation with CADE.  
Investigate clustered cases in an area or institution to determine source of infection and mode of 
transmission. A common vehicle (such as water, food or association with a child care center) should 
be sought and applicable preventive or control measures should be instituted. Control of person-to-
person transmission requires special emphasis on personal cleanliness and sanitary disposal of feces. 
Consult with the epidemiologist on-call at the CADE at (800) 362-2736.  CADE can help determine a 
course of action to prevent further cases and can perform surveillance for cases that may cross 
several county lines and therefore be difficult to identify at a local level. 
 
Note: Refer to the Iowa’s Foodborne Illness Outbreak Investigation Manual for comprehensive 
information on investigating foodborne illness complaints and outbreak.  
 
4) ADDITIONAL INFORMATION 
 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for HUS can 
be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
 
 
References  
American Academy of Pediatrics. 2006 Red Book: Report of the Committee on Infectious Diseases, 
27th Edition. Illinois, American Academy of Pediatrics, 2006. 
CDC Website. Escherichia coli O157:H7. www.cdc.gov/nczved/dfbmd/disease_listing/stec_gi.html  
Heymann, D.L., ed., Control of Communicable Diseases Manual, 19th Edition. Washington, DC, 
American Public Health Association, 2008. 
 
Additional Resources 
 Centers for Disease Control and Prevention: www.cdc.gov/ecoli/general/index.html#what_shiga  
 Iowa Division of Inspections and Appeals, Food Inspections: 
 www.state.ia.us/government/dia/index.html 
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FACT SHEET Hemolytic Uremic Syndrome  
                                     (HUS) 
 
What is Hemolytic Uremic Syndrome (HUS)? 
HUS is an illness in which the red blood cells are destroyed and the kidneys fail. HUS is a condition that can 
follow diarrhea caused by certain kinds of bacteria, including E. coli O157:H7  (and other E. coli strains) or 
Shigella dysenteriae. It can be serious, however, only a small percent of people with E. coli  or Shigella 
dysenteriae develop HUS.  Not all cases of HUS are caused by infection with these bacteria. 
 
How is HUS spread? 
HUS cannot be spread between people.  However, the bacteria E. coli (O157:H7  and others) and Shigella 
dysenteriae, that can cause HUS, can be spread to others if personnel hygiene is not good.  Handwashing and 
correct food handling are always important. 
 
Who gets HUS? 
Anyone can get HUS but children under five and the elderly are at higher risk. 
  
What are the symptoms of HUS? 
People with HUS may have less urine output, tiredness, or sometimes, blood in the urine. 
 
How soon do symptoms appear? 
HUS caused by E. coli (O157:H7  and others) or Shigella dysenteriae infection usually occurs within three 
weeks after onset of diarrhea. 
   
What should you do if you think you may have HUS?  
Contact your doctor right away.  
 
Can HUS occur more than once? 
HUS can occur following any infection with E. coli (O157:H7  and others)   or Shigella dysenteriae, or 
sometimes after other less common bacterial infections. 
  
How is HUS prevented? 
Handwashing and safe food handling greatly reduce the risk of HUS by reducing the chances of becoming 
infected with E. coli (O157:H7  and others)  or Shigella dysenteriae.   
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Hemolytic Uremic Syndrome (HUS) 
                  
                                                                            Agency: 
Investigator:                                          Phone number:        
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
 
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis 
date: 
 
     /     /      Onset date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak related:  Yes      No      Unknown Title:  ARNP    DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure setting:       Address line 1:       
Epi-linked:  Yes  No  Unk  To whom: _____________  
Address line 2: 
 
      
Location acquired:  In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
Laboratory: 
 
      Accession #: 
 
      
Collection 
date: 
 
     /     /      
 
Date received: 
 
     /     /      
Specimen 
source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
  Serotype:    
 
Laboratory: 
 
      Accession #: 
 
      
Collection 
date: 
 
     /     /      
 
Date received: 
 
     /     /      
Specimen 
source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
  Serotype:    
 
Laboratory: 
 
      Accession #: 
 
      
Collection 
date: 
 
     /     /      
 
Date received: 
 
     /     /      
Specimen 
source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
  Serotype:    
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OCCUPATIONS 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Ext:                    Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties: 
Health care worker type: 
 Yes      No      Unknown 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Ext:                    Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /       
       Isolated at entry: 
 
 Yes    No    Unk 
Isolation type 
(entry): 
 
      
Days 
hospitalized:        Currently isolated: 
 
 Yes    No    Unk 
Current isolation 
type: 
 
      
 
CLINICAL INFO & DIAGNOSIS 
 
Developed anemia:  Yes    No    Unknown Diarrhea within 3 weeks of onset of HUS:  Yes    No    Unk 
Microangiopathic changes present:  Yes    No    Unknown Clinical indicators: 
 Elevated creatine level      Proteinuria 
 Hematuria 
Antacids taken:  Yes    No    Unknown Brand Name:       
HUS 
Diagnosis  Yes    No    Unk Onset Date      /     /      
TTP 
Diagnosis  Yes    No    Unk Onset Date      /     /      
 
S
ym
pt
om
s 
Diarrhea 
Nausea 
Vomiting 
Headache 
Muscle weakness 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
      Days/Hours 
      Days/Hours 
      Days/Hours 
      Days/Hours 
      Days/Hours 
Abdominal cramps 
Chills 
Fever 
Visible bloody 
diarrhea 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
      Days/Hours 
      Days/Hours 
      Days/Hours 
      Days/Hours 
 
First symptom:       
Most severe 
symptom:       
Date returned to normal 
activities:      /     /      
 
OTHER LAB FINDINGS 
Food, Medication, or 
environmental samples tested?  Yes    No    Unk 
Describe 
samples:       
For what were the samples 
tested ? 
 E. coli or EHEC 
 Salmonella      Shigella 
 
Laboratory:       Positive?  Yes    No    Unk 
PFGE 
performed?  Yes    No    Unk 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
PFGE Pattern: 
IAX Pattern       JXB Pattern       XbaI-Pattern       BInI-Pattern       
 
TREATMENT 
 
Antibiotics prescribed?   Yes    No    Unknown 
  
Antibiotic:       
  
Antibiotic:  
 
 
Antibiotic:  
Date 
started:      /     /      
Date 
started:      /     /      
Date 
started:      /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
RISK FACTORS/TRAVEL (include 10 days before onset of diarrhea) 
 
Traveled within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
Restaurants visited?  Yes    No    Unknown   If Yes, complete the table below:    
Restaurant Adress/Zip Date visited Foods eaten Others ill? 
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
 
Attended Group Gatherings?  Yes    No    Unknown  If Yes, complete the following table: 
Type of gathering Address/Zip Date visited Foods consumed Foods prepared Others ill? 
            
 
     /     /      
             Yes    
 No    Unk             
            
 
     /     /      
             Yes    
 No    Unk             
            
 
     /     /      
             Yes    
 No    Unk             
 
Dietary Information – In the 10 days prior to onset of diarrheal symptoms did the case: 
 
Purchase food products?  Yes    No    Unknown   If Yes, complete the table below: 
Store name Address City/State/Zip County Date purchased 
                        
 
     /     /      
                        
 
     /     /      
                        
 
     /     /      
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
 
  The incubation period for 
HUS is 2 to 7 days after 
onset of bloody diarrhea 
1 – 3 weeks after onset 
of diarrhea 
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Meat and poultry 
Were any of the following 
consumed?  Poultry      Ground meat      Meat other than ground meat:  
Was the meat fully cooked?  Yes    No    Unknown 
List all source/types:       
List all brand names:       
From dates consumed:      /     /     ,      /     /      To dates consumed:      /     /     ,      /     /      
 
Other meat and poultry products 
Deli/luncheon meat  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Raw/partially 
cooked eggs:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
 
Unpasturized products 
Unpasteurized 
milk:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Unpasteurized 
juice:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Other 
unpasteurized 
products: 
 Yes    No    Unk 
From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
 
Other products 
Health supplements:  Yes    No    Unk From date consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Infant formula:  Yes    No    Unk From date consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Baby food:  Yes    No    Unk From date consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Fruits and vegetables 
Raw fruits:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Raw vegetables:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Other 
Leftover foods consumed: 
 Yes    No    Unk 
Reheated: 
 Yes    No    Unk 
 
From date consumed:      /     /      
 
To date consumed:      /     /      
Animal Exposures – In the 10 days prior to the onset of diarrhea  
Check all that apply 
Visit or live on a farm: 
Exposed to manure: 
Farm animal contact: 
 Yes    No    Unknown 
 Yes    No    Unknown 
 Yes    No    Unknown 
 
 
Animals:       
 
Reptile contact: 
Reptile lived with case: 
 
 Yes    No    Unknown 
 Yes    No    Unknown 
 
 Iguana    Lizard    Turtle    Other ________________________ 
Other animal contact in home: 
 
 Yes    No    Unknown Animal:       Animal sick:  Yes    No    Unk 
Visited a petting zoo: 
 
 Yes    No    Unknown Touched animals: 
 
 Yes    No    Unk Animal:       
Zoo name:       Address/Zip/County:       
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Water Exposures – In the 10 days prior to the onset of diarrhea 
Went swimming?  Yes    No    Unknown   If Yes, complete the table below: 
Type Location Type Date visited Facility name/ Street address & Zip 
 Hot tub/spa 
 Kiddie pool 
 River/stream 
 Lake 
 
 Pond  
 Water park 
 Swimming pool 
 Water fountain/ splash pad 
 Other_________________ 
 Hotel/motel 
 Indoor private 
 Indoor public   
 Outdoor private 
 Outdoor public 
     /     /      
 
 
 
 
 
Water supply 
Home:  Bottled 
 Commercial Delivery 
 Municipal 
 Rural water 
 Well 
 
School:  Bottled 
 Commercial Delivery 
 Municipal 
 Rural water 
 Well 
 
Work:  Bottled 
 Commercial Delivery 
 Municipal 
 Rural water 
 Well 
 
Child care:  Bottled 
 Commercial Delivery 
 Municipal 
 Rural water 
 Well 
 
 
Other Exposures – In the 10 days prior to the onset of diarrhea did the case: 
Wear diapers:  Yes    No    Unk Have contact with diapers:  Yes    No    Unknown 
    
     
Have contact with 
immunocompromised person:  Yes    No    Unk Setting: 
 Home 
 Work      Other ______________________________________ 
Have sex with someone with 
similar symptoms:  Yes    No    Unk 
Sexual 
preference: 
 Hetero 
 Homo 
 Bisexual 
 Unknown 
     
Participate in outdoor 
activities:  Yes    No    Unk Activities: 
 Camping 
 Canoeing 
 Fishing 
 Hiking 
 Hunting 
 Rafting  Trapping 
 
 
Number of people living in case’s household:          
 
Are there close contacts of the case with same symptoms:   Yes    No    Unknown 
 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
 
CONTACTS 
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HEPATITIS A 
 
Also known as: Infectious hepatitis, Epidemic hepatitis, Epidemic jaundice, 
Catarrhal jaundice, Type A hepatitis, HA, HAV 
 
Responsibilities: 
Hospital: Report by IDSS, facsimile, or phone  
Lab: Report by IDSS, facsimile, or phone  
Physician: Report by facsimile, or phone 
Local Public Health Agency (LPHA): Follow-up required 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY  
 
A. Agent 
Hepatitis A is an infection primarily affecting the liver caused by the hepatitis A virus (HAV), a 
nonenveloped RNA virus that is classified as a picornavirus.   
  
B. Clinical Description 
Initial symptoms: - Over 70% of infections in children <6 years of age are asymptomatic.  The 
proportion of symptomatic infections increases with age. The onset of hepatitis A in adults is usually 
abrupt. Initial symptoms may include low grade fever (usually < 39.5o C), myalgia, mild headache, 
malaise, anorexia, nausea and abdominal discomfort; some individuals may experience diarrhea. 
 
Subsequent symptoms: One to seven days after initial symptoms jaundice (yellowing of the skin and 
sclera), dark urine and clay-colored stool may occur. Among older children and adults, infection is 
typically symptomatic, with jaundice occurring in > 70 % of patients. The duration of a typical course 
of hepatitis A is 2 – 6 weeks.  
 
Complications: may involve a prolonged, relapsing hepatitis, which can occur for up to one year.  
Relapsing hepatitis occurs in about 15% of cases. Hepatitis A is rarely fatal and has no chronic carrier 
state. The elderly and persons with chronic liver disease are at greater risk of fulminant (rapid and 
severe) hepatitis A. The greatest morbidity and mortality occurs in person greater than 50 years old.  
Hepatitis A is clinically indistinguishable from other types of hepatitis. It must be diagnosed through 
laboratory testing for hepatitis A IgM. 
  
C. Reservoir 
Humans with active infections (symptomatic or not) are the only natural reservoir for this disease. It 
is rarely found in chimpanzees or other primates. 
 
D. Modes of Transmission 
The primary modes of transmission are direct or indirect person-to-person spread via the fecal-oral 
route, including sexual contact, or ingestion of contaminated food or water. Transmission occurs 
most frequently among close contacts, especially in households and extended family settings. 
Virtually any food can be involved including ready-to-eat or uncooked food (sandwiches, salads, ice 
cream, strawberries, etc.), which can become contaminated by an infected food worker with poor 
hygiene; inadequate treatment of stool-contaminated drinking water (a rare source of hepatitis A in 
Iowa); contaminated produce (such as lettuce or strawberries irrigated or processed with 
contaminated water); or shellfish harvested from fecally contaminated waters and then consumed 
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raw or undercooked.  The foods most commonly contaminated are raw, wet, and rough, such as 
lettuce and ice.  Because the virus is present in blood during the illness prodrome, HAV has been 
transmitted on rare occasions by blood transfusion.  Hepatitis A has been transmitted among drug 
users by fecally contaminating drug paraphernalia that is being shared. 
 
E. Incubation Period 
The incubation period for hepatitis A ranges from 15 -50 days, with an average of 28 − 30 days. The 
incubation period may be shorter with a greater hepatitis A virus (HAV) dose. 
 
F. Period of Communicability or Infectious Period 
Individuals are usually most infectious from 1 week before their symptoms begin to several days after 
onset of jaundice. Viral shedding in the stool is greatest during the week before symptom onset, until 
several days after onset.  Virus excretion begins to decline at the onset of clinical illness, and has 
decreased significantly 7 – 10 days after onset of symptoms.  If diarrhea exists, the patient’s ability 
to transmit the virus is greatly enhanced. HAV infection provides lifelong immunity. 
For public health intervention, a case is considered to be potentially infectious from 14 days before 
the onset of symptoms to 7 days after onset of symptoms.  However, prolonged viral excretion (up to 
6 months) has been documented in infants and children.  Chronic shedding of HAV in feces does not 
occur. 
  
G. Epidemiology 
Hepatitis A has a worldwide distribution and occurs as sporadic cases and outbreaks. In countries 
where sanitation is poor, infection is common and occurs at an early age. Adults, therefore, are 
usually immune and outbreaks are uncommon. In developed countries, disease transmission is a 
problem in child care settings with diapered children, among household and sexual contacts of acute 
cases, among travelers to countries where the disease is common, and among the institutionalized.  
In some situations drug users can be at high risk. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A.  Purpose of Surveillance and Reporting 
• To identify whether the case may be a source of infection for other persons (e.g., a 
diapered child, child care attendee, drug user or food handler) and if so, to prevent further 
transmission. 
• To identify sources of public health concern (e.g., a salad bar prepared by an infectious 
food handler) and to stop transmission from such a source. 
• To quickly identify contacts so that post exposure prophylaxis with hepatitis A vaccine or 
Immune Globulin (IG) can be given as soon as possible and within 14 days of last exposure. 
 
B.  Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report. The preferred reporting method is by immediate phone call. The reporting phone 
number for IDPH Center for Acute Disease Epidemiology (CADE) is (800) 362-2736; fax number 
(515) 281-5698. 
 
Due to potentially serious public health implications, it is requested that acute or active (IgM +) cases 
of hepatitis A identified in food service workers, child care employees and attendees be reported by 
phone to CADE immediately (800) 362-2736, so post-exposure prophylaxis can be started as soon as 
possible for contacts at high risk of disease. These are considered public health emergencies.  
 
Laboratory Testing Services Available 
The University of Iowa State Hygienic Laboratory (SHL) tests single serum samples for Hepatitis A 
IgM antibody utilizing enzyme immunoassays.  Accurate information about date of collection, dates of 
onset of symptoms, travel history, vaccination and disease history are essential for test 
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interpretation. For additional information on submitting samples or testing, contact the State Hygienic 
Laboratory at (319) 335-4500, or visit: www.shl.uiowa.edu/  
 
C.  Local Public Health Agency Follow-Up Responsibilities 
Case Investigation 
a. Confirm the diagnosis. 
1) Was a hepatitis A IgM serology done? 
Yes. Continue to step 2 
No. Is the case epidemiologically linked to a confirmed case or a documented 
outbreak of hepatitis A?  
An epidemiologically linked case is a case that meets the clinical case definition and occurs in a 
person who has an epidemiologic link with a person who has laboratory-confirmed hepatitis A 
(i.e., household or sexual contact with an infected person during the 15-50 days before the onset 
of symptoms). 
Yes. Continue to b. 
    No. Assess if serology testing for hepatitis A IgM is indicated. If not indicated, no 
further investigation is necessary. 
2) Is the individual's anti-HAV IgM positive? 
Yes. Continue to step b. 
No. No further case investigation is necessary.  
 
b. Completing the Hepatitis A Case Investigation. 
Utilizing the Iowa Disease Surveillance System (IDSS) is the preferred way to conduct the 
investigation. The local public health agency (LPHA) should complete the Hepatitis A 
investigation by contacting the healthcare provider and interviewing the case and others who 
may be able to provide the pertinent information. Much of the information required can be 
obtained from the case’s healthcare provider, other involved medical providers, or the 
medical record. The case record will aid in determining the most probable source of the 
infection, whether the case is likely to transmit the infection to others, and whether contacts 
should be given hepatitis A vaccine or immune globulin (IG).  
 
c. Determine if the case is associated with a common-source outbreak.  If yes, contact 
CADE at (800) 362-2736. 
• Does the case know of other persons with hepatitis A or with similar   
symptoms? 
• Have any other cases investigated provided similar information (e.g., history 
of eating raw oysters from a particular food establishment, etc.)? 
• If the case is child care-associated, refer to the managing special situations 
section for appropriate follow-up.   
 
d. The main objective in following up a case of hepatitis A is to determine whether the case is 
likely to have transmitted the infection to others.  
• Determine when the acute symptoms occurred and period of communicability of 
the case (two weeks before to one week after onset.) 
• Determine whether the case is likely to have transmitted the infection to others.  
Likely transmission can occur in situations where a case is identified as a food 
handler, a patient care provider or is an employee or child at a child care setting 
during their infectious period. 
e. Use the following guidelines to complete the case investigation form: 
1) Onset: Because a case of hepatitis A is most infectious in two weeks before symptom onset 
until one week after, be sure to accurately record each symptom and its date of onset. If 
onset of symptoms is unclear, use the date when jaundice was first noticed as the date of 
onset.  
2) Occupation: These questions (food handler, employment sections) are asked to determine  
the case’s risk of transmitting the illness during the period of communicability (14 days 
before onset of symptoms to 7 days after) via food, including during patient care which can 
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involve feeding. Determine whether the case is a food handler or patient care provider. If 
so, appropriate control measures need to be instituted. If the case is a foodservice 
worker, child care, or healthcare provider, call CADE immediately at (800) 362-
2736.  
3) Child care settings (and other similar settings): These questions are asked because 
hepatitis A is spread through the fecal-oral route. Children with hepatitis A are often 
asymptomatic; however, they may still be shedding the virus in their stool. Persons who are 
exposed to the fecal material of these cases could be exposed to hepatitis A. Determine 
whether the case is a child, resident or employee in a supervised care facility. If so, 
appropriate control measures need to be instituted.  See child care assessment tool in the 
Epi Manual’s Hepatitis A section. 
4) Risk factors/travel: Using the incubation period for hepatitis A (2 to 6 weeks), ask the 
case about food consumption, supervised care settings, and other exposures during the 
incubation period before the illness started. 
a. Contact with known cases: These questions are asked because hepatitis A can be 
spread through household or sexual contact. 
b. Vaccination history for hepatitis A. Document previous doses of hepatitis A vaccine, 
if any.  
c. Travel history: These questions are asked in order to identify where the patient may 
have become infected. Because of poor sanitation and overcrowding, hepatitis A is 
endemic in many developing countries. A recent history of foreign travel may be 
indicative of foreign exposure. 
d. Food consumption: Questions about raw shellfish consumption should be asked 
because occasionally hepatitis A virus infection has been associated with ingestion of 
uncooked or partially cooked shellfish grown in sewage-contaminated waters. Ask about 
other high-risk foods such as salads, ice and sandwiches with lettuce and tomato.  If it 
is suspected that the case became infected through the consumption of shellfish or 
other food(s), the LPHA should notify CADE, which can work in coordination with the 
Department of Inspection and Appeals Food and Consumer Safety Division to determine 
if additional control measures are warranted. 
e.  Contacts: Complete contact information documenting type of contact, symptoms (if 
present) and whether post exposure prophylaxis (PEP) was given, as well as the type of 
PEP given. 
 
4). Every effort should be made to complete the investigation because of the potential 
for outbreak with this disease. If several attempts have been made to obtain case 
information, but have been unsuccessful (e.g., the case or healthcare provider does not return 
calls or respond to a letter, or the case refuses to divulge information or is too ill to be 
interviewed), complete the IDSS case investigation form with as much information as can be 
gathered and notify CADE, which may be able to assist in the investigation.  
   
After completing the case investigation, enter information into IDSS or fax along with lab reports 
to CADE at (515) 281-5698. 
 
3) CONTROLLING FURTHER SPREAD 
 
A.  Isolation and Quarantine Requirements 
Minimum Period of Isolation of Patient 
All hospitalized patients are on Standard Precautions. 
Diapered or incontinent patients should be placed on Contact Precautions:  
Infants and children <3 years of age for duration of hospitalization 
Children 3-14 years of age for 2 weeks after onset of symptoms 
>14 years of age for I week after onset of symptoms    
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At home, counsel the patient to modify activities in order to prevent transmission until the end of the 
infectious period or one week after onset of symptoms. The patient should not prepare food for 
others, and practice good handwashing after toileting.  Persons assisting a patient with toileting 
should practice good hand washing and wash the patient’s hands after toileting.  
 
Persons who are child care or healthcare providers and food handlers should not work until 7 days 
after onset of jaundice or two weeks after the onset of symptoms. 
 
Minimum Period of Quarantine of Contacts 
None 
 
B. Protection of Contacts of a Case 
Persons who have documentation of previous hepatitis A disease or of receiving hepatitis A vaccine at 
least one month before an HAV exposure do not need post-exposure prophylaxis. For public health 
intervention, a case is considered to be potentially infectious from 14 days before the onset of 
symptoms to 7 days after onset of symptoms. Fecal shedding of the virus peaks during the 2 weeks 
before onset of symptoms until several days after onset. If diarrhea exists, it greatly enhances a 
case’s ability to transmit virus.  Control measures are implemented through the administration of 
hepatitis A vaccine or immune globulin (IG) to the people who had contact (see definition of contact 
directly below) with the case during their infectious period. Healthy persons between the ages of 12 
months and up to and including 40 years of age can receive single antigen hepatitis A vaccine or IG. 
Hepatitis A vaccine is preferred for this age group. For persons 41 years of age or older, IG is 
preferred but vaccine can be used if IG cannot be obtained. IG should be used for children under the 
age of 12 months. 
 
The safety of hepatitis A vaccination during pregnancy has not been determined; however, because 
hepatitis A vaccine is produced from inactivated hepatitis A virus, the theoretic risk to the developing 
fetus is expected to be low. The risk associated with vaccination should be weighed against the risk 
for hepatitis A in pregnant women who might be at high risk for exposure to hepatitis A.  
 
Post exposure prophylaxis should be administered as soon as possible and within 14 days of last 
exposure to an infectious case. Persons who receive immune globulin and for whom hepatitis A 
vaccine is recommended for other reasons should receive a dose of hepatitis A vaccine to provide 
long term protection at the same time they receive IG. This would include persons routinely 
recommended to receive hepatitis A vaccine as listed below. For persons who receive vaccine, the 
second dose should be administered through their healthcare provider according to the licensed 
schedule to complete the series. Combination hepatitis A and B vaccine is not to be used for post 
exposure prophylaxis. In persons exposed more than 14 days ago, vaccine or IG treatment will not 
prevent the illness. Those persons should watch for symptoms of hepatitis A and practice good 
hygiene, including frequent hand washing with soap and water.  They should see their healthcare 
provider and notify public health if symptoms develop.   
 
A contact is defined as: 
All household members; sexual contacts; persons who have shared illicit drugs with the case, food 
handling employees who work with the case; and anyone consuming uncooked foods or foods 
handled after cooking prepared by an infectious case that had diarrhea or poor hygienic practices at 
the time of food preparation. Other household-like contacts (e.g. baby sitter that comes in routinely). 
 
Immune Globulin: 
The following persons should not receive immune globulin: 
1. Persons with known immunoglobulin A (IgA) deficiency. 
2. Persons with severe thrombocytopenia or any blood coagulation disorder which would 
contraindicate intramuscular injections. 
Caution should be used in giving IG to a patient with a history of anaphylactic reactions to immune 
globulins. IG is not recommended for persons who have clinical symptoms strongly indicative of hepatitis  
A. 
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Immune globulin may interfere with immunizations for measles, mumps, rubella, and chickenpox.   
These live attenuated vaccines should not be given for at least three (3) months after administration of 
IG. Also, if it is necessary to administer IG within the 2 weeks following MMR or varicella vaccine the 
vaccine should be repeated. The repeat dose of MMR or varicella vaccine should not be given sooner than 
three (3) months after IG.  
 
Hepatitis A Vaccine 
Persons routinely recommended to receive hepatitis A vaccine: 
• Children at 12–23 months of age. Vaccination should be integrated into the routine 
childhood vaccination schedule. Children who are not vaccinated by 2 years of age can 
be vaccinated at subsequent visits. 
• Travelers to high or intermediate risk countries. 
• Men who have sex with other men. 
• Persons who use illegal drugs. 
• Persons who have clotting factor disorders.  
• Those who work with hepatitis A-infected primates or with hepatitis A virus in a 
laboratory setting. 
• Susceptible persons who have chronic liver disease.  
• Susceptible persons who either are awaiting or have received liver transplants should be 
vaccinated. 
• Any person one year old or older who wants protection from Hepatitis A. 
 
C.  Managing Special Situations 
Child Care  
If a confirmed case of hepatitis A occurs in a child care setting, parents and staff must be notified. 
Hepatitis A fact sheets should be provided at that time.  
Hepatitis A vaccine or IG should be administered to all previously unvaccinated staff members and 
attendees of child care or homes if 
1) One or more cases of hepatitis A are recognized in children or employees. In centers that do not 
provide care to children who wear diapers, hepatitis A vaccine or IG need be administered only to 
classroom contacts of the index case.  
2) Cases are recognized in two or more households of center attendees. In centers that do not 
provide care to children who wear diapers, hepatitis A vaccine or IG need be administered only to 
classroom contacts of the index case.  
When an outbreak occurs (i.e., hepatitis A cases in three or more families), hepatitis A vaccine or IG 
should also be considered for members of households that have children (center attendees) in 
diapers.  
• Enforce policies about hand hygiene (with children and staff) and disinfection of objects 
and environmental surfaces with appropriate bleach solutions or other solutions that state they 
kill HAV. 
• Make sure all parents and staff notify the health department if any person in their 
household is diagnosed with hepatitis A. 
 
Exclusion Guidelines 
People who are sick with hepatitis A can return to the program no less than two weeks after the 
illness started or one week after onset of jaundice.  
Schools and Work Settings 
Hepatitis A postexposure prophylaxis is not routinely indicated when a single case occurs in an 
elementary or secondary school or other work setting and the source of the infection is outside the 
school or work setting. Careful hygienic practices should be emphasized, including availability of hand 
hygiene supplies. Hepatitis A vaccine or IG should be administered to persons who have had close 
contact with the index case if an epidemiologic investigation indicates HAV transmission has occurred 
among students in a school.  
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Hospitals 
When a person who has hepatitis A is admitted to a hospital, staff members should be using standard 
precautions and therefore not be exposed to hepatitis A. Routine administration of hepatitis A post-
exposure prophylaxis should not be needed: instead, careful hygienic practices should be 
emphasized. Hepatitis A vaccine or IG should be administered to persons who have close contact 
with index patients if an epidemiologic investigation indicates HAV transmission has occurred among 
patients or between patients and staff members in a hospital. 
 
If a hospital staff member is diagnosed with hepatitis A and is considered a food handler then the 
food handler guidelines must be followed.    
 
Cases who are healthcare providers should not work until 7 days after onset of jaundice or two 
weeks after the onset of symptoms. 
 
Community Residential Programs 
Actions taken in response to a case of HAV in a community residential program should be handled on 
a case-by-case basis. Management of contacts will depend on the level of hygiene of the case and 
the type of facility. Roommates should be given hepatitis A vaccine or IG as soon as possible, and 
within 14 days of last exposure. If hepatitis A occurs in a staff member of a residential program, the 
case should be considered a food handler if there was an opportunity to feed, distribute medication, 
prepare foods or perform oral hygiene during the 2 weeks prior to symptom onset and 1 week after 
symptom onset. Consult with an epidemiologist at CADE by calling (800) 362-2736. 
 
Food Handler  
A food handler is any person directly preparing or handling food, including a patient care or child care 
provider, or homemaker.    
 
A confirmed case of hepatitis A in a food handler is a public health emergency and requires that risk 
for both co-workers and the public be assessed immediately. If a food handler is a laboratory-
confirmed case of hepatitis A, all other food handling employees in the facility must receive hepatitis 
A vaccine or IG as soon as possible, unless the contact can produce documentation of hepatitis A 
virus (HAV) vaccination or can show serologic immunity to HAV disease. Even after receiving hepatitis 
A vaccine or IG, they should wash hands correctly and protect READY-TO-EAT FOOD from 
contamination introduced by bare hand contact for the next 6 weeks to prevent the spread of 
infection.  If the employee does become sick, the employee should stop working immediately and be 
tested for HAV IgM antibodies.  
 
In order to determine if the public needs to be notified of possible exposure to HAV, a complete food 
handling history of the case for the 2 weeks before and one week after symptom onset needs to be 
done. This history should include consistency of correct handwashing procedure, presence of 
diarrhea, dates worked, job duties, foods prepared, and whether gloves or other barrier protection 
were used by the food handler. See the Epi Manual’s Hepatitis A section for the food handler 
assessment worksheet. Please call CADE at (800) 362-2736 to help determine the risk to the general 
public and to arrange shipment of prophylactic hepatitis A vaccine or IG. 
 
Cases who are food handlers should not work until 7 days after onset of jaundice or two weeks after 
the onset of symptoms. 
 
      Refer to Acute Hepatitis A Management in the Food Handler flowchart. 
 
Hepatitis A vaccine or IG administration to patrons is usually not recommended, but can be 
considered if: 
• During the time when the food handler was likely to be infectious they had diarrhea or 
poor hygienic practices and directly handled foods served uncooked or handled foods after 
cooking, and 
• Patrons can be identified and treated within 2 weeks after the exposure. 
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• In settings where repeated exposures to HAV might have occurred (e.g., institutional 
cafeterias), stronger consideration for more widespread hepatitis A vaccine IG use may be 
warranted. 
 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
If the number of reported cases in a city/town is higher than usual, or if an outbreak is suspected, 
investigate clustered cases in the area or institution to determine the source of infection and mode of 
transmission. A common vehicle (such as food or association with a child care center) should be 
sought and applicable preventive or control measures should be instituted. Control of person-to-
person transmission requires special emphasis on personal cleanliness and sanitary disposal of feces. 
Consult with the epidemiologist at CADE by calling (800) 362-2736. CADE can help determine a 
course of action to prevent further cases and can perform surveillance for cases that may cross 
several county lines and therefore be difficult to identify at a local level. 
 
D.  Preventive Measures  
Personal Preventive Measures/Education 
Individuals can avoid exposure to the virus by taking the following measures. 
• Wash hands thoroughly with soap and water, especially before handling or eating food, 
after toilet use, and after changing diapers. 
• In child care or residential programs, dispose of feces in a sanitary manner. 
• Avoid sexual practices that may permit fecal-oral transmission. Latex barrier protection 
should be emphasized as a way to prevent the spread of HAV to a case’s sexual partners as well 
as being a way to prevent exposure to and transmission of other pathogens. 
• Consider vaccination of those at high-risk of contracting hepatitis A. Iowa residents who 
should be vaccinated include the following: 
-  Persons (> 12 months of age) traveling to or working in countries with high or intermediate 
rates of hepatitis A, such as Central or South America, the Caribbean, Mexico, Asia (except 
Japan), Africa, and southern or eastern Europe.  The second dose should be given 6 months or 
later after the first. 
-  Men who have sex with men. 
-  Illegal drug users, whether injecting or not. 
-  Persons with chronic liver disease (not just infection), including those who are awaiting or have 
received liver transplants. 
-  Persons who receive clotting factor concentrates.  
-  Persons who have occupational risk for infection; specifically, those who work with HAV-
infected primates or with HAV in a research laboratory setting. Sewage workers do not need to 
be vaccinated. 
 
International Travel 
Travelers to areas where hepatitis A is endemic should receive hepatitis A vaccine before travel. The 
first dose of hepatitis A vaccine should be administered as soon as travel is considered. One dose of 
single-antigen hepatitis A vaccine administered at any time before departure may provide adequate 
protection for most healthy individuals. For optimal protection, older adults, immunocompromised 
persons, and persons with chronic liver disease or other chronic medical conditions who are traveling 
to an area where risk of transmission is high less than two weeks after the initial dose, may also be 
administered IG, but at a different anatomic injection site. Completion of the vaccine series according 
to the licensed schedule is necessary for long-term protection. However, contraindications to the 
vaccine may preclude individuals from receiving it. If an individual is allergic to a component of the 
vaccine or is <12 months old (vaccine is not licensed for this age group), that individual should not 
receive the vaccine. In addition, travelers should pay attention to what they eat and drink. This step 
is extremely important because the vaccine is not 100% effective and immunity conferred from IG 
wears off over time (3-6 months). Taking precautions such as those listed below will help prevent 
other illnesses as well, including travelers’ diarrhea, cholera, dysentery, and typhoid fever. 
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Recommendations to travelers include the following.  
• "Boil it, cook it, peel it, or forget it."   
• Drink only bottled or boiled water, keeping in mind that bottled carbonated water is safer 
than non-carbonated water.  
• Ask for drinks without ice unless the ice is made from bottled or boiled water. 
• Avoid Popsicles and flavored ices that may have been made with contaminated water.  
• Eat foods that have been thoroughly cooked and are still hot and steaming.  
• Avoid raw vegetables and fruits that cannot be peeled. Vegetables like lettuce are easily 
contaminated and are very hard to wash well.  
• Peel your own raw fruits or vegetables and do not eat the peelings.  
• Avoid foods and beverages from street vendors.  
  
For more information regarding international travel and hepatitis A, contact the CDC’s Traveler’s 
Health Office at (877) 394-8747 or through the Internet at http://www.cdc.gov/travel . 
 
4) ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Hepatitis 
A can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
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FACT SHEET HEPATITIS A 
 (viral or infectious hepatitis) 
 
What is hepatitis A? 
Hepatitis A is a liver disease caused by hepatitis A virus. In children it may be very mild, but some adults 
who develop hepatitis A are ill enough to miss about four to six weeks of work.   
 
Who gets hepatitis A? 
Anyone can get hepatitis A, however, individuals who travel to countries where hepatitis A is common, 
intimate and household contacts of infected individuals, men who have sex with men and those who use 
illegal drugs are at an increased risk of becoming infected.   
 
How soon do symptoms appear? 
Time from infection to illness is 15 - 50 days with an average of 28 - 30 days. 
 
How is the virus spread? 
The hepatitis A virus is found in the feces (stool) of infected persons.  It is usually spread by putting 
something in your mouth that has been contaminated by the stool of a person infected with hepatitis A. 
Hepatitis A may be spread by food that has been handled by infected persons who do not wash their hands 
carefully.  Hepatitis A may also be spread by drinking water contaminated with human feces and the 
sharing of contaminated drug paraphernalia.   
 
What are the symptoms of hepatitis A? 
Fever, loss of appetite, nausea, vomiting, abdominal pains, and a general feeling of being ill are usually the 
first symptoms.  These symptoms are typically followed in a few days by dark ("tea-colored") urine and 
jaundice (yellowing of the skin and the whites of the eyes).  Infected persons usually feel better after one to 
two weeks, although they may continue to feel tired for a few more weeks.  Infected children under the age 
of three often do not become ill. 
 
How long can an infected person spread the virus? 
An infected person can spread the virus for one to two weeks before symptoms appear and for one week 
after jaundice occurs. Occasionally infants and children may spread the virus for longer periods of time. 
 
Can a person get hepatitis A again? 
After infection with hepatitis A, a person generally will not become infected again.  However, there are 
different kinds of hepatitis infections and infection with hepatitis A will not protect against getting other 
types of hepatitis. 
 
Is there a vaccine to prevent hepatitis A? 
Yes, the vaccine is recommended for all children at age 12-23 months, travelers to areas where disease is 
common, men who have sex with men, users of injecting and non-injecting illicit drugs, residents of a 
community experiencing an outbreak of hepatitis A, individuals with chronic liver disease, and individuals 
with clotting-factor disorders. 
 
What is the treatment for hepatitis A? 
Once a person is ill, there are no special medicines that will help.  Generally, bed rest is all that is needed.  
Since hepatitis is an illness of the liver, infected persons should avoid drinking alcohol or taking drugs or 
medicines (including aspirin and Tylenol) without first asking their doctor. 
 
What can be done after a person comes in contact with a person infected with hepatitis A? 
Hepatitis A vaccine or immune globulin are both shots given to help prevent hepatitis A.  Hepatitis A is not 
spread at school, work, or by brief casual visits to the home of an infected person so fellow workers, 
schoolmates, etc., will not need to get a shot.  Hepatitis A vaccine or immune globulin is recommended for 
all household members and close contacts (including sexual and drug sharing contacts) of a person with 
hepatitis A.  The shot should be given as soon as possible and within 14 days of last contact with someone 
who has hepatitis A. 
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How can the spread of hepatitis A be stopped? 
The spread of hepatitis A can be stopped by always washing hands thoroughly with soap and warm water 
after using the toilet or changing diapers. When changing diapers make sure child’s hands are washed after 
the diaper change. Children should be taught to always wash their hands with soap after using the toilet.  
People with diarrhea, regardless of the cause should not prepare foods for others. Washing hands before 
preparing any food is important. 
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CONFIDENTIAL                                                              Iowa Department of Public Health 
Hepatitis A                     Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome: 
 Survived this illness     Died from this illness 
 Died unrelated to this illness    Unknown 
Date of Death      /     /      First name: 
 
      
Event exception 
 Case could not be found 
 Case could not be interviewed 
 Case refused interview 
 Other – see notes 
Provider title:  ARNP   
 DO 
 MD 
 NP  PA 
Outbreak 
related:  Yes      No      Unknown     
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes   No  Unk To whom: ______________  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 Blood/serum 
 Other       
 
Result date: 
 
     /     /      
 
Result type: 
 
 Preliminary      Final  
Test type: 
 
 IgM HAV 
Result: 
 Positive 
 Negative 
 Borderline  
 
Organism: 
 
Hepatitis A virus  
 IgG HAV 
 Total IgM/IgG HAV  
 Equivocal 
 Not done 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 Blood/serum 
 Other       
 
Result date: 
 
     /     /      
 
Result type: 
 
 Preliminary      Final 
 
Test type: 
 
 IgM HAV Result:  Positive 
 
Organism: 
 
Hepatitis A virus 
 
 IgG HAV 
 Total IgM/IgG HAV  
 Negative 
 Borderline 
 Equivocal 
 Not done 
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Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Result date: 
 
     /     /      
 
Result type: 
 
 Preliminary      Final 
 
Test type: 
 
 IgM HAV Result:  Positive 
 
Organism: 
 
Hepatitis A virus 
 
 IgG HAV 
 Total IgM/IgG HAV  
 Negative 
 Borderline 
 Equivocal 
 Not done 
 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
 Laboratorian  Nursing 
 Nurse practitioner 
 Physician Physician assistant 
 Other       
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
 Laboratorian  Nursing 
 Nurse practitioner 
 Physician Physician assistant 
 Other            
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
 
Jaundice:  Yes    No    Unk 
Onset 
date: 
 
     /     /      
Date 
resolved:      /     /      
 
Dark urine:  Yes    No    Unk 
Onset 
date: 
 
     /     /      
Date 
resolved:      /     /      
 
Diarrhea:  Yes    No    Unk 
Onset 
date: 
 
     /     /      
Date 
resolved:      /     /      
Other symptoms:  Abdominal pain  Anorexia 
 Fever 
 Malaise  Nausea 
Testing reason: 
 
 Elevated liver enzymes 
 Exposure to risk factor associated with hepatitis A 
 Symptoms of disease other than elevated liver enzymes 
 Testing for immunity to hepatitis A 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
 Exposure to someone with confirmed hepatitis A  Screening for blood/plasma donation 
ALT performed?  Yes    No    Unk 
Result (in 
IU/l): 
 
      
Expected min (in 
IU/l): 
 
      
Expected max in 
IU/): 
 
      
AST performed?  Yes    No    Unk 
Result (in 
IU/l): 
 
      
Expected min (in 
IU/l): 
 
      
Expected max in 
IU/): 
 
      
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
 
RISK FACTORS/TRAVEL 
In the last30 days have you known someone with jaundice (yellow skin or eyes)  Yes    No    Unknown  
 If yes Name ____________________________  Relationship ________________________ 
In the last30 days have you known someone that has been diagnosed with hepatitis A  Yes    No    Unknown 
 If yes Name ____________________________  Relationship ________________________ 
Vaccinated for hepatitis A?  Yes    No    Unknown 
  
Date vaccinated: 
 
     /     /      
  
Date vaccinated: 
 
     /     /      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
Number of vaccinations:       
In the 50 days prior to the onset of the symptoms did the case: 
Travel within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Travel within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Travel outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
Visit restaurants?  Yes    No    Unknown 
If Yes, complete the table below:    
Establishment name Address/Zip Date visited Foods consumed Others ill? 
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
 
Attend Group Gatherings?  Yes    No    Unknown 
If Yes, complete the following table: 
Location of gathering Address/Zip Date visited Foods consumed Others ill? 
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
Dietary Information – In the 50 days prior to onset of symptoms did the case consume: 
Raw shellfish:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       
List all brand 
names:       
Unpasteurized 
Mexican-style cheese:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       
List all brand 
names:       
Other unpasteurized 
products:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand       
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation period for 
hepatitis A is 15-50 
days; average of 28-30 
days. 
Hepatitis A is communicable 14 
days prior to the onset of 
symptoms to 7 days after onset.  
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names: 
Raw fruits:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       
List all brand 
names:       
Raw vegetables:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       
List all brand 
names:       
Other Exposures – In the 50 days prior to the onset of symptoms did the case: 
Wear diapers:  Yes    No    Unk Have contact with diapers:  Yes    No    Unknown 
    
 Do street drugs or inject steroids:  Yes    No    Unk  
     
Have sex with someone with similar symptoms:  Yes    No    Unk Sexual preference:  Hetero  Homo 
 Bisexual 
 Unknown 
 
 
 
Number of people living in case’s household:          Close contacts with the case and/or same exposures?      Yes    No    Unk 
 
Close contacts of case or close contacts with same exposures 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                       
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Significant other 
 Friend/acquaintance 
 Work/school/child care 
 Healthcare provider 
 Unknown/Other       
Documented history of 
hepatitis A disease?  Yes    No    Unk 
Im
m
un
e 
gl
o
b
ul
in
 Contact wt:       
H
ep
 A
 v
ac
ci
n
e 
Date 
vaccinated:      /     /      
Received IG within 14 
days of exposure?   Yes    No    Unk Date given:      /     /      
Vaccine 
manufacturer:       
Previously vaccinated 
for hepatitis A?   Yes    No    Unk Dose:       Unit:       Vaccine type:       
Vaccinated for hepatitis 
A w/in 14 days of 
exposure? 
 Yes    No    Unk 
Route:       
Number of 
vaccinations:       
 
Name DOB Gender Address/Phone  
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                       
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Significant other 
 Friend/acquaintance 
 Work/school/child care 
 Healthcare provider 
 Unknown/Other       
Documented history of 
hepatitis A disease?  Yes    No    Unk 
Im
m
un
e 
gl
o
b
ul
in
 Contact wt:       
H
ep
 A
 v
ac
ci
n
e 
Date 
vaccinated:      /     /      
Received IG within 14 
days of exposure?   Yes    No    Unk Date given:      /     /      
Vaccine 
manufacturer:       
Previously vaccinated 
for hepatitis A?   Yes    No    Unk Dose:       Unit:       Vaccine type:       
Vaccinated for hepatitis 
A w/in 14 days of 
exposure? 
 Yes    No    Unk 
Route:       
Number of 
vaccinations:       
 
Name DOB Gender Address/Phone  
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                       
CONTACTS 
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 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Significant other 
 Friend/acquaintance 
 Work/school/child care 
 Healthcare provider 
 Unknown/Other       
Documented history of 
hepatitis A disease?  Yes    No    Unk 
Im
m
un
e 
gl
o
b
ul
in
 Contact wt:       
H
ep
 A
 v
ac
ci
n
e 
Date 
vaccinated:      /     /      
Received IG within 14 
days of exposure?   Yes    No    Unk Date given:      /     /      
Vaccine 
manufacturer:       
Previously vaccinated 
for hepatitis A?   Yes    No    Unk Dose:       Unit:       Vaccine type:       
Vaccinated for hepatitis 
A w/in 14 days of 
exposure? 
 Yes    No    Unk 
Route:       
Number of 
vaccinations:       
 
NOTES:       
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FACT SHEET       HEPATITIS  A 
FOOD HANDLERS                                     (infectious hepatitis) 
 
What is hepatitis A? 
Hepatitis A is a virus that causes liver disease.  In children it may be very mild, but some adults who 
develop hepatitis A are ill enough to miss about 4 to 6 weeks of work.   
 
Who gets hepatitis A? 
Anyone can get hepatitis A, but it occurs more often in children. 
 
What are the symptoms of hepatitis A? 
Fever, loss of appetite, nausea, vomiting, tiredness, occasionally frequent loose stools, and a general feeling 
of being ill are usually the first symptoms.  These symptoms may be followed in a few days by dark ("tea-
colored") urine and jaundice (yellowing of the skin and the whites of the eyes).  Infected persons usually 
feel better after 1-2 weeks.  They may continue to feel tired for a few more weeks. 
 
How soon do symptoms appear? 
The first symptoms usually appear after about 1 month after infection, but can develop anytime between 2 
to 6 weeks after infection. 
 
How is the virus spread? 
The hepatitis A virus is found in the feces (stool) of infected persons.  For transmission or spread to occur, 
the hepatitis A virus must enter the mouth of a susceptible individual.  Foods may be contaminated when 
infected food handlers do not wash their hands carefully and directly touch foods that are eaten uncooked 
or food after it has been cooked.  
 
How long can an infected person spread the virus? 
An infected person can spread the virus for 1-2 weeks before symptoms appear and for 1 week after 
symptom onset occurs. 
 
Can a person get hepatitis A again? 
After one infection with hepatitis A, a person cannot get it again.  However, there are different kinds of 
hepatitis; infection with hepatitis A will not protect against getting other types of hepatitis. 
 
What is the treatment for hepatitis A? 
Once a person is ill, there are no special medicines that will help.  Generally, bed rest is all that is needed.  
Hepatitis is an illness of the liver.  Infected persons should avoid drinking alcohol or taking drugs or 
medicines (including aspirin and Tylenol) without first asking their doctor. 
 
What can be done after a person comes in contact with a person infected with hepatitis A? 
Post exposure prophylaxis can be give within 14 days of the last exposure to reduce the risk of coming 
down with disease. This is a "shot" given to help prevent hepatitis A.  Co-workers of food handlers infected 
with hepatitis A are advised to get the shot as soon as possible, but at least within 14 days after contact 
with someone with disease.  This shot is also recommended for all household members and close (including 
sexual and drug sharing) contacts of a person with hepatitis A.  This shot must be given within 14 days.  It 
is important to note that the shot does not guarantee that hepatitis A will not occur, however it may lower 
the risk of serious illness. 
 
Is there a vaccine to prevent hepatitis A? 
The hepatitis A vaccine was licensed in the U.S. in June 1995.  It is recommended for all children at age 12-
23 months, travelers to areas where disease is more common, military personnel, certain ethnic and 
geographic populations, people living in, or relocating to areas of where hepatitis A is common, persons 
engaging in high-risk sexual activity (such as men who have sex with men), users of illicit injectable drugs, 
and residents of a community experiencing an outbreak of hepatitis A.  
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How can the spread of hepatitis A be stopped? 
The spread of hepatitis A can be stopped by always washing hands thoroughly with soap and warm water 
after using the toilet.  It is extremely important that food handler employees not handle food or drinks 
when they feel ill.  Employees should notify their local county health department if they develop signs or 
symptoms similar to those of hepatitis A. 
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FOOD HANDLER SUSPECTED OF HAVING HEPATITIS WORKSHEET 
 
Investigator working situation  __________________________________ Date Reported _______________ 
Name of food establishment  _________________________________________________________________ 
Address ______________________________________________City _________________________________ 
 
Persons to notify (date/time when notified)      
CADE Epidemiologist      ________________________  Local PHN ____________________________  
County Board of Health   ________________________  DPS  ________________________________ 
Sanitarian  __________________________________ 
 
ILLNESS 
Patient Name _________________________________  Age ____  Sex __  Race ______________________ 
Date of Onset of Symptoms _____________________Physician 
________________________________ 
Hospitalized?  Yes __  No __  Name of Hospital _________________________________________________ 
 
Symptoms Yes  No  
Fever ___  ___ Date fever began ___________________ 
Fatigue ___  ___ Date fatigue began __________________ 
Nausea/Vomiting ___  ___ Date nausea/vomiting began __________ 
Dark Urine ___  ___ Date dark urine began __________________ 
Jaundice ___  ___ Date jaundice began __________________ 
Diarrhea ___  ___ Date diarrhea began __________________ 
 
Has person received hepatitis A vaccine previously  Yes        No 
If yes dates received  dose 1 ______- _______- ______  dose 2 ______- _______- ______   
 
Known or suspected source/risk factors (e.g., contact to confirmed case, drug user) ______________________ 
__________________________________________________________________________________________ 
 
Known or suspected other disease possibly causing symptoms (e.g., cirrhosis, gall bladder disease) 
___________________________________________________________________________________________________ 
 
      LAB RESULTS 
 
 
 
 
 
Positive 
 
Negative 
 
Not Done 
 
Liver Enzymes 
Laboratory:  
Total HAV 
(IgG/IgM) 
 
 
 
 
 
 
 
AST (SGPT) 
 
Telephone No.: 
 
HAV-IgM 
 
 
 
 
 
 
 
ALT (SGOT) 
 
Date Blood Drawn: 
 
 
 
 
 
 
 
 
 
Total Bilirubin 
 
 
 
HBsAg 
 
 
 
 
 
 
 
 
 
 
 
Anti-
HBsAg 
 
 
 
 
 
 
 
 
 
 
 
HCV anti 
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WORK HISTORY 
Has the employee handled high-risk foods in the past 2 weeks?  Yes __  No __ 
List Foods 
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_____________________________________________________________________________ 
Did the food establishment serve the same people multiple times during the infectious period of the employee? (Ex. 
Business cafeteria where people may eat many times a week.) Yes __  No __ 
Describe________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________ 
 
Food handling practices (use of gloves, ice scooper, mix with hands, etc.) 
_______________________________________________________________________________________________
_______________________________________________________________________________________________ 
 
Are foods held over to the next day? ___ If yes, which foods? ____________________________________________ 
_______________________________________________________________________________________________ 
  
Date(s) of sanitarian inspection _________________ Name of sanitarian__________________________  
 
Were soap, toilet paper and paper towels available when the sanitarian inspected?  Yes __  No __ 
Dates worked and job responsibilities during the last 2 weeks: 
 
Date 
 
Shifts/Hours    
Worked 
 
Did Not 
Work (X) 
 
Describe Specific Duties and Type of Food Handled 
 
Today 
 
 
 
 
 
 
 
 1 
 
 
 
 
 
 
 
 2 
 
 
 
 
 
 
 
 3 
 
 
 
 
 
 
 
 4 
 
 
 
 
 
 
 
 5 
 
 
 
 
 
 
 
 6 
 
 
 
 
 
 
 
 7 
 
 
 
 
 
 
 
 8 
 
 
 
 
 
 
 
 9 
 
 
 
 
 
 
 
10 
 
 
 
 
 
 
 
11 
 
 
 
 
 
 
 
12 
 
 
 
 
 
 
 
13 
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List all other dates and shifts worked during infectious period (2 weeks prior to onset to 1 week after onset) 
 
________________________________________________________________________________________ 
 
________________________________________________________________________________________ 
 
Dates and duties verified by employer?  Yes __  No __   By employee?  Yes __  No __ 
 
HYGIENE 
 
Does patient give history of hand washing after each trip to bathroom?  Yes __  No __ 
 
Did patient give accurate information regarding hand washing facilities (soap--liquid vs. bar, color, availability of 
towels, etc.)? ___________________________________________________________________________ 
 
Employer's or colleague's impression of hygiene ______________________________________________ 
 
Local Health Department's impression of hygiene (appearance and history)  Adequate __   Inadequate __ 
 
_____ Post exposure prophylaxis given to other food handlers by private resources (# persons) 
 
_____ Public announcement for patrons (date announcement made _____________) 
 
Dates and food involved ____________________________________________ 
 
___________________________________________________________________ 
 
Average number of customers served each day _____________ 
 
Number of persons given post exposure prophylaxis at LHD ______________ 
 
Dates and hours of post exposure prophylaxis clinics 
____________________________________________________________________________ 
 
Estimated number of LHD person-hours for follow-up ___________________ 
 
SIX-WEEK FOLLOW-UP 
 
Number of secondary cases which occurred that were likely due to this food establishment ____________________ 
 
Name of Investigator ____________________________ Date investigation completed __________________ 
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Acute Hepatitis A 
Management in the Food 
Handler 
*PEP = Post-exposure prophylaxises (Hepatitis A vaccine for persons age 1 year through age 40 years; for those age <1 year or over age 40 years, 
pregnant, or have other medical contraindications use immune globulin -IG-dose 0.02 ml/kg of body weight) 
**Communicable period = 2 weeks prior to 1 week after the onset of symptoms 
***HAV = Hepatitis A virus 
****Individual evaluation includes:  exact work schedule, dates, times, specific  food handler duties for each shift during communicable period 
Strongly consider PEP* for all exposed. 
Yes 
No 
Yes 
No 
Food handler 
with suspected 
hepatitis A 
Contact CADE 
(800) 362-2736 
or 
(515) 323-4360 
No prophylaxis given (too 
late to protect exposed 
customers). 
Did the food handler have contact with 
high-risk items (uncooked food, handling 
food after cooking, ice, etc)? 
Can PEP* be 
administered to 
exposed customers 
within 2 weeks ** of 
the last exposure? 
Have persons who ate 
food prepared by the 
HAV*** infected food 
handler had repeated 
exposures? 
Discuss with CADE - 
probably no prophylaxis 
needed for customers. 
Probably low risk.  Individual evaluation**** 
required.  Consider giving PEP* to other kitchen and 
restaurant employees. 
Is the food handler positive 
for IgM anti-HAV***? No further action necessary. 
Did food handler have 
good hygiene and no 
diarrhea? 
Probably low risk.  Individual evaluation**** 
required.  Consider giving PEP* to other kitchen and 
restaurant employees. 
Exclude HAV*** infected food 
handler from work until 1 week 
after onset of symptoms. 
Contact CADE for 
addressing future risk 
and educational needs. 
Contact CADE for 
consultation and 
providing PEP. 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
No 
No 
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FACT SHEET         HEPATITIS A  
CHILD CARE CENTER ADMINISTRATORS 
 
 
What is Hepatitis A? 
Hepatitis A, formerly known as "infectious hepatitis," is an infection of a person's liver that is caused by a 
virus.  Approximately 20,000 cases of hepatitis A are reported each year in the United States.  In various 
communities, 15-40% of reported hepatitis A cases are associated with spread within child care centers. 
 
What are the symptoms of Hepatitis A? 
The illness usually produces a sudden fever, nausea, vomiting, a general tired or weak feeling, dark-
colored urine and jaundice (yellowing of the skin and whites of the eyes).  These symptoms begin about 
2-6 weeks after contact with the virus.  School-age children and adults will usually become ill, but many 
children less than 3 years of age may have no symptoms.  An adult who develops hepatitis A may 
be ill long enough to miss about one month of work.  Most people recover completely. 
 
How is Hepatitis A spread? 
Persons become infected by getting hepatitis A virus into their mouths.  The virus is found in the stool 
(bowel movement or feces) of an infected person for about 2 weeks before becoming ill and for 1 week 
after symptoms develop. Infected children who have no symptoms are as able to spread 
hepatitis A as infected children who are ill.  In child care centers, the virus can spread by direct 
contact with infected children, during diaper changing, or by playing with stool-contaminated objects 
(toys, etc.). 
 
How is Hepatitis A diagnosed? 
The diagnosis of hepatitis A is made by a doctor based on the person's symptoms and on blood tests.  An 
infected person with no symptoms will still show signs of hepatitis A infection in the person’s blood. 
 
What can prevent illness if a person is exposed to Hepatitis A? 
Post exposure prophylaxis can be given to reduce the risk of coming down with disease. This is a shot 
that is given to prevent hepatitis A.  It is most effective if given within 2 weeks after contact with a 
person who has hepatitis A.   
 
What should be done when a child care center has Hepatitis A? 
Since fewer than one in ten infected diaper-aged children have symptoms, outbreaks in child care centers 
commonly are not recognized until workers and parents begin getting ill.  If hepatitis is found in a child 
care center, the center should not close and parents should be discouraged from transferring their 
children to other centers.  Transferring children only serves to spread the illness to other centers. 
 
How can Hepatitis A be prevented? 
Increasing good hygiene practices in staff, parents and children can successfully stop the spread of 
hepatitis.  Prevention measures include the following: 
1. Wash hands carefully with soap, warm water, and friction for at least 15 seconds after changing 
any diapers or handling stool-soiled material from any persons. 
2. Wash hands carefully with soap, warm water, and rubbing together for at least 15 seconds after 
each bowel movement. 
3. Make soap easily accessible to all employees and children.  
4. Ensure that all children wash hands with warm running water and soap and dry hands with 
disposable towels after each trip to the bathroom. 
5. Dispose of soiled paper diapers and place stool-soiled cloth diapers in a bag that seals tightly for 
return to parent. 
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6. Change diapers on a changing table with an impermeable surface.  Clean the changing table with 
an appropriate solution (a 1:100 dilution, or one-quarter cup of bleach per gallon of water, 
prepared daily and dispensed in a spray bottle).  Spray the surface with this solution after each 
diaper change and wipe with a disposable towel.  Diapering should not take place on any play 
tables or tables on which food is prepared or children eat. 
7. Separate food preparation and feeding duties strictly from diaper-changing and toilet cleaning 
responsibilities. 
8. Wash toys at least daily with a bleach solution. 
9. Wash any stool-soiled items (floor, beds, toys, etc.) immediately. 
10. Disinfect accessory items (such as containers of baby powder or jars of Vaseline) daily as they 
can accidentally be soiled during a diaper-change. 
11. Ensure all children wash their hands with warm running water and soap before meals or snacks. 
12. Wash hands carefully before preparing or handling any food. This step is especially 
important. 
 
IF YOU BECOME AWARE OF A POSSIBLE CASE OF HEPATITIS IN A CHILD, FAMILY MEMBER, 
OR WORKER IN THE CHILD CARE CENTER, YOU SHOULD IMMEDIATELY NOTIFY THE 
____________________ LOCAL HEALTH DEPARTMENT AT PHONE ______________ 
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FACT SHEET        HEPATITIS A 
CHILD CARE 
 
What is Hepatitis A? 
Hepatitis A, formerly known as infectious hepatitis, is an infection of a person's liver, which is caused by a 
virus.  Approximately 20,000 cases of hepatitis A are reported each year in the United States.  In various 
communities, 15% - 40% of reported hepatitis A cases are associated with spread within child care 
centers. 
 
What are the symptoms of Hepatitis A? 
The illness usually produces a sudden fever, nausea, vomiting, a general tired or weak feeling, dark-
colored urine and jaundice (yellowing of skin and whites of eyes).  These symptoms begin about 2 - 6 
weeks after contact with the virus.  School-age children and adults will usually become ill, but many 
children less than 3 years of age may have no symptoms.  An adult who develops hepatitis A may 
be ill long enough to miss about one month of work.  Most people recover completely. 
 
How do you get Hepatitis A? 
Persons become infected by getting hepatitis A virus into their mouths.  The virus is found in the stool 
(bowel movement or feces) of an infected person for about two weeks before becoming ill and for 1-2 
weeks after jaundice develops.  Infected children who have no symptoms are as able to spread hepatitis 
A as infected children who are ill.  The virus can be spread by direct contact with infected children, during 
diaper-changing, or by playing with stool-contaminated toys and other objects.   
 
How is Hepatitis A diagnosed? 
The diagnosis of hepatitis A is made by a doctor based on the person's symptoms and on blood tests.  An 
infected person with no symptoms will still show signs of the hepatitis A infection in the person’s blood. 
 
What can prevent illness if a person is exposed to Hepatitis A? 
Post exposure prophylaxis can be given within 14 days of exposure. This is a shot that is given to prevent 
hepatitis.  This will reduce the risk of coming down with the illness if given within 2 weeks after the last 
contact with a person who has hepatitis A.   
 
What should be done when a child care center has Hepatitis A? 
Since fewer than 1 in 10 infected diaper-aged children have symptoms, outbreaks in child care centers 
commonly are not recognized until workers and parents begin getting ill.  If hepatitis is found in a child 
care center, the center should not close and parents should be discouraged from transferring their 
children to other centers.  Transferring children only helps spread the disease to other centers. 
 
How can Hepatitis A be prevented? 
Increasing good hygiene practices in staff, parents and children can successfully stop the spread of 
hepatitis.  Prevention measures include the following: 
 
• Wash hands carefully with soap, warm water, and friction for at least 15 seconds after 
changing any diapers or handling stool-soiled material from any persons. 
• Wash hands carefully with soap, warm water, and rubbing together for at least 15 seconds 
after each bowel movement.3. Make soap easily accessible to all employees and children.   
• Ensure that all children wash hands with warm running water and soap and dry hands with 
disposable towels after each trip to the bathroom. 
• Dispose of soiled paper diapers and place stool-soiled cloth diapers in plastic bag that seals 
tightly to return to parent for laundering. 
• Change diapers on a changing table with an impermeable surface.  Clean the changing 
table with an appropriate solution (a 1:100 dilution, or one-quarter cup of bleach per 
gallon of water, prepared daily and dispensed in a spray bottle).  Spray the surface with 
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this solution after each diaper change and wipe with a disposable towel.  Diapering should 
not take place on any play tables or tables on which food is prepared or children eat. 
• Separate food preparation and feeding duties strictly from diaper-changing and toilet 
cleaning responsibilities. 
• Wash toys at least daily with a bleach solution. 
• Disinfect accessory items (such as containers of baby powder or jars of Vaseline) daily as 
they can accidentally be soiled during a diaper-change. 
• Wash any stool-soiled items (floor, beds, toys, etc.) immediately. 
• Ensure all children wash their hands with warm running water and soap before meals or 
snacks. 
• Wash hands carefully before preparing or handling any food. This step is 
especially important. 
 
If you become aware of a possible case of hepatitis in a child, family member, or worker in 
the child care center, you should immediately notify the 
_______________________________ Health Department at (      )_____ _______ 
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CHILD CARE CENTER ASSESSMENT WORKSHEET 
 
  I. GENERAL INFORMATION 
 
Name of Center: ________________________________ Date: _________________ 
 
Address: ______________________________________ Director: _______________ 
 
Phone No: _________________________  No. Staff Members: __________________ 
 
Reason for Visit (Outbreak, routine, referral, etc.): _____________________________ 
 
Is the Center Licensed?  Yes __ No __  DHS Licensing Pending: _________________ 
 
Days & Hours of Operation: _____________ No. of Children Licensed for: _________ 
 
No. Children Enrolled:  _________________ Children’s' Age Range: _____ to _______ 
 
Drop-in Accepted:  Yes __  No __  Approximate Number of Drop-ins Each Week ____ 
 
 II. ROOMING AND STAFF ARRANGEMENTS 
  
 1. Total Number of Classrooms:  ____ List age groups in each room and No. 
enrolled: 
 
Age Group       No. Enrolled 
 
____________________  __________________ 
 
____________________  __________________ 
 
____________________  __________________ 
 
____________________  __________________ 
 
____________________           ___________________ 
 
2. Are children separated by age group at all times (including early morning, late evening)? 
Yes __  No __  If no: 
 
a. During what time period are children together in the morning? ________________________ 
 
b. What time are they together in the afternoon? _______________________________________ 
 
c. At what other times are they together? _______________________________________________ 
 
3. Are any children transferred to or from another center on a regular basis?  Yes __  No __ 
If yes, explain: 
_____________________________________________________________________ 
_____________________________________________________________________________________
____________________________________________________ 
 
4. Do workers ever interchange age group assignments (including breaks, due to illness, etc.)? 
Yes __  No __
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III. FOOD HANDLING 
 
1. How many cooks prepare food? _________ 
 
2. Who prepares food if the cook is ill? _______________________________________________ 
 
3. Does the cook ever work directly with the children?  Yes __  No __ 
If yes, with diapered children?  Yes __  No __ 
 
4. List all routine meals/snacks served at the child care center and approximate time served. 
 
___________________________  _____________________________ 
 
___________________________  _____________________________ 
 
___________________________  _____________________________ 
 
___________________________  _____________________________ 
 
5. Is food preparation done at the center?  Yes __  No __ 
If no:  Where? __________________________________________________________________ 
 
6. Was a food service inspection performed in response to this disease report?  (If yes, attach copy of 
report). 
 
Yes __  Date _________________  Name of sanitarian: _________________________ 
No  __  If no, explain: _____________________________________________________ 
 
IV. HYGIENE/SANITATION ASSESSMENT 
 
The following questions reflect issues that should be assessed by observation during a tour of the center.  
"Yes" responses reflect optimal standards for prevention of disease transmission.  "No" responses indicate 
a potential risk for transmission to occur. 
 
A. Toilet Facilities 
 
1. Total number of bathrooms in center: ___  Total No. of changing tables: ____ 
 
2. Are the following available at each sink in center? 
Soap:  Yes __  No __  Paper towels:  Yes __  No __ 
 
3. Is toilet paper available at each toilet in the center?  Yes __  No __ 
 
4. Are sinks, soap dispensers, and disposable towels in toddler bathrooms at child level 
and/or are step stools in place by sink?  Yes __  No __ 
 
5. Are sinks adjacent to all changing tables and toilets or potty chairs?  Yes __  No __ 
 
6. Do the sinks produce hot water:  Yes __  No __ 
 
7. Do the toilets flush properly?  Yes __  No __ 
 
8. Is a covered trash container available at each sink and changing table? 
Yes __  No __ 
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B. Hygiene Factors 
 
1. Is there an organized pattern for handwashing after toileting and before meals? 
Yes __  No __ 
 
2. Are children supervised for handwashing each time they attend the bathroom?   
Yes __  No __ 
 
3. Are disposable wipes used for cleaning during diaper changing?  Yes __  No __ 
 
4. Is there an education program developed and used to promote handwashing among staff 
and children?  Yes __  No __ 
 
C. Housekeeping 
 
1. Are the following clean? 
 
Yes No     Yes     No 
 
Walls  __ __  Toilets/Potty Chairs __ __ 
 
Walkers  __ __  Cribs __ __  
 
High Chairs __ __  Playpens __ __ 
 
Tables  __ __  Toys __ __  
 
Sinks   __ __  Door Handles __ __ 
 
Floors  __ __  Chairs __ __ 
 
2. Is a labeled, properly working spray bottle of bleach solution (1/4 cup bleach per gallon 
of water) available at (If other disinfectant is used, please note the specific brand.) 
 
Yes No 
 
Each changing table?  __ __ 
Near each eating area?  __ __ 
In each bathroom?  __ __ 
 
3. Is the bleach solution changed daily?  Yes __  No __ 
If no, how often? _________________________________________________________ 
 
4. Are changing table surfaces of a nonpermeable, washable material in good condition? 
Yes __  No __ 
 
5. Are crib mattresses covered with a nonpermeable, washable material in good condition? 
Yes __  No __ 
 
6. Are toys washed with bleach solution or disinfectant daily?  Yes __  No __ 
If no, how often? _______________________________________________ 
 
7. Are cribs, playpens, high chairs and walkers washed with bleach solution or disinfectant 
daily?  Yes __  No __ 
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If no, how often? _________________________________________________________ 
 
8. Are all linens washed daily in hot water?  Yes __  No __ 
If no, how often? _________________________________________________________ 
 
9. Is the center mopped or vacuumed daily?  Yes __  No __ 
If no, how often? _________________________________________________________ 
 
     10. Are eating tables cleaned with bleach solution prior to serving meals?  Yes __  No __   
If no, how often? _________________________________________________________ 
 
     11. Are bathrooms disinfected daily?  Yes __  No __ 
If no, how often? _________________________________________________________ 
 
D. Other Issues 
 
1. Are children assigned the following items for their own personal use daily? 
 
Yes No 
Sleeping Cot __ __ 
High Chair  __ __ 
Walker  __ __ 
Playpen  __ __ 
Crib   __ __ 
 
2. Are children's clothing kept separated (e.g., by individual hangers, baskets, etc.)? 
Yes __  No __ 
 
3. Are obviously ill children (diarrhea, vomiting, fever, upper respiratory infections) 
excluded from the center immediately?  Yes __  No __ 
 
E. Remarks:     
 
_________________________________________________________________________________________
_________________________________________________________________________________________
_________________________________________________________________________________________
_________________________________________________________________________________________
_________________________________________________________________________________________
_________________________________________________________________________________________
_________________________________________________________________________________________
_________________________________________________________________________________________ 
_________________________________________________________________________________________
_________________________________________________________________________________________
_________________________________________________________________________________________
_________________________________________________________________________________________
_________________________________________________________________________________________
_________________________________________________________________________________________
_________________________________________________________________________________________
_________________________________________________________________________________________ 
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Child Care Center:  _________________________  Case list 
 
 
For use by county health department to tabulate data on all confirmed cases of hepatitis associated with the above named child care center 
(children, employees, and household contacts). 
 
Case 
Number 
Date Case 
Interviewed 
Case name Age Name & age of child care 
center contact(s) or child 
care center classroom 
Date of onset 
of symptoms 
How Case Confirmed  
Check Box 
Other:  (for example, 
food handler, other child 
care, centers follow-up 
calls, doctor contact) 
      IGM Liver 
Tests 
Clinical 
Symptoms 
  
           
           
           
           
           
           
N
u
m
b
e
r 
o
f 
c
a
s 
e
s 
Date of onset of symptoms 
First 
case 
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INDIVIDUAL/PARENTAL CONSENT FOR IMMUNE GLOBULIN 
 
Hepatitis A is a type of viral hepatitis formerly known as infectious hepatitis.  The virus is shed in the 
bowel movement of the infected person.  People become infected by getting the hepatitis A virus into 
their mouth.  This can occur through close contact with an infected person (such as household or sexual 
contact or by handling the diapers of an infected child) or through eating or drinking contaminated food 
or water. 
 
The virus causes an infection of the liver.  The disease most often causes no symptoms in young 
children; however, in older children and adults, symptoms can range from a mild illness lasting 1-2 weeks 
to severe nausea, vomiting and jaundice (turning yellow) lasting several weeks. 
 
Immune globulin (formerly called gamma globulin) is a shot that may prevent hepatitis A if it is given 
within two weeks of exposure to the virus.  However, in some cases immune globulin may not prevent 
hepatitis.  Other than local pain from the injection, the side effects from immune globulin are exceedingly 
rare.  The immune globulin shot your child receives may interfere with immunizations for, measles, 
mumps, rubella, and chickenpox.  If your child received one of these immunizations in the two weeks 
before receiving immune globulin, it should be repeated at a later date.  Check with your healthcare 
provider.  Your child should not receive any of the above immunizations for at least 3 months after 
receiving immune globulin.  
****************************************************************************** 
I am requesting immune globulin be given to ____________________________.  I have read the above 
statements and I have had the opportunity to ask questions.  I understand the risks and benefits of 
immune globulin and I release this child care center, the nurse administering the serum, the local health 
department, and the Iowa Department of Public Health from responsibility. 
 
 
___________________________________ _____________________ 
Signature - Parent/Guardian/Patient Date 
 
 
___________________________________ _____________________ 
Witness       Date 
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OPTIONS FOR Hepatitis A vaccine or IMMUNE GLOBULIN (IG) ADMINISTRATION FOR CHILD 
CARE CENTERS  
 
1. Local health department (LHD) staff can give the shots at the child care center either for fixed 
payment, volunteer donation, or at no charge.  This is the preferred option to ensure 
compliance. 
 
2. Parents and children may go to their private physician for the shots. 
 
3. Child care centers can arrange at their expense for a physician to write the prescription for the 
hepatitis A vaccine or IG and syringes and a clinic can be held at the child care center for 
administration (clinic staffed by the LHD or by medical professionals associated with the child care 
center). 
 
4. LHD staff can give the shots at the LHD during certain hours for definite groups of people (either 
for fixed payment, volunteer donation, or at no charge). 
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(Options) 
 
THE hepatitis A vaccine or IMMUNE GLOBULIN SHOT CAN BE GIVEN BY YOUR DOCTOR OR 
AT YOUR HOSPITAL EMERGENCY ROOM.  FURTHER QUESTIONS CAN BE ANSWERED BY 
YOUR DOCTOR OR BY CALLING THE ______________________ LOCAL HEALTH 
DEPARTMENT AT (PHONE NUMBER). 
 
 OR 
 
For your convenience, the ______________ Local Health Department will hold a shot clinic 
at the child care center from (time) on (day).  No person will receive an injection without a 
signed Informed Consent Form (attached). 
 
Sincerely, 
 
 
 
__________________________ 
 (Name) 
 
 
__________________________ 
(Health Department) 
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QUESTIONNAIRE TO PARENTS ABOUT HEPATITIS 
CHILD CARE CENTER ____________________________________________________________________________________________________ 
FAMILY NAME: _________________________________________________________________________________________________________ 
HOME ADDRESS: ________________________________________________ PHONE: HOME: ___________________ OFFICE: _______________ 
Please answer the following questions for each person in your household and for close family contacts (e.g., grandparents, aunts, 
etc.). 
IF ANSWER IS YES, PLEASE GIVE DATE OF ONSET. 
 
Name: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Occupation: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Employer: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the past three 
months has this person 
had: 
 
 
(Date) 
 
 
Yes 
 
 
No 
 
 
(Date) 
 
 
Yes 
 
 
No 
 
 
(Date) 
 
 
Yes 
 
 
No 
 
 
(Date) 
 
 
Yes 
 
 
No 
 
 
(Date) 
 
 
Yes 
 
 
No 
 
 
(Date) 
 
 
Yes 
 
 
No 
 
Nausea 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vomiting 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abdominal Pain 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Loss of Appetite 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diarrhea 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dark Urine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yellow Skin or Eyes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Has this person been 
diagnosed as having 
hepatitis in past 3 
months? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Has this person 
received an immune 
globulin shot for 
hepatitis in past 3 
months? If yes, give 
date. 
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SAMPLE COVER LETTER TO PARENTS 
Accompanying Questionnaire 
 
Dear Parent: 
 
We have recently been notified that within the past _______ weeks that _______ case(s) of hepatitis A 
(infectious hepatitis) have occurred in persons associated with the _________________________ Child 
Care Center. 
 
To accurately assess the current situation at this child care center, the center and the _______________  
Local Health Department are asking that you complete the accompanying questionnaire.  Please fill out 
the questionnaire completely so that we can determine what, if any, further control measures need to be 
taken.  Please return the questionnaire to the _____________________ Child Care Center 
tomorrow. 
 
For your information we are including a "Fact Sheet" about hepatitis A that should be helpful in 
answering questions you may have. 
 
Thank you. 
 
Sincerely, 
 
 
 
__________________________ 
          (Name) 
 
 
__________________________ 
(Local Health Department) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SAMPLE LETTER TO PARENTS-ONE CASE 
 
Dear Parents: 
 
[To be used when child care center does not provide care to diapered children] 
Following our recent investigation of ____________________________ Child Care Center, it appears 
there is only one case of hepatitis A in (child, employee, use appropriate word) the center.  To limit the 
possibility of spread of the disease at the center, we recommend that all previously unvaccinated children 
and staff in the affected classroom receive hepatitis A vaccine or immune globulin as soon as possible.  
Currently, we do not recommend hepatitis A vaccine or immune globulin for other children or any 
household contacts of children at the center.  If any members of your household become ill with fever, 
nausea or vomiting, fatigue, dark urine, or yellow skin or eyes, please call the _____________________ 
Local Health Department at (phone number). 
 
[To be used when child care center provides care to diapered children] 
Following our recent investigation of ____________________________ Child Care Center, it appears 
there is one case of hepatitis A in (child, employee, use appropriate word) the center.  To limit the 
possibility of spread of the disease at the center, we recommend that all previously unvaccinated children 
and staff receive hepatitis A vaccine or immune globulin as soon as possible.  If any members of your 
household become ill with fever, nausea or vomiting, fatigue, dark urine, or yellow skin or eyes, call the 
_____________________ Local Health Department at (phone number). 
 
The immune globulin shot your child receives may interfere with immunizations for, measles, mumps, 
rubella, and chickenpox.  If your child received one of these immunizations in the two weeks before 
receiving immune globulin, it should be repeated at a later date. Your child should not receive any of the 
above immunizations for at least 3 months after receiving immune globulin. Check with your healthcare 
provider  
 
(Optional) 
 
For your convenience, the _______________________ Local Health Department will hold a shot clinic at 
the child care center from (time) on (day).  No person will receive an injection without a signed 
Informed Consent Form (attached). 
 
Sincerely, 
 
 
 
__________________________  
           (Name)   
 
 
 
___________________________ 
(Local Health Department) 
SAMPLE LETTER TO PARENTS-OUTBREAK 
 
Dear Parents: 
 
We have evidence that there is an outbreak of hepatitis A in _____________ Child Care Center.  Our 
evaluation of the cases of hepatitis in this child care center has led public health make several 
recommendations at this time for the families, children, and staff associated with the center. 
 
Post exposure prophylaxis of either hepatitis A vaccine or Immune globulin (IG), which are 
both shots, give protection against hepatitis A disease if given before exposure to the virus 
or within the first two weeks after the last exposure.  IG is protective for approximately 2-3 
months. 
 
1. WE RECOMMEND THAT POST EXPOSURE PROPHYLAXIS BE GIVEN AS SOON AS 
POSSIBLE TO: 
 
a. All children who attend ________________ Child Care Center (unless the child has ever had 
hepatitis A infection, hepatitis A vaccine, or has had immune globulin in the past month). 
 
b. All parents, brothers, sisters and other close contacts of diapered children (unless that person 
has ever had hepatitis A infection, hepatitis A vaccine, or has had immune globulin in the past 
month). 
 
c. Close contacts of non-diapered children who may be at increased risk of developing hepatitis; 
these should consult their physician regarding the need for post exposure prophylaxis. 
 
2. The immune globulin shot your child receives may interfere with immunizations for measles, 
mumps, rubella, and chickenpox.  If your child received one of these immunizations in the two weeks 
before receiving immune globulin, it should be repeated at a later date.  Your child should not receive any 
of the above immunizations for at least 3 months after receiving immune globulin. Check with your 
healthcare provider. 
 
3. Good hygiene is of utmost importance and must be stressed.  Strict handwashing and cleanliness 
can successfully stop transmission of hepatitis A.  PLEASE read the hygiene recommendations on 
the Fact Sheet: Hepatitis A in Child Care. 
 
4. Please notify _____________ Local Health Department at (phone number) if you or any of your 
family members are diagnosed as having hepatitis A. 
 
5. Please do not remove your child(ren) from this child care center as this can increase the spread of 
hepatitis by introducing the disease into other centers, nurseries, or homes. Since they may have 
already been exposed at the current child care, disrupting the child’s life by sending them to a new 
child care is not productive. 
 
 
 
 
 
SAMPLE LETTER TO ADMINISTRATOR-ONE CASE  
 
Dear Administrator (Or Name): 
 
[To be used when child care center does not provide care to diapered children] 
Following our investigation, it appears there is only one case of hepatitis A in a (child, employee, use 
appropriate word) of _______________________ Child Care Center.  To limit the possibility of spread of 
the disease at the center, we recommend that children and employees in the (e.g. two-year old, toddler, 
etc.) classroom receive hepatitis A vaccine or immune globulin as soon as possible.  Currently we do NOT 
recommend post exposure prophylaxis for other children and employees in the center or household 
contacts of any of the children.  Please notify __________________ Local Health Department of any 
further cases in child care employees, children, or household contacts of children, as our 
recommendations would then be revised. 
 
[To be used when child care center provides care to diapered children] 
Following our investigation of _______________________ Child Care Center, it appears there is one case 
of hepatitis A in (child, employee – use appropriate word) the center.  To limit the possibility of spread of 
the disease at the center, we recommend that all previously unvaccinated children and staff receive 
hepatitis A vaccine or immune globulin as soon as possible.  If any members of your household become 
ill with fever, nausea or vomiting, fatigue, dark urine, or yellow skin or eyes call the Local Health 
Department at (insert phone number). 
 
 
 (Optional) 
 
For your convenience, the _____________________ Local Health Department will hold a shot clinic at 
the child care center from (time) on (day).  No person will receive an injection without a signed Consent 
Form. 
 
Sincerely, 
 
 
 
__________________________ 
(Name) 
 
 
__________________________ 
(Local Health Department) 
 
SAMPLE LETTER TO ADMINISTRATOR-OUTBREAK 
 
Dear Administrator (Or Name): 
 
Following our investigation of the occurrence of hepatitis A in _____________ Child Care Center, we have 
evidence that hepatitis A has been spread within the center.  To prevent further transmission of hepatitis 
A within your center, we are making the following recommendations: 
1. The center should not accept new admissions or drop-ins for 6 weeks following the diagnosis of 
the last associated case of hepatitis A.  Alternatively, you can:   
 
a. require that all new enrollees have proof of an injection with hepatitis A vaccine or immune 
globulin prior to admission (the IG will protect them for 2 - 3 months, a completed hepatitis A 
vaccine series for many years), or  
 
b. separate any new enrollees or drop-ins from the current group of children and use a staff 
member who would not work with any of the current group of children.  We strongly 
discourage entirely closing the center (even temporarily) as this would merely spread the 
illness to other centers. 
 
2. Hepatitis A vaccine or immune globulin are shots which can be given to prevent the disease if it is 
given before exposure to the virus or within the first 2 weeks after last exposure.  Both will 
decrease the risk of coming down with disease. IT WILL NOT PREVENT THE DISEASE IF 
GIVEN JUST BEFORE THE ONSET OF SYMPTOMS.  Hepatitis A vaccine or immune globulin is 
strongly recommended to be given as soon as possible to: 
 
a. All current staff who have no past history of hepatitis A infection or receiving hepatitis A 
vaccine and who have not received immune globulin in the past month. 
 
b. All children in the center who have no past history of hepatitis A infection or hepatitis A 
vaccine, and who have not received immune globulin in the past month. 
 
c. Close family contacts (parents, brothers and sisters, etc.) of all diapered children enrolled, if 
the contact has no past history of hepatitis A infection or hepatitis A vaccine, or has not 
received immune globulin in the past month. 
 
d. Any new staff employed in the child care center in the period extending from now to six weeks 
after the last case of hepatitis A associated with this outbreak occurs. 
 
Administration of live virus vaccine (e.g. measles, mumps, rubella, chickenpox) should be delayed for at 
least 3 months, following receipt of immune globulin. 
  
In light of the fact that immune globulin is only effective for 2-3 months, if effective control measures are 
not implemented and this outbreak extends for two or more months, it may be necessary to repeat the 
administration of immune globulin to persons at a later date. 
 
It will be your responsibility to call the local health department each Friday to report any 
newly recognized cases. 
  
 
Once six weeks have elapsed since the last diagnosed case, all restrictions will be lifted.  It should be 
emphasized that unless these recommendations are complied with, your center is likely to see cases of 
hepatitis A for some time. 
 
If we can be of assistance at any time please contact us. 
 
 (Optional) 
 
For your convenience, the __________________________ Local Health Department will 
hold a shot clinic at your center from (time) on (day). 
 
Sincerely, 
 
 
 
__________________________ 
(Name) 
 
 
__________________________ 
(Local Health Department) 
 
 
SAMPLE RELEASE LETTER TO ADMINISTRATOR 
 
Dear Administrator: 
 
We have had no reported cases of hepatitis A associated with __________ Child Care Center in the last 
six weeks.  We feel the outbreak of hepatitis is resolved.  Therefore, the restrictions on ____________ 
Child Care Center are officially lifted and you may resume your normal admission procedures.  Please 
continue to maintain hygiene recommendations and resume enforcement of the immunization law.  
 
Thank you for your cooperation. 
 
Sincerely, 
 
 
 
__________________________ 
(Name) 
 
 
__________________________ 
(Local Health Department) 
 
 
 
 
 
 
SAMPLE LETTER TO PARENTS TO COMPLETE HEPATITIS INVESTIGATION 
 
Dear Parent: 
 
It has been six weeks since a case of hepatitis A associated with __________________ Child Care Center 
has been reported to us.  If any family members or other close contacts of your child have been 
diagnosed as having hepatitis or had a hepatitis-like illness (nausea, vomiting, lack of appetite, fatigue, 
abdominal pain, yellow skin or eyes) in the past six weeks, please call ________________ Local Health 
Department at (phone) as soon as possible.  Thank you for your cooperation. 
 
Sincerely, 
 
 
 
__________________________ 
  (Name) 
 
 
__________________________ 
(Local Health Department) 
 
 
 
 
 
 
 
Tabulation Sheet 
 
Child Care Center  ________________________________  Date of Questionnaire  ___________________________ 
 
List names and other information requested below on each person identified by the parents’ questionnaire survey who has YELLOW SKIN 
OR EYES OR DARK URINE AND ANY TWO OF THE OTHER SYMPTOMS LISTED ON THE QUESTIONNAIRE. 
 
Contact each person by phone and complete the information on the Viral Hepatitis Case Report Form.  Recommend medical confirmation 
if diagnosis is probable. 
 
If case is confirmed, place the name of the case on the Case List.   
 
Key, N= Nausea, V= Vomiting, AP = Abdominal Pain, LOA = Loss of Appetite, D = Diarrhea, DU = Dark Urine, Y = Yellow skin or eyes 
 
Name of Person with 
symptoms & Relationship 
to child care center child 
Name and age of 
child care center 
contact  
Phone: 
Home: 
Work: 
Symptoms 
(use key) 
Date 
Contacted 
Doctor’s name and 
phone 
Probable Case  
Yes          No 
Confirmed Case 
Yes            No 
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HEPATITIS B 
 
Also known as:  Serum hepatitis, Australian antigen hepatitis, epidemic jaundice 
 
Responsibilities: 
Hospital: Report by IDSS, facsimile, phone, or mail 
Lab: Report by IDSS, facsimile, phone, or mail 
Physician: Report by facsimile, phone, or mail 
Local Public Health Agency (LPHA): Follow-up is required. Report by IDSS, facsimile, phone, or mail 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Hepatitis B virus (HBV) is a small, double-shelled virus in the Hepadnaviridae family.  The virus has a small 
circular DNA genome that is partially double-stranded.  HBV contains numerous antigenic components, including 
HBsAg, hepatitis B core antigen (HBcAg), and hepatitis B e antigen (HBeAg). 
 
B. Clinical Description 
Symptoms & Onset – The prodromal phase from initial symptoms to onset of jaundice usually lasts from 3 - 10 days.  
It is nonspecific and is characterized by insidious onset of malaise, anorexia, nausea, vomiting, right upper quadrant 
abdominal pain, fever, headache, myalgias, skin rashes, arthralgias and arthritis, and dark urine, beginning 1 to 2 
days before the onset of jaundice.  The jaundice phase is variable, but usually lasts from 1 - 3 weeks, characterized 
by jaundice, light or gray stools, hepatic tenderness and hepatomegaly (splenomegaly is less common).  During 
convalescence, malaise and fatigue may persist for weeks or months, while jaundice, anorexia, and other symptoms 
disappear.  Less than 10% of children and approximately 30% of adults will experience jaundice. 
 
Complications – Fulminant hepatitis occurs in about 1% - 2% of persons, with mortality rates of  
63% - 93%.  About 200 - 300 Americans die of fulminant disease each year.  Although the consequences of 
acute HBV infection can be severe, most of the serious complications associated with HBV infection are due to 
chronic infection.  Those that are chronically infected are infected for life and can pass the virus to others, even 
without symptoms.  Approximately 10% of all acute HBV infections progress to chronic infection.  As many as 
90% of infants who acquire HBV infection from their mothers at birth become chronic carriers.  Of children who 
become infected with HBV between 1 year and 5 years of age, 30% - 50% become chronic carriers.  By 
adulthood, the risk of becoming a chronic carrier is decreased to 6% - 10%.  Persons with chronic infection are 
often asymptomatic and may not be aware that they are infected, yet are capable of infecting others.  Chronic 
infection is responsible for most HBV-related morbidity and mortality, including chronic hepatitis, cirrhosis, liver 
failure, and hepatocellular carcinoma.  Chronic active hepatitis develops in more than 25% of chronic carriers, 
and often results in cirrhosis.  An estimated 3,000 - 4,000 persons die of hepatitis B-related cirrhosis each year in 
the United States.  Persons with chronic HBV infection are at 12 - 300 times higher risk of hepatocellular 
carcinoma than non-carriers.  An estimated 1,000 - 1,500 die each year in the United States of hepatitis B-
related liver cancer. 
 
C. Reservoirs 
Humans are the only known reservoir.  
 
D. Modes of Transmission 
Spread – HBV is transmitted by parenteral or mucosal exposure to HBsAg-positive body fluids from persons who 
are carriers or have acute HBV infection.  The highest concentrations of the virus are in the blood and serous 
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fluids; lower titers are found in other fluids, such as saliva and semen.  Saliva can be a vehicle of transmission 
through bites; however, other types of exposure to saliva, including kissing, are unlikely modes of transmission.  
There appears to be no transmission of HBV via tears, sweat, urine, stool, or droplet nuclei. 
Person-to-person – In the United States, the most important route of transmission is by sexual contact, either 
heterosexual or homosexual, with an infected person.  Fecal-oral transmission does not appear to occur.  
However, transmission among homosexual men occurs possibly via contamination from asymptomatic rectal 
mucosal lesions. 
 
Direct percutaneous inoculation by needles during injection drug use is another mode of HBV transmission.  
Transmission of HBV may also occur by other percutaneous exposure, including tattooing, ear piercing, and 
acupuncture, as well as needle-sticks or other injuries from sharp instruments sustained by medical personnel.  
These encounters account for only a small proportion of reported cases in the United States.  Breaks in the skin 
without overt needle puncture, such as fresh cutaneous scratches, abrasions, burns, or other lesions, may also 
serve as routes for entry.   
 
Contamination of mucosal surfaces with infective serum or plasma may occur in the laboratory during mouth 
pipetting, or by eye splashes or other direct contact with mucous membranes of the eyes or mouth, such as 
hand-to-mouth or hand-to-eye when contaminated with infective blood or serum.  Transfer of infective material 
to skin lesions or mucous membranes via inanimate environmental surfaces may occur by touching surfaces of 
various types of contaminated hospital equipment.  Contamination of mucosal surfaces with infective secretions 
could also occur with contact of semen. 
 
Perinatal transmission from mother to infant at birth is very efficient.  If the mother is positive for both HBsAg 
and HBeAg, 70% - 90% of infants will become infected in the absence of postexposure prophylaxis.  The risk of 
perinatal transmission is about 20% if the mother is positive only for HBsAg; up to 90% of these infected infants 
will become HBV carriers.  An estimated 15% - 25% of these carriers will ultimately die at an early age of liver 
failure secondary to chronic active hepatitis, cirrhosis, or primary hepatocellular carcinoma. 
 
E. Incubation period 
The incubation period of HBV infection is an average of 60 - 90 days, with a range of 45 - 180 days. 
 
F. Period of Communicability or Infectious Period 
Persons with either acute or chronic HBV infection should be considered infectious any time that HBsAg is 
present in the blood.  When symptoms are present in persons with acute HBV infection, HBsAg can be found in 
the blood and body fluids of infected persons for several weeks before and days, weeks, or months after the 
onset of symptoms.  Persons who have chronic hepatitis B (known as carriers) will be positive for HBsAg and 
remain infectious indefinitely. 
 
G. Epidemiology 
The frequency of infection and patterns of transmission vary in different parts of the world.  Approximately 45% 
of the global population live in areas with a high prevalence of chronic HBV infection (>8% of the population is 
HBsAg-positive); 43% in areas with a moderate prevalence (2% to 7% of the population is HBsAg-positive); and 
12% in areas with a low prevalence (<2% of the population is HBsAg-positive).  
 
In China, Southeast Asia, most of Africa, most Pacific Islands, parts of the Middle East, and the Amazon Basin, 
8% to l5% of the population carry the virus. The lifetime risk of HBV infection is greater than 60%, and most 
infections are acquired at birth or during early childhood, when the risk of developing chronic infections is 
greatest. In these areas, because most infections are asymptomatic, very little acute disease related to HBV 
occurs, but rates of chronic liver disease and liver cancer among adults are very high. In the United States, 
Western Europe, and Australia, HBV infection is a disease of low endemicity. Infection occurs primarily during 
adulthood, and only 0.1% to 0.5% of the population is chronically infected. Lifetime risk of HBV infection is less 
than 20% in low prevalence areas. 
 
The incidence of reported hepatitis B in the U.S. peaked in the mid-1980s with about 26,000 cases reported each 
year.  Reported cases have declined since that time and fell below 10,000 cases for the first time in 1996.  In 
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1999, a provisional total of 6,495 cases were reported.  The decline in cases during the 1980s and early 1990s is 
generally attributed to reduction of transmission among homosexual men and injection drug users as a result of 
HIV prevention. 
Reported cases of HBV infection represent only a fraction of cases that actually occur.  In 2009, a total of 3,374 
cases of acute hepatitis B were reported to CDC, resulting from an estimated 38,000 new infections. Because 
many HBV infections are either asymptomatic or never reported, the actual number of new infections is 
estimated to be approximately tenfold higher. An estimated 800,000 to 1.4 million persons in the United States 
are chronically infected with HBV and an additional 5,000 – 8,000 persons become chronically infected each 
year. 
 
H. Bioterrorism Potential 
None 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
1. To identify sources/sites of transmission and to prevent spread from such sources. 
2. To ensure identification of infected pregnant women and prevent perinatal transmission. 
 
The following table contains selected hepatitis B serologic markers (what’s looked for in blood samples) and 
their definitions. These results help determine which phase of infection, resolution or immunity a person is in.  
These are results relevant to the reporting requirements. 
 
Interpretation of the Hepatitis B Panel 
Tests Results  Interpretation 
HBsAg 
anti-HBc 
anti-HBs 
negative 
negative 
negative 
    
Susceptible 
   
HBsAg 
anti-HBc 
anti-HBs 
negative 
positive 
positive 
   
 Immune due to natural infection 
    
HBsAg 
anti-HBc 
anti-HBs 
negative 
negative 
positive 
Immune due to hepatitis B vaccination** 
HBsAg 
anti-HBc 
IgM anti-HBc 
anti-HBs 
positive 
positive 
positive 
negative 
   
Acutely 
infected 
   
HBsAg 
anti-HBc 
IgM anti-HBc 
anti-HBs 
positive 
positive 
negative 
negative 
    
Chronically 
infected 
    
HBsAg 
anti-HBc 
anti-HBs 
negative 
positive 
negative 
Four 
interpretations 
possible * 
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* Four Interpretations: 
1. Might be recovering from acute HBV infection.  
2. Might be distantly immune and test not sensitive enough to detect very low level of anti-HBs in serum.  
3. Might be susceptible with a false positive anti-HBc.  
4. Might be undetectable level of HBsAg present in the serum and the person is actually chronically infected.  
** Antibody response (anti-HBs) can be measured quantitatively or qualitatively. A protective antibody response is reported quantitatively as 10 or more 
milliinternational units (>=10mIU/mL) or qualitatively as positive. Post-vaccination testing should be completed 1-2 months after the third vaccine dose for 
results to be meaningful.  
Definitions 
• Hepatitis B Surface Antigen (HBsAg): Present in acute and chronic cases and persists in chronic 
carriers.  The presence of HBsAg indicates that the person is infectious. The body normally produces 
antibodies to HBsAg as part of the normal immune response to infection.  
• Hepatitis B Surface Antibody (anti-HBs): The presence of anti-HBs is generally interpreted as indicating 
recovery and immunity from HBV infection. Anti-HBs also develop in a person who has been successfully 
vaccinated against hepatitis B.  
• Total Hepatitis B Core Antibody (anti-HBc): Appears at the onset of symptoms in acute hepatitis B and 
persists for life. The presence of anti-HBc indicates previous or ongoing infection with hepatitis B virus (HBV) 
in an undefined time frame.  
• IgM Antibody to Hepatitis B Core Antigen (IgM anti-HBc): This antibody appears during acute or 
recent HBV infection and is present for about 6 months.  This is the best test to diagnose acute hepatitis B.  
Additional Tests 
• Hepatitis B e antigen (HBeAg): This marker is used to identify persons infected with hepatitis B who are 
at increased risk for transmitting HBV.  E antigen is seen transiently in most infections and persists 
indefinitely in some carriers.     
• Hepatitis B DNA: May be ordered by a physician to determine the viral load in a patient.  The test indicates 
infection with hepatitis B but does not distinguish between acute and chronic infection.  
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider must report. 
The preferred method of reporting is by utilizing the Iowa Disease Surveillance System (IDSS).  However, if IDSS 
is not available, the reporting number for IDPH Center for Acute Disease Epidemiology (CADE) is (800) 362-
2736; fax number (515), 281-5698, mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
Des Moines, IA 50319-0075 
 
Note: Healthcare providers, hospitals and laboratories are reminded to report all cases of HBsAg-positive 
pregnant women. 
 
C.  Local Public Health Agency Follow-up Responsibilities 
Case Investigation 
 
1. Confirm the diagnosis.  Contact the patient’s health care provider to verify the test result and 
interpretation.  Also verify that the patient has been informed of his or her diagnosis.  If a provider cannot 
be reached within 72 hours of the initial attempt to contact the provider, proceed with the investigation.  Be 
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sure to inform the patient that you were unable to contact his/her provider and that additional follow-up with 
that provider may be needed to confirm the diagnosis and/or discuss treatment options.   
a. See the “Interpretation of the Hepatitis Panel” above for test result interpretation.   
b. Acute cases of hepatitis B must have symptoms of hepatitis B to be counted as an acute case 
according to CDC case definitions (see Additional Information).  If symptoms are not present then 
the case should still be investigated and reported to CADE.   
c. Symptomatic reported cases without profile results may be considered confirmed cases when found 
to be epidemiologically related to an HBsAg-positive case within the previous 6 months of their 
onset (e.g., jaundiced IV drug user who relates sharing a needle with a case reported 3 months 
ago). 
2. Complete a Hepatitis B case investigation (in IDSS) for all suspected or confirmed cases of hepatitis B. 
3. Make appropriate recommendations for prevention of transmission and identify contacts at risk.  Efforts 
should be made to locate contacts and inform them of their exposure, making certain to maintain client 
confidentiality.  Locating contacts who are at high risk of infection or who may have significant 
consequences (e.g., a sexual contact that is pregnant) is especially important. Language-specific materials 
can be found at www.cdc.gov/hepatitis/Resources/PatientEdMaterials.htm   
4. Make necessary interventions to stop transmission to others (e.g., blood banks must be notified if the case 
donated or received blood or blood products within the past 6 months, physicians of pregnant clients should 
be contacted to ensure proper follow-up of the newborn, etc.).  If it appears that an outbreak may be 
occurring (i.e., two or more current cases with suspected common source), contact the Center for Acute 
Disease Epidemiology (CADE) at 800-362-2736. 
5. Many risk factors are common to hepatitis B and HIV, therefore clients who may also be at risk of HIV 
infection (e.g., IV drug users), should be tested for HIV.  A list of current confidential HIV test sites is 
available through the HIV/AIDS/Hepatitis Program at (515) 281-6801 or 
www.idph.state.ia.us/HivStdHep/HIV-AIDS.aspx?prog=Hiv&pg=HivPrev  
 
3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements 
There are no isolation restrictions or quarantine requirements for patients with HBV, except for exclusion from 
organ and blood donation. Patients should also be provided with counseling to modify activities to prevent 
further transmission.  
 
B.  Protection of Contacts of a Case 
Immunization of contacts: Products available for postexposure prophylaxis include hepatitis B immune globulin 
(HBIG) and hepatitis B vaccine.  
 
1. Infants born to HBsAg-positive mothers should be treated as follows: 
a. Give HBIG (0.5 ml IM) and hepatitis B vaccine (0.5ml IM) according to the following table. 
Immunoprophylaxis of Infants Born to HBsAg-positive Mothers 
Vaccine/HBIG Dose  Age 
First hepatitis B vaccine Birth (within 12 hours) 
HBIG1 Birth (within 12 hours) 
Second hepatitis B vaccine 1–2 months 
Third hepatitis B vaccine 6 months 
1 Give HBIG (0.5ml IM) simultaneously with, but at a different site from, the first dose of hepatitis B 
vaccine. 
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b. Screen the infant for HBsAg and anti-HBs 1 to 2 months and after the third dose of hepatitis B 
vaccine, when the child is at least 9 to 15 months of age, to monitor the success or failure of the 
immunization. If HBsAg is not present and anti-HBs antibody is present, children can be considered 
protected.   
c. Infants who do not respond to the initial vaccine series (anti-HBs-negative) and are not HBsAg-
positive should be given a second 3-dose series of hepatitis B vaccine (same schedule as initial 
series) and be re-screened at 1 to 2 months after the last dose.  
d. Infants weighing less than 2,000 grams (4.4 lbs) should receive single-antigen hepatitis B vaccine 
(birth dose) and HBIG within 12 hours of birth, administered at different injection sites.   
e. For preterm infant weighing less than 2,000 grams, the initial vaccine dose (birth dose) should not 
be counted as part of the vaccine series because of the potentially reduced immunogenicity of 
hepatitis B vaccine in these infants.   
f. The second dose of HBV vaccine should be given when the infant is chronologically one month of 
age regardless of weight.  The third dose should be administered one month following the second 
dose, and the fourth dose should be given six months following the second dose.  Thus, a total of 
four doses of HBV vaccine are recommended in this circumstance.   
g. Infants who become HBsAg-positive should be referred to a pediatric hepatologist for follow-
up and the parents should be counseled. Since HBV infection is a reportable disease, the HBsAg-
positive infant should be reported to Iowa Department of Public Health. 
 
2. Infants born to mothers whose HBsAg status is not known should be treated as follows: 
a. The hepatitis B vaccine should be given within 12 hours of birth while awaiting HBsAg test results 
on the mother. If the mother is determined to be positive, the infant should receive HBIG as soon 
as possible, within 7 days of birth. This child should then complete the 3-dose hepatitis B 
vaccination series according to the table in Section 3) B. The child should then be screened for 
HBsAg and anti-HBs at 9 to 15 months of age, as described in Section 3) B above.  
b. If the mother is determined to be HBsAg-negative, the infant should complete the 3-dose 
hepatitis B vaccine series according to ACIP recommendations, as in chart above. 
c. Infants weighing less than 2,000 grams (4.4 lbs) should receive hepatitis B vaccine (birth dose) and 
HBIG within 12 hours of birth if the mother’s status is not determined within that timeframe.  
 
3. Unvaccinated infants exposed to a primary caretaker with acute hepatitis B should receive HBIG 
(0.5 mL) and should initiate and complete the 3-dose hepatitis B vaccine series according to the table above 
as soon as possible. Infants who have already started the vaccine series do not need HBIG, and should 
complete the vaccination series on schedule. 
 
4. Sexual contacts of a person with acute hepatitis B, if susceptible, should receive a single dose of HBIG 
(0.06 mL/kg), if the HBIG can be given within 14 days of the last sexual exposure. In addition, sexual 
contacts should initiate and complete a 3-dose series of hepatitis B vaccine according to the table in Section 
3) D.   
 
5. Sexual contacts of persons with chronic hepatitis B, if susceptible, should initiate and complete the 3-
dose series of hepatitis B vaccine according to the table in Section 3) D.  
 
6. Nonsexual household contacts of a person with acute hepatitis B, if susceptible, who have had a 
blood exposure to the index patient (such as sharing toothbrushes or razors) should receive a single dose of 
HBIG (0.06 mL/kg) and should initiate and complete the 3-dose series of hepatitis B vaccine according to the 
table in section 3) D.  The 3-dose hepatitis B vaccination series should also be considered for contacts who 
do not have a blood exposure; children and adolescents, especially, should be vaccinated according to the 
table in Section 3) D. 
 
7. All household contacts, including infants, of persons with chronic hepatitis B, if susceptible, should 
initiate and complete the 3-dose series of hepatitis B vaccine according to the table in Sections 3) D.   
 
8. Persons with percutaneous or mucous membrane exposures to either an acute or chronic case, if 
susceptible, should receive postexposure prophylaxis according to the table below.  
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Recommended Post-exposure Prophylaxis for Percutaneous or 
Permucosal Exposure to Hepatitis B Virus 
Vaccination status of  
Exposed person 
Treatment when source is found to be: 
HBsAg1-positive HBsAg-
negative 
Unknown or not tested 
Unvaccinated Administer 1 dose of HBIG3 and 
initiate hepatitis B vaccine 
series 
Initiate hepatitis 
B vaccine series 
Initiate hepatitis B vaccine 
series 
Previously vaccinated: 
  Known responder2 
No treatment No treatment No treatment 
Previously vaccinated: 
  Known non-responder 
2 doses of HBIG, or 1 dose of 
HBIG and initiate revaccination4 
No treatment If known high-risk source, 
treat as if source were 
HBsAg-positive 
Previously vaccinated: 
  Response unknown 
Test exposed person for anti-
HBs5 
• If adequate, no treatment 
• If inadequate, 1 dose of 
HBIG and a vaccine 
booster dose6 
No treatment 
Test exposed person for anti-
HBs5 
• If adequate, no 
treatment 
• If inadequate, vaccine 
booster dose6 
1 Hepatitis B surface antigen. 
2 Responder is defined as a vaccinated person with adequate levels of serum antibody to HBsAg (i.e., anti HBs > 10 mIU/mL). 
3 Hepatitis B immune globulin; dose 0.06 mL/kg, intramuscularly. 
4 Persons known not to have responded to a 3-dose vaccine series and to revaccination with 3 additional doses should be given 2 doses of HBIG (0.06 ml/kg), 
one dose as soon as possible after exposure and the second 1 month later. 
5 Adequate serum antibody response to hepatitis B surface antigen is > 10 mIU/mL. 
6 The person should be evaluated for antibody response after the vaccine booster dose. For persons who received HBIG, anti-HBs testing should be done when 
passively acquired antibody from HBIG is no longer detectable (e.g., 4–6 mo.); if they did not receive HBIG, anti-HBs testing should be done 1–2 months after 
the vaccine booster dose. If anti-HBs is found to be inadequate (< 10 mIU/mL) after the vaccine booster dose, 2 additional doses should be administered to 
complete a 3-dose revaccination series. 
Table adapted from: American Academy of Pediatrics. Red Book 2006: Report of the Committee on Infectious Diseases, 27th Edition. Illinois, American Academy 
of Pediatrics, 2006:302. 
 
C.  Managing Special Situations  
1. School and Child care  
a. The risk of transmission of HBV in school and child care settings has always been very low. This risk is now 
even lower because the proportion of susceptible children is decreasing as requirements for hepatitis B 
immunization for entry into kindergarten have been implemented. To prevent the transmission of hepatitis B 
and other bloodborne disease in these settings, however, the following guidelines should be followed: 
b. Primary prevention: Ensure compliance with all hepatitis B immunization requirements. Vaccination is also 
recommended for unvaccinated classmates of hepatitis B carriers who behave aggressively (e.g., biting) or 
who have medical conditions, such as open skin lesions (e.g., generalized dermatitis or bleeding problems), 
that increase the risk of exposing others to infectious blood or serous secretions.  
c. Secondary prevention: Persons exposed to potentially infectious blood or other body fluids should be 
treated according to the guidelines for “Postexposure Prophylaxis for Percutaneous or Permucosal Exposure 
to Hepatitis B Virus” outlined in the table above. However, in the case of a bite by a person whose hepatitis 
B status is unknown, it is unlikely that it will result in transmission and blood testing is not recommended for 
either biter or victim. The risk of HBV acquisition when a susceptible child bites an HBV carrier is not known. 
However, most experts would not give HBIG to the susceptible biting child who does not have oral mucosal 
disease when the amount of blood transferred is small. 
d. Notification: Parents may wish to inform the school nurse or child care program director about a child who 
is a known hepatitis B carrier to allow for proper precautions and assessment of behavior issues that could 
facilitate transmission. However, this is not necessary since policies and procedures to manage exposure to 
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blood or blood-containing materials should already be established and implemented. Parents of other 
children attending the school/child care do not need to be informed. 
e. Exclusions: Adults and children ill with acute hepatitis B should stay home until they feel well, and fever 
and jaundice are gone. There is no reason to exclude a person with hepatitis B from employment or 
attendance once they have recovered from acute infection. Admission of a known hepatitis B carrier with 
specific risk factors, such as biting, open rashes or sores that can’t be covered or bleeding problems should 
be assessed on an individual basis by the child’s doctor, school/child care and responsible public health 
authorities. Because these children pose a risk to others in child care, consideration may be given to 
exclusion from child care until the aggressive behavior ceases or until all contacts have been vaccinated. 
However, as the proportion of children who are immunized over time has increased , concern about bites 
and HBV transmission has also decreased. 
f. Prevention Guidelines: Whether or not individual hepatitis B carriers have been identified, it is important 
that school staff receive regular training on the prevention of bloodborne disease. Personnel should be 
educated about Standard Precautions for handling blood or blood-containing materials. All students should 
receive age-appropriate instruction regarding the potential dangers of contact with other people’s blood and 
other body fluids. Some Standard Precautions include: 
• Follow all procedures for handwashing and cleanliness.  
• Always treat all blood as potentially dangerous fluid and observe universal precautions, 
including using disposable gloves when cleaning or removing blood or body fluid spills.  
• Do not permit sharing of personal items that may become contaminated with blood or body 
fluids, such as toothbrushes, eating utensils, etc.  
• Cover open skin lesions.  
• Place disposable items contaminated with blood or body fluids in plastic bags in covered 
containers. 
• Store contaminated clothing or washable items separately in plastic bag, and send them home 
with the owner for proper cleaning.  
• Wash and sanitize surfaces of contaminated objects with a dilute solution of 1/4 cup household 
bleach in 1 gallon of water (1:100 dilution) applied for at least 30 seconds, made up on a daily 
basis, or disinfect objects by boiling objects for 10 minutes. 
• Supervise closely to discourage and prevent aggressive behavior. 
• Provide age-appropriate education to adolescents and young adults about prevention of 
sexually transmitted diseases, including hepatitis B. 
 
D.   Reported Incidence Is Higher than Usual/Outbreak Suspected 
If the number of reported cases in your city/town is higher than usual, or if an outbreak is suspected, 
investigate clustered cases in an area or institution to determine source of infection. If evidence indicates a 
common source, applicable preventive or control measures should be instituted. Consult with an 
epidemiologist at the Center for Acute Disease Epidemiology at (800) 362-2736 for assistance in 
investigation and the implementation and recommendation of other control measures.  
 
E.   Preventive Measures  
General control and prevention measures include implementing all hepatitis B immunization requirements 
and recommendations, as described below. 
1. Pre-exposure Prophylaxis: The Iowa Department of Public Health recommends hepatitis B vaccine 
for the following groups: 
a. Newborns  
i. All newborns should receive monovalent hepatitis B vaccine soon after birth and before hospital 
discharge. 
ii. Following the birth dose, the hepatitis B series should be completed with either monovalent 
hepatitis B or a combination vaccine containing hepatitis B.  The second dose should be 
administered at 1-2 months of age.  The final dose should be administered at 6 months of age.  
Administering 4 doses of hepatitis B vaccine is permissible (e.g., when combination vaccines are 
administered after the birth dose). 
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Routine Schedule for Infant Hepatitis B Vaccination 
 
Dose Usual Age Minimum Interval 
1 Birth - 2 months -- 
2 1–2 months 1 month 
3 6 months 2 months1 
and 4 months from 1st dose 
1 Do not administer before 6 months of age 
b. Children and adolescents 18 years or younger 
i. State Immunization Requirements: Hepatitis B vaccine is required for all children who enroll in 
kindergarten if born on or after July 1, 1994.  
c. Adults over 18 who are at risk 
i. Adults at risk for HBV infection include: 
• People who have more than one sex partner in 6 months 
• Men who have sex with other men 
• Sex contacts of infected people 
• People who inject illegal drugs 
• People whose jobs expose them to human blood (The Occupational Safety and Health 
Administration (OSHA) of the US Department of Labor has issued a regulation requiring 
employers of workers at risk for occupational exposure to HBV to offer HBV immunization to 
these employees at the employer’s expense) 
• Household contacts of persons with chronic HBV infection 
• Hemodialysis patients 
 
Routine Schedule for Adolescent & Adult Hepatitis B Vaccination  
 
Dose Usual Interval Minimum Interval 
1 -- -- 
2 1 month 4 weeks 
3 5 months 8 weeks * 
*Third dose must be separated from first dose by at least 16 weeks 
 
ii. Hepatitis B vaccine is produced by 2 manufacturers; both vaccines are available in pediatric and 
adult formulations. 
 
1. Birth through 19 years (pediatric formulation) 
2. Adults (> 20 years of age) (adult formulation) 
 
iii. Doses given at less than the minimum intervals should not be counted as part of the vaccination 
series.  Do not restart series, no matter how long since previous dose. 
 
iv. For adults and children with normal immune status, booster doses of vaccine are not 
recommended, nor are routine serologic testing to assess immune status of vaccinees indicated. 
 
4) ADDITIONAL INFORMATION 
 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Hepatitis B can be 
found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top   
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria in this 
chapter. (CSTE case definitions are used by the state health department and the CDC to maintain uniform 
standards for national reporting.)  
 
Iowa Department of Public Health Reviewed 12/13                          Hepatitis B 9 
Guide to Surveillance, Investigation, Reporting 
References 
American Academy of Pediatrics. 2006 Red Book: Report of the Committee on Infectious Diseases, 27th Edition. 
Illinois, American Academy of Pediatrics, 2006. 
CDC. A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the 
United States  Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2005;  
54(RR16);1-23 
CDC. Immunization of Healthcare Workers: Recommendations of the Advisory Committee on Immunization 
Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR. 1997; 
46:RR-18 
Heymann, David L., ed., Control of Communicable Diseases Manual, 19th Edition. Washington, DC, American 
Public Health Association, 2008. 
Epidemiology and Prevention of Vaccine Preventable Diseases, Ninth  Edition, January 2006, Department of 
Health and Human Services, Centers for Disease Control and Prevention. 
 
Resources 
 
www.cdc.gov/ncidod/diseases/hepatitis/b/index.htm 
Iowa Department of Public Health Reviewed 12/13                          Hepatitis B 10 
FACT SHEET                                    HEPATITIS B 
 
What is hepatitis B? 
Hepatitis B is a virus that enters the bloodstream and then infects the liver.  Clinical signs and symptoms occur more 
often in adults than in infants or children.  Approximately 10% of all people infected with hepatitis B will stay 
infected for a lifetime, however infants and young children infected with hepatitis B have a 90 percent chance of 
becoming lifelong carriers of the disease.  Long-term infection may result in liver disease or cancer. 
 
Who gets hepatitis B? 
Anyone can get hepatitis B. However, certain people have a greater chance of becoming infected; these people include 
babies born to hepatitis-b positive mothers, IV drug users, sexual partners of infected persons, and medical and dental 
workers.  
 
How is the hepatitis B spread? 
Hepatitis B is most often spread from person to person through contact with infected semen, vaginal secretions, or blood. 
Having sex with an infected person and sharing needles for drug use are two very common ways that people become 
infected. Babies born to infected mothers and people who live in the house with a "carrier" of hepatitis B are also at risk. 
 
What are the symptoms of Hepatitis B? 
Symptoms may be mild or they may be very severe.  Symptoms may include extreme tiredness, nausea, vomiting, 
fever, headache, skin rashes, stomach pain, tea-colored urine, and yellowing of skin and eyes (jaundice). Most people 
infected with hepatitis B do not develop all symptoms and may never know they are infected. 
 
How soon do the symptoms of Hepatitis B appear? 
Loss of appetite and stomach pain commonly appears within 2 to 3 months, but can occur from 6 weeks to 6 months 
after infection.   
 
How long can an infected person spread the virus? 
A person can spread the virus as long as it remains in their blood.  Most adults will get rid of the virus within 4 to 6 
months; however, about 1 out of every 10 infected adults will become lifelong “carriers”, meaning they will probably 
never get rid of the virus. Nine out of 10 infected babies will become life-long "carriers".  Most hepatitis B carriers 
have no symptoms of hepatitis, but some will develop serious liver disease years later.  Most hepatitis B carriers do 
not look or feel sick.  However, they may eventually develop serious liver diseases such as cirrhosis or liver cancer.  
Even though carriers may feel healthy, they can still spread the hepatitis B virus to other people. 
 
How is hepatitis B diagnosed? 
A blood test is used to detect infection with the hepatitis B virus. 
 
Can a person get hepatitis B again?  
If antibodies develop, one infection with the hepatitis B virus protects a person form getting it again.  Carriers remain 
infected for life.  However, there are different kinds of hepatitis; infection with hepatitis B will not stop a person from 
getting other types of hepatitis. 
 
What is the treatment for hepatitis B? 
There is no specific treatment for acute HBV infection.  People who are sick with hepatitis B should see a doctor for 
advice about how to control their symptoms.  25-40% of adults with chronic HBV infection and liver disease achieve 
long-term remission after treatment with interferon-alfa. 
  
What can be done if a person comes into contact with someone infected with hepatitis B? 
Hepatitis B immune globulin (HBIG) and hepatitis B vaccine can prevent infection if given within 7 days after an 
exposure.  This treatment is available from doctors in your community.  Infants, whose mothers have hepatitis B 
receive HBIG and begin vaccination at time of birth.  Remaining vaccinations should be completed by 6 months of age.  
Additionally, the baby will have blood tests at 9-12 months to be sure the vaccine has protected them from hepatitis B 
disease.  
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How can infection with hepatitis B be prevented? 
Never share needles for drug use, ear piercing, tattooing, or any other purpose.  Avoid contact with the blood or wound 
drainage of any other person.  Use condoms when having sex.   
 
Is there a vaccine to prevent hepatitis B? 
Yes, there is a vaccine to protect against hepatitis B.  It is recommended for children, adolescents, and all newborn 
babies before they leave the hospital (usually within the first 24 hours of birth), and persons who are at high risk for 
infection or anyone wishing to lower his or her risk of getting hepatitis B.  A three dose series will protect the majority 
of people who are vaccinated. 
 
Information for persons with acute or chronic hepatitis B 
 
What can you do to take care of yourself? 
 Avoid alcoholic beverages and street drugs.  They will damage your liver. 
 Avoid taking prescription or over-the-counter medicines unless your doctor tells you it is OK. 
 Eat a healthy diet (low fat) and get enough rest.  If you are vomiting after eating tell your doctor. 
 See your doctor for a check-up. 
 Persons with acute hepatitis:  Discuss with your doctor about having a blood test (6 months after you first 
became infected) to see if you have become a carrier of hepatitis B.  Carriers may develop serious liver 
disease in the future and can pass the disease on to others. 
 Women with chronic hepatitis:  Discuss with your doctor about having a blood test every 6-12 months to 
make sure your liver is healthy and there is not a liver cancer developing.  Talk to your doctor about having 
a special test (called an "ultrasound") done on your liver occasionally. 
 If you get pregnant, tell your doctor you have hepatitis B.  
 Women with acute hepatitis:  The baby will need to receive hepatitis B immune globulin and the first dose of 
the hepatitis B vaccine at birth.  The baby will need to complete the vaccine series by 6 months of age and 
then have post-vaccination testing to assure they are protected.   
 Persons with chronic hepatitis: It is important that your baby receive hepatitis B immune globulin and the first 
dose of the hepatitis B vaccine immediately after birth to prevent infection from occurring. The baby will need 
to complete the vaccine series by 6 months of age and then have post-vaccination testing to assure they are 
protected.   
 Contact the American Liver Foundation for more information (toll-free: 1-800-223-0179). 
 
What can you do to protect others? 
• Cover all cuts and sores with a bandage and wash hands well after touching blood or body fluids. 
• Throw away any items that have your blood on them, such as bandages and menstrual pads, in plastic bags 
and close tightly.  Wash hands well after touching your blood or body fluids. 
• Clean up blood spills with paper towels.  Then clean the area with a bleach solution (1 part bleach to 100 parts 
water, one-quarter cup bleach to a gallon of water). 
• Tell your sex partner that you have hepatitis B, use a condom, and encourage your partner to be tested and, 
vaccinated against hepatitis B. 
• Have your sex partners and all those living in your household to see a doctor for testing and for hepatitis B 
vaccination. Do not allow anyone to come into contact with your blood or body fluids. 
• Do not share chewing gum, toothbrushes, razors, scissors, needles for ear piercing, nail files, or anything else 
that may come in contact with your blood or body fluids. 
• Do not share food, drink, cigarettes, lipstick, or lip balm. 
• Do not share syringes and needles. 
• Do not donate blood, plasma, body organs, sperm, or breast milk. 
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What is Hepatitis B? 
The hepatitis B virus (HBV) is a DNA virus and is a major cause of acute and chronic hepatitis, cirrhosis, and liver 
cancer.  Each year in the U.S. alone, there are approximately 78,000 new infections, and there are an estimated 
200,000-300,000 million carriers in the world. 
 
How is Hepatitis B transmitted? 
Hepatitis B virus (HBV) can be transmitted percutaneously (needlestick), permucosally (blood into eye, sexual 
intercourse), non-intact skin (blood or secretions into open wounds/cuts/dermatitis, etc.), perinatally, and continuous 
close contact.   
Because HBV is stable on environmental surfaces for at least 7 days, indirect inoculation can occur via inanimate 
objects (such as toothbrushes and razors).  It is not transmitted via the fecal-oral route (as hepatitis A is). 
 
What is the incubation period? 
The incubation period is 45-180 days, averaging between 60 and 90 days. 
 
What is the period of communicability? 
Hepatitis B surface antigen (HBsAg) can be identified in serum from 30-60 days postexposure and persists for 
variable periods of time.  Approximately 10% of infected adults will become chronic carriers. 
 
How is Hepatitis B diagnosed? 
Hepatitis B is diagnosed through two different antigen-antibody responses detected in the blood (HBsAg, anti-HBc 
IgM). 
 
How is Hepatitis B prevented? 
Pre-exposure 
 Receive the hepatitis B vaccine. 
 Use safe sex practices, always use a condom 
 Protect from coming in contact with the blood or other body fluids of others 
Post-exposure prophylaxis: 
 Hepatitis B vaccine 
Hepatitis B immune globulin (HBIG):  Temporary, passive protection  
 
Is a booster dose of Hepatitis B vaccine needed? 
If a person has three documented doses of hepatitis B vaccine a booster dose is NOT recommended. 
 
Are extended intervals in vaccination acceptable?  
• If a patient has had a dose of vaccine and the interval between that dose and the one they seek now is 
longer than the recommended timeframe they do not need to re-start the series.  Finish the series. If the 
series is interrupted after the first dose, the second dose should be administered as soon as possible, and 
the second and third doses should be separated by an interval of at least 8 weeks. If only the third dose has 
been delayed, it should be administered as soon as possible.  
 
Who should be vaccinated? 
Persons who are at risk for exposure to blood, blood products or blood-contaminated fluid should be vaccinated.  
These include:  
 healthcare workers 
 clients and staff of institutions for the developmentally disabled 
  hemodialysis patients 
 sexually active homosexual and bisexual men 
  users of illicit injectable drugs 
  recipients of certain blood products 
  household and sexual contacts of hepatitis B carriers 
  inmates of long term correctional facilities 
 sexually active heterosexual persons with multiple sexual partners 
 babies born to hepatitis B-positive mothers 
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 international travelers who plan to spend more than 6 months in areas of high endemicity and who will have 
close contact with the local population.   
 all children born on or after July 1, 1994 must show proof of receiving three doses of hepatitis B vaccine to 
be enrolled in a licensed child care center or school per Iowa Administrative Code 641.1. 
 
What should be done after a known or suspected exposure? 
For ANY exposure of a person not previously vaccinated, hepatitis B vaccine is ALWAYS recommended.  Exposure 
should be reported and a postexposure evaluation done.  Treatment will depend on the vaccination status of the 
exposed, the vaccine responder status of the exposed and the hepatitis status of the source if known.   
 
What measures need to be taken for the pregnant women and the newborn? 
Prenatal screening of all pregnant women identifies those who are HBsAg positive.  Immediate treatment of infants 
born to HBsAg positive mothers with HBIG and Hepatitis B vaccine is recommended.  If the mother is not currently 
infected with hepatitis B but presents during prenatal care with risk factors, vaccination is indicated.  Pregnancy is 
not a contraindication to vaccination. 
 
Does HBIG and Hepatitis B vaccine interfere with routine childhood immunizations? 
Vaccinations with live virus vaccines should be deferred until about 3 months after administration of HBIG.  The 
hepatitis B vaccine does not interfere with other childhood immunizations. 
 
Is risk of transmission in child care centers high? 
No, the risk of transmission in child care centers appears to be extremely low.  Standard Precautions apply. 
 
When is a person no longer infectious? 
If a person is HBsAg and HBc IgM negative, then they are no longer infectious. 
 
What if there appears to be an outbreak? 
If there are 2 or more current cases with a suspected common source, contact the Center for Acute Disease 
Epidemiology at (800) 362-2736. 
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Who should be tested for hepatitis B?  
All pregnant women should be tested routinely for HBsAg during an early prenatal visit (e.g., first trimester) in 
each pregnancy, even if they have been previously vaccinated, tested, or previously HBsAg positive. 
 
In special situations, an additional HBsAg test can be ordered during the third trimester.  This should be 
considered if the patient develops symptoms, is exposed to HBV, or engages in high risk behavior (e.g., having 
had more than one sex partner in the previous 6 months, having a HBsAg positive sex partner, evaluation or 
treatment for a sexually transmitted disease [STD], or recent/current injection-drug use). 
 
Are some people more likely to have hepatitis B than others?  
Residents and descendents of certain countries and regions of the world are more prone to HBsAg infection as 
the disease was, or currently is, endemic.  Patients from the following countries/regions may have an increased 
risk for HBsAg infection:  Afghanistan, Africa, rural Alaska, Albania, Bangladesh, Bosnia and Herzegovina, 
Bulgaria, Cambodia, China, Eastern Europe, Haiti, Hawaii, India, Indonesia, Iran, Iraq, Korea, Laos, Malaysia, 
the Middle East, Myanmar, Pakistan, the Pacific Islands, Philippines, Romania, the former Soviet Union, South 
America’s Amazon Basin, Sri Lanka, Syria, Taiwan, Thailand, or Vietnam. 
 
What if a patient was not tested before they arrive at the hospital for delivery?  
Women who were not screened prenatally, those who engage in behaviors that put them at high risk for 
infection (see high risk behaviors on the previous page) and those with clinical hepatitis should be tested at the 
time of admission for delivery. Women admitted for delivery without documentation of HBsAg test results 
should have blood drawn and tested as soon as possible after admission. While test results are pending, all 
infants born to women without documentation of HBsAg test results should receive the first dose of single-
antigen hepatitis B vaccine within 12 hours of birth. 
 
Care of infants born to HBsAg-positive mothers: 
If the mother is determined to be HBsAg positive and the child weighs 2,000 grams (4.4 lbs) or more at birth:  
 Give infant HBIG and HBV vaccine within 12 hours of birth 
 Continue vaccine series on an accelerated schedule beginning at 1-2 months of age and completing 
the 3 dose series by 6 months  
 Check quantitative anti-HBs and HBsAg after completion of vaccine series at 9-12 months of age. 
 
If the mother is determined to be HBsAg positive and the child weighs 2,000 grams (4.4 lbs) or less at 
 birth:  
 Give infant HBIG and HBV vaccine within 12 hours of birth 
 Continue vaccine series on an accelerated schedule beginning at 1-2 months of age and completing 
the 3 dose series by 6 months  
 Do not count birth dose as part of vaccine series.  The second dose of HBV vaccine should be given 
when the infant is chronologically one month of age regardless of weight.  The third dose should be 
administered one month following the second dose, and the fourth dose should be given six months 
following the second dose.  Thus, a total of four doses of HBV vaccine are recommended in this 
circumstance.  Immunize with 4 doses of vaccine.  
 Check quantitative anti-HBs and HBsAg after completion of vaccine series at 9-12 months of age 
 
Care of infants born to HBsAg status-unknown mothers:  
If the mother’s HBsAg status is unknown and the child weighs 2,000 grams (4.4 lbs) or more at birth: 
 Test mother for HBsAg immediately after admission 
 Give infant HBV vaccine within 12 hours of birth 
 Give infant HBIG (within 7 days) if mother tests HBsAg positive.  If the mother’s HBsAg status remains 
unknown at the time of discharge it may be appropriate to provide HBIG to the child prior to release 
from the hospital.  Efforts should be made to determine HBsAg status prior to discharge, but in the 
absence of this information and faced with a situation where it is uncertain the child will receive 
appropriate follow-up, providing HBIG may be appropriate.  
 Continue vaccine series beginning at 1-2 months of age according to the recommended schedule 
based on mother’s HBsAg status  
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If the mother’s HBsAg status is unknown and the child weighs 2,000 grams (4.4 lbs) or less at birth:  
 Test mother for HBsAg immediately after admission 
 Give infant HBV vaccine within 12 hours of birth 
 Give infant HBIG if mother tests HBsAg positive OR if mother’s HBsAg result is not available within 12 
hours of birth  
 Do not count birth dose as part of vaccine series, immunize with 4 doses of vaccine 
 Continue vaccine series beginning at 1-2 months of age according to the recommended schedule 
based on mother’s HBsAg status  
 Check quantitative anti-HBs and HBsAg after completion of vaccine series at 9-12 months of age 
 
Care for HBsAg negative mothers: 
If the mother is determined to be HBsAg negative, the vaccine series should be completed according to the 
Recommended Childhood and Adolescent Immunization Schedule (birth, 1-2, and 6-18 months). 
 
What if there are extended intervals between doses of vaccine?  
All doses not violating the minimum intervals are valid.  It is not necessary to restart the vaccine series if there 
is an extended interval between doses.  The minimum interval between the first and second dose is 28 days. 
The minimum interval between the second and third dose is 2 months and 4 months from the first dose, as 
long as the third dose is given after 6 months of age. 
 
Why should the infant have post vaccination serology?  
Post-vaccination serology for infants born to HBsAg positive mothers is the method of confirming protection 
from HBV.  Post-vaccination serology is a key component to case management of the child.  Post-vaccination 
testing for HBsAg and quantitative anti-HBs should be performed after completion of the vaccine series 3 to 9 
months following the final dose of hepatitis B vaccine (generally at the 12 month well-child visit, although 
encouraged to be performed earlier if applicable).   
 
It is very important the provider order quantitative anti-HBs.  Without ordering a quantitative anti-HBs, there is 
no way to determine the antibody concentration and thus determine if the infant is protected (greater than 10 
mIU/mL) or needs further doses of vaccine (less than 10 mIU/mL). 
 
Testing should not be performed before age 9 months to avoid detection of anti-HBs from HBIG administered 
during infancy.  Anti-HBc testing of infants is not recommended because passively acquired maternal anti-HBc 
might be detected in infants born to HBV-infected mothers to age 24 months.  
 
What is the follow-up for test results?  
HBsAg-negative infants with anti-HBs levels equal to or greater than 10mIU/mL are protected and need no 
further medical management. 
HBsAg-negative infants with anti-HBs levels less than 10mIU/mL should be revaccinated with a second 3-dose 
series (either using spacing of doses at 0, 2, and 4-month intervals or 0, 1, and 4-month intervals) and 
retested 1 month after the final dose of vaccine. 
Infants who are HBsAg positive should receive appropriate follow-up including periodic evaluation for liver 
function.   
 
What about others living in the same house as the HBsAg positive mother?  
Other children in the home should have verified vaccination status and possible serologic testing.   
Sex partners of HBsAg-positive persons should be counseled to use methods (e.g., condoms) to protect 
themselves from sexual exposure to infectious body fluids (e.g., semen or vaginal secretions) unless they have 
demonstrated immunity after vaccination (i.e., anti-HBs >10 mIU/mL) or previously infected (anti-HBc 
positive).  Additionally, household contacts should be counseled to refrain from sharing household articles (e.g., 
toothbrushes, razors, nail clippers and files, or personal injection equipment) that could become contaminated 
with blood 
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FACT SHEET        HEPATITIS B 
Information for Persons with Acute Hepatitis 
 
What is hepatitis B? 
Hepatitis B is a virus that enters the bloodstream and then infects the liver. 
 
How is the virus spread? 
Hepatitis B is most often spread from person to person through contact with infected semen, vaginal secretions, or blood. 
Having sex with an infected person and sharing needles for drug use are two very common ways that people become 
infected. Babies born to infected mothers and people who live in the house with a "carrier" of hepatitis B are also at risk. 
 
What happens after a person is exposed to hepatitis B? 
After a person is exposed to hepatitis B, several things may happen: 1) they may not become infected, 2) they may 
become infected but not get sick, or 3) they may become infected and get sick. 
 
How soon do the symptoms appear? 
It takes anywhere from 2 - 6 months after exposure before the symptoms of infection show. 
 
What are the symptoms? 
Symptoms include being very tired, nausea, vomiting, fever, stomach pain, tea-colored urine, and yellowing of skin and 
eyes (jaundice). Symptoms may be mild or they may be very severe. Remember, most people infected with hepatitis B do 
not develop all these symptoms and may never know they are infected. 
 
How long can an infected person spread the virus? 
Most adults with hepatitis B will get rid of the virus within 4 to 6 months but are able to spread the infection during this 
time.  After their body gets rid of the infection they will no longer be capable of giving the infection to others and they can 
never get it again. However, about one out of every 10 infected adults, and as many as 9 of 10 infected babies, will 
become life-long "carriers" of hepatitis B, meaning that they do not get rid of the virus and can infect others. Most hepatitis 
B carriers have no symptoms of hepatitis, but some will develop serious liver disease years later. 
 
What can you do to take care of yourself? 
• Avoid alcoholic beverages and street drugs.  They will damage your liver. 
• Avoid taking prescription or over-the-counter medicines unless your doctor tells you it is OK. 
• Eat a healthy diet (low fat) and get enough rest.  If you are vomiting after eating tell your doctor. 
a. See your doctor for a check-up and discuss having a blood test (6 months after you first became infected) to 
see if you have become a carrier of hepatitis B.  Carriers may develop serious liver disease in the future and 
can pass the disease on to others. 
• If you get pregnant, tell your doctor you have hepatitis B. The baby will need to receive hepatitis B immune 
globulin and the first dose of the hepatitis B vaccine at birth.  The baby will also need to complete the vaccine 
series by 6 months of age and then have post-vaccination testing to assure they are protected.  
• Contact the American Liver Foundation for more information (toll-free: 1-800-223-0179). 
 
What can you do to protect others? 
• Cover all cuts and sores with a bandage and wash hands well after touching blood or body fluids. 
• Throw away any items that have your blood on them, such as bandages and menstrual pads, in plastic bags and 
close tightly.  Wash hands well after touching your blood or body fluids. 
• Clean up blood spills with paper towels.  Then clean the area with a bleach solution (1 part bleach to 100 parts 
water, one-quarter cup bleach to a gallon of water). 
• Tell your sex partner that you have hepatitis B, use a condom, and encourage your partner to be tested and, if 
necessary, vaccinated against hepatitis B. 
• Have your sex partners and all those living in your household to see a doctor for testing and for hepatitis B 
vaccination. Do not allow anyone to come into contact with your blood or body fluids. 
• Do not share chewing gum, toothbrushes, razors, scissors, needles for ear piercing, nail files, or anything else that 
may come in contact with your blood or body fluids. 
• Do not share food, drink, cigarettes, lipstick, or lip balm. 
• Do not share syringes and needles 
• Do not donate blood, plasma, body organs, sperm, or breast milk 
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CONFIDENTIAL                                                                                         Iowa Department of Public Health 
Hepatitis B/C (acute or chronic) 
                    Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Married         
 Parent with partner     
 Separated     Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Long-term care     
resident:  Yes      No      Unknown        Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Facility name:       
Parent/Guardian 
name: 
 
      
Facility phone: (     )-     -        Type:        
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Onset 
date: 
 
     /     /      
Diagnosis 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome: 
 Survived this illness     Died from this illness 
 Died unrelated to this illness    Unknown 
Date of Death      /     /      First name: 
 
      
Event exception 
 Case could not be found 
 Case could not be interviewed 
 Case refused interview 
 Other – see notes 
Provider type:  ARNP    DO 
 MD 
 NP  PA 
Outbreak 
related:  Yes      No      Unknown  
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS (LIST ALL CURRENT AND PREVIOUS LAB RESULTS) 
 
 
Laboratory: 
 
      
Test type: 
Hepatitis B/D 
 Hepatitis B surface antigen (HBsAg) 
 Hepatitis B core IgM antibody (IgM HBc/IgM anti-HBc)  
 
Accession #: 
 
       
 Hepatitis B e antigen (HBeAg) 
 Hepatitis B core antibody total IgM/IgG antibody (HBc total/anti-HBc) 
 
Collection date: 
 
     /     /       
 Hepatitis B core IgG antibody (IgG HBc/IgG anti-HBc) 
 Hepatitis B DNA (HBV DNA) 
 
Date received: 
 
     /     /       
 Hepatitis B surface antibody (anti-HBs) 
 Hepatitis D (anti-HDV) 
Specimen 
source: 
 
      Test type: 
Hepatitis C 
 Hepatitis C antibody (anti-HCV) 
 Hepatitis C RIBA (HCV RIBA)  
 Hepatitis C DNA QL  
 Hepatitis C RNA (HCV RNA) 
 Hepatitis C Genotype  Hepatitis C IgG 
(EIA) 
 
Result date: 
 
     /     /      Result type:  Preliminary      Final Result:  Positive    Negative     
 
 
  
Center for Acute Disease Epidemiology         Fax: 515-281-5698                          Hepatitis B/C investigation form                          Revised Mar-15         1 
CONFIDENTIAL PATIENT NAME: ______________________________                           Iowa Department of Public Health 
 
 
 
Laboratory: 
 
      
Test type: 
Hepatitis B/D 
 Hepatitis B surface antigen (HBsAg) 
 Hepatitis B core IgM antibody (IgM HBc/IgM anti-HBc)  
 
Accession #: 
 
       
 Hepatitis B e antigen (HBeAg) 
 Hepatitis B core antibody total IgM/IgG antibody (HBc total/anti-HBc) 
 
Collection date: 
 
     /     /       
 Hepatitis B core IgG antibody (IgG HBc/IgG anti-HBc) 
 Hepatitis B DNA (HBV DNA) 
 
Date received: 
 
     /     /       
 Hepatitis B surface antibody (anti-HBs) 
 Hepatitis D (anti-HDV) 
Specimen 
source: 
 
      
Test type: 
Hepatitis C 
 Hepatitis C antibody (anti-HCV) 
 Hepatitis C RIBA (HCV RIBA)  
 Hepatitis C DNA QL  
 Hepatitis C RNA (HCV RNA) 
 Hepatitis C Genotype  
 Hepatitis C IgG (EIA)  
 
Result date: 
 
     /     /      Result type:  Preliminary      Final Result:  Positive    Negative     
 
 
Laboratory: 
 
      
Test type: 
Hepatitis B/D 
 Hepatitis B surface antigen (HBsAg) 
 Hepatitis B core IgM antibody (IgM HBc/IgM anti-HBc)  
 
Accession #: 
 
       
 Hepatitis B e antigen (HBeAg) 
 Hepatitis B core antibody total IgM/IgG antibody (HBc total/anti-HBc) 
 
Collection date: 
 
     /     /       
 Hepatitis B core IgG antibody (IgG HBc/IgG anti-HBc) 
 Hepatitis B DNA (HBV DNA) 
 
Date received: 
 
     /     /       
 Hepatitis B surface antibody (anti-HBs) 
 Hepatitis D (anti-HDV) 
Specimen 
source: 
 
      
Test type: 
Hepatitis C 
 Hepatitis C antibody (anti-HCV) 
 Hepatitis C RIBA (HCV RIBA)  
 Hepatitis C DNA QL  
 Hepatitis C RNA (HCV RNA) 
 Hepatitis C Genotype  
 Hepatitis C IgG (EIA)  
 
Result date: 
 
     /     /      Result type:  Preliminary      Final Result:  Positive    Negative     
 
 
Laboratory: 
 
      
Test type: 
Hepatitis B/D 
 Hepatitis B surface antigen (HBsAg) 
 Hepatitis B core IgM antibody (IgM HBc/IgM anti-HBc)  
 
Accession #: 
 
       
 Hepatitis B e antigen (HBeAg) 
 Hepatitis B core antibody total IgM/IgG antibody (HBc total/anti-HBc) 
 
Collection date: 
 
     /     /       
 Hepatitis B core IgG antibody (IgG HBc/IgG anti-HBc) 
 Hepatitis B DNA (HBV DNA) 
 
Date received: 
 
     /     /       
 Hepatitis B surface antibody (anti-HBs) 
 Hepatitis D (anti-HDV) 
Specimen 
source: 
 
      
Test type: 
Hepatitis C 
 Hepatitis C antibody (anti-HCV) 
 Hepatitis C RIBA (HCV RIBA)  
 Hepatitis C DNA QL  
 Hepatitis C RNA (HCV RNA) 
 Hepatitis C Genotype  
 Hepatitis C IgG (EIA) 
 
Result date: 
 
     /     /      Result type:  Preliminary      Final Result:  Positive    Negative     
 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties: 
Health care worker type: 
 Yes      No      Unknown 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
 
 
CLINICAL INFO & DIAGNOSIS 
 
Date of First Hep B Symptom Onset:      /     /      Date of First Hep C Symptom Onset:      /     /      
Has the case ever had any of the following symptoms of 
hepatitis B or C (check all that apply)?      Yes     No 
Did the patient ever have elevated liver enzymes attributed to hepatitis B or C?           
  Yes     No    Unk   
 Jaundice  
 Dark urine 
 Fatigue 
 Nausea 
 Vomiting 
 Anorexia 
 Upper right quadrant pain 
 Clay-colored stools 
 Other       
Why was this person tested for Hepatitis B/C (check all that apply)? 
 Needle stick or other exposure 
 Symptoms of hepatitis B or C 
 Elevated liver enzymes 
 Pregnancy screen 
Does the case have symptoms now (last 180 days) or did they 
occur in the past?  Presently symptomatic Past symptoms 
 Check for immunity due to vaccination 
 Resolved infection 
 Screening for blood/plasma donation  
 Follow-up on previous diagnosis 
 Screening for insurance 
 Other, please list reason       
ALT performed?  Yes    No    Unk Result (in IU/l):       Expected min (in IU/l):       Expected max in IU/):       
AST performed?  Yes    No    Unk Result (in IU/l):       Expected min (in IU/l):       Expected max in IU/):       
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
CASE HISTORY 
Was the case diagnosed with hepatitis B?  
Year of diagnosis:            
Treated for hep B: 
Treatment successful: 
 Yes   No    Unk 
 
 Yes   No    Unk 
 Yes   No    Unk 
Has the case ever had an organ/tissue 
transplant? 
 
Has case ever received a tattoo? 
 
 Yes   No    Unk 
 
 Yes   No    Unk 
Was the case diagnosed with hepatitis C? 
Year of diagnosis:            
Treated for hep C: 
Treatment successful: 
 Yes   No    Unk 
 
 Yes   No    Unk 
 Yes   No    Unk 
If YES, was it done in a commercial 
parlor/shop: 
Name and location of parlor/shop: 
 
 Yes   No    Unk 
                
                     
Case’s mother born outside the U.S.? 
If YES, what country: 
 
Case born outside the U.S.? 
If YES, what country: 
 Yes   No    Unk 
                     
 
 Yes   No    Unk 
                     
Case ever used needles for injection of 
street drugs or steroids (even once)? 
 
Has the case ever shared needles or 
works for injecting drugs (even once)? 
 
 Yes   No    Unk 
 
 Yes   No    Unk 
 
Does the case speak English? 
If No, what language: 
 
 Yes   No    Unk 
                     
Has the case ever snorted cocaine or 
other street drugs (even once)? 
 
Is the case a military veteran? 
 
 Yes   No    Unk 
 
 Yes   No    Unk 
Case ever had contact with a 
confirmed or suspected 
acute/chronic case of hep B or C? 
  Yes   No    Unk  
If YES, type of contact:  
 Sexual   Yes   No    Unk 
Does the case currently serve in the 
military? 
 
 Yes   No    Unk 
 
 Household  Yes   No    Unk 
 Blood to Mucous Membrane  Yes   No    Unk 
 Needle sharing  Yes   No    Unk 
 Other   Yes   No    Unk 
Has the case ever received or been exposed 
to blood or blood products? 
If YES, approximate years received or exposed: 
 Yes   No    Unk 
     ,      ,       
Is the case currently in prison? 
If NO, have you ever been in prison? 
 Yes   No    Unk 
 Yes   No    Unk 
Sexual orientation?  Men     Women   
 Both 
If YES, then list dates to and from:      /     /     -
     /     /      
Number of sexual partners in lifetime?  0    ≤10    >10   
 
In the 6 months prior to illness did the case… 
Case ever had contact with a confirmed or suspected acute/chronic case of hep B or C? 
  Yes   No    Unk 
If YES, type of contact: 
 Sexual   Yes   No    Unk 
 Household  Yes   No    Unk 
 Blood to Mucous Membrane  Yes   No    Unk 
 Needle sharing  Yes   No    Unk 
 Other   Yes   No    Unk 
Work in the: 
Medical  Yes  No  Unk       Dental   Yes  No  Unk       
Other field involving contact with human blood or other body fluids   Yes  No  Unk 
Degree of contact with blood:  Frequent  Infrequent  Unk 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.   
The incubation period for 
hepatitis B is 45 to 180 days. 
Hepatitis C is 2 weeks to 6 
months 
Hepatitis B is communicable as long as individual is 
HBsAg positive. Hepatitis C indefinitely 
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Received blood or blood products? 
If YES, list dates received:      /     /     ,      /     /     ,      /     /      
 Yes  No  Unk 
Receive dialysis?  Yes  No  Unk 
Used needles for injection of street drugs or steroids?  Yes  No  Unk 
Had dental work or oral surgery?  Yes  No  Unk 
Had surgery?  Yes  No  Unk 
Acupuncture?  Yes  No  Unk 
Body Piercing?   Yes  No  Unk 
Received a tattoo? 
If YES, was it done in a commercial parlor/shop? 
Name and location of parlor/shop:                                          
 Yes 
 Yes 
 No 
 No 
 Unk 
 Unk 
Have you ever had an accidental needle stick?  Yes  No  Unk 
 
VACCINATION HISTORY 
Has the patient ever received any doses of the hepatitis B vaccine?   Yes    No    Unknown 
 Date 
vaccinated: 
 
     /     /      
 
Date vaccinated: 
 
     /     /      
 
Date vaccinated: 
 
     /     /      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
 
Number of vaccinations:       
 
Was antibody testing done within 
1-6 months after last dose?   Yes    No    Unk If yes, was the antibody test:  Positive    Negative    Unk 
 
Has the patient been vaccinated for hepatitis A?  Yes    No    Unknown 
 Date 
vaccinated: 
 
     /     /      
 
Date vaccinated: 
 
     /     /      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
 
Number of vaccinations:       
 
 
Is the case pregnant?        Yes       No      Unknown  
Anticipated delivering hospital:    
Has the patient given birth in the last 6 months?       Yes       No      Unknown     Hospital:        
Trimester 
tested:  1
st      2nd      3rd  Providers  Last name:       
Infant’s 
 Last name:  
Providers 
First name:       
Infants  
First name:  Provider type:  ARNP    DO    MD    NP    PA 
Infant alias:  Facility name:       
DOB:      /     /      Gender: 
 Female      
 Male      Address:        
Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unk 
 White 
 Asian 
Zip code:       City:       
 
State:       County:       
  Phone: (     )-     -      Type:       
Infant serology tested:      Yes      No      Unk    
Date:      /     /      Date:      /     /      
HBsAg result:  Positive    Negative    Not done   HBsAg result:  Positive    Negative    Not done   
Anti-HBs result:  Positive    Negative    Not done   Anti-HBs result:  Positive    Negative    Not done   
CONTACTS 
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Infant immune 
to hepatitis B:  Infant immune    Infant not immune 
Infant immune 
to hepatitis B:  Infant immune    Infant not immune 
 
Number of people living in case’s household:          
  
Contacts requiring prophylaxis for hepatitis B- see Epi Manual for guidance on identifying contacts 
Name DOB Gender Relationship to case: 
           /     /       Male  Female 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/guardian 
 Sexual contact 
 Family member  
     (non-household) 
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other 
    Address/Phone                              Zip code 
 
      
 
     -     -            
HBIG received   Yes    No    Unk Date given      /     /      
Vaccinated for hep B?  
 Yes    No    Unk 
Tested for HBsAg? 
 Yes    No    Unk 
Tested for Anti-HBs? 
 Yes    No    Unk 
Date(s) 
vaccinated:      /     /     ,     /     /     ,     /     /      Date:      /     /      Date:      /     /      
# of vaccinations:       Result:  Result:  
Is contact a 
case? 
 Yes 
 No If this contact is a case create a new event and/or case for this contact. 
 
Name DOB Gender Relationship to case: 
           /     /       Male  Female 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/guardian 
 Sexual contact 
 Family member  
     (non-household) 
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other 
    Address/Phone                              Zip code 
 
      
 
     -     -            
HBIG received   Yes    No    Unk Date given      /     /      
Vaccinated for hep B?  
 Yes    No    Unk 
Tested for HBsAg? 
 Yes    No    Unk 
Tested for Anti-HBs? 
 Yes    No    Unk 
Date(s) 
vaccinated:      /     /     ,     /     /     ,     /     /      Date:      /     /      Date:      /     /      
# of vaccinations:       Result:  Result:  
Is contact a 
case? 
 Yes 
 No If this contact is a case create a new event and/or case for this contact. 
 
 
NOTES       
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Contact Information  
 
State Perinatal Hepatitis B 
Prevention Program 
Coordinator 
Bethany Kintigh RN, BSN 
Perinatal Hepatitis B Prevention Program 
Bureau of Immunization and Tuberculosis   
Iowa Department of Public Health  
321 East 12th Street 
Des Moines, IA  50319 
Bethany.Kintigh@idph.iowa.gov  
515/281-7228 
800-831-6293, ext. 7  
Fax:  1-800-831-6292 
 
Iowa Immunization Program  www.idph.state.ia.us/ImmTB/Immunization.aspx?prog=Im
m&pg=ImmHome 
 
Contact Number 1-800-831-6293 
 
Clearinghouse for the 
hepatitis B Brochures  
1-319-398-5133 
FAX 1-319-395-7797 
www.idph.state.ia.us/ImmTB/Products.aspx?prog=Imm&pg=Pro
ducts 
 
 
University of Iowa Hygienic 
Lab  
General Web Address:  www.shl.uiowa.edu/ 
 
Serology Request Form for Testing:  
www.shl.uiowa.edu/kitsquotesforms/serologyrequestform.pdf 
 
 
IDPH Center for Acute 
Disease Epidemiology  
www.idph.state.ia.us/adper/cade.asp 
 
Contact Number: (515) 242-5935 or 1-800-362-2736 
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Statement of Iowa Law and HIPAA 
 
Iowa Code 
Chapter 139A 
and 641 Iowa 
Adm. Code 
Chapter 1 
The Iowa Department of Public Health (IDPH), local boards of health, and 
local health departments are authorized to access medical records and 
other information of patients who are infected with or suspected to be 
infected with a reportable disease.  Iowa law clearly outlines all reportable 
diseases and conditions and investigation methods for reportable diseases 
such as hepatitis B.  (641 IAC chapter 1) 
 
Iowa law further requires health care providers and laboratories to assist in 
public health disease investigations:  “A health care provider and a public, 
private, or hospital clinical laboratory shall assist in a disease investigation 
conducted by the department, a local board, or local department.  A health 
care provider and a public, private, or hospital clinical laboratory shall 
provide the department, local board, or local department with all 
information necessary to conduct the investigation, including but not limited 
to medical records; exposure histories; medical histories; contact 
information; and test results necessary to the investigation, including 
positive, pending, and negative test results.”  (Iowa Code section 139A.3; 
641 IAC 1.4(3))   
  
HIPAA  Because of the state law requirements listed above, the HIPAA privacy rule 
expressly permits covered entities (including providers and clinics) to report 
disease information and participate in a public health disease investigation 
without obtaining consent or authorization from the patient.   (45 CFR 
160.203(c); 45 CFR 164.512(a)(1); 45 CFR 164.512(b)(1)(i))  For this reason, 
IDPH and local public health authorities conducting a hepatitis B investigation 
are authorized to access patient specific information directly from providers, 
clinics, and hospitals without obtaining a consent or release from the patient.  
IDPH and local public health authorities may therefore conduct all activities 
outlined in the IDPH EPI Manual, Section 2 (Disease Reporting and Case 
Investigation) and Section 3 (Controlling Further Spread), including case 
investigation of infants born to HBsAg-positive women, without obtaining 
consent or authorization from the patient.   
For full text of IDPH’s HIPAA statement visit:  
www.idph.state.ia.us/hipaa_statement.asp 
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When a 
Parent 
Refuses to 
Provide 
Information 
Parents are not legally required to assist in a case investigation absent the 
issuance of a subpoena by the department. There have been instances 
where a parent has refused to provide information to the investigating nurse 
regarding the HBsAg and/or immunization status of household contacts.   
 
If this occurs while investigating a case, reiterate to the parent the reason for 
collecting the information, assure them of its confidentiality, and inform them 
that you will seek the rest of the information needed to complete the Perinatal 
Hepatitis B Carrier Follow-up Report form directly from the health care 
provider(s)(both mother's and baby's health care provider).   
 
If they continue to refuse to provide information, document the discussion on 
the Perinatal Hepatitis B Carrier Follow-up Report form and notify the 
Perinatal Hepatitis B Prevention Program coordinator not to contact the 
parent. 
 
As stated above, parents are not required to assist in our case investigation 
and there should not be pressure applied to them to gain information on the 
status of household members.  Adequate information regarding the HBsAg 
positive mother and resulting child is obtainable through medical providers.   
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Hepatitis B Vaccine and HBIG  
 
Hepatitis B 
Vaccine 
 HBsAg is the antigen used in hepatitis B vaccination. Vaccines 
available in the United States use recombinant DNA technology to 
express HBsAg in yeast. 
 Since March 2000, hepatitis B vaccines produced for distribution in 
the United States do not contain thimerosal as a preservative or 
contain only a trace amount (<1.0 mcg mercury/mL) resulting from 
the manufacturing process.  
 Hepatitis B vaccine is available as a single-antigen formulation and 
also in fixed combination with other vaccines. Two single-antigen 
vaccines are available in the United States: Recombivax HB® 
(Merck) and Engerix-B® (GlaxoSmithKline).  Only single antigen 
vaccine should be used for the birth dose. 
 Of the three licensed combination vaccines two are used for 
vaccination of infants and young children: Comvax® (Merck & Co) 
and Pediarix® (GlaxoSmithKline).   
Hepatitis B vaccine doses are found in appendix 6 on page 217. 
 
Hepatitis B 
Immune 
Globulin  
(HBIG) 
HBIG provides passively acquired anti-HBs and temporary protection (i.e., 
3-6 months) when administered in standard doses.  HBIG is typically used 
as an adjunct to hepatitis B vaccine for post-exposure immunoprophylaxis 
to prevent HBV infection.  
HBIG is prepared from the plasma of donors with high concentrations of 
anti-HBs.  HBIG that is commercially available in the United States does not 
contain thimerosal.  
 
Availability 
of Hepatitis 
B Vaccine 
and HBIG 
The VFC program will support requests for four doses of hepatitis B vaccine 
for routine vaccination of infants when using combination vaccines. 
However, the Iowa VFC Program asks providers to consider using single 
antigen hepatitis B vaccine when appropriate.  If a client is unable to pay for 
the hepatitis B vaccine or HBIG* contact:  
Bethany Kintigh, RN, BSN 
Iowa Department of Public Health, Immunization Program 
321 East 12th Street 
Des Moines, IA  50319 
1-800-831-6293, ext. 7 
*IDPH does not keep HBIG on hand.  It is vital that we receive notification as soon as 
the need is identified so that we may order the product directly from the 
manufacturer.   
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HBsAg Testing  
 
Purpose HBsAg is the confirmatory test to indicate a patient is currently infected with 
the hepatitis B virus.     
 
HBsAg and 
Infection 
The presence of a confirmed HBsAg positive result is indicative of ongoing 
HBV infection. All HBsAg positive persons should be considered infectious. 
In newly infected persons, HBsAg is the only serologic marker detected 
during the first 3-5 weeks after infection, and it persists for variable periods at 
very low levels. The average time from exposure to detection of HBsAg is 30 
days (range: 6-60 days).   
 
University 
Hygienic 
Laboratory 
and Testing  
Perinatal serological specimens can be submitted to the University of Iowa 
State Hygienic Laboratory (SHL) for anyone who is unable to pay for the 
testing.  Those who wish to submit specimens to SHL should contact them at 
319-335-4500.  For lab slips and instructions on submission go to their Web 
page: www.shl.uiowa.edu.  Click on “Kits, Quotes, and Forms” then scroll 
down to the “clinical” section – click on S and then select “Serology Test 
Request Form.”  If the patient is known to be pregnant please be sure to 
mark the “Maternal HBV” box under “Patient History”. 
 
SHL will notify the Iowa Department of Public Health (IDPH) of HBsAg 
positive patients.  
  
Reporting of 
HBsAg 
positive 
Tests 
If the woman has a positive HBsAg test, the case must be reported to the 
Iowa Department of Public Health, Center for Acute Disease Epidemiology 
within one week of diagnosis per Iowa Administrative Code 614 Chapter 1.  
The case may be reported by: 
 Phone (1-800-362-2763) 
 Secure fax (515-281-5698) or 
 In writing 
The form for reporting a hepatitis B case is located in the EPI Manual, 
Hepatitis B section at: 
www.idph.state.ia.us/adper/common/pdf/epi_manual/hepatitis_b.pdf 
 
ACTION 1. If the lab slip comes to you directly from a provider or lab, confirm that the 
case was reported to IDPH by using IDSS or contacting CADE.   
2. Complete Section I of the IDPH “Perinatal Hepatitis B Carrier Follow-Up 
Report” form. 
3. If the case is an existing “chronic” case in IDSS, a “maternal hepatitis B” 
event will be created to allow preservation of original chronic case file and 
capture of current pregnancy/hepatitis information.   
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Hepatitis B Serology  
HBsAg: Hepatitis B surface antigen is a marker of infectivity. Its presence indicates either acute or chronic HBV infection. 
anti-HBs: Antibody to hepatitis B surface antigen is a marker of immunity. Its presence indicates an immune response to 
HBV infection, an immune response to vaccination, or the presence of passively acquired antibody. (It is also 
known as HBsAb, but this abbreviation is best avoided since it is often confused with abbreviations such as 
HBsAg.) 
anti-HBc 
(total):  
Antibody to hepatitis B core antigen is a nonspecific marker of acute, chronic, or resolved HBV infection. It is not 
a marker of vaccine-induced immunity. It may be used in pre-vaccination testing to determine previous exposure 
to HBV infection. (It is also known as HBcAb, but this abbreviation is best avoided since it is often confused with 
other abbreviations.) 
IgM anti-HBc: IgM antibody subclass of anti-HBc. Positivity indicates recent infection with HBV (<6 mos). Its presence indicates 
acute infection. 
HBeAg: Hepatitis B "e" antigen is a marker of a high degree of HBV infectivity, and it correlates with a high level of HBV 
replication. It is primarily used to help determine the clinical management of patients with chronic HBV infection. 
Anti-HBe: Antibody to hepatitis B "e" antigen may be present in an infected or immune person. In persons with chronic 
HBV infection, its presence suggests a low viral titer and a low degree of infectivity. 
HBV-DNA: HBV Deoxyribonucleic acid is a marker of viral replication. It correlates well with infectivity. It is used to assess 
and monitor the treatment of patients with chronic HBV infection. 
 
Tests Results Interpretation Vaccinate? 
HBsAg 
anti-HBc 
anti-HBs 
negative 
negative 
negative 
susceptible vaccinate if indicated 
HBsAg 
anti-HBc 
anti-HBs 
negative 
negative 
positive with 
>10mIU/mL* 
immune due to 
vaccination 
no vaccination necessary 
HBsAg 
anti-HBc 
anti-HBs 
negative 
positive 
positive 
immune due to natural 
infection 
no vaccination necessary 
HBsAg 
anti-HBc 
IgM anti-HBc 
anti-HBs 
positive 
positive 
positive 
negative 
acutely infected no vaccination necessary 
HBsAg 
anti-HBc 
IgM anti-HBc 
anti-HBs 
positive 
positive 
negative 
negative 
chronically infected no vaccination necessary 
(may need treatment) 
HBsAg 
anti-HBc 
anti-HBs 
negative 
positive 
negative 
four interpretations 
possible† 
use clinical judgment 
 
* Post-vaccination testing, when it is recommended, should be performed 1–2 months after the last dose of vaccine. Infants born to HBsAg-positive mothers should be tested 3–9 
months after the last dose. 
†1. May be recovering from acute HBV infection 
 2. May be distantly immune, but the test may not be sensitive enough to detect a very low level of anti-HBs in serum 
 3. May be susceptible with a false positive anti-HBc 
 4. May be chronically infected and have an undetectable level of HBsAg present in the serum 
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Test Name Value Interpretation Action 
HBsAg Hepatitis B Surface Antigen Negative     
anti-HBc Hepatitis B Core Antibody Negative Susceptible to HBV Vaccinate for HBV 
anti-HBs Hepatitis B Surface Antibody Negative     
          
HBsAg Hepatitis B Surface Antigen Negative     
anti-HBc Hepatitis B Core Antibody Negative Immune to HBV due to vaccination None Required 
anti-HBs Hepatitis B Surface Antibody Positive     
          
HBsAg Hepatitis B Surface Antigen Negative     
anti-HBc Hepatitis B Core Antibody Positive Immune to HBV due to infection Counsel & Treat as Clinically Indicated 
anti-HBs Hepatitis B Surface Antibody Positive     
          
HBsAg Hepatitis B Surface Antigen Positive     
anti-HBc Hepatitis B Core Antibody Positive Acute HBV infection Report & Counsel 
anti-HBc (IgM) Hepatitis B Core Antibody (IgM) Positive     
anti-HBs Hepatitis B Surface Antibody Negative     
          
HBsAg Hepatitis B Surface Antigen Positive     
anti-HBc (IgG) Hepatitis B Core Antibody (IgG) Positive Chronic HBV infection Report & Counsel 
anti-HBc (IgM) Hepatitis B Core Antibody (IgM) Negative     
anti-HBs Hepatitis B Surface Antibody Negative     
          
      4 Possible Interpretations   
HBsAg Hepatitis B Surface Antigen Negative  1. Recovering from acute HBV Report & Counsel 
anti-HBc Hepatitis B Core Antibody Positive 2. Distantly immune, ↓ anti-HBV in serum None Required 
anti-HBs Hepatitis B Surface Antibody Negative 3. False pos anti-HBc=Susceptible to HBV R/O False Positive anti-HBc 
      4. Chronic, with ↓ level of HBsAg in serum Report & Counsel 
          
anti-HBe Hepatitis B Be Antibody Positive Resolved acute HBV infection or F/U Testing: HBV DNA, HBeAg, 
      inactive (non-replicating) chronic infection HBsAg and HBcAb 
          
HBeAg Hepatitis B Be Antigen Positive Active viral replication-high level of infectivity Report & Counsel 
      Seen in both acute HBV & Actively replicating chronic HBV   
          
HBeAg Hepatitis B Be Antigen Negative Mutant form of HBV Report & Counsel 
HBV DNA Hepatitis B DNA Positive Active viral replication with high level of infectivity   
          
HBeAg Hepatitis B Be Antigen Negative     
HBV DNA Hepatitis B DNA Negative Chronic Carrier: Asymptomatic with Normal LFT's Report & Counsel 
HBsAg Hepatitis B Surface Antigen Positive Non-active viral replication and non-infectious to others Annual blood tests to monitor 
anti-HBc (IgG) Hepatitis B Core Antibody (IgG) Positive   progression of disease 
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Screening of Pregnant Women  
 
Purpose Timely identification of pregnant women who are HBsAg positive provides 
the opportunity to council the woman and initiate appropriate case 
management to prevent further transmission of the virus to the neonate and 
other susceptible household contacts.  
  
Country of 
Origin 
Residents and descendents of certain countries and regions of the world are 
more prone to HBsAg infection as the disease was, or currently is, endemic.  
Clients from the following countries/regions may have an increased risk for 
HBsAg infection:   
 
Afghanistan, Africa, rural Alaska, Albania, Bangladesh, Bosnia and 
Herzegovina, Bulgaria, Cambodia, China, Eastern Europe, Haiti, Hawaii, 
India, Indonesia, Iran, Iraq, Korea, Laos, Malaysia, the Middle East, 
Myanmar, Pakistan, the Pacific Islands, Philippines, Romania, the former 
Soviet Union, South America’s Amazon Basin, Sri Lanka, Syria, Taiwan, 
Thailand, or Vietnam. 
 
Early Testing All pregnant women should be tested routinely for HBsAg during an 
early prenatal visit (e.g., first trimester) in each pregnancy, even if they have 
been previously vaccinated, tested, or previously HBsAg positive. 
 
In special situations, an additional HBsAg test can be ordered during the third 
trimester.  This should be considered if the patient develops symptoms, is 
exposed to HBV, or engages in high risk behavior (e.g., having had more 
than one sex partner in the previous 6 months, having a HBsAg positive sex 
partner, evaluation or treatment for a sexually transmitted disease [STD], or 
recent/current injection-drug use). 
 
  
Transfer of 
Test Results  
Women who are HBsAg positive should have a copy of the original 
laboratory report indicating her HBsAg status provided to the hospital or birth 
center where delivery is planned and to the health-care provider who will 
care for the newborn. 
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Screening of Pregnant Women, Cont. 
 
Admission 
Testing 
Women who were not screened prenatally, those who engage in behaviors 
that put them at high risk for infection (see high risk behaviors on the 
previous page) and those with clinical hepatitis should be tested at the time 
of admission for delivery. 
Women admitted for delivery without documentation of HBsAg test results 
should have blood drawn and tested as soon as possible after admission. 
While test results are pending, all infants born to women without 
documentation of HBsAg test results should receive the first dose of single-
antigen hepatitis B vaccine within 12 hours of birth. 
 
When 
Testing is not 
Feasible 
 
When HBsAg testing of pregnant women is not feasible (i.e., in remote areas 
without access to a laboratory), all infants should receive hepatitis B vaccine 
less than 12 hours after birth and should complete the hepatitis B vaccine 
series according to the recommended schedule.  Administration of HBIG is 
not necessary for these infants. 
 
HBsAg 
Positive 
Mother 
If the mother is determined to be HBsAg positive and the child weighs 2,000 
grams (4.4 lbs) or more at birth:  
 Give infant HBIG and HBV vaccine within 12 hours of birth 
 Continue vaccine series on an accelerated schedule beginning at 1-2 
months of age and completing the 3 dose series by 6 months  
 Check quantitative anti-HBs and HBsAg after completion of vaccine 
series at 9-12 months of age 
 
If the mother is determined to be HBsAg positive and the child weighs 2,000 
grams (4.4 lbs) or less at birth:  
 Give infant HBIG and HBV vaccine within 12 hours of birth 
 Continue vaccine series on an accelerated schedule beginning at 1-2 
months of age and completing the 3 dose series by 6 months  
 Do not count birth dose as part of vaccine series, immunize with 4 
doses of vaccine.  
 Check quantitative anti-HBs and HBsAg after completion of vaccine 
series at 9-12 months of age 
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Screening of Pregnant Women, Cont. 
 
HBsAg  
Status 
Unknown 
Mother 
If the mother’s HBsAg status is unknown and the child weighs 2,000 grams 
(4.4 lbs) or more at birth: 
 Test mother for HBsAg immediately after admission 
 Give infant HBV vaccine within 12 hours of birth 
 Give infant HBIG (within 7 days) if mother tests HBsAg positive.  If the 
mother’s HBsAg status remains unknown at the time of discharge it 
may be appropriate to provide HBIG to the child prior to release from 
the hospital.  Efforts should be made to determine HBsAg status prior 
to discharge, but in the absence of this information and faced with a 
situation where you are unsure the child will receive appropriate 
follow-up, providing HBIG may be appropriate.  
 Continue vaccine series beginning at 1-2 months of age according to 
the recommended schedule based on mother’s HBsAg status  
 
If the mother’s HBsAg status is unknown and the child weighs 2,000 grams 
(4.4 lbs) or less at birth:  
 Test mother for HBsAg immediately after admission 
 Give infant HBV vaccine within 12 hours of birth 
 Give infant HBIG if mother tests HBsAg positive OR if mother’s 
HBsAg result is not available within 12 hours of birth  
 Do not count birth dose as part of vaccine series, immunize with 4 
doses of vaccine 
 Continue vaccine series beginning at 1-2 months of age according to 
the recommended schedule based on mother’s HBsAg status  
 Check quantitative anti-HBs and HBsAg after completion of vaccine 
series at 9-12 months of age 
 
HBsAg 
Negative 
Mother 
If the mother is determined to be HBsAg negative, the vaccine series should 
be completed according to the Recommended Childhood and Adolescent 
Immunization Schedule (birth, 1-2, and 6-18 months). 
 
ACTION 1. Confirm with the women’s provider that a copy of the original laboratory 
report indicating her HBsAg status was provided to the hospital where 
delivery is planned. 
2. Contact hospital notifying them of mother’s plans for delivery and status.  
3. Contact the child’s health-care provider and discuss vaccination and HBIG as 
well as serology.  
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HBsAg Positive Pregnant Women 
 
HBV 
Education   
HBsAg positive pregnant women should receive information on hepatitis B 
that includes:  
 Modes of transmission and how to prevent transmission  
 Perinatal concerns (e.g., there is no contraindication for infants of 
HBsAg positive mothers to be breast fed beginning immediately after 
birth.  Although HBsAg can be detected in breast milk, there is no 
evidence that HBV can be transmitted by breastfeeding) 
 Prevention of HBV transmission to contacts, including the importance 
of post-exposure prophylaxis for the newborn, other household 
contacts, sexual partners, and needle-sharing contacts 
 Substance abuse treatment, if appropriate  
 Medical evaluation and possible treatment of chronic hepatitis B 
  
ACTION Contact the woman and provide the following information:  
1. How you acquired her name (i.e., hepatitis B is a reportable disease in the 
state of Iowa and the lab and her provider are required to report the case). 
2. Explain your role and discuss what services you will provide to her and 
household contacts (case management, notification of providers/birth 
hospital or center, immunization services for eligible contacts, and testing 
for hepatitis B status). 
3. Explain what information you will be collecting while her case is “open.”  
Collect the pertinent information for the visit (delivery plans and household 
contact information). 
4. Provide her with the “Hepatitis B and Moms-to-Be” Brochure.  
5. Discuss the importance of the baby completing the vaccine series by six 
months of age (an infected unprotected baby has a 90% chance of 
becoming a chronic carrier) and of post-vaccination serology.  
6. Enter all case information into IDSS under the “Follow-Up hep B” tab.  
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Intervention for Infants Born to HBsAg+ Mothers 
 
Term Infants All infants born to HBsAg positive women should receive single-antigen 
hepatitis B vaccine (birth dose) and HBIG within 12 hours of birth, 
administered at different injection sites.  
 
Dose Timing 
#1 Birth dose 
#2 28 days from dose #1 
#3 
2 months from dose #2 AND 4 months from dose 
#1 AND the infant is 6 months of age (minimum 
age 24 weeks) 
For information on combination vaccines (Comvax and Pediarix) see the 
following page. 
 
Preterm 
Infants 
Infants weighing less than 2,000 g (4.4 lbs) born to HBsAg positive mothers 
should receive single-antigen hepatitis B vaccine (birth dose) and HBIG 
within 12 hours of birth, administered at different injection sites.   
 
For preterm infants weighing less than 2,000 g, the initial vaccine dose (birth 
dose) should not be counted as part of the vaccine series because of the 
potentially reduced immunogenicity of hepatitis B vaccine in these infants.   
 
The second dose of HBV vaccine should be given when the infant is 
chronologically one month of age regardless of weight.  The third dose 
should be administered one month following the second dose, and the fourth 
dose should be given six months following the second dose.  Thus, a total of 
four doses of HBV vaccine are recommended in this circumstance. 
  
Extended 
Intervals 
Between 
Doses 
All doses not violating the minimum intervals are valid.  It is not necessary 
to restart the vaccine series if there is an extended interval between 
doses.  
 
The minimum interval between the first and second dose is 28 days. The 
minimum interval between the second and third dose is 2 months and 4 
months from the first dose, as long as the third dose is given after 6 months 
of age (see chart above).  
  
 
 
Iowa Department of Public Health, Immunization Program March 2010 13 
Perinatal Hepatitis B Prevention Program Guide 
____________________________________________   
 
 
Intervention for Infants Born to HBsAg+ Mothers, Cont. 
 
Pediarix Pediarix (GSK) is a combination vaccine that contains DTaP, hepatitis B, and 
IPV.  Typically Pediarix is given at 2, 4 and 6 months of age.  When giving 
Pediarix after a birth dose of hepatitis B, the infant will receive a total of 4 
doses of hepatitis B vaccine.  Four doses of HBV is permissible when 
using combination vaccines.   
 
There is a flow-chart describing how to administer Pediarix and the use of 
single antigen hepatitis B vaccine in the section titled “Pediarix Series for 
Hepatitis B Vaccine.” (page 22) 
 
Serologic testing following the Pediarix series is performed 3 months after 
the last dose of vaccine (typically given at 6 months of age).  Testing can be 
done as early as 9 months of age, but is often performed at the routine well 
child visit at 12 months.  Testing should not be done prior to 9 months of age 
to avoid detection of the anti-HBs from HBIG administered at birth.  For more 
serology information see the section titled “Post-Vaccination Serology.” 
 
Comvax  Comvax (Merck) is a combination vaccine that contains HIB and hepatitis B 
vaccines.  Comvax is typically given at 2, 4 and 12 months of age.  When 
giving Comvax, after the birth dose of hepatitis B, the infant will receive a 
total of 4 doses of hepatitis B vaccine.  Four doses of HBV is permissible 
when using combination vaccines.  
 
CDC does not recommend giving 5 doses of HBV.  When using the 
Comvax series some providers want to add an additional dose of monovalent 
hepatitis B vaccine at 6 months of age and then continue giving the Comvax 
series leading to 5 total HBV doses.  5 doses of HBV is not recommended.   
 
If the provider uses a monovalent HBV at 6 months of age, (so the child is 
complete with the HBV series at 6 months) they should not use Comvax at 
12 months of age (because the child already has 4 HBV), but should instead 
use single antigen Hib (Pedvax) to complete the series. 
 
There is a flow-chart describing how to administer Comvax and the use of 
single antigen hepatitis B vaccine and HIB in the section titled “Comvax 
Series for Hepatitis B Vaccine.” (Page 23) 
 
Serologic testing following the Comvax series is performed 3 months after 
the last dose of vaccine (typically given at 12 months of age).  Testing can be 
done as early as 4 weeks after the last dose of vaccine is given.  For more 
serology information see the section titled “Post-Vaccination Serology.” 
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Intervention for Infants Born to HBsAg+ Mothers, Cont. 
 
ACTION 1. Contact the birth hospital to complete the infant’s information and 
HBIG/vaccination status in Section II of the “Perinatal Hepatitis B Carrier 
Follow-up Report” form (Appendix 1). 
2. Contact the infant’s provider and give them the Hepatitis B vaccine and 
HBIG information.  Stress the importance of adhering to the accelerated 
schedule (3rd dose at 6 months) and post-vaccination serology at 12 
months.   
3. Follow the infant through the vaccine series and document vaccination 
dates.  
4. After each dose of vaccine enter dates into IDSS under the “Follow-Up hep 
B” tab.  
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Post-Vaccination Serology  
 
Purpose Post-vaccination serology for infants born to HBsAg positive mothers is the 
method of confirming protection from HBV.  Post-vaccination serology is a 
key component to case management of the child.  
 
Post-
Vaccination 
Serology 
after the 
Initial Series 
Post-vaccination testing for HBsAg and quantitative anti-HBs should be 
performed after completion of the vaccine series 3 to 9 months 
following the final dose of hepatitis B vaccine (generally at the 12 month 
well-child visit, although encouraged to be performed earlier if applicable).   
 
It is very important to have the provider order quantitative anti-HBs.  
Without ordering a quantitative anti-HBs, there is no way to determine the 
antibody concentration and thus determine if the infant is protected (greater 
than 10 mIU/mL) or needs further doses of vaccine (less than 10 mIU/mL). 
See “Test Results” section below.  
 
Testing should not be performed before age 9 months to avoid detection of 
anti-HBs from HBIG administered during infancy.  Anti-HBc testing of infants 
is not recommended because passively acquired maternal anti-HBc might be 
detected in infants born to HBV-infected mothers to age 24 months.  
 
The AAP and ACIP have both recommended the use of combination 
vaccines, such as Comvax of Pediarix, when indicated.  However, 
combination vaccines can create differences in timing as to when post-
vaccination serology is performed.   
 
Pediarix: the last dose of Pediarix should be given at 6 months, and 
serology should be drawn 3 months later at the 9 month visit.  There are 
some clinics that prefer to bring the child back at the routine 12 month visit 
and test them at that time.  This is permissible, although it is preferred to test 
the child after 9 months of age so that revaccination can begin sooner, if 
necessary.   
 
Comvax:  the last dose of Comvax should be given at 12 months of age, and 
serology should be drawn 1 month (4 weeks) later.  There are some clinics 
that prefer to bring the child back at the routine 18 month visit and test them 
at that time.  This is permissible although not ideal.  It is preferred to test the 
child 1 month after the last dose of Comvax so that revaccination can begin 
sooner, if necessary.   
 
There is an option to give Comvax for the first 2 doses of the series then give 
single antigen HBV at 6 months of age with a Pedvax Hib at 12 months of 
age.  This method would allow the provider to draw serology as early as 9 
months of age.  See page 23 for more detail. 
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Post-Vaccination Serology, Cont. 
 
Post-
Vaccination 
Serology 
More Than 
Two Years 
after 
Completing 
the Series 
Post-vaccination serology done more than two years after the third dose of 
vaccine causes difficulty in interpreting the anti-HBs result because antibody 
levels begin to decrease in the blood below detectable levels, even though 
the child may still have active immunity.  
The child should receive one additional dose of vaccine (it is permissible to 
have 5 total doses in the series in this instance) and then have HBsAg and 
quantitative anti-HBs serology drawn 4-6 weeks after that dose to check 
immunity.  This single dose is designed to “wake up” the immune response 
and then allow determination of protection.  
 
Test Results  
 
HBsAg negative Infants:  
 HBsAg-negative infants with anti-HBs levels equal to or greater than 
10mIU/mL are protected and need no further medical management. 
 HBsAg-negative infants with anti-HBs levels less than 10mIU/mL 
should be revaccinated with a second 3-dose series (either using 0, 
2, 4 months or 0, 1, 4 months schedule) and retested 1 month after 
the final dose of vaccine. 
 
Infants who are HBsAg positive should receive appropriate follow-up 
including periodic evaluation for liver function.   
 
 
Test Results  
Continued 
Post-vaccination serology done more than two years after the third 
dose of vaccine with results of anti-HBs negative and HBsAg negative, 
the child should receive one additional dose of HBV vaccine and then have a 
serology done 1 month after the final dose.  
Post-vaccine serology was done less than one year after the third dose 
of vaccine with results of anti-HBs negative and HBsAg negative, the 
child should receive 3 more doses of HBV vaccine followed by serology done 
1 month after the final dose.  
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ACTION 1. Complete Section III of the “Perinatal Hepatitis B Carrier Follow-up Report” 
form (Appendix 1) upon post-vaccination serology and if necessary assist 
with referrals for HBsAg positive infant. Enter information into IDSS under 
the “Follow-Up Hep B” tab.  
2. Immediately notify IDPH Perinatal Hepatitis B Prevention Program 
Coordinator of HBsAg positive infant by calling 1-800-831-6293, ext. 7. 
3. Notify IDPH Perinatal Hepatitis B Prevention Program Coordinator after 
serologic testing is completed and all data for case has been entered.  
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Testing and Vaccination of Household and Sexual Contacts 
 
Transmission 
Reduction 
Sex partners of HBsAg-positive persons should be counseled to use 
methods (e.g., condoms) to protect themselves from sexual exposure to 
infectious body fluids (e.g., semen or vaginal secretions) unless they have 
demonstrated immunity after vaccination (i.e., anti-HBs >10 mIU/mL) or 
previously infected (anti-HBc positive). 
 
Additionally, household contacts should be counseled to refrain from sharing 
household articles (e.g., toothbrushes, razors, nail clippers and files, or 
personal injection equipment) that could become contaminated with blood. 
 
Pre and Post-
Vaccination  
Serologic 
Testing and 
Vaccination  
Screening is usually cost-effective, and should be considered in groups with 
a high risk of HBV infection (prevalence of HBV markers 20% or higher) such 
as men who have sex with men, injection-drug users, Alaska natives, Pacific 
Islanders, children of immigrants from endemic-disease countries, and family 
members of HBsAg-positive persons. 
Unvaccinated sex partners, household contacts, and needle-sharing contacts 
should be tested for susceptibility to HBV infection and should receive the 
first dose of hepatitis B vaccine immediately after collection of the blood 
sample for serologic testing.  
Susceptible persons should complete the vaccine series using an age-
appropriate vaccine dose and schedule (see Adult Vaccine and Vaccine 
Efficacy below).  Persons who have begun the series in the past but did not 
complete it should now complete the full series.  It is not necessary to 
restart the vaccine series if there is an extended interval between 
doses. 
 
Post-Vaccination serologic testing is also recommended for sex partners of 
HBsAg-positive persons. When necessary, post-vaccination testing should 
be performed 1–2 months after completion of the vaccine series. 
 
Children at 
Risk 
Children who are not infected at birth remain at risk from long-term 
interpersonal contact with their infected mothers.  In one study, 38% of 
infants who were born to HBsAg positive mothers and who were not infected 
prenatally became infected by 4 years of age. 
In addition, children living with any chronically infected persons are at risk for 
becoming infected through percutaneous or mucosal exposures to blood or 
infectious body fluids (e.g., sharing a toothbrush, contact with exudates from 
dermatologic lesions, contact with HBsAg-contaminated surfaces). HBV 
transmission rates to susceptible household contacts of chronically infected 
persons have varied (range: 14%–60%).   
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Testing and Vaccination of Household and Sexual Contacts, Cont. 
 
Availability 
of HBV 
Vaccine 
HBV vaccine provided by IDPH for contacts of HBsAg positive women is 
limited to children through the age of 18, primary sexual contacts, household 
contacts, and needle sharing partners who have no method of payment for 
vaccine.  Vaccine may be ordered from IDPH on an as needed basis and is 
not routinely maintained.   
 
IDPH makes available HBV vaccine for children through 18 years of age who 
are living with a HBsAg positive woman and is provided at no cost to the 
client through the VFC Program.  Agencies may administer HBV vaccine to 
these children in the same manner they would to any other VFC eligible child 
and no special arrangements are necessary to obtain vaccine through IDPH. 
Agencies that identify a susceptible adult contact of a HBsAg positive woman 
are to contact the State Perinatal HBV Prevention Program Coordinator at 1-
800-831-6293, ext. 7 to make arrangements to receive HBV vaccine. HBV 
vaccine is made available to adult household contacts (persons over the age 
of 19) through non-federal funding.   
Clients immunized with state supplied vaccine must be entered and 
maintained in IRIS (Iowa’s Immunization Registry Information System).  
Vaccine administration recommendations and inventory requirements must 
be followed in accordance with current IDPH Immunization Program 
protocols.  
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Testing and Vaccination of Household and Sexual Contacts, Cont. 
 
Adult 
Vaccination 
and Vaccine 
Efficacy  
Adults 20 years of age and older should receive 1 mL (10 mcg) of pediatric or 
adult formulation Recombivax HB (Merck) or 1 mL (20 mcg) of adult 
formulation Engerix-B (GlaxoSmithKline). The pediatric formulation of 
Engerix-B is not approved for use in adults. 
 
The usual schedule for adults is two doses separated by no less than 4 
weeks, and a third dose 4–6 months after the second dose. If an 
accelerated schedule is needed, the minimum interval between the first two 
doses is 4 weeks, and the minimum interval between the second and third 
doses is 8 weeks. However, the first and third doses should be separated 
by no less than 16 weeks. Doses given at less than these minimum 
intervals should not be counted as part of the vaccination series 
 
 
 
 
 
 
 
 
*anti-HBs antibody titer of 10mIU.mL or higher 
**preterm infants less than 2kg have been shown to respond to vaccination less often. 
***factors that may lower vaccine response rates are age >40 years, male, smoking, obesity, and immune 
deficiency 
Protection* by Age Group and Dose 
Dose Infants** Teens and Adults*** 
1 16%-40% 20%-30% 
2 89%-95% 75%-80% 
3 98%-100% 90%-95% 
 
ACTION 1. Obtain household contact information and complete pre-vaccination 
serologic testing of unvaccinated primary sexual partners and adult 
household contacts.   
2. Assure children living in the household are either vaccinated or currently 
receiving the HBV vaccine series.  
3. As needed, make arrangements for vaccination and testing of susceptible 
contacts.  
4. Complete Section IV of the “Perinatal Hepatitis B Carrier Follow-up Report” 
form (Appendix 1).  Enter data into IDSS on the “Follow-Up Hep B” tab 
under contacts.  
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Checklist for Follow-Up of Infants 
 
Purpose To outline the steps to be carried out by local public health for follow-up of 
infants born to women who are hepatitis B carriers. 
 
It is important to incorporate these steps into your work plan to ensure proper 
prophylaxis of infants and household contacts of women who are carriers of 
hepatitis B.   
  
Checklist Please see “HBsAg+ Exposed Infants Follow-Up Checklist” on page 24. 
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Pediarix Series for Hepatitis B Vaccine 
3 Dose versus 4 Dose Series 
 
 
*Pediarix contains DTaP, IPV and Hep B 
 
Single Antigen 
 
Birth Dose Hepatitis B Vaccine (HBV) #1 
Single Antigen 
2 Months of Age 
Pediarix* 
DTaP, IPV 
HBV #2 
   
 
HBV min. interval 4 weeks 
HBV min. interval 8 weeks DTaP and IPV min. interval 4 weeks 
4 Months of Age 
DTaP and IPV single 
antigen vaccines  
NO HBV given 
4 Months of Age 
Pediarix  
DTaP, IPV  
HBV #3 
 
6 Months of Age 
Pediarix  
DTaP, IPV  
HBV #3 
 
HBV min. interval rules: 
8 weeks from dose #3 
AND 16 weeks from dose 
#1 AND the child must be 
at least 6 months old (24 
weeks) 
6 Months of Age 
Pediarix  
DTaP, IPV  
HBV #4 
 
HBV min. interval rules: 
8 weeks from dose #3 
AND 16 weeks from dose 
#1 AND the child must be 
at least 6 months old (24 
weeks) 
Pediarix 3 
Dose Series 
(4 Total 
HBV) 
Pediarix 2 
Dose Series 
and Single 
Antigen (3 
Total HBV) 
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Comvax Series for Hepatitis B Vaccine 
3 Dose versus 4 Dose 
Series
 
★ do not use Comvax at this appointment  
Birth Dose Hepatitis B Vaccine (HBV) #1 
Single Antigen 
2 Months of Age 
Comvax 
Hib #1 
HBV #2 
   
 
4 Months of Age 
Comvax 
Hib #2 
HBV #3 
4 Months of Age 
Pedvax* 
Single antigen Hib 
Hib#2 
6 Months of Age 
Single antigen Hep B 
HBV #4 
 
6 Months of Age 
Single antigen Hep B 
HBV #3 
 
Comvax Series 
with 3 Hib and 
3 HBV 
12 Months of Age 
Pedvax 
Single antigen Hib 
Hib#3 
12 Months of Age 
Comvax 
Hib #3 
HBV #4 
Mother HBsAg- Mother HBsAg
+
 
12 Months of Age★ 
Pedvax 
Single antigen Hib 
Hib#3 
HBV min. interval 4 weeks 
Hib min. interval 4 weeks 
Final dose of Hib must be after 
12 months of age 
HBV min. interval rules: 
8 weeks from dose #3 AND 16 
weeks from dose #1 AND the 
child must be at least 6 months 
old (24 weeks) 
 
HBV min. interval 8 weeks 
Hib min. interval 4 weeks 
HBV min. interval rules: 
8 weeks from dose #3 AND 16 
weeks from dose #1 AND the 
child must be at least 6 months 
old (24 weeks) 
 
Final dose of Hib must be after 
12 months of age 
HBV min. interval rules: 
8 weeks from dose #3 AND 16 
weeks from dose #1 AND the 
child must be at least 6 months 
old (24 weeks) 
 
Final dose of Hib must be after 
12 months of age 
 
Comvax Series 
with 3 Hib and 
 4 HBV 
*PedVax – contains HIB and is a 3 dose series 
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Reference Material  
 
IDPH Brochures Immunize for a Better Life Hepatitis B Brochure for 
providers and mothers are available free of charge from 
the clearinghouse 1-19-398-5133. 
  
Hepatitis B and Mom’s to Be 
Brochure 
Available from Bethany Kintigh, State Perinatal Hepatitis B 
Prevention Program Coordinator. 1-800-831-6293 ext. 7. 
  
Hepatitis B Recommendation 
Alert  
Pre-printed copies are available from Bethany Kintigh, 
State Perinatal Hepatitis B Prevention Program 
Coordinator.  1-800-831-6293 ext. 7 or on the IDPH 
webpage at: 
www.idph.state.ia.us/adper/common/pdf/hepatitis/hep_b_a
lert_march_2006.pdf 
  
VIS Statements in multiple 
languages 
 www.immunize.org/vis/index.htm#hepatitisb 
 
  
CDC National Immunization 
Program Homepage 
 www.cdc.gov/nip/default.htm 
 
  
Immunization Action 
Coalition Homepage 
 www.immunize.org 
 
  
Hepatitis B Foundation  www.hepb.org/ 
 
  
Parents of Kids with 
Infections Diseases 
www.pkids.org/index2.htm 
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HBsAg+ Exposed Infants Follow-Up Checklist 
Prior to Delivery: 
 Contact the mother’s provider.  Make sure they are aware of her HBsAg positive lab result, the indicated 
immunoprophylaxis (HBIG) for the infant, and provide the brochure “Perinatal Hepatitis B Providers 
Guide.”  
 
 Contact the hospital or delivery center to make sure that they will have HBIG on hand and that the 
mother’s HBsAg status is noted in her prenatal record. 
 
 Prior to delivery, call, write, or make a home visit to the client and provide perinatal hepatitis B educational 
materials (including the “Hepatitis B and Moms-to-Be Brochure”).  
 
 Complete Section I of the IDPH “Perinatal Hepatitis B Carrier Follow-Up Report Form” with demographic 
information on mom.  Educate the client on how to reduce risk of transmission of hepatitis B to her infant 
and household members.  
 
 Complete Section IV on the IDPH “Perinatal Hepatitis B Carrier Follow-Up Report Form” Identify 
susceptible household contacts (children and sexual contacts) and encourage them to be tested and 
vaccinated.   
After Delivery:  
 Complete Section II of the IDPH “Perinatal Hepatitis B Carrier Follow-Up Report Form” with the infant’s 
birth date and dates for HBIG and the 1st dose of vaccine. 
 
 Notify the client’s pediatric provider of the mother’s positive HBsAg status and remind them that the infant 
should receive the 2nd dose of vaccine at one to two months and the 3rd dose of vaccine at 6 months 
of age as well as post-vaccination serology between 9 and 12 months of age.  Make follow-up calls or 
visits with the client to make sure that her baby has gone in for his/her vaccinations and serology test. 
 
 At 12 months of age, collect post-vaccination serology results. Be sure the provider tests for both 
HBsAg and quantitative Anti-HBs.  Complete Section II of the IDPH “Perinatal Hepatitis B Carrier 
Follow-Up Report Form.” 
 
 If infant doesn’t develop an antibody response to the HBV vaccine and remains negative for hepatitis B 
infection, call the clinic and fax/send a request to ensure that a second series of HBV vaccine is given. 
 
 Complete the IDPH “Perinatal Hepatitis B Carrier Follow-Up Report Form” with all shot dates and test 
results and fax/send to IDPH.   
Periodically update the Perinatal Hepatitis B Prevention Program with your progress at the following intervals: 
 After Section I is completed for mom and household contacts have been identified (Section IV) 
 After contacts have completed the first does in the series, or had serology to indicate no vaccine is needed (Section 
IV). 
 After the baby is born and HBIG and birth dose of vaccine have been given. 
 Upon completion of each dose of vaccine in the series for newborn and contacts. 
 Upon completion of serology for infant and closing of case.  
 
Please send results by fax (1-800-831-6292) or e-mail to: Bethany.Kintigh@idph.iowa.gov or by mail to:   
Bethany Kintigh, RN, BSN IDPH Immunization Program, 321 East 12th Street, Des Moines, IA  50319 
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Letter to Mothers 
 
ADD YOUR LETTER HEAD 
 
 
Date 
 
 
Dear _________________:  
 
 
Congratulations on the birth of your new baby NAME!  Your baby received HBIG and the first 
dose of hepatitis B vaccine on DATE at HOSPITAL NAME.  It is very important that your child 
receive the second and third dose of hepatitis B vaccine on time.   
 
This letter is to remind you that the second hepatitis B vaccination is due no later than 
two months of age.  The third hepatitis B vaccination is due at six months of age.   
 
Your baby’s health care provider will test your child’s blood for the hepatitis B virus between 
9 months and one year of age.  After the blood work is completed and if your baby needs 
no further doses of hepatitis B vaccine, we will close your case.   
 
I have enclosed information regarding hepatitis B.  If you have any questions, you may 
contact the Perinatal Hepatitis B Prevention Program at YOUR PHONE HERE.  Thanks for 
your cooperation.   
 
Sincerely, 
 
 
 
 
YOUR NAME 
Perinatal Hepatitis B Prevention Program 
YOUR AGENCY 
 
Enc. 
Note:  Please bring this letter with you to your baby’s next doctor appointment for 
his/her second Hepatitis B shot. 
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Letter to Mother’s Provider 
 
ADD YOUR LETTER HEAD 
 
 
Date 
 
 
Dear _________________:  
 
The Iowa Department of Public Health received a report for NAME AND DOB indicating she 
is hepatitis B surface antigen (HBsAg) positive and pregnant.   
 
As you know, CDC recently published a MMWR titled “A Comprehensive Immunization 
Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States,” 
December 23, 2005.  In that publication CDC laid out the vital role a practitioner plays in 
preventing perinatal transmission of the hepatitis B virus.  I have included a brochure for you 
to review that outlines the recommendations made in the December 2005 MMWR.  The other 
brochure included in this letter for your patient, stressing the importance of vaccinating her 
child against HBV infection.   
 
Please remember two critical steps that need to be taken for your patient:  
1. Send a copy of the original lab slip indicating her HBsAg positive status to the birth 
hospital or center prior to delivery.  
2. Be sure that the child receives Hepatitis B Immune Globulin (HBIG) and the first 
dose of Hepatitis B Vaccine within 12 hours of birth.   
 
If you have any questions regarding the Iowa Perinatal Hepatitis B Prevention Program 
please contact me at YOUR NUMBER or the state coordinator, Bridget Konz, RN at 1-800-
831-6293 ext. 7.   
 
Your office may already have a policy in place to address HBV and birth transmission.  We 
appreciate you reviewing this letter and making every effort to protect this child and stop the 
transmission of HBV at birth.   
 
Sincerely,  
 
 
 
 
YOUR NAME 
Perinatal Hepatitis B Prevention Program 
YOUR AGENCY 
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General Letter to Hospitals Pre Birth   
 
ADD YOUR LETTERHEAD 
 
 
Date 
 
Regarding: Pregnant Mother with Hepatitis B 
 
 
Dear OB STAFF CONTACT:  
 
MOTHER’S NAME AND DOB is HBsAg positive and pregnant.  Her estimated due date is 
DUE DATE.  Currently she plans to deliver at your hospital.   
 
Upon delivery, her child should receive the first dose of hepatitis B vaccine (HBV) and 
HBIG (Hepatitis B Immune Globulin) within 12 hours of birth.   
 
Please complete the enclosed form “Perinatal Hepatitis B Hospital Report” regarding the 
administration of the HBV birth dose and HBIG.  Upon completion, please fax this form to 
YOUR FAX NUMBER.   (FORM FOUND IN APPENDIX 2) 
 
For patients that have no means of payment for HBIG and hepatitis B vaccine, please contact 
me.  The Iowa Department of Public Health can provide these important vaccinations without 
charge through the Vaccines for Children Program (VFC).  However, IDPH does not 
maintain HBIG on hand so advance warning is necessary to order this product from the 
manufacturer.     
 
If you have any questions regarding the Iowa Perinatal Hepatitis B Prevention Program 
please contact me at YOUR NUMBER or the state coordinator, Bridget Konz, RN at 1-800-
831-6293 ext. 7.   
 
 
Sincerely, 
 
 
 
YOUR NAME 
Perinatal Hepatitis B Prevention Program 
YOUR AGENCY 
 
Enc 
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General Letter to Baby’s Provider Pre Birth 
 
ADD YOUR LETTERHEAD 
 
 
Date 
 
Regarding: Pregnant Mother with Hepatitis B 
 
 
Dear Health Care Provider:  
 
MOTHER’S NAME is HBsAg positive and pregnant.  Her estimated due date is DUE DATE.  
Currently she plans to deliver her baby at HOSPITAL NAME and bring her child to your clinic 
for well-child checkups and immunizations.  This child should receive the first dose of 
hepatitis B vaccine (HBV) and HBIG within 12 hours of birth.  Due to the exposure to hepatitis 
B at birth, it is very important that this child receive the 2nd and 3rd dose of vaccine on time. 
 
In adherence with the Recommended Childhood and Adolescent Immunization Schedule, we 
recommend that infants born to HBsAg positive mothers receive their second dose of HBV 
at one-two months of age, followed by the third dose at six months of age.   
 
Post-vaccination serologic testing is essential for these infants.  Both HBsAg and 
quantitative anti-HBs lab tests should be performed after completion of the vaccine series; 
three to nine months following the final dose of hepatitis B vaccine (generally at the 12 month 
visit, although can be drawn as early as 9 months of age).  Without serologic testing the 
outcome of the preventive therapy is unknown and opportunities to revaccinate or treat are 
missed.  I will be following up with your office regarding the test results.  
 
If you have any questions regarding the Iowa Perinatal Hepatitis B Prevention Program 
please contact me at YOUR NUMBER or the state coordinator, Bridget Konz, RN at 1-800-
831-6293 ext. 7.   
 
 
Sincerely, 
 
 
 
YOUR NAME 
Perinatal Hepatitis B Prevention Program 
YOUR AGENCY 
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General Letter to Baby’s Provider Post Birth 
 
ADD YOUR LETTERHEAD 
 
 
Date 
 
Regarding: CHILDS NAME/BIRTH DATE 
 
 
Dear Health Care Provider:  
 
CHILDS NAME birth date BIRTH DATE was born to an identified HBsAg positive mother 
NAME.  This child is planning to come to your clinic for well-child checkups and 
immunizations.  This child received the first dose of hep B vaccine and HBIG on DATE at 
HOSPITAL NAME.  It is very important that this child receive 2nd and 3rd dose of vaccine on 
time. 
 
In adherence with the Recommended Childhood and Adolescent Immunization Schedule, we 
recommend that infants born to HBsAg positive mothers receive their second dose at one-
two months of age, followed by the third dose at six months of age.   
 
Post-vaccination serologic testing is essential for these infants.  Both HBsAg and 
quantitative anti-HBs lab tests should be performed after completion of the vaccine series; 
three to nine months following the final dose of hepatitis B vaccine (generally at the 12 
month visit, although can be drawn as early as 9 months of age).  Without serologic testing 
the outcome of the preventive therapy is unknown and opportunities to revaccinate or treat 
are missed.  Please complete the enclosed form and return to me at YOUR FAX NUMBER.  
 
If you have any questions regarding the Iowa Perinatal Hepatitis B Prevention Program 
please contact me at YOUR NUMBER or the state coordinator, Bridget Konz, RN at 1-800-
831-6293 ext. 7.   
 
 
Sincerely, 
 
 
 
YOUR NAME 
Perinatal Hepatitis B Prevention Program 
YOUR AGENCY 
 
Enc. 
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Fax for Providers to Report HBV Vaccine Administration 
 
ON YOUR LETTERHEAD 
 
 
Please complete the following information regarding Hepatitis B vaccination series and post-
vaccination serology for:  INFANT NAME AND DOB. 
 
 
Perinatal Hepatitis B Prevention Checklist 
 
 
 HBV – 2nd dose due at 1 month of age 
 
 Date given: _______________________________ 
 
   Faxed results to (YOUR FAX) 
   
 
 
 
 HBV – 3rd dose due at 6 months of age 
 
 Date given:  _____________________________ 
 
   Faxed results to (YOUR FAX) 
 
 
 
 Post vaccination serology drawn between 9-12 months of age (not before 9 months of age) 
 
 HBsAg Results ___________________________ 
 
 Quantitative anti-HBs Results ___________________________ 
 
 Faxed results to (YOUR FAX) 
 
 
 
If you have any questions regarding Iowa Perinatal Hepatitis B Prevention Program please 
contact me at YOUR NUMBER or the state coordinator, Bridget Konz, RN at 1-800-831-6293 
ext. 7.   
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Letter Providers Regarding Serology 
 
ADD YOUR LETTERHEAD 
 
 
Date 
 
Regarding: CHILDS NAME/BIRTH DATE 
 
Dear Health Care Provider:  
 
CHILDS NAME birth date BIRTH DATE was exposed to hepatitis B (HBV) at birth and is now 
due for post-vaccination serologic testing for HBV.  Testing for immunity is essential for 
these infants.  Both HBsAg and quantitative anti-HBs lab tests should be performed after 
completion of the vaccine series; three to nine months following the final dose of hepatitis B 
vaccine (generally at the 12 month visit, although can be drawn as early as 9 months of 
age).   
 
Without serologic testing the outcome of the preventive therapy is unknown and opportunities 
to revaccinate or treat are missed.  Please complete the serologic testing results below or fax 
me a copy of the child’s lab slip to me at YOUR FAX NUMBER.  
 
Post vaccination serology drawn between 9-12 months of age (not before 9 months of age) 
 
 HBsAg Results ___________________________ 
 
 Quantitative anti-HBs Results ___________________________ 
 
If you have any questions regarding the Iowa Perinatal Hepatitis B Prevention Program 
please contact me at YOUR NUMBER or the state coordinator, Bridget Konz, RN at 1-800-
831-6293 ext. 7.   
 
 
Sincerely, 
 
 
 
YOUR NAME 
Perinatal Hepatitis B Prevention Program 
YOUR AGENCY 
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Letter Providers Regarding Overdue Serology 
 
ADD YOUR LETTERHEAD 
 
 
Date 
 
Regarding: CHILDS NAME/BIRTH DATE 
 
Dear Health Care Provider:  
 
CHILDS NAME birth date BIRTH DATE was exposed to hepatitis B at birth and is now past 
due for post-vaccination serologic testing for hepatitis B.  Testing for immunity is 
essential for these infants.  Both HBsAg and quantitative anti-HBs lab tests should be 
performed after completion of the vaccine series; three to nine months following the final 
dose of hepatitis B vaccine (generally at the 12 month visit).   
 
This child is now older than 18 months and needs to be tested soon to determine 
immunity and if revaccination is needed.  
 
Without serologic testing the outcome of the preventive therapy is unknown and opportunities 
to revaccinate or treat are missed.  Please complete the serologic testing results below or fax 
me a copy of the child’s lab slip to me at YOUR FAX NUMBER.  
 
Post vaccination serology drawn at ________months of age 
 
 HBsAg Results ___________________________ 
 
 Quantitative anti-HBs Results ___________________________ 
 
If you have any questions regarding the Iowa Perinatal Hepatitis B Prevention Program 
please contact me at YOUR NUMBER or the state coordinator, Bridget Konz, RN at 1-800-
831-6293 ext. 7.   
 
 
Sincerely, 
 
 
 
YOUR NAME 
Perinatal Hepatitis B Prevention Program 
YOUR AGENCY 
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Fax to Providers Regarding Serology 
 
ADD YOUR LETTERHEAD 
 
DATE:  
 
FROM:   
 
TO:  
 
SUBJECT:  Hepatitis B Serology Information  
 
As part of the surveillance of reportable disease in Iowa, The Iowa Department of Public 
Health, Perinatal Hepatitis B Prevention Program needs the Hepatitis B serology information 
for children born to Hepatitis B positive mothers (Iowa Administrative Code 641, Chapter 1). 
 
The child listed below was exposed to hepatitis B at birth and has completed the hepatitis B 
vaccine series.  This infant is now due for the serology testing.  The Centers or Disease 
Control and Prevention and the Iowa Department of Public Health recommend post-
vaccination testing at 12 months of age, although can be drawn as early as 9 months of 
age.  Without serologic testing the outcome of preventative therapy is unknown and 
opportunities to revaccinate or treat the child are missed.  
 
Please fax the following information to YOUR NAME AND FAX: 
 
Child’s Name_______________________________ DOB_______________________ 
 
Mother’s Name______________________________ DOB_______________________ 
 
Test Date:__________________________________ 
  
Test Results:  
Hepatitis B Surface Antigen (HBsAg) __________________________________ 
 
Quantitative Hepatitis B Surface Antibody (anti-HBs) ____________________________ 
 
If you have questions regarding the Iowa Perinatal Hepatitis B Prevention Program, please contact the State 
coordinator:  
Bethany Kintigh, RN, BSN 
Iowa Department of Public Health, Immunization Program 
321 East 12th Street 
Des Moines, IA  50319 
P: 1-800-831-6293 ext.7 
Bethany.Kintigh@idph.iowa.gov 
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Letter Providers Regarding 2nd Series of Immunization  
 
ADD YOUR LETTERHEAD 
 
Date 
 
Regarding: CHILDS NAME/BIRTH DATE 
 
Dear Health Care Provider:  
 
CHILDS NAME birth date BIRTH DATE was exposed to hepatitis B (HBV) at birth.  Subsequently, this 
child received HBV vaccination and post-vaccination serologic testing.  Unfortunately, according to 
the serology report, the child does not show immunity to hepatitis and requires a second 3 
dose series of HBV vaccine.   
 
The recommended approach is to complete a second 3-dose series of vaccine (again at 0, 2 and 4 
months) and re-test for both HBsAg and anti-HBs 1-2 months after the third dose of vaccine. If anti-
HBs and HBsAg are still negative after revaccination, the infant is considered a non-responder to 
hepatitis B vaccine. 
 
Please complete the following information regarding Hepatitis B vaccination series and post-
vaccination serology for this infant: 
 
 HBV 4 – first dose in second vaccine series (0 months) Date given______________ 
   Faxed results to (YOUR FAX) 
   
 HBV5 – second dose in second vaccine series (2 month) Date given___________ 
   Faxed results to (YOUR FAX) 
 
 HBV 6 – third dose in second vaccine series (4 months) Date given___________ 
   Faxed results to (YOUR FAX) 
 
Post vaccination serology drawn 1-2 months after last dose of vaccine  
 HBsAg Results ___________________________ 
 
 Quantitative anti-HBs Results ___________________________ 
 Faxed results to (YOUR FAX) 
 
If you have any questions regarding the Iowa Perinatal Hepatitis B Prevention Program please contact 
me at YOUR NUMBER or the state coordinator, Bridget Konz, RN at 1-800-831-6293 ext. 7.   
 
 
Sincerely, 
 
 
YOUR NAME 
Perinatal Hepatitis B Prevention Program 
YOUR AGENCY 
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Letter Providers Regarding Second Serology 
 
ADD YOUR LETTERHEAD 
 
 
Date 
 
Regarding: CHILDS NAME/BIRTH DATE 
 
Dear Health Care Provider:  
 
CHILDS NAME birth date BIRTH DATE was exposed to hepatitis B at birth, received two full 
series of HBV vaccine, and is now due for the hepatitis b post-vaccination serologic testing 
for the second series.  
 
Both HBsAg and quantitative anti-HBs lab tests should be performed 1-2 months after 
completion of the second vaccine series.   
 
Please complete the serologic testing results below, or fax me a copy of the child’s lab slip to 
me at YOUR FAX NUMBER.  
 
Post vaccination serology drawn at 1-2 months after the final dose of vaccine: 
 
 HBsAg Results ___________________________ 
 
 Quantitative anti-HBs Results ___________________________ 
 
 
If the child fails to seroconvert after the second series of vaccine, and is HBsAg negative, 
they should be considered susceptible to HBV infection.  Council the parents or guardians 
regarding precautions to prevent HBV infection and the need to obtain HBIG prophylaxis if 
any known or probable parenteral exposure to HBsAg-positive blood (CDC Pink Book, 9th 
Edition) 
 
If you have any questions regarding the Iowa Perinatal Hepatitis B Prevention Program 
please contact me at YOUR NUMBER or the state coordinator, Bridget Konz, RN at 1-800-
831-6293 ext. 7.   
 
 
Sincerely, 
 
 
YOUR NAME 
Perinatal Hepatitis B Prevention Program 
YOUR AGENCY 
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Letter to Postmaster Regarding Last Known Address 
 
ADD YOUR LETTERHEAD 
 
 
Date 
 
US Postmaster 
Address of Main Post Office 
City of Question 
 
Dear Postmaster: 
 
YOUR AGENCY NAME has been working with the following individual, ADD MOM’S NAME, 
with a last known address of: 
LIST ADDRESS HERE 
 
We have been unable to contact this individual and would like your assistance in determining 
whether they may have moved to a different address.  If known, please provide our agency 
with an updated address for this individual in the section below.  
 
Forwarding Address: 
 
 
 
A stamped, self-addressed envelope has been provided for your convenience.  Thank you for 
your time and assistance.  Please feel free to contact me at YOUR NUMBER if you have any 
questions about this letter.  
 
Sincerely, 
 
 
 
YOUR NAME 
YOUR AGENCY NAME 
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  Perinatal Hepatitis B Carrier Follow-Up Report 
 Immunization Program  
 
Bethany Kintigh,RN, BSN Perinatal Hepatitis B Coordinator   Person Completing form:______________________________ 
(515) 281-7228 or 1-800-831-6293 (extension #7) 
FAX 1-800-831-6292                                                                                             Date Faxed:________________________________________ 
Bethany.Kintigh@idph.iowa.gov 
     
This form is designed to facilitate the follow-up of a Perinatal Hepatitis B case. The follow-up consists of determining if the patient is pregnant, confirming the delivery, assuring 
appropriate care for the infant as well as gaining information on susceptible household contacts.  Please complete and fax to 1-800-831-6292.   
I. Screening Data (Mother) 
 
Name  DOB  
Address  City/State/ Zip  
County  Pt. Phone  
   
Race/Ethnicity:  
 Asian/Pacific Islander 
American Indian/ Alaskan Native  
Black/ African American     
 
 
Hispanic/ Latino 
White    
Other _________________ 
Unknown 
Is the client  foreign born        Yes             No 
 
If yes, country of origin: ______________________ 
 
Is the client English speaking?     Yes      No 
 
If no, what language? ________________________ 
Following Physician  Phys Phone  
Clinic Name  Phys Fax  
Address  City/State/ Zip  
 
Is the patient pregnant?   Yes      No      Aborted spontaneous, elected, or medically indicated    
 
Anticipated Date of Delivery  
Anticipated Delivery Hospital  
Address of Hospital  Phone  
  City/State/Zip  
HBsAg Test Results Positive           Negative Date Tested  
  
 When was mother tested (check one):  Pre-preg.  1st Trimester 2nd Trimester 3rd Trimester   At Delivery 
II. Immunization/Prophylaxis/Follow-up on Infant (complete separate forms for multiple births) 
 
Infant’s Name  Sex   Female         Male 
  Race/Ethnicity:  Asian/Pacific Islander  American Indian/ Alaskan Native  Black/ African American  Hispanic/ Latino  White  Other  Unknown 
Date and Time of Birth:  Birth Weight  
Date HBIG Given  Given Within 12 Hours of Birth?   Yes        No 
HBV Given Dose 1    Dose 2  Dose 3  Dose 4  
Infant on IRIS:     Yes        No Vaccine Used for Series:     Comvax        Pediarix      Hep. B only  
Infant’s Health Care Provider  Phone  
Clinic Name  Fax  
Address  City/State/Zip  
 
III. Post-Vaccination Infant Serology   (recommended  3-9 months after final dose of Hep B vaccine; generally at 12 months of age) 
 
HBsAg Testing Date:           Positive      Negative     Not Tested  
Anti-HBs Testing Date:        Positive      Negative Value:        Not Tested 
Comments:  
 
Iowa Department of Public Health ● 321 East 12th Street, Lucas State Office Building ● Des Moines, Iowa 50319  Rev 12-1-2006 
 IV. Summary of All Household Contacts 
 
Contact’s Name:  DOB  Sex:   Male   Female 
Serologic Testing:   HBsAG Result:    Positive Negative     Date      
 Anti-HBc Result Value  Date  
Dates Hepatitis B Vaccine Given:   Hepatitis B Only     Combination (Twinrix, Comvax, Pediarix)     Entered into IRIS?    Yes    No 
Dose 1  Dose 2  Dose 3  Dose 4  
 
 
Contact’s Name:  DOB  Sex:   Male   Female 
Serologic Testing:   HBsAG Result:    Positive Negative     Date      
 Anti-HBc Result Value  Date  
Dates Hepatitis B Vaccine Given:   Hepatitis B Only     Combination (Twinrix, Comvax, Pediarix)     Entered into IRIS?    Yes    No 
Dose 1  Dose 2  Dose 3  Dose 4  
 
 
Contact’s Name:  DOB  Sex:   Male   Female 
Serologic Testing:   HBsAG Result:    Positive Negative     Date      
 Anti-HBc Result Value  Date  
Dates Hepatitis B Vaccine Given:   Hepatitis B Only     Combination (Twinrix, Comvax, Pediarix)     Entered into IRIS?    Yes    No 
Dose 1  Dose 2  Dose 3  Dose 4  
 
 
Number of household contacts identified? ___________ 
Number of contacts tested for anti-HBc? ___________      # of positives  __________ 
Number of contacts tested that were susceptible (neg for anti-HBc, neg for HBsAg, neg for anti-HBs)?__________ 
Number of contacts lost to follow-up or not tested? ___________ 
 
Comments (include reasons for non-compliance or not testing and possible risk factors): 
 
 
 
 
 
 
 
 
 
 
 
Reminders for Vaccination and Testing  
At birth 
 Infants born to mothers who are HBsAg positive should receive hepatitis B vaccine and hepatitis B immune globulin (HBIG) within 12 hours of birth. 
 Infants born to mothers whose HBsAg status is unknown, who are greater than 2,000g (4.4 lbs) at birth, should receive hepatitis B vaccine (HBV) within 12 
hours after birth.  Infants weighing less than 2,000g at birth should receive HBIG concurrently with HBV vaccine but at a separate site.    The mother should have 
blood drawn as soon as possible to determine her HBsAg status; if she is HBsAg positive, the infant should receive HBIG as soon as possible (no later than age 1 
week).   
 Full-term infants who are medically stable and weigh greater than 2,000 g born to HBsAg-negative mothers should receive single-antigen hepatitis B 
vaccine before hospital discharge – Birth dose. 
 Preterm infants weighing less than 2,000 g born to HBsAg-negative mothers should receive the first dose of vaccine 1 month after birth or at hospital discharge. 
After the birth dose 
 All infants should complete the hepatitis B vaccine series with either single-antigen vaccine or combination vaccine, according to a recommended vaccination 
schedule. Infants born to HBsAg positive mothers should complete vaccination by 6 months of age.  
 Infants born to HBsAg-positive mothers should be tested for HBsAg and antibody to HBsAg 3-9 months after HBV vaccine completion. 
Post-vaccination testing for anti-HBs and HBsAg should be performed 3-9 months after the final dose of HBV vaccine (generally at the 12 month well-child visit). 
Testing should not be performed before age 9 months to avoid detection of anti-HBs from HBIG administered during infancy and to maximize the likelihood of 
detecting late HBV infection. Anti-HBc testing of infants is not recommended because passively acquired maternal anti-HBc might be detected in infants born to HBV 
infected mothers to age 24 months.  
 
Source:  MMWR, Vol. 54/No. RR-16/ December 23, 2005 
 
**If needed, the Iowa Department of Public Health can supply the hepatitis B vaccine and Hepatitis B Immune Globulin for the baby. 
Iowa Department of Public Health 
Bureau of Disease Prevention and Immunization  
Perinatal Hepatitis B Hospital Report Immunization Program  
 
 
Please complete the information that applies and FAX to: Bethany Kintigh RN, BSN Perinatal Hepatitis B Coordinator 
Questions:  Please call: 1-800-831-6293 ext. 7   Fax: 1-800-831-6292 
 
For Women known to be HBsAg Positive 
  Administer hepatitis B immune 
 globulin (HBIG) and Hepatitis B 
 vaccine within 12 hours of birth. 
 
 If your hospital is having difficulty 
 obtaining HBIG please call IDPH at   
 1-800-831-6293. 
 
For Women whose HBsAg status is Unknown 
  Perform stat HBsAg screening for all women admitted for delivery whose 
 status is unknown.  
 
 While test results are pending, administer hepatitis B vaccine within 12 
hours of birth. If the mother is later found to be positive, her infant 
should receive the additional protection of HBIFG as soon as possible 
and before the infant is discharged, HBIG must be given within 7 days of 
birth.    
 
Name of Hospital: ___________________________________  Date Sent: __________________________ 
 
City of Hospital:_____________________________________  Mothers Hospital Record #:_____________ 
 
Note:  Only report if mother is HBsAg Positive. 
Mothers Information HBsAg(+) Test Date (if done in hospital)* 
First Name Last Name 
Date of Birth: Phone: 
Address: EDC: 
City/Zip: Alternate Phone (i.e. relative): 
Physician’s Name: Clinic Name:  
Race:  
 Asian/Pacific Islander    
American Indian/ Alaskan Native  
Black/ African American     
Hispanic/ Latino 
White    
Other ______________________________ 
Unknown 
 
Is the client  foreign born        Yes             No 
If yes, country of origin: ______________________ 
Is the client English speaking?     Yes       No 
If no, what language? _______________________ 
*Please send a copy of the labs with this form. 
 
Infant’s Information Hospital Record #:  
First Name Last Name 
Date of Birth: Birth weight:                                   Sex:    Male       Female 
Date of HBIG Date of HBV Vaccine: 
HBIG given within 12 Hours of Birth    Yes        No  Child entered into IRIS   Yes        No 
IMPORTANT 
Clinic where baby will receive next dose of vaccine ________________________________________________ 
 
Infant’s Physician Name and Phone:____________________________________________________________ 
 
 
Iowa Department of Public Health                                For More information Please Call:  1-800-831-6293, ext 7 
Bureau of Disease Prevention and Immunization    
321 East 12th Street / Lucas State Office Bldg./ Des Moines IA  50319 
http://www.idph.state.ia.us/adper/immunization.asp   Form:  12-1-2006 
HBsAg+ Exposed Infants Follow-Up Checklist 
Prior to Delivery: 
 Contact the mother’s provider.  Make sure they are aware of her HBsAg positive lab result, the 
indicated immunoprophylaxis (HBIG) for the infant, and provide the brochure “Perinatal Hepatitis B  
Providers Guide.”  
 
 Contact the hospital or delivery center to make sure that they will have HBIG on hand and that the 
mother’s HBsAg status is noted in her prenatal record. 
 
 Prior to delivery, call, write, or make a home visit to the client and provide perinatal hepatitis B 
educational materials (including the “Hepatitis B and Moms-to-B Brochure”).  
 
 Complete Section I of the IDPH “Perinatal Hepatitis B Carrier Follow-Up Report Form” with 
demographic information on mom.  Educate the client on how to reduce risk of transmission of 
hepatitis B to her infant and household members.  
 
 Complete Section IV on the IDPH “Perinatal Hepatitis B Carrier Follow-Up Report Form”. Identify 
susceptible household contacts (children and sexual contacts) and encourage them to be tested 
and vaccinated.   
 
After Delivery:  
 Complete Section II of the IDPH “Perinatal Hepatitis B Carrier Follow-Up Report Form” with the 
infant’s birth date and dates for HBIG and the 1st dose of vaccine. 
 
 Notify the client’s pediatric provider of the mother’s positive HBsAg status and remind them that the 
infant should receive the 2nd dose of vaccine at one to two months and the 3rd dose of vaccine 
at 6 months of age as well as post-vaccination serology at 12 months of age.  Make follow-up 
calls or visits with the client to make sure that her baby has gone in for his/her vaccinations and 
serology test. 
 
 At 12 months of age, collect post-vaccination serology results. Be sure the provider tests for 
both HBsAg and Anti-HBs.  Complete Section II of the IDPH “Perinatal Hepatitis B Carrier Follow-
Up Report Form.” 
 
 If infant doesn’t develop an antibody response to the HBV vaccine and remains negative for 
hepatitis B infection, call the clinic or fax/send a request to ensure that a second series of HBV 
vaccine is given. 
 
 Complete the IDPH “Perinatal Hepatitis B Carrier Follow-Up Report Form” with all shot dates and 
test results and fax/send to IDPH.   
 
Periodically update the Perinatal Hepatitis B Prevention Program with your progress at the following intervals: 
 After Section I is completed for mom and household contacts have been identified (Section IV) 
 After contacts have completed the first does in the series, or had serology to indicate no vaccine is needed 
(Section IV). 
 After the baby is born and HBIG and birth dose of vaccine have been given. 
 Upon completion of each dose of vaccine in the series for newborn and contacts. 
 Upon completion of serology for infant and closing of case.  
 
Please send results by fax (1-800-831-6292) or e-mail Bethany.Kintigh@idph.iowa.gov or to:   
Bethany Kintigh, RN, BSN IDPH Immunization Program, 321 East 12th Street, Des Moines, IA  50319 
Appendix 4 General Information for Patients 
Appendix 4 links:  
Frequently Asked Questions About Hepatitis B: www.immunize.org/catg.d/p4090.pdf 
Hepatitis B Vaccine VIS:  www.cdc.gov/vaccines/pubs/vis/default.htm#hepa 
 
 
Appendix 5 General Information for Providers 
Appendix 5 links: 
Guidelines for Standing Orders:  www.immunize.org/catg.d/p2130.pdf 
Sample Standing Orders: www.immunize.org/catg.d/p3076a.pdf 
 
Appendix 6 Hepatitis B Chapter from the CDC Pink Book 
Appendix 6 links:  
CDC Pink Book Chapter on Hepatitis B: www.cdc.gov/vaccines/pubs/pinkbook/downloads/hepb.pdf 
 
Appendix 7 Iowa Administrative Code 614, Chapter 1 
Appendix 7 links:  
Iowa Administrative Code Chapter 641.1: www.legis.state.ia.us/Rules/Current/iac/641iac/6411/6411.pdf 
 
Appendix 8 MMWR December 23, 2005  
Appendix 8 links:  
MMWR: Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in 
the United States: www.cdc.gov/mmwr/PDF/rr/rr5416.pdf 
 
Appendix 9 Hepatitis B Chapter from IDPH Epidemiology 
Manual 
 
Appendix 9 link: 
IDPH EPI Manual – Hepatitis B Chapter: 
www.idph.state.ia.us/idph_universalhelp/main.aspx?system=IdphEpiManual 
 
HEPATITIS C 
 
Also known as Non-A Non-B Hepatitis, HCV Infection 
 
Responsibilities: 
Hospital: Report by IDSS, facsimile, mail or phone 
Lab: Report by IDSS, facsimile, mail or phone 
Physician: Report by IDSS, facsimile, mail or phone 
Local Public Health Agency (LPHA): Followup dependent on local agency protocol 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Etiologic Agent 
Hepatitis C is caused by an RNA virus (in the Flaviviridae family). Multiple hepatitis C virus (HCV) genotypes 
exist, with type 1 being most common in the United States. 
 
B. Clinical Description 
Hepatitis C is a disease with varying rates of progression. In general, its course is slowly progressive. For people 
who are recently infected, only 20% - 30% will experience any related acute symptoms. Therefore, it is 
uncommon for people to be diagnosed with HCV infection in the acute stage. About 15% of HCV-infected 
individuals completely recover spontaneously (reasons for this are still unknown), however the remainder 
develops chronic infection.  
 
Most people are asymptomatic during the first decade or two of chronic hepatitis C. Some patients will 
experience a range of symptoms including fatigue, headaches, joint aches, muscle aches, nausea, jaundice, loss 
of appetite, and/or abdominal pain. Of those chronically infected, about 20% eventually develop cirrhosis or 
cancer of the liver [hepatocellular cancer (HCC)]. Cirrhosis can lead to liver failure in some people and 
predispose them to the development of liver cancer. The progression chart (under Hepatitis C in the Epi Manual) 
illustrates the natural history of hepatitis C. Factors related to more serious clinical outcomes include drinking 
alcohol, coinfection with hepatitis A, hepatitis B, or HIV, and taking medications or food supplements that harm 
the liver.  
 
Treatment of chronic hepatitis C with pegylated interferon with or without ribavirin is indicated for some 
individuals and may result in a sustained response with elimination of virus in up to 50% - 80% of those 
receiving a full 6 - 12 months of treatment.  
 
C. Reservoirs 
Infected humans are the only known source of this disease. 
 
D. Modes of Transmission 
Hepatitis C is a bloodborne pathogen; it is predominantly spread via percutaneous exposure to infectious blood 
or blood products. Currently, the most prevalent mode of transmission is sharing needles or syringes to inject 
illicit drugs. Blood transfusions pose an extremely limited risk today, but for those patients who received a blood 
transfusion prior to July 1992, the risk was approximately 1 in 200 transfused units. Sexual and vertical (mother 
to infant) transmission of hepatitis C does occur, but does not appear to be an efficient mode of transmission. 
Other potential risks for transmission include long-term hemodialysis, occupational blood exposure, and tattooing 
or body piercing with non-sterilized equipment. Hepatitis C is not spread via casual contact, kissing, sneezing, 
hugging, breast milk, or sharing glasses or utensils.   
E. Incubation Period 
The incubation period for hepatitis C ranges from 2 weeks to 6 months, with an average incubation period of 6 - 
9 weeks.  
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F. Infectious Period 
Infectiousness with HCV is variable; anyone with a positive test for HCV antibody should be considered infectious 
until more extensive testing can be done to rule out the presence of the virus in the blood. The virus can usually 
be detected in an infected person’s blood within 1 - 3 weeks after the initial exposure. The degree of correlation 
between quantity of circulating virus and infectiousness is not clearly established.  
 
G. Epidemiology 
Hepatitis C has a worldwide distribution. In the United States an estimated 3-4 million people are infected with 
HCV. It is thought that there are currently about 17,000 new cases of hepatitis C infection each year. HCV 
infection occurs among persons of all ages, with the highest incidence of acute hepatitis C (new cases) occurring 
among persons aged 20 - 39 years. Prevalence is highest among groups with specific risk factors, especially 
injection drug users, patients with hemophilia or on long-term hemodialysis, prisoners, and people who received 
blood or organ products prior to July 1992. HCV infection is highly prevalent (50% – 95%) among injection drug 
users (IDUs) and rapidly acquired after drug users first inject drugs. Several studies have now shown that HCV 
transmission among IDUs is associated with both direct and indirect sharing of injection equipment such as 
cookers and cotton. The risk of occupational exposure for healthcare workers has been estimated to be 1.8% 
per incident of hollow-bore needle stick exposure to HCV-infected blood. Perinatal transmission is estimated as 
being about 5%, although if the mother is coinfected with HIV, the risk may be increased to approximately 15%. 
 
Hepatitis C is a reportable disease in Iowa.  The majority of newly reported cases are not people with new 
(acute) disease, but those with chronic infection. There is a large population of undiagnosed people who were 
infected in the past.  
 
H.  Bioterrorism Potential 
None. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To provide information to HCV-infected persons on how to prevent exposing others.  
• To identify HCV-infected patients to ensure that they are educated on the need for medical 
evaluation, how to reduce disease progression, and to provide referrals to medical or support services. 
• To determine the prevalence of HCV in specific populations and geographic locations to better direct 
HCV prevention and service activities. 
 
B.  Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider must report 
cases of hepatitis C. Report any case with a positive result on any of the following tests: 
• EIA (ELISA) HCV antibody 
• RIBA  
• Viral RNA by RT-PCR or bDNA 
• Genotype testing 
 
Note: Please feel free to consult with the Adult Viral Hepatitis Prevention Coordinator at the Bureau of HIV, STD, 
and Hepatitis at (515) 281-5027 for assistance in interpreting laboratory results or if you have any other 
questions regarding a case of hepatitis C infection.  
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider must 
report. The preferred method of reporting is by utilizing the Iowa Disease Surveillance System (IDSS).  
However, if IDSS is not available to your facility the reporting number for IDPH Center for Acute Disease 
Epidemiology (CADE) is (800) 362-2736; fax number (515), 281-5698, mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
Des Moines, IA 50319-0075 
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Postage-paid disease reporting forms are available free of charge from the IDPH clearinghouse.   
Call (319) 398-5133 or visit the website: 
healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295 to request a supply. 
 
Laboratory Testing Services Available  
The State of Iowa University Hygienic Laboratory (SHL) does not provide routine HCV antibody testing for the 
general public. Testing is generally conducted through hospital and commercial clinical laboratories.  Some 
county health departments are currently offering the HCV EIA antibody test.  Please contact the Adult Viral 
Hepatitis Prevention Coordinator at the Bureau of HIV, STD, and Hepatitis at (515) 281-5027 for the listing of 
county health departments offering this service. 
 
3) CONTROLLING FURTHER SPREAD 
 
A.  Isolation and Quarantine Requirements  
Minimum Period of Isolation of Patient 
No restrictions except for exclusion from organ and blood donation and counseling to modify activities in order to 
prevent transmission. 
 
Note: Sexual transmission of hepatitis C does occur, but is infrequent. 
 
Minimum Period of Quarantine of Contacts 
None 
  
B.  Protection of Contacts of a Case 
Personal surveillance for high-risk contacts is recommended. Personal surveillance is defined as the practice of 
close medical or other supervision of contacts without restricting their movements in order to promote 
recognition of infection or illness. 
 
Standard Precautions for cases are recommended to prevent exposing others to blood and body fluids. Immune 
Globulin prophylaxis is not effective and is not recommended for those exposed to HCV-infected individuals, such 
as healthcare workers who receive a needle stick with a contaminated needle. 
 
C.  Managing Special Situations 
There are no specific regulations regarding HCV infection in child care settings, food service environments, or in 
schools or community residential programs. HCV is not spread via casual contact or through food or water. As 
long as Standard Precautions are maintained, HCV will not be spread to others in these settings. No one who is 
HCV-infected should be excluded from attending or working in any of these settings on the basis of their HCV 
infection. 
 
D.  Preventive Measures 
The role of the local health department in managing hepatitis C is largely educating infected persons how to care 
for themselves and avoid spreading infection to others. Little epidemiologic investigation is required except data 
collection for case reports. Prevention and education includes information on how the disease is transmitted, 
how to avoid transmitting it, and how patients can protect themselves from more liver damage. Offer the 
information and support below to newly identified cases. 
1. Provide basic instruction on transmission of HCV and emphasize the need for ongoing medical 
evaluation. Treatment is available and the patient should be referred to their healthcare provider for 
treatment options. 
2. If the patient is a current injection drug user, provide referrals to needle access and disposal programs 
and drug treatment programs. This will help prevent the spread of hepatitis C to other individuals. 
3. Educate on the need to completely abstain from alcohol to help protect the liver. If a patient needs or 
wants support to stop drinking, provide referrals to appropriate treatment or support services. 
4. Discuss medications that should be avoided (e.g., acetaminophen) as high doses of certain medications 
can damage the liver. All patients should discuss any medications (including over-the-counter medications), 
dietary supplements, and herbs with a healthcare provider prior to taking them to be certain they will not 
damage their liver. 
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5. Provide information on hepatitis A and B immunization. (Refer to the Hepatitis A and B chapters in this 
manual.) 
6. Discuss sexual transmission of HCV. Indicate that HCV may be transmitted during sex. All contact with 
blood during sex should be avoided. Emphasize latex barrier protection as a way to prevent the spread of 
HCV, as well as being a way to prevent the exposure to and transmission of other pathogens. 
7. Discuss household transmission of HCV. Household transmission is rare, but to ensure that it does not 
happen, the patient should not share razors, toothbrushes, nail clippers, or any other item that could be 
contaminated with blood with other household members. 
8. Inform the patient that they should not be restricted from working, preparing food, or taking part in 
their daily activities unless they have specific symptoms that make it difficult to do so. There are no 
recommendations suggesting that HCV-infected persons change their exercise routines or have any dietary 
restrictions. 
 
4) ADDITIONAL INFORMATION 
 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Hepatitis C can be 
found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria in this 
chapter. (CSTE case definitions are used by the state health department and the CDC to maintain uniform 
standards for national reporting.)  
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 CDC Hepatitis C website: www.cdc.gov/hepatitis/HCV/index.htm  
www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/Diagnosis_of_HEP_C_
Update.Aug%20_09pdf.pdf  
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FACT SHEET  HEPATITIS C 
Acute and Carrier Information    (Non A-Non B, Hep C, HCV) 
What is Hepatitis C? 
Hepatitis C is a virus that infects the liver.   
 
Who is at risk for Hepatitis C? 
IV drug users, persons receiving blood products (such as transfusions) or organ transplants prior to July 1992, 
persons receiving clotting factors before 1987, healthcare workers, chronic hemodialysis patients, infants born to 
infected mothers, and persons with multiple sexual partners are at risk for hepatitis C.  The mode of transmission is 
unknown in about 10% of cases. 
 
How do people get Hepatitis C? 
The hepatitis C virus is most often spread through contact with infected blood.  Sharing needles for injection drug use 
is a very common way people become infected.  Having sex with an infected person, living in the household with 
someone who has hepatitis C, and being born to an infected mother are other ways people could become infected, 
although the risk of contracting the virus in these ways is not as common as having a blood exposure.  The role of 
sexual transmission is not clear, but high-risk sexual activity (multiple partners or a history of STDs) is a risk factor.  In 
1992 a test for hepatitis C was developed and is used to screen every unit of donated blood, so that getting a 
transfusion is now considered safe.  There is no evidence that hepatitis C can be transmitted by casual contact, 
through foods, or by coughing or sneezing.  There is no evidence of hepatitis C being transmitted through breast milk. 
 
What are the symptoms of Hepatitis C? 
Symptoms may include being very tired, nausea, vomiting, fever, stomach pain, tea-colored urine, and yellowing of 
the skin and eyes (jaundice).  Most people infected with hepatitis C will have only a few mild symptoms and may 
never know they were infected.  However, all infected people can spread the virus, even when they do not feel sick.  
Only about 25 - 35% of infected persons will develop symptoms however.   
 
How long can an infected person spread the virus? 
The virus can be spread from one or more weeks before symptoms begin and throughout the time the person has the 
virus.  About 15% of infected people will recover from the infection and get rid of the virus within a few weeks or 
months.  Approximately two thirds of people infected with hepatitis C however will not get rid of the virus and will 
have the virus for the rest of their lives.  As long as a person has the virus, that person can transmit it to other 
people.   
 
How is Hepatitis C diagnosed? 
Infection by the hepatitis C virus can be determined by a simple blood test that detects antibodies against HCV.  Your 
healthcare provider may ask that additional diagnostic tests be run. 
 
Can a blood test tell if I am no longer infected? 
Other blood tests are available to check for the actual levels of the virus in the blood, and a liver biopsy could be done 
to determine the extent of liver damage done by the virus.   
 
How is Hepatitis C treated? 
At this time, long-acting pegylated interferon, or a combination of pegylated interferon with Ribavirin are being used 
to treat hepatitis C.  Depending on the type of hepatitis C (genotype) a person has, treatment can last from 24-48 
weeks.  Effectiveness rates vary from 50-80% depending on the type of hepatitis C, as well as how well the person is 
able to tolerate the treatment program.   
 
What can I do to take care of myself if I have hepatitis C? 
• Avoid alcoholic beverages and street drugs.  They will damage your liver. 
• Avoid taking prescription or over-the-counter medicines, dietary supplements, or herbs unless your doctor tells 
you it is OK.  Certain types of medications or supplements can damage your liver. 
• Eat a healthy diet (low fat, non-spicy sometimes helps) and get plenty of rest.  If you are vomiting after 
eating, tell your doctor. 
• See your doctor and follow the doctor’s instructions carefully.  Your doctor will want to do blood tests 
occasionally to see how your liver is working. 
Iowa Dept. of Public Health Reviewed 12/13  Hepatitis C Acute and Carrier Information Fact Sheet  1 
Iowa Department of Public Health 
• If you get pregnant, tell your doctor you have hepatitis C.  
What can I do to protect others? 
• Cover all cuts and sores with a bandage. 
• Throw away all items that have your blood on them in plastic bags and close the bag tightly. 
• Wash your hands well after touching your blood or body fluids. 
• Clean up blood spills with paper towels.  Next, clean the area with a bleach solution (1 part bleach to 
100 parts water or one-quarter cup bleach per gallon of water). 
• Talk with your sex partner about your hepatitis C and discuss the possibility of using a latex condom 
during sex.  Although the risk of transmitting the virus sexually is low, it is possible to transmit hepatitis C this 
way. 
• Do not share any items that may have your blood on them (even if you cannot see the blood), such 
as toothbrushes, razors, and needles used for ear-piercing, tattooing, or drug use or other drug use items. 
• Do not donate blood, plasma, semen, or body organs.
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FACT SHEET HEPATITIS C 
 (Non A-Non B, Hep C, HCV) 
 
What is Hepatitis C? 
Hepatitis C is a virus that infects the liver.   
 
Who is at risk for Hepatitis C? 
IV drug users, persons receiving blood products (such as transfusions) or organ transplants prior to July 1992, 
persons receiving clotting factors before 1987, healthcare workers, chronic hemodialysis patients, infants born to 
infected mothers, and persons with multiple sexual partners are at highest risk for hepatitis C.   
 
How do people get Hepatitis C? 
The hepatitis C virus is spread through contact with contaminated blood.  It can also be spread through close 
household contact.  The role of sexual transmission is not clear, but high-risk sexual activity (multiple partners or 
history of STD’s) is a risk factor.  It can also be transmitted from a pregnant woman to her baby.  The mode of 
transmission is unknown in about 10% of cases. 
 
Can Hepatitis C be spread from person-to-person? 
Yes.  Several routes have been described, but the parenteral (blood to blood) route is the most common.  Sexual 
transmission accounts for approximately 15% of all transmission, although it is not thought to be efficiently 
transmitted sexually.  Mother to infant transmission does occur in about 5% - 6% of infant cases.  There is no 
evidence that hepatitis C can be transmitted by casual contact, through foods, or by coughing or sneezing.  There is 
also no evidence of hepatitis C being transmitted through breast milk. 
 
What are the symptoms of Hepatitis C? 
Most people who are infected with hepatitis C do not have symptoms and lead normal lives. Infection with hepatitis C 
may cause mild symptoms, which usually develop slowly and may include feeling very tired, loss of appetite, stomach 
pain, nausea and vomiting.  Jaundice (yellow skin and eyes) does not commonly occur. Rarely, hepatitis C may result 
in death.   
 
How soon do symptoms appear? 
It takes from 2 weeks to 6 months (usually 6 - 9 weeks) after exposure before symptoms appear.  Only about 25% - 
35% of infected persons will develop symptoms however.   
 
How long will symptoms last? 
Approximately two thirds of people infected with hepatitis C will continue with chronic infection and could potentially 
develop symptoms related to liver disease.  It is estimated that approximately 20% of those people chronically 
infected with hepatitis C will develop cirrhosis, with the risk of liver cancer increasing to 1-4% per year once a person 
has cirrhosis.  About 1% - 4% of HCV infected people die due to the disease. 
 
How is Hepatitis C diagnosed? 
Infection by the hepatitis C virus can be determined by a simple and specific blood test that detects antibodies against 
HCV.  The antibody is insufficient to provide immunity and the test does not distinguish between acute or chronic 
infection.  If the initial test is positive, a second test should be done to confirm the diagnosis and exclude laboratory 
error.  A liver biopsy can determine the extent of liver damage done by the virus.   
 
How is Hepatitis C treated? 
At this time, long-acting pegylated interferon, or a combination of pegylated interferon with Ribavirin are being used 
to treat hepatitis C.  Depending on the type of hepatitis C (genotype) a patient has, treatment can last from 24 - 48 
weeks.  Effectiveness rates vary from 50% - 80% depending on the type of hepatitis C and how well the patient is 
able to tolerate the treatment program.   
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How can Hepatitis C be prevented? 
There is no vaccine available for hepatitis C.   
• Don’t share IV drug needles, syringes, water or works.     
• Avoid handling or sharing anything that may have the blood of an infected person on it, such as toothbrushes, 
razors, straws used for cocaine, needles used for piercing or tattooing, or other personal care articles.   
• If you are a healthcare worker, always follow routine barrier precautions and safely handle needles and other 
sharps.   
• A 10% solution of household bleach is believed to kill the virus, and is recommended for the cleaning up of 
blood spills. 
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Fact Sheet        HEPATITIS C 
Information for Health Professionals 
 
What is Hepatitis C? 
Formerly known as non-A, non-B hepatitis, hepatitis C is an RNA virus that accounts for about 20% of all 
cases of acute hepatitis. There are over 4 million people infected in the U.S., and over 30,000 acute new infections 
each year. Hepatitis C is responsible for 8-10,000 deaths per year and is the leading cause for liver transplantation in 
the U.S. 
 
How is Hepatitis C transmitted? 
Several routes have been described, but the parenteral route, injection drug use, needle-stick accidents, and 
transfusion of infected blood or blood products (especially prior to 1990), is the most common. The role of sexual 
transmission is not clear, but high-risk sexual activity (multiple partners, history of STD’s) is a risk factor. Hepatitis C 
can be transmitted perinatally to about 5% - 6% of infants. Also, chronic hemodialysis is considered a risk factor. 
Mode of transmission is unknown in a significant number of patients. There is NO evidence that hepatitis C can be 
transmitted by casual contact, through foods or by coughing or sneezing. 
 
What are the symptoms? 
Patients can be completely asymptomatic. Only about 25% - 35% will develop malaise, weakness, or 
anorexia. Other possible symptoms include nausea, vomiting, abdominal pain, and jaundice (when the whites of the 
eyes and the skin turn yellow). 
 
What is the incubation period? 
The incubation period is 2 weeks to 6 months. 
 
How is Hepatitis C diagnosed? 
There are numerous blood tests, including enzyme immunoassay for HCV antibody and recombinant 
immunoblot assay (RIBA). HCV RNA can generally be detected in the blood within 1 - 3 weeks of exposure. 
Virtually all patients develop liver cell injury as shown by increased ALT levels. Liver biopsy is generally required to 
determine the extent of liver disease regardless of the ALT level. 
 
What are the potential outcomes/consequences of becoming infected? 
Hepatitis C is self-limited in only 15% of cases. A persistent infection develops in as many as 85% of patients with 
acute hepatitis C. This is due to the fact that HCV is not easily cleared by the host’s immunologic defenses. The 
natural history of the disease differs according to geography, alcohol use, virus characteristics, and coinfection with 
other viruses. Fulminant, rapid liver failure is rare. Cirrhosis develops in at least 20% within two decades of onset. 
Risk of liver cancer (hepatocellular carcinoma (HCC)) occurs in about 1% - 5% after 20 years. Once cirrhosis 
develops, then the risk of HCC increases to 1% - 4% per year. 
 
How is Hepatitis C treated? 
At this time, treatment with Alpha-interferon (IFN) with Ribavirin is being used, which is considered firstline 
treatment for most patients. All persons with HCV should be vaccinated against hepatitis A and B. Complete 
abstinence from alcohol is a must. 
 
Who should be treated? 
Many factors should be considered in determining who should be treated. Contraindications to IFN include 
persistently normal or near-normal ALT levels, major depressive illness, cytopenias, hyperthyroidism, renal 
transplantation, and evidence of autoimmune disease. Active alcohol or drug use may also be a contraindication to 
treatment. Most contraindications are not absolute and should be decided on a case-by-case basis. 
 
Is there a pre-exposure vaccine available as there is for Hepatitis A and B? 
There is currently no available vaccine to prevent infection with hepatitis C. There is also no post-exposure 
prophylaxis with hepatitis C as there is for hepatitis A and B. 
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What is recommended for postexposure testing? 
Individuals who have been or may have been exposed need baseline and 6 month testing for HCV and ALT. Any 
positive HCV antibody test should be followed by further confirmatory testing. 
 
How is transmission prevented? 
• Adherence to standard precautions is essential. 
• HCV(+) persons should refrain from donating blood, organs, tissues, or semen. 
• Safer sexual practices, such as use of latex condoms.  
• In households with an HCV(+) member, sharing razors and toothbrushes should be avoided. Covering open 
wounds is recommended. It is NOT necessary to avoid close contact with family members or to avoid 
sharing meals or utensils. There is also NO evidence to justify exclusion of HCV(+) children or adults from 
participation in social, educational, and employment activities. 
• Pregnancy is NOT contraindicated in HCV-infected individuals. There is also no evidence that breast-feeding 
transmits HCV from mother to baby; therefore, it is considered safe. Babies born to HCV(+) mothers should 
be tested for anti-HCV at one year. 
• Needle exchange and other safer injection drug use programs may be of benefit in reducing parenterally 
transmitted diseases. 
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HEPATITIS D 
 
Also known as: Viral hepatitis D, Hepatitis delta virus, Delta agent hepatitis, Delta 
associated hepatitis  
 
Responsibilities: 
Hospital: Report by IDSS, facsimile, mail, or phone  
Lab: Report by IDSS, facsimile, mail, or phone 
Physician: Report by facsimile, mail, or phone 
Local Public Health Agency (LPHA): Follow-up required 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Hepatitis delta virus (HDV) is a small virus-like particle made up of a hepatitis B surface antigen and the 
delta antigen and a single strand of DNA.  It cannot infect a cell itself; it can only replicate if there is a co-
infection with hepatitis B virus (HBV).  Infection with HDV can occur at the same time as HBV or can occur 
at a later date in a person with chronic hepatitis B.     
 
B. Clinical Description 
Symptoms:  Signs and symptoms resemble hepatitis B and may be severe.  These symptoms are fatigue, 
nausea, vomiting, fever, stomach pain, tea-colored urine, and jaundice.  The infection may be self-limiting 
or it may progress to chronic infection.  Children may have a very severe course of disease.  Infection with 
HDV in a person with chronic hepatitis B may be misdiagnosed as a worsening of hepatitis B.  One quarter 
to one half of fulminant cases of hepatitis B (those that are rapidly fatal) are associated with concurrent 
infection with HDV.   
 
Onset: is usually sudden. 
 
Complications: of hepatitis D are the same as that of hepatitis B.  Infection can lead to rapid death from 
liver cell necrosis or the infection can become chronic, leaving the person a carrier of disease and may 
lead to cirrhosis of the liver or liver cancer.  
 
C. Reservoirs 
Humans are the only reservoir.  
 
D. Modes of Transmission 
Hepatitis D is usually spread though exposure to blood or serous fluids, often by contaminated needles or 
syringes, or by use of contaminated plasma derivatives such as clotting factor.  The virus can also be 
spread sexually. 
 
E. Incubation period 
Approximately 2 to 8 weeks. 
 
F. Period of Communicability or Infectious Period 
Blood is potentially contagious during all phases of active HDV infection.  Peak infectivity is probably just 
before onset of symptoms.   
 
G. Epidemiology 
 Iowa Dept. of Public Health  Reviewed  7/15  Hepatitis D 1 
 
The disease is present worldwide but the prevalence of HDV infection varies widely.  It is estimated that 
10 million people are jointly infected with HDV and HBV.  It is found in populations where hepatitis B is 
endemic.  
  
H. Bioterrorism Potential 
None. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To identify sources and sites of transmission and to prevent spread from those sources. 
• To ensure identification of infected pregnant women and to prevent perinatal transmission to their 
babies. 
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider must 
report. The preferred reporting method is through the Iowa Disease Surveillance System (IDSS). The 
reporting phone number for IDPH Center for Acute Disease Epidemiology (CADE) is (800) 362-2736; fax 
number (515) 281-5698, mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
Des Moines, IA 50319-0075 
 
Postage-paid disease reporting forms are available free of charge from the IDPH clearinghouse.   
Call (319) 398-5133 or visit the website: 
healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295 to request a supply. 
 
Laboratory Testing Services Available 
The University of Iowa State Hygienic Laboratory (SHL) can refer serum specimens for Hepatitis D virus 
testing. Information about date of collection, date of onset of symptoms, travel history, vaccination and 
disease history are essential for test interpretation. For additional information on submitting samples or 
testing, contact the SHL at (319) 335-4500 or visit: www.shl.uiowa.edu/  
 
C.  Local Public Health Agency Follow-up Responsibilities 
Case Investigation 
 
1. If case has not previously been diagnosed with hepatitis B, see the description of hepatitis B for full 
information on case investigation. 
2. Laboratory confirmation of hepatitis D infection requires anti-HepD to be positive as well as HBsAg or 
IgM anti-HBc positive. In most persons with HBV-HDV co-infection, both IgM antibody to HDV (anti-
HDV) and IgG anti-HDV are detectable during the course of infection. However, in about 15% of 
patients the only evidence of HDV infection may be the detection of either IgM anti-HDV alone during 
the early acute period of illness or IgG anti-HDV alone during convalescence. Tests for IgM anti-HDV, 
HDAg and HDV RNA by PCR are only available in research laboratories 
3. For all suspected or confirmed cases of hepatitis D, complete the Hepatitis B/C case investigation in 
IDSS.   
4. If several attempts have been made to obtain case information, but have been unsuccessful (e.g., the 
case or healthcare provider does not return calls or respond to a letter, or the case refuses to divulge 
information or is too ill to be interviewed), please fill out the form in IDSS with as much information as 
has been gathered. Select the appropriate reason under the Event tab in the Event Exception field.  
5. If access to IDSS is not possible, please FAX the form to CADE at (515) 281-5698. 
6. Institution of disease control measures is an integral part of case investigation. It is the responsibility 
of the local public health agency to understand, and, if necessary, institute the control guidelines 
listed below.  These are more fully outlined in the hepatitis B section. 
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3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements 
Same as hepatitis B:  No exclusion of cases is required except for exclusion from organ and blood 
donation and counseling to prevent transmission.  
 
B.  Protection of Contacts of a Case 
See recommendations for hepatitis B.  Preventing infection with hepatitis B will prevent hepatitis D for 
those not infected with hepatitis B. Administration of hepatitis B immune globulin (HBIG) and hepatitis B 
vaccine will not protect against hepatitis D in those already infected with hepatitis B. 
  
C.  Managing Special Situations 
1.  Percutaneous or permucosal exposure to Hepatitis B and D virus 
Follow guidelines for postexposure prophylaxis for hepatitis B in hepatitis B section.   
 
2.  Reported Incidence Is Higher than Usual/Outbreak Suspected 
If the number of reported cases in your local area is higher than usual, or an outbreak is suspected, 
investigate clustered cases to determine source of infection.  If evidence indicates a common source, 
appropriate control measures should be instituted.  Consult with the epidemiologist on call at CADE at 
(800) 362-2736 for assistance in investigation and control measures. 
  
D. Preventive Measures 
The best way to prevent HDV infection is to prevent infection with hepatitis B.  Immunization with 
hepatitis B vaccine will also prevent infection with hepatitis D if a person is not already infected with 
hepatitis B.  The only way to prevent HDV infection for those already infected with hepatitis B is to avoid 
contact with blood and serous fluid, to never share needles for drug use, ear piercing, tattooing or other 
purpose, and to use condoms when having sex.  The use of hepatitis B immune globulin, (HBIG), immune 
globulin (IG) or hepatitis B vaccine will not protect people against hepatitis D in those who are infected 
with chronic hepatitis B infection. 
 
See hepatitis B section for information on immunization against hepatitis B.  
 
4) ADDITIONAL INFORMATION 
 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Hepatitis D can 
be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria in 
this chapter. (CSTE case definitions are used by the state health department and the CDC to maintain 
uniform standards for national reporting.)  
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FACT SHEET                                                   HEPATITIS D 
(Viral hepatitis D, Hepatitis delta virus, Delta agent hepatitis, Delta associated 
hepatitis) 
  
What is hepatitis D? 
Hepatitis D is a virus that infects the liver.  Hepatitis D, or Delta hepatitis, is always associated with a 
hepatitis B infection.  A person may recover from Delta hepatitis or it may progress to chronic hepatitis. 
  
Who gets hepatitis D? 
Hepatitis D can only occur if the person has hepatitis B.  Hepatitis D virus (HDV) and hepatitis B virus (HBV) 
may infect a person at the same time or HDV infection may occur in persons with chronic HBV infection.   
  
How is the virus spread? 
The hepatitis D virus is spread by exposure to blood and serous body fluids, contaminated needles and syringes, 
and via sexual transmission. 
  
What are the symptoms? 
Onset of hepatitis D is usually sudden.  Symptoms include tiredness, nausea, vomiting, fever, stomach pain, 
tea-colored urine, and yellowing of the skin and eyes (jaundice).  Hepatitis D infection in someone with chronic 
hepatitis B may be misdiagnosed as a worsening of chronic hepatitis B. 
  
How soon do the symptoms appear? 
Symptoms occur approximately 2 - 8 weeks after infection. 
  
How long can an infected person spread the virus? 
A person can spread the virus as long as it remains in their blood.  The highest risk of exposure occurs just 
before the onset of acute illness. 
  
How is hepatitis D diagnosed? 
A blood test is used to detect infection with the hepatitis D virus. 
  
Can a person get hepatitis D again? 
If antibodies develop, one infection with the hepatitis D virus protects a person from getting it again.  Since 
there are different kinds of hepatitis, infection with hepatitis D will not stop a person from getting other types of 
hepatitis. 
  
What is the treatment for hepatitis D?            
There is no specific treatment that can make the infection go away.  People who are sick with hepatitis D should 
see a doctor for advice about how to control their symptoms. 
  
What can be done if a person comes into contact with someone infected with hepatitis D? 
If the person does not have hepatitis B, they will not get hepatitis D.  If the person has hepatitis B there is 
nothing that can be done to protect the person from hepatitis D.  Hepatitis B immune globulin (HBIG), immune 
globulin (IG) and hepatitis B vaccine do not protect hepatitis B carriers from infection by HDV. 
  
How can infection with hepatitis D be prevented? 
Never share needles for drug use, ear piercing, tattooing, or any other purpose.  Avoid contact with the blood or 
wound drainage of any other person.  Use condoms when having sex. 
  
Is there a vaccine to prevent hepatitis D? 
Yes, there is a vaccine to protect against hepatitis D.  For those persons not previously infected with hepatitis B 
the hepatitis B vaccine will protect them.  This works by protecting against hepatitis B, which in turn protects 
against HDV.  Protection is given because only people infected with hepatitis B virus can become infected with 
hepatitis D virus. 
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Hepatitis E                    Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider title: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes   No  Unk To whom: ______________  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 Blood/serum 
 Other       
 
Result date: 
 
     /     /      
 
Result type: 
 
 Preliminary      Final 
 
Test type: 
 
 Result:  Positive 
 
Organism: 
 
Hepatitis E virus  
   Negative  Not done 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 Blood/serum 
 Other       
 
Result date: 
 
     /     /      
 
Result type: 
 
 Preliminary      Final 
 
Test type: 
 
 Result:  Positive 
 
Organism: 
 
Hepatitis E virus  
   Negative  Not done 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 Blood/serum 
 Other       
 
Result date: 
 
     /     /      
 
Result type: 
 
 Preliminary      Final 
 
Test type: 
 
 Result:  Positive 
 
Organism: 
 
Hepatitis E virus  
   Negative  Not done 
 
 
 
  
Center for Acute Disease Epidemiology                                            Fax: 515-281-5698                                         Hepatitis E               Revised Mar-15    1 
CONFIDENTIAL PATIENT NAME: ______________________________                           Iowa Department of Public Health 
EXPOSURE PERIOD COMMUNICABLE PERIOD 
 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
 
Jaundice:  Yes    No    Unk 
Onset 
date: 
 
     /     /      
Date 
resolved:      /     /      
 
Dark urine:  Yes    No    Unk 
Onset 
date: 
 
     /     /      
Date 
resolved:      /     /      
 
Diarrhea:  Yes    No    Unk 
Onset 
date: 
 
     /     /      
Date 
resolved:      /     /      
Other symptoms:  Abdominal pain  Anorexia 
 Fever 
 Malaise  Nausea 
Testing reason: 
 
 Elevated liver enzymes 
 Exposure to risk factor associated with hepatitis A 
 Exposure to someone with confirmed hepatitis A 
 
 Symptoms of disease other than elevated liver enzymes 
 Testing for immunity to hepatitis A 
ALT performed?  Yes    No    Unk 
Result (in 
IU/l): 
 
      
Expected min (in 
IU/l): 
 
      
Expected max in 
IU/): 
 
      
AST performed?  Yes    No    Unk 
Result (in 
IU/l): 
 
      
Expected min (in 
IU/l): 
 
      
Expected max in 
IU/): 
 
      
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
 
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation period for 
hepatitis A is 15-50 
days; average of 28-30 
days. 
Hepatitis A is communicable 1 
week prior to the onset of 
symptoms to 7-10 days after onset.  
Center for Acute Disease Epidemiology                                            Fax: 515-281-5698                                       Hepatitis E               Revised Mar-15      2 
CONFIDENTIAL PATIENT NAME: ______________________________                           Iowa Department of Public Health 
RISK FACTORS/TRAVEL 
 
Vaccinated for hepatitis A?  Yes    No    Unknown 
  
Date vaccinated: 
 
     /     /      
  
Date vaccinated: 
 
     /     /      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
 
Number of vaccinations:       
THER LABORATORY FINDING 
In the 50 days prior to the onset of the symptoms did the case: 
Travel within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Travel within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Travel outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
Visit restaurants?  Yes    No    Unknown 
If Yes, complete the table below:    
Establishment name Address/Zip Date visited Foods consumed Others ill? 
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
 
Attend Group Gatherings?  Yes    No    Unknown 
If Yes, complete the following table: 
Location of gathering Address/Zip Date visited Foods consumed Others ill? 
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
 
Dietary Information – In the 50 days prior to onset of symptoms did the case consume: 
Raw shellfish:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       
List all brand 
names:       
Unpasteurized 
Mexican-style cheese:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       
List all brand 
names:       
Other unpasteurized 
products:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       
List all brand 
names:       
Raw fruits:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       
List all brand 
names:       
Raw vegetables:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       
List all brand 
names:       
Other Exposures – In the 50 days prior to the onset of symptoms did the case: 
Wear diapers:  Yes    No    Unk Have contact with diapers:  Yes    No    Unknown 
    
 Do street drugs or inject steroids:  Yes    No    Unk  
     
Have sex with someone with similar symptoms:  Yes    No    Unk Sexual preference:  Hetero  Homo 
 Bisexual 
 Unknown 
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Number of people living in case’s household:          Close contacts with the case and/or same exposures?      Yes    No    Unk 
 
Close contacts of case or close contacts with same exposures 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
Same 
exposures 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
      
 
     /     /      
 Restaurant    
 Gatherings   
 Food 
 Animal 
 Water 
 
 Yes 
 No 
      
      
If this contact is a case create a new event and/or case for this contact. 
Documented history of 
hepatitis A/E disease?  Yes    No    Unk 
Im
m
un
e 
gl
o
b
ul
in
 
Contact wt:       
H
ep
 A
 v
ac
ci
n
e 
Date 
vaccinated:      /     /      
Received IG within 14 
days of exposure?   Yes    No    Unk Date given:      /     /      
Vaccine 
manufacturer:       
Previously vaccinated for 
hepatitis A?   Yes    No    Unk Dose:       Unit:       Vaccine type:       
Vaccinated for hepatitis A 
w/in 14 days of exposure?  Yes    No    Unk Route:       
Number of 
vaccinations:       
 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
Same 
exposures 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
      
 
     /     /      
 Restaurant    
 Gatherings   
 Food 
 Animal 
 Water 
 
 Yes 
 No 
      
      
If this contact is a case create a new event and/or case for this contact. 
Documented history of 
hepatitis A/E disease?  Yes    No    Unk 
Im
m
un
e 
gl
o
b
ul
in
 
Contact wt:       
H
ep
 A
 v
ac
ci
n
e 
Date 
vaccinated:      /     /      
Received IG within 14 
days of exposure?   Yes    No    Unk Date given:      /     /      
Vaccine 
manufacturer:       
Previously vaccinated for 
hepatitis A?   Yes    No    Unk Dose:       Unit:       Vaccine type:       
Vaccinated for hepatitis A 
w/in 14 days of exposure?  Yes    No    Unk Route:       
Number of 
vaccinations:       
 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
Same 
exposures 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
      
 
     /     /      
 Restaurant    
 Gatherings   
 Food 
 Animal 
 Water 
 
 Yes 
 No 
      
      
If this contact is a case create a new event and/or case for this contact. 
Documented history of 
hepatitis A/E disease?  Yes    No    Unk 
Im
m
un
e 
gl
o
b
ul
in
 
Contact wt:       
H
ep
 A
 v
ac
ci
n
e 
Date 
vaccinated:      /     /      
Received IG within 14 
days of exposure?   Yes    No    Unk Date given:      /     /      
Vaccine 
manufacturer:       
Previously vaccinated for 
hepatitis A?   Yes    No    Unk Dose:       Unit:       Vaccine type:       
Vaccinated for hepatitis A 
w/in 14 days of exposure?  Yes    No    Unk Route:       
Number of 
vaccinations:       
 
CONTACTS 
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HEPATITIS E 
 
Also known as: Viral hepatitis E, Enteric non-A non –B hepatitis, “A-like” non-A non-
B hepatitis 
 
Responsibilities: 
Hospital: Report by IDSS, facsimile, mail, or phone  
Lab: Report by IDSS, facsimile, mail, or phone 
Physician: Report by facsimile, mail, or phone 
Local Public Health Agency (LPHA): Follow-up required 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736  
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Hepatitis E virus (HEV) is a spherical, nonenveloped, single-stranded RNA virus.  It is classified in the 
Heperviridae family. 
 
B. Clinical Description 
Symptoms:  Signs and symptoms resemble hepatitis A.  These symptoms include fever, malaise, 
anorexia, nausea and abdominal pain followed by jaundice.  The severity can range from a mild 
illness lasting 1 - 2 weeks to severe disease lasting several months.  It has a relatively low case-
fatality rate (≤4%), which increases with age.  Unlike hepatitis A, the fatality rate in pregnant women 
can be 10-30%, particularly those in their third trimester. 
 
Onset is usually sudden. 
 
Complications of hepatitis E are uncommon. There is no evidence of a chronic form.  
 
C. Reservoirs 
Humans are the only known reservoir, however, domestic animals, including pigs, may be a reservoir.   
 
D. Modes of Transmission 
Hepatitis E is usually spread through the fecal-oral route. Contaminated water is the most commonly 
documented route.  Fecal-oral transmission probably also occurs person to person.  Recent studies 
show that hepatitis E may be a zoonotic infection.  
 
E. Incubation period 
The range is 15 - 64 days; mean incubation period has ranged from 26 - 42 days in recent outbreaks. 
 
F. Period of Communicability or Infectious Period 
This period is unknown.  HEV has been detected in stool 14 days after onset of jaundice, and 4 
weeks after ingestion of contaminated food or water, persisting for 2 weeks.   
 
G. Epidemiology 
Outbreaks and sporadic cases have occurred over a wide geographic area, primarily in countries with 
poor sanitation.  Highest rates of disease occur in young to middle-aged adults; younger age groups 
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may have disease without jaundice or be asymptomatic.  Hepatitis E is believed to be uncommon in 
the United States. When HEV infection does occur, it is usually the result of travel to a developing 
country where Hepatitis E is endemic. 
 
H. Bioterrorism Potential 
None. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To identify sources and sites of transmission and to prevent spread from those sources. 
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report. The preferred method of reporting is by utilizing the Iowa Disease Surveillance System 
(IDSS).  However, if IDSS is not available, the reporting number for IDPH Center for Acute Disease 
Epidemiology (CADE) is (800) 362-2736; fax number (515), 281-5698, mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
Des Moines, IA 50319-0075 
 
Laboratory Testing Services Available 
The University of Iowa State Hygienic Laboratory (SHL) can refer serum specimens for Hepatitis E 
virus testing. Accurate information about date of collection, date of onset of symptoms, travel history, 
vaccination and disease history are essential for test interpretation. For additional information on 
submitting samples or testing, contact the State Hygienic Laboratory at (319) 335-4500. 
 
C.  Local Public Health Agency Follow-up Responsibilities 
Case Investigation 
 
1. Verify the diagnosis. 
a. Diagnosis of hepatitis E requires clinical illness similar to viral hepatitis A (elevated liver 
enzymes and or jaundice or dark urine plus at least 2 other symptoms including nausea, 
vomiting, fever, diarrhea, or malaise with abrupt onset). 
AND  
b. A history of travel out of the country to an underdeveloped country or a country known 
to have endemic or epidemic hepatitis E. 
AND 
c. The patient is not known or suspected of having risk factors for hepatitis B or C. 
AND  
d. The hepatitis lab profile is negative for anti HAV-IgM, negative for HBsAg and if 
performed, negative for anti-HCV.   
2. For all cases of hepatitis E, complete the Hepatitis E Case Investigation form in IDSS.   
3. If several attempts have been made to obtain case information, but have been unsuccessful 
(e.g., the case or healthcare provider does not return calls or respond to a letter, or the case 
refuses to divulge information or is too ill to be interviewed), please fill out the form with as 
much information as possible.  Select the appropriate reason under the Event tab in the Event 
Exception field. 
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4. Complete the IDSS case investigation form. If IDSS is unavailable after completing the form, 
place the form in an envelope marked “Confidential” to the Center for Acute Disease 
Epidemiology.  The mailing address is:  
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th Street 
Des Moines, IA 50319-0075 
5. Make appropriate recommendations for preventing the spread of illness.  See below. 
 
3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements 
Same as hepatitis A. Enteric precautions should be used until 2 weeks following onset of jaundice.    
 
B.  Protection of Contacts of a Case 
Immune globulin is not effective for protecting household or close contacts.  Persons with hepatitis E 
should not prepare foods for others for 14 days after onset of jaundice.  
  
C.  Managing Special Situations 
If the case is a food handler, child care or healthcare provider, or has potentially exposed a group of 
individuals in a setting where good hygiene might be questionable, such as on a camping trip, 
contact CADE (800) 362-2736 immediately for advice.     
 
D. Preventive Measures 
The best way to prevent hepatitis E is to prevent exposure to contaminated water or other sources of 
fecal contamination when traveling to endemic areas.  The use of immune globulin prepared from 
donors from the United States or Europe is not likely to provide protection from infection 
 
4) ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Hepatitis 
E can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
 
References  
American Academy of Pediatrics. 2006 Red Book: Report of the Committee on Infectious Diseases, 
27th Edition. Illinois, American Academy of Pediatrics, 2006. 
CDC Website:  www.cdc.gov/hepatitis/ChooseE.htm  
Heymann, D.L., ed. Control of Communicable Diseases Manual, 19th Edition. Washington, DC, 
American Public Health Association, 2008. 
 
Additional Resources 
www.cdc.gov/ncidod/diseases/hepatitis/ 
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What is Hepatitis E? 
Hepatitis E (HEV) is a liver disease caused by the hepatitis E virus (HEV). Hepatitis E, however, does not 
occur often in the United States. 
 
Who is at risk for Hepatitis E? 
Mostly people who travel to developing countries that have inadequate environmental sanitation. 
 
How do you get Hepatitis E? 
HEV is transmitted primarily by the fecal-oral route. Fecally contaminated drinking water is the most 
commonly documented method of transmission. 
 
How long can an infected person spread the virus? 
Not known.  It is believed to be up to 2 weeks. 
 
What are the symptoms of Hepatitis E? 
Typical symptoms of acute hepatitis E include abdominal pain, anorexia, dark urine, fever, enlarged liver, 
jaundice, tiredness, nausea, and vomiting. 
 
How soon do the symptoms appear? 
Symptoms can appear between 15 – 64 days after infection. 
  
How is hepatitis E diagnosed? 
Specific blood tests are needed to diagnosis hepatitis E. 
 
Can a person get hepatitis E again? 
This is unknown at this time. 
 
What is the treatment for hepatitis E?  
Supportive care only.   The person usually gets well without treatment.        
  
Is there a vaccine to prevent hepatitis E? 
No 
 
How can Hepatitis E be prevented? 
Travelers to areas where HEV is found should drink only bottled or boiled water or carbonated (bubbly) 
drinks in cans or bottles.  Avoid tap water, fountain drinks, and ice cubes if water purity is unknown.  Also 
avoid uncooked shellfish, and uncooked fruit/vegetables not peeled or prepared by traveler. 
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Human Immunodeficiency Virus 
(HIV) 
 
Also known as:  HIV/AIDS, Acquired Immune Deficiency Syndrome (AIDS) 
 
Responsibilities: 
Hospital: Report cases, deaths of persons with HIV/AIDS, and births by HIV-infected women 
by mail or phone 
Lab: Report results of positive HIV detection tests, cultures, viral loads (any level, including less 
than the detectable limits of the test), and CD4+ cell counts (any level) by mail or secure 
electronic transmission. 
Physician: Report all new patients and HIV diagnoses, AIDS diagnoses, and deaths of persons 
with HIV/AIDS (from any cause) by mail or phone. 
Local Public Health Agency (LPHA): Follow-up generally not required 
 
Iowa Department of Public Health 
HIV Reporting:  (515) 242-5141 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
The human immunodeficiency virus is an RNA retrovirus of the lentivirus subgroup, meaning that it 
contains RNA as its inner core of nucleic acid.  Two types of HIV have been identified: type 1 (HIV-1) 
and type 2 (HIV-2).  Although the two types are distinct, they produce similar symptoms and disease.  
Type 1 predominates in the United States, and it is the most pathogenic.  HIV targets and destroys 
CD4+ T-lymphocyte (helper or T4) cells, leaving a person vulnerable to attack by other organisms 
and agents, including cancer.  Acquired Immune Deficiency Syndrome (AIDS) indicates the late 
manifestation of HIV infection, in which severe immunosuppression is present.  A diagnosis of AIDS 
occurs when the CD4+ cell count falls below 200 cells/microliter or 14% of total lymphocytes, or 
when one of 26 indicator diseases is diagnosed.   
 
B. Clinical Description 
Symptoms: of recent HIV infection, called acute retroviral syndrome, are present in 80 – 90% of 
people with primary HIV infection.  The syndrome is characterized by flu-like symptoms that may 
include fever, malaise, lymphadenopathy, pharyngitis, headache, night sweats, myalgia, and rash. 
These may last for 1-2 weeks. Symptoms of advanced HIV disease are variable but may include 
wasting, candidiasis, persistent generalized lymphadenopathy, pneumococcal and other bacterial 
pneumonia, Kaposi’s sarcoma, and oral hairy leukoplakia.  
 
Onset: of acute retroviral syndrome occurs 2 – 3 weeks after viral transmission, with seroconversion 
and recovery occurring shortly thereafter.  Symptoms of advanced disease occur, on average, 8 – 10 
years after infection (without treatment), but this may range from a few months to over 15 years.  
 
Advanced disease: includes increased risk of opportunistic infections and conditions, including active 
tuberculosis, Pneumocystis jiroveci (formerly P. carinii) pneumonia, cervical cancer, B-cell lymphoma, 
disseminated histoplasmosis and coccidioidomycosis, and progressive multifocal 
leukoencephalopathy.  Co-infection with other sexually transmitted diseases or viral hepatitis can 
substantially alter the course of the illness, shortening the time to diagnosis of AIDS. 
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C. Reservoirs 
Common reservoirs: Humans are the only known reservoir. 
 
D. Modes of Transmission 
Spread is person to person through sexual contact; the sharing of HIV-contaminated needles, 
syringes, and injection paraphernalia; transfusion of infected blood or its components; transplantation 
of infected tissues or organs; or breastfeeding.  Infants may become infected before, during, or after 
birth to an infected mother.  Less than one-fourth of infants carried by infected mothers become 
infected.  With treatment of the mother and newborn infant, this can be lowered considerably.  HIV is 
not transmitted by casual contact, kissing, mosquitoes, or items in the environment.   
 
E. Incubation period 
The incubation period is highly variable.  Antibodies can generally be detected 3 weeks to 3 months 
after infection.  Without effective treatment, approximately 50% of infected adults will develop AIDS 
within 10 years.  The incubation time for infants is shorter than in adults. 
 
F. Period of Communicability or Infectious Period 
The period of communicability begins shortly after transmission and continues throughout life.  
Epidemiological studies indicate that transmission potential is highest shortly after infection and 
during late stages of disease.  The presence of other STDs can increase infectiousness.   
 
G. Epidemiology 
In 2013, CDC estimates that 1.2 million people are living with HIV infection and 1 in 6 people are 
unaware they are infected. By the end of 2012, over 1.1 million AIDS cases and over 636,000 deaths 
among persons with AIDS had been reported to CDC for the United States and its dependent areas.  
HIV infection (without an AIDS diagnosis) is now reportable by name in all 50 states.  CDC estimates 
that approximately 50,000 persons become infected with HIV in the United States each year, and this 
has been relatively stable since 1990.  Globally, 35.3 million people were living with HIV/AIDS in 2012 
and approximately 2.3 million people become newly infected with HIV each year.  
 
Iowa averages approximately 115 HIV diagnoses and 75 AIDS diagnoses per year. For additional 
information, visit: www.idph.state.ia.us/HivStdHep/HIV-AIDS.aspx?prog=Hiv&pg=HivSurv    
 
H. Bioterrorism Potential 
None. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To monitor trends in HIV diagnoses, AIDS diagnoses, and prevalence of persons living with 
HIV/AIDS so that prevention and treatment funds may be targeted efficiently and prevention 
programs may be evaluated. 
• To interrupt disease transmission chains by providing partner counseling and testing. 
• To assure referral services for persons recently diagnosed with HIV infection. 
• To monitor perinatal exposures to HIV infection and morbidity in infants born to HIV-infected 
women. 
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Reportable conditions indicative of HIV infection include:  
• Confirmed positive results on any HIV diagnostic test, including antibody tests, antigen tests, 
cultures, and qualitative polymerase chain reaction (PCR) tests.  
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• All levels of quantitative tests (viral loads), including RT-PCR, branched chain DNA, and 
NASBA viral load assays.  Results less than the detectable limit of the test should be 
reported. 
• Acquired Immune Deficiency Syndrome (AIDS) and AIDS-defining conditions. 
• All levels of CD4+ T-lymphocyte cell counts.  Values for the absolute count and the 
percentage of total lymphocytes should be included. 
• Birth of an infant to an HIV-infected mother (perinatal exposure) or any (positive, negative, or 
undetectable) non-antibody detection test (antigen test, viral culture, viral load, or qualitative 
PCR detection test) on an infant less than or equal to 18 months of age.  These are tests 
indicative of perinatal exposures.  Negative antibody tests (EIA, immunofluorescence, or 
Western blot) should not be reported. 
• Death of a person with HIV/AIDS, from any cause. 
 
Physicians or other healthcare providers must report cases within 7 days of a positive HIV test; 
diagnosis of HIV, AIDS, or AIDS-defining conditions; or upon first examination or treatment for 
HIV/AIDS (for new patients who have been previously diagnosed elsewhere).  Hospitals or care 
providers should report births of infants to HIV-infected women (i.e., perinatal exposures). 
 
Patient demographics, laboratory information, and patient history should be reported on form CDC 
50.42A for adults and adolescents (≥ 13 years of age) and form CDC 50.42B for pediatric HIV or AIDS 
cases and perinatal exposures to HIV.  Case report forms may be obtained from the HIV/AIDS Program 
at (515) 242-5141.   
 
Laboratory personnel should forward results of tests directly to the Iowa Department of Public 
Health.  Optional, postage-paid envelopes are available at the Clearinghouse. Request “03” envelopes 
at (319-398-5133) or send reports to the address below.  
 
 Case report forms and laboratory results may be addressed directly to: 
 Iowa Department of Public Health    
 Bureau of HIV, STD and Hepatitis (03) Confidential    
321 East 12th Street  
Des Moines, IA   50319-0075 
 
C.  Local Public Health Agency Follow-up Responsibilities 
Case Investigation 
Partner notification and referral services will be provided by disease prevention specialists employed 
by the Iowa Department of Public Health, or by Black Hawk, Linn, Polk, or Scott county health 
departments. 
 
3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements 
None. 
 
B. Protection of Contacts of a Case 
To protect future contacts, all cases receive education on prevention of further spread. 
 
The Iowa Department of Public Health will initiate the voluntary partner notification program for all 
persons who are newly diagnosed with HIV infection.  Healthcare providers can facilitate this process 
by describing the program to the patient, providing the patient with the department’s brochure 
entitled, “Partner/Spousal Notification for HIV/AIDS,” and encouraging the patient to meet with the 
department’s disease prevention specialist assigned to his or her region. 
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Patients’ names and times of exposures are not used in the notification of partners.  HIV testing is 
offered to all partners free of charge and appropriate referrals to other services are provided during 
the partner counseling sessions. Partner notification brochures are available in English and Spanish 
from the Clearinghouse at (319) 398-5133. 
 
Physicians may assist the disease prevention specialists with the collection of partner notification 
information.  In such cases, the physician should collect the following information:  Partner name, 
address, home phone number, age and/or date of birth, race, sex, partner/marital status, height, 
size/build, general description of the partner, and dates of first and last exposure.  Any other 
information that may help in locating and counseling the partner may also be included, such as 
medical conditions, place of employment, cell phone numbers, or other unusual 
circumstances/situations. 
 
Iowa code also allows for direct notification of an identifiable sexual or needle-sharing partner when 
the partner is deemed to be in imminent danger of infection and the HIV-infected client will not agree 
to participate in voluntary partner notification.  Healthcare providers may contact the HIV/AIDS 
Program’s surveillance office (515-242-5141) for more information or to request assistance with 
partner notification or the direct notification of a third party.  Physicians may also notify identifiable 
third parties directly.  The Iowa Administrative Code 641-11.18 outlines procedures for direct 
notification by physicians. 
 
C. Managing Special Situations 
Occupational Exposures in Non-clinical Settings 
If a care provider (including EMT, fire fighters, peace officers, and volunteers) sustains a significant 
exposure to blood or other potentially infectious fluids from an individual, that individual is deemed to 
consent to a test to determine the presence of HIV infection (or other infectious blood-borne 
pathogens) upon certification of a Report of Exposure to HIV or Other Infectious Disease form [See 
Iowa Code 139A.19 and Iowa Administrative Code 641-11.21 to 11.26].  The individual is also 
deemed to consent to notification of the care provider of the test results.  These consents are 
contingent upon submission of a significant exposure report by the care provider and its certification 
by an infection preventionist or physician.  [Significant exposure report forms are available from the 
Clearinghouse at (319) 398-5133]. 
 
The hospital or clinic to which the individual was delivered shall conduct the testing.  If the individual 
is delivered to an institution administered by the Iowa Department of Corrections, testing shall be 
conducted by the staff physician of the institution.  If the individual is delivered to jail, testing shall 
be conducted by the attending physician of the jail or the county medical examiner.  The sample and 
test results shall only be identified by a number. 
 
If the test results are positive, the hospital or other person performing the test shall notify the 
subject of the test and ensure the performance of counseling and reporting requirements in the same 
manner as for an individual from whom consent was obtained.  The report to the department shall 
include the name of the individual tested along with other required demographic information.  The 
hospital or other person performing the test shall notify the care provider or the designated 
representative of the care provider who shall then notify the care provider who sustained the 
exposure. 
 
Occupational Exposures in Clinical Settings 
 
If a care provider sustains a significant exposure to blood or other potentially infectious fluids from an 
adult patient in a clinical setting (including home-health settings), a previously signed general 
consent for medical care shall include testing to determine the presence of HIV (or other infectious 
blood-borne pathogens) and notification of the care provider of the test results. Minors should be 
handled in the same way as an exposure that occurred in a non-clinical setting (see above).  The 
adult patient shall be informed of the exposure and of the test(s) performed.  
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If the test results are positive, the hospital or other person performing the test shall notify the adult 
patient of the results and ensure the performance of counseling and reporting requirements in the 
same manner as for an individual from whom consent was obtained.  The report to the department 
shall include the name of the individual tested along with other required demographic information.  
The hospital or other person performing the test shall notify the care provider or the designated 
representative of the care provider who shall then notify the care provider who sustained the 
exposure.   
 
Information on post-exposure prophylaxis protocols is available 24 hours a day at the National 
Clinicians’ Post-Exposure Prophylaxis Hotline at (888) 448-4911.  
 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
Report to the Iowa Department of Public Health at (515) 242-5141. 
  
D. Preventive Measures 
Preventive Measures/Education (Iowa Code 141A.4) 
Testing and education shall be offered to all persons who are at risk for HIV infection.  Risk factors 
include male-to-male sex; injection drug use; testing positive for an STD; exchange of sex for money 
or drugs; blood transfusion before 1986; immigration from a high-incidence country; or having a sex 
partner who is HIV positive or who is in one of the previous risk groups.   
 
All pregnant women shall be tested for HIV infection as part of the routine panel of prenatal tests.  A 
pregnant woman shall be notified that HIV screening is recommended for all prenatal patients and 
that the she will receive an HIV test as part of the routine panel of prenatal tests unless she declines 
the test.  A declination shall be documented in her medical record.  Information about HIV 
prevention, risk reduction, and treatment opportunities to reduce the possible transmission of HIV to 
the fetus shall be made available to all pregnant women. 
 
Free HIV counseling, testing, and referral sites are available across the state for persons with risk 
factors. Visit: www.idph.state.ia.us/HivStdHep/HIV-AIDS.aspx?prog=Hiv&pg=HivPrev for a current 
list of places and times. 
 
Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women 
in Health-Care Settings 
The CDC issued revised recommendations for HIV testing in health care settings in September 2006.  
They recommend routine opt-out testing for HIV for all patients aged 13 to 64 years of age unless 
the prevalence of undiagnosed HIV infection in the patient population has been determined to be less 
than 0.1 percent (1 per 1,000 patients).  They also recommend that separate written consent for HIV 
testing should not be required; general consent for medical care should be considered sufficient.  The 
full recommendations can be found at: www.cdc.gov/mmwr/preview/mmwrhtml/rr5514a1.htm    
 
4) ADDITIONAL INFORMATION 
 
Consent and Education Requirements for HIV testing (Iowa Code 141A.6) 
Prior to undergoing an HIV test, information concerning testing and any means of obtaining 
additional information regarding HIV infection and risk reduction shall be made available to the 
subject of the test.   
 
Testing of Adults 
If an individual signs a general consent form for the performance of medical tests or procedures, the 
signing of an additional consent form for the specific purpose of consenting to an HIV-related test is 
not required during the time in which the general consent form is in effect.  If an individual has not 
signed a general consent form for the performance of medical tests and procedures or the consent 
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form is no longer in effect, a health care provider shall obtain oral or written consent prior to 
performing an HIV-related test.  If an individual is unable to provide consent, the individual’s legal 
guardian may provide consent.  If the individual’s legal guardian cannot be located or is unavailable, 
a health care provider may authorize the test when the test results are necessary for diagnostic 
purposes to provide appropriate urgent medical care. 
 
Testing of minors 
Minors have the legal capacity to act and give consent for diagnosis and treatment of sexually 
transmitted diseases, including HIV, without the consent of a parent, custodian, or guardian (see 
Iowa Code 139A.35). 
 
Before undergoing an HIV test, however, a minor must be informed that the legal guardian will be 
notified by the testing facility if the test is confirmed as positive.  Minors must give written consent 
for HIV testing and treatment services (see Iowa Code 141A.7 (3).  The consent form should indicate 
that the minor understands that his or her legal guardian will be notified if the test is confirmed as 
positive. 
 
Surveillance Case Definitions 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for HIV/AIDS 
can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
 
Iowa Epidemiological Profile of HIV/AIDS and Sexually Transmitted Diseases 
Visit: www.idph.state.ia.us/HivStdHep/HIV-AIDS.aspx?prog=Hiv&pg=HivSurv  
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Additional Resources 
HIV/AIDS Program web site, Iowa Department of Public Health.   
www.idph.state.ia.us/HivStdHep/HIV-AIDS.aspx?prog=Hiv&pg=HivHome  
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CONFIDENTIAL                                                                       Iowa Department of Public Health 
Novel Influenza A              Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis 
date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider title: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes   No  Unk To whom: ______________  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Influenza virus Subtype: 
 
        
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Influenza virus Subtype: 
 
        
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Influenza virus Subtype: 
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OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
Fever  Yes   Feverish, but temp not taken   No    Unk Highest known fever:        °F/C  
 
Cough  Yes    No    Unk Seizures  Yes    No    Unk 
Sore throat  Yes    No    Unk Headache  Yes    No    Unk 
Runny nose  Yes    No    Unk Shortness of breath  Yes    No    Unk 
Conjunctivitis  Yes    No    Unk Vomiting  Yes    No    Unk 
Diarrhea  Yes    No    Unk   
Other symptoms (specify)  
Other complications (specify)  
 
Was the patient admitted to the 
intensive care unit? 
 
 Yes    No    Unk 
Did the patient require mechanical 
ventilation?    Yes    No    Unk 
Did the patient have a chest x-ray 
or CAT scan performed?    Normal      Abnormal      Test not performed      Unknown 
If abnormal: Was there evidence of pneumonia?  Yes    No    Unk 
 Did this patient have acute 
respiratory distress syndrome?  Yes    No    Unk 
Did the patient handle samples (animal or human) suspected of containing 
influenza virus in a laboratory or other setting?  Yes    No    Unk 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
OTHER LAB FINDINGS 
 
Leukopenia 
(white blood cell count <5,000 leukocytes/mm3)  Yes    No    Unk 
Lymphopenia 
(total lymphocytes <800/mm3 or lymphocytes <15% of total WBC)  Yes    No    Unk 
Thrombocytpenia 
(total platelets <150,000/mm3)  Yes    No    Unk 
Were specimen sent to the Centers for Disease Control and Prevention (CDC)?  
Date sent Specimen type CDC Lab Specimen ID CDC (lab) unique ID 
    
    
    
    
 
 
TREATMENT 
 
Antivirals prescribed:   Yes    No    Unknown 
  
Antiviral:       
 
Antiviral:       
 
Antiviral:       
Date started:      /     /      Date started:      /     /      Date started:      /     /      
Discontinued:      /     /      Discontinued:      /     /      Discontinued:      /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
 
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Vaccinated with for SEASONAL influenza:  Yes    No    Unknown 
  
Date 
vaccinated: 
 
     /     /      
  
Date 
vaccinated: 
 
     /     /      
  
Date 
vaccinated: 
 
     /     /      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Vaccine: 
 
      
  
Vaccine: 
 
      
  
Vaccine: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
  
Type: 
 
 Inactivated 
 Live attenuated 
 Unknown 
  
Type: 
 
 Inactivated 
 Live attenuated 
 Unknown 
  
Type: 
 
 Inactivated 
 Live attenuated 
 Unknown 
 
 
Does the patient have any underlying medical conditions?  Yes    No    Unk 
If yes, please specify  
 
Is the patient immune compromised for reason such as HIV infection, cancer, chronic corticosteroid therapy, diabetes, or organ 
transplantation recipient?   Yes    No    Unk 
If yes to immune compromised specify reason:   
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation 
period for novel 
influenza A is up 
to 7 days.  
Novel influenza A is 
communicable 24 hours before the 
onset of symptoms to 7 days after 
OR until symptoms resolve, 
whichever is longer.   
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In the 7 days prior to the onset of symptoms did the case: 
Traveled within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
 
Has the patient had family members or close contacts with pneumonia or influenza-like illness?    Yes    No    Unk 
 
Did the patient have close contacts (within 6 feet of a person who is a suspect, probable, or confirmed Novel influenza A case with significant 
personal interaction (i.e. caring for, speaking to, or touching))?    Yes    No    Unk 
 
 
Number of people living in case’s household:          
 
Close contacts of the case (For more contacts, print/copy additional contact pages.)  
Name DOB Gender Address/Phone 
           /     /      
 Male 
 Female 
 
Zip code:                     Phone:         -         -         
 
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 Cough 
 Sore throat 
 Runny nose 
 Conjunctivitis 
 Diarrhea 
 Seizures 
 Headache 
 Shortness of 
breath 
 Vomiting 
 Other specify 
below 
     /     /      
 
 Yes 
 No 
 
 
Other symptoms: 
 
Name DOB Gender Address/Phone 
           /     /      
 Male 
 Female ________________________ Zip code:                     Phone:         -         -         
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 Cough 
 Sore throat 
 Runny nose 
 Conjunctivitis 
 Diarrhea 
 Seizures 
 Headache 
 Shortness of breath 
 Vomiting 
 Other specify below 
     /     /      
 
 Yes 
 No 
 
 
Other symptoms: 
 
Name DOB Gender Address/Phone 
           /     /      
 Male 
 Female ________________________ Zip code:                     Phone:         -         -         
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 Cough 
 Sore throat 
 Runny nose 
 Conjunctivitis 
 Diarrhea 
 Seizures 
 Headache 
 Shortness of breath 
 Vomiting 
 Other specify below 
     /     /      
 
 Yes 
 No 
 
 
Other symptoms: 
 
NOTES:       
 
 
 
 
 
CONTACTS 
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LEGIONELLOSIS 
 
Also known as:  Legionnaires’ disease 
 
Responsibilities: 
Hospital: Report by IDSS, facsimile, mail, or phone, follow-up required  
Lab: Report by IDSS, facsimile, mail, or phone  
Physician: Report by facsimile, mail, or phone  
Local Public Health Agency(LPHA): Follow-up required 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax:  (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Legionellosis is an infection caused by Legionella species, with Legionella pneumophila being the 
most common. Numerous serogroups are commonly recognized, although Legionella pneumophila 
serogroup 1 is most commonly associated with serious illness. 
 
B. Clinical Description 
Symptoms: Legionellosis has two distinct forms: Legionnaires’ disease, which is the more severe form 
of the infection, and Pontiac fever, which is milder. The most common initial symptoms for 
Legionnaires’ disease and Pontiac fever are anorexia, myalgia, malaise and headache. This is rapidly 
followed by fever (up to 102 − 105° F.), chills and a non-productive cough. Other symptoms may 
include abdominal pain and diarrhea. 
 
Onset: Can be rapid. 
 
Complications: Legionnaires’ disease is associated with pneumonia. The case-fatality rate overall is  
5% −30%. Pontiac fever is not associated with pneumonia or death and cases usually recover in  
2 - 5 days without treatment. Legionnaires’ disease usually cannot be distinguished from other forms 
of pneumonia and requires specific tests to confirm the diagnosis. 
 
C. Reservoirs 
Common reservoirs: Legionella species are commonly found in the environment. They have been 
found in many different kinds of water and water systems, such as hot and cold-water taps and 
showers, creeks, ponds, whirlpool spas, and cooling towers and evaporative condensers of large air-
conditioning systems. Outbreaks of legionellosis have been linked to these sources, as well as to 
decorative fountains, humidifiers, respiratory therapy devices and grocery store vegetable misters. 
These bacteria are most likely to reproduce in high numbers in warm, stagnant water, and its 
presence may be correlated with the presence of free-living amoeba. 
 
D. Modes of Transmission 
Airborne: Legionellosis is transmitted via the airborne route after inhalation of aerosols from water 
sources contaminated with the bacteria. There is no evidence to suggest transmission of Legionella 
from auto air-conditioners or household window air-conditioning units that do not use water as their 
coolant. 
 
Person-to-person: Legionellosis is not transmitted from person-to-person. 
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E. Incubation period 
The incubation period for Legionnaires’ disease is from 2 - 10 days, but most often 5 - 6 days.  
 
The incubation for Pontiac fever is from 5 - 72 hours, but most often 24 - 48 hours. 
 
F. Period of Communicability or Infectious Period 
Legionellosis is not communicable from person-to-person. Water sources may continue to spread 
Legionella organisms until corrective treatment is completed.    
 
G. Epidemiology 
Legionnaires’ disease was named after an outbreak that occurred in Philadelphia in 1976, among 
people attending a convention of the American Legion. Legionellosis has a worldwide distribution with 
cases reported from North America, Australia, Africa, South America and Europe. An estimated 8,000 
to 18,000 people develop Legionnaires’ disease in the United States each year. Most of these are 
single, isolated cases not associated with an outbreak. Outbreaks usually occur in the summer and 
fall, though cases occur year-round. Serologic surveys have shown a prevalence of antibodies to 
Legionella pneumophila serogroup 1 at a titer of >1:128 in 1−20% of the population, thus many 
infections go unnoticed. The illness most often affects older people and males, especially those who 
smoke or have chronic lung disease. Other risk factors include immunosuppressive therapy and 
immunosuppressive diseases, such as AIDS and diabetes. Legionella is estimated to be responsible 
for between 0.5% - 5% of cases of community-acquired pneumonias. 
  
H. Bioterrorism Potential 
None. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
To identify sources of public health concern (e.g., a contaminated water source) and to stop 
transmission from such a source. 
  
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report. The preferred reporting method is through the Iowa Disease Surveillance System 
(IDSS). The reporting phone number for IDPH Center for Acute Disease Epidemiology (CADE) is 
(800) 362-2736; fax number (515) 281-5698, mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
Des Moines, IA 50319-0075 
 
Postage-paid disease reporting forms are available free of charge from the IDPH clearinghouse.   
Call (319) 398-5133 or visit the website: 
healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295 to request a 
supply. 
 
Laboratory Testing Services Available 
The University of Iowa State Hygienic Laboratory (SHL) cultures and tests submitted sputum, 
bronchi-pharyngeal and environmental samples and referred bacterial cultures for Legionella 
pneumophila.  Clinical specimens and water should be shipped on wet ice in a sterile container.  
Cultures should be submitted on either CYE or chocolate agar.  Sampling kits can be obtained from 
the State Hygienic Laboratory.  For additional information regarding submitting samples or for further 
information, contact the SHL at (319) 335-4500, or visit: www.shl.uiowa.edu/  
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C.  Local Public Health Agency Follow-up Responsibilities 
Case Investigation: A case investigation should be performed for any diagnosed case of Legionellosis 
in Iowa. 
 
Case Investigation 
a. It is the local public health agency (LPHA) responsibility, in conjunction with the hospital 
infection preventionist, to complete an IDSS Legionellosis case investigation by interviewing the 
case and others who may be able to provide information. Much of the information required can 
be obtained from the case’s healthcare provider or the medical record. 
b. Use the following guidelines to assist in completing the IDSS investigation: 
1) Record the demographic information and occupation. 
2) Complete the “Clinical Info and Diagnosis” section, providing diagnosis, date of symptom 
onset, whether hospitalized (and associated dates) and outcome of disease. (One use of 
this section is to distinguish cases of Legionnaires’ disease from Pontiac fever, when 
possible [e.g., x-ray diagnosed pneumonia indicates Legionnaires’ disease]). The 
investigator may need to ask the healthcare provider to submit a copy of the medical record 
or enlist his/her aid in completing these sections of the case report form. 
3) Record the case’s exposures during the 2 weeks before illness onset. Ask questions about 
travel history in order to help identify where the patient became infected. 
4) Provide information regarding “Risk Factors” because legionellosis often affects people who 
have certain conditions or who smoke.  
5) If several attempts have been made to obtain case information, but have been unsuccessful 
(e.g., the case or healthcare provider does not return your calls or respond to a letter, or 
the case refuses to divulge information or is too ill to be interviewed), please indicate this in 
the Notes in IDSS. When using IDSS, select the appropriate reason under the Event tab in 
the Event Exception field. 
c. If not using IDSS, mail (in an envelope marked “Confidential”) to IDPH, Center for Acute 
Disease Epidemiology (CADE). The mailing address is:  
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th Street 
Des Moines, IA 50319-0075 
     d.    Institution of disease control measures is an integral part of case investigation. It is the LPHA   
responsibility to understand, and, if necessary, institute the control guidelines listed below in 
Section 3), Controlling Further Spread.    
 
3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements 
None. 
 
B.  Protection of Contacts of a Case 
None.  
 
C. Managing Special Situations 
 
Response to a Single Case of Community-Acquired Legionellosis  
One case of legionellosis does not require any further investigation other than completing the IDSS  
investigation. See Section 2) C, Case Investigation. Some people report that they must have gotten 
the infection from a particular place such as work or their places of worship or recreation. Since 
Legionella can be found in a wide variety of water sources at low levels, unless several cases occur 
that implicate a “source”, it is difficult to prove a particular source was the cause of illness. It is not 
recommended that a water source be tested or decontaminated based on one community-acquired 
case. 
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Response to Healthcare Associated Legionellosis  
A laboratory-confirmed case of legionellosis occurring in a patient hospitalized continuously for 
greater than 10 days before the onset of illness is considered a case of healthcare associated 
legionellosis. When a case of healthcare associated legionellosis occurs in a hospital or long-term care 
facility, the infection preventionist at the facility should enhance surveillance efforts for additional 
cases. If more cases are identified, measures should be taken to identify the source and eliminate the 
contamination. See Section 3) D below. Additionally, refer to the CDC Guidelines for Preventing 
Healthcare Associated Pneumonia, which are listed in the references section. 
       
Reported Incidence Is Higher than Usual/Outbreak Suspected 
If the number of reported cases in a particular city/town is higher than usual, or if an outbreak is 
suspected, investigate clustered cases in the area or institution to determine possible sources of 
infection. A source of infection could be a cooling tower, decorative fountain, whirlpool spa, grocery 
store mister, etc. If the investigation indicates a common source, testing of water samples should be 
done and applicable preventive or control measures should be instituted. Testing water sources is a 
specialized procedure and will require the assistance of environmental professionals. A confirmed 
source should be cleaned and decontaminated according to established protocols and a schedule of 
continued testing must be put in place for a period of time determined on a case-by-case basis. 
Consult with a CADE epidemiologist at (800) 362-2736 for assistance in investigating, testing, and 
implementing control measures.  CADE can also perform surveillance for cases regionally that may be 
difficult to identify at a local level. 
 
D.   Preventive Measures/Education 
To avoid future exposures: 
• Cooling towers should be drained when not in use and mechanically cleaned and 
maintained according to the manufacturer’s recommendations. 
• Tap water should not be used in respiratory therapy devices. 
• Hotels, cruise ships and other owners of whirlpool spas and decorative fountains should 
maintain them according to the manufacturer’s recommendations, have adequate levels of 
chlorine or other disinfectant at all times, and keep current on protocols for public health safety. 
• After outbreaks, vigilant monitoring of proven sources should be maintained. 
 
4) ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for 
Legionellosis can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
 
References 
American Academy of Pediatrics. 2003 Red Book: Report of the Committee on Infectious Diseases, 
26th Edition. Illinois, American Academy of Pediatrics, 2003. 
CDC.  Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC 
and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR 
2004;53(RR03):1-36. 
CDC Website. Legionellosis: Legionnaires’ Disease and Pontiac Fever. 
www.cdc.gov/legionella/index.html   
Heymann, D., ed. Control of Communicable Diseases Manual, 19th Edition. Washington, DC, American 
Public Health Association, 2008. 
Fiore, A.E., et al. Epidemic Legionnaires’ Disease Two Decades Later: Legionellosis Sources, New 
Diagnostic Methods. Clinical Infectious Diseases. 1998; 26:426−433. 
 
 
Iowa Dept. of Public Health Revised 12/13      Legionellosis 4 
Iowa Department of Public Health 
FACT SHEET                  LEGIONNAIRES’ DISEASE 
For Health Professionals  (Legionellosis) 
 
What is Legionnaires’ disease? 
Legionellosis is an infection caused by the bacteria Legionella pneumophila. The infection has two distinct forms: 
Legionnaires' disease, the more severe form of infection, which includes pneumonia, and Pontiac fever, a milder flu-
like illness.  See the Pontiac fever fact sheet for more information. 
   
What are the symptoms of Legionnaires’ disease? 
Persons with Legionnaires’ disease usually have fever, chills, cough, body aches, headache, tiredness, loss of 
appetite, and occasionally diarrhea. Laboratory tests may indicate decreased kidney function. Chest x-rays often 
show pneumonia. The incubation period for Legionnaires’ disease is 2 - 10 days. 
 
How is Legionnaires’ disease spread? 
Outbreaks of legionellosis have been associated with a water source (e.g., air conditioning cooling towers, whirlpool 
spas, showers) contaminated with Legionella bacteria. Persons may be exposed to these aerosols in homes, 
workplaces, hospitals, or public places.  
 
Who gets Legionnaires’ disease? 
People of any age may get Legionnaires' disease. Males, especially middle-aged and older males, particularly those 
who smoke or have chronic lung disease, are at higher risk. Also at increased risk are persons whose immune system 
is suppressed by diseases such as cancer, chronic renal failure, diabetes, or AIDS. Those that take drugs that 
suppress the immune system are also at higher risk.   
 
How is Legionnaires’ disease diagnosed?  
The diagnosis of legionellosis requires tests that are not routinely performed on persons with fever or pneumonia. 
Diagnosis depends on isolation of the causative organism on special media, its demonstration by direct 
immunoflorescent (IF) stain of involved tissue or respiratory secretions, or detection of antigens of Legionella 
pneumophila serogroup 1 in urine by radioimmunoassay (RIA) or by a fourfold or greater rise in indirect 
immunoflorescent antibody test (IFA) titer between an acute phase serum and one drawn 3-6 weeks later. 
 
How long is a person infectious? 
Legionnaires’ disease is not spread person to person. 
 
What is the treatment for Legionnaires’ disease? 
Erythromycin is the antibiotic currently recommended for treating persons with Legionnaires' disease. In severe 
cases, a second drug, rifampin, may be used but should not be used alone.  Penicillin, cephalosporins and 
aminoglycosides are ineffective.  Other drugs are available for patients unable to tolerate erythromycin.   
 
Do infected people need to be excluded from school, work, or child care? 
No. 
 
Where is the Legionella bacterium found?  
Legionella organisms can be found in many types of water systems. However, the bacteria reproduce to high 
numbers in warm, motionless water (95-115o F), such as that found in certain plumbing systems and hot water 
tanks, cooling towers and evaporative condensers of large air-conditioning systems, and whirlpool spas. 
 
What can be done to help prevent Legionnaires’ disease? 
Improved design and maintenance of cooling towers and plumbing systems to limit the growth and aerosolization of 
Legionella organisms are the foundations of legionellosis prevention.  During outbreaks, health department 
investigators seek to identify the source of disease transmission and recommend appropriate prevention and control 
measures, such as decontamination of the water source. 
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FACT SHEET                                   Legionnaires’ Disease 
                                                                                                           (Legionellosis) 
 
What is Legionnaires’ disease? 
Legionnaire’s disease is caused by a bacterium that causes two different illnesses. Legionnaire’s disease is 
more severe, sometimes causing severe breathing difficulty or pneumonia. Pontiac fever is a more mild 
form, often causing a flu-like illness (see Pontiac fever fact sheet). Both of these syndromes tend to attack 
people who have weak immune systems. 
 
What are the symptoms of an infection with Legionnaires’ disease? 
Persons with Legionnaires’ disease usually have fever, chills, cough, body aches, headache, tiredness, 
loss of appetite, and occasionally diarrhea.  
 
How soon do symptoms appear? 
For Legionnaires’ disease, it usually takes 2 - 10 days. 
 
How is Legionnaires’ disease spread? 
Whirlpool outbreaks of Legionnaires’ disease have occurred after persons have inhaled the fine spray 
(aerosols) that come from a water source (e.g., air conditioning cooling towers, spas, showers). Persons 
may be exposed to these aerosols in homes, workplaces, hospitals, or public places.  
 
Who gets Legionnaires’ disease? 
People of any age may get Legionnaires' disease, but the illness most often affects males, especially 
middle-aged and older males, particularly those who smoke or have chronic lung disease. Also at 
increased risk are persons whose immune system is suppressed by diseases such as cancer, chronic renal 
failure, diabetes, or AIDS. Those that take drugs that suppress the immune system are also at higher 
risk.   
 
How long is a person infectious? 
You cannot get Legionnaires’ disease from another person.  
 
What is the treatment for Legionnaires’ disease? 
Antibiotics are used to treat Legionnaires’ disease.  
 
Do infected people need to be excluded from school, work, or child care? 
No. 
 
What can be done to help prevent the spread of Legionnaires’ disease? 
Improved design and maintenance of cooling towers and plumbing systems to limit the growth and 
aerosolization of Legionella organisms are the foundations of Legionnaires’ disease prevention.  During 
outbreaks, health department investigators seek to identify the source of disease transmission and 
recommend appropriate prevention and control measures, such as decontamination of a water source. 
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FACT SHEET                                         PONTIAC FEVER 
 
What is Pontiac fever? 
Pontiac fever is a mild form of Legionnaires’ disease that often causes a flu-like illness. 
 
What are the symptoms of Pontiac fever? 
Persons with Pontiac fever usually have fever, chills, cough, body aches, headache, tiredness, loss of 
appetite, and occasionally diarrhea.  
 
How soon do symptoms appear? 
The time between the patient's exposure to the bacterium and the onset of illness generally ranges from 
a few hours to 2 days. 
 
How is Pontiac fever spread? 
Outbreaks of Pontiac fever have occurred after persons have inhaled the fine spray (aerosols) that come 
from a contaminated water source (e.g., air conditioning cooling towers, spas, showers). Persons may be 
exposed to these aerosols in homes, workplaces, hospitals, or public places.  
 
Who gets Pontiac fever? 
Persons of any age can get Pontiac fever.  It occurs most commonly in persons who are healthy.  
 
Can Pontiac fever spread from person to person? 
You cannot get Pontiac fever from another person.  
 
What is the treatment for Pontiac fever? 
Pontiac fever is usually not treated with antibiotics and usually requires no specific treatment.  People 
recover without treatment. 
 
Do infected people need to be excluded from school, work, or child care? 
No. 
 
What can be done to help prevent Pontiac fever? 
Improved design and maintenance of cooling towers and plumbing systems to limit the growth and spray 
of Legionella organisms are the keys to Pontiac fever prevention.  During outbreaks, health department 
investigators seek the source of the disease and recommend appropriate prevention and control 
measures, such as cleaning the water source.  
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FACT SHEET                            PONTIAC FEVER 
For Health Professionals                                                                                                       
 
What is Pontiac fever? 
Pontiac fever is a mild disease recognized as a distinctly different clinical and epidemiological form of 
legionnaire’s disease. The clinical symptoms occur after exposure to Legionella, but represent a reaction 
to inhaled antigen rather than bacterial invasion. 
   
What are the symptoms of Pontiac Fever? 
Persons with Pontiac fever experience fever and muscle aches and do not get pneumonia.  They 
generally recover in 2 - 5 days without treatment.  The time between exposure and onset of Pontiac 
fever is shorter, generally a few hours to 2 days. 
 
How is Pontiac Fever spread? 
Outbreaks of Pontiac fever have occurred after persons have inhaled aerosols from a water source (e.g., 
air conditioning cooling towers, whirlpool spas, showers) contaminated with Legionella bacteria. Persons 
may be exposed to these aerosols in homes, workplaces, hospitals, or public places.  
 
Who gets Pontiac fever? 
Pontiac fever most commonly occurs in persons who are otherwise healthy. 
 
How is Pontiac fever diagnosed?  
The diagnosis of Pontiac fever requires tests not routinely performed on persons with fever or 
pneumonia. Diagnosis depends upon isolation of the causative organism on special media, its 
demonstration by direct (immunoflorescent) IF stain of involved tissue or respiratory secretions, detection 
of antigens of Legionella pneumophila serogroup 1 in urine by radioimmunoassay (RIA), or by a fourfold 
or greater rise in immunoflorescent antibody test (IFA) titer between an acute phase serum and one 
drawn 3 - 6 weeks later. 
 
How long is a person infectious? 
Pontiac fever is not spread person to person. 
 
What is the treatment for Pontiac fever? 
Pontiac fever requires no specific treatment.  
 
Do infected people need to be excluded from school, work, or child care? 
No. 
 
Where is the Legionella  bacterium found?  
Legionella organisms can be found in many types of water systems. The bacteria reproduce to high 
numbers in warm, motionless water (95-115o F), such as that found in certain plumbing systems and hot 
water tanks, cooling towers and evaporative condensers of large air-conditioning systems, and whirlpool 
spas.  
 
What can be done to help prevent the spread of Pontiac fever? 
Improved design and maintenance of cooling towers and plumbing systems limit the growth and 
aerosolization of Legionella organisms are the foundations of Pontiac fever prevention.  During outbreaks, 
health department investigators seek to identify the source of disease transmission and recommend 
appropriate prevention and control measures, such as decontamination of the water source. 
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CONFIDENTIAL              Iowa Department of Public Health 
Legionellosis                  Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Disease type  Legionnaires Disease           Pontiac Fever 
Diagnosis 
date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome: 
 Survived this illness     Died from this illness 
 Died unrelated to this illness    Unknown 
Date of Death      /     /      First name: 
 
      
Event exception 
 Case could not be found 
 Case could not be interviewed 
 Case refused interview 
 Other – see notes  
Provider title:  ARNP   
 DO 
 MD 
 NP 
 PA 
Outbreak 
related:  Yes      No      Unknown  
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
      Serogroup 
 
        Other                 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
      Serogroup 
 
        Other                 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
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Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
      Serogroup 
 
        Other                 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting:          
Health care worker type: 
 Yes      No      Unknown 
 
Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting:          
Health care worker type: 
 Yes      No      Unknown 
 
Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
S
ym
pt
om
s 
Fever:  Yes    No    Unknown Onset date:          /     /      
Highest known fever:       
 Celsius      Fahrenheit 
Abdominal pain 
Anorexia 
Cough 
Diarrhea 
Fever 
  
  
  
  
  
Headache 
Malaise 
Muscle pain 
Pneumonia 
Shortness of breath 
  
  
  
  
  
 
TREATMENT 
 
Antibiotics prescribed?   Yes    No    Unknown 
  
Antibiotic:       
  
Antibiotic:       
 
 
Antibiotic:       
Date 
started:      /     /      
Date 
started: 
 
     /     /      
Date 
started: 
 
     /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 
 mg      ml     IU 
 
Unit: 
 
 mg      ml     IU 
 
Unit: 
 
 mg      ml     IU 
# of days:       
# of times 
a day:       # of days:       
# of times 
a day:       # of days:       
# of times 
a day:       
Route:       Route:       Route:       
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Traveled within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
 
Have dialysis: 
 
 Yes    No    Unknown 
Visit a hospital:  Yes    No    Unknown 
Date 
visited:      /     /      
 
Facility name: 
 
Address: 
 
City: 
 
      State: 
 
      
 
Zip code:       County:       
Phone: 
 
(     )-     -      
 
Ext: 
 
      
 
Type: 
 
      
 
Water exposures  
Went swimming?  Yes    No    Unknown 
If Yes, complete the table below: 
Types: 
 Hot tub/spa 
 Kiddie pool 
 River/stream 
 Lake 
 Pond 
 
 
 Water park 
 Swimming pool 
 Water fountain/splash pad 
 
Location 
types: 
 Hotel/motel 
 Indoor private 
 Indoor public 
 Outdoor private 
 Outdoor public 
Facility 
names:  
Date(s) 
swam:      /     /     ,      /     /     ,      /     /      
Address:  City/State/Zip:  County:  
 
Other exposures ATORY  
Worked with a Case:       Yes    No    Unknown From date:  
 
     /     /      
 
  To date: 
 
     /     /      
Lived with another Case:       Yes    No    Unknown From date:  
 
     /     /      
 
  To date: 
 
     /     /      
Received organ transplant:  Yes    No    Unknown Date received:      /     /      Organ type:  
Cancer:  Yes    No    Unknown From date:  
 
     /     /      
 
  To date: 
 
     /     /      
Received radiation therapy:  Yes    No    Unknown From date:  
 
     /     /      
 
  To date: 
 
     /     /      
Received chemotherapy:  Yes    No    Unknown From date:  
 
     /     /      
 
  To date: 
 
     /     /      
Smoked cigarettes:  Yes    No    Unknown Packs per day: 
 >2 packs a day                    1 to 2 packs a day                                      
 Less than a pack a day         
 
 
NOTES:       
 
 
 
 
 
 
 
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  
The incubation period for legionellosis is 
2-10 days, with an average of 5-6 days. 
The incubation period for Pontiac Fever is 
5-72 hours 
Person to person transmission of legionellosis has not 
been documented. 
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LISTERIOSIS 
 
 
Responsibilities: 
Hospital: Report invasive disease by phone or mail, send isolate to State Hygienic Lab (SHL) - 
(319) 335-4500 
Lab: Report invasive disease by IDSS, phone or mail, send isolate to SHL - (319) 335-4500 
Physician: Report by IDSS, facsimile, mail, or phone  
Local Public Health Agency (LPHA): Follow up required 
Hospital Infection Preventionist: Follow up required 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax:  (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A.  Agent 
Listeriosis is caused by the bacterium Listeria monocytogenes.  
 
B.  Clinical Description 
Listeriosis is typically manifested as meningoencephalitis or bacteremia in newborns and adults. It 
may cause fever and spontaneous abortion in pregnant women. Symptoms of meningoencephalitis 
include fever, headache, stiff neck, nausea and vomiting. The onset may be sudden or, in the elderly 
and in those who are immunocompromised, it may be more gradual. Delirium and coma may occur. 
Newborns, the elderly, immunocompromised persons, and pregnant women are most at risk for 
severe symptoms.  Infections in healthy persons may be asymptomatic or only amount to a mild flu-
like illness. Papular lesions on hands and arms may occur from direct contact with infectious material.  
The case-fatality rate in infected newborn infants is about 30% and approaches 50% when onset 
occurs in the first 4 days of life.  
 
C.  Reservoirs 
Principal reservoir for L. monocytogenes is in soil, forage, water, mud and silage.  Other reservoirs 
include mammals, fowl and people.  Soft cheeses may support the growth of Listeria during ripening 
and have caused outbreaks.  Unlike most other foodborne pathogens, Listeria can multiply at 
refrigerator temperatures.    
 
D.  Modes of Transmission 
Listeriosis may be acquired by the fetus in utero or during passage through the birth canal. Listeriosis 
can also be transmitted through ingestion of contaminated foods, especially pasteurized soft cheeses 
and ready-to-eat foods. 
 
E.  Incubation Period 
Variable; outbreak cases have occurred 3 - 70 days following a single exposure to an implicated 
product.  Median incubation is estimated to be 3 weeks. 
 
F.  Period of Communicability or Infectious Period 
Although Listeria may be shed for several months in the stool of infected persons, person-to-person 
transmission is rare. Following delivery, mothers of infected newborns may shed Listeria for 7 - 10 
days in vaginal secretions or urine. 
 
G.  Epidemiology 
Listeria is widely distributed in nature. Most cases of human listeriosis are believed to occur 
sporadically, but foodborne and healthcare associated outbreaks have been documented. Foods 
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associated with infection include unpasteurized milk, soft cheeses, processed meats and 
contaminated vegetables. Newborns, the elderly, immunocompromised persons and pregnant women 
are at greater risk of infection. CDC estimates that approximately 1600 illnesses and 260 deaths due 
to listeriosis occur annually in the United States. About 30% of diagnosed cases occur within the first 
3 weeks of life. 
 
H.  Bioterrorism Potential 
       None. 
  
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A.  Purpose of Surveillance and Reporting 
To track the occurrence of listeriosis so that sources of major public health concern (e.g., food 
sources) may be identified and control measures initiated. 
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report. The preferred method of reporting is by utilizing the Iowa Disease Surveillance System 
(IDSS).  However, if IDSS is not available to your facility, the reporting number for the Center for 
Acute Disease Epidemiology (CADE) is (800) 362-2736; fax number (515) 281-5698. The mailing 
address is: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
Des Moines, IA 50319-0075 
 
Postage-paid disease reporting forms are available free of charge from the IDPH clearinghouse.   
Call (319) 398-5133 or visit the website: 
healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295 to request a 
supply. 
 
C. Local Public Health Agency Follow-Up Responsibilities 
Case Investigation 
a. It is the LPHA or the local infection preventionist’s responsibility to complete a Listerosis case 
investigation by interviewing the case and others who may be able to provide pertinent 
information. Much of the information required can be obtained from the case’s healthcare 
provider or the medical record. 
 
b. Use the following guidelines to assist you in completing the investigation: 
1) Record the demographic information, occupation (if applicable), date reported, date 
investigation started and date of diagnosis. 
2) Record the clinical information. 
3) Indicate the type of infection caused by Listeria monocytogenes.   
4) Indicate the type of specimen from which Listeria was isolated, the type of lab test used, 
and date the first positive culture was obtained. If other lab tests were used diagnostically 
(e.g., bacterial antigen screen) please indicate the type of test(s) used and date(s) tested. 
5) If the case was diagnosed while pregnant or within 2 weeks of delivery, indicate 
outcome of pregnancy and associated dates.  
6) If it is suspected that the case became infected through food and part of an outbreak, refer 
to IDPH Foodborne Manual.  
 
c. After gathering the information, the preferred method of reporting is by entering the data into 
the Iowa Disease Surveillance System (IDSS), or faxing the case report form to CADE’s secure 
fax at (515) 281-5698, or by mailing the IDSS case investigation form to:  
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IDPH, CADE 
Lucas State Office Building, 5th Floor  
321 East 12th Street 
Des Moines, Iowa 50319 
 
d. If several attempts have been to obtain case information, but have been unsuccessful (e.g., the 
case or healthcare provider does not return your calls or respond to a letter, or the case refuses 
to divulge information or is too ill to be interviewed), enter as much information as possible. 
Enter into the Notes section any reason why it could not be filled out completely.  If using IDSS, 
select the appropriate reason under the Event tab in the Event Exception field. 
 
e. Institution of disease control measures is an integral part of case investigation. It is the LPHA 
responsibility to understand, and, if necessary, institute the control guidelines listed below in 
Section 3), Controlling Further Spread.    
 
3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements  
None.  
 
B. Protection of Contacts of a Case 
Discard any suspect foods. 
 
C.  Managing Special Situations 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
If the number of reported cases of listeriosis in the LPHA’s jurisdiction is higher than usual, or if an 
outbreak is suspected, consult with an epidemiologist at CADE at (800) 362-2736.  Investigate to 
determine the source of infection and mode of transmission. A common vehicle, such as food, should 
be sought and applicable preventive or control measures should be instituted. CADE can help 
determine a course of action to prevent further cases and can perform surveillance for cases across 
county lines and therefore be difficult to identify at a local level. 
 
Note: Refer to IDPH’s Foodborne Manual for comprehensive information on investigating 
foodborne illness complaints and outbreaks.  
 
Multi-State Clusters 
The Centers for Disease Control and Prevention (CDC) is working to identify and analyze multi-state 
clusters of listeriosis. Cases that may be part of such clusters will require additional follow-up and 
data collection from the local public health agency. CADE will provide directions on follow-up activities 
for such situations on a case-by-case basis. 
 
D.  Preventive Measures 
Environmental Measures 
Implicated food items must be removed from the environment. A decision about testing implicated 
food items can be made in consultation with CADE. CADE can help coordinate pickup and testing of 
food samples. If a commercial product is suspected, CADE will coordinate follow-up with relevant 
outside agencies.  
Note: Refer to Iowa’s Foodborne Illness Outbreak Investigation Manual for comprehensive 
information in investigating foodborne illness complaints and outbreak. 
 
 
 
Personal Preventive Measures/Education 
General recommendations:  
• Thoroughly cook raw food from animal sources, such as beef, pork, or poultry.  
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• Wash raw vegetables thoroughly before eating.  
• Keep uncooked meats separate from vegetables and from cooked foods and ready-to-eat foods.  
• Avoid unpasteurized (raw) milk or foods made from unpasteurized milk.  
• Wash hands, knives, and cutting boards after handling uncooked foods.  
• Consume perishable and ready-to-eat foods as soon as possible.  
 
Recommendations for persons at high risk, such as pregnant women and persons with weakened 
immune systems, in addition to the recommendations listed above:  
• Do not eat hot dogs, luncheon meats, or deli meats, unless they are reheated until steaming hot.  
• Avoid getting fluid from hot dog packages on other foods, utensils, and food preparation 
surfaces, and wash hands after handling hot dogs, luncheon meats, and deli meats.  
• Do not eat soft cheeses such as feta, Brie, and Camembert, blue-veined cheeses, or Mexican-
style cheeses such as queso blanco, queso fresco, and Panela, unless they have labels that 
clearly state they are made from pasteurized milk.  
• Do not eat refrigerated pâtés or meat spreads. Canned or shelf-stable pâtés and meat spreads 
may be eaten.  
• Do not eat refrigerated smoked seafood, unless it is contained in a cooked dish, such as a 
casserole. Refrigerated smoked seafood, such as salmon, trout, whitefish, cod, tuna or mackerel, 
is most often labeled as "nova-style," "lox," "kippered," "smoked," or "jerky." The fish is found in 
the refrigerator section or sold at deli counters of grocery stores and delicatessens. Canned or 
shelf-stable smoked seafood may be eaten.  
 
4) ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Listeriosis 
can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
 
References 
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Additional Resources 
     Iowa Division of Inspections and Appeals, Food Inspections 
     www.profoodsafety.org/  
     State Hygienic Laboratory at the University of Iowa www.shl.uiowa.edu   
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FACT SHEET LISTERIOSIS 
 
What is listeriosis? 
Listeriosis is an uncommon bacterial infection.  It can cause infection in the brain or blood stream, abortion 
in pregnant women, symptoms as mild as flu-like illness, or no symptoms at all. Listeriosis is found in soil, 
cattle forage, water, mud and silage.  Other sources are infected domestic and wild mammals, fowl and 
people.   
 
Who is at risk for listeriosis? 
Anyone can get listeriosis, but it is seen more often in newborns, the elderly, people with diseases of the 
immune system and pregnant women. 
 
How do you get listeriosis? 
Listeriosis is associated with drinking raw or contaminated milk, soft cheeses, contaminated vegetables, 
and uncooked ready-to-eat meats.  Newborns can get the infection from the mother before birth or as 
they pass through the birth canal. 
 
What are the symptoms of listeriosis infection? 
People infected with listeriosis may have an acute, mild illness with a fever, or infection of the brain or fluid 
surrounding the brain causing sudden fever, intense headache, nausea and vomiting, delirium, and coma.  
People may also have an infection in the heart muscle or lesions in the liver or skin.   
 
How soon do symptoms appear? 
Symptoms have occurred anywhere from 3 - 70 days following an exposure. The average time frame to 
disease is about 3 weeks.   
 
How long will symptoms of listeriosis last? 
Mothers of infected newborn infants may shed the infectious agent in vaginal discharges and urine for 7 - 
10 days after delivery. However, some infected individuals may shed the organisms in their stools for 
several months. 
 
Do infected people need to be excluded from work or school? 
Since listeriosis is found in the feces (stool), people with diarrhea (especially children in child care centers or 
people who handle food) should not go to school or work.  Most infected people may return when their 
diarrhea stops if they carefully wash their hands after using the toilet, diapering, and before handling food.  
 
What is used to treat listeriosis? 
Antibiotics can be used to treat listeriosis. 
 
How can listeriosis be prevented? 
Recommendations for all individuals  
1.   Keep uncooked meats separate from vegetables, cooked foods and ready-to-eat foods. 
2. Thoroughly wash raw vegetables before eating. 
3. Avoid raw/unpasteurized milk or foods made from raw milk. 
4. Wash hands, knives, and cutting boards after handling uncooked foods. 
5. Read and follow label instructions to “keep refrigerated” and “use by” a certain date. 
  
Recommendations to high risk individuals 
Persons at increased risk for listeriosis such as pregnant women, the elderly, and those with 
immunosuppressive conditions can decrease the risk if they: 
1. Avoid unpasteurized soft cheeses such as feta, Brie, Camembert and blue cheese. 
2. Thoroughly heat leftover foods or ready-to-eat foods such as hot dogs or processed luncheon meats 
before eating. 
3. Although the risk of listeriosis associated with foods from delicatessen counters is relatively low, 
pregnant women and immunosuppressed persons may choose to avoid these foods or to thoroughly 
reheat cold cuts before eating.  
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Listeriosis                          Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome: 
 Survived this illness     Died from this illness 
 Died unrelated to this illness    Unknown 
Date of Death      /     /      First name: 
 
      
Event exception 
 Case could not be found 
 Case could not be interviewed 
 Case refused interview 
 Other – see notes Paper only 
 
   
Outbreak 
related:  Yes      No      Unknown Provider title: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes   No  Unk To whom: ______________  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Result date: 
 
     /     /      
 
Result type: 
 
 Preliminary      Final 
 
Test type: 
 
      Result: 
 Negative    
 Positive 
 
Organism: 
 
Listeria  Type (e.g. serotype): 
 
monocytogenes   Other                 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Result date: 
 
     /     /      
 
Result type: 
 
 Preliminary      Final 
 
Test type: 
 
      Result: 
 Negative    
 Positive 
 
Organism: 
 
Listeria Type (e.g. serotype): 
 
monocytogenes   Other                 
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Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Result date: 
 
     /     /      
 
Result type: 
 
 Preliminary      Final 
 
Test type: 
 
      Result: 
 Negative    
 Positive 
 
Organism: 
 
Listeria Type (e.g. serotype): 
 
monocytogenes   Other                 
 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
Symptoms:    
 Coma   
 Encephalitis 
 Endocarditis   
 Fever  
  Headache 
 Nausea 
 Septicemia   
 Vomiting   Abscesses or lesions present:  Yes    No    Unknown 
 
Diagnosed while pregnant:  Yes    No    Unknown 
 
While pregnant, tested for listeriosis:  Yes    No    Unk 
Pregnancy outcome:  1st trimester  2nd trimester    
 Live birth    
 Miscarriage Test positive:  Yes    No    Unk 
 
 3rd trimester    
 Abortion         
 Stillbirth 
Result date:      /     /      
Outcome date:      /     /       
 
Infant less than 4 weeks of age at 
onset:  Yes    No    Unknown  
 
     
Center for Acute Disease Epidemiology                         Fax: 515-281-5698      Do not complete shaded areas           Listeriosis         Revised Mar-15 2 
CONFIDENTIAL PATIENT NAME: ______________________________                           Iowa Department of Public Health 
EXPOSURE PERIOD COMMUNICABLE PERIOD 
 
 
OTHER LAB FINDINGS 
 
PFGE Pattern (stool specimen from case) 
Was PFGE performed:  Yes    No    Unk 
IA-XbaI 
Pattern:       
IA-BlnI 
 Pattern:       
CDC-XbaI 
Pattern:       
CDC-BInI 
Pattern:       
 
Environmental specimen testing 
Food, medication or environmental samples tested?  Yes    No    Unk 
Describe samples:       
What were the 
samples tested for? 
 E. coli or EHEC   Salmonella   
 Listeria                Shigella 
 Campylobacter 
 Other testing (specify) :       
List positive 
samples:    Laboratory:  
  IA-XbaI pattern:       IA-BlnI pattern:       
PFGE performed?  Yes    No    Unk CDC-XbaI pattern:       CDC-BInI pattern:       
 
TREATMENT 
Antibiotics prescribed?   Yes    No    Unknown 
  
Antibiotic:       
  
Antibiotic:       
 
 
Antibiotic:       
Date 
started:      /     /      
Date 
started:      /     /      
Date 
started:      /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
 
INFECTION TIMELINE 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
In the 3 weeks before the onset of symptoms did the case purchase food products: 
Store name Address City/State/Zip County Date purchased 
                        
 
     /     /      
                        
 
     /     /      
                        
 
     /     /      
 
Dietary Information – In the 3 weeks prior to onset of symptoms did the case consume the following: 
Unpasturized products 
Unpasteurized 
milk:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Unpasteurized 
cheese:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Other 
unpasteurized 
products: 
 Yes    No    Unk 
From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
 
Meat and poultry products 
Deli/luncheon meats:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation period for 
Listeriosis is 3-70 days. 
Median incubation period 
is estimated to be 3 
weeks. 
Listeriosis is communicable for several 
months. New mothers can shed virus 7-
10 days after delivery in vaginal 
secretions and urine.  
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Raw hot dog:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Pre-cooked/smoked 
seafood:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
 
 
 
Are there symptomatic contacts of the case with same exposures:   Yes    No    Unknown 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
 
NOTES:       
 
 
 
CONTACTS 
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LYME DISEASE 
 
Also known as:  Lyme borreliosis and Tickborne meningopolyneuritis 
 
Responsibilities: 
Hospital: Report by IDSS, mail, fax or phone 
Infection Preventionist: Report by IDSS, mail, fax or phone 
Lab: Report by IDSS, mail, fax or phone 
Physician: Report by mail, fax or phone 
Local Public Health Agency (LPHA): Follow-up required 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Lyme disease (LD) is caused by the corkscrew-shaped bacterium (spirochete) Borrelia burgdorferi. 
 
B. Clinical Description 
Lyme disease is a systemic, tick-borne disease with a variety of manifestations, including 
dermatologic, rheumatologic, neurologic, and cardiac abnormalities. The best clinical marker for the 
disease is erythema migrans (EM), the initial skin lesion that occurs in 60%-80% of patients. 
EM is a skin lesion that typically begins as a red macule or papule and expands over a period of days 
to weeks to form a large round lesion, often with partial central clearing. Secondary lesions also may 
occur. Round erythematious lesions occurring within several hours of a tick bite represent 
hypersensitivity reactions and do not qualify as EM. For most patients, the expanding EM lesion is 
accompanied by other acute symptoms, particularly fatigue, fever, headache, mildly stiff neck, 
arthralgia, or myalgia.  These symptoms are typically intermittent. Laboratory confirmation is 
recommended for persons with no known exposure. 
 
Early Localized 
Signs and symptoms during the early illness tend to be nonspecific and include fever, muscle aches, 
headache, mild neck stiffness, and joint pain. Erythema migrans (EM) occurs at the site of the tick 
bite in approximately 90% of cases, although when these painless lesions occur in a location hidden 
from view (armpit, back, etc.), the patient does not often see them. Typically, EM rashes are circular 
and grow to a diameter of 5 to 15 cm, although the shape can be triangular, oval, or irregular. EM 
frequently clears in the center, resulting in the classic “bull’s-eye” presentation, but this does not 
always occur. The rash may be reported as warm or itchy, but it is usually painless.   
 
Early Disseminated 
In untreated persons, multiple EM rashes may appear within 3 to 5 weeks after the tick bite. These 
secondary lesions, indicative that the infection has spread into the blood, resemble the primary lesion 
but tend to be smaller. Common signs of early disseminated disease also include mild eye infections 
and the paralysis of facial muscles (Bell’s palsy). More systemic signs of this stage are headache, 
fatigue, and muscle and joint pain. At this stage, disruptions of heart rhythm occur in < 10% of 
cases. 
 
Late 
Most commonly, late disease is marked by recurrent arthritis (swelling and pain) in the knees and 
shoulders. Other joints may also be involved. Neurological signs may involve impairment of mood, 
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sleep, or memory; paralysis of facial muscles; pain or tingling sensations in the extremities; and less 
commonly, meningitis and encephalitis. Late-stage symptoms can persist for several years, but tend 
to resolve spontaneously. 
 
Generally, prophylactic antibiotic therapy is not indicated after a tick bite, as the risk of infection with 
B. burgdorferi after a tick bite is relatively low, even in endemic areas.  
 
C. Reservoirs 
The primary vectors for Lyme Disease (LD) are Ixodes ticks, a distinct genus from the larger and 
better-known dog tick (Dermacentor variabilis). In Iowa, the prominent vector is I. scapularis, or the 
deer tick. Ticks acquire the spirochete that causes LD during their young, larval stage by feeding on 
infected animals, especially the white-footed mouse. The tick poses the greatest threat of 
transmitting infectious organisms to animals and humans when it bites during its next (nymphal) 
stage of life. Nymphs are most abundant between May and July, and they are typically found in 
grasses and brush. Towards the end of summer through fall, the ticks mature to the adult stage. 
Although adult ticks remain capable of transmitting B. burgdorferi to humans, they are less likely to 
do so. 
 
D. Modes of Transmission 
Lyme disease is acquired from a tick bite. Laboratory data suggest that the tick must usually remain 
attached for 24 to 48 hours before the transmission of B. burgdorferi can occur. Since bites from I. 
scapularis are often painless and may occur on parts of the body that are difficult to observe, cases 
of diagnosed LD frequently have no known history of a tick bite. 
 
E. Incubation period 
EM typically develops between 7 - 10 days after exposure (range 3 - 32 days).  However, an infected 
individual can remain asymptomatic until the later stages of LD, several months to one year later. 
 
F. Period of Communicability or Infectious Period 
Lyme disease is not communicable from person-to-person. 
 
G. Epidemiology 
Lyme disease is the most commonly reported vectorborne illness in the U.S.  In 2009, it was the 5th 
most common nationally notifiable disease. In 2010, 94% of Lyme disease cases were reported from 
12 states: Connecticut, Delaware, Maine, Maryland, Massachusetts, Minnesota, New Jersey, New 
Hampshire, New York, Pennsylvania, Virginia, and Wisconsin. 
 
The incidence of Lyme disease is associated with the density of infected tick vectors. While most 
cases in the United States have been reported in the Northeast, West, and upper Midwest, nearly all 
states have reported cases. LD incidence varies greatly among states, among counties, and by 
season. Most cases occur between April and October, when the risk of contact with nymphal ticks is 
greatest. In Iowa most cases occur in the northeast corner of the state. 
  
H. Bioterrorism Potential 
None. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To identify where Lyme disease occurs in Iowa. 
• To recognize areas in Iowa where Lyme disease incidence has changed (increased or decreased). 
• To focus preventive education. 
• To target tick control measures. 
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B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report. The preferred method of reporting is by utilizing IDSS.  However, if IDSS is not 
available, the reporting number for the IDPH Center for Acute Disease Epidemiology (CADE) is (800) 
362-2736; fax number (515), 281-5698, mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
Des Moines, IA 50319-0075 
 
Postage-paid disease reporting forms are available free of charge from the IDPH clearinghouse.   
Call (319) 398-5133 or visit the website: 
healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295 to request a 
supply. 
 
Laboratory Testing Services Available 
Laboratory confirmation of infection with B. burgdorferi is established when a laboratory isolates the 
spirochete from tissue or body fluid, detects diagnostic levels of IgM or IgG antibodies to the 
spirochete in serum or cerebrospinal fluid, or detects a significant change in antibody levels in paired 
acute and convalescent serum samples. Since the immune response to spirochetes is relatively slow, 
serological tests often remain negative for several weeks after exposure. The Centers for Disease 
Control and Prevention (CDC) recommends that, initially, serum specimens be tested by a sensitive 
test such as an enzyme immunoassay (EIA) or immunofluorescent assay (IFA). Samples with positive 
or equivocal results from these tests should be re-tested using a standardized Western blot 
procedure. 
 
The University of Iowa State Hygienic Laboratory (SHL) will perform Lyme disease confirmatory 
testing by Western blot assay on either acute or convalescent sera that are either positive or 
equivocal by a Lyme-specific test, such as EIA or IFA. The State Hygienic Laboratory will also identify 
ticks potentially carrying B. burgdorferi.  Finally, the State Hygienic Laboratory will also refer samples 
to the CDC for testing.  For more information about submitting sera for testing or ticks for 
identification, contact the SHL at (319) 335-4500. 
 
C.  Local Public Health Agency Follow-up Responsibilities 
Case Investigation: The Iowa Disease Surveillance System (IDSS) is the preferred method of 
completing disease investigations.   
 
If the patient is unable or unwilling to be interviewed during the investigation, in IDSS select the 
appropriate reason under the Event tab in the Event Exception field. 
 
3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements 
 None. 
 
B.  Protection of Contacts of a Case 
None. 
 
C. Preventive Measures 
Generally, prophylactic antibiotic therapy is not indicated because the risk of infection with B. 
burgdorferi after a tick bite is relatively low, even in endemic areas.  
 
Offer the following advice to the public to reduce risk for Lyme disease. 
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Environmental Measures 
Prevention of Lyme disease involves keeping wildlife (especially deer and rodents) out of your 
backyard and making your yard less attractive to ticks. 
• Remove leaf litter and brush from around your home. 
• Prune low-lying bushes to let in more sunlight. 
• Mow lawns regularly. 
• Make sure any plants near your home are not varieties that attract deer. 
• Keep woodpiles in sunny areas off the ground. 
• Clean up the ground around bird feeders. 
• If you are going to use insecticides around your home, always follow the label instructions and 
never apply these chemicals near streams or other bodies of water. 
 
Preventive Measures/Education 
The best preventive measure is to avoid tick-infested areas. If in areas where contact with ticks may 
occur, individuals should be advised of the following: 
• Wear long-sleeved shirts and long, light-colored pants tucked into socks or boots. 
• Stay on trails when walking or hiking and avoid high grass. 
• Use insect repellants properly. Repellants that contain DEET (diethyltoluamide) should be used in 
concentrations no higher than 15% for children and 30% for adults. Remember, repellants are 
not recommended to be used on infants. Permethrin is a repellant that can only be applied to 
clothing, not exposed skin.  
• After each day spent in tick-infested areas, check yourself, your children, and your pets for ticks. 
Areas ticks prefer most include the back of the knee, armpit, scalp, groin, and back of the neck. 
• Promptly remove any attached tick using fine-point tweezers. The tick should not be squeezed or 
twisted, but grasped close to the skin and pulled straight out with steady pressure. Once 
removed, the tick should be drowned in rubbing alcohol or flushed down the toilet. 
 
4) ADDITIONAL INFORMATION 
If a tick is available it may be sent for testing.  Place tick in plastic bag, with a tissue and one to two 
drops of water, seal, place in envelope with your name, address, and phone number and mail to: 
 
Iowa State University 
Department of Entomology 
440 Science II 
Ames, IA  50011-3240 
 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Lyme 
Disease can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
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FACT SHEET                   LYME DISEASE 
 
What is Lyme disease? 
Lyme disease is an illness that is spread by infected ticks.  It may affect the skin, nervous system, heart and 
joints. Most cases occur in June and July.  
 
Who gets Lyme disease? 
Anyone can get Lyme disease, especially if they spend long amounts of time outdoors in areas where 
infected ticks are found. 
 
How is Lyme disease spread? 
People get Lyme disease from a tick bite.  Persons who are bitten by a tick but do not remove the tick 
immediately have a higher chance of getting Lyme disease.  Lyme disease cannot be spread from person 
to person. 
 
What are the symptoms of Lyme disease? 
The illness usually starts as a large circular red rash at or near the site of the tick bite.  The rash may 
increase in size and can eventually look like a "bull's eye" with a clear center. The rash is frequently not 
identified.  Along with the rash, other "flu-like" symptoms such as fever, headache, fatigue, stiff neck, 
muscle and joint pain may be present.  These can last for several weeks.  Swelling and pain in the large 
joints may come and go for many years.  If left untreated, further symptoms can develop within a few 
weeks to months after the rash occurs. 
 
How soon do symptoms appear? 
The rash or flu-like symptoms usually begin within a month after the tick bite. 
 
What is the treatment for Lyme disease? 
Antibiotics.  Tetracycline, doxycycline, and penicillin are all used (but only penicillin is used in children under 
the age of 7 years). 
 
Can a person get Lyme disease more than once? 
Yes.  One infection with Lyme disease does not protect a person from getting it again. 
 
How should a tick be removed? 
All ticks should be removed as soon as possible.  The best way is to use tweezers to grab the tick as close 
to the skin as possible and pull it straight out. Do not use a twisting motion as it may leave part of the tick 
embedded. Do not squeeze the tick's body when removing it.  Do not handle ticks with bare hands.  Wash 
your hands after removing a tick.  You may want to apply an antiseptic on the bite. 
 
How can Lyme disease be prevented? 
    1. Do not walk barelegged in tall grass or woods where ticks may be found. 
    2.   Wear a long-sleeved shirt, long pants, and high socks.  Tuck pants legs into socks.  Wear light-
colored clothing so crawling ticks can be seen more easily. 
    3.   Conduct "tick checks" every two to three hours if spending a lot of time outdoors.  Check all of your 
skin (you may need help to do this) for ticks every day you spend in areas with lots of ticks.  The 
ticks are most often found on the thigh, arms, underarms, and legs.  Ticks can be very small, so 
look for new "freckles." 
    4.   Use tick repellents containing the ingredients DEET for skin applications, bearing in mind that lower 
concentrations should be used on children, reapplying more often. Use Permethrin (on clothing).  
Always follow the directions on the can.  These repellents can be found at the local drugstore.  
Wash off all repellents after going indoors. 
    5.   Remove any attached ticks immediately, using the method above.  
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CONFIDENTIAL                                                                                            Iowa Department of Public Health 
Lyme Disease                   Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider title: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
 
Result type: 
 
 Preliminary      Final 
 
Result date: 
 
     /     /      Result:  Positive    Negative   
 
Organism: 
 
Borrelia burgdorferi  
   
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
 
Result type: 
 
 Preliminary      Final 
 
Result date: 
 
     /     /      Result:  Positive    Negative   
 
Organism: 
 
Borrelia burgdorferi  
   
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
 
Result type: 
 
 Preliminary      Final 
 
Result date: 
 
     /     /      Result:  Positive    Negative   
 
Organism: 
 
Borrelia burgdorferi  
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OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
Fever:  Yes    No    Unk  Onset Date:       /     /      Duration (days):       
Highest 
known fever:       °F/C 
 
 
Other symptoms: 
 
 Arthralgia 
 Fatigue 
 Headache 
 Mild, stiff neck 
 Muscle pain 
Life threatening complications:  Adult respiratory distress syndrome 
 Disseminated intravascular coagulopathy 
 Meningitis/Encephalitis 
 Renal failure 
Did the health care provider for the case diagnose Lyme disease?    Yes    No    Unk 
Erythema migrans 
diagnosed by 
physician 
present:  Yes    No    Unk Onset Date:       /     /      Lesion greater than or equal to 5 cm:  Yes   No  Unk 
 
Late 
manifestations: 
 
 2nd/3rd degree atrioventricular (AV) block 
 Bilateral facial palsy 
 Encephalitis/Encephalomyelitis 
 Cranial neuritis 
 
 Recurrent, brief attacks of joint swelling 
 Lymphocytic meningitis 
 Radiculoneuropathy 
 
OTHER LAB FINDINGS 
 
Higher antibody result in CSF 
than in serum:  Yes    No    Unknown Leukopenia:  Yes    No    Unknown 
Thrombocytopenia:  Yes    No    Unknown Elevated hepatic transaminases:  Yes    No    Unknown 
 
TREATMENT 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
Antibiotics prescribed?   Yes    No    Unknown 
 
  
Antibiotic:       
  
Antibiotic:       
 
 
Antibiotic:       
Date 
started:      /     /      
Date 
started:      /     /      
Date 
started:      /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
 
Therapeutic medications 
prescribed:  Yes    No    Unknown List medications: 
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Did the case spend time in a wooded, brushy, or grassy area within 30 days of the onset of symptoms? 
Location name: 
 
Address: 
 
 
  
City/State/County: 
 
Zip: 
  
Is Lyme disease endemic in this county?  Yes    No    Unk  
 
Location name: 
 
Address: 
 
 
  
City/State/County: 
 
Zip: 
  
Is Lyme disease endemic in this county?  Yes    No    Unk  
 
In the 30 days prior to onset of symptoms 
did the case find a tick on his/her body?  Yes    No    Unk Date found:  
 
     /     /      
 
 
NOTES:       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation period for 
lyme disease is 3-30 
days after tick exposure.  
There is no evidence of 
person to person transmission 
of lyme disease.  
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Guide to Surveillance, Investigation, and Reporting 
MALARIA 
 
Responsibilities: 
Hospital: Report by IDSS, facsimile, mail or phone 
Lab: Report by IDSS, facsimile, mail or phone 
Physician: Report by facsimile, mail or phone 
Local Public Health Agency (LPHA): Report by IDSS, facsimile, mail or phone.  
Follow-up required. 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
There are four Plasmodium species (sporozoan parasites) that cause malaria in humans. They are 
Plasmodium vivax, P. malariae, P. ovale and P. falciparum.  
 
B. Clinical Description 
Symptoms: The classic symptoms of malaria are high fever with chills, sweats, and headache, which 
may be paroxysmal (occurring at intervals or with remissions and intensification of symptoms). The 
fever and paroxysmal symptoms generally occur in cycles of 1 - 3 days depending on the species 
causing the infection. Other symptoms can include malaise, nausea, vomiting, diarrhea, cough, 
arthralgia (joint aches), respiratory distress and abdominal and back pain. Paleness and jaundice may 
also be present. Enlargement of the liver and spleen (hepatosplenomegaly) may occur and is more 
prominent in chronic infections. Infection with P. falciparum is potentially acutely fatal and most 
commonly manifests as a febrile illness with or without coagulation defects, shock, renal and liver 
failure, acute encephalopathy, pulmonary and cerebral edema, and coma. The case-fatality rate for 
falciparum malaria is 10−40% in the absence of prompt treatment. 
 
Duration of an untreated primary attack can vary from a week to a month or longer. Relapses of P. 
vivax and P. ovale infections can occur at irregular intervals. Malaria infections may persist for life 
(chronic infections), with or without recurrent episodes of fever.  
 
C. Reservoirs 
Humans are the only important reservoir for human malaria. Non-human primates are naturally 
infected by many malarial species that can potentially infect humans, but natural transmission from 
non-human primates to humans is extremely rare. 
 
D. Modes of Transmission 
• Malaria is transmitted by the bite of an infected female Anopheles mosquito. 
 
• Rarely congenital (from mother to fetus) transmission may occur as well as transmission through 
transfusions or the use of contaminated needles. 
 
E. Incubation Period 
A. The time between the infective bite and the appearance of clinical symptoms is approximately 
7−14 (9-14) days for P. falciparum, 8−14 (12-18) days for P. vivax and P. ovale, and 7−30 (18-
40) days for P. malariae.  
B. With some strains of P. vivax, mostly from temperate areas, there may be a prolonged incubation 
period of 8 − 10 (6-12) months; even longer incubations may occur with P. ovale.  
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C. With infections acquired by blood transfusion, the incubation period is dependant on the number 
of parasites infused; it is usually short, but may range up to 2 months. 
 
F. Period of Communicability or Infectious Period 
Malaria is not directly communicable from person-to-person except for congenital transmission; 
however, during parasitemia, the disease may be transmitted to other persons through blood 
transfusion or through shared contaminated needles. Infected human hosts remain infectious for 
Anopheles mosquitoes for prolonged periods of time (1 − 3 years, or longer, depending on the 
species) if they are not adequately treated.   
 
G. Epidemiology 
Malaria is endemic throughout the tropical areas of the world. About half of the world’s population 
lives in areas where transmission occurs frequently. In 2010 an estimated 219 million cases of 
malaria occurred worldwide and 660,000 people died, with most (91%) in the African Region. Areas 
with the highest prevalence include sub-Saharan Africa, parts of Central and South America, India, 
and parts of Oceania and Southeast Asia. Transmission is also possible in more temperate climates 
such as in the United States, where Anopheles mosquitoes are present. Mosquitoes in airplanes flying 
from tropical climates have been the source of occasional cases in persons working or living near 
international airports (“airport malaria”) and further transmission of imported cases by local 
mosquitoes has been documented. However, nearly all of the malaria cases reported annually in the 
United States (approximately 1500) are acquired abroad. P. vivax and P. falciparum are the most 
common species worldwide. The worldwide spread of strains of chloroquine-resistant P. falciparum 
and P. vivax is of increasing importance. Resistance to other antimalarial drugs is now occurring in 
many areas where the drugs are widely used. The only cases occurring in Iowa are imported. 
 
H.  Bioterrorism Potential 
None. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A.  Purpose of Surveillance and Reporting 
• To identify imported cases of malaria. 
• To ensure that cases are appropriately contained and treated to prevent the introduction of 
malarial parasites into American mosquito populations. 
• To identify cases acquired in the United States, if they occur, so appropriate active surveillance 
and mosquito control interventions can be implemented. 
• To provide travelers with appropriate preventive health information. 
 
B.  Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report. The preferred method of reporting is by utilizing the Iowa Disease Surveillance System 
(IDSS).  However, if IDSS is not available, the reporting number for IDPH Center for Acute Disease 
Epidemiology (CADE) is (800) 362-2736; fax number (515), 281-5698, mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th Street 
Des Moines, IA 50319-0075 
 
Postage-paid disease reporting forms are available free of charge from the IDPH clearinghouse.   
Call (319) 398-5133 or visit the website: 
healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295 to request a 
supply. 
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Laboratory Testing Services Available   
The University of Iowa State Hygienic Laboratory (SHL) performs testing for malaria.  Healthcare 
providers may send thick and thin blood smears to SHL.  The CDC conducts testing for malaria by 
serologic tests only under special circumstances (e.g., serum of a blood donor suspected of being a 
source of transfusion-related malaria or serum for laboratories conducting malaria-related studies) or 
with prior approval. For approval of serologic testing and further information contact SHL parasitology 
at (319) 335-4500. The SHL website is: www.shl.uiowa.edu/  
 
C. Local Public Health Agency Follow-up Responsibilities  
 
Case Investigation 
It is the LPHA responsibility to complete a Malaria case investigation by interviewing the case and 
others who may be able to provide pertinent information. Much of the information required can be 
obtained from the case’s healthcare provider or medical record. 
 
1. Use the following guidelines to assist in completing the form: 
a. Record the demographic information, date of symptom onset, pregnancy status, healthcare 
provider information, and whether hospitalized (including location and associated dates).  
b. Record laboratory results, particularly the species of malaria, and the laboratory that 
performed the testing. 
c. Record information about whether and where the case has spent time out of the country in 
the past four years, including duration of stay and date returned. 
d. Indicate whether the case took malaria prophylaxis and, if so, what kind. 
e. Record whether the case has had a history of malaria within the past 12 months. 
f. Record whether the case has had a blood transfusion within the past 12 months. Note: If the 
patient is a recent blood donor, this information should be provided to CADE as soon as 
possible so CDC and other appropriate agencies can be notified. 
g. Be sure to record all clinical complications and whether the illness was fatal. 
h. Indicate which therapy was given for this illness. 
2. There is a “notes” section in IDSS which can be used to document other relevant aspects of the 
investigation that are not captured elsewhere (e.g., other risk information such as recent history 
of injection drug use or perinatal transmission, history of malaria prior to the last 12 months, 
any medical care received abroad.) 
3. If several attempts have been made to obtain case information, but have been unsuccessful 
(e.g., the case or healthcare provider does not return calls or respond to a letter, or the case 
refuses to divulge information or is too ill to be interviewed), contact IDPH and enter as much 
information as has been gathered. If using IDSS, select the appropriate reason under the Event 
tab in the Event Exception field. 
4. After completing the investigation, enter into IDSS, or send FAX and attach lab report(s) and 
mail (in an envelope marked “confidential”) to IDPH, Center for Acute Disease Epidemiology.  
The mailing address is:  
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th Street 
Des Moines, IA 50319-0075 
FAX:  515-281-5698 
 
3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements 
Minimum Period of Isolation of Patient  
No restrictions except for exclusion from blood donation.  
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Minimum Period of Quarantine of Contacts 
No restrictions.  
 
B.  Protection of Contacts of a Case 
None. 
 
C.  Managing Special Situations 
Locally Acquired Case 
A case of malaria acquired in the United States is possible but such cases are rare.  A case acquired 
in Iowa is even less likely.  If it is determined during the course of an investigation that a case does 
not have a recent travel history to an endemic country, measures such as investigating areas visited 
by the case to locate the focus of infection and surveillance of other people for illness may be 
necessary. Contact the Center for Acute Disease Epidemiology at (800) 362-2736.   
 
D.  Preventive Measures 
International Travel 
• People traveling to malaria-endemic parts of the world should be notified of their risk of 
contracting the disease and control measures they can take to protect themselves from 
mosquitoes. Travelers can take prophylactic antimalarial drugs prescribed by their healthcare 
provider and use repellents, wear protective clothing and use mosquito nets when rooms are not 
screened.  
• Detailed recommendations for preventing malaria are available 24 hours a day from the CDC 
Malaria Hotline, which can be accessed by telephone at (770) 488-7788, by fax at  (888) CDC-
FAXX or (888) 232-3299, or CDC’s website:   www.cdc.gov/malaria/  
• Travelers and recent immigrants from malaria-endemic regions with symptoms suggestive of 
malaria should be referred to a healthcare provider for prompt testing and treatment. Failure to 
treat individuals with malaria could lead to their becoming a local source of malaria transmission 
to mosquitoes if bitten, then to other people bitten by those mosquitoes. This is unusual, but has 
occurred in the United States.  
 
4) ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Malaria 
can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
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FACT SHEET MALARIA 
 
What is Malaria? 
Malaria is a parasite that spreads by infecting one after another two types of hosts: humans and female 
Anopheles mosquitoes. In humans, the parasites grow and multiply first in the liver cells and then in the red cells 
of the blood. In the blood, successive broods of parasites grow inside the red cells and destroy them, releasing 
daughter parasites ("merozoites") that continue the cycle by invading other red cells. 
 
Who is at risk for Malaria? 
Your greatest risk will happen when you travel outside the United States to places where there is malaria, 
for example South America, Southeast Asia, or sub-Saharan Africa.  However, even if you live in the 
United States, under very rare circumstances you could get malaria.  
 
How do you get Malaria? 
Usually, people get malaria by being bitten by a female mosquito. Only mosquitoes infected with malaria 
parasites (from a previous blood meal taken on an infected person) can transmit malaria. Very rarely, 
malaria can also be transmitted through blood transfusion, organ transplant, or shared use of 
contaminated needles or syringes. Malaria may also be transmitted from a mother to her fetus before or 
during delivery ("congenital" malaria).  
 
Can Malaria be spread from person-to-person? 
Malaria is not spread from person to person like a cold or the flu. You cannot get malaria from casual contact 
with malaria-infected people. 
 
What are the symptoms of Malaria? 
The classical (but rarely observed) malaria attack lasts 6 - 10 hours. It consists of: a cold stage 
(sensation of cold, shivering), a hot stage (fever, headaches, vomiting; seizures in young children), and 
finally a sweating stage (sweats, return to normal temperature, tiredness).  
 
More commonly, the patient has the following symptoms: fever, chills, sweats, headaches, nausea and 
vomiting, body aches, and general malaise.  
 
How soon will symptoms appear? 
The incubation period in most cases is from 7 - 30 (9-40) days. 
 
How can Malaria be prevented? 
In areas where malaria is common, prevent infected mosquitoes from biting you and take antimalarial 
drugs. Destroy the mosquitoes' breeding sites so that the mosquitoes cannot reproduce, and apply 
permethrin insecticides to the walls inside the home to kill adult mosquitoes.  Sleep inside bed nets, 
which will be even more effective if they have been treated with insecticides. Sleep in houses that are 
screened or air-conditioned, and avoid exposure to mosquitoes between dusk and dawn. If outdoors, 
apply insect repellants containing DEET to exposed skin and long-sleeved clothing or clothing treated with 
permethrin. 
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Malaria                           Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome: 
 Survived this illness     Died from this illness 
 Died unrelated to this illness    Unknown 
Date of Death      /     /      First name: 
 
      
Event exception 
 Case could not be found 
 Case could not be interviewed 
 Case refused interview 
 Other – see notes 
Provider title:  ARNP    DO 
 MD 
 NP  PA 
Outbreak 
related:  Yes      No      Unknown  
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Result date: 
 
     /     /      
 
Result type: 
 
 Preliminary      Final 
 
Test type: 
 
      Result: 
 Positive 
 Negative 
 
Organism: 
 
Plasmodium Type (e.g. serotype): 
 ovale 
 malariae 
 vivax 
 falciparum  
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Result date: 
 
     /     /      
 
Result type: 
 
 Preliminary      Final 
 
Test type: 
 
      Result: 
 Positive 
 Negative 
 
Organism: 
 
Plasmodium Type (e.g. serotype): 
 ovale 
 malariae 
 vivax 
 falciparum  
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Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Result date: 
 
     /     /      
 
Result type: 
 
 Preliminary      Final 
 
Test type: 
 
      Result: 
 Positive 
 Negative 
 
Organism: 
 
Plasmodium Type (e.g. serotype): 
 ovale 
 malariae 
 vivax 
 falciparum  
 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unknown 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
Symptoms: 
 Fever             
 Anorexia         
 Backache     
 Chills                   
 Cough 
 Encephalitis       
 Fatigue           
 Headache 
 Hypoglycemia      
 Joint pain 
 Muscle pain 
 Nausea 
 Otitis media 
 Photophobia 
 Pneumonia 
 Renal failure 
 Sweats  
Complications:  Anemia 
 ARDS 
 Cerebral malaria 
 Renal failure 
 
TREATMENT 
 
Antibiotics prescribed?   Yes    No    Unknown 
Antibiotic: 
 Artemether 
 Artesunate 
 Chloroquine 
 Doxycycline 
 Lumefantrine 
 Mefloquine 
 Quinidine gluconate 
 Quinine dihydrochloride 
 Sulfadoxine-pyrimethamine 
 Tetracycline 
 Other 
Antibiotic: 
 Artemether 
 Artesunate 
 Chloroquine 
 Doxycycline 
 Lumefantrine 
 Mefloquine 
 Quinidine gluconate 
 Quinine dihydrochloride 
 Sulfadoxine-pyrimethamine 
 Tetracycline 
 Other 
Antibiotic: 
 Artemether 
 Artesunate 
 Chloroquine 
 Doxycycline 
 Lumefantrine 
 Mefloquine 
 Quinidine gluconate 
 Quinine dihydrochloride 
 Sulfadoxine-pyrimethamine 
 Tetracycline 
 Other 
Date 
started: 
 
     /     /      
Date 
started: 
 
     /     /      
Date 
started: 
 
     /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
# of times 
a day:       
 
Route: 
 
      
# of times a 
day:       
 
Route: 
 
      
# of times 
a day:       
 
Route: 
 
      
Antibiotic: 
 Artemether 
 Artesunate 
 Chloroquine 
 Doxycycline 
 Lumefantrine 
 Mefloquine 
 Quinidine gluconate 
 Quinine dihydrochloride 
 Sulfadoxine-pyrimethamine 
 Tetracycline 
 Other 
Antibiotic: 
 Artemether 
 Artesunate 
 Chloroquine 
 Doxycycline 
 Lumefantrine 
 Mefloquine 
 Quinidine gluconate 
 Quinine dihydrochloride 
 Sulfadoxine-pyrimethamine 
 Tetracycline 
 Other 
Antibiotic: 
 Artemether 
 Artesunate 
 Chloroquine 
 Doxycycline 
 Lumefantrine 
 Mefloquine 
 Quinidine gluconate 
 Quinine dihydrochloride 
 Sulfadoxine-pyrimethamine 
 Tetracycline 
 Other 
Date 
started: 
 
     /     /      
Date 
started: 
 
     /     /      
Date 
started: 
 
     /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
# of times 
a day:       
 
Route: 
 
      
# of times a 
day:       
 
Route: 
 
      
# of times 
a day:       
 
Route: 
 
      
 
Antibiotic: 
 Artemether 
 Artesunate 
 Chloroquine 
 Doxycycline 
 Lumefantrine 
 Mefloquine 
 Quinidine gluconate 
 Quinine dihydrochloride 
 Sulfadoxine-pyrimethamine 
 Tetracycline 
 Other 
Antibiotic: 
 Artemether 
 Artesunate 
 Chloroquine 
 Doxycycline 
 Lumefantrine 
 Mefloquine 
 Quinidine gluconate 
 Quinine dihydrochloride 
 Sulfadoxine-pyrimethamine 
 Tetracycline 
 Other 
Antibiotic: 
 Artemether 
 Artesunate 
 Chloroquine 
 Doxycycline 
 Lumefantrine 
 Mefloquine 
 Quinidine gluconate 
 Quinine dihydrochloride 
 Sulfadoxine-pyrimethamine 
 Tetracycline 
 Other 
Date 
started: 
 
     /     /      
Date 
started: 
 
     /     /      
Date 
started: 
 
     /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
# of times 
a day:       
 
Route: 
 
      
# of times a 
day:       
 
Route: 
 
      
# of times 
a day:       
 
Route: 
 
      
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Risk Factors/Travel Information – In the 12 months  prior to onset of symptoms 
Traveled within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
Received blood/blood 
products:  Yes    No    Unk Date(s) received:      /     /        
Received organ 
transplant:  Yes    No    Unk Date received:      /     /       
Organ type:  Cornea      Heart      Kidney      Other                      
Malaria in the past 12 
months:  Yes    No    Unk Malaria type:   Falciparum      Malariae      Ovale      Vivax 
From date:      /     /      To date:      /     /       
 
NOTES:       
 
 
 
 
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation period for 
malaria 9 days to 12  
months 
Humans can infect mosquitoes 
and transfusional transmission 
can occur. Person to person is 
not documented.  
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MEASLES 
 
Also known as: Rubeola, Hard measles, Red measles, Morbilli 
 
Responsibilities: 
Hospital: Report by phone immediately 
Lab: Report by phone immediately 
Physician: Report by phone immediately 
Local Public Health (LPHA):  Report by phone immediately. Follow-up required 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY   
 
A. Agent 
Measles is caused by the measles virus (genus Morbillivirus, family Paramyxoviridae). 
 
B. Clinical Description 
Measles is an acute, highly communicable viral disease characterized by fever (generally as high as 
104o-105oF), cough, coryza, conjunctivitis, and maculopapular rash (the 3 C’s plus rash). Koplik spots 
(small spots with white or bluish-white centers on an erythematous base) may be present on the 
buccal mucosa. The rash is red and blotchy and appears on the third to seventh day; the rash begins 
on the face (hairline) proceeding downward and outward, reaching the hands and feet. Complications 
can include diarrhea, otitis media, pneumonia, encephalitis (1 per 1,000 cases), and death (1–3 per 
1,000 cases), in the United States.  Serious complications occur mostly from pneumonia and 
occasionally from encephalitis.  Immune compromised individuals are at increased risk for 
pneumonitis, encephalitis, and death. These complications can occur in 20–80% of HIV-infected and 
patients receiving chemotherapy. The characteristic rash sometimes does not develop in these 
patients. Asymptomatic carriage has not been documented. 
 
C. Reservoirs 
Humans are the only host. 
 
D. Modes of Transmission 
Measles is transmitted airborne by droplet spread, direct contact with nasal or throat secretions of an 
infected person, and, less commonly by articles freshly soiled with nose and throat secretions. 
Measles is one of the most highly infectious diseases.  
 
E. Incubation Period 
The time from exposure to symptom onset is about 10 days with a usual range of 7 - 18 days.  
Occasionally onset is as long as 19 - 21 days from exposure.  The rash usually appears about 14 days 
after exposure. Immune globulin given later than the third day of the incubation period, may extend 
the incubation period 
 
F. Period of Communicability or Infectious Period 
From 1 day before the beginning of the prodromal period (this is usually about 4 days before rash 
onset) to 4 days after the first appearance of the rash; (this is calculated by counting the day of rash 
onset as day zero). Immunocompromised patients may have prolonged excretion of the virus in their 
secretions and can be infectious for the entire duration of their illness. Measles is highly infectious, 
with up to 5,000 infectious particles excreted per hour. Infectious particles may remain suspended in 
Report Immediately 
by phone 
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the air for up to 2 hours, this is dependent upon the room’s ventilation, sunlight exposure and 
relative humidity. Thus someone may contract the disease without ever being in the same room with 
an infected person. There is >90% secondary attack rate in susceptible persons. 
 
G. Epidemiology 
Measles occurs worldwide. In the temperate zones, peak incidence is in late winter and early spring. 
One dose of MMR vaccine induces measles immunity in about 95% of people who receive it; 
however, due to measles’ extreme infectiousness, two doses, resulting in 99% immunity, are 
necessary to prevent outbreaks. Two doses, administered one month apart with the first dose being 
after 12 months of age, are recommended. 
 
In developing countries, case fatality rates average 3% – 5% but can range as high as 10% – 30% 
in some localities, and measles is the eighth leading cause of death worldwide. Since 1995, the 
incidence of measles in the United States has been very low, with only a few hundred cases reported 
each year. Indigenous transmission has been interrupted, thus almost all U.S. cases are imported, 
often from Europe and Asia. (Cases are considered imported from another country if the rash occurs 
within 18 days of entering the U.S. and the illness cannot be linked to local transmission.) 
 
In the spring of 2004 Iowa had 3 cases of measles, the first from exposure in a foreign country and 2 
cases from the first case.  During 2008, more measles cases were reported in the US than in any 
other year since 1997. Since 2004, Iowa has had occasional individual cases reported, but not every 
year. 
 
H.  Bioterrorism Potential 
None. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A.  Purpose of Surveillance and Reporting 
• To identify all cases and susceptible exposed people rapidly and to prevent additional cases and 
further transmission of this highly contagious disease. 
• To identify the source of infection so as to better understand how and why the case(s) occurred. 
•   To help in the international effort to eliminate indigenous transmission of measles from the 
Western Hemisphere. 
 
B.  Laboratory and Healthcare Provider Reporting Requirements   
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
immediately report any suspected or confirmed case. The reporting number for IDPH Center for 
Acute Disease Epidemiology (CADE) is (800) 362-2736. After business hours, call the Iowa State 
Patrol Office at (515) 323-4360 and they will page a member of the on-call CADE staff. 
 
What to Report to the Iowa Department of Public Health 
• A case of rash illness accompanied by fever, or 
• A suspect case of measles (with or without fever), as diagnosed by a healthcare provider, or 
• Positive IgM serologic test for measles (this is the preferred method), or 
• Significant rise between acute- and convalescent-phase titers in serum measles IgG, or 
• Total antibody level by any standard serologic assay, or Isolation of measles virus from a clinical 
specimen. 
 
Case investigation 
 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
report. Measles is an immediately reportable disease. Call the reporting number for IDPH Center for 
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Acute Disease Epidemiology (CADE) at (800) 362-2736 immediately upon identifying a suspect 
measles case. 
After completing the investigation and gathering case information, enter the information into the 
Iowa Disease Surveillance System (IDSS), or FAX the report form with supporting laboratory 
documentation to (515) 281-5698 or mail (in an envelope marked “Confidential”) to the IDPH/CADE, 
mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
Des Moines, IA 50319-0075 
 
Laboratory Testing Services Available 
Suspect measles cases should be reported immediately to the Iowa Department of Public Health,  
Center for Acute Disease Epidemiology (CADE) at (800) 362-2736 or after hours, 515-323-4360. At  
that time, CADE will consult on appropriate testing to be ordered and specimen transport to the State 
Hygienic Laboratory (SHL). Public health response should not be delayed pending the return of  
laboratory results. 
 
By using the Iowa SHL, transport time is significantly less, and results can be obtained more quickly. 
When submitting specimens to SHL, check the box in the demographics section of the order form  
directly below the clinician’s phone number and signature. This indicates the testing is being  
completed because of an imminent public health threat and the test will be performed without charge 
to the patient. Three specimens are needed (serum and two swabs): 
 
1. Blood Specimen for Serologic Testing 
• Measles IgM test—obtain testing when patient first presents, do not wait. Ideally, the 
specimen should be drawn at least 3 days after onset of rash to minimize the possibility 
of false negative results. Tests that are negative in the first 72 hours after rash onset 
should be repeated. IgM is detectable for at least 28 days after rash onset.  
• Measles total antibody paired-titer test—the measles IgM test above is greatly preferred 
because it provides an earlier result. SHL will run both an IgM and IgG if appropriate.  
• Often it is appropriate to also request a serologic test for rubella IgM, since the signs and 
symptoms of rubella infection may mimic measles. 
• Serology-collection for adults, 7 to 10 ml of blood in a red top or serum separator tube 
(SST), for infants, 2 to 3 ml of blood in a red top or serum separator tube (SST). Send to 
SHL on a cold pack, (not frozen) with a completed virus “Serology” test request form. 
 
2. Nasopharyngeal Swab and Throat Swab: 
These specimens should also be obtained when the suspect case first presents to the health care 
provider. 
• RT-PCR for measles and virus culture requires a nasopharyngeal swab and a throat swab 
collected and placed in separate M4 viral transport media (VTM). The VTM is kept cold 
and should be sent on a cold pack, (not frozen) with a completed "Viral and Chlamydia 
Detection and Bacterial PCR". Measles RT-PCR will be sent to CDC for testing as 
appropriate. 
• Virus culture for further characterization of the virus 
o Viral isolates will be sent to CDC for genotyping. Viral genotyping is an important 
component of measles surveillance and can help determine the source of the 
virus. (i.e. country of origin) 
 
Shipment of specimens— SHL will conduct testing for suspect measles cases at no charge. Please 
request serologic testing for IgM and IgG antibodies as appropriate, RT-PCR for measles (to be sent 
to CDC), and virus culture for measles. Contact the SHL virus-serology laboratory at (319) 335-4277 
or (319) 335-4500. 
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Ship using overnight, express mail, on ice packs to 
 
State Hygienic Lab 
Virus-Serology Laboratory 
102 Oakdale Campus, # H102 
Iowa City, IA 52242-5002 
 
For assistance with courier service, please contact SHL (319)335-4500 or IDPH (800)362- 2736. 
C.  Initial Questions to Ask Healthcare Provider and Patient 
In order to assess the likelihood that a suspect case is a true case prior to laboratory testing, IDPH 
and/or other public health staff helping in the investigation should ask about: 1) symptoms (rash 
onset, other clinical findings cough, coryza, conjunctivitis other) 2) measles immunization history, 3) 
country of origin and length of residence in US, 4) recent history of travel (to where and dates), 5) 
whether there were any recent out-of-town visitors (from where and dates), and 6) whether there 
was any recent contact with anyone with similar symptoms. 
 
3) CONTROLLING FURTHER SPREAD 
 
Minimum Period of Isolation of Patient 
Through the 4th day after the onset of rash (counting the day of rash onset as day zero). 
 
Minimum Period of Quarantine of Contacts 
Students and staff born in or after 1957, who are not appropriately immunized and do not have 
serologic evidence of immunity, will be excluded from school from the 5th through the 21st day after 
their exposure. If exposure was continuous and/or if multiple cases occur, susceptibles will be 
excluded through the 21st day after rash onset in the last case. Healthcare workers who are not 
appropriately immunized and do not have serologic evidence of immunity will be excluded from work 
from the 5th day after their first exposure through the 21st day after their last exposure. These 
restrictions for students, school staff, and healthcare workers apply even if they had received IG. 
 
A. Protection of Contacts of a Case 
1. Implement control measures before serologic confirmation. 
 
2. Inquire about contact with a known or suspected case or travel during the measles exposure 
period (8–18 days prior to onset). 
 
3. Isolate the case during his/her infectious period, as defined above. 
 
4. Identify all those exposed. Think in terms of the “zones of exposure” and consider members of 
the following groups, if they were in contact with the case during his/her infectious period. 
• Household members 
• School/child care contacts (students and staff) 
• Staff and patients at medical facility where patient was seen (including staff with and without 
direct patient contact) 
• Individuals at workplace of case (especially child care centers, schools, and medical settings) 
• Members of the same religious/social groups 
• Members of sports teams, or other extracurricular groups 
• Bus or carpool associates 
• Close friends 
• Persons potentially exposed at social events, travel sites, etc. 
 
Note: Measles is so contagious that sometimes everyone at an entire institution is considered 
exposed.   
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5. Identify high-risk susceptibles with whom the case had contact during his/her infectious 
period. Pregnant women, immunocompromised individuals, and infants < 12 months old should 
be referred to their healthcare provider. 
 
6. Identify all other susceptibles, that is, individuals w ithout proof of immunity as 
defined below: 
 
• Born in the United States before January 1, 1957  
(Year of birth as proof of immunity does not apply in healthcare settings); or 
• Two doses of measles containing vaccine, given at least 4 weeks apart, with both doses 
administered at >12 months of age; or 
• Serologic proof of immunity. 
• Documentation of physician-diagnosed measles 
Note:   
• Foreign-born individuals must have documentation of immunization or serologic proof of 
immunity. “Born before 1957” is not acceptable (see below for explanation). 
• Susceptibles include those with medical and religious exemptions to immunization. 
 
Year of Birth as Proof of Immunity—Epidemiologic data indicate that most individuals born in 
the United States before January 1, 1957 are immune to measles. This has not been found to 
apply to those born in other countries, where the epidemiology of measles is not well known and 
where measles immunization may not have been routine. 
 
Exceptions to the “1957 Rule” are employees in healthcare settings. Because persons born 
before 1957 have acquired measles in healthcare settings, vaccination of these older employees, 
including those who are United States-born, with 1 dose of measles, mumps, rubella (MMR) 
vaccine is recommended. Data suggest that healthcare personnel have a risk of acquiring 
measles that is 13-fold greater than that of the general population. Measles is highly 
transmissible and frequently misdiagnosed during the prodromal stage. It is essential that all 
healthcare personnel have documentation of measles immunity, regardless of their length of 
employment or whether they are involved in patient care. Although persons born before 1957 are 
generally considered to be immune to measles, serologic studies indicate that 5% - 9% of 
healthcare personnel born before 1957 may not be immune. 
 
7. Immunize all susceptibles. All susceptibles >12 months of age, for whom vaccine is not 
contraindicated, must be immunized, keeping in mind the following: 
 
• MEASLES VACCINE GIVEN WITHIN 72 HOURS OF EXPOSURE CAN PREVENT 
DISEASE. 
 
• The combined MMR vaccine is the preferred formulation for all those >12 months of age. It 
will provide additional protection against mumps and rubella. 
 
• Vaccinating an individual who may be incubating measles is NOT harmful. 
 
• Vaccinate susceptibles even if it is >72 hours post-exposure. It will protect against exposure 
to the next potential generation of cases. In addition, the situation should be viewed as an 
opportunity to vaccinate. 
 
• Immunization during an outbreak. During an outbreak, MMR may be given. However, 
seroconversion rates after MMR immunization are significantly lower in children immunized 
before the first birthday than are seroconversion rates in children immunized after the first 
birthday. Therefore, children immunized before their first birthday should be reimmunized 
with MMR at 12-15 months old (at least 4 weeks after initial measles immunization) and 
again at school entry (4-6years). 
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8. Consider recommending immune globulin (IG) for susceptibles with contraindications to 
measles vaccine if it is within 6 days of exposure. IG may be used within 6 days of exposure for 
susceptible household or other contacts for whom risk of complications is very high (particularly 
contacts under 1 year old, pregnant women or immunocompromised persons), or for whom 
measles vaccine is contraindicated. 
• The dose is 0.25ml/kg (0.11ml/lb) up to a maximum of 15 ml. 
• For immunocompromised persons 0.5 ml/kg is given, up to a maximum of 15 ml. 
 
Live measles vaccine should be given 5-6 months later to those for whom vaccine is not    
contraindicated. 
 
9. Isolation/exclusion (non-healthcare settings): 
a. Case 
Isolate and exclude the case during his/her infectious period (from 4 days before 
through 4 days after rash onset, counting the day of rash onset as day zero). 
He/she may return to normal activities on the 5th day. 
 
Criteria for isolation/exclusion of cases are more rigorous for immunocompromised 
individuals and for others in healthcare settings.  
 
b. Contacts 
• Susceptibles include all unvaccinated individuals without proof of immunity as 
specified in sections 5 and 6 above, including: 
 
   -   Medical/religious exemptions 
-   Individuals who have other contraindications to MMR vaccine 
- Those vaccinated >72 hours post exposure. 
- Those that received IG will be assessed on an individual basis 
 
• Quarantine susceptibles on days 5–21 post exposure. 
 
• Several criteria are used to determine when to quarantine susceptible contacts, and 
when they can return to normal activities, as outlined below. 
 
-   If there was a discrete (one-time) exposure— quarantine on days 5 through 21 
from that exposure. They may return to normal activities on the 22nd day. 
 
-   If there was continuous exposure— quarantine on days 5 through 21 from the 
day of rash onset in the case. (However, in healthcare settings, exclusion must begin 
5 days after the earliest exposure and extend through 21 days from the last 
exposure.) They may return to normal activities on the 22nd day. 
 
-   If there is more than one case of measles—susceptibles will need to be 
quarantined until 21 days after the onset of rash in the last reported case in the 
outbreak setting. They may return to normal activities on the 22nd day. 
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Summary of Measles Exclusion Requirements 
 
Case and Symptomatic Contacts Asymptomatic Contacts 
Isolate through the 4th day after rash onset 
(count day of rash onset as day zero).  They 
may return to normal activities on the 5th day. 
One case: Quarantine susceptibles for 5–21 days 
post-exposure. 
Multiple cases: Quarantine susceptibles for 21 days 
from date of rash onset in last case. 
Healthcare settings: Exclude or quarantine 
susceptibles from 5 days after the earliest exposure 
through 21 days after the last exposure. 
 
10.  Conduct surveillance for 2 incubation periods after rash onset in the last case or the last 
exposure in the setting, whichever is later. 
 
B.  Managing Special Situations 
1.   School Settings 
Remember to determine if there are any: 
• Pregnant teachers, staff (including those without direct contact with students) and students (do 
not forget about student teachers) anywhere in the school. 
• Immunocompromised individuals among the students, teachers and staff anywhere in the school. 
• Medical/religious exemptions anywhere in the school, among both students and staff.  It is 
particularly important to identify these individuals in the classroom and grade of cases.  
Remember, these susceptible individuals must be excluded from attending school until 
2 incubation periods after the last case. 
 
Exclusion criteria: 
• Susceptible contacts, including those in classrooms, extracurricular activities, and other 
settings, who have already received one dose of MMR and receive a second dose of 
measles vaccine within 72 hours of exposure, can be readily readmitted; otherwise, 
they should be excluded as discussed above.   
 
• In some settings, individuals who have received their first or second dose >72 hours post 
exposure, but within a specified time period (as determined by the Iowa 
Department of Public Health and with the local board of health), may be allowed to 
continue to attend classes. 
 
If multiple cases occur, guidelines may be revised to include other classrooms and their teachers. 
 
Interactions in sports and other extracurricular activities facilitate the spread of measles. 
Additional recommendations to prevent the spread of measles between schools can be found in the 
table below, “Control Guidelines for Sports Teams and Extracurricular Groups.” 
 
Iowa Department of Public Health 
Control Guidelines for Sports Teams and Extracurricular Groups 
Control guidelines DIFFER and are dependent on whether measles is currently occurring at your 
institution. Schools without cases, but that will be involved with an institution that is 
experiencing cases, also need to follow control guidelines. Please refer to the appropriate 
category below for the recommendations for your facility. 
A.  At the School where Measles Cases Are Reported: 
  
1.  All students, staff, supporters and media personnel leaving to attend activities at other schools or 
participating in sports or other group activities at your school must have proof of immunity as 
defined below: 
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• Born in the United States before January 1, 1957, or 
• Two doses of measles vaccine with both doses administered at >12 months of age, given at 
least 4 weeks apart (the second dose must have been given before the rash onset of 
the first case, or within 72 hours of exposure to the known case), or 
• Serologic proof of immunity 
• Documentation of physician-diagnosed measles 
 
If the second dose of measles-containing vaccine is given >72 hours after the onset of the first case, 
the student must wait 21 days before participating in sporting events or traveling to another 
school.  If multiple cases occur, the student must wait until 21 days after the onset of rash in the last 
reported case in the outbreak setting. 
 
2.  Notify the schools to which students are traveling and inform them of: 
 
• The cases or suspected cases at your school 
 
• The immune status of your students and staff who will be traveling to the other school 
B.  Schools without Measles Cases Receiving Students from or Traveling to a School with 
Measles Cases: 
 
All students, staff, supporters and media personnel, participating in activities with students from a 
school with cases, must have proof of immunity as defined below. 
 
• Born in the United States before January 1, 1957, or 
• Documentation of physician-diagnosed measles 
• Two doses of measles vaccine with both doses administered at >12 months of age, given at 
least 4 weeks apart (as outlined above), or 
• Serologic proof of immunity 
 
 
2.   Healthcare Settings 
Recommendations for healthcare facilities are more rigorous.  
a. Proof of immunity—The risk of acquiring measles in medical settings is up to 13-fold higher 
than in other settings. Therefore, documentation of immunity is extremely important.   
• All staff born on or after January 1, 1957 should have proof of two doses of measles vaccine 
or serologic proof of immunity, with a second dose having been given <72 hours after 
exposure.   
• Medical personnel born before January 1, 1957 have acquired measles from cases in medical 
facilities.  Therefore, strong consideration should be given to requiring at least one dose of 
measles vaccine for staff born before 1957.  Vaccinating immune persons is not harmful. 
• In special high-risk healthcare settings such as transplant, oncology, neonatal units, etc., 
exclusion criteria should be even more rigorous. Infection prevention personnel may wish to 
exclude all susceptible personnel even if they have been immunized within 72 hours. 
 
b. Initial management of patients with febrile rash illness—Assess and screen all patients 
with febrile rash illness, either prior to or immediately on arrival at the intake area. 
• Escort patients to a separate waiting area or place immediately in a private room. 
• Both patients and staff should wear appropriate masks/respirators (masks for patients to 
prevent generation of particles, and respirators for staff, if possible, to filter airborne 
particles). 
• If not admitted, maintain airborne precautions (including while patient is exiting the facility, 
e.g., separate exit). Patients should be instructed to remain in isolation at home, through 4 
days after rash onset (with onset of rash being day zero). 
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• Measles virus can remain suspended in the air for up to 2 hours. Therefore, we recommend 
that susceptible patients NOT be placed in a room, which has been occupied by a suspect 
case for 2 hours following the case’s exit from that room. 
 
c. Infectious period  
• Cases are considered to be infectious from 4 days before rash onset through 4 days after 
rash onset, counting the day of rash onset as day zero. Therefore, cases are considered 
infectious for a total of 9 days. 
• Immunocompromised patients may have prolonged excretion of viral particles in their 
secretions, and should be considered infectious for the duration of their illness. 
 
d. Exclusion/isolation of cases   
• Personnel who become sick should be excluded from work for 4 days after they develop a 
rash consistent with measles. They may return on the 5th day. 
• If admitted, patients should be on airborne precautions (in addition to standard 
precautions) while infectious (4 days before rash onset through 4 days after rash onset) in a 
negative pressure room. They may be taken off isolation on the 5th day. 
• If not admitted, patients should maintain respiratory isolation while exiting the facility, 
e.g., mask, separate exit, and remain in isolation at home through 4 days after rash onset. 
They may return to normal activities on the 5th day. 
 
e. Exclusion/isolation of contacts—The exclusion periods are extended in the healthcare 
setting.   
• Susceptible staff contacts should be excluded from the 5th day after the earliest exposure 
through the 21st day after the last exposure to the case during his/her potential infectious 
period (as defined above). They may return on the 22nd day. 
• Susceptible hospitalized patient contacts should be placed in airborne infection 
isolation, includes negative pressure room, from day 5 after the earliest exposure through 
day 21 after the last exposure to the case during his/her potential infectious period (as 
defined above). They may be taken off isolation on the 22nd day. 
The above recommendations are summarized in the table below, “Measles Control in Medical 
Settings.” 
 
Iowa Department of Public Health 
Measles Control in Medical Settings 
 
This table summarizes additional control measures to decrease nosocomial measles transmission. 
 
1.  Assess and screen all patients with rash illness or with other potential airborne diseases, prior to 
arrival at intake area, i.e. outside. 
 
2.  Escort patients to a negative pressure private room.  
 
3.  Both patients and staff should wear appropriate masks/respirators (masks for patients to prevent 
generation of particles, and respirators for staff, if possible, to filter airborne particles). 
 
4.  If admitted: maintain on airborne precautions (in addition to standard precautions) while infectious in 
a negative pressure room. (Patients are considered infectious for 4 days before through 4 days after 
rash onset, counting the day of rash onset as day zero.) 
 
5.  If not admitted: maintain respiratory isolation, including while patient is exiting the facility, (e.g., 
mask, separate exit). Ideally the patient would be assessed outside of the healthcare facility.  Patient 
should remain in isolation at home through 4 days after rash onset, counting the day of rash onset as 
day zero. The patient may resume normal activities on the 5th day. 
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6.  Avoid placing susceptibles in a room, which has been occupied by a suspect case for 2 hours following 
the case’s exit. 
 
7.  Identify all contacts among patients and staff:   
• This includes patients and families in the waiting and examination rooms up to 2 hours after index 
case was present; 
• Includes all staff both with and without direct patient contact; 
• Due to airborne route of transmission, those exposed often include everyone at the entire facility. 
 
8. Identify susceptibles (particularly high-risk susceptibles) and offer: 
• MMR as soon as possible but within 72 hours of exposure (will most likely prevent illness if given 
in this window), or 
• For high-risk susceptibles and those ineligible for vaccination, IG as soon as possible but within <6 
days after exposure (may modify or prevent illness, but a recipient can still be considered 
infectious)  
 
9.   Notify infection prevention, employee health, department heads and the healthcare providers of 
exposed patients. 
• Post a “Measles Alert.”  
 
10. Exclusion of susceptibles:   
• All staff born in or after 1957, who have not received a second dose of measles vaccine <72 hours 
post exposure, must be excluded from 5 days after their earliest exposure through 21 
days after their last exposure to the case during his/her potential infectious period.  
• All staff born before 1957 that have not received 1 dose of MMR <72 hours post exposure must 
be excluded 5 through 21 days post exposure.   
• Staff who contract measles should be excluded for 4 days after their first day of rash onset.   
In special high-risk healthcare settings such as transplant, oncology, neonatal units, etc., exclusion 
criteria should be even more rigorous. Infection prevention personnel may wish to exclude all 
susceptible personnel even if they have been immunized within 72 hours. 
 
3.   Management and MMR Vaccination of HIV-Infected Individuals and their Contacts 
The American Academy of Pediatrics (AAP) and the Advisory Committee on Immunization Practices 
(ACIP) have recently revised their recommendations regarding the management of HIV-infected 
individuals exposed to measles, as well as the routine MMR immunization of those with HIV infection, 
particularly those with severe immunosuppression. These guidelines, applicable to children and 
adults, are summarized below. 
 
a. Management of HIV-Infected Individuals Exposed to Measles 
1) MMR or IG should be given, depending on the situation: 
• Asymptomatic HIV-infected individuals who are not severely 
immunosuppressed (i.e., with higher age-specific CD4+ T-lymphocyte counts or 
percentages than those in the table on the next page), if susceptible and exposed < 3 
days prior should receive MMR vaccine. 
 
• Asymptomatic HIV-infected individuals who are not severely 
immunosuppressed (i.e., with higher age-specific CD4+ T-lymphocyte counts or 
percentages than those in the table on the next page), if susceptible and exposed 3–6 
days prior should receive 0.25cc/kg IM immune globulin (maximum 15cc). Live measles 
vaccine should be given 5-6 months later to those for whom vaccine is not 
contraindicated. 
 
• Symptomatic HIV-infected individuals who are severely immunosuppressed 
(as defined in the table on the next page), regardless of past history of immunizations or 
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disease, unless they have recent serologic proof of immunity should receive IG 0.5cc/kg 
IM (15cc max). 
 
2) If an individual has received intravenous immune globulin (IVIG) (400 mg/kg) < 3 weeks 
before exposure, no additional IG is required. However, some experts recommend an 
additional dose of IVIG if > 2 weeks have elapsed since last treatment. (Remember, when 
deciding to vaccinate these individuals, MMR vaccine should be given > 2 weeks before any 
IG or other blood products.) 
 
b. Management of Contacts of HIV-Infected Individuals Who Are Themselves Exposed 
to Measles 
• If they are susceptible and exposed < 3 days prior, they should receive MMR vaccine.  
There is no shedding from the MMR vaccine. 
• If they are susceptible and exposed 3–6 days prior, they should receive IG and live 
measles vaccine should be given 5-6 months later to those for whom the vaccine is not 
contraindicated. 
 
c. General Guidelines for the Use of MMR Vaccine in HIV-infected and Potentially HIV-
infected Individuals 
1) Prevaccination HIV testing is NOT recommended. 
 
2) MMR vaccine is recommended for routine immunization of individuals with asymptomatic 
HIV infection who do not have evidence of severe immunosuppression. 
 
3) MMR vaccine should be considered for all symptomatic HIV-infected persons who do not 
have evidence of severe immunosuppression, as defined in the table below. 
 
4) It is now recommended that severely immunocompromised HIV-infected individuals 
(as defined by low CD4+ counts or low percent of CD4+ circulating lymphocytes—see table 
below) should NOT receive MMR or other measles-containing vaccines.  
Measles-containing vaccines are contraindicated for HIV infected individuals with 
the following: 
 
 
Age Group 
 
Total CD4+ Count 
 
or 
CD4+ as a % of 
Total Lymphocytes 
< 12 mo. < 750/mcL or < 15% 
1-5 years < 500/mcL or < 15% 
6-12 years < 200/mcL or < 15% 
> 13 years < 200/mcL or < 14% 
 
5) It is now recommended that severely immunocompromised HIV-infected individuals 
(as defined by low CD4+ counts or low percent of CD4+ circulating lymphocytes—see above 
table) should NOT receive MMR or other measles-containing vaccines.  
 
6) Since the immunologic response to vaccines is often poor in HIV-infected patients, the first 
dose of MMR should be given as early as possible after 12 months old. This will increase the 
chance of an adequate immune response, before further deterioration of the immune system. 
 
7) Give the second dose of MMR 4 weeks after the first. This will increase the likelihood of 
seroconversion. 
 
8) During outbreak situations only, consider giving the first dose of monovalent measles 
vaccine or MMR if monovalent is unavailable at 6–11 months of age to those infants who are 
not severely immunocompromised. Remember, these children must be revaccinated with 
2 doses of MMR beginning at 12 months of age. 
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C.  Preventive Measures 
Personal Preventive Measures/Education 
Vaccination, including routine childhood vaccination, catch-up vaccination of adolescents, and 
targeted vaccination of high-risk adult groups (including international travelers), is the best 
preventive measure against measles. It is particularly important to vaccinate susceptible household 
contacts of high-risk susceptibles who cannot themselves be vaccinated, such as 
immunocompromised individuals, pregnant women, and infants. Good personal hygiene (which 
consists of proper handwashing, disposal of used tissues, not sharing eating utensils, etc.) is also 
important in preventing measles.   
 
Please refer to the most current versions of the Advisory Committee on Immunization Practices 
(ACIP) statement on measles, rubella, and mumps.  
 
4) ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Measles 
can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
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FACT SHEET                                                              MEASLES 
       (Rubeola, Hard measles, Red measles, Morbilli) 
 
What is measles? 
Measles is an acute, highly communicable viral disease. Complications include diarrhea, ear infection, 
pneumonia, brain swelling and death. 
 
Who gets measles? 
Anyone, regardless of age, who has not had measles or has not been adequately immunized, may get the 
disease. Most cases occur in unimmunized preschoolers and young adults. 
  
How is measles spread? 
Measles is spread through the air by droplets from the nose, throat, and mouth of an infected person by 
coughing, sneezing, or simply talking. 
 
How soon do infected people get sick? 
The fever usually a start 7 - 18 days after infection, rash appears approximately 14 days after infection. 
  
What are the symptoms of measles? 
Measles causes a high fever, cough, runny nose, watery eyes, and a red rash that moves from the face to the 
rest of body. The symptoms may last from 1 - 2 weeks. 
 
How long is an infected person able to spread measles? 
An infected person is able to spread measles from 4 days before the rash starts to 4 days after the rash 
appears. 
  
What should you do if you think you may be infected? 
Call your healthcare provider and discuss your symptoms and any possible exposure before showing up at the 
clinic. The physician will advise you to either come to the clinic or arrange for you to be seen at a different 
location so other people are not exposed. 
  
Can a person get measles again? 
No. One attack of measles provides protection for life. 
 
What is the treatment for measles? 
There is no specific treatment for measles disease. Treating the symptoms such as a fever with Tylenol and 
itching with cool soaks may provide some relief.  However, infants with high fever (>101.4) and children with 
headaches should be seen and treated by a doctor.  
 
Should people who have been around a person infected with measles be treated? 
Live measles vaccine provides permanent protection and may prevent disease if given within 72 hours of 
exposure. Immune globulin (IG) may prevent or modify disease if given within 6 days of exposure. 
 
How can the spread of measles be stopped? 
Vaccinate anyone who has not had measles or who has not had 2 measles vaccinations. Children require 2 doses 
for school entry. Adults born in and after 1957 also need vaccination, if they can not provide proof of 2 doses of 
vaccine, or the results of a blood test showing evidence of immunity. 
 
Does measles vaccine cause reactions? 
Adverse reactions following measles vaccination are generally mild and usually consist of fever and brief rash 5 - 
12 days post vaccination. MMR vaccine does not contain thimerosol; there is no evidence that any vaccine causes 
autism or autism spectrum disorder. On rare occasions (1 in every million doses) a child may have a more serious 
reaction to MMR vaccine such as inflammation of the brain (encephalitis). MMR vaccine may be administered to 
egg-allergic children without prior routine testing or the use of special protocols. 
 
Where can a person receive measles vaccine? 
You may receive your vaccines from your doctor, your local public health clinic, WIC providers, or where 
your baby gets their well baby check-ups. 
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Measles                                  Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis 
date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider title: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes   No  Unk To whom: ______________  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Measles virus  
 
   
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Measles virus  
 
   
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Measles virus  
 
   
 
 
  
Center for Acute Disease Epidemiology                                                    Fax: 515-281-5698                   Measles                           Revised Feb-11          1 
CONFIDENTIAL                     PATIENT NAME: ______________________________                Iowa Department of Public Health 
 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
S
ym
pt
om
s 
Fever  Yes    No    Unk Onset date:      /     /      Duration:       hrs/days 
Date returned to normal 
activities:      /     /      
Cough  Yes    No    Unk Onset date:      /     /      
O
th
er
 s
ym
pt
om
s  Abdominal cramps     
 Backache     
 Chills    
 Encephalitis     
 Fatigue     
 Fever   
 Sore throat 
 Vomiting  
 Headache 
 Joint pain     
 Muscle pain     
 Nausea     
 Otitis media 
 Photophobia    
 
Runny nose  Yes    No    Unk Onset date:      /     /      
Red eyes w/t 
drainage  Yes    No    Unk Onset date:      /     /      
Diarrhea  Yes    No    Unk Onset date:      /     /      
Thrombocytopenia  Yes    No    Unk Onset date:      /     /      
Arthritis  Yes    No    Unk Onset date:      /     /       
Other 
complications:       Describe:       
   
Rash:  Yes    No    Unk Onset date:      /     /      Duration:       hours/days 
Fever continued w/t rash:   Yes    No    Unk Rash spreading:  Yes    No    Unk 
Rash equally distributed:  Yes    No    Unk Rash appeared at once:  Yes    No    Unk 
Lesions present:  Yes    No    Unk  Rash initial location:  Arms    Face    Legs    Trunk     Inside mouth 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
 
       cm    Heaviest lesion area:  Arms    Face    Legs    Trunk    Scalp 
# of days for first lesion to crust:       days Areas present:  Inside mouth      Palms         Soles 
Lesions in same stage of 
development:  Yes    No    Unk Severity: 
 < 50 lesions          
 50 – 249 lesions 
 250 – 500 lesions        
> 500 lesions 
Rash characteristics: 
 Burning     
 Confluent lesions      
 Could be felt (papule) 
 Could not be felt (macule) 
 Discrete lesions                               
 Distinct sharp borders 
 Dusky brown 
 Marked itching 
Numbness 
 Painful   
 Peeling skin       
 Pustule 
 Reddish    
 Scaling/crusting 
Koplik’s spots:  Yes    No    Unk    
Healthcare provider visited:  Yes    No    Unk Date(s) visited:      /     /     ,      /     /     ,      /     /      
Swollen lymph nodes:  Yes    No    Unk Location:       
 
TREATMENT 
 
Antivirals prescribed:   Yes    No    Unknown 
  
Antiviral:       
 
Antiviral:       
 
Antiviral:       
Date 
started:      /     /      
Date 
started:      /     /      
Date 
started:      /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
 
Therapeutic medications prescribed?  Yes    No    Unk 
List medications:       
 
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Vaccinated with MMR:  Yes    No    Unknown 
  
Date 
vaccinated: 
 
     /     /      
  
Date 
vaccinated: 
 
     /     /      
  
Date 
vaccinated: 
 
     /     /      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
 
Number of vaccinations:       
 
In the 21 days prior to the onset of symptoms did the case: 
Traveled within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
 
Born outside the U.S.? 
 
 Yes    No    Unknown Country outside the U.S.: 
 
Immunocompromised? 
 
 Yes    No    Unknown 
 
 
 
 
 
 
 
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation 
period for measles 
is up to 21 days.  
Measles is communicable 1 day 
before the onset of symptoms to 4 
days after the rash appearance.  
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In the 1 day prior to the onset of rash through 4 days after the onset of rash did the case: 
Use public transportation:  Yes    No    Unk 
Date(s) used: Time(s) used: Type: Route: 
     /     /                        
     /     /                        
     /     /                        
 
Visit a doctor’s office, clinic or hospitals:   Yes    No    Unknown 
If Yes, complete the following table: 
Facility 
name:       
 
 
 
Facility 
name:       
 
Address: 
 
      
 
Address:       
Zip 
code: 
 
      
 
City: 
 
      
Zip 
code: 
 
      
 
City: 
 
      
      
State:       
 
County: 
 
      
      
State:       
 
County: 
 
      
Phone: (     )-     -      
 
   Type:       Phone: (     )-     -      
 
   Type:       
Date 
visited:      /     /      
Time 
visited:       
Date 
visited:      /     /      
Time 
visited:       
Provider 
name:       Title:       
Provider 
name:       Title:       
 
Visit a public places:  Yes    No    Unknown 
If Yes, complete the following table: 
Location name Address/City/State/Zip Phone Date(s) visited Time visited 
            (     )-     -      
 
     /     /            
            (     )-     -      
 
     /     /            
            (     )-     -      
 
     /     /            
 
Attend religious gatherings:  Yes    No    Unknown 
If Yes, complete the following table: 
Location name Address/City/State/Zip Date(s) attended Time attended  Describe interactions: 
            
 
     /     /                   
            
 
     /     /                   
            
 
     /     /                   
 
Attend family gatherings:  Yes    No    Unknown 
If Yes, complete the following table: 
Location name Address/City/State/Zip Date(s) attended Time attended  Describe interactions: 
            
 
     /     /                   
            
 
     /     /                   
            
 
     /     /                   
 
Attend other gatherings:  Yes    No    Unknown 
If Yes, complete the following table: 
Location name Address/City/State/Zip Date(s) attended Time attended  Describe interactions: 
            
 
     /     /                   
            
 
     /     /                   
            
 
     /     /                   
 
Setting Acquired: 
Child care 
Church 
College 
Correctional Facility 
Doctors office 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
Hospitalized 
International traveler 
Military 
Hospital ER/ 
Outpatient 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 
Home 
School 
Urgent care 
Work 
Other 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
      
Disease traced within 2 generations of known 
international import?  Yes    No    Unk 
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Number of people living in case’s household:          
Close contacts of the case (For more than one contact, print/copy additional contact pages.)  
Last name:       Address:       
First name:        City/State/Zip:       County:       
DOB:      /     /      Age:       Phone:       Type:       
Gender:  Female      Male      Other Symptoms present:  Yes    No    Unk Onset date:      /     /      
  If this contact has an onset date before this case then create a new case and event. 
Symptoms: 
Fever  
Runny nose  
Rash  
Chills  
Fatigue  
Joint pain  
Nausea  
Photophobia  
Sore throat  
 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
 
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
Vomiting  
Cough  
Red eyes w/t discharge  
Backache  
Encephalitis  
Headache  
Muscle pain  
Otitis media  
Pneumonia  
Swollen lymph nodes  
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
Vaccinated for measles (MMR):  Yes    No    Unk Number of vaccinations:       
 
Date vaccinated:      /     /      
 
Date vaccinated:      /     /      
 
Date vaccinated:      /     /      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
Exposed to measles:  Yes    No    Unk Received MMR within 3 days of exposure:  Yes    No    Unk 
Received IG within 6 
days of exposure:  Yes    No    Unk Date received:      /     /      Dose:       Unit:       Route:       
Tested for immunity:  Yes    No    Unk Result:  IgM+    IgM-    IgG+    IgG- Is this contact a case?  Yes    No    Unk 
 
NOTES:       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONTACTS 
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Name DOB 
Exposed to 
case 
Vaccinated 
for measles 
Number 
of 
doses 
Dates of 
vaccination 
Received MMR 
due to this 
exposure 
Received IG 
due to this 
exposure Notes 
           /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk            /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk       
           /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk            /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk       
           /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk            /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk       
           /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk            /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk       
           /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk            /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk       
           /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk            /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk       
           /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk            /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk       
           /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk            /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk       
           /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk            /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk       
           /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk            /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk       
           /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk            /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk       
           /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk            /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk       
           /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk            /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk       
           /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk            /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk       
           /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk            /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk       
           /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk            /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk       
           /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk            /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk       
           /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk            /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk       
           /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk            /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk       
           /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk            /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk       
           /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk            /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk       
           /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk            /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk       
           /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk            /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk       
           /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk            /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk       
           /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk            /     /      
 Yes    No   
 Unk 
 Yes    No   
 Unk       
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Guide to Surveillance, Investigation, and Reporting 
Meningococcal Infection  
(Invasive) 
 
Also known as: Spinal or bacterial Meningitis, Meningococcemia 
 
Responsibilities: 
Hospital/Infection Preventionist: Report by phone immediately  
Lab: Report by phone immediately; send all isolates from invasive sites to SHL for testing and 
serogrouping 
Physician: Report by phone immediately 
Local Public Health Agency (LPHA): Follow-up required 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Invasive meningococcal infections are caused by the bacterium Neisseria meningitidis 
(meningococcus), a gram-negative diplococcus. There are 13 serogroups of N. meningitidis; nine of 
these serogroups are known to cause invasive disease (A, B, C1+, C1-, L, X, Y, W-135, and Z) in 
humans.  
 
Note: Other organisms, including several viruses, can cause meningitis. This chapter is only referring 
to meningitis caused by N. meningitidis. 
 
B. Clinical Description 
Symptoms 
Invasive infection with N. meningitidis may cause several clinical syndromes, including meningitis, 
bacteremia, sepsis or pneumonia. Symptoms of meningitis (infection of the meninges, the 
membrane covering the brain and spinal cord) typically include the sudden onset of a stiff neck, high 
fever and headache. A petechial rash (small red pinpoints that do not blanch when compressed) may 
also be present. Nausea, vomiting and mental confusion are often also present. Meningococcemia 
(infection of the blood) typically presents with the abrupt onset of fever, chills, malaise, prostration 
and rash (urticarial, maculopapular, purpuric or petechial).  
 
Onset is usually abrupt.  
 
Complications  
Fulminant cases who present with purpura (large areas of subdermal bleeds), disseminated 
intravascular coagulation, shock, and/or coma and may lead to death within hours, despite 
appropriate therapy. The case-fatality rate for meningococcal meningitis and meningococcemia is 
about 5% − 15%, even with appropriate antibiotic treatment. Persons with certain complement 
deficiencies (blood disorders that cause immunosuppression) are more susceptible, as are persons 
without a spleen or a functioning spleen. 
 
C. Reservoirs 
Humans are the only known reservoir of N. meningitidis.  Approximately 5 to 10% of the population 
may carry this bacteria in the nasopharynx at any given time. 
Report  Immediately 
by Phone 
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D. Modes of Transmission 
The principal mode of transmission of N. meningitidis is person-to-person through direct contact with 
a case’s oral or nasal secretions. The bacteria may also be spread through droplets or via an 
inanimate vehicle contaminated with saliva (e.g., a cigarette, baby’s toy or water bottle). 
 
E. Incubation period 
The incubation period ranges from 2 − 10 days, with an average incubation period of 3 − 4 days.  
Due to the asymptomatic carrier state, it is usually difficult to determine when exposure occurs. 
 
F. Period of Communicability or Infectious period 
Cases remain infectious as long as meningococci are present in oral secretions or until 24 hours after 
initiation of treatment with the appropriate antibiotic.  Most carriers do not easily spread the 
organism. 
 
G. Epidemiology 
Sporadic cases and occasional outbreaks of invasive meningococcal disease occur worldwide. A 
“meningitis belt” extends from sub-Saharan Africa into India/Nepal, and invasive meningococcal 
disease due to N. meningitidis serogroup A is considered endemic in these areas. Epidemics of 
meningococcal meningitis also occur in this meningitis belt every 8 - 12 years and last from 2 - 4 
years. Seasonal variations occur in these epidemics.  Highest rates usually occur in dry, hot seasons, 
(December through June). The prevalent serotypes of N. meningitidis in other parts of the world may 
vary over time and by geography. 
 
In the United States, the largest number of cases of invasive meningococcal disease usually occurs 
during the winter and early spring, coincident with an increase in the occurrence of acute respiratory 
infections. Historically in the U.S., cases of invasive meningococcal disease were most commonly 
seen in children <11 years old. Sporadic cases of meningococcal disease account for more than 98% 
of cases. Meningococcal pneumonia is more commonly seen in older patients. In the U.S., outbreaks 
of invasive meningococcal disease occur most frequently in crowded conditions (i.e., military bases, 
college dormitories). Cases of invasive meningococcal disease in the U.S. are most often caused by 
serogroups B, C and Y (each accounting for approximately 30% of reported cases), although other 
serogroups are also seen sporadically. Epidemics of invasive disease are most commonly associated 
with serogroups C and Y. Serogroup A is seen rarely in the U.S. Over the last 10 years, Iowa reported 
cases have averaged 29 per year, with deaths averaging 3 per year. In 2011, Iowa reported 12 
cases; 6 were group B, 4 were group Y, 2 were group W-135, and 2 were undetermined. 
 
Meningococcal carriage: N. meningitidis typically colonizes the nose and throat of 5-10% of the 
general population at any given time. These carriers are generally asymptomatic, and carriage of the 
bacteria may act as an immunizing exposure. By young adulthood, the majority of people in the 
United States have measurable antibody to the pathogenic serogroups of N. meningitidis.  Carriers 
can spread the bacteria to others through saliva and respiratory secretions. Factors that increase 
colonization are antecedent upper respiratory tract infection, household crowding and both active and 
passive smoking.  
 
H. Bioterrorism Potential 
None. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To identify close contacts of the case and provide recommendations for appropriate preventive 
measures and thus prevent further spread of infection. 
• To provide information about the disease, its transmission, and methods of prevention.  
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• To promptly identify clusters or outbreaks of disease and initiate appropriate prevention and 
control measures. 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
immediately report any suspected or confirmed case. The disease reporting number for the Center 
for Acute Disease Epidemiology (CADE) is (800) 362-2736.After business hours, call the Iowa State 
Patrol Office at (515) 323-4360 and they will page a member of the on-call CADE staff. 
 
Laboratory Testing Services Available  
The State Hygienic Laboratory (SHL) will confirm and serogroup isolates of N. meningitidis.  
Laboratories are required to submit all isolates cultured from normally sterile sites for serogrouping. 
This serogrouping aids in public health surveillance and prevention of transmission. In addition, SHL 
will isolate the organism from appropriate clinical samples upon request. For more information on 
submitting specimens, contact SHL at (319) 335-4500, or visit: www.shl.uiowa.edu/  
 
Note: Isolates obtained from sputum or throat cultures are not considered to come from sterile sites; 
therefore N. meningitidis from these sites is in itself not indicative of invasive disease and is not 
reportable. If a patient with culture-positive sputum has an illness compatible with invasive 
meningococcal disease, this should be reported and the appropriate sterile sites should then be 
cultured.  
 
C.  Local Public Health Agency Follow-up Responsibilities 
Case Investigation 
a. Report suspect or confirmed cases of meningococcal disease immediately to CADE by calling 
(800) 362-2736. This disease requires immediate follow-up with prophylaxis given to contacts of 
the case. 
 
b. After notification of CADE, it is the LPHA, along with the hospital infection preventionist’s, 
responsibility to investigate by asking the questions on and complete an Invasive Meningococcal 
Disease Case Investigation form by interviewing the case and/or others who may be able to 
provide pertinent information. CADE staff is available 24/7 to assist in the follow-up of a case. 
The preferred method of case investigation is by using the Iowa Disease Surveillance System 
(IDSS). 
 
c. The main focus when following up a case of invasive meningococcal disease is to prevent 
additional cases of disease in contacts of the case. The investigation form will assist in collecting 
the appropriate information for complete contact identification and referral.  
 
d. The first step to following up a case of invasive meningococcal infection is to confirm the 
diagnosis.  Often, reported cases of “meningitis” are ultimately found to be caused by bacteria 
other than Neisseria meningitidis or by a virus. Ask for antigen testing if antibiotics were started 
before cultures were taken.  When N. meningitidis is suspected or confirmed, public health 
actions need to be taken quickly to protect contacts.  
 
e. Use the following guidelines to assist you in completing the Meningococcal Disease Case 
Investigation form. 
1) Accurately record the demographic information, collecting as much case information as 
possible, including address, place of work, occupation, and child care or school information. 
2) If the case is hospitalized, collect hospital and transfer hospital information, if applicable. 
Hospital laboratories, direct caregivers and infection prevention practitioners are key in 
obtaining information for confirming a diagnosis.  
3)   Collect clinical information on the case including laboratory data, clinical manifestations, and 
onset date information. This information is best collected from the infection prevention 
practitioner at the hospital or the case’s healthcare provider. 
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4) Collect as much information as possible about the case’s activities and contacts during the 7 
days prior to the onset of illness.  This information may be obtained from the case, the 
case’s family and friends, school or child care personnel, or others involved with the case. 
Those who meet the definition of a close contact (see Section 4B below) of a case of 
invasive meningococcal disease must be educated on risk of disease and the importance of 
receiving prophylaxis. They should immediately be referred to their healthcare provider for 
appropriate post-exposure antibiotic therapy. Sample letters for notifying contacts in a 
school, child care or office are at the end of this chapter. 
 
f. Use the following guidelines to assist you in completing the Meningococcal Disease Case 
Investigation form or entering the information into the Iowa Disease Surveillance System (IDSS) 
1) Specify the type of infection caused by N. meningitidis.   
2) Indicate the type of specimen from which N. meningitidis was isolated/identified. 
3) List the laboratory tests performed.  For example, N. meningitidis was culture-confirmed or 
identified by bacterial antigen screen. Also include the date the specimen was drawn for the 
first positive culture.  
4) If known, provide the serogroup and antibiotic resistance information.  
5) If the case attends child care or school, list the child care/school name and provide a 
contact name and phone number.  
6) If the case attends college, indicate the name of the college, the case’s year in school, and 
the case’s living situation. 
7) If the case has received meningococcal vaccine, record the type of vaccine used, date 
administered, and reason for administration.  
8) If you have made several attempts to obtain case information, but have been unsuccessful 
(e.g., the case or healthcare provider does not return your calls or respond to a letter, or 
the case refuses to divulge information or is too ill to be interviewed), call CADE and then 
fill out the form with as much information as you have gathered. Note on the form the 
reason why it could not be filled out completely.  Contact CADE immediately if key 
information is difficult to obtain. 
 
g. After completing the Meningococcal Disease Case Investigation form, enter information into IDSS 
or fax to (515) 281-5698.  
  
h. Institution of disease control measures is an integral part of case investigation. It is the LPHA 
responsibility to understand and institute the control guidelines listed below in Section 4). 
 
4) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements 
Minimum Period of Isolation of Patient 
Until 24 hours after the initiation of appropriate antibiotic therapy.  
 
Minimum Period of Quarantine of Contacts 
None.  
 
B.  Chemoprophylaxis is recommended for the following: 
Case: 
If neither a third generation cephlosporin nor ciprofloxacin was given as treatment, patients with 
meningococcal invasive disease should receive antibiotic prophylaxis prior to discharge to ensure 
elimination of nasopharyngeal carriage  
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Contacts: 
Because the rate of secondary disease for close contacts is highest immediately after onset of disease 
in the index patient, antimicrobial chemoprophylaxis should be administered as soon as possible 
(ideally <24 hours after identification of the index patient). Conversely, chemoprophylaxis 
administered >14 days after onset of illness in the index patient is probably of limited or no value.  
Chemoprophylaxis is indicated for persons who in the 7 days before onset of illness or until 24 hours 
after the case had begun an effective antibiotic had close contact with the case. The definition of 
close contact is not precise but is intended to include to include persons who have had prolonged (8 
hours or more) contact while in close proximity (3 feet is the general limit for large-droplet spread) to 
the case who have been directly exposed to the cases oral secretions. Close contact examples 
include: 
 Household contact, 
 Child care contact, 
 Direct saliva contact with the case through kissing or sharing items like toothbrushes, water 
bottles or eating utensils, 
 Mouth – to – mouth resuscitation or unprotected contact during endotracheal intubation,  
 Frequently slept or ate in the same dwelling, 
 Passengers seated directly next to the index case during airline flights lasting more than 8 
hours, and 
 Laboratory workers 
o All laboratory work with cultures of known or suspect N. meningitidis must be 
performed inside a biological safety cabinet. If a laboratory worker has been exposed 
via manipulating a known N. meningitidis culture outside of a biological safety 
cabinet, prophylactic antibiotic treatment is recommended to reduce the risk of 
infection and colonization.   
 
Contacts who have previously received meningococcal vaccination should still receive 
chemoprophylaxis. Contacts should receive chemoprophylaxis as soon as possible, preferably within 
24 hours after the index case has been identified, though diminishing levels of benefit may still be 
realized even with delays of up to 2 weeks.  
Close contact does not include casual contacts at work or school or hospital employees who give 
routine care, even with 8 hours of contact within the previous week 
 
Contacts of the case should be identified and referred to their healthcare provider for antibiotic 
prophylaxis.   
 
Any contact that develops symptoms suggestive of meningococcal disease within 3-4 weeks after 
exposure should be evaluated promptly by a physician. 
 
Recommendations for chemoprophylaxis are based on the assumption that persons of any age may 
be susceptible to meningococcal infections. Refer to table 2-4. Routine throat or nasopharyngeal 
culture of contacts is not helpful in determining who warrants chemoprophylaxis and unnecessarily 
delays the process. 
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Table 2-4. Chemoprophylaxis of Contacts to Meningococcal Disease 
Drug                                                                      Contacts                                                        
Dosage 
Rifampin* 
 
Children <1 month 
 
5 mg/kg BID x 2 days 
 
 Children >1 month 
 
10 mg/kg (maximum single dose 
600 mg) BID x 2 days 
 Adults 600 mg BID x 2 days 
Ceftriaxone Children <15 years 125 mg IM (single dose) 
 Adults, teenagers >15 250 mg IM (single dose) 
 
Ciprofloxacin** Nonpregnant adults 
(>18 years of age) 
500 mg PO (single dose) 
 
 
BID = twice daily 
Note on Rifampin: 
*Rifampin is not recommended for pregnant women who are contacts of cases because the effect of Rifampin on the fetus has not 
been established.  If contact is pregnant have her contact her OB/GYN doctor immediately for consultation on appropriate antibiotic 
prophylaxis. 
*Side effects of Rifampin include: orange discoloration of urine, discoloration of soft contact lenses (removal recommended for 
duration of chemoprophylaxis), decreased effectiveness of oral contraceptives, discoloration of teeth, nausea, vomiting, and 
diarrhea.  These are uncommon when giving only 4 doses for prophylaxis. 
**Ciprofloxacin is not usually recommended for persons younger than 18 years of age or for pregnant or lactating women, because 
studies in animals have shown it causes cartilage damage in immature animals. The drug can be used for chemoprophylaxis in 
children when no acceptable alternative is available. There have been no reports of irreversible adverse effects in cartilage or age-
associated adverse events among children and adolescents.  
 
Resource available at end of chapter - Neisseria Meningitidis Invasive Disease Chemoprophylaxis 
Algorithm 
 
Rifampin Preparations for Administration (Meningococcal disease) 
Persons taking rifampin should be informed that orange discoloration of urine, discoloration of soft 
contact lenses, and decreased effectiveness of oral contraceptives could occur. 
Rifampin prophylaxis is best administered through the private physician and local pharmacy. However 
occasionally help must be given, i.e., contact has no doctor, pharmacy closed or has no rifampin.  In 
these cases, call CADE. Dosages are calculated on weight and a prescription label with directions should 
accompany any rifampin dispensed.  
 
There are two satisfactory procedures for the administration of rifampin to young children.  
1. Rifampin Suspension may be available at the local pharmacy. When stored in the refrigerator, this 
suspension is stable for six weeks. In order to assure a uniform dosage, it is extremely important to 
shake the suspension vigorously just before the administration of each dose to the patient. 
2. Applesauce Mix* 
- Empty the contents of one rifampin 300 mg capsule in six teaspoons of applesauce and mix thoroughly 
(preparation contains 50 mg/5 ml or per teaspoon). 
- Dosage must be calculated and family counseled on number of teaspoons to administer. 
- Unused applesauce mixed with rifampin should be immediately discarded. New applesauce-rifampin mix 
should be made for each dose. 
*Preparation of Choice 
Note: Rifampin administration has not been approved in any other preparation or solution. 
If the contact’s healthcare provider is not available, contact the local board of health physician or CADE 
for assistance. 
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C.  Managing Special Situations 
Child Care  
Please contact CADE (800) 362-2736 immediately to discuss. 
 
A case of invasive meningococcal illness in a child care setting often causes panic among parents and 
the community. Although the risk of transmission in this setting remains relatively low, 
chemoprophylaxis for all the children in the child care class or the child care facility may be 
recommended because the physical interactions between young children often involve direct saliva 
contact.  
 Chemoprophylaxis is recommended for: 
1. All children and employees in child care who have had direct saliva contact or have been in the 
same classroom for greater than 8 hours with the case in the week before onset or until 24 hours 
after the case was started on an effective antibiotic. 
2. Chemoprophylaxis is not routinely recommended for children in the same classroom of the case 
who have not had direct saliva contact or greater than 8 hours contact with the case in the 
previous week. 
 
Surveillance for additional cases of disease should also be heightened. Contact the CADE to report 
suspect or confirmed cases in a child care (or any other setting). An epidemiologist will work to 
ensure contacts are identified and notified. In addition, surveillance for new cases of disease should 
continue at the facility for at least 2 incubation periods (20 days) after the onset of the first case. If 
multiple cases occur, contact CADE immediately and continue surveillance for 2 incubation periods 
after the onset of the last case.  
 
Resources at end of section:  
• Fact Sheet for DCC Administrators 
• Parent and Employee Advisory Letter, Meningococcal Disease in a Child Care Center (case 
reported within 14 days after case’s last day in child care) 
• Parent and Employee Advisory Letter, Meningococcal Disease in a Child Care Center (case 
reported more than 14 days after case’s last day in child care) 
 
School  
A case of invasive meningococcal illness in a school often causes panic among parents and the 
community. Although the risk of transmission in a school remains relatively low, the age and activities 
of the case will determine the extent of chemoprophylaxis necessary. Because the physical 
interactions between children often involve direct saliva contact, chemoprophylaxis for all the children 
in the case’s class may be recommended, i.e. mentally handicapped students or very young children. 
An elementary, high school, or college student usually has a more defined group of close contacts 
and chemoprophylaxis may be more targeted.  
 
Careful assessment and identification of contacts is needed to define the scope of chemoprophylaxis 
recommended. An epidemiologist will work with the local health agency to ensure an assessment and 
identification of contacts is completed and those needing post exposure prophylaxis are notified. 
Surveillance for additional cases of disease should also be heightened. Contact CADE to report 
suspect or confirmed cases. In addition, surveillance for new cases of disease should continue at the 
school for at least 20 days after the onset of the case. If multiple cases occur, contact CADE 
immediately and continue surveillance for 2 incubation periods (20 days) after the onset of the last 
case.  
 
Community Residential Program  
If a case of meningococcal disease occurs in a residential program, close contacts of the case should 
be referred to their healthcare provider for chemoprophylaxis. The activity in the facility should be 
assessed to determine the level of interaction between residents. The facility may be considered a 
“household setting” and require chemoprophylaxis of all residents, or the chemoprophylaxis may be 
more targeted. Contact the CADE for assistance in following up a case of invasive meningococcal 
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disease in residential programs. In addition, surveillance for new cases of disease in the facility 
should continue for at least 2 incubation periods (20 days) after the onset of the first case. If multiple 
cases occur, contact CADE immediately and continue surveillance for 2 incubation periods after the 
onset of the last case. 
 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
If the number of reported cases in a jurisdiction is higher than usual for the time of year, or if an 
outbreak is suspected, contact CADE immediately at (800) 362-2736. This situation may warrant an 
investigation of clustered cases to determine a course of action to prevent further cases. The IDPH 
can perform surveillance for clusters of illness that may cross several county lines and therefore be 
difficult to identify at a local level.  To assist in outbreak identification, it is critical that all invasive site 
Neisseria meningococcal isolates are sent to State Hygienic Laboratory (SHL) for serogrouping. 
 
D. Preventive Measures 
Personal Preventive Measures/Education 
To prevent additional cases: 
• Refer close contacts to healthcare providers for appropriate chemoprophylaxis. 
• Advise contacts of signs and symptoms of illness and refer them to their healthcare provider should 
they experience any symptoms compatible with invasive meningococcal disease.  
• Provide contacts with a Meningococcal Disease Fact Sheet. 
 
To avoid future exposures, advise individuals to:  
• Practice good hygiene and handwashing technique. 
• Avoid sharing food, beverages, cigarettes or eating utensils. 
• Consider immunization in certain circumstances (see below).  
 
Immunization 
Two vaccines protecting against four serogroups (A, C, Y, and W-135) of N. meningitidis are 
available.  All 11-12 years olds should be vaccinated with meningococcal conjugate vaccine (MCV4). 
A booster dose should be given at age 16 years. For adolescents who receive the first dose at age 13 
through 15 years, a one-time booster dose should be administered, preferably at age 16 through 18 
years, before the peak in increased risk. Adolescents who receive their first dose of MCV4 at or after 
age 16 years do not need a booster dose.  
The Advisory Committee on Immunization Practices (ACIP) recommends that a student entering 
college get a booster dose of vaccine if they received the vaccine more than 5 years before starting 
college or if they never received one. 
The vaccine is also recommended for travelers to countries where meningitis is endemic, certain 
high-risk individuals (those with terminal complement component deficiencies and those with 
anatomic or functional asplenia), laboratory personnel who are exposed routinely to N. meningitidis in 
solution that may be aerosolized, college freshman living in dormitories, military recruits, and in the 
case of an outbreak of invasive disease.  
 
Meningococcal conjugated vaccine (MCV4) is preferable to meningococcal polysaccharide vaccine 
(MPSV4) for vaccination of children aged 2-10 years who are at increased risk for meningococcal 
disease. These children include travelers to or residents of countries in which meningococcal disease 
is hyperendemic or epidemic, children who have terminal complement component deficiencies and 
children who have anatomic or functional asplenia. Additionally, MCV4 is preferred to MPSV4 for use 
among children aged 2-10 years for control of meningococcal disease outbreaks. 
 
The ACIP recommends that healthcare providers of college students provide information to students 
and their parents about meningococcal disease and the benefits of vaccination. In particular, 
vaccination should be made easily available to freshman students, (especially those living in group 
settings like dorms). Iowa law requires that colleges with on campus housing educate incoming 
students on the vaccine.   
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N. meningitidis is spread through direct contact with oral or nasal secretions of a carrier. A closed 
setting such as a college dormitory, combined with high-risk behaviors in college students (alcohol 
consumption, exposure to tobacco smoke, sharing food or beverages, activities involving the 
exchange of saliva, etc.), may cause some college students to be at greater risk for invasive 
infection. Healthcare providers should discuss these risk factors and the likelihood that their patients 
will be involved in high-risk behaviors when evaluating patients for the administration of 
meningococcal vaccine.  
 
4) ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Meningitis 
can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
 
Comment 
• Positive antigen test results from urine or serum samples are unreliable for diagnosing 
meningococcal disease, but can be used to assist in diagnosis if a positive result is obtained. 
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Additional Resources 
CDC. Epidemiology and Prevention of Vaccine-Preventable Diseases. (The Pink Book), 12th ed. 
Washington DC: Public Health Foundation, April, 2011. 
www.cdc.gov/vaccines/pubs/pinkbook/downloads/mening.pdf  
National Foundation for Infectious Diseases, The Changing Epidemiology of Meningococcal Disease 
Among U.S. Children, Adolescents and Young Adults, November, 2004 
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Iowa Dept. of Public Health Revised 9/12  Meningococcal Infection 9 
Guide to Surveillance, Investigation, and Reporting 
 
 
 
 
 
 
 
 
 
Neisseria meningitidis Invasive Disease 
Chemoprophylaxis
Prophylaxis No Prophylaxis
Household contacts
Direct Saliva Contact
Child care attendees
Laboratory workers at risk
Casual Contacts at work or 
school
Hospital employees who give
routine care
Chemoprophylaxis is indicated for persons having household-like and or 
direct saliva contact with the case in the week before onset or until 24 hours after
the case has begun an effective antibiotic. Chemoprophylaxis is also indicated for 
laboratory workers who have manipulated a known N. menigitidis culture outside of a 
biological safety cabinet.
Chemoprophylaxis should be initiated within 24 hours of case identification, but no 
later than 14 days after exposure.
Vaccine is used in outbreak situations, not for postexposure chemoprophylaxis
Questions? Call 1.800.362.2736
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FACT SHEET                        MENINGOCOCCAL INVASIVE DISEASE 
FOR CHILD CARE ADMINISTRATORS 
 
What is meningococcal invasive disease? 
Meningococcal invasive disease, including meningitis, is a serious and potentially lethal infection.  
Meningococcal disease has caused numerous epidemics in the past, but currently in the U.S., 
outbreaks are sporadic and rare.  In the U.S., approximately 2000-3000 cases of meningococcal 
disease are reported annually and approximately 10% of the cases die.  Iowa averages 29 cases 
and 3 deaths per year. Meningococcus can affect persons of any age. Children less than 2 years 
of age are most often affected, however almost one half of cases occur in persons over 15 years 
old. 
 
How is meningococcal invasive disease spread? 
Many healthy children and adults unknowingly carry meningococcal bacteria in their nose and 
throat without any symptoms.  Usually, the bacteria stay in the nose and throat for a while and 
will then disappear.  The bacteria are spread from person-to-person by direct contact with the 
organisms found in nose and throat secretions.  This typically requires prolonged direct contact 
or direct saliva contact.  The reason that the organism disappears in some people and produces 
illness in others is not clearly understood but is probably related to individual susceptibility. 
 
What are symptoms of meningococcal invasive disease? 
Symptoms of meningococcal invasive disease include a sudden onset of high fever, irritability, 
and lethargy.  If meningitis develops, intense headache, nausea, vomiting, stiff neck, or a bulging 
soft spot (in infants) is typically present.  A generalized rash may also be present. 
 
How common is meningococcal invasive disease in child cares? 
Clusters of meningococcal disease in child care rarely occur.  The risk of spread at child care is 
about 1%, however, due to the severity of the illness and high mortality of cases, preventive 
measures are recommended for any contacts of a case. 
 
What is the treatment for exposure to meningococcal invasive disease? 
Specific antibiotics eliminate the organism from the nose and throat of persons carrying it, 
reducing the risk of contacts developing a serious infection.  Antibiotics are recommended for all 
child care (usually only classroom) contacts (adults or children) having close or direct saliva 
contact with the case in the week prior to onset of illness or hospitalization.  Antibiotics are not 
recommended for non-classroom contacts who have had only brief, casual contact with the case. 
 
Rifampin is the treatment of choice for person less than 18 years of age.  Persons who are known 
to be allergic to rifampin, and women who are pregnant or who might be pregnant should not 
take rifampin. However, other antibiotics may be used in these circumstances.  Persons wearing 
soft contact lenses should remove the lenses for the two day treatment period as rifampin may 
discolor them.  Rifampin will turn the urine a reddish-orange color and may decrease the 
effectiveness of birth control pills. 
 
For further information, contact your local health department or the Iowa Department of Public 
health, CADE at (800) 362-2736. 
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FACT SHEET MENINGOCOCCAL DISEASE 
 (Spinal meningitis, Meningococcemia, Neisseria meningitis) 
 
What is meningococcal disease? 
Meningococcal disease is a severe bacterial infection of the blood and meninges (the thin 
covering of the brain and spinal cord).  It is a relatively rare disease.   
 
What are the symptoms of meningococcal disease? 
Infection with the bacteria can cause fever, headache, nausea, vomiting, rash, a stiff neck and 
occasionally death. 
 
How soon do symptoms appear? 
The symptoms may appear 2 - 10 days after infection, but usually about  3 - 4 days after 
exposure. 
 
How is meningococcal disease spread? 
Meningococcal disease spreads by contact with mucus or droplets from the nose and throat of an 
infected person.  Meningitis and septicemia (an infection of the blood) caused by N. meningitidis 
can be spread by direct contact with saliva, such as kissing or sharing items like eating utensils, 
drinks or cigarettes.  Pneumonia caused by N. meningitidis can also be transmitted by droplets.  
Some people carry the bacteria in their nose and throat without any signs of illness, while others 
may develop serious symptoms. 
 
Who gets meningococcal disease? 
Anyone, but it is more common in infants, children and young adults. 
 
How long is a person infectious? 
A person may spread the disease from the time they are first infected until the germ is no longer 
present in discharge from the nose and throat.  The bacteria usually disappear from the throat 
and nose 24 hours after appropriate antibiotics are started. 
 
What is the treatment for meningococcal disease? 
Antibiotics.  Once the initial infection is treated, the person may also need another antibiotic to 
clear the bacteria from the nose and throat and reduce the chances of spreading it to others. 
 
Can a person get this disease again? 
Probably not. 
 
Do infected people need to be excluded from school, work, or child care? 
Yes, people with meningitis should be excluded from public places until a doctor says it is OK to 
return. 
 
Should people who have been around a person infected with meningococcal disease be 
treated? 
Household members, child care center attendees and staff, and close friends of infected persons 
need to ask their doctor about antibiotics.  Persons who have had casual contact such as sitting 
or standing next to someone in a classroom, office or factory do not need treatment. 
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Is there a vaccine to prevent meningococcal disease? 
Yes.  Two vaccines protecting against most strains of N. meningitidis are available. A dose of 
vaccine is recommended for persons 11-12 years of age or on entry into high school. A booster 
dose should be given at age 16 years. A student entering college should get a dose of vaccine if 
they received the vaccine more than 5 years before starting college or had never received one.  
 
The vaccine is also recommended for travelers where the disease is common and certain high-
risk individuals, including laboratory personnel who are exposed routinely to N. meningitides, 
college freshman living in dormitories, and military recruits. For more information, contact your 
physician or county health department.   
 
What can be done to help prevent the spread of meningococcal disease? 
Anyone with cold- or flu-like symptoms should cough or sneeze into a disposable tissue or into 
their sleeve.  Do not share food, drink, eating utensils or cigarettes with others.   Frequent 
handwashing is always helpful in reducing the chances of catching diseases. 
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Note: Sample letter to be adapted on Local or state health department letterhead and to be 
used when case is reported within 14 days after case's last day in child care. 
 PARENT AND EMPLOYEE ADVISORY LETTER 
 Meningococcal Disease in a Child Care Center 
 
Dear Parents of (name of child): 
 
Your child has been in contact with a child who has been diagnosed as having [(meningococcal 
meningitis) or (a serious meningococcal infection) - use applicable description].  The disease is caused by 
bacteria that can cause an infection or meningitis in people of any age.  Persons who have had close, 
personal contact to a person with a meningococcal infection have a slight risk of developing a serious 
infection.  Because your child was in the same classroom with the child with the 
meningococcal infection the week before illness, the Iowa Department of Public Health and 
the ___________________ Health Department recommend that your child take an 
antibiotic, called rifampin.  Rifampin eliminates the bacteria from the nose and throat of persons 
carrying it, which may help protect contacts from developing a serious meningococcal infection.  Please 
contact your private physician to obtain this medication for your child.  Persons who are known to be 
allergic to rifampin and women who are pregnant or who might be pregnant should not take rifampin, 
however other antibiotics may be used in these circumstances.  Persons wearing soft contact lenses 
should remove the lenses for the two day period as rifampin may discolor them.  Rifampin will turn the 
urine a reddish-orange color.  Rifampin may also decrease the effectiveness of birth control pills. 
 
Watch for the following signs of infection in your child:  fever, severe headache, stiff neck, 
nausea, vomiting or rash.  If your child develops any of these symptoms in the next few 
weeks, you should contact his/her health care provider, explain the symptoms and tell the 
health care provider that your child was in contact with a child who had [(meningococcal 
meningitis) or (a serious meningococcal infection)]. 
 
Please feel free to contact the ______________ Health Department at (telephone number) or the Iowa 
Department of Public Health, Center for Acute Disease Epidemiology (CADE) at (800)362-2736 if you 
have questions regarding this subject. 
 
Note for child care employees: Employees having greater than 8 hours household-like and or 
direct saliva contact with the child with meningococcal disease in the week before illness 
should also receive an antibiotic.  Meningococcal disease can affect persons of all ages. 
 
Sincerely, 
 
___________________________________ _________________________________ 
(Name)     (Local Health Department) 
 
 
NOTE FOR YOUR DOCTOR: Rifampin for prevention of meningococcal disease is 10 mg/kg 
twice daily for 2 days (maximum dose 600 mg/dose or 1200 mg/day); for infants <1 month of 
age, 5 mg/kg twice daily for 2 days. Ciprofloxacin 500 mg orally once for nonpregnant persons 
18 or older or Ceftriaxone 125 mg IM once for persons up to age 15, for those >15 years of 
age 250 mg IM once.  
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Meningococcal, invasive disease 
         Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Long-term care     
resident:  Yes      No      Unknown        Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Facility name:       
Parent/Guardian 
name: 
 
      
Facility phone: (     )-     -        Type:        
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Onset 
date: 
 
     /     /      
Diagnosis 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome: 
 Survived this illness     Died from this illness 
 Died unrelated to this illness    Unknown 
Date of death      /     /      First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider type: 
 ARNP   
 DO 
 MD 
 NP  PA 
Event exception 
 Case could not be found 
 Case could not be interviewed 
 Case refused interview 
 Other – see notes   
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes   No  Unk To whom: ______________  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
Specimen 
source: 
 
      Result: 
 Positive 
 Negative    No growth 
 
Date received: 
 
     /     /      Test type:  PCR  
 Gram stain 
 Culture 
 Serogroup: 
 A 
 B 
 C 
 W-135      
 Y 
Result type:  Preliminary      Final Collection date: 
 
     /     /       
 
Accession #: 
 
      
 
Result date: 
 
     /     /      
 
Organism: 
 
Neisseria meningitidis 
 
 
Laboratory: 
 
      
Specimen 
source: 
 
      Result: 
 Positive 
 Negative    No growth 
 
Date received: 
 
     /     /      Test type: 
 PCR 
 
 Gram stain 
 Culture Serogroup:  A  B 
 C 
 W-135      
 Y Result type:  Preliminary      Final Collection date: 
 
     /     /       
 
Accession #: 
 
      
 
Result date: 
 
     /     /      
 
Organism: 
 
Neisseria meningitidis 
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Laboratory: 
 
      Specimen 
source: 
 
      Result: 
 Positive 
 Negative    No 
growth 
 
Date received: 
 
     /     /      Test type:  PCR 
 Gram stain 
 Culture Serogroup:  A  B 
 C 
 W-135      
 Y Result type:  Preliminary      Final 
Collection 
date: 
 
     /     /       
 
Accession #: 
 
      
 
Result date: 
 
     /     /      
 
Organism: 
 
Neisseria meningitidis 
 
OCCUPATIONS 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties: 
Health care worker type: 
 Yes      No      Unknown 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties: 
Health care worker type: 
 Yes      No      Unknown 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
OTHER DEMOGRAPHIC INFO 
 
Attending a college 
or university:  Yes    No    Unk 
 
College/University name: 
 
      
Student status:  Active   Inactive Year in college:  Freshman    Sophomore    Junior   Senior    Grad student 
Housing:  Other  Apartment    Dormitory  Single-family home with family   Single-family home with students 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
 
CLINICAL INFO & DIAGNOSIS 
 
Spinal tap  Yes No  Unk 
Date:      /     /      
Normal:  Yes No  Unk 
Spinal fluid protein level: _______ 
Unit:  mg/dL   g/L   µmol/L 
Spinal fluid glucose level: ______ 
Unit:  mg/dL  µmol/L 
White blood count: ___________ 
Unit:  cells/mm3  cells/mL 
 
TREATMENT 
 
Antibiotics prescribed?   Yes    No    Unknown 
  
Antibiotic:       
  
Antibiotic:       
 
 
Antibiotic:       
Date 
started:      /     /      
Date 
started:      /     /      
Date 
started:      /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 
 mg      ml     IU 
 
Unit: 
 
 mg      ml     IU 
 
Unit: 
 
 mg      ml     IU 
# of times a 
day:       Route:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Vaccinated for meningococcal:   Yes    No    Unknown 
  
Date vaccinated: 
 
     /     /      
  
Date vaccinated: 
 
     /     /      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
 
Number of vaccinations:       
 
 
Number of people living in case’s household:          
 
Additional close contacts of the case:   Yes    No    Unknown 
 
Close contacts of the case 
Name DOB Gender Address/Phone 
           /     /      
 Male 
 Female ________________________ Zip code:                     Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
  
       
Post exposure prophylaxis given?  Yes    No    Unk  
Antibiotic:                             Date started:             Dose:                 Unit:                   # of days:      # times/day:        Route: 
_________________            /     /            ______       mg   ml   IU     ________      _________        _________________ 
If this contact is a case create a new event and/or case for this contact. 
Purpura fulminans 
present:  Yes  No  Unk 
 
Antibiotic resistance 
testing performed:  Yes  No  Unk 
Resistant to ampicillin: 
Resistant to chloramphenicol: 
Resistant to rifampin: 
Resistant to sulfa: 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk   
Infection type:  Bacteremia  Meningitis  Pericarditis  Peritonitis   Pneumonia  Other 
Other infection type 
(specify):  
CONTACTS 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation period for 
Meningococcal invasive 
disease is 2-10 days. 
Meningococcal invasive 
disease may spread person to 
person until 24 hours after the 
start of effective antibiotics.  
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Name DOB Gender Address/Phone 
           /     /      
 Male 
 Female ________________________ Zip code:                     Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
  
       
Post exposure prophylaxis given?  Yes    No    Unk  
Antibiotic:                             Date started:             Dose:                 Unit:                   # of days:      # times/day:        Route: 
_________________            /     /            ______       mg   ml   IU     ________      _________        _________________ 
If this contact is a case create a new event and/or case for this contact. 
 
Name DOB Gender Address/Phone 
           /     /      
 Male 
 Female ________________________ Zip code:                     Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
  
       
Post exposure prophylaxis given?  Yes    No    Unk  
Antibiotic:                             Date started:             Dose:                 Unit:                   # of days:      # times/day:        Route: 
_________________            /     /            ______       mg   ml   IU     ________      _________        _________________ 
If this contact is a case create a new event and/or case for this contact. 
 
Name DOB Gender Address/Phone 
           /     /      
 Male 
 Female ________________________ Zip code:                     Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
  
       
Post exposure prophylaxis given?  Yes    No    Unk  
Antibiotic:                             Date started:             Dose:                 Unit:                   # of days:      # times/day:        Route: 
_________________            /     /            ______       mg   ml   IU     ________      _________        _________________ 
If this contact is a case create a new event and/or case for this contact. 
 
Name DOB Gender Address/Phone 
           /     /      
 Male 
 Female ________________________ Zip code:                     Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
  
       
Post exposure prophylaxis given?  Yes    No    Unk  
Antibiotic:                             Date started:             Dose:                 Unit:                   # of days:      # times/day:        Route: 
_________________            /     /            ______       mg   ml   IU     ________      _________        _________________ 
If this contact is a case create a new event and/or case for this contact. 
 
 
NOTES:       
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MUMPS 
 
Also known as: Infectious Parotitis 
      
Responsibilities: 
Hospital: Report by IDSS, facsimile, phone or mail 
Lab: Report by IDSS, facsimile, phone or mail 
Physician: Report by facsimile, phone or mail 
Local Public Health Agency (LPHA): Report by IDSS, facsimile, phone or mail. 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax:  (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Etiologic Agent 
Mumps is caused by the mumps virus (genus Paramyxovirus, family Paramyxoviridae). 
 
B. Clinical Description 
Mumps is a systemic disease characterized by swelling of the salivary glands, which usually lasts 
several days. However, about one-third of infections do not cause clinically apparent salivary gland 
swelling. Respiratory symptoms are common. Encephalitis occurs rarely, and permanent sequelae or 
death is uncommon. Infection in adulthood is likely to produce a more severe disease, including 
mastitis, which occurs in up to 31% of females aged > 15 years, and orchitis, which occurs in 20% –
30% of post-pubertal males. Other rare complications include arthritis, renal involvement, 
myocarditis, cerebellar ataxia, pancreatitis, and hearing impairment. Mumps infection during the first 
trimester of pregnancy can increase the risk of spontaneous abortion, although no evidence exists 
that it causes congenital malformations. While death due to mumps is rare, more than half the 
fatalities occur in those > 19 years of age. 
 
Mumps should not be ruled out in someone who is vaccinated if he or she has clinically consistent 
symptoms.  
 
Note: Swelling of the salivary glands can also be caused by infection with cytomegalovirus, 
parainfluenza virus types 1 and 3, influenza A, Coxsackie A, echovirus, lymphocytic choriomeningitis 
virus, HIV, and non-infectious causes such as drugs, tumors, immunologic diseases, and obstruction 
of the salivary duct.  
 
C. Reservoirs 
Humans are the only known reservoirs.   
 
D. Modes of Transmission 
Mumps is transmitted by droplet or direct contact with nasopharyngeal secretions of an infected 
person, and by the airborne route.  
 
E. Incubation Period 
The incubation period is usually 16 – 18 days, with a range of 12 – 25 days 
 
F. Period of Communicability or Infectious Period 
Virus has been isolated from saliva (from 7 days before the onset of parotitis to 9 days afterwards) 
and from urine (six days prior to fifteen days after).  Infectiousness occurs between 3 days before 
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symptom onset until four days after or until symptoms resolve.  Unapparent infections can be 
communicable. 
 
G. Epidemiology 
Mumps occurs worldwide. In the United States, it is endemic year-round, historically peaking in 
winter and spring; however seasonality no longer is evident, due to widespread immunization. Eighty-
five percent of adults have serologic evidence of immunity. About one-third of the infections do not 
cause apparent parotitis but those infected can still transmit disease; most infections in children < 2 
years of age are subclinical. The incidence of mumps in the U.S. has declined since the vaccine came 
into use in 1967. In 1986 and 1987, there was a relative resurgence of mumps, apparently due to the 
absence of comprehensive state immunization requirements as well as, in some instances, vaccine 
failure. The number of mumps cases reported in the U.S. declined steadily from 1989 to 2005, but a 
multi-state outbreak of Mumps in 2006 resulted in over 6000 reported cases, including almost 2000 
cases in Iowa. Outbreaks in highly vaccinated populations still occur, probably due to vaccine 
mismanagement or vaccine failure. 
 
H. Bioterrorism Potential 
None 
 
2) REPORTING CRITERIA AND LABORATORY TESTING SERVICES 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
report. The reporting number for IDPH Center for Acute Disease Epidemiology (CADE) is (800) 362-
2736.  After completing the investigation and gathering the information to complete the investigation 
form, enter information into the Iowa Disease Surveillance System (IDSS), or FAX the report form 
with supporting laboratory documentation to  (515) 281-5698 or mail (in an envelope marked 
“Confidential”) to the IDPH/CADE, mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
Des Moines, IA 50319-0075 
 
Postage-paid disease reporting forms are available free of charge from the IDPH clearinghouse.   
Call (319) 398-5133 or visit the website: 
healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295 to request a supply. 
 
A. What to Report to the Iowa Department of Public Health 
• A suspect or confirmed case of mumps, as diagnosed by a healthcare professional, or 
• Isolation of mumps virus from clinical specimen, or 
• Significant rise between acute and convalescent phase titers in serum mumps IgG antibody level 
by any standard serologic assay, or 
• Positive serologic test for mumps IgM antibody. 
 
B. Laboratory Testing Services Available 
• Laboratory tests should be conducted on anyone with symptoms compatible with mumps 
without other apparent cause, regardless of vaccination history.   
• All specimens described below should be obtained for all patients with suspected mumps.  
 
1) Testing for Mumps Virus: The specimen should reflect the pathology of disease. Specimens 
sent to the University of Iowa State Hygienic Lab (SHL) should be submitted with a completed 
SHL “Viral Test” request form. Test request forms and specimen collection and shipment 
instructions can be found at the SHL web site at www.shl.uiowa.edu/kitsquotesforms/ . Unlabeled 
specimens will not be tested. 
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Parotid gland duct swab for polymerase chain reaction testing (in M4 viral transport medium) 
may be collected from date of onset of symptoms to 9 days after onset of symptoms. Massage 
the parotid (salivary) glands for 30 seconds prior to swabbing the buccal cavity (the space near 
the upper rear molars between the check and the teeth).  Place swab into M4 Viral Transport 
Medium and do not remove swab.  Specimen must be stored and shipped cold (on ice packs).  
Laboratories have M4 transport tubes available in the SHL Biodefense kits (blue box), herpes kits, 
and virus isolation kits. 
 
2) Serologic Testing: collect 7-10 ml blood in a red top or serum separator tube (SST) with a   
completed SHL Serology Test Request form and ship either a) with culture specimens cold (on 
ice packs) or, b) at ambient temperature.  Test request forms and instructions for collection and 
shipment of specimens can be found at the SHL web site at 
www.shl.uiowa.edu/kitsquotesforms/.   Serum for mumps virus IgM should be collected 3 to 5 
days after symptom onset. Mumps virus IgM peaks at 1 – 2 weeks after symptom onset. 
 
Contact SHL at (319) 335-4500 to request test kits, specimen collection instructions, test request 
forms, and shipping instructions or visit www.shl.uiowa.edu  
 
3) DISEASE REPORTING AND CASE INVESTIGATION 
A.  Purpose of Surveillance and Reporting 
• To identify cases and susceptible exposed people rapidly and to prevent further spread of the 
disease. 
• To confirm mumps infection as the cause of glandular swelling/pain. 
• To distinguish between failure to vaccinate and vaccine failure and development of a plan to 
address the problems. 
 
B.  Initial Questions to Ask Healthcare Provider and Patient 
To assess the likelihood that a suspect case is a true case prior to laboratory testing, LPHA and/or 
other public health staff helping in the investigation should ask about: 1) symptoms, 2) mumps 
immunization history, 3) recent history of dental work, 4) recent history of travel (to where and 
dates), 5) whether there were any recent out-of-town visitors (from where and dates), and 6) 
whether there was any recent contact with anyone with similar symptoms. 
 
4) CONTROLLING FURTHER SPREAD 
This section provides detailed control guidelines that are an integral part of case investigation.  
 
A. Minimum Period of Isolation of Patient 
From day of onset of symptoms to 4 days after (This includes the first day of symptoms as day zero; 
totaling 5 days after the onset of symptoms as the period of communicability.) 
 
B.  Protection of Contacts of a Case (includes outbreak situations) 
Identify and immunize susceptible people within the same community.  Susceptible persons are 
defined as those who have not had two MMRs or MMRVs.  Note: mumps (MMR or MMRV) vaccination 
will not prevent infection in a person who has been recently exposed, but vaccinating may prevent 
future outbreaks. 
• Case: Exclude through 5 days after onset of symptoms (counting the day of symptom onset as 
day zero). The suspect case may return to normal activities on the 6th day or once symptoms 
have resolved, whichever is later.  
• Contacts: All contacts should be evaluated for vaccination status.  If a person does not have 2 
doses, refer for vaccination.  If person has a contraindication or refuses vaccination, educate on 
personal protective measures and symptoms of mumps.  Contacts may continue normal activities 
in the absence of symptoms.  Note: mumps (MMR or MMRV) vaccination will not prevent 
infection in a person who has been recently exposed, but vaccinating may prevent future 
outbreaks. 
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1. Conduct active surveillance for mumps for 2 incubation periods (50 days) after onset of the last 
case. 
2. Mumps vaccine, preferably MMR or MMRV, should be administered to all susceptible persons.  As 
with any vaccine, there will be some individuals who will not gain immunity after the receipt of 
the mumps vaccine.  Because effectiveness is not 100%, a second dose of mumps-containing 
vaccine is recommended for individuals who have previously received only one dose.  
Furthermore, birth before 1957 does not guarantee mumps immunity, thus mumps vaccine 
should be considered for those born before 1957, especially in outbreak situations.   
 
C. Managing Mumps in Healthcare Settings 
1. Proof of immunity: Birth in the U.S. before 1957 does not guarantee mumps immunity. Therefore, all 
healthcare workers should have documentation of at least one dose, preferably two doses, of 
mumps-containing vaccine on or after the first birthday or serologic proof of immunity. An effective 
routine MMR or MMRV vaccination program for healthcare workers (in addition to standard 
precautions) is the best approach to prevent nosocomial transmission. 
2. Isolation of patients: 
• Patients should be placed on Droplet Precautions for the duration of their hospitalization.  
Unusual circumstances may need consultation with the Iowa Department of Public Health. 
•  Exposed susceptible patients should be placed on Droplet Precautions from the 12th day after the 
earliest exposure through the 26th day after the last exposure. They may be taken off precautions 
on the 27th day. 
3. Exclusion of staff: 
• Personnel who become sick should be excluded from work at least 5 days after the onset of 
symptoms (counting the day of symptom onset as day zero) or until symptoms resolve, 
whichever is later. These staff should be excluded from high-risk (i.e. patient’s requiring a 
protective environment such as cancer unit, burn unit, bone marrow recipients, special-care 
nursery) patient contact at least 9 days after the onset of symptoms (counting the day of 
symptom onset as day zero) or until symptoms resolve, whichever is later. 
• Personnel who have been exposed to a mumps case and are susceptible (have no serological 
evidence of immunity) should be vaccinated and should remain home from the 12th day after the 
1st exposure through the 26th day after their last exposure.  Consult with IDPH for special 
situations. 
Note: All new staff should be assessed for mumps immunity. 
4. Surveillance: Conduct active surveillance for mumps for 2 incubation periods (50 days) after onset of 
the last case. 
 
D. Preventive Measures 
      Personal Preventive Measures/Education 
Vaccination with MMR or MMRV of all susceptibles is the best preventive measure against mumps.  
Susceptibles are defined as anyone who has not had 2 doses of MMR or MMRV.  Good personal 
hygiene (which consists of proper hand hygiene, disposal of used tissues, not sharing eating utensils, 
etc.) is also important.  For more information on the measles, mumps and rubella vaccine, see the 
ACIP vaccine information statement.  
 
Additional Information 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Mumps 
can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top   
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
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FACT SHEET        MUMPS 
 (Infectious parotitis) 
            
What is mumps? 
It is an infection caused by the mumps virus. 
 
How is mumps spread? 
Mumps is spread by airborne transmission with mucus or droplets from the nose or throat of an infected 
person, usually when a person coughs or sneezes.  
 
Who gets mumps? 
Anyone, but it is more common in infants, children and young adults. Of people who are not immunized, 
>85% will have mumps by adulthood, but symptoms may have been mild and therefore not recognized.    
 
What are the symptoms of mumps? 
The most common symptoms are fever, headache, and swollen salivary glands under the jaw. The disease 
can lead to hearing loss, aseptic meningitis (infection of the covering of the brain and spinal cord) and, in 
20% to 30% of males who have reached puberty, the disease can cause painful, swollen testicles. 
 
How soon do symptoms appear? 
They may appear 12 - 25 days after infection, but usually within 18 days. 
 
How long is an infected person able to spread the disease? 
A person can spread disease from 3 days before they become ill until four days after or until symptoms 
resolve.  Unapparent infections can be communicable. 
 
What is the treatment for mumps? 
There is no specific treatment.  Supportive care should be given as indicated. 
 
Is there a vaccine to prevent mumps? 
Yes. Two doses of mumps-containing vaccine, given as combination MMR vaccine, separated by at least 4 
weeks, are routinely recommended for all children. The first dose is given on or after the first birthday; 
the second is given at 4 - 6 years of age. MMR is a live, attenuated vaccine. Pregnant women and 
persons with immunodeficiency or immunosuppression should not receive live attenuated vaccines. 
 
What can be done to stop the spread of mumps?   
Anyone with mumps should not go back to child care, school, work, or other public places until 5 days after 
symptoms began or until they are well whichever is longer. People who are contacts to a mumps case 
should have their immunization status evaluated.  Anyone who is not immune and has not received 2 doses 
of a mumps-containing vaccine should be vaccinated.  Persons who may have been exposed should be 
educated on the signs and symptoms of mumps disease and should seek medical attention as soon as any 
of these symptoms begin.  
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Mumps                           Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider title: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes   No  Unk To whom: ______________  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
Laboratory: 
 
      Accession #: 
 
      
Collection 
date: 
 
     /     /      
 
Date received: 
 
     /     /      
Specimen 
source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Mumps virus 
Type (e.g. 
serotype): 
 
        
 
Laboratory: 
 
      Accession #: 
 
      
Collection 
date: 
 
     /     /      
 
Date received: 
 
     /     /      
Specimen 
source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Mumps virus 
Type (e.g. 
serotype): 
 
        
 
Laboratory: 
 
      Accession #: 
 
      
Collection 
date: 
 
     /     /      
 
Date received: 
 
     /     /      
Specimen 
source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Mumps virus 
Type (e.g. 
serotype): 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
Classic symptoms 
Swelling OR pain of parotid gland:  Yes    No    Unk 
Swelling OR pain of sublingual or submandibular (submaxillary) glands:  Yes    No    Unk 
Did the glandular swelling or pain last at least 2 days:  Yes    No    Unk 
 
Other symptoms  
 Fever 
 Orchitis 
 Parotitis 
 Swollen lymph nodes  
 
Complications 
 Aseptic meningitis   
 Deafness    
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation period for 
mumps is 16 to 18 days 
days (range 12-25 days) 
Mumps is maximally 
communicable for 2 days 
before to  4 days after onset.   
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RISK FACTORS/TRAVEL 
 
If pregnant during illness, how many weeks gestation was case at time of onset:       
 
Vaccinated for mumps:   Yes    No    Unknown 
 Date 
vaccinated: 
 
     /     /      
 
Date vaccinated: 
 
     /     /      
 
Date vaccinated: 
 
     /     /      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
 
Number of vaccinations:       
If not vaccinated, reason: 
 Lab evidence of previous disease 
 Medical contraindication 
 Parental refusal 
 Religious exemption 
 Under age 7 months 
 
  Other 
 Unknown 
 
Transmission 
setting: 
 Day care 
 School 
 Doctor’s office 
 Hospital ward 
 Hospital ER 
 Hospital outpatient clinic 
 Home 
 Work 
 Unknown 
 College 
 Military 
 Correctional facility  
 Church 
 International travel 
 Other       
Disease traced within 2 generations of 
known international import?  Yes    No    Unk 
   
 
Risk Factors/Travel Information – In the 5 days prior to onset of symptoms had the case: 
Traveled within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
 
Number of people living in case’s household:          
 
Are there close contacts of the case with similar symptoms:   Yes    No    Unknown 
Close contacts with similar symptoms 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
 
NOTES:       
 
 
 
 
 
CONTACTS 
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 PERTUSSIS   
 
Also known as: Whooping Cough 
 
Responsibilities: 
Hospital: Report by IDSS, facsimile, phone, or mail  
Lab: Report by IDSS, facsimile, phone, or mail 
Physician: Report by facsimile, phone, or mail 
Local Public Health Agency (LPHA): Report by IDSS, Follow-up required 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY  
 
A.  Agent 
Pertussis is caused by Bordetella pertussis, a gram-negative bacillus. 
 
B.  Clinical Description   
Symptoms: Pertussis symptoms may vary by illness stage as described below: 
o Catarrhal stage: This is the most contagious stage of pertussis. The illness begins 
insidiously, similar to a common cold, with cough, sneezing, and/or a runny nose, 
sometimes lasting up to two weeks. 
o Paroxysmal stage: The classic symptoms start with a whooping cough of five to 15 
consecutive coughs per single breath, followed by a high-pitched whoop as the 
person deeply inhales. Moments later another round of coughing occurs, sometimes 
accompanied by gagging and vomiting. The infected person usually appears normal 
between attacks. The cough is usually worse at night. Fever is most often absent or 
minimal throughout the course of the disease. The paroxysmal stage can last one to 
six weeks. 
o Convalescent stage: This stage can persist for three weeks to three months 
(seven weeks on average). Even after recovery, classic coughing episodes may recur 
for months.  This is usually because the person is developing another upper 
respiratory infection that may irritate the previously damaged airways.  
 
The clinical presentation of pertussis is variable and its diagnosis challenging. 
o Infants under six months old may present with apnea and cyanosis rather than a 
whooping cough, and usually appear quite ill. 
o Older children and adults also can have atypical manifestations, with persistent 
cough lasting > two weeks with no whoop, or they may present with more classical 
symptoms. They may also present with milder symptoms that mimic bronchitis or 
asthma. 
 
Onset: Pertussis onset is acute or insidious with an irritating cough. 
 
Complications: Complications from pertussis include pneumonia, seizures, encephalopathy, 
and death. 
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Duration: With or without treatment, the illness persists for three weeks to three months; the 
average duration is seven weeks. 
 
C. Reservoir 
Humans are the only known reservoir. 
 
D. Modes of Transmission 
Spread: Pertussis is most commonly spread by contact with respiratory droplets or by contact 
with airborne droplets of respiratory secretions. It occurs rarely by contact with an infected 
person’s freshly contaminated articles.  
 
E. Incubation Period 
The incubation period is usually nine to 10 days, with a range of six to 20 days. 
 
F. Period of Communicability or Infectious Period   
Persons with pertussis are most infectious during the catarrhal period and the first two weeks 
after cough onset (i.e., approximately 21 days).  For the purpose of surveillance and workup:  
The person is most efficient at spreading disease once the cough begins. To determine the 
period of communicability, take cough onset and go out 21 days or until person has 
completed the first five full days of an appropriate antibiotic.  
 
G. Epidemiology 
• Young infants (particularly preterm infants) are at highest risk for acquiring clinical 
pertussis and associated complications.  Adolescents and adults are often the source of 
infection for infants. 
• Pertussis occurs worldwide. It is endemic, with peaks occurring every two to five years. 
• Pertussis exhibits no distinct seasonality in the U.S.; however, it may increase in the 
summer and fall. 
• Long-term carriage (i.e., several months) of B. pertussis probably does not occur.  
However, it has been documented that persons can become infected and remain 
asymptomatic.  Transmission from asymptomatic infected persons to others may occur 
but is less likely than for symptomatic persons since asymptomatic persons do not have a 
cough. 
• Pertussis is highly infectious, with secondary attack rates of 80 to 90 percent among 
susceptible household contacts. 
• Pertussis vaccine is 70 to 90 percent effective. Immunity wanes five to 10 years after the 
last dose of pertussis vaccine is given. 
 
H. Bioterrorism Potential  
None. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting  
• To identify sources and sites of transmission and any additional cases. 
• To identify close contacts and recommend prophylaxis for those at risk for severe 
complications due to pertussis or those who may come in contact with those at risk for 
severe complications due to pertussis. 
• To monitor the effectiveness of outbreak control strategies. 
• To provide data for monitoring the effectiveness of new vaccine formulations.  
• To analyze vaccination status by age to determine whether the problem is predominantly 
failure to vaccinate or vaccine failure. 
• To characterize the epidemiology of pertussis disease in Iowa. 
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B.  Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare 
provider must report. The preferred method of reporting is by utilizing the Iowa Disease 
Surveillance System (IDSS).  However, if IDSS is not available, the reporting number for IDPH 
Center for Acute Disease Epidemiology (CADE) is (800) 362-2736; fax number (515), 281-
5698, mailing address: IDPH, CADE 
       Lucas State Office Building, 5th Floor 
        321 E. 12th St. 
   Des Moines, IA 50319-0075 
 
Reporting forms are available at: 
http://healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295. 
 
C.  Laboratory Testing: 
• Who should be tested for pertussis? 
o Any person presenting with symptoms consistent with pertussis, regardless of 
contact with a case or an outbreak situation. 
• Who should not be tested for pertussis? 
o Asymptomatic persons, regardless of contact with a case or an outbreak 
situation. 
• Do symptomatic contacts of laboratory confirmed cases need to be tested? 
o It is not necessary to test the first “ring” out from a laboratory confirmed case if 
the contact was exposed while the lab confirmed case was infectious, proper 
incubation time has elapsed, and the signs and symptoms are compatible with 
pertussis.  
o It is recommended that the second “ring” out from a laboratory confirmed case 
be tested (e.g., contacts of a contact of a laboratory confirmed case). 
• What test should be performed? 
o Polymerase chain reaction (PCR) testing is recommended and should be used for 
laboratory confirmation. 
o Serologic testing is not yet standardized and is not widely available. Due to lack 
of association between antibody levels and immunity to pertussis, results of 
serologic testing are difficult to interpret.   
• Where can testing be performed? 
o PCR testing is available at the State Hygienic Laboratory.  For more information 
on testing services provided by SHL, call 319-335-4500 or visit: 
www.shl.uiowa.edu/. 
• Specimen Collection and Handling: 
o PCR is a very sensitive test and precautions should be taken to prevent cross-
contamination of specimens (i.e., changing gloves and use of sterile scissors or 
decontamination of scissors using bleach solution) for each patient.  
o If possible, specimens should be collected prior to start of antibiotic treatment. 
However, PCR detects both live and dead bacteria, so it does not indicate active 
disease.   
o A properly obtained nasopharyngeal swab, wash, or aspirate is essential for 
optimal test results. Collection and handling instructions for each specimen type 
are described below.  
o Nasopharyngeal swab testing kits consisting of slides, media and swabs in 
mailing containers can be ordered from the State Hygienic Laboratory at (319) 
335-4500. 
 
Nasopharyngeal Swab: 
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1. Gently insert nasopharyngeal swab into a nostril until the posterior 
nasopharynx is reached. Use a dacron or calcium alginate swab, not cotton. 
2. Leave the swab in place for 10 to 30 seconds. 
3. Slowly remove with a rotating motion. 
4. Place swab tip into 1.5 ml screw cap tube. Cut the 
excess length of the wire shaft with a sterile scissors, 
and cap the tube tightly. Treatment of scissors with 10 
percent bleach prior to use is effective in removing 
contamination with bacterial DNA from other sources. 
5. Repeat process to collect a second swab, and place in 
the glass vial containing the Regan-Lowe transport 
medium. Cut off excess length of shaft, and cap the 
tube tightly. 
6. If the kit does not contain Regan-Lowe transport 
medium, then place second swab in the replicate 1.5 
ml screw cap tube provided in the kit. 
7. Label specimens, wrap in absorbent material, and 
place in a biohazard bag and seal. Use a single 
biohazard bag for each patient’s specimens. Place the completed Test Request 
Form in the outside pocket of the biohazard bag. 
 
Nasal Wash: Instill several milliliters of sterile saline into nostrils while patient’s 
head is tilted back. Bring patient’s head forward and catch saline flowing from the 
nostrils in a small container. Pour specimen (minimum volume 0.2 ml) into the 1.5 
ml sterile tube contained in the kit.  
 
Nasopharyngeal Aspirate: A small catheter with a suction trap or bulb aspirator is 
inserted through the nostrils into the nasopharynx. Apply suction while slowly 
removing the catheter or aspirator tip. The catheter or aspirator should be flushed 
with sterile saline or viral transport medium and contents (minimum volume 0.2 
ml) placed into the 1.5 ml sterile tube contained in the kit. 
 
o Test result interpretation: 
 
Positive results indicate that the bacterium was detected in the specimen.  
 
Negative results indicate that the bacterium was not detected in the specimen.  
Note: negative results may occur if the patient is tested greater than three weeks 
after symptom onset. 
 
Equivocal results occur occasionally, meaning the PCR test does not clearly indicate a 
positive OR negative result. The clinician must then determine if the clinical 
symptoms and epidemiologic factors indicate a likely pertussis diagnosis or not. 
Public health follow up should depend on this determination.  
 
Indeterminate results rarely occur.  Indeterminate results are generally caused by an 
inadequate specimen or interfering substances in the specimen that inhibited the 
reaction. Retesting can be considered. Ultimately, the clinician must determine if the 
clinical symptoms and epidemiologic factors indicate a likely pertussis diagnosis or 
not. Public health follow up should depend on this determination.  
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D.  Local Public Health Agency (LPHA) Follow-Up Responsibilities 
 
Case Investigation 
1. Pertussis follow-up and case investigation is undertaken by the local public health agency 
(LPHA) and coordinated, if necessary, with IDPH Center for Acute Disease Epidemiology 
(CADE). 
2. LPHA is responsible for conducting pertussis follow-up.  Case investigation includes but is 
not limited to the following steps.  
a. Confirm the case’s diagnosis. 
b. Conduct the case interview, using the case interview form included this chapter and 
also in the Iowa Disease Surveillance System (IDSS).  
c. Identify all household contacts, close contacts at high risk of developing severe 
illness, and contacts who themselves have close contact with individuals at high risk.  
d. Determine whether any of the identified contacts are symptomatic.  
- Recommend prophylaxis for asymptomatic close contacts (See Section 3. C. Post 
Exposure Antimicrobial Prophylaxis Recommendations on page 7).  
- Symptomatic contacts should receive antibiotic treatment, possibly test, and be 
isolated until they have completed the first five days of the full course of an 
appropriate antibiotic (symptomatic contacts who refuse antibiotics should stay 
home through 21 days after cough onset). Symptomatic contacts are considered 
“epi-linked cases” and should be investigated as new cases and reported 
accordingly into the Iowa Disease Surveillance System (IDSS). 
- If symptomatic contacts have already coughed for more than 21 days at the time 
of diagnosis, the individual is no longer contagious to others. In most cases 
neither treatment nor isolation are indicated (See Section 3. B. Recommended 
Treatment Protocol on page 6 and Section 3. C. Post Exposure Antimicrobial 
Prophylaxis Recommendations on page 7.) 
e. Use the Iowa Disease Surveillance System (IDSS) to complete the Pertussis Case 
Investigation form. If IDSS is not available, paper forms can be used. This will drive 
the investigation.  If paper forms are used, fax to the Center for Acute Disease 
Epidemiology (CADE) at (515)281-5698. 
 
Contact the assigned field epidemiologist with questions or if assistance is needed. (800-362-
2736) 
 
 
3) CONTROLLING FURTHER SPREAD AND PREVENTING DISEASE  
 
A. Identifying close contacts and high risk populations 
 
Close Contact: While each situation should be evaluated separately and exposure defined 
based on information acquired through the investigation, close contacts are generally defined 
as persons who:  
• Shared confined space in close proximity with a symptomatic case patient for 
greater than one hour; 
• Had direct face-to-face contact for a period (not defined) with a symptomatic 
case while they were infectious; or 
• Had direct contact with respiratory, oral, or nasal secretions from a symptomatic 
case-patient (e.g., an explosive cough or sneeze in the face, sharing food, 
sharing eating utensils during a meal, kissing, mouth-to-mouth resuscitation, or 
performing a medical exam including examination of the nose and throat). 
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High Risk Populations: The following groups are generally considered to be at high risk of 
developing severe illness: 
• Infants and women in their third trimester of pregnancy -- severe and sometimes 
fatal pertussis-related complications occur in infants aged <12 months, especially 
among infants aged <4 months. Women in their third trimester of pregnancy 
may be a source of pertussis to their newborn infant. 
• All persons with pre-existing health conditions that may be exacerbated by a 
pertussis infection (for example, but not limited to immunocompromised persons 
and patients with moderate to severe medically treated asthma). 
B. Recommended Treatment Protocol: 
The symptoms of pertussis may be modified if treatment is begun early, during the catarrhal 
stage. If started later in the course of the illness, treatment will decrease the infectious 
period, but may not decrease the duration of cough or severity of disease.   
 
If symptomatic people are already beyond their infectious period, which ends 21 days after 
cough onset, treatment is generally not beneficial. However, for certain high-risk settings or 
individuals (such as pregnant women in their third trimester or infants less than 12 months), 
healthcare providers may consider extending the period for initiating treatment up to six 
weeks after symptoms start.  
 
A specific class of antibiotics called macrolides is most effective against pertussis. The table 
below summarizes recommended oral antibiotics and dosages by age group.  
 
Summary of oral macrolide treatment by age group.  
(Recommended Antimicrobial Agents for the Treatment and Postexposure Prophylaxis of 
Pertussis, 2005 CDC Guidelines, available at: 
www.cdc.gov/mmwr/preview/mmwrhtml/rr5414a1.htm?s_cid=rr5414a1_e) 
 
 
Age group 
 
 
 
Azithromycin 
 
  Clarithromycin  
 
 Erythromycin 
<1 month 
 
 
 
 
 
 
 
 
1-5 months  
 
 
 
Infants (aged 
≥6 months) 
and children 
 
 
 
Recommended agent. 
10 mg/kg per day in 
a single dose for 5 
days (only limited 
safety data available) 
 
 
 
 
10 mg/kg per day in 
a single dose for 5 
days. 
 
10 mg/kg in a single 
dose on day 1, then 5 
mg/kg per day 
(maximum: 500 mg) 
on days 2-5. 
 
Not recommended. 
(safety data 
unavailable) 
 
 
 
 
 
 
15 mg/kg per day in 
2 divided doses for 7 
days. 
 
15 mg/kg per day in 
2 divided doses 
(maximum: 1 g per 
day) for 7 days. 
 
 
Not recommended. 
Erythromycin is 
associated with infantile 
pyloric stenosis. Use if 
azithromycin is 
unavailable. 40-50 mg/kg 
per day in 4 divided doses 
for 14 days  
 
40-50 mg/kg per day in 4 
divided doses for 14 days. 
 
 
40-50 mg/kg per day 
(maximum: 2 g per day) 
in 4 divided doses for 14 
days. 
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Adults 500 mg in a single 
dose on day 1, then 
250 mg per day on 
days 2-5. 
1 g per day in 2 
divided doses for 7 
days.  
 
2 g per day in 4 divided 
doses for 14 days. 
 
 
 
Trimethoprim sulfamethoxazole (TMP-SMZ) may be used as an alternative agent in patients 
aged ≥2 years who are allergic to macrolides, who cannot tolerate macrolides, or who are 
infected, rarely, with a macrolide-resistant strain of Bordetella pertussis.  
• The recommended dose in children is trimethoprim 8 mg/kg/day, sulfamethoxazole 40 
mg/kg/day in two divided doses for 14 days.  
• For adults, the recommended dose is trimethoprim 320 mg/day, sulfamethoxazole 1600 
mg/day in two divided doses for 14 days.  
NOTE: Because of the risk of kernicterus, TMP-SMZ should not be given to pregnant women, 
nursing mothers, premature neonates, or infants <two months of age.  
 
NOTE: Only limited data from small clinical trials are available that confirm the microbiologic 
effectiveness of macrolides in infants < six months of age with pertussis, who are more likely 
to be partially or  unimmunized and whose colonization is more likely to be prolonged 
compared with older, previously immunized individuals with pertussis.  
• Nevertheless, considering theoretical rationale, in vitro effectiveness, safety and clinical 
data in older individuals with pertussis, and treatment adherence issues, the macrolides 
listed above may be used as a first line agent in infants 1 to 6 months of age. 
• For infants <1 month of age, the risk of developing severe pertussis and life threatening 
complications outweighs the potential risk of infantile hypertrophic pyloric stenosis (IHPS) 
that is associated with macrolide use. All infants <1 month of age who receive any 
macrolide should be monitored for the development of IHPS and, as with other 
antibiotics with limited experience, for other serious adverse events.  
 
C. Post Exposure Antimicrobial Prophylaxis Recommendations 
The primary goal of post exposure antimicrobial prophylaxis is to prevent death and serious 
complications from pertussis in individuals at increased risk of severe disease. Appropriate 
administration of antimicrobial prophylaxis to asymptomatic contacts can prevent 
symptomatic infection.   
 
Prophylaxis is generally indicated when:  
A. The asymptomatic contact was exposed to the case during the case’s infectious 
period (<21 days after onset of cough in the case), and  
B. The asymptomatic contact’s last exposure to the infectious case occurred <21 days 
(one incubation period) ago.   
However, at their discretion, healthcare providers could consider prophylaxis of high-risk 
close contacts up to six weeks after exposure. 
 
Prophylaxis is generally recommended for the following groups, regardless of their 
immunization status:  
1. All household contacts (within families, secondary attack rates have been 
demonstrated to be high, even when household contacts are current with 
immunizations),  
2. Close contacts at high risk of developing severe illness, or  
3. Close contacts who themselves have close contact with either infants under 12 
months, pregnant women in their third trimester, or individuals with pre-existing 
health conditions that may be exacerbated by a pertussis infection. 
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4. All contacts in high risk settings that include infants (<12 months) or pregnant 
women in their 3rd trimester (such as neonatal intensive care units, childcare 
settings, and maternity wards).  
(See Section A. Identifying close contacts and high risk populations on page 5, for further 
clarification of “close contacts” and “high risk”)  
 
A broader use of PEP may be recommended in rare situations.  Please contact your field 
epidemiologist or CADE for consultation or questions regarding these situations.  
 
The recommended antibiotics and dosage by age group is identical for treatment and 
prophylaxis.  Therefore, refer to the table in Section 3.B Recommended Treatment Protocol 
on page 6 for the schedule.  
 
D. Isolation 
Cases: 
o If the patient has already coughed for more than 21 days at the time of diagnosis, 
the individual is no longer contagious to others and isolation is not indicated.  
o Cases who have been coughing fewer than 21 days should stay home (this includes 
exclusion from social settings such as school, child care, work, church, and the mall) 
until they have completed the first five days of the full course of an appropriate 
antibiotic. During this time, they also should not have visitors.  
o Cases who refuse antibiotics should stay home (this includes exclusion from social 
settings such as school, child care, work, church, and the mall) through 21 days after 
cough onset.  During this time, they should not have visitors. 
 
Asymptomatic contacts: 
o Prophylactic antibiotics are offered (to household contacts, close contacts at high risk 
of developing severe illness, and to close contacts who themselves have close 
contact with persons at high risk) to prevent others from becoming ill with pertussis 
or spreading the disease to those at high risk for severe disease.  
o Therefore, asymptomatic close contacts are not contagious and they do not need to 
be excluded from social settings.  They should be monitored for the development of 
symptoms. 
 
Symptomatic contacts (Epi-link case): 
o Symptomatic contacts should be referred to a physician for treatment and testing if 
appropriate (See section 2.C. Laboratory Testing on page 3).  
o If symptomatic contacts have already coughed for 21 days at the time of diagnosis, 
the individual is no longer contagious to others and isolation is not indicated.  
o Symptomatic contacts, who have coughed fewer than 21 days, should be placed on 
antibiotics, isolated to home, and considered infectious until having completed the 
first five days of the full course of an appropriate antibiotic.  
o Symptomatic contacts who refuse antibiotics should stay home (this includes 
exclusion from social settings such as school, child care, work, church, and the mall) 
through 21 days after cough onset.  During this time, they should not have visitors. 
o If the physician defers antibiotics until diagnostic test results are available, the 
symptomatic contact should be excluded from social settings until results become 
available.  If results are negative, the individual may return immediately unless the 
clinician makes the diagnosis of pertussis on the basis of clinical and epidemiologic 
data.   
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E. Vaccination and Preventive Measures 
The focus of vaccination is the prevention of the spread of pertussis in general; therefore 
all contacts that are not up to-date with DTaP/DTP/Tdap should be brought up-to-date.   
 
For current recommendations for vaccination, visit the IDPH Bureau of Immunization and 
Tuberculosis web page at: 
www.idph.state.ia.us/ImmTB/Immunization.aspx?prog=Imm&pg=ImmHome. 
 
The follow points provide additional detail and clarification related to pertussis 
immunizations:  
• Active immunization started after exposure will not protect against disease resulting 
from that exposure, but it is not contraindicated. It will decrease the risk for disease 
from future exposure.  The best protection is obtained by adhering to the 
recommended schedule.   
• Assess the immunization status of close contacts. Children who are unimmunized or 
underimmunized should have immunization initiated, completing the series with 
minimum intervals.  
• Children who have received their third dose of DTP/DTaP >six months before 
exposure should receive a fourth dose. 
• Supplemental vaccination is not recommended for children who are up-to-date for 
age. 
• While the use of an accelerated routine schedule of pertussis vaccination for infants 
(e.g., aged <two months at initial vaccination) during pertussis outbreaks is 
considered an acceptable outbreak control measure, it is usually not recommended 
because it would not match the schedule of other needed vaccinations.  DTaP 
vaccines are not licensed for use in infants less than six weeks of age. The impact of 
implementing an accelerated schedule is likely to be modest, but could result in some 
decrease in pertussis morbidity among infants between 14 weeks and six months of 
age. 
• Pertussis vaccine does not protect against infection by B. parapertussis.  
• Many experts recommend children (especially infants aged <12 months) who have 
had a history of pertussis disease complete the routine vaccination series for 
pertussis with DTaP.  This is because the duration of protection from pertussis 
disease is unknown and the diagnosis of pertussis can be difficult to confirm, 
especially if testing methods other than PCR are used.  At least one study found that 
infants (age<12 months) may have a suboptimal immune response following 
pertussis disease. 
 
While routine vaccination is the best preventive measure against pertussis, good personal 
hygiene (which consists of proper hand hygiene, disposal of used tissues, etc.) is also important.  
 
F. Managing Special Situations: While the basic principles of case investigation, treatment of 
cases, and close contact prophylaxis also apply to these settings, additional considerations are 
included below.  
 
Schools and Preschools: (If preschool is part of larger childcare setting, see child care 
center section below.) 
 
Pertussis outbreaks have occurred even with high vaccine coverage levels (persons with 
three or more doses of pertussis containing vaccine).  Often outbreaks are not limited to a 
single class or grade.  Attack rates vary by grade and school activities.  Transmission in 
school settings may include other children, the teacher in the classroom, or other social 
groups such as athletic teams or clubs. 
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Prophylaxis recommendations follow those outlined in Section 3. C. Post Exposure 
Antimicrobial Prophylaxis Recommendations on page 7. When identifying close contacts, it is 
important to determine if there are any patterns of interaction that would increase exposure 
time among a group (such as children living in the same neighborhood, riding the same bus, 
going to the same school, and participating in the same activities, etc.). 
 
The following checklist should be used when investigating cases and outbreaks in school 
and preschool settings:   
 
Work with the school nurse and appropriate teachers to take the following actions: 
1.  Identify close contacts among students and staff who interact directly with the case.  
2.  Evaluate close contacts (students and staff) for cough illness.  
3.  Refer close contacts to their healthcare provider for appropriate treatment, isolation, 
or prophylaxis (see Section 3. B. Recommended Treatment Protocol on page 6, Section 
C. Post Exposure Antimicrobial Prophylaxis Recommendations page 7, and Section 3.D. 
Isolation on page 8).  A School/Childcare Close Contact Letter Template is included in 
this chapter for distribution among close contacts; these may be issued on the stationery 
of the local public health agency or the affected institution.  
 
4. Consider sending a general notification home with all students, acknowledging that 
there has been a case of pertussis in the school and encouraging parents to ensure their 
children are “up to date” on vaccine (in particular the adolescent booster) and to be 
aware of signs and symptoms and what to do if they occur. A School-wide / Childcare-
wide General Notification Pertussis Letter Template is included in this chapter; these may 
be issued on the stationery of the local public health agency or the affected institution. 
 
5.  Request that all teachers in the school refer coughing students to the nurse’s office. 
 
6.  Maintain a pertussis surveillance log that includes a line listing for all symptomatic 
individuals with cough onset and duration, labs, antibiotic type and start and finish date, 
location (in schools, grade and home room), and other symptoms present. On a separate 
list, keep track of the close contacts, recording the names and locations of students and 
staff (classrooms, teams, etc.).  See school contact letter included in this chapter.  
 
NOTE:  Close Contact letters that recommend consideration of prophylactic antibiotics 
given to minors should be accompanied by a phone or email to parents notifying them of 
the letter.  This follow-up could be performed by secretarial staff, for example, and does 
not have to be done by a health professional.  This additional phone or email 
communication is NOT necessary for the school-wide, general notification letter. 
 
Childcare:  
Usually children in child care centers have extensive contact with each other and it can 
be difficult to distinguish individuals with or without significant exposure.  
 
Exposures occurring in child care settings without children less than 12 months of age 
(no infants in the childcare center) should be managed in accordance with Section 3.C. 
Post Exposure Antimicrobial Prophylaxis Recommendations on page 7.  
   
For cases occurring in child care settings with children less than 12 months of age (there 
are infants in the childcare center), the recommendations are based upon whether 
children are divided into multiple classrooms.   
• If there are multiple classrooms that do not intermingle, and:  
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o The exposure occurs in a room with children less than 12 months of age, it is 
recommended that the case’s entire class and assigned staff be considered 
close contacts and they should all be advised to receive prophylaxis (because 
they are or have contact close contact with a child less than 12 months). 
o The exposure occurs in a room with children greater than 12 months of age, 
all children should be considered exposed and prophylaxis should be 
managed in accordance with Section 3.C. Post Exposure Antimicrobial 
Prophylaxis Recommendations on page 7. 
 In this situation, it would be appropriate to distribute the 
School/Childcare Close Contact Letter Template to all children and 
staff assigned to the same classroom as the case.  
o In both cases, the School-wide / Childcare-wide General Notification 
Pertussis Letter Template should be distributed to all children and staff in the 
facility (all classrooms).  
 
• If the child care center is not divided into separate classes, it is recommended that 
the entire center and all staff be considered close contacts and receive prophylaxis 
(because they have contact close contact with a child less than 12 months).   
o In this situation, the School/Childcare Close Contact Letter Template would 
be appropriate to distribute to all children/families and staff. 
 
In home-based child care settings with at least one child less than 12 months of age, it is 
recommended that all children and all child care providers (including any members of the 
child care providers’ families who had any contact with the case during their infectious 
period) receive prophylaxis.  
• In this situation, the School/Childcare Close Contact Letter Template would be 
appropriate to distribute to all children/families and staff. 
 
 Offices and other facilities:  
The basic principles of case and contact investigation, treatment of cases, and 
prophylaxis of close contacts apply (see Section 3. B. Recommended Treatment Protocol 
on page 6, Section C. Post Exposure Antimicrobial Prophylaxis Recommendations page 7, 
and Section 3.D. Isolation on page 8).  A General Close Contact Letter Template for 
distribution among close contacts is included in this chapter; these may be issued on the 
stationery of the local public health agency or the affected facility.  
 
Depending upon the situation and facility a general notification letter may also be 
appropriate. A General Pertussis Notification Letter Template is also included in this 
chapter; these may be issued on the stationery of the local public health agency or the 
affected facility. 
 
NOTE:  Close Contact letters, which recommend prophylactic antibiotics according to the 
high risk criteria, that are given to minors should be accompanied by a phone or email to 
parents notifying them of the letter.  This follow-up could be performed by secretarial 
staff, for example, and does not have to be done by a health professional.  This 
additional phone or email communication is NOT necessary for the general notification 
letter. 
 
Healthcare Facilities: 
In healthcare settings, surveillance should be initiated immediately after identification of 
a suspect case and continue through two incubation periods (42 days) after the date of 
cough onset in the last case. Healthcare provider’s pertussis vaccination should be up-to 
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date. A single dose of Tdap is recommended for all health care personnel who have not 
previously received Tdap as an adult.  
 
Regardless of their vaccination status, healthcare providers should use appropriate masks 
in the presence of a patient with cough illness to prevent exposures from occurring.   
• Healthcare workers exposed to a case who have appropriately followed Standard 
Precautions and Droplet Precautions (including wearing a mask) during close contact 
with the case, do not require prophylaxis. 
• Recommendations for healthcare workers exposed to a case, who have not 
appropriately followed Standard Precautions and Droplet Precautions (did not wear a 
mask) during close contact with the case, are based upon the setting and patient 
populations they serve:  
o Asymptomatic healthcare workers, who work with patients at risk for severe 
pertussis (see Section 3. A. Identifying close contacts and high risk 
populations on page 5) should receive prophylaxis (see Section 3. C. Post 
Exposure Antimicrobial Prophylaxis Recommendations on page 7). Examples 
of these high risk settings would include neonatal intensive care units, cancer 
treatment units, and maternity wards.  
o Other asymptomatic healthcare workers, who do not work with high risk 
patients, can be monitored for 21 days after exposure and prophylaxis is not 
required.  If the healthcare worker becomes symptomatic, they should be 
excluded immediately. 
• When cases occur within healthcare facilities (i.e., a patient is hospitalized with 
pertussis):  
o Apply Droplet and Standard Precautions to all staff, patients, and families in 
close contact with the case.  
In healthcare settings, “close contact” is defined as the following: 
1. having face-to-face contact, within three feet of the case; this 
includes conducting a medical examination, obtaining a 
nasopharyngeal swab, suctioning, intubating, performing 
bronchoscopy or similar procedure without appropriate PPE; 
2. conducting any procedure that induces coughing of the case, 
even if farther from the case than three feet without appropriate 
PPE; 
3. coming into mucosal contact with respiratory, oral, or nasal 
secretions of the case directly; and 
4. sharing a room with the case. 
o The basic principles of case and contact investigation, treatment of cases, 
and prophylaxis of close contacts apply (see Section 3. B. Recommended 
Treatment Protocol on page 6, Section C. Post Exposure Antimicrobial 
Prophylaxis Recommendations page 7, and Section 3.D. Isolation on page 8). 
o Providers, department heads, infection prevention, employee health, and 
other relevant personnel/departments should be notified of the case. 
 
Other:  
Institutional Setting:   
In institutional settings (e.g. correctional facilities), prophylaxis recommendations may 
vary depending upon this situation.  Please contact your field epidemiologist or CADE for 
consultation or questions regarding these situations. 
 
Repeat Exposures:  
When continued transmission of pertussis is evident, multiple rounds of antibiotics are 
not recommended unless:  
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1) the close contact is determined to be at high risk, or 
2) the close contact has close contact with persons at high risk. 
(Section 3. A. Identifying close contacts and high risk populations on page 5)     
 
Rather than repeating a course of antibiotics, close contacts determined not to be at high 
risk and not to have close contact with persons at high risk, should be monitored for 
onset of signs and symptoms of pertussis for 21 days.   
 
ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for 
Pertussis can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top. 
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the 
criteria in this chapter. (CSTE case definitions are used by the state health department and 
the CDC to maintain uniform standards for national reporting.)  
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Additional Resources 
  
CDC website providing Guidelines for the Control of Pertussis Outbreaks: 
www.cdc.gov/vaccines/pubs/pertussis-guide/guide.htm.  
 
CDC Advisory Committee on Immunization Practices Link to recommendations including 
pertussis:  www.cdc.gov/vaccines/pubs/ACIP-list.htm.  
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FACT SHEET    PERTUSSIS  
 (Whooping Cough) 
 
What is pertussis (whooping cough)? 
Pertussis is a disease caused by bacteria.  It causes severe spells of coughing.  These spells can interfere 
with eating, drinking and breathing.  Pertussis can lead to pneumonia, convulsions, inflammation of the 
brain (encephalitis) and sometimes death. 
 
Who can get pertussis? 
Pertussis can occur at any age.  It is most common in infants less than one year old, but anyone can get 
it.  Pertussis can be hard to diagnose in teens and adults because their symptoms often look like a cold 
with a nagging cough. 
 
How is pertussis spread? 
Pertussis is spread through the air after an infected person coughs or sneezes.  Other people breathe in 
infected droplets. 
 
What are the symptoms of pertussis? 
Pertussis starts like a cold with symptoms of runny nose and an irritating cough.  Within one to two 
weeks the cough develops into coughing fits.  The fits are a series of violent coughs during which the 
victim struggles for breath.  A gasping for air, which produces a high-pitched whooping sound, follows 
the coughing.  The coughing fits occur more frequently at night, and are often followed by vomiting.  
Between spells, the person usually appears to be well.  Adults, teens, and vaccinated children may have 
milder symptoms. 
 
How long is an infected person able to spread pertussis? 
Without treatment an infected person can spread the disease from the time he or she starts coughing 
until 21 days after the start of the cough.  After five days of treatment with an appropriate antibiotic, an 
infected person cannot spread the disease. 
 
Can a person get pertussis again? 
Yes.   
 
How is pertussis diagnosed? 
A doctor may think a patient has pertussis because of the symptoms, but a sample of mucus must be 
taken from the back of the nose for testing.  This sample is then sent for testing to determine whether 
the patient has pertussis. 
 
What is the treatment for pertussis? 
Treatment with an appropriate antibiotic may help if given early in the illness.  Other treatments such as 
fluids, oxygen, and mild sedation may help the child during the prolonged period of severe coughing. 
 
Should people who have been around a person with pertussis be treated? 
People with symptoms should see their healthcare provider. 
 
Even without symptoms, all household contacts and other close contacts determined to be at high risk for 
severe pertussis or in contact with someone at high risk and who don’t have symptoms should receive 
postexposure prophylaxis (PEP), regardless of age or vaccine status.   
 
Vaccination status should be assessed. 
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How can pertussis be prevented? 
Pertussis may be prevented through routine immunization.  Pertussis is spread through the air after an 
infected person coughs or sneezes.  Other people breathe in infected droplets.  Cover your mouth when 
you cough, stay away from others when they are coughing, wash your hands frequently.  Ask your health 
care clinician/local public health department about vaccine for adolescents/adults. 
 
Where is pertussis vaccine available? 
All county health departments in Iowa give this vaccine.  You may also check with your private health 
care provider. 
 
Where can you get more information? 
• Your doctor or nurse, your local health department (listed in the telephone book under local 
government). 
• Iowa Department of Public Health, Bureau of Disease Prevention and Immunization, (800) 831-
6293. 
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FACT SHEET   PERTUSSIS 
Information for health professionals (Whooping Cough) 
 
What is pertussis (whooping cough)? 
Pertussis is caused by the Bordetella pertussis, and can cause severe spells of coughing 
that lasts weeks to months. These spells can interfere with eating, drinking, sleeping 
and breathing. Pertussis can lead to pneumonia, convulsions, encephalitis and 
sometimes death (especially in young children). In adolescents and adults the most 
common symptom is a prolonged cough lasting over 2 weeks. 
 
Who can get pertussis? 
Pertussis can occur at any age. It is most commonly diagnosed in infants less than one 
year old, but anyone can get it.  
 
How is pertussis spread? 
Pertussis is spread through the air after an infected person coughs or sneezes. 
 
What are the symptoms of pertussis? 
Pertussis often begins with cold-like symptoms (runny nose and irritating cough). Within 
one to two weeks the cough develops into coughing spells, where the patient has violent 
coughs, and struggles for breath. A gasping for air, which produces a high-pitched 
whooping sound, (mainly in infants), follows the coughing, and gives the disease its 
name. This whoop is almost never heard in older children or adults. In all ages, these 
coughing spells frequently occur at night, and can be followed by vomiting and cyanosis. 
Between spells, the person usually appears to be well. Adults, teens, and those 
vaccinated typically have milder symptoms. 
 
How long is an infected person able to spread pertussis? 
Without effective antibiotic treatment an infected person can spread the disease from 
the time he or she starts coughing through 21 days after the start of the cough. After 
five days of treatment with an appropriate antibiotic, the patient is no longer considered 
infectious. 
 
Can a person get pertussis again? 
Yes. Disease does not confer lifetime immunity. Up-to-date vaccinations significantly 
reduce the risk of disease.  
 
How is pertussis diagnosed? 
A properly obtained nasopharyngeal swab or aspirate is essential for optimal test results. 
Nasopharyngeal swab testing kits (consisting of slides, media and swabs in mailing 
containers) can be ordered from the State Hygienic Laboratory (SHL) at (319) 335-4500 
or www.shl.uiowa.edu/kitsquotesforms/. The best test for pertussis is the Polymerase 
chain reaction (PCR) test, which is available at SHL.  
 
What is the treatment for pertussis? 
Early treatment with an appropriate antibiotic will reduce the severity and length of 
illness. Unfortunately, antibiotics given more than 21 days after the cough began will not 
change the course of illness and is not recommended. However, for certain high-risk 
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settings or individuals, healthcare providers may consider extending the period for 
initiating treatment up to 6 weeks after symptoms start.  
 
How should those around a pertussis patient be treated? 
Symptomatic contacts need evaluation and treatment as warranted. 
 
All household contacts and other close contacts determined to be at high risk for severe 
pertussis or in contact with someone at high risk and who are asymptomatic, should 
receive post exposure prophylaxis (PEP), regardless of age or vaccine status.   
 
When continued transmission of pertussis is evident, multiple rounds of antibiotics are 
not recommended unless:  
1) the close contact is determined to be at high risk, or 
2) the close contact has close contact with persons at high risk. 
 
Rather than repeating a course of antibiotics, close contacts determined not to 
be at high risk and not to have close contact with persons at high risk, should be 
monitored for onset of signs and symptoms of pertussis for 21 days.   
 
If repeat prophylaxis is appropriate, the additional points should be considered:   
• If the repeat exposure occurred less than 5 days after completion of the 
initial course of azithromycin (5 day course), no additional prophylaxis is 
needed.   
• If the repeat exposure occurred more than 5 days after completion of the 
initial course of azithromycin or if a different prophylactic antibiotic 
(Clarithromycin, Erythromycin, or TMP-SMZ) was prescribed for the first 
exposure, another course of antibiotics should be prescribed.   
 
Vaccination status should be assessed and brought up to date. 
 
How can pertussis be prevented? 
Pertussis may be prevented through routine immunization.   
 
Instruct everyone to cover their mouth and nose when coughing and sneezing and to 
wash hands frequently. Everyone, including healthcare providers should be up-to-date 
on pertussis vaccine (the new tetanus booster contains pertussis vaccine). 
   
When examining a person with a cough illness, a surgical mask should be worn for 
protection. Wearing of a mask at the appropriate times will reduce the need for post-
exposure antibiotics. Remember, prophylactic antibiotics are recommended regardless of 
vaccine status. 
 
Where can you get more information or call for consultation? 
Iowa Department of Public Health, Center for Acute Disease Epidemiology, (800)362-
2736 or visit:  
www.idph.state.ia.us/CADE/DiseaseIndex.aspx?disease=Pertussis 
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CONFIDENTIAL                                                                            Iowa Department of Public Health 
Pertussis                       Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider title: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes   No  Unk To whom: ______________  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      Test type:  Culture      PCR 
Result type: 
 
 Preliminary    Final 
 
Result date: 
 
     /     /      Result: 
 Negative     No growth 
 Positive 
 
Organism: 
 
       
 
  Indeterminate  Equivocal 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      Test type:  Culture      PCR 
Result type: 
 
 Preliminary    Final 
 
Result date: 
 
     /     /      Result: 
 Negative     No growth 
 Positive 
 
Organism: 
 
       
 
  Indeterminate  Equivocal 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      Test type:  Culture      PCR 
Result type: 
 
 Preliminary    Final 
 
Result date: 
 
     /     /      Result: 
 Negative     No growth 
 Positive 
 
Organism: 
 
       
 
  Indeterminate  Equivocal 
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CONFIDENTIAL           PATIENT NAME: ___________________________________                Iowa Department of Public Health 
EXPOSURE PERIOD COMMUNICABLE PERIOD 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
 Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting:          
Health care worker type: 
 Yes      No      Unknown 
 
Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting:          
Health care worker type: 
 Yes      No      Unknown 
 
Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
Note: The cough duration, cough type, and symptoms must be documented for IDPH to status case. 
 
 
S
ym
pt
om
s 
Cough:  Yes    No    Unk Cough type: 
 Paroxysmal    
 Whoop 
 Other 
Onset 
Date:      /     /      
Symptoms: 
 
 Apnea event 
 Pneumonia 
 Post-tussive vomiting 
 Seizures 
 None listed above 
Chest X-ray 
done:  Yes    No    Unk 
X-ray 
result:  
X-ray date      /     /      
Encephalopathy  Yes    No    Unk 
Pneumonia:  Yes    No    Unk Final interview 
date:      /     /      
Cough at final 
interview: 
 Yes    
 No    Unk 
Duration 
in days: 
 
      
 
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
 
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  Average incubation period 
for pertussis is 9-10 days 
with a range of 6-20 days. 
Pertussis is communicable for 
21 days after the start of 
symptoms or five days after the 
start of antibiotics.  
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TREATMENT 
 
Antibiotics prescribed?   Yes    No    Unknown 
  
Antibiotic:       
  
Antibiotic:       
 
 
Antibiotic:       
Date 
started:      /     /      
Date 
started:      /     /      
Date 
started:      /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
 
RISK FACTORS/TRAVEL 
 
Traveled within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
 
S
et
tin
g 
A
cq
ui
re
d Child care 
Church 
College 
Correctional Facility 
Doctors office 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
Home 
Hospital ward 
Hospital outpatient 
Hospital ER 
International travel  
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
Military 
School 
Work 
Other 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
      
S
ec
on
da
ry
 
sp
re
ad
 Child care 
Church 
College 
Correctional Facility 
Doctors office 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
Home 
Hospital ward 
Hospital outpatient 
Hospital ER 
International travel 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
Military 
School 
Work 
Other 
 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
      
 
 
 
Worked with a case:    Yes    No    Unk 
 
From date:  
 
     /     /      
 
  To date: 
 
     /     /      
Lived with another case:  Yes    No    Unk 
 
From date:  
 
     /     /      
 
  To date: 
 
     /     /      
 
 
Vaccinated for pertussis?  Yes    No    Unk 
V
ac
ci
na
tio
n 
Date vaccinated:      /     /      
 
Date vaccinated:      /     /      
 
Date vaccinated:      /     /      
 
Lot #: 
 
      
 
Lot #: 
 
      
 
Lot #: 
 
      
 
Vaccine type: 
 
      
 
Vaccine type: 
 
      
 
Vaccine type: 
 
      
 
Manufacturer: 
 
      
 
Manufacturer: 
 
      
 
Manufacturer: 
 
      
 
Date vaccinated:      /     /      
  
Date vaccinated:      /     /      
  
Date vaccinated:      /     /      
 
Lot #: 
 
      
 
Lot #: 
 
      
 
Lot #: 
 
      
 
Vaccine type: 
 
      
 
Vaccine type: 
 
      
 
Vaccine type: 
 
      
 
Manufacturer: 
 
      
 
Manufacturer: 
 
      
 
Manufacturer: 
 
      
 
# of vaccinations:       
 
Reason not 
vaccinated (check 
only one): 
 Religious exemption 
 Medical contraindication 
 Previous disease confirmed by culture or MD 
 Parent refusal 
 Age less than 7 months 
 Other       
 Unknown 
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CONTACTS 
 
Number of people who may have been exposed by the case:       
 
Number of people prophylaxed:       
 
List Contacts with symptoms. Initiate an IDSS case and start an investigation for each symptomatic contact listed. 
 
Name    Address (if different from case)                                Phone number           . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOTES:       
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(General Close Contact Letter Template- Pertussis) 
Dear:  
 You/your child have/has been exposed to pertussis (whooping cough).  Pertussis is an infection that affects the airways and 
is easily spread from person to person by coughing or sneezing.  It causes a severe cough that can last for weeks or months, 
sometimes leading to coughing fits and/or vomiting.  Anyone can get pertussis, but it can be very dangerous for infants and 
people with weakened immune systems or lung problems.   
Recommendations:  
1. If you/your child have/has a cough: 
Make an appointment with your/your child’s healthcare provider as soon as possible and tell the healthcare 
provider that you/your child have/has been exposed to pertussis.  
• Keep your child /stay home from work and activities until your/your child’s healthcare provider 
determines that you/your child do/does not have pertussis.  
• If your/your child’s healthcare provider determines that you/your child does have/has pertussis, it is 
important that you/your child continue/s to stay home from work/school/childcare and other activities 
until you/your child have/has been on an antibiotic for five days.  If you/your child has already been 
coughing for more than 21 days you/your child is no longer contagious so will not need antibiotics and will 
not need to stay home.  However, you/your child may have spread pertussis to others during those 21 
days.  
• If your/your child’s healthcare provider confirms (via testing or examination) that you/your child do/does 
NOT have pertussis, you/your child can return to work/school/childcare and other activities at any time. 
2.   If you/your child do/does NOT have a cough:  
• If you/your child are/is  
- pregnant in your/their third trimester, or 
- is less that 12 months of age, or 
- have/has a weakened immune system or lung problems (like severe asthma or cystic fibrosis) 
you / your child needs to be started on antibiotics to prevent them from becoming ill.  Ask your /your 
child’s healthcare provider to prescribe antibiotics to you/your child as soon as possible to prevent 
pertussis.  
• And if you/your child live/s with or has a lot of contact with any of the following high risk people, ask your  
healthcare provider to prescribe antibiotics for you/your child as soon as possible so that you / your child 
does not give pertussis to them: 
- A woman who is pregnant in her third trimester,  
- An infant younger than 12 months old, or  
- Anyone with a weakened immune system or lung problems (like severe asthma or cystic fibrosis).  
• If you/your child do/does not meet the criteria listed above (you/your child is/are not, do not have, and 
do/does not have contact with pregnant women, infants less than 12 months of age, and weakened 
immune system/lung problems), you/your child do not need to receive antibiotics because of your / your 
child’s pertussis exposure. 
• However, please watch for signs of pertussis (such as a cough) for 21 days and call your/your child’s 
healthcare provider if you/they start coughing. At that time tell your/your child’s health care provider that 
you/your child were exposed to pertussis.   
Please make sure your family’s vaccinations for pertussis are up-to-date. If you need the Tdap vaccine, contact your 
healthcare provider or call [insert contact] to find a vaccine provider near you.  
When you go to a healthcare provider for pertussis, please show this letter to him or her.  If you have any questions or 
concerns, please call us at [insert contact].  
Sincerely,   
 
Dear Colleague:  
 Your patient may have been exposed to pertussis.  
 If your patient does not have symptoms of pertussis: 
National guidelines state:  As a precaution to protect vulnerable individuals, if your patient meets one or more of the 
following criteria, we recommend antibiotic prophylaxis:  
• Your patient is or has ongoing close contact with a woman who is pregnant in her third trimester. 
• Your patient is or has ongoing close contact with an infant less than 12 months old.   
• Your patient is or has ongoing close contact with a person with pre-existing health conditions that may be 
exacerbated by a pertussis infection (such as immunocompromised persons and patients with moderate to severe 
medically treated asthma).  
 
If your patient does not meet any of the criteria listed above, antibiotic prophylaxis is not recommended. However, please 
educate your patient on how to watch for signs and symptoms.  
If your patient does have symptoms of pertussis: 
 [insert public health agency],  the Iowa Department of Public Health, and national guidelines recommend the following 
actions when assessing and treating patients exposed to pertussis :  
If your patient has been coughing for less than 21 days: 
1. Collect nasopharyngeal swabs, nasal aspirate, or nasal wash for pertussis PCR testing and send the specimens to 
the State Hygienic Laboratory for testing.  
2. Do not delay treatment with appropriate antibiotics while waiting for laboratory results if there is no alternative 
diagnosis. 
3. Document and communicate all clinical decisions related to pertussis to [insert public health agency or school 
name and contact information] (this includes children for whom pertussis has been ruled out) so that appropriate 
public health action can continue to be taken.  
4. Strongly consider antibiotic prophylaxis for all household members, this is especially important if a pregnant 
woman, an infant less than 12 months old, or anyone with a pre-existing health conditions that may be 
exacerbated by a pertussis infection lives in the household.  
If you patient has been coughing for 21 days or more: 
1. Testing for pertussis is not recommended as the infection has resolved even though the symptoms may continue 
for weeks due to damage done by the infection.  Testing after 3 weeks of cough is of limited benefit since PCR and 
culture are only sensitive during the first 2-3 weeks of cough when bacterial DNA is still present in the 
nasopharynx.  
2. Treatment is generally no longer necessary after 21 days.  However, because they are at higher risk of severe 
disease, infants or pregnant women in their third trimester could be treated up through 6 weeks after cough 
onset. 
3. The patient is no longer infectious and can return to work/school/childcare/ and other activities. 
For all households:  Please make sure that all pertussis vaccinations are up to date for all household members or refer for 
vaccination [insert contact].  
Additional clinical and laboratory guidance may be found on the IDPH website: 
www.idph.state.ia.us/CADE/DiseaseIndex.aspx?disease=Pertussis. 
Should you have any questions or concerns, please call [insert contact]. 
Sincerely,  
(General Pertussis Notification Letter Template) 
Dear: 
 This note is to let you know that at least one person at your (work, church) has been identified as having 
pertussis and is being treated with antibiotics.   Pertussis is an infection that affects the airways and is easily 
spread from person to person by coughing or sneezing.  It causes a severe cough that can last for weeks or 
months, sometimes leading to coughing fits and/or vomiting.  Anyone can get pertussis, but it can be very 
dangerous for infants and people with weakened immune systems or lung problems.   
Letters have already been sent to those people that the public health investigation identified as being at highest 
risk of becoming ill. If you have not received a previous letter you are not at high risk of getting pertussis.     
However, since pertussis has been confirmed at your (work, church) public health recommends that you make 
sure your family’s vaccinations are up-to-date. Basic protection against pertussis is provided by childhood 
pertussis vaccine, but this protection can decrease over time. Therefore, children (11 years of age and over) and 
all adults should get a booster shot for pertussis (Tdap) to boost their immunity. If you or a family member 
needs any pertussis vaccines, contact your healthcare provider or call [insert contact].  
For more information on pertussis, please visit: (insert Webpage) or contact your local public health 
department. 
Sincerely, 
               (School-Childcare Close Contact Letter) 
 
Dear Parent or Guardian:  
 
Your child has been exposed to pertussis (whooping cough).  Pertussis is an infection that affects the airways and is easily 
spread from person to person by coughing or sneezing.  It causes a severe cough that can last for weeks or months, 
sometimes leading to coughing fits and/or vomiting.  Anyone can get pertussis, but it can be very dangerous for infants and 
people with weakened immune systems or lung problems.   
 
Recommendations:  
1. If your child has a cough: 
Make an appointment with your child’s healthcare provider as soon as possible and tell the healthcare 
provider that your child has been exposed to pertussis.  
• Keep your child home from school and other activities outside of your home (such as afterschool 
activities, trips to the grocery store, or playing at another child’s house)  until your child’s healthcare 
provider determines that your child does not have pertussis.  
• If your child’s healthcare provider determines that child does have pertussis, it is important that your child 
continues to stay home from school and other activities until your child has been on an antibiotic for five 
days.  If your child has already been coughing for more than 21 days your child is no longer contagious so 
will not need antibiotics and will not need to stay home. However, your child may have spread pertussis 
to others during those 21 days.   
• If your child’s healthcare provider confirms (via testing or examination) that your child do NOT have 
pertussis, your child can return to school and other activities at any time. 
2.   If your child does NOT have a cough:  
• And your child is  
i. pregnant in her third trimester, or 
ii. is less that 12 months of age, or 
iii. has a weakened immune system or lung problems (such as severe asthma or cystic fibrosis),  
your child needs to be started on antibiotics to prevent them from becoming ill. Ask your child’s 
healthcare provider to prescribe antibiotics as soon as possible to prevent pertussis.  
• And if your child lives with or has a lot of contact with any of the following high risk people, ask your  
healthcare provider to prescribe antibiotics for your child as soon as possible so that your child does not 
give pertussis to them: 
i. A woman who is pregnant in her third trimester,  
ii. An infant younger than 12 months old, or  
iii. Anyone with a weakened immune system or lung problems (like severe asthma or cystic fibrosis).  
• If your child does not have a cough nor meets either of the criteria listed above (your child is not, does not 
have, or does not have contact with pregnant women in their third trimester, infants less than 12 months 
of age, and persons with weakened immune systems or lung problems), your child does not need to 
receive antibiotics because of their pertussis exposure.   
• However, please watch for signs of pertussis such as a cough for 21 days and call your child’s healthcare 
provider if they start coughing. At that time tell your help care provider that your child was exposed to 
pertussis.   
Please make sure your family’s vaccinations for pertussis are up-to-date. Contact your healthcare provider or call [insert 
contact] to find a vaccine provider near you.  
When you go to a healthcare provider for pertussis, please show this letter to him or her.  If you have any questions or 
concerns, please call us at [insert contact].  
 
 
BACK OF LETTER 
Dear Colleague:  
 Your patient may have been exposed to pertussis.  
 If your patient does not have symptoms of pertussis: 
National guidelines state:  As a precaution to protect vulnerable individuals, if your patient meets one or more of the 
following criteria, we recommend antibiotic prophylaxis:  
2. Your patient is or has ongoing close contact with a woman who is pregnant in her third trimester. 
3. Your patient is or has ongoing close contact with an infant less than 12 months old.   
4. Your patient is or has ongoing close contact with a person with pre-existing health conditions that may be 
exacerbated by a pertussis infection (such as immunocompromised persons and patients with moderate to severe 
medically treated asthma).  
 
If your patient does not meet any of the criteria listed above, antibiotic prophylaxis is not recommended. However, please 
educate your patient on how to watch for signs and symptoms.  
If your patient does have symptoms of pertussis: 
 [insert public health agency],  the Iowa Department of Public Health, and national guidelines recommend the following 
actions when assessing and treating patients exposed to pertussis :  
If your patient has been coughing for less than 21 days: 
1. Collect nasopharyngeal swabs, nasal aspirate, or nasal wash for pertussis PCR testing and send the specimens to 
the State Hygienic Laboratory for testing.  
2. Do not delay treatment with appropriate antibiotics while waiting for laboratory results if there is if no alternative 
diagnosis. 
3. Document and communicate all clinical decisions related to pertussis to [insert public health agency or school 
name and contact information] (this includes children for whom pertussis has been ruled out) so that appropriate 
public health action can continue to be taken.  
4. Strongly consider antibiotic prophylaxis for all household members, this is especially important if a pregnant 
woman, an infant less than 12 months old, or anyone with a pre-existing health conditions that may be 
exacerbated by a pertussis infection lives in the household.  
If you patient has been coughing for 21 days or more: 
1. Testing for pertussis is not recommended as the infection has resolved even though the symptoms may continue 
for weeks due to damage done by the infection.  Testing after 3 weeks of cough is of limited benefit since PCR and 
culture are only sensitive during the first 2-3 weeks of cough when bacterial DNA is still present in the 
nasopharynx.  
2. Treatment is generally no longer necessary after 21 days.  However, because they are at higher risk of severe 
disease, infants or pregnant women in their third trimester could be treated up through 6 weeks after cough 
onset. 
3. The patient is no longer infectious and can return to work/school/childcare/ and other activities. 
For all households:  Please make sure that all pertussis vaccinations are up to date for all household members or refer for 
vaccination [insert contact].  
Additional clinical and laboratory guidance may be found on the IDPH website: 
www.idph.state.ia.us/CADE/DiseaseIndex.aspx?disease=Pertussis. 
Should you have any questions or concerns, please call [insert contact]. 
Sincerely,  
(School-wide / Childcare-wide General Notification Pertussis Letter Template) 
Dear Parent or Guardian:  
This note is to let you know that at least one person at (insert name of school / childcare center) has been 
identified as having pertussis and is being treated with antibiotics.   Pertussis is an infection that affects the 
airways and is easily spread from person to person by coughing or sneezing.  It causes a severe cough that can 
last for weeks or months, sometimes leading to coughing fits and/or vomiting.  Anyone can get pertussis, but it 
can be very dangerous for infants and people with weakened immune systems or lung problems.   
Letters have already been sent to the parents of children who the public health investigation identified as being 
at highest risk of becoming ill. If you have not received a previous letter your child is not at high risk of getting 
pertussis.     
However, since pertussis has been confirmed at your child’s school/childcare center public health recommends 
that you make sure your family’s vaccinations are up-to-date. Basic protection against pertussis is provided by 
childhood pertussis vaccine, but this protection can decrease over time. Therefore, children (11 years of age and 
over) and all adults should get a booster shot for pertussis (Tdap) to boost their immunity. If you or a family 
member needs any pertussis vaccines, contact your healthcare provider or call [insert contact].  
For more information on pertussis, please visit: (insert Webpage) or contact your local public health 
department. 
Sincerely, 
 
Iowa Department of Public Health 
Pertussis Outbreak Worksheet 
Case 
Name:               IDSS #:  
  
Address:  
 
Phone: ________________  
 
School/Etc  
Ref 
# Name Age 
 
Phone County of Residence 
Case/epi-
link/close contact 
Cough 
onset 
date 
Signs and 
Symptoms 
NP 
swab 
date 
Antibiotics 
(type/date 
started) 
Setting Relationship Other  Concerns 
1             
2             
3             
4             
5             
6             
7             
8             
9             
10             
11             
12             
13             
14             
15             
16             
17             
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Pertussis Outbreak Worksheet 
Ref 
# Name Age 
 
Phone County of Residence 
Case/epi-
link/close contact 
Cough 
onset 
date 
Signs and 
Symptoms 
NP 
swab 
date 
Antibiotics 
(type/date 
started) 
Setting Relationship Other  Concerns 
18             
19             
20             
21             
22             
23             
24             
25             
26             
27             
28             
29             
30             
31             
32             
33             
34             
35             
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Pertussis Outbreak Worksheet 
 
Ref 
# Name Age 
 
Phone County of Residence 
Case/epi-
link/close contact 
Cough 
onset 
date 
Signs and 
Symptoms 
NP 
swab 
date 
Antibiotics 
(type/date 
started) 
Setting Relationship Other  Concerns 
36             
37             
38             
39             
40             
41             
42             
43             
44             
45             
46             
47             
48             
49             
50             
51             
52             
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PLAGUE 
 
Potential Bioterrorism Agent Category A 
 
Also known as Pestis, Bubonic Plague, Black Plague, Black Death 
 
Responsibilities: 
Hospital/Infection Preventionist: Report by phone immediately 
Lab: Report by phone immediately 
Physician: Report by phone immediately 
Local Public Health Agency (LPHA): Follow-up required.  Iowa Department of Public 
Health will lead the follow-up investigation.  
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 282-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Etiologic Agent 
Plague is caused by the bacterium Yersinia pestis.  It is a zoonotic disease of rodents and their fleas, 
which can be spread to humans. 
  
B. Clinical Description 
The initial signs and symptoms of plague in humans are usually non-specific, and include fever, chills, 
malaise, sore muscles (myalgia), nausea, sore throat, headaches, and weakness. Bubonic plague, the 
most common form, is a syndrome that includes painful swelling of lymph nodes. Pneumonic plague 
refers to a form affecting the lungs; septicemic plague is a form caused by disseminated infection of 
the blood stream. Meningeal plague, or plague affecting the membranes lining the brain and spinal 
cord, is rare. Both pneumonic and septicemic plague can be primary or secondary to another form of 
plague. Untreated bubonic plague is fatal in 50% − 60% of cases, while untreated primary septicemic 
and pneumonic plague are fatal in 100% of cases.  
 
C. Reservoirs 
Certain wild rodents and their fleas carry Y. pestis. In the United States, ground squirrels and prairie 
dogs in the western U.S. are the primary reservoirs of Y. pestis. Lagomorphs (rabbits and hares), wild 
carnivores (meat-eating mammals) and domestic cats may also be a source of infection to people.  
There is probably no wild reservoir in Iowa. 
 
D. Modes of Transmission 
Plague is acquired primarily through the bite of an infected flea or through inhalation of airborne 
Yersinia pestis, either through proximity to a human or animal case of pneumonic plague or by 
accidental exposure in a laboratory. Plague can also be acquired by handling tissues of infected 
animals or by being bitten or scratched by an infected animal.  
 
E. Incubation Period 
From 1 - 7 days. 
 
 
 
 
Report Immediately 
by Phone  
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F. Period of Communicability or Infectious Period 
Patients with pneumonic plague are considered infectious throughout their symptomatic illness and 
for 72 hours following initiation of antibiotic treatment. Discharge from lesions in patients with 
bubonic plague is considered infectious.  
 
G. Epidemiology 
Wild rodent plague exists in large areas of South America, Africa, Eastern Europe and Asia. In 2007, 
7 countries reported 2021 cases with 156 deaths.  Among these, 99.6% of cases were reported from 
Africa.  In the United States, wild rodent plague occurs primarily in ground squirrels and prairie dogs 
in the western part of the country. Human cases there occur sporadically, usually following exposure 
to wild rodents or their fleas. Approximately 10 people are diagnosed with plague each year in the 
United States. Five instances of primary plague pneumonia through cat-to-human transmission have 
been recorded.  No person-to-person transmission has been documented in the United States since 
1925. 
 
H. Bioterrorism Potential  
Category A Agent Y. pestis is considered a potential bioterrorism agent. If effectively disseminated, 
Y. pestis could cause a serious public health challenge in limiting casualties and controlling other 
repercussions.  All cases of plague need to be reported immediately by phone.  (See 
reporting requirements below). 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To identify potential sources of transmission in the United States (such as wild rodents or other 
animals). 
• To identify sources of transmission and geographical areas of risk outside of the United States. 
• To stop transmission from such sources. 
• To identify cases and clusters of human illness that may be associated with a bioterrorist event. 
• To assess appropriate treatment.  
 
B. Laboratory and Healthcare Provider Reporting Requirement 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
immediately report any suspected or confirmed case. Report any suspicion of plague called to your 
attention by a healthcare provider or any positive laboratory result pertaining to plague. Also, report 
any potential exposure to plague that may be the result of bioterrorism. The reporting number for 
IDPH Center for Acute Disease Epidemiology (CADE) is (800) 362-2736. If after business hours, call 
IDPH at the same number and instructions will be given on how to reach on-call staff.  
 
Laboratory Testing Services Available  
The University of Iowa State Hygienic Laboratory (SHL) provides services for testing clinical 
specimens for Yersinia pestis and for confirmation of isolates from sentinel laboratories. Sentinel 
laboratories can send specimens (blood, tissue biopsies, discharge fluid, vesicle fluid, etc.) to SHL.  
Isolates submitted from other laboratories will be confirmed and/or identified. Additionally, SHL 
requests that all laboratories submit all isolates cultured for further identification as rapidly as 
possible, to aid in the public health surveillance necessary for this illness.  SHL needs to be contacted 
before samples are submitted. For more information on submitting samples, contact SHL at 319-335-
4500. 
 
C. Local Public Health Agency (LPHA) Follow-up Responsibilities 
Case Investigation 
 
a. The most important thing an LPHA can do if it learns of a suspect or confirmed case 
of plague, or a potential exposure that may be a bioterrorism event, is to 
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immediately call IDPH, any time of the day or night. The number for the 24-hour disease 
reporting hotline is (800) 362-2736. 
 
b. Case investigation of plague in Iowa residents will be directed by IDPH Center for Acute Disease 
Epidemiology. If a bioterrorism event is suspected, IDPH and other authorities will work closely 
with the local public health agency and provide instructions and information on how to proceed. 
c. The local public health agency may asked to assist in investigating cases that live within their 
communities, including gathering the following:  
1) The case’s name, age, address, phone number, status (hospitalized, at home, deceased), 
and parent/guardian information, if applicable. 
2) The name and phone number of the hospital where the case is or was hospitalized. 
3) The name and phone number of the case’s attending physician. 
4) The name and phone number of the infection-control official at the hospital. 
5) The names and phone numbers of patients seen by a healthcare provider before 
hospitalization or of other hospitals if seen at more than one hospital.    
 
d. Disease control is an integral part of case investigation. It is the LPHA responsibility to 
understand, and, if necessary, institute the control guidelines listed below (in Section 4), in 
Controlling Further Spread.    
 
3) CONTROLLING FURTHER SPREAD 
 
A.  Isolation and Quarantine Requirements 
• Minimum Period of Isolation of Patient   
Droplet Precautions are indicated when caring for patients with plague until pneumonia is 
excluded and appropriate antibiotic therapy has been initiated. In patients with pneumonic 
plague, Droplet Precautions should be maintained for 72 hours after starting treatment. For 
patients with bubonic plague, Standard Precautions are advised. 
 
• Minimum Period of Quarantine of Contacts 
See Section 4) B, Protection of Contacts, below.  
 
B.  Protection of Contacts of a Case 
• Cases with pneumonic plague are considered infectious throughout their symptomatic illness 
and for 72 hours following initiation of antibiotic treatment. People who have been in household 
or face-to-face contact with a case with pneumonic plague during the infectious period should be 
educated regarding signs and symptoms and recommended prophylaxis, and referred to their 
healthcare provider for antibiotic prophylaxis. They should be placed under surveillance for 
symptoms for 7 days. If contacts of a pneumonic plague case are unable to receive antibiotic 
prophylaxis, they should be placed under a strict quarantine for a 7-day period. 
• Bubonic plague is generally not transmitted person-to-person.  Quarantine would generally not 
be required. 
 
C.  Managing Special Situations 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
If multiple cases of plague occur, or if an outbreak is suspected, an investigation to determine the 
source of infection and mode of transmission (e.g., contact with diseased rodents) is needed. Plague 
in Iowa would most likely be associated with travel to the western part of the United States or 
another country with a known outbreak. Contact the Center for Acute Disease Epidemiology as soon 
as possible. The Center can help determine a course of action to prevent further cases and can 
perform surveillance for cases across county lines. 
 
Note: If bioterrorism is suspected, IDPH and other authorities will work closely with local public 
health and public safety and provide instructions and information on how to proceed. 
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D.  Preventive Measures 
Personal Preventive Measures/Education 
When handling the bubo aspirate and blood, laboratory personnel must use gloves and care to avoid 
aerosolization of these infected fluids.  Laboratory workers who process the cultures should be 
alerted to take precautions; however, standard bacteriologic techniques that safeguard against skin 
contact with and aerosolization of cultures should be adequate. 
 
To avoid plague, people should reduce the likelihood of being bitten by infected fleas or being 
exposed to patients with pneumonic plague by: 
• Understanding the modes of transmission and heeding any plague advisories while visiting the 
southwest U.S. 
• Preventing rodent access to food and shelter by ensuring appropriate storage and disposal of 
food, garbage and refuse. 
• Using insect repellents while camping in rural plague-infected areas avoiding and reporting dead 
or sick animals to park rangers or public health authorities. 
• Preventing flea infestations of pet dogs and cats. 
• Avoiding unnecessary contact with rodents or rabbits, and using protective gloves if handling is 
necessary. 
 
Additionally, a Y. pestis vaccine is recommended for persons whose occupations put them at high risk 
for exposure to Y. pestis or plague-infected rodents... Also, vaccine may be considered for persons 
traveling to, or residing in, areas with epizootic or epidemic plague.   
 
National and International Travel  
• For more information regarding national/international travel and plague, contact the CDC’s 
Traveler’s Health Office at (877) 394-8747 or through the Internet at www.cdc.gov/travel.  
 
4)  ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Plague 
can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
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Plague                                              Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider title: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes   No  Unk To whom: ______________  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Result date: 
 
     /     /      
 
Result type: 
 
 Preliminary      Final 
 
Test type: 
 
      Result: 
 Positive 
 Negative    
 
Organism: 
 
Yersinia pestis Antigen: 
 
        
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Result date: 
 
     /     /      
 
Result type: 
 
 Preliminary      Final 
 
Test type: 
 
      Result: 
 Negative    
 Positive 
 
Organism: 
 
Yersinia pestis Antigen: 
 
        
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Result date: 
 
     /     /      
 
Result type: 
 
 Preliminary      Final 
 
Test type: 
 
      Result: 
 Negative    
 Positive 
 
Organism: 
 
Yersinia pestis Antigen: 
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OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
Type: Bubonic Pharangeal 
 Yes    No    Unk 
 Yes    No    Unk 
Pneumonic 
Septicemic 
 Yes    No    Unk 
 Yes    No    Unk 
 
Fever:  Yes    No    Unk 
 
Onset date: 
 
     /     /      
 
Highest known fever: 
 
          Celsius    Fahrenheit 
Cough:  Yes    No    Unk 
Onset 
date:       /     /      
Productive 
cough:  Yes    No    Unk 
Onset 
date:       /     /      
Bubo:  Yes    No    Unk Bubo: Cervical Auxillary 
 Left    Right 
 Left    Right  
Femoral 
Inguinal 
 Left    Right  
 Left    Right 
Bubo size: 
 
       inches  cent 
 
Tender: 
 
 Yes    No    Unk 
Chest x-ray: 
 
 Yes    No    Unk Date: 
 
     /     /      
 
Result: 
 
 
 
TREATMENT 
 
Antibiotics prescribed:   Yes    No    Unknown 
  
Antibiotic:       
  
Antibiotic:       
 
 
Antibiotic:       
Date 
started:      /     /      
Date 
started:      /     /      
Date 
started:      /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Traveled within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
Worked with a Case:    Yes    No    Unk 
 
From date:  
 
     /     /      
 
  To date: 
 
     /     /      
Lived with another Case:  Yes    No    Unk 
 
From date:  
 
     /     /      
 
  To date: 
 
     /     /      
 
CONTACTS 
 
Number of people living in case’s household:       
 
Others in contact or with the same exposures 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
 
 
NOTES:       
 
 
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation period for 
Plague is 1-7 days. 
Plague is typically spread by infected 
fleas. Plague may be spread person 
to person if there is contact with pus 
from suppurating buboes.  
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POLIOMYELITIS 
 
Also known as: Polio, Polioviral Fever and Infantile Paralysis  
 
Responsibilities: 
Hospital: Report immediately by phone 
Lab: Report immediately by phone, send isolate to University Hygienic Lab (ULH) 
Physician: Report immediately by phone 
Local Public Health Agency (LPHA): Follow-up required.  Iowa Department of Public 
Health will lead the follow-up investigation.  
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Polio is caused by poliovirus (genus Enterovirus), which has three serotypes. Type 1 virus is most 
frequently involved in epidemics and is most often isolated from paralytic cases of poliomyelitis. Type 
3 and, to a lesser degree, types 1 and 2 can also cause paralysis.  All three are contained in the 
vaccine.  
 
B. Clinical Description 
Infection with poliovirus results in a spectrum of manifestations. The overwhelming majority of 
infections (95%) are asymptomatic. About 4 − 8% of infected individuals will experience non-specific 
viral symptoms, such as a low-grade fever, headache, sore throat, nausea, abdominal pain, 
constipation, diarrhea, and/or vomiting (referred to as abortive disease). About 1−2% of infections 
will result in aseptic meningitis, involving stiffness of the back, neck and/or legs, at times with 
paresthesias, a few days after the minor illness has resolved. Less than 1% of infections will progress 
to acute flaccid paralysis (AFP) with loss of reflexes in the involved limbs, usually with fever present 
(paralytic poliomyelitis). Please note, today in the U.S., the most common cause of AFP is Guillain-
Barré syndrome (GBS). Polio has been eradicated from the western hemisphere.   
 
Progression to paralytic poliomyelitis usually occurs within 2 − 4 days and rarely continues after the 
fever subsides. Spinal paralysis is typically asymmetric and more severe proximally than distally. 
Paralysis may compromise respiration and swallowing. After the acute episode, many patients 
recover at least some muscle function and prognosis for recovery can usually be established within 6 
months after onset of paralytic disease. Between 2 – 5% of paralytic infections in children are fatal, 
in adults it is up to 15 – 30%. Risk factors for paralytic disease include larger inoculum of poliovirus, 
increasing age, pregnancy, strenuous exercise, tonsillectomy, and intramuscular injections 
administered while the patient is infected with poliovirus.  
 
C. Reservoirs 
Humans are the only known host.  
 
D. Modes of Transmission 
The principal mode of transmission is person-to-person by the fecal-oral route.  Transmission via oral 
secretions, such as saliva, is very uncommon but may account for some cases. In rare instances, the 
virus may be transmitted by contaminated sewage or water. Asymptomatic individuals, especially 
children, comprise a significant source of infections. No reliable evidence of spread by insects exists. 
Report Immediately 
by phone   
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No long-term carrier state is known. In temperate climates, poliovirus infections are most common in 
the summer and fall. 
 
E. Incubation period 
Paralytic polio: The incubation period is usually 7 - 14 days, with a range of 3 - 35 days. 
 
F. Period of Communicability or Infectious Period 
The period of communicability is not precisely defined. It appears to be greatest 7 - 10 days before 
and after onset of clinical symptoms, when poliovirus is present in the throat and excreted in the 
highest quantities in the feces. Poliovirus can continue to be shed in the feces for 3 - 6 weeks. 
Poliovirus can be found in throat secretions as early as 36 hours and in the feces 72 hours after 
exposure to infection in both symptomatic and asymptomatic cases. 
 
G. Epidemiology 
Prior to the widespread use of polio vaccine, poliomyelitis occurred worldwide. Polio was epidemic in 
the U.S. for the first half of the 20th century with over 20,000 cases of paralytic disease in 1952. The 
first inactivated poliovirus vaccine (IPV) was introduced in 1955, monovalent oral poliovirus vaccine 
(OPV) in 1961, trivalent (TOPV) in 1963, and enhanced inactivated poliovirus vaccine (eIPV) in 1987. 
After the introduction of vaccination, the reported number of cases of poliomyelitis in the U.S. 
dropped to <100 in 1965 and <10 cases in 1973. The last cases of indigenously-transmitted wild-
type poliovirus in the U.S. were in 1979. The last case of wild-type polio disease in the Western 
Hemisphere was detected in Peru in 1991. The Western Hemisphere was declared free from 
indigenous wild-type poliovirus transmission in 1994.  Poliomyelitis is now on the verge of worldwide 
eradication. 
 
Almost the entire world is now considered polio-free. Worldwide efforts to eradicate polio in the few 
countries where the disease is still endemic are underway. Strategies include: (1) achieving and 
maintaining high vaccination coverage among infants < 1 year old; (2) developing sensitive 
surveillance systems for AFP including  a laboratory network; (3) conducting National Immunization 
Days; (4) and conducting “mopping-up” campaigns to directly target geographic areas known to be 
high risk for polio transmission. The number of countries where poliovirus continues to be isolated 
has decreased substantially, with Afghanistan, Egypt, India, Niger, Nigeria, and Pakistan the major 
areas of wild-type virus circulation. 
 
Due to the success of global efforts towards eradication and the elimination of indigenously 
transmitted disease in the Western Hemisphere, cases of paralytic poliomyelitis in the industrialized 
countries have become almost non-existent. During the period 1980−94, there was an average of 8−9 
cases of paralytic polio reported annually in the U.S. Most of these cases were vaccine-associated 
paralytic poliomyelitis (VAPP), which can occur after receipt of OPV. This very rare disease accounted 
for an average of 8 reported cases per year in the US, during the period 1980−94 (or 1 case for every 
2.4 million doses of OPV distributed). The risk for VAPP is highest after receipt of the first dose of 
poliovirus vaccine, occurring at one case per 750,000 doses distributed. Since 1986, the only cases of 
paralytic poliomyelitis occurring in the US have been vaccine-associated.  
 
In January 1997, in an effort to reduce the risk of VAPP, a sequential polio vaccination schedule (IPV 
for doses 1 and 2, OPV for doses 3 and 4) was recommended in the US. With the continued success 
of worldwide efforts to eradicate poliovirus and in the interest of completely eliminating the 
occurrence of VAPP, an all-IPV immunization schedule was initiated on January 1, 2000 in the US. 
 
Despite the great achievement in polio eradication in the U.S., vigilance is needed because of the 
possibility of importation of wild poliovirus from areas of the world where it is endemic. The 
importation of wild poliovirus from polio-endemic regions of the world may occur among under-
immunized (1) tourists, (2) immigrants revisiting their countries of origin, or (3) members of religious 
groups opposed to vaccination, regardless of travel history. In 1992−93 an outbreak occurred in the 
Netherlands among members of a religious group that refuse immunization. Poliovirus has also been 
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isolated from members of a similar religious group in Canada, although no cases of disease occurred. 
Polio remains endemic in three countries: Afghanistan, Nigeria and Pakistan. Transmission has been 
re-established in Angola, Chad, and the Democratic Republic of the Congo. Several more countries 
had ongoing outbreaks in 2011 due to importations of poliovirus. 
 
H. Bioterrorism Potential 
None. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To distinguish between wild-type and vaccine-associated polio and to identify susceptible people 
exposed to wild-type polio. 
• To maintain indigenous transmission rates of wild-type poliovirus at zero. 
• To identify cases of VAPP that might occur secondary to immunization with OPV given in another 
country. 
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report any suspected or confirmed cases of polio immediately. The reporting number for IDPH 
Center for Acute Disease Epidemiology (CADE) is (800) 362-2736. If after business hours, call IDPH 
at the same number and instructions will be given on how to reach on-call staff. 
 
Laboratory Testing Services Available 
After communicating with IDPH, contact the University of Iowa State Hygienic Laboratory (SHL) 
bacteriology department at (319) 335-4500 for further instructions. 
 
The likelihood of poliovirus isolation is highest from stool specimens, intermediate from pharyngeal 
swabs, and very low from blood or spinal fluid.  The isolation of poliovirus from stool specimens 
contributes to the diagnostic evaluation but does not constitute proof of a causal association of such 
viruses with paralytic poliomyelitis.  Isolation of virus from the cerebrospinal fluid (CSF) is diagnostic 
but is rarely accomplished.   
 
To increase the probability of poliovirus isolation, at least two stool specimens and two throat  swabs 
should be obtained 24 hours apart from patients with suspected poliomyelitis as early in the course of 
the disease as possible (i.e., immediately after poliomyelitis is considered as a possible differential 
diagnosis), but ideally within the first 14 days after onset of paralytic diseased.  Specimens should be 
sent to the State Hygienic Lab.   
 
C.  Local Public Health Agency Follow-up Responsibilities 
Polio follow-up and case investigation is undertaken by the Local Public Health Agency (LPHA) and 
will be coordinated if necessary with IDPH Bureau of Disease Prevention and Immunization.    
 
Initial Question to Ask Healthcare Provider and Patient 
In order to assess the likelihood that a suspect case is a true case prior to laboratory testing, LPHA 
and/or other public health staff helping in the investigation should ask about: 1) clinical information, 
2) polio immunization history of case and close contacts, 3) pertinent medical history including 
underlying illness/immunosuppression, 4) membership in religious/social group that might refuse 
immunization, 5) country of origin and length of residence in US, 6) recent history of travel (where 
and dates), 7) whether there were any recent out-of-town visitors (from where and dates), and 8) 
whether occupation entails handling of specimens that might contain poliovirus (e.g., lab work). 
 
3) CONTROLLING FURTHER SPREAD 
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A. Minimum Period of Isolation of a Suspect or Confirmed Case 
Place case on enteric precautions for six weeks after onset of symptoms or until poliovirus can no 
longer be recovered from feces (the number of negative specimens needed will be determined by the 
IDPH on a case-by-case basis). 
 
B. Minimum Period of Quarantine of Contacts 
None. 
 
C. Protection of Contacts of a Case   
Implement control measures as described below while waiting for laboratory confirmation. While 
indigenous transmission of wild-type poliovirus in the United States (and the Western Hemisphere as 
a whole) has not occurred since 1991, the importation of poliovirus from polio-endemic regions may 
occur among under-immunized (1) tourists, (2) immigrants revisiting their countries of origin, or (3) 
members of religious groups who might refuse immunization, regardless of travel history. Polio-
endemic regions include Afghanistan, Egypt, India, Niger, Nigeria, and Pakistan. An IDPH 
epidemiologist can help assess the likelihood of exposure to wild-type polio.  
 
OPV is still being used outside of the U.S. Vaccine-associated paralytic poliomyelitis (VAPP) should 
also be considered as a cause of paralysis, especially if a patient has onset of paralysis after receipt 
of a first dose of OPV. No control measures are indicated if the case is determined to likely be VAPP. 
It is also possible that the case of paralysis is due to an infectious agent other than poliovirus, such 
as enterovirus, or due to some other noninfectious cause, and therefore not contagious. Therefore, it 
is crucial that laboratory testing be initiated to determine if the causative agent of paralysis is 
poliovirus and to differentiate wild-type from vaccine strain poliovirus. 
 
Identify individuals or groups who may have been exposed to the case. Also, attempt to identify the 
route of introduction of poliovirus into the community. To identify these groups, think in terms of 
“zones of exposure” and consider members of the following groups: 
• Household members 
• School/ child care associates (students/attendees and staff) 
• Staff and patients at medical facility where patient was cared for, especially if there was the 
potential for direct contact with feces or oral secretions 
• Religious/social groups  
• Sports teams and other extracurricular groups 
• Bus mates 
• Close friends 
• Travelers from polio-endemic regions such as Afghanistan, Egypt, India, Niger, Nigeria, and 
Pakistan 
• Any other persons who may have come in direct contact with the case’s feces or oral secretions  
 
Identify high-risk susceptibles who had contact with the case during infectious period: 
• Pregnant women should be referred to their obstetricians. (In child care or school settings 
remember to determine whether teachers, student-teachers, staff or students are pregnant.) 
• Immunocompromised individuals should be referred to their healthcare providers. 
• Infants < 6 weeks old (who are too young to have been vaccinated) should be referred to their 
pediatricians. 
 
Identify and vaccinate all other susceptibles > 6 weeks old with IPV (if not contraindicated).  These 
are individuals without proof of immunity, including those with medical or religious exemptions to 
immunization.  Proof of immunity to poliovirus is defined as: 
• For children (< 18 years of age): documentation of receipt of > 4 doses of polio vaccine with a 
minimum interval of 4 weeks between doses; only 3 doses are needed when the third dose is 
given on or after the fourth birthday.   
• For adults (> 18 years of age): documentation of receipt of > 3 doses of polio vaccine with a 
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minimum interval of 4 weeks between doses with documentation of > 1 booster dose.  
 
Remember, an individual who has received a primary series consisting of > 3 doses of vaccine AND 
has received > 1 booster dose does NOT need to receive another dose. 
 
Note: 
• Vaccinating an exposed individual who may be incubating poliovirus is not harmful.  
Immune globulin (IG) has been found to be of no value as postexposure prophylaxis and is not 
recommended. (If the use of OPV for a mass vaccination campaign to control a polio outbreak in 
the U.S. is indicated, the CDC will advise the IDPH on how to obtain an emergency supply of 
OPV, who should receive OPV, and any other pertinent control measures.) 
Apply precautions and isolate/exclude as follows: 
• Case: Place on enteric precautions and exclude for 6 weeks after onset or until virus can no 
longer be recovered from feces (the number of negative specimens needed will be determined on 
a case-by-case basis).  
• Contacts: Administer IPV; do not exclude.  
 
Surveillance 
Active surveillance for acute flaccid paralysis and other symptoms of polio infection should continue 
for at least 2 incubation periods (i.e., up to 70 days) beyond the onset of the last case in an area. 
 
D. Preventive Measures 
Vaccination, including routine childhood vaccination, catch-up vaccination of adolescents, and 
targeted vaccination of high-risk adult groups, is the best preventive measure against polio. Good 
personal hygiene (particularly proper handwashing) is also very important. 
 
Routine Polio Childhood Immunization Recommendations 
An all-IPV polio immunization schedule is now the recommended schedule. OPV is no longer 
recommended and is not available in the U.S. Four doses of IPV are usually needed to complete the 
primary series: doses are recommended at ages 2 months, 4 months, 6-18 months, and 4−6 years. 
At least 28 days are needed between doses, although a 6−8 week interval is preferred between doses 
2 and 3 and a 6-month interval is preferred between doses 3 and 4. Only 3 doses are needed when 
the third dose is given on or after the fourth birthday. Polio vaccine is not routinely recommended for 
those > 18 years unless there is potential for exposure. 
 
Polio Vaccine and Adults 
Routine vaccination of persons >18 years of age residing in the U.S. is not necessary. However, polio 
vaccination is indicated for the following groups: 
• Laboratory workers who handle poliovirus; 
• Healthcare workers caring for polio patients; 
• Persons traveling to regions of the world where polio is endemic or epidemic. 
 
Polio Vaccination and Travel 
In assessing the risk to a traveler for polio transmission, healthcare providers are urged to 
determine first if their patients will truly be traveling to a polio endemic or epidemic area, 
including Afghanistan, Egypt, India, Niger, Nigeria, and Pakistan. Visit: www.cdc.gov/travel to 
obtain information on the risk of transmission of poliovirus in specific countries.  
 
If travel to a polio-endemic or epidemic region is anticipated, please review the patient’s history 
of polio immunization. Ninety percent or more of vaccine recipients develop protective immunity 
to all three poliovirus types after two doses, and at least 99% are immune following three doses.  
• If the patient has received a complete primary series of > 3 doses of polio vaccine, 
administer a booster dose of IPV. Remember, a single booster dose is all that is needed. 
• If the patient is unimmunized or partially immunized, follow an accelerated schedule to 
complete as much of the series as possible before departure, as outlined in the table below: 
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Weeks Available Accelerated IPV Schedule* 
> 8 weeks 3 doses, given 4 weeks apart 
4-7 weeks 2 doses, given 4 weeks apart 
< 4 weeks 1 dose 
        *1st dose may be given as early as 6 weeks of age 
 
4) ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Polio can 
be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
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Information for Health Professionals                 (Polio) 
 
What is poliomyelitis? 
A viral infection most often recognized by the acute onset of flaccid paralysis.  Poliovirus infection occurs in the 
GI track with spread to the regional nodes and in a minority of cases, to the nervous system.    
 
Who gets poliomyelitis? 
Prior to the widespread use of polio vaccine, poliomyelitis occurred worldwide. Polio was epidemic in the 
U.S. for the first half of the 20th century with over 20,000 cases of paralytic disease in 1952. The first 
inactivated poliovirus vaccine (IPV) was introduced in 1955, monovalent oral poliovirus vaccine (OPV) in 
1961, trivalent in 1963, and enhanced inactivated poliovirus vaccine (eIPV) in 1987. After the introduction 
of vaccination, the reported number of cases of poliomyelitis in the U.S. dropped to <100 in 1965 and 
<10 cases in 1973. The last cases of indigenously-transmitted wild-type poliovirus in the U.S. were in 
1979. The last case of wild-type polio disease in the Western Hemisphere was detected in Peru in 1991. 
The Western Hemisphere was declared free from indigenous wild-type poliovirus transmission in 1994.   
 
Almost the entire world is now considered polio-free.  Worldwide efforts to eradicate polio in countries 
where the disease is still endemic are underway. Strategies include: (1) achieving and maintaining high 
vaccination coverage among infants < 1 year old; (2) developing sensitive surveillance systems for AFP 
and a laboratory network; (3) conducting National Immunization Days; (4) and conducting “mopping-up” 
campaigns to directly target geographic areas known to be high risk for polio transmission. The number 
of countries where poliovirus continues to be isolated has decreased substantially, with Afghanistan, 
Nigeria, and Pakistan remaining the major areas of wild-type virus circulation. War and civil unrest has 
helped fuel outbreaks of Polio in Chad, Angola, and the Congo. 
 
How is the poliomyelitis spread? 
The principal mode of transmission is person-to-person by the fecal-oral or oral-oral route, with the fecal-
oral route predominating. Transmission via oral secretions, such as saliva, is possible and may account 
for some cases. In rare instances, the virus may be transmitted by contaminated sewage or water. 
Asymptomatic individuals, especially children, comprise a significant source of infections. No reliable 
evidence of spread by insects exists. No long-term carrier state is known. In temperate climates, 
poliovirus infections are most common in the summer and fall. 
 
What are the symptoms? 
Infection with poliovirus results in a spectrum of manifestations. The overwhelming majority of infections 
(95%) are clinically inapparent. Some 4 − 8% of infected individuals will experience non-specific viral 
symptoms, such as a low-grade fever, headache, sore throat, nausea, abdominal pain, constipation, 
diarrhea, and/or vomiting (abortive disease). Some 1−2% of infections will result in aseptic meningitis, 
involving stiffness of the back, neck and/or legs, at times with paresthesias, a few days after the minor 
illness has resolved. Less than 1% of infections will progress to acute flaccid paralysis (AFP) with loss of 
reflexes in the involved limbs, usually with fever present (paralytic poliomyelitis). Please note, today in 
the U.S., the most common cause of AFP is Guillain-Barré syndrome.   
 
How soon do the symptoms appear? 
Progression to paralytic poliomyelitis usually occurs within 2 − 4 days and rarely continues after the fever 
subsides.  
 
How long can an infected person spread the virus? 
The period of communicability is not precisely defined. It appears greatest 7-10 days before and after 
onset of clinical symptoms, when poliovirus is present in the throat and excreted in the highest quantities 
in the feces. Poliovirus can continue to be shed in the feces for 3 to 6 weeks. Poliovirus can be found in 
throat secretions as early as 36 hours and in the feces 72 hours after exposure to infection in both 
symptomatic and asymptomatic cases. 
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 What are the criteria for significant exposure to poliomyelitis? 
Identify individuals or groups who may have been exposed to the case. Also, attempt to identify the 
route of introduction of poliovirus into the community. To identify these groups, think in terms of “zones 
of exposure” and consider members of the following groups: 
• Household members 
• School/child care associates (students/attendees and staff) 
• Staff and patients at medical facility where patient was cared for, especially if there was the 
potential for direct contact with feces or oral secretions 
• Religious/social groups  
• Sports teams and other extracurricular groups 
• Bus mates 
• Close friends 
• Travelers from polio-endemic regions such Afghanistan, Egypt, India, Niger, Nigeria, and Pakistan 
• Any other persons who may have come in direct contact with the case’s feces or oral secretions  
 
What are poliomyelitis isolation guidelines? 
Place case on enteric precautions for six weeks after onset of symptoms or until poliovirus can no longer 
be recovered from feces (the number of negative specimens needed will be determined by the IDPH on a 
case-by-case basis). 
 
Can a person get poliomyelitis again? 
Adults who contract paralytic poliomyelitis during childhood may develop the post-polio syndrome 30 to 40 
years later.  Post-polio syndrome is characterized by slow onset of muscle pain and exacerbation of weakness.     
 
What is the treatment for poliomyelitis?   
None. Supportive treatment and attention during the acute illness to the complications of paralysis 
requires expert knowledge and equipment, especially for patients in need of respiratory assistance.   
 
Is there a vaccine to prevent poliomyelitis? 
Yes, there is a vaccine to protect against poliomyelitis. An all-IPV polio immunization schedule is now the 
recommended schedule. OPV is no longer recommended and is not available in the U.S. Four doses of 
IPV are usually needed to complete the primary series: doses are recommended at ages 2 months, 4 
months, 6-18 months, and 4−6 years. At least 28 days are needed between doses, although a 6−8 week 
interval is preferred between doses 2 and 3 and a 6-month interval is preferred between doses 3 and 4. 
Only 3 doses are needed when the third dose is given on or after the fourth birthday. Polio vaccine is not 
routinely recommended for those > 18 years unless there is potential for exposure. 
 
Routine vaccination of persons >18 years old residing in the U.S. is not necessary. However, polio 
vaccination is indicated for the following groups: 
• Laboratory workers who handle poliovirus; 
• Healthcare workers caring for polio patients; 
• Persons traveling to regions of the world where polio is endemic or epidemic. 
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Poliomyelitis                 Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider title: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Result date: 
 
     /     /      
 
Result type: 
 
 Preliminary      Final 
 
Test type: 
 
      Result: 
 Positive 
 Negative 
 
Organism: 
 
Poliovirus Type:         
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Result date: 
 
     /     /      
 
Result type: 
 
 Preliminary      Final 
 
Test type: 
 
      Result: 
 Positive 
 Negative 
 
Organism: 
 
Poliovirus Type:         
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Result date: 
 
     /     /      
 
Result type: 
 
 Preliminary      Final 
 
Test type: 
 
      Result: 
 Positive 
 Negative 
 
Organism: 
 
Poliovirus Type:         
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OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting:          
Health care worker type: 
 Yes      No      Unknown 
 
Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting:          
Health care worker type: 
 Yes      No      Unknown 
 
Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
S
ym
pt
om
s Paralysis:  Yes    No    Unk Onset date:      /     /      Paralysis sites:       
    
 Fever 
Headache 
Muscle pain 
Nausea 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
Paralysis 
Stiff neck 
Trouble swallowing 
Vomiting 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk  
    
Tensilon test 
performed:  Yes    No    Unk EMG performed:  Yes    No    Unk 
Nerve conduction 
test performed:  Yes    No    Unk 
 
Date of test: 
 
     /     /      
 
Date of test: 
 
     /     /      Date of test: 
 
     /     /      
Results:  Positive  Negative 
 Equivocal 
 Unknown 
Results compatible 
with polio:  Yes    No    Unk Result:  
      
60-day 
residual 
symptoms: 
 Yes    No    Unk 
Fever 
Headache 
Muscle pain 
Nausea 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
Paralysis 
Stiff neck 
Trouble swallowing 
Vomiting 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Vaccinated for Polio?  Yes    No    Unknown 
 Date 
vaccinated: 
 
     /     /      
 
Date vaccinated: 
 
     /     /      
 
Date vaccinated: 
 
     /     /      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
 
Number of vaccinations:       
 
In the 35 days prior to the onset of symptoms did the case: 
Traveled within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
Exposed to potential cases:  
 Yes    No    Unk 
Country 
outside U.S.:       From date:      /     /      
To 
date:      /     /      
 
Work with a case:    Yes    No    Unk 
 
From date:  
 
     /     /      
 
  To date: 
 
     /     /      
Lived with another case:  Yes    No    Unk 
 
From date:  
 
     /     /      
 
  To date: 
 
     /     /      
Contact w/t OPV recipient:  Yes    No    Unk 
 
Lived w/t recipient: 
 
 Yes    No    Unk 
 
Age of recipient: 
 
      
Recipient relationship:  Child care contact  Close contact not living in household  Household 
  
THER LABO 
 
Number of people living in case’s household:       
 
Close contacts with similar symptoms 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
NOTES:       
 
 
CONTACTS 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start 
and end of communicable 
period.  
  
Average incubation period for 
polio is 7-14 days for paralytic 
cases; possibly 3 to 35 days. 
Polio is communicable from several 
days after infection to 6 weeks after 
infection with or without symptoms. 
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PSITTACOSIS 
 
Potential Bioterrorism Agent: Category B 
 
Also known as: Parrott fever, Omithosis  
 
Responsibilities: 
Hospital: Report by IDSS, mail, facsimile, or phone 
Lab: Report by IDSS, mail, facsimile, or phone 
Physician: Report by mail, facsimile, or phone  
Local Public Health Agency (LPHA): Report by IDSS, mail, facsimile, or phone. 
Follow-up required 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Chlamydia psittaci is the bacterium that causes psittacosis.  It is an obligate intracellular parasite. 
 
B. Clinical Description 
Symptoms can include high fever, headache, rash, myalgia (muscle aches), chills, and upper or lower 
respiratory tract disease. A cough may or may not be present. 
 
Onset of respiratory symptoms often seem milder than expected based on chest x-ray findings. 
 
Complications such as systemic illness can occur with pneumonia. Human disease can be severe 
(including encephalitis and myocarditis), especially in untreated elderly people, although it is usually 
mild or moderate for others. Relapses of illness may occur.  Occasionally fatal in untreated patients. 
 
C. Reservoirs 
Common reservoirs C. psittaci is found primarily in psittacine birds (parrots, parakeets, macaws, love 
birds, and cockatoos); pigeons and some poultry (turkeys, geese and ducks) may also shed the 
infectious agent. 
 
D. Modes of Transmission 
Spread: Pet birds, especially psittacine birds are often implicated, especially when owners clean a 
cage with dried droppings. Occupational exposure can also occur when workers are exposed to areas 
with contaminated dust during clean up, repair or demolition. Laboratory infections have occurred as 
well. Farms or rendering plants may be a source of exposure for workers. Many seemingly healthy 
birds may shed the agent when stressed by crowding or transport.  Dramatic outbreaks may occur in 
poultry packing plant workers. 
 
Airborne: Human illness occurs from inhalation of the bacteria in dried droppings, secretions, and 
dust from feathers of infected birds. 
 
Person-to-person: transmission (through paroxysmal coughing during acute illness) has only rarely 
been reported. 
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E. Incubation period 
The incubation period for psittacosis can range from 1−4 weeks, but it is usually 7 - 14 days. 
 
F. Period of Communicability or Infectious Period 
Infected birds, including those that appear to be healthy, can be lifetime carriers or have continuous 
or intermittent shedding periods of weeks or even months. If humans are contagious at all, it is 
during paroxysmal coughing with acute illness. 
 
G. Epidemiology 
Psittacosis occurs worldwide and in all seasons, with some increase in winter months owing to 
maintaining the agent in ambient air. Most human cases are sporadic and are usually confined within 
families. Human outbreaks of psittacosis occasionally occur in individual households, pet shops, 
aviaries, and avian exhibits in zoos. Outbreaks among birds can occur in poultry flocks or other 
groups of birds such as in pet stores. Quarantine of imported birds and treatment of birds with 
antibiotics reduces the risk of disease transmission from birds.   
 
In Iowa no cases have been reported in the last 5 years. 
 
H. Bioterrorism Potential 
Category B Agent:  Psittacosis has been identified as a potential category B bioterrorism agent as a 
respiratory threat. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To identify and control outbreaks. 
• To help identify the source (e.g., pet stores, workers in a facility with excess dust or 
unrecognized bird droppings) and prevent further transmission. 
• To monitor the emergence of psittacosis in new areas and new risk groups. 
• To design more effective control or prevention methods. 
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report. The preferred method of reporting is by utilizing the Iowa Disease Surveillance System 
(IDSS).  However, if IDSS is not available to your facility the reporting number for IDPH Center for 
Acute Disease Epidemiology (CADE) is (800) 362-2736; fax number (515) 281-5698, mailing address: 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th Street 
Des Moines, IA 50319-0075 
 
Postage-paid disease reporting forms are available free of charge from the IDPH clearinghouse.   
Call (319) 398-5133 or visit the website: 
healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295  to request a supply. 
 
Consult with CADE (1-800-362-2736) or the University of Iowa State Hygienic Laboratory (SHL) (319-
335-4500) concerning proper specimen collection and testing. 
Report any of the following: 
• Isolation of C. psittaci from respiratory secretions; or  
• Fourfold or greater increase in antibody against C. psittaci by complement fixation (CF); or 
microimmunofluorescence (MIF) to a reciprocal titer of greater than or equal to 32 between 
paired acute- and convalescent-phase serum specimens ; or  
• Presence of immunoglobulin M antibody (IgM) against C. psittaci by MIF to a reciprocal titer of 
greater than or equal to 16. 
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C.  Local Public Health Agency Follow-up Responsibilities 
Case Investigation 
a. It is the LPHA responsibility to complete a case investigation by interviewing the case and others 
who may be able to provide pertinent information. Much of the information can be obtained 
from the case’s healthcare provider or the medical record. 
b. Use the following guidelines to complete the IDSS form: 
1) Accurately record the demographic information (including full name and address), date of 
symptom onset, healthcare provider information, whether hospitalized (including location 
and associated dates), therapy received, and outcome of disease (e.g., recovered, died).  
2) Diagnostic tests: Complete questions on the type(s), date(s), and result(s) of any diagnostic 
tests. 
3) Exposure history: Use the approximate incubation period range for psittacosis (1−4 weeks). 
Specifically, focus on the period beginning about 1 week prior to the case’s onset date back 
to approximately 4 weeks before onset for the following exposures: 
a) Occupation/duties: Determine the occupation of the case. Determine whether the case 
had any occupational exposure to birds or other animals (e.g., farmer, pet store worker, 
poultry plant worker).  
b) Bird contact: Ask the case about contact with birds (psittacine birds, pigeons, domestic 
fowl, or other birds). If possible, indicate the type, number of birds, and health of the 
birds to which the case was exposed. 
c) Contact with a human case of psittacosis: Ask the case if he/she had recent contact 
with a person with pneumonia. 
d) Indicate where and when any of the above exposures occurred. 
4) Investigation of source: Record any information regarding the testing of birds suspected as 
the case’s source of infection. 
5) If several unsuccessful attempts have been made to obtain case information, (e.g., the case 
or healthcare provider does not return calls or respond to a letter, or the case refuses to 
divulge information or is too ill to be interviewed), complete the IDSS form with as much 
information as possible. If using IDSS, select the appropriate reason under the Event tab in 
the Event Exception field. 
c. Complete the form in IDSS or, if mailing, attach the lab report(s) and mail (in an envelope 
marked “Confidential”) to IDPH the Center for Acute Disease Epidemiology.  The mailing 
address is:  
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th Street 
Des Moines, IA 50319-0075 
d. Institution of disease control measures is an integral part of case investigation. It is the LPHA 
responsibility to understand, and, if necessary, institute the control guidelines listed below. 
  
3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements 
 None. 
 
B.  Protection of Contacts of a Case 
 None. 
 
C.  Managing Special Situations 
Disease in Birds  
Psittacosis diagnosed in a bird is reportable to the Iowa Dept. of Agriculture and Land Stewardship 
(IDALS). They in turn will notify the Center for Acute Disease Epidemiology (CADE). If evidence 
suggests that humans have been exposed to infected birds or become sick with psittacosis, the local 
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board of health will be asked to assist CADE in investigating the situation, ensuring that any sick 
persons receive medical attention, and educating exposed individuals about their potential risk. In 
cases without human illness, the local board of health should be aware of the situation so that 
concerned individuals can be given information about psittacosis, their risk of exposure, and the need 
to see a physician if they have been exposed and develop respiratory illness. 
 
When a bird in or purchased from a pet store has been diagnosed with psittacosis, whether or not 
human cases have occurred as a result of exposure to the diseased bird, control measures in birds 
will be instituted by the IDALS. These measures include quarantine and treating exposed birds and 
properly disinfecting cages and other surfaces. Other control measures, including notifying the pet 
store owner and workers of the diagnosis and their possible risk of disease, and notifying the public 
who may have visited the store by posting public health notices at the store, will be made in 
collaboration with CADE. Also, depending on the situation, CADE may contact individuals who have 
purchased birds from the facility to inform them about psittacosis, the possibility that their birds may 
be carriers, and the potential risks to their health. 
In addition to pet shops and veterinary offices, other high-risk environments in which psittacosis can 
occur include poultry farms and specialty bird shows. Where a diseased bird is identified, control 
measures similar to those described above (e.g., quarantine and treating exposed birds, disinfecting 
the animal’s environment and notifying exposed individuals about their disease risk) will be instituted 
by IDALS in conjunction with CADE.   
 
Contact the Iowa Department of Agriculture and Land Stewardship (IDALS), (515) 281-8601 (after 
hours 515-242-0247) with question about the disease in animals. For information about the risk to 
humans, contact CADE at (800) 362-2736, if after hours instructions will be given on hours to reach 
on-call staff 
 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
If an outbreak is suspected, investigate to determine the source of infection and mode of 
transmission. A common vehicle, such as a cluster of sick birds in a pet store, should be sought and 
applicable preventive or control measures should be instituted.  Consult with the epidemiologist on-
call at CADE at (800) 362-2736. CADE can help determine a course of action to prevent further cases 
and can perform surveillance for cases that may cross jurisdictions and therefore be difficult to 
identify at a local level. 
 
D. Preventive Measures 
To avoid exposure IDPH recommends: 
• Obtain birds only from a licensed pet store or aviary. 
• Pet owners and animal handlers should be made aware of the dangers of household or 
occupational exposure to infected birds and the risk of inhalation of dried bird droppings, even 
from seemingly healthy birds. 
• Medical personnel who take care of people in poultry processing plants or other workers in high-
risk occupations should learn to include psittacosis in their differential diagnosis for workers who 
become sick with febrile illness and myalgia. 
• Psittacine birds that are bought, traded, or otherwise procured should be raised and handled in a 
way that prohibits psittacosis spread. Tetracycline can be used to control or prevent disease in 
birds, although treatment failures can occur. 
• Pet stores, farms, or processing plants that are epidemiologically linked to human psittacosis 
should be part of a surveillance effort to identify other cases. Any infected birds should be 
treated or destroyed, and the environs should be thoroughly disinfected. 
 
4) ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions Psittacosis 
can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
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CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
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FACT SHEET           PSITTACOSIS 
 (Parrot fever, Omithosis) 
 
What is psittacosis? 
Psittacosis is a disease found primarily in certain birds (parrots, parakeets) and other poultry (turkeys, 
geese and ducks, as well as other birds such as pigeons) that can be transmitted to humans. 
 
What are the symptoms of psittacosis? 
Symptoms include fever, headache, rash, muscle aches, chills, and upper or lower respiratory disease. 
Human disease can be severe, especially for untreated elderly people, but it is most often mild or moderate 
in others. 
 
How soon do symptoms appear? 
Symptoms can take from 1-4 weeks to appear, but it is usually 1-2 weeks. 
 
How is psittacosis spread? 
Human illness occurs from breathing in bacteria from dried droppings, secretions, and dust from feathers of 
infected birds. Many seemingly healthy birds have the bacteria and they can spread it when stressed from 
travel or crowding. Pet birds are often the source for human infection. 
 
Who gets psittacosis infection? 
Anyone can get psittacosis if they are exposed to the dust and droppings of infected birds.   
 
How long is a person infectious? 
This isn’t certain. Most people aren’t very contagious, and if so, only when there is severe coughing from 
the disease.  Birds can have lifelong infections.   
 
What is the treatment for this illness? 
Tetracycline type antibiotics are used to treat this disease.  
 
Do infected people need to be excluded from school, work, or child care? 
No. People who are infected and have a cough should be instructed to cough into a tissue or a 
handkerchief. 
 
What can be done to help prevent the spread of psittacosis? 
• Obtain birds only from a licensed pet store or aviary. 
• Pet owners and animal handlers should be made aware of the dangers of household or 
occupational exposure to infected birds and the risk of inhalation of dried bird droppings, even 
from seemingly healthy birds. 
• Special care should be taken by bird owners to clean cages, etc with the least amount of 
disturbance of dried droppings, feathers, and dust. 
• Birds that are bought, traded, or otherwise procured should be raised and handled in a way that 
prohibits psittacosis spread. 
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MEMORANDUM 
 
 
TO: State Public Health Veterinarians 
 State Epidemiologists 
 State Veterinarians 
 Interested Pet Bird Professionals  
 
FROM: Kathleen A. Smith, DVM MPH 
 Chair, Psittacosis Compendium 
 
RE: Compendium of Measures To Control Chlamydophila psittaci Infection 
Among Humans (Psittacosis) and Pet Birds (Avian Chlamydiosis), 2009 
 
 
 
 
On behalf of the National Association of State Public Health Veterinarians, I am pleased to 
provide you with a copy of the Compendium of Measures to Control Chlamydophila psittaci 
Infection Among Humans (Psittacosis) and Pet Birds (Avian Chlamydiosis), 2009. The 
Compendium committee and consultants believe these updates and revisions will aid public 
health officials, physicians, veterinarians, and the pet bird industry to control this disease in 
birds and in people.  
 
This Compendium updates the 2008 Compendium. Notable changes in the 2009 
Compendium are as follows: 
 
Infection in Humans, Laboratory Testing 
 At the time of this report, microimmunofluorescence (MIF) testing kits will no longer be 
available through FOCUS Diagnostic Laboratories.  As a result, the committee 
recommends that the individual laboratories listed in Table 1 be contacted directly to 
ascertain the testing options they provide for human specimens.   
 
Appendix 1: Testing Methods for C. psittaci in Birds:  
 
 Elementary Body Agglutination (EBA) testing is no longer being offered by Texas 
Veterinary Medical Diagnostic Laboratory. It is still described under the section titled 
“Tests for antibodies” as other laboratories may conduct this test in the future 
 
Appendix 2: Treatment Options for Birds with Avian Chlamydiosis: 
 The “Recommendations for Treating and Caring for Infected and Exposed Birds” 
section was moved from the Prevention and Control Recommendation section in the 
main document to the beginning of Appendix 2. These recommendations are critical for 
treatment success and placing them in the treatment section ensures a greater likelihood 
that they will be reviewed.  
 A statement was added that it is important for avian facility managers to provide 
employees with simple, concise written treatment procedures to ensure treatment 
success. 
 More emphasis is placed on recommending doxycycline over other tetracycline 
antibiotics for the treatment of avian chlamydiosis 
 Routine prophylactic antibiotic treatment is now discouraged as it may cause adverse 
effects and could generate resistant strains of C. psittaci and other bacteria. 
 
The final, and probably the most significant, update is that the Centers for Disease Control 
and Prevention (CDC) and the University of Georgia College of Veterinary Medicine have 
collaborated on the development of a new diagnostic test for C. psittaci.i 
 
Genetic studies have indicated that there are at least seven avian genotypes of C. psittaci.  
Distinguishing these serotypes currently requires multiple confirmatory tests and is very 
time consuming.  A real-time polymerase chain reaction (PCR) assay, targeting the ompA 
gene has been developed which uses Light Upon extension (LUX TM) chemistry and high 
resolution melt (HRM) analysis that can accurately and quickly differentiate these 
genotypes.  This test may become a valuable epidemiologic tool to evaluate human 
outbreaks and link human/avian transmission in the future.   The CDC is interested in 
applying this diagnostic tool in select cases or outbreaks.  Therefore, if you have suspect 
human cases and are willing to submit samples for molecular testing, please contact:  
 
Laura Conklin MD 
Medical Epidemiologist, Respiratory Diseases Branch 
Centers for Disease Control and Prevention 
1600 Clifton Road NE, MS C-23 
Atlanta, GA  30333 
Tel: 404-639-4747 
Fax: 404-639-3970 
Email: dvj3@cdc.gov 
 
To help control this disease and protect public health, the Compendium committee and its 
consultants encourage you to distribute this 2009 version of the Compendium to health 
officials, veterinarians, and the pet bird industry in your state and actively promote the 
document as a standard.  We would also like to request that if you update any web links to 
this document that you please delete any previous Compendiums, as we want to ensure that 
interested people access the most current version.   
 
This document will be reviewed and updated on an as needed basis.  The most recent 
version, along with sample case report forms and associated client materials can be accessed 
on the National Association of State Public Health Veterinarians website at 
http://www.nasphv.org.   
 
 
                                                          
i Mitchel, S.L. Wolf, B.J. et al, Genotyping of Chlamydophila psittaci using Real-Time PCR and High 
Resolution melt Analysis. J Clin Microbiol 2009;47:175-181 
 
 Compendium of Measures To Control Chlamydophila psittaci Infection Among 
Humans (Psittacosis) and Pet Birds (Avian Chlamydiosis), 2009 
 
National Association of State Public Health Veterinarians (NASPHV) 
 
SUMMARY 
 
Psittacosis, also known as parrot fever and ornithosis, is a bacterial infection of humans that can cause 
severe pneumonia and other serious health problems. It is caused by Chlamydophila psittaci, formerly known 
as Chlamydia psittaci. From 2002 through 2007, 91 human cases of psittacosis were reported to the Centers 
for Disease Control and most resulted from exposure to infected pet birds, usually cockatiels, parakeets, 
parrots, and macaws. In birds, C psittaci infection is referred to as avian chlamydiosis. Infected birds shed the 
bacteria through feces and nasal discharges, and humans become infected from exposure to these materials. 
This compendium provides information about psittacosis and avian chlamydiosis to public health officials, 
physicians, veterinarians, the pet bird industry, and others concerned with controlling these diseases and 
protecting public health. The recommendations in this compendium provide standardized procedures for 
controlling avian chlamydiosis in birds, a vital step to protecting human health. This document will be 
reviewed and revised as necessary. 
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INTRODUCTION 
 
Chlamydophila psittaci is a member of the family Chlamydiaceae. Currently there are eight serovars and nine 
genotypes described which in the future may prove of importance in the epidemiology of the disease in 
animals and humans1.  In some cases, these obligate intracellular bacteria can be transmitted from birds to 
humans. In humans, the resulting infection is referred to as psittacosis (also known as parrot fever and 
ornithosis). Psittacosis typically causes influenza-like symptoms and can lead to severe pneumonia and 
nonrespiratory health problems. With appropriate treatment, the disease is rarely fatal. From 2002 to 2007, 91 
human cases of psittacosis were reported to the CDC (mean 15, range 12-21)2. This is likely an 
underrepresentation of the actual number as milder cases may not seek medical attention or be reported. 
Persons at risk include those exposed to pet birds, pigeons, and poultry and in specific occupations such as 
laboratory and wildlife workers. Human infection can result from brief exposure to infected birds or their 
contaminated excretions or secretions.  
In this compendium, C psittaci infection in birds is referred to as avian chlamydiosis. Chlamydial 
organisms have been isolated from over 460 bird species from 30 orders3 but are most commonly identified in 
psittacine (parrot-type) birds, especially cockatiels and budgerigars (also called parakeets or budgies). Among 
caged, nonpsittacine birds, infection with Chlamydiaceae organisms occurs most frequently in pigeons and 
doves. Avian chlamydiosis can occur but is infrequently diagnosed in canaries and finches.4 The 
recommendations in this compendium provide standardized procedures for controlling avian chlamydiosis in 
the pet bird population, an essential step in efforts to control psittacosis among humans. This compendium is 
intended to guide public health officials, physicians, veterinarians, the pet bird industry, and others concerned 
with the control of C psittaci infection and the protection of public health. 
 
INFECTION IN HUMANS (PSITTACOSIS) 
 
Transmission 
The disease resulting from C psittaci infection in humans is called psittacosis and most infections are 
typically acquired from exposure to psittacine birds. Transmission has also been documented from poultry and 
free-ranging birds, including doves, pigeons, birds of prey and shore birds. Infection with C psittaci usually 
occurs when a person inhales organisms that have been aerosolized from dried feces or respiratory tract 
secretions of infected birds. Other means of exposure include mouth-to-beak contact and handling infected 
birds’ plumage and tissues. Even brief exposures can lead to symptomatic infection; therefore, certain patients 
with psittacosis might not recall or report having any contact with birds. Currently, pet birds are thought to 
pose a low risk to immunocompromized persons.5 Person-to-person transmission has been suggested but not 
proven.6 Standard infection-control precautions are sufficient for humans with psittacosis, and specific 
isolation procedures (e.g., private room, negative pressure air flow, and masks) are not indicated. 
 
Clinical Signs and Symptoms 
The onset of illness typically follows an incubation period of 5 to 14 days, but longer periods have been 
reported. The severity of the disease ranges from inapparent illness to systemic illness with severe pneumonia. 
Before antimicrobial agents were available, 15% to 20% of humans with C psittaci infection died. Currently, 
mortality is extremely rare. Humans with symptomatic infections typically have abrupt onset of fever, chills, 
headache, malaise, and myalgia. They usually develop a nonproductive cough that can be accompanied by  
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breathing difficulty and chest tightness. A pulse-temperature dissociation (fever without increased pulse rate), 
enlarged spleen, and nonspecific rash are sometimes observed.  Auscultatory findings may underestimate the 
extent of pulmonary involvement. Radiographic findings may include lobar or interstitial infiltrates. The 
differential diagnosis of pneumonia caused by psittacosis includes infection with Coxiella burnetii, 
Histoplasma capsulatum, Mycoplasma pneumoniae, Legionella spp, C. pneumoniae or other Chlamydiaceae, 
and respiratory viruses such as influenza. Chlamydophila psittaci can affect organ systems other than the 
respiratory tract, resulting in endocarditis, myocarditis, hepatitis, arthritis, keratoconjunctivitis, encephalitis, 
and more recently, ocular adnexa lymphoma.7. Severe illness with respiratory failure, thrombocytopenia, and 
hepatitis has been reported. 
 
Case Definition 
The CDC and the Council of State and Territorial Epidemiologists (CSTE) have established case 
definitions for epidemiologic surveillance.8 These definitions should not be used as the sole criteria for 
establishing a clinical diagnosis or determining medical management. A patient is considered to have a 
confirmed case of psittacosis if clinical illness is compatible with psittacosis and the case is laboratory 
confirmed by one of three methods:  
• C psittaci is cultured from respiratory secretions,  
• there is a 4-fold or greater increase in antibody against C psittaci by complement fixation (CF) or 
microimmunofluorescence (MIF) to a reciprocal titer of  ≥32 between paired acute- and convalescent-
phase serum samples, or 
• there is presence of immunoglobulin M antibodies against C psittaci by MIF to a reciprocal titer of ≥16.  
 
A patient is considered to have a probable case of psittacosis if clinical illness is compatible with 
psittacosis and the patient is epidemiologically linked to a confirmed case (either an avian case or has common 
exposure with another human case) or the patient has supportive serology (e.g., a single antibody titer of ≥32, 
detected by CF or MIF in at least one serum sample obtained after onset of symptoms).  
 
Diagnosis 
Most diagnoses are established by clinical presentation and positive antibodies against C. psittaci in paired 
sera using MIF. The MIF is more sensitive and specific than the previously used CF tests; however, there is 
still some cross-reactivity with other chlamydiae, such as C. pneumoniae, C. trachomatis, and C. felis. Acute-
phase serum specimens should be obtained as soon as possible after onset of symptoms, and convalescent-
phase serum specimens should be obtained at least two weeks after the first specimen. Because antimicrobial 
treatment can delay or diminish the antibody response, a third serum sample 4-6 weeks after the acute sample 
might help confirm the diagnosis. Acute and convalescent sera should be tested simultaneously at the same 
laboratory.  
The infectious agent can also be isolated from the patient’s sputum, pleural fluid, or clotted blood during 
acute illness and before treatment with antimicrobial agents; however, culture of C. psittaci is performed by 
few laboratories because of technical difficulty and safety concerns. Certain polymerase chain reaction (PCR) 
assays can be used to document organism nucleic acid in clinical samples to distinguish C psittaci from other 
chlamydial species and to genotype C. psittaci amplicons.9  Because proper sample collection techniques and 
handling are critical for obtaining accurate test results, clinical laboratories should be contacted for specifics 
on specimen submission. 
  
Laboratories that Test Human Specimens for Chlamydiaceae 
Information about laboratory testing is available from state public health departments. Few commercial 
laboratories have the capability to differentiate chlamydial species by MIF. Certain laboratories accept human 
specimens to confirm C. psittaci infection (Table 1). Other sources might be available. 
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Table 1: Laboratories that test human specimens for Chlamydophila psittaci 
Laboratory Tests Performed Telephone NumberWebsite
Focus Diagnostics (Quest 
subsidiary) Cypress, CA 
MIF (IgM, IgA, IgG) Culture 
 
 (800) 445-4032 
www.focusdx.com
Laboratory Corp of America 
Burlington, NC  MIF (IgM, IgG) Culture 
 (800) 222-7566  
www.labcorp.com
Specialty Labs,  Santa Monica, 
CA 
MIF (IgM, IgG, IgA) 
PCR (pleural fluid only) 
  (800) 421-4449 
www.specialtylabs.com 
Viromed Minnetonka, MN 
  MIF (IgG, IgM) Culture 
 (800) 582-0077 
www.viromed.com
Response and Surveillance 
Laboratory, Respiratory Diseases 
Branch, CDC Atlanta, GA** 
MIF (requires paired sera),PCR, 
Culture, genotyping 
(multiple specimen types) 
 (404) 639-4921
*MIF = microimmunofluorescence, PCR = polymerase chain reaction assay 
**CDC is a reference laboratory and samples must be submitted through State Health Departments 
 
Treatment 
Tetracycline antibiotics are the drug of choice for C. psittaci infection in humans.  Mild to moderate cases 
can be treated with oral doxycycline (100 mg every 12 hours) or tetracycline hydrochloride (500 mg every six 
hours) for a minimum of 10 days.  Severely ill patients should be treated with IV doxycycline hyclate 
(4.4mg/kg/day divided into two infusions, maximum 100 mg/dose). Antibiotic therapy should be continued for 
at least 10-14 days after fever abates.  Most C. psittaci infections are responsive to antibiotics within 1-2 days, 
however relapses can occur.  Although in-vivo efficacy has not been determined, macrolide antibiotics are 
considered the best alternative agents in patients for whom tetracyclines are contraindicated (e.g. children <8 
years of age, pregnant women, and persons allergic to tetracyclines).10   
 
INFECTION IN BIRDS (AVIAN CHLAMYDIOSIS) 
 
Transmission 
C. psittaci is excreted in the feces and nasal discharges of infected birds. The organism is environmentally 
labile but can remain infectious for over a month if protected by organic debris (e.g., litter and feces). Some 
infected birds can appear healthy and shed the organism intermittently. Shedding can be exacerbated by stress 
factors, including reproductive activities, relocation, shipping, crowding and chilling.  
 
Clinical signs 
The usual duration between exposure to C. psittaci and onset of illness ranges from 3 days to several 
weeks. However, active disease can appear with no identifiable exposure. Whether the bird has acute or 
chronic signs of illness or dies depend on the species of bird, virulence of the strain, infectious dose, stress 
factors, age and extent of treatment or prophylaxis. 
Signs of avian chlamydiosis are non-specific and include lethargy, anorexia and ruffled feathers. Other 
signs include serous or mucopurulent ocular or nasal discharge, diarrhea and excretion of green to yellow-
green urates. Severely affected birds may become anorectic and produce sparse, dark green droppings, 
followed by emaciation, dehydration and death. 
 
Case Definitions 
Clinical signs may not always be evident in all infected birds. A confirmed case of avian chlamydial 
infection is defined on the basis of one of the following:  
• isolation of C. psittaci from a clinical specimen,  
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• identification of chlamydial antigen by use of immunofluorescence (fluorescent antibody) on the 
bird’s tissues,  
• a ≥ 4-fold change in serologic titer in two specimens from the bird obtained at least two weeks apart 
and assayed simultaneously at the same laboratory, or  
• identification of Chlamydiaceae within macrophages in smears or tissues (e.g. liver, conjunctival, 
spleen, respiratory secretions) stained with Gimenez or Macchiavello stain. Clinical signs may not be 
evident. 
 
A probable case of avian chlamydial infection is defined as compatible illness and one of the following:  
• a single high serologic titer as defined by the laboratory in a specimen obtained after onset of signs or 
• Chlamydiaceae antigen (identified by use of enzyme-linked immunosorbent assay [ELISA], PCR, or 
fluorescent antibody) in feces, a cloacal swab specimen or respiratory tract or ocular exudates. 
 
A suspected case of avian chlamydial infection is defined as:  
• a compatible illness that is not laboratory confirmed but is epidemiologically linked to a confirmed 
case in a human or bird,  
• a bird with no clinical signs and a single high serologic titer or detection of chlamydial antigen,  
• compatible illness with positive results from a nonstandardized test or a new investigational test, or  
• compatible illness that is responsive to appropriate therapy. 
 
Diagnosis  
Several diagnostic methods are available for identifying avian chlamydiosis in birds (see Appendix 1)   
 
Treatment 
Treatment should be supervised by a licensed veterinarian (see Appendix 2). 
 
PREVENTION AND CONTROL RECOMMENDATIONS 
 
Aviary and pet shop owners are encouraged to implement recommendations such as those described in the 
Model Aviary Program.11 Such programs encourage disease prevention and improve animal health and the 
human-animal bond.  To prevent transmission of C. psittaci to humans and birds, specific control measures are 
recommended: 
• Educate persons at risk. Inform all persons in contact with birds or bird-contaminated materials about the 
zoonotic nature of the disease. By the time infection is recognized in a group of birds, a critical period for 
pathogen accumulation and dissemination has already occurred. Bird caretakers with respiratory or 
influenza-like symptoms should seek medical attention and inform their health care provider about bird 
contact. 
• Protect persons at risk. When cleaning cages or handling potentially infected birds, caretakers should 
wear protective clothing, which includes gloves, eyewear, a disposable surgical cap, and an appropriately 
fitted respirator12 with N95 or higher rating. Surgical masks might not be effective in preventing 
transmission of C. psittaci. In addition, necropsies of potentially infected birds should be performed in a 
biological safety cabinet. Wet the carcass with detergent and water to prevent aerosolization of infectious 
particles. 
• Maintain accurate records of all bird-related transactions for at least one year to aid in identifying 
sources of infected birds and potentially exposed persons. Records should include the date of purchase, 
species of birds purchased, individual bird identification, source of birds, and any identified illnesses or 
deaths among birds. In addition, the seller should record the name, address, and telephone number of the 
customer and individual bird identification (e.g., band or microchip number). 
• Avoid purchasing or selling birds that have signs consistent with avian chlamydiosis. Signs are 
nonspecific and may include lethargy, ocular or nasal discharge, diarrhea, ruffled feathers or low body 
weight. 
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• Avoid mixing birds from multiple sources. To prevent epornitics (disease outbreaks) and pathogen 
transmission to humans, additional control and prevention methods (e.g. health screening, extended 
quarantine) may be required when birds from multiple sources are mixed. 
• Quarantine newly acquired or exposed and isolate ill birds. Isolation should include housing in a 
separate air space from other birds and noncaretakers. Quarantine birds, including those that have been to 
shows, exhibitions, fairs, and other events for at least 30 days and test before adding them to a group.  
• Test birds before they are to be boarded or sold on consignment. House them in a room separate from 
other birds pending test results (see Appendix 1). 
• Screen birds with frequent public contact (e.g., bird encounters, long term care facilities, schools). 
Such testing may be used to reduce potential human exposure from birds. Specific protocols should be 
established in consultation with a veterinarian, recognizing that some birds may demonstrate persistent 
IgG antibodies in the absence of active infection (see Appendix 1). 
• Practice preventive husbandry. Position cages to prevent the transfer of fecal matter, feathers, food, and 
other materials from one cage to another. Do not stack cages and be sure to use solid-sided cages or 
barriers if cages are adjoining. The bottom of the cage should be made of a wire mesh. Substrate/litter that 
will not produce dust (e.g., newspapers) should be placed underneath the mesh. Clean all cages, food 
bowls, and water bowls daily. Soiled bowls should be emptied, cleaned with soap and water, rinsed, placed 
in a disinfectant solution, and rinsed again before reuse. Between occupancies by different birds, cages 
should be thoroughly scrubbed with soap and water, disinfected, and rinsed in clean running water. 
Exhaust ventilation should be sufficient to prevent accumulation of aerosols and prevent cross 
contamination of rooms. 
• Control the spread of infection. Isolate birds requiring treatment. Rooms and cages where infected birds 
were housed should be cleaned immediately and disinfected thoroughly. Workers should wear appropriate 
protective clothing. When the cage is being cleaned, transfer the bird to a clean cage. Thoroughly scrub the 
soiled cage with a detergent to remove all fecal debris, rinse the cage, disinfect it (most disinfectants 
require 5-10 minutes of contact time) and rerinse the cage to remove the disinfectant. Discard all items that 
cannot be adequately disinfected (e.g., wooden perches, ropes, nest material, substrate/litter). Minimize the 
circulation of feathers and dust by wet-mopping the floor frequently with disinfectants and preventing air 
currents and drafts within the area. Reduce contamination from dust by spraying the floor with a 
disinfectant or water before sweeping it. A vacuum cleaner or pressure washer may aerosolize infectious 
particles and should be used with caution. Frequently remove waste material from the cage (after 
moistening the material), and burn or double-bag the waste for disposal. Care for healthy birds before 
handling isolated or sick birds. There is no documented transmission of C. psittaci via ventilation systems 
from pet bird aviaries or pet stores to humans, nor are there any studies specific for C. psittaci viability in 
these systems. Properly maintained ventilation systems are at low risk of harboring C. psittaci.13 
Theoretically, desiccation from forced air movement may reduce viability of the organism.  Use of a high 
efficiency particulate air (HEPA) filter on air system return may be an option to reduce particulate matter 
in the air. 
• Use disinfection measures. All surfaces should be thoroughly cleaned of organic debris before 
disinfection. C. psittaci is susceptible to many disinfectants and detergents as well as heat; however, it is 
resistant to acid and alkali. Examples of effective disinfectants include 1:1,000 dilution of quaternary 
ammonium compounds (e.g., Roccal®, Zephiran®), 1% Lysol® or freshly prepared 1:32 dilution of 
household bleach (½ cup/gallon).  Many disinfectants are respiratory irritants for both humans and birds 
and should be used in a well-ventilated area. Avoid mixing disinfectants with any other product. 
 
Recommendations for Treating and Caring for Infected and Exposed Birds  
All birds with confirmed or probable avian chlamydiosis should be isolated and treated, preferably under 
the supervision of a veterinarian (Appendix 2).  
 
Responsibilities of bird owners, physicians, and veterinarians 
Humans exposed to birds with avian chlamydiosis should seek medical attention if they develop influenza-
like symptoms or other respiratory tract illnesses. The physician should consider psittacosis in ill patients 
exposed to birds and collect specimens for laboratory analysis if indicated. Psittacosis in humans is a 
Nationally Notifiable Disease14 and most states require physicians to report cases of psittacosis to the 
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appropriate state or local public health authorities. Early and specific treatment for psittacosis should be 
initiated. Timely diagnosis and reporting can help identify the source of infection and control the spread of 
disease. Local and state public and/or animal health authorities may conduct epidemiologic investigations and 
institute additional disease control measures. Birds that are suspected sources of human infection should be 
referred to veterinarians for evaluation and treatment.  
Veterinarians should consider a diagnosis of avian chlamydiosis for any lethargic bird that has nonspecific 
signs of illness, especially if the bird was recently purchased. If avian chlamydiosis is suspected, the 
veterinarian should submit appropriate laboratory specimens to confirm the diagnosis. Laboratories and 
attending veterinarians should follow local and state regulations or guidelines regarding case reporting. 
Veterinarians should work closely with authorities on investigations and inform clients that infected birds 
should be isolated and treated. In addition, they should educate clients about the public health hazard posed by 
C. psittaci and the appropriate precautions that should be taken to avoid the risk for transmission. 
 
Local and state epidemiologic investigations 
Local health authorities should report suspected cases to their state health department.15 Public health and 
animal health authorities at the local or state level may need to conduct cooperative epidemiologic 
investigations to control the transmission of C psittaci among humans and birds. An epidemiologic 
investigation should be initiated if a bird with confirmed or probable avian chlamydiosis was either: 
• procured from a pet store, breeder, or dealer within 60 days of the onset of signs of illness;  
• linked to a person with confirmed or probable psittacosis; or  
• associated with several other suspect avian cases from the same source.  
 
Other situations can be investigated at the discretion of the appropriate local or state public health 
department or animal health authorities.  
Investigations involving recently purchased birds should include a visit to the site where the infected bird 
is located and identification of the location where the bird was originally procured (e.g., pet shop, dealer, 
breeder, or quarantine station). Authorities should document the number and types of birds involved, the health 
status of potentially affected persons and birds, locations of facilities where birds were housed, relevant 
ventilation-related factors and any treatment protocol.16 Suspect birds should be tested as recommended 
(Appendix 1). Examination of sales records for follow up of other birds that had contact with the infected bird 
may be considered.  
 
Quarantine of birds 
Depending on the state’s regulatory authority, animal or public health officials may issue a quarantine for 
all affected and exposed birds on premises where C. psittaci infection has been identified. The purpose of 
imposing a quarantine is to prevent further pathogen transmission. Reasonable options should be made 
available to the owners and operators of pet stores. Preferably, the owner of quarantined birds should treat the 
birds in a separate quarantine area to prevent exposure to the public and other birds.  Alternatively, and with 
the approval of authorities, the owner can sell the birds after at least 7 days of treatment, provided that the new 
owner agrees in writing to continue the quarantine and treatment and is informed of the disease hazards. After 
completion of the treatment or removal of the birds, quarantine can be lifted after the premises are thoroughly 
cleaned and disinfected. Environmental testing can be valuable in evaluating the effectiveness of cleaning and 
disinfection. The area can then be restocked with birds. 
 
Bird importation regulations 
Large-scale commercial importation of psittacine birds from foreign countries ended in 1993 with the 
implementation of the Wild Bird Conservation Act.17 Limited importation of personal pets and avicultural 
specimens is permitted at this time. Illegally imported (smuggled) birds are a potential source of C. psittaci 
infection to domestic birds and people. The United States Department of Agriculture, Animal Plant Health and 
Inspection Service, Veterinary Services still regulates the legal importation of pet birds to ensure that exotic 
poultry diseases are not introduced into the United States.18 These regulations are set forth in the Code of 
Federal Regulations, Title 9, Chapter 1. Current minimum treatment protocols under these regulations are not 
always sufficient to resolve infection in all birds. 
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Appendix 1 
TESTING METHODS FOR C. PSITTACI IN BIRDS 
 
Bacteria are classified as Chlamydophila psittaci on the basis of shared biochemical characteristics and 
genome composition. The individual chlamydial organisms that meet these classification criteria are not 
identical and represent life forms that have evolved, and continue to evolve, through infection of both ancient 
and naïve hosts. Diversity in the organism, the level of exposure, and the host response may cause spurious 
test results in some individual animals. 
Diagnosis of avian chlamydiosis can be difficult, especially in the absence of clinical signs. A single 
testing method might not be adequate. Therefore, use of a combination of culture, antibody-detection and 
antigen-detection methods is recommended, particularly when only one bird is tested. Although there is no 
epidemiologic evidence of increased risk to young, elderly, or immunocompromised humans, more rigorous 
testing should be considered for birds in contact with these individuals. Consultation with an experienced 
avian veterinarian may help when selecting tests and interpreting results. Because proper sample collection 
techniques and handling are critical for obtaining accurate test results, clinical laboratories should be contacted 
for specifics on specimen submission. 
 
Pathologic diagnosis 
 In birds with avian chlamydiosis, cloudy air sacs and enlargement of the liver and spleen may be observed, 
but no specific gross lesion is pathognomonic. Chromatic or immunologic staining of tissue or impression 
smears can be used to identify organisms in necropsy and biopsy specimens. 
 
Bacteriologic culture 
 Use of culture is recommended to avoid limitations associated with other tests. Tissue specimens from the 
liver and spleen are the preferred necropsy specimens. In live birds, combined conjunctival, choanal and 
cloacal swab specimens or liver biopsy specimens are ideal for diagnosis. Live birds being screened for C 
psittaci might not shed the microorganism daily. Therefore, to optimize recovery, serial fecal specimens 
should be collected for 3 to 5 consecutive days and pooled for submission as a single sample. 
 Chlamydophila species are obligate intracellular bacteria that must be isolated in tissue culture or 
embryonating chicken eggs.  Specialized laboratory facilities and training are necessary for reliable 
identification of chlamydial isolates and adequate protection of microbiologists. The diagnostic laboratory 
should be contacted for specific procedures required for collection and submission of specimens. The proper 
handling of specimens is critical for maintaining the viability of organisms for culture, and a special transport 
medium is required. Following collection, specimens should be refrigerated and sent to the laboratory packed 
in ice but not frozen. 
 
Tests for antibodies 
 A positive serologic test result is evidence that the bird was infected by Chlamydiaceae at some point, but 
it might not indicate that the bird has an active infection. False-negative results can occur in birds that have 
acute infection when specimens are collected before seroconversion. Treatment with an antimicrobial agent 
can diminish the antibody response. However, IgG titers may persist following successful treatment.    
  When specimens are obtained from a single bird, serologic testing is most useful when signs of disease 
and the history of the flock or aviary are considered and serologic results are compared with white blood cell 
counts and serum activities of liver enzymes. A >4-fold increase in the titer of paired samples or a combination 
of a titer and antigen identification is needed to confirm a diagnosis of avian chlamydiosis. 
 
• Elementary-body agglutination (EBA) - The elementary body is the infectious form of C psittaci. 
Elementary-body agglutination is commercially available and detects IgM antibodies, an indicator of 
early infection. Titers >10 in budgerigars, cockatiels, and lovebirds and titers >20 in larger birds are 
frequently detected in cases of recent infection. However, increased titers can persist after treatment is 
completed. 
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• Indirect Fluorescent Antibody Test (IFA) - Polyclonal secondary antibody is used to detect host 
antibodies (primarily IgG). Sensitivity and specificity varies with the immunoreactivity of the 
polyclonal antibody to various avian species. Low titers may occur because of non-specific reactivity. 
 
• Complement fixation (CF) - Direct CF is more sensitive than agglutination methods. False-negative 
results are possible in specimens from parakeets, young African gray parrots, and lovebirds. High 
titers can persist after treatment and complicate interpretation of subsequent tests. Modified direct CF 
is more sensitive than direct CF. 
 
Tests for antigen 
Tests for antigen detect the organism. These tests give rapid results and do not require live, viable 
organisms; however, false-positive results from cross-reacting antigens can occur. False-negative results can 
occur if there is insufficient antigen or if shedding is intermittent. As with all nonculture tests, results must be 
evaluated in conjunction with clinical findings. 
 
• Enzyme-Linked Immunosorbent Assay (ELISA) - ELISA tests were originally developed for 
identification of Chlamydia trachomatis in humans. The exact sensitivity and specificity of these tests 
for identifying other Chlamydiaceae are not known. They are now occasionally used to identify 
suspected C. psittaci in birds. If a bird has a positive ELISA result but is healthy, the veterinarian 
should attempt to verify that the bird is shedding antigen via isolation of the organism. When a 
clinically ill bird has a negative ELISA result, a diagnosis of avian chlamydiosis cannot be excluded 
without further testing (e.g., culture, serologic testing or polymerase chain reaction [PCR] assay).  
 
• Fluorescent Antibody Test (FA) - Monoclonal or polyclonal antibodies, fluorescein staining 
techniques and fluorescent microscopy are used to identify the organism in impression smears or other 
specimens. These tests have similar advantages and disadvantages to ELISA. This test is utilized by 
some state diagnostic laboratories. 
 
Tests for DNA 
 Numerous laboratories offer diagnostic testing using polymerase chain reaction assay (PCR). PCR 
amplification can be sensitive and specific for detection of target DNA sequences in collected specimens (e.g., 
combined conjunctival, choanal and cloacal swab specimens and blood). Results differ between laboratories 
because there are no standardized PCR primers and laboratory techniques and sample handling may vary. 
Because of the sensitivity of the assay, samples for PCR must be collected using techniques to avoid 
contamination from the environment or other birds. PCR does not differentiate between viable and nonviable 
microorganisms.  Test results must be interpreted in light of clinical presentation and other laboratory tests. 
 
Additional tests 
Additional diagnostic techniques are in use or under development. Readers are encouraged to research 
peer-reviewed reports on such tests before use. 
 
Laboratories that test avian specimens for C psittaci 
Table 2 lists government and university laboratories that perform chlamydial diagnostic tests. There 
are numerous private laboratories that provide similar services. Inclusion in Table 2 does not imply 
endorsement by the National Association of State Public Health Veterinarians or constituent institutions. 
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Table 2: Laboratories that test avian specimens for Chlamydiaceae 
Laboratory Tests Performed* Telephone NumberWebsite
Diagnostic Center for Population 
and Animal Health,  Michigan State 
University, East Lansing, MI              
Culture, PCR (517) 353-2296 www.dcpah.msu.edu
Comparative Pathology Laboratory, 
University of Miami,  Miami, FL ELISA (antigen), IFA PCR 
(305)585-6303 
www.pathology.med.miami.edu 
Infectious Diseases Laboratory 
(IDL), University of Georgia 
College of Veterinary Medicine, 
Athens, GA 
Culture PCR, IFA (305) 585-6303 www.vet.uga.edu/sams/idl
Veterinary Medical Diagnostic 
Laboratory (VMDL) 
 College Station, TX 
Culture, PCR,  DCF 
(979) 845-3414  
http://tvmdlweb.tamu.edu/ 
Diagnostic Virology Lab, National 
Veterinary Service Laboratory 
(NVSL), VS, APHIS,USDA, Ames 
IA**    
CF, Culture       (515) 663-7551
http://www.aphis.usda.gov/animal_health/lab_info_services/about_dvl.shtml
*CF = Complement fixation, EBA = Elementary body agglutination, ELISA= Enzyme-linked immunosorbent assay, IFA = 
Immunofluorescent antibody, PCR =Polymerase chain reaction assay, DCF – Direct compliment fixation, DCF = Direct florescent 
antibody 
 
**NVSL is a USDA reference laboratory and samples must be submitted through State Veterinary Diagnostic Laboratories 
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Appendix 2 
 
TREATMENT OPTIONS FOR BIRDS WITH AVIAN CHLAMYDIOSIS 
 
Routine prophylactic antibiotic treatment is highly discouraged as it may cause adverse affects and could 
generate resistant strains of C. psittaci and other bacteria 
Treatment of avian chlamydiosis can be difficult. Although treatment protocols are usually successful, 
knowledge is evolving and no protocol ensures safe treatment or complete elimination of infection in every 
bird. Therefore, treatment for avian chlamydiosis should be supervised by a licensed veterinarian after 
consultation with an experienced avian veterinarian.  
 
General Recommendations for Treating and Caring for Infected and Exposed Birds  
• The recommended treatment period for avian chlamydiosis has historically been 45 days, except in 
budgerigars where 30 days of treatment can be effective.  
• Avian facility managers should provide employees with simple, concise written treatment procedures 
to assure treatment success. 
• Sick birds may consume inadequate amounts of medicated food or water, so they should be initially 
treated with drugs delivered directly by mouth or injection.   
• Protect birds from undue stress (e.g., chilling, relocation), poor husbandry, and malnutrition. These 
problems reduce the effectiveness of treatment and promote the development of secondary infections 
with other bacteria or yeast. 
• Observe the birds daily, and weigh them every 3 to 7 days. If the birds are not maintaining weight, 
have them reevaluated by a veterinarian. 
• Remove oyster shell, mineral blocks, and cuttlebone during treatment. High dietary concentrations of 
calcium and other minerals inhibit the absorption of tetracyclines. In hand-fed neonates where dietary 
calcium is required, the calcium and tetracycline should be given at least 4 to 6 hours apart 
• Isolate birds that are to be treated in clean and uncrowded cages. 
• Good husbandry practices should be followed to prevent opportunistic infections: 
o clean up all spilled food promptly 
o wash food and water containers daily. 
o provide appropriate vitamins daily. 
• Continue medication for the full treatment period to avoid incomplete resolution of the infection.   
• Birds may have reduced chlamydial shedding within days of treatment initiation. 
• Treated birds can be reinfected; therefore contaminated aviaries should have a final thorough cleaning 
and disinfection several days before treatment ends.  
• Post-treatment testing should be conducted no sooner than two weeks after treatment is completed. 
 
Treatment Using Doxycycline 
 Doxycycline is presently the drug of choice for treating birds with avian chlamydiosis. It is better 
absorbed and more slowly eliminated than other tetracyclines. This allows doxycycline to be effective with 
lower drug doses (improving palatability with food or water-based administration) or administered less 
frequently (improving ease of treatment). Treated birds should be monitored for signs of doxycycline 
toxicosis. Toxicosis can cause general signs of illness (signs of depression, inactivity and decreased appetite), 
green- or yellow-stained urine and altered results of hepatic tests (high serum activities of aspartate 
aminotransferase and lactate dehydrogenase and high serum concentration of bile acids). If toxicosis occurs, 
administration should be stopped and supportive care provided until the bird recovers. Treatment with a 
different regimen or lower doxycycline dose can be started at a later date. Below are several options for 
treatment. Options should not be combined in the same day. 
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• Doxycycline medicated feed for budgerigars and cockatiels—It is critical to use the recommended 
doxycycline formulation and dietary ingredients to achieve safe and effective results. The following 
medicated diet19 can be used to treat avian chlamydiosis:  
1. Mix 1 part cracked steel-cut oats with 3 parts hulled millet (measured by volume).  
2. To each kilogram of oat-seed mixture, add 5 to 6 mL of sunflower oil. Mix thoroughly to coat all 
seeds. 
3. Add 300 mg of doxycycline hyclate (from capsules) per kilogram of oat-seed-oil mixture, and mix 
thoroughly to ensure that oats and seeds are evenly coated.  
Prepare fresh medicated oat-seed-oil mixture daily because doxycycline stability in this diet is unknown. 
Feed as the sole diet. The oats and hulled millet seed are available at health food stores. Small-sized millet 
should be selected. Sunflower oil is available in grocery stores. Doxycycline hyclate capsules are available 
in 50- and 100-mg sizes. 
• Doxycycline medicated water—Results of pharmacologic studies indicate that doses of 200 to 400 mg of 
doxycycline hyclate/L of water for cockatiels, 400 to 600 mg/L for Goffin’s cockatoos, and 800 mg/L for 
African gray parrots will maintain therapeutic concentrations.20,21 Research data are lacking for other 
species, but empiric use of 400 mg/L of water has been successful for many psittacine birds. Medicated 
water should be prepared daily and provided in clean bowls, rather than water bottles. Do not use 
medicated water for budgerigars as it will not maintain therapeutic concentrations.16    
• Orally administered doxycycline—Doxycycline is the drug of choice for oral administration; either the 
monohydrate or calcium-syrup formulations can be used. Dosage recommendations are as follows: 25 to 
35 mg/kg every 24 hours for cockatiels, 25-50 mg/kg for Senegal parrots, blue-fronted and orange-winged 
Amazon parrots; and 25 mg/kg every 24 hours for African gray parrots, Goffin’s cockatoos, blue and gold 
macaws and green-winged macaws. Precise dosages cannot be extrapolated for other species; however, 25 
to 30 mg/kg every 24 hours is the recommended starting dosage for cockatoos and macaws, and 25 to 50 
mg/kg every 24 hours is recommended for other psittacine species. If the bird regurgitates or refuses the 
drug, another treatment method should be used. 
• Injectable doxycycline— The only suitable doxycycline formulation for intramuscular injection is 
Vibramycin SF IVa (Vibrovenos®), a a specific European formulation that can be imported into the U.S. 
(Table 3).  It is effective if administered at doses of 75 to 100 mg/kg, IM, every 5 to 7 days for the first 4 
weeks and subsequently every 5 days for the duration of treatment. This formulation can cause irritation at 
the injection site, but it is usually tolerated. Other injectable doxycycline hyclate formulations may cause 
severe tissue reactions if given IM.  
 
Alternative treatment regimens 
 
• Injectable Oxytetracycline - Limited information exists to guide the use of an injectable, long-acting 
oxytetracycline product LA-200.b Current dosage recommendations are as follows: SC injection of 75 
mg/kg every 3 days in Goffin’s cockatoos, blue-fronted and orange-winged Amazon parrots, and blue and 
gold macaws. 22  This dosage might be suitable for other species but has not been tested. This product 
causes irritation at the site of injection and is best used to initiate treatment in ill birds or those that are 
reluctant to eat. After stabilization with oxytetracycline treatment, the birds should receive another form of 
treatment to reduce the irritation that is caused by repeated oxytetracycline injection. 
 
 
______________________________________ 
a.    Pfizer Laboratories, London, England 
b. Pfizer Laboratories, Exton, Penn. 
__________________________________________ 
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• Chlortetracycline (CTC) Medicated Feed - Chlortetracycline medicated feed has historically been used 
for flock treatment, however doxycycline regimens are preferred. If used, CTC medicated feed should be 
the only food provided to the birds during the entire treatment. Birds’ acceptance of medicated feed is 
variable. Thus, food consumption should be monitored. Acceptance can be enhanced by first adapting the 
birds to a similar, nonmedicated diet. Treatment begins when the birds accept the medicated feed as the 
sole food in their diet. The following options are available: 
• Medicated mash diets (i.e., >1% CTC with <0.7% calcium) prepared with corn, rice, and hen’s 
scratch.23 
• Pellets and extruded products containing 1% CTC can be used. They are available and appropriate for 
use with pet birds. Select a pellet size appropriate for the size of bird being treated.24, 25  
• A special diet might be necessary for lories and lorikeets, which feed on nectar and fruit in the wild.26 
 
Treatment Methods Not Recommended 
 Use of water medicated with chlortetracycline (Aureomycin), oxytetracycline (Terramycin) or other 
tetracycline products (except doxycycline) is not recommended. These products may reduce water 
consumption, are not likely to be effective and may interfere with disease testing. 
 
Sources of Medications 
 The following sources (Table 3) are not listed as an endorsement of the companies or products. Other 
sources might be available. 
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Table 3: Sources of medication for avian chlamydiosis 
Contact Product 
Telephone Number 
Website 
DOXYCYCLINE 
Local pharmacies 1.Docycycline hyclate capsules 50 & 100 mg 
2. Doxycycline calcium oral suspension 
3. Doxycycline monohydrate oral suspension 
4. Vibramycin 50 & 100 mg capsules 
Dr. Gerry M. Dorrestein 
Wilhelminalaan 19A 
5512BJ Vessem 
The Netherlands 
 
Vibramycin SF I.V.* 
Tel: 000 316 11057602 
Fax: 000 313 02533131 
 
dorresteingm@planet.nl 
MEDICATED FEED 
Avi-Sci Inc., St. Johns, MI 
 
Chlortetracycline, 1% Tel: 800.942.3438 
mike@avi-sci.com
Roudybush, Paso Robles, 
CA 
Chlortetracycline, 1% Tel: 800.326.1726 
www.roudybush.com
Ziegler Brothers Inc. 
Gardners, PN 
Chlortetracycline, 1% 
(special order, 50# minimum) 
Tel: 800.841.6800 
www.zeiglerfeed.com
CHLORTETRACYCLINE   POWDER 
Fort Dodge Animal Health 
Fort Dodge, IA 
 
Aureomycin, (chlortetracycline 
hydrochloride) soluble powder 
concentrate, 4 oz packets 
Tel: 800.685.5656 
fdorder@FDAH.com
Phibro Animal Health 
Fairfield, NJ 
CLTC 100 (Chlortetracycline 
hydrochloride), 22% (100 gm/lb) 
Tel: 888.403.0074 
www.phibroah.com
Agrilaboratories Inc. 
St. Joseph, MO 
 
CTC (Chlortetracycline 
hydrochloride), soluble powder,  
25.6 oz. packet (102 g CTC) 
Tel: 800.542.8916 
www.agrilabs.com
TETRACYCLINE POWDER 
Agrilaboratories Inc. 
St. Joseph, MO 
 
Tetra – bac 324 (Tetracycline 
hydrochloride), soluble powder, 
324 g/lb concentration 
Tel: 800.542.8916 
www.agrilabs.com
OXYTETRACYCLINE  POWDER 
Agrilaboratories Inc. 
St. Joseph, MO 
 
Agrimycin – 343 (Oxytetracycline 
hydrochloride), soluble powder,  
343 g/lb concentration 
Tel: 800.542.8916 
www.agrilabs.com
*Investigational New Animal Drug Application (INADA) is no longer required, Contact the FDA at (301) 594-0796 about 
obtaining a personal import letter.  
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Psittacosis, Technical Information; Center for Disease Control and Prevention 
http://www.cdc.gov/ncidod/dbmd/diseaseinfo/psittacosis_t.htm 
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http://www.mass.gov/Eeohhs2/docs/dph/cdc/factsheets/psittacosis_birds_people.pdf  
 
Psittacosis Fact Sheet: Public Health: Seattle and King Counties  
http://www.kingcounty.gov/healthservices/health/communicable/diseases/psittacosis.aspx  
 
 
Medical and Public Health Professionals  
 
Ohio Dept. of Health Infectious Disease Control Manual   http://www.odh.ohio.gov/pdf/IDCM/psitta.pdf 
 
Psittacosis Control Guidelines for Local Health Departments; Virginia Dept of Health 
http://www.vdh.virginia.gov/epidemiology/DEE/otherzoonosis/documents/Psittacosis/Psittacosis%20for%20LHD%2
0revApr06%20e.pdf  
 
 WebMD’s “emedicine” site http://www.emedicine.com/med/topic1951.htm    
 
Occupational Health and Safety  
Hazard Information Bulletin on psittacosis; Occupational Safety and Health Association 
http://www.osha.gov/dts/hib/hib_data/hib19940808.html  
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http://www.azdhs.gov/phs/edc/edrp/es/pdf/psittacosisset.pdf  
 
Psittacosis; Canadian Center for Occupational Health and Safety 
http://www.ccohs.ca/oshanswers/diseases/psittacosis.html  
 
 
Veterinarians and Animal Professionals  
 
Eidson M. Zoonosis Update. Psittacosis/avian chlamydiosis. J Am Vet Med Assoc 2002;221:1710–1712. 
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CONFIDENTIAL                                                                        Iowa Department of Public Health 
Psittacosis                     Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider title: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
LABORATORY FINDINGS 
 
Laboratory: 
 
      Accession #: 
 
      
Collection 
date: 
 
     /     /      
 
Date received: 
 
     /     /      
Specimen 
source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Chlamydia psittaci     
 
Laboratory: 
 
      Accession #: 
 
      
Collection 
date: 
 
     /     /      
 
Date received: 
 
     /     /      
Specimen 
source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Chlamydia psittaci     
 
Laboratory: 
 
      Accession #: 
 
      
Collection 
date: 
 
     /     /      
 
Date received: 
 
     /     /      
Specimen 
source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Chlamydia psittaci     
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OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
S
ym
pt
om
s 
Chest Pain 
Chills 
Cough 
Encephalitis 
Headache 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
Muscle pain 
Myocarditis 
Rash 
Thrombophlebitis 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 
TREATMENT 
 
Antibiotics prescribed?   Yes    No    Unknown 
 
  
Antibiotic: 
 
      
  
Antibiotic: 
 
      
 
 
Antibiotic: 
 
      
 
Date started: 
 
     /     /      
 
Date started: 
 
     /     /      
 
Date started: 
 
     /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
Number of 
times a day: 
 
      
Number of times 
a day: 
 
      
Number of times a 
day: 
 
      
 
Route: 
 
      
 
Route: 
 
      
 
Route: 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
In the 4 weeks prior to the onset of symptoms, did the case: 
Have contact with birds or 
contaminated environments: 
Duck 
Goose 
Love bird 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
Parakeet 
Parrot 
Pigeon 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
Turkey      Yes    No    Unk 
 
Other bird: 
 
Which bird:       
 
Which bird:       
 
Which bird:       
Contact date:      /     /      Contact date:      /     /      Contact date:      /     /      
Location name:       Location name:       Location name:       
Address:       Address:       Address:       
City:       City:       City:       
State/Zip:       State/Zip:       State/Zip:       
Phone: (     )-     -         Phone: (     )-     -         Phone: (     )-     -         
 
 
Contacts with the same exposures?      Yes    No    Unknown 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
CONTACTS 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation period for 
psittacosis is 5 to 19 days. 
Psittacosis is rarely communicable 
person to person. Laboratory 
infections can occur. 
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Guide to Surveillance, Investigation, and Reporting 
RABIES 
(Human and Animal) 
 
Also known as: Hydrophobia and Lyssa 
 
 
Responsibilities: 
Hospital: Report human cases immediately by phone 
Infection Preventionist: Assess in-house exposures to hospitalized human cases 
Lab: Report all human cases immediately by phone, animal positive cases report by phone or 
mail 
Physician: Report human cases immediately by phone 
Local Public Health Agency (LPHA): Assess case exposures and other potential 
human exposures 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
The virus that causes rabies is a rhabdovirus of the genus Lyssavirus. 
 
B. Clinical Description 
Animal Rabies 
Rabies is primarily a disease of the central nervous system. Animals with rabies can appear normal, 
meek (“dumb rabies”), or may be aggressive (“furious rabies”). Animals with furious rabies often 
exhibit aggressive or unusually excited behavior; they may excessively salivate and attack other 
animals or humans. Dumb rabies may be more difficult to detect; animals may seem tame, wounded, 
or dazed. These animals have been described as acting disoriented or suffering from some paralysis.  
While these behaviors are commonly reported, an animal’s behavior is not a reliable indicator of 
whether it has rabies. 
 
Human Rabies 
Rabies is a fatal infection, which usually progresses over 2 – 21 days.  A prodromal phase, lasting 2 – 
10 days, is characterized by pain and numbness/tingling at the site of the bite (present in 50% – 
80% of cases), and nonspecific complaints such as fatigue, headache and fever. Behavioral changes 
may also be apparent, including apprehension, anxiety, agitation, irritability, insomnia and 
depression.  The prodromal phase is quickly followed by the neurologic phase, during which the 
patient may suffer disorientation and hallucinations; paralysis; episodes of terror and excitement; 
hydrophobia; hyperventilation; hypersalivation; and seizures. These symptoms are invariably followed 
by coma and death. Once symptoms have begun, there is usually no treatment or cure; prevention is 
the only tool. 
 
Rabies should be considered in patients with signs or symptoms of encephalitis or myelitis, including 
autonomic instability, dysphagia, hydrophobia, paresis, and paresthesia, particularly if a nonspecific 
prodrome preceded the onset of these signs by three to four days. Progressive worsening of 
neurologic signs is characteristic of rabies and should be considered as a positive indicator for rabies. 
Laboratory tests to rule out common encephalitides (herpes, enteroviruses, arboviruses) should be 
performed. Negative results of these tests would increase the likelihood of rabies as the diagnosis. If 
Report human 
cases immediately  
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a patient presents with symptoms similar to the ones described above, but the neurologic status does 
not change and the illness continues for longer than three weeks, rabies is unlikely as the diagnosis. 
 
Positive Indicators for Rabies  
Nonspecific prodrome prior to onset of neurologic signs  
Neurologic signs consistent with encephalitis or myelitis  
 dysphagia  
 hydrophobia  
 paresis  
Progression of neurologic signs  
Negative test results for other etiologies of encephalitis  
 
      Negative Indicators for Rabies  
Improvement or no change in neurologic status  
Illness with ≥ 2 to 3 week duration  
      
 
C. Reservoirs 
All species of mammals are susceptible to rabies infection.  During 2009, a total of 35 cases of animal 
rabies were reported in Iowa. Twenty-five reported animal cases were wildlife species: 13 skunks, 11 
bats and 1 squirrel.  In addition, 5 cows, 3 cats, and 2 dogs tested positive for rabies. This data 
reflects only the tested animals that might have exposed humans or other domestic animals to 
rabies, and does not represent all rabid animals in Iowa.  See 
www.idph.state.ia.us/Rabies/Resources.aspx  for more information. 
 
D. Modes of Transmission 
Rabies is spread via the virus-laden saliva of an infected animal through a bite or saliva contact with 
mucous membranes or a fresh break in the skin. Breaks in the skin or mucous membrane exposure 
to nervous tissue (brain, spinal cord) of an infected animal also pose a transmission threat. Bites of 
some animals, such as bats, can inflict injury so minor that it goes undetected.  Airborne spread (for 
example, in a cave with many bats, or in a laboratory through rabies virus or specimens) is rare, but 
has been reported.  Rabies is not transmitted through contact with blood, urine, skunk spray, or 
feces of an infected animal. 
 
Person-to-person spread has been documented after organs and corneas were transplanted from 
rabies infected individuals. Two non-laboratory-confirmed cases of person-to-person rabies 
transmission in Ethiopia have been described; the reported route of exposure in both cases was 
direct saliva contact (a bite and a kiss).   
 
E. Incubation period 
Animal Rabies 
Depending on the animal, the incubation period may vary from a few weeks to a few years, but is 
typically 1 - 3 months.  
 
Human Rabies 
The incubation period is usually 3 - 8 weeks, but can rarely range from as few as 9 days (although 9-
day incubation periods have not been documented in the U.S. with native strains of rabies) to as 
many as 7 years. Less than 1% of human cases have an incubation period longer than 6 months. The 
incubation period is typically related to the site of exposure; e.g., the incubation period is usually 
shorter if the virus is inoculated closer to the central nervous system or in a highly innervated area. 
The incubation period also typically depends on exposure severity (more virus exposure results in a 
shorter incubation period) and the age of the exposed person (younger age generally results in a 
shorter incubation period).   
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F. Period of Communicability or Infectious Period 
Animal Rabies 
Animals are not infectious until virus is present in their saliva, which happens around the time of 
clinical onset of illness. Dogs, cats and ferrets may shed virus in their saliva for 3 – 7 days before the 
onset of clinical signs, and continue to shed virus until death. The shedding/communicability period 
for most wild animals has not been determined, although it appears that skunks may shed virus up to 
18 days before death. Carcasses of animals with rabies may contain infectious virus, depending on 
temperature and environmental conditions. Rabies virus may persist in a frozen carcass for many 
weeks; however drying and sunlight rapidly deactivate rabies virus. A dried carcass or dried saliva 
does not contain live rabies virus. 
 
Human Rabies 
The period during which a patient is potentially infectious may begin up to 1 week before symptom 
onset and last until death. Saliva is considered potentially infectious, as are cerebrospinal fluid and 
organs (although viral concentrations in humans are 3 – 4 times lower than in dogs).  
 
G.  Epidemiology 
Animal rabies 
Animal rabies exists in most parts of the world. In the United States, Hawaii is the only state that has 
never reported an indigenously-acquired rabies case in humans or animals. In 2010, wild animals 
accounted for approximately 92% of reported cases of animal rabies in the U.S. Nationally, raccoons 
continue to be the most frequently reported rabid wildlife species (36.5% of all animal cases in 
2010), followed by skunks (23.5%), bats (23.2%), foxes (6.6%), and other wild animals including 
rodents and lagomorphs (1.9%).  
In the U.S., domestic species accounted for 8% of all rabid animals reported in 2010. The number of 
reported rabid domestic animals increased among cats and decreased among dogs, horses, sheep, 
and goats during 2010. In 2010, cases of rabies in cats increased 1.0% compared with the number 
reported in 2009. The number of rabies cases reported in cats is routinely 3-4 times that of rabies 
reported in cattle or dogs. In 2010 approximately 1.1% of cats and 0.3% of dogs tested for rabies 
were found positive.       
 
Human Rabies 
Worldwide an estimated 35,000–40,000 human rabies deaths occur each year. The vast majority of 
these deaths occur in developing countries. In the United States from 1995 through 2008, there 
were 49 human cases, of which 48 were fatal.  Four cases were the result of solid tissue organ 
transplantation; 30 cases were associated with bat variants; one was associated with the raccoon 
variant; one was associated with the fox variant; and eight were associated with the canine variant. 
The most recent human cases of rabies in Iowa occurred in 1951 and 2002. The 2002 case was 
caused by the bat strain of rabies virus.  
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To understand the rabies risk to people bitten or exposed to animal saliva or infectious 
materials 
• To provide information on proper post exposure treatment for humans exposed 
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report human rabies immediately, and animal rabies within 3 days to IDPH Center for Acute 
Disease Epidemiology (CADE) is (800) 362-2736; fax number (515) 281-5698, mailing address: 
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IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
Des Moines, IA 50319-0075 
 
Reporting forms are available free of charge from the clearinghouse.   
Call ((319) 398-5133) to request a supply. Orders can also be processed online at 
healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295 
  
C.  Local Public Health Agency Follow-up Responsibilities 
  
a. The most important thing a local county health department can do if it learns of a 
suspected or confirmed case of human rabies is to immediately call IDPH, any time 
of the day or night.  The 24-hour phone number for the Center for Acute Disease 
Epidemiology is (800) 362-2736. 
 
b. Case investigation of human rabies in Iowa residents will be directed by IDPH Center for Acute 
Disease Epidemiology. 
 
c. Following immediate notification of IDPH, the LPHA may be asked to assist in investigating 
cases living within its community, including gathering the following information:  
1) The case’s name, age, address, phone number, status (hospitalized, at home, deceased), 
and parent/guardian information, if applicable. 
2) The name and phone number of the hospital where the case is or was hospitalized. 
3) The name and phone number of the case’s attending physician. 
4) The name and phone number of the infection preventionist at the hospital. 
5) The names and phone numbers of all healthcare providers and hospitals that cared for the 
patient.  
  
d. Institution of disease control measures is an integral part of case investigation. The LPHA is 
responsible for understanding and, if necessary, instituting the control guidelines listed in 
Section 3), Controlling Further Spread.    
 
3) CONTROLLING FURTHER SPREAD 
 
A. Human Isolation and Quarantine Requirements 
Minimum Period of Isolation of Patient 
Standard Precautions for the duration of illness (e.g., until death). 
 
Minimum Period of Quarantine of Contacts 
None for humans.  
 
B. Protection of Contacts of a Case 
1.  Protection of Humans Exposed to Animals 
 
Under Iowa Code Chapter 351.39, Local Boards of Health are responsible for collecting human 
exposure reports and enforcing animal confinement.    
 
The need for post-exposure rabies prophylaxis should be evaluated in three steps and can be 
phrased in the form of three questions:  
1) is the animal species known to carry rabies?   
2) did an actual exposure occur? and  
3) can the animal be tested?  
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Step 1.  Is the animal species known to carry rabies? 
 
Wild Animals:  
In wild animals the rabies risk varies by species: 
• High-risk animals are those that commonly carry rabies.  In Iowa, these include skunks, bats, 
raccoons, foxes, and coyotes.  
• Medium-risk animals have very rarely been found to carry rabies in the US (extremely rare in 
Iowa) large rodents such as beaver, muskrat, groundhog, and woodchuck. 
• Low-risk animals that almost never carry rabies include small rodents, opossum, and 
lagomorphs.  This includes mice, squirrels, chipmunks, and rabbits.  
 
Dogs, Cats, Ferrets, Horses and Livestock:  
These animals can be infected with rabies virus. Exposures to dogs, cats, horses, and livestock need 
to be carefully evaluated, since a potential exists for these animals to harbor the virus.   
 
Other Species:  
CADE is available for consultation call 800-362-2736 during business hours or 515-323-4360 after 
hours.   
 
Once it has been determined that the animal involved is a potential carrier of rabies, the clinician 
should move to the second step. (Whether or not an animal has been vaccinated is immaterial to 
assessment because, though vaccination decreases the risk of the animal being rabid, it is not a 
guarantee). 
 
Step 2.  Did an exposure actually occur? 
Rabies is transmitted by introducing the virus into open cuts or wounds in skin or via mucous 
membranes.  The virus will not cross intact skin.  Since the virus is present in saliva, actual exposures 
to the virus require bites, saliva contact to mucous membranes, or  contamination of fresh, open 
cuts, wounds, or abrasions with saliva.   
 
Other nonsalivary exposures to rabies virus rarely occur, and include exposure to large amounts of 
aerosolized rabies virus (e.g. explorers of caves colonized by rabid bats); infected organs (e.g., 
corneas) transplanted from patients who died of unrecognized rabies; and exposure of open wounds 
or mucous membranes to other potentially infectious material (nervous tissue) from a rabid animal.  
If the material containing the virus is dry, the virus can be considered noninfectious.  Other contact, 
such as petting a rabid animal or contact with the blood, urine, skunk spray, or feces, does not 
constitute an exposure and is not an indication for prophylaxis.  
 
Bats pose a unique problem. The bite of a bat can be so small that it may be undetected. People 
found in rooms with bats, who are unable to state, “I know I was not bitten,” should be considered 
potentially exposed. For example persons that awaken to find a bat in the room or children alone 
with a bat in a room should be considered exposed to rabies. 
 
Once it has been determined that a potential exposure occurred, the clinician should move to the 
third step. (Can the animal be tested?). 
 
Step 3.  Can the animal be tested?   
 
Bats 
If available, the bat should be tested for rabies.  If the bat is unavailable for testing, PEP should be 
considered. 
 
 Wild Animals 
High risk animals should be euthanized and submitted for rabies testing. Since viral shedding periods 
are not known for these animals, quarantine is not appropriate.  In cases in which the animals are 
unavailable for testing, they should be assumed rabid.  
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Medium-risk animals have rarely been found to carry rabies in the US and have very rarely if ever 
been found to be rabid in Iowa.  If the animal is available, it should be submitted for testing.  If the 
animal is not available, the exposed person should consult with their personal physician to determine 
whether prophylaxis is warranted.     
 
Lower-risk animal exposures almost never require human rabies PEP, unless the circumstances 
surrounding the exposure were unusual (such as an unprovoked bite by an animal acting strangely).  
 
Dogs, Cats or Ferrets 
Dogs, cats and ferrets that have bitten or otherwise exposed a human and appear healthy may be 
quarantined for 10 days in lieu of euthanasia and testing. If at any time during the quarantine period, 
a dog, cat, or ferret shows signs of rabies the animal should be immediately euthanized and tested.   
 
Dogs, cats and ferrets that are incubating rabies will begin to exhibit signs of the disease very soon 
after they begin shedding virus in saliva. If an animal remains healthy during the 10-day quarantine, 
it could not have been shedding rabies virus in its saliva at the time of the bite or exposure.  This 
does not guarantee that the animal is not incubating rabies; it only indicates that the animal was not 
infectious at the time in which the human was exposed.   
 
A dog, cat, or ferret that is not available for observation or testing should be considered potentially 
rabid and post-exposure prophylaxis should be initiated.  If capture of the dog, cat, or ferret is likely 
in the near future, prophylaxis may be delayed up to 72 hours.  If the animal is not located within 72 
hours PEP should be initiated.   
 
Livestock 
Recommendations for livestock that expose humans are determined on a case-by-case basis. Contact 
IDPH (800) 362-2736 for consultation.  
 
Other Animal Species 
For exposure to other animal species, recommendations are made on a case-by-case basis. Contact 
IDPH (800) 362-2736 for consultation. 
 
Note:  If a patient is bitten above the shoulder, IDPH recommends that the health care provider 
consider starting Post Exposure Prophylaxis immediately, as opposed to waiting and observing the 
animal for 10 days.  The closer the point of exposure is to the brain, the shorter the distance in which 
the virus must travel, potentially resulting in a shorter incubation period. If the animal subsequently 
tests negative for rabies, or if the animal is quarantined and is healthy at the end of 10 days 
(quarantines can only be conducted in dogs, cats, and ferrets) Post Exposure Prophylaxis can be 
discontinued at that time.  If Post Exposure Prophylaxis is discontinued before the series is completed 
and the patient is exposed again in the future, the entire Post Exposure Prophylaxis series should be 
administered.  If the Post Exposure Prophylaxis series is completed and the patient is exposed again 
in the future, only two doses of rabies vaccine on days 0 and 3 should be administered.   
 
Laboratory Submission of Animal Specimens 
Rabies testing requires examination of the animal’s brain, so the animal should be euthanized without 
damage to the head. Samples should be refrigerated prior to submission to the laboratory, and 
freezing should be avoided. Samples determined to be unsuitable for testing or indeterminate should 
be assumed positive and PEP should be administered accordingly.   
 
There are two laboratories in Iowa that provide animal rabies testing services: State Hygienic 
Laboratory and Iowa State University Veterinary Diagnostic Laboratory.  
 
State Hygienic Laboratory (SHL):  
 
SHL is the designated state public health laboratory in Iowa.  SHL receives state funding enabling 
them to provide free testing services for diseases of public health concern.  Therefore, SHL will test 
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potentially rabid animals that have exposed humans free of charge.  SHL does not provide testing for 
animal to animal exposures; therefore those samples should be submitted to Iowa State University 
Veterinary Diagnostic Laboratory.      
 
Iowa State University Veterinary Diagnostic Laboratory (ISU VDL):  
 
ISU VDL has historically provided animal rabies testing as a service to veterinarians who may be 
ruling out rabies as one of several differential diagnosis.   However, in recent years ISU VDL has 
received an increasing number of requests for rabies testing of domestic, livestock, and wildlife 
species where the submitter is only requesting rabies testing without additional diagnostics.  While 
ISU VDL is willing and able to provide that service to the public, healthcare, and veterinary 
communities, they do not receive any state or federal funding to support testing.  Therefore, ISU VDL 
must charge for the testing to cover their operating expenses.  ISU VDL will provide rabies testing for 
cases of animal and/or human exposure.   
 
Specimen Submission and Transportation:   
Specimen Preservation:  
 If the specimen will not be submitted for testing immediately, it should be 
refrigerated until transported or shipped.  
 DO NOT FREEZE THE SPECIMEN 
  
Specimen Transport:  
 Private vehicle is the fastest and preferred way to get the specimen to the 
laboratory.  
• Double bag the specimen 
• Place the specimen in a hard sided container, such as a Styrofoam cooler 
• Place ice packs around the double bagged specimen to keep it cool during 
transport 
• Include the appropriate Rabies Test Request Form from SHL or ISU 
• Call the appropriate laboratory before departure  
 Commercial courier service, such as FedEx, can also be used.  
• Double bag the specimen 
• Place the double bagged specimen in a hard sided container, such as a 
Styrofoam cooler.  
• Place ice packs around the double bagged specimen to keep it cool -DO NOT 
FREEZE.  
• Place the completed Rabies Test Request Form in a separate plastic bag to 
prevent it from becoming wet or contaminated. Place the bagged Rabies Test 
Request Form in the hard sided container. 
– Firmly secure the lid of the hard sided container.   
– Package (place in a box) the hard sided container and ship.   
– Ship via overnight courier. 
 
NOTE: Improper packaging and/or delayed delivery may compromise the integrity of the brain 
material rendering the specimen unsatisfactory for testing. 
 
Specimen submission guidelines:  
 Large/medium animals- If only requesting rabies testing, a veterinarian needs to 
remove the head and only the head should be submitted for testing*.  
 Bats- Try not to crush the skull of the bat.  Submit the entire animal. 
 Small animals (mice, squirrels, etc): Submitting the entire animal is preferred.  
 
*If a veterinarian is requesting other diagnostics from ISU VDL all appropriate 
samples should also be included.  In some cases, this may mean that the 
entire animal should be submitted.   
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Laboratory Contact Information:  
 
SHL:   
319-335-4500 or 800-421-4692 (answered all hours)    
 
ISU VDL:   
During business hours call 515-294-1950 – after hours call 515-290-1969    
 
2.  Protection of Domestic Animals Exposed to a Rabid or Potentially Rabid 
Animal  
Longer quarantine periods are required for domestic animals exposed to a rabid or potentially rabid 
animal (without human exposure). Quarantines may range from 45 days to 6 months depending on 
the animal’s vaccination status. Euthanasia may sometimes be recommended. The latest 
recommendations and requirements concerning the quarantine of animals exposed to a rabid or 
potentially rabid animal can be obtained from the Compendium of Animal Rabies Prevention and 
Control, 2008 National Association of State Public Health Veterinarians, Inc. (NASPHV) 
www.nasphv.org/Documents/RabiesCompendium.pdf  
 
3.  Protection of Humans Exposed to a Rabid or Potentially Rabid Animal or 
Human  
 
Severe Bites above the Shoulder  
If a patient is bitten above the shoulder, IDPH recommends the health care provider consider starting 
post exposure prophylaxis immediately.  The closer the point of exposure is to the brain, the shorter 
the distance in which the virus must travel, therefore potentially resulting in a shorter disease 
incubation period.  
 
If the animal subsequently tests negative for rabies, or if the animal is quarantined and is healthy at 
the end of 10 days (quarantines can only be conducted in dogs, cats, and ferrets) Post Exposure 
Prophylaxis can be discontinued at that time.  If Post Exposure Prophylaxis is discontinued before the 
series is completed and the patient is exposed again in the future, the entire Post Exposure 
Prophylaxis series should be administered.  If the Post Exposure Prophylaxis series is completed and 
the patient is exposed again in the future, only two doses of rabies vaccine on days 0 and 3 should 
be administered.   
 
Human Post Exposure Prophylaxis  
• Immediately and thoroughly wash all bite wounds and scratches with soap and water.  
Simple wound cleaning has been shown to markedly reduce the risk of rabies.   
• Tetanus prophylaxis should be considered  
• Risk of bacterial infections should be assessed and addressed. 
 
1. Treatment of persons who have not previously received rabies vaccine or have not 
previously received rabies post-exposure treatment. 
a. Immunocompetent patients: 
• Four 1-mL vaccine doses of HDCV or PCECV should be administered 
intramuscularly to previously unvaccinated persons as soon as possible after 
exposure on days 0, 3, 7, and 14 (day 0 is the day the post exposure prophylaxis 
is started).   
• One dose of rabies immunoglobulin (HRIG), 20 IU/kg, should also be 
administered on day 0. 
o If anatomically feasible, the full dose of HRIG should be thoroughly 
infiltrated in the area around the wound. The rest should be 
administered intramuscularly at a different site than the vaccine.  
o If HRIG is not given with the first post-exposure dose of vaccine, it must 
be given within eight days after the first dose of vaccine.   
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b. Immunocompromised patients:  
• Five 1-mL vaccine doses of HDCV or PCECV should be administered 
intramuscularly to previously unvaccinated persons as soon as possible after 
exposure on days 0, 3, 7, 14, and 28.   
• One dose of rabies immunoglobulin (HRIG), 20 IU/kg, should also be 
administered on day 0. 
o If anatomically feasible, the full dose of HRIG should be thoroughly 
infiltrated in the area around the wound. The rest should be 
administered intramuscularly at a different site than the vaccine.  
o If HRIG is not given with the first post-exposure dose of vaccine, it must 
be given within eight days after the first dose of vaccine.   
 
How is immunocompromised defined in terms of rabies vaccination?  
The decision of whether individuals are immunocompromised should be determined by a 
physician. However, to assist with this determination, persons with the below conditions 
may need to receive five doses of rabies vaccine (consult with their healthcare provider).  
 
A. Persons with  immunocompromising conditions or on specific medications (non-HIV) 
• Examples include but are not limited to:  
A. Congenital immunodeficiency 
B. Leukemia 
C. Lymphoma 
D. Generalized malignancy  
E. Therapy with alkylating agents, antimetabolites, radiation, or large 
amounts of corticosteroids.  
F. Antimalarial medications 
 
B. Persons with HIV infection 
A. Both symptomatic and asymptomatic patients with HIV infection  
  
C. Persons with conditions that cause limited immune deficits  
A. Examples include but are not limited to:  
A. Renal failure 
B. Diabetes (uncontrolled) 
C. Alcoholic cirrhosis 
D. Asplenia  
 
When rabies pre- or postexposure prophylaxis is administered to an immunosuppressed 
person, one or more serum samples should be tested for rabies virus-neutralizing antibody by 
the RFFIT test to ensure that an acceptable antibody response has developed after 
completing the series.   
If no acceptable antibody response is detected after the final dose in the pre- or 
postexposure prophylaxis series, the patient should be managed in consultation with their 
physician and appropriate public health officials. 
 
2. Treatment of persons who have either received pre-exposure vaccination or have previously 
received rabies post-exposure treatment (according to the current protocols and with 
approved products, if unsure contact CADE for consultation): 
a. Two IM doses (1.0 ml each) of vaccine should be administered on days 0 and 3.  
Human Rabies Immune Globulin should NOT be administered.  
 
Exposure to a Human Potentially Infected with Rabies 
Standard Precautions for respiratory secretions should be in place for persons suspected or 
confirmed to have rabies. Articles soiled with saliva should be disinfected. Attending personnel 
should be protected (gloves, gowns, face protection) against any exposure to saliva. If a patient 
who has rabies (or is suspected of having rabies) exposes another person to saliva (through a 
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bite or via infectious material exposure to an open wound or mucous membrane), rabies PEP of 
the contact should be started. Other people from the patient’s home, social, and work 
environment should be contacted to review their potential exposure.   
 
4.   Precautions and Contraindications to Rabies Prophylaxis 
a. Immunosuppression.  Corticosteroids, other immunosuppressive agents, or 
immunosuppressive illness can interfere with the development of active immunity and 
predispose the patient to developing rabies. Immunosuppressive agents should not be 
administered during post-exposure therapy, unless essential for the treatment of other 
conditions.   
b. Pregnancy.  Because of the potential consequences of inadequately treated rabies exposure, 
pregnancy is not considered a contraindication to post-exposure prophylaxis. Several studies 
have shown no indication of increased incidence of abortion, premature births or fetal 
abnormalities associated with rabies vaccination.  Rabies exposure or diagnosis of rabies in 
the mother is not an indication for pregnancy termination.  
c. Allergies.   When a patient with a history suggesting hypersensitivity to any rabies vaccine 
component must be given the vaccine, antihistamines can be used; epinephrine should be 
readily available to counteract anaphylactic reactions, and the person should be carefully 
observed in a medical setting during vaccination. 
 
C. Preventive Measures 
 
Environmental Measures 
Human rabies control relies on controlling rabies in the animal population, therefore animal 
quarantine regulations and vaccination laws should be enforced.  Under Iowa Code Chapter 351.39, 
Local Boards of Health are responsible for collecting human exposure reports and enforcing animal 
confinement.  In Iowa, all dogs over 6 months of age are required to be vaccinated against rabies.  
Rabies vaccination is strongly encouraged in all companion animals (including horses) and valuable 
livestock.   
 
Pre-Exposure Vaccination 
Pre-exposure vaccination is recommended for persons in the following categories: 
• Veterinarians 
• Animal handlers 
• Laboratory workers who handle rabies virus 
• Persons living in or visiting countries where rabies is endemic 
• Others whose occupations or hobbies bring them into contact with potentially rabid animals  
 
Pre-Exposure Vaccination Protocol:  
 Three 1.0 ml injections of vaccine given intramuscularly on each of days 0, 7, and 21 or 28.   
 
NOTE:  Pre-exposure vaccination does NOT eliminate the need for prompt post-exposure 
prophylaxis.  If persons who have completed the pre-exposure vaccination series are 
subsequently exposed to rabies, the following protocol should be followed (as stated on page 7):  
 Two IM doses (1.0 ml each) of vaccine, on days 0 and 3.  Human Rabies 
Immune Globulin should NOT be administered.  
 
Monitoring Pre-Exposure Vaccination Titers:  
 
Persons who work with live rabies virus in research laboratories or vaccine production facilities 
and are under continuous risk of inapparent rabies virus exposure should have their serum rabies 
antibody titer measured every 6 months.  Acceptable antibody level is 1:5 titer by the rapid 
fluorescent focus inhibition test (RFFIT) technique. See page 15 for laboratories performing the 
serologic tests.  If the antibody level is less than 1:5, booster doses of vaccines should be 
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administered to maintain a serum titer corresponding to at least complete neutralization at a 1:5 
serum dilution by RFFIT.    
Persons who frequently come in contact with potentially rabid animals, such as veterinarians, 
veterinary technicians, animals control officers, or wildlife officers, should have a serum 
sample tested for rabies antibody every 2 years.  If their antibody level is less than complete 
neutralization at a 1:5 serum dilution by the RFFIT, the person should receive a single booster 
dose of vaccine.   
 
Education  
 
Offer the following advice to the public to help prevent rabies: 
• Vaccinate pets; dogs are required by law to be vaccinated. Although not required by state 
law, cat, ferret, horse and valuable livestock vaccinations are recommended.  
• Do not feed or handle wild or stray animals. Avoid sick animals or those that act strangely. 
• Do not touch or handle dead animals. 
• Contact local animal control officer with questions about the capture of an animal or handling 
of a carcass. 
• Cover garbage cans and keep pet food indoors, so wild animals are not attracted. 
• Do not keep wild animals as pets, which is often illegal as well as dangerous. 
• Never handle bats. A bat bite or scratch may be small and go unnoticed. People who awaken 
to find a bat in the room or children awake or asleep with a bat in a room may require PEP.  
• Recommend that travelers to developing countries with endemic rabies receive pre-exposure 
prophylaxis if they will be visiting in situations where exposure is likely (e.g., camping, hiking, 
backpacking, or away from areas where treatment for a bite wound is available). Travelers 
should be warned to avoid petting or otherwise having contact with stray animals. 
 
Note: For more information about international travel and rabies, contact the CDC Traveler’s Health 
Office at (877) 394-8747 or via the internet at www.cdc.gov/travel 
 
4) ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Rabies 
can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
 
Programs for Uninsured and Underinsured Patients 
Patient assistance programs that provide medications to uninsured or underinsured patients are 
available for rabies vaccine and Immune globulin. 
Sanofi Pasteur’s Patient Assistance Program (providing Imogam ® Rabies-HT and Imovax ® Rabies 
as well as other vaccines) is now administered through the Franklin Group. A healthcare professional 
or patient can either contact the Franklin Group directly, or call the customer service team (1-800-
VACCINE) who will transfer them to the Franklin Group. The Franklin Group will review the 
application against the eligibility criteria. For more information about the program or to request an 
application, please contact the Sanofi Pasteur, Inc. Patient Assistance Program (Franklin Group) at 1 
(866) 801-5655. 
Novartis’ Patient Assiatance Program for RabAvert ® is managed through RX for Hope and can be 
accessed at 800-244-7668. Instructions and request forms are also available at the Rx for Hope 
website RabAvert Patient Assistance Program . 
 
References 
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Additional Resources 
• Iowa Department of Public Health – Rabies Resources:  
    www.idph.state.ia.us/Rabies/   
• CDC Resources: www.cdc.gov/mmwr/preview/mmwrhtml/rr5902a1.htm  
www.cdc.gov/mmwr/preview/mmwrhtml/rr57e507a1.htm?s_cid=rr57e507 
_e%0d%0a  
• Compendium for animal rabies control:  www.nasphv.org/Documents/RabiesCompendium.pdf  
 
CONSULTANTS:   Iowa Department of Public Health 
   During regular business hours call:  (800) 362-2736 
   After hours call:  (515) 323-4360  
 
LABORATORIES:   
University of Iowa State Hygienic Laboratory 
(SHL) 
Oakdale Campus 
University of Iowa 
Iowa City, IA 52242 
Tel:  (319) 335-4500 or (800) 421-4692 
(answered all hours) 
www.shl.uiowa.edu/kitsquotesforms/rabiesslip.pdf  
 
 
 
Iowa State University Veterinary Diagnostic Lab 
(VDL)  
College of Veterinary Medicine    
Iowa State University     
Ames, IA 50011     
Tel:  (515) 294-1950 or after hours (515) 290-
1969 (Veterinary Teaching Hospital) 
http://vetmed.iastate.edu/sites/default/files/vdl/forms/Rabie
sForm.pdf 
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Laboratories that perform the Rapid Fluorescent Focus Inhibition Test  
(the CDC recognized test for assessing human antibody levels) 
 
INTERPRETATION:  A titer of 1:5 is considered adequate. 
SHIPPING INFORMATION:  Please send the following information with your specimen: 
1. Address of person or institution responsible for receiving the results 
and billing information. 
2. Complete vaccination history if possible. 
3. All serum samples that are potentially pathogenic to humans should 
be labeled or marked with red tape or sticker. 
 
 SEND SAMPLES TO (any one of the following): 
    
K-State Rabies Laboratory 
Manhattan/K-State Innovation Center 
2005 Research Park Circle 
Manhattan, KS 66502 
Main telephone:  (785) 532-4483 
Fax:  (785) 532-4522 or (785) 532-4474 
Email: rabies@vet.k-state.edu 
Web address: www.vet.ksu.edu/rabies 
 
Atlanta Health Associates        
309 Pirkle Ferry Road, Suite D300     
Cumming, GA 30040      
(770) 205-9091 or (800) 717-5612 
FAX: (770) 204-9021 
Web address: www.atlantahealth.net/  
      
 
Auburn University College of Veterinary Medicine     
Note: Only animal specimens tested. 
Dept. of Pathobiology, Virology Lab  
261 Greene Hall        
Auburn University, AL 36849-5519   
(334) 844-2659  
www.vetmed.auburn.edu/diagnostics  
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CURRENT LICENSED RABIES IMMUNIZING PRODUCTS FOR HUMANS: 
 
Human Rabies Vaccine 
A) Imovax TM  Rabies 
Human diploid cell vaccine 
  Sanofi Pasteur Inc 
  Box 187 Discovery Dr 
  Swiftwater, PA 18370-0187 
  (800) 822-2463 
  (570) 839-7187 
  fax: (570) 839-0955 
  www.sanofipasteur.us  
 
B) RabAvert TM  
Purified chick embryo cell culture 
Novartis 
4560 Horton Street 
Emeryville, CA 94608-2916 
(800) 244-7668 
fax: (510)923-3434 
MN # (510) 655-8730 
www.rabavert.com  
 
Human Rabies Immune Globulin (HRIG) 
A) Hyperrab  
  Talecris Biotherapeutics Inc 
  PO Box 110526 
  4101 Research Commons 
  79 T. W. Alexander Dr 
  Research Triangle Park, NC 27709 
  (800) 243-4153  
  www.talecrisbiousa.com  
 
B) Imogam Rabies 
  Sanofi Pasteur Inc. 
  Box 187 Discovery Dr 
  Swiftwater, PA 18370-0187 
  (800) 822-2463 
  (570) 839-7187 
  fax: (570) 839-0955 
  www.sanofipasteur.us  
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FACT SHEET         RABIES 
 
What is rabies? 
Rabies is a disease of the brain caused by a virus.  It results from exposure to an animal with rabies.  
Rabies in humans is always fatal. 
 
Who gets rabies? 
Anyone can get rabies after exposure to a rabid animal.  Rabies is spread when the virus from the animal's 
saliva (mouth) gets through a person's skin via open cuts or wounds or in the mouth or eyes. The chance 
that rabies infection will result varies with the type of the contact or "exposure." 
 
What is exposure to rabies? 
There are two types of exposure.  One type is a bite (any penetration of the skin by teeth). The second is a 
non-bite exposure in which saliva or brain and spinal cord (neural) tissue from an animal with rabies gets 
into any, wound, open skin, eyes, nose, or mouth.   
 
Bats pose a different problem. The bite of a bat can be so small that it may not be seen. People found in 
rooms with bats, who are unable to state, “I know I was not bitten,” should be considered potentially 
exposed. For example persons that awaken to find a bat in the room or children alone with a bat in a 
room should be considered exposed to rabies. 
 
What animals get rabies?  
Some animals are more likely to be infected with rabies than others.  For example, meat-eating wild animals 
(especially skunks, raccoons, foxes, coyotes, bobcats and bats) most often get rabies.  All domestic animals 
(such as dogs, cats, horses, and cattle) can be infected.  Rodents (such as squirrels, hamsters, and mice) 
and lagomorphs (including rabbits and hares) rarely get rabies. 
 
How can you tell if an animal is rabid? 
Although some animals with rabies look and act normal, most will develop one of two distinct forms of the 
disease.  One form is called "furious rabies." The infected animal is easily over-excited or angered.  The 
other is "dumb rabies." In this type of rabies, the infected animal becomes calm and paralyzed (has 
difficulty moving).  Usually, animals become irritable, restless, and nervous.  An infected animal may have a 
tendency to eat unusual things like sticks, straw, stones, and soil.  Difficulty swallowing causes the animal 
to drool saliva, but a drooling dog is not always a rabid dog.  The only way to tell for sure whether an 
animal has rabies is to kill it in a humane manner and test its brain for the rabies virus. 
 
How long can animals spread rabies? 
Dogs and cats can spread rabies for several days before they become ill, and during illness.  The amount of 
time varies for other animals. 
 
What should you do if you are exposed to a rabid animal? 
Immediately wash all bite wounds and scratches thoroughly with soap and water.  Contact a doctor as soon 
as possible. Treatment for exposed individuals includes both human rabies immune globulin (HRIG) and 
rabies vaccine.  Individuals previously immunized or treated for rabies exposure should receive only booster 
immunizations of rabies vaccine. 
 
How can rabies be prevented? 
• Vaccination of pets against rabies is the best way to reduce human exposure.   
• Avoid contact with all wild animals.  
• Do not keep wild animals as pets.   
• Control of stray animals can decrease both animal and human exposure to rabies.   
• Animals that have had contact with an animal that might have rabies should be reported to a 
veterinarian. 
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RABIES: Frequently Asked Questions 
For the Human and Animal Health Communities 
 
 IDPH provides general recommendations for rabies post exposure prophylaxis (treatment) 
based upon nationally accepted guidance.  However, the decision of whether to administer 
post exposure prophylaxis (treatment) should be made on a case by case basis by the patient 
and their health care provider.  
 IDPH is available for rabies consultation: call 800-362-2736 during business hours and 515-
323-4360 after hours (Iowa State Patrol will contact the IDPH person on call).     
 
1)  Patient reports finding bats in their home on multiple occasions.  
 Assess the risk of exposure and treat accordingly.  Refer to the “Rabies Exposure 
Management for Bat-related Incidents Flowchart” available on the rabies page of the 
IDPH website.  www.idph.state.ia.us/Rabies/Resources.aspx  
 Recommend bat proofing the home 
o Iowa DNR licenses nuisance wildlife control operators.  Some of these 
operators specialize in bat proofing.  Link to licensed operators: 
www.iowadnr.gov/Hunting/LandownerAssistance/NuisanceWildlifeControl.asp
x  
 If bat proofing is not effective, pre-exposure vaccination could be considered.  
Ensure that patients understand even with pre-exposure vaccination, if they are 
exposed to a potentially rabid animal they will need 2 booster vaccinations (on days 
0 and 3). 
 
2)  Patient has recently completed the rabies post exposure prophylaxis (treatment) 
series and was re-exposed to a potentially rabid animal.    
 After determining that the person was exposed, administer 2 booster vaccinations on 
day 0 and day 3.  (Do not administer Rabies Immunoglobulin) 
 If the patient experiences multiple re-exposures, indicating multiple series of 
boosters in a relatively short amount of time, contact IDPH for consultation.  
 
3)  Patient is pregnant and was exposed to a potentially rabid animal. 
 Because of the potential consequences of inadequately treated rabies exposure, 
pregnancy is not considered a contraindication to post-exposure prophylaxis 
(treatment).  
 Several studies have shown no indication of increased incidence of abortion, 
premature births or fetal abnormalities associated with rabies vaccination.   
 Rabies exposure or diagnosis of rabies in the mother is not an indication for 
pregnancy termination.  
 If the risk of exposure to rabies is substantial, pre-exposure vaccination might also 
be indicated during pregnancy. 
 
4)  Patient was scratched by a potentially rabid cat. 
 Rabies is most commonly transmitted through a bite, but can also be transmitted via 
saliva and nervous tissue contact to an open wound or mucous membrane.  
 Nationally, there has been some concern over the risk associated with being 
scratched by potentially rabid cats (because cats commonly lick their claws).  
However, there has not been any definitive national guidance released on this issue, 
and IDPH is not aware of any documented cases of transmission via an animal 
scratch.  
 Therefore, IDPH does not generally recommend post exposure prophylaxis 
(treatment) based upon scratch exposure alone.    
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5)  Patient woke up to find a bat in the next room or elsewhere in the home.   
 Recommendations state that if a bat is found in the same room as a sleeping person, 
small child, or incapacitated person it should be tested.  If the bat is not available for 
testing it should be assumed positive and post exposure prophylaxis (treatment) 
should be considered.  If a bat is found elsewhere in the home, post exposure 
prophylaxis (treatment) is generally not recommended by IDPH.   
 
6)  An immunosuppressed patient was exposed to a potentially rabid animal. 
 Corticosteroids, other immunosuppressive agents, anti-malarials, and 
immunosuppressive illnesses can interfere with the development of active immunity 
after post-exposure prophylaxis (treatment).  Immunosuppressive agents should not 
be administered during post-exposure prophylaxis (treatment) unless essential for 
the treatment of other conditions.  When post-exposure prophylaxis (treatment) is 
administered to an immunosuppressed person, it is especially important that a serum 
sample be tested for rabies antibody to ensure that an acceptable antibody response 
has developed.   
 Patients who are immunosuppressed by disease or medications should postpone pre-
exposure vaccinations and consider avoiding activities for which rabies pre-exposure 
prophylaxis is indicated. When this course is not possible, immunosuppressed 
persons who are at risk for rabies should be vaccinated and their antibody titers 
checked.  
7) A patient with a history of hypersensitivity to components of the rabies vaccine 
was exposed to a potentially rabid animal.  
 When a person with a history of serious hypersensitivity to rabies vaccine must be 
revaccinated, antihistamines can be administered. Epinephrine should be readily 
available to counteract anaphylactic reactions, and the person should be observed 
carefully immediately after vaccination. 
8)  A patient was bitten by a domestic animal, who is responsible for implementing 
the animal quarantine?  
 Under Iowa Code Chapter 351.39, Local Boards of Health are responsible for 
collecting human exposure reports and enforcing animal confinement or testing.  In 
most jurisdictions, this function is fulfilled by local animal control, local public or 
environmental health, or the sheriff’s departments.  Please contact your local officials 
for clarification.   
 
9)  The patient has submitted the potentially rabid animal for rabies testing.  Can 
post exposure prophylaxis (treatment) be delayed pending test results? 
 In general, yes, if the animal is available to test administration of post exposure 
prophylaxis (treatment) should be delayed pending results.  If the test results are 
positive, indeterminate, or unsuitable, post exposure prophylaxis (treatment) should 
be administered immediately.  (Consult with IDPH if exposure is above the shoulders, 
severe or unusual, or if there is a delay in testing of animal.) 
 
10)  The patient received pre exposure vaccination prior to 1980 or has previously 
received post exposure prophylaxis (treatment) that varied from the current protocol.  
What is the recommended protocol for post exposure prophylaxis (treatment) for this 
exposure?  
 If the exposed patient received pre exposure vaccination with a product that is not 
currently approved and has never had their titer checked, it is recommended that the 
patient receive the entire post exposure prophylaxis (treatment) protocol (RIG + the 
4 or 5 dose vaccination series).  
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o In general, patients who received pre exposure vaccination after 1980 should 
have received a currently approved product.  
 Approved products include: Human Diploid Cell Vaccine, Rabies 
Vaccine Adsorbed (fetal rhesus lung diploid cell culture), and Purified 
Chick Embryo Cell Vaccine.   
 The current post exposure (treatment) prophylaxis protocol includes administration 
of RIG + the 4 or 5 dose vaccination series.  If the exposed patient has not received 
the current RIG + the 4 or 5 dose vaccination series in the past, the entire currently 
approved (RIG + the 4 or 5 dose vaccination series) protocol should be administered.    
 IDPH is available for rabies consultation: call 800-362-2736 during business hours 
and 515-323-4360 after hours (Iowa State Patrol will contact the IDPH person on 
call).     
 
11)  If the patient was bitten above the shoulders, should post exposure (treatment) 
prophylaxis be delayed pending observation or laboratory testing?  
 If the patient was bitten above the shoulders, the health care provider should 
consider initiating the appropriate post exposure (treatment) immediately.  
 The closer the point of exposure is to the brain, the shorter the distance in which the 
virus must travel, therefore potentially resulting in a shorter disease incubation 
period. 
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Rabies (human)               Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider title: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes   No  Unk To whom: ______________  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Result date: 
 
     /     /      
 
Result type: 
 
 Preliminary      Final 
 
Test type: 
 
      Result: 
 Positive 
 Negative    
 
Organism: 
 
Rabies virus Animal species: 
 
        
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Result date: 
 
     /     /      
 
Result type: 
 
 Preliminary      Final 
 
Test type: 
 
      Result: 
 Positive 
 Negative    
 
Organism: 
 
Rabies virus       Animal species: 
 
        
 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Result date: 
 
     /     /      
 
Result type: 
 
 Preliminary      Final 
 
Test type: 
 
      Result: 
 Positive 
 Negative    
 
Organism: 
 
Rabies virus       Animal species: 
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OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
Fever: 
 
 Yes   No    Unk Onset date: 
 
     /     /      
 
Duration: 
 
      Hours/Days Highest known fever: 
 
      C/F 
        
Other 
symptoms: 
Agitation 
Aversion to 
airflow on face 
Aversion to 
water 
Coma 
Delirium 
 
 Yes   No    Unk 
 Yes   No    Unk 
 
 Yes   No    Unk 
 
 Yes   No    Unk 
 Yes   No    Unk 
 
Encephalitis 
Excitability 
Fever 
Headache 
Malaise 
 
 Yes   No    Unk 
 Yes   No    Unk 
 Yes   No    Unk 
 Yes   No    Unk 
 Yes   No    Unk 
 
 
Muscle 
weakness 
Paralysis 
Seizures 
Sensory 
changes 
Trouble 
swallowing 
 
 
 Yes   No    Unk 
 
 Yes   No    Unk 
 Yes   No    Unk 
 Yes   No    Unk 
 
 Yes   No    Unk 
Bite 
present: 
 Yes   No    Unk Bite location: Neck/head 
Upper extremity 
Trunk 
Lower extremity 
 Yes   No    Unk 
 Yes   No    Unk 
 Yes   No    Unk 
 Yes   No    Unk 
Site cleaned 
at time of 
event: 
 
 Yes   No    Unk 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
 
TREATMENT 
 
 Pre-exposure vaccination 
 
Vaccinated for rabies:  Yes    No    Unknown    
  
Date vaccinated: 
 
     /     /      
  
Date vaccinated: 
 
     /     /      
  
Date vaccinated: 
 
     /     /      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
         
  
Date vaccinated: 
 
     /     /      
  
Date vaccinated: 
 
     /     /      
  
Date vaccinated: 
 
     /     /      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
 
Number of vaccinations:       
 
Post-exposure treatment 
 
Rabies Immune Globulin:   Yes    No    Unknown      
Date given:       
Dose:       Unit:       
Route:       
 
Vaccinated for this exposure:  Yes    No    Unknown 
  
Date vaccinated: 
 
     /     /      
  
Date vaccinated: 
 
     /     /      
  
Date vaccinated: 
 
     /     /      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
         
  
Date vaccinated: 
 
     /     /      
  
Date vaccinated: 
 
     /     /      
  
Date vaccinated: 
 
     /     /      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
 
Therapeutic medication prescribed:  Yes    No    Unk List medications:  
   
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Risks 8 weeks prior to onset of symptoms: 
Traveled within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation period for 
rabies is 3 to 8 weeks. 
Rabies is communicable in people 3-7 days 
before the onset of symptoms through the 
duration of illness. Communicability in 
animals varies by animal.   
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Animal contact:  Yes    No    Unknown    
Animal:         Bats 
Beavers 
Cats 
Cattle 
Coyote 
Dogs 
 Yes  No  Unknown 
 Yes  No  Unknown 
 Yes  No  Unknown 
 Yes  No  Unknown 
 Yes  No  Unknown 
 Yes  No  Unknown 
Goats 
Horses 
Pigs 
Raccoon 
Sheep 
Skunk 
 Yes  No  Unknown 
 Yes  No  Unknown 
 Yes  No  Unknown 
 Yes  No  Unknown 
 Yes  No  Unknown 
 Yes  No  Unknown 
Animal type:   Domestic 
Stray 
Wild 
Unknown 
 Yes   No    Unk 
 Yes   No    Unk 
 Yes   No    Unk 
 Yes   No    Unk 
Animal breed: 
 Animal 
description: 
 
     
Exposure type: 
Bat in house 
Bat in sleeping area 
Bat or animal bite 
 Yes   No    Unk 
 Yes   No    Unk 
 Yes   No    Unk 
Contact with saliva 
Scratch 
Unknown 
 Yes   No    Unk 
 Yes   No    Unk 
 Yes   No    Unk 
     
Date exposure 
occurred:      /     /      
Animal vaccination 
status: 
 Unvaccinated 
 Vaccinated 
 Vaccine not current 
 Unknown 
Animal 
vaccination date:      /     /      Was bite provoked:  Yes   No    Unk 
 
 
Exposure site information 
Address:       
Animal disposition                  
 Lost to follow-up 
Deceased and sent for testing 
Deceased and NOT sent for testing 
Ill and under quarantine 
Ill and NOT under quarantine 
Healthy and under quarantine 
Healthy after 10 days of quarantine 
 Yes No  Unk 
 Yes No  Unk 
 Yes No  Unk 
 Yes No  Unk 
 Yes No  Unk 
 Yes No  Unk 
 Yes No  Unk 
City:       State:       
Zip:       County:       
Phone:       Type:       
 
Animal Owner known:  Yes    No    Unknown  
Animal control name/veterinarian:       Animal quarantine site information 
Facility 
name:       
Address:       Address:       
City:       State:       City:       State:       
Zip:       County:       Zip:       County:       
Phone: 
 
(     )-     -      Type:       Phone: 
 
(     )-     -      Type:       
 
 
Contacts with the same exposures?      Yes    No    Unknown 
 
Contacts with the same exposures as the case or exposures to the case (while case was symptomatic) 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
 
NOTES:       
 
 
CONTACTS 
Center for Acute Disease Epidemiology                                                  Fax: 515-281-5698   Rabies      Revised Mar-15               4   
PRE-EXPOSURE VACCINATION AND  
POST-EXPOSURE PROPHYLAXIS 
(TREATMENT) PROTOCOLS: 
 
Pre-exposure Vaccination:  
 
 
Three 1.0-mL injections of vaccine IM on days 0, 
7, and 21 or 28 
(1.0-mL dose is standard for all patients) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*These recommendations are taken from the 
CDC Human Rabies Prevention, MMWR. This 
document is accessible on the IDPH website: 
www.idph.state.ia.us/Rabies/Resources.aspx   
 
 
Post-exposure Prophylaxis:  
(treatment) 
 
 Wound Cleaning: immediately cleanse with 
soap and water.  Use a virucidal agent such as 
povidone- iodine solution to irrigate the 
wound.  
 
 Patients who HAVE NOT received Pre-
exposure vaccination or a previous 
course of Post-exposure Prophylaxis 
(treatment):  
 Rabies Immunoglobulin: 
20IU/kg body weight.  If possible 
the full dose should be infiltrated 
around the wound and any 
remaining volume should be 
administered IM at a site distant 
from the vaccine administration.  
 Vaccine:  
o Immune competent 
patients: Four 1.0-mL 
injections of vaccine IM on 
days 0, 3, 7, and 14. (1.0-
mL dose is standard for all 
patients) 
o Immune suppressed 
patients:  Five  1.0-mL 
injections of vaccine IM on 
days 0, 3, 7, 14, and 28. A 
titer check should also be 
performed between days 42 
and 56. 
 Patients who HAVE received Pre-
exposure vaccination or a previous 
course of Post-exposure Prophylaxis 
(treatment) according to the currently 
accepted protocols:  
  Vaccine ONLY: two 1.0-mL 
injections of vaccine IM on days 0, 3 
Iowa Dept. of Public Health Reviewed 12/13 Rabies Pre-Exposure Vaccination and Post-Exposure Prophylaxis Protocols  
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 I.  Background on Rabies, also known as Hydrophobia or Lyssa 
(Source: IDPH Epi Manual) 
 
THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
The virus that causes rabies is a rhabdovirus of the genus Lyssavirus. 
 
B. Clinical Description 
Animal Rabies 
Rabies is primarily a disease of the central nervous system. Animals with rabies can appear normal, 
meek (“dumb rabies”), or may be aggressive (“furious rabies”). Animals with furious rabies often 
exhibit aggressive or unusually excited behavior; they may excessively salivate and attack other 
animals or humans. Dumb rabies may be more difficult to detect; animals may seem tame, wounded, 
or dazed. These animals have been described as acting disoriented or suffering from some paralysis, 
for example dogs may present with paralysis of the lower jaw and their tongue may be hanging out.  
While these behaviors are commonly reported, an animal’s behavior alone is not a reliable indicator 
of whether it has rabies.  Rabies should be considered in mammals with signs or symptoms of 
encephalitis or myelitis, including autonomic instability, dysphagia, hydrophobia, paresis, and 
paresthesia. 
 
Human Rabies 
Rabies is a fatal infection, which usually progresses over 2 – 21 days.  A prodromal phase, lasting 2 – 
10 days, is characterized by pain and numbness/tingling at the site of the bite (present in 50% – 80% 
of cases), and nonspecific complaints such as fatigue, headache and fever. Behavioral changes may 
also be apparent, including apprehension, anxiety, agitation, irritability, insomnia and depression.  
The prodromal phase is quickly followed by the neurologic phase, during which the patient may suffer 
disorientation and hallucinations; paralysis; episodes of terror and excitement; hydrophobia; 
hyperventilation; hypersalivation; and seizures. These symptoms are invariably followed by coma and 
death. Once symptoms have begun, the illness is almost always fatal. 
 
Rabies should be considered in patients with signs or symptoms of encephalitis or myelitis, including 
autonomic instability, dysphagia, hydrophobia, paresis, and paresthesia, particularly if a nonspecific 
prodrome preceded the onset of these signs by three to four days. Progressive worsening of 
neurologic signs is characteristic of rabies and should be considered as a positive indicator for rabies. 
Laboratory tests to rule out common encephalitides (herpes, enteroviruses, arboviruses) should be 
performed. Negative results of these tests would increase the likelihood of rabies as the diagnosis. If 
a patient presents with symptoms similar to the ones described above, but the neurologic status does 
not change and the illness continues for longer than three weeks, rabies is unlikely as the diagnosis. 
C. Reservoirs 
All species of mammals are susceptible to rabies infection.   
 
D. Modes of Transmission 
Rabies is spread via the virus-laden saliva of an infected animal through a bite or saliva contact with 
mucous membranes or a fresh break in the skin. Breaks in the skin or mucous membrane exposure to 
nervous tissue (brain, spinal cord) of an infected animal also pose a transmission threat. Bites of some 
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 animals, such as bats, can inflict injury so minor that it goes undetected.  Airborne spread (for 
example, in a cave with many bats, or in a laboratory through rabies virus or specimens) has 
occurred.  Rabies is not transmitted through contact with blood, urine, skunk spray, or feces of an 
infected animal. 
 
Person-to-person spread has been documented after organs and corneas were transplanted from 
rabies infected individuals. Two nonlaboratory-confirmed cases of person-to-person rabies 
transmission in Ethiopia have been described.  The reported route of exposure in both cases was 
direct saliva contact (a bite and a kiss).   
 
E. Incubation period 
Animal Rabies 
Depending on the animal, the incubation period may vary from a few weeks to a few years, but is 
typically 1 - 3 months. Some animals, such as dogs and cats, have been studied extensively. The 
incubation period of their disease is commonly three to five weeks. 
 
Human Rabies 
The incubation period is usually 3 - 8 weeks, but can rarely range from as few as 9 days (although 9-
day incubation periods have not been documented in the U.S. with native strains) to as many as 7 
years. Less than 1 percent of human cases have an incubation period longer than 6 months. The 
incubation period is typically related to the site of exposure; e.g., the incubation period is usually 
shorter if the virus is inoculated closer to the central nervous system or in a highly innervated area. 
The incubation period also depends on exposure severity (more virus results in a shorter incubation 
period) and the age of the exposed person (younger age generally results in a shorter incubation 
period).   
 
F. Period of Communicability or Infectious Period 
Animal Rabies 
Animals are not infectious until virus is present in their saliva, which happens around the time of 
clinical onset of illness. Dogs, cats and ferrets may shed virus in their saliva for 3 – 7 days before the 
onset of clinical signs, and continue to shed virus until death. The shedding/communicability period 
for most wild animals has not been determined, although skunks may shed virus up to 18 days before 
death. Carcasses of animals with rabies may contain infectious virus, depending on temperature and 
environmental conditions. Rabies virus may persist in a frozen carcass for many weeks; drying and 
sunlight rapidly deactivate rabies virus. Dried saliva does not contain live rabies virus. 
 
Human Rabies 
The period during which a patient is potentially infectious may begin up to 1 week before symptom 
onset and last until death. Saliva is considered potentially infectious, as are cerebrospinal fluid and 
organs (although viral concentrations in humans are 3 – 4 times lower than in dogs).  
 
G.  Epidemiology 
Animal rabies 
Animal rabies exists in most parts of the world. In the United States, Hawaii is the only state that has 
never reported an indigenously-acquired rabies case in humans or animals. In the U.S., domestic 
species accounted for 7% of all rabid animals reported in 2008. The number of reported rabid 
domestic animals increased among cats and cattle and decreased among dogs, horses, sheep, and 
goats during 2008.   In 2008, cases of rabies in cats increased 12.2% compared with the number 
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 reported in 2007. The number of rabies cases reported in cats is routinely 3-4 times that of rabies 
reported in cattle or dogs. In 2008 approximately 1% of cats and 0.3% of dogs tested for rabies were 
found positive. 
      Human Rabies 
Worldwide an estimated 35,000–40,000 human rabies deaths occur each year. The vast majority of 
these deaths occur in developing countries. In the United States from 1995 through 2006, there 
were 37 human cases, of which 36 were fatal.  Four cases were the result of solid tissue organ 
transplantation; 28 cases were associated with bat variants; one was associated with the raccoon 
variant; and eight were associated with the canine variant. The most recent human cases of rabies in 
Iowa occurred in 1951 and 2002.   The 2002 case was caused by the bat strain of rabies virus.  
 
 
ASSESSING THE NEED FOR HUMAN POST-EXPOSURE PROPHYLAXIS (PEP) 
Assessing the need to provide post-exposure prophylaxis to humans exposed to animals suspected to 
have rabies should be determined by asking a series of questions.  Each question needs to be answered to 
determine if PEP needs to be initiated.  The questions to ask include:    
1) Is the animal species known to carry rabies?   
2) Did an actual exposure occur?  
3) Can the animal be tested or quarantined?  
 
Question 1.  Is the animal species known to carry rabies? 
Wild Animals:  
In wild animals the rabies risk varies by species: 
• High-risk animals are those that are known to commonly carry rabies.  In Iowa, these include 
skunks, bats, raccoons, foxes, and coyotes.  
• Medium-risk animals have very rarely been found to carry rabies in Iowa and may include 
large rodents such as beaver, muskrat, and woodchuck. 
• Low-risk animals are those that almost never carry rabies when they are demonstrating 
normal behavior.  These include small rodents, squirrels, opossum, and lagomorphs 
(rabbits).  If these species are acting abnormally you should consider them potentially rabid.  
 
Dogs, Cats, Ferrets, Horses and Livestock:  
Dogs, cats, ferrets, horses, and livestock periodically test positive for rabies each year in Iowa. 
 
Other Species:  
Contact CADE for consultation. Call 800-362-2736 during business hours or 515-323-4360 after hours.   
 
Question 1 Interpretation: 
If it has been determined that the animal involved is a potential carrier of rabies, the clinician should 
move to the second question. (Whether or not an animal has been vaccinated is immaterial to 
assessment because, though vaccination decreases the risk of the animal being rabid, it is not a 
guarantee.) 
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 Question 2.  Did an exposure actually occur? 
Rabies is primarily transmitted through saliva or neural tissue contact to open wounds (including 
through bites) or mucous membranes.  The virus will not cross intact skin.  Review the following lists 
to determine if a rabies exposure has occurred. 
 
Salivary exposures could include: 
• Bites 
• Saliva contact to mucous membranes 
• Saliva contamination of an open wound 
 
Non-salivary exposures could include: 
• Neural tissue contact to an open wound or mucous membrane (ie. if a person shoots an 
animal in the head and is splattered with brain material in eyes, nose, or mouth) 
• Organ transplants from patients who died of undiagnosed rabies infection 
• Exposure to large amounts of aerosolized rabies virus (e.g., explorers of caves colonized by 
rabid bats). 
 
Situations that are not considered rabies exposures and do not indicate PEP: 
• Petting a rabid animal 
• Contact with blood, urine, scent of skunks, and feces 
 
Bats pose a unique problem. The bite of a bat can be so small that it may be undetected. In addition 
to the exposures listed above, review the following lists to determine if a rabies exposure has 
occurred. 
 
Additional situations that are also considered potential exposures include: 
• People that awaken from sleep to find a bat in the room they are sleeping in 
• A bat is found in a room with children or incapacitated individuals without supervision 
• If a person has direct physical contact with a bat and cannot definitely say they were not 
bitten (i.e. a bat flies into a person’s arm) 
 
A situation that is not considered an exposure includes: 
• People that are awake and find themselves in a room with a bat and can state that they 
were not bitten by the bat 
 
 
Question 2 Interpretation: 
If it has been determined that a potential exposure occurred, the clinician should move to the third 
question to determine if the animal involved can be tested or quarantined.  
 
Question 3.  Can the animal be tested or quarantined?   
Bats 
If available, the bat should be tested for rabies.  If the bat is unavailable for testing, PEP is 
recommended. 
 
 Wild Animals 
High risk animals should be euthanized and submitted for rabies testing. In cases in which the animals 
are unavailable for testing, they should be assumed rabid and PEP is recommended.  
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All medium-risk animals and any low-risk animal behaving abnormally.  If the animal is available, it 
should be submitted for testing.  If the animal is not available, PEP should be considered and the 
exposed person should consult with their personal physician to make the determination.      
 
Dogs, Cats or Ferrets 
Dogs, cats and ferrets that have bitten or exposed a human to their saliva and appear healthy may be 
quarantined for 10 days in lieu of euthanasia and testing. If at any time during the quarantine period, 
a dog, cat, or ferret shows signs of rabies, the animal should be immediately euthanized and tested.   
 
Dogs, cats and ferrets that are incubating rabies will begin to exhibit signs of the disease very soon 
after they begin shedding virus in saliva. If an animal remains healthy during the 10-day quarantine, it 
could not have been shedding rabies virus in its saliva at the time of the bite or saliva exposure.  This 
does not guarantee that the animal is not incubating rabies; it only indicates that the animal was not 
infectious at the time in which the human was exposed.   
 
A dog, cat, or ferret that is not available for observation or testing should be considered potentially 
rabid and PEP is recommended.  If capture of the dog, cat, or ferret is likely in the near future, 
prophylaxis may be delayed up to 72 hours.  If the animal is not located within 72 hours PEP should 
be initiated.   
 
Other Animal Species 
For exposure to other animal species, recommendations are made on a case-by-case basis. Contact 
IDPH for consultation.  
 
HUMAN POST-EXPOSURE PROPHYLAXIS PROTOCOL  
Severe Bites above the Shoulder  
If a patient is bitten above the shoulder, IDPH recommends starting PEP immediately.  The closer the 
point of exposure is to the brain, the shorter the distance in which the virus must travel, therefore 
potentially resulting in a shorter disease incubation period.  
 
If the animal subsequently tests negative for rabies, or if the animal is quarantined and is healthy at 
the end of 10 days (quarantines can only be conducted in dogs, cats, and ferrets) Post Exposure 
Prophylaxis can be discontinued at that time.  If Post Exposure Prophylaxis is discontinued before the 
series is completed and the patient is exposed again in the future, the entire Post Exposure 
Prophylaxis series should be administered.  If the Post Exposure Prophylaxis series is completed and 
the patient is exposed again in the future, only two doses of rabies vaccine on days 0 and 3 should be 
administered.   
 
Human Post Exposure Prophylaxis  
·         Immediately and thoroughly wash all bite wounds and scratches with soap and water.  Simple   
wound cleaning has been shown to markedly reduce the risk of rabies.   
·         Tetanus prophylaxis should be considered  
·         Risk of bacterial infections should be assessed and addressed. 
 
1. Treatment of persons who have not previously received rabies vaccine or have not 
previously received rabies post-exposure treatment. 
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 a.     Immunocompetent patients: 
·         Four 1-mL vaccine doses of HDCV or PCECV should be administered 
intramuscularly to previously unvaccinated persons as soon as possible after 
exposure on days 0, 3, 7, and 14 (day 0 is the day the post exposure prophylaxis 
is started).   
·         One dose of rabies immunoglobulin (HRIG), 20 IU/kg, should also be 
administered on day 0. 
o    If anatomically feasible, the full dose of HRIG should be thoroughly 
infiltrated in the area around the wound. The rest should be 
administered intramuscularly at a different site than the vaccine.  
o    If HRIG is not given with the first post-exposure dose of vaccine, it must 
be given within eight days after the first dose of vaccine.   
b.    Immunocompromised patients:  
·         Five 1-mL vaccine doses of HDCV or PCECV should be administered 
intramuscularly to previously unvaccinated persons as soon as possible after 
exposure on days 0, 3, 7, 14, and 28.   
·         One dose of rabies immunoglobulin (HRIG), 20 IU/kg, should also be 
administered on day 0. 
o    If anatomically feasible, the full dose of HRIG should be thoroughly 
infiltrated in the area around the wound. The rest should be 
administered intramuscularly at a different site than the vaccine.  
o    If HRIG is not given with the first post-exposure dose of vaccine, it must 
be given within eight days after the first dose of vaccine.   
 
How is immunocompromised defined in terms of rabies vaccination?  
The decision of whether individuals are immunocompromised should be determined by 
a physician. However, to assist with this determination, persons with the below 
conditions may need to receive five doses of rabies vaccine (consult with their 
healthcare provider).  
 
A.    Persons with  immunocompromising conditions or on specific medications (non-
HIV) 
                                         Examples include but are not limited to:  
1) Congenital immunodeficiency 
2) Leukemia 
3) Lymphoma 
4) Generalized malignancy  
5) Therapy with alkylating agents, antimetabolites, radiation, or large 
amounts of corticosteroids.  
6) Antimalarial medications 
 
B.     Persons with HIV infection 
 Both symptomatic and asymptomatic patients with HIV infection  
  
C.    Persons with conditions that cause limited immune deficits  
                                       Examples include but are not limited to:  
1) Renal 
failure 
2) Diabetes 
(uncontrolled) 
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 3) Alcoholi
c cirrhosis 
4) Asplenia  
 
When rabies pre- or postexposure prophylaxis is administered to an immunosuppressed 
person, one or more serum samples should be tested 1—2 weeks after vaccination for rabies 
virus-neutralizing antibody by the RFFIT test to ensure that an acceptable antibody response 
has developed after completing the series.   
 
If no acceptable antibody response (complete neutralization of virus at a 1:5 serum dilution 
is considered acceptable) is detected after the final dose in the pre- or postexposure 
prophylaxis series, the patient should be managed in consultation with their physician and 
appropriate public health officials. 
 
2.     Treatment of persons who have either received pre-exposure vaccination or have previously 
received rabies post-exposure treatment (according to the current protocols and with 
approved products, if unsure contact CADE for consultation): 
a.     Two IM doses (1.0 ml each) of vaccine should be administered on days 0 and 3.  
Human Rabies Immune Globulin should NOT be administered.  
 
Exposure to a Human Potentially Infected with Rabies 
Contact isolation for respiratory secretions should be in place for persons suspected or 
confirmed to have rabies. Articles soiled with saliva should be disinfected. Attending personnel 
should be protected (gloves, gowns, face protection) against any exposure to saliva. If a patient 
who has rabies (or is suspected of having rabies) exposes another person to saliva (through a bite 
or via infectious material exposure to an open wound or mucous membrane), rabies PEP of the 
contact should be started. Other people from the patient’s home, social, and work environment 
should be contacted to review their potential exposure.   
 
Precautions and Contraindications to Rabies Prophylaxis 
For information on contraindications and precautions see the Human Rabies Prevention 
Recommendations of the Advisory Committee on Immunization Practices available on the CDC 
Web site: http://www.cdc.gov/mmwr/PDF/rr/rr5703.pdf . 
 
 
RECOMMENDATIONS FOR DOMESTIC ANIMALS EXPOSED TO RABID OR 
POTENTIALLY RABID ANIMALS 
This section refers to any animal exposed to a confirmed or suspected rabid animal. Wild mammalian 
carnivores or bats that are not available or suitable for testing should be regarded as rabid animals. 
 
Dogs, Cats, or Ferrets 
Unvaccinated dogs, cats, and ferrets exposed to a rabid animal should be euthanized 
immediately. If the owner is unwilling to have this done, the animal should be placed in strict 
isolation for 6 months. Isolation in this context refers to confinement in an enclosure that 
precludes direct contact with people and other animals. Rabies vaccine should be administered 
upon entry into isolation or 1 month prior to release to comply with pre-exposure vaccination 
recommendations.  Animals overdue for a booster vaccination should be considered 
unvaccinated.  
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There are currently no USDA licensed biologics for post-exposure prophylaxis of previously 
unvaccinated domestic animals, and there is evidence that the use of vaccine alone will not 
reliably prevent the disease in these animals.  
 
Dogs, cats, and ferrets that are currently vaccinated should be revaccinated immediately, kept 
under the owner’s control, and observed for 45 days. Any illness in an isolated or confined 
animal should be reported immediately to the local health department. If signs suggestive of 
rabies develop, the animal should be euthanized and the head shipped for testing. 
 
Livestock 
All species of livestock are susceptible to rabies; cattle and horses are the most frequently 
reported infected species.  
 
Livestock exposed to a rabid animal and currently vaccinated with a vaccine approved by USDA 
for that species should be revaccinated immediately and observed for 45 days.  
 
Unvaccinated livestock should be euthanized immediately. If the animal is not euthanized it 
should be kept under close observation for 6 months. Any illness in an animal under observation 
should be reported immediately to the local health department and veterinarian. If signs 
suggestive of rabies develop, the animal should be humanely euthanized and the head removed 
by a licensed veterinarian and shipped for testing. 
 
Multiple rabid animals in a herd or herbivore-to-herbivore transmission are uncommon; 
therefore, restricting the rest of the herd if a single animal has been exposed to or infected by 
rabies is usually not necessary. 
 
Handling and consumption of tissues from exposed animals may carry a risk for rabies 
transmission. Risk factors depend in part on the site(s) of exposure, amount of virus present, 
severity of wounds, and whether sufficient contaminated tissue has been excised. If an exposed 
animal is to be slaughtered for consumption, it should be done immediately after exposure and 
all tissues should be cooked thoroughly. Persons handling exposed animals, carcasses, and 
tissues should use barrier precautions. Historically, federal guidelines for meat inspectors 
required that any animal known to have been exposed to rabies within 8 months be rejected for 
slaughter. USDA Food and Inspection Service (FSIS) meat inspectors should be notified if such 
exposures occur in food animals prior to slaughter. 
 
Rabies virus may be widely distributed in tissues of infected animals. Tissues and products from a 
rabid animal should not be used for human or animal consumption. Pasteurization temperatures 
will inactivate rabies virus, therefore, inadvertently drinking pasteurized milk or eating 
thoroughly cooked animal products does not constitute a rabies exposure.  
 
Other Animals 
Other mammals exposed to a rabid animal should be euthanized immediately. Animals 
maintained in USDA-licensed research facilities or accredited zoological parks should be 
evaluated on a case-by-case basis. 
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 Source: The Compendium of Animal Rabies Prevention and Control, 2008 National Association of 
State Public Health Veterinarians, Inc. (NASPHV) 
http://www.nasphv.org/documentsCompendia.html  
 
PREVENTIVE MEASURES 
Environmental Measures 
Human rabies control relies on controlling rabies in the animal population, therefore animal 
quarantine regulations and vaccination laws should be enforced.  In Iowa, all dogs over 6 months of 
age are required to be vaccinated against rabies by a licensed veterinarian.  The state department of 
agriculture and land stewardship recognizes the standards set forth in the Compendium of Animal 
Rabies Prevention and Control Guidelines.   Currently, there are approved rabies vaccines for use in 
dogs and other animals that are as young as 3 months of age.  Rabies vaccination is strongly 
encouraged in all companion animals (including horses) and valuable livestock. 
 
Education  
Offer the following advice to the public to help prevent rabies: 
• Vaccinate pets; dogs are required by law to be vaccinated. Although not required by law, cat, 
ferret, horse and valuable livestock vaccinations are recommended.  
• Do not feed or handle wild or stray animals. Avoid sick animals or those that act strangely. 
• Do not touch or handle dead animals. 
• Contact local animal control officer with questions about the capture of an animal or 
handling of a carcass. 
• Cover garbage cans and keep pet food indoors, so wild animals are not attracted. 
• Do not keep wild animals as pets, which is often illegal as well as dangerous. 
• Never handle bats. A bat bite or scratch may be small and go unnoticed. People who awaken 
to find a bat in the room or children awake or asleep with a bat in a room may require PEP.  
• Recommend that travelers to developing countries with endemic rabies receive pre-
exposure prophylaxis if they will be visiting in situations where exposure is likely (e.g., 
camping, hiking, backpacking, or away from areas where treatment for a bite wound is 
available). Travelers should be warned to avoid petting or otherwise having contact with 
stray animals. 
 
Note: For more information about international travel and rabies, contact the CDC Traveler’s Health 
Office at (877) 394-8747 or via the internet at http://www.cdc.gov/travel 
 
HUMAN PRE-EXPOSURE VACCINATION  
Pre-exposure vaccination is recommended for persons in the following categories: 
• Veterinarians 
• Animal handlers 
• Laboratory workers who handle rabies virus 
• Persons living in or visiting countries where rabies is endemic 
• Others whose occupations or hobbies bring them into contact with potentially rabid animals  
 
Pre-Exposure Vaccination Protocol:  
Three 1.0 ml injections of vaccine given intramuscularly on each of days 0, 7, and 21 or 28.   
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NOTE:  Pre-exposure vaccination does NOT eliminate the need for prompt post-exposure 
prophylaxis.  If persons who have completed the pre-exposure vaccination series are 
subsequently exposed to rabies, the following protocol should be followed (as stated on page 7):  
 Two IM doses (1.0 ml each) of vaccine, on days 0 and 3.  Human Rabies 
Immune Globulin should NOT be administered.  
 
Monitoring Pre-Exposure Vaccination Titers:  
 
Persons who work with live rabies virus in research laboratories or vaccine production facilities 
and are under continuous risk of unapparent rabies virus exposure should have their serum 
rabies antibody titer measured every 6 months.  Acceptable antibody level is 1:5 titer by the 
rapid fluorescent focus inhibition test (RFFIT) technique. See the list of laboratories performing 
the serologic test below.  If the antibody level is less than 1:5, booster doses of vaccines should 
be administered to maintain a serum titer corresponding to at least complete neutralization at a 
1:5 serum dilution by RFFIT.    
 
Persons who frequently come in contact with potentially rabid animals, such as veterinarians, 
veterinary technicians, animals control officers, or wildlife officers, should have a serum sample 
tested for rabies antibody every 2 years.  If their antibody level is less than complete 
neutralization at a 1:5 serum dilution by the RFFIT, the person should receive a single booster 
dose of vaccine.   
 
Laboratories that perform the Rapid Fluorescent Focus Inhibition Test 
(the CDC recognized test for assessing human antibody levels) 
INTERPRETATION:  A titer of 1:5 is considered adequate. 
SHIPPING INFORMATION:  Please send the following information with your specimen: 
1. Address of person or institution responsible for receiving the 
results and billing information. 
2. Complete vaccination history if possible. 
3. All serum samples that are potentially pathogenic to humans 
should be labeled or marked with red tape or sticker. 
 
 SEND SAMPLES TO (any one of the following): 
    
K-State Rabies Laboratory 
Manhattan/K-State Innovation Center 
2005 Research Park Circle 
Manhattan, KS 66502 
Main telephone:  (785) 532-4483 
Fax:  (785) 532-4522 or (785) 532-4474 
Email: rabies@vet.k-state.edu 
Web address: http://www.vet.ksu.edu/rabies 
 
Atlanta Health Associates        
309 Pirkle Ferry Road, Suite D300     
Cumming, GA 30040      
(770) 205-9091 or (800) 717-5612 
FAX: (770) 204-9021 
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 Web address: http://www.atlantahealth.net/  
      
 
Auburn University College of Veterinary Medicine     
Note: Only animal specimens tested. 
Dept. of Pathobiology, Virology Lab 
261 Greene Hall        
Auburn University, AL 36849-5519   
(334) 844-2659  
Web address: 
http://www.vetmed.auburn.edu/uploads/6b/61/6b61faa8c3b81bcdc55ef2f6ffbd7ece/RFFITform_10_09.
pdf  
 
 
INDIGENT PATIENT PROGRAMS 
Patient assistance programs that provide medications to uninsured or underinsured patients are available 
for rabies vaccine and Immune globulin. 
Sanofi Pasteur’s Patient Assistance Program (providing Imogam ® Rabies-HT and Imovax ® Rabies as well 
as other vaccines) is now administered through the Franklin Group. A healthcare professional or patient 
can either contact the Franklin Group directly, or call the customer service team (1-800-VACCINE) who will 
transfer them to the Franklin Group. The Franklin Group will review the application against the eligibility 
criteria. For more information about the program or to request an application, please contact the Sanofi 
Pasteur, Inc. Patient Assistance Program (Franklin Group) at 1 (866) 801-5655. 
Novartis’ Patient Assiatance Program for RabAvert ® is managed through RX for Hope and can be accessed 
at 800-244-7668. Instructions and request forms are also available at the Rx for Hope website 
https://www.rxhope.com/PAP/info/PAPList.aspx?drugid=319&fieldType=drugid .
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 II.  Animal Rabies Testing Resources in Iowa 
There are two laboratories in Iowa that provide animal rabies testing services: University of Iowa 
Hygienic Laboratory and Iowa State University Veterinary Diagnostic Laboratory.  
 
University of Iowa Hygienic Laboratory (UHL):  
 
UHL is the designated state public health laboratory in Iowa.  UHL receives state funding enabling them 
to provide free testing services for diseases of public health concern.  Therefore, UHL will test potentially 
rabid animals that have exposed humans free of charge.  UHL does not provide testing for animal to 
animal exposures; therefore those samples should be submitted to Iowa State University Veterinary 
Diagnostic Laboratory.      
 
Iowa State University Veterinary Diagnostic Laboratory (ISU VDL):  
 
ISU VDL has historically provided animal rabies testing as a service to veterinarians who may be ruling 
out rabies as one of several differential diagnosis.   However, in recent years ISU VDL has received an 
increasing number of requests for rabies testing of domestic, livestock, and wildlife species where the 
submitter is only requesting rabies testing without additional diagnostics.  While ISU VDL is willing and 
able to provide that service to the public, healthcare, and veterinary communities, they do not receive 
any state or federal funding to support testing.  Therefore, ISU VDL must charge for the testing to cover 
their operating expenses.  ISU VDL will provide rabies testing for cases of animal and/or human 
exposure.   
 
Specimen Submission and Transportation:   
Specimen Preservation:  
 If the specimen will not be submitted for testing immediately, it should be refrigerated 
until transported or shipped.  
 DO NOT FREEZE THE SPECIMEN 
  
Specimen Transport:  
 Private vehicle is the fastest and preferred way to get the specimen to the laboratory.  
• Double bag the specimen 
• Place the specimen in a hard sided container, such as a Styrofoam cooler 
• Place ice packs around the double bagged specimen to keep it cool during 
transport 
• Include the appropriate Rabies Test Request Form from UHL or ISU 
• Call the appropriate laboratory before departure  
 Commercial courier service, such as FedEx, can also be used.  
• Double bag the specimen 
• Place the double bagged specimen in a hard sided container, such as a Styrofoam 
cooler.  
• Place ice packs around the double bagged specimen to keep it cool -DO NOT 
FREEZE.  
• Place the completed Rabies Test Request Form in a separate plastic bag to prevent 
it from becoming wet or contaminated. Place the bagged Rabies Test Request 
Form in the hard sided container. 
– Firmly secure the lid of the hard sided container.   
– Package (place in a box) the hard sided container and ship.   
– Ship via overnight courier. 
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NOTE: Improper packaging and/or delayed delivery may compromise the integrity of the brain material 
rendering the specimen unsatisfactory for testing. 
 
Specimen submission guidelines:  
 Large/medium animals- If only requesting rabies testing, a veterinarian needs to 
remove the head and only the head should be submitted for testing*.  
 Bats- Try not to crush the skull of the bat.  Submit the entire animal. 
 Small animals (mice, squirrels, etc): Submitting the entire animal is preferred.  
 
*If a veterinarian is requesting other diagnostics from ISU VDL all appropriate samples 
should also be included.  In some cases, this may mean that the entire animal should be 
submitted.   
 
Laboratory Contact Information:  
 
UHL:   
319-335-4500 or 800-421-4692 (answered all hours)    
 
ISU VDL:   
During business hours call 515-294-1950 – after hours call 515-290-1969    
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 III. Quarantine Authority and Enforcement   
 
Authority to mandate that an animal be placed in quarantine: 
(Dogs, cats, and ferrets are the only animals that can be quarantined according to national 
recommendations.) 
 
 State of Iowa Law:  
351.39 Confinement . 
If a local board of health receives information that an animal has bitten a person or that a dog or 
animal is suspected of having rabies, the board shall order the owner to confine such animal in the 
manner it directs.  If the owner fails to confine such animal in the manner directed, the animal shall be 
apprehended and impounded by such board, and after ten days the board may humanely destroy the 
animal.  If such animal is returned to its owner, the owner shall pay the cost of impoundment.  This 
section shall not apply if a police service dog or a horse used by a law enforcement agency and acting 
in the performance of its duties has bitten a person. 
[C66, 71, 73, 75, 77, 79, 81, §351.39] 
2001 Acts, ch 19, §1; 2001 Acts, ch 176, §68 
 
351.36  Enforcement. 
Local health and law enforcement officials shall enforce the provisions of sections 351.33 to 351.43 
relating to vaccination and impoundment of dogs.  Such public officials shall not be responsible for any 
accident or disease of a dog resulting from the enforcement of the provisions of said sections. 
[C66, 71, 73, 75, 77, 79, 81, §351.36] 
 
 
Quarantine Enforcement   
Several years ago, the Iowa Department of Public Health surveyed counties to get a better 
understanding of how they respond to potential rabies exposure cases.  While some counties had 
extremely detailed protocols for addressing rabies exposure situations, others did not.   
 
Most counties responded that animal bites were addressed by one the following entities:  
 Local public health 
 Local environmental health  
 County sheriff’s department 
 Local law enforcement 
 Local animal control  
 
In addition, most counties responded that depending upon the circumstances of the exposures, they 
may allow animal owners to conduct in-home quarantines but also mandate out-of-the-home 
quarantines as well.  Some of the factors they use to determine which type of quarantine to mandate 
include:  
 
In-Home Quarantine:  
 Animal’s rabies vaccinations are current 
 Owners are cooperative and seem trustworthy 
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  Owners have the ability to confine animal to the property to prevent escape or exposure to 
other humans or animals. Such as leash control or fenced yard.  
 
Many counties also have processes in place to follow-up with the owner at the end of 10 days:  
– Some counties require the owner to schedule a veterinary visit at the end of 10 days so that 
the veterinarian can verify that the animal is alive and is not showing symptoms that could 
be consistent with rabies.  
– In other counties, public health, environmental health, or law enforcement will visit the 
home to make sure the animal is still alive and is not showing clinical symptoms.  
– Several counties also indicated that they call the owner at the end of the 10 days to verify 
verbally that the animal is alive and not showing clinical signs. 
 
Out-of-the-Home Quarantine:  
 Not current on rabies vaccinations 
 Owners are not cooperative 
 Owners do not have the ability to satisfactorily confine the animal  
 
Most counties responded that when they mandate out-of-the-home quarantines, the animals 
are typically housed in one of the following: 
– A local animal shelter or humane society, with which the county holds a contract for service.   
– A local veterinary clinic, with which the county holds a contract for service.   
 
Most counties responded that expenses related to the quarantine and / or testing of owned animals 
were the responsibility of the animal owner.  Expenses accrued during the quarantine and / or testing of 
stray animals were the responsibility of the local board of health in most counties.   
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V.  Exposure flow charts (all mammals and bats) 
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VI.   Rabies Statistics 
 
ANIMAL RABIES IN IOWA:  
In 2009, 35 cases of animal rabies were reported in Iowa, which is a slight increase from 2008 (see Table 1 below). 
Rabies was identified most frequently in wildlife species including 13 skunks, 11 bats, and one squirrel. Five cases 
were diagnosed in domestic species including 3 cats and 2 dogs. Five cows tested positive. 
 
Table 1: Positive Rabies Cases 2001-2009 
Species 2001 2002 2003 2004 2005 2006 2007 2008 2009 Total
Bat 31 27 47 47 60 28 13 11 11 275
Skunk 28 27 38 28 33 13 5 7 13 192
Cat 10 7 8 11 5 7 7 9 3 67
Cow 10 12 3 10 7 4 0 1 5 52
Dog 2 3 6 3 2 2 5 1 2 26
Horse 3 2 3 0 1 3 1 0 0 13
Fox 1 0 0 1 0 0 0 0 0 2
Squirrel 0 0 0 0 0 0 0 0 1 1
Badger 0 0 1 0 0 0 0 0 0 1
Total 85 78 106 100 108 57 31 29 35 629  
 
As illustrated on the map below, cases were distributed across the state.  
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During 2009, 1694 animals in Iowa were tested for rabies and 35 were confirmed positive (2.07%). The percent 
positive varies greatly by species, see the Table 2 below. It is important to note that this data is greatly influenced 
by the number of animals tested. Many animals are tested because they exhibit unusual behavior or clinical signs 
making them more likely to be infected with the rabies virus. For these reasons, the percentages should not be 
considered representative of the true distribution of disease within the animal population in Iowa. 
 
Table 2: Percent Positive by Species in 2009 
Species Positive Total Tested  % Positive 
Dogs 2 369 0.54% 
Cows 5 86 5.81% 
Cats  3 444 0.68% 
Bat 11 558 1.97% 
Squirrel 1 17 5.88% 
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 Appendix 1:  
SAMPLE:  Rabies Exposure Investigation Protocol 
 
In County/City X potential rabies exposures of humans, including those reported by the general public, 
health care providers, or veterinarians should be referred to: 
   
 Agency/Name:   ___________________________ 
 Contact Information:   _____________                   _  
(For example: County Public Health/County Environmental Health/Sheriff’s Department/Local Animal Control) 
 
This entity serves as the primary point of contact for potential rabies exposures of humans. This primary 
point of contact will assess each potential rabies exposure individually.  If the animal which potentially 
exposed the human is a dog, cat, or ferret, the primary point of contact will determine whether the 
animal should be quarantined in accordance with the Compendium of Animal Rabies Prevention and 
Control, 2008. 
 
If it is determined that the animal should be quarantined, the primary point of contact will decide 
whether an in-home or out-of-the-home quarantine is most appropriate.  The decision will be based 
upon several factors, including but not limited to the following.    
In-Home Quarantines may be allowed under the following circumstances:  
 If the animal is current its rabies vaccinations 
 If the owners are cooperative and seem trustworthy 
 If the owners have the ability to confine animal to the property. 
 
Out-of-the-Home Quarantines may be required under the following circumstances:  
 If the animal is not current on rabies vaccinations 
 If the owners are not cooperative 
 If the owners do not have the ability to satisfactorily confine the animal  
 
At end of an in-home quarantine period, the primary point of contact will confirm that the animal is still 
alive and not showing symptoms of rabies infection by ______________________ (veterinary 
confirmation is recommended).  
 
County/City X has an agreement with X veterinary clinic/ humane society/shelter to provide out-of-the-
home quarantine services for stray and / or owned animals.   
 
It is the responsibility of the animal owner to pay for any fees associated with animal quarantines and/or 
testing.  
 
Expenses related to quarantine and/or testing of stray animals are the responsibility of 
__________________ .   
 
 
 
Last Updated 07-08-2010 24 
 SAMPLE: RABIES EXPOSURE REPORTING FORM 
REPORT:
Caller Name: _________________________________ 
Caller Phone Number:  ________________________ 
Completed by: ________________________________ 
Date of Report: ______________________
Relationship to Exposed Patient: _______________ 
PERSON EXPOSED:  
First Name: __________________________________ 
Last Name: ______________________________ 
Age: _____ Male:   Female:  
Street:  _________________________________ 
City: _____________________ State: _______ 
Zip: ___________ 
Home Phone: ______________________ 
Alternate Phone: _________________ 
Patient’s Physician: _______________________ 
Clinic/Hospital: __________________________ 
Phone: _________________________________ 
Is patient hospitalized? Y  / N  
Other information: __________________________ 
 
Guardian: _______________________________
DESCRIPTION OF EXPOSURE: 
Exposure date: ___________________Time: _________  
Street: ________________________________________ 
City: ___________________________________ 
County:_____________________ State: ________ 
Summary:__________________________________________
___________________________________ 
_______________________________________ 
______________________________________ 
Bite: Y  / N  
Bite Location: ______________________ 
Explain the Non-bite Exposure:_______________ 
__________________________________________________
____________________________ 
Were others exposed?  Y   / N  
 If yes, please list:_________________________ 
 
ANIMAL:  
Species: ____________________________ 
Wild   Stray  Owned  
If Applicable:  
Breed: ______________ 
Age: _________ Sex: _________ 
Current Rabies Vaccine: Y /N   
Animal Owner Name:______________________ 
Address: ______________________________________ 
City: ___________________________________ 
County: _____________________ State: _____ 
Owner Phone: ______________________ 
 
Owner’s Veterinarian: _____________________ 
Clinic Name: ___________________________________ 
Clinic Address: _________________________________ 
Clinic City: ___________County:___________________  
Clinic Phone: ____________________ 
  
Is the animal available for testing?  Y  / N  
Is animal available for observation? Y  / N  
Where is the animal now? ________________
 
RECOMMENDATIONS:  
Nothing- no exposure occurred   
 
Owner must confine animal in the home for 10 days (dogs, cats, 
ferrets only). If symptomatic euthanize and test, administer PEP 
based upon results  
 
Animal will be confined in the veterinary clinic/shelter for 10 days 
(dogs, cats, ferrets only).  If symptomatic euthanize and test, 
administer PEP based upon results   
Shelter/clinic name and location ____________________________ 
 
 
Euthanize animal and test immediately. Administer PEP based upon 
results   
 
Recommended patient consult their healthcare provider  
 
Bite above shoulders, give PEP immediately, discontinue if tests 
negative    
 
Recommended bat proofing  
 
Other: ___________________________________
Iowa Department of Public Health Rabies Consultation:  
800-362-2736 or 515-323-4360 after hours 
 
     
 
THIS REPORTING FORM CONTAINS CONFIDENTIAL INFORMATION 
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 SAMPLE: Veterinary Certification Form 
 
 
On (date), I examined the following animal.  Upon physical examination, the 
animal was not exhibiting clinical symptoms consistent with rabies virus 
infection.  
 
Animal Name:  ___________________________ 
Species:  ___________________________ 
Owners Name:  ___________________________ 
Address:   ___________________________ 
City/State/Zip:  ___________________________ 
Phone:   ___________________________ 
 
 
Veterinarians Name:  _____________________ 
Clinic Address:    _____________________ 
Phone:    _____________________ 
Signature:    _____________________ 
 
 
 
 
 
 
 
 
 
 
 
 
Template developed by the Iowa Department of Public Health  
and the Iowa Veterinary Medical Association 
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Appendix 2: Clarification of Rabies Revaccination Requirements 
(Source: Iowa Veterinary Medical Association Communiqué, Issued July, 2009) 
 
Iowa law requires all dogs over six months of age to have a current rabies vaccination with a USDA-approved 
rabies vaccine.  Canine rabies vaccination must be administered by a licensed veterinarian and the veterinarian is 
required to issue a tag and a certificate of vaccination.  The tag is required to be attached to the collar of the dog.  
Iowa law also adds this exception “dogs kept in kennels and not allowed to run at large shall not be subject to the 
vaccination requirement.” 
 
Iowa law does not require rabies vaccination for cats. Important note: Local county and city ordinances may 
require vaccinations for cats and other animals.  Local law takes precedence if it is more restrictive than state law.  
Rabies vaccination may be administered to cats, ferrets, livestock and other domestic animals for which there is an 
approved vaccine by non-veterinarians.  Only a licensed, accredited veterinarian can issue and sign a rabies 
certificate.   
 
Iowa law requires rabies vaccine frequency and procedure follow the recommendations from the Compendium of 
Animal Control prepared by the National Association of State Public Health Veterinarians. 
 
Rabies revaccination 
An initial rabies vaccine should be boostered in one year.  At that point, Iowa law follows the vaccine 
manufacturer’s recommendation for booster vaccination.  If a 3 year vaccine is administered, the vaccine should 
be boostered prior to the 3 year expiration date.  There are no studies available that indicate duration of immunity 
after administering a vaccination to a dog that has passed the three year expiration date.  Therefore, because 
rabies is a zoonotic disease and nearly 100% fatal when contracted by humans, Iowa Department of Agriculture 
rules require a booster vaccine in one year if the 3 year vaccine has expired.  The subsequent booster vaccine 
would expire in 3 years if a three year approved product is used.  It has come to the attention of the IVMA that our 
members are recommending a number of different protocols for rabies revaccinations in a dog that has an expired 
three year vaccination.  The IVMA recommends all veterinarians follow Iowa law and recommend a one year 
vaccination booster if an animals’ three year vaccine has expired.  Link to the Compendium for Animal Rabies 
Control: www.nasphv.org/Documents/RabiesCompendium.pdf  
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Appendix 3: Rabies Considerations with Animals in Public Settings 
Source: Compendium of Measures to Prevent Disease Associated with Animals in 
Public Settings, 2009 (Morbidity and Mortality Weekly Report, May 1, 2009/Vol. 58/ No. RR-5) 
 
Exposure to Rabies 
Certain venues encourage or permit the public to be in contact with animals, resulting in millions of human-animal 
interactions each year. These settings include county or state fairs, petting zoos, animal swap meets, pet stores, 
zoologic institutions, circuses, carnivals, educational farms, livestock birthing exhibits, educational exhibits at 
schools and child-care facilities, and wildlife photo opportunities. Although human-animal contact has many 
benefits, many human health problems are associated with these settings, including infectious diseases, exposure 
to rabies, and injuries.  Although no human rabies deaths caused by animal contact in public settings have been 
reported, multiple rabies exposures have occurred, requiring extensive public health investigations and medical 
follow-up. 
 
For example, thousands of persons have received rabies postexposure prophylaxis (PEP) after being exposed to 
rabid or potentially rabid animals, including bats, cats, goats, bears, sheep, horses, and dogs, at various venues: a 
pet store in New Hampshire, a county fair in New York State, petting zoos in Iowa, and Texas, school and rodeo 
events in Wyoming, a horse show in Tennessee, and summer camps in New York. Substantial public health and 
medical care challenges associated with potential mass rabies exposures include difficulty in identifying and 
contacting persons, correctly assessing exposure risks, and providing timely medical prophylaxis. Prompt 
assessment and treatment are critical to prevent this disease, which is usually fatal. 
 
Recommendations:  
Rabies: All animals should be housed to reduce potential exposure to wild animal rabies reservoirs. Mammals 
should also be up-to-date on rabies vaccinations. These steps are particularly critical in areas where rabies is 
endemic and in venues where animal contact is encouraged (e.g., petting zoos). Because of the extended 
incubation period for rabies, unvaccinated mammals should be vaccinated at least 1 month before they have 
contact with the public.  
 
If no licensed rabies vaccine exists for a particular species (e.g., goats, swine, llamas, and camels) that is used in a 
setting where public contact occurs, consultation with a veterinarian regarding off-label use of rabies vaccine is 
recommended. Use of off-label vaccine does not provide the same level of assurance as vaccine labeled for use in a 
particular species; however, off-label use of vaccine might provide protection for certain animals and thus 
decrease the probability of rabies transmission. Vaccinating slaughter-class animals before displaying them at fairs 
might not be feasible because of the vaccine withdrawal period that occurs as a result of antibiotics used as 
preservatives in certain vaccines. Mammals that are too young to be vaccinated should be used in exhibit settings 
only if additional restrictive measures are available to reduce risks (e.g., using only animals that were born to 
vaccinated mothers and housed to avoid rabies exposure). In animal contact settings, rabies testing should be 
considered for animals that die suddenly. 
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Guide to Surveillance, Investigation, and Reporting 
Rocky Mountain Spotted Fever 
 
Also known as: North American tick typhus, New World spotted fever, RMSF, Tick 
fever 
 
Responsibilities: 
Hospital: Report by IDSS, facsimile, mail, or phone 
Lab: Report by IDSS, facsimile, mail, or phone 
Physician: Report by facsimile, mail, or phone 
Local Public Health Agency (LPHA): Report by IDSS, facsimile, mail, or phone.  Follow-up 
required 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A.  Agent 
Rocky Mountain spotted fever (RMSF) is caused by the bacterium Rickettsia rickettsii. 
 
B.  Clinical Description 
Initial Symptoms include moderate to high fever, nausea, vomiting, significant malaise, muscle pain, 
severe headache, chills, and eye inflammation.  
 
Later Signs and Symptoms include rash, abdominal pain, joint pain, and diarrhea. Over half of cases 
develop a rash or small bruises on the arms and legs, which typically appears 3-5 days after the 
onset of illness. The rash spreads to the palms and soles, and then to much of the body. Among 
untreated individuals, these signs and symptoms typically persist for 2 - 3 weeks, and the case-
fatality rate ranges from 13% - 25%. The classic triad of findings for this disease is fever, rash, and 
history of tick bite, but this combination is often not present when the patient initially seeks care.    
 
Onset of RMSF is sudden. 
 
Complications: More advanced manifestations include decrease in red blood cells (anemia) and 
platelets (thrombocytopenia), severe clotting disorders, involvement of the major organ systems, and 
shock. Severe cases can result in long-term neurological illness. If the disease is promptly recognized 
and treated, death is uncommon. For the United States, the reported case-fatality rate for RMSF has 
been 3% - 5% in recent years.   
 
C.  Reservoirs 
The primary vector for RMSF is the tick, which also serves as a reservoir. Only members of the tick 
family Ixodidae (hard ticks) are naturally infected with Rickettsia rickettsii. Among ticks, R. rickettsii is 
spread through eggs, and between life stages. This species is maintained in nature by a complex 
cycle involving ticks and mammals; several small wild animals and dogs may develop antibodies to R. 
rickettsii, but their role as possible reservoirs in the maintenance of RMSF is uncertain. Humans are 
considered accidental hosts, and are not involved in the natural transmission cycle of this pathogen. 
 
D.  Modes of Transmission 
RMSF is acquired from a tick bite. Laboratory data suggest that the tick must remain attached for 
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4 - 6 hours before transmission of R. rickettsii to occur. Less commonly, infections may occur 
following exposure to crushed tick tissues, fluids, or tick feces when these fluids get into cuts or 
scratches.   
 
E.  Incubation Period 
Signs of RMSF typically develop one week after exposure (range 3 - 14 days). The length of the 
incubation period is associated with the magnitude of exposure to R. rickettsii. 
 
F.  Period of Communicability or Infectious Period 
RMSF is not communicable from person to person. 
 
G.  Epidemiology 
RMSF is a seasonal disease, occurring throughout the United States during the months of April 
through September, when the risk of contact with ticks is most likely. RMSF is uncommon in Iowa. 
The risk of mortality from RMSF is higher for men, people over the age of 40, non-whites, and 
individuals who do not develop (or recognize) the typical rash. Two-thirds of RMSF cases occur in 
children under the age of 15 years as they tend to spend more time in tick-infested areas. While rare, 
accidental transmission in the laboratory setting has been reported. 
 
The incidence of RMSF has increased during the last decade, from less than 2 cases per million 
persons in 2000 to over 8 cases per million persons 2008. During the same time period, the 
proportion of RMSF cases resulting in death (case fatality) has declined to a low of less than 0.5%. 
 
H. Bioterrorism Potential 
None 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A.  Purpose of Surveillance and Reporting 
• To identify where RMSF occurs in Iowa, and to recognize changes in disease incidence in the 
state. 
• To focus preventive education, and to target tick control measures. 
 
B.  Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report. After completing the investigation and gathering the information to complete the report 
form, enter the information into the Iowa Disease Surveillance System (IDSS), or FAX the report form 
with supporting laboratory documentation as follows: The reporting number for IDPH Center for 
Acute Disease Epidemiology (CADE) is (800) 362-2736; fax number (515) 281-5698, or mail (in an 
envelope marked “Confidential”) to IDPH/CADE mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
Des Moines, IA 50319-0075 
 
Laboratory Testing services Available  
The University of Iowa State Hygienic Laboratory (SHL) tests single serum samples for R. rickettsii 
utilizing Indirect Fluorescence Antibody tests.  Laboratory confirmation involves a single IFA 
serological titer of ≥1:64. The State Hygienic Laboratory will identify ticks potentially carrying R. 
rickettsii. For more information on either sera or tick specimen submission, call the SHL at (319) 335-
4500. 
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C.  Local Public Health Agency Follow-Up Responsibilities 
Case Investigation 
a. The LPHA is responsible for completing the case investigation form in IDSS by interviewing the 
case and others who may be able to provide pertinent information. Much of the information 
required on the form can be obtained from the case’s healthcare provider or the medical record. 
b. Use the following guidelines in completing the IDSS form: 
1) Accurately record demographic information, occupation, whether hospitalized (including 
location and associated dates), date of symptom onset, symptoms, laboratory information, 
treatment information, healthcare provider information, and disease outcome (e.g., 
recovered, died).  
2) Exposure history: Use the incubation period range for Rocky Mountain spotted fever (3-14 
days). Specifically, focus on the period beginning a minimum of 3 days prior to onset and 
ending no more than 14 days before onset for the following exposures: 
a) Determine if a tick bit the case. If yes, record information about the duration of tick 
attachment, date(s) and geographic location(s) where the bite occurred.  
b) Travel history: Determine the geographic area(s) visited by the case. 
3) If the patient was diagnosed at the same time with another tick-borne disease (such as 
Lyme disease, ehrlichiosis, or babesiosis) please refer to other chapters in this manual and 
complete the appropriate IDSS case report forms. 
4) If several unsuccessful attempts have been made to obtain case information (the case or 
healthcare provider does not return calls or respond to a letter, or the case refuses to 
divulge information or is too ill to be interviewed), complete the IDSS form with as much 
information as possible. Make notations in IDSS “Notes” why any information is incomplete. 
If unable to get information, in IDSS select the appropriate reason under the Event tab in 
the Event Exception field. 
 
If assistance is needed, contact CADE at (800) 362-2736; epidemiologists are available to 
answer questions about completing a case investigation.   
 
c. Institution of disease control measures is an integral part of case investigation. It is the LPHA 
responsibility to understand, and, if necessary, institute the control guidelines listed below in 
Section 3), Controlling Further Spread. 
 
3) CONTROLLING FURTHER SPREAD 
 
A.  Isolation and Quarantine Requirements 
None. 
 
B. Protection of Contacts of a Case 
None. 
 
C.  Managing Special Situations 
None. 
 
D.  Preventive Measures 
Environmental Measures 
Provide individuals the following information: Prevention of Rocky Mountain spotted fever involves 
making one’s property less attractive to ticks. 
• Remove leaf litter and brush from around the home. 
• Mow lawns regularly, and prune low-lying bushes to let in more sunlight. 
• Keep woodpiles in sunny areas off the ground. 
• If insecticides are used around the home, always follow the label instructions. Never use near 
streams or other bodies of water. 
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Personal Preventive Measures/Education 
The best preventive measure is to avoid tick-infested areas. In areas where contact with ticks may 
occur, individuals should be advised of the following: 
• Wear long-sleeved shirts and long, light-colored pants tucked into socks or boots to make it 
easier to see ticks crawling on your clothing, and to prevent ticks from crawling up the inside of 
the pants legs. 
• Stay on trails when walking or hiking. 
• Use insect repellants properly. Repellants that contain DEET (diethyltoluamide) should be used in 
concentrations no higher than 30% for children. Remember, repellants should never be used on 
infants. Permethrin is a repellant that can be applied only to clothing, not exposed skin.  
• After each day spent in a tick-infested area, thoroughly check yourself, children, and pets for 
ticks. Remove any tick found on the body.  Clothing should also be checked. 
• Promptly remove any attached tick using fine-point tweezers. The tick should not be squeezed or 
twisted, but grasped close to the skin and pulled straight out with steady pressure. Once 
removed, the tick should be drowned in rubbing alcohol or the toilet. 
 
4)  ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Rocky 
Mountain Spotted Fever can be found at:  
www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
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FACT SHEET    Rocky Mountain Spotted Fever 
 (RMSF, tick fever) 
 
What is Rocky Mountain spotted fever? 
Rocky Mountain spotted fever (RMSF) is a disease caused by a bacterium spread by ticks.  It is 
uncommon in Iowa.  Most people with RMSF become ill between April and September. 
 
Who gets RMSF? 
Anyone can get RMSF, especially people who spend a lot of time outdoors in areas where ticks are 
found. 
 
How is RMSF spread? 
RMSF is acquired from the bite of an infected tick. Less commonly, people become ill after 
crushing a tick with their hands, because its body fluids get into cuts or scratches.  RMSF cannot be 
spread from person to person. 
 
What are the symptoms of RMSF? 
RMSF usually causes a sudden high fever that may last 2 - 3 weeks if untreated. Fevers of 105-106o 
F are common.  Severe headache, rash, abdominal pain, joint pain, diarrhea, and muscle aches 
may also occur. 
 
How soon do symptoms appear? 
Symptoms typically develop 5 - 10 days after the tick bite.  Not everyone who is infected 
develops a rash. 
 
What is the treatment for RMSF? 
Antibiotics such as tetracycline, doxycycline or chloramphenicol are used to treat RMSF. 
 
Can a person get RMSF more than once? 
Probably not. 
 
How should a tick be removed? 
Any tick should be removed as soon as possible.  The best way is to use tweezers to grab the tick 
as close to the skin as possible and pull it straight out.  Do not squeeze the tick's body when 
removing it.  Do not handle ticks with bare hands.  Wash your hands after removing a tick.  Apply 
an antiseptic on the bite.   
 
How can RMSF be prevented? 
1. Do not walk bare-legged in tall grass or woods where ticks are found. 
2. Wear a long-sleeved shirt, long pants, and high socks.  Tuck pants legs into socks.  Wear 
light-colored clothing so crawling ticks can be seen more easily. 
3. Conduct "tick checks" every two or three hours if spending a lot of time outdoors.  Check 
all of your skin for ticks every day (you may need help to do this).  Ticks are most often 
found on the thighs, arms, underarms, and legs.  Parents should check children for ticks, 
especially in the hair, when returning from potentially tick-infested areas.  Ticks may be 
carried into the household on clothing and pets.  Both should be examined carefully. 
4. Use tick repellents containing DEET for skin applications (using a lower concentration on 
children, but applying more often) or permethrin (apply to clothing).  Always follow 
directions on the can.  Wash off all repellents after going indoors. 
       5.   Remove any attached ticks immediately, using the method above. 
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CONFIDENTIAL                                                                       Iowa Department of Public Health 
Rocky Mountain Spotted Fever 
        Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Long-term care     
resident:  Yes      No      Unknown        Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Facility name:       
Parent/Guardian 
name: 
 
      
Facility phone: (     )-     -        Type:        
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Onset 
date: 
 
     /     /      
Diagnosis 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider type: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes   No  Unk To whom: ______________  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
 
Result type: 
 
 Preliminary      Final 
 
Result date: 
 
     /     /      Result:  Positive    Negative   
Organism: Rickettsia rickettsii     
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
 
Result type: 
 
 Preliminary      Final 
 
Result date: 
 
     /     /      Result:  Positive    Negative   
Organism: Rickettsia rickettsii     
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
 
Result type: 
 
 Preliminary      Final 
 
Result date: 
 
     /     /      Result:  Positive    Negative   
Organism: Rickettsia rickettsii     
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OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties: 
Health care worker type: 
 Yes      No      Unknown 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties: 
Health care worker type: 
 Yes      No      Unknown 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
Fever:  Yes    No    Unk  Onset Date:       /     /      Duration (days):       
Highest 
known fever:       °F/C 
 
Other symptoms: 
 Anemia 
 Fatigue 
 Headache 
 Muscle pain 
 
 
 Nausea 
 Rash 
 vomiting 
Life threatening complications:  
 Adult respiratory distress syndrome 
 Disseminated intravascular coagulopathy 
 Meningitis/Encephalitis 
 Renal failure 
The following questions are relevant for Lyme disease only. 
Did the health care provider for the case diagnose Lyme disease?    Yes    No    Unk 
Erythema migrans 
diagnosed by 
physician 
present:  Yes    No    Unk Onset Date:       /     /      Lesion greater than or equal to 5 cm:  Yes   No  Unk 
 
Late 
manifestations: 
 
 2nd/3rd degree atrioventricular (AV) block 
 Bilateral facial palsy 
 Encephalitis/Encephalomyelitis 
 Cranial neuritis 
 
 Recurrent, brief attacks of joint swelling 
 Lymphocytic meningitis 
 Radiculoneuropathy 
 
OTHER LAB FINDINGS 
 
Higher antibody result in CSF 
than in serum:  Yes    No    Unknown Leukopenia:  Yes    No    Unknown 
Thrombocytopenia:  Yes    No    Unknown Elevated hepatic transaminases:  Yes    No    Unknown 
 
TREATMENT 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
 
Antibiotics prescribed?   Yes    No    Unknown 
 
  
Antibiotic:       
  
Antibiotic:       
 
 
Antibiotic:       
Date 
started:      /     /      
Date 
started:      /     /      
Date 
started:      /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 
 mg      ml     IU 
 
Unit: 
 
 mg      ml     IU 
 
Unit: 
 
 mg      ml     IU 
# of times a 
day:       Route:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
 
Therapeutic medications 
prescribed:  Yes    No    Unknown List medications: 
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Did the case spend time in a wooded, brushy, or grassy area within 14 days of the onset of symptoms? 
Location name: 
 
Address: 
 
 
  
City/State/County: 
 
Zip: 
  
Is Lyme disease endemic in this county?  Yes    No    Unk  
 
Location name: 
 
Address: 
 
 
  
City/State/County: 
 
Zip: 
  
Is Lyme disease endemic in this county?  Yes    No    Unk  
 
In the 14 days prior to onset of symptoms 
did the case find a tick on his/her body?  Yes    No    Unk Date found:  
 
     /     /      
 
NOTES:       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation period for 
RMSF is 3-14 days after 
tick exposure.  
RMSF is not directly 
transmitted person to person.  
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RUBELLA  
 
 
Also known as German Measles or Three-Day measles 
 
Responsibilities: 
Hospital: Report by IDSS, mail, facsimile or phone 
Lab: Report by IDSS, mail, facsimile, or phone 
Physician: Report by mail, facsimile, or phone 
Local Public Health Agency (LPHA): Report by IDSS, mail, facsimile or phone. 
Follow-up required. 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY   
 
A. Etiologic Agent 
Rubella is caused by rubella virus (genus Rubivirus, family Togaviridae). 
 
B. Clinical Description 
When contracted after birth, rubella is usually a mild disease characterized by a generalized 
maculopapular rash, swollen lymph nodes, and slight fever. Transient inflammation of the joints 
rarely occurs in children, but is common in adolescents and adults, especially women (up to 70%).  
Encephalitis occurs (1 per 5,000 cases, more frequently in women) and hemorrhagic manifestations 
(1 per 3,000 cases, more often in children) are rare complications. Up to 50% of infections occur 
without recognized rash. 
 
Rubella is of greatest danger to the fetus. Up to 90% of infants born to mothers infected in the first 
trimester will develop the physical anomalies referred to as congenital rubella syndrome (CRS).  CRS 
is characterized by complications, which include blindness, heart defects, deafness, behavioral 
disorders, mental retardation, growth retardation, bone disease, enlarged liver and spleen, 
thrombocytopenia, and purple skin lesions. Some effects may not be apparent at birth. 
 
Reinfection has been demonstrated on rare occasions, but only very rarely has resulted in CRS. 
 
Clinical Case Definition 
• Acute onset of generalized maculopapular rash 
• Temperature >37.2°C (99°F), if measured 
• Arthralgia/arthritis, or lymphadenopathy, or conjunctivitis 
• Serologic confirmation (IgM or 4-fold increase in IgG) 
Clinical diagnosis is UNRELIABLE. Serologic confirmation is critical. 
 
Case Classifications 
Suspected.  A case of any generalized rash illness of acute onset. 
 
Probable.   A case that meets the clinical case definition, has noncontributory or no serologic or 
virologic testing, and is not epidemiologically linked to a laboratory confirmed case. 
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Confirmed.  A case that is laboratory confirmed or that meets the clinical case definition and is 
epidemiologically linked to a laboratory confirmed case.  
 
C.  Reservoirs 
Humans are the only known host. 
 
D. Modes of Transmission 
Rubella is transmitted person-to-person by droplet or direct contact with the nasopharyngeal 
secretions of an infected person or with the nasopharyngeal secretions or urine of an infant with CRS. 
 
E. Incubation Period 
The incubation period is usually 14 -17 days, with a range of 14–21 days. 
 
F. Period of Communicability or Infectious Period 
The infectious period is usually from 7 days before to at least 4 days after rash onset. 
Infants with CRS shed virus in nasopharyngeal secretions and urine for a longer period; a small 
proportion of them continue to be infectious for 1 year or more.  
 
G. Epidemiology 
Rubella occurs worldwide. In the temperate zones, peak incidence is in late winter and early spring. 
Before the widespread use of rubella vaccine, which was licensed in 1969, peaks of rubella incidence 
occurred in the United States every 6–9 years, and most cases occurred in children. Now that 
children are well immunized, most cases have occurred in young, unvaccinated adults in college and 
occupational settings. Recent serologic surveys indicate that about 10% of young adults are 
susceptible to rubella. 
 
In recent years in the U.S. and Iowa, outbreaks have occurred among immigrant populations due to 
lack of rubella vaccination programs in their countries of origin.  Outbreaks occur predominately in 
workplaces and communities at large.  CRS disproportionately affects infants born to foreign-born 
women. The last case of Rubella reported in Iowa was in 2001. 
 
H. Bioterrorism Potential 
None. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of surveillance and reporting 
 
• To identify all cases and susceptible exposed people and to prevent further spread of 
infection, especially to pregnant women. 
• To ensure appropriate management of exposed pregnant women and their babies. 
• To monitor the effectiveness of outbreak control strategies. 
• To identify cases of congenital rubella infection or syndrome that may occur after a 
cluster or outbreak of rubella. 
 
B. Laboratory and Healthcare Provider Reporting Requirement 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report. The preferred method of reporting is by utilizing the Iowa Disease Surveillance 
System (IDSS).  However, if IDSS is not available to your facility the reporting number for IDPH 
Center for Acute Disease Epidemiology (CADE) is (800) 362-2736; fax number (515) 281-5698, 
mailing address: 
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IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
Des Moines, IA 50319-0075 
 
 
Postage-paid disease reporting forms are available free of charge from the IDPH clearinghouse.   
Call (319) 398-5133 or visit the website: 
healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295 to request a supply. 
 
What to Report to the Iowa Department of Public Health 
• A case of rash illness accompanied by fever, or 
• A suspect case of rubella (with or without fever), as diagnosed by a healthcare provider; or 
• Positive serologic test for rubella IgM; or 
• Significant rise between acute and convalescent phase titers in serum rubella IgG or total 
antibody level by any standard serologic assay; or 
• Isolation of rubella virus from a clinical specimen. 
• A suspect or confirmed case of congenital rubella syndrome (CRS) in a child (usually a 
baby), as diagnosed by a healthcare provider (the CRS case definition appears under 
“Additional Information” at the end of this chapter). 
 
Laboratory Services Available 
1. Serologic Testing for Non-Congenital Rubella 
• Rubella IgM test: False positive rubella IgM results can occur in persons with 
parvovirus infection, infectious mononucleosis, or rheumatologic disease.  IDPH 
recommends submission of specimens to the State Hygienic Laboratory (SHL) for testing. 
The specimen should be drawn NO earlier than 3 days after onset of rash, to minimize 
the possibility of false negative results.  It can be drawn as late as 6 weeks after the 
onset of the rash. (If serum is collected prior to the third day and tests are negative, a 
follow-up specimen may be requested.).  
 
• Rubella total antibody paired-titer test: Testing for rubella IgM is greatly preferred 
because it provides an earlier result. However, SHL also performs a paired titer test. 
Acute serum (IgM) should be collected 7-10 days after onset of rash. Convalescent 
serum (IgG) should be collected 14 days later. 
 
• Shipment of sera:  SHL will conduct the IgM testing for rubella and measles at no 
charge.  Please request IgM testing for measles and rubella.  Contact the virus-serology 
laboratory at (319) 335-4277. Transport via courier may be arranged, if possible.  
 
• If sera must be shipped, send it overnight by Federal Express to the following address: 
 
State Hygienic Laboratory 
Virus-Serology Laboratory 
102 Oakdale Campus, #H101 OH 
Iowa City, IA 52242-5002 
 
• For more information, visit: www.shl.uiowa.edu/  
 
C. Local Public Health Agency Roles and Control Measure Responsibilities 
1. Implement control measures before serologic confirmation.  This is especially important in 
settings involving pregnant women (obstetric-gynecologic and prenatal clinics). 
2. Isolate case during infectious period as defined above.   
• The individual must stay home during infectious period; if hospitalized, the patient 
must be placed in droplet isolation for seven days after the onset of rash.   
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• For congenital rubella, place infant in Contact Precautions during any admission until 
1 year old, unless nasopharyngeal and urine cultures are negative for virus after the 
age of 3 months.  
3. In order to identify those exposed, identify “zones of exposure” such as place of work 
(including sites which employ individuals from other countries where rubella is prevalent), 
school, family, child care, etc. 
4. Identify high-risk susceptibles that the index case has had contact with during infectious 
period. 
• Immunocompromised individuals should be referred to their physicians. 
5. Identify susceptibles.  These are individuals without proof of immunity. 
PROOF OF IMMUNITY TO RUBELLA1 
 
• Documentation of rubella vaccination on or after the first birthday, 
unless pregnant. 
•  Serologic proof of immunity.2 
 
1 Remember, persons born outside the US (without written proof of immunity) are 
more likely to be susceptible, especially if they have been in the US for only a short 
time. 
2 Documentation of serologic evidence of immunity is the only acceptable 
proof of immunity for pregnant women.   
 
Physician-diagnosed disease or born before 1957 is not acceptable proof of immunity. 
 
6. Immunize all susceptibles for whom it is not contraindicated, keeping in mind the following: 
• Rubella containing vaccine will not prevent development of disease after infection. 
• Vaccinating an individual who may be incubating rubella is not harmful. 
7.  Child care and school settings: 
• Determine if there are any susceptible: 
a. Pregnant teachers, staff, volunteers, student teachers, or students. 
b.   Immunocompromised individuals. 
c. Medical/religious vaccine exemptions anywhere in the classroom or school of 
the suspected case. 
• These individuals, if medically appropriate, should be encouraged to receive vaccine and 
may self exclude during the time frames described above. 
 
D.   Initial Questions to Ask Healthcare Provider and Patient 
In order to assess the likelihood that a suspect case is a true case prior to laboratory testing, IDPH 
and/or LPHA staff conducting the investigation should ask about:  
• Symptoms 
• Rubella immunization history 
• Country of origin and length of residence in US 
• Recent travel history (location and dates) 
• Whether there were any recent out-of-town visitors location and dates) 
• Whether there was any recent contact with anyone with similar symptoms 
 
2) CONTROLLING FURTHER SPREAD  
 
A.  Isolation and Quarantine Requirements  
Current recommendations of CDC and IDPH are as follows: 
 
Non-congenital rubella: 
Minimum Period of Isolation of Patient 
7 days after onset of rash. 
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Minimum Period of Quarantine of Contact 
Healthcare workers who are not appropriately immunized or do not have serologic evidence of 
immunity will be excluded from work from day 7 through day 21 after their last exposure.  When 
multiple cases occur, susceptibles need to be excluded until 21 days after the onset of the last case 
at the workplace. 
 
Congenital rubella: 
Minimum Period of Isolation of Patient 
Isolation from susceptible persons for the first year of life or until two cultures of clinical specimens 
(nasopharyngeal secretions or urine) obtained 1 month apart after 3 months old 
are negative for rubella virus. Household and other contacts should be adequately immunized.   
 
Minimum Period of Quarantine of Contacts 
No restrictions except for susceptibles. Same as for non-congenital rubella, above. 
 
B.  Protection of Contacts of a case 
 
C.  Managing Special Situations 
Control guidelines for three situations ---1) rubella in healthcare facilities, 2) when a pregnant 
woman has been exposed, and 3) infants with CRS—are presented below. Note that these situations 
are not mutually exclusive. 
 
Situation 1: Rubella in healthcare facilities 
If a confirmed or suspect case of rubella has visited a healthcare facility during his/her infectious 
period, contact the infection prevention staff and go over the following recommendations with them: 
 
1.  Identify all susceptible high-risk patients, volunteers and staff exposed to the rubella 
case. Pregnant women and immunosuppressed individuals should be referred to their healthcare 
providers to determine if they are immune.   
Pregnancy and Immune Globulin. Routine use of IG for postexposure prophylaxis is not 
recommended, even for susceptible pregnant women, because IG does not guarantee prevention 
of fetal infection. The only time IG may be considered is when exposure occurs early in 
pregnancy and termination is not an option. 
2. Identify all other susceptible exposed patients and staff at the facility. Primary care 
providers of exposed infants should be notified. Proof of immunity is defined as: 
PROOF OF IMMUNITY TO RUBELLA1 
 
• Documentation of rubella vaccination on or after the first birthday,  
•  Serologic proof of immunity.2 
 
1 Remember, persons born outside the US (without written proof of immunity) are more likely 
to be susceptible, especially if they have been in the US for only a short time. 
2 Documentation of serologic evidence of immunity is the only acceptable proof of 
immunity for pregnant women. 
 
3.   Notify healthcare providers of all exposed patients. 
4. Immunize all susceptible patients and staff. Live-virus rubella vaccine given after exposure 
has not been demonstrated to prevent illness, but theoretically could prevent illness if 
administered within 3 days of exposure. All susceptibles who are >12 months old (and for whom 
it is not contraindicated) should receive rubella vaccine given as the combined formulation of 
measles, mumps, rubella (MMR) vaccine.  
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Previous administration of human anti-Rho(D) immune globulin (RhoGam) does not generally 
interfere with an immune response to rubella vaccine. However, women who have received anti-
Rho immune globulin should be serologically tested 6–8 weeks after vaccination to assure that 
seroconversion occurred. If other antibody-containing blood products are needed for other 
reasons, they should be administered at least 2 weeks before and deferred for up to 11 months 
after administration of MMR vaccine.  (Refer to General Recommendations on Vaccination at: 
www.cdc.gov/vaccines/hcp/acip-recs/index.html  
5. Exclude susceptible staff. Ideally, all hospital employees should be immune.  It is important to 
note that screening programs alone are not adequate.  Vaccination of susceptible hospital 
personnel, both male and female (e.g., volunteers, trainees, nurses, physicians) must follow. 
Unlike measles, vaccinating immediately postexposure does not prevent an individual from 
acquiring rubella. Therefore, all susceptible individuals without proof of immunity, including those 
just vaccinated, can become infectious and must be excluded on days 7 through 21 
postexposure. They may return on the 22nd day.  If additional cases occur, the exclusion period 
may need to be extended. 
6.   Isolate susceptible patients and suspect/confirmed cases. Susceptible patients >12 
months of age should be vaccinated and placed on Droplet Precautions for days 7–21 after 
exposure. They may be taken off precautions on the 22nd day. All suspect and confirmed cases 
should be placed on Droplet Precautions during their infectious period. The infectious period for 
rubella is 7 days before rash onset through 7 days after rash onset.  
7. Conduct surveillance for two incubation periods (46 days) after the last exposure in the 
facility, and report all suspect cases of rubella to the Iowa Department of Public Health at (800) 
362-2736. 
8. Place any new cases of rash illness on Droplet Precautions or exclude for 7 days after 
rash onset. A blood specimen should be obtained 3 days after rash onset and sent to SHL. New 
cases should be reported to the Iowa Department of Public Health. 
 
Situation 2: Pregnant women who might have been exposed to Rubella 
All exposed pregnant women should be screened to determine if they: 
1. were infected during pregnancy, 
2. are susceptible or  
3. were immune before pregnancy.  
 
Because of the seriousness of CRI, immunity must be documented by a verified, dated record of a 
positive serologic test. Pregnant women without documented immunity should be tested for the 
presence of rubella IgG and IgM antibodies as outlined in this section. Identifying susceptible 
pregnant women is critical, so they can be isolated from further exposure, monitored for infection, 
and vaccinated postpartum. Pregnant women with evidence of infection during pregnancy should be 
evaluated to verify rubella infection and determine gestational age at time of infection, if possible, to 
assess the possibility of risk to the fetus.  
Regardless of the point in pregnancy in which the exposure occurred (because of the possibility of 
late effects), and regardless of whether the woman had symptoms of rubella (because of the high 
proportion of asymptomatic infections). Diagnostic testing of the baby will be necessary if rubella 
infection in the mother was not reliably ruled out, as reflected below: 
 
 Pregnant woman’s lab results 
Possible 
conclusions  
Rubella IgM-neg. 
and no rise in IgG 
Rubella IgM-pos. or 
significant rise in IgG 
Maternal infection 
neither confirmed nor 
ruled out prior to 
delivery 
Woman infected? No Yes Unknown 
Need to follow 
baby? 
No Yes—see Attachment 
A 
Yes—see Attachment A 
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Situation 3: Infants with CRS 
 
In cases of suspect or confirmed CRS in an infant, contact the infection prevention staff in any facility 
in which the infant was seen, as well as care providers of the mother and the infant and review the 
following recommendations with them: 
 
1. Immediately place all suspect cases of CRS on Contact Precautions. Infants with 
CRS shed virus in their urine and nasopharyngeal secretions and can remain infectious for 1 
year or more after birth. Both the American Academy of Pediatrics in the Red Book and the 
Centers for Disease Control and Prevention (CDC) in the CDC Guidelines for Isolation and 
Precautions in Hospitals recommend Contact Precautions. 
2. Place all suspect cases of rubella on Droplet Precautions during their infectious period. 
The infectious period for rubella is from 7 days before until 7 days after rash onset.  
3. Identify all high-risk patients and staff exposed to the CRS and/or rubella case(s).  
Pregnant women and immunosuppressed individuals should be referred to their healthcare 
providers to determine if they are immune.   
4. Pregnancy and Immune Globulin. Routine use of IG for postexposure prophylaxis is not 
recommended, even for susceptible pregnant women, because IG does not guarantee prevention 
of fetal infection. The only time IG may be considered is when infection occurs early in pregnancy 
and termination is not an option. 
5. Identify all other susceptible exposed patients and staff at the facility. Healthcare 
providers of exposed infants should be notified. If a baby with CRS has been in a nursery where 
visitors and other family members have spent significant amounts of time, the immunity of those 
exposed to the baby should be evaluated. Proof of immunity is defined below: 
 
PROOF OF IMMUNITY TO RUBELLA1 
 
• Documentation of rubella vaccination on or after the first 
birthday. 
•  Serologic proof of immunity.2 
 
1 Remember, persons born outside the US (without written proof of immunity) are 
more likely to be susceptible, especially if they have been in the US for only a short 
time. 
2 Documented serologic evidence of immunity is the only acceptable proof of 
immunity for pregnant women. 
 
6. Notify healthcare providers of all exposed patients. 
 
7. Immunize all susceptible patients and staff. Live-virus rubella vaccine given after exposure 
has not been demonstrated to prevent illness, but theoretically could prevent illness if 
administered within 3 days of exposure. All susceptibles who are >12 months old (and for whom 
it is not contraindicated) should receive rubella vaccine given as the combined formulation of 
measles, mumps, rubella (MMR) vaccine.  
 
Previous administration of human anti-Rho(D) immune globulin (RhoGam) does not generally 
interfere with an immune response to rubella vaccine. However, women who have received anti-
Rho immune globulin should be serologically tested 6–8 weeks after vaccination to assure that 
seroconversion occurred. If other antibody-containing blood products are needed for other 
reasons, they should be administered at least 2 weeks before and deferred for up to 11 months 
after administration of MMR vaccine. 
8.   Exclude susceptible staff. Unlike measles, vaccinating immediately postexposure does not 
prevent an individual from acquiring rubella. Therefore, all susceptible individuals without proof 
of immunity, including those just vaccinated, can become infectious and must be excluded on 
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days 7 through 21 postexposure. They may return on the 22nd day. If additional cases occur, the 
exclusion period may need to be extended. 
9.  Isolate susceptible patients and suspect/confirmed cases. Susceptible patients >12 
months old should be vaccinated and placed on Droplet Precautions for days 7–21 after 
exposure. They may be taken off precautions on the 22nd day. All suspect and confirmed cases 
should be placed on Droplet Precautions during their infectious period. The infectious period for 
rubella is 7 days before until 7 days after rash onset.  
10. Collect specimens for diagnostic testing on infants with suspect CRS and their 
mothers. 
11. Conduct surveillance for two incubation periods (46 days) after the last exposure in the facility, 
and report all suspect cases of rubella to IDPH (800) 362-2736. 
 12. Take the opportunity to review the facility’s policy on post-partum immunization of 
susceptible women.  Birthing facilities should be encouraged to adopt a policy of routine post-
partum vaccination.   
 
D. Preventive Measures 
Vaccination, including routine childhood vaccination, catch-up vaccination of adolescents, and 
targeted vaccination of high-risk adult groups (such as international travelers and adults born outside 
the US), is the best preventive measure. Workers born outside the United States are a potentially 
susceptible population in which outbreaks may occur after importation of the virus from areas where 
rubella is endemic.  Vaccinating against rubella in workplaces is a strategy to reach this susceptible 
population and can be a critical step in eliminating indigenous rubella.  
 
The continuing occurrence of rubella among women of childbearing age indicates the need to 
continue vaccination of susceptible women in this age group. The absence of evidence of vaccine 
teratogenicity suggests that the practice is safe. Vaccination of susceptible women of childbearing 
age should: 
• be part of routine general medical and gynecological outpatient care; 
• take place in all family-planning settings; and 
• be provided routinely before discharge from any hospital, birthing center, or other medical 
facility, unless a specific contraindication exists. (Note: Previous administration of human anti-
Rho(D) immune globulin (RhoGam) does not generally interfere with an immune response to 
rubella vaccine. However, women who have received anti-Rho immune globulin should be 
serologically tested 6–8 weeks after vaccination to assure that seroconversion occurred.) 
 
Rubella Vaccination of women of childbearing age: 
 
Women who are pregnant or who intend to become pregnant within 4 weeks should not receive live 
rubella or MMR vaccine.  The Advisory Committee on Immunization Practices (ACIP) recommends 
that vaccine providers ask a woman if she is pregnant or likely to become pregnant in the next 4 
weeks.  Those who are pregnant or intend to become pregnant should not be vaccinated.  All other 
women should be vaccinated after being informed of the theoretical risks of vaccination during 
pregnancy and the importance of not becoming pregnant during the 4 weeks following vaccination.  
ACIP does not recommend routine pregnancy screening of women before rubella vaccination.  
 
Please refer to the most current versions of the ACIP statement on measles, rubella, and mumps 
(listed under References, below), IDPH’s Immunization Guidelines, and IDPH’s Iowa’s Vaccine for 
Children Program Eligibility Criteria for details about MMR vaccine, the recommended schedule, who 
should and shouldn’t get the vaccine, and who is eligible to receive state-supplied vaccine. These, as 
well as other relevant resources, are available through the IDPH Clearinghouse at (319) 398-5133 or 
visit: healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295  
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4) ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Rubella 
can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
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What is rubella? 
Rubella, also called German measles, is a contagious disease that usually causes a red rash that spreads 
over most of the body.  While rubella is generally a mild illness, if it infects pregnant woman, particularly 
early during pregnancy, it can result in congenital rubella syndrome and cause serious birth defects.   
 
What are the symptoms of rubella? 
In children, rash is usually the first symptom.  In older children and adults, there is often a period of low-
grade fever, swollen glands, cold-like symptoms, and tender joints before the rash appears. 
 
How is rubella spread? 
The germs that cause rubella live in the nose, mouth, and throat, and are sprayed into the air when an 
infected person sneezes, coughs, or talks.  Other people nearby can then inhale the germs.  The first 
symptoms may appear within 14 days after a person is exposed.   
 
Who gets rubella? 
Rubella is most common among preschool age children, but anyone can get it.  Rubella can be hard to 
diagnose because some people do not have all of the symptoms.  Vaccinated persons are almost always 
protected. 
 
Is rubella dangerous? 
Rubella is generally a mild disease but it is very dangerous to unborn babies if a woman is pregnant.  Up to 
half of the women who catch rubella when they are pregnant will lose their babies or have babies born with 
heart disease, blindness, and deafness or have problems with learning. 
 
How is rubella diagnosed? 
A doctor may think a patient has rubella because of the symptoms, but a blood test is the only way to be 
sure that a person has rubella. A laboratory then tests the blood sample to determine whether the patient 
has rubella. 
 
Can rubella be prevented? 
Yes, there is a vaccine to prevent rubella.  It is given along with measles and mumps vaccines in a single 
shot called MMR.  Two doses of vaccine, given in a series usually starting at 12 months of age, are needed 
to protect a child from rubella.  The vaccine is usually not recommended for children younger than 12 
months old. 
 
Is rubella vaccine safe? 
Yes, it is safe for most people, but as with any medicine, there can be small risks that could occur after 
taking the vaccine.  Most people who have problems with the vaccine may see soreness, redness, or 
swelling where the shot was given.  Rarely, a person may have a rash, fever, swelling of the gland in the 
cheeks, neck or under the jaw, or have a seizure (caused by fever). 
 
Where can you get more information? 
The Iowa Department of Public Health, Immunization Program (800) 831-6293. 
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CONFIDENTIAL           Iowa Department of Public Health 
Rubella                                   Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis 
date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome: 
 Survived this illness     Died from this illness 
 Died unrelated to this illness   Unknown 
Date of death      /     /      First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider title: 
 ARNP   
 DO 
 MD 
 NP  PA 
Event exception 
 Case could not be found 
 Case could not be interviewed 
 Case refused interview 
 Other – see notes   
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes   No  Unk To whom: ______________  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Rubella virus  
 
   
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Rubella virus  
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Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Rubella virus  
 
   
 
OCCUPATIONS 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
S
ym
pt
om
s 
Fever  Yes    No    Unk Onset date:      /     /      Duration:       hrs/days 
Date returned to normal 
activities:      /     /      
Cough  Yes    No    Unk Onset date:      /     /      
O
th
er
 s
ym
pt
om
s  Abdominal cramps     
 Backache     
 Chills    
 Encephalitis     
 Fatigue     
 Fever   
 Sore throat 
 Vomiting  
 Headache 
 Joint pain     
 Muscle pain     
 Nausea     
 Otitis media 
 Photophobia    
 
Runny nose  Yes    No    Unk Onset date:      /     /      
Red eyes w/t 
drainage  Yes    No    Unk Onset date:      /     /      
Diarrhea  Yes    No    Unk Onset date:      /     /      
Thrombocytopenia  Yes    No    Unk Onset date:      /     /      
Arthritis  Yes    No    Unk Onset date:      /     /       
Other 
complications:       Describe:       
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
Rash:  Yes    No    Unk Onset date:      /     /      Duration:       hours/days 
Fever continued w/t rash:   Yes    No    Unk Rash spreading:  Yes    No    Unk 
Rash equally distributed:  Yes    No    Unk Rash appeared at once:  Yes    No    Unk 
Lesions present:  Yes    No    Unk  Rash initial location:  Arms    Face    Legs    Trunk     Inside mouth 
 
       cm    Heaviest lesion area:  Arms    Face    Legs    Trunk    Scalp 
# of days for first lesion to crust:       days Areas present:  Inside mouth      Palms         Soles 
Lesions in same stage of 
development:  Yes    No    Unk Severity: 
 < 50 lesions          
 50 – 249 lesions 
 250 – 500 lesions        
> 500 lesions 
Rash characteristics: 
 Burning     
 Confluent lesions      
 Could be felt (papule) 
 Could not be felt (macule) 
 Discrete lesions                               
 Distinct sharp borders 
 Dusky brown 
 Marked itching 
Numbness 
 Painful   
 Peeling skin       
 Pustule 
 Reddish    
 Scaling/crusting 
Koplik’s spots:  Yes    No    Unk    
Healthcare provider visited:  Yes    No    Unk Date(s) visited:      /     /     ,      /     /     ,      /     /      
Swollen lymph nodes:  Yes    No    Unk Location:       
 
TREATMENT 
 
Antivirals prescribed:   Yes    No    Unknown 
  
Antiviral:       
 
Antiviral:       
 
Antiviral:       
Date 
started:      /     /      
Date 
started:      /     /      
Date 
started:      /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
 
Therapeutic medications prescribed?  Yes    No    Unk 
List medications:       
 
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Vaccinated with MMR:  Yes    No    Unknown 
  
Date 
vaccinated: 
 
     /     /      
  
Date 
vaccinated: 
 
     /     /      
  
Date 
vaccinated: 
 
     /     /      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
 
Number of vaccinations:       
 
In the 21 days prior to the onset of symptoms did the case: 
Traveled within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
  Country outside the U.S.: 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation 
period for rubella 
is 14-21 days. 
Rubella is communicable 7 days 
before the onset of symptoms to 4 
days after the rash appearance.  
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Born outside the U.S.?  Yes    No    Unknown 
 
Immunocompromised? 
 
 Yes    No    Unknown 
 
In the 7 days prior to the onset of rash through 4 days after the onset of rash did the case: 
Use public transportation:  Yes    No    Unk 
Date(s) used: Time(s) used: Type: Route: 
     /     /                        
     /     /                        
     /     /                        
 
Visit a doctor’s office, clinic or hospitals:   Yes    No    Unknown 
If Yes, complete the following table: 
Facility 
name:       
 
 
 
Facility 
name:       
 
Address: 
 
      
 
Address:       
Zip 
code: 
 
      
 
City: 
 
      
Zip 
code: 
 
      
 
City: 
 
      
      
State:       
 
County: 
 
      
      
State:       
 
County: 
 
      
Phone: (     )-     -      
 
   Type:       Phone: (     )-     -      
 
   Type:       
Date 
visited:      /     /      
Time 
visited:       
Date 
visited:      /     /      
Time 
visited:       
Provider 
name:       Title:       
Provider 
name:       Title:       
 
Visit a public places:  Yes    No    Unknown 
If Yes, complete the following table: 
Location name Address/City/State/Zip Phone Date(s) visited Time visited 
            (     )-     -      
 
     /     /            
            (     )-     -      
 
     /     /            
            (     )-     -      
 
     /     /            
 
Attend religious gatherings:  Yes    No    Unknown 
If Yes, complete the following table: 
Location name Address/City/State/Zip Date(s) attended Time attended  Describe interactions: 
            
 
     /     /                   
            
 
     /     /                   
            
 
     /     /                   
 
Attend family gatherings:  Yes    No    Unknown 
If Yes, complete the following table: 
Location name Address/City/State/Zip Date(s) attended Time attended  Describe interactions: 
            
 
     /     /                   
            
 
     /     /                   
            
 
     /     /                   
 
Attend other gatherings:  Yes    No    Unknown 
If Yes, complete the following table: 
Location name Address/City/State/Zip Date(s) attended Time attended  Describe interactions: 
            
 
     /     /                   
            
 
     /     /                   
            
 
     /     /                   
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Setting Acquired: 
Child care 
Church 
College 
Correctional Facility 
Doctors office 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
Hospitalized 
International traveler 
Military 
Hospital ER/ 
Outpatient 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 
Home 
School 
Urgent care 
Work 
Other 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
      
Disease traced within 2 generations of known 
international import?  Yes    No    Unk 
  
 
 
Number of people living in case’s household:          
Close contacts of the case (For more than one contact, print/copy additional contact pages.)  
Last name:       Address:       
First name:        City/State/Zip:       County:       
DOB:      /     /      Age:       Phone:       Type:       
Gender:  Female      Male      Other Symptoms present:  Yes    No    Unk Onset date:      /     /      
  If this contact has an onset date before this case then create a new case and event. 
Symptoms: 
Fever  
Runny nose  
Rash  
Chills  
Fatigue  
Joint pain  
Nausea  
Photophobia  
Sore throat  
 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
 
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
Vomiting  
Cough  
Red eyes w/t discharge  
Backache  
Encephalitis  
Headache  
Muscle pain  
Otitis media  
Pneumonia  
Swollen lymph nodes  
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
Vaccinated for measles (MMR):  Yes    No    Unk Number of vaccinations:       
 
Date vaccinated:      /     /      
 
Date vaccinated:      /     /      
 
Date vaccinated:      /     /      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
Exposed to measles:  Yes    No    Unk Received MMR within 3 days of exposure:  Yes    No    Unk 
Received IG within 6 
days of exposure:  Yes    No    Unk Date received:      /     /      Dose:       Unit:       Route:       
Tested for immunity:  Yes    No    Unk Result:  IgM+    IgM-    IgG+    IgG- Is this contact a case?  Yes    No    Unk 
 
NOTES:       
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SALMONELLOSIS (Non-Typhoid) 
 
Potential Bioterrorism Agent: Category B 
 
Responsibilities: 
Hospital: Report by IDSS, facsimile, mail or phone 
Lab: Report by IDSS, facsimile, mail or phone 
Physician: Report by facsimile, mail or phone 
Local Public Health Agency (LPHA): Report by IDSS, facsimile, mail or phone.  
Follow-up required 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Salmonellosis is caused by Salmonella bacteria other than Salmonella typhi, (the Salmonella species 
that causes typhoid fever).  There are approximately 2,000 known serotypes; only about 200 are 
detected in the U.S. in any given year.  Infection may begin as acute diarrhea and develop into 
septicemia (blood infections) or focal infection. Infectious dose of Salmonella is usually over 10, 000 
organisms. 
 
B. Clinical Description 
Symptoms of Salmonellosis are diarrhea (sometimes bloody), headache, stomach cramps, fever, 
nausea, and sometimes vomiting. The infection may also appear as septicemia, an abscess, arthritis 
or cholecystitis.  
 
Onset of illness may begin as acute enterocolitis and develop into septicemia or focal infection. 
Anorexia and diarrhea often persist for several days. 
 
Complications include dehydration that may be severe, especially among infants and the elderly, and 
invasive disease may occur. Occasionally, the infectious agent may localize in any tissue of the body, 
produce abscesses and cause septic arthritis, cholecystitis, endocarditis, meningitis, pericarditis, 
pneumonia, pyoderma, or pyelonephritis. Deaths are uncommon, except in the very young, the very 
old, the debilitated and the immunosuppressed. It is estimated that 400 fatal cases occur each year; 
a few cases are complicated by chronic arthritis. 
C. Reservoirs 
Common reservoirs: humans, livestock, pets, poultry and other birds, reptiles and amphibians. Most 
infected animals are chronic carriers and may be asymptomatic. 
 
D. Modes of Transmission 
Spread via the fecal-oral route.  By far the most common mode of transmission is ingestion of food or 
water that has been contaminated with animal feces. This includes raw or undercooked poultry, 
meats, and raw milk or milk products. Eggs can become infected “in utero,” thus should be cooked 
until no longer runny, or pasteurized egg products used. In addition, reptiles such as iguanas, snakes 
and lizards are often chronic carriers of these bacteria and can be sources of infection.  
 
Person-to-person spread can occur when an infected food handler contaminates food.   A large dose 
of organisms is usually needed to cause infection, but the infectious dose may be lower for certain 
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susceptible groups such as children, the elderly and the immunocompromised. Most often, person-to-
person spread occurs among household contacts, preschool children in child care, and the elderly and 
developmentally disabled living in residential facilities.  Transmission can also occur person-to-person 
through certain types of sexual contact (e.g. fecal - oral contact). 
 
E. Incubation period 
The incubation period can vary from 6 - 72 hours but is usually about 12 - 36 hours. Longer 
incubation periods of up to 16 days have been documented and may not be uncommon following 
low-dose ingestion. The higher the infectious dose of the organism, the shorter the incubation period. 
 
F. Period of Communicability or Infectious Period 
The disease is communicable for as long as infected persons excrete Salmonella bacteria in their 
stool, but most likely while diarrhea exists. This can last from days to months, depending on the 
serotype, but rarely lasts more than one year. Treatment with antibiotics can prolong carriage. 
However, due to large infectious dose, transmission from carriers is very uncommon. 
 
G. Epidemiology 
Salmonellosis has a worldwide distribution, with approximately 1.4 million cases occurring annually in 
the United States alone.  An estimated 1.2 million cases occur annually in the United States; of these, 
approximately 42,000 are laboratory-confirmed cases reported to CDC. Salmonella serotypes 
Enteritidis, Typhimurium, and Newport account for about half of culture-confirmed Salmonella 
isolates reported by public health laboratories in the U.S.  
About 60-80% of cases are sporadic, but large outbreaks have occurred in institutional settings and 
nationwide from common food sources. The largest common-vehicle outbreak of salmonellosis ever 
recognized in the United States was caused by ice cream made by a large national producer when 
the ice cream premix was transported in contaminated tanker trucks.  
 
H. Bioterrorism Potential 
Category B Agent: Salmonella has been used as a bioterrorism agent. In one well-known example 
in 1984, a religious sect in Oregon deliberately contaminated salad bars at restaurants with 
Salmonella to disrupt an election process.  Over 700 people became ill. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To identify whether the case may be a source of infection for others (e.g., a diapered child, 
child care attendee or food handler) and, if so, to prevent further transmission. 
• To identify transmission sources of public health concern (e.g. a restaurant or a 
commercially distributed food product) and to stop transmission from such sources. 
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report. The preferred method of reporting is by utilizing the Iowa Disease Surveillance 
System (IDSS).  However, if IDSS is not available to your facility, the reporting number for IDPH 
Center for Acute Disease Epidemiology (CADE) is (800) 362-2736; fax number (515) 281-5698, 
mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th Street 
Des Moines, IA 50319-0075 
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Postage-paid disease reporting forms are available free of charge from the IDPH clearinghouse.   
Call (319) 398-5133 or visit the website 
healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295 to request a supply. 
 
C.  Local Public Health Agency (LPHA) Follow-up Responsibilities 
Case Investigation  
a. It is the LPHA responsibility to complete an Salmonella Case Investigation form by interviewing 
the case and others who may be able to provide pertinent information.  Much of the information 
on the form can be obtained from the case’s healthcare provider or the medical record.  
b. Use the following guidelines in completing the form: 
1. Accurately record the demographic information, date of symptom onset, symptoms, and 
medical information. 
2. When asking about exposure history (food, travel, activities, etc.), use the incubation-
period range for salmonellosis (6 – 72 hours). Specifically, focus on the period beginning 
a minimum of 6 hours prior to the case’s onset back to no more than 72 hours before 
onset. 
3. If possible, record any restaurants at which the case ate, including food items(s) and 
date consumed. 
4. Ask questions about travel history and outdoor activities to help identify where the case 
became infected. 
5. Ask questions about water supply because salmonellosis may be acquired through water 
consumption. 
6. Household/close contact, pet or other animal contact, child care, and food handler 
questions are designed to examine the case’s risk of having acquired the illness from, or 
potential for transmitting it to, these contacts. Ask specifically about exposure to reptiles. 
Determine whether the case attends or works at a child care or healthcare facility and/or 
is a food handler. 
7. Ask if the patient knows others who have similar illness about the same time. 
If several attempts have been made to obtain case information, but have been 
unsuccessful (e.g., the case or healthcare provider does not return your calls or respond 
to a letter, or the case refuses to divulge information or is too ill to be interviewed), 
please fill out the form with as much information as can be gathered. Please note on the 
form the reason why it could not be filled out completely. If using IDSS, select the 
appropriate reason under the Event tab in the Event Exception field. 
 
c. After completing the IDSS case investigation form, transmit to IDPH by entering the completion 
date in the investigation complete field under the event tab.   
 
Iowa Department of Public Health 
Attn: CADE 
Lucas State Office Building 
321 E. 12th Street 
Des Moines, IA 50309-0075 
 
Or FAX to (515) 281-5698 
 
3) CONTROLLING FURTHER SPREAD 
For uncomplicated cases, no antibiotic treatment is recommended.  Antibiotics may encourage the 
development of the carrier state and may lead to resistant strains or more severe infections. 
However, infants under 2 months of age, the elderly, the debilitated, those with sickle disease, 
persons infected with HIV, or patients with continued or high fever or manifestations of extra 
intestinal infection, should be given antibiotic therapy. 
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A. Isolation and Quarantine Requirements 
Exclude persons with salmonellosis from food preparation and direct child and patient care until 
diarrhea is resolved.  Children in child care should be excluded until diarrhea ceases. Consult with the 
staff at CADE if any clarification is needed. 
 
 
B.  Protection of Contacts of a Case 
None  
 
C.  Managing Special Situations 
 
Child care 
Since salmonellosis can be transmitted person-to-person through fecal-oral transmission, it is 
important to carefully follow up on cases of salmonellosis in a child care. General recommendations 
include: 
• Children or staff with Salmonella infection who have diarrhea should be excluded until their 
diarrhea is gone. 
• Good hand hygiene must be practiced at all times. 
 
School 
Since salmonellosis may be transmitted person–to-person through fecal-oral transmission, it is 
important to follow up carefully on cases of salmonellosis in a school.  General recommendations 
include:  
• Students or staff with Salmonella infection who have diarrhea should be excluded until their 
diarrhea is gone. 
• Good hand hygiene must be practiced at all times. 
 
Community Residential Programs 
Actions taken in response to a case of salmonellosis in a community residential program will depend 
on the type of program and the level of functioning of the residents.  Exclude persons with 
salmonellosis from food preparation and patient care until diarrhea is resolved. 
 
In long-term care facilities, residents with salmonellosis should be placed on standard and contact 
precautions until their symptoms subside. Staff members who give direct patient care (e.g. feed 
patients, give mouth or denture care, or give medications) are considered food handlers and are 
subject to food handler restrictions.  Exclude persons with salmonellosis from food preparation, direct 
child and patient care until diarrhea is resolved.  In addition, staff members with Salmonella infection 
who are not food handlers should not work until their diarrhea is gone. 
 
In residential facilities for the developmentally disabled, staff and clients with salmonellosis must 
refrain from handling or preparing food for other residents until their diarrhea has subsided. In 
addition, staff members with Salmonella infection who are not food handlers should not work until 
their diarrhea is gone. 
 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
If the number of reported cases of Salmonella in your city or town is higher than usual, or if an 
outbreak is suspected, investigate to determine the source of infection and mode of transmission. A 
common vehicle (such as food or association with a child care center) should be sought and 
applicable preventive or control measures should be instituted. Control of person-to-person 
transmission requires special emphasis on personal cleanliness and sanitary disposal of feces. Consult 
with the regional epidemiologist or CADE if assistance is needed. CADE can help determine a course 
of action to prevent further cases and can perform surveillance for cases that may cross jurisdictional 
lines. 
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D. Preventive Measures 
Environmental Measures 
Implicated food items must be removed from the environment. A decision about testing them can be 
made in consultation with CADE and the State Hygienic Laboratory (SHL). CADE can help coordinate 
pickup and testing of food samples.  If a commercial product is suspected, the Department of 
Inspections and Appeals (DIA), or their contracted agency, will coordinate follow-up with relevant 
agencies. 
 
Note: The role of the DIA is to provide policy and technical assistance with the environmental 
investigation. This includes interpreting the Iowa Code, conducting a HACCP risk assessment, 
initiating enforcement actions and collecting food samples. 
 
The general policy of the University of Iowa State Hygienic Laboratory (SHL) is only to test food 
samples implicated in suspected outbreaks, not in single cases, except when botulism is suspected.  
The LPHA may suggest that the holders of food implicated in single case incidents locate a private 
laboratory that will test food or store the food in their freezer for a period in case additional reports 
are received. However, a single, confirmed case with leftover food consumed within the incubation 
period most likely will not be considered for testing. 
 
Since Salmonella is sometimes implicated in foods that have wide, sometimes national, distribution, it 
is critical that all Salmonella isolates be sent to SHL for “DNA fingerprinting.”  This allows 
investigators to connect Iowa illnesses and those in other parts of the country.  
 
Preventive Measures/Education 
To avoid future exposures, recommend that people:  
•    Make sure to thoroughly cook all food products from animals, especially poultry and eggs, 
and avoid consuming raw eggs, unpasteurized milk, or other unpasteurized dairy products.  
When preparing dishes where eggs may not be cooked (such as eggnog or sauces) use 
pasteurized egg products.  Eggs can be contaminated with Salmonella from the chicken 
before the shell is formed.  About 1 in 200 eggs from an infected flock may be contaminated.  
The risk is lower for all eggs. Only 1 in 10,000 eggs on the supermarket shelves are likely to 
be contaminated with Salmonella enteritidis. 
• Always wash hands thoroughly with soap and water before eating or preparing food, after 
using the toilet, after changing diapers, and after touching their pets or other animals 
(especially reptiles). 
• Wash the child’s hands as well as their own after changing diapers. 
• Dispose of feces in a sanitary manner in all settings. 
• Keep food that will be eaten raw, such as vegetables, from becoming contaminated by 
animal-derived food products.  Wash all foods that will be eaten rare before eating. 
• Avoid letting infants or young children touch reptiles, such as turtles, snakes or iguanas, or 
their cages. 
• Avoid reptiles when choosing pets if there are infants, elderly or immunocompromised people 
in the home. 
• Do not use reptiles as classroom pets in a child care or schools with children younger than 5 
years old. 
• Avoid sexual practices that may permit fecal-oral transmission. Latex-barrier protection 
should be emphasized as a way to prevent the spread of salmonellosis to sexual partners as 
well as to prevent the exposure to, and transmission of, other pathogens. 
 
4) ADDITIONAL INFORMATION 
 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for 
Salmonella can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
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CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
 
References 
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CDC web site, Salmonellosis; www.cdc.gov/salmonella/   
Heymann, D.L., ed. Control of Communicable Diseases Manual, 19thh Edition. Washington, DC, 
American Public Health Association, 2008. 
 
  
Additional Resources 
USDA web site providing latest information on salmonellosis in animals 
www.aphis.usda.gov/  
FDA web site providing the latest food recalls: 
www.fda.gov/opacom/7alerts.html 
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What is Salmonella? 
Salmonella is a common bacterial infection of the gut.  Several hundred people develop this disease in Iowa 
each year, mostly in the summer.  
 
Who gets Salmonella? 
Anyone, but it occurs most often in infants and children. 
 
How are Salmonella bacteria spread? 
Usually transmitted to humans by eating foods contaminated with animal feces. Contaminated foods are 
often of animal origin, such as beef, poultry, milk, or eggs, but all foods, including vegetables, may 
become contaminated. Food may also become contaminated by the unwashed hands of an infected food 
handler.  
 
Salmonella may also be found in the feces of some pets, especially those with diarrhea, and people can 
become infected if they do not wash their hands after contact with these feces. Reptiles (turtles, snakes, 
lizards, etc) are particularly likely to harbor Salmonella and people should always wash their hands 
immediately after handling a reptile, even if the reptile is healthy. Adults should also be careful that 
children wash their hands after handling a reptile.  Homes with infants or immunocompromised persons 
should not have reptiles (turtles, iguanas, other lizards, and snakes) as pets. 
 
What are the symptoms of Salmonella infection? 
People infected with Salmonella may have mild or severe diarrhea, fever, and sometimes vomiting. Blood 
infections can be very serious, especially in the very young or very old.  Typhoid fever is the most severe 
type of Salmonella infection. 
 
How soon after infection with Salmonella do symptoms appear? 
Diarrhea and fever usually occur 12 - 36 hours after infection, with a range of 6 – 72 hours. Longer 
incubations periods up to 16 days have been seen when exposed to low doses of salmonella. 
 
Where are Salmonella found? 
Salmonella are found everywhere, but most often in raw meats, uncooked eggs, contaminated water, "raw" 
(unpasteurized) milk and cheese.  Pet turtles, iguanas, snakes, other reptiles, baby chickens, ducks, dogs, 
and cats can also carry Salmonella. 
 
How long can an infected person carry Salmonella? 
For several days and possibly many months.  Infants and people treated with antibiotics may carry the 
bacteria longer than others. 
 
Do infected people need to be excluded from work or school? 
Since Salmonella is found in the feces (stool), people with diarrhea (especially children in child care centers 
or people who handle food) should not go to school or work.  Most infected people may return to work or 
school when their diarrhea stops if they carefully wash their hands after using the toilet and before handling 
food.  
 
What is the treatment for Salmonella? 
Most people will recover without treatment. Persons with severe diarrhea, especially small children and 
elderly people, should see a doctor. 
 
How can Salmonella be prevented? 
1. Always refrigerate meats. 
2. Always cook meats completely.  Never eat raw meat. 
3. Always cook eggs or food containing raw eggs. 
4. Avoid unpasteurized milk or foods made with unpasteurized milk. 
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5. Wash hands carefully before and after preparing food. 
6. Wash counter tops, cuttings boards and any utensil after use on raw meat or eggs. 
7. Always wash hands carefully with soap and warm water after using the toilet or handling dirty diapers. 
8. Make sure that infant’s and children’s hands are washed after diaper changing.   
9. Make sure everyone washes their hands with soap and warm water after handling pets, especially 
reptiles. 
10. If making foods, such as eggnog, homemade ice cream or sauces that include raw eggs, use 
pasteurized eggs.  These can be found at grocery stores, in the refrigerated section, as liquid or shell 
eggs. 
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Salmonella      
(non-typhi/paratyphi serotypes)       Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider title: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes   No  Unk  To whom:______________  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
Laboratory: 
 
      Accession #: 
 
      
Collection 
date: 
 
     /     /      
 
Date received: 
 
     /     /      
Specimen 
source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Salmonella  Serotype:    
 
Laboratory: 
 
      Accession #: 
 
      
Collection 
date: 
 
     /     /      
 
Date received: 
 
     /     /      
Specimen 
source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Salmonella  Serotype:    
 
Laboratory: 
 
      Accession #: 
 
      
Collection 
date: 
 
     /     /      
 
Date received: 
 
     /     /      
Specimen 
source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Salmonella  Serotype:    
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OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /       
       Isolated at entry: 
 
 Yes    No    Unk 
Isolation type 
(entry): 
 
      
Days 
hospitalized:        Currently isolated: 
 
 Yes    No    Unk 
Current isolation 
type: 
 
      
 
CLINICAL INFO & DIAGNOSIS 
 
HUS 
Diagnosis  Yes    No    Unk Onset Date      /     /      
TTP 
Diagnosis  Yes    No    Unk Onset Date      /     /      
 
S
ym
pt
om
s 
Diarrhea 
Nausea 
Vomiting 
Headache 
Muscle weakness 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
      Days/Hours 
      Days/Hours 
      Days/Hours 
      Days/Hours 
      Days/Hours 
Visible bloody 
diarrhea  
Fever 
Abdominal cramps 
Chills 
 
 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 
      Days/Hours 
      Days/Hours 
      Days/Hours 
      Days/Hours 
 
First symptom:       
Most severe 
symptom:       
Date returned to normal 
activities:      /     /      
 
OTHER LAB FINDINGS 
 
Clinical specimen from case 
Was PFGE performed:  Yes    No    Unk 
IA-XbaI 
Pattern       
IA-BlnI 
 Pattern       
CDC-XbaI 
Pattern       
CDC-BInI 
Pattern       
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
Environmental specimen testing 
Food, Medication, or 
environmental samples tested?  Yes    No    Unk 
Describe 
samples: (circle positives)       
For what were the samples 
tested? 
 E. coli or EHEC  Salmonella   
 Shigella              Other testing (specify): 
Laboratory:       Positive?  Yes    No    Unk 
PFGE 
performed?  Yes    No    Unk 
IA-XbaI 
Pattern       
IA-BlnI 
 Pattern       
CDC-XbaI 
Pattern       
CDC-BInI 
Pattern       
 
TREATMENT 
 
Antibiotics prescribed?   Yes    No    Unknown 
 
  
Antibiotic:       
  
Antibiotic:       
 
 
Antibiotic:       
Date 
started:      /     /      
Date 
started:      /     /      
Date 
started:      /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Risk Factors/Travel Information – In the 3 days prior to onset of symptoms did the case: 
Tr
av
el
 
Travel within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       Departure date:      /     /      Return date:      /     /      
Travel within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Travel outside U.S.?   
 Yes    No    Unk Country:       Departure date:      /     /      Return date:      /     /      
 
Visit restaurants?  Yes    No    Unknown 
If Yes, complete the table below:   County and address are missing from this table 
Establishment name Address/Zip Date visited Foods consumed Others ill? 
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
 
Attend Group Gatherings (e.g. weddings, parties)?  Yes    No    Unknown 
If Yes, complete the following table: 
Location name Address/Zip Date visited Foods consumed Others ill? 
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
 
Where did the case purchase groceries in the 2 weeks before the onset of symptoms: 
Store name Address City/State/Zip County Date purchased 
                        
 
     /     /      
                        
 
     /     /      
                        
 
     /     /      
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation period for 
Salmonella is 6 hours to 
3 days. 
Salmonella is communicable for 
several days to weeks. A temporary 
carrier state lasting months exists.  
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Dietary Information – In the 3 days prior to onset of symptoms did the case consume the following: 
Meat and poultry 
Any of these meat 
products?  Poultry      Ground beef      Meat other than ground meat (salami, jerky, wild game) 
Was the meat fully cooked?  Yes    No    Unknown 
List all source/types:       
List all brand names:       
From dates consumed:      /     /     ,      /     /      To dates consumed:      /     /     ,      /     /      
 
Other meat and poultry products 
Deli/lunch meat  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Raw/partially 
cooked eggs or in 
foods (e.g. cookie 
dough): 
 Yes    No    Unk 
From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
 
Unpasturized products 
Unpasteurized 
milk:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Unpasteurized 
juice:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Other 
unpasteurized 
products: 
 Yes    No    Unk 
From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
 
Other products 
Health supplements:  Yes    No    Unk From date consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Infant formula:  Yes    No    Unk From date consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Baby food:  Yes    No    Unk From date consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
 
Fruits and vegetables 
Raw fruits:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Raw vegetables:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
 
Other 
Leftover foods consumed: 
 Yes    No    Unk 
Reheated: 
 Yes    No    Unk 
 
From date consumed:      /     /      
 
To date consumed:      /     /      
Describe leftovers consumed: 
 
 
Animal Exposures – In the 3 days prior to the onset of symptoms did the case: 
Check all that apply 
Visit or live on a farm: 
Exposed to manure: 
Have farm animal contact: 
 Yes    No    Unknown 
 Yes    No    Unknown 
 Yes    No    Unknown 
 
 
Animals:       
 
Have reptile contact: 
Reptile lived with case: 
 
 Yes    No    Unknown 
 Yes    No    Unknown 
 
 Iguana    Lizard    Turtle    Snake    Other _____________________ 
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Have other animal  
contact in home: 
 
 Yes    No    Unknown Animal:       Animal sick:  Yes    No    Unk 
Visit a petting zoo: 
 
 Yes    No    Unknown Touched animals: 
 
 Yes    No    Unk Animal:       
Zoo name:       Address/Zip/County:       
 
Water Exposures – In the 3 days prior to the onset of symptoms did the case 
Go swimming?  Yes    No    Unknown 
If Yes, complete the table below: 
 
Water Type Location Type Dates visited Facility name /  Street address & Zip 
 Hot tub/spa 
 Kiddie pool 
 River/stream 
 Lake 
 
 Pond  
 Water park 
 Swimming pool 
 Water fountain/ splash pad 
 Other_________________ 
 Hotel/motel 
 Indoor private 
 Indoor public   
 Outdoor private 
 Outdoor public 
From 
     /     /      
To 
     /     /      
 
 
 
 
Drinking water supply 
Home:  Bottled 
 Commercial Delivery 
 Municipal 
 Rural water 
 Well 
 
School:  Bottled 
 Commercial Delivery 
 Municipal 
 Rural water 
 Well 
 
Work:  Bottled 
 Commercial Delivery 
 Municipal 
 Rural water 
 Well 
 
Child care:  Bottled 
 Commercial Delivery 
 Municipal 
 Rural water 
 Well 
 
 
Other Exposures – In the 3 days prior to the onset of symptoms did the case: 
Wear diapers  Yes    No    Unk Have contact with diapers:  Yes    No    Unk 
    
Have contact with 
immunocompromised person:  Yes    No    Unk Setting: 
 Home 
 Work      Other _______________________________________ 
     
Have sex with someone with 
similar symptoms:  Yes    No    Unk 
Sexual 
preference: 
 Hetero 
 Homo 
 Bisexual 
 Unknown 
 
 
Number of people living in case’s household:          
 
Are there close contacts of the case with same symptoms:   Yes    No    Unknown 
 
Close contacts of the case with the same symptoms 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
Same 
exposures 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
      
 
     /     /      
 Restaurant    
 Gatherings   
 Food 
 Animal 
 Water 
 
 Yes 
 No 
      
      
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
Same 
exposures 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
      
 
     /     /      
 Restaurant    
 Gatherings   
 Food 
 Animal 
 Water 
 
 Yes 
 No 
      
      
If this contact is a case create a new event and/or case for this contact. 
 
NOTES:       
 
 
 
 
 
CONTACTS 
Center for Acute Disease Epidemiology                      Fax: 515-281-5698                         Salmonella                          Revised Mar-15                  5  
Guide to Surveillance, Investigation, and Reporting 
Severe Acute Respiratory  
Syndrome 
 
Also known as:  SARS 
 
 
Responsibilities: 
Hospital:  Immediately by phone 
Infection Preventionist: Interview patient for risk factors 
Lab: Report immediately by phone. Specimens should be sent to the State Hygienic Laboratory 
(SHL) 
Physician: Report immediately by phone 
Local Public Health Agency (LPHA): Immediate follow-up required 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
SARS is caused by a member of the family coronaviridae, called SARS–associated coronavirus (SARS-
CoV).  The disease was first reported in Asia in 2003. 
  
B. Clinical Description 
Symptoms: SARS begins with a flu-like syndrome characterized by fever (>100.4o F), fatigue, 
headache, chills, myalgia, malaise, anorexia and, in some cases, diarrhea. 
 
Onset of SARS occurs 3-10 days after infection with acute onset of fever.  Dry cough and respiratory 
symptoms may begin 2 –7 days later.  
 
Complications: Most patients develop pneumonia. 
 
C. Reservoirs 
Cave-dwelling bats in the genus Rhinolophus (Chinese horseshoe bats) are a reservoir of SARS-like 
coronaviruses closely related to those responsible for the SARS epidemic.  
 
D. Modes of Transmission 
Person-to-person: The virus that causes SARS is thought to be transmitted most readily by 
respiratory droplets produced when an infected person coughs or sneezes. 
 
Fomite: The virus also can spread when a person touches a surface or object contaminated with 
infectious droplets and then touches his or her mouth, nose, or eyes. 
 
Airborne: It is possibly spread more broadly through the air or by other ways that are not currently 
known. 
 
E. Incubation Period 
Report Immediately   
by Phone 
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The incubation period for SARS is typically 3 –10 days, although in some cases it may be as long as 
10 days.  In a very small proportion of cases, incubation periods of up to 14 days have been 
reported. 
 
F. Period of Communicability or Infectious Period 
Persons with SARS are most likely to be contagious only when they have symptoms, such as fever or 
cough.  Patients are most contagious during the second week of illness.  Maximum period of 
communicability is less than 21 days. 
 
G. Epidemiology 
SARS is a viral respiratory illness recognized as a global threat in March 2003, after first appearing in 
Southern China in November 2002.  During November 2002 through July 2003, 8,098 people 
worldwide became sick with SARS.  Of these, 774 died.  In the U.S., eight cases of SARS were 
laboratory-confirmed during the 2003 outbreak. The cases all had either a history of travel to 
countries where SARS was occurring or close contact to a confirmed case. 
 
H. Bioterrorism Potential 
None.  
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To assess the magnitude of the disease in different areas and among different risk groups. 
• To identify outbreaks as soon as possible. 
• To monitor for the emergency of SARS in new areas and new risk groups. 
• To implement control or prevention.   
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
report any suspected or confirmed cases of SARS. The reporting number for IDPH Center for Acute 
Disease Epidemiology (CADE) is (800) 362-2736. If calling after business hours, call the Iowa State 
Patrol Office at (515) 323-4360 and they will page a member of the on-call CADE staff. 
 
C.  Local Public Health Agency Follow-up Responsibilities 
Case Investigation 
a. Case investigation of SARS disease in Iowa residents will be directed by IDPH, Center for Acute 
Disease Epidemiology (CADE). 
b. Following notification of IDPH, the LPHA(s) may be asked to assist in completing the case 
investigation.  Contact CADE for proper forms.  Interviewing the case and others who may be ill 
to provide pertinent information will help in completing forms. 
c. Contact tracing will be needed and people assessed as soon as possible, along with initiation of 
isolation or quarantine, if applicable. 
 
3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements 
In healthcare settings, suspected SARS patients should be immediately triaged and placed in airborne 
isolation, including negative pressure rooms.  Healthcare providers must wear masks (N95 if 
available), eye protection, gowns and gloves. 
• In some instances, contacts of SARS patients may be managed by using passive or active 
monitoring.  Monitoring consists of direct contact – by phone or in person – with the health 
department or a designee at least once a day to assess the affected person for symptoms 
and address any needs.  Frequent monitoring (e.g., twice a day) can reduce the interval 
between the onset of symptoms and the institution of precautions.  Passive monitoring relies 
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on the affected person to contact health authorities if symptoms develop.  Persons with 
high-risk exposures (e.g., healthcare workers involved in aerosol-generating procedures on a 
SARS patient) may require activity restrictions in addition to monitoring.  
• Quarantine of contacts may be used during a large outbreak or in situations of high-risk 
exposures (e.g., if transmission from a particular case has been demonstrated by emergence 
of secondary cases among one or more contacts). 
 
B.  Protection of Contacts of a Case 
• All close contacts of SARS cases  should be in quarantine and should be advised to: 
o Be vigilant for fever (e.g., measure temperature twice a day), respiratory symptoms, 
and other symptoms of early SARS-CoV illness for 10 days after exposure. 
o Contact a designated health department staff member if symptoms develop so that 
clinical evaluation can be performed without delay. 
o Inform the healthcare provider in advance of a visit to a healthcare facility about 
possible exposure to SARS-CoV. 
 
C.  Managing Special Situations 
Reported Incidence Is Higher than Usual/Outbreak Suspected:  
Refer to healthcare facility SARS plan or IDPH SARS Response Plan. 
  
Exposure of a Laboratory Worker  
• Clinical laboratories performing routine hematology, urinalysis, and clinical chemistry studies, 
and microbiology laboratories performing diagnostic tests on serum, blood, or urine 
specimens, should follow standard laboratory practices, including standard precautions, 
when handling potential SARS-CoV specimens. For additional information, see 
www.osha.gov./SLTC/bloodbornepathogens/index.html 
• Microbiology and pathology laboratories performing diagnostic tests on stool or respiratory 
specimens should handle potential SARS-CoV specimens using standard Bio-safety Level 
(BSL)-2 work practices in a Class II biological safety cabinet.  
 
SARS transmission has occurred in several researchers working with SARS virus.  All laboratorians 
must take appropriate precautions when handling specimens to be tested for SARS.  Send all 
specimens to SHL. Do not perform tests in the hospital laboratory. 
 
D. Preventive Measures 
Preventive Measures/Education 
• All healthcare providers should know and follow appropriate isolation precautions when 
caring for a suspect or confirmed SARS patient. 
• Contacts of SARS patients should be educated on signs and symptoms and who to contact 
should symptoms occur. 
• Isolation and quarantine should be instituted as indicated. 
 
4) ADDITIONAL INFORMATION 
 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for SARS can 
be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
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FACT SHEET         Severe Acute Respiratory Syndrome 
                                                              (SARS) 
 
What is SARS? 
Severe Acute Respiratory Syndrome (SARS) is a disease that can cause severe difficulty breathing and 
pneumonia. 
 
Who can be infected? 
Anyone can become infected but cases of SARS have been reported mainly among people who have had 
direct close contact with an infected person, such as those sharing a household with a SARS patient and 
healthcare workers who did not use infection prevention procedures while taking care of a SARS patient. 
In the United States, there have been signs of community spread, though spread to close contacts and 
healthcare workers has not occurred. 
 
How does SARS Spread? 
The main way that SARS appears to spread is by close person-to-person contact. Most cases of SARS 
have involved people who cared for or lived with someone with SARS, or who had direct contact with 
infectious material (for example, respiratory secretions) from a person who has SARS. Potential ways in 
which SARS can be spread include touching the skin of other people or objects that are dirty with 
infectious droplets and then touching your eye(s), nose, or mouth. This can happen when someone who 
is sick with SARS coughs or sneezes droplets onto themselves, other people, or nearby surfaces. It also is 
possible that SARS can be spread more broadly through the air or by other ways that are currently 
unknown. 
 
What are the symptoms of SARS? 
Symptoms of SARS will begin within 10 days of exposure. In general, SARS begins with a fever greater 
than 100.4°F [>38.0°C]. Other symptoms may include headache, an overall feeling of discomfort, and 
body aches. Some people also experience mild respiratory symptoms. After 2 - 7 days, SARS patients 
may develop a dry cough and have trouble breathing, frequently leading to pneumonia. 
 
What is the cause of SARS? 
Scientists at CDC and other laboratories have detected a previously unknown virus. This has been named 
SARS-associated coronavirus (SARS-CoV).   
 
Are there travel recommendations related to SARS? 
When SARS is occurring in the world, CDC will issue recommendations and guidelines for people who 
may be affected.  CDC will also issue travel alerts for areas where SARS may be present but no 
transmission is occurring. In these areas, CDC recommends that U.S. travelers observe precautions to 
safeguard their health. These precautions include frequent handwashing and staying away from ill 
people. 
 
Travelers to areas reporting SARS cases should avoid settings where transmission is most likely to occur, 
such as health care facilities, caring for SARS patients, and residences of SARS patients. 
 
What should people do if they think they might have SARS? 
People who have had potential exposure to SARS and/or have had contact with someone with SARS 
should monitor their health status for 10 days after their last possible exposure. People with symptoms of 
SARS (fever greater than 100.4°F [>38.0°C] accompanied by a cough and/or difficulty breathing) should 
limit their contact with others and call their healthcare provider to arrange to be seen in a safe manner at 
a clinic or emergency room. Do not go to a clinic or emergency room without calling ahead. To help 
healthcare providers make a diagnosis, tell them about any recent travel to places where SARS has been 
reported or whether there was contact with someone who had these symptoms. Cover your mouth and 
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nose with tissue when coughing or sneezing. If you have a surgical mask, wear it during close contact 
with other people. A mask can reduce the number of droplets coughed into the air. 
 
If you have SARS and are being cared for at home, you should: 
Follow the instructions given by your state or local health department, which will include: 
Staying home until 10 days after temperature has returned to normal and respiratory symptoms have 
gone away. Other instructions may be:  
• Do not go to work, school, or public areas. 
• Wash your hands often and well, especially after you have blown your nose. 
• Cover your mouth and nose with tissue when you sneeze or cough. 
• If possible, wear a surgical mask when around other people in your home. If you can’t wear a 
mask, the members of your household should wear one when they are around you. 
• Do not share silverware, towels, or bedding with anyone in your home until these items have 
been washed with soap and hot water. 
• Clean surfaces (counter or tabletops, door knobs, bathroom fixtures, etc.) that have been 
contaminated by body fluids (sweat, saliva, mucous, or even vomit or urine) from the SARS 
patient with a household disinfectant used according to the manufacturer’s instructions. Wear 
disposable gloves during all cleaning.  Throw these out when you are done. Do not re-use them. 
If clothing has become soiled with body fluids, it should be changed. 
• Follow these instructions for 10 days after fever and respiratory symptoms are gone. 
 
If you are caring for someone at home who has SARS, you should: 
• Be sure that the patient has contacted a healthcare provider and is following instructions for 
medication and care. 
• Be sure that all members of your household are washing their hands frequently with soap and 
warm water or using alcohol-based hand wash. 
• Wear disposable gloves if you have direct contact with body fluids of a SARS patient. However, 
the wearing of gloves is not a substitute for good hand hygiene. After contact with body fluids of 
a SARS patient, remove the gloves, throw them out, and wash your hands. Do not wash or re-
use the gloves. 
• Encourage patients with SARS to cover their mouth and nose with a tissue when coughing or 
sneezing. If possible, the patient should wear a surgical mask during close contact with other 
people in the home. If the patient cannot wear a surgical mask, other members of the household 
should wear one when in the same room with that person. 
• Do not use silverware, towels, bedding, clothing, or other items that have been used by the 
patient until these items have been washed with soap and hot water. 
• Clean surfaces (counter or tabletops, door knobs, bathroom fixtures, etc.) that have been 
contaminated by body fluids (sweat, saliva, mucous, or even vomit or urine) with a household 
disinfectant used according to the manufacturer’s instructions. Wear disposable gloves during all 
cleaning.  Throw these out when done. Do not re-use them. If clothing has become soiled with 
body fluids, it should be changed. 
• Follow these instructions for 10 days after the patient’s fever and respiratory symptoms have 
gone away. 
• If you develop a fever or respiratory symptoms, call your healthcare provider immediately and tell 
him or her that you have had close contact with a SARS patient. 
 
What laboratory tests are available for SARS? 
Several laboratory tests can be used to detect SARS-CoV.  A reverse transcription polymerase chain 
reaction (RT-PCR) test can detect SARS-CoV in clinical specimens such as blood, stool and nasal 
secretions. Diagnosis is a combination of history, symptoms and tests results. 
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What should be done for healthy people returning to the U.S. from areas of risk? 
The risk in a healthy individual traveler is extremely low. A traveler with no symptoms needs to monitor 
for a fever > 100.4 F and/or cough for 10 days after leaving the affected area. If symptoms develop, 
contact a healthcare provider immediately by phone.  Do not go to a clinic or hospital without phoning 
first so proper isolation precautions can be immediately taken to prevent spread.  
 
This fact sheet provides basic information about the disease and what is being done to fight its spread. 
To find out more about SARS, go to CDC's SARS web site: www.cdc.gov/niosh/topics/SARS/  
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CONFIDENTIAL                                                                                                                                 Iowa Department of Public Health 
SARS                                 Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Facility phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome: 
 Survived this illness     Died from this illness 
 Died unrelated to this illness    Unknown 
Date of death      /     /      First name: 
 
      
Event exception 
 Case could not be found 
 Case could not be interviewed 
 Case refused interview 
 Other – see notes 
Provider title:  ARNP   
 DO 
 MD 
 NP  PA 
Outbreak 
related:  Yes      No      Unknown  
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes   No  Unk To whom: ______________  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
 
Result type: 
 
 Preliminary      Final 
 
Result date: 
 
     /     /      Result: 
 Positive 
 Negative    
 
Organism: 
 
SARS-CoV  
   
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
 
Result type: 
 
 Preliminary      Final 
 
Result date: 
 
     /     /      Result: 
 Positive 
 Negative    
 
Organism: 
 
SARS-CoV  
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Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
 
Result type: 
 
 Preliminary      Final 
 
Result date: 
 
     /     /      Result: 
 Positive 
 Negative    
 
Organism: 
 
SARS-CoV  
   
 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’ 
(If yes, complete the following sections for each known occupation) 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
Initial classification 
(select one): 
 Severe respiratory illness with no known epi link 
 mild to moderate respiratory illness and epi link including possible SARS exposure 
 Severe respiratory illness and epi link including possible SARS exposure 
 Mild to moderate respiratory illness and epi link including likely SARS exposure 
 Severe respiratory illness and epi link including likely SARS exposure 
 Clinically compatible illness and laboratory confirmation of SARS-CoV 
 
Fever:  Yes    No    Unk 
Onset Date:  
     /     /      
 
Duration:       hours/days 
 
Highest known fever:       
C/F 
Other symptoms: 
 
 Chills 
 Cough 
 
 Diarrhea 
 Fever 
 
 Shortness of breath 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
 
 
Health care provider visited:   Yes    No    Unknown 
If Yes, complete the following table: 
Facility 
name:         
 
Address: 
 
      
Zip 
code: 
 
      
 
City: 
 
      
      
State:       
 
County: 
 
        
Phone: (     )-     -      
 
   Type:       
Date 
visited:      /     /      
Time 
visited:       
Provider 
name:       Title:        
 
 Chest x-ray done: 
 
 Yes    No    Unk 
 
Date: 
 
     /     /      
 
Result: 
 
      
Pneumonia:  Yes    No    Unk 
 
Suggestive of RDS:  Yes    No    Unk 
CAT scan done: 
 
 Yes    No    Unk 
 
Date:      /     /      
 
Result: 
 
      
 
Updated classification 
(select one): 
 
 Severe respiratory illness with no known epi link 
 Mild to moderate respiratory illness and epi link including possible SARS exposure 
 Severe respiratory illness and epi link including possible SARS exposure 
 Mild to moderate respiratory illness and epi link including likely SARS exposure 
 Severe respiratory illness and epi link including likely SARS exposure 
 Clinically compatible illness and laboratory confirmation of SARS-CoV 
 Not a case: negative serology (> 28 days post onset) 
 Not a case: alternative diagnosis accounts for illness  
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Risk Factors/Travel Information – In the 10 days prior to onset of symptoms: 
 
Traveled 
within Iowa: 
 Yes    No   
 Unk 
Departure 
date:      /     /      
Traveled 
within Iowa: 
 Yes    No   
 Unk 
Departure 
date:      /     /      
City within 
Iowa:   
 
 Yes    No   
 Unk Return date:      /     /      
City within 
Iowa:   
 Yes    No   
 Unk Return date:      /     /      
Type: 
 
 Airline 
 Automobile 
 Bus 
Cruise ship 
 Train 
Company 
name:  
Type: 
 Airline 
 Automobile 
 Bus 
Cruise ship 
 Train 
Company 
name:  
Transport #:  Transport #:  
Tour group: 
 
 Yes    No   
 Unk 
Symptomatic 
during travel: 
 Yes    No    
 Unk Tour group: 
 Yes    No   
 Unk 
Symptomatic 
during travel: 
 Yes    No    
 Unk 
 
Traveled 
within U.S.: 
 Yes    No   
 Unk 
Departure 
date:      /     /      
Traveled 
within U.S.: 
 Yes    No   
 Unk 
Departure 
date:      /     /      
City, State  
 
 Yes    No   
 Unk Return date:      /     /      City State    
 
 Yes    No   
 Unk Return date:      /     /      
Type: 
 
 Airline 
 Automobile 
 Bus 
Cruise ship 
 Train 
Company 
name:  
Type: 
 Airline 
 Automobile 
 Bus 
Cruise ship 
 Train 
Company 
name:  
Transport #:  Transport #:  
Tour group: 
 
 Yes    No   
 Unk 
Symptomatic 
during travel: 
 Yes    No    
 Unk Tour group: 
 Yes    No   
 Unk 
Symptomatic 
during travel: 
 Yes    No    
 Unk 
 
Travel 
outside 
U.S.: 
 Yes    No   
 Unk 
Departure 
date:      /     /      
Traveled 
outside U.S.: 
 Yes    No   
 Unk 
Departure 
date:      /     /      
City Country: 
 
 Yes    No   
 Unk Return date:      /     /      City Country  
 Yes    No   
 Unk Return date:      /     /      
Type:  
 Airline 
Company 
name:  
Type:  Airline 
 Automobile 
Company 
name:  
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation period for 
SARS is 3 to 10 days 
SARS is communicable for 
up to 21 daysafter onset of 
symptoms 
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 Automobile 
 Bus 
Cruise ship 
 Train Transport #:  
 Bus 
Cruise ship 
 Train 
Transport #:  
Tour group: 
 
 Yes    No   
 Unk 
Symptomatic 
during travel: 
 Yes    No    
 Unk Tour group: 
 Yes    No   
 Unk 
Symptomatic 
during travel: 
 Yes    No    
 Unk 
Contact with confirmed or 
probable SARS CoV case:  Yes    No    Unknown 
Contact with epi-linked SARS 
CoV case:  Yes    No    Unknown 
 
 
Number of people living in case’s household:          
 
Are there close contacts of the case with similar symptoms:   Yes    No    Unknown 
Close contacts with similar symptoms 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
Did the case recently travel to an 
area with SARS transmission?  Yes    No    Unknown If yes, where: 
 
      
 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
Did the case recently travel to an 
area with SARS transmission?  Yes    No    Unknown If yes, where: 
 
      
 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
 
           /     /      
 
 Yes 
 No 
       
       
If this contact is a case create a new event and/or case for this contact. 
Did the case recently travel to an 
area with SARS transmission?  Yes    No    Unknown If yes, where: 
 
      
 
Notes: 
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11. Classification of patient by state of municipality (using CSTE/CDC definitions): SEE APPENDIX B1 
Initial Classification (check one only): Updated Classification (check one only): 
Report Under Investigation (RUI) 
□ RUI-1 
□ RUI-2  
□ RUI-3  
□ RUI-4 
OR SARS disease classification 
□ Probable SARS-CoV Case 
□ Confirmed SARS-CoV Case 
□ RUI-1 
□ RUI-2  
□ RUI-3  
□ RUI-4 
□ Probable SARS-CoV Case 
□ Confirmed SARS-CoV Case 
□ Not a case: negative serology (>28 days post onset) 
□ Not a case: alternative diagnosis accounts for illness 
Date Updated (most recent):  
__ __ / __ __ / __ __ __ __ 
m    m       d    d         y    y    y    y 
 
13. Alternative Diagnosis 
Was an alternative respiratory pathogen 
detected? 
 
□ Yes 
□ No  
□ Unknown 
If yes indicate which one (see list below): _________________________________________________ 
Alternative pathogen (e.g., Influenza A, Influenza B, RSV, rhinovirus, adenovirus, Streptococcus pneumoniae, 
Haemophilus influenzae, Mycoplasma, Chlamydia pneumoniae, human parainfluenza virus 1, human parainfluenza 2, 
human parainfluenza 3,  human metapneumovirus, Legionella sp., other.):  
14. List specimens sent to the CDC 
Chose from the following specimens to enter below:  
Whole blood, plasma, serum (acute), serum (convalescent), NP swab, NP aspirate, broncheoalveolar lavage 
specimen, OP swab, tracheal aspirate, pleural tap, urine, stool, tissue. 
Specimen 1: 
___________________ 
If ‘Tissue’, Specify: ____________ Date Sent: __ __ / __ __ / __ __ __ __ 
                  m    m       d    d         y    y    y    y 
Specimen 2: 
___________________ 
If ‘Tissue’, Specify: ____________ Date Sent: __ __ / __ __ / __ __ __ __ 
                  m    m       d    d         y    y    y    y 
Specimen 3: 
___________________ 
If ‘Tissue’, Specify: ____________ Date Sent: __ __ / __ __ / __ __ __ __ 
                  m    m       d    d         y    y    y    y 
Specimen 4: 
___________________ 
If ‘Tissue’, Specify: ____________ Date Sent: __ __ / __ __ / __ __ __ __ 
                  m    m       d    d         y    y    y    y 
Specimen 5: 
___________________ 
If ‘Tissue’, Specify: ____________ Date Sent: __ __ / __ __ / __ __ __ __ 
                  m    m       d    d         y    y    y    y 
Specimen 6: 
___________________ 
If ‘Tissue’, Specify: ____________ Date Sent: __ __ / __ __ / __ __ __ __ 
                  m    m       d    d         y    y    y    y 
Specimen 7: 
___________________ 
If ‘Tissue’, Specify: ____________ Date Sent: __ __ / __ __ / __ __ __ __ 
                  m    m       d    d         y    y    y    y 
Specimen 8: 
___________________ 
If ‘Tissue’, Specify: ____________ Date Sent: __ __ / __ __ / __ __ __ __ 
                  m    m       d    d         y    y    y    y 
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SHIGELLOSIS 
 
Potential Bioterrorism Agent: Category B 
  
Also known as: Bacillary dysentery, Shigella 
 
Responsibilities: 
Hospital: Report by facsimile, mail or phone 
Lab: Report by facsimile, mail or phone 
Physician: Report by facsimile, mail or phone 
Local Public Health Agency (LPHA): Follow-up required 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax:  (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Shigellosis refers to disease caused by any bacteria in the genus Shigella. There are four Shigella 
species: S. dysenteriae (Group A), S. flexneri (Group B), S. boydii (Group C), and S. sonnei (Group 
D). Groups A, B, C, and D are further divided into 12, 14, and 18 serotypes, respectively, but S. 
sonnei consists of only one serotype.  Some strains produce enterotoxin and Shiga toxin, which 
probably play a role in destructive ulcerations in the intestines once the organisms have invaded. This 
explains the watery and sometimes bloody diarrhea seen the first or second day of illness. 
 
B. Clinical Description 
Symptoms: are characterized by diarrhea accompanied by fever, nausea and sometimes, vomiting, 
cramps and tenesmus (painful, especially ineffectual straining at stool or urination). 
 
Onset: typically includes blood and mucus in stools, resulting from mucosal ulcerations and minute 
abscesses caused by the invasive organisms. Milder cases may have a watery diarrhea. Illness is 
usually self-limited, lasting an average of 4 - 7 days 
 
Complications: The most common complication is dehydration, but they may also include convulsions 
in young children. The severity of illness is a function of the host (age and preexisting nutritional 
state), the serotype, and bacteria’s ability to produce toxin. Death is uncommon in U.S., but common 
worldwide.   
 
C. Reservoirs 
Common reservoirs: Humans are the only significant reservoir. 
 
D. Modes of Transmission 
Person-to-Person: Transmitted via the fecal-oral route. People shedding bacteria may contaminate 
food by failing to properly wash their hands before food handling, potentially causing large numbers 
of people to become ill.  A very small dose of Shigella is needed to cause illness (probably 10 – 100 
organisms); thus, it can be easily spread.  Person-to-person spread typically occurs among household 
contacts, pre-school children in child care, and the elderly and developmentally disabled living in 
residential facilities. Secondary attack rate in households can be as high as 40%. Transmission can 
also occur person-to-person through certain types of sexual contact (e.g., oral-anal contact).  
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Foodborne: Flies can potentially spread the bacteria by landing on contaminated feces and then on 
food. This is most common during international travel. 
Waterborne:  Fecal contaminated recreational water, such as fill and drain wading pools, can be a 
source for spread. 
 
E. Incubation period 
The incubation period can vary from 12 - 96 hours, but is usually about 24 - 72 hours. It can be up to 
a week for S. dysenteriae. 
 
F. Period of Communicability or Infectious Period 
The disease is communicable as long as infected people excrete Shigella in their stool. This usually 
lasts for about 4 weeks from onset of illness; however, people are most infectious while having 
diarrhea. Effective antibiotic treatment has been shown to decrease the shedding period to a few 
days. 
 
G. Epidemiology 
Shigellosis has a worldwide distribution, with approximately 600,000 deaths reported annually 
throughout the world. Two-thirds of these cases and most of the deaths are in children under 10.  
Secondary attack rates can be as high as 40% in households. Every year about 14,000 cases are 
reported in the U.S.  Approximately 100 cases are reported in Iowa annually. Outbreaks most often 
occur in child care centers, among men who have sex with men, and in jails. Outbreaks have also 
been caused by contaminated imported food. S. sonnei is the most common Shigella species reported 
in Iowa. Diapered children playing in “kiddie” pools or other recreational water for young children 
filled with tap water without addition of chlorine or bleach can also easily spread Shigella. 
 
H. Bioterrorism Potential 
Category B Agent: Shigella has been identified as a potential category B bioterrorism agent as a 
food safety threat. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To determine whether a case may be a source of infection for others (e.g., a diapered child, child 
care attendee or food handler) and if so, to prevent further transmission. 
• To identify transmission sources of public health concern (e.g., a restaurant or a commercially 
distributed food product) and to stop transmission.  
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report. The preferred method of reporting is by utilizing the Iowa Disease Surveillance System 
(IDSS).  However, if IDSS is not available, the reporting number for IDPH Center for Acute Disease 
Epidemiology (CADE) is (800) 362-2736; fax number (515) 281-5698, mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th Street 
Des Moines, IA 50319-0075 
 
Postage-paid disease reporting forms are available free of charge from the IDPH clearinghouse.   
Call (319) 398-5133 or visit the website: 
healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295 to request a supply. 
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Laboratory Testing Services Available 
The University of Iowa State Hygienic Laboratory (SHL) provides testing of stool specimens for the 
presence of Shigella and will confirm and speciate isolates of Shigella obtained from clinical 
specimens at other laboratories. All laboratories are required to submit all isolates cultured for further 
identification to aid in the public health surveillance necessary for this illness and to prevent further 
transmission. For more information call SHL at (319)-335-4500.  
 
SHL will test implicated food items from a cluster or outbreak.  Food samples are submitted through 
consultation with SHL and the Centers for Acute Disease Epidemiology by the local public health 
department. 
 
C.  Local Public Health Agency Follow-up Responsibilities 
Case Investigation 
Following notification, the LPHA(s) will complete an official investigation. Information can be entered 
into IDSS by interviewing the case and others who may be able to provide pertinent information. 
Much of the information required can be obtained from the healthcare provider or the medical record.  
 
a. Use the following guidelines to complete the investigation: 
1) Accurately record the demographic information, date of symptom onset, symptoms, 
diagnostic testing, date of specimen collection, laboratory conducting the testing, species 
identification and serotyping. Please, request isolates to be sent to the SHL.  
2) When asking about exposure history (food, travel, activities, etc.), use the incubation period 
for shigellosis (12–96 hours). Specifically, focus on the period beginning a minimum of 12 
hours prior to the case’s onset back to 96 hours before onset. 
3) Record any restaurants at which the case ate during the incubation period, including food 
item(s) and date consumed. If it is suspected that the case became infected through food, 
further investigation may be needed  
4) Ask about travel history and outdoor activities to help identify where the case may have 
been infected. 
5) Ask about the case’s water supply as well as recreational water activities because Shigella 
may be acquired through water consumption.   
6) A case history that includes household/close contacts, antimicrobial treatment, pet or other 
animal contact, child care, and food-handler questions is designed to look for possible 
exposure and also to assess potential for transmitting and risk to others. Important 
information from a public health perspective would include child care attendance or 
employment or food handling.  
7)  If repeated attempts to obtain case information have been unsuccessful (e.g., the case or 
healthcare provider does not return calls or respond to a letter, or the case refuses to 
divulge information or is too ill to be interviewed), please complete the investigation with as 
much information as possible.  Please note on the form the reason why it could not be filled 
out completely. If using IDSS, select the appropriate reason under the Event tab in the 
Event Exception field. 
 
b. After compiling the information, enter into IDSS (the preferred method for investigation) or 
complete the investigation form, attach lab report(s) when available and fax (515) 281-5698 or 
mail (in an envelope marked “Confidential”) to IDPH Center for Acute Disease Epidemiology.  
The mailing address is:  
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th Street 
Des Moines, IA 50319-0075 
 
c. Disease-control measures are an integral part of case investigation. It is the LPHA responsibility 
to understand, and, if necessary, institute the control guidelines listed below. 
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3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements 
Food handlers, healthcare providers and people in child care with shigellosis must be excluded.  
 
Minimum Period of Isolation of Patient 
For food handlers and child care employees and attendees and direct care givers, two negative stool 
cultures must be obtained after resolution of diarrhea before they may return to work/school/child 
care. If a case has been treated with an antimicrobial, the stool specimen shall not be submitted until 
at least 48 hours after completion of therapy and the two specimens must be taken at least 24 hours 
apart. Good hand hygiene must be practiced. 
 
Minimum Period of Quarantine of Contacts 
Food handlers, healthcare providers and child care attendees who are contacts to a case and 
symptomatic with diarrhea shall be considered the same as a case and they must comply with the 
above requirements. 
 
Note: A food handler is any person directly preparing or handling food.  This can include a patient-
care or child care provider.  See glossary for a more complete definition. 
 
B.  Protection of Contacts of a Case 
Instructions for stringent hand-hygiene practices will be shared with all cases as well as their 
contacts. 
 
C.  Managing Special Situations 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
Child care  
Since shigellosis may be easily transmitted person-to-person through the fecal-oral route and fecal 
contamination is common in toddlers, it is important to carefully follow up on cases of shigellosis in 
child care settings.  General recommendations include:  
 
• Children with Shigella infection who have diarrhea should be excluded until their diarrhea is gone 
and have 2 negative stool cultures taken at least 24 hours apart.  If treated with antibiotics, wait 
48 hours after completion of antibiotics before obtaining the first stool specimen and allow an 
additional 24 hours before obtaining the second specimen.  
• Children with Shigella infection who have no diarrhea but do have positive stool cultures and are 
not otherwise ill should be excluded as above. 
• Staff of child care programs who have Shigella in their stools should be excluded as above.   
• Always ensure thorough cleaning of the child care and disinfection of related items (such as 
toys). 
 
School  
Since shigellosis may be easily transmitted person-to-person via the fecal-oral route, it is important to 
carefully follow up on cases of shigellosis in a school.  General recommendations include:  
 
• Students or non food-handling staff with Shigella infection who have diarrhea should be excluded 
until their diarrhea is gone. 
 
• Students or staff with Shigella positive cultures who do not handle food, have no diarrhea, and 
are not otherwise sick may go to school if good hand hygiene is practiced. 
 
• Students or staff who handle food and have Shigella infection (symptomatic or not) must not 
prepare food until their diarrhea is gone and they have two negative stool tests (submitted at 
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least 48 hours after completion of antibiotic therapy, if antibiotics are given, and taken at least 24 
hours apart).  
 
• Ensure routine thorough cleaning of the environment.  
 
Community Residential Programs 
Actions taken in response to a case of shigellosis in a community residential program will depend on 
the type of program and the functional level of the residents.  
 
In long-term care facilities, residents with shigellosis should be placed on Standard (including enteric) 
Precautions until their symptoms subside and they test negative for Shigella. Staff members who give 
direct patient care (e.g., feed patients, provide mouth or denture care, or give medications) are 
considered food handlers and are subject to food handler restrictions as listed above.  In addition, 
staff members with Shigella infection who are not food handlers should not work until their diarrhea 
is completely resolved (no diarrheal stools for 24 hours).   
 
In residential facilities for the developmentally disabled, staff and clients with shigellosis must refrain 
from handling or preparing food for other residents until their symptoms have subsided and they 
have 2 stool tests negative for Shigella (submitted at least 48 hours after completion of antibiotic 
therapy, if antibiotics are given and taken at least 24 hours apart).  In addition, staff members with 
Shigella infection who are not food handlers should not work until diarrhea is gone, and they must 
practice good hand hygiene when they return to work.  Routine thorough cleaning of the 
environment must also occur. 
 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
If the number of reported cases of shigellosis in your city/town seems higher than usual, or if an 
outbreak is suspected, more intensive investigation is warranted. That includes looking for a common 
source. A common vehicle (such as water, food, or association with a child care) should be sought 
and appropriate preventive or control measures should be instituted. Control of person-to-person 
transmission requires special emphasis on personal cleanliness and sanitary disposal of feces. Consult 
with the epidemiologist on-call at the Center for Acute Disease Epidemiology (CADE) or the regional 
epidemiologist for guidance on prevention and surveillance for additional cases. 
 
Note:  Refer to Iowa’s Foodborne Illness Outbreak Investigation Manual. 
  
D. Preventive Measures 
Educate families with cases in households on ways to control spread. 
 
Shigella organisms readily develop antibiotic resistance; thus, antibiotics should be used judiciously. 
  
Environmental Measures 
If a water source is implicated it must be shut down. 
 
Implicated food must not be served. Samples of the food should be obtained before any disposal of 
food items. The decision about testing the food can be made in consultation with the CADE and the 
State Hygienic Laboratory (SHL). CADE can help coordinate pick up and testing of food samples. If a 
commercial product is suspected, CADE will coordinate follow-up with relevant agencies such as Iowa 
Department of Inspections and Appeals (DIA). 
 
Note: The role of the DIA is to provide policy and technical assistance, such as interpreting the Iowa 
Food Code, conducting a hazard analysis critical control point (HACCP) risk assessment, initiating 
enforcement actions and collecting food samples, with the environmental investigation.  
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The general policy of the SHL is to test only food samples implicated in suspected outbreaks, not 
single cases (except when botulism is suspected). The local public health agency (LPHA) may suggest 
that the handlers of food suspected in a single case locate a private laboratory that will test or freeze 
the food for a period of time in case additional reports are received.  
   
To prevent Shigella and other pathogens transmitted by the fecal-oral route, it is 
recommended that people: 
• Always wash their hands thoroughly with soap and water before eating or preparing food, after 
using the toilet, and after changing diapers. 
•  Wash children’s hands as well as their own after changing diapers. 
• In child care settings, dispose of feces in a sanitary manner. 
•  Scrub their hands with soap and water, when caring for someone with diarrhea, after cleaning 
the bathroom, helping the person use the toilet, or changing diapers, soiled clothes or soiled 
sheets. 
• Avoid sexual practices that may permit fecal-oral transmission. Latex barrier protection should be 
emphasized to prevent the spread of shigellosis to sexual partners and to prevent the exposure 
to, and transmission of, other pathogens. 
• Keep flies from contaminating food. 
• Routinely clean the environment thoroughly. 
• Clean environment with household disinfectant or bleach and water solution (one quarter cup 
bleach per gallon of water, mixed fresh daily). 
 
International Travel 
The following recommendations can be helpful for travelers to developing countries. 
• “Boil it, cook it, peel it, or forget it."   
• Drink only bottled or boiled water, keeping in mind that bottled carbonated water is safer than 
uncarbonated water.  
• Ask for drinks without ice unless the ice is made from bottled or boiled water. Avoid popsicles 
and flavored ices that may have been made with contaminated water.  
• Eat foods that have been thoroughly cooked and are still hot and steaming.  
• Avoid raw vegetables and fruits that cannot be peeled. Vegetables like lettuce are easily 
contaminated and are often inadequately washed. 
• Peel your own raw fruits or vegetables and do not eat the peelings.  
• Avoid foods and beverages from street vendors.  
 
Note: For more information on international travel, contact the Center for Disease Control and 
Prevention (CDC), Traveler’s Health Office, at (877) 394-8747 or through the Internet at 
www.cdc.gov/travel. 
 
4) ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Shigellosis 
can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
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FACT SHEET SHIGELLOSIS 
 (Shigella) 
 
What is Shigellosis? 
Shigellosis is an infection of the gut caused by the bacterium, Shigella.  Most people become ill in the 
summer and early fall.   
 
What are the symptoms of an infection with Shigella bacteria? 
A person(s) infected with Shigella may have mild to severe diarrhea, fever, and painful bloody, mucous 
stools.  Some infected person(s) may not have any symptoms. 
 
How soon do symptoms appear? 
Diarrhea may appear 12 hours to 4 days after infection, but usually within 1 - 3 days. 
 
How is Shigella spread? 
Shigella is found in the feces (stool) of an infected person(s).  It is very easily spread by close contact with 
an infected person or eating contaminated food or drinking contaminated water.  Once one person in the 
family is ill it is common for other family members to become ill. 
 
Who gets Shigellosis? 
Anyone can get Shigellosis. Young children, especially those in child care centers, or living in crowded 
conditions, are infected more often. 
 
How long is a person infectious? 
During the time a person is ill and up to four weeks after the illness.  
 
What is the treatment?  
Most people will recover without treatment. People with severe diarrhea, especially small children and 
elderly people, should see a doctor. 
 
Do infected people need to be excluded from school, work, or child care? 
Since Shigella is found in the feces (stool), and is easily spread, people with diarrhea should not go to child 
care, school, or work. For people who handle food, child care workers or attendees, or healthcare workers, 
treatment should be considered. These people should have two negative stool cultures, taken at least 24 
hours apart and not more than 48 hours after antibiotics stopped, if given, before they return to work or 
child care.    
 
How can you prevent the spread of these bacteria? 
Good handwashing with soap and running warm water for no less than 15 seconds (about the time it takes 
to sing “happy birthday” or “the ABC” song), that includes particular attention to the front and back of the 
hands and between the fingers, and particular attention to around and underneath the fingernails, must be 
practiced. Good handwashing must be done every time people use the toilet, change a diaper, or before 
they eat or prepare any food.  Infants and children must also have their hands washed, as above, after 
diapers have been changed or after using the toilet and before eating.  If children are helping to prepare 
food, their hands must be washed beforehand.  
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Shigellosis 
                                       Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak related:  Yes      No      Unknown Provider title:  ARNP    DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure setting:       Address line 1:       
Epi-linked:  Yes   No  Unk To whom: _________________  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
Laboratory: 
 
      Accession #: 
 
      
Collection 
date: 
 
     /     /      
 
Date received: 
 
     /     /      
Specimen 
source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Shigella  Serotype:    
 
Laboratory: 
 
      Accession #: 
 
      
Collection 
date: 
 
     /     /      
 
Date received: 
 
     /     /      
Specimen 
source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Shigella  Serotype:    
 
Laboratory: 
 
      Accession #: 
 
      
Collection 
date: 
 
     /     /      
 
Date received: 
 
     /     /      
Specimen 
source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Shigella  Serotype:    
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OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /       
       Isolated at entry: 
 
 Yes    No    Unk 
Isolation type 
(entry): 
 
      
Days 
hospitalized:        Currently isolated: 
 
 Yes    No    Unk 
Current isolation 
type: 
 
      
 
CLINICAL INFO & DIAGNOSIS 
 
HUS 
Diagnosis  Yes    No    Unk Onset Date      /     /      
TTP 
Diagnosis  Yes    No    Unk Onset Date      /     /      
 
S
ym
pt
om
s 
Diarrhea 
Nausea 
Vomiting 
Headache 
Muscle weakness 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
      Days/Hours 
      Days/Hours 
      Days/Hours 
      Days/Hours 
      Days/Hours 
Visible bloody 
diarrhea  
Fever 
Abdominal cramps 
Chills 
 
 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 
      Days/Hours 
      Days/Hours 
      Days/Hours 
      Days/Hours 
 
First symptom:       
Most severe 
symptom:       
Date returned to normal 
activities:      /     /      
 
OTHER LAB FINDINGS 
 
Clinical specimen from case 
Was PFGE performed:  Yes    No    Unk 
IA-XbaI 
Pattern       
IA-BlnI 
 Pattern       
CDC-XbaI 
Pattern       
CDC-BInI 
Pattern       
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
Environmental specimen testing 
Food, Medication, or 
environmental samples tested?  Yes    No    Unk 
Describe 
samples: (circle positives)       
For what were the samples 
tested? 
 E. coli or EHEC  Salmonella   
 Shigella              Other testing (specify): 
Laboratory:       Positive?  Yes    No    Unk 
PFGE 
performed?  Yes    No    Unk 
IA-XbaI 
Pattern       
IA-BlnI 
 Pattern       
CDC-XbaI 
Pattern       
CDC-BInI 
Pattern       
 
TREATMENT 
 
Antibiotics prescribed?   Yes    No    Unknown 
 
  
Antibiotic:       
  
Antibiotic:       
 
 
Antibiotic:       
Date 
started:      /     /      
Date 
started:      /     /      
Date 
started:      /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Risk Factors/Travel Information – In the 4 days prior to onset of symptoms did the case: 
Tr
av
el
 
Travel within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       Departure date:      /     /      Return date:      /     /      
Travel within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Travel outside U.S.?   
 Yes    No    Unk Country:       Departure date:      /     /      Return date:      /     /      
 
Visit restaurants?  Yes    No    Unknown 
If Yes, complete the table below:   County and address are missing from this table 
Establishment name Address/Zip Date visited Foods consumed Others ill? 
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
 
Attend Group Gatherings (e.g. weddings, parties)?  Yes    No    Unknown 
If Yes, complete the following table: 
Location name Address/Zip Date visited Foods consumed Others ill? 
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
 
Purchase groceries in the 2 weeks before the onset of symptoms: 
Store name Address City/State/Zip County Date purchased 
                        
 
     /     /      
                        
 
     /     /      
                        
 
     /     /      
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation period for 
Shigella is 12 hours to 4 
days. 
Shigella is communicable for several 
days to weeks. A temporary carrier 
state lasting months exists.  
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Dietary Information – In the 4 days prior to onset of symptoms did the case consume the following: 
Meat and poultry 
Any of these meat 
products?  Poultry      Ground beef      Meat other than ground meat (salami, jerky, wild game) 
Was the meat fully cooked?  Yes    No    Unknown 
List all source/types:       
List all brand names:       
From dates consumed:      /     /     ,      /     /      To dates consumed:      /     /     ,      /     /      
 
Other meat and poultry products 
Deli/lunch meat  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Raw/partially 
cooked eggs or in 
foods (e.g. cookie 
dough): 
 Yes    No    Unk 
From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
 
Unpasturized products 
Unpasteurized 
milk:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Unpasteurized 
juice:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Other 
unpasteurized 
products: 
 Yes    No    Unk 
From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
 
Other products 
Health supplements:  Yes    No    Unk From date consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Infant formula:  Yes    No    Unk From date consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Baby food:  Yes    No    Unk From date consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
 
Fruits and vegetables 
Raw fruits:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Raw vegetables:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
 
Other 
Leftover foods consumed: 
 Yes    No    Unk 
Reheated: 
 Yes    No    Unk 
 
From date consumed:      /     /      
 
To date consumed:      /     /      
Describe leftovers consumed: 
 
 
Animal Exposures – In the 4 days prior to the onset of symptoms did the case: 
Check all that apply 
Visit or live on a farm: 
Exposed to manure: 
Have farm animal contact: 
 Yes    No    Unknown 
 Yes    No    Unknown 
 Yes    No    Unknown 
 
 
Animals:       
 
Have reptile contact: 
Reptile lived with case: 
 
 Yes    No    Unknown 
 Yes    No    Unknown 
 
 Iguana    Lizard    Turtle    Snake    Other _____________________ 
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Have other animal  
contact in home: 
 
 Yes    No    Unknown Animal:       Animal sick:  Yes    No    Unk 
Visit a petting zoo: 
 
 Yes    No    Unknown Touched animals: 
 
 Yes    No    Unk Animal:       
Zoo name:       Address/Zip/County:       
 
Water Exposures – In the 4 days prior to the onset of symptoms did the case 
Go swimming?  Yes    No    Unknown 
If Yes, complete the table below: 
Water Type Location Type Dates visited Facility name /  Street address & Zip 
 Hot tub/spa 
 Kiddie pool 
 River/stream 
 Lake 
 
 Pond  
 Water park 
 Swimming pool 
 Water fountain/ splash pad 
 Other_________________ 
 Hotel/motel 
 Indoor private 
 Indoor public   
 Outdoor private 
 Outdoor public 
From 
     /     /      
To 
     /     /      
 
 
 
 
Drinking water supply 
Home:  Bottled 
 Commercial Delivery 
 Municipal 
 Rural water 
 Well 
 
School:  Bottled 
 Commercial Delivery 
 Municipal 
 Rural water 
 Well 
 
Work:  Bottled 
 Commercial Delivery 
 Municipal 
 Rural water 
 Well 
 
Child care:  Bottled 
 Commercial Delivery 
 Municipal 
 Rural water 
 Well 
 
 
Other Exposures – In the 8 days prior to the onset of symptoms did the case: 
Wear diapers  Yes    No    Unk Have contact with diapers:  Yes    No    Unk 
    
Have contact with 
immunocompromised person:  Yes    No    Unk Setting: 
 Home 
 Work      Other _______________________________________ 
     
Have sex with someone with 
similar symptoms:  Yes    No    Unk 
Sexual 
preference: 
 Hetero 
 Homo 
 Bisexual 
 Unknown 
 
 
Number of people living in case’s household:          
 
Are there close contacts of the case with same symptoms:   Yes    No    Unknown 
 
Close contacts of the case with the same symptoms 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
Same 
exposures 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
      
 
     /     /      
 Restaurant    
 Gatherings   
 Food 
 Animal 
 Water 
 
 Yes 
 No 
      
      
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case                      List symptoms Symptom  onset date 
Same 
exposures 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
      
 
     /     /      
 Restaurant    
 Gatherings   
 Food 
 Animal 
 Water 
 
 Yes 
 No 
      
      
If this contact is a case create a new event and/or case for this contact. 
 
NOTES:       
 
 
 
 
 
CONTACTS 
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SMALLPOX 
 
Potential Bioterrorism Agent:  Category A 
 
Responsibilities: 
Hospital: Report immediately by phone 
Lab: Report immediately by phone, send specimens for testing to State Hygienic Laboratory 
Physician: Report immediately by phone 
Local Public Health Agency (LPHA): ): Immediate follow-up required.  Iowa 
Department of Public Health will lead the follow-up investigation. 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
After Hours:  Iowa State Patrol Office at (515) 323-4360 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Smallpox is caused by the variola virus that emerged in human populations thousands of years ago. 
Except for laboratory stockpiles, the variola virus has been eradicated in the world.  
 
B. Clinical Description 
Symptoms: There is a clinical spectrum of disease with smallpox. Smallpox occurs in two clinical 
forms: variola major and variola minor. Variola major causes a more severe form of smallpox, with a 
more extensive rash and higher fever. Variola major has four distinct syndromes: ordinary (the most 
frequent type, accounting for 90% or more of cases); modified (mild and occurring in previously 
vaccinated persons); flat; and hemorrhagic (rare and very severe). Historically, variola major has an 
overall fatality rate of about 30%; however, flat and hemorrhagic smallpox usually are fatal. Variola 
minor is a less common presentation of smallpox, and a much less severe disease, with death rates 
historically of 1% or less. 
 
Onset:  The first symptoms of smallpox include fever, malaise, head and body aches, and 
sometimes vomiting. The fever is usually high, in the range of 1010 to 1040 Fahrenheit. At this time, 
people are usually too sick to carry on their normal activities. This is called the prodrome phase and 
may last for 2 - 4 days. 
 
A rash emerges first as small red spots on the tongue and in the mouth. These spots develop into 
sores that break open and spread large amounts of the virus into the mouth and throat. This is when 
the person is most contagious. Around the time the sores in the mouth break down, a rash appears 
on the skin, starting on the face and spreading to the arms and legs and then to the hands and feet. 
Usually the rash spreads to all parts of the body within 24 hours. As the rash appears, the fever 
usually falls and the person may start to feel better. By the third day of the rash, the lesions become 
raised bumps. By the fourth day, the bumps fill with a thick, opaque fluid and often have a 
depression in the center that looks like a bellybutton. (This is a major distinguishing characteristic of 
smallpox.) Fever often will rise again at this time and remain high until scabs form.  The bumps 
become pustules—sharply raised, usually round and firm to the touch as if there’s a small round 
object under the skin. People often say the bumps feel like BB pellets embedded in the skin. The 
pustules begin to form a crust and then scab. By the end of the second week after the rash appears 
most of the sores have scabbed over. The scabs begin to fall off, leaving marks on the skin that 
eventually becomes pitted scars. Most scabs will have fallen off three weeks after the rash appears. 
The person is contagious to others until all of the scabs have fallen off.  
Report Immediately 
by phone 
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Complications: arthritis was a common complication, all others are rare.  They may include secondary 
bacterial infection of skin lesions, sepsis, corneal ulceration and keratits, pulmonary edema, 
bronchopneumonia due to secondary bacterial infection, diarrhea, extensive viral infection of the 
intestinal mucous membrane, orchitis, hematuria, and encephalitis. 
 
C. Reservoirs 
Common reservoirs: Humans are the only natural reservoir for smallpox.  However, in the aftermath 
of the events of September and October, 2001, there is heightened concern that the variola virus 
might be used as an agent of bioterrorism.   
 
D. Modes of Transmission 
Spread: Generally, direct and fairly prolonged face-to-face contact is required to spread smallpox 
from person to person. 
 
Airborne: On rare occasions, smallpox has been spread by virus carried in the air in enclosed settings 
such as buildings, buses, and trains. 
 
Person-to-person: Smallpox also can be spread through direct contact with infected bodily fluids, 
scabs of lesions, or contaminated objects such as bedding or clothing.   
 
E. Incubation period 
This incubation period averages about 12 - 14 days, but can range from 7 - 17 days. 
 
F. Period of Communicability or Infectious Period 
At about four days into illness a rash emerges first on the tongue and mouth and spreads to the rest 
of the body.  A person is contagious from the time the rash appears until all the scabs have fallen off.  
This is approximately 3 weeks. 
 
G. Epidemiology 
Smallpox outbreaks had occurred from time to time for thousands of years, but the disease is now 
eradicated after a successful worldwide vaccination program. The last case of smallpox in the United 
States was in 1949. The last naturally occurring case in the world was in Somalia in 1977. After the 
disease was eradicated from the world, routine vaccination against smallpox among the general 
public was stopped because it was no longer necessary for prevention.  Vaccination of healthcare 
response teams and the military against smallpox has been reinstated due to the potential use of 
smallpox as a biological weapon. 
 
Except for laboratory stockpiles, the variola virus has been eliminated.  
 
H. Bioterrorism Potential 
Category A: There are concerns that the smallpox virus could be used for bioterrorism.  
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To identify individual cases and outbreaks as soon as possible. 
• To assess the magnitude of the disease. 
• To work in conjunction with law enforcement and homeland security to identify the source of 
cases as soon as possible. 
• To put in place effective control or prevention methods.  Please refer to state smallpox information at 
www.idph.state.ia.us/CADE/DiseaseIndex.aspx?disease=Smallpox  
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B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
immediately report any suspected or confirmed case. The reporting number for IDPH Center for 
Acute Disease Epidemiology (CADE) is (800) 362-2736.  If you are calling after business hours you 
may call the Iowa State Patrol Office at (515) 323-4360 and they will page a member of the on-call 
CADE staff. 
 
Laboratory Testing Services Available 
After communicating with IDPH, contact the University of Iowa State Hygienic Laboratory (SHL) at 
(319) 335-4500 for further instructions. 
 
C.  Local Public Health Agency Follow-up Responsibilities 
Case Investigation 
a) Case investigation of suspected smallpox disease in Iowa residents will be directed by the IDPH 
Center for Acute Disease Epidemiology (CADE). 
b) Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report a suspected smallpox case immediately. Any suspected cases of smallpox should be 
reported immediately to IDPH, Center for Acute Disease Epidemiology (CADE) at (800) 362-2736. 
Instructions for reporting are given at this number after normal business hours. 
c) Institution of disease control measures is an integral part of case investigation. It is the LPHA’s 
responsibility to understand, and, if necessary, institute the control guidelines listed below. 
 
3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements 
All suspect and known cases will be isolated at an appropriate site, which may include a healthcare 
facility or at home. When caring for smallpox patient adhere to Standard, Contact and Airborne 
Precautions. This includes an N 95 or better mask, goggles, gloves and gown and if hospitalized, a 
negative pressure room. All persons caring for smallpox patients should be vaccinated for smallpox.  
 
All susceptible contacts will be in quarantine until an incubation period has passed.  Quarantine 
orders will be issued by IDPH or the local public health agency.  Release from quarantine will be done 
by written notice. 
 
B.  Protection of Contacts of a Case 
Contacts of cases should be given smallpox vaccine as soon as possible, ideally within five days of 
exposure.  This may prevent or reduce the severity of disease. 
 
C.  Managing Special Situations 
If a suspect or known case of smallpox infection is reported in your county or if you suspect an 
outbreak, immediately consult with the epidemiologist on-call for CADE at (800) 362-2736. CADE can 
help determine a course of action to prevent further cases and can perform surveillance for cases 
that may cross several county lines and therefore be difficult to identify at a local level. 
  
D. Preventive Measures 
Environmental Measures 
The best way to prevent smallpox is to vaccinate all those potentially exposed and susceptible. Refer 
to smallpox section of your local public health agency’s bioemergency plan.  
 
Preventive Measures/Education 
People involved in smallpox response should  
• Annually update knowledge about smallpox and response to an event. 
• Maintain adequate numbers of trained key responders. 
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4) ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Smallpox can 
be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria in 
this chapter. (CSTE case definitions are used by the state health department and the CDC to maintain 
uniform standards for national reporting.)  
 
References 
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FACT SHEET                                                       SMALLPOX 
 
What is Smallpox? 
Smallpox is a viral disease unique to humans. The last case of smallpox occurred in 1977 in Somalia. 
 
How is the disease transmitted? 
Generally, direct and fairly prolonged face-to-face contact is required to spread smallpox from person to 
person. On rare occasions smallpox has been spread by virus carried in the air in enclosed settings such 
as buildings, buses, and trains.  Person-to-person spread can be through direct contact with infected 
bodily fluids.  It can also be spread through contact with contaminated objects such as bedding or 
clothing.   
 
If I am exposed to smallpox or have disease do I have to stay home? 
If you have been in close contact to someone with smallpox you will receive smallpox vaccine as soon as 
possible and may be asked to stay home until 14 days after the last known exposure to a case.  If you 
have disease, you will need to stay home or in a healthcare facility until all scabs have fallen off, usually 
around 21-28 days. 
 
What are the symptoms of Smallpox? 
The first symptoms may include high fever, fatigue, and head and backaches. A characteristic rash, most 
prominent on the face, arms, and legs, follows in 2-3 days. The rash starts with flat red lesions that 
appear at the same time. The lesions become pus-filled and begin to crust early in the second week. 
Scabs develop and then separate and fall off after about 3-4 weeks. 
 
How soon do the symptoms appear? 
Symptoms usually appear in about 12 days, but onset can range from 7 - 17 days. 
 
How long is someone infectious?  
A person can spread smallpox until all scabs have fallen off, usually about 21 – 28 days after rash 
appears. 
 
What is the treatment for Smallpox? 
There is no proven treatment for smallpox. Patients with smallpox can benefit from supportive therapy 
(intravenous fluids, medicine to control fever or pain, etc.) and antibiotics for any secondary bacterial 
infections that may occur. 
 
Can I get vaccinated against Smallpox? 
Routine vaccination for smallpox ended in 1972, since smallpox no longer naturally occurs in the world. 
Vaccination against smallpox is not recommended to prevent the disease in the general public and 
therefore is not available. However, if a person gets exposed to smallpox, there is vaccine available, and 
if given within 5 days after exposure, the vaccine can lessen the severity of or even prevent illness. 
 
What if I have had the smallpox vaccine? 
All persons are at risk for smallpox, even if they had the vaccine earlier in their lifetime. 
 
How does my doctor tell the difference between smallpox and chickenpox? 
The lesions that develop with smallpox develop at the same pace and appear identical. Chickenpox 
lesions develop in successive crops. The smallpox rash is most prominent on the face, arms, and legs, 
while the chickenpox rash is most prominent on the trunk. 
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Smallpox                                Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis 
date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider title: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes   No  Unk To whom: ______________  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Variola virus  
 
   
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Variola virus  
 
   
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Variola virus  
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OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
S
ym
pt
om
s 
Fever  Yes    No    Unk Onset date:      /     /      Duration:       hrs/days 
Date returned to normal 
activities:      /     /      
Cough  Yes    No    Unk Onset date:      /     /      
O
th
er
 s
ym
pt
om
s  Abdominal cramps     
 Backache     
 Chills    
 Encephalitis     
 Fatigue     
 Fever   
 Sore throat 
 Vomiting  
 Headache 
 Joint pain     
 Muscle pain     
 Nausea     
 Otitis media 
 Photophobia    
 
Runny nose  Yes    No    Unk Onset date:      /     /      
Red eyes w/t 
drainage  Yes    No    Unk Onset date:      /     /      
Diarrhea  Yes    No    Unk Onset date:      /     /      
Thrombocytopenia  Yes    No    Unk Onset date:      /     /      
Arthritis  Yes    No    Unk Onset date:      /     /       
Other 
complications:       Describe:       
   
Rash:  Yes    No    Unk Onset date:      /     /      Duration:       hours/days 
Fever continued w/t rash:   Yes    No    Unk Rash spreading:  Yes    No    Unk 
Rash equally distributed:  Yes    No    Unk Rash appeared at once:  Yes    No    Unk 
Lesions present:  Yes    No    Unk  Rash initial location:  Arms    Face    Legs    Trunk     Inside mouth 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
 
       cm    Heaviest lesion area:  Arms    Face    Legs    Trunk    Scalp 
# of days for first lesion to crust:       days Areas present:  Inside mouth      Palms         Soles 
Lesions in same stage of 
development:  Yes    No    Unk Severity: 
 < 50 lesions          
 50 – 249 lesions 
 250 – 500 lesions        
> 500 lesions 
Rash characteristics: 
 Burning     
 Confluent lesions      
 Could be felt (papule) 
 Could not be felt (macule) 
 Discrete lesions                               
 Distinct sharp borders 
 Dusky brown 
 Marked itching 
Numbness 
 Painful   
 Peeling skin       
 Pustule 
 Reddish    
 Scaling/crusting 
Koplik’s spots:  Yes    No    Unk    
Healthcare provider visited:  Yes    No    Unk Date(s) visited:      /     /     ,      /     /     ,      /     /      
Swollen lymph nodes:  Yes    No    Unk Location:       
 
TREATMENT 
 
Antivirals prescribed:   Yes    No    Unknown 
  
Antiviral:       
 
Antiviral:       
 
Antiviral:       
Date 
started:      /     /      
Date 
started:      /     /      
Date 
started:      /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
 
Therapeutic medications prescribed?  Yes    No    Unk 
List medications:       
 
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Vaccinated for smallpox:  Yes    No    Unknown 
  
Date 
vaccinated: 
 
     /     /      
  
Date 
vaccinated: 
 
     /     /      
  
Date 
vaccinated: 
 
     /     /      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
 
Number of vaccinations:       
 
In the 17 days prior to the onset of symptoms did the case: 
Traveled within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
 
Born outside the U.S.? 
 
 Yes    No    Unknown Country outside the U.S.: 
 
Immunocompromised? 
 
 Yes    No    Unknown 
 
 
 
 
 
 
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation 
period for 
smallpox is 7-17 
days. 
Smalllpox is communicable from 
the time rash occurs (about 4 days) 
until all scabs have fallen off (about 
3 weeks).  
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In the 4 days after the onset of rash until about 3 weeks after the rash started: 
Use public transportation:  Yes    No    Unk 
Date(s) used: Time(s) used: Type: Route: 
     /     /                        
     /     /                        
     /     /                        
 
Visit a doctor’s office, clinic or hospitals:   Yes    No    Unknown 
If Yes, complete the following table: 
Facility 
name:       
 
 
 
Facility 
name:       
 
Address: 
 
      
 
Address:       
Zip 
code: 
 
      
 
City: 
 
      
Zip 
code: 
 
      
 
City: 
 
      
      
State:       
 
County: 
 
      
      
State:       
 
County: 
 
      
Phone: (     )-     -      
 
   Type:       Phone: (     )-     -      
 
   Type:       
Date 
visited:      /     /      
Time 
visited:       
Date 
visited:      /     /      
Time 
visited:       
Provider 
name:       Title:       
Provider 
name:       Title:       
 
Visit a public places:  Yes    No    Unknown 
If Yes, complete the following table: 
Location name Address/City/State/Zip Phone Date(s) visited Time visited 
            (     )-     -      
 
     /     /            
            (     )-     -      
 
     /     /            
            (     )-     -      
 
     /     /            
 
Attend religious gatherings:  Yes    No    Unknown 
If Yes, complete the following table: 
Location name Address/City/State/Zip Date(s) attended Time attended  Describe interactions: 
            
 
     /     /                   
            
 
     /     /                   
            
 
     /     /                   
 
Attend family gatherings:  Yes    No    Unknown 
If Yes, complete the following table: 
Location name Address/City/State/Zip Date(s) attended Time attended  Describe interactions: 
            
 
     /     /                   
            
 
     /     /                   
            
 
     /     /                   
 
Attend other gatherings:  Yes    No    Unknown 
If Yes, complete the following table: 
Location name Address/City/State/Zip Date(s) attended Time attended  Describe interactions: 
            
 
     /     /                   
            
 
     /     /                   
            
 
     /     /                   
 
Setting Acquired: 
Child care 
Church 
College 
Correctional Facility 
Doctors office 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
Hospitalized 
International traveler 
Military 
Hospital ER/ 
Outpatient 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 
Home 
School 
Urgent care 
Work 
Other 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
      
Disease traced within 2 generations of known 
international import?  Yes    No    Unk 
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Number of people living in case’s household:          
Close contacts of the case (For more than one contact, print/copy additional contact pages.)  
Last name:       Address:       
First name:        City/State/Zip:       County:       
DOB:      /     /      Age:       Phone:       Type:       
Gender:  Female      Male      Other Symptoms present:  Yes    No    Unk Onset date:      /     /      
  If this contact has an onset date before this case then create a new case and event. 
Symptoms: 
Fever  
Runny nose  
Rash  
Chills  
Fatigue  
Joint pain  
Nausea  
Photophobia  
Sore throat  
 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
 
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
Vomiting  
Cough  
Red eyes w/t discharge  
Backache  
Encephalitis  
Headache  
Muscle pain  
Otitis media  
Pneumonia  
Swollen lymph nodes  
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
Onset date: 
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
     /     /      
 
NOTES:       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONTACTS 
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FACT SHEET   Vancomycin-Resistant Staphylococcus aureus 
VRSA 
 
What is Staphylococcus aureus 
Staphylococcus aureus, often simply referred to a “staph,” are bacteria (germs) commonly found on the 
skin and in the noses of healthy people.  Occasionally, staph can cause infection. Staph bacteria are one 
of the most common causes of skin infections in the U.S.  Most of these infections are minor (such as 
pimples, boils, and other skin conditions) and can be treated without antibiotics. Staph bacteria can also 
cause serious and sometimes fatal infections, such as bloodstream infections, surgical wound infections, 
and pneumonia. In the past, most serious infections were treated with a type of antibiotic related to 
penicillin.  Over the past 50 years, treatment of these infections has become more difficult because staph 
bacteria have become resistant to various antibiotics, including the commonly used penicillin-related 
antibiotics. 
 
What are VISA and VRSA? 
Vancomycin intermediate Staph aureus (VISA) and vancomycin resistant staph aureus (VRSA) are specific 
types of antibiotic-resistant staph bacteria.  While most staph bacteria are susceptible to the antibiotic 
vancomycin, some have developed resistance.  VISA and VRSA cannot be successfully treated with 
vancomycin because it no longer kills them.  To date all VISA and VRSA infections have been susceptible 
to other antibiotics.                                                
Who gets VISA and VRSA infections? 
Persons that have developed VISA and VRSA infections often have had several other health problems 
such as diabetes and kidney disease, previous infections with methicillin-resistant Staphylococcus aureus 
(MRSA), tubes going into their bodies such as intravenous (IV) catheters, recent hospitalizations, and 
recently been given vancomycin and other antibiotics. 
 
What should I do if I think I have a Staph, MRSA, VISA, or VRSA infection? 
See your healthcare provider. 
 
Are VISA and VRSA infections treatable? 
Yes. To date, all VISA and VRSA infections have been susceptible to several other antibiotics.  
 
How can the spread of VISA and VRSA be prevented? 
Use of appropriate infection control practices, like wearing gloves when caring for someone with VISA or 
VRSA and washing hands with plain or antimicrobial soap after removing gloves, by anyone caring for 
someone infected can reduce the spread of VISA and VRSA. 
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SYPHILIS 
 
Also known as: Syph, the pox, bad blood  
 
Responsibilities: 
Hospital: Report by mail or phone 
Lab: by mail 
Physician: Report by mail or phone 
Local Public Health Agency (LPHA): Follow-up Iowa Department of Public Health  
 
Iowa Department of Public Health 
Sexually Transmitted Disease Reporting:  (515) 281-3031 
 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Syphilis is a sexually transmitted disease (STD) caused by the bacterium Treponema pallidum, 
subspecies pallidum, a spirochete. It has often been called “the great imitator” because so many of 
the signs and symptoms are indistinguishable from those of other diseases. 
 
B. Clinical Description 
• Primary Stage: The primary stage of syphilis is usually marked by the appearance of a single sore 
(called a chancre) at the site of infection. Primary lesions are not confined to the genital area; 
they may be seen on the lips, tongue, tonsils, nipples, fingers, anus, or other area that comes in 
contact with the infection. The chancre may not be visible if inside the vagina, anus or mouth. 
The time between infection with syphilis and the start of the first symptom can range from 10 to 
90 days (average 21 days). The chancre is usually firm, round, small and painless. The chancre 
lasts 3 to 6 weeks and it heals without treatment. However, if adequate treatment is not 
administered, the infection progresses to the secondary stage. 
 
• Secondary Stage:  Skin rash and mucous membrane lesions characterize the secondary stage. 
This stage typically starts with the development of a rash on one or more areas of the body. The 
rash usually does not cause itching. Rashes associated with secondary syphilis can appear as the 
chancre is healing or several weeks after the chancre has healed. The characteristic rash of 
secondary syphilis may appear as rough, red or reddish brown spots both on the palms of the 
hands and the soles of the feet. However, rashes with a different appearance may occur on other 
parts of the body, sometimes resembling rashes caused by other diseases. Sometimes rashes 
associated with secondary syphilis are so faint that they may not be noticed. Other symptoms of 
secondary syphilis may include fever, swollen lymph glands, sore throat, patchy hair loss, 
headaches, weight loss, muscle aches and fatigue. These symptoms may last 2 - 6 weeks (4 
weeks average) and they may recur. The signs and symptoms of secondary syphilis will resolve 
with or without treatment, but without treatment, the infection will progress to the latent and 
late stages of disease. 
 
• Latent/Late Stage: Latent syphilis is the stage in which no observable clinical signs or symptoms 
are present to suggest infection, yet the serologic tests for syphilis are reactive. The latent stage 
of syphilis begins when secondary symptoms disappear. Early latent syphilis is defined as latent 
disease within the first year after infection. Late latent infection is when more than a year has 
passed since the patient became infected and there are no signs of disease. The reason for 
separating latent stages into early and late is that secondary relapses generally do not occur 
following the first year and that early latent disease it treated with a single dose of long acting 
benzathine penicillin vs. three doses for late latent disease. Without treatment, the bacteria 
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remain in the body even though there may be no clinical signs and symptoms.  In the late stages 
of syphilis, it may subsequently damage the internal organs, including the brain, nerves, eyes, 
heart, blood vessels, liver, bones and joints. This internal damage may show up many years 
later. Signs and symptoms of the late stage of syphilis include difficulty coordinating muscle 
movements, paralysis, numbness, gradual blindness, deafness and dementia. This damage may 
be serious enough to cause death. For more information on neurosyphilis, cardiovascular syphilis, 
and other late stage syphilis, please contact the Sexually Transmitted Disease Program at 515-
281-3031, or see the Centers for Disease Control and Prevention’s STD Treatment Guidelines 
2010 for more information: www.cdc.gov/std/treatment/2010/default.htm  
 
• Onset  
Primary – 10 to 90 days (average 21 days) 
Secondary – 6 weeks to 6 months 
Early Latent – 6 months to 1 year 
Late Latent – More than one year after infection 
Late Stage – Years after initial infection 
 
• Complications Pregnant women MUST be treated with long-acting benzathine penicillin during 
pregnancy to reduce the risk of transmitting the infection to their unborn children. Please see the 
Centers for Disease Control and Prevention’s STD Treatment Guidelines 2010 for more 
information: www.cdc.gov/std/treatment/2010/default.htm 
 
C. Reservoirs 
Common reservoirs: Humans. 
 
D. Modes of Transmission 
Spread:  By direct contact with infectious exudates from obvious or concealed, moist, early lesions of 
skin and mucous membranes of infected people during sexual contact, most often in the primary 
stage of infection. Transmission by kissing occurs rarely. Transplacental infection of the fetus occurs 
during the pregnancy of an infected woman. 
 
Rarely, transmission can occur through blood transfusion if the donor is in the early stages of 
disease.  Blood donations are screened for syphilis, but early infections may not show up on 
screening tests. Infection by contact with contaminated articles may be theoretically possible but is 
extraordinarily rare. Health professionals have developed primary lesions on the hands following 
clinical examination of infectious lesions. 
 
E. Incubation period 
Primary syphilis - from 10 days to 3 months, usually 3 weeks. 
 
F. Period of Communicability or Infectious Period 
Communicability exists when moist mucocutaneous lesions of primary and secondary syphilis are 
present. However, the distinction between the infectious primary and secondary stages and the 
noninfectious early latent stage of syphilis is somewhat arbitrary with regard to communicability, 
since primary and secondary stage lesions may not be apparent to the infected individual. The lesions 
of secondary syphilis may recur with decreasing frequency up to four years after infection. However, 
transmission of infection is rare after the first year. Consequently, in the United States infectious 
early syphilis is usually defined as ending after the first year of infection. 
 
Transmission of syphilis from mother to fetus is most probable during early maternal syphilis but can 
occur throughout the latent period. Infected infants may have moist mucocutaneous lesions that are 
more widespread than in adult syphilis and are a potential source of infection. 
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G. Epidemiology 
In the United States, health officials reported 46,042 cases of syphilis in 2011, including 13,970 cases 
of primary and secondary (P&S) syphilis.  Cases among males, and particularly among men who have 
sex with men (MSM), have increased since 2000. The rate of P&S syphilis increased 3.8% among 
men (from 7.9 cases to 8.2 cases per 100,000 men) between 2010 and 2011.  These cases have 
been associated with high rates of HIV co-infection and high-risk sexual behavior.  Case rates are 
lower among women; the rate of P&S syphilis decreased 9.1% among women from 2010 to 2011, 
from 1.1 to 1.0 cases per 100,000 women.  Finally, after an increase of 18% during 2006-2008, the 
overall rate of congenital syphilis decreased, from 10.5 to 8.5 cases per 100,000 live births during 
2008-2011.  This decrease in the rate of congenital syphilis likely reflects the decrease in the rate of 
P&S syphilis among women during 2008-2011.     
The number of syphilis cases in Iowa is increasing as well. Total syphilis case numbers increased 
from 29 in 2005 to 70 in 2011. Healthcare providers should be vigilant to watch for signs of primary 
and secondary syphilis, and take care to conduct thorough social history, including travel and sexual 
activity in high syphilis incidence areas. 
 
H. Bioterrorism Potential:  
None. 
  
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To interrupt disease transmission, the Iowa Department of Public Health (IDPH) provides 
partner counseling and referral services for persons recently diagnosed with syphilis 
infection, and their exposed partner(s). 
• To monitor trends in syphilis diagnoses so that prevention and treatment funds may be 
targeted efficiently, and prevention programs may be evaluated. 
• To monitor perinatal exposures to syphilis infection and morbidity in infants born to syphilis-
infected women. 
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139A) stipulates that the laboratory and healthcare providers must 
report syphilis. Laboratory personnel should forward results of tests directly to the Iowa Department 
of Public Health. 
 
All confirmed laboratory diagnoses of syphilis are to be reported to the IDPH STD Program by mail or 
phone.   
 
Healthcare Providers must complete an “Iowa Confidential Report of Sexually Transmitted Diseases 
and HIV Infection” morbidity report within 3 days of diagnosing a positive syphilis infection.  
Healthcare Providers are to provide a date of birth, home address, phone number and treatment 
information on each reported case.  Providers should also report any partner information that is 
available, including treatment information for the partners. 
 
Laboratory personnel should forward results of tests directly to the IDPH STD Program.  ”Iowa 
Confidential Report of Sexually Transmitted Diseases and HIV Infection,” “Laboratory Report of Tests 
Processed for STD,” and postage paid envelopes (coded #00) are available at the clearinghouse at 
http://healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=303 .  Send completed 
reports to the address below: 
 
Iowa Department of Public Health 
STD Program (#00) 
321 East 12th Street, 5th Floor 
Des Moines, IA 50319-0075 
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C.  Local Public Health Agency Follow-up Responsibilities 
Case Investigation 
Partner notification and referral services will be provided by Disease Prevention Specialists employed 
by the IDPH, or by Black Hawk, Linn, Polk, or Scott county health departments. 
 
3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements 
None. 
 
B. Protection of Contacts of a Case 
The IDPH will initiate the partner notification program with all persons who are newly diagnosed with 
syphilis infection.  Healthcare providers can facilitate this process by describing the program to the 
patient and encouraging the patient to meet with the disease prevention specialist assigned to his or 
her region. 
 
Patients’ names and times of exposures are not used in the notification of partners.  Syphilis testing 
is offered to all partners free of charge and appropriate referrals to other services are provided during 
the partner counseling sessions. 
 
Physicians should assist the disease prevention specialists with the collection of partner information 
for notification.  In such cases, the physician should collect the following information:  Partner name, 
address, home phone number, age and/or date of birth, race, sex, partner/marital status, height, 
size/build, general description of the partner, and dates of first and last exposure.  Any other 
information that may help in locating and counseling the partner may also be included, such as 
medical conditions, place of employment, cell phone numbers, or other unusual circumstances/ 
situations. 
 
C. Managing Special Situations 
Occupational Exposures 
None. 
 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
Report unusual cases to the Iowa Department of Public Health at (515) 281-3031. 
  
D. Preventive Measures 
Preventive Measures/Education 
Risk reduction counseling/education and testing should be offered to all persons with risk factors for 
syphilis infection and transmission. 
 
The best way to avoid transmission of sexually transmitted diseases is to abstain from sexual contact, 
or to be in a long-term mutually monogamous relationship with a partner who has been tested and is 
known to be uninfected. 
 
Latex male condoms for vaginal, oral or anal sex, when used consistently and correctly, can reduce 
the risk of transmission of syphilis. 
 
The Centers for Disease Control STD Treatment Guidelines provide specific recommendations for STD 
prevention services that should be provided for all sexually active men who have sex with men 
(MSM). www.cdc.gov/std/treatment/2010/default.htm The first recommendation for this population is 
that STD screening be performed at least annually.   
 
Any genital symptoms such as an unusual sore or rash should be a sign to stop having sex and 
consult a healthcare provider immediately.   If a person has been diagnosed with syphilis (or any 
other STD), he or she must notify all recent sex partners so they can see a healthcare provider and 
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be treated.  The person and all of his or her sex partners must avoid sex until they have completed 
their treatment for syphilis. Disease prevention specialists will assist infected patients with this 
process. 
 
In addition to treatment for syphilis, an infected patient should be tested for other sexually 
transmitted diseases including HIV. 
 
See  
http://hivtest.cdc.gov/STDTesting.aspx  
for a current list of sites which can provide STD testing, as well as HIV testing and counseling. 
 
For information on STD/HIV testing sites, please call the Iowa Department of Public Health STD 
Program at 515-281-3031. 
 
4) ADDITIONAL INFORMATION 
 
Laboratory criteria for diagnosis 
Darkfield examinations and direct fluorescent antibody tests of lesion exudates or tissue are the 
definitive methods for diagnosing early syphilis. A presumptive diagnosis is possible with the use of 
two types of serologic tests for syphilis: a) nontreponemal tests (e.g., Venereal Disease Research 
Laboratory [VDRL] and Rapid Plasma Reagin [RPR]) and b) treponemal tests (e.g., fluorescent 
treponemal antibody absorbed [FTA-ABS] and T. pallidum particle agglutination [TP-PA]). The use of 
only one type of serologic test is insufficient for diagnosis, because false-positive nontreponemal test 
results may occur secondary to various medical conditions. 
 
Nontreponemal test antibody titers usually correlate with disease activity, and results should be 
reported quantitatively. A fourfold change in titer, equivalent to a change of two dilutions (e.g., from 
1:16 to 1:4 or from 1:8 to 1:32), is considered necessary to demonstrate a clinically significant 
difference between two nontreponemal test results that were obtained using the same serologic test. 
Sequential serologic tests in individual patients should be performed by using the same testing 
method (e.g., VDRL or RPR), preferably by the same laboratory. The VDRL and RPR are equally valid 
assays, but quantitative results from the two tests cannot be compared directly because RPR titers 
often are slightly higher than VDRL titers. Nontreponemal tests usually become nonreactive with time 
after treatment; however, in some patients, nontreponemal antibodies can persist at a low titer for a 
long period of time, sometimes for the life of the patient. This response is referred to as the “serofast 
reaction.” 
 
Most patients who have reactive treponemal tests will have reactive tests for the remainder of their 
lives, regardless of treatment or disease activity. However, 15%-25% of patients treated during the 
primary stage revert to being serologically nonreactive after 2-3 years. Treponemal test antibody 
titers correlate poorly with disease activity and should not be used to assess treatment response. 
 
Case Definitions 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Syphilis 
can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
 
 
 
Treatment 
Long acting Penicillin G, administered parenterally, is the preferred drug for treatment of all stages of 
syphilis. The preparation(s) used (i.e., benzathine, aqueous procaine, or aqueous crystalline), the 
dosage, and the length of treatment depend on the stage and clinical manifestations of disease. 
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However, neither combinations of benzathine penicillin and procaine penicillin nor oral penicillin 
preparations are considered appropriate for the treatment of syphilis. 
 
The efficacy of penicillin for the treatment of syphilis was well established through clinical experience 
before the value of randomized controlled clinical trials was recognized. Therefore, almost all the 
recommendations for the treatment of syphilis are based on the opinions of persons knowledgeable 
about STDs and are reinforced by case series, clinical trials, and 50 years of clinical experience. 
 
For treatment information related to the stages of syphilis, recommended dosage, and special 
considerations, please refer to the 2010 CDC STD Treatment Guidelines. 
www.cdc.gov/std/treatment/2010/default.htm 
 
References 
Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2007 
Supplement, Syphilis Surveillance Report. Atlanta, GA: U.S. Department of Health and Human 
Services, Centers for Disease Control and Prevention, March 2009.  
Centers for Disease Control and Prevention.  Sexually Transmitted Diseases Treatment Guidelines 
2010.  MMWR 2010; 59, RR-12 www.cdc.gov/std/treatment/2010/default.htm 
Heymann, D.L., ed. Control of Communicable Diseases Manual, 19th Edition. Washington, DC, 
American Public Health Association, 2008. 
Notification And Surveillance of Reportable Communicable and Infectious Diseases, Poisonings and 
Conditions.  Iowa Code 2003 Section 139A. 
 
Additional Resources 
CDC website with most current guidelines for prevention, surveillance, and treatment: 
www.cdc.gov/std/syphilis/default.htm 
HIV/AIDS Program web site, Iowa Department of Public Health.   
www.idph.state.ia.us/HivStdHep/  
CDC Factsheet 
www.cdc.gov/std/Syphilis/STDFact-Syphilis.htm 
Syphilis and Men Who Have Sex With Men (MSM) 
www.cdc.gov/std/syphilis/STDFact-MSM-Syphilis.htm  
The National Plan to Eliminate Syphilis from the United States 
www.cdc.gov/stopsyphilis/plan.htm 
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For Health Professionals 
 
What is Syphilis? 
Syphilis is a sexually transmitted disease (STD) caused by the bacteria Treponema pallidum. It 
has often been called “the great imitator” because so many of the signs and symptoms are 
indistinguishable from those of other diseases.  
 
How common is Syphilis? 
In the United States, health officials reported 46,042 cases of syphilis in 2011, including 13,970 
cases of primary and secondary (P&S) syphilis.  Cases among males, and particularly among men 
who have sex with men (MSM), have increased since 2000. The rate of P&S syphilis increased 
3.8% among men (from 7.9 cases to 8.2 cases per 100,000 men) between 2010 and 2011.  
These cases have been associated with high rates of HIV co-infection and high-risk sexual 
behavior.  Case rates are lower among women; the rate of P&S syphilis decreased 9.1% among 
women from 2010 to 2011, from 1.1 to 1.0 cases per 100,000 women.  Finally, after an increase 
of 18% during 2006-2008, the overall rate of congenital syphilis decreased, from 10.5 to 8.5 
cases per 100,000 live births during 2008-2011.  This decrease in the rate of congenital syphilis 
likely reflects the decrease in the rate of P&S syphilis among women during 2008-2011.     
The number of syphilis cases in Iowa is increasing as well. Total syphilis case numbers increased 
from 29 in 2005 to 70 in 2011.  
How do people get syphilis? 
Syphilis is passed from person to person through direct skin-to-skin contact with a syphilis sore. 
Sores occur mainly on the external genitals (private areas), vagina, anus, or in the rectum. Sores 
also can occur on the lips and in the mouth. Transmission of the organism occurs during vaginal, 
anal, or oral sex. Pregnant women with the disease can pass it to the babies they are carrying. 
Syphilis cannot be spread through contact with toilet seats, doorknobs, swimming pools, hot 
tubs, bathtubs, shared clothing, or eating utensils. 
 
What are the signs and symptoms in adults? 
Many people infected with syphilis do not have any symptoms for years, yet remain at risk for 
late complications if they are not treated. Although transmission appears to occur from persons 
with sores who are in the primary or secondary stage, many of these sores are unrecognized. 
Thus, most transmission is from persons who are unaware of their infection. 
Primary Stage -The primary stage of syphilis is usually marked by the appearance of a 
single sore (called a chancre), but there may be multiple sores. The time between 
infection with syphilis and the start of the first symptom can range from 10 to 90 days 
(average 21 days). The sore is usually firm, round, small, and painless. It appears at the 
spot where syphilis bacteria entered the body. The sore lasts 3 to 6 weeks, and it heals 
without treatment. However, if proper treatment is not administered, the infection 
progresses to the secondary stage. 
Secondary Stage - A skin rash and sores in the mouth or private areas will begin in the 
secondary stage. This stage usually starts with the development of a rash on one or 
more areas of the body. The rash usually does not cause itching. Rashes associated with 
secondary syphilis can appear as the primary sore is healing or several weeks after the 
sore has healed. The usual rash of secondary syphilis appears to be rough, red, or 
reddish brown spots on the palms of the hands and the bottoms of the feet. However, 
rashes with a different appearance may occur on other parts of the body, sometimes 
resembling rashes caused by other diseases. Sometimes rashes associated with 
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secondary syphilis are so faint that they are not noticed. In addition to rashes, symptoms 
of secondary syphilis may include fever, swollen glands, sore throat, patchy hair loss, 
headaches, weight loss, muscle aches, and fatigue. The signs and symptoms of 
secondary syphilis will go away with or without treatment, but without treatment, the 
infection will progress to the latent and late stages of disease. 
Late Stage - The latent (hidden) stage of syphilis begins when secondary symptoms 
(the rash) disappear. Without treatment, the infected person will continue to have 
syphilis even though there are no signs or symptoms; the infection remains in the body. 
In the late stages of syphilis, it may damage the internal organs, including the brain, 
nerves, eyes, heart, blood vessels, liver, bones, and joints. This internal damage may 
show up many years later. Signs and symptoms of the late stage of syphilis include 
difficulty with muscle movements, paralysis, numbness, gradual blindness, and memory 
loss. This damage may be serious enough to cause death. 
 
How does syphilis affect a pregnant woman and her baby? 
The syphilis bacteria can infect the baby of a woman during her pregnancy. Depending on how 
long a pregnant woman has been infected, she may have a high risk of having a stillbirth (a baby 
born dead) or of giving birth to a baby who dies shortly after birth. An infected baby may be born 
without signs or symptoms of disease. However, if not treated immediately, the baby may 
develop serious problems within a few weeks. Untreated babies may become developmentally 
delayed, blind, deaf, have seizures, or die. Pregnant women MUST be treated with long-acting 
benzathine penicillin during pregnancy to reduce the risk of transmitting the infection to their 
unborn child. Please see the Centers for Disease Control and Prevention STD Treatment 
Guidelines 2010 for more information: www.cdc.gov/std/treatment/2010/default.htm.  
 
How is syphilis diagnosed? 
A blood test is the usual way to determine whether someone has syphilis. Shortly after infection 
occurs, the body produces a response to the syphilis bacteria, called antibodies.  The antibodies 
can be detected by an accurate, safe, and inexpensive blood test. A low level of antibodies will 
stay in the blood for months or years even after the disease has been successfully treated. 
Because untreated syphilis in a pregnant woman can infect and possibly kill her developing baby, 
every pregnant woman should have a blood test for syphilis.  
 
What is the link between syphilis and HIV? 
Genital sores caused by syphilis make it easier for syphilis to enter the body and for a person to 
acquire HIV infection sexually.  Having other STDs is also an important predictor for becoming 
HIV infected, because STDs are acquired by having unprotected sex.  
 
What is the treatment for syphilis? 
Syphilis is easy to cure in its early stages. A single injection of penicillin, an antibiotic, will cure a 
person who has had syphilis for less than a year. Additional doses are needed to treat someone 
who has had syphilis for longer than a year. For people who are allergic to penicillin, other 
antibiotics are available to treat syphilis. However, if a woman is pregnant and is allergic to 
penicillin, she must see her doctor so they can treat the allergy, because she must be treated 
with penicillin so her baby is not infected.  There are no home remedies or over-the-counter 
drugs that will cure syphilis. Treatment will kill the syphilis bacteria and prevent further damage, 
but it will not repair damage that has already occurred.  
 
Because effective treatment is available, it is important that persons be screened for syphilis on 
an on-going basis if they participate in unprotected sex.  
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Persons who receive syphilis treatment must abstain from sexual contact with new partners until 
the syphilis sores are completely healed. Persons with syphilis must notify their sex partners so 
that they also can be tested and receive treatment if necessary.  
 
Will syphilis recur? 
Having syphilis once does not protect a person from getting it again. Following successful 
treatment, people can still be susceptible to re-infection. Only laboratory tests can confirm 
whether someone has syphilis. Because syphilis sores can be hidden inside the mouth or private 
areas, it may not be obvious that a sex partner has syphilis. Talking with a healthcare provider 
will help to determine the need to be re-tested for syphilis after treatment has been received. 
 
How can syphilis be prevented? 
• The surest way to avoid transmission of sexually transmitted diseases, including syphilis, 
is to abstain from sexual contact or to be in a long-term mutually monogamous 
relationship with a partner who has been tested and is known to not have syphilis. 
• Avoiding alcohol and drug use may also help prevent transmission of syphilis because 
these activities may lead to risky sexual behavior. It is important that sex partners talk to 
each other about their HIV status and history of other STDs so that preventive action can 
be taken.  
• Sores from STD’s, like syphilis, can occur in both the male and female private areas. You 
can prevent contact with the sore by using a latex condom. Correct and consistent use of 
latex condoms can reduce the risk of syphilis, genital herpes and other STD’s, only when 
the infected area or site of potential exposure is protected.  
• Condoms lubricated with spermicides (especially Nonoxynol-9 or N-9) are no more 
effective than other lubricated condoms in protecting against the transmission of STDs. 
Based on findings from several research studies, N-9 may itself cause genital lesions, 
providing a point of entry for HIV and other STDs. In June 2001, the CDC recommended 
that N-9 not be used as a microbicide or lubricant during anal intercourse.  
• Transmission of a STD, including syphilis cannot be prevented by washing the genitals, 
urinating, and or douching after sex. Any unusual discharge, sore, or rash, particularly in 
the groin area, should be a signal to refrain from having sex and to see a doctor 
immediately.  
 
Where can I get more information? 
Iowa Department of Public Health STD Program 
www.idph.state.ia.us/HivStdHep/  
 
Division of STD Prevention (DSTDP) 
Centers for Disease Control and Prevention 
www.cdc.gov/std 
 
Personal health inquiries and information about STDs: 
CDC National STD and AIDS Hotlines 
(800) 227-8922 or (800) 342-2437 
En Espanol (800) 344-7432 
TTY for the Deaf and Hard of Hearing (800) 243-7889 
 
 
STD Treatment Guidelines: 
Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 
2010. 
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Guide to Surveillance, Investigation, and Reporting 
TETANUS 
 
Also known as:  Lockjaw disease 
 
Responsibilities: 
Hospital: Report by IDSS, facsimile, mail or phone 
Lab: Report by facsimile, mail or phone 
Physician: Report by IDSS, facsimile, mail or phone 
Local Public Health Agency (LPHA): Report by IDSS, mail, facsimile, or phone. Follow-up 
required 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Tetanus is caused by a potent toxin produced by Clostridium tetani, a spore-forming, anaerobic, 
gram-positive bacillus. 
 
B. Clinical Description 
Generalized tetanus is an acute, often fatal neurologic disease characterized by painful skeletal 
muscular contractions. The toxin blocks nerve signals telling muscles not to contract in response to 
voluntary contractions of opposing muscles. Onset is gradual, occurring over 1 - 7 days. The muscle 
stiffness usually first involves the jaw (lockjaw) and neck and progresses to severe generalized 
muscle spasms, which frequently are aggravated by any external stimulus, such as a loud noise. 
Severe spasms persist for one week or more and subside over a period of weeks in those who 
recover. C. tetani usually enters the body through a penetrating or puncture wound. In the presence 
of anaerobic (low oxygen) conditions, the spores germinate. Toxins are produced, and disseminated 
via blood and lymphatics. Toxins act at several sites within the central nervous system, including 
peripheral motor end plates, spinal cord, brain, and sympathetic nervous system. The typical clinical 
manifestations of tetanus are caused when tetanus toxin interferes with release of neurotransmitters, 
which block inhibitor impulses, resulting in sustained spasms. This leads to unopposed muscle 
contraction and spasm. Seizures may occur, and the autonomic nervous system may also be 
affected. 
 
Neonatal tetanus, which arises from infection of the umbilical stump, is a form of generalized tetanus. 
However, inability to nurse is the most common presenting sign. Localized tetanus is manifested by 
local muscle spasms in areas contiguous to a wound, although history of an injury or an apparent 
portal of entry may be lacking. Cephalic tetanus is a rare form of the disease and involves the cranial 
nerves, especially the facial area. It is associated with infected wounds of the head and neck, 
including ear infections. Both localized and cephalic tetanus may precede generalized tetanus.  
 
Complications of the disease include laryngospasm (spasm of the vocal cords) and/or spasm of the 
muscles of respiration, leading to interference with breathing; fractures of the spine or long bones, 
resulting from sustained contractions and convulsions; and hyperactivity of the autonomic nervous 
system, which may lead to hypertension and/or an abnormal heart rhythm. Other complications may 
include increased susceptibility to nosocomial infections, pulmonary embolism (particularly in drug 
addicts and elderly patients), and aspiration pneumonia. The case-fatality rate ranges from 10% - 
90%; it is highest in infants and the elderly and varies inversely with the length of the incubation 
period and the availability of experienced intensive care unit personnel and resources. 
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Tetanus disease does not confer immunity. Patients who survive the disease should be given a 
complete series of vaccine.  
 
Laboratory confirmation is of little help.  The organism is rarely recovered from the site of infection, 
and usually there is no detectable serological response. 
 
C. Reservoirs 
Clostridium tetani is a normal inhabitant of soil and animal and human intestines. It is ubiquitous in 
the environment, especially where contamination by excreta is frequent. 
 
D. Modes of Transmission 
There is no person-to-person transmission of tetanus. Wounds, recognized or unrecognized, are the 
sites at which the organism enters the body, multiplies, and produces toxin. Cases of tetanus have 
followed injuries considered too trivial for medical consultation. 
 
E. Incubation period 
The incubation period ranges from 2 days to months, with most cases occurring within 14 days. In 
neonates the incubation period is usually 5 - 14 days. In general, shorter incubation periods are 
associated with more heavily contaminated wounds, more severe disease, and a worse prognosis. 
 
F. Period of Communicability or Infectious Period 
There is no infectious period because tetanus in not transmitted person-to-person.  
 
G. Epidemiology 
Tetanus occurs worldwide and is more frequent in warmer climates and months, partly because of 
the frequency of contaminated wounds. Despite the availability of tetanus toxoid (TT), tetanus 
continues to have a substantial health impact in the world. In 1997, neonatal tetanus alone 
accounted for an estimated 277,400 deaths worldwide. Tetanus is sporadic and relatively uncommon 
in the United States and most industrial countries, mostly because of widespread use of tetanus 
toxoid as part of routine immunizations and improved wound management. During 2001 through 
2008, the last years for which data have been compiled, a total of 233 tetanus cases was reported, 
an average of 29 cases per year. Among the 197 cases with known outcomes the case-fatality rate 
was 13%. Almost all reported cases have occurred in people who had never been vaccinated or who 
completed a primary series but had not had a booster dose in the preceding 10 years. In the U.S., 
49% tetanus cases occurred in persons 50 years of age or older. Neonatal tetanus is rare in the U.S., 
with only two cases reported since 1989. Neither of the infants’ mothers had ever received tetanus 
toxoid.  
 
Heroin users, particularly those who inject themselves subcutaneously with quinine-cut heroin, 
appear to be at high risk for tetanus. Quinine is used to dilute heroin and may actually favor growth 
of C. tetani. 
 
During 1995−97, acute injuries such as punctures, lacerations, and abrasions accounted for 64% of 
reported cases of tetanus in the U.S. Approximately one-third of all reported cases were not due to 
acute injury, and some had no known injury at all. Today, tetanus in the U.S. affects primarily older 
adults. The last reported case of neonatal tetanus in the U.S. occurred in 1998 in Montana in a 
newborn whose umbilical stump had been treated with nonsterile clay.  The last case in Iowa was in 
2000. From 1994 through 2006, Iowa had 5 cases of tetanus reported, 2 of which were known to be 
fatal. Both fatalities were elderly women who had never received Td vaccine.  Elderly women may be 
at greater risk of illness and death because they may never have received vaccine.  Males often were 
vaccinated in the military, thus may at least have some protection.   
 
H. Bioterrorism Potential 
None. 
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 2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To assure early evaluation and, where appropriate, treatment with tetanus-diphtheria toxoid (Td) 
and/or tetanus immune globulin (TIG) and hospitalization. 
• To identify groups and areas in which risk of disease is highest (due to under-immunization, 
occupation, other practices, etc.) to initiate prevention efforts, such as catch-up vaccination. 
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report. The preferred method of reporting is by utilizing the Iowa Disease Surveillance System 
(IDSS).  However, if IDSS is not available to your facility the reporting number for IDPH Center for 
Acute Disease Epidemiology (CADE) is (800) 362-2736; fax number (515) 281-5698, mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th Street 
Des Moines, IA 50319-0075 
 
Postage-paid disease reporting forms are available free of charge from the IDPH clearinghouse.   
Call (319) 398-5133 or visit the website: 
healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295 to request a supply. 
 
C.  Local Public Health Agency Follow-up Responsibilities 
With assistance from the hospital infection preventionist, complete an investigation using the Iowa 
Disease Surveillance System (IDSS).  The following data are epidemiologically important and should 
be collected in the course of case investigation. Additional information may be collected at the 
direction of IDPH. 
Demographic information:  
Name, Address, State of residence, Date of birth, Age, Sex, Ethnicity, Race, Occupation 
Reporting Source: 
County, Earliest date reported 
Clinical: 
Hospitalization and duration of stay, Date of onset of symptoms, Type of tetanus disease, 
Wound location and management, Complications, Pre-existing conditions (e.g., diabetes, 
chronic otitis media), Outcome (case survived or died), Date of death 
Treatment: 
Prophylaxis with Td and TIG, Date started,  
Vaccine Information: 
Dates of vaccination (prior tetanus toxoid history including Td, Tdap, etc), Time since last 
dose of tetanus-containing vaccine, Manufacturer of vaccine, Lot number, If not 
vaccinated, reason 
Epidemiological: 
Risk factors for disease such as history of a wound or injury, recent injection drug use, 
tattooing, or body piercing 
For neonatal cases, maternal country or origin and number of years of residence in the U.S. 
 
3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements 
None. 
 
B. Protection of Contacts of a Case 
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No immunization or prophylaxis is necessary for contacts of a case. If the patient is hospitalized, 
Standard Precautions should be used.  
 
C. Preventive Measures 
Personal Preventive Measures/Education 
Vaccination, including routine childhood vaccination and tetanus-containing boosters beginning at age 
11−12 years and continuing every 10 years thereafter, is the best preventive measure against 
tetanus. (Note: Tdap is recommended as a booster at age 11-12) Diphtheria-containing formulations 
should always be used and one dose with acellular pertussis vaccine . The Advisory Committee on 
Immunization Practices (ACIP) recommends that all children receive a routine series of five doses of 
tetanus- and diphtheria-containing vaccine at ages 2, 4, 6,and 15-18 months followed by a booster at 
4-6 years of age. Booster doses of diphtheria and tetanus toxoids should be administered beginning 
at age 11−12 years (Tdap) (provided at least 5 years have passed since the last dose) and every 10 
years thereafter (Td). DTaP and DT should be used in persons < 7 years of age, whereas Td is the 
preferred preparation for persons > 7 years of age. The Td catch-up schedule for those starting 
immunization at > 7 years of age consists of 3 doses. The second dose is usually given 1−2 months 
after the first dose, and the third dose 6 months after the second dose. 
 
There are four vaccines used to prevent diphtheria, tetanus and pertussis: DTaP, Tdap, DT, and Td. 
Two of these (DTaP and DT) are given to children younger than 7 years of age, and two (Tdap and 
Td) are given to older children and adults. Several other combination vaccines contain DTaP along 
with other childhood vaccines. Children should get 5 doses of DTaP, one dose at each of the 
following ages: 2, 4, 6, and 15-18 months and 4-6 years. DT does not contain pertussis, and is used 
to complete the series if a child has a valid contraindication to pertussis vaccine. Td is a tetanus-
diphtheria vaccine given to adolescents and adults as a booster shot every 10 years, or after an 
exposure to tetanus. Tdap is similar to Td but also contains protection against pertussis. A single 
dose of Tdap is recommended to replace one dose of Td. Tdap is licensed for ages 10 through 64 
years. Healthcare providers and the public must be educated on the necessity of primary 
immunization with tetanus-diphtheria toxoid and 10-year booster doses; the hazards of puncture 
wounds and closed injuries, and the potential need after injury for active and/or passive prophylaxis. 
Because tetanus is preventable, each case should be considered a failure to vaccinate and should be 
used as a means of determining how to prevent further failures from occurring. Surveillance 
information should be used to raise awareness of the importance of immunization and to characterize 
persons or places in which additional efforts are required to raise immunization levels and decrease 
disease incidence. 
 
Tetanus prophylaxis in patients with wounds is based on careful assessment of whether the wound is 
clean or contaminated, the immunization status of the patient, proper use of tetanus toxoid and/or 
TIG, wound cleaning and where required, surgical debridement and proper use of antibiotics. 
 
Table 1. Guide to Tetanus Prophylaxis in Routine Wound Management 
 
Vaccination History Clean minor wounds 
Td*b                               TIGc 
All other wounds a 
Td*                                      TIGc 
Unknown or < 3 Yes No Yes  Yes 
> 3 dosesd   No+ No    No** No 
+Yes if more than 10 years since last dose 
*Tdap may be substituted for Td if the person has not previously received Tdap and is 10 years or 
older 
** Yes is more tan 5 years since last dose 
 
Environmental Measures 
Sterilization of hospital supplies will prevent the infrequent instances of tetanus that may occur in a 
hospital from contaminated sutures, instruments, or plaster casts.   
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4) ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Tetanus 
can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
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(Lockjaw disease) 
 
What is tetanus? 
Tetanus is a disease caused by a toxin formed by the bacteria Clostridium tetani. It grows without 
oxygen at the site of an injury and has a short and relatively severe course that is often fatal. 
 
What are the symptoms of a tetanus infection? 
The illness is characterized by painful muscle contractions, especially stiffness and convulsive 
spasms of the jaw and neck muscles and the upper body or trunk muscles.  A common first sign of 
tetanus in older children and adults is painful stiffness of stomach muscles. 
 
How soon do symptoms appear? 
Illness usually starts in 3 - 21 days, although it may occur as soon as 1 day depending on the type 
and location of the wound; the average is 10 days.  A shorter time to illness is associated with a 
dirtier wound and more severe illness. 
 
How does tetanus spread? 
Tetanus spores are introduced into the body, usually through a puncture wound dirty with soil or 
animal or human feces. They may also be introduced through cuts, scraps, burns and trivial or 
unnoticed wounds, or by infected, contaminated street drugs.  Tetanus may follow elective surgery, 
ear infections, or dental infection.  Tetanus is not spread from person to person. 
 
Who gets tetanus? 
Anyone may get the illness, regardless of age.  If a person has suffered a wound or injury and has 
not been adequately immunized against tetanus and received a booster shot every ten years, 
tetanus may occur.  Most current cases occur in older adults who have not gotten a booster shot 
every 10 years to maintain protection. 
 
For how long is a person infectious? 
There is no infectious period because tetanus in not spread from person-to-person. Tetanus is 
the only vaccine-preventable disease that is not contagious. 
 
What is the treatment for this illness? 
Antibiotics play almost no role in the treatment of tetanus.  Other drugs may be used by the 
healthcare provider.     
 
Do infected people need to be excluded from school, work, or child care? 
No, tetanus is not spread from person-to-person. 
 
What can be done to help prevent the spread of tetanus? 
Tetanus can be prevented by vaccination and keeping that protection up-to-date with a booster 
shot every 10 years.   
Iowa Dept. of Public Health Reviewed 10/12   Tetanus Fact Sheet 
CONFIDENTIAL                                                                          Iowa Department of Public Health 
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Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -      
  
Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider title: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS - NONE 
 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
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Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
Was this case in the intensive 
care unit for this disease?  Yes    No    Unk If yes, for how many days?       
Outcome one month after onset:  Recovered  Convalescing    Died 
  
If case died from tetanus, list 
date of death:      /     /      
  
 
OTHER DEMOGRAPHIC INFORMATION 
 
If case under 28 days old at onset, collect the following information 
Mother’s information 
Mother’s age (in years): 
 
    /    /    .     Mother’s date of birth : 
 
    /    /    .     Mother’s arrival in the U.S.:     /    /    . 
Mother’s tetanus toxoid history 
Did mother receive Tetanus toxoid before child onset:  Yes    No    Unknown 
How long before child onset:  < 6 hours   7- 23 hours   1 - 4 days   5 - 9 days   10 - 14 days   15 + days 
Years since last dose:                       . 
Infant’s information 
Birthplace of infant: 
 
 
 
 Hospital                   Home   
 Other – see notes   Unknown 
Delivered by: 
 
 
 
 Physician                 Nurse   
 Licensed midwife     Unlicensed midwife 
 Other – see notes    Unknown 
 
CLINICAL INFO & DIAGNOSIS 
 
Symptoms:  Generalized spasms    Painful muscle spasms 
Type of tetanus 
disease: 
 Cephalic 
 Generalized 
 Localized  
 Unknown/Other       
Pre-existing wound 21 days prior to onset:  Yes    No    Unk Wound location:  Head  Trunk 
 Upper extremity 
 Lower extremity 
Wound type: 
 Abrasion                     
 Avulsion   
 Burn                           
Compound fracture    
 Crush  
Frostbite                         
 Linear laceration 
 Puncture  
 Stellate laceration 
Wound 
depth: 
 
 1 cm or less 
 More than 1 cm 
Signs of infection:  Yes    No    Unk Contaminated:  Yes    No    Unk 
Devitalized, ischemic, or denervated tissue:  Yes    No    Unk Date wound occurred:      /     /            
Setting: 
 Automobile 
 Farm/yard 
 Home 
 Petting zoo 
 Work 
Other indoor/outdoor setting:  
Other details:       
 
Health care provider visited:   Yes      No      Unk  
Wound debridement performed:   Yes      No      Unk How soon after the injury:   <6 hours  6-23 hours 
 1-4 days 
 5-9 days 
 10-14 days 
 15+ days 
      
Performed by a healthcare provider:  Yes      No      Unk Other associated conditions:  Abscess  Ulcer 
 Blister 
 Gangrene 
 Cellulitis 
 Other  
 None 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
 
TREATMENT 
 
Antibiotics prescribed?   Yes    No    Unknown 
  
Antibiotic:       
  
Antibiotic:       
 
 
Antibiotic:       
Date 
started:      /     /      
Date 
started:      /     /      
Date 
started:      /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
 
For the illness, were any of the following treatments required: 
Ventilator:  Yes    No    Unk Duration in days:       
 
Tetanus immune globulin (TIG) received?   Yes    No    Unknown  
How soon after the injury:  < 6 hours   7 – 23 hours   1 – 4 days   5 – 9 days   10 – 14    > 15 days days 
 
 
How soon after onset:  < 6 hours   7 – 23 hours   1 – 4 days   5 – 9 days   10 – 14    > 15 days days 
Date 
started:       Number of days:       
Dose:       Unit: 
 
      
Number of times each 
day:       
Route:       
 
 
Tetanus toxoid received before onset?           Yes    No    Unknown 
Date 
started:       Number of days:       
Dose:       Unit: 
 
      Number of times each day:       
Route:       
 
 
Therapeutic medication prescribed:  Yes    No    Unk List medications:  
Days in ICU: ___________________   
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Street drugs or steroids injected:   Yes    No    Unknown 
 
Ever served in the Military or National Guard?  Yes    No    Unknown 
 If yes, what was your year of entry?       
 
Vaccinated for tetanus:   Yes    No    Unknown 
 
Date vaccinated: 
 
     /     /      
 
Date vaccinated: 
 
     /     /      
 
Date vaccinated: 
 
     /     /      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
 
Number of vaccinations:       
Does this case have diabetes:  Yes    No    Unk Insulin dependent:  Yes    No    Unk 
 
NOTES:       
 
 
 
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation period for 
tetanus is 3 to 21 days. 
No direct person to 
person transmission.  
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TOXIC SHOCK SYNDROME 
 
Also known as: TSS  
 
Responsibilities: 
Hospital: Report by IDSS, facsimile, mail, or phone.  
Infection Preventionist: Report by IDSS, facsimile, mail, or phone. Assists with case 
investigation 
Lab: Report by IDSS, facsimile, mail, or phone.  
Physician: Report by facsimile, mail, or phone.  
Local Public Health Agency(LPHA):  Report by IDSS, facsimile, mail, or phone.  
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Toxic shock syndrome (TSS) is a serious complication of infection with strains of Staphylococcus 
aureus that produce TSS toxin-1 (TSST-1) or strains of Streptococcus pyogenes that produce 
pyrogenic exotoxin A. S. pyogenes is more commonly known as group A streptococcus (GAS).  
 
B. Clinical Description 
TSS is a severe toxin-mediated illness with sudden onset of high fever, vomiting, profuse watery 
diarrhea, and myalgia, followed by hypotension and potentially shock. During the acute phase of the 
illness, a “sunburn-like” rash is present. One to two weeks after onset, desquamation of the skin 
occurs, especially on the soles and palms. Typically, the fever is higher than 102°F, the systolic blood 
pressure is <90 mm Hg and three or more of the following organ systems are involved:  
 
• gastrointestinal,  
• muscular,  
• mucous membranes (including vagina, pharynx, conjuctiva),  
• renal,  
• hepatic,  
• respiratory,  
• hematologic, or  
• central nervous system.  
       
Blood, cerebrospinal fluid and throat cultures are negative for pathogens other than S. aureus or 
GAS. Rocky Mountain spotted fever, leptospirosis and measles should be ruled out. TSS can be fatal. 
 
C. Reservoirs 
Humans are the primary reservoir for both S. aureus and GAS. 
 
D.  Modes of Transmission 
While TSS itself is not communicable from person-to-person, the organisms that cause TSS are. S. 
aureus is transmitted from person-to-person through direct contact with lesions or contaminated 
respiratory secretions. Airborne transmission is rare but has been documented in small children with 
respiratory disease.  
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GAS is transmitted from person-to-person through large respiratory droplets or direct contact with 
infected lesions. GAS can also be transmitted through ingestion of contaminated food, most 
commonly eggs, milk and milk products, resulting in outbreaks of GAS pharyngitis.  
 
With both S. aureus and GAS, indirect contact through objects is rarely associated with illness, but it 
has occurred in schools through contaminated wrestling mats and in child care centers through play 
food and other shared toys. 
 
D. Incubation period 
The incubation period for S. aureus infection is variable, with a 4 - 10 day average. For GAS infection 
it approximately 1 to 3 days. The median incubation period for post-surgical TSS is 2 days. 
 
E. Period of Communicability or Infectious Period 
TSS itself is not communicable from person-to-person. With S. aureus, the infectious period lasts as 
long as lesions drain or the carrier state exists. In untreated, uncomplicated GAS cases, the infectious 
period may be 10 - 21 days; if purulent discharge is present, the infectious period may be extended 
to weeks or months. Persons with untreated GAS pharyngitis may carry and transmit the bacteria for 
weeks or months, with decreasing contagiousness 2 - 3 weeks after illness onset.  
 
F. Epidemiology 
In 1980, TSS became widely recognized when an association between TSS and the use of tampons 
was established. Since that time, the proportion of TSS cases associated with menstruation has 
decreased. Cases of TSS have been associated with childbirth, abortions, vaginal infections, surgical 
wound infections, focal lesions of the bone or respiratory tract, and cutaneous or subcutaneous 
lesions. The source of infection is unknown in up to one-third of cases. Cases are seen in both males 
and females.  
 
Persons considered at risk for TSS include: 1) menstruating women using tampons or other inserted 
vaginal devices (such diaphragms or contraceptive sponges), and 2) persons with focal S. aureus or 
GAS infections.  
  
G. Bioterrorism Potential 
None. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To identify household and other close contacts for possible culture and treatment of the 
underlying bacterial cause. 
• To identify transmission sources of public health concern (e.g., contaminated food or a 
healthcare worker who is a GAS carrier) and to stop transmission from such sources. 
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report. The preferred method of reporting is by utilizing IDSS.  However, if IDSS is not 
available, the reporting number for IDPH Center for Acute Disease Epidemiology (CADE) is (800) 
362-2736; fax number (515), 281-5698, mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
Des Moines, IA 50319-0075 
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Laboratory Testing Services Available 
The State Hygienic Laboratory (SHL) does not provide services for the testing to confirm TSS. 
However, SHL will test specimens for the presence of S. aureus or Beta Strep Group A. In some 
outbreak circumstances, isolates may be sent to Centers for Disease Control and Prevention (CDC) 
for toxin testing. For more information contact SHL at (319) 335-4500, or visit: www.shl.uiowa.edu/  
 
C. Hospital Infection Preventionist will have the information necessary to initiate 
case follow-up. 
The hospital Infection Preventionist usually completes the investigation, utilizing the Iowa Disease 
Surveillance System (IDSS). 
a. Use the following guidelines to complete the investigation:  
1) Record the demographic information, date of symptom onset, and hospitalized dates. If the 
case is a menstruating woman, collect information on tampon and sanitary napkin/minipad 
use, including the brand and style of product, as well as date of onset of last menstrual 
period. 
2) Clinical findings, laboratory data and culture information are all important in defining a case. 
Collect the data for these sections of the case investigation as completely as possible. 
3) If several attempts have been made to obtain case information, but have been unsuccessful, 
fill out the form with as much information as possible.  Enter into the Notes section the 
reason why it could not be filled out completely.   If using IDSS, select the appropriate 
reason under the Event tab in the Event Exception field. 
4) After completing the investigation, enter the information into IDSS or fax to (515) 281-5698 
or mail (in an envelope marked “Confidential”) to IDPH/CADE, mailing address:  
Iowa Department of Public Health 
Center for Acute Disease Epidemiology 
Lucas State Office Building 
321 East 12th St. 
Des Moines, IA 50319-0075 
5) Local public health shall assist with case follow-up as necessary and review the investigation 
and assure it is complete. 
 
d. Institution of disease control measures is an integral part of case investigation. It is the LPHA 
responsibility to understand, and, if required by IDPH, to institute the control guidelines listed 
below.  
 
3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements 
None. 
 
B.  Protection of Contacts of a Case 
If it has been determined that the case was caused by GAS, household contacts of the case should 
have throat cultures taken, and if positive for GAS, be treated with antibiotics. Other close contacts 
should be evaluated and cultured if symptomatic. 
 
C.  Managing Special Situations 
Child Care 
If the TSS is caused by GAS, consider throat cultures for all symptomatic child care attendees and 
staff who are contacts of the case, with subsequent antibiotic treatment of those found to be GAS 
culture positive. Contact the Center for Acute Disease Epidemiology (CADE) for assistance in 
managing follow-up of a case in child care. 
 
School 
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If the TSS is caused by GAS, consider throat cultures for all symptomatic classroom members and 
other close contacts of the case, with subsequent antibiotic treatment of those found to be GAS 
culture-positive. Contact the Center for Acute Disease Epidemiology (CADE) for assistance in 
managing follow-up of a case in a school. 
 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
If you suspect an outbreak, investigate to determine the source of infection and mode of 
transmission. Seek a common exposure, such as association with a child care center, and institute 
applicable preventive or control measures. Control of person-to-person transmission requires special 
emphasis on personal cleanliness and handwashing. Consult CADE for assistance. 
 
H. Preventive Measures 
Environmental Measures 
Advise child care centers to clean toys daily using an approved disinfectant and to discourage the use 
of play food, which facilitates the transmission of not only this bacterium but many others as well. 
Also advise schools to frequently sanitize shared sports equipment, such as wrestling and gymnastics 
mats. 
 
I.  Personal Preventive Measures/Education 
To avoid exposure, advise individuals to: 
• Use the lowest absorbency tampon and change frequently. Discontinue tampon use immediately 
and call their healthcare provider if they develop a high fever and vomiting or diarrhea during 
menstruation. 
• Follow directions for use of diaphragms or contraceptive sponges and do not leave the device in 
place for more than 30 hours.  
• Complete the full course of treatment if prescribed antibiotics for staphylococcus or streptococcus 
infections. 
 
4) ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Toxic 
Shock Syndrome can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
 
References 
American Academy of Pediatrics. 1997 Red Book: Report of the Committee on Infectious Diseases, 
24th Edition. Illinois, American Academy of Pediatrics, 1997.  
CSTE Position Statement Number: 10-ID-14  
Heymann, D.L., ed. Control of Communicable Diseases Manual, 19th Edition. Washington, DC, 
American Public Health Association, 2008. 
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 (TSS) 
 
What is toxic shock syndrome? 
Toxic shock syndrome (TSS) is a serious complication of infection with strains of Staphylococcus aureus that 
produce TSS toxin-1 (TSST-1) or strains of Streptococcus pyogenes that produce pyrogenic exotoxin A. S. 
pyogenes is more commonly known as group A streptococcus (GAS).  
 
Who is at risk for toxic shock syndrome? 
Any one is at risk, however, menstruating women, women who use barrier contraceptive devices, persons 
who have undergone nasal surgery, and persons with postoperative staphylococcal wound infections are at 
highest risk. 
 
How do you get toxic shock syndrome? 
TSS has been associated with use of tampons and intravaginal contraceptive devices in women and 
occurs as a complication of skin abscesses or surgery in either sex. 
 
Can toxic shock syndrome be spread from person-to-person? 
TSS itself is not communicable from person-to-person.  
 
What are the symptoms of toxic shock syndrome? 
Toxic shock syndrome (TSS) is characterized by sudden onset of fever, chills, vomiting, diarrhea, muscle 
aches and rash. It can rapidly progress to severe and intractable hypotension and multisystem dysfunction.  
 
How soon will symptoms appear? 
The incubation period for TSS ranges from 1 - 10 days, on average.  
 
How can toxic shock syndrome be prevented? 
To avoid exposure, advise individuals to: 
• Use the lowest absorbency tampon and change frequently. Discontinue tampon use immediately and 
call their healthcare provider if they develop a high fever and vomiting or diarrhea during menstruation. 
• Follow directions for use of diaphragms or contraceptive sponges and do not leave the device in place 
for more than 30 hours.  
• Complete the full course of treatment if prescribed antibiotics for staphylococcus or streptococcus 
infections. 
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CONFIDENTIAL                                                                                         Iowa Department of Public Health 
Toxic Shock Syndrome                        
       Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome: 
 Survived this illness     Died from this illness 
 Died unrelated to this illness    Unknown 
Date of Death      /     /      First name: 
 
      
Event exception 
 Case could not be found 
 Case could not be interviewed 
 Case refused interview 
 Other – see notes 
Provider title:  ARNP    DO 
 MD 
 NP  PA 
Outbreak 
related:  Yes      No      Unknown  
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
 Type (e.g. serotype): 
 
        
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
 Type (e.g. serotype): 
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Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
 Type (e.g. serotype): 
 
        
 
 
 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
Fever:  Yes    No    Unk Onset date:      /     /      Highest known fever:       C/F 
 
Rash:  Yes    No    Unk Rash characteristics:  Burning                  Confluent lesions    
 Discrete lesions    
 Distinct sharp borders   
 Painful    
 Peeling skin 
Soft tissue necrosis:  Yes    No    Unk 
 Could be felt (papule)       
 Could not be felt (macule) 
 
 Marked itching 
 Dusky brown                     
 Numbness 
 Pustule                              
 Reddish 
 Scaling/crusting 
  
Necrotizing fascitis present:  Yes    No    Unk DIC:  Yes    No    Unk Lowest systolic blood pressure:       
Other symptoms present: 
 Abdominal pain         
 Confusion                  
 Conjuntival hyperemia  
 Diarrhea    
 Injected tongue         
 Muscle pain 
 Oropharyngeal hyperemia       
 Seizures                     
 Sore throat 
 Vaginal discharge     
 Vaginal hyperemia    
 Vaginal ulceration 
 Vomiting                      
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
OTHER LAB FINDINGS 
 
CBC performed:  Yes   No    Unk ALT performed:  Yes   No    Unk 
WBC count (in mm3):       Result (in IU/l):       
Neutrophils (in %):       Expected minimum (in IU/l):       
Metamyelocytes (in %):       Expected maximum (in IU/l):       
Myelocytes (in %):       AST performed:  Yes   No    Unk 
Bands (in %):       Result (in IU/l):       
Platelet count 
 (in mm3):       Expected minimum (in IU/l):       
Highest platelet value 
(in mm3):       Expected maximum (in IU/l):       
Bilirubin (in mg/dl):       Urinalysis performed:  Yes   No    Unk 
Creatine (in mg/dl):       WBC/HPF(in cells/mcl):       
Creatine 
phosphokinase (in IU/l):       RBC/HPF (in cells/mcl):       
Hypoalbuminemia:  Yes   No    Unk Protein:  1      2      3      4 
Pyuria:  Yes   No    Unk   
 
Chest x-ray done:  Yes No  Unk 
 
Date: 
 
     /     /      
 
Result: 
 
      
 
TREATMENT 
 
Antibiotics prescribed?   Yes    No    Unknown  
 
  
Antibiotic:       
  
Antibiotic:       
 
 
Antibiotic:       
Date 
started:      /     /      
Date 
started:      /     /      
Date 
started:      /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Similar illness in past:  Yes   No    Unk # of episodes:  1      2      3    >3 
Tampon used:  Yes   No    Unk Napkin used:  Yes   No    Unk Mini-pad used:  Yes   No    Unk 
Brand name:  Assure  Kotex 
 Store brand 
 Tampax  
Brand 
name:       Brand name:       
 
 OB 
 Playtex  
Odor protection 
type: 
 Deodorized 
 Non-deodorized Odor protection type: 
 Deodorized 
 Non-deodorized 
 
 Pursettes 
 Rely 
Absorbency:  Lite 
 Regular 
Absorbency:  Lite 
 Regular 
 
Other       
 
 Super 
 Super plus  
 Super 
 Super plus  
Insertion type:  Plastic inserter   Stick inserter     
Odor protection type: 
 
 Deodorized 
 Non-deodorized 
Sponge or 
diaphragm 
used:  Yes   No    Unk 
Surgical 
procedures:  Yes   No    Unk 
Absorbency: 
 
 Lite 
 Regular 
Postpartum/ 
post abortion:  Yes   No    Unk 
Skin lesions 
(scratch or cut):  Yes   No    Unk 
 
 Super 
 Super plus     
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation period for 
Toxic shock syndrome 
is unknown. 
There is no person to 
person transmission of 
this disease.  
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Guide to Surveillance, Investigation, and Reporting 
TRICHINOSIS 
 
Also known as:  Trichinellosis 
 
Responsibilities: 
Hospital: Report by IDSS, facsimile, mail, or phone 
Infection preventionist: Report by IDSS, facsimile, mail, or phone 
Lab: Report by IDSS, facsimile, mail, or phone 
Physician: Report by facsimile, mail, or phone  
Local Public Health Agency (LPHA):  Report by IDSS, mail, facsimile, or phone. Follow-up 
required 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Trichinosis is caused by Trichinella spiralis, a parasitic intestinal roundworm. Multiple species of 
Trichinella are capable of causing infection in mammals, but T. spiralis is the most common cause of 
human infection.  
 
B. Clinical Description 
Trichinosis in humans can range from asymptomatic to fatal, depending on the infective dose. In the 
week following ingestion of infected meat, a patient may experience nausea, vomiting, diarrhea and 
abdominal discomfort, as the released larvae mature and attach to the intestinal mucosa. A sudden 
onset of muscle soreness and pain, fever, edema of the upper eyelid and urticarial rash, 2 - 8 weeks 
after ingestion, is characteristic of earlier infection, as larvae migrate into muscle tissue. Eye pain, 
photophobia, thirst, profuse sweating, chills, weakness and a rapid increase in eosinophil counts on 
blood exam may also occur. Recurring fever up to 104°F usually stops after 1 - 6 weeks. In the most 
severe infections, cardiac and neurologic complications, sometimes leading to death, may occur in 
the 3rd - 6th week. 
  
C. Reservoirs 
Swine, dogs, cats, horses, rodents and many wild animals, such as bear, wolf, wild boar, fox and 
Arctic marine mammals, can serve as reservoirs for Trichinella. 
 
D. Modes of Transmission 
Transmission occurs by ingestion of raw or undercooked meats containing Trichinella cysts. Pork and 
pork products are the most likely source. Beef products, which may become inadvertently adulterated 
with raw pork during processing, may also be a source. As many as 30% of domestic cases of 
trichinosis are thought to correlate with ingestion of meat from wild game animals. There is no 
person-to-person spread of trichinosis. 
 
E. Incubation period 
Gastrointestinal symptoms may appear within a few days after infection; appearance of systemic 
symptoms ranges from 5 - 45 days. The usual incubation period is 8 - 15 days. If large numbers of 
cysts are ingested, symptoms may occur more rapidly. 
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F. Period of Communicability or Infectious Period 
Trichinosis is not transmitted directly from person-to-person. Animal hosts may remain infective for 
months, and meat from these animals remains infective until the larvae are killed by sufficient 
cooking, freezing or irradiation. 
   
G. Epidemiology 
Trichinosis occurs worldwide, and affects people of all ages. The incidence of disease is dependent on 
local customs regarding eating pork or undercooked meats. Over the past 40 years, few cases of 
trichinellosis have been reported in the United States, and the risk of trichinellosis from commercially 
raised and properly prepared pork is very low. However, eating undercooked wild game, particularly 
bear meat, puts one at risk for acquiring this disease. 
 
H. Bioterrorism Potential 
None. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
 To identify sources of public health concern (e.g., undercooked Trichinella-infected pork sold 
at a restaurant) and stop transmission at the source. 
 To identify and control outbreaks. 
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report. The preferred method of reporting is by utilizing the Iowa Disease Surveillance System 
(IDSS).  However, if IDSS is not available to your facility the reporting number for IDPH Center for 
Acute Disease Epidemiology (CADE) is (800) 362-2736; fax number (515) 281-5698, mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th Street 
Des Moines, IA 50319-0075 
 
Postage-paid disease reporting forms are available free of charge from the IDPH clearinghouse.   
Call (319) 398-5133 or visit the website: 
healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295 to request a supply. 
 
Laboratory Testing Services Available  
The University of Iowa State Hygienic Laboratory tests single serum samples utilizing Enzyme 
Immunoassay. For more information about submitting specimens, contact the State Hygienic 
Laboratory at (319) 335-4500. 
 
C.  Local Public Health Agency Follow-up Responsibilities 
Case Investigation: Complete the investigation using IDSS. The investigation will likely focus on 
suspect meat that has been ingested.  
 
3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements 
 None. 
B. Protection of Contacts of a Case 
None. 
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C.  Managing Special Situations 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
If an outbreak is suspected, investigate to determine the source of infection and mode of 
transmission. A common vehicle, such as food should be sought, and applicable preventive or control 
measures instituted (e.g., removing an implicated food item from the environment). Consult with the 
epidemiologist on-call at the Center for Acute Disease Epidemiology (CADE) at (800) 362-2736. The 
Center can help determine a course of action to prevent further cases, and perform surveillance for 
cases that cross county lines. 
 
D. Preventive Measures 
To avoid future exposure, individuals should be made aware of the following: 
• Thoroughly cook pork, pork products and wild game until the meat is no longer pink Allow 
sufficient cooking time so that all parts of the meat reach an internal temperature of at least 
170°F. Freezing pork less than 6 inches thick for 20 days at 5°F will kill the larvae, but 
freezing wild game meats may leave some larvae alive, so this meat must always be 
thoroughly cooked. 
• Grind pork in a separate grinder from other foods, and thoroughly disinfect the grinder 
between products. 
• Thoroughly cook all meats from wild animals. Meat products should be processed by heating, 
freezing or irradiation prior to drying or smoking for jerky. 
• Cook any meat fed to pigs or other animals being raised for human consumption. Hogs 
should not be allowed to eat uncooked carcasses of other animals, including rats, which may 
be infected with trichinosis. 
• Be aware that curing (salting), drying, smoking, or microwaving meat does not consistently 
kill infective larvae. 
 
Individuals known to have recently ingested the same product as the case being investigated should 
consult with a healthcare provider regarding treatment options. 
 
4) ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for 
Trichinosis can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
Comment: 
In an outbreak setting, at least one case must be laboratory confirmed. Associated cases should be 
reported as confirmed if the patient shared an epidemiologically implicated meal or ate an 
epidemiologically implicated meat product and has either a positive serologic test for trichinosis or a 
clinically compatible illness.  
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What is trichinosis? 
Trichinellosis, also called trichinosis (TRICK-a-NO-sis), is caused by eating raw or undercooked pork and 
wild game products infected with the larvae of a species of worm called Trichinella. Infection occurs 
worldwide, but is most common in areas where raw or undercooked pork, such as ham or sausage, is 
eaten. 
 
What are the symptoms of trichinosis? 
Nausea, diarrhea, vomiting, fatigue, fever, and abdominal discomfort are the first symptoms of 
trichinellosis. Headaches, fevers, chills, cough, eye swelling, aching joints and muscle pains, itchy skin, 
diarrhea, or constipation follow the first symptoms. If the infection is heavy, patients may experience 
difficulty coordinating movements, and have heart and breathing problems. In severe cases, death can 
occur. In mild to moderate infections, most symptoms subside within a few months. Fatigue, weakness, 
and intermittent muscle aches may last for months. 
 
How soon do symptoms appear? 
Abdominal symptoms can occur 1 – 2 days after infection. Later symptoms usually start 2 - 8 weeks after 
eating contaminated meat. Symptoms may range from very mild to severe, and relate to the number of 
infectious worms consumed. Often, mild cases of trichinellosis are not specifically diagnosed, and are 
assumed to be the flu or other common illnesses. 
 
How is trichinosis spread? 
When a human or animal eats meat that contains infective Trichinella cysts, the acid in the stomach 
dissolves the hard covering of the cyst and releases the worms. The worms pass into the small intestine 
and, in 1-2 days, become mature. After mating, adult females lay eggs. Eggs develop into immature 
worms, which penetrate the wall of the intestine, travel through the arteries, and are transported to 
muscles. Within the muscles, the worms curl into balls, and encyst (become enclosed in a capsule). 
Infection occurs when these encysted worms are consumed in meat. 
 
Who gets trichinosis? 
If you eat raw or undercooked meats, particularly pork, bear, wild feline (such as a cougar), fox, dog, 
wolf, horse, seal, or walrus, you are at risk for trichinellosis. 
 
How long is a person infectious? 
Infection can only occur by eating raw or undercooked meat containing Trichinella worms.  It is not 
spread from person to person. 
 
What is the treatment for this illness? 
Several safe and effective prescription drugs are available. Treatment should begin as soon as possible, 
and the decision to treat is based upon symptoms, exposure to raw or undercooked meat, and laboratory 
test results. 
 
Do infected people need to be excluded from school, work, or child care? 
No.  Infection can only occur by eating raw or undercooked meat containing the worms. 
 
What can be done to help prevent the spread of these worms? 
• Cook meat products until the juices run clear, or to an internal temperature of 170 o F.  
• Freeze pork less than 6 inches thick for 20 days at 5 o F to kill any worms.  
• Cook wild game meat thoroughly. Freezing wild game meats, even for long periods of time, may 
not effectively kill all worms.  
• Cook all meat fed to pigs or other wild animals.  
• Do not allow hogs to eat uncooked carcasses of other animals, including rats, which may be 
infected.  
• Clean meat grinders thoroughly after preparing ground meats.  
• Curing (salting), drying, smoking, or microwaving meat does not consistently kill the worms.  
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Trichinellosis 
                                 Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider title: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
 
Result type: 
 
 Preliminary      Final 
 
Result date: 
 
     /     /      Result: 
 Positive 
 Negative    
 
Organism: 
 
Trichinella Type (e.g. serotype): 
 
       
 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
 
Result type: 
 
 Preliminary      Final 
 
Result date: 
 
     /     /      Result: 
 Positive 
 Negative    
 
Organism: 
 
Trichinella Type (e.g. serotype): 
 
       
 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
 
Result type: 
 
 Preliminary      Final 
 
Result date: 
 
     /     /      Result: 
 Positive 
 Negative    
 
Organism: 
 
Trichinella Type (e.g. serotype): 
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OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
Fever:  Yes    No    Unk Onset date:      /     /      Highest known fever:       C/F 
 
Eosinophilla:  Yes    No    Unk Absolute #:       Percent:       
Periorbital edema:  Yes    No    Unk Myalgia:  Yes    No    Unk 
 
 
 
OTHER LAB FINDINGS 
 
Biopsy 
performed: 
 
 Yes   No   Unk 
 
Date: 
 
     /     /      
 
Site: 
 
      
 
Result: 
 
      
 
TREATMENT 
 
Antibiotics prescribed?   Yes    No    Unknown 
  
Antibiotic:       
  
Antibiotic:       
 
 
Antibiotic:       
Date started:      /     /      
Date 
started:      /     /      Date started:      /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Dietary Information – In the 45 days prior to onset of symptoms did the case consume the following: 
Meat and poultry 
Pork:  Yes    No    Unk 
Pork type:  Bacon  Chops 
 Ham 
 Roast 
 Sausage 
 Wild Boar  Other       
List all brand names:       
Obtained where: 
 
 Butcher shop 
 Direct from farm 
 Hunted/Trapped 
 Restaurant /Eating establishment 
 Supermarket/Grocery store 
 Unknown 
Preparation: 
 
 Dried jerky 
 Ground 
 Marinated 
 No further processing 
 Smoked 
 Other       
Cooking method: 
 
 Broiled 
 Dehydrated 
 Fried 
 Grilled 
 Open-fire roasting 
 Roasted 
 Smoked 
 Uncooked  Unknown 
From dates consumed:      /     /     ,      /     /      To dates consumed:      /     /     ,      /     /      
Meat other than pork:  Yes    No    Unk   
Meat type:  Bear    Bison  
 Hamburger   
 Venison   Other       
List all brand names:       
Obtained where: 
 
 Butcher shop 
 Direct from farm 
 Hunted/Trapped 
 Restaurant /Eating establishment 
 Supermarket/Grocery store 
 Unknown 
Preparation: 
 
 Dried jerky 
 Ground 
 Marinated 
 No further processing 
 Smoked 
 Other       
Cooking method: 
 
 Broiled 
 Dehydrated 
 Fried 
 Grilled 
 Open-fire roasting 
 Roasted 
 Smoked 
 Uncooked  Unknown 
From dates consumed:      /     /     ,      /     /      To dates consumed:      /     /     ,      /     /      
 
NOTES:       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation period for 
Trichinellosis 8 to 15 
days; range of 5-45 days. 
Trichinellosis is not 
transmitted person to 
person.  
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TUBERCULOSIS 
 
Also known as: TB, Consumption  
 
Responsibilities: 
Hospital: Report by facsimile, mail or phone 
Infection Preventionist: Notify Iowa TB Control Program 
Lab: Report presumptive/positive cultures of TB 
Physician: Report all suspected or active cases by mail or phone 
Local Public Health Agency (LPHA): Follow-up required 
 
Iowa Department of Public Health TB Control Program: (515) 281-8636 or  
(515) 281-7504 
Secure Fax: (515) 281-4570 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent   
TB is a communicable disease caused by Mycobacterium tuberculosis, sometimes referred to as the 
tubercle bacillus. It is spread primarily by tiny airborne particles (droplet nuclei) expelled from a 
person who has infectious TB. If another person inhales air containing these droplet nuclei, 
transmission may occur. Some bacilli reach the alveoli, where they are ingested by macrophages. 
Infection begins with the multiplication of tubercle bacilli within these alveolar macrophages. Some of 
the bacilli spread through the bloodstream when the macrophages die; however, the immune system 
response usually contains the bacilli and prevents the development of disease. Persons who are 
infected but who do not have TB disease are asymptomatic and not infectious; such persons usually 
have a positive reaction to the tuberculin skin test (PPD). Only 10% of infected persons will develop 
TB disease at some time in their lives, but the risk is considerably higher for persons who are 
immunosuppressed, especially those with HIV infection. Although the majority of TB disease in adults 
is pulmonary, TB can occur in almost any anatomical site or as disseminated disease.  
 
B. Clinical Description 
Symptoms: The general symptoms of TB disease include feeling sick or weak, weight loss, fever, and 
night sweats. The symptoms of pulmonary TB include coughing, chest pain, and coughing up blood. 
Other symptoms depend on the part of the body that is affected. 
 
Onset:  Persons at the highest risk of becoming infected with tuberculosis are close contacts — 
persons who have had prolonged, frequent, or intense contact with a person with infectious TB. 
Close contacts may be family members, roommates, friends, co-workers, or others. Data collected by 
CDC since 1987 show that infection rates have been relatively stable, ranging from 30% for the 
contacts of infectious TB patients.  
 
Complications: Person’s with TB can develop life-threatening complications.  Worldwide, 
approximately two million people die each year from TB.  If treated properly and early enough, 
people with TB can be cured.   
 
Infants/children -- LTBI: Because of their age, infants and young children with LTBI are known to 
have been infected recently, and thus are at a high risk of their infection progressing to disease.  
Infants and young children are also more likely than older children and adults to develop life-
threatening forms of TB.  Children <5 years of age who are close contacts should receive 
treatment for LTBI even if the tuberculin skin test result and chest radiograph do not suggest TB, 
because infected infants may be anergic as late as 6 months of age.  A second tuberculin test 
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should be done 8 – 10 weeks after the last exposure to infectious TB.  Treatment of LTBI can be 
discontinued if all of the following conditions are met: 
• The infant is at least 6 months of age; 
• The second tuberculin skin test is negative; 
• The second test was performed at least 8 weeks after the child was last exposed to infectious 
TB. 
Infants/children –TB disease:  Because of the high risk of disseminated tuberculosis in infants 
and children younger than 5 years of age, treatment should be started as soon as the diagnosis 
of tuberculosis is suspected. 
 
C. Reservoirs 
Common reservoirs:  Humans 
 
Less Common reservoirs:  Livestock, wildlife, mainly for m. bovis. 
 
D. Modes of Transmission 
Spread: TB germs are placed in the air when a person with pulmonary TB disease of the lungs or 
throat coughs, sneezes, speaks or sings. When a person inhales air that contains TB germs, he or she 
may become infected. Pulmonary Tuberculosis (TB) is spread from person to person through the air. 
It usually affects the lungs, but it can also affect other parts of the body, such as the brain, kidneys, 
or spine. People with TB infection (and not disease) do not feel sick and do not have any symptoms. 
However, they may develop TB disease at some time in the future. 
 
People with TB disease are most likely to spread it to people they spend time with every day, such as 
family members or co-workers. If someone thinks they have been around someone who has TB 
disease, they should go to their medical provider or the local health department for tests. It is 
important to remember that people who have TB infection but not TB disease cannot spread the 
germs to others. 
 
E. Incubation period 
For people with latent TB infection (LTBI) and no risk factors, the risk of LTBI developing into disease 
is about 10% over a lifetime. For people with TB infection and diabetes, the risk is 3 times higher, or 
about 30% over a lifetime. For people with TB infection and HIV infection, the risk is about 7% to 
10% PER YEAR, a very high risk over a lifetime. 
 
F. Period of Communicability or Infectious Period 
In general, patients who have suspected or confirmed active TB should be considered infectious if (a) 
they are coughing, undergoing cough-inducing procedures, or their sputum smears are positive for 
acid-fast bacilli; and (b) they are not receiving therapy, have just started therapy, or have a poor 
clinical or bacteriologic response to therapy. The infectious period is closed when the following 
criteria are satisfied: 1) effective treatment (as demonstrated by M. tuberculosis susceptibility results) 
for >2 weeks; 2) diminished symptoms; and 3) mycobacteriologic response (e.g., decrease in grade 
of sputum smear positivity detected on sputum-smear microscopy). The exposure period for 
individual contacts is determined by how much time they spent with the index patient during the 
infectious period. Multidrug-resistant TB (MDR TB) can extend infectiousness if the treatment 
regimen is ineffective. Any index patient with signs of extended infectiousness should be continually 
reassessed for recent contacts. 
 
More stringent criteria should be applied for setting the end of the infectious period if particularly 
susceptible contacts are involved. A patient returning to a congregate living setting or to any setting 
in which susceptible persons might be exposed should have at least three consecutive negative 
sputum AFB smear results from sputum collected >8 hours apart (with one specimen collected during 
the early morning) before being considered noninfectious. 
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G. Epidemiology 
One third of the world’s population is infected with the TB bacteria and each year over 9 million 
people around the world become ill from it. An estimated 10 - 15 million persons in this country are 
infected with M. tuberculosis. TB disease may develop in these persons at some time in the future. 
For current TB data, please refer to the IDPH TB Control webpage:  
www.idph.state.ia.us/ImmTB/TB.aspx?prog=Tb&pg=TbHome  
 
H. Bioterrorism Potential 
None. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting: 
 Prevention and control efforts should include three priority strategies:  
• Identifying and treating all persons who have TB disease 
• Finding and evaluating persons who have been in contact with TB patients to determine 
whether they have TB infection or disease, and treating them appropriately 
• Testing high-risk groups for TB infection to identify candidates for treatment of latent 
infection and to ensure the completion of treatment. 
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report suspected/confirmed M. tuberculosis. 
 
What to report: 
• Pulmonary and extrapulmonary sites of disease should be reported to IDPH within one working 
day. This includes laboratory confirmed or clinically suspected tuberculosis disease. 
• Latent tuberculosis infection (LTBI) is not reportable.   
• IDPH provides medication free of charge for anyone to treat both LTBI and TB disease. 
 
How to report tuberculosis: 
Call or FAX: IDPH TB Control Program 
(515) 281-8636 or (515) 281-7504  
Fax (515) 281-4570. 
 
IDPH TB Control Program requests that tuberculosis cases be reported by phone to help 
ensure timely public health follow-up measures. 
 
Specimens should be submitted to: 
State Hygienic Laboratory 
UI Research Park - Coralville 
Iowa City, IA 52242-5002 
 319-335-4500 or 800-421-IOWA 
 
Postage-paid disease reporting forms are available free of charge from the Iowa TB Control Program 
at (515) 281-8636 or (515) 281-7504. 
Both outpatient and inpatient facilities that offer services for TB patients should have ready access to 
laboratory and diagnostic services. Access to radiological services includes radiography equipment, 
trained radiography technicians, and radiograph interpretation by a qualified person. Radiograph 
findings and reports should be available within 24 hours. 
Laboratory services should be readily accessible to provide results of acid-fast bacilli smear 
examinations within 24 hours of specimen collection.  The State Hygienic Lab is designated to 
process all isolates for TB in the state.   Smear results are available within 24 hours from receipt of 
the specimen.  All initial positive smears are telephoned to the submitting facility.   
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AMPLIFIED MYCOBACTERIUM TUBERCULOSIS Direct (MTD) Test 
Description: Direct target-amplified nucleic acid probe test for the in vitro diagnostic detection of 
Mycobacterium tuberculosis complex rRNA in acid-fast bacilli (AFB) smear positive and negative 
concentrated sediments from sputum, bronchial specimens, or tracheal aspirates. For testing 
information, call the State Hygienic Laboratory at 319-335-4500 or the IDPH TB Control Program at 
515-281-8636/515-281-7504. 
The use of the BACTEC liquid culture system and DNA probes for M. tuberculosis continue to aid in 
rapidly and accurately isolating and identifying cultures of mycobacteria. All isolates are tested for 
drug susceptibilities.  All M. tuberculosis identifications and susceptibility results are telephoned to the 
submitter immediately. The TB Control Program also receives these reports. 
 
C.  Local Public Health Agency Follow-up Responsibilities 
Case Investigation 
 
Contact Investigation 
Prompt and thorough contact investigation is essential for the control of TB. The purpose of the 
investigation is to find contacts who (1) have TB disease so that they can be given treatment, and 
further transmission can be stopped, (2) have latent TB infection (LTBI) so they can be given 
treatment, and (3) are at high risk of developing TB disease and therefore require treatment until 
LTBI can be excluded. 
 
The local health departments are legally responsible for ensuring that a complete and timely contact 
investigation is done for the TB cases reported in its area. Therefore, health departments should 
work closely with other agencies (e.g., managed care organizations, private providers) to ensure the 
prompt reporting of suspected TB cases. The health department should work closely with other 
agencies to plan the contact investigation and receive a report of the results. Occasionally, a contact 
investigation may be conducted by people outside of the health department, but under the 
supervision of the health department. 
 
Contact investigations should be discussed with the TB Control Program Manager.  The results of all 
contact investigations must be submitted to the Iowa TB Control Program.  Forms used to document 
investigations are available by calling the program at (515) 281-7504 or (515) 281-8636. 
 
3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements 
Suspected or active cases of infectious TB should be isolated to home and not return to normal 
activities until they meet the criteria for non-infectiousness (see Period of Communicability or 
Infectious Period).  Persons already living in the household may continue to do so.  These persons 
are free to continue their normal activities.  People not previously exposed should refrain from 
entering the environment until the patient is no longer infectious.  
 
Although TB care and treatment are often provided by other medical care providers, the health 
department has the ultimate responsibility for ensuring that TB patients do not transmit M. 
tuberculosis to others. Health departments must ensure that medical services are available, 
accessible, and acceptable for TB patients, suspects, contacts, and others at high risk, without regard 
to the patients’ ability to pay for such services. 
 
B.  Protection of Contacts of a Case 
The local health department will identify and evaluate all close contacts of suspected or active cases 
of TB.  These contacts will be evaluated to determine if they have latent tuberculosis infection or 
active disease.   
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C.  Managing Special Situations 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
      Report unusual cases to the Iowa TB Control Program at (515) 281-7504. 
  
Exposure of a Laboratory Worker  
      Confer with Iowa TB Control Program or Infection Preventionist at the place of exposure. 
  
D. Preventive Measures 
Environmental Measures 
The second level of the hierarchy is the use of engineering controls to prevent the spread and reduce 
the concentration of infectious droplet nuclei. These controls include (a) direct source control using 
exhaust ventilation, (b) controlling the direction of airflow to prevent the contamination of air in areas 
adjacent to the infectious source, (c) diluting and removing contaminated air via general ventilation, 
and (d) cleaning the air via air filtration or ultraviolet germicidal irradiation 
 
Preventive Measures/Education 
Call the Iowa TB Control Program at (515) 281-8636 or (515) 281-7504. 
 
4) ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for 
Tuberculosis can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
 
 
In the United States, the vast majority of TB cases are caused by Mycobacterium tuberculosis, 
sometimes referred to as the tubercle bacillus.  M. tuberculosis and six very closely related 
mycobacterial species (M. bovis, M. africanum, and M. microti, M. canetii, M. caprae, M. pinnipeddi) 
can cause tuberculosis disease, and they compose what is known as the M. tuberculosis complex. 
Mycobacteria other than those comprising the M. tuberculosis complex are called nontuberculous 
mycobacteria.  Nontuberculous mycobacteria may cause pulmonary disease resembling TB. 
 
References 
Centers For Disease Control and Prevention – Division of Tuberculosis Elimination www.cdc.gov/tb/  
Heymann, D.L., ed. Control of Communicable Diseases Manual, 19th Edition. Washington, DC, American 
Public Health Association, 2008. 
 
 
Additional Resources 
Treatment of Tuberculosis:  MMWR June 20, 2003 / 52(RR11); 1-77 
www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm       
IDPH TB website: www.idph.state.ia.us/ImmTB/TB.aspx?prog=Tb&pg=TbHome  
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FACT SHEET                                          TUBERCULOSIS  
 (TB, Consumption) 
 
What is tuberculosis?   
Tuberculosis (TB) is a disease that is spread from person to person through the air. TB usually affects the 
lungs, but it can also affect other parts of the body, such as the brain, the kidneys, or the spine. 
 
Who is at risk for tuberculosis?   
The main risk groups are HIV positive persons, close contacts of active cases of TB and recent immigrants  
(within last 5 years) from countries where TB is much more common.   
 
How does someone get tuberculosis?   
Anyone can get TB – the risk groups previously defined are most likely to acquire TB.  
 
Can tuberculosis be spread from person-to-person?  
Yes, TB is a disease that is spread from person to person through the air. Usually, prolonged close contact with  
someone with infectious TB must occur before someone becomes infected. 
What are the symptoms of tuberculosis? 
People with a positive skin test for TB but no signs of illness (latent TB infection) have the germ that 
causes TB in their bodies. They are not sick because the germs are inactive in their bodies. They cannot 
spread the germs to others. However, these people may develop TB disease in the future. They are often 
prescribed medication to prevent them from developing the disease. 
People with TB disease have germs that are active in their body. They usually have symptoms of TB, 
such as, coughing, weight loss, fever, or night sweats. Usually, people with TB disease of the lungs or 
throat are capable of spreading the disease to others. They are prescribed drugs that can cure TB. 
How long will symptoms last?   
For active disease, symptoms will usually persist unless treated properly with anti- TB medications. 
 
How is tuberculosis diagnosed?   
A test on material coughed up from the lungs is done to confirm diagnosis.  Even if the test is negative 
for TB, a healthcare provider may diagnosis TB based on symptoms.   
  
How is tuberculosis treated?   
The first-line anti-TB agents that form the core of treatment regimens include isoniazid (INH), rifampin 
(RIF), ethambutol (EMB), and pyrazinamide (PZA).  These medications must be taken for 6 - 12 months. 
 
How can tuberculosis be prevented?   
Those with latent tuberculosis infection (LTBI) should complete a 6-9 month course of INH.   
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Tuberculosis Control Program 
Patient Information Sheet for Treatment of Latent Tuberculosis Infection 
 
For patients receiving preventative therapy with Isoniazid or Rifampin, the Department of Public Health requests 
the following data for epidemiological purposes. Please complete this form and return in the enclosed postage 
paid envelope or fax it to 515-281-4570. Thank you. 
 
M. Patricia Quinlisk, M.D. 
 Date: ______________                                                   State Epidemiologist and Medical Director 
 
Name:  _______________________________________________ Sex:  M    F 
 
Address:  _________________________________________________ Phone:  (____)_____________ 
 
City:  ___________________________ Zip:  ________________   County: ______________________ 
 
Date of birth:  __________________     
 
Mantoux skin test date: ______________ Results:  ____________mm 
*Results should be read and recorded in mm of induration only and should not include area of erythema. 
 
Chest x-ray date (Please include chest x-ray report with fax) _____________  
Normal______ Abnormal__________________________________ 
Has TB disease been ruled out? Yes_____     
              No______   
 
Diagnosis: Latent Tuberculosis Infection: Yes____ No____  
Planned course of treatment:  INH 300 mg qd x: 9 months_____ 6 months_____ Other: ____________ 
    (Attach Prescription) 
Pyridoxine (Vit. B6):  25 mg qd x 6months_____ or 9 months______ (Available for medical conditions in which 
neuropathy is common – diabetes, uremia, alcoholism, malnutrition, HIV infection, pregnancy). 
 
Suspected TB Disease/Confirmed TB Disease 
Please report all suspected cases of TB disease by phone: 
Nurse Consultant – 515-281-8636 or Program Manager – 515-281-7504 
 
Physician:  ___________________________________ Phone:  (____)____________________ 
 
Address:  _______________________________________________________________________ 
 
City:  _____________________________________ Zip:  ______________________ 
 
Person making referral:  ______________________________ Phone:  (____)_______________ 
 
Please send medication to (circle one):  County Public Health Department       
      OR 
     Physician’s Office 
 
Lucas State Office Building, 321 E. 12th Street, Des Moines, IA 50319-0075  515-281-7689  www.idph.state.ia.us 
DEAF RELAY (Hearing or Speech Impaired) 711 or 1-800-735-2942 
 
TULAREMIA 
 
Potential Bioterrorism Agent: Category A     
 
Also known as: Rabbit Fever, Deer Fly Fever  
 
Responsibilities: 
Lab: Report immediately by phone if bioterrorism suspected, otherwise weekly 
Physician: Report immediately by phone if bioterrorism suspected, otherwise weekly 
Local Public Health Agency (LPHA): Report immediately by phone if bioterrorism 
suspected.  
Local Public Health Agency (LPHA): Follow-up required.  Iowa Department of Public 
Health will lead the follow-up investigation.  
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent  
Francisella tularensis is a gram-negative bacterium.  Two types occur in the United States: Type A is 
biovar tularensis and Type B is biovar palaeoarctica.  Type A is more virulent than Type B and has a 
lower infective dose.    
  
B. Clinical Description 
Symptoms:   There are at least six types of clinical symptoms, depending on the route of infection and 
the strain of bacteria present.  Nearly all cases have a rapid onset of fever.  If bacteremia develops it 
may last for two weeks in untreated cases.  Lesions may contain the bacteria for a month.  The most 
common categories of illness are as follows:  
Ulceroglandular:  Patients have large, tender lymph nodes and a non-healing skin ulcer at the site 
of infection, often with fatigue, chills, and malaise. 
Glandular: Patients have one or more enlarged painful nodes that may be filled with purulent 
exudate. 
Pneumonic (pulmonary): This may be a primary infection following inhalation of the organisms or 
secondary to bacteremia; plague-like symptoms that may include a non-productive cough, difficulty 
breathing and chest pain.  Patchy infiltrates may be seen on the chest X-ray. 
Typhoidal: This is a rare form, with enlarged and inflamed mesenteric lymph nodes, septicemia, 
abdominal pain, diarrhea, vomiting and gastrointestinal bleeding.   
Oropharyngeal:  This form results from ingestion of bacteria in food or water leading to painful 
pharyngitis, abdominal pain, diarrhea, and vomiting. 
Oculoglandular: Patients have painful, purulent conjunctivitis with enlarged lymph nodes of the 
neck or near the ears and usually accompanied with fever, chills and malaise. 
    
Onset:  Most cases have a rapid onset of fever. Symptoms usually appear 3 to 5 days after exposure to 
the bacteria, but can take as long as 14 days.  
Complications: The case fatality of type A tularemia is 5% - 15% if untreated. The case fatality rate in 
pneumonic or primary septicemia is 30 to 60% if untreated.  Pneumonia may complicate all clinical types 
of tularemia and requires prompt identification and specific treatment to prevent fatal outcomes.   
 
C. Reservoirs 
Report Immediately 
by phone 
If bioterrorism suspected 
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Common reservoirs:  Type A infections are acquired from rabbits or Dermacentor ticks, including the 
common dog tick or wood tick.   
 
Less common reservoirs:  Type B infection is associated with a wide variety of mammalian hosts: 
rabbits, hares, and some rodents such as beavers and muskrats are particularly important.  Ticks, 
mosquitoes, and deer flies may serve as vectors for the disease.  Humans, however, do not usually 
transmit the infection to others. 
 
D. Modes of Transmission 
Spread: Tularemia may have the most varied modes of spread of any bacterial agent.   
• Direct Contact: This can occur when skinning or dressing game.  
• Arthropod Vector:  The bacteria may be spread by the bite of tick, either Dermacentor 
andersoni (wood tick) or D. variabilis (dog tick) or amblyomma americana (lone star tick) or a 
bite from deer flies or horse flies. 
• Ingestion:  Through contaminated food such as undercooked rabbit meat or drinking 
contaminated water. 
• Inhalation: Infectious aerosols can be generated when handling animal carcasses or cleaning 
areas where there may be dried rodent carcasses, running over a rabbit’s nest with the lawn 
mower, or from the dust generated while moving contaminated hay, grain or soil. 
• No direct person-to-person transmission   
 
Survival of Organism:  Francisella tularensis can survive for weeks to months in cool water or mud, 
for up to 3 months in tap water and in dry straw for as long as 6 months. Routine water purification 
is very effective at killing F. tularensis.    
 
E. Incubation period 
The incubation period ranges from 1 - 14 days, but is usually 3 - 5 days.   
 
F. Period of Communicability or Infectious Period 
The infectious agent may be found in the blood of untreated patients during the first two weeks of 
disease and in lesions for a month or more.  Flies can remain infective for 14 days after infection and 
ticks through their lifetime.  Rabbit meat frozen at 5° F can remain infective for over three years. 
 
G. Epidemiology 
Tularemia is found throughout North America and in many parts of continental Europe, Russia, China 
and Japan.  In the United States, it occurs all months of the year.  It is a risk for hunters during the 
fall and early winter, for lawn care workers in the summer when mowing over rabbits, providing an 
aerosol, and in spring in summer for children when ticks and flies are most prevalent.  Type A 
tularemia is found only in North America where it is common in rabbits and is transmitted by a tick 
bite.  Type B strains in North America are found in mammals other than rabbits.  
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H. Bioterrorism Potential 
Category A: Francisella tularensis is considered a possible weapon of bioterrorism.  If the organism 
were effectively disseminated it could cause a serious challenge to limit the numbers of casualties 
and to control other repercussions of an attack.  
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To determine cases and clusters of cases that could be associated with a bioterrorism event 
 
• To focus prevention and control efforts 
 
• To determine whether a source of infection may be a public health concern 
  
B. Laboratory and Healthcare Provider Reporting Requirements 
Tularemia requires immediate reporting if the provider reasonably believes or suspects that that 
Francisella tularensis infection may be the result of a deliberate act of terrorism.  Tularemia is also 
reportable if it is a cause or suspected cause of an outbreak, which would be an uncommon situation 
given its usual modes of spread.   
 
Laboratory Testing Services Available 
The University of Iowa State Hygienic Laboratory (SHL) provides services for testing clinical 
specimens for Francisella tularensis and for confirmation of isolates from sentinel laboratories. 
Sentinel laboratories can send specimens (blood, tissue biopsies, discharge fluid, vesicle fluid, etc.) to 
SHL.  Isolates submitted from other laboratories will be confirmed and/or identified. Additionally, all 
laboratories are asked to submit all isolates cultured for further identification to aid in the public 
health surveillance and necessary to prevent the spread of this disease.  SHL must be contacted 
before samples are submitted for safety purposes. For more information on submitting samples, 
contact SHL at 319-335-4500, or visit: www.shl.uiowa.edu/  
 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report. The preferred method of reporting a case that is NOT SUSPECTED of being related to 
bioterrorism is by utilizing the Iowa Disease Surveillance System (IDSS).  However, if IDSS is not 
available, the reporting number for IDPH Center for Acute Disease Epidemiology (CADE) is (800) 362-
2736; fax number (515) 281-5698. 
    
C.  Local Public Health Agency Follow-up Responsibilities 
Case Investigation:  Investigation of cases is directed by the Iowa Department of Public Health 
Center for Acute Disease Epidemiology (CADE).  The cooperation of local public health agencies, 
laboratories, and medical providers is requested.  
 
3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements 
Standard Precautions.  Quarantine is not required. 
 
B.  Protection of Contacts of a Case 
No prophylaxis for contacts to a case is necessary.  Standard Precautions for inpatients with a 
draining lesion or for pulmonary symptoms should be used. 
 
C.  Managing Special Situations 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
If an outbreak is suspected, it should be reported immediately due to seriousness of illness and 
potential of intentional infection. 
Exposure of a Laboratory Worker  
      Requires immediate reporting so prophylactic treatment may be implemented. 
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D. Preventive Measures 
Environmental Measures 
In general, environmental measures are unnecessary.  If contaminated water or food or agricultural 
materials are suspected, action should be taken in consultation with the Center for Acute Disease 
Epidemiology.   
 
Preventive Measures/Education 
• Hunters should wear gloves when skinning wild game, keep their hands/gloves away from their 
eyes and thoroughly wash their hands after handling wild game carcasses. Wild game meat 
should be cooked “well done” (to at least 150° F/65° C). 
• Drink only treated water when in wilderness areas to avoid bacterial and protozoan diseases that 
can be transmitted via surface water. 
• Use DEET-based insect repellents to reduce the possibility of fly or tick bites. Use insect 
repellants properly. Repellants that contain DEET (N,N-diethyl-m-toluamide) should be used in 
concentrations no higher than 15% for children and 30% for adults. Avoid overuse of DEET-
based products; excess application can lead to adverse reactions. Remember, repellants should 
never be used on infants. Permethrin is a repellant that can only be applied onto clothing, not 
exposed skin.  
• Avoid tick-infested areas. In areas where contact with ticks may occur, individuals should be 
advised of the following: 
• Wear long-sleeved shirts and long, light-colored pants tucked into socks or boots. 
• Stay on trails when walking or hiking and try to avoid high grass. 
• After each day spent in tick-infested areas, check yourself, your children, and your pets for ticks. 
Parts of the body ticks like most include the back of the knee, armpit, scalp, groin, and back of 
the neck. 
• Promptly remove any attached tick using fine-point tweezers. The tick should not be squeezed or 
twisted, but grasped close to the skin and pulled straight out with steady pressure. Once 
removed, the tick should be drowned in rubbing alcohol or the toilet. 
• Notify laboratories when sending in specimens for possible cases are sent in for testing. 
 
4) ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Tularemia 
can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
 
References 
American Academy of Pediatrics. 2003 Red Book: Report of the Committee on Infectious Diseases, 
26th Edition. Illinois, American Academy of Pediatrics, 2003. 
CDC website: Tularemia at www.cdc.gov/Tularemia/  
Heymann, D.L., ed. Control of Communicable Diseases Manual, 20th Edition. Washington, DC, 
American Public Health Association, 2015. 
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www.bt.cdc.gov/agent/tularemia/  
Iowa Dept. of Public Health Reviewed  8/15  Tularemia 2 
FACT SHEET TULAREMIA 
 
What is tularemia? 
Tularemia is an illness that affects both animals and man.  It is caused by the bacteria Francisella 
tularensis, which can live for 3 - 4 months in mud, water, or the carcasses of dead animals.  Humans can 
catch tularemia by handling infected animals or from bites by infected flies, mosquitoes, or ticks. 
 
What are the symptoms of an infection with tularemia? 
Most people become ill in either the summer or winter.  In the summer, the ticks that carry tularemia 
become more active.  During the winter hunting season, illness can result from contact with infected 
rabbits (usually skinning them).  Usually there is sudden onset of fever with headache and fatigue that 
lasts for several weeks.  With skin contact or a tick bite, there will be an ulcer (open sore) with swelling 
of the lymph nodes (glands under the jaw and arms, neck etc.), and a rash may also be present.  Eating 
or drinking food or water containing the bacteria, may produce a throat infection, stomach pain, diarrhea 
and/or vomiting.  Breathing dust containing the bacteria may produce a pneumonia-like illness.  Fever, 
chills, headache, chest pain and coughing may also occur.   
 
How soon do symptoms appear? 
Symptoms usually appear within 1 - 14 days after exposure to the bacteria.  The average time is 3 - 5 
days. 
 
How is tularemia spread? 
Contact with small animals such as rabbits, hares, rodents, birds, or their ticks transmit tularemia.  
Handling carcasses of infected animals (e.g., hunters while skinning the animal), ingesting undercooked 
infected meat, drinking contaminated water and inhalation of dust from contaminated soil, grain or hay 
transmits tularemia.  It is also transmitted by tick bites but rarely is it transmitted through the bite of an 
infected animal (e.g., coyote, squirrel, skunk, hog, cat, or dog).  It is not spread from human to human. 
 
Who gets tularemia infection? 
Any person can become infected.  Numerous wild animals especially rabbits, hares, voles, muskrats, 
beavers and some domestic animals; as well as various hard ticks can carry or become ill with tularemia.  
People become infected if they spend a lot of time outdoors or are in close contact with any of the before 
mentioned animals or ticks. 
 
For how long is a person infectious? 
People cannot spread tularemia so this is not a concern. 
 
What is the treatment for tularemia? 
Antibiotics are prescribed and most people fully recover.  If someone has been exposed, an antibiotic 
should be started as soon as possible.  
 
Do infected people need to be excluded from school, work, or child care? 
No, because they do not transmit the disease. 
 
What can be done to help prevent the spread of tularemia? 
Rubber gloves should be worn when skinning or handling animals, especially rabbits.  Wild rabbit and 
rodent (such as squirrel) meat should be cooked completely before eating.  Avoid tick bites, by using 
insect and tick repellents and wearing long sleeves and pants when spending long periods of time 
outside.  In the spring and summer, look for attached ticks every two to three hours when spending time 
outside.  Remove any attached ticks immediately.  Avoid swimming, drinking, bathing in untreated water 
where infection is prevalent among wild animals. Persons working in laboratories with this bacterium 
must take protective measures, including the use of face masks, gowns, and impervious gloves, and 
negative pressure microbiological cabinets. 
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FACT SHEET TULAREMIA 
For Health Professionals                                                  (rabbit fever, deer fly fever) 
 
What is tularemia? 
Tularemia is a zoonotic disease caused by the bacterium Francisella tularensis.  
 
What are the symptoms of tularemia? 
Ulceroglandular tularemia (75-85% of cases) presents with a local ulcer, painful regional 
lymphadenopathy, fever, chills, headache and malaise.  Glandular tularemia (5-10% of cases) results in 
fever and tender lymphadenopathy but no skin ulcer.  Typhoidal tularemia (5-15 % of cases) presents 
with fever, headache, malaise, substernal discomfort, prostration, weight loss and a non-productive 
cough.  Pneumonia is very common. Oculoglandular tularemia (1-2% of cases) presents with unilateral, 
painful, purulent conjunctivitis with preauricular or cervical lymphadenopathy.  Oropharyngeal tularemia 
refers to primary ulceroglandular disease confined to the throat with acute exudative or membranous 
pharyngotonsillitis and cervical lymphadenopathy.  The case fatality rate without treatment is 5% for the 
ulceroglandular form and 35% for the typhoidal form.  All ages are susceptible, and recovery is followed 
by permanent immunity. 
 
How soon do symptoms appear? 
Symptoms usually appear within 1-14 days after infection with the bacteria.  Average is within 3-5 days. 
 
How is tularemia transmitted? 
Contact with small animals such as rabbits, hares, rodents, birds, and their ticks transmit tularemia.  
Transmission can occur when handling carcasses of infected animals (hunters while skinning), ingesting 
undercooked infected meat, drinking contaminated water and inhalation of dust from contaminated soil, 
grain or hay.  It is also transmitted by tick bites and rarely through the bite of an infected animal. 
 
Who gets tularemia infection? 
Anyone can get tularemia if they spend much time outdoors in areas where ticks, deerflies and 
mosquitoes can be found.   
 
How is the diagnosis made? 
A high index of suspicion is associated with a compatible history of persistent skin ulcers present from 
handling diseased carcasses. Routine culture is possible but difficult. The diagnosis can be established 
retrospectively by serology.  Serum antibodies usually appear in the second week of the disease. 
Examination of skin ulcer exudate, lymph node aspirates and other clinical specimens by Florescent 
Antibody (FA) test may provide rapid diagnoses.  Diagnostic biopsy of actual infected lymph nodes should 
be done only under specific treatment since it will often induce a bacteremia.   
 
What is the treatment for tularemia? 
Streptomycin or gentamicin for 7 - 14 days is the treatment of choice.  
 
What are the isolation precautions used for tularemia infections? 
Standard Precautions are recommended for healthcare workers.  Laboratory related infections with this 
organism do occur.  Persons working in laboratories with this bacterium must take protective measures, 
including the use of facemasks, gowns, and impervious gloves, and negative pressure microbiological 
cabinets. 
 
Is there a vaccine or post-exposure prophylaxis for tularemia? 
Yes, a live attenuated tularemia vaccine is available as an investigational new drug.  It is of proven 
effectiveness in preventing laboratory-acquired tularemia a well as in experimentally exposed human 
volunteers.  Post-exposure prophylaxis for tularemia may include treatment with streptomycin, 
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gentamicin, doxycycline, or ciprofloxacin in the incubation period of tularemia and continuing treatment 
daily for 14 days. This might protect against symptomatic infection. 
 
Do infected people need to be excluded from school, work, or child care? 
No. 
 
Reference: 
 
Inglesby, TV, Henderson DA, et al. Abstract: “Consensus Statement: Tularemia as a Biological Weapon: 
Medical and Public Health Management” Abstracted from Journal of the American Medical Association, 
June 6, 2001; vol. 285, no. 21: 2763-2773. www.bt.cdc.gov/agent/tularemia/tularemia-biological-
weapon-abstract.pdf 
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FACT SHEET   TULAREMIA 
For Veterinarians 
 
What is Tularemia? 
Francisella tularensis is an intercellular bacterial pathogen that causes the zoonotic disease tularemia and 
can affect a wide range of animals including small mammals, birds and humans.  Hunters, hikers and 
people in rural settings are more likely to come in contact with infected rabbits or ticks that have fed on a 
diseased animal.  The organism is spread to people from the insect bites; direct contact from skinning a 
wild rabbit or by preparing or eating improperly cooked game meat. Occurrence of the disease follows a 
bimodal cycle with higher numbers of humans infected in July due to ticks and in December due to the 
hunting season.  Inhalation exposure can occur if large numbers of the organism are aerosolized in a 
confined space. 
 
What are the clinical signs associated with tularemia? 
In animals, the signs are often associated with tick infestation resulting in a high fever, weight loss and 
death.  Sheep have been noted to abort and dogs have the ulceroglandular disease that is common in 
human tularemia. The organism incubates for 1 - 14 days in humans and symptoms vary with the site of 
entry.  Most humans will present with a lymphadenitis and ulcers, if inoculated through direct contact.  If 
infected meat was consumed, the oropharynx will be affected and gastrointestinal signs will surface. 
 
How can infection with Francisella tularensis be diagnosed? 
Serologic testing, with a four-fold rise in titer, is the standard method of identifying infection. Culture and 
inoculation of hamsters can also be performed, but poses a health risk for laboratory workers.  Necropsy 
of animals will reveal massive organ involvement with necrosis of liver, spleen, and lymph nodes, and 
poses a significant health risk to the veterinarian.    
 
How is tularemia treated? 
The first step is removal of any ticks as soon as possible.  The best way is to use tweezers to grab the 
tick as close to the skin as possible and pull it straight out.  Do not squeeze the tick’s body when 
removing it.  Do not handle ticks with bare hands.  Wash your hands after removing a tick.  You may 
want to apply an antiseptic on the bite.  Streptomycin or gentamycin given for 7 – 14 days is the drug of 
choice for humans.  Tetracycline has been found to inhibit Francisella tularensis in sheep that have been 
diagnosed with tularemia abortion.  
 
How can tularemia be prevented? 
Tick and insect repellents should be used when walking in the outdoors. A thorough tick check of humans 
and their pets should be performed often and upon returning inside.  All ticks should be removed from 
humans and dogs as soon as possible. Skinning wild rabbits should be performed in a well-ventilated area 
and protective gloves should be worn.  Francisella tularensis is killed by heat, but not by freezing.  
Thorough cooking of rabbit and other game meat will render it safe for consumption, but placing raw 
meat in the freezer will maintain the organisms’ viability.  Also in recent years tularemia transmission has 
occurred during landscaping work or lawn mowing over or around dead animals.  It is best to remove 
dead animals before mowing, roto-tilling, bailing or other landscaping activity.   
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CONFIDENTIAL                                                                                          Iowa Department of Public Health 
Tularemia                               Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Facility phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
Diagnosis date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome: 
 Survived this illness     Died from this illness 
 Died unrelated to this illness    Unknown 
Date of death      /     /      First name: 
 
      
Event exception 
 Case could not be found 
 Case could not be interviewed 
 Case refused interview 
 Other – see notes 
Provider title:  ARNP   
 DO 
 MD 
 NP  PA 
Outbreak 
related:  Yes      No      Unknown  
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
 
Result type: 
 
 Preliminary      Final 
 
Result date: 
 
     /     /      Result: 
 Positive 
 Negative    
 
Organism: 
 
Francisella  Type (e.g. serotype): 
 
       
 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
 
Result type: 
 
 Preliminary      Final 
 
Result date: 
 
     /     /      Result: 
 Positive 
 Negative    
 
Organism: 
 
Francisella  Type (e.g. serotype): 
 
       
 
 
Tularemia type: 
 Glandular 
 Intestinal 
 Oculoglandular 
 
 Oropharyngeal 
 Pneumonic 
 
 Typhoidal 
 Ulceroglandular 
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Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
 
Result type: 
 
 Preliminary      Final 
 
Result date: 
 
     /     /      Result: 
 Positive 
 Negative    
 
Organism: 
 
Francisella  Type (e.g. serotype): 
 
       
 
 
 
 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
 
CLINICAL INFO & DIAGNOSIS 
 
Symptoms: 
 Abdominal pain 
 Chills 
 Diarrhea 
 Fever 
 Headache 
 Malaise 
 Pneumonia 
 Red eyes w/ discharge 
 Sore throat 
 Swollen lymph nodes 
 Ulcer 
Lesion location:   
 
OTHER LAB FINDINGS 
 
Biopsy 
performed: 
 
 Yes   No   Unk 
 
Date: 
 
     /     /      
 
Site: 
 
      
 
Result: 
 
      
 
TREATMENT 
 
Antibiotics prescribed?   Yes    No    Unknown 
  
Antibiotic:       
  
Antibiotic:       
  
Antibiotic:       
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
Date 
started:      /     /      
Date 
started: 
 
     /     /      
Date 
started: 
 
     /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 
 mg      ml     IU 
 
Unit: 
 
 mg      ml     IU 
 
Unit: 
 
 mg      ml     IU 
# of days:       
# of times 
a day:       # of days:       
# of times 
a day:       # of days:       
# of times 
a day:       
Route:       Route:       Route:       
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Vaccinated for tularemia:   Yes    No    Unknown 
 Date 
vaccinated: 
 
     /     /      
 
Date vaccinated: 
 
     /     /      
 
Date vaccinated: 
 
     /     /      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
 
Number of vaccinations:       
 
Water Exposures – In the 14 days prior to the onset of symptoms:   
Untreated water drank/swallowed:  Yes    No    Unk Untreated water source:  Lake    Ocean  Pond   Stream  River 
Location 
names:       
Address: 
 
City/State/Zip: 
 
County: 
 
 
Animal 
contact:  
 Beavers 
 Cats 
 Hares 
 Mice 
 Muskrats 
 Rabbits 
 Rats 
 Sheep 
 Squirrels 
 Voles 
Bitten by fleas or 
other insects:  Yes    No    Unk 
Tick found:  Yes    No    Unk Date found:      /     /        
Tick species: 
 Deer tick 
 Dog tick       Other:       Tick embedded:  Yes    No    Unk  
 
Exposed to potential 
infection sources:  Yes    No    Unk Possible tularemia sources: 
 Laboratory  
 Livestock handling 
 Packing plant 
 Unpasteurized dairy product 
 
NOTES:       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation period for 
tularemia is 1 to 14 
days. 
No person to person 
transmission exists. 
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TYPHOID FEVER 
 
 
Potential Bioterrorism Agent: Category B 
 
Responsibilities: 
Hospital: Report by IDSS, facsimile, mail or phone 
Lab: Report by IDSS, facsimile mail or phone 
Physician: Report by IDSS, facsimile, mail or phone 
Local Public Health Agency (LPHA): Follow-up required 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A.  Agent 
Typhoid fever is caused by the bacillus Salmonella enterica subspecies enterica serovar Typhi 
(commonly S. Typhi).  
 
B.  Clinical Description 
Symptoms: Typhoid fever causes fever, headache, malaise, anorexia, bradycardia, splenomegaly, and 
constipation more often than diarrhea in adults. Rose colored spots occur on the trunk in 25% of 
light-skinned patients and a nonproductive cough often occurs in the early stage of illness. 
 
Onset: Illness is usually not abrupt and varies from mild illness with low-grade fever to severe clinical 
disease with abdominal discomfort and multiple complications. Inapparent or mild illnesses occur, 
especially in endemic areas. 
 
Complications include intestinal perforation and hemorrhage, kidney failure, and peritonitis. The case-
fatality rate of 10-20% observed in the pre-antibiotic era falls below 1% with prompt antibiotic 
therapy. Relapses may occur in 15-20% of patients with typhoid fever.   
A major concern with typhoid fever is that a carrier state may follow illness. Typhoid fever can be 
present in both feces and urine chronically after acute infection. The chronic carrier state is most 
common (2-5%) among persons infected during middle age. Carriers frequently have biliary tract 
abnormalities including gallstones. The chronic urinary carrier state may occur with schistosome 
infections. 
 
C.  Reservoirs 
Common reservoirs: Humans may become transient or permanent carriers.  
 
D.  Modes of Transmission 
Spread: Via ingestion of food and water contaminated by feces and urine of patients and carriers. 
Important vehicles for transmission include shellfish (particularly oysters) from sewage contaminated 
beds, raw fruit, vegetables fertilized by human feces, contaminated milk/milk products and 
unidentified cases. Flies may contaminate foods, allowing the organism to multiply to infectious 
doses. Epidemiological data suggest that waterborne transmission may involve less contamination 
than foodborne transmission.  
Person-to-person: Rare  
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E.  Incubation period 
Depending on the inoculum size and host factors, the incubation period may range from 3 to over 60 
days. The usual range is 8-14 days.  
 
F.  Period of Communicability or Infectious Period 
The disease is communicable for as long as infected persons excrete the bacilli in their stool or urine, 
usually from the first week throughout convalescence; variable thereafter.  Approximately 10% of 
untreated typhoid patients discharge bacilli for 3 months after symptom onset; 2-5% become 
carriers.   
 
G.  Epidemiology 
Typhoid fever has a worldwide distribution, with approximately 400 cases per year in the United 
States, mostly among travelers. An estimated 21 million cases of typhoid fever and 200,000 deaths 
occur worldwide.  
 
H.  Bioterrorism Potential 
Category B Agent: As with other Salmonella organisms, S. Typhi has potential to be used as a 
bioweapon similar to other fecal-oral transmission agents. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To identify whether the case may be a high risk for spread to others (e.g., a diapered child, 
child care attendee, healthcare provider, or food handler) and, if so, to prevent further 
transmission. 
• To identify transmission sources of public health concern (e.g. a restaurant or a 
commercially distributed food product) and to stop transmission from such sources. 
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report. The preferred method of reporting is by utilizing the Iowa Disease Surveillance System 
(IDSS).  However, if IDSS is not available to your facility the reporting number for IDPH Center for 
Acute Disease Epidemiology (CADE) is (800) 362-2736; fax number (515) 281-5698, mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th Street 
Des Moines, IA 50319-0075 
 
Postage-paid disease reporting forms are available free of charge from the IDPH clearinghouse.   
Call (319) 398-5133 or visit the website: 
healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295  to request a supply. 
 
 
C.  Local Public Health Agency (LPHA) Follow-up Responsibilities 
Case Investigation  
a. It is the LPHA responsibility to complete an investigation by interviewing the case or legal 
guardian of the case and others who may be able to provide pertinent information. Using IDSS is 
the preferred method of conducting the investigation. Much of the information can be obtained 
from the case’s healthcare provider or the medical record.  
b. Use the following guidelines in completing the investigation: 
1. Accurately record the demographic information, date of symptom onset, symptoms, and 
medical information. 
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2. When asking about exposure history (food, travel, activities, etc.), use the usual 
incubation-range for typhoid fever (8 – 14 days).  
3. If possible, record any restaurants at which the case ate, including food items(s) and 
date consumed. 
4. Ask questions about travel history and outdoor activities to help identify where the case 
became infected. 
5. Ask questions about water supply because typhoid fever may be acquired through water 
consumption. 
6. Household/close contact, school, work, travel, and food handler questions are designed 
to examine the case’s risk of having acquired the illness from, or potential for 
transmitting it to, these contacts.  
7. Ask if the patient knows others who had a similar illness about the same time. 
8. If several attempts have been made to obtain case information, but have been 
unsuccessful (e.g., the case or healthcare provider does not return your calls or respond 
to a letter, or the case refuses to divulge information or is too ill to be interviewed), 
please request help from CADE epidemiologists (800) 362-2736.  
 
After completing the investigation and gathering the information, enter the information into IDSS, or FAX 
the report form with supporting laboratory documentation to  (515) 281-5698 or mail (in an envelope 
marked “Confidential”) to the IDPH/CADE mailing address. 
 
3) CONTROLLING FURTHER SPREAD 
 
Fluoroquinolones appear to be the drug of choice in adults. However, the recent emergence of 
resistance to fluoroquinolones prevents its indiscriminate use in primary care facilities. If a typhoid 
isolate is known to be sensitive to traditional first-line antibiotics, oral chloramphenicol, amoxicillin or 
trimethoprim-sulfoxazole (particularly in children) should be used in accordance with local 
antimicrobial sensitivity patterns. Short-term, high dose corticosteroid treatment, combined with 
specific antibiotics and supportive care, reduces mortality in critically ill patients. 
 
A. Isolation and Quarantine Requirements 
Hospital care is desirable during acute typhoid illness. All hospitalized patients should be on Standard 
Precautions. Use Contact Precautions for diapered or incontinent persons for duration of illness or to 
control institutional outbreaks.  
 
Quarantine is not applicable. 
 
B.  Protection of Contacts of a Case 
 Administration of typhoid vaccine is of limited value for family, household and nursing contacts who 
have been or will be exposed to active cases. Vaccine should be considered for those exposed to 
carriers of typhoid.  
 
C.  Managing Special Situations 
Contact the Center for Acute Disease Epidemiology (CADE), (800) 362-2736, for consultation for 
persons identified as chronic carriers or who continue to have positive stool cultures after acute 
disease. 
 
In the case of situations that are not covered below contact CADE, (800) 362-2736, for consultation. 
 
Food handlers 
Return to work should be after 3 consecutive negative stool cultures (and urine in patients with 
schistosomiasis) at least 24 hours apart and at least 48 hours after completion of antimicrobials. 
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Hand hygiene education shall occur before return to work. Good hand hygiene must be practiced at 
all times. 
 
Child care/School 
Since typhoid fever can be transmitted person-to-person through fecal-oral transmission, it is 
important to carefully follow up on cases in a child care setting. General recommendations for typhoid 
fever include: 
• For staff or children 5 years of age and older who are fecally continent, 24 hours without a 
diarrheal stool is required before returning. 
• For children younger than 5 years of age or individuals who are diapered or fecally incontinent, 3 
consecutive negative stool cultures (and urine in patients with schistosomiasis) at least 24 hours 
apart and at least 48 hours after completion of antimicrobials are required before returning. 
• Good hand hygiene must be practiced at all times. 
 
Business 
Since typhoid fever can be transmitted person–to-person through fecal-oral transmission, it is 
important to follow up carefully on each case.  General recommendations include:  
• For staff (exception for food handlers), 24 hours without a diarrheal stool is recommended before 
returning to a business setting.   
 
• Staff with S. typhi in their stool who do not have diarrhea or vomiting and do not handle food 
may remain if proper hygienic practices are maintained.  
 
• Good hand hygiene must be practiced at all times. 
 
Health Care Provider 
Return to work should be after 3 consecutive negative stool cultures (and urine in patients with 
schistosomiasis) at least 24 hours apart and at least 48 hours after completion of antimicrobials.  
Good hand hygiene must be practiced at all times. 
 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
Any case of typhoid fever is unusual in the U.S, so it is important to determine the source of infection 
and mode of transmission. Careful follow-up of cases to ensure proper isolation and identify “chronic 
carrier” status is important. Control of person-to-person transmission requires special emphasis on 
personal cleanliness and sanitary disposal of feces. Consult with the regional epidemiologist or CADE 
if assistance is needed. CADE can help determine a course of action to prevent further cases and can 
perform surveillance for cases that may cross jurisdictional lines. 
 
D. Preventive Measures 
Environmental Measures 
Proper sanitation of public and private facilities is critical to prevent typhoid fever. Routine sanitation 
measures should include: 
• Education of the public regarding proper handwashing, which includes providing suitable 
handwashing facilities in public places, especially in food service, child care, or health care 
settings. 
• Proper disposal and treatment of human sewage. Latrines should be fly-proof and properly 
designed and situated.  
• Public and private water supplies should be protected, purified, and chlorinated (as needed). 
Backflow prevention devices should be installed between potable water and non-potable 
water systems.  
• Scrupulous cleanliness in food preparation and handling are important. Proper temperature 
maintenance of raw and cooked foods is critical, as well as avoiding cross contamination of 
raw meats and items already prepared to eat.  
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• All milk and milk products should be pasteurized before consumption. 
• Limit the collection and marketing of shellfish to supplies from approved sources. 
 
Education 
To avoid possible exposures, recommend that people:  
• Always wash their hands thoroughly with soap and water before eating or preparing food, 
after using the toilet, and after changing diapers. This is important for the entire household 
of a case as household members can become transient or long term carriers.  
• Dispose of feces in a sanitary manner in all settings. 
• Keep food that will be eaten raw, such as vegetables, from becoming contaminated by 
animal-derived food products.  Wash all foods that will be eaten raw before eating. 
• Receive typhoid vaccination when traveling to endemic high-risk areas. Visit 
www.cdc.gov/travel/ for current information on endemic high-risk areas. The World Health 
Organization (WHO) also recommends that school-age children who live in such areas receive 
vaccination. An oral, live vaccine is available and usually consists of 3-4 doses.  
• In non-endemic areas there is no recommendation for vaccine except for those who are 
subject to unusual occupational exposures (e.g. clinical microbial technicians or household 
members of known carriers). 
 
4) ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Typhoid 
Fever can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
 
References 
CDC web site, Typhoid Fever. www.cdc.gov/nczved/divisions/dfbmd/diseases/typhoid_fever/  
Heymann, D.L., ed. Control of Communicable Diseases Manual, 19th Edition. Washington, DC, 
American Public Health Association, 2008. 
 
Additional Resources 
 
IDPH web site: www.idph.state.ia.us/adper/  
World Health Organization site: www.who.int/topics/typhoid_fever/en/   
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What is typhoid fever? 
Typhoid fever is an illness caused by the germ Salmonella Typhi. In the United States about 400 cases 
are reported each year. Most of these are acquired while traveling outside of the U.S. Typhoid fever is 
still common in the developing world, where it affects about 21 million persons each year. 
 
Who gets typhoid fever? 
Anyone can catch it, but it is more common in less-developed countries. People in the U.S. usually get 
typhoid fever when traveling to countries where it is common. 
 
How is typhoid fever spread? 
People with typhoid fever have the germ in their feces (stool) or urine. If they do not wash their hands 
after using the restroom, it can be spread to others. Food may also become contaminated by the 
unwashed hands of an infected food handler.  
 
What are the symptoms of typhoid fever infection? 
People with typhoid fever may have fever, headache, general discomfort, loss of appetite, and 
constipation more often than diarrhea in adults. Typhoid fever can be very serious, especially in the very 
young or very old. 
 
How soon after infection with typhoid fever do symptoms appear? 
Symptoms usually occur 8 - 14 days after infection, with a range of 3 – 60 days. 
 
Where are typhoid fever bacteria found? 
The germ that causes typhoid fever is found in the feces (stool) of people who have the infection. It is not 
naturally occurring in most communities in the U.S. Some people can carry the bacteria for long periods of 
time without illness, and can still spread it to others. 
 
How long can an infected person carry typhoid fever? 
For several days and possibly several months. Tests can show if people are still carrying the bacteria. 
 
Do infected people need to be excluded from work or school? 
Since the bacteria that causes typhoid fever is found in the feces (stool), ill people with should not go to 
school or work until 24 hours have passed without a watery or liquid stool.  Health care providers and food 
handlers should have 3 negative cultures of feces before returning to work. For school staff (who are not 
food handlers) or children 5 years of age and older (who are not in diapers and have control of their 
bowels), 24 hours without a diarrheal stool is required before returning.  When returning to work or 
school, it is very important that careful handwashing is done after using the toilet and before handling food.  
 
Do infected people need to be excluded from child care? 
Since the bacteria that causes typhoid fever is found in the feces (stool), children younger than 5 years of 
age who are in diapers, or who do not have control of their bowels should not go to child care until 3 
negative stool cultures are obtained after treatment with antibiotics.  Staff or children 5 years of age and 
older who are not in diapers and have control of their bowels, should not return until 24 hours without a 
diarrheal stool has passed. When returning to child care it is important that careful handwashing is done 
after using the toilet and before handling food.  
 
What is the treatment for typhoid fever? 
Antibiotics are used to treat typhoid fever.   
 
How can typhoid fever be prevented? 
• Always wash hands thoroughly with soap and water before eating or preparing food, after using 
the toilet, and after changing diapers. 
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• People who are ill with typhoid fever should be excluded from handling food and providing 
patient care.  
• All milk and milk products should be pasteurized before consumption. 
• Get typhoid vaccination when traveling to high-risk areas outside of the U.S.  
• When traveling to countries where typhoid fever is more common, drink bottled water, eat only 
properly cooked food or fruits and vegetables that can be peeled and avoid ice in drinks. Go to 
wwwn.cdc.gov/travel/default.aspx or check with your health care provider or health department 
for more advice on safe travel. 
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CONFIDENTIAL                                                                                         Iowa Department of Public Health 
Typhoid fever  
(including paratyphoid)                          Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Facility phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider title: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes   No  Unk To whom: ______________  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Salmonella  Type (e.g. serotype): 
 Typhi 
 Paratyphi A 
 Paratyphi B 
 Paratyphi C  
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Salmonella  Type (e.g. serotype): 
 Typhi 
 Paratyphi A 
 Paratyphi B 
 Paratyphi C  
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
Result type:  Preliminary    Final 
 
Result date:      /     /      Result:  Positive   Negative   
 
Organism: 
 
Salmonella  Type (e.g. serotype): 
 Typhi 
 Paratyphi A 
 Paratyphi B 
 Paratyphi C  
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OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
OTHER DEMOGRAPHIC INFO 
 
Citizenship:                                         Unknown 
 
CLINICAL INFO & DIAGNOSIS 
 
Was the patient ill with typhoid or paratyphoid fever?  Yes    No    Unk 
Removed “Date of onset” associated with above question. No need for it.  
 
Fever:  Yes No    Unk Fever onset date:      /     /      Duration:       Hours/Days 
Highest known fever:       C/F Rash or rose spots:  Yes  No   Unk Onset date:      /     /      
Symptoms: 
 
 Abdominal cramps   
 Anorexia 
 Chills 
 Diarrhea 
 Fever  
 Headache 
 Malaise 
 Muscle weakness 
 Nausea     
 Rash   
 Splenomegaly  
 Visible bloody diarrhea 
 Vomiting  
 
 
OTHER LAB FINDINGS 
 
PFGE Pattern (stool specimen from patient) 
Was PFGE performed:  Yes    No    Unk 
IA-XbaI 
Pattern       
IA-BlnI 
 Pattern       
CDC-XbaI 
Pattern       
CDC-BInI 
Pattern       
 
Was antibiotic sensitivity testing performed?  Yes    No    Unk 
If Yes, was the organism resistant to:                    Ampicillin 
Chloramphenicol 
Tremthoprim-sulfamethozazole 
Floroquinolones 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
 Yes    No    Unk 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
TREATMENT 
 
Antibiotics prescribed?   Yes    No    Unknown 
  
Antibiotic:       
  
Antibiotic:       
 
 
Antibiotic:       
Date 
started:      /     /      
Date 
started: 
 
     /     /      
Date 
started: 
 
     /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 
 mg      ml     IU 
 
Unit: 
 
 mg      ml     IU 
 
Unit: 
 
 mg      ml     IU 
# of days:       
# of times 
a day:       # of days:       
# of times 
a day:       # of days:       
# of times 
a day:       
Route:       Route:       Route:       
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Vaccinated for typhoid fever within 5 years of onset:   Yes    No    Unknown 
 
Date vaccinated: 
 
     /     /      
 
Date vaccinated: 
 
     /     /      
  
Lot #: 
 
      
  
Lot #: 
 
      
  
Vaccine type: 
 Killed typhoid shot 
 Oral Ty21a or Vivotif four pill series 
 ViCPS or Typhim Vi shot 
  
Vaccine type: 
 Killed typhoid shot 
 Oral Ty21a or Vivotif four pill series 
 ViCPS or Typhim Vi shot 
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
 
Number of vaccinations:       
 
Risk Factors/Travel Information – In the 60 days prior to onset of symptoms had the case: 
Traveled within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
Lived outside of the United States?  Yes    No    Unknown 
Country:  Date of most recent return or entry to the U.S.:      /     /      
Country:  Date of most recent return or entry to the U.S.:      /     /      
Country:  Date of most recent return or entry to the U.S.:      /     /      
 
What was the purpose of the international travel?  
 Business  Immigration to U.S.  
 Tourism  Other 
 Visiting relatives or friends  
 
Visited restaurants?  Yes    No    Unknown 
If Yes, complete the table below:   County and address are missing from this table 
Restaurant City/State/Zip Date visited Foods eaten Others ill? 
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation period for 
typhoid fever is 3 to 60 days, 
usual range 8-14. Paratyphoid is 
1-10 days  
Typhoid fever is communicable for 
first week throughout convalescence. 
2%-5% of untreated cases become 
lifetime carriers. 
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Attended Group Gatherings (e.g. weddings, parties)?  Yes    No    Unknown 
If Yes, complete the following table: 
Location of gathering City/State/Zip Date visited Foods eaten Others ill? 
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
            
 
     /     /      
       Yes    
 No    Unk       
 
 
Contact with foreign travelers: 
 
 Yes   No   Unknown 
 
Contact with human excreta: 
 
 Yes   No   Unknown 
 
Dietary Information – In the 60 days prior to onset of symptoms did the case consume the following: 
Seafood 
Shellfish:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
 
Unpasturized products 
Unpasteurized 
milk:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Unpasteurized 
juice:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Other 
unpasteurized 
products: 
 Yes    No    Unk 
From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
 
Fruits and vegetables 
Raw fruits:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
Raw vegetables:  Yes    No    Unk From dates consumed:      /     /      To dates consumed:      /     /      
List all source/types:       List all brand names:       
 
Animal Exposures – In the 60 days prior to the onset of symptoms did the case have the following exposures: 
Check all that apply 
Visit or live on a farm: 
Exposed to manure: 
Farm animal contact: 
 Yes    No    Unknown 
 Yes    No    Unknown 
 Yes    No    Unknown 
 
 
Animals:       
 
Reptile contact: 
Reptile lived with case: 
 
 Yes    No    Unknown 
 Yes    No    Unknown 
 
 Iguana    Lizard    Turtle    Snake    Other _____________________ 
 
Number of people living in case’s household:          
 
Are there close contacts of the case with similar symptoms:   Yes    No    Unknown 
 
Close contacts with similar symptoms and/or exposures 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case:                      List symptoms Symptom  onset date 
Same 
exposures 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
      
     /     /       Restaurant    
 Gatherings   
 Food 
 Animal 
 Water 
 Yes 
 No 
      
      
If this contact is a case create a new event and/or case for this contact. 
 
 
 
 
CONTACTS 
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Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case:                      List symptoms Symptom  onset date 
Same 
exposures 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
      
     /     /       Restaurant    
 Gatherings   
 Food 
 Animal 
 Water 
 Yes 
 No 
      
      
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case:                      List symptoms Symptom  onset date 
Same 
exposures 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
      
     /     /       Restaurant    
 Gatherings   
 Food 
 Animal 
 Water 
 Yes 
 No 
      
      
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case:                      List symptoms Symptom  onset date 
Same 
exposures 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
      
     /     /       Restaurant    
 Gatherings   
 Food 
 Animal 
 Water 
 Yes 
 No 
      
      
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case:                      List symptoms Symptom  onset date 
Same 
exposures 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
      
     /     /       Restaurant    
 Gatherings   
 Food 
 Animal 
 Water 
 Yes 
 No 
      
      
If this contact is a case create a new event and/or case for this contact. 
Name DOB Gender Address/Phone 
           /     /       Male 
 Female 
 
      Zip code:       Phone:       -       -       
Relationship to case:                      List symptoms Symptom  onset date 
Same 
exposures 
 Is contact a 
case? 
 Spouse 
 Child 
 Sibling 
 Roommate 
 Parent/ guardian 
 Sexual contact 
 Family member (non-household)  
 Friend/acquaintance 
 Contact- work/school/etc 
 Unknown/Other       
      
     /     /       Restaurant    
 Gatherings   
 Food 
 Animal 
 Water 
 Yes 
 No 
      
      
If this contact is a case create a new event and/or case for this contact. 
 
NOTES:       
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VIRAL HEMORRHAGIC FEVER 
 
Potential Bioterrorism Agent:  Category A 
 
Also known as: VHF 
 
Includes: Lassa, Marburg, Ebola, Crimean-Congo, South American 
 
Responsibilities: 
Hospital:  Report by phone immediately 
Lab:  Report by phone immediately, Send isolates to State Hygienic Laboratory (SHL) for 
confirmation 
Physician: Report by phone immediately 
Local Public Health Agency (LPHA):  Iowa Department of Public Health will lead the 
follow-up investigation.    Follow up will be entered in IDSS. 
Iowa Department of Public Health 
Disease Reporting Hotline: (800)-362-2736 
After Hours: Iowa State Patrol Office at (515) 323-4360 and they will page a member of 
the on-call CADE staff. 
Secure Fax:  (515) 281-5698 
 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Viral hemorrhagic fevers (VHFs) include numerous zoonotic diseases, all of which cause a 
hemorrhagic syndrome in humans. VHFs are known to be caused by filoviruses, arenaviruses, 
bunyaviruses, and flaviviruses. Some of the specific VHFs include Ebola, Marburg, Lassa, Junin 
(Argentine VHF), Machupo (Bolivian VHF), Sabia (Brazilian VHF), Guanarito (Venezuelan VHF), 
Crimean Congo hemorrhagic and Rift Valley fever. Because of its extremely high fatality rate and the 
importation of the virus into the United States in non-human primates, Ebola hemorrhagic fever has 
been the most publicized in the United States. VHFs have been recognized by the Centers for Disease 
Control and Prevention (CDC) as being among the top agents of concern for potential bioterrorist 
weapons. 
 
B. Clinical Description 
The onset of viral hemorrhagic fever is usually sudden. The duration of illness can vary from a few 
days to a couple of weeks. Patients may present with a brief prodrome characterized by nonspecific 
signs, including fever, headache, malaise, weakness, irritability, dizziness, muscle aches, and nausea 
and vomiting. As signs progress, they may include low blood pressure, sustained fever, sweats, rash, 
diarrhea, swelling around the eyes, flushing, and redness of the eyes. As signs become more serious, 
the patient becomes prostrate and may develop pain in the throat, chest, or abdomen, as well as 
petechiae and ecchymoses (bruises). Bleeding occurs from mucous membranes (including 
nosebleeds, and bleeding gums, vomit, urine, stools and sputum), and the patient will often go into 
shock. Encephalopathy, hepatitis, intention tremors, and reduced white blood cell and platelet levels 
are frequently seen, and renal failure may occur. Mortality rates for VHFs vary depending on the 
agent and strain, and can be from 10% to 90%. 
Report immediately 
by phone 
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C. Reservoirs 
 
Many wild and domestic animals, ticks, and mosquitoes are known to carry some of the VHF agents, 
although the reservoirs have not been identified for all VHF agents. Rodents are known to be the 
carriers of Lassa, Junin, Machupo, Guanarito, Crimean Congo hemorrhagic and Rift Valley fever 
viruses. Mosquitoes, ticks and animals (including rodents, foxes, hares, and groundfeeding birds) are 
known to carry bunyaviruses that cause VHF. Primates are the only non-human animals known to 
have been affected by Ebola and Marburg hemorrhagic fever viruses. However, because these 
infections are associated with a rapid and often fatal illness in these animals, they are not considered 
reservoirs. Once certain VHF viral infections establish themselves in human populations, rapid person-
to-person spread may occur. 
 
D. Modes of Transmission 
The mode of transmission for index cases of VHF in any outbreak is animal, tick or mosquito to 
human. Once a human has acquired infection with a VHF agent, transmission may occur person-to-
person. Persons become infected through contact with infectious blood or secretions from infected 
persons or animals. Individuals have acquired VHFs through sexual contact. Bedding or other fomites 
may serve as a source of infection. Medical equipment that has not been properly cleaned or 
sterilized has been responsible for the spread of some VHFs, and laboratory workers manipulating 
specimens have acquired rare cases. For most VHFs, direct physical contact with infectious blood or 
secretions is thought to be required for transmission. However, for some VHFs, such as some of the 
arenaviruses, aerosol spread is considered likely. 
 
E. Incubation period 
The incubation periods for VHFs range from 1 to 21 days, with an average of 3 to 10 days. 
 
F. Period of Communicability or Infectious Period 
Infected individuals are generally considered infectious for a variable period preceding the onset of 
symptoms (up to about 3 weeks for some VHFs) and during the course of clinical symptoms. Virus 
may remain in the blood and secretions for months after an individual recovers. Contaminated 
bedding and medical equipment may remain infectious for several days. 
 
G. Epidemiology 
Viruses of VHFs are primarily infectious agents in wild animals, birds, mosquitoes and ticks. Individual 
VHFs occur in different geographic regions. Outbreaks, when they occur, tend to be sporadic. 
Outbreaks of Ebola virus hemorrhagic fever in imported non-human primates used for research have 
occurred in the U.S. In one instance, individuals working with infected primates developed antibody 
to Ebola, suggesting exposure, but the individuals did not become clinically ill. There is speculation 
that this particular strain of Ebola virus (called Ebola Reston) may be unable to cause clinical disease 
in humans. 
 
H. Bioterrorist Potential 
Category A The viruses that cause VHFs are considered potential bioterrorist agents. If acquired and 
properly disseminated, these viruses could cause a serious public health challenge in terms of ability 
to limit the numbers of casualties and control other repercussions from such an attack. 
 
 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Local Public Health Agency Follow-up Responsibilities:   
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Case Investigation 
a. The most important thing a LPHA can do upon learning of a suspect or confirmed 
case of viral hemorrhagic fever, or potential exposure, is to immediately call IDPH, 
CADE, any time at (800) 362-2736. 
 
b. Iowa Department of Public Health will lead the follow-up investigation.  Call the 
Center for Acute Disease Epidemiology immediately at (800) 362-2736. 
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and healthcare provider 
immediately report any suspicion of viral hemorrhagic fever called to your attention by a healthcare 
provider or laboratory.  
 
The reporting number for IDPH Center for Acute Disease Epidemiology (CADE) is (800) 362-2736, if 
calling after business hours, call the Iowa State Patrol Office at (515) 323-4360 and they will page a 
member of the on-call CADE staff. 
 
Laboratory Testing Services Available  
Consult with CADE and the University of Iowa State Hygienic Laboratory (SHL) for any questions 
about laboratory testing. 
 
C.  Local Public Health Agency Follow-up Responsibilities 
 
Case Investigation 
a. The most important thing a LPHA can do upon learning of a suspect or confirmed case 
of viral hemorrhagic fever, or potential exposure to viral hemorrhagic fever, if 
bioterrorism is suspected, is to immediately call IDPH any time at (800) 362-2736. 
 
b. Case investigation of viral hemorrhagic fever in Iowa residents will be directed by IDPH. If a 
bioterrorism event is suspected, IDPH and other response authorities will work closely with LPHAs 
and provide instructions/information on how to proceed. 
 
c. Following immediate notification of IDPH, the LPHA may be asked to assist in investigating cases 
that live within their communities, including gathering the following:  
1) The case’s name, age, address, phone number, status (hospitalized, at home, deceased), 
and parent/guardian information, if applicable. 
2) The name and phone number of the hospital where the case is or was hospitalized. 
3) The name and phone number of the case’s attending physician. 
4) The name and phone number of the infection prevention staff at the hospital. 
5) If the patient was seen by a healthcare provider before hospitalization, or seen at more than 
one hospital, be sure to document these names and phone numbers as well.   
 
3) CONTROLLING FURTHER SPREAD 
 
A. Isolation and Quarantine Requirements  
All efforts to isolate or quarantine cases or their contacts of viral hemorrhagic fevers will depend on 
exactly which viral hemorrhagic fever is identified and will be directed by the Iowa Department of Public 
Health.  
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4) ADDITIONAL INFORMATION 
 
References 
CDC. Viral Hemorrhagic Fever website: wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-
diseases-related-to-travel/viral-hemorrhagic-fevers.htm  
Heymann, D.., ed., Control of Communicable Diseases Manual, 19th Edition. Washington, DC, 
American Public Health Association, 2008. 
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FACT SHEET Viral Hemorrhagic Fevers 
 
What are viral hemorrhagic fevers? 
Viral hemorrhagic fevers (VHFs) refer to a group of illnesses that are caused by several distinct families of 
viruses. VHF is used to describe a severe syndrome of illnesses that may affect multiple organ systems in 
the body. Usually the overall vascular system is damaged and the body’s ability to regulate itself is impaired. 
Some types of VHF cause relatively mild illnesses, but many of these viruses cause severe, life-threatening 
disease, such as Ebola, Lassa, Crimean-Congo and Marburg.  
 
What are the symptoms of an infection with viral hemorrhagic fevers? 
Specific signs and symptoms vary by the type of VHF, but initial signs and symptoms often include fever, 
fatigue, dizziness, muscle aches, loss of strength, and exhaustion.  People with severe cases of VHF often 
show signs of bleeding under the skin, in internal organs, or from body orifices like the mouth, eyes, and 
ears. Severely ill cases may develop shock, nervous system malfunction, coma, delirium, and seizures.  
 
How soon do symptoms appear? 
Depending on the specific virus involved, symptoms can appear within 1 to 21 days after exposure. 
 
How are viral hemorrhagic fevers spread? 
Most VHF viruses are zoonotic. This means that these viruses naturally reside in an animal reservoir host 
or arthropod vector. Rodents and arthropods are likely the main reservoirs for the viruses that cause 
VHFs. The hosts of some VHFs remain unknown such as with Ebola and Marburg viruses.  
 
VHF viruses are initially transmitted to humans when the activities of infected hosts and humans overlap, 
as follows: 
• VHFs carried in rodents are transmitted to humans when they come into contact with rodent 
urine, fecal matter, saliva, or other secretions. 
• VHFs associated with arthropod vectors are spread most often when the vector mosquito or tick 
bites a human, or when a human crushes a tick into a small wound.  
• Humans may become infected when caring for or slaughtering livestock that have become 
infected. 
• Some VHFs (Ebola, Marburg, Lassa, others)  can spread directly from one person to another. This 
can occur directly, through close contact with infected body fluids, or indirectly through contact 
with objects contaminated such as needles with infected body fluids. 
 
Who gets viral hemorrhagic fever infections? 
Viruses that cause VHFs are distributed over much of the globe. However, since each virus is associated 
with one or more particular host species, the virus and the disease it causes are usually seen only where 
the host species lives. Therefore, the risk of getting VHFs caused by these viruses is restricted to those 
areas.  
 
Although people usually become infected only in areas where the host lives, occasionally people become 
infected by a host that has been exported from its native habitat, or by a person who gets infected and 
travels elsewhere. 
 
For how long is a person infectious? 
This is not known with certainty for all VHFs. As long as the blood and secretions of an infected person 
contain the virus, a person is infectious. This has ranged to over 2 months in some cases. 
 
What are the treatments for viral hemorrhagic fevers? 
 Patients generally receive supportive therapy since there is no other treatment or established cure for 
VHFs. Some antiviral drugs have been effective in treating individuals with VHFs.  
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Do infected people need to be excluded from school, work, or child care? 
Yes, for those VHFs that can be transmitted from one person to another. Ill persons should remain home 
until testing shows a they are no longer infectious. 
 
What can be done to help prevent the spread of viral hemorrhagic fevers? 
Avoiding close physical contact with infected people and their body fluids is the most important way of 
controlling the spread of disease.   
 
Prevention efforts also include avoiding contact with animal or insect host species which includes: 
• Controlling rodent populations 
• Discouraging rodents from entering or living in homes and workplaces 
• Safe cleanup of rodent nests and droppings 
• Appropriate control of arthropod vectors 
• Use of insect repellent 
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CONFIDENTIAL                                                                                         Iowa Department of Public Health 
Viral Hemorrhagic Fever 
                              Agency:  
           
Investigator:                                             Phone number:                                          
FOR STATE USE ONLY 
Status:   Confirmed      Probable 
              Suspect          Not a case  
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis 
date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome:  Survived this illness     Died from this illness  Died unrelated to this illness    Unknown First name: 
 
      
Outbreak 
related:  Yes      No      Unknown Provider time: 
 ARNP   
 DO 
 MD 
 NP  PA 
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
 
Result type: 
 
 Preliminary      Final 
 
Result date: 
 
     /     /      Result: 
 Positive 
 Negative 
 
Organism: 
 
 Type (e.g. serotype): 
 
       
 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
 
Result type: 
 
 Preliminary      Final 
 
Result date: 
 
     /     /      Result: 
 Positive 
 Negative 
 
Organism: 
 
 Type (e.g. serotype): 
 
       
 
 
 
Laboratory: 
 
      
 
Accession #: 
 
      
 
Collection date: 
 
     /     /      
 
Date received: 
 
     /     /      Specimen source: 
 
      
 
Test type: 
 
      
 
Result type: 
 
 Preliminary      Final 
 
Result date: 
 
     /     /      Result: 
 Positive 
 Negative 
 
Organism: 
 
 Type (e.g. serotype): 
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OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
Symptoms:  Diarrhea    Fever   
 Headache   
 Maculopapular rash   
 Malaise   
 Muscle pain   
 Renal failure   
 Shock   
 Sore throat  
 Vomiting 
 
OTHER LAB FINDINGS 
 
Thrombocytopenia:  Yes    No    Unknown Lymphopenia:  Yes    No    Unknown 
 
TREATMENT 
 
Antivirals prescribed:   Yes    No    Unknown 
  
Antiviral:       
 
Antiviral:       
 
Antiviral:       
Date 
started:      /     /      
Date 
started:      /     /      
Date 
started:      /     /      
 
Dose: 
 
      
 
Dose: 
 
      
 
Dose: 
 
      
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
 
Unit: 
 mg     
 ml    
 IU 
# of 
days:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
# of times a 
day:       Route:       
 
 
 
 
 
 
 
Therapeutic medications prescribed?  Yes    No    Unk 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
List medications:       
 
 
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Risk Factors/Travel Information – In the 1 to 21 days prior to onset of symptoms did the case consume the following: 
Traveled within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
Exposures – In the 1 to 21 days prior to the onset of symptoms did the case have the following exposures: 
Animal contact:  Yes    No    Unk Animal:  Chimpanzees  Forest duikers 
 Gorillas 
 Monkeys 
     
Exposed to potential 
infection sources:  Yes    No    Unk Possible VHF sources: 
 Injected drugs 
 Needle stick 
 Contact with blood or other body fluids 
 Contact with deceased person 
 
NOTES:       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
  The incubation period for 
viral hemorrhagic fever 
1 – 21 days depending 
on the specific virus 
Viral hemorrhagic fever can 
be transmitted as long as the 
virus is present in body fluids  
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WEST NILE VIRUS 
 
Also Known as: WNV 
 
 
Responsibilities: 
Hospital: Report by IDSS, facsimile, mail or phone, Infection Preventionist involvement in 
follow-up may vary. 
Lab: Report by IDSS, facsimile, mail, or phone 
Physician: Report by facsimile, mail, or phone 
Local Public Health Agency (LPHA): Report by IDSS, facsimile, mail, or phone. Initiates 
Follow-up, works with Infection Preventionist 
 
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY   
 
A. Agent  
West Nile Virus is a flavivirus first found in Africa, West Asia, and the Middle East. It is closely related 
to St. Louis encephalitis virus, which is found in the United States. Presence of the virus was first 
identified in the United States in 1999. The virus can infect humans, birds, mosquitoes, horses and 
other mammals.   
 
B. Clinical Description   
Non-neuroinvasive disease: West Nile Fever is another type of illness that can occur in people who 
become infected with the virus. It is characterized by fever, headache, tiredness, aches, and 
sometimes rash. Although the illness can be as short as a few days, even healthy people have been 
sick for several weeks.   
 
Neuroinvasive disease: Neuroinvasive disease is a severe manifestation of WNV because it affects a 
person’s nervous system. Neuroinvasive disease includes: West Nile encephalitis (inflammation of the 
brain), West Nile meningitis (inflammation of the membrane around the brain and the spinal cord), 
and West Nile meningoencephalitis (inflammation of the brain and the membrane surrounding it). 
Clinical syndromes may include aseptic meningitis, myelitis, and encephalitis. Less common 
neurological syndromes may include cranial and peripheral neuritis/neuropathies, including Guillain-
Barré syndrome.  It is important to understand that neuroinvasive disease is not just limited to 
encephalitis and meningitis.  
 
Symptoms  
(Non-neuroinvasive disease): Most people who are infected with the West Nile virus will not have any 
type of illness. It is estimated that about 20% of the people who become infected will develop West 
Nile fever. Symptoms include fever, headache, tiredness, and body aches, and occasionally a skin 
rash on the trunk of the body and swollen lymph glands. 
 
Symptoms (Neuroinvasive disease): Symptoms  include headache, high fever, neck stiffness, 
stupor, disorientation, coma, tremors, convulsions, muscle weakness, and paralysis. It is estimated 
that approximately 1 in 150 persons infected with the West Nile virus will develop a more severe 
form of disease. 
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C. Reservoirs 
West Nile Virus is carried by birds. WNV has been identified in more than 200 species of birds found 
dead in the United States. The virus usually stays in birds and the mosquitoes that feed on them. 
Rarely, other kinds of mosquitoes that also bite people and horses pick up the viruses. Humans and 
horses are considered dead-end hosts, meaning they do not transmit the virus on further.  
 
D. Modes of Transmission 
WNV is spread to humans by the bite of an infected mosquito. There have been documented cases of 
intrauterine, transfusion-associated, and organ transplant transmission of WNV. Improvements to the 
sensitivities of the tests used to screen blood will reduce the risk of transmission.  
 
E.  Incubation Period 
The incubation period for WNV disease is typically 2 to 6 days but ranges from 2 to 14 days and can 
be several weeks in immunocompromised people. 
  
F. Period of Communicability or Infectious Period  
West Nile encephalitis is NOT transmitted from person-to-person. For example, a person cannot get 
West Nile virus from touching or kissing a person who has the disease, or by caring for someone with 
the disease. 
 
G. Epidemiology  
Before the fall of 1999, WNV had not been documented in the Western Hemisphere. WNV was first 
isolated in the West Nile Province of Uganda in 1937. The first epidemic was in Israel during the 
1950s. In 1999, human cases of WNV were identified in New York City. Iowa first identified WNV in a 
bird in 2001. The first human cases occurred in Iowa in 2002 and 147 human WNV cases were 
identified in 2003. In 2009, 9 cases were reported in Iowa, and in 2012 31 cases were reported.  
 
Individuals who spend time outdoors, when mosquitoes are present (typically spring through fall in 
Iowa), are at risk of being bitten by an infected mosquito. The more time individuals spend outdoors, 
the greater the risk of being bitten by an infected mosquito. Individuals over 50 years of age are at 
an increased risk of becoming ill with severe symptoms if bitten by an infected mosquito. The 
seasonality of WNV transmission is variable and depends on the geographic location of exposure, the 
specific cycles of viral transmission, and local climatic conditions. 
 
H. Bioterrorism Potential 
None. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To identify locally acquired cases of WNV infection in humans to help target mosquito control 
measures. 
• To identify cases of other arboviral infections in Iowa residents or visitors to determine whether 
they are imported or locally acquired. 
• To identify cases of WNV infection to understand the epidemiology of this emerging disease in 
our area. 
• To provide residents of Iowa and travelers to the state with appropriate preventive health 
information. 
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Laboratory and Healthcare Provider Reporting Requirements   
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report. The preferred method of reporting is by utilizing the Iowa Disease Surveillance System 
(IDSS).  However, if IDSS is not available, the reporting number for IDPH Center for Acute Disease 
Epidemiology (CADE) is (800) 362-2736; fax number (515) 281-5698, mailing address: 
 
IDPH, CADE 
Lucas State Office Building, 5th Floor 
321 E. 12th St. 
Des Moines, IA 50319-0075 
 
Postage-paid disease reporting forms are available free of charge from the IDPH clearinghouse.   
Call (319) 398-5133 or visit the website: 
healthclrhouse.drugfreeinfo.org/cart.php?target=category&category_id=295 to request a supply. 
 
Laboratory Testing Services Available  
The University of Iowa State Hygienic Laboratory (SHL) performs antibody detection for West Nile 
virus using enzyme immunoassay (EIA) methods. Single acute sera and cerebrospinal fluid (CSF) are 
tested for the presence of IgM antibodies. WNV antibodies develop soon after onset and peak around 
8 days, therefore, sera and CSF collected 5-10 days post onset are ideal specimens for testing. The 
presence of IgM antibody usually indicates recent infection by this virus; however, it has been shown 
that IgM antibodies to WNV may persist for many months after onset. IgG testing is not routinely 
done.  Confirmatory testing, if indicated, is performed at the CDC. Accurate information about date of 
specimen collection, date of onset of symptoms, travel history, vaccination and disease history are 
helpful for test result interpretation. For information on specimen submission and testing, contact 
SHL at (319) 335-4500. Additional information, test request forms, and sample collection instructions 
can be found at the SHL web site at: www.shl.uiowa.edu/  
 
C. Local Public Health Agency Follow-Up Responsibilities 
Case Investigation 
a. The local public health agency (LPHA) should follow-up on reported cases of WNV.  
b. Neuroinvasive disease includes diagnoses of West Nile encephalitis, West Nile meningitis or West 
Nile meningoencephalitis, neuritis/neuropathies, or myelitis. The severe WNV illnesses typically 
require hospitalization. The LPHA should work with the infection preventionist (IP) at the hospital 
to complete the WNV case investigation in IDSS. 
c. Non-neuroinvasive disease includes WNV Fever and any other diagnoses of WNV including 
symptoms consistent with the illness and/or clinically apparent disease not involving encephalitis, 
meningitis or meningoencephalitis (neurological involvement).  LPHA will complete the 
investigation for WNV. 
d. Asymptomatic test positives include individuals who have been infected with and tested positive 
for WNV without becoming ill (remaining asymptomatic or without clinically apparent disease). 
Please note in IDSS if this is the situation. 
e. If  several attempts have been made to obtain case information, but have been unsuccessful 
(e.g., the case or healthcare provider does not return calls or respond to a letter, or the case 
refuses to divulge information or is too ill to be interviewed), complete the investigation with as 
much information as has been gathered. Please note the reason why it could not be completed. 
If using IDSS, select the appropriate reason under the Event tab in the Event Exception field. 
 
3) CONTROLLING FURTHER SPREAD 
A. Isolation and Quarantine Requirements 
 None 
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B. Protection of Contacts of a Case 
None 
 
C. Managing Special Situations   
 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
If an outbreak is suspected, contact IDPH/CADE at (800) 362-2736. The situation may warrant an 
investigation of clustered cases or implementation of effective prevention and control measures (e.g., 
spraying for mosquitoes). CADE can assist in determining a course of action to prevent further cases 
and can perform surveillance for cases across county lines that can be difficult to identify at a local 
level. 
 
D.  Preventive Measures  
Surveillance 
 
In Iowa, CADE, Iowa State University, the State Hygienic Laboratory, and the Iowa Department of 
Agriculture and Land Stewardship conduct surveillance for arboviral diseases including West Nile 
virus, through mosquito trapping and testing, sentinel chicken testing, dead bird collection and 
testing, and through the monitoring of human and equine cases. Results of these surveillance efforts 
are used to detect the presence of the virus to help target prevention and control measures 
throughout the state.  
 
CADE, in cooperation with other state agencies, may provide guidance in the use of pesticides for the 
control of mosquitoes (e.g., “mosquito fogging”). However, decisions regarding the use of larvicides 
and/or adulticides for mosquito control are typically made by local cities and towns based on 
mosquito habitat and density, primarily for control of nuisance mosquitoes. 
 
Personal Preventive Measures/Education 
The easiest and best way to avoid WNV is to prevent mosquito bites. When outdoors, use insect 
repellents containing DEET (N, N-diethyl-meta-toluamide) and follow the directions on the package. 
DEET is the most effective insect repellent available. Repellants containing picaridin and oil of lemon 
eucalyptus have also been found to be effective.  
 
A higher percentage of DEET in a repellent does not provide better protection, just longer protection. 
DEET concentrations higher than 50% do not increase the length of protection. The recommended 
concentration of DEET for adults is 30% and 10% for children and infants over 2 months of age. 
According to the label, oil of lemon eucalyptus products should NOT be used on children under 3 
years. Use repellents at the lowest effective concentration. Wash treated skin with soap and water 
after returning indoors. Wear long-sleeved shirts, long pants, and socks when possible. Spray 
clothing with products containing DEET or permethrin, as mosquitoes may bite through thin clothing. 
Permethrin should only be used on clothing; do not apply it directly to skin. Wash treated clothing 
before wearing it again. Many mosquitoes are most active at dusk and dawn; consider staying 
indoors during these hours.  
Environmental Preventive Measures 
Make sure to have good screens on windows and doors to keep mosquitoes out. Get rid of mosquito 
breeding sites by eliminating old tires and tin cans, as well as emptying standing water from 
flowerpots, buckets, barrels and children’s wading pools when not in use. Change the water in pet 
dishes and replace the water in birdbaths weekly. Drill holes in tire swings so water drains out. 
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4) ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for West Nile 
Virus can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
Comment 
Interpreting arboviral laboratory results  
• Serologic cross-reactivity. In some instances, arboviruses from the same genus produce 
cross-reactive antibodies. In geographic areas where two or more closely-related arboviruses 
occur, serologic testing for more than one virus may be needed and results compared to 
determine the specific causative virus. For example, such testing might be needed to distinguish 
antibodies resulting from infections within genera, e.g., flaviviruses such as West Nile, St. Louis 
encephalitis, Powassan, Dengue, or Japanese encephalitis viruses.  
• Rise and fall of IgM antibodies. For most arboviral infections, IgM antibodies are generally 
first detectable at 3 to 8 days after onset of illness and persist for 30 to 90 days, but longer 
persistence has been documented (e.g, up to 500 days for West Nile virus). Serum collected 
within 8 days of illness onset may not have detectable IgM and testing should be repeated on a 
convalescent-phase sample to rule out arboviral infection in those with a compatible clinical 
syndrome.  
• Persistence of IgM antibodies. Arboviral IgM antibodies may be detected in some patients 
months or years after their acute infection. Therefore, the presence of these virus-specific IgM 
antibodies may signify a past infection and be unrelated to the current acute illness. Finding 
virus-specific IgM antibodies in CSF or a fourfold or greater change in virus-specific antibody 
titers between acute- and convalescent-phase serum specimens provides additional laboratory 
evidence that the arbovirus was the likely cause of the patient’s recent illness. Clinical and 
epidemiologic history also should be carefully considered.  
• Persistence of IgG and neutralizing antibodies. Arboviral IgG and neutralizing antibodies 
can persist for many years following a symptomatic or asymptomatic infection. Therefore, the 
presence of these antibodies alone is only evidence of previous infection and clinically compatible 
cases with the presence of IgG, but not IgM, should be evaluated for other etiologic agents.  
• Arboviral serologic assays. Assays for the detection of IgM and IgG antibodies commonly 
include enzyme-linked immunosorbent assay (ELISA), microsphere immunoassay (MIA), or 
immunofluorescence assay (IFA). These assays provide a presumptive diagnosis and should have 
confirmatory testing performed. Confirmatory testing involves the detection of arboviral-specific 
neutralizing antibodies utilizing assays such as plaque reduction neutralization test (PRNT).  
• Other information to consider. Vaccination history, detailed travel history, date of onset of 
symptoms, and knowledge of potentially cross-reactive arboviruses known to circulate in the 
geographic area should be considered when interpreting results.  
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Additional Resources 
Additional information regarding WNV, pesticide use, occupational exposures and other topics may be 
obtained using the following websites: 
Environmental Protection Agency www.epa.gov/pesticides/health/mosquitoes/. 
U.S. Department of Labor/OSHA www.osha.gov/dts/shib/shib082903b.html 
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CONFIDENTIAL                                                                                                Iowa Department of Public Health 
West Nile Virus         Investigator:  
 
Agency:                                                 Phone number:                                          
FOR STATE USE ONLY 
Status:    Confirmed       Probable 
 Suspect          
 Not a case 
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Phone: (     )-     -        Type:               Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Long-term care     
resident:  Yes      No      Unknown 
Parent/Guardian 
name: 
 
      
Facility name:       
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Diagnosis date: 
 
     /     /      
Onset 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome: 
 Survived this illness     Died from this illness 
 Died unrelated to this illness    Unknown 
Date of death      /     /      First name: 
 
      
Event exception 
 Case could not be found 
 Case could not be interviewed 
 Case refused interview 
 Other – see notes 
Provider title:  ARNP   
 DO 
 MD 
 NP  PA 
Outbreak 
related:  Yes      No      Unknown  
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
 
LABORATORY FINDINGS 
 
 
Laboratory: 
 
      
Specimen 
source: 
 
      
 
Test type: 
 Serology (EIA/ELISA/MIA) 
 Serology (IFA) 
 PRNT 
 PCR      Other            
 
Accession #: 
 
      
 
Result date: 
 
     /     /       
 
Collection date: 
 
     /     /      Test type: 
 Acute 
 Convalescent 
 IgM 
 IgG Result type:  Preliminary      Final 
 
Date received: 
 
     /     /      
 
Organism: 
 
West Nile virus Result: 
 Negative 
 Positive 
 Equivocal 
 Indeterminate 
 
 
Laboratory: 
 
      
Specimen 
source: 
 
      
 
Test type: 
 Serology (EIA/ELISA/MIA) 
 Serology (IFA) 
 PRNT 
 PCR      Other            
 
Accession #: 
 
      
 
Result date: 
 
     /     /       
 
Collection date: 
 
     /     /      Test type: 
 Acute 
 Convalescent 
 IgM 
 IgG Result type:  Preliminary      Final 
 
Date received: 
 
     /     /      
 
Organism: 
 
West Nile virus Result: 
 Negative 
 Positive 
 Equivocal 
 Indeterminate 
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Laboratory: 
 
      
Specimen 
source: 
 
      
 
Test type: 
 Serology (EIA/ELISA/MIA) 
 Serology (IFA) 
 PRNT 
 PCR      Other            
 
Accession #: 
 
      
 
Result date: 
 
     /     /       
 
Collection date: 
 
     /     /      Test type: 
 Acute 
 Convalescent 
 IgM 
 IgG Result type:  Preliminary      Final 
 
Date received: 
 
     /     /      
 
Organism: 
 
West Nile virus Result: 
 Negative 
 Positive 
 Equivocal 
 Indeterminate 
 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties in 
lab or health care setting: 
Health care worker type: 
 Yes      No      Unknown 
 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown  
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
  
CLINICAL INFO & DIAGNOSIS 
 
Physician 
diagnosis: 
 Encephalitis 
 Meningitis 
 Meningoencephalitis 
 Fever 
 Asymptomatic 
 Hepatitis/jaundice 
 Multi-system organ failure 
 Other            
 Clinical 
classification: 
 Neuroinvasive  
 Non-neuroinvasive 
  
 
 
Symptoms:  Acute flaccid paralysis 
 Altered mental state 
 Anorexia 
 Coma 
 Confusion 
 Cranial nerve palsies 
 Diarrhea 
 Double vision 
 Eye pain 
 Fatigue 
 Fever 
 Gait/balance difficulty 
 Headache 
 Joint pain 
 Muscle pain 
 Nausea 
 Photophobia 
 Rash 
 Stiff neck 
 Swollen lymph nodes 
 Tremors 
 Vertigo 
 Vomiting 
 Other symptoms:                           
 
Pre-existing Conditions 
Before your West Nile virus (WNV) infection, did a health care provider ever tell he/she had any of the following medical conditions? 
 Diabetes 
 High blood pressure (hypertension) 
 Heart attack (myocardial infarction) 
 Angina or coronary artery disease 
 Congestive heart failure 
 Stroke 
 Chronic obstructive pulmonary disease (COPD) 
 Chronic liver disease 
 Kidney disease or failure 
 Bone marrow transplant 
 Alcoholism 
 Case had none of the conditions listed 
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
 
Before WNV infection, did the case ever 
have a solid organ transplant? 
 
 Yes    No    Unk 
 
If yes, what organ was transplanted:       
  If yes, what year was the transplant:       
Before WNV infection, has the case ever 
had cancer?  Yes    No    Unk If yes, what cancer type(s):       
  If yes, what year were you diagnosed:       
  If yes, are you currently being treated for cancer:  Yes      No      Unk 
Before WNV infection, did the case have 
any medical condition that limited 
his/her ability to fight infection?  Yes    No    Unk If yes, what condition:       
At the time WNV infection was diagnosed, was the case taking any of the following types of prescription medications or treatments? 
 Chemotherapy      
 Other treatments for cancer  
 Hemodialysis 
 Other treatments for kidney disease 
 Oral or injected steroids      
 Inhaled steroids         
 Insulin or other medications to treat diabetes 
 Medications to treat high blood pressure  
 Medications to treat coronary artery disease   
 Medications to treat congestive heart failure  
 Medications that suppress the immune system 
 Case was not on any medications/treatments listed 
    
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Ever vaccinated for Yellow fever  Yes    No    Unk                    Ever vaccinated for Japanese encephalitis (JE)?   Yes    No    Unk 
 
If yes, list MOST RECENT vaccination information ONLY: 
 Disease: Yellow fever  Disease: Japanese encephalitis (JE)  
 Date 
vaccinated: 
 
     /     /      
 Date 
vaccinated: 
 
     /     /      
 
  
Lot #: 
 
      
  
Lot #: 
 
      
 
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
 
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
 
 
Risk Factors/Travel Information  
In the 2 to 15 days prior to onset of symptoms did the case:  
Traveled within Iowa?  
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Traveled outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
Exposed to mosquitoes:  Yes    No    Unk    
Use a mosquito repellent:  Yes    No    Unk If yes, how often?  Always    Most of the time 
  If yes, 
what type? 
 DEET 
 Lemon eucalyptus oil 
If the patient is female, was she:  
 sometimes   
 Never 
  Picaridin  
 Other            
Breastfeeding?  Yes    No    Unk    
 
In the 30 days prior to onset of symptoms did the case: 
Donate blood, blood products, 
organs or tissues?  Yes    No    Unk Date donated:      /     /        
Receive blood or blood products?  Yes    No    Unk Date received:      /     /        
Receive organs or tissue?  Yes    No    Unk Date received:      /     /        
 
Case acquired infection: 
 
 Naturally 
 Transplantation  
 
 Transfusion  
 Trans-placental  
 
 Breastfeeding  
 Occupationally 
 Unknown   
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
 The incubation period for 
West Nile virus is 2 to 
15 days.  
Transmission person to person only in 
utero, through transplantation, blood 
donation and breast milk.  
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What is West Nile virus? 
West Nile virus is a mosquito-borne virus that is commonly found in Africa, West Asia, and the Middle 
East.  It is closely related to St. Louis encephalitis virus found in the United States. While the virus mainly 
infects mosquitoes and birds, mosquitoes can transmit the virus to people and other animals.  The virus 
was first identified in the West Nile district of Uganda in 1937. It was first reported in the United States in 
1999, when 62 cases and 7 deaths in humans from West Nile virus infection were reported in the New 
York City area.  
 
Should the West Nile virus be a concern for people in Iowa? 
Yes. Since 1999, West Nile has spread across the continental United States. The virus was identified in a 
dead crow in the eastern part of Iowa in September 2001.  Human cases in Iowa have been reported 
every year since 2002.     
 
How is West Nile virus spread? 
Mosquitoes can get West Nile virus when feeding on infected birds.  Mosquitoes can then spread the 
virus to people through a bite.  West Nile virus cannot be spread by person-to-person contact such as 
kissing, touching, or caring for an infected person. West Nile virus can also rarely be transmitted to 
humans who receive infected organs by transplantation or who receive transfusions of infected blood or 
blood products.  
 
Is a person that is bitten by a mosquito in an area known to have West Nile virus likely to 
get infected? 
No.  The chance of getting infected with the virus is low. Even in areas where the virus is circulating, very 
few mosquitoes are infected with the virus and not all mosquitoes can successfully transmit the virus. 
Most people who become infected with West Nile virus following a mosquito bite do not develop any 
symptoms.   
 
What are the symptoms of West Nile virus? 
Most people who are infected with West Nile virus either have no symptoms or experience mild illness 
such as fever, headache, and body aches before fully recovering.  Some persons may develop a skin rash 
and swollen lymph glands.  In <1% of infections, particularly in those persons over age 50, West Nile 
virus can cause serious disease, such as encephalitis (inflammation of the brain) or meningitis 
(inflammation of the lining of the brain and spinal cord).  These conditions may result in permanent brain 
damage, or on rare occasions, can be fatal.  Symptoms of severe disease can include severe headache, 
high fever, stiff neck, confusion, loss of consciousness, tremors, muscle weakness, and paralysis. 
 
How is an infection with West Nile virus diagnosed and treated? 
A healthcare provider can diagnose West Nile virus through special tests.  There is no vaccine or specific 
treatment, though a physician may prescribe medications to reduce symptoms.  In severe cases, 
hospitalization may be required.  Persons who have been exposed (i.e. bit by a mosquito), but have not 
developed symptoms do not need to be tested. Your healthcare provider should be contacted if you 
develop severe symptoms.  
 
How can an infection with West Nile virus be prevented? 
Protect yourself from mosquito bites and eliminate mosquito breeding sites: 
• Insect repellents containing DEET, permethrin, picaridin, IR3535, or oil of lemon eucalyptus have 
shown to be effective against mosquitoes.  Permethrin repellants should be applied to clothing only 
and should not be used on the skin. Products containing up to 30% DEET have been shown to be the 
most effective and are safe for adults, including pregnant women and children over 2 months of age. 
DEET should be applied sparingly only to exposed skin and should not be used underneath clothing.  
• Repellent products must state any age restriction. If there is none, EPA has not required a restriction 
on the use of the product. The American Academy of Pediatrics has recommends that repellents with 
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DEET should not be used on infants less than 2 months old. According to the label, oil of lemon 
eucalyptus products should NOT be used on children under 3 years.  
• Wear light colored, long-sleeved shirts and long pants whenever you are outdoors for long periods of 
time or when mosquitoes are most active. 
• Make sure doors and windows have tight fitting screens. Repair or replace screens that have holes or 
tears.  
• Eliminating mosquito-breeding sites (they breed by laying eggs in standing water) by removing 
sources of standing water in outdoor areas where you work or play.  Specific activities include the 
following: 
• Turning over or removing items where rainwater can collect, such as ceramic pots, toys, 
buckets, tires, wading pools, and tarps covering firewood and boats; 
• Changing water in birdbaths and pet bowls every 3-4 days; 
• Making sure roof gutters are clean and in good repair; 
• Repairing leaky outdoor faucets, air conditioners, and hoses; and 
• Stocking ornamental ponds with mosquito dunks or fish that eat mosquito larvae. 
    
Is donating blood or getting blood transfusions or organ transplants safe? 
Donating blood is safe and individuals are still encouraged to donate.  However, those individuals who 
present with symptoms of West Nile, or who are experiencing any kind of illness, will not be allowed to 
donate blood.  Blood centers are taking precautions to be sure that donors who have been diagnosed 
with West Nile have fully recovered before being allowed to donate. People who have been diagnosed 
with West Nile virus should not be allowed to donate blood for 120 days from the start of their symptoms 
or their laboratory diagnosis, whichever is later.  All blood banks are screening for West Nile virus and will 
dispose of positive blood.  Persons who develop symptoms of West Nile virus infection within four weeks 
of receiving a blood transfusion or organ transplantation or whose symptoms begin in the weeks 
following the blood or organ donation are advised to contact their healthcare provider.    
 
Can a West Nile infected pregnant woman infect her unborn child?  
There have been reports of mother-to-fetus transmission of West Nile virus in humans. Pregnant women 
should take precautions to reduce their risk for West Nile virus and other arboviral infections by avoiding 
mosquitoes, wearing protective clothing and using repellents containing DEET. It is not recommended 
that pregnant women or newborns be screened for West Nile. 
 
What should I do if I find a dead bird? 
Finding a dead bird near your home does not necessarily put you at increased risk for West Nile virus. 
West Nile virus infection is not likely to be transmitted by direct contact with dead birds.  Dead birds, 
however, can carry a variety of diseases, and should never be handled with bare hands.  Use gloves to 
carefully place dead birds in double-plastic bags and then place in the outdoor trash or bury. 
 
Can animals be infected with West Nile virus? 
Animals become infected the same way that humans become infected – through the bite of an infected 
mosquito. Horses can experience severe and fatal disease like humans, and cats and dogs can also 
become infected, but rarely develop disease.   Animals infected with West Nile virus do not spread the 
disease to humans. Contact your veterinarian to arrange for vaccination of your horses or if you suspect 
your pet or animal might have been infected with West Nile virus.  
 
Where can additional information regarding WNV be found? 
• Iowa Department of Public Health at www.idph.state.ia.us  
• State Hygienic Laboratory (SHL) www.uhl.uiowa.edu 
• Centers for Disease Control and Prevention www.cdc.gov/ 
• Iowa State University’s Department of Entomology www.ent.iastate.edu/  
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FACT SHEET       WEST NILE VIRUS 
For Health Professionals 
 
What is West Nile Virus? 
West Nile Virus (WNV) is an arbovirus (a virus carried by arthropods) that was first identified in the West 
Nile region of Uganda in 1937.  It belongs to the family of viruses termed Flaviviridae and it is similar to 
other arboviruses such as St. Louis encephalitis virus and Yellow Fever virus. The virus first appeared in 
the United States in 1999 in the New York City area. Human cases in Iowa have been reported every year 
since 2002, suggesting the disease has become endemic here.  
 
How is the virus transmitted? 
The principal transmission cycle of WNV involves several species of mosquitoes and birds.  Humans are 
incidental hosts that acquire the WNV infection primarily by the bite of an infected mosquito.  However, 
several atypical modes of WNV transmission have been described: organ transplant, receipt of blood 
products, breastfeeding and intrauterine transmission. These modes of transmission are expected to occur 
infrequently. There is no evidence that WNV can be spread by person-to-person contact. 
 
What are the signs and symptoms of WNV? 
Approximately 80% of persons bitten by an infected mosquito will develop no symptoms at all.  A mild 
disease, termed “West Nile fever, occurs in 20% of those infected and is characterized as a febrile illness 
of sudden onset. Less than one percent of those infected will develop a severe neurological form of the 
disease (West Nile encephalitis, meningitis). Poliomyelitis, a flaccid paralysis syndrome associated with 
WNV infection, is less common than meningitis or encephalitis. This syndrome is generally characterized 
by the acute onset of asymmetric limb weakness or paralysis in the absence of sensory loss is easily 
confused with Guillain-Barré syndrome. Pain sometimes precedes the paralysis. The paralysis can occur in 
the absence of fever, headache, or other common symptoms associated with WNV infection. Involvement 
of respiratory muscles, leading to acute respiratory failure, can sometimes occur. 
 
Clinical Features of Mild Infection: Fever, headache, fatigue, skin rash on the trunk of the body, 
swollen lymph glands, eye pain, anorexia, or vomiting. 
 
Clinical Features of Severe Infection: Fever, gastrointestinal symptoms, weakness, change in mental 
status, or a maculopapular or morbilliform rash involving the neck, trunk, arms, or legs. 
Neurological presentations include:   
• Ataxia and extrapyramidal signs    • Optic neuritis 
• Seizures       • Myelitis 
• Polyradiculitis      • Flaccid paralysis is sometimes seen. 
• Although not observed in recent outbreaks, myocarditis, pancreatitis, and fulminant hepatitis have 
been described. 
 
What is the incubation period and how long do symptoms last? 
The incubation period for WNV infection is about 2 to 14 days, although longer incubation periods have 
been documented in immunosuppressed persons.  Symptoms of mild disease usually last 3 to 6 days, 
however, WNV sequela may include mild weakness and memory loss lasting several weeks, and the CDC 
reports neurological effects may be permanent in those who had the severe form of the disease. 
 
Who is at high risk for acquiring WNV? 
Persons over the age of 50 appear to be at greatest risk for a WNV infection progressing to the more 
serious encephalitis/meningitis, although WNV can infect persons of all ages.  
 
How is WNV diagnosed?  
• The most efficient diagnostic method is detection of IgM antibody to WNV in serum collected within 8 
to 14 days of illness onset or CSF collected within 8 days of illness onset using an enzyme 
immunosorbent assay (EIA).    
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• IgM antibody does not cross the blood-brain barrier; IgM antibody in CSF strongly suggests central 
nervous system infection.  
• WNV-specific IgM has persisted in patients for >500 days. Positive serologic tests must be correlated 
with clinical presentation, season and potential exposure to WNV.  
• A positive IgG antibody test from a single sample is not diagnostic for acute infection. IgG may be 
present in blood for reasons not related to a recent WNV infection, such as yellow fever vaccination, 
infection with a virus related to WNV, or evidence of a past exposure to a related virus.  The test is less 
specific, i.e. may produce false-positive results.  
• Serological tests for WNV can cross react with other closely related flaviviruses (Japanese encephalitis, 
St. Louis encephalitis, yellow fever, dengue). Patients who have been recently vaccinated against or 
recently infected with related flaviviruses may have positive WNV results. 
 
Is a convalescent specimen necessary? 
Collection of a convalescent specimen at least 2 weeks post onset should be considered on patients with 
clinical symptoms consistent with WNV infection where the acute sample was collected less than 8 days 
post symptom onset and tested negative for IgM antibody; or where the acute specimen yielded an 
equivocal or indeterminate result.    
    
 What are the indications for testing for WNV?  
• Clinically compatible illness during transmission season. In Iowa, transmission is likely to occur from 
June through October, with peak activity in August to mid-September.  
• Providers should consider if there is any clinical value in testing patients with mild fevers of unknown 
origin in the absence of neurological signs.  
• Encephalitis cases of unknown etiology.  
• Aseptic meningitis cases, although at this time of year, such cases may be caused by enteroviruses; 
CSF testing by PCR for enterovirus is recommended.  
• Patients with flaccid paralysis or neurological symptoms following a febrile illness.  
• Pregnant or breast-feeding women with a compatible febrile illness and exposure history.  
• Patients with onset of compatible illness within 2 weeks of receiving blood products or having donated 
blood.  
 
How is WNV treated? 
No specific treatment for WNV is currently available and there are no vaccines for human use. Treatment 
for mild illness is usually not necessary. In severe cases, treatment consists of supportive care that often 
involves hospitalization, intravenous fluids, respiratory support, and prevention of secondary infections.  
 
What specimens need to be submitted to test for WNV? 
• WNV testing for patients with encephalitis or meningitis can be obtained at the State Hygienic 
Laboratory (SHL). Acute serum is best collected at 8 days following symptom onset and convalescent 
serum from 14 - 21 days following symptom onset. Specimens must be submitted with the current SHL 
version request form (SHL website at www.uhl.uiowa.edu or (319) 335-4500 for request forms and 
shipping instructions). 
• For mild illness (West Nile fever), WNV testing is available at most commercial laboratories. Please 
contact your clinical laboratory for information.  
 
How should a case of WNV be reported? 
Please contact the Iowa Department of Public Health at (800) 362-2736 to report a case. 
 
Where can additional information regarding WNV be found? 
• The Iowa Department of Public Health, Center for Acute Disease Epidemiology at (800) 362-2736 or  
www.idph.state.ia.us  
• State Hygienic Laboratory (SHL): www.uhl.uiowa.edu 
• Iowa State University’s Department of Entomology:  www.ent.iastate.edu/  
• Centers for Disease Control and Prevention: www.cdc.gov 
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FACT SHEET        WEST NILE VIRUS  
For Senior Citizens 
 
What is West Nile Virus? 
West Nile virus is a mosquito-borne virus that is commonly found in parts of Africa, West Asia, and the 
Middle East and in 1999 it was identified in the United States. Since 1999, West Nile has spread across 
the United States infecting humans, birds, horses and other animals.  In 2003, Iowa reported 147 
infected residents including six deaths. West Nile virus is spread to humans, birds, and other animals 
through the bite of an infected mosquito. 
 
Why should senior citizens be concerned about West Nile? 
Persons over the age of 50 are at increased risk of developing the severe form of West Nile.   
Very few mosquitoes are infected with the West Nile virus and most persons who are bit by an infected 
mosquito will never develop illness. Some persons will develop a mild illness with symptoms of headache 
and/or slight fever, and <1% of those persons bit by an infected mosquito will develop the severe form 
of West Nile virus. Severe infections, including encephalitis (inflammation of the brain), are characterized 
by high fever, headache, confusion, muscle aches and weakness, seizures, and paralysis. You should 
contact your healthcare provider if you develop severe symptoms. It is not necessary to contact your 
physician if you have been bit by a mosquito and have no symptoms.  
 
Senior citizens can prevent West Nile by avoiding mosquito bites: 
• Limit outdoor activities during prime mosquito hours of dawn and dusk. 
• Shoes, socks, long pants, and a long-sleeved shirt should be worn when outdoors for long 
periods of time or when mosquitoes are most active. Clothing should be light colored and 
made of woven material. Shirts should be tucked in with the collar buttoned. 
• Use an insect repellent containing DEET.  Concentrations of up to 30% DEET is safe for 
adults; reapply as necessary. Follow all label instructions for application use.  
• Use mosquito netting when sleeping outdoors or in unscreened structures. 
• Repair holes in screens and make sure both screens and doors are tight fitting. 
 
Senior citizens can prevent West Nile by eliminating mosquito breeding sites:  
• Eliminate areas of standing water on your property where mosquitoes can breed. 
• Turn over or remove items in your yard where rainwater can collect, such as ceramic pots, 
toys, buckets, tin cans, wheelbarrows, wading pools, plastic containers, and tarps covering 
firewood. 
• Make sure roof gutters are clean and in good repair. 
• Change water in birdbaths and pet bowls every 3-4 days. 
• Repair leaky outdoor faucets, air conditioners, and hoses. 
• Do not over water lawns, shrubs, or flowers. 
• Stock ornamental ponds and water gardens with mosquito dunks or fish that eat mosquito 
larvae.  
• Keep grass cut short and shrubbery trimmed. 
• Dispose of old tires or drill drainage holes in tires used in landscaping. 
• Keep trashcans covered. 
 
For more information on West Nile virus visit: www.idph.state.ia.us 
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FACT SHEET   DEET (N,N-diethyl-m-toluamide) 
 
What is DEET? 
DEET, also known as N,N-diethyl-m-toluamide or N,N-diethly-3-methylbenamide, is the active chemical 
ingredient in most insect repellents applied to the skin. It has been tested against a variety of biting 
insects and has been proven to be an effective insect repellent for mosquitoes, ticks, black flies, fleas, 
and no-see-ums. Both the World Health Organization and Centers for Disease Control and Prevention 
recommend the use of DEET-based repellents to protect against insect-borne diseases such as West Nile 
virus. 
 
SAFE and EFFECTIVE USE of DEET 
DEET is safe when used according to label directions. DEET was developed by the U.S. Army in 1946 for 
use by military personnel in insect-infested areas and was first registered in the United States in 1957. 
However a few incidents of toxic reactions to DEET have occurred even when the product was used 
properly. 
 
The length of time that an insect repellent will provide protection from mosquito bites depends on the 
concentration of DEET in the product. A higher percentage of DEET in a repellent does not provide better 
protection, just longer protection. It has been proven that products with a DEET concentration over 50% 
do not increase the length of protection. A higher percentage of DEET should be used if you are outdoors 
for a long period of time and a lower percentage of DEET should be used if you are outdoors for a short 
period of time. 
 
Products containing up to 30% DEET have been found to be safe for adults. No definitive studies exist in 
the scientific literature about what concentration of DEET is safe for children. The American Academy of 
Pediatrics states that insect repellents containing DEET with a concentration of 30% appear to be as safe 
as products with a concentration of 10% when used according to the directions on the product label. 
DEET is not recommended for use on children under 2 months of age; most experts agree it is safe to 
apply insect repellent with low concentrations of DEET to children over 2 months of age. The safest 
approach for infants and children under 2 years is to minimize exposure to mosquitoes. 
 
The Environmental Protection Agency and the Centers for Disease Control and Prevention recommend 
the following guidelines for using insect repellents containing DEET: 
 Read and carefully follow product label directions and precautions. 
 Apply repellent sparingly on exposed skin and/or clothing. 
 Do not apply DEET underneath clothing. 
 Do not apply repellent near eyes, lips, or mouth. 
 Never apply DEET over cuts, wounds, or irritated skin. 
 Avoid using sprays in enclosed areas. Do not use DEET near food. 
 Do not apply repellent to the hands of young children. 
 Do not allow young children to apply repellents themselves. 
 After returning indoors, wash treated skin with soap and warm water. 
 Avoid over application. Heavy application is not necessary to achieve protection. 
 Wash treated clothing before wearing again. 
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FACT SHEET         Mosquito Repellents 
 
Avoid mosquito bites by:  
•  Applying approved insect repellents (listed below).  
•  Wearing protective clothing, such as long sleeves, long pants, socks and shoes. 
• Being aware of peak hours of mosquito activity: dusk and dawn. 
 
CDC Approved/EPA Registered Mosquito Repellents:  
1. DEET  
• The American Academy of Pediatrics recommends that repellents with DEET should 
not be used on infants less than 2 months old. 
• Repellents that contain up to 30 percent DEET are safe for children.  
• Refer to the IDPH DEET fact sheet for more information. 
2. Picaridin  
3. Oil of Lemon Eucalyptus or PMD  
• Should not to be used on children under the age of three years. 
4. IR3535  
5. Permethrin   
• Only recommended for use on clothing, shoes, bed nets, and camping gear. 
Permethrin should not be applied directly on skin.   
 
Mosquito proof your home by:  
• Emptying water from flower pots, pet food and water dishes, birdbaths, swimming pool covers, 
buckets, barrels, and cans. This should be done at least once or twice weekly.  
• Checking for clogged rain gutters and cleaning them out.  
• Removing discarded tires and other items that could collect water.  
• Checking for containers or trash in places that may be hard to see, such as under bushes or 
under your home.  
 
How often should mosquito repellent be applied? 
The label directions on the repellent should always be followed.  Length of protection against mosquito 
bites varies with the amount of the active ingredient, environmental factors such as temperature and 
humidity, amount of physical activity/perspiration, water exposure, and other factors.   
 
What precautions should be followed when using insect repellents? 
• Read and carefully follow product label directions and precautions. 
• Apply repellent sparingly on exposed skin and/or clothing. 
• Do not apply repellent near eyes, lips, or mouth. 
• Never apply repellents over cuts, wounds, or irritated skin. 
• Avoid using sprays in enclosed areas.  
• Do not use repellents near food. 
• Do not apply repellent to the hands of young children. 
• Do not allow young children to apply repellent to themselves. 
• After returning indoors, wash treated skin with soap and warm water. 
• Avoid over application. Heavy application is not necessary to achieve protection. 
• Wash treated clothing before wearing again. 
 
Can mosquito repellents be used with sunscreen? 
Yes. People can, and should, use both a sunscreen and an insect repellent when they are outdoors. 
Follow the instructions on the package for proper application of each product. In general, the 
recommendation is to apply sunscreen first, followed by repellent. 
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YELLOW FEVER 
 
 
Responsibilities: 
Hospital: Report immediately by phone 
Lab: Report immediately by phone 
Physician: Report immediately by phone 
Local Public Health Agency (LPHA): Follow-up required.  Iowa Department of Public 
Health will lead the follow-up investigation.  
 
Iowa Department of Public Health 
Disease Reporting Hotline: (800) 362-2736 
Secure Fax: (515) 281-5698 
 
1) THE DISEASE AND ITS EPIDEMIOLOGY 
 
A. Agent 
Yellow fever is a mosquito-borne viral illness. It is caused by the yellow fever virus, which is in the 
genus Flavivirus and family Flaviviridae.  
 
B. Clinical Description 
Many cases of yellow fever are so mild they go undetected. Yellow fever is only known to occur in 
Africa and South and Central America. 
 
Symptoms: In typical cases of recognized illness, sudden onset of fever, chills, headache, backache, 
generalized muscle pain, prostration, nausea and vomiting, jaundice, and albuminuria (the presence 
of protein in the urine) may occur. Most infections resolve at this stage. 
 
Complications: In more severe cases of illness, after a brief remission of hours to a day, there is 
progression to liver and kidney failure and to hemorrhagic symptoms, including nosebleeds, bleeding 
gums, bloody vomiting and bloody stools. Twenty to 50% of severe cases with jaundice are fatal. 
The overall case-fatality rate is 20-50 percent. Lifetime immunity follows yellow fever recovery.  
 
C. Reservoirs 
Monkeys are the primary reservoirs in forested areas of Africa and South America. Humans and 
Aedes aegypti mosquitoes are involved in the infective cycle in urban areas. 
 
D. Modes of Transmission 
Yellow fever has two different transmission cycles that affect humans, the urban cycle and the jungle 
cycle. 
 
Urban cycle: The virus is transmitted among humans by the bite of an infective house-dwelling Aedes 
aegypti mosquito. Monkeys play little or no role as a reservoir. 
 
Jungle cycle: Several species of mosquitoes are vectors and transmit virus from monkey to monkey. 
Humans are involved in the jungle cycle accidentally if bitten by infected mosquitoes. In South 
America, sporadic infection of humans occurs almost exclusively in forestry and agricultural workers 
through occupational exposure, however outbreaks can and do occur. Direct person-to-person spread 
of yellow fever does not occur. 
 
E. Incubation Period 
The incubation period for yellow fever is 3 - 6 days.  
 
Report Immediately 
By Phone  
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F. Period of Communicability or Infectious Period 
Yellow fever is not transmitted from person-to-person. The blood of patients is infective for 
mosquitoes from shortly before onset of fever until 3 - 5 days of illness. The incubation period in 
Aedes aegypti mosquitoes is commonly 9 - 12 days at the usual tropical temperatures. Once infected, 
mosquitoes remain so for life.  
 
G.  Epidemiology  
Yellow fever is now endemic only to certain regions of South and Central America and Africa.  Any 
cases in Iowa are likely due to recent travel abroad. 
 
H.  Bioterrorism Potential 
None. 
 
2) DISEASE REPORTING AND CASE INVESTIGATION 
 
A. Purpose of Surveillance and Reporting 
• To identify imported cases of yellow fever to understand the global epidemiology of endemic and 
epidemic yellow fever. 
• To ensure that cases are appropriately contained to prevent the introduction of virus into native 
mosquito populations. 
• To identify locally acquired cases, if they occur, so appropriate active surveillance and mosquito 
control interventions can be taken. 
• To identify cases that may be part of a larger, worldwide outbreak. 
• To provide travelers with appropriate preventive health information. 
 
B. Laboratory and Healthcare Provider Reporting Requirements 
Iowa Administrative Code 641-1.3(139) stipulates that the laboratory and the healthcare provider 
must report immediately. The reporting phone number for IDPH Center for Acute Disease 
Epidemiology (CADE) is (800) 362-2736; fax number (515) 281-5698. 
 
Laboratory Testing Services Available  
Laboratory testing for yellow fever is not available at the University of Iowa State Hygienic Laboratory 
(SHL). However, the SHL serology laboratory will forward specimens to the Centers for Disease 
Control and Prevention (CDC) for yellow fever testing. CDC requests that physicians submit complete 
case history information with the specimens. For additional information on submitting samples, 
contact SHL Serology at 319-335-4500, or visit: www.shl.uiowa.edu/   
 
C. Local Public Health Agency Follow-Up Responsibilities 
 
Case Investigation 
a. Case investigation of yellow fever in Iowa residents will be directed by IDPH Center for Acute 
Disease Epidemiology (CADE).  
 
b. Following notification of IDPH, the LPHA(s) may be asked to assist in an investigation of a case 
of yellow fever by interviewing the case and others who may be able to provide pertinent 
information. Most of the information required can be obtained from the medical provider or the 
medical record. Use the following guidelines to assist in conducting an investigation:  
1) Confirm the diagnosis of Yellow Fever with the case’s healthcare provider and request a 
copy of all laboratory tests used to diagnose the illness. 
2) Record the case’s demographic information.  
3) Record the date of symptom onset, symptoms, date of diagnosis, hospitalization information 
(if applicable), and outcome of disease (e.g., recovered, died). 
4) Exposure history: use the approximate incubation period range for yellow fever (3−6 days). 
Specifically, focus on the period beginning 3 days prior to the onset date back to 
approximately 6 days before onset for travel history: determine the date(s) and geographic 
area(s) traveled to by the case.  
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5) If there is NO history of travel outside of the United States within 6 days prior to illness 
onset notify IDPH immediately and begin active surveillance for additional cases where the 
individual may have traveled, their home and work. 
6) Include information about the case’s yellow fever vaccination status, including the date 
most recently vaccinated. 
7) If several attempts to obtain case information have been made, but have been unsuccessful 
(e.g., the case or healthcare provider does not return calls or respond to a letter, or the 
case refuses to divulge information or is too ill to be interviewed), please gather as much 
information as possible, notify CADE and enter as much information as is possible through 
the Iowa Disease Surveillance System (IDSS). 
 
3) CONTROLLING FURTHER SPREAD  
 
A. Isolation and Quarantine Requirements 
None. 
 
B. Protection of Contacts of a Case  
It is important to prevent mosquitoes from biting a case for at least 5 days after onset of illness. 
Mosquito control can be done by screening sickrooms, spraying with insecticides and using bed nets. 
These measures can prevent transmission of yellow fever from infected mosquitoes to contacts of a 
case.  Concerns over local transmission should be small.  
 
C. Managing Special Situations   
Locally Acquired Case 
As noted above in Section C 4), a locally acquired case of yellow fever would be an unusual 
occurrence. Contact the Iowa Department of Public Health immediately at (800) 362-2736 and 
request assistance if the case is believed to be acquired locally. Environmental measures such as 
investigating local areas visited by the case to locate the focus of infection and surveillance of other 
people for illness may be necessary.   
 
Reported Incidence Is Higher than Usual/Outbreak Suspected 
If an outbreak is suspected, investigate to determine the source of infection and mode of 
transmission. A common exposure to or association with A. aegypti mosquitoes (e.g., travelers 
returning from endemic countries) should be sought and applicable preventive or control measures 
should be instituted. Contact IDPH using the disease reporting hotline (800) 362-2736 as soon as 
possible. CADE can help determine a course of action to prevent further cases and can perform 
surveillance for cases that may cross several town lines and therefore be difficult to identify at a local 
level. 
 
D. Preventive Measures 
International Travel and Vaccination 
• A live vaccine is recommended for everyone over 9 months old who will be living in or traveling 
to endemic areas, and required by international regulations for travel to and from certain 
countries. Pregnant women should not be vaccinated except when travel to an endemic area is 
unavoidable and if an increased risk for exposure exists. .  
• In unusual circumstances, physicians considering vaccinating infants aged <9 months or 
pregnant women should contact the Division of Vector-Borne Infectious Diseases (970) 221-
6400) or the Division of Global Migration and Quarantine (404) 498-1600) at CDC for advice (see 
Precautions and Contraindications). 
• Without a valid certificate of immunization against yellow fever, many countries require a 6-day 
quarantine of travelers coming from or going to recognized yellow fever zones of Africa and 
South America.  
• Travelers to yellow fever endemic countries are encouraged to protect themselves from 
mosquitoes by using repellents, wearing protective clothing and using mosquito nets when rooms 
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are not screened. Unlike other vectors, the principal mosquito vectors of yellow fever bite during 
daytime hours. 
• For more information regarding international travel and the yellow fever vaccine, contact the 
CDC’s Traveler’s Health Office at (877) 394-8747 or at www.cdc.gov/travel 
 
ADDITIONAL INFORMATION 
The Council of State and Territorial Epidemiologists (CSTE) surveillance case definitions for Yellow 
Fever can be found at:  www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm#top  
 
CSTE case definitions should not affect the investigation or reporting of a case that fulfills the criteria 
in this chapter. (CSTE case definitions are used by the state health department and the CDC to 
maintain uniform standards for national reporting.)  
 
Additional Information 
 
In this Epi Manual: 
DEET Fact Sheet 
Mosquito Repellents Fact Sheet 
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FACT SHEET       YELLOW FEVER 
 
What is Yellow Fever? 
Yellow fever is a rapidly occurring viral illness of short duration with symptoms that may be mild to severe. 
 
How is Yellow Fever spread? 
Yellow fever is spread by the bite of an infected mosquito. A mosquito carries the virus from one person to 
another after sucking the blood of an infected person or animal, typically a monkey, and later biting a 
healthy person. 
 
Who gets Yellow Fever? 
All individuals are at risk except for those who have had yellow fever in the past or those who have been 
properly vaccinated against the virus.  Those most at risk are travelers to areas where the virus is found, 
including South America and Africa.  Yellow fever is not known to exist outside of these areas. 
 
What are the symptoms of Yellow Fever? 
Symptoms of yellow fever include sudden onset of fever, chills, headache, backache, all over muscle pain, 
a loss of strength and nausea and vomiting. Severe cases may include jaundice (a yellowing of skin and 
eyes), albuminuria (the presence of protein in the urine), and anuria (absence of urine). 
 
How soon do symptoms appear? 
Symptoms usually occur within 3 - 6 days after being bitten by an infected mosquito. 
 
How long will symptoms last? 
Symptoms usually resolve quickly after they develop. However, the illness may progress to more serious 
complications after a brief remission of hours to a day. These complications may include liver or kidney 
failure, as well as hemorrhagic symptoms including: nosebleeds, bleeding gums, or visible blood in vomit 
and stools. The overall case-fatality rate is 20 – 50%. Lifetime immunity follows yellow fever recovery. 
 
How is Yellow Fever prevented? 
Preventing exposure to infected mosquitoes is the best means of protection from the virus causing yellow 
fever. Although yellow fever is not usually found in Iowa, cases have been associated with very recent 
travel to areas where yellow fever is present.  Mosquitoes in Iowa do not carry yellow fever but they can 
carry other viruses.  Personal protection is the best way to prevent exposure to any virus spread by 
mosquitoes.  Please review the DEET fact sheet and follow the recommendations to reduce the risk of being 
bitten by mosquitoes.  This recommendation is appropriate when being outdoors in Iowa, South America or 
Africa. 
 
There is a vaccine available to help prevent infection and illness from yellow fever. People traveling to South 
America and Africa who will be at an increased risk should be vaccinated prior to traveling to these areas. 
Most countries where yellow fever is found typically require travelers to be vaccinated before visiting. 
Contact your local health department or the Iowa Department of Public Health for a vaccination site nearest 
you. 
 
Can infection with Yellow Fever occur more than once? 
No, recovery from yellow fever is followed by immunity against future infections. 
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CONFIDENTIAL                                                                                           Iowa Department of Public Health 
Yellow Fever              
 
Investigator:  
       Agency:                                                Phone number:                                          
FOR STATE USE ONLY 
Status:    Confirmed       Probable 
 Suspect          
 Not a case 
Reviewer initials:       
Referred to another state:       
 
CASE   
 
Last name:       Date of Birth:      /     /           Estimated?  Age:       
First and middle 
name:       Gender:  Female      Male      Other       
Maiden name:       Suffix:                  Pregnant:  Yes    No    Unk 
Est. delivery 
date:      /     /      
Address line: 
 
      
         Marital 
status: 
 Single                         
 Divorced         
 Married               
 Parent with partner 
 Separated 
 Widowed 
Zip:       City:       Race: 
 American Indian or Alaskan Native 
 Black or African American 
 Hawaiian or Pacific Islander 
 Unknown 
 White 
 Asian   State:       County:       
Long-term care     
resident:  Yes      No      Unknown        Ethnicity:  Hispanic or Latino      Not Hispanic or Latino      Unknown 
Facility name:       
Parent/Guardian 
name: 
 
      
Facility phone: (     )-     -        Type:        
Parent/Guardian 
phone: (     )-     -      Type:       
 
EVENT  
 
Onset 
date: 
 
     /     /      
Diagnosis 
date: 
 
     /     /      
H
ea
lth
ca
re
 p
ro
vi
de
r 
in
fo
rm
at
io
n 
 
Last name: 
 
      
Event outcome: 
 Survived this illness     Died from this illness 
 Died unrelated to this illness    Unknown 
Date of death      /     /      First name: 
 
      
Event exception 
 Case could not be found 
 Case could not be interviewed 
 Case refused interview 
 Other – see notes 
Provider type:  ARNP  DO 
 MD 
 NP  PA 
Outbreak 
related:  Yes      No      Unknown  
Outbreak name:       Facility name:       
Exposure 
setting:       Address line 1:       
Epi-linked:  Yes      No      Unknown  
Address line 2: 
 
      
Location 
acquired: 
 In USA, in reporting state      
 In USA, outside reporting state       Zip code: 
 
      
 
City: 
 
      
  Outside USA   
 Unknown       State:       
 
County: 
 
      
 
State: 
 
      
 
Country: 
 
      Phone : (     )-     -      
 
   Type:       
LABORATORY FINDINGS 
 
Laboratory: 
 
      
Specimen 
source: 
 
      
 
Test type: 
 Serology (ELISA) 
 PCR      Other            
 
Accession #: 
 
      
 
Result date: 
 
     /     /      Result type:  Preliminary      Final 
 
Collection date: 
 
     /     /      Test type: 
 Acute 
 Convalescent 
 IgM 
 IgG Result: 
 Negative 
 Positive 
 Equivocal 
 Indeterminate 
 
Date received: 
 
     /     /      Organism: Yellow  fever virus Type:  
 
 
Laboratory: 
 
      
Specimen 
source: 
 
      
 
Test type: 
 Serology (ELISA) 
 PCR      Other            
 
Accession #: 
 
      
 
Result date: 
 
     /     /      Result type:  Preliminary      Final 
 
Collection date: 
 
     /     /      Test type: 
 Acute 
 Convalescent 
 IgM 
 IgG Result: 
 Negative 
 Positive 
 Equivocal 
 Indeterminate 
 
Date received: 
 
     /     /      Organism: Yellow  fever virus Type:  
 
 
Laboratory: 
 
      
Specimen 
source: 
 
      
 
Test type: 
 Serology (ELISA) 
 PCR      Other            
 
Accession #: 
 
      
 
Result date: 
 
     /     /      Result type:  Preliminary      Final 
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CONFIDENTIAL PATIENT NAME: ______________________________                           Iowa Department of Public Health 
 
Collection date: 
 
     /     /      Test type: 
 Acute 
 Convalescent 
 IgM 
 IgG Result: 
 Negative 
 Positive 
 Equivocal 
 Indeterminate 
 
Date received: 
 
     /     /      Organism: Yellow  fever virus Type:  
 
OCCUPATIONS 
 
Interpret ‘occupation’ very loosely and consider every person to have at least one ‘occupation’. 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties: 
Health care worker type: 
 Yes      No      Unknown 
 Yes      No      Unknown 
      
 
Occupation type: 
 
      Job title: 
 
      
Worked after 
symptom onset: 
 
 Yes      No      Unknown Facility name: 
 
      
Date worked from: 
 
     /     /      Address: 
 
      
Date worked to: 
 
     /     /      Zip code: 
 
      
Removed from 
duties: 
 
 Yes      No      Unknown City: 
 
      
 
State: 
 
      
 
County: 
 
      
Date removed: 
 
     /     /      Phone: 
 
(     )-     -        Type: 
Handle food: 
Attend or provide child care: 
Attend school: 
Work in a lab setting: 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
 Yes      No      Unknown 
Work in a health care setting: 
Direct patient care duties: 
Health care worker type: 
 Yes      No      Unknown 
 Yes      No      Unknown 
      
 
HOSPITALIZATIONS 
 
Was the case hospitalized?  Yes    No    Unknown 
Hospital: 
 
      Isolated at entry: 
 
 Yes    No    Unk Isolation type (entry): 
 
      
Admission date: 
 
     /     /      
 
Discharge date: 
 
     /     /      
 
Days hospitalized: 
 
    
Currently isolated: 
 
 Yes    No    Unk 
 
Current isolation type: 
 
      
  
 
CLINICAL INFO & DIAGNOSIS 
 
Physician 
diagnosis: 
 Encephalitis 
 Meningitis 
 Meningoencephalitis 
 Fever 
 Asymptomatic 
 Hepatitis/jaundice 
 Multi-system organ failure 
 Other            
 Dengue hemorrhagic 
fever/ Dengue shock  
Clinical 
classification: 
 Neuroinvasive  
 Non-neuroinvasive 
  
 
 
Symptoms:  Acute flaccid paralysis 
 Altered mental state 
 Anorexia 
 Coma 
 Confusion 
 Cranial nerve palsies 
 Diarrhea 
 Double vision 
 Eye pain 
 Fatigue 
 Fever 
 Gait/balance difficulty 
 Headache 
 Joint pain 
 Muscle pain 
 Nausea 
 Photophobia 
 Rash 
 Stiff neck 
 Swollen lymph nodes 
 Tremors 
 Vertigo 
 Vomiting 
 Other symptoms:                           
 
Pre-existing Conditions 
Before your West Nile virus (WNV) infection, did a health care provider ever tell he/she had any of the following medical conditions? 
 Diabetes 
 High blood pressure (hypertension) 
 Heart attack (myocardial infarction) 
 Angina or coronary artery disease 
 Congestive heart failure 
 Stroke 
 Chronic obstructive pulmonary disease (COPD) 
 Chronic liver disease 
 Kidney disease or failure 
 Bone marrow transplant 
 Alcoholism 
 Case had none of the conditions listed 
 
Before WNV infection, did the case ever 
have a solid organ transplant? 
 
 Yes    No    Unk 
 
If yes, what organ was transplanted:       
  If yes, what year was the transplant:       
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EXPOSURE PERIOD COMMUNICABLE PERIOD 
Before WNV infection, has the case ever 
had cancer?  Yes    No    Unk If yes, what cancer type(s):       
  If yes, what year were you diagnosed:       
  If yes, are you currently being treated for cancer:  Yes      No      Unk 
Before WNV infection, did the case have 
any medical condition that limited 
his/her ability to fight infection?  Yes    No    Unk If yes, what condition:       
At the time WNV infection was diagnosed, was the case taking any of the following types of prescription medications or treatments? 
 Chemotherapy      
 Other treatments for cancer  
 Hemodialysis 
 Other treatments for kidney disease 
 Oral or injected steroids      
 Inhaled steroids         
 Insulin or other medications to treat diabetes 
 Medications to treat high blood pressure  
 Medications to treat coronary artery disease   
 Medications to treat congestive heart failure  
 Medications that suppress the immune system 
 Case was not on any medication/treatments listed 
    
INFECTION TIMELINE 
 
 
    ______________________________________Onset________________________________________ 
 
 
 
 
 
RISK FACTORS/TRAVEL 
 
Ever vaccinated for Yellow Fever or Japanese encephalitis (JE)?   Yes    No    Unknown 
If yes, list MOST RECENT vaccination information ONLY: 
 Disease:  Yellow fever  JE 
 Disease:  Yellow fever  JE 
 
 
Date vaccinated: 
 
     /     /      
 
Date vaccinated: 
 
     /     /      
 
  
Lot #: 
 
      
  
Lot #: 
 
      
 
  
Vaccine type: 
 
      
  
Vaccine type: 
 
      
 
  
Manufacturer: 
 
      
  
Manufacturer: 
 
      
 
 
Number of vaccinations:       
 
Risk Factors/Travel Information  
In the 15 days prior to onset of symptoms did the case:  
Travel within Iowa? 
 Yes    No    Unk 
City in 
Iowa:       
Departure 
date:      /     /      
Return 
date:      /     /      
Travel within U.S.?  
 Yes    No    Unk State:       City:       
Departure 
date:      /     /      
Return 
date:      /     /      
Travel outside U.S.?   
 Yes    No    Unk Country:       
Departure 
date:      /     /      
Return 
date:      /     /      
 
Exposed to mosquitoes:  Yes    No    Unk    
Use a mosquito repellent:  Yes    No    Unk If yes, how often?  Sometimes    Never 
  If yes, 
what type? 
 Picaridin 
 DEET 
If the patient is female, was she:  
 Always   
 Most of the time 
  Oil of lemon eucalyptus 
 Other            
Pregnant? 
Breastfeeding? 
 Yes    No    Unk 
 Yes    No    Unk 
   
 
NOTES:       
 
 
 
 
 
 
 
 
Enter onset date in dark-line 
box. Enter dates for start of 
exposure period and start and 
end of communicable period.  
 The incubation period for 
Yellow fever is 3 to 6 
days. 
No direct person to 
person transmission.  
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Acronyms 
 
ACIP 
Advisory Committee on Immunization 
Practices 
ACPHP 
Academic Center for Public Health 
Preparedness 
AIDS 
Acquired Immune Deficiency Syndrome 
AIIR 
Airborne infection isolation room  
ALT 
Alanine amiontransferase 
AMA 
American Medical Association 
APHL 
Association of Public Health Laboratories 
ASPH 
Association of Schools of Public Health 
AST 
Aspartate transaminase 
AVA 
Anthrax Vaccine Adsorbed 
AVRP 
Anthrax Vaccine Research Program 
ASPH 
Association of Schools of Public Health 
ASTHO 
Association of State and Territorial Health 
Officials 
ATSDR 
Agency for Toxic Substances and Disease 
Registry 
CADE 
Center for Acute Disease Epidemiology 
CBRN 
Chemical, Biological, Radiological/Nuclear 
CDC 
Centers for Disease Control and Prevention 
CDOR 
Center for Disaster Operations and Response 
CHI 
Consolidated Health Informatics 
CIA 
Central Intelligence Agency 
CIO 
Centers, Institutes and Office 
CISM  
Critical Incident Stress Management 
CLIA 
Clinical Laboratory Improvements Act 
CPHP 
Centers for Public Health Preparedness 
COOP 
Continuity of Operations Plan 
CSTE 
Council of State and Territorial Epidemiologists 
DEEDS 
Division of Epidemiology, EMS, and Disaster 
Operations 
DNA 
Deoxyribonucleic Acid 
DHHS 
Department of Health and Human Services 
DHS 
Department of Homeland Security 
DOE 
Department of Energy 
ECS 
Emergency Communication System 
EOC 
Emergency Operations Center 
EPA 
Environmental Protection Agency 
Epi-X 
Epidemic Information Exchange 
EIS 
Epidemic Intelligence Service 
EISO 
Epidemic Intelligence Service Officer 
ELISA 
Enzyme Linked Immunosorbent Assay 
ELR 
Electronic Laboratory-Based Reporting 
EPO 
Epidemiology Program Office  
ERT 
Emergency Response Team 
FBI 
Federal Bureau of Investigation  
FEMA 
Federal Emergency Management Agency 
FMO 
Financial Management Office 
FDA 
Food and Drug Administration 
FRP 
Federal Response Plan 
FRERP 
Federal Radiological Emergency Response Plan 
FTE 
Full Time Equivalent 
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GIS 
Geographic Information System 
GMP 
Good Manufacturing Practices 
GPRA 
Government Performance and Results Act of 
1993 
HACCP 
Hazard Analysis Critical Control Point 
HAN 
Health Alert Network 
HICPAC 
Healthcare Infection Control Practices Advisory 
Committee 
HIPAA 
Health Insurance Portability and Accountability 
Act 
HPP 
Hospital Preparedness Program 
HIV 
Human Immunodeficiency Virus 
ICRC 
Injury Control Research Center 
ICS 
Incident Command System 
IDSS 
Iowa Disease Surveillance System 
IDPH 
Iowa Department of Public Health 
IM 
Intramuscular 
IMS 
Incident Management System 
IOM 
Institute of Medicine 
IT 
Information Technology 
IV 
Intravenous 
LPHA 
Local Public Health Agency 
LRN 
Laboratory Response Network 
ME  
Medical examiner 
MSEHPA 
Model State Emergency Health Powers Act  
NACCHO 
National Association for City and County 
Health Officials  
NCBDDD 
National Center for Birth Defects and 
Developmental Disease  
NCCDPHP 
National Center for Chronic Disease Prevention 
and Health Promotion  
NCEH 
National Center for Environmental Health  
NCHS 
National Center for Health Statistics  
NCHSTP 
National Center for HIV, STD and TB 
Prevention 
NCID 
National Center for Infectious Disease  
NCIPC 
National Center for Injury Prevention and 
Control 
NEDSS 
National Electronic Disease Surveillance 
System 
NGO 
Non-Governmental Organization 
NHSN 
National Healthcare Safety Network 
NIP 
National Immunization Program 
NIOSH 
National Institute for Occupational Safety and 
Health 
NIH 
National Institutes of Health  
NLTN 
National Laboratory Training Network  
NPHIC 
National Public Health Information Coalition 
NPPTL 
National Personal Protective Technology 
Laboratory 
NPS 
National Pharmaceutical Stockpile 
NYCDOH 
New York City Department of Health 
OC 
Office of Communication 
OHS 
Office of Health and Safety 
OTPER 
Office of Terrorism Preparedness and 
Emergency Response 
OD 
Office of the Director  
OSEP 
Office of Security and Emergency 
Preparedness 
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PPE 
Personal Protective Equipment  
PCP 
Pneumocystis Carinii Pneumonia 
PCR 
Polymerase Chain Reaction 
PFGE 
Pulse Field Gel Electrophoresis 
PHA 
Public Health Advisor 
PH 
Public Health 
PHEP 
Public Health Emergency Preparedness 
PHER 
Public Health Emergency Response 
PHIN 
Public Health Information Network  
PHPPO 
Public Health Practice Program Office  
PMR 
Preventive Medicine Resident 
PVS 
Pre-Event Vaccination System 
SAP 
Select Agent Program 
SARS  
Severe Acute Respiratory Syndrome 
SCBA 
Self Contained Breathing Apparatus  
SLPP 
State and Local Preparedness Program 
SME  
State Medical Examiner 
SNS 
Strategic National Stockpile  
SVP 
Smallpox Vaccination Program 
SWOC 
Strengths, Weaknesses, Opportunities and 
Challenges 
TARU 
Technical Advisory Response Unit  
TED 
Training, Education and Demonstration 
Package 
TOPOFF 
Top Officials 
TRPLT 
Terrorism Response and Preparation 
Leadership Team 
US 
United States 
USDA 
United States Department of Agriculture 
VAERS 
Vaccine Adverse Effects Reporting System 
VFC 
Vaccines for Children 
VIG 
Vaccinia Immune Globulin 
VMI 
Vendor Managed Inventory 
WaterCAD 
Water Computer Aided Design 
WHO 
World Health Organization 
XML 
Extensible Markup Language 
24x7 
Twenty four hours a day, seven days a week 
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Antigen -    That part of an agent (bacteria, virus, etc.) capable of stimulating the 
production of specific antibodies. 
 
Antibody -   An immunoglobulin found in tissue fluids and blood serum that is 
produced in response to the stimulus of a specific antigen and is 
capable of combining with that antigen to neutralize or destroy it. 
 
Airborne precautions -    Precautions that apply to patients known or suspected to be infected 
with epidemiologically important pathogens that can be transmitted 
widely by air currents and may become inhaled by or deposited on a 
susceptible host within the same room or, depending on environmental 
factors, over a longer distance from the source patient.  These 
precautions are designed to reduce the risk of such airborne 
transmission of infectious agents through personal protection devices, 
such as N95 masks, and special air handling and ventilation systems, 
such as airborne infection isolation rooms.  (Adapted from CDC/HICPAC 
guidelines.) 
 
Airborne infection isolation room (AIIR) - A single patient room in which environmental factors 
are controlled to minimize the transmission of infectious agents that 
can be transmitted by the airborne route. These rooms have specific 
requirements for controlled ventilation, negative pressure, and air 
filtration and monitoring that are detailed in Guideline for 
Environmental Infection Control in Health-Care Facilities, 2003. 
Arthralgia -   Pain in a joint without objective signs (see arthritis). 
 
Arthritis -   Swelling, redness, tenderness, or other specific signs of inflammation 
in a joint. 
 
Aseptic -   Absence of infectious microorganisms; free from infection; sterile.  
(Sometimes used to mean absence of bacteria, example; aseptic 
meningitis may be caused by virus). 
 
Asymptomatic -   Without objective evidence of disease or condition. 
 
Attack Rate -   A measure of the frequency of cases of a disease in a narrowly 
defined population during a specific interval of time, as in epidemics (# 
of cases/# of people exposed x 100).  Usually expressed as a percent. 
 
Bacteria -    Unicellular microorganism.  There are three principal forms:  spherical 
or ovoid forms called cocci; rod-shaped forms called bacilli or vibrios; 
and spiral forms called spirilla or spirochetes. 
 
Bioemergency -     A situation in which a pathogen poses an immediate and severe threat 
to the lives or health of people in Iowa, to the extent that day-to-day 
operations of public health authorities are insufficient to address this 
threat.    
 
Carrier -   A person or animal that harbors a specific infectious agent (but 
manifests no discernible clinical disease) and is a potential source of 
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infection for man or animals.  The carrier state can occur in an 
individual after an infection (which was either asymptomatic or 
symptomatic and resolved). 
 
Case -    An infected or diseased person or animal having specific clinical, 
laboratory, or epidemiologic characteristics. 
 
Case Definition -    A set of standard criteria for deciding whether a person has a particular 
disease or health-related condition, by specifying clinical criteria and 
limitations on time, place, and person (Retrieved from CDC at 
www.cdc.gov/osels/ph_surveillance/nndss/casedef/index.htm  on 
3/15/11). 
 
Case Fatality Rate -   A measure of the likelihood that an ill person (i.e., one who exhibits 
symptoms) will die as a result of that illness (adapted from Gordis, 
2000:44); can be expressed by the ratio:  
number who die within a specified time after disease onset or diagnosis 
number ill 
 
Chemoprophylaxis - The administration of a medicine, including antibiotics, to prevent the 
development of an infection or prevent the progression of an infection 
to clinical disease.  Example: Rifampin for exposure to meningococcal 
disease. 
 
Cohort -   Any defined group of persons selected for a special purpose or study.  
(From the Latin cohors, warriors, the tenth part of a legion). 
 
Cohorting -    Method to isolate separate infectious persons from susceptible ones by 
grouping persons with the same infection together.  Cohorting of staff 
is to assign specific staff to a group of patients and not have them do 
care on the unaffected clients. 
 
Colonization -  Propagation of a microorganism on or within a host without causing 
cellular injury or infection.  A colonized host can serve as a source of 
infection.  Carriers are often said to be colonized with a pathogen. 
 
Communicable Disease - An illness which is caused by a specific infectious agent or its toxic 
products, and which arises through transmission of that agent or its 
products from a reservoir to a susceptible host. 
           
Complement -  A chemical in the immune system which can provoke the disintegration 
of bacteria.  It is present in all sera.  Complement is not an antibody 
but may work with antibodies to destroy bacteria. 
 
Contact -   A person or animal that has been in such association with an infected 
person or animal, or a contaminated environment, as to have had an 
opportunity to acquire the etiologic agent. 
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Contact Precautions - Precautions that apply to patients known or suspected to be infected or 
colonized with epidemiologically important microorganisms that can be 
transmitted by direct or indirect contact.  Direct-contact transmission 
involves skin-to-skin contact and physical transfer of microorganisms to 
a susceptible host from an infected or colonized person, while indirect-
contact transmission involves contact of a susceptible host with a 
contaminated intermediate object.  (Adapted from CDC/HICPAC 
guidelines.) 
 
Culture -   The growth of microorganisms on or in substances (especially 
laboratory media prepared for this purpose). 
 
Droplets -   Liquid particles expelled into the air during the act of talking, spitting, 
singing, coughing, or sneezing.  Droplets are formed through 
aerosolization of secretions present in the mouth, nasopharynx and 
bronchi.  They can contain infectious microorganisms. 
 
Droplet Nuclei -  The dried residues of droplets which may contain one or more 
infectious microorganisms.  In contrast to droplets, droplet nuclei can 
remain suspended in the air for long periods. 
 
Droplet Precautions -   Precautions that apply to any patient known or suspected to be 
infected with epidemiologically important pathogens that can be 
transmitted by infectious droplets generated from the source person 
during coughing, sneezing, or talking or during the performance of 
certain procedures such as suctioning or bronchoscopy.  Unlike 
airborne precautions, because droplets travel only short distances (< 3 
ft.) and do not remain suspended in the air, special air handling and 
ventilation are not required to prevent droplet transmission.  (Adapted 
from CDC/HICPAC guidelines.) 
 
Ecchymosis -  A large, irregularly formed hemorrhagic area of skin.  Like a large 
bruise the color is blue-black changing to a greenish-brown or yellow.  
May occur with a large bruise. 
 
Epidemic -   The occurrence of cases of a disease in human populations in a 
particular geographic area clearly in excess of the usual incidence. 
 
Common-source epidemic - An epidemic in which one human or one 
animal or specific vehicle (e.g., food or water) is responsible for 
transmitting the agent to the case/s identified. 
 
Point-source epidemic - like a common source but limited to a short 
time period (e.g., a meal). 
 
Propagated-source epidemic - An epidemic in which infections are 
transmitted from person to person or animal to animal in such a 
fashion that identified cases cannot be attributed to a single source. 
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Epidemiologist -  A person who applies epidemiologic principles and methods to the 
prevention and control of disease. 
 
Epidemiology -  The study of the distribution and causes/risk factors of disease in 
human populations. 
 
Epidemiologically linked case - A case in which a) the patient has had contact with one or more 
persons who either have/had the disease or have been exposed to a 
point source of infection (i.e., a single source of infection, such as an 
event leading to a foodborne-disease outbreak, to which all confirmed 
case-patients were exposed) and b) transmission of the agent by the 
usual modes of transmission is plausible. A case may be considered 
epidemiologically linked to a laboratory-confirmed case if at least one 
case in the chain of transmission is laboratory confirmed.  
 
Erythema -   Redness of the skin due to capillary dilatation. 
 
Etiology -   The study or theory of the causes of disease.  An etiologic agent is that 
which causes disease. 
 
Exposure -   The opportunity of a susceptible host to acquire an infection by either a 
direct or indirect mode of transmission.  Example: being bitten by an ill 
skunk is a potential exposure to rabies. 
 
Fomites -   Inanimate objects, such as toys or articles of clothing, which can 
become contaminated and, therefore, be a vehicle for transmission.  
 
Fungi -   Simple, dependent plants including molds, rusts, mushrooms, 
toadstools, lichens and yeasts.  Some forms are pathogenic to animals. 
 Example:  vaginal "yeast infections". 
 
Hand Hygiene -    A general term that applies to hand washing, antiseptic handwash, 
antiseptic hand rub, or surgical hand antisepsis. (CDC) 
Health Care Provider -   A person who is trained and licensed to give health care. Also, a place 
licensed to give health care. Doctors, nurses, hospitals, skilled nursing 
facilities, some assisted living facilities and certain kinds of home health 
agencies are examples of health care providers. (From the Medicare 
web site.) 
 
Host -    Organisms, including humans, that are capable of being infected by a 
specific agent. 
 
Hypothesis -   An unproven assertion or statement based on available information, 
which commonly deals with the identity of an etiologic agent, the 
source of infection and the mode of transmission.  Its role is to provide 
a rational basis for further investigation. 
 
Illness -     A subjective state, or experience, characterized by the impairment of 
normal physiological function and affecting part or all of an organism 
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(Last, 2001:90 and Princeton University, retrieved 3/10/04). 
 
Immune Globulin -  A sterile solution of proteins made up of antibodies that are present in 
adult human blood.  Example: RIG - rabies immune globulin.  
 
Immunoglobulin -   A protein that functions as an antigen receptor.   
 
Immunity -   Immunity is often used to refer to antibody status. 
 
Passive immunity refers to antibodies acquired from an outside source 
either naturally (by maternal transfer) or artificially (by inoculation of 
specific protective antibodies -- convalescent or immune serum, or 
immune globulin).  Passive immunity is of brief duration (days or 
months). 
 
Active immunity lasts years, and is acquired either naturally (by actual 
infection), or artificially (by inoculation with a vaccine). 
 
Immunodeficient -  Lacking in the ability to mount an immune response in response to an 
antigen. 
 
Incidence -   Number of new cases of a disease occurring within a particular 
population during a specified period of time. 
 
Index Case -   The first case among a number of similar cases which are 
epidemiologically related.  Index cases are often identified as a source 
of contamination or infection. 
 
Induration -    Extremely hard or firm tissue (e.g. what is measured in a reactive 
Tuberculin skin test) 
 
Infection -   The entry and multiplication of an infectious agent in body tissues of 
man or animal, resulting in cellular injury. 
 
Infectious Agent -  An organism, usually a microorganism but including larger parasites 
(such as worms), that is capable of producing infection or infectious 
disease. 
 
Infectious Disease - A disease of man or animal resulting from an invasion of the body by 
pathogenic agents and the reaction of the tissues to these agents 
and/or the toxins they produce. 
 
Infection Control Precautions - Measures used for decreasing the risk of transmission of 
microorganisms, particularly in health care facilities or when otherwise 
providing medical care.  These fall into standard, contact, droplet, and 
airborne categories, which are also defined in this section. (Adapted 
from CDC/HICPAC guidelines) 
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Infectivity -    A measure of the likelihood that a person exposed to a pathogen will 
become infected (i.e., the agent enters, multiplies, and survives within 
the host) (adapted from Nelson, 2001:27); can be expressed by the 
ratio: 
    number infected _ 
       number exposed 
 
Infestation -   The lodgment, development, and reproduction of arthropods (e.g., 
scabies, lice on the body or in the clothing.) 
 
Inflammation -  Normal tissue response to cellular injury or foreign material, 
characterized by dilation of small blood vessels (capillaries) that usually 
cause erythema (redness) and warmth and mobilization of defense 
cells (blood and tissue white blood cells that form pus). 
 
Isolation -   The separation, for the period of communicability, of infected persons 
or animals from those that are not infected, in such places and under 
such conditions as will prevent the direct or indirect transmission of the 
infectious agent from those infected to those who may be susceptible 
or who may spread the agent to others. 
 
Mean -   Called "the average" in arithmetic.  The mean is calculated by adding 
together all the observed values and dividing by the number of 
observations. 
 
Monospot -   Agglutination test to detect the Epstein-Barr virus (the cause of 
mononucleosis). 
 
Morbidity -   Any departure from a state of well-being. 
 
Myalgias -   Tenderness or pain in the muscles. 
 
Nanometer -   One billionth of a meter. 
 
Nosocomial Infection - An infection resulting from exposure to a source within a health-care 
facility.  The term is applied to such infections transmitted between 
inpatients, visitors, and hospital personnel. 
 
Nosocomial -   A term used to denote a new disease or condition acquired within a 
healthcare setting, for example a hospital-acquired infection. 
Outbreak -   The occurrence of two or more cases of a disease which are 
epidemiologically related. 
 
Pandemic -   An epidemic disease affecting people in several countries or continents. 
 Example:  In 1919, there was an influenza pandemic. 
 
Parasite -   An organism (often microbial) which lives in or on another organism, at 
their expense. Parasites are not necessarily harmful to their host. 
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Pathogen -   An agent capable of causing disease. 
 
Pathogenicity -   The ability of an agent to cause disease in a susceptible host. 
 
Permucosal -  By means of a mucous membrane.  Example:  Permucosal spread of 
hepatitis B can occur, especially in health care settings. 
 
Personal Protective Equipment - The equipment and clothing required to mitigate the risk of 
injury from or exposure to hazardous conditions encountered during 
the performance of duty.  (From the National Oceanographic and 
Atmospheric Association) 
 
Petechiae -   Small, purplish, hemorrhagic spots on the skin, mucous membranes, or 
serous surfaces.  These are small areas under the skin, which may be 
due to an abnormality of blood clotting mechanism. 
 
Phagocyte -   A cell which engulfs and destroys foreign particles or microorganisms 
by digestion. 
 
Primary Case -    The person who first introduces a disease into a defined group, such as 
a family, and therefore the means by which members of this group 
may contract the disease.  Compare with the definition for index case 
(adapted from Last, 2001:142 and Gordis, 2000:22). 
Prodromal Period -  The prodromal period is that lapse of time between the first vague 
symptom of disease and the full clinical syndrome upon which a 
diagnosis can be based. 
 
Prophylaxis -  Measures taken to prevent the development or spread of disease. 
 
Protozoa -   A unicellular animal which usually reproduces asexually by fission.  
 
Public Health Disaster - Defined in Iowa Code section 135.140 as “a state of disaster 
emergency proclaimed by the governor in consultation with the 
department [i.e., IDPH] pursuant to section 29C.6 for a disaster which 
specifically involves an imminent threat of an illness or health condition 
that meets any of the following conditions of paragraphs I and II: 
 
 I.  Is reasonably believed to be caused by any of the following: 
 a. Bioterrorism or other act of terrorism. The appearance of a novel or 
previously controlled or eradicated infectious agent or biological toxin.  
A chemical attack or accidental release. 
b. An intentional or accidental release of radioactive material. 
c. A nuclear or radiological attack or accident. 
 
     II. Poses a high probability of any of the following: 
a. A large number of deaths in the affected population.  A large 
number of serious or long-term disabilities in the affected 
population. 
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b. Widespread exposure to an infectious or toxic agent that poses a   
significant risk of substantial future harm to a large number of the 
affected population.” 
Although this statutory definition includes the conditions for a “bio-
emergency,” as defined earlier in this section, it also encompasses 
conditions that are not addressed in this plan, including chemical, 
radioactive, radiological, and nuclear incidents.  Also, not every set of 
conditions that may be considered a bio-emergency by IPDH officials 
will result in the proclamation of a public health disaster. 
 
Purpura -   A small hemorrhage in the skin, mucous membrane or serosal (serous 
membrane) surface which can have various manifestations. 
Hemorrhage into the skin becomes red, then darkens into purple, then 
brownish-yellow and finally disappears in 2-3 weeks.  Areas of 
discoloration do not disappear under fingertip pressure. 
 
Quarantine -    The limitation of freedom of movement of persons or animals that have 
been exposed to a communicable disease, within specified limits 
marked by placards, for a period of time equal to the longest usual 
incubation period of the disease. 
 
Ratio -   A measure of the frequency of one group of events (e.g., the number 
of males having a specified disease) relative to the frequency of a 
different group of events (e.g., the number of females having the 
specified disease).  Example:  The male to female ratio for legionellosis 
is 2.5/1. 
 
Resistance -    The sum total of host mechanisms which interpose barriers to invasion 
or multiplication of infectious agents, or that prevent damage by the 
agent's toxic products.  
  
Reservoir -    The habitat where the etiologic agent of a disease normally thrives, 
grows, and replicates. A reservoir may be human (anthroponotic), 
animal (zoonotic), or a nonliving environment, such as soil or water 
(sapronotic).  A characteristic feature of most diseases with non-human 
reservoirs is that once transmitted to humans, the epidemic chain is 
usually aborted, although the clinical course might be sometimes quite 
severe, even fatal. (Hubálek:403). 
Rickettsia -   A class of bacteria, which like viruses, can only multiply inside other 
cells. 
 
Risk -    The likelihood that a person having specified characteristics (e.g., age, 
sex, immune status) will acquire a specified disease. 
 
Secondary Attack Rate - The frequency of new disease cases among close contacts of known 
cases.  Secondary attack rates are usually calculated for household 
contacts.  Example:  The household secondary attack rate for Shigella 
can be over 50%. 
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Sepsis -   When a symptomatic person is found to have pathogenic 
microorganisms or their toxins in the blood. 
 
Serotyping -   The characterization of different strains of a microorganism by the 
reaction of different stocks of sera with that organism.   
 
Sign -    Objective (can be detected by others) evidence of a disease. 
 
Sporadic Case -  A case with no known epidemiological relationship to any other case(s). 
Standard Precautions -   Precautions designed for the care of all patients in health care facilities 
regardless of their diagnosis or presumed infection status and intended 
to reduce the risk of transmission of microorganisms from both 
recognized and unrecognized sources of infection.  The main focus is 
on hand hygiene, the use of protective barriers, and the proper 
handling of clinical waste.  The precautions apply to (1) blood; (2) all 
body fluids, secretions, and excretions (except sweat), regardless of 
whether or not they contain visible blood; (3) non-intact skin; and, (4) 
mucous membranes.  (Adapted from CDC/HICPAC guidelines.) 
 
Surveillance of Disease - The continuing scrutiny of the aspects of the occurrence and spread of 
a disease that are pertinent to effective control. 
 
Susceptible -  A person or animal lacking sufficient resistance to a particular 
pathogenic agent to prevent disease if exposed. 
 
Symptom -   Subjective (cannot be detected by others) evidence of a disease. 
 
Syndrome -   The set of signs and symptoms which typify a particular disease. 
 
Toxin -   Proteins or conjugated protein substances which can cause disease. 
They are produced by some higher plants, certain animals, and 
pathogenic bacteria. 
 
Toxoid -    A preparation containing detoxified toxin.  Toxoids are used to induce 
specific active immunity to the related toxin. 
 
Transmission Mode -  The means by which disease organisms are spread. For the purposes 
of this plan, the term applies to how they are spread to humans. 
Travel Advisory -   A recommendation against nonessential travel to the area(s) for which 
it is issued.  Travel advisories are issued when the health risk for 
travelers is thought to be high, and are intended to reduce the number 
of travelers to high-risk areas and the risk for spreading disease to 
other areas. (Adapted from CDC guidance). 
Travel Alert -  A lower-level notice than a travel advisory that provides information 
about the disease outbreak and informs travelers how to reduce their 
risk of acquiring the infection.  An alert does not include a 
recommendation against nonessential travel to the area.  (Adapted 
from CDC guidance). 
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Triage -     The process for sorting ill or injured people into groups based on their 
need for or expected benefit from medical treatment.  The purpose is 
to provide for the efficient use of medical and nursing staff and 
associated facilities. 
Vaccine -   A preparation containing killed or living whole microorganisms or a 
fraction of the organisms having antigenic properties.  Vaccine is 
employed to induce, in the recipient, a specific active immunity to an 
infectious agent (usually an antibody response). 
 
Vector -    An insect (e.g., tick) or any living carrier that transports an infectious 
agent from a source of infection to a susceptible host. 
 
Vehicle -   An object or substance that can carry microorganism to a new host. 
 
Virus -   Minute organisms not visible with ordinary light microscopy.  They can 
reproduce only inside of a host cell.  
 
Virulence -   The amount of power and the degree of pathogenicity possessed by 
organisms. 
 
Zoonosis -   An infection or an infectious disease transmissible under natural 
conditions between animals and man. 
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